PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Nesvorny, D; Bottke, WF; Dones, L; Levison, HF				Nesvorny, D; Bottke, WF; Dones, L; Levison, HF			The recent breakup of an asteroid in the main-belt region	NATURE			English	Article							SYSTEM DUST BANDS; FAMILIES; ORIGIN	The present population of asteroids in the main belt is largely the result of many past collisions(1,2). Ideally, the asteroid fragments resulting from each impact event could help us understand the large-scale collisions that shaped the planets during early epochs(3-5). Most known asteroid fragment families, however, are very old and have therefore undergone significant collisional and dynamical evolution since their formation(6). This evolution has masked the properties of the original collisions. Here we report the discovery of a family of asteroids that formed in a disruption event only 5.8 +/- 0.2 million years ago, and which has subsequently undergone little dynamical and collisional evolution(6,7). We identified 39 fragments, two of which are large and comparable in size (diameters of similar to19 and similar to14 km), with the remainder exhibiting a continuum of sizes in the range 2-7 km. The low measured ejection velocities suggest that gravitational reaccumulation after a collision may be a common feature of asteroid evolution. Moreover, these data can be used to check numerical models of larger-scale collisions(8).	SW Res Inst, Boulder, CO 80302 USA		Nesvorny, D (corresponding author), SW Res Inst, 1050 Walnut St,Suite 426, Boulder, CO 80302 USA.		Levison, Harold F/C-6061-2013	Levison, Harold F/0000-0001-5847-8099				Benz W, 1999, ICARUS, V142, P5, DOI 10.1006/icar.1999.6204; Binzel RP, 1996, SCIENCE, V273, P946, DOI 10.1126/science.273.5277.946; Bottke WF, 2001, SCIENCE, V294, P1693, DOI 10.1126/science.1066760; Canup RM, 2001, NATURE, V412, P708, DOI 10.1038/35089010; CLARK BE, IN PRESS ASTEROIDS, V3; DERMOTT SF, 1984, NATURE, V312, P505, DOI 10.1038/312505a0; Durda DD, 1998, ICARUS, V135, P431, DOI 10.1006/icar.1998.5960; Fujiwara A., 1989, ASTEROIDS, VII, P240; Grogan K, 2001, ICARUS, V152, P251, DOI 10.1006/icar.2001.6638; Hirayama K., 1918, ASTRON J, V31, P185, DOI [10.1086/104299, DOI 10.1086/104299]; Jedicke R, 1998, ICARUS, V131, P245, DOI 10.1006/icar.1997.5876; LEVISON HF, 1994, ICARUS, V108, P18, DOI 10.1006/icar.1994.1039; MARTI K, 1992, ANNU REV EARTH PL SC, V20, P221, DOI 10.1146/annurev.ea.20.050192.001253; MARZARI F, 1995, ICARUS, V113, P168, DOI 10.1006/icar.1995.1014; Michel P, 2001, SCIENCE, V294, P1696, DOI 10.1126/science.1065189; MILANI A, 1994, ICARUS, V107, P219, DOI 10.1006/icar.1994.1020; MILANI A, 1994, NATURE, V370, P40, DOI 10.1038/370040a0; MORBIDELLI A, 1995, ICARUS, V118, P132, DOI 10.1006/icar.1995.1181; Nesvorny D, 2002, ICARUS, V157, P155, DOI 10.1006/icar.2002.6830; ZAPPALA V, 1994, ASTRON J, V107, P772, DOI 10.1086/116897; ZAPPALA V, IN PRESS ASTEROIDS, V3; 2002, ASTEROIDS DYNAMIC SI; 2002, IAU MINOR PLANET CTR	25	184	185	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 13	2002	417	6890					720	722		10.1038/nature00789	http://dx.doi.org/10.1038/nature00789			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	561QY	12066178				2022-12-28	WOS:000176154700038
J	Ekins-Daukes, S; Simpson, CR; Helms, PJ; Taylor, MW; McLay, JS				Ekins-Daukes, S; Simpson, CR; Helms, PJ; Taylor, MW; McLay, JS			Burden of corticosteroids in children with asthma in primary care: retrospective observational study	BRITISH MEDICAL JOURNAL			English	Article									Univ Aberdeen, Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland; Univ Aberdeen, Dept Gen Practice & Primary Care, Aberdeen AB25 2ZD, Scotland; Univ Aberdeen, Dept Child Hlth, Aberdeen AB25 2ZD, Scotland	University of Aberdeen; University of Aberdeen; University of Aberdeen	McLay, JS (corresponding author), Univ Aberdeen, Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland.		Simpson, Colin R/L-7180-2014; Simpson, Colin/I-3974-2019	Simpson, Colin R/0000-0002-5194-8083; Simpson, Colin/0000-0002-5194-8083				Agertoft L, 2000, NEW ENGL J MED, V343, P1064, DOI 10.1056/NEJM200010123431502; *NIH, 1997, 2 NAT ASTHM ED PREV; Patel L, 2001, ARCH DIS CHILD, V85, P330, DOI 10.1136/adc.85.4.330; Wagener JS, 1998, J PEDIATR-US, V132, P381, DOI 10.1016/S0022-3476(98)70003-4; Whitelaw FG, 1996, BRIT J GEN PRACT, V46, P181	5	14	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 8	2002	324	7350					1374	1374		10.1136/bmj.324.7350.1374	http://dx.doi.org/10.1136/bmj.324.7350.1374			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BQ	12052808	Green Published, Bronze			2022-12-28	WOS:000176234100023
J	Suarez, PG; Floyd, K; Portocarrero, J; Alarcon, E; Rapiti, E; Ramos, G; Bonilla, C; Sabogal, I; Aranda, E; Dye, C; Raviglione, M; Espinal, MA				Suarez, PG; Floyd, K; Portocarrero, J; Alarcon, E; Rapiti, E; Ramos, G; Bonilla, C; Sabogal, I; Aranda, E; Dye, C; Raviglione, M; Espinal, MA			Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru	LANCET			English	Article							MULTIDRUG-RESISTANT TUBERCULOSIS; DYNAMICS; HEALTH	Background There are no data on the feasibility and cost-effectiveness of using second-line drugs to treat patients with chronic tuberculosis, many of whom are infected with multidrug resistant (MDR) strains of Mycobacterium tuberculosis, in low or middle-income countries. Methods A national programme to treat chronic tuberculosis patients with a directly observed standardised 18-month daily regimen, consisting of kanamycin (3 months only), ciprofloxacin, ethionamide, pyrazinamide, and ethambutol, was established in Peru in 1997. Compliance and treatment outcomes were analysed for the cohort started on treatment between October, 1997, and March, 1999. Total and average costs were assessed. Cost-effectiveness was estimated as the cost per DALY gained. Findings 466 patients were enrolled; 344 were tested for drug susceptibility and 298 (87%) had MDR tuberculosis. 225 patients (48%) were cured, 57 (12%) died, 131 (28%) did not respond to treatment, and 53 (11%) defaulted. Of the 413 (89%) patients who complied with treatment, 225 (55%) were cured. Among MDR patients, resistance to five or more drugs was significantly associated with an unfavourable outcome (death, non-response to treatment, or default; odds ratio 3.37, 95% CI 1.32-8.60; p=0.01). The programme cost US$0.6 million per year, 8% of the National Tuberculosis Programme budget, and US$2381 per patient for those who completed treatment. The mean cost per DALY gained was $211 ($165 at drug prices projected for 2002). Interpretation Treating chronic tuberculosis patients with high levels of MDR with second-line drugs can be feasible and cost-effective in middle-income countries, provided a strong tuberculosis control programme is in place.	Minist Hlth, Natl TB Control Programme, Lima, Peru		Espinal, MA (corresponding author), WHO, Stop TB Dept, CH-1211 Geneva, Switzerland.		Suarez, Pedro G/AAD-2278-2019; BONILLA-ASALDE, CÉSAR ANTONIO/AHH-6777-2022; Dye, Christopher/AIC-4659-2022	Suarez, Pedro G/0000-0001-9825-1761; BONILLA-ASALDE, CÉSAR ANTONIO/0000-0002-4470-1939; RAVIGLIONE, Mario/0000-0002-9331-2067; Dye, Christopher/0000-0002-2957-1793				[Anonymous], 1996, GLOBAL BURDEN DIS CO; Avendano M, 2000, Can Respir J, V7, P383; BAYONA J, 1999, INT C I TROP MED TUB; Chaulet P, 1996, DRUGS, V52, P103, DOI 10.2165/00003495-199600522-00021; de Jonghe E, 1994, Int J Health Plann Manage, V9, P151, DOI 10.1002/hpm.4740090204; Drummond MF, 2015, METHODS EC EVALUATIO; Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537; Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706; FARMER PE, 2000, J RESP DIS, V21, P53; Geerligs WA, 2000, INT J TUBERC LUNG D, V4, P758; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; Gold MR, 1996, COST EFFECTIVENESS H; Gupta R, 2001, SCIENCE, V293, P1049, DOI 10.1126/science.1061861; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; Lew W., 1996, THESIS LONDON SCH HY; LOPEZ AD, 2000, 9 GPE; *MIN SAL, 2000, PROGR NAC CONTR TUB; *MIN SAL, 1997, 1 EST VIG RES MED AN; *MIN SAL, 1998, TUB PER INF 1997; *MIN SAL, 1999, TUB PER INF 1998; *MIN SAL VIG USAID, 2001, IMP EC TUB PER 1999; Ministerio de Salud, 2001, ACT DOCTR NORM PROC; Murray CJL, 1998, INT J TUBERC LUNG D, V2, pS9; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; Pathania VS, 1999, VACCINE, V17, P1926, DOI 10.1016/S0264-410X(98)00462-9; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; SHEPARD DS, 1996, AIDS DEV ROL GOV C S; Styblo K, 1991, EPIDEMIOLOGY TUBERCU; Suarez PG, 2001, J INFECT DIS, V184, P473, DOI 10.1086/322777; Tahaoglu K, 2001, NEW ENGL J MED, V345, P170, DOI 10.1056/NEJM200107193450303; TELZAK EE, 1995, NEW ENGL J MED, V333, P907, DOI 10.1056/NEJM199510053331404; Vynnycky E, 1998, EPIDEMIOL INFECT, V121, P309, DOI 10.1017/S0950268898001113; White VLC, 2000, THORAX, V55, P962, DOI 10.1136/thorax.55.11.962; WHO, 1997, GUID MAN DRUG RES TU; *WHO, 1997, GLOB TUB PROGR TREAT; *WHO, 2001, COMM DIS PROGR GLOB; *WORLD BANK, 1993, WORLD DEV REP 1993 I; *WORLD BANK, 2001, PER DAT PROF; World Health Organization, 1996, INV HLTH RES DEV REP	39	201	208	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 8	2002	359	9322					1980	1989		10.1016/S0140-6736(02)08830-X	http://dx.doi.org/10.1016/S0140-6736(02)08830-X			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076553				2022-12-28	WOS:000176232500010
J	Zalaudek, I; Hofmann-Wellenhof, R; Cerroni, L; Kerl, H				Zalaudek, I; Hofmann-Wellenhof, R; Cerroni, L; Kerl, H			White dysplastic melanocytic naevi	LANCET			English	Article							NEVI	We describe three cases of a new variant of dysplastic melanocytic naevi (DMN), which is characterised by complete lack of pigmentation. Clinically, white DMN were non-pigmented white to pale-red macules with accentuated skin markings, and had a silvery, shiny appearance under tangential light. Histology showed characteristic features of DMN-ie, non-typical melanocytes arranged as solitary units and nests at the dermoepidermal junction and in the papillary dermis, and mild stromal changes. Association with malignant melanoma in all three patients emphasises the importance of this morphological type of DMN as a possible precursor to, or marker of, malignant melanoma.	Graz Univ, Dept Dermatol, A-8036 Graz, Austria	University of Graz	Zalaudek, I (corresponding author), Graz Univ, Dept Dermatol, A-8036 Graz, Austria.		Zalaudek, Iris/AAL-5436-2020; Zalaudek, Iris/E-5910-2010	Zalaudek, Iris/0000-0002-7878-4955; Zalaudek, Iris/0000-0002-7878-4955				ACKERMAN AB, 1990, AM J DERMATOPATH, V12, P193, DOI 10.1097/00000372-199004000-00012; Ackerman AB., 1994, PITFALLS HISTOPATHOL; GROSSHANS E, 1994, ANN DERMATOL VENER, V121, P7; HALL WH, 1992, JAMA-J AM MED ASSOC, V268, P1314, DOI 10.1001/jama.1992.03490100112037; Knoell KA, 1997, ARCH DERMATOL, V133, P992, DOI 10.1001/archderm.133.8.992	5	7	7	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 8	2002	359	9322					1999	2000		10.1016/S0140-6736(02)08834-7	http://dx.doi.org/10.1016/S0140-6736(02)08834-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076557				2022-12-28	WOS:000176232500014
J	[Anonymous]				[Anonymous]			Getting a handle on obesity	LANCET			English	Editorial Material																			0	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 8	2002	359	9322					1955	1955						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076544				2022-12-28	WOS:000176232500001
J	Reichow, MK; Saunders, AD; White, RV; Pringle, MS; Al'Mukhamedov, AI; Medvedev, AI; Kirda, NP				Reichow, MK; Saunders, AD; White, RV; Pringle, MS; Al'Mukhamedov, AI; Medvedev, AI; Kirda, NP			40Ar/39Ar dates from the West Siberian Basin: Siberian flood basalt province doubled	SCIENCE			English	Article							PERMIAN-TRIASSIC BOUNDARY; AGE; GEOCHRONOLOGY; IMPACT; TRAPS; PLUME	Widespread basaltic volcanism occurred in the region of the West Siberian Basin in central Russia during Permo-Triassic times. New 40Ar/39Ar age determinations on plagioclase grains from deep boreholes in the basin reveal that the basalts were erupted 249.4 +/- 0.5 million years ago. This is synchronous with the bulk of the Siberian Traps, erupted further east on the Siberian Platform. The age and geochemical data confirm that the West Siberian Basin basalts are part of the Siberian Traps and at least double the confirmed area of the volcanic province as a whole. The larger area of volcanism strengthens the link between the volcanism and the end-Permian mass extinction.	Univ Leicester, Dept Geol, Leicester LE1 7RH, Leics, England; SUERC, E Kilbride G75 0QF, Lanark, Scotland; Inst Geochem, Irkutsk 664033, Russia; Inst Geol Oil & Gas, Novosibirsk 630090, Russia	University of Leicester; Scottish Universities Research & Reactor Center; Irkutsk Science Centre of the Russian Academy of Sciences; A.P. Vinogradov Institute of Geochemistry of the Siberian Branch of the RAS; Russian Academy of Sciences; Trofimuk Institute of Petroleum Geology & Geophysics	Saunders, AD (corresponding author), Univ Leicester, Dept Geol, Leicester LE1 7RH, Leics, England.	ads@le.ac.uk	Pringle, Malcolm/ABD-5663-2020					ALMUKHAMEDOV AI, 1999, RUSS GEOL GEOPHYS, V40, P1550; BASU AR, 1995, SCIENCE, V269, P822, DOI 10.1126/science.269.5225.822; Becker L, 2001, SCIENCE, V291, P1530, DOI 10.1126/science.1057243; Bowring SA, 1998, SCIENCE, V280, P1039, DOI 10.1126/science.280.5366.1039; CAMPBELL IH, 1992, SCIENCE, V258, P1760, DOI 10.1126/science.258.5089.1760; Courtillot V, 1999, EVOLUTIONARY CATASTR; Courtillot Vincent, 1994, Israel Journal of Earth Sciences, V43, P255; DALRYMPLE GB, 1995, GEOCHIM COSMOCHIM AC, V59, P2071; ERWIN DH, 1994, NATURE, V367, P231, DOI 10.1038/367231a0; Farley KA, 2001, SCIENCE, V293, P2343; Fedorenko V.A., 1996, INT GEOL REV, V38, P99, DOI DOI 10.1080/00206819709465327; LIGHTFOOT PC, 1993, CONTRIB MINERAL PETR, V114, P171, DOI 10.1007/BF00307754; LURYE ML, 1964, FLOOD BASALTS, P13; Min KW, 2000, GEOCHIM COSMOCHIM AC, V64, P73, DOI 10.1016/S0016-7037(99)00204-5; Min KW, 2001, EARTH PLANET SC LETT, V185, P121, DOI 10.1016/S0012-821X(00)00365-4; MITCHELL C, 1994, MINERAL MAG A, V58, P617; Mundil R, 2001, EARTH PLANET SC LETT, V187, P131, DOI 10.1016/S0012-821X(01)00274-6; PRINGLE MS, 1995, TERRA NOVA, V3, P120; RENNE PR, 1991, SCIENCE, V253, P176, DOI 10.1126/science.253.5016.176; RENNE PR, 1995, EARTH PLANET SC LETT, V131, P165, DOI 10.1016/0012-821X(95)00015-5; RENNE PR, 1995, SCIENCE, V269, P1413, DOI 10.1126/science.269.5229.1413; Renne PR, 1998, CHEM GEOL, V145, P117, DOI 10.1016/S0009-2541(97)00159-9; Schissel D, 2001, GEOL SOC AM SPEC PAP, P291; Schmitz MD, 2001, GEOCHIM COSMOCHIM AC, V65, P2571, DOI 10.1016/S0016-7037(01)00616-0; Self S., 1997, GEOPH MONOG SERIES, V100, P381; SHARMA M, 1997, GEOPH MONOG SERIES, V100, P273; Twitchett RJ, 2001, GEOLOGY, V29, P351, DOI 10.1130/0091-7613(2001)029<0351:RASCOM>2.0.CO;2; Venkatesan TR, 1997, CHEM GEOL, V138, P303, DOI 10.1016/S0009-2541(97)00006-5; Westphal M, 1998, GEOPHYS J INT, V134, P254, DOI 10.1046/j.1365-246x.1998.00557.x; Wignall PB, 2001, EARTH-SCI REV, V53, P1, DOI 10.1016/S0012-8252(00)00037-4; YORK D, 1969, EARTH PLANET SC LETT, V5, P320; Zolotukhin V., 1988, CONTINENTAL FLOOD BA, P273	32	228	259	4	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	2002	296	5574					1846	1849		10.1126/science.1071671	http://dx.doi.org/10.1126/science.1071671			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052954	Green Accepted			2022-12-28	WOS:000176054300042
J	Stoll, S; Delon, J; Brotz, TM; Germain, RN				Stoll, S; Delon, J; Brotz, TM; Germain, RN			Dynamic imaging of T cell-dendritic cell interactions in lymph nodes	SCIENCE			English	Article							IN-VIVO; ANTIGEN PRESENTATION; IMMUNOLOGICAL SYNAPSE; LYMPHOCYTES; ACTIVATION; CD4; REDISTRIBUTION; INFECTION; IMMUNITY; MOESIN	T cell immune responses begin within organized lymphoid tissues. The pace, topology, and outcomes of the cellular interactions that underlie these responses have, so far, been inferred from static imaging of sectioned tissue or from studies of cultured cells. Here we report dynamic visualization of antigen-specific T cells interacting with dendritic cells within intact explanted lymph nodes. We observed immunological synapse formation and prolonged interactions between these two coil types, followed by the activation, dissociation, and rapid migration of T cells away from the antigenic stimulus. This high-resolution spatiotemporal analysis provides insight into the nature of cell interactions critical to early immune responses within lymphoid structures.	NIAID, Lymphocyte Biol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA; NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Germain, RN (corresponding author), NIAID, Lymphocyte Biol Sect, Immunol Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.		Germain, Ronald N./Z-1945-2019; Germain, Ronald/ABE-7090-2020; Brotz, Tilmann M/R-6599-2016	Brotz, Tilmann M/0000-0001-8212-459X; Delon, Jerome/0000-0003-0222-1192	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000545, ZIAAI000758, Z01AI000758, ZIAAI000545] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; CALDWELLCC, 2001, J IMMUNOL, V167, P6140; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; Delon J, 1998, J EXP MED, V188, P1473, DOI 10.1084/jem.188.8.1473; Delon J, 2001, IMMUNITY, V15, P691, DOI 10.1016/S1074-7613(01)00231-X; Delon J, 2000, CURR BIOL, V10, pR923, DOI 10.1016/S0960-9822(00)00870-8; Dustin ML, 1997, P NATL ACAD SCI USA, V94, P3909, DOI 10.1073/pnas.94.8.3909; Garside P, 1998, SCIENCE, V281, P96, DOI 10.1126/science.281.5373.96; Germain RN, 2001, SCIENCE, V293, P240, DOI 10.1126/science.1062946; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Gunzer M, 2000, IMMUNITY, V13, P323, DOI 10.1016/S1074-7613(00)00032-7; HOLLANDER GA, 1992, J IMMUNOL, V149, P438; Ingulli E, 1997, J EXP MED, V185, P2133, DOI 10.1084/jem.185.12.2133; Jenkins MK, 2001, ANNU REV IMMUNOL, V19, P23, DOI 10.1146/annurev.immunol.19.1.23; Krummel MF, 2000, SCIENCE, V289, P1349, DOI 10.1126/science.289.5483.1349; LIPSKY PE, 1975, J EXP MED, V141, P138, DOI 10.1084/jem.141.1.138; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Reichert P, 2001, J IMMUNOL, V166, P4278, DOI 10.4049/jimmunol.166.7.4278; Serrador JM, 1998, BLOOD, V91, P4632, DOI 10.1182/blood.V91.12.4632.412k17_4632_4644; So PTC, 2000, ANNU REV BIOMED ENG, V2, P399, DOI 10.1146/annurev.bioeng.2.1.399; Sousa CRE, 2001, IMMUNITY, V14, P495; Sousa CRE, 1999, CURR OPIN IMMUNOL, V11, P392, DOI 10.1016/S0952-7915(99)80066-1; SPRENT J, 1971, CELL IMMUNOL, V2, P171, DOI 10.1016/0008-8749(71)90036-0; STOLL S, UNPUB; Tanchot C, 2001, J IMMUNOL, V167, P2030, DOI 10.4049/jimmunol.167.4.2030; Valitutti S, 1996, EUR J IMMUNOL, V26, P2012, DOI 10.1002/eji.1830260907	28	563	592	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 7	2002	296	5574					1873	1876		10.1126/science.1071065	http://dx.doi.org/10.1126/science.1071065			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052961				2022-12-28	WOS:000176054300050
J	Queitsch, C; Sangster, TA; Lindquist, S				Queitsch, C; Sangster, TA; Lindquist, S			Hsp90 as a capacitor of phenotypic variation	NATURE			English	Article							ARABIDOPSIS-THALIANA; PLASTICITY; POPULATION; EVOLUTION; SELECTION; GENETICS; FAMILY; STRESS	Heat-shock protein 90 (Hsp90) chaperones the maturation of many regulatory proteins and, in the fruitfly Drosophila melanogaster, buffers genetic variation in morphogenetic pathways. Levels and patterns of genetic variation differ greatly between obligatorily outbreeding species such as fruitflies and self-fertilizing species such as the plant Arabidopsis thaliana. Also, plant development is more plastic, being coupled to environmental cues. Here we report that, in Arabidopsis accessions and recombinant inbred lines, reducing Hsp90 function produces an array of morphological phenotypes, which are dependent on underlying genetic variation. The strength and breadth of Hsp90's effects on the buffering and release of genetic variation suggests it may have an impact on evolutionary processes. We also show that Hsp90 influences morphogenetic responses to environmental cues and buffers normal development from destabilizing effects of stochastic processes. Manipulating Hsp90's buffering capacity offers a tool for harnessing cryptic genetic variation and for elucidating the interplay between genotypes, environments and stochastic events in the determination of phenotype.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Comm Genet, Chicago, IL 60637 USA	University of Chicago; Howard Hughes Medical Institute; University of Chicago	Lindquist, S (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.							ABBOTT RJ, 1989, HEREDITY, V62, P411, DOI 10.1038/hdy.1989.56; Alonso-Blanco C, 1998, PLANT J, V14, P259, DOI 10.1046/j.1365-313X.1998.00115.x; Ballare CL, 1999, TRENDS PLANT SCI, V4, P97, DOI 10.1016/S1360-1385(99)01383-7; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Callahan HS, 1997, BIOESSAYS, V19, P519, DOI 10.1002/bies.950190611; Donohue K, 2000, EVOLUTION, V54, P1956, DOI 10.1111/j.0014-3820.2000.tb01240.x; Dorn LA, 2000, EVOLUTION, V54, P1982, DOI 10.1111/j.0014-3820.2000.tb01242.x; DURRANT A, 1962, HEREDITY, V17, P27, DOI 10.1038/hdy.1962.2; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Hansen TF, 2000, J THEOR BIOL, V207, P495, DOI 10.1006/jtbi.2000.2189; KIMURA M, 1991, P NATL ACAD SCI USA, V88, P5969, DOI 10.1073/pnas.88.14.5969; Krishna P, 2001, CELL STRESS CHAPERON, V6, P238, DOI 10.1379/1466-1268(2001)006<0238:THFOPI>2.0.CO;2; Kuittinen H, 1997, HEREDITY, V79, P144, DOI 10.1038/hdy.1997.137; Ludwig MZ, 2000, NATURE, V403, P564, DOI 10.1038/35000615; MATHER K, 1953, HEREDITY, V7, P297, DOI 10.1038/hdy.1953.41; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; Mayfield JA, 2001, SCIENCE, V292, P2482, DOI 10.1126/science.1060972; McLaren A, 1999, TRENDS GENET, V15, P169, DOI 10.1016/S0168-9525(99)01732-1; Milioni D, 1997, PLANT MOL BIOL, V35, P955, DOI 10.1023/A:1005874521528; Pigliucci M, 1998, BIOL J LINN SOC, V64, P17, DOI 10.1006/bijl.1997.0193; Queitsch C, 2000, PLANT CELL, V12, P479, DOI 10.1105/tpc.12.4.479; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Stratton DA, 1998, HEREDITY, V81, P144, DOI 10.1046/j.1365-2540.1998.00369.x; Waddington CH, 1942, NATURE, V150, P563, DOI 10.1038/150563a0; WADDINGTON CH, 1953, EVOLUTION, V7, P118, DOI 10.2307/2405747; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	27	988	1041	1	141	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	2002	417	6889					618	624		10.1038/nature749	http://dx.doi.org/10.1038/nature749			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050657				2022-12-28	WOS:000176001200039
J	Soubeyrand, B; Plotkin, SA				Soubeyrand, B; Plotkin, SA			Microbial evolution - Antitoxin vaccines and pathogen virulence	NATURE			English	Article							DIPHTHERIA; PERTUSSIS		Aventis Pasteur, Dept Med Affairs, F-69007 Lyon, France; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Aventis Pasteur, Doylestown, PA 18901 USA	Sanofi-Aventis; Sanofi France; University of Pennsylvania; Sanofi-Aventis	Soubeyrand, B (corresponding author), Aventis Pasteur, Dept Med Affairs, F-69007 Lyon, France.							Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Bergamini M, 2000, EPIDEMIOL INFECT, V125, P105, DOI 10.1017/S0950268899004331; EWALD PW, 1996, CONCEPTS VACCINE DEV, P1; GALAZKA A, 2001, J INFECT DIS S, V181, P2; Gandon S, 2001, NATURE, V414, P751, DOI 10.1038/414751a; MORTIMER AE, 1999, VACCINES, P140; Pappenheimer AM., 1984, BACTERIAL VACCINES, P1; Schneerson R, 1996, LANCET, V348, P1289, DOI 10.1016/S0140-6736(96)05243-9; Taranger J, 2001, CLIN INFECT DIS, V33, P1004, DOI 10.1086/322639	9	18	18	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	2002	417	6889					609	610		10.1038/417609b	http://dx.doi.org/10.1038/417609b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050654				2022-12-28	WOS:000176001200036
J	Thomas, EJ; Studdert, DM; Brennan, TA				Thomas, EJ; Studdert, DM; Brennan, TA			The reliability of medical record review for estimating adverse event rates	ANNALS OF INTERNAL MEDICINE			English	Article							CARE; ERRORS; UTAH	Background: The data used by the U.S. Institute of Medicine to estimate deaths from medical errors come from a study that relied on nurse and physician reviews of medical records to detect the errors. Objective: To measure the reliability of medical record review for detecting adverse events and negligent adverse events. Design: medical record review. Setting: Hospitalizations in Utah and Colorado In 1992. Measurements: After three independent reviews of 500 medical records, the following were measured: reliability and the effect of varying criteria for reviewer confidence in and reviewer agreement about the presence of adverse events. Results: For agreements in judgments of adverse events among the three sets of reviews, the kappa statistics ranged from 0.40 to 0.41 (95% CIs ranged from 0.30 to 0.51) for adverse events and from 0.19 to 0.23 (CIs, 0.05 to 0.37) for negligent adverse events. Rates for adverse events and for negligent adverse events varied substantially depending on the degree of agreement and the level of confidence that was required among reviewers. Conclusion: Estimates of adverse event rates from medical record review, including those reported by the Institute of Medicine in its 2000 report on medical errors, are highly sensitive to the degree of consensus and confidence among reviewers.	Univ Texas, Houston Med Sch, Houston, TX 77030 USA; Harvard Univ, Birgham & Womens Hosp, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Boston, MA USA; Massachusetts Med Univ S Carolina, Charleston, SC USA	University of Texas System; University of Texas Health Science Center Houston; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Medical University of South Carolina	Thomas, EJ (corresponding author), Univ Texas, Houston Med Sch, 6431 Fannin MSB 1-122, Houston, TX 77030 USA.		Studdert, David/AAF-3116-2021	Studdert, David/0000-0003-0585-5537				BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BLUMENTHAL D, 1994, JAMA-J AM MED ASSOC, V272, P1867, DOI 10.1001/jama.272.23.1867; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1989, MED CARE, V27, P1148, DOI 10.1097/00005650-198912000-00006; ELMORE JG, 1992, J CLIN EPIDEMIOL, V45, P567, DOI 10.1016/0895-4356(92)90128-A; Hayward RA, 2001, JAMA-J AM MED ASSOC, V286, P415, DOI 10.1001/jama.286.4.415; Hofer TP, 2000, MED CARE, V38, P152, DOI 10.1097/00005650-200002000-00005; Kohn KT, 2000, ERR IS HUMAN BUILDIN; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; Leape LL, 2000, JAMA-J AM MED ASSOC, V284, P95, DOI 10.1001/jama.284.1.95; Localio AR, 1996, ANN INTERN MED, V125, P457, DOI 10.7326/0003-4819-125-6-199609150-00005; ONEIL AC, 1993, ANN INTERN MED, V119, P370, DOI 10.7326/0003-4819-119-5-199309010-00004; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Thomas EJ, 1999, INQUIRY-J HEALTH CAR, V36, P255; Thomas EJ, 2000, MED CARE, V38, P261, DOI 10.1097/00005650-200003000-00003; Wilson RM, 1995, MED J AUSTRALIA, V163, P458, DOI 10.5694/j.1326-5377.1995.tb124691.x	16	197	203	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 4	2002	136	11					812	816		10.7326/0003-4819-136-11-200206040-00009	http://dx.doi.org/10.7326/0003-4819-136-11-200206040-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558KG	12044129				2022-12-28	WOS:000175964500004
J	Shao, F; Merritt, PM; Bao, ZQ; Innes, RW; Dixon, JE				Shao, F; Merritt, PM; Bao, ZQ; Innes, RW; Dixon, JE			A Yersinia effector and a pseudomonas avirulence protein define a family of cysteine proteases functioning in bacterial pathogenesis	CELL			English	Article							SYRINGAE PV PHASEOLICOLA; DISEASE RESISTANCE; VIRULENCE PLASMID; ESCHERICHIA-COLI; RHO GTPASES; GENE; PSEUDOTUBERCULOSIS; BINDING; KINASE; IDENTIFICATION	A Yersinia effector known as YopT and a Pseudomonas avirulence protein known as AvrPphB define a family of 19 proteins involved in bacterial pathogenesis. We show that both YopT and AvrPphB are cysteine proteases, and their proteolytic activities are dependent upon the invariant C/H/D residues conserved in the entire YopT family. YopT cleaves the posttranslationally modified Rho GTPases near their carboxyl termini, releasing them from the membrane. This leads to the disruption of actin cytoskeleton in host cells. The proteolytic activity of AvrPphB is essential for autoproteolytic cleavage of an AvrPphB precursor as well as for eliciting the hypersensitive response in plants. These findings provide new insights into mechanisms of animal and plant pathogenesis.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Indiana University System; Indiana University Bloomington	Dixon, JE (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	jedixon@umich.edu	Innes, Roger/A-5244-2010	Innes, Roger/0000-0001-9634-1413	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046451, R29GM046451] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46451] Funding Source: Medline; PHS HHS [18024] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aktories K, 2000, BIOL CHEM, V381, P421, DOI 10.1515/BC.2000.054; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arabidopsis Genome Initiative, 2000, Nature (London), V408, P796, DOI 10.1038/35048692; Barrett AJ, 2001, BIOL CHEM, V382, P727, DOI 10.1515/BC.2001.088; Black DS, 2000, MOL MICROBIOL, V37, P515, DOI 10.1046/j.1365-2958.2000.02021.x; Bonas U, 2002, CURR OPIN MICROBIOL, V5, P44, DOI 10.1016/S1369-5274(02)00284-9; Boquet P, 2000, MICROBES INFECT, V2, P837, DOI 10.1016/S1286-4579(00)90369-1; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Cheng LW, 2000, TRENDS MICROBIOL, V8, P214, DOI 10.1016/S0966-842X(99)01665-0; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; Collmer A, 2000, P NATL ACAD SCI USA, V97, P8770, DOI 10.1073/pnas.97.16.8770; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Figueroa C, 2001, J BIOL CHEM, V276, P28219, DOI 10.1074/jbc.M101763200; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; GALYOV EE, 1993, NATURE, V361, P730, DOI 10.1038/361730a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; HANCOCK JF, 1995, METHOD ENZYMOL, V255, P237; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Innes RW, 2001, MOL PLANT PATHOL, V2, P109, DOI 10.1046/j.1364-3703.2001.00057.x; Iriarte M, 1998, MOL MICROBIOL, V29, P915, DOI 10.1046/j.1365-2958.1998.00992.x; JENNER C, 1991, MOL PLANT MICROBE IN, V4, P553, DOI 10.1094/MPMI-4-553; Jia Y, 2000, EMBO J, V19, P4004, DOI 10.1093/emboj/19.15.4004; Juris SJ, 2000, P NATL ACAD SCI USA, V97, P9431, DOI 10.1073/pnas.170281997; Juris SJ, 2002, CELL MICROBIOL, V4, P201, DOI 10.1046/j.1462-5822.2002.00182.x; Lerm M, 2000, FEMS MICROBIOL LETT, V188, P1; Lesser CF, 2001, EMBO J, V20, P1840, DOI 10.1093/emboj/20.8.1840; Nicholls L, 2000, MOL MICROBIOL, V35, P275, DOI 10.1046/j.1365-2958.2000.01690.x; Nimchuk Z, 2000, CELL, V101, P353, DOI 10.1016/S0092-8674(00)80846-6; Orbach MJ, 2000, PLANT CELL, V12, P2019, DOI 10.1105/tpc.12.11.2019; Orth K, 2000, SCIENCE, V290, P1594, DOI 10.1126/science.290.5496.1594; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Orth K, 2002, CURR OPIN MICROBIOL, V5, P38, DOI 10.1016/S1369-5274(02)00283-7; Palmer LE, 1998, MOL MICROBIOL, V27, P953, DOI 10.1046/j.1365-2958.1998.00740.x; Puri N, 1997, MOL PLANT MICROBE IN, V10, P247, DOI 10.1094/MPMI.1997.10.2.247; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; ROSQVIST R, 1988, INFECT IMMUN, V56, P2139, DOI 10.1128/IAI.56.8.2139-2143.1988; ROSQVIST R, 1990, MOL MICROBIOL, V4, P657, DOI 10.1111/j.1365-2958.1990.tb00635.x; SASAKI T, 1993, J BIOL CHEM, V268, P23959; SIMONICH MT, 1995, MOL PLANT MICROBE IN, V8, P637, DOI 10.1094/MPMI-8-0637; SMITH MJ, 1993, TETRAHEDRON LETT, V34, P223, DOI 10.1016/S0040-4039(00)60552-X; Sorg I, 2001, INFECT IMMUN, V69, P7535, DOI 10.1128/IAI.69.12.7535-7543.2001; Swiderski MR, 2001, PLANT J, V26, P101, DOI 10.1046/j.1365-313x.2001.01014.x; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; von Pawel-Rammingen U, 2000, MOL MICROBIOL, V36, P737, DOI 10.1046/j.1365-2958.2000.01898.x; Warren RF, 1999, GENETICS, V152, P401; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zumbihl R, 1999, J BIOL CHEM, V274, P29289, DOI 10.1074/jbc.274.41.29289	54	361	382	0	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 31	2002	109	5					575	588		10.1016/S0092-8674(02)00766-3	http://dx.doi.org/10.1016/S0092-8674(02)00766-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	558GL	12062101	Bronze			2022-12-28	WOS:000175957900007
J	Rugg-Gunn, FJ; Eriksson, SH; Symms, MR; Barker, GJ; Thom, M; Harkness, W; Duncan, JS				Rugg-Gunn, FJ; Eriksson, SH; Symms, MR; Barker, GJ; Thom, M; Harkness, W; Duncan, JS			Diffusion tensor imaging in refractory epilepsy	LANCET			English	Article								Diffusion tensor Imaging Is an Imaging method that Is sensitive to the molecular movement of water, which Indicates cellular Integrity and pathology. A patient with refractory epilepsy and normal conventional MRI was examined with diffusion tensor Imaging. An area of abnormal diffusion In the right frontal lobe was Identified and surgically resected. The patient had a good clinical outcome. Histopathological examination of the resected tissue showed gliosis. Our findings may affect the Investigation of similar patients, and provide histopathological confirmation of diffusion abnormalities.	Natl Soc Epilepsy & Res, MRI Unit, Dept Clin & Expt Epilepsy, London, England; Inst Neurol, Dept Neuroimmunol Neuroinflammat & Multiple Scler, NMR Res Unit, London WC1N 3BG, England; UCL, Natl Hosp Neurol & Neurosurg, London, England	University of London; University College London; University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Duncan, JS (corresponding author), Natl Soc Epilepsy, Gerrards Cross SL9 0RJ, Bucks, England.	j.duncan@ion.ucl.ac.uk	Barker, Gareth J/C-9616-2009	Barker, Gareth J/0000-0002-5214-7421; Duncan, John S/0000-0002-1373-0681	MRC [G9805989] Funding Source: UKRI; Medical Research Council [G9805989] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Rugg-Gunn FJ, 2001, BRAIN, V124, P627, DOI 10.1093/brain/124.3.627; Vinters Harry V., 1993, P593; ZENTNER J, 1995, J NEUROL NEUROSUR PS, V58, P666, DOI 10.1136/jnnp.58.6.666	5	73	79	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 18	2002	359	9319					1748	1751		10.1016/S0140-6736(02)08615-4	http://dx.doi.org/10.1016/S0140-6736(02)08615-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049867				2022-12-28	WOS:000175740500015
J	Mahon, MJ; Donowitz, M; Yun, CC; Segre, GV				Mahon, MJ; Donowitz, M; Yun, CC; Segre, GV			Na+/H+ exchanger regulatory factor 2 directs parathyroid hormone 1 receptor signalling	NATURE			English	Article							OK CELLS; PROTEIN-BINDING; PHOSPHOLIPASE-C; PEPTIDE; DOMAIN; PDZ; INHIBITION; TRANSPORT; CALCIUM; PTH		Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21205 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Johns Hopkins University	Segre, GV (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.				NIDDK NIH HHS [P01 DK044484, R01 DK061418] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044484, R01DK061418] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Amizuka N, 1997, ENDOCRINOLOGY, V138, P469, DOI 10.1210/en.138.1.469; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Bringhurst FR, 2001, PARATHYROIDS BASIC C, P227; CLEMENS TL, 2001, PARATHYROIDS, P261; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; GAICH G, 1993, ENDOCRINOLOGY, V132, P1402, DOI 10.1210/en.132.3.1402; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; IIDAKLEIN A, 1995, J BIOL CHEM, V270, P8458, DOI 10.1074/jbc.270.15.8458; Isales CM, 2000, AM J PHYSIOL-ENDOC M, V279, pE654, DOI 10.1152/ajpendo.2000.279.3.E654; KAUFMANN M, 1994, ENDOCRINOLOGY, V134, P1173, DOI 10.1210/en.134.3.1173; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; KRAYERPAWLOWSKA D, 1991, J MEMBRANE BIOL, V120, P173, DOI 10.1007/BF01872400; Marcus R, 2001, PARATHYROIDS BASIC C, P93; MCCAULEY LK, 1992, ENDOCRINOLOGY, V130, P300, DOI 10.1210/en.130.1.300; MIYAUCHI A, 1990, AM J PHYSIOL, V259, pF485, DOI 10.1152/ajprenal.1990.259.3.F485; ORLOFF JJ, 1992, AM J PHYSIOL, V262, pE599, DOI 10.1152/ajpendo.1992.262.5.E599; RESHKIN SJ, 1991, J MEMBRANE BIOL, V124, P227, DOI 10.1007/BF01994356; SCHLUTER KD, 1995, BIOCHEM J, V310, P439, DOI 10.1042/bj3100439; Segre G. V., 2001, PARATHYROIDS BASIC C, P245; SMOGORZEWSKI M, 1993, AM J PHYSIOL, V264, pH1998, DOI 10.1152/ajpheart.1993.264.6.H1998; Strewler GJ, 2001, PARATHYROIDS BASIC C, P213; Sutliff RL, 1999, ENDOCRINOLOGY, V140, P2077, DOI 10.1210/en.140.5.2077; TANAKA H, 1995, AM J PHYSIOL-RENAL, V268, pF330, DOI 10.1152/ajprenal.1995.268.2.F330; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Traebert M, 2000, AM J PHYSIOL-RENAL, V278, pF792, DOI 10.1152/ajprenal.2000.278.5.F792; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Wade JB, 2001, AM J PHYSIOL-CELL PH, V280, pC192, DOI 10.1152/ajpcell.2001.280.1.C192; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; YAMAMOTO I, 1988, ENDOCRINOLOGY, V122, P1208, DOI 10.1210/endo-122-4-1208; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	31	237	242	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 20	2002	417	6891					858	861		10.1038/nature00816	http://dx.doi.org/10.1038/nature00816			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075354				2022-12-28	WOS:000176285600049
J	Biedermann, BC; Sahner, S; Gregor, M; Tsakiris, DA; Jeanneret, C; Pober, JS; Gratwohl, A				Biedermann, BC; Sahner, S; Gregor, M; Tsakiris, DA; Jeanneret, C; Pober, JS; Gratwohl, A			Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease	LANCET			English	Article							BONE-MARROW TRANSPLANTATION; IDENTIFICATION; APOPTOSIS; CELLS; DNA	Background Vascular endothelial cells form the interface between recipient tissues and circulating alloreactive donor T cells after allogeneic stem cell transplantation. Vascular injury has been seen in patients with acute graft versus host disease (GVHD) in the skin. We aimed to see whether vascular injury mediated by cytotoxic T lymphocytes and microvessel loss arises in patients with chronic GVHD. Methods We investigated eight patients with acute GVHD and ten with chronic GVHD for signs of endothelial injury and microvessel loss by measurement of von Willebrand factor (vWF) in plasma and blood vessel density in biopsy samples taken from lesional skin. Controls consisted of nine patients without GVHD who survived for longer than 100 days and nine healthy people. Inflammation and endothelial injury were assessed in selected samples by immunostaining for CD8 T cells, activated cytotoxic T lymphocytes, and vascular endothelial cells. Findings We identified more extensive loss of microvessels in the skin of patients with GVHD (median 66 capilllaries/mm(2); IQR 16-98) than of healthy controls (205 capilliaries/mm(2); 157-226; p=0.005). Patients with GVHD had higher concentrations of vWF (238%; 168-288) than did those without GVHD (102%; 88-118; p=0.0005). Perivascular CD8 T cell infiltrates in skin correlated with vWF plasma concentrations in patients with GVHD (p=0.01), and activated cytotoxic T lymphocytes and endothelial injury were present in these same samples. Interpretation Host endothelial cells are a target of alloreactive donor cytotoxic T lymphocytes. Substantial blood vessel loss may lead to impaired blood perfusion and tissue fibrosis, the hallmark lesion of chronic GVHD.	Univ Hosp Bruderholz, Dept Med, CH-4101 Bruderholz, Switzerland; Univ Hosp, Dept Res, Basel, Switzerland; Univ Hosp, Div Haematol, Basel, Switzerland; Cantonal Inst Pathol, Liestal, Switzerland; Yale Univ, Sch Med, Boyer Ctr Mol Med, New Haven, CT USA	Yale University	Biedermann, BC (corresponding author), Univ Hosp Bruderholz, Dept Med, CH-4101 Bruderholz, Switzerland.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062188] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62188] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; Artlett CM, 1998, NEW ENGL J MED, V338, P1186, DOI 10.1056/NEJM199804233381704; ATKINSON K, 1986, BRIT J DERMATOL, V114, P145, DOI 10.1111/j.1365-2133.1986.tb02793.x; BLANN AD, 1995, BRIT J HAEMATOL, V90, P244, DOI 10.1111/j.1365-2141.1995.tb05143.x; Dong CM, 1996, LAB INVEST, V74, P921; DUMLER JS, 1989, AM J PATHOL, V135, P1097; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Goldman JM, 1998, BONE MARROW TRANSPL, V21, P1, DOI 10.1038/sj.bmt.1701089; Gouw ASH, 2002, TRANSPLANTATION, V73, P243, DOI 10.1097/00007890-200201270-00016; GRATWHOL AA, 1977, ANN INTERN MED, V87, P703, DOI 10.7326/0003-4819-87-6-703; HRUBAN RH, 1990, AM J PATHOL, V137, P871; Libby P, 2001, IMMUNITY, V14, P387, DOI 10.1016/S1074-7613(01)00119-4; Majolino I, 1996, BONE MARROW TRANSPL, V17, P555; Meehan SM, 1997, LAB INVEST, V76, P639; Nelson JL, 1998, LANCET, V351, P559, DOI 10.1016/S0140-6736(97)08357-8; Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; Socie G, 1999, NEW ENGL J MED, V341, P14, DOI 10.1056/NEJM199907013410103; TSAKIRIS DA, 1995, SCHWEIZ MED WSCHR, V125, P416; Vogelsang GB, 2001, BLOOD, V97, P1196, DOI 10.1182/blood.V97.5.1196; Zecca M, 2000, Paediatr Drugs, V2, P29	21	191	202	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 15	2002	359	9323					2078	2083		10.1016/S0140-6736(02)08907-9	http://dx.doi.org/10.1016/S0140-6736(02)08907-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086762				2022-12-28	WOS:000176194600010
J	Lin, AM; Fu, BH; Guo, JM; Zeng, QL; Dang, GM; He, WG; Zhao, Y				Lin, AM; Fu, BH; Guo, JM; Zeng, QL; Dang, GM; He, WG; Zhao, Y			Co-seismic strike-stip and rupture length produced by the 2001 M-s 8.1 Central Kunlun earthquake	SCIENCE			English	Article							TIBET; TECTONICS; ASIA; DEFORMATION; KINEMATICS; COLLISION; EURASIA; INDIA; FAULT	Field investigations show that the surface wave magnitude (M-s) 8.1 Central Kunlun earthquake (Tibetan plateau) of 14 November 2001 produced a nearly 400-kilometer-long surface rupture zone, with as much as 16.3 meters of left-lateral strike-slip along the active Kunlun fault in northern Tibet. The rupture length and maximum displacement are the largest among the co-seismic surface rupture zones reported on so far. The strike-slip motion and the large rupture length generated by the earthquake indicate that the Kunlun fault partitions its deformation into an eastward extrusion of Tibet to accommodate the continuing penetration of the Indian plate into the Eurasian plate.	Shizuoka Univ, Fac Sci, Inst Geosci, Shizuoka 4228529, Japan; Chinese Acad Sci, Lanzhou Inst Geol, Lanzhou 730000, Peoples R China; Chinese Acad Geol Sci, Inst Geomech, Beijing 100081, Peoples R China; Seismol Inst Lanzhou, Lanzhou 730000, Peoples R China; Seismol Bur Qinghai Prov, Xining, Peoples R China	Shizuoka University; Chinese Academy of Sciences; Institute of Geology & Geophysics, CAS; Chinese Academy of Geological Sciences	Lin, AM (corresponding author), Shizuoka Univ, Fac Sci, Inst Geosci, 836 Ohya, Shizuoka 4228529, Japan.	slin@ipc.shizuoka.ac.jp	Guo, Jianming/F-4425-2016; Zhao, Yue/K-3287-2012	Guo, Jianming/0000-0002-3652-5816; 				[Anonymous], [No title captured]; AVOUAC JP, 1993, GEOPHYS RES LETT, V20, P895, DOI 10.1029/93GL00128; *CCDSN, 2002, MOM TENS SOL QINGH X; *CHIN SEISM BUR, 2002, 2001 QINGH MS 8 1 EA; *HARV U, 2002, M111401A HARV U; JIA Y, 1988, RES EARTHQUAKE FAULT, P66; KIDD WSF, 1988, PHILOS T R SOC A, V327, P337, DOI 10.1098/rsta.1988.0133; KIKUCHI M, 2002, 111 ERI U TOK; Larson KM, 1999, J GEOPHYS RES-SOL EA, V104, P1077, DOI 10.1029/1998JB900043; Meyer B, 1998, GEOPHYS J INT, V135, P1, DOI 10.1046/j.1365-246X.1998.00567.x; MOLNAR P, 1987, GEOLOGY, V15, P249, DOI 10.1130/0091-7613(1987)15<249:GEFAFI>2.0.CO;2; MOLNAR P, 1978, J GEOPHYS RES, V83, P5361, DOI 10.1029/JB083iB11p05361; MOLNAR P, 1975, SCIENCE, V189, P419, DOI 10.1126/science.189.4201.419; Peltzer G, 1999, SCIENCE, V286, P272, DOI 10.1126/science.286.5438.272; Peltzer G, 1996, J GEOPHYS RES-SOL EA, V101, P27943, DOI 10.1029/96JB02698; Shen ZK, 2001, J GEOPHYS RES-SOL EA, V106, P30607, DOI 10.1029/2001JB000349; *USGS, 2002, RAP MOM TENS SOL SO; Van der Woerd J, 1998, GEOLOGY, V26, P695, DOI 10.1130/0091-7613(1998)026<0695:HLSRDB>2.3.CO;2; Van der Woerd J, 2000, GEOPHYS RES LETT, V27, P2353, DOI 10.1029/1999GL011292; Wang Q, 2001, SCIENCE, V294, P574, DOI 10.1126/science.1063647; Yeats R.S., 1997, GEOLOGY EARTHQUAKES; ZHAO G, 1996, EARTHQUAKE RES CHINA, V12, P107	22	189	258	7	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 14	2002	296	5575					2015	2017		10.1126/science.1070879	http://dx.doi.org/10.1126/science.1070879			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065833				2022-12-28	WOS:000176273300049
J	Leach, MJ				Leach, MJ			Retinal hemorrhages in acute leukemia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									N Glasgow Univ Hosp NHS Trust, Glasgow G21 3UW, Lanark, Scotland	University of Glasgow	Leach, MJ (corresponding author), N Glasgow Univ Hosp NHS Trust, Glasgow G21 3UW, Lanark, Scotland.								0	1	1	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	2002	346	23					E6	E6		10.1056/ENEJMicm971009	http://dx.doi.org/10.1056/ENEJMicm971009			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	559EK	12050334				2022-12-28	WOS:000176012500007
J	Chaiyakunapruk, N; Veenstra, DL; Lipsky, BA; Saint, S				Chaiyakunapruk, N; Veenstra, DL; Lipsky, BA; Saint, S			Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: A meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Article							CENTRAL VENOUS CATHETERS; BLOOD-STREAM INFECTION; PROSPECTIVE RANDOMIZED TRIAL; CRITICALLY-ILL PATIENTS; PREVENTION; MORTALITY; CONSEQUENCES; DISINFECTION; ANAPHYLAXIS; CULTURES	Purpose: Bloodstream infections related to use of catheters, particularly central-line catheters, are an important cause of patient morbidity, mortality, and increased health care costs. This study evaluated the efficacy of skin disinfection with chlorhexidine gluconate compared with povidone-iodine solution in preventing catheter-related bloodstream infection. Data Sources: Multiple computerized databases (1966 to 2001), reference lists of identified articles, and queries of principal investigators and antiseptic manufacturers. Study Selection: Randomized, controlled trials comparing chlorhexidine gluconate with povidone-iodine solutions for catheter-site care. Data Extraction: Using a standardized form, two reviewers abstracted data on study design, patient population, intervention, and incidence of catheter-related bloodstream infection from all included studies. Data Synthesis: Eight studies involving a total of 4143 catheters met the inclusion criteria. All studies were concluded in a hospital setting, and various catheter types were used. The summary risk ratio for catheter-related bloodstream infection was 0.49 (95% CI, 0.28 to 0.88) in patients whose catheter sites were disinfected with chlorhexidine gluconate Instead of povidone-iodine. Among patients with a central vascular catheter, chlorhexidine gluconate reduced the risk for catheter-related bloodstream infection by 49% (risk ratio, 0.51 [CI 0.27 to 0.97]). Conclusions: These results suggest that incidence of bloodstream infections is significantly reduced In patients with central vascular lines who receive chlorhexidine gluconate versus povidone-iodine for insertion-site skin disinfection. Use of chlorhexidine gluconate is a simple and effective means of reducing vascular catheter-related infections.	Naresuan Univ, Pitsanuloak, Thailand; Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA; Univ Michigan, Ann Arbor, MI 48109 USA; Ann Arbor Vet Adm Med Ctr, Ann Arbor, MI USA	Naresuan University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Michigan System; University of Michigan	Veenstra, DL (corresponding author), Univ Washington, Pharmaceut Outcomes Res & Policy Program, Box 357630, Seattle, WA 98195 USA.	veenstra@u.washington.edu	Saint, Sanjay/AAF-5126-2019	Lipsky, Benjamin A./0000-0001-9886-5114				ARNOW PM, 1993, CLIN INFECT DIS, V16, P778, DOI 10.1093/clind/16.6.778; AYLIFFE GAJ, 1984, INFECT CONT HOSP EP, V5, P23, DOI 10.1017/S0195941700058756; BRUNBUISSON C, 1987, ARCH INTERN MED, V147, P873, DOI 10.1001/archinte.147.5.873; CLEMENCE MA, 1995, AM J INFECT CONTROL, V23, P5, DOI 10.1016/0196-6553(95)90002-0; Darouiche RO, 1999, NEW ENGL J MED, V340, P1, DOI 10.1056/NEJM199901073400101; DENTON GW, 1991, DISINFECTION STERILI, P274; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Ebo DG, 1998, J ALLERGY CLIN IMMUN, V101, P128, DOI 10.1016/S0091-6749(98)70205-2; Gottardi W, 1991, DISINFECTION STERILI, P151; HALEY RW, 1980, J INFECT DIS, V141, P248, DOI 10.1093/infdis/141.2.248; Humar A, 2000, CLIN INFECT DIS, V31, P1001, DOI 10.1086/318145; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; LARSSON HBW, 1992, MAGN RESON IMAGING, V10, P7, DOI 10.1016/0730-725X(92)90367-9; LEBLANC A, 1999, CANADIAN INTRAVENOUS, V15, P48; Legras A, 1997, REANIMATION URGENCES, V6, P5; Light RJ, 1984, SUMMING SCI REVIEWIN; LOWBURY EJL, 1974, BRIT J SURG, V61, P19, DOI 10.1002/bjs.1800610106; MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; Mallaret MR, 1997, MED MALADIES INFECT, V27, P827, DOI 10.1016/S0399-077X(97)80054-6; MARTIN MA, 1989, ANN INTERN MED, V110, P9, DOI 10.7326/0003-4819-110-1-9; Meffre C, 1995, HYGIENES, V9, P45; Mimoz O, 1996, CRIT CARE MED, V24, P1818, DOI 10.1097/00003246-199611000-00010; OKANO M, 1989, ARCH DERMATOL, V125, P50, DOI 10.1001/archderm.125.1.50; PEACOCK SJ, 1995, LANCET, V346, P191, DOI 10.1016/S0140-6736(95)91254-1; Pearson ML, 1996, AM J INFECT CONTROL, V24, P262; PETITTI DB, 2000, METANALAYSIS DECISIO; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; Raad I, 1998, LANCET, V351, P893, DOI 10.1016/S0140-6736(97)10006-X; RUSSELL AD, 1993, J HOSP INFECT, V25, P229, DOI 10.1016/0195-6701(93)90109-D; Saint S, 2000, INFECT CONT HOSP EP, V21, P375, DOI 10.1086/501776; Sheehan G, 1993, INT C ANT AG CHEM WA, P414; SHELTON DM, 1991, ADV PERIT D, V7, P120; SMITH RL, 1991, CHEST, V100, P164, DOI 10.1378/chest.100.1.164; SMYLIE HG, 1973, BMJ-BRIT MED J, V4, P586, DOI 10.1136/bmj.4.5892.586; Snellman E, 1999, J AM ACAD DERMATOL, V40, P771, DOI 10.1016/S0190-9622(99)70164-7; Torricelli R, 1996, CLIN EXP ALLERGY, V26, P112, DOI 10.1111/j.1365-2222.1996.tb00064.x; Veenstra DL, 1999, JAMA-J AM MED ASSOC, V281, P261, DOI 10.1001/jama.281.3.261; Veenstra DL, 1999, JAMA-J AM MED ASSOC, V282, P554, DOI 10.1001/jama.282.6.554; YONG D, 1995, MED J AUSTRALIA, V162, P257, DOI 10.5694/j.1326-5377.1995.tb139880.x; ZAMORA JL, 1985, SURGERY, V98, P25	41	377	394	0	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 4	2002	136	11					792	801		10.7326/0003-4819-136-11-200206040-00007	http://dx.doi.org/10.7326/0003-4819-136-11-200206040-00007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558KG	12044127				2022-12-28	WOS:000175964500002
J	Reynolds, EH				Reynolds, EH			Folic acid, ageing, depression, and dementia	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NUTRITIONAL-STATUS; FOLATE-DEFICIENCY; MENTAL-DISORDERS; HOMOCYSTEINE; VITAMIN-B-12; METHYLATION; ENHANCEMENT; DISEASE		Kings Coll London, Inst Epileptol, London SE5 9PJ, England	University of London; King's College London	Reynolds, EH (corresponding author), Kings Coll London, Inst Epileptol, London SE5 9PJ, England.	reynolds@buckles.u-net.com						Botez M.I., 1979, FOLIC ACID NEUROLOGY; BOTEZ MI, 1977, EUR NEUROL, V16, P230, DOI 10.1159/000114904; BOTEZ MI, 1979, FOLIC ACID NEUROLOGY, P435; BOTTIGLIERI T, 1990, J NEUROL NEUROSUR PS, V53, P1096, DOI 10.1136/jnnp.53.12.1096; Bottiglieri T, 2000, J NEUROL NEUROSUR PS, V69, P228, DOI 10.1136/jnnp.69.2.228; Bottiglieri T, 2000, J NEUROL NEUROSUR PS, V69, P562; BOTTIGLIERI T, 1995, FOLATE HLTH DIS, P435; BROCKER P, 1986, SEM HOP PARIS, V62, P2135; CARNEY MWP, 1990, J AFFECT DISORDERS, V19, P207, DOI 10.1016/0165-0327(90)90093-N; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; Coppen A, 2000, J AFFECT DISORDERS, V60, P121, DOI 10.1016/S0165-0327(00)00153-1; COPPEN A, 1986, J AFFECT DISORDERS, V10, P9, DOI 10.1016/0165-0327(86)90043-1; GODFREY PSA, 1990, LANCET, V336, P392, DOI 10.1016/0140-6736(90)91942-4; GOODWIN JS, 1983, JAMA-J AM MED ASSOC, V249, P2917, DOI 10.1001/jama.249.21.2917; HOMMES OR, 1979, FOLIC ACID NEUROLOGY; LaRue A, 1997, AM J CLIN NUTR, V65, P20, DOI 10.1093/ajcn/65.1.20; PASSERI M, 1993, AGING-CLIN EXP RES, V5, P63, DOI 10.1007/BF03324128; RAPIN JR, 1988, TRENDS BIOMED GERONT, V1, P221; REYNOLDS EH, 1973, BRIT MED J, V2, P398, DOI 10.1136/bmj.2.5863.398; REYNOLDS EH, 1968, BRAIN, V91, P197, DOI 10.1093/brain/91.2.197; Reynolds EH, 2002, J NEUROL NEUROSUR PS, V72, P567, DOI 10.1136/jnnp.72.5.567; REYNOLDS EH, 1984, LANCET, V2, P196; REYNOLDS EH, 1970, BRIT J PSYCHIAT, V117, P287, DOI 10.1192/S0007125000193250; Riggs KM, 1996, AM J CLIN NUTR, V63, P306, DOI 10.1093/ajcn/63.3.306; RUNCIE J, 1979, FOLIC ACID NEUROLOGY, P493; Selhub J, 2000, AM J CLIN NUTR, V71, p614S; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; SHORVON SD, 1980, BRIT MED J, V281, P1036, DOI 10.1136/bmj.281.6247.1036; SNEATH P, 1973, Age and Ageing, V2, P177, DOI 10.1093/ageing/2.3.177; Snowdon DA, 2000, AM J CLIN NUTR, V71, P993; Wahlin TBR, 2001, BIOL PSYCHOL, V56, P247, DOI 10.1016/S0301-0511(01)00079-5; Wang HX, 2001, NEUROLOGY, V56, P1188, DOI 10.1212/WNL.56.9.1188	32	145	148	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 22	2002	324	7352					1512	1515		10.1136/bmj.324.7352.1512	http://dx.doi.org/10.1136/bmj.324.7352.1512			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	567ZL	12077044	Green Published			2022-12-28	WOS:000176517900029
J	Ghosh, S; Parthasarathy, R; Rosenbaum, TF; Aeppli, G				Ghosh, S; Parthasarathy, R; Rosenbaum, TF; Aeppli, G			Coherent spin oscillations in a disordered magnet	SCIENCE			English	Article							GLASSES; RELAXATION	Most materials freeze when cooled to sufficiently low temperature. We find that magnetic dipoles randomly distributed in a solid matrix condense into a spin liquid with spectral properties on cooling that are the diametric opposite of those for conventional glasses. Measurements of the nonlinear magnetic dynamics in the low-temperature liquid reveal the presence of coherent spin oscillations composed of hundreds of spins with lifetimes of up to 10 seconds. These excitations can be labeled by frequency and manipulated by the magnetic fields from a loop of wire and can permit the encoding of information at multiple frequencies simultaneously.	Univ Chicago, James Franck Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Phys, Chicago, IL 60637 USA; NEC Res Inst, Princeton, NJ 08540 USA	University of Chicago; University of Chicago; NEC Corporation	Rosenbaum, TF (corresponding author), Univ Chicago, James Franck Inst, 5640 S Ellis Ave, Chicago, IL 60637 USA.	t-rosenbaum@uchicago.edu	Parthasarathy, Raghuveer/A-5958-2008	Parthasarathy, Raghuveer/0000-0002-6006-4749				BINDER K, 1986, REV MOD PHYS, V58, P801, DOI 10.1103/RevModPhys.58.801; BURIN AL, 1995, J LOW TEMP PHYS, V100, P309, DOI 10.1007/BF00751512; Chamberlin RV, 1999, PHYS REV LETT, V83, P5134, DOI 10.1103/PhysRevLett.83.5134; COPPERSMITH SN, 1985, PHYS REV B, V31, P4049, DOI 10.1103/PhysRevB.31.4049; Cugliandolo LF, 2000, PHYS REV LETT, V85, P3448, DOI 10.1103/PhysRevLett.85.3448; DEBYE P, 1929, POLAR MOL, P90; DIXON PK, 1990, PHYS REV LETT, V65, P1108, DOI 10.1103/PhysRevLett.65.1108; Gammaitoni L, 1998, REV MOD PHYS, V70, P223, DOI 10.1103/RevModPhys.70.223; Gershenfeld NA, 1997, SCIENCE, V275, P350, DOI 10.1126/science.275.5298.350; Giraud R, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.057203; HANSEN PE, 1975, PHYS REV B, V12, P5315, DOI 10.1103/PhysRevB.12.5315; Kikkawa JM, 1997, SCIENCE, V277, P1284, DOI 10.1126/science.277.5330.1284; LUTTINGER JM, 1946, PHYS REV, V70, P954, DOI 10.1103/PhysRev.70.954; Moerner W. E., 1988, PERSISTENT SPECTRAL; Mydosh J. A., 1993, SPIN GLASSES EXPT IN; REICH DH, 1987, PHYS REV LETT, V59, P1969, DOI 10.1103/PhysRevLett.59.1969; REICH DH, 1990, PHYS REV B, V42, P4631, DOI 10.1103/PhysRevB.42.4631; SALVINO DJ, 1994, PHYS REV LETT, V73, P268, DOI 10.1103/PhysRevLett.73.268; Schiener B, 1996, SCIENCE, V274, P752, DOI 10.1126/science.274.5288.752; SIMON A, 1992, PHYS REV LETT, V68, P3375, DOI 10.1103/PhysRevLett.68.3375; STEPHEN MJ, 1981, J PHYS C SOLID STATE, V14, P1665, DOI 10.1088/0022-3719/14/11/026; WU WH, 1991, PHYS REV LETT, V67, P2076, DOI 10.1103/PhysRevLett.67.2076	23	72	73	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	2002	296	5576					2195	2198		10.1126/science.1070731	http://dx.doi.org/10.1126/science.1070731			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077409	Green Accepted, Green Submitted			2022-12-28	WOS:000176379000050
J	Hogan, DA; Kolter, R				Hogan, DA; Kolter, R			Pseudomonas-Candida interactions: An ecological role for virulence factors	SCIENCE			English	Article							TWITCHING MOTILITY; CYSTIC-FIBROSIS; AERUGINOSA; PATHOGENICITY; ALBICANS; PLANTS; PROTEINS; BIOFILM; ANIMALS; FLORA	Bacterial-fungal interactions have great environmental, medical, and economic importance, yet few have been well characterized at the molecular level. Here, we describe a pathogenic interaction between Pseudomonas aeruginosa and Candida albicans, two opportunistic pathogens. P. aeruginosa forms a dense biofilm on C. albicans laments and kills the fungus. In contrast, P. aeruginosa neither binds to nor kills yeast-form C. albicans. Several P. aeruginosa virulence factors that are important in disease are involved in the killing of C. albicans laments. We propose that many virulence factors studied in the context of human infection may also have a role in bacterial-fungal interactions.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Kolter, R (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	rkolter@hms.harvard.edu		Hogan, Deborah A./0000-0002-6366-2971	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058213] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58213] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonso A, 1999, ENVIRON MICROBIOL, V1, P421, DOI 10.1046/j.1462-2920.1999.00052.x; BEATSON SA, IN PRESS J BACTERIOL; Braun BR, 1997, SCIENCE, V277, P105, DOI 10.1126/science.277.5322.105; BROOK I, 1992, CLIN INFECT DIS, V15, P955, DOI 10.1093/clind/15.6.955; Burns JL, 1999, J INFECT DIS, V179, P1190, DOI 10.1086/314727; Chaffin WL, 1998, MICROBIOL MOL BIOL R, V62, P130, DOI 10.1128/MMBR.62.1.130-180.1998; CHET I, 1994, APPL BIOCHEM BIOTECH, V48, P37, DOI 10.1007/BF02825358; CotaGomez A, 1997, INFECT IMMUN, V65, P2904, DOI 10.1128/IAI.65.7.2904-2913.1997; Davies DG, 1998, SCIENCE, V280, P295, DOI 10.1126/science.280.5361.295; GARBAYE J, 1994, NEW PHYTOL, V128, P197, DOI 10.1111/j.1469-8137.1994.tb04003.x; Hahn HP, 1997, GENE, V192, P99, DOI 10.1016/S0378-1119(97)00116-9; HEMADY RK, 1995, OPHTHALMOLOGY, V102, P1026; Hendrickson EL, 2001, J BACTERIOL, V183, P7126, DOI 10.1128/JB.183.24.7126-7134.2001; Hermann C, 1999, MYCOSES, V42, P619, DOI 10.1046/j.1439-0507.1999.00519.x; HOGAN D, UNPUB; KERR JR, 1994, J CLIN MICROBIOL, V32, P525, DOI 10.1128/JCM.32.2.525-527.1994; Lo HJ, 1997, CELL, V90, P939, DOI 10.1016/S0092-8674(00)80358-X; Mahajan-Miklos S, 1999, CELL, V96, P47, DOI 10.1016/S0092-8674(00)80958-7; Merz AJ, 2000, NATURE, V407, P98, DOI 10.1038/35024105; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; O'Toole GA, 1998, MOL MICROBIOL, V30, P295, DOI 10.1046/j.1365-2958.1998.01062.x; Odds FC., 1988, CANDIDA CANDIDOSIS; PALLERONI N, 2000, PROKARYOTES; PARDEE AB, 1959, J MOL BIOL, V1, P165, DOI 10.1016/S0022-2836(59)80045-0; RAHME LG, 1995, SCIENCE, V268, P1899, DOI 10.1126/science.7604262; Rahme LG, 2000, P NATL ACAD SCI USA, V97, P8815, DOI 10.1073/pnas.97.16.8815; Reimmann C, 1997, MOL MICROBIOL, V24, P309, DOI 10.1046/j.1365-2958.1997.3291701.x; Tan MW, 1999, P NATL ACAD SCI USA, V96, P2408, DOI 10.1073/pnas.96.5.2408; Titball RW, 1998, J APPL MICROBIOL, V84, p127S; WELCH DF, 1987, J CLIN MICROBIOL, V25, P1730, DOI 10.1128/JCM.25.9.1730-1734.1987; Woods DE, 1997, CAN J MICROBIOL, V43, P541, DOI 10.1139/m97-077	31	431	445	1	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	2002	296	5576					2229	2232		10.1126/science.1070784	http://dx.doi.org/10.1126/science.1070784			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077418				2022-12-28	WOS:000176379000061
J	Knesel, KM; Davidson, JP				Knesel, KM; Davidson, JP			Insights into collisional magmatism from isotopic fingerprints of melting reactions	SCIENCE			English	Article							DISEQUILIBRIUM; GRANITE; SEGREGATION; CONSTRAINTS; LEUKOGRANITE; GENERATION; EXTRACTION; CRUST	Piston-cylinder experiments in the granite system demonstrate that a variety of isotopically distinct melts can arise from progressive melting of a single source. The relation between the isotopic composition of Sr and the stoichiometry of the observed melting reactions suggests that isotopic signatures of anatectic magmas can be used to infer melting reactions in natural systems. Our results also indicate that distinct episodes of dehydration and fluid-fluxed melting of a single, metapelitic source region may have contributed to the bimodal geochemistry of crustally derived leucogranites of the Himalayan orogen.	Univ Queensland, Dept Earth Sci, Brisbane, Qld 4072, Australia; Univ Durham, Dept Earth Sci, Durham DH1 3LE, England	University of Queensland; Durham University	Knesel, KM (corresponding author), Univ Queensland, Dept Earth Sci, Brisbane, Qld 4072, Australia.	k.knesel@earth.uq.edu.au						AYERS JC, 1992, AM MINERAL, V77, P1080; Ayres M, 1997, MINERAL MAG, V61, P29, DOI 10.1180/minmag.1997.061.404.04; BAKER MB, 1994, GEOCHIM COSMOCHIM AC, V58, P2811, DOI 10.1016/0016-7037(94)90116-3; BARBERO L, 1995, J GEOPHYS RES-SOL EA, V100, P15745, DOI 10.1029/95JB00036; BROWN M, 1995, J GEOPHYS RES-SOL EA, V100, P15655, DOI 10.1029/95JB00517; Chen CH, 1996, EARTH PLANET SC LETT, V143, P125, DOI 10.1016/0012-821X(96)00122-7; DLEMOS RS, 1992, J GEOL SOC LONDON, V149, P487, DOI 10.1144/gsjgs.149.4.0487; France-Lanord C., 1988, T R SOC EDINBURGH EA, V79, P183; George MT, 1996, TECTONOPHYSICS, V260, P167, DOI 10.1016/0040-1951(96)00082-0; GUILLOT S, 1995, LITHOS, V35, P221, DOI 10.1016/0024-4937(94)00052-4; Hammouda T, 1996, EARTH PLANET SC LETT, V144, P109, DOI 10.1016/0012-821X(96)00144-6; Harris N, 1998, GEOL SOC SPEC PUBL, V138, P171, DOI 10.1144/GSL.SP.1996.138.01.10; HARRIS N, 1995, J GEOPHYS RES-SOL EA, V100, P15767, DOI 10.1029/94JB02623; Harrison TM, 1999, J PETROL, V40, P3, DOI 10.1093/petrology/40.1.3; HERTOGEN J, 1976, GEOCHIM COSMOCHIM AC, V40, P313, DOI 10.1016/0016-7037(76)90209-X; Knesel KM, 1996, GEOLOGY, V24, P243, DOI 10.1130/0091-7613(1996)024<0243:IDDMOG>2.3.CO;2; Knesel KM, 1999, CONTRIB MINERAL PETR, V136, P285, DOI 10.1007/s004100050539; LEFORT P, 1981, J GEOPHYS RES, V86, P545, DOI 10.1029/JB086iB11p10545; PatinoDouce AE, 1998, J PETROL, V39, P689, DOI 10.1093/petroj/39.4.689; PEFORD N, 2001, EARTH PLANET SC LETT, V193, P483; PETFORD N, 1995, J GEOPHYS RES-SOL EA, V100, P15735, DOI 10.1029/94JB03259; Rushmer T, 1996, T ROY SOC EDIN-EARTH, V87, P73, DOI 10.1017/S0263593300006490; RUTTER EH, 1995, J GEOPHYS RES-SOL EA, V100, P15697, DOI 10.1029/94JB03388; SAWYER EW, 1991, J PETROL, V32, P701, DOI 10.1093/petrology/32.4.701; Tommasini S, 1997, EARTH PLANET SC LETT, V148, P273, DOI 10.1016/S0012-821X(97)00031-9	25	98	118	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	2002	296	5576					2206	2208		10.1126/science.1070622	http://dx.doi.org/10.1126/science.1070622			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077413				2022-12-28	WOS:000176379000054
J	Matzuk, MM; Burns, KH; Viveiros, MM; Eppig, JJ				Matzuk, MM; Burns, KH; Viveiros, MM; Eppig, JJ			Intercellular communication in the mammalian ovary: Oocytes carry the conversation	SCIENCE			English	Review							GROWTH-DIFFERENTIATION FACTOR-9; FOLLICLE-STIMULATING-HORMONE; MOUSE OOCYTES; MEIOTIC COMPETENCE; GRANULOSA-CELLS; ACQUISITION; TRANSCRIPTION; MATURATION; OVULATION; MUTATION	The production of functional female gametes is essential for the propagation of all vertebrate species. The growth of oocytes within ovarian follicles and their development to mature eggs have fascinated biologists for centuries, and scientists have long realized the importance of the ovarian follicle's somatic cells in nurturing oogenesis and delivering the oocyte to the oviduct by ovulation. Recent studies have revealed key roles of the oocyte in folliculogenesis and established that bidirectional communication between the oocyte and companion somatic cells is essential for development of an egg competent to undergo fertilization and embryogenesis. The challenge for the future is to identify the factors that participate in this communication and their mechanisms of action.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Jackson Lab, Bar Harbor, ME 04609 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Jackson Laboratory	Matzuk, MM (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA.	mmatzuk@bcm.tmc.edu	Burns, Kathleen/A-3360-2011; Viveiros, Maria/P-4120-2015	Burns, Kathleen/0000-0003-1620-3761	NCI NIH HHS [CA60651, CA62392] Funding Source: Medline; NEI NIH HHS [EY07102] Funding Source: Medline; NICHD NIH HHS [HD23839, HD07495, HD32067, HD33438] Funding Source: Medline; NIGMS NIH HHS [GM07330] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD023839, R01HD032067, R01HD033438] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD033438, P30HD007495] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA060651, R01CA062392] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brinster RL, 2002, SCIENCE, V296, P2174, DOI 10.1126/science.1071607; BROWER PT, 1982, DEV BIOL, V90, P144, DOI 10.1016/0012-1606(82)90219-6; BURNS KH, IN PRESS MOL BIOL RE; Carabatsos MJ, 2000, DEV BIOL, V226, P167, DOI 10.1006/dbio.2000.9863; CHESNEL F, 1994, DEV BIOL, V161, P285, DOI 10.1006/dbio.1994.1028; CHESNEL F, 1995, MOL REPROD DEV, V40, P503, DOI 10.1002/mrd.1080400414; De la Fuente R, 2001, DEV BIOL, V229, P224, DOI 10.1006/dbio.2000.9947; Deng W, 2001, INT REV CYTOL, V203, P93; Dierich A, 1998, P NATL ACAD SCI USA, V95, P13612, DOI 10.1073/pnas.95.23.13612; Dong JW, 1996, NATURE, V383, P531, DOI 10.1038/383531a0; Donovan PJ, 2001, CONT ENDOCRINOL, P147; Durlinger ALL, 1999, ENDOCRINOLOGY, V140, P5789, DOI 10.1210/en.140.12.5789; Elvin JA, 2000, MOL CELL ENDOCRINOL, V159, P1, DOI 10.1016/S0303-7207(99)00185-9; Eppig JJ, 2002, P NATL ACAD SCI USA, V99, P2890, DOI 10.1073/pnas.052658699; Eppig JJ, 2001, REPRODUCTION, V122, P829, DOI 10.1530/rep.0.1220829; Galloway SM, 2000, NAT GENET, V25, P279, DOI 10.1038/77033; Howell CY, 2001, CELL, V104, P829, DOI 10.1016/S0092-8674(01)00280-X; Kono T, 1996, NAT GENET, V13, P91, DOI 10.1038/ng0596-91; Kumar TR, 1997, NAT GENET, V15, P201, DOI 10.1038/ng0297-201; Mizunuma H, 1999, ENDOCRINOLOGY, V140, P37, DOI 10.1210/en.140.1.37; NOTHIAS JY, 1995, J BIOL CHEM, V270, P22077, DOI 10.1074/jbc.270.38.22077; PETERS H, 1969, ACTA ENDOCRINOL-COP, V62, P98, DOI 10.1530/acta.0.0620098; Richards JS, 2002, ANNU REV PHYSIOL, V64, P69, DOI 10.1146/annurev.physiol.64.081501.131029; SORENSEN RA, 1976, DEV BIOL, V50, P531, DOI 10.1016/0012-1606(76)90172-X; Soyal SM, 2000, DEVELOPMENT, V127, P4645; Tong ZB, 2000, NAT GENET, V26, P267, DOI 10.1038/81547; Varani S, 2002, MOL ENDOCRINOL, V16, P1154, DOI 10.1210/me.16.6.1154; WICKRAMASINGHE D, 1991, DEV BIOL, V143, P162, DOI 10.1016/0012-1606(91)90063-9; Wilson T, 2001, BIOL REPROD, V64, P1225, DOI 10.1095/biolreprod64.4.1225; Yan CN, 2001, MOL ENDOCRINOL, V15, P854, DOI 10.1210/me.15.6.854; Zhao Ming, 2002, Rev Endocr Metab Disord, V3, P19, DOI 10.1023/A:1012744617241	31	666	701	3	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	2002	296	5576					2178	2180		10.1126/science.1071965	http://dx.doi.org/10.1126/science.1071965			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077402				2022-12-28	WOS:000176379000043
J	Weihofen, A; Binns, K; Lemberg, MK; Ashman, K; Martoglio, B				Weihofen, A; Binns, K; Lemberg, MK; Ashman, K; Martoglio, B			Identification of signal peptide peptidase, a presenilin-type aspartic protease	SCIENCE			English	Article							REGULATED INTRAMEMBRANE PROTEOLYSIS; GAMMA-SECRETASE; PROTEINS; TRANSPORT	Signal peptide peptidase (SPP) catalyzes intramembrane proteolysis of some signal peptides after they have been cleaved from a preprotein. In humans, SPP activity is required to generate signal sequence-derived human lymphocyte antigen-E epitopes that are recognized by the immune system, and to process hepatitis C virus core protein. We have identified human SPP as a polytopic membrane protein with sequence motifs characteristic of the presenilin-type aspartic proteases. SPP and potential eukaryotic homologs may represent another family of aspartic proteases that promote intramembrane proteolysis to release biologically important peptides.	ETH Honggerberg, Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland; Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Martoglio, B (corresponding author), ETH Honggerberg, Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland.	bruno.martoglio@bc.biol.ethz.ch	Lemberg, Marius K/B-8881-2016; Weihofen, Andreas/A-1566-2011; Ashman, Keith/G-2328-2011	Lemberg, Marius K/0000-0002-0996-1268; Weihofen, Andreas/0000-0001-6265-9087				Brachmann CB, 1998, YEAST, V14, P115; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; BRUNNER J, 1989, METHOD ENZYMOL, V172, P628; Chan YM, 1999, NEURON, V23, P201, DOI 10.1016/S0896-6273(00)80771-0; DURRER P, 1995, J BIOL CHEM, V270, P17575, DOI 10.1074/jbc.270.29.17575; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Huppert S, 2001, DEV CELL, V1, P590, DOI 10.1016/S1534-5807(01)00081-8; Lee JR, 2001, CELL, V107, P161, DOI 10.1016/S0092-8674(01)00526-8; Lemberg MK, 2001, J IMMUNOL, V167, P6441, DOI 10.4049/jimmunol.167.11.6441; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; Martoglio B, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P265; MCLAUCHLAN J, UNPUB; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sisodia SS, 2001, TRENDS NEUROSCI, V24, pS2, DOI 10.1016/S0166-2236(00)01987-1; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Szelke M., 1985, ASPARTIC PROTEINASES, P421; Weihofen A, 2000, J BIOL CHEM, V275, P30951, DOI 10.1074/jbc.M005980200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077	24	442	461	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	2002	296	5576					2215	2218		10.1126/science.1070925	http://dx.doi.org/10.1126/science.1070925			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077416				2022-12-28	WOS:000176379000057
J	Imai, H; Obara, K; Diamond, PJ; Omodaka, T; Sasao, T				Imai, H; Obara, K; Diamond, PJ; Omodaka, T; Sasao, T			A collimated jet of molecular gas from a star on the asymptotic giant branch	NATURE			English	Article							PLANETARY-NEBULAE; OH/IR STARS; H2O MASERS; CIRCUMSTELLAR ENVELOPES; BIPOLAR OUTFLOWS; EVOLVED STARS; WATER MASERS; PROTOPLANETARY; PROTOSTARS	Evolved stars of about one solar mass are in general spherically symmetric, yet the planetary nebulae that they produce in the next phase of their evolution tend not to exhibit such symmetry. Collimated 'jets' and outflows of material have been observed(1-5) up to similar to0.3 parsec from the central stars of planetary nebulae, and precession of those jets has been proposed(1) to explain the observed asymmetries. Moreover, it has recently been shown 6 theoretically that magnetic fields could launch and collimate such jets. Here we report the detection of a collimated and precessing jet of molecular gas that is traced by water-vapour maser spots similar to500 astronomical units (AU) from the star W43A in Aquila. We conclude that the jet is formed in the immediate vicinity of the star, and infer that elongated planetary nebulae are formed by jets during the short period, of less than 1,000 years, when the star makes its transition through the proto-planetary nebula phase to become a planetary nebula.	Mizusawa Astrogeodynam Observ, Mizusawa, Iwate 0230861, Japan; Kagoshima Univ, Dept Phys, Kagoshima 8900065, Japan; Univ Manchester, Jodrell Bank Observ, Macclesfield SK11 9DL, Cheshire, England; Natl Astron Observ, VERA Project Off, Tokyo, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); Kagoshima University; University of Manchester; Jodrell Bank Centre for Astrophysics; National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ)	Imai, H (corresponding author), Joint Inst VLBI Europe, Postbus 2, NL-7990 AA Dwingeloo, Netherlands.							Alcolea J, 2001, ASTRON ASTROPHYS, V373, P932, DOI 10.1051/0004-6361:20010535; Bachiller R, 1996, ANNU REV ASTRON ASTR, V34, P111, DOI 10.1146/annurev.astro.34.1.111; Blackman EG, 2001, NATURE, V409, P485, DOI 10.1038/35054008; Bloemhof EE, 2000, ASTROPHYS J, V533, P893, DOI 10.1086/308714; CHANDLER F, 1999, ASTRON ASTROPHYS, V343, P571; CHAPMAN JM, 1986, MON NOT R ASTRON SOC, V220, P513, DOI 10.1093/mnras/220.3.513; COOKE B, 1985, ASTROPHYS J, V295, P175, DOI 10.1086/163363; DIAMOND PJ, 1985, MON NOT R ASTRON SOC, V212, P1; DIAMOND PJ, 1988, VLBI ITS IMPACT ASTR, P249; ELITZUR M, 1992, ASTROPHYS J, V394, P221, DOI 10.1086/171574; Elitzur M., 1992, ASTRONOMICAL MASERS; Furuya RS, 2000, ASTROPHYS J, V542, pL135, DOI 10.1086/312925; Genzel R., 1977, Astronomy and Astrophysics Supplement Series, V30, P145; Herman J., 1985, Astronomy & Astrophysics Supplement Series, V59, P523; HOWARD BE, 2000, ASP C SERIES, V199, P115; LANE AP, 1987, ASTROPHYS J, V323, P756, DOI 10.1086/165869; Lewis BM, 2001, ASTROPHYS J, V560, P400, DOI 10.1086/322428; LIKKEL L, 1992, ASTRON ASTROPHYS, V256, P581; Marvel KB, 1997, PUBL ASTRON SOC PAC, V109, P1286, DOI 10.1086/134010; Miranda LF, 2001, NATURE, V414, P284, DOI 10.1038/35104518; MORRIS M, 1987, PUBL ASTRON SOC PAC, V99, P1115, DOI 10.1086/132089; NAKASHIMA J, 2002, OBSERVATIONAL STUDY; Nyman LA, 1998, ASTRON ASTROPHYS SUP, V127, P185, DOI 10.1051/aas:1998343; Sahai R, 1998, ASTRON J, V116, P1357, DOI 10.1086/300504; Sahai R, 1999, ASTROPHYS J, V514, pL115, DOI 10.1086/311955; Torrelles JM, 2001, NATURE, V411, P277, DOI 10.1038/35077020; UCHIDA Y, 1985, PUBL ASTRON SOC JPN, V37, P515; VANDERVEEN WECJ, 1988, ASTRON ASTROPHYS, V194, P125; Zijlstra AA, 2001, MON NOT R ASTRON SOC, V322, P280, DOI 10.1046/j.1365-8711.2001.04113.x; Zinnecker H, 1998, NATURE, V394, P862, DOI 10.1038/29716	30	109	109	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 20	2002	417	6891					829	831		10.1038/nature00788	http://dx.doi.org/10.1038/nature00788			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075345				2022-12-28	WOS:000176285600040
J	Fletcher, RH; Fairfield, KN				Fletcher, RH; Fairfield, KN			Vitamins for chronic disease prevention in adults - Clinical applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							D DEFICIENCY; FOLIC-ACID; FOLATE; BONE; EAT	Vitamin deficiency syndromes such as scurvy and beriberi are uncommon in Western societies. However, suboptimal intake of some vitamins, above levels causing classic vitamin deficiency, is a risk factor for chronic diseases and common in the general population, especially the elderly. Suboptimal folic acid levels, along with suboptimal levels of vitamins B-6 and B-12, are a risk factor for cardiovascular disease, neural tube defects, and colon and breast cancer; low levels of vitamin D contribute to osteopenia and fractures; and low levels of the antioxidant vitamins (vitamins A, E, and C) may increase risk for several chronic diseases. Most people do not consume an optimal amount of all vitamins by diet alone. Pending strong evidence of effectiveness from randomized trials, it appears prudent for all adults to take vitamin supplements. The evidence base for tailoring the contents of multivitamins to specific characteristics of patients such as age, sex, and physical activity and for testing vitamin levels to guide specific supplementation practices is limited. Physicians should make specific efforts to learn about their patients' use of vitamins to ensure that they are taking vitamins they should, such as folate supplementation for women in the childbearing years, and avoiding dangerous practices such as high doses of vitamin A during pregnancy or massive doses of fat-soluble vitamins at any age.	Harvard Univ, Med Sch Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med,Div Gen Med & Primary Care, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	Harvard Pilgrim Health Care; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Brigham & Women's Hospital; Harvard Medical School	Fletcher, RH (corresponding author), Harvard Univ, Med Sch Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA.							BILEZIKIAN JP, 1994, JAMA-J AM MED ASSOC, V272, P1942, DOI 10.1001/jama.1994.03520240070044; *COMM DIET HLTH NR, 1989, DIET HLTH IMPL RED C; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Feskanich D, 2002, JAMA-J AM MED ASSOC, V287, P47, DOI 10.1001/jama.287.1.47; Flood A, 2000, JNCI-J NATL CANCER I, V92, P1706, DOI 10.1093/jnci/92.21.1706; GLOTH FM, 1995, JAMA-J AM MED ASSOC, V274, P1683, DOI 10.1001/jama.274.21.1683; HILLMAN RS, 1982, ANNU REV MED, V33, P345, DOI 10.1146/annurev.me.33.020182.002021; *I MED, 2000, REF INT VIT C VIT E; *I MED, 2000, DIET REF INT THIAM R; *I MED, 2001, DIET REF INT VIT A V; Institute of Medicine. Food and Nutrition Board, 1999, DIET REF INT CALC PH; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477; Molloy AM, 1997, LANCET, V349, P1591, DOI 10.1016/S0140-6736(96)12049-3; NAURATH HJ, 1995, LANCET, V346, P85, DOI 10.1016/S0140-6736(95)92113-3; Oakley GP, 1998, NEW ENGL J MED, V338, P1060, DOI 10.1056/NEJM199804093381509; *OFF DIS PREV HLTH, 2002, HLTH PEOPL; Snow CF, 1999, ARCH INTERN MED, V159, P1289, DOI 10.1001/archinte.159.12.1289; WALD N, 1991, LANCET, V338, P131; Wald NJ, 2001, LANCET, V358, P2069, DOI 10.1016/S0140-6736(01)07104-5; Ward M, 1997, QJM-MON J ASSOC PHYS, V90, P519, DOI 10.1093/qjmed/90.8.519; Williams PG, 1996, J AM DIET ASSOC, V96, P490, DOI 10.1016/S0002-8223(96)00135-6	23	162	174	2	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	2002	287	23					3127	3129		10.1001/jama.287.23.3127	http://dx.doi.org/10.1001/jama.287.23.3127			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563NK	12069676	Bronze			2022-12-28	WOS:000176262300028
J	McDermott, MM; Greenland, P; Liu, K; Guralnik, JM; Celic, L; Criqui, MH; Chan, C; Martin, GJ; Schneider, J; Pearce, WH; Taylor, LM; Clark, E				McDermott, MM; Greenland, P; Liu, K; Guralnik, JM; Celic, L; Criqui, MH; Chan, C; Martin, GJ; Schneider, J; Pearce, WH; Taylor, LM; Clark, E			The ankle brachial index is associated with leg function and physical activity: The walking and leg circulation study	ANNALS OF INTERNAL MEDICINE			English	Article							PERIPHERAL ARTERIAL-DISEASE; LOWER-EXTREMITY FUNCTION; VASCULAR-DISEASE; INTERMITTENT CLAUDICATION; SUBSEQUENT DISABILITY; CALTRAC ACCELEROMETER; CARDIOVASCULAR HEALTH; SKELETAL-MUSCLE; WOMENS HEALTH; 6-MINUTE WALK	Background: The ankle brachial index (ABI) is a noninvasive, reliable measure of lower-extremity ischemia. However, the relationship between ABI and lower-extremity function has not been well studied. Objective: To describe the association between the ABI and lower-extremity function. Design: Cross-sectional study. Setting: 3 academic medical centers in the Chicago area. Participants: 740 men and women (460 with peripheral arterial disease). Measurements: Accelerometer-measured physical activity over 7 days, 6-minute walk, 4-m walking velocity, standing balance, and ABI. Results: 33% of participants with peripheral arterial disease had intermittent claudication. Fewer than 40% of participants with an ABI less than 0.40 walked continuously for 6 minutes compared with more than 95% of participants with an ABI between 1.00 and 1.50. Compared with an ABI of 1.10 to 1.50, an ABI less than 0.50 was associated with shorter distance walked in 6 minutes (beta-regression coefficient = -523 ft [95% Cl, -592 to -454 ft]; P < 0.001), less physical activity (beta = -514.8 activity units [Cl, -657 to -373 activity units]; P < 0.001), slower 4-m walking velocity (beta = -0.21 m/s [Cl, -0.27 to -0.15 m/s]; P < 0.001), and less likelihood of maintaining a tandem stand for 10 seconds (odds ratio, 0.37 [Cl, 0.18 to 0.76]; P = 0.007), after adjustment for typical confounders. Associations between ABI and function were stronger than associations between leg symptoms and function. Conclusions: The ABI, a noninvasive test that can be performed in a medical office, is more closely associated with leg function in persons with peripheral arterial disease than is intermittent claudication or other leg symptoms. These data support the use of the ABI to identify abnormal lower-extremity function.	Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Catholic Hlth Partners, Chicago, IL USA; NIA, Bethesda, MD 20892 USA; Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; Evanston Hosp Corp, Skokie, IL USA; Oregon Hlth Sci Med Ctr, Portland, OR USA	Northwestern University; Feinberg School of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of California System; University of California San Diego; NorthShore University Health System; Oregon Health & Science University	McDermott, MM (corresponding author), 675 N St Clair,Suite 18-200, Chicago, IL 60611 USA.		Greenland, Philip/ABD-5528-2021		NCRR NIH HHS [RR-00048] Funding Source: Medline; NHLBI NIH HHS [R01-HL58099] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058099] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; BOULT C, 1994, J GERONTOL, V49, pM28, DOI 10.1093/geronj/49.1.M28; BREARLEY S, 1992, ANN ROY COLL SURG, V74, P169; Criqui M H, 1996, Vasc Med, V1, P65; CRIQUI MH, 1985, CIRCULATION, V71, P516, DOI 10.1161/01.CIR.71.3.516; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; ETTINGER WH, 1994, J AM GERIATR SOC, V42, P1035, DOI 10.1111/j.1532-5415.1994.tb06206.x; FARINON AM, 1984, CLIN NEUROPATHOL, V3, P240; FARKOUH M, IN PRESS INT J ANGIO; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; FRIED LP, 1994, J CLIN EPIDEMIOL, V47, P747, DOI 10.1016/0895-4356(94)90172-4; Fried LP, 1999, J CLIN EPIDEMIOL, V52, P27, DOI 10.1016/S0895-4356(98)00124-3; Guralnik J.M., 1995, WOMENS HLTH AGING ST; Guralnik JM, 2000, J GERONTOL A-BIOL, V55, pM221, DOI 10.1093/gerona/55.4.M221; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; HARRISON TR, 1994, HARRISON PRINCIPLES, P1135; Hedberg B, 1989, Eur J Vasc Surg, V3, P315, DOI 10.1016/S0950-821X(89)80067-2; Hirsch AT, 2001, JAMA-J AM MED ASSOC, V286, P1317, DOI 10.1001/jama.286.11.1317; Lyness JM, 1997, ARCH INTERN MED, V157, P449, DOI 10.1001/archinte.157.4.449; McDermott MM, 2000, J VASC SURG, V32, P1164, DOI 10.1067/mva.2000.108640; McDermott MM, 1999, ARCH INTERN MED, V159, P387; McDermott MM, 2000, CIRCULATION, V101, P1007, DOI 10.1161/01.CIR.101.9.1007; McDermott MM, 2001, JAMA-J AM MED ASSOC, V286, P1599; McDermott MM, 2001, J GEN INTERN MED, V16, P384, DOI 10.1046/j.1525-1497.2001.016006384.x; McDermott MM, 2000, ANGIOLOGY, V51, P91, DOI 10.1177/000331970005100201; MCDERMOTT MM, 1994, J GEN INTERN MED, V9, P445, DOI 10.1007/BF02599061; MCKENNA M, 1991, ATHEROSCLEROSIS, V87, P119, DOI 10.1016/0021-9150(91)90014-T; McLafferty RB, 2000, J VASC SURG, V31, P870, DOI 10.1067/mva.2000.106422; MILLER DJ, 1994, MED SCI SPORT EXER, V26, P376; Moffatt C, 1995, J Wound Care, V4, P134; Montgomery PS, 1998, J AM GERIATR SOC, V46, P706, DOI 10.1111/j.1532-5415.1998.tb03804.x; Myers K A, 1987, Eur J Vasc Surg, V1, P245, DOI 10.1016/S0950-821X(87)80075-0; Newman AB, 1997, J AM GERIATR SOC, V45, P1472, DOI 10.1111/j.1532-5415.1997.tb03198.x; NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837; OLIN JW, 1998, AM J MED CONTINUING, P10; Pasini FL, 1996, ANGIOLOGY, V47, P569, DOI 10.1177/000331979604700605; REGENSTEINER JG, 1993, CIRCULATION, V87, P413, DOI 10.1161/01.CIR.87.2.413; REGENSTEINER JG, 1993, ANGIOLOGY, V44, P1, DOI 10.1177/000331979304400101; Richardson M T, 1995, J Cardiopulm Rehabil, V15, P107, DOI 10.1097/00008483-199503000-00003; RODRIGUEZSANCHEZ C, 1991, HISTOL HISTOPATHOL, V6, P63; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; SALLIS JF, 1990, MED SCI SPORT EXER, V22, P698, DOI 10.1249/00005768-199010000-00023; Swan PD, 1997, BRIT J SPORT MED, V31, P235, DOI 10.1136/bjsm.31.3.235; TIERNEY LM, 1995, CURRENT MED DIAGNOSI, P396; VOGT MT, 1994, J AM GERIATR SOC, V42, P923, DOI 10.1111/j.1532-5415.1994.tb06581.x	47	392	413	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 18	2002	136	12					873	883		10.7326/0003-4819-136-12-200206180-00008	http://dx.doi.org/10.7326/0003-4819-136-12-200206180-00008			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563JL	12069561				2022-12-28	WOS:000176252500004
J	Smith, JB; Haynes, MK				Smith, JB; Haynes, MK			Rheumatoid arthritis - A molecular understanding	ANNALS OF INTERNAL MEDICINE			English	Review							INTERCELLULAR-ADHESION MOLECULE-1; GROWTH-FACTOR-BETA; MEMORY T-CELLS; MONOCLONAL-ANTIBODY; SYNOVIAL TISSUE; NITRIC-OXIDE; MESSENGER-RNA; ARTICULAR CHONDROCYTES; GENE-THERAPY; IN-VIVO	The application of molecular Immunology techniques In the study of rheumatoid arthritis has resulted in an explosion of knowledge on the risk factors for the disease, predictors of disease severity, the molecular mechanisms of Inflammatory responses, and mechanisms of tissue destruction. We know, for example, that inheriting certain genes In the major histocompatibility complex partly dictates susceptibility and severity of rheumatoid arthritis. These genes and others in the major histocompatibility complex are critical for the occurrence of immune responses both constructive (prevention of infection, surveillance for malignant cells) and destructive (development of autoimmune diseases). We also now understand mechanisms of cell communication, regulation of immune responses, how the cells that mediate Immune responses and tissue injury accumulate In tissues, and how the injury occurs. The knowledge Itself Is satisfying, but more Important, based on this knowledge, effective and reasonably safe treatments that address basic mechanisms of the disease process have been developed and are now widely used. In fact, the newer treatments represent the "tip of the iceberg," and as our basic knowledge Increases, so too will the armamentarium with which we can fight rheumatoid arthritis and other similar autoimmune diseases.	Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA	Jefferson University	Smith, JB (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, 613 Curtis Bldg, Philadelphia, PA 19107 USA.							BERENBAUM F, 1994, FEBS LETT, V340, P51, DOI 10.1016/0014-5793(94)80171-1; Borzi RM, 1999, FEBS LETT, V455, P238, DOI 10.1016/S0014-5793(99)00886-8; Breedveld FC, 1999, RHEUMATOLOGY, V38, P11; BREEDVELD FC, 1999, ANN RHEUM DIS S1, V58, pI1; BRENNAN FM, 1990, CLIN EXP IMMUNOL, V81, P278; BRENNAN FM, 1990, EUR J IMMUNOL, V20, P2141, DOI 10.1002/eji.1830200938; Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO;2-U; BUCHAN G, 1988, CLIN EXP IMMUNOL, V73, P449; BURMESTER GR, 1983, SCAND J IMMUNOL, V17, P69, DOI 10.1111/j.1365-3083.1983.tb00767.x; CAMPBELL IK, 1986, BIOCHEM J, V237, P117, DOI 10.1042/bj2370117; CHEN QY, 1994, INT J CANCER, V56, P755, DOI 10.1002/ijc.2910560524; CHU CQ, 1991, CLIN EXP IMMUNOL, V86, P380; COOPER SM, 1991, ARTHRITIS RHEUM, V34, P537, DOI 10.1002/art.1780340505; Crilly A, 1999, ANN RHEUM DIS, V58, P114, DOI 10.1136/ard.58.2.114; CUSH JJ, 1992, ARTHRITIS RHEUM, V35, P1434, DOI 10.1002/art.1780351206; Das P, 1999, HUM IMMUNOL, V60, P575, DOI 10.1016/S0198-8859(99)00059-2; DE WMR, 1991, J EXP MED, V174, P1209; Decker J L, 1984, Ann Intern Med, V101, P810; Dittel BN, 1997, J IMMUNOL, V158, P4065; EDWARDS JCW, 1994, J ANAT, V184, P493; ELLIOTT MJ, 1994, INT ARCH ALLERGY IMM, V104, P112, DOI 10.1159/000236718; EVANS CH, 1995, AGENT ACTION SUPPL, V47, P107; EVANS CH, 1995, ANN MED, V27, P543, DOI 10.3109/07853899509002466; FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219; FIRESTEIN G S, 1991, Current Opinion in Rheumatology, V3, P398, DOI 10.1097/00002281-199106000-00012; FIRESTEIN GS, 1990, J IMMUNOL, V144, P3347; FIRESTEIN GS, 1995, J CLIN INVEST, V96, P1631, DOI 10.1172/JCI118202; FRIEDMAN SM, 1991, J EXP MED, V174, P891, DOI 10.1084/jem.174.4.891; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; GUDMUNDSSON S, 1992, SCAND J IMMUNOL, V36, P681, DOI 10.1111/j.1365-3083.1992.tb03128.x; GUNTHER M, 1994, ARTHRITIS RHEUM, V37, P395, DOI 10.1002/art.1780370314; HAMMER J, 1995, J EXP MED, V181, P1847, DOI 10.1084/jem.181.5.1847; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; Harriman G, 1999, ANN RHEUM DIS, V58, P61; Harris E D Jr, 1994, Curr Opin Rheumatol, V6, P287, DOI 10.1097/00002281-199405000-00007; Haynes MK, 1997, J REPROD IMMUNOL, V35, P65, DOI 10.1016/S0165-0378(97)00036-3; HERZOG C, 1989, J AUTOIMMUN, V2, P627, DOI 10.1016/S0896-8411(89)80002-2; HOLT I, 1991, EUR J CLIN INVEST, V21, P479, DOI 10.1111/j.1365-2362.1991.tb01398.x; HOPKINS SJ, 1988, CLIN EXP IMMUNOL, V72, P422; HOWELL MD, 1991, P NATL ACAD SCI USA, V88, P10921, DOI 10.1073/pnas.88.23.10921; JACOBY RK, 1973, BRIT MED J, V2, P96, DOI 10.1136/bmj.2.5858.96; JENKINS RN, 1993, J CLIN INVEST, V92, P2688, DOI 10.1172/JCI116886; KASID A, 1988, J IMMUNOL, V141, P690; KATSIKIS PD, 1994, J EXP MED, V179, P1517, DOI 10.1084/jem.179.5.1517; KAVANAUGH AF, 1994, ARTHRITIS RHEUM, V37, P992, DOI 10.1002/art.1780370703; Kavanaugh AF, 1997, ARTHRITIS RHEUM, V40, P849, DOI 10.1002/art.1780400511; KLARESKOG L, 1981, SCAND J IMMUNOL, V14, P183, DOI 10.1111/j.1365-3083.1981.tb00198.x; Kobayashi T, 2000, GENE THER, V7, P527, DOI 10.1038/sj.gt.3301127; KOCH AE, 1991, LAB INVEST, V64, P313; Lotz M, 1999, RHEUM DIS CLIN N AM, V25, P269, DOI 10.1016/S0889-857X(05)70067-3; Mack M, 1999, ARTHRITIS RHEUM, V42, P981, DOI 10.1002/1529-0131(199905)42:5<981::AID-ANR17>3.0.CO;2-4; MALEFYT RD, 1993, J IMMUNOL, V150, P4754; Masi A T, 1976, Semin Arthritis Rheum, V4, P299; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; Moreland LW, 1996, J RHEUMATOL, V23, P1353; Moreland LW, 1998, J RHEUMATOL, V25, P221; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NELSON JL, 1991, TISSUE ANTIGENS, V38, P145, DOI 10.1111/j.1399-0039.1991.tb01888.x; NEPOM GT, 1987, J CLIN IMMUNOL, V7, P1, DOI 10.1007/BF00915418; OLLIER W, 1992, RHEUM DIS CLIN N AM, V18, P741; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; Panayi GS, 1999, RHEUMATOLOGY, V38, P8; POULTER LW, 1982, CLIN EXP IMMUNOL, V48, P381; ROBERTS AB, 1992, KIDNEY INT, V41, P557, DOI 10.1038/ki.1992.81; Schirmer M, 1998, J IMMUNOL, V161, P1018; Schulze-Koops H, 1998, J RHEUMATOL, V25, P2065; SchulzeKoops H, 1997, ARTHRITIS RHEUM, V40, P639, DOI 10.1002/art.1780400408; SMITH JB, 1989, RHEUMATOL INT, V9, P53, DOI 10.1007/BF00270245; STAMENKOVIC I, 1988, P NATL ACAD SCI USA, V85, P1179, DOI 10.1073/pnas.85.4.1179; STASTNY P, 1978, NEW ENGL J MED, V298, P869, DOI 10.1056/NEJM197804202981602; STCLAIR EW, 1999, ANN RHEUM DIS S1, V59, pI99; STRAND V, 1993, ARTHRITIS RHEUM-US, V36, P620, DOI 10.1002/art.1780360508; Suzuki N, 1999, INT IMMUNOL, V11, P553, DOI 10.1093/intimm/11.4.553; TAK PP, 1995, CLIN IMMUNOL IMMUNOP, V77, P236, DOI 10.1006/clin.1995.1149; TAYLORROBINSON AW, 1994, EUR J IMMUNOL, V24, P980, DOI 10.1002/eji.1830240430; THOMAS R, 1992, ARTHRITIS RHEUM-US, V35, P1455, DOI 10.1002/art.1780351209; THORNBERRY NA, 1995, PROTEIN SCI, V4, P3; VANDERVEEN RC, 1993, J NEUROIMMUNOL, V48, P213, DOI 10.1016/0165-5728(93)90194-4; vanRoon JAG, 1996, ARTHRITIS RHEUM, V39, P829, DOI 10.1002/art.1780390516; VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707; WEINBERG JB, 1994, J EXP MED, V179, P651, DOI 10.1084/jem.179.2.651; Westermann J, 2001, ANN INTERN MED, V135, P279, DOI 10.7326/0003-4819-135-4-200108210-00013; WEYAND CM, 1992, J CLIN INVEST, V89, P2033, DOI 10.1172/JCI115814; WEYAND CM, 1992, ARTHRITIS RHEUM-US, V35, P990, DOI 10.1002/art.1780350903; WEYAND CM, 1992, ANN INTERN MED, V117, P801, DOI 10.7326/0003-4819-117-10-801; WILLIAMS WV, 1992, J CLIN INVEST, V90, P326, DOI 10.1172/JCI115866; WONG GHW, 1994, J IMMUNOL, V152, P1751; WORDSWORTH BP, 1992, SPRINGER SEMIN IMMUN, V14, P59; WU JY, 1993, J IMMUNOL, V151, P4325; XU WD, 1989, J CLIN INVEST, V83, P876, DOI 10.1172/JCI113971; Yao QP, 2000, J GENE MED, V2, P210, DOI 10.1002/(SICI)1521-2254(200005/06)2:3<210::AID-JGM101>3.0.CO;2-P; Yoshizaki K, 1998, SPRINGER SEMIN IMMUN, V20, P247, DOI 10.1007/s002810050033	92	94	99	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 18	2002	136	12					908	922		10.7326/0003-4819-136-12-200206180-00012	http://dx.doi.org/10.7326/0003-4819-136-12-200206180-00012			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563JL	12069565				2022-12-28	WOS:000176252500008
J	Graham, J; Ramirez, A; Love, S; Richards, M; Burgess, C				Graham, J; Ramirez, A; Love, S; Richards, M; Burgess, C			Stressful life experiences and risk of relapse of breast cancer: observational cohort study	BRITISH MEDICAL JOURNAL			English	Article							SURVIVAL; RECURRENCE; PROGNOSIS; WOMEN	Objective To confirm, using an observational cohort design, the relation between severely stressful life experiences and relapse of breast cancer found in a previous case-control study. Design Prospective Mow up for five years of a cohort of women newly diagnosed as having breast cancer, collecting data on stressful life experiences, depression, and biological prognostic factors. Setting NHS breast clinic, London; 1991-9. Participants A consecutive series of women aged under 60 newly diagnosed as having a primary operable breast tumour 202/222 (91%) eligible women participated in the first life experiences interview 170 (77%) provided complete interview data either up to 5 years after diagnosis or to recurrence. Main outcome measure Recurrence of disease. Results We controlled for biological prognostic factors (lymph node infiltration and tumour histology), and found no increased risk of recurrence in women who had had one or more severely stressful life experiences in the year before diagnosis compared with women who did not (hazard ratio 1.01, 95% confidence interval 0.58 to 1.74, P=0.99). Women who had had one or more severely stressful life experiences in the 5 years after diagnosis had a lower risk of recurrence 0.52, 0.29 to 0.95, P=0.03) than those who did not. Conclusion These data do not confirm an earlier finding from a case-control study that severely stressful life experiences increase the risk of recurrence of breast cancer. Differences in case control and prospective methods may explain the contradictory results. We took the prospective study as the more robust, and the results suggest that women with breast cancer need not fear that stressful experiences will precipitate the return of their disease.	St Thomas Hosp, Guys Kings & St Thomas Sch Med, Adamson Ctr, Canc Res UK London Psychosocial Grp, London SE1 7EH, England; Inst Hlth Sci, Ctr Stat Med, Canc Res UK Med Stat Grp, Oxford OX3 7LF, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Cancer Research UK; University of Oxford	Graham, J (corresponding author), St Thomas Hosp, Guys Kings & St Thomas Sch Med, Adamson Ctr, Canc Res UK London Psychosocial Grp, London SE1 7EH, England.			Love, Sharon/0000-0002-6695-5390				BARRACLOUGH J, 1992, BRIT MED J, V304, P1078, DOI 10.1136/bmj.304.6834.1078; BARRACLOUGH J, 1993, BRIT MED J, V307, P25; Brown G., 1978, SOCIAL ORIGINS DEPRE; Edelman S, 2000, J PSYCHOSOM RES, V49, P149, DOI 10.1016/S0022-3999(00)00153-7; FAWZY FI, 1993, ARCH GEN PSYCHIAT, V50, P681; FORSEN A, 1991, PSYCHOTHER PSYCHOSOM, V55, P176, DOI 10.1159/000288427; FUNCH DP, 1983, J PSYCHOSOM RES, V27, P77, DOI 10.1016/0022-3999(83)90112-5; Giraldi T, 1997, PSYCHOTHER PSYCHOSOM, V66, P229, DOI 10.1159/000289140; HAYWARD JL, 1978, SEMIN ONCOL, V5, P445; Kiecolt-Glaser JK, 1999, EUR J CANCER, V35, P1603, DOI 10.1016/S0959-8049(99)00197-5; Kvikstad A, 1996, INT J CANCER, V67, P165, DOI 10.1002/(SICI)1097-0215(19960717)67:2<165::AID-IJC2>3.3.CO;2-4; KVIKSTAD A, 1995, BRIT J CANCER, V71, P1343, DOI 10.1038/bjc.1995.261; MAUNSELL E, 1998, PSYCHOONCOLOGY S, V7, P281; RAMIREZ AJ, 1989, BRIT MED J, V298, P291, DOI 10.1136/bmj.298.6669.291; SPIEGEL D, 1989, LANCET, V2, P888; Spitzer RL, 1990, STRUCTURED CLIN INTE	16	44	47	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 15	2002	324	7351					1420	1422		10.1136/bmj.324.7351.1420	http://dx.doi.org/10.1136/bmj.324.7351.1420			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	565CQ	12065263	Bronze, Green Published			2022-12-28	WOS:000176351400015
J	McCulloch, P; Taylor, I; Sasako, M; Lovett, B; Griffin, D				McCulloch, P; Taylor, I; Sasako, M; Lovett, B; Griffin, D			Randomised trials in surgery: problems and possible solutions	BRITISH MEDICAL JOURNAL			English	Article							GASTRIC-CANCER; LEARNING-CURVE; CHOLECYSTECTOMY; DISSECTION; SURVIVAL; LESSONS; PATIENT	The quality and quantity of randomised trials of surgical techniques is acknowledged to be limited. According to Peter McCulloch and colleagues, however, some aspects of surgery present special difficulties for randomised trials. In this article they analyse what these difficulties are and propose some solutions for improving the standards of clinical research in surgery.	Univ Liverpool, Ctr Clin Sci, Univ Hosp Aintree, Acad Surg Unit, Liverpool L9 7AL, Merseyside, England; UCL Royal Free & Univ Coll Med Sch, Dept Surg, London W1W 7EJ, England; Natl Canc Ctr, Gastr Surg Div, Chuo Ku, Tokyo, Japan; Basildob Hosp, Basildon SS16 5NL, England; Orthopaed Ctr, Nuffield Dept Orthopaed Surg, Oxford OX3 7LD, England	University of Liverpool; University of London; University College London; UCL Medical School; National Cancer Center - Japan; Nuffield Orthopaedic Centre	McCulloch, P (corresponding author), Univ Liverpool, Ctr Clin Sci, Univ Hosp Aintree, Acad Surg Unit, Long Lane, Liverpool L9 7AL, Merseyside, England.	petermcculloch@cs.com		McCulloch, Peter/0000-0002-3210-8273				BARKUN JS, 1992, LANCET, V340, P1116, DOI 10.1016/0140-6736(92)93148-G; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Black N, 1996, BRIT MED J, V312, P1215; BONENKAMP JJ, 1995, LANCET, V345, P745, DOI 10.1016/S0140-6736(95)90637-1; Bonenkamp JJ, 1999, NEW ENGL J MED, V340, P908, DOI 10.1056/NEJM199903253401202; CHALMERS TC, 1975, MED CLIN N AM, V59, P1035, DOI 10.1016/S0025-7125(16)32001-6; Clarke D, 2001, WORLD J SURG, V25, P819, DOI 10.1007/s00268-001-0011-x; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Cuschieri A, 1999, BRIT J CANCER, V79, P1522, DOI 10.1038/sj.bjc.6690243; DEGUILI M, 1998, J CLIN ONCOL, V16, P1; DOLL R, 1994, ANN NY ACAD SCI, V703, P313; ELLIS J, 1995, LANCET, V346, P407, DOI 10.1016/S0140-6736(95)92781-6; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Gray RG, 2000, LANCET, V355, P1588; Howes N, 1997, BRIT J SURG, V84, P1220; Kapiteijn E, 1999, EUR J SURG, V165, P410, DOI 10.1080/110241599750006613; Lovegrove J, 1997, LANCET, V350, P1128, DOI 10.1016/S0140-6736(97)06507-0; LOVETT B, 2000, EUR J SURG ONCOL, V26, P840; MCMAHON AJ, 1994, LANCET, V343, P135, DOI 10.1016/S0140-6736(94)90932-6; Mohammed MA, 2001, LANCET, V357, P463, DOI 10.1016/S0140-6736(00)04019-8; NESBIT ME, 1982, CANCER RES, V42, P674; NEUGEBAUER E, 1995, SURG ENDOSC-ULTRAS, V9, P550; Parikh D, 1996, BRIT J SURG, V83, P1595, DOI 10.1002/bjs.1800831134; POLLOCK A V, 1989, Theoretical Surgery, V4, P163; POLLOCK AV, 1993, BRIT J SURG, V80, P964, DOI 10.1002/bjs.1800800807; Poloniecki J, 1998, BRIT MED J, V316, P1697, DOI 10.1136/bmj.316.7146.1697; Ramsay C R, 2001, Health Technol Assess, V5, P1; SOLOMON MJ, 1995, SURGERY, V118, P459, DOI 10.1016/S0039-6060(05)80359-9; SOLOMON MJ, 1994, SURGERY, V115, P707; Testori A, 1999, MELANOMA RES, V9, P587, DOI 10.1097/00008390-199912000-00008; TUNEVALL TG, 1991, WORLD J SURG, V15, P383, DOI 10.1007/BF01658736; VANDERLINDEN W, 1980, SURGERY, V87, P258; VANRIJ AM, 1995, BRIT J SURG, V82, P1500, DOI 10.1002/bjs.1800821117; VOGELZANG NJ, 1995, UROLOGY, V46, P220, DOI 10.1016/S0090-4295(99)80197-6; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WANGENSTEEN OH, 1978, RISE SURG, P425	36	514	526	1	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 15	2002	324	7351					1448	1451		10.1136/bmj.324.7351.1448	http://dx.doi.org/10.1136/bmj.324.7351.1448			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	565CQ	12065273	Green Published			2022-12-28	WOS:000176351400025
J	Sommers, CL; Park, CS; Lee, J; Feng, CG; Fuller, CL; Grinberg, A; Hildebrand, JA; Lacana, E; Menon, RK; Shores, EW; Samelson, LE; Love, PE				Sommers, CL; Park, CS; Lee, J; Feng, CG; Fuller, CL; Grinberg, A; Hildebrand, JA; Lacana, E; Menon, RK; Shores, EW; Samelson, LE; Love, PE			A LAT mutation that inhibits T cell development yet induces lymphoproliferation	SCIENCE			English	Article							TYROSINE RESIDUES; CD5 EXPRESSION; ACTIVATION; RECEPTOR; LINKER; RAS; PHOSPHORYLATION; SELECTION; APOPTOSIS	Mice homozygous for a single tyrosine mutation in LAT (linker for activation of T cells) exhibited an early block in T cell maturation but later developed a polyclonal lymphoproliferative disorder and signs of autoimmune disease. T cell antigen receptor (TCR)-induced activation of phospholipase C-gamma 1 (PLC-gamma1) and of nuclear factor of activated T cells, calcium influx, interleukin-2 production, and cell death were reduced or abrogated in T cells from LAT mutant mice. In contrast, TCR-induced Erk activation was intact. These results identify a critical role for integrated PLC-gamma1 and Ras-Erk signaling through LAT in T cell development and homeostasis.	NICHHD, Lab Mammalian Genes & Dev, NIH, Bethesda, MD 20892 USA; NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Div Therapeut Prot, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA)	Love, PE (corresponding author), NICHHD, Lab Mammalian Genes & Dev, NIH, Bethesda, MD 20892 USA.	pel@helix.nih.gov		Fuller, Claudette/0000-0003-4741-4609	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001803] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001803] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aguado E, 2002, SCIENCE, V296, P2036, DOI 10.1126/science.1069057; Azzam HS, 1998, J EXP MED, V188, P2301, DOI 10.1084/jem.188.12.2301; CARRERA AC, 1989, J BIOL CHEM, V264, P15650; Ebinu JO, 2000, BLOOD, V95, P3199; Genot E, 2000, CURR OPIN IMMUNOL, V12, P289, DOI 10.1016/S0952-7915(00)00089-3; Kane LP, 1996, J IMMUNOL, V156, P4594; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; Lin J, 2001, J BIOL CHEM, V276, P29588, DOI 10.1074/jbc.M102221200; Paz PE, 2001, BIOCHEM J, V356, P461, DOI 10.1042/0264-6021:3560461; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; Sommers CL, 2001, J EXP MED, V194, P135, DOI 10.1084/jem.194.2.135; SOMMERS CL, UNPUB; vonBoehmer H, 1995, ANN NY ACAD SCI, V766, P52, DOI 10.1111/j.1749-6632.1995.tb26648.x; Weichert TR, 1997, IMMUNOLOGY, V90, P30, DOI 10.1046/j.1365-2567.1997.00133.x; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	20	225	235	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 14	2002	296	5575					2040	2043		10.1126/science.1069066	http://dx.doi.org/10.1126/science.1069066			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065840				2022-12-28	WOS:000176273300057
J	Mehta, MR; Lee, AK; Wilson, MA				Mehta, MR; Lee, AK; Wilson, MA			Role of experience and oscillations in transforming a rate code into a temporal code	NATURE			English	Article							HIPPOCAMPAL PYRAMIDAL CELLS; PHASE-PRECESSION; THETA-RHYTHM; RECEPTIVE-FIELDS; PLACE FIELDS; SPATIAL MAP; DYNAMICS; SEQUENCES; NEURONS; V1	In the vast majority of brain areas, the firing rates of neurons, averaged over several hundred milliseconds to several seconds, can be strongly modulated by, and provide accurate information about, properties of their inputs. This is referred to as the rate code. However, the biophysical laws of synaptic plasticity require precise timing of spikes over short timescales (< 10 ms)(1,2). Hence it is critical to understand the physiological mechanisms that can generate precise spike timing in vivo, and the relationship between such a temporal code and a rate code. Here we propose a mechanism by which a temporal code can be generated through an interaction between an asymmetric rate code and oscillatory inhibition. Consistent with the predictions of our model, the rate(3,4) and temporal(5-7) codes of hippocampal pyramidal neurons are highly correlated. Furthermore, the temporal code becomes more robust with experience. The resulting spike timing satisfies the temporal order constraints of hebbian learning. Thus, oscillations and receptive field asymmetry may have a critical role in temporal sequence learning.	MIT, RIKEN MIT Neurosci Res Ctr, Dept Brain & Cognit Sci, Ctr Learning & Memory, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); RIKEN	Mehta, MR (corresponding author), MIT, RIKEN MIT Neurosci Res Ctr, Dept Brain & Cognit Sci, Ctr Learning & Memory, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Mehta, Minesh P./AAB-8915-2019	Mehta, Minesh P./0000-0002-4812-5713				Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; Blum KI, 1996, NEURAL COMPUT, V8, P85, DOI 10.1162/neco.1996.8.1.85; Bose A, 2000, J COMPUT NEUROSCI, V9, P5, DOI 10.1023/A:1008976210366; BUZSAKI G, 1985, ELECTROEN CLIN NEURO, V61, P77, DOI 10.1016/0013-4694(85)91075-2; Chance FS, 1998, J NEUROSCI, V18, P4785; Ekstrom AD, 2001, NEURON, V31, P631, DOI 10.1016/S0896-6273(01)00401-9; Hasselmo ME, 2000, ANN NY ACAD SCI, V911, P418; Hirase H, 1999, EUR J NEUROSCI, V11, P4373, DOI 10.1046/j.1460-9568.1999.00853.x; HOPFIELD JJ, 1995, NATURE, V376, P33, DOI 10.1038/376033a0; Jensen O, 1996, LEARN MEMORY, V3, P279, DOI 10.1101/lm.3.2-3.279; Kamondi A, 1998, HIPPOCAMPUS, V8, P244, DOI 10.1002/(SICI)1098-1063(1998)8:3<244::AID-HIPO7>3.0.CO;2-J; KONIG P, 1995, NEURAL COMPUT, V7, P469, DOI 10.1162/neco.1995.7.3.469; Levy W. B., 1989, COMPUTATIONAL MODELS, P243, DOI DOI 10.1016/S0079-7421(08)60113-9; Livingstone MS, 1998, NEURON, V20, P509, DOI 10.1016/S0896-6273(00)80991-5; Magee JC, 2001, J NEUROPHYSIOL, V86, P528, DOI 10.1152/jn.2001.86.1.528; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Mehta M. R., 1996, COMPUTATIONAL NEUROS, P741; Mehta MR, 2000, NEURON, V25, P707, DOI 10.1016/S0896-6273(00)81072-7; Mehta MR, 2001, NEUROSCIENTIST, V7, P490, DOI 10.1177/107385840100700605; Mehta MR, 1997, P NATL ACAD SCI USA, V94, P8918, DOI 10.1073/pnas.94.16.8918; Mehta MR, 2000, NEUROCOMPUTING, V32, P905, DOI 10.1016/S0925-2312(00)00259-9; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; Rao RPN, 2001, NOVART FDN SYMP, V239, P208; Skaggs WE, 1996, HIPPOCAMPUS, V6, P149, DOI 10.1002/(SICI)1098-1063(1996)6:2<149::AID-HIPO6>3.0.CO;2-K; Toth K, 1997, J PHYSIOL-LONDON, V500, P463, DOI 10.1113/jphysiol.1997.sp022033; Tsodyks MV, 1996, HIPPOCAMPUS, V6, P271, DOI 10.1002/(SICI)1098-1063(1996)6:3<271::AID-HIPO5>3.3.CO;2-Q; Wallenstein GV, 1997, J NEUROPHYSIOL, V78, P393, DOI 10.1152/jn.1997.78.1.393; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; Zar JH., 1999, BIOSTAT ANAL, V663rd	30	463	472	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 13	2002	417	6890					741	746		10.1038/nature00807	http://dx.doi.org/10.1038/nature00807			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	561QY	12066185				2022-12-28	WOS:000176154700045
J	Clark, S				Clark, S			HIV/AIDS in Africa, 2002	LANCET			English	Editorial Material									Lancet, London NW1 7BY, England		Clark, S (corresponding author), Lancet, London NW1 7BY, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 8	2002	359	9322					1960	1960		10.1016/S0140-6736(02)08848-7	http://dx.doi.org/10.1016/S0140-6736(02)08848-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076549				2022-12-28	WOS:000176232500006
J	Burns, MA				Burns, MA			Analytic chemistry: Everyone's a (future) chemist	SCIENCE			English	Editorial Material							MICROFABRICATION; BIOLOGY; DEVICES		Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Burns, MA (corresponding author), Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA.							Burns MA, 1998, SCIENCE, V282, P484, DOI 10.1126/science.282.5388.484; Figeys D, 2000, ANAL CHEM, V72, p330A, DOI 10.1021/ac002800y; Gardner JW, 1999, ELECT NOSES PRINCIPL; Jain KK, 2001, SCIENCE, V294, P621, DOI 10.1126/science.294.5542.621; Jensen KF, 2001, CHEM ENG SCI, V56, P293, DOI 10.1016/S0009-2509(00)00230-X; Khandurina J, 2002, J CHROMATOGR A, V943, P159, DOI 10.1016/S0021-9673(01)01451-0; Landers JP, 1997, HDB CAPILLARY ELECTR, V2nd; Lee J, 2002, SENSOR ACTUAT A-PHYS, V95, P259, DOI 10.1016/S0924-4247(01)00734-8; Mitchell P, 2001, NAT BIOTECHNOL, V19, P717, DOI 10.1038/90754; Moore G. E., 1965, ELECTRONICS, V38, P1, DOI DOI 10.1109/JPROC.1998.658762; Pollack MG, 2000, APPL PHYS LETT, V77, P1725, DOI 10.1063/1.1308534; Quake SR, 2000, SCIENCE, V290, P1536, DOI 10.1126/science.290.5496.1536; RAMSEY JM, 2001, P MICR TOT AN SYST 2; REID TR, 2001, CHIP; Sammarco TS, 1999, AICHE J, V45, P350, DOI 10.1002/aic.690450215; SHOJI S, 1994, J MICROMECH MICROENG, V4, P157, DOI 10.1088/0960-1317/4/4/001; Terray A, 2002, SCIENCE, V296, P1841, DOI 10.1126/science.1072133; Whitesides GM, 2001, ANNU REV BIOMED ENG, V3, P335, DOI 10.1146/annurev.bioeng.3.1.335; WISE KD, 1991, SCIENCE, V254, P1335, DOI 10.1126/science.1962192; 1999, NATURE GENET S, V21	20	46	47	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 7	2002	296	5574					1818	1819		10.1126/science.1073562	http://dx.doi.org/10.1126/science.1073562			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052944				2022-12-28	WOS:000176054300032
J	Gaspoz, J; Coxson, PG; Goldman, PA; Williams, LW; Kuntz, KM; Hunink, MGM; Goldman, L				Gaspoz, J; Coxson, PG; Goldman, PA; Williams, LW; Kuntz, KM; Hunink, MGM; Goldman, L			Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; MEDICARE BENEFICIARIES; MORTALITY; STROKE; HEALTH; RISK; PREVALENCE; OUTCOMES; DECLINE; QUALITY	Background: Both aspirin and clopidogrel reduce the rate of cardiovascular events in patients with coronary heart disease. We estimated the cost effectiveness of the increased use of aspirin, clopidogrel, or both for secondary prevention in patients with coronary heart disease. Methods: We used the Coronary Heart Disease Policy Model, a computer simulation of the U.S. population, to estimate the incremental cost effectiveness (in dollars per quality-adjusted years of life gained) of four strategies in patients over 35 years of age with coronary disease from 2003 to 2027: aspirin for all eligible patients (i.e., those who were not allergic to or intolerant of aspirin), aspirin for all eligible patients plus clopidogrel for patients who were ineligible for aspirin, clopidogrel for all patients, and the combination of aspirin for all eligible patients plus clopidogrel for all patients. Results: The extension of aspirin therapy from the current levels of use to all eligible patients for 25 years would have an estimated cost-effectiveness ratio of about $11,000 per quality-adjusted year of life gained. The addition of clopidogrel for the 5 percent of patients who are ineligible for aspirin would cost about $31,000 per quality-adjusted year of life gained. Clopidogrel alone in all patients or in routine combination with aspirin had an incremental cost of more than $130,000 per quality-adjusted year of life gained and remained financially unattractive across a wide range of assumptions. However, clopidogrel alone or in combination with aspirin would cost less than $50,000 per quality-adjusted year of life gained if its price were reduced by 70 to 82 percent, to $1.00 and $0.60 per day, respectively. Conclusions: Increased prescription of aspirin for secondary prevention of coronary heart disease is attractive from a cost-effectiveness perspective. Because clopidogrel is more costly, its incremental cost effectiveness is currently unattractive, unless its use is restricted to patients who are ineligible for aspirin.	Hop Univ, Dept Med, Med Clin 2, CH-1211 Geneva 14, Switzerland; Hop Univ, Div Cardiol, CH-1211 Geneva 14, Switzerland; Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Erasmus Univ, Sch Med, Dept Radiol, Rotterdam, Netherlands; Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, Rotterdam, Netherlands	University of Geneva; University of California System; University of California San Francisco; Harvard University; Harvard T.H. Chan School of Public Health; Erasmus University Rotterdam; Erasmus University Rotterdam	Gaspoz, J (corresponding author), Hop Univ, Dept Med, Med Clin 2, 24 Rue Micheli du Crest, CH-1211 Geneva 14, Switzerland.	jean-michel.gaspoz@hcuge.ch			AHRQ HHS [R01 HS06258] Funding Source: Medline; NHLBI NIH HHS [R01 HL46315] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006258] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046315] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDHOUS P, 1994, SCIENCE, V263, P24, DOI 10.1126/science.8272863; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1994, BMJ-BRIT MED J, V308, P81, DOI DOI 10.1136/BMJ.308.6921.81; *ANT TRIAL COLL, 1998, BMJ-BRIT MED J, V286, P320; Awtry EH, 2000, CIRCULATION, V101, P1206, DOI 10.1161/01.CIR.101.10.1206; Ayanian JZ, 1997, ARCH INTERN MED, V157, P2570, DOI 10.1001/archinte.157.22.2570; Bennett CL, 2000, NEW ENGL J MED, V342, P1773, DOI 10.1056/NEJM200006153422402; Bratzler D W, 1997, J Okla State Med Assoc, V90, P219; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; Cairns JA, 1998, CHEST, V114, p611S, DOI 10.1378/chest.114.5_Supplement.611S; *CLOP UNST ANG PRE, 2001, NEW ENGL J MED, V345, P1716; *CLOP UNST ANG PRE, 2001, NEW ENGL J MED, V345, P1506; DOBKIN B, 1995, NEUROLOGY, V45, pS6; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V264, P41, DOI 10.1001/jama.264.1.41; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; Goldman L, 2001, J AM COLL CARDIOL, V38, P1012, DOI 10.1016/S0735-1097(01)01512-1; Gorelick PB, 1999, STROKE, V30, P1716, DOI 10.1161/01.STR.30.8.1716; Gum PA, 2001, JAMA-J AM MED ASSOC, V286, P1187, DOI 10.1001/jama.286.10.1187; Hankey GJ, 2000, LANCET, V356, P269, DOI 10.1016/S0140-6736(00)02498-3; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; Hedman J, 1999, INT J EPIDEMIOL, V28, P717, DOI 10.1093/ije/28.4.717; Hennekens CH, 1997, CIRCULATION, V96, P2751, DOI 10.1161/01.CIR.96.8.2751; Hugenholtz P G, 1991, Acta Med Port, V4 Suppl 1, p16S; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; Johannesson M, 1997, NEW ENGL J MED, V336, P332, DOI 10.1056/NEJM199701303360503; KRUMHOLZ HM, 1995, CIRCULATION, V92, P2841, DOI 10.1161/01.CIR.92.10.2841; Krumholz HM, 1996, ANN INTERN MED, V124, P292, DOI 10.7326/0003-4819-124-3-199602010-00002; *MED EC STAFF, 2000, DRUG TOP RED BOOK; Morris S, 1997, HEALTH ECON, V6, P589, DOI 10.1002/(SICI)1099-1050(199711)6:6<589::AID-HEC286>3.0.CO;2-D; OSTER G, 1994, STROKE, V25, P1149, DOI 10.1161/01.STR.25.6.1149; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; PEDERSEN TR, 1994, LANCET, V344, P1383; Phillips KA, 2000, JAMA-J AM MED ASSOC, V284, P2748, DOI 10.1001/jama.284.21.2748; Rolka DB, 2001, DIABETES CARE, V24, P197, DOI 10.2337/diacare.24.2.197; Sarasin FP, 2000, ARCH INTERN MED, V160, P2773, DOI 10.1001/archinte.160.18.2773; Stafford RS, 2000, CIRCULATION, V101, P1097, DOI 10.1161/01.CIR.101.10.1097; Stinett AA, 1996, COST EFFECTIVENESS H, P349; Tsevat J, 2001, AM HEART J, V141, P727, DOI 10.1067/mhj.2001.114805; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; Yusuf S, 2001, NEW ENGL J MED, V345, P494	44	188	195	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 6	2002	346	23					1800	1806		10.1056/NEJM200206063462309	http://dx.doi.org/10.1056/NEJM200206063462309			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	559EK	12050341	Bronze			2022-12-28	WOS:000176012500008
J	Moss, T; Stefanovsky, VY				Moss, T; Stefanovsky, VY			At the center of eukaryotic life	CELL			English	Review							RNA-POLYMERASE-I; RIBOSOMAL TRANSCRIPTION; RDNA TRANSCRIPTION; UBF; PHOSPHORYLATION; ACETYLATION; RB	The ribosomal RNA genes encode the enzymatic scaffold of the ribosome and thereby perform perhaps the most basic of all housekeeping functions. However, recent data suggests that they might also control important aspects of cell behavior.	Univ Laval, Ctr Rech Hotel Dieu Quebec, Ctr Canc Res, Quebec City, PQ G1R 2J6, Canada; Univ Laval, Ctr Rech Hotel Dieu Quebec, Dept Med Biol, Quebec City, PQ G1R 2J6, Canada	Laval University; Laval University	Moss, T (corresponding author), Univ Laval, Ctr Rech Hotel Dieu Quebec, Ctr Canc Res, 9 Rue McMahon, Quebec City, PQ G1R 2J6, Canada.			Moss, Thomas (Tom)/0000-0003-2047-4783				Bordi L, 2001, MOL BIOL CELL, V12, P753, DOI 10.1091/mbc.12.3.753; BOUKHGALTER B, 2002, IN PRESS GENE; Fath S, 2001, P NATL ACAD SCI USA, V98, P14334, DOI 10.1073/pnas.231181398; Hannan KM, 2000, ONCOGENE, V19, P4988, DOI 10.1038/sj.onc.1203875; Hirschler-Laszkiewicz I, 2001, NUCLEIC ACIDS RES, V29, P4114, DOI 10.1093/nar/29.20.4114; Iben S, 2002, CELL, V109, P297, DOI 10.1016/S0092-8674(02)00729-8; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; O'Sullivan AC, 2002, MOL CELL BIOL, V22, P657, DOI 10.1128/MCB.22.2.657-668.2002; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Panov KI, 2001, MOL CELL BIOL, V21, P2641, DOI 10.1128/MCB.21.8.2641-2649.2001; Paule MR., 1998, TRANSCRIPTION RIBOSO; Pelletier G, 2000, MOL CELL, V6, P1059, DOI 10.1016/S1097-2765(00)00104-0; Santoro R, 2001, MOL CELL, V8, P719, DOI 10.1016/S1097-2765(01)00317-3; Shou WY, 2001, MOL CELL, V8, P45, DOI 10.1016/S1097-2765(01)00291-X; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Strohner R, 2001, EMBO J, V20, P4892, DOI 10.1093/emboj/20.17.4892; Tian QJ, 2001, DEVELOPMENT, V128, P407; Voit R, 2001, P NATL ACAD SCI USA, V98, P13631, DOI 10.1073/pnas.231071698; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000	19	158	164	0	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 31	2002	109	5					545	548		10.1016/S0092-8674(02)00761-4	http://dx.doi.org/10.1016/S0092-8674(02)00761-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	558GL	12062097	Bronze			2022-12-28	WOS:000175957900003
J	Baba, T; Takeuchi, F; Kuroda, M; Yuzawa, H; Aoki, K; Oguchi, A; Nagai, Y; Iwama, N; Asano, K; Naimi, T; Kuroda, H; Cui, L; Yamamoto, K; Hiramatsu, K				Baba, T; Takeuchi, F; Kuroda, M; Yuzawa, H; Aoki, K; Oguchi, A; Nagai, Y; Iwama, N; Asano, K; Naimi, T; Kuroda, H; Cui, L; Yamamoto, K; Hiramatsu, K			Genome and virulence determinants of high virulence community-acquired MRSA	LANCET			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; STRAINS; GENE; EXPRESSION; SEQUENCE; PROTEIN	Background A new type of meticillin-resistant Staphylococcus aureus (MRSA), designated community-acquired MRSA, is becoming increasingly noticeable in the community, some strains of which cause fatal infections in otherwise healthy individuals. By contrast with hospital-acquired MRSA, community-acquired MRSA is more susceptible to non beta-lactam antibiotics. We investigated the high virulence potential of certain strains of this bacterium. Methods We ascertained the whole genome sequence of MW2, a strain of community-acquired MRSA, by shotgun cloning and sequencing, MW2 caused fatal septicaemia and septic arthritis in a 16-month-old girl in North Dakota, USA, in 1998. The genome of this strain was compared with those of hospital-acquired MRSA strains, including N315 and Mu50. Findings Meticillin resistance gene (mecA) in MW2 was carried by a novel allelic form (type IVa) of staphylococcal cassette chromosome mec (SCCmec), by contrast with type II in N315 and Mu50. Type IVa SCCmec did not carry any of the multiple antibiotic resistance genes reported in type II SCCmec. By contrast, 19 additional virulence genes were recorded in the MW2 genome. All but two of these virulence genes were noted in four of the seven genomic islands of MW2. Interpretation MW2 carried a range of virulence and resistance genes that was distinct from those displayed on the chromosomes of extant S aureus strains. Most genes were carried by specific allelic forms of genomic islands in the MW2 chromosome. The combination of allelic forms of genomic islands is the genetic basis that determines the pathogenicity of medically important phenotypes of S aureus, including those of community-acquired MRSA strains.	Juntendo Univ, Dept Bacteriol, Bunkyo Ku, Tokyo 1138421, Japan; Natl Inst Technol & Evaluat, Tokyo, Japan; New Energy & Ind Technol Dev Org, Tokyo, Japan; Int Med Ctr Japan, Res Inst, Tokyo, Japan; Org Pharmaceut Safety & Res, Tokyo, Japan; Minnesota Dept Hlth, Minneapolis, MN USA	Juntendo University; National Center for Global Health & Medicine - Japan; Minnesota Department of Health (MHD)	Hiramatsu, K (corresponding author), Juntendo Univ, Dept Bacteriol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	hiram@med.juntendo.ac.jp		Naimi, Timothy/0000-0001-9849-4413; cui (Cui), long zhu (Longzhu)/0000-0002-8909-3885				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRAY N, 2002, AVID GLOBAL ALIGNMEN; *CDCP, 1999, MMWR-MORBID MORTAL W, V48, P707; Cui LZ, 1999, SCAND J INFECT DIS, V31, P208, DOI 10.1080/003655499750006326; Elasri MO, 2002, BONE, V30, P275, DOI 10.1016/S8756-3282(01)00632-9; Enright MC, 1999, TRENDS MICROBIOL, V7, P482, DOI 10.1016/S0966-842X(99)01609-1; FULLERPACE FV, 1986, P NATL ACAD SCI USA, V83, P9368, DOI 10.1073/pnas.83.24.9368; Gillet Y, 2002, LANCET, V359, P753, DOI 10.1016/S0140-6736(02)07877-7; Groom AV, 2001, JAMA-J AM MED ASSOC, V286, P1201, DOI 10.1001/jama.286.10.1201; Hiramatsu K, 2001, TRENDS MICROBIOL, V9, P486, DOI 10.1016/S0966-842X(01)02175-8; Katayama Y, 2001, ANTIMICROB AGENTS CH, V45, P1955, DOI 10.1128/AAC.45.7.1955-1963.2001; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; Ma XX, 2002, ANTIMICROB AGENTS CH, V46, P1147, DOI 10.1128/AAC.46.4.1147-1152.2002; Murphy E, 1989, MOBILE DNA-UK, P269; Naimi TS, 2001, CLIN INFECT DIS, V33, P990, DOI 10.1086/322693; Nilsson H, 1999, J IMMUNOL, V163, P6686; *OK U, 2002, STAPH AUR NCTC 8325; Omoe K, 2002, J CLIN MICROBIOL, V40, P857, DOI 10.1128/JCM.40.3.857-862.2002; Papageorgiou AC, 2000, TRENDS MICROBIOL, V8, P369, DOI 10.1016/S0966-842X(00)01793-5; PATTI JM, 1992, J BIOL CHEM, V267, P4766; PATTI JM, 1994, INFECT IMMUN, V62, P152, DOI 10.1128/IAI.62.1.152-161.1994; RAY BK, 1979, MOL GEN GENET, V174, P25, DOI 10.1007/BF00433301; REN KY, 1994, J EXP MED, V180, P1675, DOI 10.1084/jem.180.5.1675; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; Suzek BE, 2001, BIOINFORMATICS, V17, P1123, DOI 10.1093/bioinformatics/17.12.1123; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Williams RJ, 2000, INFECT IMMUN, V68, P4407, DOI 10.1128/IAI.68.8.4407-4415.2000; Yoshida T, 1997, MICROBIOL IMMUNOL, V41, P687, DOI 10.1111/j.1348-0421.1997.tb01912.x	28	1012	2020	1	164	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 25	2002	359	9320					1819	1827		10.1016/S0140-6736(02)08713-5	http://dx.doi.org/10.1016/S0140-6736(02)08713-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044378				2022-12-28	WOS:000175775500011
J	Stenestrand, U; Wallentin, L				Stenestrand, U; Wallentin, L			Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study	LANCET			English	Article							UNSTABLE ANGINA; THROMBOLYTIC THERAPY; CARDIAC-CATHETERIZATION; CONSERVATIVE STRATEGIES; IMMEDIATE ANGIOPLASTY; PLASMINOGEN-ACTIVATOR; CORONARY-ANGIOGRAPHY; OUTCOMES; TRIAL; ORGANIZATION	Background Randomised trials of early revascularisation in acute coronary syndromes have yielded conflicting results with respect to effects on survival. We assessed the association between revascularisation within 14 days after the index event and 1-year mortality in individuals who survived for at least 14 days after an acute myocardial infarction. Methods We studied a prospective cohort of patients admitted to the coronary care units of 61 Swedish hospitals between 1995 and 1998. We obtained 1-year mortality data from the Swedish National Cause of Death Register. We assessed 21912 individuals with first registry-recorded acute myocardial infarction, who were younger than age 80 years, and alive at day 14. Relative risk of 1-year mortality in patients who had revascularisation (n=2554) or those who did not (n=19 358) within 14 days was calculated by Cox regression analysis, adjusting for multiple covariates that affect mortality and with a propensity score that adjusted for covariates that affected the likelihood of early revascularisation. Findings At 1 year, unadjusted mortality was 9.0% (1751 deaths) in the conservative group and 3.3% (84 deaths) in the early revascularisation group. In the Cox regression analysis early revascularisation was associated with a reduction in 1-year mortality (relative risk 0.47; 95% CI 0.37-0.60; p<0.001). This relative reduction of mortality was similar in all subgroups irrespective of age, sex, baseline characteristics, previous disease manifestations, or treatment. Interpretation Early revascularisation in individuals with acute myocardial infarction is associated with substantial reduction in 1-year mortality. Our findings lend support to the use of an invasive approach early after an acute myocardial infarction.	Linkoping Univ Hosp, Dept Cardiol, SE-58185 Linkoping, Sweden; Univ Uppsala Hosp, Dept Cardiol, Uppsala, Sweden	Linkoping University; Uppsala University; Uppsala University Hospital	Stenestrand, U (corresponding author), Linkoping Univ Hosp, Dept Cardiol, SE-58185 Linkoping, Sweden.	Stenestrand@riks-hia.c.se						ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; ANDERSON HV, 1995, J AM COLL CARDIOL, V26, P1643, DOI 10.1016/0735-1097(95)00404-1; [Anonymous], 1989, NEW ENGL J MED, V320, P618; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; Chamberlain DA, 1997, LANCET, V350, P461; Cohen MG, 2001, AM HEART J, V141, P391, DOI 10.1067/mhj.2001.113216; DEBONO DP, 1991, BMJ-BRIT MED J, V302, P555; Ellis SG, 2000, AM HEART J, V139, P1046, DOI 10.1067/mhj.2000.106624; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Joffe MM, 1999, AM J EPIDEMIOL, V150, P327; Lupon J, 1999, J AM COLL CARDIOL, V34, P1947, DOI 10.1016/S0735-1097(99)00446-5; Madsen JK, 1997, CIRCULATION, V96, P748; Mulder HJGH, 2000, AM J CARDIOL, V86, P742, DOI 10.1016/S0002-9149(00)01073-0; Piegas LS, 1999, AM J CARDIOL, V84, p7M; Pilote L, 1996, NEW ENGL J MED, V335, P1198, DOI 10.1056/NEJM199610173351606; Rogers WJ, 2000, J AM COLL CARDIOL, V35, P371, DOI 10.1016/S0735-1097(99)00505-7; Serruys PW, 1999, EUR HEART J, V20, P58, DOI 10.1053/euhj.1998.1150; SIMOONS ML, 1988, LANCET, V1, P199; Stenestrand U, 2001, JAMA-J AM MED ASSOC, V285, P430, DOI 10.1001/jama.285.4.430; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; Wallentin L, 1999, LANCET, V354, P708; Ward SR, 1997, AM J CARDIOL, V79, P539, DOI 10.1016/S0002-9149(96)00812-0; Weaver WD, 1997, JAMA-J AM MED ASSOC, V278, P2093, DOI 10.1001/jama.278.23.2093; WILLIAMS DO, 1992, CIRCULATION, V85, P533, DOI 10.1161/01.CIR.85.2.533; Yusuf S, 1998, LANCET, V352, P507, DOI 10.1016/S0140-6736(97)11162-X	30	93	95	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 25	2002	359	9320					1805	1811		10.1016/S0140-6736(02)08710-X	http://dx.doi.org/10.1016/S0140-6736(02)08710-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044375				2022-12-28	WOS:000175775500008
J	Anetseder, M; Hager, M; Muller, CR; Roewer, N				Anetseder, M; Hager, M; Muller, CR; Roewer, N			Diagnosis of susceptibility to malignant hyperthermia by use of a metabolic test	LANCET			English	Article								Susceptibility to malignant hyperthermia is diagnosed by contracture test, which requires an open muscle biopsy sample. We postulated that Intramuscular injection of caffeine Increases local carbon dioxide pressure (pCO(2)) In Individuals susceptible to malignant hyperthermia but not in those who are non-susceptible or In healthy Individuals. We measured pCO(2) in the rectus femoris muscle during local stimulation with 500 muL caffeine 80 mmol/L In 12 patients susceptible to malignant hyperthermia, eight non-susceptible Individuals, and seven healthy controls. In susceptible individuals, pCO(2) temporarily Increased to a maximum of 63 mm Hg (IQR 61-69) compared with 44 mm Hg (43-47) In non-susceptible participants (p=0.003) and 42 mm Hg (41-46) in controls (p=0.003). There were no systemic side-effects. Metabolic monitoring of the highly diffusible CO2 stimulated by caffeine might allow a minimally Invasive test for susceptibility to malignant hyperthermia.	Univ Wurzburg, Dept Anaesthesiol, D-97080 Wurzburg, Germany	University of Wurzburg	Anetseder, M (corresponding author), Univ Wurzburg, Dept Anaesthesiol, J Schneider Str 2, D-97080 Wurzburg, Germany.	anets@anaesthesie.uni-wuerzburg.de						Denborough M, 1998, LANCET, V352, P1131, DOI 10.1016/S0140-6736(98)03078-5; ELLIS FR, 1984, BRIT J ANAESTH, V56, P1267; Girard T, 2001, Hum Mutat, V18, P357, DOI 10.1002/humu.1203; GRONERT GA, 1976, ANESTHESIOLOGY, V44, P36, DOI 10.1097/00000542-197601000-00008; Urwyler A, 2001, BRIT J ANAESTH, V86, P283, DOI 10.1093/bja/86.2.283	5	37	41	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 4	2002	359	9317					1579	1580		10.1016/S0140-6736(02)08506-9	http://dx.doi.org/10.1016/S0140-6736(02)08506-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047971				2022-12-28	WOS:000175460700015
J	Xu, HX; Ramsey, IS; Kotecha, SA; Moran, MM; Chong, JHA; Lawson, D; Ge, P; Lilly, J; Silos-Santiago, I; Xie, Y; DiStefano, PS; Curtis, R; Clapham, DE				Xu, HX; Ramsey, IS; Kotecha, SA; Moran, MM; Chong, JHA; Lawson, D; Ge, P; Lilly, J; Silos-Santiago, I; Xie, Y; DiStefano, PS; Curtis, R; Clapham, DE			TRPV3 is a calcium-permeable temperature-sensitive cation channel	NATURE			English	Article							RAT SENSORY NEURONS; CAPSAICIN-RECEPTOR; ION CHANNELS; NOXIOUS HEAT; CURRENTS; DEPENDENCE; CELLS	Transient receptor potential (TRP) proteins are cation-selective channels that function in processes as diverse as sensation and vasoregulation. Mammalian TRP channels that are gated by heat and capsaicin (> 43 degreesC; TRPV1 (ref. 1)), noxious heat (> 52 degreesC; TRPV2 (ref. 2)), and cooling (< 22 degrees C; TRPM8 (refs 3, 4)) have been cloned; however, little is known about the molecular determinants of temperature sensing in the range between similar to 22 degrees C and 40 degrees C. Here we have identified a member of the vanilloid channel family, human TRPV3 (hTRPV3) that is expressed in skin, tongue, dorsal root ganglion, trigeminal ganglion, spinal cord and brain. Increasing temperature from 22 degrees C to 40 degrees C in mammalian cells transfected with hTRPV3 elevated intracellular calcium by activating a nonselective cationic conductance. As in published recordings from sensory neurons, the current was steeply dependent on temperature, sensitized with repeated heating, and displayed a marked hysteresis on heating and cooling(5-10). On the basis of these properties, we propose that hTRPV3 is thermosensitive in the physiological range of temperatures between TRPM8 and TRPV1.	Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Clapham, DE (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst, Enders 1309,320 Longwood Ave, Boston, MA 02115 USA.	dclapham@enders.tch.harvard.edu	Clapham, David/S-1123-2019; Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428; 	NHLBI NIH HHS [T32 HL007572] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrew D, 2001, J PHYSIOL-LONDON, V537, P489, DOI 10.1111/j.1469-7793.2001.00489.x; BRENGELMANN GL, 1989, TXB PHYSL, V2, P1584; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Cesare P, 1999, P NATL ACAD SCI USA, V96, P7658, DOI 10.1073/pnas.96.14.7658; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; DeCoursey TE, 1998, J GEN PHYSIOL, V112, P503, DOI 10.1085/jgp.112.4.503; FUNDIN BT, 1994, EXP BRAIN RES, V99, P233; Gotoh H, 1998, BRAIN RES, V796, P319, DOI 10.1016/S0006-8993(98)00355-2; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hori A, 1999, NEUROSCI LETT, V275, P93, DOI 10.1016/S0304-3940(99)00732-6; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Liu L, 2000, PHYSIOL BEHAV, V69, P363, DOI 10.1016/S0031-9384(00)00209-2; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Nagy I, 1999, J NEUROSCI, V19, P10647, DOI 10.1523/JNEUROSCI.19-24-10647.1999; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; Qu Y, 2001, MOL CELL NEUROSCI, V18, P570, DOI 10.1006/mcne.2001.1039; Reichling DB, 1997, P NATL ACAD SCI USA, V94, P7006, DOI 10.1073/pnas.94.13.7006; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; SPRAY DC, 1986, ANNU REV PHYSIOL, V48, P625; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Vyklicky L, 1999, J PHYSIOL-LONDON, V517, P181, DOI 10.1111/j.1469-7793.1999.0181z.x; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200	30	618	663	2	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 11	2002	418	6894					181	186		10.1038/nature00882	http://dx.doi.org/10.1038/nature00882			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12077604				2022-12-28	WOS:000176710400040
J	Lain, KY; Roberts, JM				Lain, KY; Roberts, JM			Contemporary concepts of the pathogenesis and management of preeclampsia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ENDOTHELIAL DYSFUNCTION; SPIRAL ARTERIES; PREGNANCY; WOMEN; RISK; HYPERTENSION; ECLAMPSIA; INVASION		Univ Pittsburgh, Magee Womens Res Inst, Pittsburgh, PA USA; Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lain, KY (corresponding author), Magee Womens Hosp, 300 Halket St, Pittsburgh, PA 15213 USA.		Roberts, James/AAI-3283-2020	Roberts, James/0000-0002-2671-3207				*ACOG, 2002, ACOG PRACT B, V33, P1; *ACOG, 2001, ACOG PRACT B, V29, P1; ARIAS F, 1993, AM J OBSTET GYNECOL, V168, P585, DOI 10.1016/0002-9378(93)90499-9; BROWN MA, 1994, CLIN SCI, V86, P251, DOI 10.1042/cs0860251; Caritis S, 1998, NEW ENGL J MED, V338, P701, DOI 10.1056/NEJM199803123381101; Chambers JC, 2001, JAMA-J AM MED ASSOC, V285, P1607, DOI 10.1001/jama.285.12.1607; CLARK SL, 1988, AM J OBSTET GYNECOL, V158, P453, DOI 10.1016/0002-9378(88)90003-8; DEKKER GA, 1995, AM J OBSTET GYNECOL, V173, P1042, DOI 10.1016/0002-9378(95)91324-6; DULEY L, 1995, LANCET, V345, P1455; Duley L, 2002, MAGNESIUM SULPHATE V; Gifford RW, 2000, AM J OBSTET GYNECOL, V183, pS1, DOI 10.1067/mob.2000.107928; Goldenberg RL, 1998, NEW ENGL J MED, V339, P313, DOI 10.1056/NEJM199807303390506; Hubel CA, 2000, BRIT J OBSTET GYNAEC, V107, P776, DOI 10.1111/j.1471-0528.2000.tb13340.x; HUBEL CA, 1999, CHESLEYS HYPERTENSIV; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; Kupferminc MJ, 1999, NEW ENGL J MED, V340, P9, DOI 10.1056/NEJM199901073400102; Laivuori H, 1996, J CLIN ENDOCR METAB, V81, P2908, DOI 10.1210/jc.81.8.2908; Martin JN, 1999, AM J OBSTET GYNECOL, V180, P1407, DOI 10.1016/S0002-9378(99)70026-8; Matijevic R, 1999, BRIT J OBSTET GYNAEC, V106, P78, DOI 10.1111/j.1471-0528.1999.tb08089.x; MEEKINS JW, 1994, BRIT J OBSTET GYNAEC, V101, P669, DOI 10.1111/j.1471-0528.1994.tb13182.x; Redman CWG, 1999, AM J OBSTET GYNECOL, V180, P499, DOI 10.1016/S0002-9378(99)70239-5; Roberts JM, 1998, SEMIN REPROD ENDOCR, V16, P5, DOI 10.1055/s-2007-1016248; Roberts JM, 2001, LANCET, V357, P53, DOI 10.1016/S0140-6736(00)03577-7; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; ROBERTS JM, 1998, MATERNAL FETAL MED; SCHIFF E, 1994, OBSTET GYNECOL, V84, P626; SIBAI BM, 1983, OBSTET GYNECOL, V61, P571; Sibai BM, 1997, AM J OBSTET GYNECOL, V177, P1003, DOI 10.1016/S0002-9378(97)70004-8; SIBAI BM, 1990, AM J OBSTET GYNECOL, V162, P311, DOI 10.1016/0002-9378(90)90376-I	29	260	276	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	2002	287	24					3183	3186		10.1001/jama.287.24.3183	http://dx.doi.org/10.1001/jama.287.24.3183			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566FF	12076198				2022-12-28	WOS:000176415800002
J	Kihm, AJ; Kong, Y; Hong, W; Russell, JE; Rouda, S; Adachi, K; Simon, MC; Blobel, GA; Weiss, MJ				Kihm, AJ; Kong, Y; Hong, W; Russell, JE; Rouda, S; Adachi, K; Simon, MC; Blobel, GA; Weiss, MJ			An abundant erythroid protein that stabilizes free alpha-haemoglobin	NATURE			English	Article							SEVERE BETA-THALASSEMIA; EMBRYONIC STEM-CELLS; MEMBRANE SKELETON; MOUSE MODEL; PRECURSORS; APOPTOSIS; GATA-1; DIFFERENTIATION; CHAINS	The development of red blood cells (erythrocytes) is distinguished by high-level production of the oxygen carrier, haemoglobin A (HbA), a heterotetramer of alpha- and beta-haemoglobin subunits. HbA synthesis is coordinated to minimize the accumulation of free subunits that form cytotoxic precipitates(1-3). Molecular chaperones that regulate globin subunit stability, folding or assembly have been proposed to exist but have never been identified. Here we identify a protein stabilizing free a- haemoglobin by using a screen for genes induced by the essential erythroid transcription factor GATA-1 (refs 4, 5). Alpha Haemoglobin Stabilizing Protein (AHSP) is an abundant, erythroid-specific protein that forms a stable complex with free alpha- haemoglobin but not with beta-haemoglobin or haemoglobin A (alpha(2)beta(2)). Moreover, AHSP specifically protects free alpha- haemoglobin from precipitation in solution and in live cells. AHSP-gene-ablated mice exhibit reticulocytosis and abnormal erythrocyte morphology with intracellular inclusion bodies that stain positively for denatured haemoglobins. Hence, AHSP is required for normal erythropoiesis, probably acting to block the deleterious effects of free alpha- haemoglobin precipitation. Accordingly, AHSP gene dosage is predicted to modulate pathological states of alpha-haemoglobin excess, such as beta-thalassaemia.	Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA; Univ Penn, Abramson Family Canc Res Inst, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Howard Hughes Medical Institute; University of Pennsylvania	Weiss, MJ (corresponding author), Childrens Hosp Philadelphia, Div Hematol, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.		Weiss, Mitchell J/A-1245-2013; Weiss, Mitchell J/W-9814-2018	Weiss, Mitchell J/0000-0003-2460-3036	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061692] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK061692] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHMILEWITZ E, 2001, DISORDERS HAEMOGLOBI, P233; BAGLIONI C, 1966, BIBL HAEMATOL, V29, P1056; BANK A, 1969, NATURE, V222, P295, DOI 10.1038/222295a0; Centis F, 2000, BLOOD, V96, P3624; CIAVATTA DJ, 1995, P NATL ACAD SCI USA, V92, P9259, DOI 10.1073/pnas.92.20.9259; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Huang S-C, 2001, DISORDERS HEMOGLOBIN, P146; IKEDASAITO M, 1981, HEMOGLOBINS, P113; Miele G, 2001, NAT MED, V7, P361, DOI 10.1038/85515; NATHAN DG, 1966, AM J MED, V41, P815, DOI 10.1016/0002-9343(66)90039-8; NATHAN DG, 1969, J CLIN INVEST, V48, P33, DOI 10.1172/JCI106156; Pootrakul P, 2000, BLOOD, V96, P2606, DOI 10.1182/blood.V96.7.2606.h8002606_2606_2612; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; RACHMILEWITZ EA, 1974, SEMIN HEMATOL, V11, P441; RACHMILEWITZ EA, 1971, J BIOL CHEM, V246, P3356; SHAEFFER JR, 1967, BIOCHEM BIOPH RES CO, V28, P647, DOI 10.1016/0006-291X(67)90363-4; SHAEFFER JR, 1983, J BIOL CHEM, V258, P3172; SHINAR E, 1987, BLOOD, V70, P158; Shirihai OS, 2000, EMBO J, V19, P2492, DOI 10.1093/emboj/19.11.2492; SORENSEN S, 1990, BLOOD, V75, P1333; Tavill A S, 1967, Trans Assoc Am Physicians, V80, P305; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WICKRAMASINGHE SN, 1980, BRIT J HAEMATOL, V46, P401, DOI 10.1111/j.1365-2141.1980.tb05986.x; YANG BL, 1995, P NATL ACAD SCI USA, V92, P11608, DOI 10.1073/pnas.92.25.11608; YUAN J, 1993, BLOOD, V82, P374, DOI 10.1182/blood.V82.2.374.bloodjournal822374; YUAN J, 1995, BLOOD, V86, P3945, DOI 10.1182/blood.V86.10.3945.bloodjournal86103945	29	220	239	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 13	2002	417	6890					758	763		10.1038/nature00803	http://dx.doi.org/10.1038/nature00803			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	561QY	12066189				2022-12-28	WOS:000176154700049
J	van Maarle, MC; Stouthard, MEA; Marang-van de Mheen, PJ; Klazinga, NS; Bonsel, GJ				van Maarle, MC; Stouthard, MEA; Marang-van de Mheen, PJ; Klazinga, NS; Bonsel, GJ			Follow up after a family based genetic screening programme for familial hypercholesterolaemia: is screening alone enough?	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Amsterdam, Acad Med Ctr, Dept Social Med, NL-1100 DE Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Med Decis Making, NL-2300 RC Leiden, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van Maarle, MC (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Social Med, POB 22700, NL-1100 DE Amsterdam, Netherlands.	m.c.vanmaarle@amc.uva.nl	Stouthard, Marlies/GZG-4146-2022; de Mheen, Perla J. Marang-van/I-2783-2015	de Mheen, Perla J. Marang-van/0000-0003-1439-0989				*DUTCH I HLTH CAR, 1998, TREATM PREV COR HEAR; Goldstein J.L., 2001, METABOLIC MOL BASES, V11, P2863; PEDERSEN TR, 1994, LANCET, V344, P1383; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Umans-Eckenhausen M A, 1999, Ned Tijdschr Geneeskd, V143, P1157	5	12	12	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 8	2002	324	7350					1367	1368		10.1136/bmj.324.7350.1367	http://dx.doi.org/10.1136/bmj.324.7350.1367			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BQ	12052805	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000176234100020
J	Konig, P; Verschure, PFMJ				Konig, P; Verschure, PFMJ			Neuroscience: Neurons in action	SCIENCE			English	Editorial Material									Univ Zurich, ETH Zurich, Inst Neuroinformat, CH-8057 Zurich, Switzerland	ETH Zurich; University of Zurich	Konig, P (corresponding author), Univ Zurich, ETH Zurich, Inst Neuroinformat, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		König, Peter/ABB-2380-2020; verschure, paul/E-1677-2011; Verschure, Paul/AAR-2340-2021	König, Peter/0000-0003-3654-5267; Verschure, Paul/0000-0003-3643-9544				Adrian E.D., 1928, BASIS SENSATION; BRECHT M, IN PRESS SOC NEUR AB; Engel AK, 1999, CONSCIOUS COGN, V8, P128, DOI 10.1006/ccog.1999.0389; FATT P, 1951, J PHYSIOL-LONDON, V115, P320, DOI 10.1113/jphysiol.1951.sp004675; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Taylor DM, 2002, SCIENCE, V296, P1829, DOI 10.1126/science.1070291; Wessberg J, 2000, NATURE, V408, P361, DOI 10.1038/35042582; Wolpaw JR, 2000, IEEE T REHABIL ENG, V8, P164, DOI 10.1109/TRE.2000.847807	8	6	6	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 7	2002	296	5574					1817	1818		10.1126/science.1073592	http://dx.doi.org/10.1126/science.1073592			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052943				2022-12-28	WOS:000176054300031
J	Kaptchuk, TJ				Kaptchuk, TJ			The placebo effect in alternative medicine: Can the performance of a healing ritual have clinical significance?	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIALS; BLOOD-PRESSURE RESPONSE; DOUBLE-BLIND; PATIENT COMMUNICATION; TREATMENT ADHERENCE; HEALTH OUTCOMES; UNITED-STATES; HAY-FEVER; PAIN; PHYSICIANS	In alternative medicine, the main question regarding placebo has been whether a given therapy has more than a placebo effect. Just as mainstream medicine ignores the clinical significance of its own placebo effect, the placebo effect of unconventional medicine is disregarded except for polemics. This essay looks at the placebo effect of alternative medicine as a distinct entity. This is done by reviewing current knowledge about the placebo effect and how it may pertain to alternative medicine. The term placebo effect is taken to mean not only the narrow effect of a dummy intervention but also the broad array of nonspecific effects in the patient-physician relationship, including attention; compassionate care; and the modulation of expectations, anxiety, and self-awareness. Five components of the placebo effect-patient, practitioner, patient-practitioner interaction, nature of the illness, and treatment and setting-are examined. Therapeutic patterns that heighten placebo effects are especially prominent in unconventional healing, and it seems possible that the unique drama of this realm may have "enhanced" placebo effects in particular conditions. Ultimately, only prospective trials directly comparing the placebo effects of unconventional and mainstream medicine can provide reliable evidence to support such claims. Nonetheless, the possibility of enhanced placebo effects raises complex conundrums. Can an alternative ritual with only nonspecific psychosocial effects have more positive health outcomes than a proven, specific conventional treatment? What makes therapy legitimate, positive clinical outcomes or culturally acceptable methods of attainment? Who decides?	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, OMD, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Kaptchuk, TJ (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, OMD, 330 Brookline Ave, Boston, MA 02215 USA.				NCCIH NIH HHS [1R01AT00402-01, 1R21AT00553] Funding Source: Medline; NIAMS NIH HHS [U24 AR43441] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT000553, R01AT000402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adler H M, 1997, J Am Board Fam Pract, V10, P28; ADLER HM, 1973, ANN INTERN MED, V78, P595, DOI 10.7326/0003-4819-78-4-595; Affleck D C, 1966, Nebr State Med J, V51, P331; AGRAS WS, 1982, PSYCHOSOM MED, V44, P389; AMIGO I, 1993, J HYPERTENS, V11, P293, DOI 10.1097/00004872-199303000-00010; BASS MJ, 1986, J FAM PRACTICE, V23, P43; BERGMANN JF, 1994, CLIN TRIAL META-ANAL, V29, P41; BOOTZIN RR, 1976, J PERS SOC PSYCHOL, V34, P673; BRANTHWAITE A, 1981, BRIT MED J, V282, P1576, DOI 10.1136/bmj.282.6276.1576; BREWIN CR, 1989, BRIT MED J, V299, P313, DOI 10.1136/bmj.299.6694.313; BRODEUR DW, 1965, PSYCHOPHARMACOLOGIA, V7, P444, DOI 10.1007/BF00402366; BRODY H, 1980, J FAM PRACTICE, V10, P445; BROWN WA, 1992, PSYCHIAT RES, V41, P203, DOI 10.1016/0165-1781(92)90002-K; BUTLER C, 1986, BRIT J CLIN PSYCHOL, V25, P173, DOI 10.1111/j.2044-8260.1986.tb00693.x; CANNER PL, 1980, NEW ENGL J MED, V303, P1038; COOPER WD, 1983, BRIT J CLIN PRACT, V37, P99; COUCH JR, 1987, NEUROEPIDEMIOLOGY, V6, P178, DOI 10.1159/000110117; Crow R., 1999, HEALTH TECHNOL ASSES, V3, P1, DOI [DOI 10.3310/HTA3030, DOI 10.3310/hta3030]; CSORDAS T J, 1988, Medical Anthropology Quarterly, V2, P121, DOI 10.1525/maq.1988.2.2.02a00030; CSORDAS TJ, 1983, CULT MED PSYCHIAT, V7, P333, DOI 10.1007/BF00052238; CZAJKOWSKI SM, 1990, HDB HLTH BEHAV CHANG; De Craen A.J.M., 1998, PLACEBOS PLACEBO EFF; de Craen AJM, 2000, J NEUROL, V247, P183, DOI 10.1007/s004150050560; de Craen AJM, 1999, BRIT J CLIN PHARMACO, V48, P853, DOI 10.1046/j.1365-2125.1999.00094.x; de la Fuente-Fernandez R, 2001, SCIENCE, V293, P1164, DOI 10.1126/science.1060937; Di Blasi Z, 2001, LANCET, V357, P757, DOI 10.1016/S0140-6736(00)04169-6; Diener HC, 1999, CEPHALALGIA, V19, P699, DOI 10.1046/j.1468-2982.1999.019008699.x; DSOUZA MF, 1983, CLIN ALLERGY, V13, P329, DOI 10.1111/j.1365-2222.1983.tb02608.x; DWORKIN SF, 1984, PAIN, V19, P339, DOI 10.1016/0304-3959(84)90080-0; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; ERNST E, 1995, BMJ-BRIT MED J, V311, P551, DOI 10.1136/bmj.311.7004.551; Feinstein A.R., 1985, CLIN EPIDEMIOLOGY; Finkler K, 1996, SOC SCI MED, V42, P199, DOI 10.1016/0277-9536(95)00086-0; FISHER S, 1993, J NERV MENT DIS, V181, P345, DOI 10.1097/00005053-199306000-00002; Fisher S, 1964, NEUROPSYCHOPHARMACOL, V3, P149; Flaten MA, 1999, PSYCHOSOM MED, V61, P250, DOI 10.1097/00006842-199903000-00018; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; FREUND J, 1972, CLIN PHARMACOL THER, V13, P172; GALLAGHER EJ, 1993, JAMA-J AM MED ASSOC, V270, P742, DOI 10.1001/jama.270.6.742; GODFREY S, 1973, J PSYCHOSOM RES, V17, P293, DOI 10.1016/0022-3999(73)90106-2; Goetz CG, 2000, NEUROLOGY, V54, P710, DOI 10.1212/WNL.54.3.710; GRACELY RH, 1985, LANCET, V1, P43; GRYLL SL, 1978, PSYCHOPHARMACOLOGY, V57, P253, DOI 10.1007/BF00426747; HAHN RA, 1982, CULT MED PSYCHIAT, V6, P219, DOI 10.1007/BF00114192; HASHISH I, 1988, PAIN, V33, P303, DOI 10.1016/0304-3959(88)90289-8; HO KH, 1988, J PSYCHOSOM RES, V32, P197, DOI 10.1016/0022-3999(88)90055-4; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; HORWITZ RI, 1993, ARCH INTERN MED, V153, P1863, DOI 10.1001/archinte.153.16.1863; Hrobjartsson A, 2001, NEW ENGL J MED, V345, P1278; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; HROBJARTSSON A, 2001, ADV MIND BODY MED, V17, P312; Husten L, 1999, LANCET, V353, P1501, DOI 10.1016/S0140-6736(99)00077-X; Ilnyckyj A, 1997, GASTROENTEROLOGY, V112, P1854, DOI 10.1053/gast.1997.v112.pm9178676; JOHANNES L, 1998, WALL STREET J   1211, pA8; Johannes Laura, 1998, Wall St J (East Ed), pA1; JOHNSON AG, 1994, LANCET, V344, P1140, DOI 10.1016/S0140-6736(94)90637-8; KAGAN G, 1980, J INT MED RES, V8, P404, DOI 10.1177/030006058000800607; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; Kaptchuk TJ, 2000, J CLIN EPIDEMIOL, V53, P786, DOI 10.1016/S0895-4356(00)00206-7; Kaptchuk TJ, 1998, LANCET, V351, P1722, DOI 10.1016/S0140-6736(97)10111-8; Kaptchuk TJ, 1998, ANN INTERN MED, V129, P1061, DOI 10.7326/0003-4819-129-12-199812150-00011; Kaptchuk TJ, 2001, J CLIN EPIDEMIOL, V54, P541, DOI 10.1016/S0895-4356(00)00347-4; Kaptchuk TJ, 1998, ARCH INTERN MED, V158, P2215, DOI 10.1001/archinte.158.20.2215; KAPTCHUK TJ, 2001, FUNDAMENTALS COMPLEM; KAPTCHUK TJ, 2000, WEB THAT HAS NO WEAV; KAPTCHUK TJ, 1996, COMPLEMENTARY MED OB; Kincheloe J E, 1991, Quintessence Int, V22, P311; KIRMAYER LJ, 1993, CULT MED PSYCHIAT, V17, P161, DOI 10.1007/BF01379325; KIRMAYER LJ, 1994, CULT MED PSYCHIAT, V18, P183, DOI 10.1007/BF01379449; Kirsch I., 1999, EXPECTANCIES SHAPE E; KOES BW, 1992, SPINE, V17, P28, DOI 10.1097/00007632-199201000-00005; LASAGNA L, 1958, J CLIN INVEST, V37, P533, DOI 10.1172/JCI103635; LIBERMAN RP, 1967, NEUROPSYCHOPHARMACOL, V5, P557; LUPARELLO TJ, 1970, PSYCHOSOM MED, V32, P509, DOI 10.1097/00006842-197009000-00009; LYNOE N, 1993, SOC SCI MED, V36, P767, DOI 10.1016/0277-9536(93)90037-5; Macklin R, 1999, NEW ENGL J MED, V341, P992, DOI 10.1056/NEJM199909233411312; MARCHAND S, 1993, PAIN, V54, P99, DOI 10.1016/0304-3959(93)90104-W; Mattocks KM, 2000, BIOL PSYCHIAT, V47, P693, DOI 10.1016/S0006-3223(00)00839-8; McGuire Meredith, 1988, RITUAL HEALING SUBUR; McPherson K, 1997, J ROY SOC MED, V90, P652, DOI 10.1177/014107689709001205; McQuay H, 1996, PAIN, V64, P331, DOI 10.1016/0304-3959(95)00116-6; Mitchell SH, 1996, PSYCHOPHARMACOLOGY, V125, P371, DOI 10.1007/BF02246020; Moerman DE, 2000, MED ANTHROPOL Q, V14, P51, DOI 10.1525/maq.2000.14.1.51; Moncrieff J, 1998, BRIT J PSYCHIAT, V172, P227, DOI 10.1192/bjp.172.3.227; MORISON RA, 1961, ANN RHEUM DIS, V20, P179, DOI 10.1136/ard.20.2.179; NOVACK DH, 1987, J GEN INTERN MED, V2, P346, DOI 10.1007/BF02596174; OLSSON B, 1989, FAM PRACT, V6, P188, DOI 10.1093/fampra/6.3.188; ONG LML, 1995, SOC SCI MED, V40, P903, DOI 10.1016/0277-9536(94)00155-M; OTHS K, 1994, CULT MED PSYCHIAT, V18, P83, DOI 10.1007/BF01384878; Pillemer SR, 1997, ARTHRITIS RHEUM, V40, P419, DOI 10.1002/art.1780400305; Preston RA, 2000, ARCH INTERN MED, V160, P1449, DOI 10.1001/archinte.160.10.1449; RABKIN JG, 1990, AM J PSYCHIAT, V147, P1622; RILEY JN, 1977, SOC SCI MED, V11, P549, DOI 10.1016/0037-7856(77)90173-1; ROSENBERG NK, 1991, ACTA PSYCHIAT SCAND, V83, P33, DOI 10.1111/j.1600-0447.1991.tb03099.x; SCHWITZG.RK, 1968, BEHAV SCI, V13, P267, DOI 10.1002/bs.3830130402; SHAPIRO AK, 1969, INT PHARMACOPSYCHIAT, V2, P215, DOI 10.1159/000468855; SHAPIRO AP, 1954, PSYCHOSOM MED, V16, P478, DOI 10.1097/00006842-195411000-00002; Shapiro Elaine, 1997, POWERFUL PLACEBO ANC; Shetty N, 1999, CLIN NEUROPHARMACOL, V22, P207; SODERGREN SC, 1999, EXPECTANCIES SHAPE E; SOX HC, 1981, ANN INTERN MED, V95, P680, DOI 10.7326/0003-4819-95-6-680; STERNBACH RA, 1964, PSYCHOPHYSIOLOGY, V1, P67; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; STORMS MD, 1970, J PERS SOC PSYCHOL, V16, P319, DOI 10.1037/h0029835; SUCHMAN AL, 1992, CLIN PHARMACOL THER, V52, P372, DOI 10.1038/clpt.1992.157; SULLIVAN MD, 1993, J MED PHILOS, V18, P213, DOI 10.1093/jmp/18.2.213; Tambiah S.J., 1990, MAGIC SCI RELIG SCOP; Temple RJ, 1997, CONTROL CLIN TRIALS, V18, P613, DOI 10.1016/S0197-2456(97)00058-5; THOMAS KB, 1987, BRIT MED J, V294, P1200, DOI 10.1136/bmj.294.6581.1200; THOMAS KB, 1994, LANCET, V344, P1066, DOI 10.1016/S0140-6736(94)91716-7; THOMAS M, 1991, AM J CHINESE MED, V19, P95, DOI 10.1142/S0192415X91000156; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; UHLENHUTH EH, 1966, PSYCHOPHARMACOLOGIA, V9, P392, DOI 10.1007/BF00406450; van Weel C, 2001, LANCET, V357, P733, DOI 10.1016/S0140-6736(00)04176-3; Vickers AJ, 2000, J CLIN EPIDEMIOL, V53, P157, DOI 10.1016/S0895-4356(99)00139-0; WALL PD, 1993, CIBA FDN S, V174; Watts RL, 2001, PARKINSONISM RELAT D, V7, pS87; WENNBERG JE, 1990, MODERN METHODS CLIN; WHEATLEY D, 1967, LANCET, V2, P1133; WIED G L, 1953, Arztl Wochensch, V8, P623; WOLF S, 1957, J LAB CLIN MED, V49, P837; Zollman C, 1999, BRIT MED J, V319, P1486, DOI 10.1136/bmj.319.7223.1486	122	366	375	3	60	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 4	2002	136	11					817	825		10.7326/0003-4819-136-11-200206040-00011	http://dx.doi.org/10.7326/0003-4819-136-11-200206040-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	558KG	12044130				2022-12-28	WOS:000175964500005
J	Safdar, N; Maki, DG				Safdar, N; Maki, DG			The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida	ANNALS OF INTERNAL MEDICINE			English	Review							INTENSIVE-CARE-UNIT; BLOOD-STREAM INFECTIONS; VENTILATOR-ASSOCIATED PNEUMONIA; CATHETER-RELATED INFECTIONS; SKILLED NURSING FACILITY; SURGICAL-WOUND INFECTION; INTRAVENOUS THERAPY TEAM; CENTRAL VENOUS CATHETERS; URINARY-TRACT-INFECTION; AFFAIRS MEDICAL-CENTER	Recent years have witnessed a rapidly growing crisis in antimicrobial resistance, especially among microorganisms that cause nosocomial infection. To better understand common risk factors among multiresistant organisms, this review explores risk factors for nosocomial infection with methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococcus, Clostridium difficile, extended-spectrum beta-lactamase-producing gram-negative bacilli, and Candida. This review comprises data from 74 published studies; 53 (71%) were retrospective studies and addressed few risk factors or did not quantify risk. The analysis shows impressive commonality of risk factors across these diverse multiresistant organisms: advanced age; underlying diseases and severity of illness; inter-institutional transfer of the patient, especially from a nursing home; prolonged hospitalization; gastrointestinal surgery or transplantation; exposure to invasive devices of all types, especially central venous catheters; and exposure to antimicrobial drugs, especially cephalosporins. More restricted use of antibiotics, especially cephalosporins, and strategies to prevent medical device related infection and cross-infection in the hospital would yield benefit with all types of resistant organisms. Preemptive isolation of all patients with risk factors for infection by resistant organisms would very likely reduce secondary spread within the hospital. Conversely, programs that focus on only one organism or one antimicrobial drug are unlikely to succeed. Prospective studies of sufficient size that address all potential risk factors, especially individual anti-infective agents, and that use matched controls who are shown by surveillance cultures to be free of colonization by resistant organisms would enhance understanding of the epidemiology of antimicrobial resistance in institutions and guide efforts to develop more effective strategies for prevention.	Univ Wisconsin Hosp & Clin, Dept Med, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Maki, DG (corresponding author), Univ Wisconsin Hosp & Clin, Dept Med, H4-572,600 Highland Ave, Madison, WI 53792 USA.							[Anonymous], 1997, MMWR Recomm Rep, V46, P1; ARNOW PM, 1982, J TRAUMA, V22, P954, DOI 10.1097/00005373-198211000-00012; Arpin C, 2000, EPIDEMIOL INFECT, V124, P401, DOI 10.1017/S0950268899003908; Asensio A, 1996, INFECT CONT HOSP EP, V17, P20; BARTLETT JG, 2000, POCKETBOOK INFECT DI, P262; Belliveau PP, 1996, AM J HEALTH-SYST PH, V53, P1570, DOI 10.1093/ajhp/53.13.1570; Beltrami EL, 2000, AM J INFECT CONTROL, V28, P282, DOI 10.1067/mic.2000.106276; Bhavnani SM, 2000, DIAGN MICR INFEC DIS, V36, P145, DOI 10.1016/S0732-8893(99)00136-4; BITAR CM, 1987, INFECT CONT HOSP EP, V8, P15, DOI 10.1017/S0195941700066935; Bliss DZ, 1998, ANN INTERN MED, V129, P1012, DOI 10.7326/0003-4819-129-12-199812150-00004; Bologna RA, 1999, UROLOGY, V54, P982, DOI 10.1016/S0090-4295(99)00318-0; Bonten MJM, 1996, LANCET, V348, P1615, DOI 10.1016/S0140-6736(96)02331-8; Bonten MJM, 1998, ARCH INTERN MED, V158, P1127, DOI 10.1001/archinte.158.10.1127; BOYCE JM, 1994, J CLIN MICROBIOL, V32, P1148, DOI 10.1128/JCM.32.5.1148-1153.1994; Brooks S, 1998, INFECT CONT HOSP EP, V19, P333; BROOKS SE, 1992, INFECT CONT HOSP EP, V13, P98; BROSS J, 1989, AM J MED, V87, P614, DOI 10.1016/S0002-9343(89)80392-4; BROWN E, 1990, INFECT CONT HOSP EP, V11, P283; BURKE JF, 1977, ANN SURG, V186, P377, DOI 10.1097/00000658-197709000-00016; BURNIE JP, 1987, EPIDEMIOL INFECT, V99, P201, DOI 10.1017/S0950268800067030; CAPPELLO M, 1989, NEPHROL DIAL TRANSPL, V4, P988, DOI 10.1093/ndt/4.11.988; Carmeli Y, 1999, ARCH INTERN MED, V159, P2461, DOI 10.1001/archinte.159.20.2461; Coello R, 1997, J HOSP INFECT, V37, P39, DOI 10.1016/S0195-6701(97)90071-2; COLLIER J, 1985, LANCET, V1, P331; COLLINS LA, 1994, J INFECT DIS, V170, P644, DOI 10.1093/infdis/170.3.644; Cooper GS, 1996, AM J GASTROENTEROL, V91, P80; CROSSLEY K, 1979, J INFECT DIS, V139, P273, DOI 10.1093/infdis/139.3.273; Cunha BA, 1998, CRIT CARE CLIN, V14, P309, DOI 10.1016/S0749-0704(05)70397-3; Dahms RA, 1998, ARCH SURG-CHICAGO, V133, P1343, DOI 10.1001/archsurg.133.12.1343; Darouiche RO, 1999, UROLOGY, V54, P976, DOI 10.1016/S0090-4295(99)00288-5; Darouiche RO, 1999, NEW ENGL J MED, V340, P1, DOI 10.1056/NEJM199901073400101; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; DECHAMPS C, 1991, J HOSP INFECT, V18, P5, DOI 10.1016/0195-6701(91)90088-P; DEMLING RH, 1978, AM J SURG, V136, P375, DOI 10.1016/0002-9610(78)90298-2; Dever LL, 1998, AM J INFECT CONTROL, V26, P40, DOI 10.1016/S0196-6553(98)70060-4; DEVITO JM, 1985, ARCH INTERN MED, V145, P1053, DOI 10.1001/archinte.145.6.1053; DIDIER ME, 1994, 34 INT C ANGT AG CHE, V34; Do AN, 1998, CLIN INFECT DIS, V26, P954, DOI 10.1086/513952; DOEBBELING BN, 1988, ANN INTERN MED, V109, P394, DOI 10.7326/0003-4819-109-5-394; Donskey CJ, 2000, NEW ENGL J MED, V343, P1925, DOI 10.1056/NEJM200012283432604; DUNKLE LM, 1981, AM J MED, V70, P455, DOI 10.1016/0002-9343(81)90787-7; Eggimann P, 2000, LANCET, V355, P1864, DOI 10.1016/S0140-6736(00)02291-1; EKENNA O, 1993, AM J INFECT CONTROL, V21, P189, DOI 10.1016/0196-6553(93)90030-8; ENA J, 1993, JAMA-J AM MED ASSOC, V269, P598, DOI 10.1001/jama.269.5.598; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; Fekety R, 1997, CLIN INFECT DIS, V24, P324, DOI 10.1093/clinids/24.3.324; FRAIMOW HS, 1995, INFECT DIS CLIN N AM, V9, P497; Fridkin SK, 1999, CLIN INFECT DIS, V29, P245, DOI 10.1086/520193; Garbutt JM, 1999, INFECT CONT HOSP EP, V20, P664, DOI 10.1086/501562; Gerberding J, 1999, AM J INFECT CONTROL, V27, P520; GERDING DN, 1995, INFECT CONT HOSP EP, V16, P459; Gerding DN, 1997, CLIN INFECT DIS, V25, pS206, DOI 10.1086/516247; Goetz AM, 1998, AM J INFECT CONTROL, V26, P558, DOI 10.1053/ic.1998.v26.a86286; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; Gonzales R, 2001, ANN INTERN MED, V134, P479, DOI 10.7326/0003-4819-134-6-200103200-00013; GOODRICH JM, 1991, J INFECT DIS, V164, P731, DOI 10.1093/infdis/164.4.731; Greif R, 2000, NEW ENGL J MED, V342, P161, DOI 10.1056/NEJM200001203420303; HALEY RW, 1982, J INFECT DIS, V145, P875, DOI 10.1093/infdis/145.6.875; HIBBERD PL, 1994, INT C ANT AG CHEM 4, V34; Hornbuckle K, 1998, ANN ONCOL, V9, P307, DOI 10.1023/A:1008295500932; HUTIN Y, 1993, AIDS, V7, P1441, DOI 10.1097/00002030-199311000-00006; Ibelings MMS, 1998, EUR J SURG, V164, P411; Jarvis WR, 1998, CLIN INFECT DIS, V26, P1200, DOI 10.1086/520284; JARVIS WR, 1991, AM J MED, V91, pS101, DOI 10.1016/0002-9343(91)90352-X; Johnston J, 1992, Aust Clin Rev, V12, P53; *JOINT COMM ACCR H, 1989, ACCR MAN HOSP, P67; KARABINIS A, 1988, J CLIN MICROBIOL, V26, P429, DOI 10.1128/JCM.26.3.429-432.1988; KARANFIL LV, 1992, INFECT CONT HOSP EP, V13, P195, DOI 10.1086/646509; Katz DA, 1996, AM J MED, V100, P487, DOI 10.1016/S0002-9343(95)00016-X; Kent KC, 1998, ANN SURG, V227, P296, DOI 10.1097/00000658-199802000-00021; KLEIN BS, 1989, NEW ENGL J MED, V320, P1714, DOI 10.1056/NEJM198906293202603; Kollef MH, 2001, ANN INTERN MED, V134, P298, DOI 10.7326/0003-4819-134-4-200102200-00014; Kollef MH, 1997, AM J RESP CRIT CARE, V156, P1040, DOI 10.1164/ajrccm.156.4.9701046; KUNIN CM, 1977, J INFECT DIS, V135, P335, DOI 10.1093/infdis/135.2.335; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Lai KK, 1997, INFECT CONT HOSP EP, V18, P628, DOI 10.2307/30141489; LARSON E, 1985, AM J INFECT CONTROL, V13, P16, DOI 10.1016/0196-6553(85)90004-5; Lautenbach E, 1999, INFECT CONT HOSP EP, V20, P318, DOI 10.1086/501624; LECLAIR JM, 1987, NEW ENGL J MED, V317, P329, DOI 10.1056/NEJM198708063170601; LEVINE AS, 1973, NEW ENGL J MED, V288, P477, DOI 10.1056/NEJM197303082881001; LIVORNESE LL, 1992, ANN INTERN MED, V117, P112, DOI 10.7326/0003-4819-117-2-112; Loeb M, 1999, INFECT CONT HOSP EP, V20, P760, DOI 10.1086/501580; Lucas GM, 1998, CLIN INFECT DIS, V26, P1127, DOI 10.1086/520311; Lucet JC, 1996, CLIN INFECT DIS, V22, P430, DOI 10.1093/clinids/22.3.430; MAHUL P, 1992, INTENS CARE MED, V18, P20, DOI 10.1007/BF01706421; MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9; MAKI DG, 1994, INFECT CONT HOSP EP, V15, P227; MAKI DG, 1989, ARCH INTERN MED, V149, P30, DOI 10.1001/archinte.149.1.30; Maki DG, 1998, INFECT CONT HOSP EP, V19, P682; Maki DG, 1996, CLIN INFECT DIS, V23, P43; Maki DG, 1997, ANN INTERN MED, V127, P257, DOI 10.7326/0003-4819-127-4-199708150-00001; MAKI DG, 1978, ANN INTERN MED, V89, P777, DOI 10.7326/0003-4819-89-5-777; MAKI DG, 1990, P 30 INT C ANT AG CH; MAKI DG, 1998, 8 INT C INF DIS 15 1; MAKI DG, 1996, P 36 INT C ANT AG CH; MAKI DG, 1998, HOSP INFECT, P689; Maki DG, 2001, P 11 ANN M SOC HEALT, P267; MANABE YC, 1995, ANN INTERN MED, V123, P835, DOI 10.7326/0003-4819-123-11-199512010-00004; Mangram AJ, 1999, AM J INFECT CONTROL, V27, P97, DOI 10.1016/S0196-6553(99)70088-X; Maranan MC, 1997, INFECT DIS CLIN N AM, V11, P813, DOI 10.1016/S0891-5520(05)70392-5; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; McFarland LV, 1999, INFECT CONT HOSP EP, V20, P43, DOI 10.1086/501553; MCFARLAND LV, 1990, J INFECT DIS, V162, P678, DOI 10.1093/infdis/162.3.678; Mermel LA, 2000, ANN INTERN MED, V132, P391, DOI 10.7326/0003-4819-132-5-200003070-00009; Mimoz O, 1996, CRIT CARE MED, V24, P1818, DOI 10.1097/00003246-199611000-00010; Morgan AS, 1997, ANN PHARMACOTHER, V31, P970, DOI 10.1177/106002809703100902; MORRIS JG, 1995, ANN INTERN MED, V123, P250, DOI 10.7326/0003-4819-123-4-199508150-00002; MUDER RR, 1991, ANN INTERN MED, V114, P107, DOI 10.7326/0003-4819-114-2-1-107; Murray BE, 1997, AM J MED, V102, P284, DOI 10.1016/S0002-9343(99)80270-8; NAVARI RM, 1984, AM J MED, V76, P564, DOI 10.1016/0002-9343(84)90274-2; NELSON DE, 1994, INFECT CONT HOSP EP, V15, P88; Onorato M, 1999, INFECT CONT HOSP EP, V20, P26, DOI 10.1086/501556; Ostrowsky BE, 1999, ARCH INTERN MED, V159, P1467, DOI 10.1001/archinte.159.13.1467; Ostrowsky BE, 2001, NEW ENGL J MED, V344, P1427, DOI 10.1056/NEJM200105103441903; PAGE CP, 1993, ARCH SURG-CHICAGO, V128, P410; Papanicolaou GA, 1996, CLIN INFECT DIS, V23, P760, DOI 10.1093/clinids/23.4.760; Patel R, 1996, TRANSPLANTATION, V62, P926, DOI 10.1097/00007890-199610150-00010; Paterson DL, 2000, CLIN INFECT DIS, V30, P473, DOI 10.1086/313719; PATTERSON JE, 1991, AM J MED, V91, P479, DOI 10.1016/0002-9343(91)90183-X; PEAR SM, 1994, ANN INTERN MED, V120, P272, DOI 10.7326/0003-4819-120-4-199402150-00003; PELLETIER LL, 1985, INFECT CONT HOSP EP, V6, P226, DOI 10.1017/S0195941700061579; Pena C, 1997, J HOSP INFECT, V35, P9, DOI 10.1016/S0195-6701(97)90163-8; Peset V, 2000, EUR J CLIN MICROBIOL, V19, P742, DOI 10.1007/s100960000360; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; Piroth L, 1998, CLIN INFECT DIS, V27, P76, DOI 10.1086/514643; Pitout JDD, 1997, AM J MED, V103, P51, DOI 10.1016/S0002-9343(97)00044-2; PITTET D, 1994, ANN SURG, V220, P751, DOI 10.1097/00000658-199412000-00008; Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2; PITTET D, 1995, ARCH INTERN MED, V155, P1177, DOI 10.1001/archinte.155.11.1177; PLATT R, 1986, AM J EPIDEMIOL, V124, P977, DOI 10.1093/oxfordjournals.aje.a114487; Pujol M, 1996, AM J MED, V100, P509, DOI 10.1016/S0002-9343(96)00014-9; PUJOL M, 1994, EUR J CLIN MICROBIOL, V13, P96, DOI 10.1007/BF02026134; Quale J, 1996, CLIN INFECT DIS, V23, P1020, DOI 10.1093/clinids/23.5.1020; QUINTILIANI R, 1986, J INFECT DIS, V153, P645, DOI 10.1093/infdis/153.4.645; RAAD II, 1994, INFECT CONT HOSP EP, V15, P231; Rafferty ME, 1997, INFECT CONT HOSP EP, V18, P342, DOI 10.1086/647623; Rahal JJ, 1998, JAMA-J AM MED ASSOC, V280, P1233, DOI 10.1001/jama.280.14.1233; Rao GG, 1997, J HOSP INFECT, V35, P63, DOI 10.1016/S0195-6701(97)90169-9; Rapp RP, 1999, PHARMACOTHERAPY, V19, p133S; RICHET HM, 1991, REV INFECT DIS, V13, P211; Roghmann MC, 1997, CLIN INFECT DIS, V25, P1056, DOI 10.1086/516112; Roghmann MC, 1998, AM J KIDNEY DIS, V32, P254, DOI 10.1053/ajkd.1998.v32.pm9708609; ROSSETTI F, 1995, CLIN INFECT DIS, V20, P801, DOI 10.1093/clinids/20.4.801; SAMORE MH, 1994, CLIN INFECT DIS, V18, P181, DOI 10.1093/clinids/18.2.181; SANFORD JP, 2000, GUIDE ANTIMICROBIAL, P1; Schiappa DA, 1996, J INFECT DIS, V174, P529, DOI 10.1093/infdis/174.3.529; SCHWAB SJ, 1988, AM J KIDNEY DIS, V11, P166, DOI 10.1016/S0272-6386(88)80206-3; SHAY DK, 1995, J INFECT DIS, V172, P993, DOI 10.1093/infdis/172.4.993; Sherertz RJ, 2000, ANN INTERN MED, V132, P641, DOI 10.7326/0003-4819-132-8-200004180-00007; SHIMADA M, 1993, SURG TODAY, V23, P880, DOI 10.1007/BF00311366; SIMOR AE, 1993, CLIN INFECT DIS, V17, P672, DOI 10.1093/clinids/17.4.672; Slaughter S, 1996, ANN INTERN MED, V125, P448, DOI 10.7326/0003-4819-125-6-199609150-00004; Smith DW, 1999, PHARMACOTHERAPY, V19, p129S, DOI 10.1592/phco.19.12.129S.31702; Soifer NE, 1998, ARCH INTERN MED, V158, P473, DOI 10.1001/archinte.158.5.473; Spencer RC, 1999, J HOSP INFECT, V43, pS127, DOI 10.1016/S0195-6701(99)90075-0; Talon D, 1995, EUR J CLIN MICROBIOL, V14, P987, DOI 10.1007/BF01691381; TAPE TG, 1990, ANN INTERN MED, V113, P392, DOI 10.7326/0003-4819-113-5-392; THIBAULT A, 1991, INFECT CONT HOSP EP, V12, P345, DOI 10.2307/30145209; THOMAS JC, 1989, INFECT CONT HOSP EP, V10, P106, DOI 10.1086/645976; Tokars JI, 1999, INFECT CONT HOSP EP, V20, P171, DOI 10.1086/501606; TOMFORD JW, 1984, ARCH INTERN MED, V144, P1191, DOI 10.1001/archinte.144.6.1191; Tornieporth NG, 1996, CLIN INFECT DIS, V23, P767, DOI 10.1093/clinids/23.4.767; Tumbarello M, 1999, EUR J CLIN MICROBIOL, V18, P478, DOI 10.1007/s100960050327; Vaisbrud V, 1999, INFECT CONT HOSP EP, V20, P610, DOI 10.1086/501680; VALLES J, 1995, ANN INTERN MED, V122, P179, DOI 10.7326/0003-4819-122-3-199502010-00004; VANHERWEGHEM JL, 1986, NEPHRON, V42, P116, DOI 10.1159/000183648; Veenstra DL, 1999, JAMA-J AM MED ASSOC, V281, P261, DOI 10.1001/jama.281.3.261; Virk A, 2000, MAYO CLIN PROC, V75, P200; WADE JJ, 1995, J HOSP INFECT, V30, P483, DOI 10.1016/0195-6701(95)90052-7; WALKER KJ, 1993, J AM GERIATR SOC, V41, P940, DOI 10.1111/j.1532-5415.1993.tb06759.x; WARD TT, 1981, INFECT CONT HOSP EP, V2, P453, DOI 10.1017/S0195941700055715; Warren JW, 1997, INFECT DIS CLIN N AM, V11, P609, DOI 10.1016/S0891-5520(05)70376-7; Washio M, 1997, PUBLIC HEALTH, V111, P187, DOI 10.1016/S0033-3506(97)00581-7; WEY SB, 1989, ARCH INTERN MED, V149, P2349, DOI 10.1001/archinte.149.10.2349; Wiener J, 1999, JAMA-J AM MED ASSOC, V281, P517, DOI 10.1001/jama.281.6.517; Wright WL, 1997, INFECT DIS CLIN N AM, V11, P411, DOI 10.1016/S0891-5520(05)70363-9; Yates RR, 1999, CHEST, V115, p24S, DOI 10.1378/chest.115.suppl_1.24S; YOUNG GP, 1986, MED J AUSTRALIA, V144, P303, DOI 10.5694/j.1326-5377.1986.tb128379.x	178	418	440	1	40	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 4	2002	136	11					834	844		10.7326/0003-4819-136-11-200206040-00013	http://dx.doi.org/10.7326/0003-4819-136-11-200206040-00013			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558KG	12044132				2022-12-28	WOS:000175964500007
J	Ala'Aldeen, D				Ala'Aldeen, D			A non-multi resistant community MRSA exposes its genome	LANCET			English	Editorial Material							STAPHYLOCOCCUS-AUREUS; CHILDREN		Univ Nottingham Hosp, Div Microbiol, Mol Bacteriol & Immunol Grp, Nottingham NG7 2UH, England	University of Nottingham	Ala'Aldeen, D (corresponding author), Univ Nottingham Hosp, Div Microbiol, Mol Bacteriol & Immunol Grp, Nottingham NG7 2UH, England.							FERGIEJE, 2001, PEDIAT INFECT DIS J, V20, P860; Groom AV, 2001, JAMA-J AM MED ASSOC, V286, P1201, DOI 10.1001/jama.286.10.1201; Gwynne-Jones DP, 1999, J PEDIATR ORTHOPED, V19, P413, DOI 10.1097/00004694-199905000-00025; Hiramatsu K, 2001, Lancet Infect Dis, V1, P147, DOI 10.1016/S1473-3099(01)00091-3; Hiramatsu K, 2001, TRENDS MICROBIOL, V9, P486, DOI 10.1016/S0966-842X(01)02175-8; HIRAMATSU K, 1997, LANCET, V350, P1668; Hussain FM, 2001, PEDIATR INFECT DIS J, V20, P763, DOI 10.1097/00006454-200108000-00009; Ito T, 2001, ANTIMICROB AGENTS CH, V45, P1323, DOI 10.1128/AAC.45.5.1323-1336.2001; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; Ma XX, 2002, ANTIMICROB AGENTS CH, V46, P1147, DOI 10.1128/AAC.46.4.1147-1152.2002; UDO EE, 1993, J HOSP INFECT, V25, P97, DOI 10.1016/0195-6701(93)90100-E; 1999, MORB MORTAL WKLY REP, V48, P707	12	17	17	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 25	2002	359	9320					1791	1792		10.1016/S0140-6736(02)08727-5	http://dx.doi.org/10.1016/S0140-6736(02)08727-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044370				2022-12-28	WOS:000175775500003
J	Bounameaux, H; Perneger, T				Bounameaux, H; Perneger, T			Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention	LANCET			English	Editorial Material							VENOUS THROMBOEMBOLISM		Univ Hosp Geneva, Dept Internal Med, Div Angiol & Haemostasis, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Inst Social & Prevent Med, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Bounameaux, H (corresponding author), Univ Hosp Geneva, Dept Internal Med, Div Angiol & Haemostasis, CH-1211 Geneva 14, Switzerland.							Bauer KA, 2001, NEW ENGL J MED, V345, P1305, DOI 10.1056/NEJMoa011099; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; Cohen AT, 2001, THROMB HAEMOSTASIS, V85, P940; Eriksson BI, 2001, NEW ENGL J MED, V345, P1298, DOI 10.1056/NEJMoa011100; Geerts WH, 2001, CHEST, V119, p132S, DOI 10.1378/chest.119.1_suppl.132S; Herbert JM, 1997, CARDIOVASC DRUG REV, V15, P1, DOI 10.1111/j.1527-3466.1997.tb00321.x; Turpie AGG, 2001, NEW ENGL J MED, V344, P619, DOI 10.1056/NEJM200103013440901; ZELEN M, 1971, BIOMETRIKA, V58, P129, DOI 10.1093/biomet/58.1.129	8	32	34	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 18	2002	359	9319					1710	1711		10.1016/S0140-6736(02)08660-9	http://dx.doi.org/10.1016/S0140-6736(02)08660-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049854				2022-12-28	WOS:000175740500002
J	Oliver, A; Healey, A; Donaldson, C				Oliver, A; Healey, A; Donaldson, C			Choosing the method to match the perspective: economic assessment and its implications for health-services efficiency	LANCET			English	Editorial Material							WILLINGNESS-TO-PAY; CARE		Univ London London Sch Econ & Polit Sci, LSE Hlth & Social Care, London WC2A 2AE, England; Univ Calgary, Dept Econ, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada	University of London; London School Economics & Political Science; University of Calgary; University of Calgary	Oliver, A (corresponding author), Univ London London Sch Econ & Polit Sci, LSE Hlth & Social Care, Houghton St, London WC2A 2AE, England.		Oliver, Adam/CAG-2031-2022	Donaldson, Cam/0000-0003-4670-5340; Healey, Andrew/0000-0003-2013-3161				CULYER AJ, 1995, ECONOMICS; Donaldson C, 1999, SOC SCI MED, V49, P551, DOI 10.1016/S0277-9536(99)00173-2; Donaldson C, 1997, HEALTH CARE ANAL, V5, P7, DOI 10.1007/BF02678452; Donaldson C, 1996, HEALTH ECON, V5, P267, DOI 10.1002/(SICI)1099-1050(199605)5:3<267::AID-HEC209>3.0.CO;2-X; Donaldson C, 1998, PHARMACOECONOMICS, V13, P389, DOI 10.2165/00019053-199813040-00002; DONALDSON C, 1998, 9810 MCMAST U CTR HL; Drummond MF, 2015, METHODS EC EVALUATIO; Gerard K, 1993, Health Econ, V2, P59, DOI 10.1002/hec.4730020108; *MIN HLTH, 1994, ONT GUID EC AN PHARM; *NAT I CLIN EXC, 2001, COMPL TECHN APPR 200; National Institute for Clinical Excellence, 2001, TECHN GUID MAN SPONS; *NORW MED CONTR AU, 1999, NORW GUID PHARM AN C; *OHE HEED, 2000, HLTH EC EV DAT; Olsen JA, 1998, SOC SCI MED, V46, P1, DOI 10.1016/S0277-9536(97)00129-9; *SICKN FUNDS COUNC, 1999, DUTCH GUID PHARM RES; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; 1995, GUIDELINES PHARM IND	17	25	25	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 18	2002	359	9319					1771	1774		10.1016/S0140-6736(02)08664-6	http://dx.doi.org/10.1016/S0140-6736(02)08664-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	554MV	12049884				2022-12-28	WOS:000175740500032
J	Gendrel, AV; Lippman, Z; Yordan, C; Colot, V; Martienssen, RA				Gendrel, AV; Lippman, Z; Yordan, C; Colot, V; Martienssen, RA			Dependence of heterochromatic histone H3 methylation patterns on the Arabidopsis gene DDM1	SCIENCE			English	Article							DNA METHYLATION; CHROMOSOMAL-PROTEINS; A-THALIANA; CHROMATIN; SWI/SNF; GENOME; RETROTRANSPOSONS; MOBILIZATION; MAINTENANCE; TRANSPOSONS	The Arabidopsis gene DDM1 is required to maintain DNA methylation levels and is responsible for transposon and transgene silencing. However, rather than encoding a DNA methyltransferase, DDM1 has similarity to the SWI/SNF family of adenosine triphosphate dependent chromatin remodeling genes, suggesting an indirect role in DNA methylation. Here we show that DDM1 is also required to maintain histone H3 methylation patterns. In wild-type heterochromatin, transposons and silent genes are associated with histone H3 methylated at lysine 9, whereas known genes are preferentially associated with methylated lysine 4. In ddm1 heterochromatin, DNA methylation is lost, and methylation of lysine 9 is largely replaced by methylation of lysine 4. Because DNA methylation has recently been shown to depend on histone H3 lysine 9 methylation, our results suggest that transposon methylation may be guided by histone H3 methylation in plant genomes. This would account for the epigenetic inheritance of hypomethylated DNA once histone H3 methylation patterns are altered.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA; INRA CNRS, Unite Rech Genom Vegetale, F-91057 Evry, France	Cold Spring Harbor Laboratory; Cold Spring Harbor Laboratory; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Colot, V (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.		Gendrel, Anne-Valerie/E-5584-2017	Gendrel, Anne-Valerie/0000-0003-4510-0024; Lippman, Zachary/0000-0001-7668-9025				Aravin AA, 2001, CURR BIOL, V11, P1017, DOI 10.1016/S0960-9822(01)00299-8; Ascenzi R, 1999, CHROMOSOMA, V108, P345, DOI 10.1007/s004120050386; Baumbusch LO, 2001, NUCLEIC ACIDS RES, V29, P4319, DOI 10.1093/nar/29.21.4319; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Dennis K, 2001, GENE DEV, V15, P2940, DOI 10.1101/gad.929101; Flaus A, 2001, CURR OPIN GENET DEV, V11, P148, DOI 10.1016/S0959-437X(00)00172-6; Fransz PF, 2000, CELL, V100, P367, DOI 10.1016/S0092-8674(00)80672-8; Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Hirochika H, 2000, PLANT CELL, V12, P357, DOI 10.1105/tpc.12.3.357; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jeddeloh JA, 1998, GENE DEV, V12, P1714, DOI 10.1101/gad.12.11.1714; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kakutani T, 1996, P NATL ACAD SCI USA, V93, P12406, DOI 10.1073/pnas.93.22.12406; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Langst G, 2001, J CELL SCI, V114, P2561; Martienssen RA, 2001, SCIENCE, V293, P1070, DOI 10.1126/science.293.5532.1070; McCombie WR, 2000, CELL, V100, P377, DOI 10.1016/S0092-8674(00)80673-X; Miura A, 2001, NATURE, V411, P212, DOI 10.1038/35075612; MOEHS CP, 1988, PLANT MOL BIOL, V11, P507, DOI 10.1007/BF00039031; Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Rabinowicz PD, 1999, NAT GENET, V23, P305, DOI 10.1038/15479; Singer T, 2001, GENE DEV, V15, P591, DOI 10.1101/gad.193701; Stokes TL, 2002, GENE DEV, V16, P171, DOI 10.1101/gad.952102; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Verbsky ML, 2001, CURR OPIN PLANT BIOL, V4, P494, DOI 10.1016/S1369-5266(00)00206-5; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832	31	350	367	3	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 13	2002	297	5588					1871	1873		10.1126/science.1074950	http://dx.doi.org/10.1126/science.1074950			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	592UJ	12077425				2022-12-28	WOS:000177955000044
J	Lyle, JM; Bullitt, E; Bienz, K; Kirkegaard, K				Lyle, JM; Bullitt, E; Bienz, K; Kirkegaard, K			Visualization and functional analysis of RNA-dependent RNA polymerase lattices	SCIENCE			English	Article							POLIOVIRUS REPLICATION COMPLEX; ESCHERICHIA-COLI; PROTEIN 3AB; SHEETS; OLIGOMERIZATION; POLYMERIZATION; ORGANIZATION; ASSOCIATION; EXPRESSION; INFECTION	Positive-strand RNA viruses such as poliovirus replicate their genomes on intracellular membranes of their eukaryotic hosts. Electron microscopy has revealed that purified poliovirus RNA-dependent RNA polymerase forms planar and tubular oligomeric arrays. The structural integrity of these arrays correlates with cooperative RNA binding and RNA elongation and is sensitive to mutations that disrupt intermolecular contacts predicted by the polymerase structure. Membranous vesicles isolated from poliovirus-infected cells contain structures consistent with the presence of two-dimensional polymerase arrays on their surfaces during infection. Therefore, host cytoplasmic membranes may function as physical foundations for two-dimensional polymerase arrays, conferring the advantages of surface catalysis to viral RNA replication.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA; Univ Basel, Inst Med Microbiol, CH-4003 Basel, Switzerland	Stanford University; Boston University; University of Basel	Kirkegaard, K (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.	karlak@leland.stanford.edu		Bullitt, Esther/0000-0003-2447-6209	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042119] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-42119] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beckman MTL, 1998, J BIOL CHEM, V273, P6724, DOI 10.1074/jbc.273.12.6724; BIENZ K, 1992, J VIROL, V66, P2740, DOI 10.1128/JVI.66.5.2740-2747.1992; BIENZ K, 1987, VIROLOGY, V160, P220, DOI 10.1016/0042-6822(87)90063-8; Bravo A, 1998, EMBO J, V17, P6096, DOI 10.1093/emboj/17.20.6096; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; DALES S, 1965, VIROLOGY, V26, P379, DOI 10.1016/0042-6822(65)90001-2; DIAMOND SE, 1994, J VIROL, V68, P863, DOI 10.1128/JVI.68.2.863-876.1994; DOEDENS J, 1994, ARCH VIROL, P159; Egger D, 1996, J VIROL, V70, P8675, DOI 10.1128/JVI.70.12.8675-8683.1996; Flyvbjerg H, 1996, P NATL ACAD SCI USA, V93, P5975, DOI 10.1073/pnas.93.12.5975; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Hill AR, 1998, ORIGINS LIFE EVOL B, V28, P235; Hobson SD, 2001, EMBO J, V20, P1153, DOI 10.1093/emboj/20.5.1153; HOBSON SD, 2000, THESIS U COLORADO BU; Hope DA, 1997, J VIROL, V71, P9490, DOI 10.1128/JVI.71.12.9490-9498.1997; JARVIS TC, 1992, EMBO J, V11, P3135, DOI 10.1002/j.1460-2075.1992.tb05386.x; Klymkowsky MW, 1999, NAT CELL BIOL, V1, pE121, DOI 10.1038/12950; LAMA J, 1994, J BIOL CHEM, V269, P66; Lowe J, 1999, EMBO J, V18, P2364, DOI 10.1093/emboj/18.9.2364; Lyle JM, 2002, J BIOL CHEM, V277, P16324, DOI 10.1074/jbc.M112429200; LYLE JM, UNPUB; Nelsestuen GL, 1999, CHEM PHYS LIPIDS, V101, P37, DOI 10.1016/S0009-3084(99)00053-5; PATA JD, 1995, RNA, V1, P466; Paul AV, 2000, VIROLOGY, V272, P72, DOI 10.1006/viro.2000.0354; PLOTCH SJ, 1989, J VIROL, V63, P216, DOI 10.1128/JVI.63.1.216-225.1989; Rust RC, 2001, J VIROL, V75, P9808, DOI 10.1128/JVI.75.20.9808-9818.2001; Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000; VANDYKE TA, 1980, J VIROL, V35, P732, DOI 10.1128/JVI.35.3.732-740.1980; Weigel C, 1999, MOL MICROBIOL, V34, P53, DOI 10.1046/j.1365-2958.1999.01568.x; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; WINSTON S, 1980, P NATL ACAD SCI-BIOL, V77, P2834, DOI 10.1073/pnas.77.5.2834; Xiang WK, 1998, J VIROL, V72, P6732, DOI 10.1128/JVI.72.8.6732-6741.1998	37	129	133	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	2002	296	5576					2218	2222		10.1126/science.1070585	http://dx.doi.org/10.1126/science.1070585			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077417				2022-12-28	WOS:000176379000058
J	Green, LA				Green, LA			First morning back	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	2002	287	23					3053	3054		10.1001/jama.287.23.3053	http://dx.doi.org/10.1001/jama.287.23.3053			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563NK	12069651				2022-12-28	WOS:000176262300001
J	Bisset, RAL; Thomas, NB; Turnbull, IW; Lee, S				Bisset, RAL; Thomas, NB; Turnbull, IW; Lee, S			Postmortem examinations using magnetic resonance imaging: four year review of a working service	BRITISH MEDICAL JOURNAL			English	Article							DEATH CERTIFICATION; ACCURACY		N Manchester Grp Hosp, Xray Dept, Manchester M8 5RB, Lancs, England; Hope Hosp, Xray Dept, Salford M6 8HD, Lancs, England; Manchester Royal Infirm, Xray Dept, Manchester M13, Lancs, England		Bisset, RAL (corresponding author), N Manchester Grp Hosp, Xray Dept, Manchester M8 5RB, Lancs, England.							Brookes JAS, 1996, LANCET, V348, P1139, DOI 10.1016/S0140-6736(96)02287-8; CAMERON HM, 1981, J PATHOL, V133, P273, DOI 10.1002/path.1711330402; CORWIN LI, 1982, STROKE, V13, P818, DOI 10.1161/01.STR.13.6.818; ENGEL LW, 1980, AM J EPIDEMIOL, V111, P99, DOI 10.1093/oxfordjournals.aje.a112879; RON E, 1994, EPIDEMIOLOGY, V5, P48, DOI 10.1097/00001648-199401000-00009	5	54	54	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 15	2002	324	7351					1423	1424		10.1136/bmj.324.7351.1423	http://dx.doi.org/10.1136/bmj.324.7351.1423			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	565CQ	12065265	Bronze, Green Published			2022-12-28	WOS:000176351400017
J	Sutcliffe, AG				Sutcliffe, AG			Death of a child	LANCET			English	Article									Dept Community Child Hlth, London NW3 2PF, England		Sutcliffe, AG (corresponding author), Dept Community Child Hlth, Royal Free Campus, London NW3 2PF, England.			Sutcliffe, Alastair/0000-0001-8542-6155					0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 15	2002	359	9323					2104	2104		10.1016/S0140-6736(02)08910-9	http://dx.doi.org/10.1016/S0140-6736(02)08910-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086779				2022-12-28	WOS:000176194600026
J	Whitten, PS; Mair, FS; Haycox, A; May, CR; Williams, TL; Hellmich, S				Whitten, PS; Mair, FS; Haycox, A; May, CR; Williams, TL; Hellmich, S			Systematic review of cost effectiveness studies of telemedicine interventions	BRITISH MEDICAL JOURNAL			English	Article								Objectives To systematically review cost benefit studies of telemedicine. Design Systematic review of English language, peer reviewed journal articles. Data sources Searches of Medline, Embase, ISI citation indexes, and database of Telemedicine Information Exchange. Studies selected 55 of 612 identified articles that presented actual cost benefit data. Main outcome measures Scientific quality of reports assessed by use of an established instrument for adjudicating on the quality of economic analyses. Results 557 articles without cost data categorised by topic. 55 articles with data initially categorised by cost variables employed in the study and conclusions. Only 24/55 (44%) studies met quality criteria justifying inclusion in a quality review. 20/24 (83%) restricted to simple cost comparisons. No study used cost utility analysis, the conventional means of establishing the "value for money" that a therapeutic intervention represents. Only 7/24 (29%) studies attempted to explore the level of utilisation that would be needed for telemedicine services to compare favourably with traditionally organised health care. None addressed this question in sufficient detail to adequately answer it. 15/24 (62.5%) of articles reviewed here provided no details of sensitivity analysis, a method all economic analyses should incorporate. Conclusion T here is no good evidence that telemedicine is a cost effective means of delivering health care.	Michigan State Univ, Dept Telecommun, E Lansing, MI 48824 USA; Univ Liverpool, Dept Primary Care, Liverpool L69 3BX, Merseyside, England; Univ Liverpool, Dept Pharmacol, Liverpool L69 3BX, Merseyside, England; Univ Newcastle Upon Tyne, Ctr Hlth Serv Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Manchester, Sch Primary Care, Manchester M13 9PL, Lancs, England	Michigan State University; University of Liverpool; University of Liverpool; Newcastle University - UK; University of Manchester	Whitten, PS (corresponding author), Michigan State Univ, Dept Telecommun, E Lansing, MI 48824 USA.		May, Carl/A-8502-2011	Mair, Frances/0000-0001-9780-1135; May, Carl/0000-0002-0451-2690; Finch, Tracy/0000-0001-8647-735X				Currell R., 2000, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD002098; Haycox A, 1997, BRIT J CLIN PHARMACO, V43, P451, DOI 10.1046/j.1365-2125.1997.00575.x; MAY C, 2000, HLTH INFORMATICS J, V6, P64; *NHS CTR REV DISS, 1996, 4 NHS U YORK CTR REV; NHS Executive, 1998, INF HLTH INF STRAT M; PEREDNIA DA, 1995, JAMA-J AM MED ASSOC, V273, P483, DOI 10.1001/jama.273.6.483; WOOTTON R, 1998, J ROY SOC MED, V91, P289	7	313	319	0	36	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 15	2002	324	7351					1434	1437		10.1136/bmj.324.7351.1434	http://dx.doi.org/10.1136/bmj.324.7351.1434			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	565CQ	12065269	Green Published, Bronze			2022-12-28	WOS:000176351400021
J	Ahn, DG; Kourakis, MJ; Rohde, LA; Silver, LM; Ho, RK				Ahn, DG; Kourakis, MJ; Rohde, LA; Silver, LM; Ho, RK			T-box gene tbx5 is essential for formation of the pectoral limb bud	NATURE			English	Article							HOLT-ORAM-SYNDROME; SONIC-HEDGEHOG; FIN BUD; EXPRESSION; EVOLUTION; IDENTITY; SPECIFICATION; MUTATIONS	The T-box genes Tbx4 and Tbx5 have been shown to have key functions in the specification of the identity of the vertebrate forelimb (Tbx5) and hindlimb (Tbx4)(1,2). Here we show that in zebrafish, Tbx5 has an additional early function that precedes the formation of the limb bud itself. Functional knockdown of zebrafish tbx5 through the use of an antisense oligonucleotide resulted in a failure to initiate fin bud formation, leading to the complete loss of pectoral fins. The function of the tbx5 gene in the development of zebrafish forelimbs seems to involve the directed migration of individual lateral-plate mesodermal cells into the future limb-bud-producing region. The primary defect seen in the tbx5-knockdown phenotype is similar to the primary defects described in known T-box-gene mutants such as the spadetail mutant of zebrafish(3,4) and the Brachyury mutant of the mouse 5, which both similarly exhibit an altered migration of mesodermal cells. A common function for many of the T-box genes might therefore be in mediating the proper migration and/or changes in adhesive properties of early embryonic cells.	Univ Chicago, Dept Organismal Biol & Anat, Chicago, IL 60637 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	University of Chicago; Princeton University	Ahn, DG (corresponding author), Univ Chicago, Dept Organismal Biol & Anat, 1025 E 57th St, Chicago, IL 60637 USA.	dahn@midway.uchicago.edu	Rohde, Luis Augusto P/A-6426-2008	Rohde, Luis Augusto P/0000-0002-4552-4188; Rohde, Laurel/0000-0002-4329-9116				Ahn D, 2000, MECH DEVELOP, V95, P253, DOI 10.1016/S0925-4773(00)00346-4; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; Begemann G, 2000, MECH DEVELOP, V90, P299, DOI 10.1016/S0925-4773(99)00246-4; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Cohn MJ, 1999, CELL TISSUE RES, V296, P3, DOI 10.1007/s004410051261; Gibson-Brown JJ, 1998, DEVELOPMENT, V125, P2499; GibsonBrown JJ, 1996, MECH DEVELOP, V56, P93, DOI 10.1016/0925-4773(96)00514-X; Grandel H, 1998, MECH DEVELOP, V79, P99, DOI 10.1016/S0925-4773(98)00176-2; Grandel H, 2000, DEVELOPMENT, V127, P4169; Griffin KJP, 1998, DEVELOPMENT, V125, P3379; HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0; Isaac A, 1998, DEVELOPMENT, V125, P1867; Li QY, 1997, NAT GENET, V15, P21; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Nelson CE, 1996, DEVELOPMENT, V122, P1449; Neumann CJ, 1999, DEVELOPMENT, V126, P4817; Ohuchi H, 1998, DEVELOPMENT, V125, P51; Rodriguez-Esteban C, 1999, NATURE, V398, P814, DOI 10.1038/19769; Ros MA, 1996, DEVELOPMENT, V122, P2319; Russ AP, 2000, NATURE, V404, P95, DOI 10.1038/35003601; Ruvinsky I, 2000, DEV GENES EVOL, V210, P82, DOI 10.1007/s004270050014; Summerton J, 1999, BBA-GENE STRUCT EXPR, V1489, P141, DOI 10.1016/S0167-4781(99)00150-5; Takabatake Y, 2000, MECH DEVELOP, V91, P433, DOI 10.1016/S0925-4773(99)00329-9; Takeuchi JK, 1999, NATURE, V398, P810, DOI 10.1038/19762; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; WILSON V, 1995, DEVELOPMENT, V121, P877	26	169	173	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	2002	417	6890					754	758		10.1038/nature00814	http://dx.doi.org/10.1038/nature00814			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	561QY	12066188				2022-12-28	WOS:000176154700048
J	Liang, WJ; Shores, MP; Bockrath, M; Long, JR; Park, H				Liang, WJ; Shores, MP; Bockrath, M; Long, JR; Park, H			Kondo resonance in a single-molecule transistor	NATURE			English	Article							CARBON NANOTUBES; QUANTUM DOTS; ELECTRON TRANSISTOR; ANDERSON MODEL; TRANSPORT; NANOCRYSTAL; EQUILIBRIUM; STATES	When an individual molecule(1), nanocrystal(2-4), nanotube(5,6) or lithographically defined quantum dot(7) is attached to metallic electrodes via tunnel barriers, electron transport is dominated by single-electron charging and energy-level quantization(8). As the coupling to the electrodes increases, higher-order tunnelling and correlated electron motion give rise to new phenomena(9-19), including the Kondo resonance(10-16). To date, all of the studies of Kondo phenomena in quantum dots have been performed on systems where precise control over the spin degrees of freedom is difficult. Molecules incorporating transition-metal atoms provide powerful new systems in this regard, because the spin and orbital degrees of freedom can be controlled through well-defined chemistry(20,21). Here we report the observation of the Kondo effect in single-molecule transistors, where an individual divanadium molecule(20) serves as a spin impurity. We find that the Kondo resonance can be tuned reversibly using the gate voltage to alter the charge and spin state of the molecule. The resonance persists at temperatures up to 30 K and when the energy separation between the molecular state and the Fermi level of the metal exceeds 100 meV.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	Harvard University; University of California System; University of California Berkeley	Park, H (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.		Park, Hongkun/R-9842-2019	Park, Hongkun/0000-0001-9576-8829				Bachtold A, 2001, SCIENCE, V294, P1317, DOI 10.1126/science.1065824; Banin U, 1999, NATURE, V400, P542, DOI 10.1038/22979; Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; BONCA J, 1993, PHYS REV B, V47, P13137, DOI 10.1103/PhysRevB.47.13137; Cobden DH, 1998, PHYS REV LETT, V81, P681, DOI 10.1103/PhysRevLett.81.681; Cronenwett SM, 1998, SCIENCE, V281, P540, DOI 10.1126/science.281.5376.540; De Franceschi S, 2001, PHYS REV LETT, V86, P878, DOI 10.1103/PhysRevLett.86.878; GLAZMAN LI, 1988, JETP LETT+, V47, P452; Goldhaber-Gordon D, 1998, NATURE, V391, P156, DOI 10.1038/34373; Goldhaber-Gordon D, 1998, PHYS REV LETT, V81, P5225, DOI 10.1103/PhysRevLett.81.5225; GRABERT H, 1992, SINGLE CHARGE TUNNEL; HALDANE FDM, 1978, PHYS REV LETT, V40, P416, DOI 10.1103/PhysRevLett.40.416; Hewson A C, 1993, KONDO PROBLEM HEAVY; Klein DL, 1997, NATURE, V389, P699, DOI 10.1038/39535; Kouwenhoven LP, 1997, SCIENCE, V278, P1788, DOI 10.1126/science.278.5344.1788; Liang WJ, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.126801; Liang WJ, 2001, NATURE, V411, P665, DOI 10.1038/35079517; LIN HQ, 1988, PHYS REV B, V37, P1864, DOI 10.1103/PhysRevB.37.1864; MEIR Y, 1993, PHYS REV LETT, V70, P2601, DOI 10.1103/PhysRevLett.70.2601; NG TK, 1988, PHYS REV LETT, V61, P1768, DOI 10.1103/PhysRevLett.61.1768; Nygard J, 2000, NATURE, V408, P342, DOI 10.1038/35042545; Park H, 1999, APPL PHYS LETT, V75, P301, DOI 10.1063/1.124354; Park H, 2000, NATURE, V407, P57, DOI 10.1038/35024031; SCHLOTTMANN P, 1989, PHYS REP, V181, P1, DOI 10.1016/0370-1573(89)90116-6; Schmid J, 2000, PHYS REV LETT, V84, P5824, DOI 10.1103/PhysRevLett.84.5824; Shores MP, 2002, J AM CHEM SOC, V124, P2279, DOI 10.1021/ja011645h; Shores MP, 2002, J AM CHEM SOC, V124, P3512, DOI 10.1021/ja025512n; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; van der Wiel WG, 2000, SCIENCE, V289, P2105, DOI 10.1126/science.289.5487.2105; WINGREEN NS, 1994, PHYS REV B, V49, P11040, DOI 10.1103/PhysRevB.49.11040	30	1394	1422	9	317	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 13	2002	417	6890					725	729		10.1038/nature00790	http://dx.doi.org/10.1038/nature00790			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	561QY	12066180				2022-12-28	WOS:000176154700040
J	Bayer, R; Gostin, LO; Javitt, GH; Brandt, A				Bayer, R; Gostin, LO; Javitt, GH; Brandt, A			Tobacco advertising in the United States - A proposal for a constitutionally acceptable form of regulation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SMOKING	Lorillard Tobacco Co. v Reilly is the latest in a series of Supreme Court cases striking down public health regulation of advertising as a violation of the First Amendment. In its decision, the Supreme Court significantly reduced the scope of constitutionally acceptable forms of regulation of tobacco advertising and created an almost insoluble dilemma for public health authorities. Control over advertising, along with taxes and restrictions on smoking in public settings, plays an important role in the public health response to tobacco. Those committed to reducing the patterns of cigarette-related morbidity and mortality should broaden their advertising-related strategies and consider the role that greater disclosure of the health harms of tobacco can have on reducing consumption. Toward this end, we propose a comprehensive system of taxation and regulation designed to increase public appreciation and comprehension of the health risks of cigarettes. First, we consider a tax to be levied on tobacco advertising and promotion or, as an alternative, a new excise tax, the proceeds of which would be used exclusively to fund a Centers for Disease Control and Prevention-directed national antitobacco campaign. Second, all print advertising should be required to carry public health warnings equivalent to 50% of the space devoted to the advertisement. Third, manufacturers should be required to devote one full side of cigarette packages to graphic pictorials displaying the dangers of smoking. The tobacco industry would no doubt respond by declaring such efforts an unwarranted burden, an example of constitutionally suspect compelled speech. However, this would be a battle worth engaging, because it might have an impact on tobacco-related morbidity and mortality in the United States.	Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10032 USA; Georgetown Univ, Ctr Law, Ctr Law & Publ Hlth, Washington, DC USA; Johns Hopkins Sch Publ Hlth, Baltimore, MD USA; Univ Maryland, Sch Law, Baltimore, MD 21201 USA; Harvard Univ, Dept Social Med, Boston, MA 02115 USA	Columbia University; Georgetown University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University System of Maryland; University of Maryland Baltimore; Harvard University	Bayer, R (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, 722 W 168th St,9th Floor, New York, NY 10032 USA.	rb8@columbia.edu						Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; BAYER R, 1994, GEORGETOWN LAW J, V83, P79; BEAUCHAMP DE, 1988, HLTH REPUBLIC EPIDEM; Biener L, 2000, J Public Health Manag Pract, V6, P40; BRENNER DE, 1965, ATLANTIC MONTHLY SEP, P76; *CAN CANC SOC, 2002, CAN CANC SOC EV NEW; COHEN H, 1998, 98189A C RES SERV; *FED TRAD COMM, 2001, CIG REP 1999, P2; GEORGE JW, 1928, ADVERTISING SEL 1226, P23; GIANATASIO D, 2001, ADWEEK, V42, P7; Goldman LK, 1998, JAMA-J AM MED ASSOC, V279, P772, DOI 10.1001/jama.279.10.772; Gostin LO, 2002, AM J PUBLIC HEALTH, V92, P352, DOI 10.2105/AJPH.92.3.352; Gostin LO, 2001, MILBANK Q, V79, P547, DOI 10.1111/1468-0009.00221; GOSTIN LO, 1991, JAMA-J AM MED ASSOC, V266, P3178, DOI 10.1001/jama.266.22.3178; KLUGER R, 1996, ASHES ASHES AM 100 Y, P279; Saffer H, 2000, J HEALTH ECON, V19, P1117, DOI 10.1016/S0167-6296(00)00054-0; Siegel M, 2000, AM J PUBLIC HEALTH, V90, P380, DOI 10.2105/AJPH.90.3.380; Siegel M, 1998, ANN INTERN MED, V129, P128, DOI 10.7326/0003-4819-129-2-199807150-00013; SLADE J, 2001, REGULATING TOBACCO, P98; Unger JB, 2001, J HEALTH COMMUN, V6, P11, DOI 10.1080/10810730150501387; US Department of Health and Human Services, 2000, RED TOB US REP SURG; VIRELLI LJ, 2000, U PA J CONST LAW, V529, P529; WARNER KE, 1979, POLICY ANAL, V5, P435; WILKE JR, 2002, WALL STREET J   0311, pA3	24	24	24	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	2002	287	22					2990	2995		10.1001/jama.287.22.2990	http://dx.doi.org/10.1001/jama.287.22.2990			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	561EY	12052129				2022-12-28	WOS:000176128300029
J	D'Souza, AL; Rajkumar, C; Cooke, J; Bulpitt, CJ				D'Souza, AL; Rajkumar, C; Cooke, J; Bulpitt, CJ			Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis	BRITISH MEDICAL JOURNAL			English	Article							CASEI STRAIN SHIROTA; SACCHAROMYCES-BOULARDII; CLOSTRIDIUM-DIFFICILE; BIOTHERAPEUTIC AGENTS; DOUBLE-BLIND; PLACEBO; PROPHYLAXIS; EFFICACY; COLITIS	Objective To evaluate efficacy of probiotics in prevention and treatment of diarrhoea associated with the use of antibiotics. Design Meta-analysis; outcome data (proportion of patients not getting diarrhoea) were analysed, pooled, and compared to determine odds ratios in treated and control groups. Identification Studies identified by searching Medline between 1966 and 2000 and the Cochrane Library. Studies reviewed Nine randomised, double blind, placebo controlled trials of probiotics. Results Two of the nine studies investigated the effects of probiotics in children. Four trials used a yeast (Saccharomyces boulardii), four used lactobacilli, and one used a strain of enterococcus that produced lactic acid. Three trials used a combination of probiotic strains of bacteria. In all nine trials, the probiotics were given in combination with antibiotics and the control groups received placebo and antibiotics. The odds ratio in favour of active treatment over placebo in preventing diarrhoea associated with antibiotics was 0.39 (95% confidence interval 0.25 to 0.62; P <0.001) for the yeast and 0.34 (0.19 to 0.61; P < 0.01) for lactobacilli. The combined odds ratio was 0.37 (0.26 to 0.53; P < 0.001) in favour of active treatment over placebo. Conclusions The meta-analysis suggests that probiotics can be used to prevent antibiotic associated diarrhoea and that S boulardii and lactobacilli have the potential to be used in this situation. The efficacy of probiotics in treating antibiotic associated diarrhoea remains to be proved. A further large trial in which probiotics are used as preventive agents should look at the costs of and need for routine use of these agents.	Hammersmith Hosp, Imperial Coll Sch Med, Fac Med, Care Elderly Sect, London W12 0NN, England	Imperial College London	D'Souza, AL (corresponding author), Hammersmith Hosp, Imperial Coll Sch Med, Fac Med, Care Elderly Sect, London W12 0NN, England.							Adam J, 1977, GAZ MED FR, V84, P2072; Benno Y., 1996, NUTR TODAY, V31, p12S, DOI [10.1097/00017285-199611001-00004, DOI 10.1097/00017285-199611001-00004]; BLEHAUT H, 1989, BIOPHARM DRUG DISPOS, V10, P353, DOI 10.1002/bdd.2510100403; Castagliuolo I, 1999, INFECT IMMUN, V67, P302, DOI 10.1128/IAI.67.1.302-307.1999; Elmer GW, 1996, JAMA-J AM MED ASSOC, V275, P870, DOI 10.1001/jama.275.11.870; FULLER R, 1991, GUT, V32, P439, DOI 10.1136/gut.32.4.439; Gorbach SL, 1996, NUTR TODAY, V31, P25, DOI DOI 10.1097/00017285-199611001-00002; GOTZ V, 1979, AM J HOSP PHARM, V36, P754, DOI 10.1093/ajhp/36.6.754; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; Lewis SJ, 1998, J INFECTION, V36, P171, DOI 10.1016/S0163-4453(98)80008-X; MCFARLAND LV, 1995, AM J GASTROENTEROL, V90, P439; MCFARLAND LV, 1994, JAMA-J AM MED ASSOC, V271, P1913, DOI 10.1001/jama.271.24.1913; McFarland LV, 1995, MICROECOL T, V23, P46; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; ORRHAGE K, 1994, MICROB ECOL HEALTH D, V7, P17, DOI 10.3109/08910609409141570; Spanhaak S, 1998, EUR J CLIN NUTR, V52, P899, DOI 10.1038/sj.ejcn.1600663; SURAWICZ CM, 1989, GASTROENTEROLOGY, V96, P981, DOI 10.1016/0016-5085(89)91613-2; TANKANOW RM, 1990, DICP ANN PHARMAC, V24, P382, DOI 10.1177/106002809002400408; Vanderhoof JA, 1999, J PEDIATR-US, V135, P564, DOI 10.1016/S0022-3476(99)70053-3; WALTERS BAJ, 1983, GUT, V24, P206, DOI 10.1136/gut.24.3.206; WUNDERLICH PF, 1989, J INT MED RES, V17, P333, DOI 10.1177/030006058901700405; Yuki N, 1999, INT J FOOD MICROBIOL, V48, P51, DOI 10.1016/S0168-1605(99)00029-X	22	395	448	0	39	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 8	2002	324	7350					1361	1364		10.1136/bmj.324.7350.1361	http://dx.doi.org/10.1136/bmj.324.7350.1361			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BQ	12052801	Bronze, Green Published			2022-12-28	WOS:000176234100016
J	van Schayck, CP; Loozen, JMC; Wagena, E; Akkermans, RP; Wesseling, GJ				van Schayck, CP; Loozen, JMC; Wagena, E; Akkermans, RP; Wesseling, GJ			Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FLUTICASONE PROPIONATE; RESPIRATORY SYMPTOMS; CONTROLLED-TRIAL; ASTHMA; SMOKING; POPULATION; PREVALENCE; MODERATE; ADULTS; COPD	Objectives To investigate the effectiveness of case finding of patients at risk of developing chronic obstructive pulmonary disease, whether the method is suitable for use in general practice, how patients should be selected, and the time required. Design Cross sectional study. Setting Two semirural general practices in the Netherlands. Participants 651 smokers aged 35 to 70 years. Main outcome measures Short standardised questionnaire on bronchial symptoms for current smokers, lung function with a spirometer, and the quality of the spirometric curve. Results Of the 201 smokers not taking drugs for a pulmonary condition, 169 produced an acceptable curve (fulfilling American Thoracic Society criteria). Of these, 30 (18%, 95% confidence interval 12% to 24%) had a forced expiratory volume in one second (FEV1) <80% of predicted. When smokers were preselected on the basis of chronic cough, the proportion with an FEV1 < 80% of predicted increased to 27% (17 of 64; 12% to 38%). Chronic cough was a better predictor of airflow obstruction than other symptoms, such as wheeze and dyspnoea. The presence of two symptoms was a slightly better predictor than cough only (odds ratio 3.02 (1.37 to 6.64) v 2.50 (1.14 to 5.52)). Age was also a good predictor of obstruction; smokers over 60 with cough had a 48% chance of having an obstruction. The mean time needed for spirometry was four minutes. Detecting one smoker with an FEV1 < 80% of predicted cost 65 to E10. Conclusions Trained practice assistants could check all patients who smoke for chronic obstructive pulmonary disease at little cost to the practice. Cough and age are the most important predictors of the disease. By testing one smoker a day, an average practice could identify one patient at risk a week.	Univ Maastricht, Res Inst ExTra, Dept Gen Practice, NL-6200 MD Maastricht, Netherlands; Radboud Univ Nijmegen Med Ctr, Dept Gen Practice & Family & Social Med, Nijmegen, Netherlands	Maastricht University; Radboud University Nijmegen	van Schayck, CP (corresponding author), Univ Maastricht, Res Inst ExTra, Dept Gen Practice, Postbox 616, NL-6200 MD Maastricht, Netherlands.	Onno.vanschayck@hag.unimaas.nl						[Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; Anthonisen NR, 1995, JAMA-J AM MED ASSOC, V273, P1497; BARNES PJ, 1992, THORAX, V47, P408, DOI 10.1136/thx.47.6.408; BURDON JGW, 1994, EUR RESPIR J, V7, P1342, DOI 10.1183/09031936.94.07071342; Burge PS, 2000, BMJ-BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; CRAPO RO, 1998, TEST REPORT MICRO ME; denOtter JJ, 1997, BRIT J GEN PRACT, V47, P41; DOMPELING E, 1993, ANN INTERN MED, V118, P770, DOI 10.7326/0003-4819-118-10-199305150-00003; *FDN PUBL HLTH SMO, 1996, NIPO SURV SMOK AD; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; GEIJER RMM, 1997, HUISARTS WET, V40, P430; Humerfelt S, 1998, EUR RESPIR J, V11, P284, DOI 10.1183/09031936.98.11020284; Kanner RE, 1999, AM J MED, V106, P410, DOI 10.1016/S0002-9343(99)00056-X; Murray RP, 1998, J CLIN EPIDEMIOL, V51, P1317, DOI 10.1016/S0895-4356(98)00120-6; Paggiaro PL, 1998, LANCET, V351, P773, DOI 10.1016/S0140-6736(97)03471-5; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Renwick DS, 1996, THORAX, V51, P164, DOI 10.1136/thx.51.2.164; Schewe CD, 2000, MARK MANAG, V9, P48; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; Thiadens HA, 1998, BMJ-BRIT MED J, V316, P1286, DOI 10.1136/bmj.316.7140.1286; Thoracic Society of Australia and New Zealand, 1995, MOD MED AUST, V38, P132; Tirimanna PRS, 1996, BRIT J GEN PRACT, V46, P277; van den Boom G, 1998, AM J RESP CRIT CARE, V158, P1730, DOI 10.1164/ajrccm.158.6.9709003; van den Boom G, 1998, EUR RESPIR J, V11, P67, DOI 10.1183/09031936.98.11010067; Van den Boom G, 2001, AM J RESP CRIT CARE, V164, P2057, DOI 10.1164/ajrccm.164.11.2003151; van Schayck CP, 2000, THORAX, V55, P562, DOI 10.1136/thorax.55.7.562; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; XU XP, 1992, AM REV RESPIR DIS, V146, P1345, DOI 10.1164/ajrccm/146.5_Pt_1.1345; Zielinski J, 2001, CHEST, V119, P731, DOI 10.1378/chest.119.3.731	31	168	172	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 8	2002	324	7350					1370	1373		10.1136/bmj.324.7350.1370	http://dx.doi.org/10.1136/bmj.324.7350.1370			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BQ	12052807	Green Published, Bronze			2022-12-28	WOS:000176234100022
J	Anderson, RGW; Jacobson, K				Anderson, RGW; Jacobson, K			Cell biology - A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains	SCIENCE			English	Review							GPI-ANCHORED PROTEINS; RECEPTOR-MEDIATED ENDOCYTOSIS; PLASMA-MEMBRANE; BINDING DOMAIN; CHOLESTEROL; CLATHRIN; SURFACE; IDENTIFICATION; COMPLEXES; MODEL	The surface membrane of cells is studded with morphologically distinct, regions, or domains, like microvilli, cell-cell junctions, and coated pits. Each of these domains is specialized for a particular function, such as nutrient absorption, cell-cell communication, and endocytosis. Lipid domains, which include caveolae and rafts, are one of, the least understood membrane domains. These domains are high in cholesterol and sphingolipids, have a light buoyant density, and function in both endocytosis and cell signaling. A major mystery, however, is how resident molecules are targeted to lipid domains. Here,we propose that the molecular address for proteins targeted to lipid, domains is a lipid shell.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ N Carolina, Sch Med, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Anderson, RGW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA.	richard.anderson@utsouthwestern.edu						Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arbuzova A, 1998, BBA-REV BIOMEMBRANES, V1376, P369, DOI 10.1016/S0304-4157(98)00011-2; Blobel G., 1971, BIOMEMBRANE, P193; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown RE, 1998, J CELL SCI, V111, P1; Carozzi AJ, 2000, TRAFFIC, V1, P326, DOI 10.1034/j.1600-0854.2000.010406.x; CARTER WG, 1981, J BIOL CHEM, V256, P6953; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; Chen Y, 2002, BIOPHYS J, V82, P133, DOI 10.1016/S0006-3495(02)75380-0; CHERRY RJ, 1979, BIOCHIM BIOPHYS ACTA, V559, P289, DOI 10.1016/0304-4157(79)90009-1; DIETRICH C, 2001, BIOPHYS J; Dvorak AM, 2001, J HISTOCHEM CYTOCHEM, V49, P419, DOI 10.1177/002215540104900401; Epand RM, 2001, BIOCHEMISTRY-US, V40, P10514, DOI 10.1021/bi010897s; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Frank M, 2000, PROG NEUROBIOL, V60, P531, DOI 10.1016/S0301-0082(99)00039-8; Frey D, 2000, J CELL BIOL, V149, P1443, DOI 10.1083/jcb.149.7.1443; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; Gennis R. B., 1989, BIOMEMBRANES MOL STR, DOI [10.1007/978-1-4757-2065-5, DOI 10.1007/978-1-4757-2065-5]; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HOMANS SW, 1989, BIOCHEMISTRY-US, V28, P2881, DOI 10.1021/bi00433a020; Huang JY, 1999, BIOPHYS J, V76, P2142, DOI 10.1016/S0006-3495(99)77369-8; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Liu PS, 2000, J BIOL CHEM, V275, P31648, DOI 10.1074/jbc.M004599200; Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200; MAHFOUD R, IN PRESS J BIOL CHEM; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MCGOOKEY DJ, 1983, J CELL BIOL, V96, P1273, DOI 10.1083/jcb.96.5.1273; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Mineo C, 2001, HISTOCHEM CELL BIOL, V116, P109; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MONTESANO R, 1979, NATURE, V280, P328, DOI 10.1038/280328a0; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; OKADA Y, 1984, EXP CELL RES, V155, P448, DOI 10.1016/0014-4827(84)90205-2; Okamura N, 1999, BBA-MOL CELL BIOL L, V1438, P377, DOI 10.1016/S1388-1981(99)00070-0; PALADE GE, 1953, J APPL PHYS, V24, P1424; Palaniyar N, 2001, COMP BIOCHEM PHYS A, V129, P109, DOI 10.1016/S1095-6433(01)00309-9; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Radhakrishnan A, 2000, P NATL ACAD SCI USA, V97, P12422, DOI 10.1073/pnas.220418097; Reid-Taylor KL, 1999, BIOCHEM CELL BIOL, V77, P189; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SAKO Y, 1994, J CELL BIOL, V125, P1251, DOI 10.1083/jcb.125.6.1251; Sanghera N, 2002, J MOL BIOL, V315, P1241, DOI 10.1006/jmbi.2001.5322; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; SCHLESINGER MJ, 1981, ANNU REV BIOCHEM, V50, P193, DOI 10.1146/annurev.bi.50.070181.001205; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Schutz GJ, 2000, EMBO J, V19, P892, DOI 10.1093/emboj/19.5.892; Segrest JP, 2001, J LIPID RES, V42, P1346; Shin JS, 2001, SCIENCE, V293, P1447, DOI 10.1126/science.1061079; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; SIMIONESCU N, 1983, J CELL BIOL, V97, P1592, DOI 10.1083/jcb.97.5.1592; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Suzuki K, 2002, BIOPHYS J, V82, p348A; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Thompson NL, 1991, TOPICS FLUORESCENCE, P337; THOMPSON TE, 1985, ANNU REV BIOPHYS BIO, V14, P361, DOI 10.1146/annurev.biophys.14.1.361; Trigatti BL, 1999, BIOCHEM BIOPH RES CO, V255, P34, DOI 10.1006/bbrc.1998.0123; VAN MEER G, 1988, J CELL BIOCHEM, V36, P51, DOI 10.1002/jcb.240360106; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; von Poser C, 2000, J BIOL CHEM, V275, P30916, DOI 10.1074/jbc.M005559200; Wiseman PW, 2000, J MICROSC-OXFORD, V200, P14, DOI 10.1046/j.1365-2818.2000.00736.x; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; Zaltash S, 2000, BBA-BIOMEMBRANES, V1466, P179, DOI 10.1016/S0005-2736(00)00199-1	84	956	983	1	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	2002	296	5574					1821	1825		10.1126/science.1068886	http://dx.doi.org/10.1126/science.1068886			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052946				2022-12-28	WOS:000176054300034
J	Goldberg, JL; Klassen, MP; Hua, Y; Barres, BA				Goldberg, JL; Klassen, MP; Hua, Y; Barres, BA			Amacrine-signaled loss of intrinsic axon growth ability by retinal ganglion cells	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; ADULT-RATS; NEURONAL SURVIVAL; MAMMALIAN CNS; REGENERATION; RESPONSIVENESS; EXPRESSION; MOLECULES; TRANSPORT; REGROWTH	The central nervous system (CNS) loses the ability to regenerate early during development, but it is not known why. The retina has long served as a simple model system for study of CNS regeneration. Here we show that amacrine cells signal neonatal rat retina[ ganglion cells (RGCs) to undergo a profound and apparently irreversible loss of intrinsic axon growth ability. Concurrently, retinal. maturation triggers RGCs to greatly increase their dendritic growth ability. These results suggest that adult CNS neurons fail to regenerate not only because of CNS glial inhibition but also because of a loss of intrinsic axon growth ability.	Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University	Goldberg, JL (corresponding author), Stanford Univ, Sch Med, Dept Neurobiol, Sherman Fairchild Sci Bldg D231,299 Campus Dr, Stanford, CA 94305 USA.			Goldberg, Jeffrey/0000-0002-1390-7360	NATIONAL EYE INSTITUTE [U10EY011030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY11030] Funding Source: Medline; NIGMS NIH HHS [2T32GM07365] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUAYO AJ, 1987, ANN NY ACAD SCI, V495, P1, DOI 10.1111/j.1749-6632.1987.tb23661.x; Bandtlow CE, 1997, EUR J NEUROSCI, V9, P2743, DOI 10.1111/j.1460-9568.1997.tb01703.x; BRAY GM, 1987, J EXP BIOL, V132, P5; BRAY GM, COMMUNICATION; Cai D, 2001, J NEUROSCI, V21, P4731, DOI 10.1523/JNEUROSCI.21-13-04731.2001; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; CHEN DF, 1995, P NATL ACAD SCI USA, V92, P7287, DOI 10.1073/pnas.92.16.7287; CHO EYP, 1987, BRAIN RES, V419, P369, DOI 10.1016/0006-8993(87)90610-X; COHEN J, 1986, NATURE, V322, P465, DOI 10.1038/322465a0; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DAVIES AM, 1989, NATURE, V337, P553, DOI 10.1038/337553a0; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; Du J, 2000, J CELL BIOL, V150, P1423, DOI 10.1083/jcb.150.6.1423; Dusart I, 1997, J NEUROSCI, V17, P3710; Ehrengruber MU, 1998, METHOD ENZYMOL, V293, P483; Fawcett JW, 1997, CELL TISSUE RES, V290, P371, DOI 10.1007/s004410050943; Goldberg JL, 2000, ANNU REV NEUROSCI, V23, P579, DOI 10.1146/annurev.neuro.23.1.579; Goldberg JL, 2002, NEURON, V33, P689, DOI 10.1016/S0896-6273(02)00602-5; HARVEY AR, 1995, CLIN EXP PHARMACOL P, V22, P569, DOI 10.1111/j.1440-1681.1995.tb02068.x; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; MCKERRACHER L, 1990, J NEUROSCI, V10, P641; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Mi HY, 1999, J NEUROSCI, V19, P1049; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Ramon y Cajal S., 1928, CAJALS DEGENERATION; Rosentreter SM, 1998, J NEUROBIOL, V37, P541, DOI 10.1002/(SICI)1097-4695(199812)37:4<541::AID-NEU4>3.3.CO;2-C; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; Shen SL, 1999, NEURON, V23, P285, DOI 10.1016/S0896-6273(00)80780-1; Tomomura M, 2001, EUR J NEUROSCI, V14, P57, DOI 10.1046/j.0953-816x.2001.01624.x; Watson FL, 1999, J NEUROSCI, V19, P7889; YAMASAKI EN, 1993, J COMP NEUROL, V329, P277, DOI 10.1002/cne.903290209	33	356	373	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 7	2002	296	5574					1860	1864		10.1126/science.1068428	http://dx.doi.org/10.1126/science.1068428			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052959				2022-12-28	WOS:000176054300047
J	Gould, P				Gould, P			Portraits of science - Two good women, or too good to be true?	SCIENCE			English	Editorial Material																		Alic M, 1986, HYPATIAS HERITAGE HI; Cadbury Deborah, 2000, DINOSAUR HUNTERS STO; GOULD PA, 1997, THESIS U CAMBRIDGE, pCH6; KIDWELL PA, 1984, ISIS, V75, P534, DOI 10.1086/353572; OGILVIE MB, 1975, ANN SCI, V32, P149, DOI 10.1080/00033797500200191; Yeo, 1996, TELLING LIVES SCI, P195	6	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 7	2002	296	5574					1805	1806		10.1126/science.1069966	http://dx.doi.org/10.1126/science.1069966			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	559YP	12052938				2022-12-28	WOS:000176054300023
J	Liphardt, J; Dumont, S; Smith, SB; Tinoco, I; Bustamante, C				Liphardt, J; Dumont, S; Smith, SB; Tinoco, I; Bustamante, C			Equilibrium information from nonequilibrium measurements in an experimental test of Jarzynski's equality	SCIENCE			English	Article							FREE-ENERGY DIFFERENCES; FLUCTUATION THEOREM; DRIVEN	Recent advances in statistical mechanical theory can be used to solve a fundamental problem in experimental thermodynamics. In 1997, Jarzynski proved an equality relating the irreversible work to the equilibrium free energy difference, DeltaG. This remarkable theoretical result states that it is possible to obtain equilibrium thermodynamic parameters from processes carried out arbitrarily far from equilibrium. We test Jarzynski's equality by mechanically stretching a single molecule of RNA reversibly and irreversibly between two conformations. Application of this equality to the irreversible work trajectories recovers the DeltaG profile of the stretching process to within k(B)T/2 (half the thermal energy) of its best independent estimate, the mean work of reversible stretching. The implementation and test of Jarzynski's equality provides the first example of its use as a bridge between the statistical mechanics of equilibrium and nonequilibrium systems. This work also extends the thermodynamic analysis of single molecule manipulation data beyond the context of equilibrium experiments.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Biophys Grad Grp, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Bustamante, C (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	carlos@alice.berkeley.edu	Liphardt, Jan/A-5906-2012	Liphardt, Jan/0000-0003-2835-5025; Bustamante, Carlos/0000-0002-2970-0073	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM010840, R37GM010840, R01GM032543, R37GM032543] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM010840-43, GM-32543, R01 GM010840, R01 GM010840-44, GM-10840] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; Crooks GE, 1999, PHYS REV E, V60, P2721, DOI 10.1103/PhysRevE.60.2721; Crooks GE, 2000, PHYS REV E, V61, P2361, DOI 10.1103/PhysRevE.61.2361; Crooks GE, 1998, J STAT PHYS, V90, P1481, DOI 10.1023/A:1023208217925; EVANS DJ, 1993, PHYS REV LETT, V71, P2401, DOI 10.1103/PhysRevLett.71.2401; EVANS DJ, 1994, PHYS REV E, V50, P1645, DOI 10.1103/PhysRevE.50.1645; GALLAVOTTI G, 1995, PHYS REV LETT, V74, P2694, DOI 10.1103/PhysRevLett.74.2694; Hendrix DA, 2001, J CHEM PHYS, V114, P5974, DOI 10.1063/1.1353552; HERMANS J, 1991, J PHYS CHEM-US, V95, P9029, DOI 10.1021/j100176a002; Hummer G, 2001, P NATL ACAD SCI USA, V98, P3658, DOI 10.1073/pnas.071034098; Jarzynski C, 1997, PHYS REV LETT, V78, P2690, DOI 10.1103/PhysRevLett.78.2690; Jarzynski C, 2001, P NATL ACAD SCI USA, V98, P3636, DOI 10.1073/pnas.081074598; Jarzynski C, 1997, PHYS REV E, V56, P5018, DOI 10.1103/PhysRevE.56.5018; Kurchan J, 1998, J PHYS A-MATH GEN, V31, P3719, DOI 10.1088/0305-4470/31/16/003; Lebowitz JL, 1999, J STAT PHYS, V95, P333, DOI 10.1023/A:1004589714161; Liphardt J, 2001, SCIENCE, V292, P733, DOI 10.1126/science.1058498; Maes C, 1999, J STAT PHYS, V95, P367, DOI 10.1023/A:1004541830999; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; WOOD RH, 1991, J PHYS CHEM-US, V95, P6670, DOI 10.1021/j100170a054; YAMADA T, 1967, PROG THEOR PHYS, V38, P1031, DOI 10.1143/PTP.38.1031	21	915	923	7	170	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	2002	296	5574					1832	1835		10.1126/science.1071152	http://dx.doi.org/10.1126/science.1071152			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052949				2022-12-28	WOS:000176054300037
J	Curfman, GD				Curfman, GD			Perspective: Sirolimus-eluting coronary stents.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	23	25	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	2002	346	23					1770	1771		10.1056/NEJM200206063462302	http://dx.doi.org/10.1056/NEJM200206063462302			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	559EK	12050335				2022-12-28	WOS:000176012500001
J	Okuse, K; Malik-Hall, M; Baker, MD; Poon, WYL; Kong, HY; Chao, MV; Wood, JN				Okuse, K; Malik-Hall, M; Baker, MD; Poon, WYL; Kong, HY; Chao, MV; Wood, JN			Annexin II light chain regulates sensory neuron-specific sodium channel expression	NATURE			English	Article							NERVE GROWTH-FACTOR; EPITHELIAL-CELLS; PHOSPHOLIPASE A(2); PAIN PATHWAYS; NITRIC-OXIDE; SNS; CURRENTS; P11; PROTEIN; RAT	The tetrodotoxin-resistant sodium channel Na(V)1.8/SNS is expressed exclusively in sensory neurons and appears to have an important role in pain pathways(1,2). Unlike other sodium channels, Na(V)1.8 is poorly expressed in cell lines even in the presence of accessory beta-subunits(3). Here we identify annexin II light chain(4,5) (p11) as a regulatory factor that facilitates the expression of Na(V)1.8. p11 binds directly to the amino terminus of Na(V)1.8 and promotes the translocation of Na(V)1.8 to the plasma membrane, producing functional channels. The endogenous Na(V)1.8 current in sensory neurons is inhibited by antisense downregulation of p11 expression. Because direct association with p11 is required for functional expression of Na(V)1.8, disrupting this interaction may be a useful new approach to downregulating Na(V)1.8 and effecting analgesia(6).	UCL, Dept Biol, London WC1E 6BT, England; NYU, Sch Med, Dept Cell Biol & Physiol, Skirball Inst Biomol Med,Mol Neurobiol Program, New York, NY 10016 USA; NYU, Sch Med, Dept Neurosci, Skirball Inst Biomol Med,Mol Neurobiol Program, New York, NY 10016 USA	University of London; University College London; New York University; New York University	Wood, JN (corresponding author), UCL, Dept Biol, Gower St, London WC1E 6BT, England.	J.Wood@ucl.ac.uk		Chao, Moses/0000-0002-6969-3744				Akiba S, 2000, BRIT J PHARMACOL, V131, P1004, DOI 10.1038/sj.bjp.0703637; Akopian AN, 1999, NAT NEUROSCI, V2, P541, DOI 10.1038/9195; Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; Aley KO, 1998, J NEUROSCI, V18, P7008; Baker MD, 2001, TRENDS PHARMACOL SCI, V22, P27, DOI 10.1016/S0165-6147(00)01585-6; Black JA, 1997, NEUROREPORT, V8, P2331, DOI 10.1097/00001756-199707070-00046; England S, 1998, J PHYSIOL-LONDON, V511P, p124P; FANG X, 2001, SOC NEUR ABSTR; Fitzgerald EM, 1999, J PHYSIOL-LONDON, V516, P433, DOI 10.1111/j.1469-7793.1999.0433v.x; Fjell J, 1999, J NEUROPHYSIOL, V81, P803, DOI 10.1152/jn.1999.81.2.803; GARBER SS, 1989, J NEUROSCI, V9, P3976; Gold MS, 1999, P NATL ACAD SCI USA, V96, P7645, DOI 10.1073/pnas.96.14.7645; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; Isom LL, 2001, NEUROSCIENTIST, V7, P42, DOI 10.1177/107385840100700108; Kong HY, 2001, J NEUROSCI, V21, P176, DOI 10.1523/JNEUROSCI.21-01-00176.2001; LEWIN GR, 1994, EUR J NEUROSCI, V6, P1903, DOI 10.1111/j.1460-9568.1994.tb00581.x; Liu CJ, 2001, J BIOL CHEM, V276, P18925, DOI 10.1074/jbc.M101606200; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; Nilius B, 1996, J BIOL CHEM, V271, P30631, DOI 10.1074/jbc.271.48.30631; Okuse K, 1997, MOL CELL NEUROSCI, V10, P196, DOI 10.1006/mcne.1997.0657; OSBORN M, 1988, EXP CELL RES, V175, P81, DOI 10.1016/0014-4827(88)90257-1; Pawliczak R, 2001, J BIOL CHEM, V276, P44613, DOI 10.1074/jbc.M104993200; POLLARD HB, 1988, P NATL ACAD SCI USA, V85, P2974, DOI 10.1073/pnas.85.9.2974; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; Waxman SG, 1999, MUSCLE NERVE, V22, P1177, DOI 10.1002/(SICI)1097-4598(199909)22:9<1177::AID-MUS3>3.3.CO;2-G; Yao XL, 1999, J BIOL CHEM, V274, P17202, DOI 10.1074/jbc.274.24.17202	27	207	216	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	2002	417	6889					653	656		10.1038/nature00781	http://dx.doi.org/10.1038/nature00781			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050667				2022-12-28	WOS:000176001200049
J	Bilchick, KC; Wise, RA				Bilchick, KC; Wise, RA			Paradoxical physical findings described by Kussmaul: pulsus paradoxus and Kussmaulls sign	LANCET			English	Editorial Material							CONSTRICTIVE PERICARDITIS; RESPIRATION; MECHANISM		Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA	Johns Hopkins University	Bilchick, KC (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA.	kbilchi1@jhmi.edu		Wise, Robert/0000-0002-8353-2349; Bilchick, Kenneth/0000-0002-5188-3603				BAST T, 1926, LIFE TIME A KUSSMUAL; DOCK W, 1961, ARCH INTERN MED, V108, P837, DOI 10.1001/archinte.1961.03620120021004; DORNHORST AC, 1952, LANCET, V262, P746; HITZIG WM, 1942, J MT SINAI HOSP, V8, P625; JARDIN F, 1982, CIRCULATION, V66, P887, DOI 10.1161/01.CIR.66.4.887; Katz LN, 1924, ARCH INTERN MED, V33, P371, DOI 10.1001/archinte.1924.00110270092009; Kussmaul A, 1873, BERL KLIN WOCHENSCHR, P38; KUSSMAUL A, 1981, MEMOIRS OLD PHYSICIA; Kussmaul A., 1874, DEUT ARCH KLIN MED, V14, P1, DOI [10.1002/1099-0496(199601)21:1<65, DOI 10.1002/1099-0496(199601)21:1<65]; Ling LH, 1999, CIRCULATION, V100, P1380, DOI 10.1161/01.CIR.100.13.1380; Major R., 1945, CLASSIC DESCRIPTIONS, V3rd; MEYER TE, 1989, AM J CARDIOL, V64, P1069, DOI 10.1016/0002-9149(89)90817-5; SAVITT MA, 1993, AM J PHYSIOL, V265, pH1996, DOI 10.1152/ajpheart.1993.265.6.H1996; SHABETAI R, 1965, J CLIN INVEST, V44, P1882, DOI 10.1172/JCI105295; SUMMER WR, 1979, CIRC RES, V45, P719, DOI 10.1161/01.RES.45.6.719; TAKATA M, 1992, AM J PHYSIOL, V262, pH763, DOI 10.1152/ajpheart.1992.262.3.H763	16	41	49	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 1	2002	359	9321					1940	1942		10.1016/S0140-6736(02)08763-9	http://dx.doi.org/10.1016/S0140-6736(02)08763-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PL	12057571				2022-12-28	WOS:000175975700028
J	Pola, E; Pola, R; Gaetani, E; De Santis, E				Pola, E; Pola, R; Gaetani, E; De Santis, E			Tumoral calcinosis	LANCET			English	Editorial Material									Univ Cattolica Sacro Cuore, Univ Hosp, Sch Med, Dept Orthoped, Rome, Italy; Univ Cattolica Sacro Cuore, Univ Hosp, Sch Med, Dept Geriatr Sci, Rome, Italy; Univ Cattolica Sacro Cuore, Univ Hosp, Sch Med, Dept Internal Med, Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Pola, E (corresponding author), Univ Cattolica Sacro Cuore, Univ Hosp, Sch Med, Dept Orthoped, Rome, Italy.			Gaetani, Eleonora/0000-0002-7808-1491; Pola, Roberto/0000-0001-5224-2931					0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 25	2002	359	9320					1818	1818		10.1016/S0140-6736(02)08712-3	http://dx.doi.org/10.1016/S0140-6736(02)08712-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044377				2022-12-28	WOS:000175775500010
J	Elliott, R; Ong, TJ				Elliott, R; Ong, TJ			Science, medicine, and the future - Nutritional genomics	BMJ-BRITISH MEDICAL JOURNAL			English	Review							OSTEOARTHRITIS; GLUCOSAMINE; CANCER; GENE; OSTEOPOROSIS; POLYMORPHISM		Inst Food Res, Norwich NR4 7UA, Norfolk, England; TNO BIBRA, Clin Res Dev, Carshalton SM5 4DS, Surrey, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Elliott, R (corresponding author), Inst Food Res, Norwich Res Pk,Colney Lane, Norwich NR4 7UA, Norfolk, England.	ruan.elliott@bbsrc.ac.uk		Elliott, Ruan/0000-0001-5365-4508				American Institute for Cancer Research/World Cancer Research Fund American Institute for Cancer Research, 1997, FOOD NUTR PREV CANC; Baudin B, 2000, CLIN CHEM LAB MED, V38, P853, DOI 10.1515/CCLM.2000.123; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; Chard J, 2001, BMJ-BRIT MED J, V322, P1439, DOI 10.1136/bmj.322.7300.1439; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; Dongre AR, 2001, BIOPOLYMERS, V60, P206, DOI 10.1002/1097-0282(2001)60:3<206::AID-BIP10032>3.0.CO;2-5; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Groziak SM, 2000, BRIT J NUTR, V84, pS119; Howell WM, 1998, CLIN EXP ALLERGY, V28, P156, DOI 10.1046/j.1365-2222.1998.00224.x; Kelloff GJ, 2000, J NUTR, V130, p467S, DOI 10.1093/jn/130.2.467S; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Mathew C, 2001, BRIT MED J, V322, P1031, DOI 10.1136/bmj.322.7293.1031; McAlindon TE, 2000, JAMA-J AM MED ASSOC, V283, P1469, DOI 10.1001/jama.283.11.1469; Moyers S, 2001, NUTR REV, V59, P215, DOI 10.1111/j.1753-4887.2001.tb07013.x; Nguyen TV, 2000, J BONE MINER RES, V15, P392, DOI 10.1359/jbmr.2000.15.3.392; NICHOLSON JK, IN PRESS NATURE DRUG; Peterson J, 1998, NUTR RES, V18, P1995, DOI 10.1016/S0271-5317(98)00169-9; Pietrangelo A, 2002, AM J PHYSIOL-GASTR L, V282, pG403, DOI 10.1152/ajpgi.00404.2001; Reginster JY, 2001, LANCET, V357, P251, DOI 10.1016/S0140-6736(00)03610-2; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Stewart TL, 2000, J ENDOCRINOL, V166, P235, DOI 10.1677/joe.0.1660235; Towheed TE, 2001, COCHRANE DB SYST REV; Ueland PM, 2001, TRENDS PHARMACOL SCI, V22, P195, DOI 10.1016/S0165-6147(00)01675-8; Ye SQ, 2000, AM J CLIN NUTR, V72, p1275S, DOI 10.1093/ajcn/72.5.1275s	24	95	107	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 15	2002	324	7351					1438	1442		10.1136/bmj.324.7351.1438	http://dx.doi.org/10.1136/bmj.324.7351.1438			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	565CQ	12065270	Green Published			2022-12-28	WOS:000176351400022
J	Lederman, RJ; Mendelsohn, FO; Anderson, RD; Saucedo, JF; Tenaglia, AN; Hermiller, JB; Hillegass, WB; Rocha-Singh, K; Moon, TE; Whitehouse, MJ; Annex, BH				Lederman, RJ; Mendelsohn, FO; Anderson, RD; Saucedo, JF; Tenaglia, AN; Hermiller, JB; Hillegass, WB; Rocha-Singh, K; Moon, TE; Whitehouse, MJ; Annex, BH		TRAFFIC Investigators	Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial	LANCET			English	Article							PROPIONYL-L-CARNITINE; ARTERIAL-DISEASE; PENTOXIFYLLINE; PHVEGF(165); MULTICENTER; CILOSTAZOL; INJECTION	Background Recombinant fibroblast growth factor-2 (rFGF-2) improves perfusion in models of myocardial and hindlimb ischaemia. We investigated whether one or two doses of intra-arterial rFGF-2 improves exercise capacity in patients with moderate-to-severe intermittent claudication. Methods 190 patients with intermittent claudication caused by infra-inguinal atherosclerosis were randomly assigned (1:1:1) bilateral intra-arterial infusions of placebo on days 1 and 30 (n=63); rFGF-2 (30 mug/kg) on day 1 and placebo on day 30 (single-dose, n=66); or rFGF-2 (30 mug/kg) on days I and 30 (double-dose, n=61). Primary outcome was 90-day change in peak walking time. Secondary outcomes included ankle-brachial pressure index and safety. The main analysis was per protocol. Findings Before 90 days, six patients had undergone peripheral revascularisation and were excluded, and ten withdrew or had missing data. 174 were therefore assessed for primary outcome. Peak walking time at 90 days was increased by 0.60 min with placebo, by 1.77 min with single-dose, and by 1.54 min with double-dose. By ANOVA, the difference between groups was p=0.075. In a secondary intention-to-treat analysis, in which all 190 patients were included, the difference was p=0.034. Pairwise comparison showed a significant difference between placebo and single-dose (p=0.026) but placebo and double-dose did not differ by much (p=0.45). Serious adverse events were similar in all groups. Interpretation Intra-arterial rFGF-2 resulted in a significant increase in peak walking time at 90 days; repeat infusion at 30 days was no better than one infusion. The findings of TRAFFIC provide evidence of clinical therapeutic angiogenesis by intra-arterial infusion of an angiogenic protein.	Univ Michigan Hlth Syst, Div Cardiol, Ann Arbor, MI USA; Sarasota Mem Hosp, Sarasota, FL USA; Univ Arkansas Med Sci, Little Rock, AR 72205 USA; Tulane Univ, Med Ctr, New Orleans, LA USA; Nasser Smith & Pinckerton, Indianapolis, IN USA; Heart Grp, Evansville, IN USA; Prairie Cardiovasc Consultants, Springfield, IL USA; Chiron Corp, Emeryville, CA 94608 USA; Duke Univ, Durham, NC USA; Vet Affairs Med Ctr, Durham, NC USA	University of Michigan System; University of Michigan; University of Arkansas System; University of Arkansas Medical Sciences; Tulane University; Novartis; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Lederman, RJ (corresponding author), NHLBI, NIH, 10 Ctr Dr,Bldg 10,Room 2C713, Bethesda, MD 20892 USA.	lederman@nih.gov	lederman, robert j/C-6305-2009	lederman, robert j/0000-0003-1202-6673; Anderson, R. David/0000-0003-3490-3286				Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; Brevetti G, 1999, J AM COLL CARDIOL, V34, P1618, DOI 10.1016/S0735-1097(99)00373-3; COOPER LT, IN PRESS VASC MED; Dawson DL, 1998, CIRCULATION, V98, P678, DOI 10.1161/01.CIR.98.7.678; Folkman J, 1998, CIRCULATION, V97, P1108, DOI 10.1161/01.CIR.97.12.1108; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; GARDNER AW, 1991, MED SCI SPORT EXER, V23, P402; Girolami B, 1999, ARCH INTERN MED, V159, P337, DOI 10.1001/archinte.159.4.337; Hendel RC, 2000, CIRCULATION, V101, P118, DOI 10.1161/01.CIR.101.2.118; Henry T, 1999, CIRCULATION, V100, P573; Hiatt WR, 2001, AM J MED, V110, P616, DOI 10.1016/S0002-9343(01)00704-5; Hiatt WR, 2001, NEW ENGL J MED, V344, P1608, DOI 10.1056/NEJM200105243442108; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; KANNEL WB, 1985, J AM GERIATR SOC, V33, P13, DOI 10.1111/j.1532-5415.1985.tb02853.x; Laham RJ, 2000, J AM COLL CARDIOL, V36, P2132, DOI 10.1016/S0735-1097(00)00988-8; Lazarous DF, 2000, J AM COLL CARDIOL, V36, P1239, DOI 10.1016/S0735-1097(00)00882-2; Lederman RJ, 2001, AM J CARDIOL, V88, P192, DOI 10.1016/S0002-9149(01)01622-8; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Money SR, 1998, J VASC SURG, V27, P267, DOI 10.1016/S0741-5214(98)70357-X; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; Pocock SJ., 2013, CLIN TRIALS PRACTICA; PORTER JM, 1982, AM HEART J, V104, P66, DOI 10.1016/0002-8703(82)90642-1; Schumacher B, 1998, CIRCULATION, V97, P645, DOI 10.1161/01.CIR.97.7.645; SIMONS M, IN PRESS CIRCULATION; *TASC WORK GROUP, 2000, J VASC SURG, V31, pS67; Unger EF, 2000, AM J CARDIOL, V85, P1414, DOI 10.1016/S0002-9149(00)00787-6	27	381	406	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 15	2002	359	9323					2053	2058		10.1016/S0140-6736(02)08937-7	http://dx.doi.org/10.1016/S0140-6736(02)08937-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086757				2022-12-28	WOS:000176194600005
J	Fu, YX; Djupsund, K; Gao, HF; Hayden, B; Shen, K; Dan, Y				Fu, YX; Djupsund, K; Gao, HF; Hayden, B; Shen, K; Dan, Y			Temporal specificity in the cortical plasticity of visual space representation	SCIENCE			English	Article							UNDERLYING CONTRAST ADAPTATION; LONG-TERM POTENTIATION; CAT STRIATE CORTEX; SYNAPTIC PLASTICITY; RECEPTIVE-FIELDS; DYNAMIC CHANGES; CELLS; CONNECTIVITY; ORIENTATION; DEPRESSION	The circuitry and function of mammalian visual cortex are shaped by patterns of visual stimuli, a plasticity likely mediated by synaptic modifications. In the adult cat, asynchronous visual stimuli in two adjacent retinal regions controlled the relative spike timing of two groups of cortical neurons with high precision. This asynchronous pairing induced rapid modifications of intracortical connections and shifts in receptive fields. These changes depended on the temporal order and interval between visual stimuli in a manner consistent with spike timing-dependent synaptic plasticity. Parallel to the cortical modifications found in the cat, such asynchronous visual stimuli also induced shifts in human spatial perception.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Dan, Y (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA.	ydan@uclink4.berkeley.edu	Hayden, Benjamin/J-7994-2013	Hayden, Benjamin/0000-0002-7678-4281; Dan, Yang/0000-0002-3818-877X				Abbott LF, 2000, NAT NEUROSCI, V3, P1178, DOI 10.1038/81453; Abbott LF, 1996, CEREB CORTEX, V6, P406, DOI 10.1093/cercor/6.3.406; AERTSEN AMHJ, 1985, BRAIN RES, V340, P341, DOI 10.1016/0006-8993(85)90931-X; AHISSAR E, 1992, SCIENCE, V257, P1412, DOI 10.1126/science.1529342; Alonso JM, 1998, NAT NEUROSCI, V1, P395, DOI 10.1038/1609; Bair W, 1999, CURR OPIN NEUROBIOL, V9, P447, DOI 10.1016/S0959-4388(99)80067-1; Boettiger CA, 2001, NEURON, V31, P809, DOI 10.1016/S0896-6273(01)00403-2; Carandini M, 1997, SCIENCE, V276, P949, DOI 10.1126/science.276.5314.949; Chance FS, 1998, J NEUROSCI, V18, P4785; DAS A, 1995, J NEUROPHYSIOL, V74, P779, DOI 10.1152/jn.1995.74.2.779; DEANGELIS GC, 1995, P NATL ACAD SCI USA, V92, P9682, DOI 10.1073/pnas.92.21.9682; Deneve S, 1999, NAT NEUROSCI, V2, P740, DOI 10.1038/11205; Edeline JM, 1999, PROG NEUROBIOL, V57, P165, DOI 10.1016/S0301-0082(98)00042-2; Efron B., 1994, MONOGRAPHS STAT APPL; Eysel UT, 1998, NEUROREPORT, V9, P949, DOI 10.1097/00001756-199803300-00034; Feldman DE, 2000, NEURON, V27, P45, DOI 10.1016/S0896-6273(00)00008-8; Froemke RC, 2002, NATURE, V416, P433, DOI 10.1038/416433a; FU YL, UNPUB; Gerstner W, 1996, NATURE, V383, P76, DOI 10.1038/383076a0; Gilbert CD, 1998, PHYSIOL REV, V78, P467, DOI 10.1152/physrev.1998.78.2.467; KAPADIA MK, 1994, J NEUROSCI, V14, P451; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; MAFFEI L, 1973, SCIENCE, V182, P1036, DOI 10.1126/science.182.4116.1036; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; MARLIN S, 1993, J NEUROPHYSIOL, V69, P2209, DOI 10.1152/jn.1993.69.6.2209; Mehta MR, 2000, NEURON, V25, P707, DOI 10.1016/S0896-6273(00)81072-7; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; PETTET MW, 1992, P NATL ACAD SCI USA, V89, P8366, DOI 10.1073/pnas.89.17.8366; RAO RPN, 2000, ADV NEURAL INFORMATI; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; Sanchez-Vives MV, 2000, J NEUROSCI, V20, P4267; Schuett S, 2001, NEURON, V32, P325, DOI 10.1016/S0896-6273(01)00472-X; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; Sjostrom PJ, 2001, NEURON, V32, P1149, DOI 10.1016/S0896-6273(01)00542-6; Song S, 2000, NAT NEUROSCI, V3, P919, DOI 10.1038/78829; Trachtenberg JT, 2000, SCIENCE, V287, P2029, DOI 10.1126/science.287.5460.2029; Yao HS, 2001, NEURON, V32, P315, DOI 10.1016/S0896-6273(01)00460-3; Zhang LI, 1998, NATURE, V395, P37, DOI 10.1038/25665	39	114	114	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	2002	296	5575					1999	2003		10.1126/science.1070521	http://dx.doi.org/10.1126/science.1070521			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065829				2022-12-28	WOS:000176273300044
J	Cox, SR				Cox, SR			Everything	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	2002	287	22					2913	2914		10.1001/jama.287.22.2913	http://dx.doi.org/10.1001/jama.287.22.2913			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	561EY	12052101				2022-12-28	WOS:000176128300001
J	Grundmann, H; Tami, A; Hori, S; Halwani, M; Slack, S				Grundmann, H; Tami, A; Hori, S; Halwani, M; Slack, S			Nottingham Staphylococcus aureus population study: prevalence of MRSA among elderly people in the community	BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham Hosp, Queens Med Ctr, Div Microbiol & Infect Dis, Nottingham NG7 2UH, England; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; Univ Nottingham, Nottingham NG7 2RD, England; Nottingham Hlth Author, Nottingham, England	University of Nottingham; University of London; London School of Hygiene & Tropical Medicine; University of Nottingham	Grundmann, H (corresponding author), Univ Nottingham Hosp, Queens Med Ctr, Div Microbiol & Infect Dis, Nottingham NG7 2UH, England.			Tami, Adriana/0000-0002-1918-9144; HORI, Satoshi/0000-0001-5205-1270				Chambers HF, 2001, EMERG INFECT DIS, V7, P178, DOI 10.3201/eid0702.010204; Hori S, 2002, J HOSP INFECT, V50, P25, DOI 10.1053/jhin.2001.1130; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; *NOTT HLTH AUTH, 1995, AIM HLTH YEAR 2000 A, P3; Public Health Laboratory Service, 1997, COMMUN DIS REP CDR W, V7, P191	5	45	46	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 8	2002	324	7350					1365	1366		10.1136/bmj.324.7350.1365	http://dx.doi.org/10.1136/bmj.324.7350.1365			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BQ	12052803	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000176234100018
J	Koopmans, PP				Koopmans, PP			Clinical endpoints in trials of drugs for cancer: time for a rethink?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHEMOTHERAPY; SURVIVAL		Radboud Univ Nijmegen Med Ctr, Dept Gen Internal Med, Nijmegen, Netherlands	Radboud University Nijmegen	Koopmans, PP (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Gen Internal Med, Nijmegen, Netherlands.	p.koopmans@aig.azn.nl						Biomarkers Definitions Working Group, 2001, CLIN PHARMACOL THER, V69, P90; Borst-Eilers E, 2000, LANCET, V356, pS6, DOI 10.1016/S0140-6736(00)91992-5; Buyse M, 2000, LANCET, V356, P373, DOI 10.1016/S0140-6736(00)02528-9; Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3; Collins R, 2001, LANCET, V357, P373, DOI 10.1016/S0140-6736(00)03651-5; Croockewit A, 2000, LANCET, V356, P1771, DOI 10.1016/S0140-6736(05)71965-6; Freedberg KA, 2001, NEW ENGL J MED, V344, P824, DOI 10.1056/NEJM200103153441108; Gunnars B, 2001, ACTA ONCOL, V40, P175, DOI 10.1080/02841860151116222; Horton R, 2001, LANCET, V357, P1544, DOI 10.1016/S0140-6736(00)04776-0; KESSLER DA, 1995, SCI AM           MAR, P26; Kessler KM, 2001, CLIN PHARMACOL THER, V69, P1, DOI 10.1067/mcp.2001.112690; KOOPMANS PP, 1995, BRIT MED J, V310, P1305, DOI 10.1136/bmj.310.6990.1305; Lindblom A, 2000, BMJ-BRIT MED J, V320, P424, DOI 10.1136/bmj.320.7232.424; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; WARE JE, 1993, BRIT MED J, V306, P1429, DOI 10.1136/bmj.306.6890.1429; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; 1993, DRUGS THER B, V31, P77; 1995, DRUG THER B, V33, P33	18	7	7	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 8	2002	324	7350					1389	1391		10.1136/bmj.324.7350.1389	http://dx.doi.org/10.1136/bmj.324.7350.1389			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BQ	12052814	Green Published			2022-12-28	WOS:000176234100029
J	Song, XQ; Zhu, CH; Doan, C; Xie, T				Song, XQ; Zhu, CH; Doan, C; Xie, T			Germline, stem cells anchored by adherens junctions in the Drosophila ovary niches	SCIENCE			English	Article							E-CADHERIN; REARRANGEMENT; MECHANISMS; DIVISIONS; ARMADILLO; ENCODES	How stem cells are recruited to and maintained in their niches is crucial to understanding their regulation and use in regenerative medicine. Here, we demonstrate that DE-cadherin-mediated cell adhesion is required for anchoring germline stem cells (GSCs) in their niches in the Drosophila ovary. Two major components of this adhesion process, DE-cadherin and Armadillo/beta-catenin, accumulate at high levels in the junctions between GSCs and cap cells, one of the niche components. Removal of these proteins from GSCs results in stem cell loss. Furthermore, DE-cadherin is required for recruiting GSCs to their niche. Our study demonstrates that anchorage of GSCs in their niche by DE-cadherin-mediated adhesion is important for stem cell maintenance and function.	Stowers Inst Med Res, Kansas City, MO 64110 USA	Stowers Institute for Medical Research	Xie, T (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.	tgx@stowers-institute.org			NICHD NIH HHS [HD 17608] Funding Source: Medline; NIGMS NIH HHS [R01 GM064428, 1R01 GM64428-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064428] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cox DN, 2000, DEVELOPMENT, V127, P503; de Cuevas M, 1997, ANNU REV GENET, V31, P405, DOI 10.1146/annurev.genet.31.1.405; Deng W, 1997, DEV BIOL, V189, P79, DOI 10.1006/dbio.1997.8669; Donovan PJ, 2001, NATURE, V414, P92, DOI 10.1038/35102154; Forbes AJ, 1996, DEVELOPMENT, V122, P1125; Godt D, 1998, NATURE, V395, P387, DOI 10.1038/26493; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; Gonzalez-Reyes A, 1998, DEVELOPMENT, V125, P3635; King FJ, 2001, MOL CELL, V7, P497, DOI 10.1016/S1097-2765(01)00197-6; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; Lin HF, 1998, CURR OPIN CELL BIOL, V10, P687, DOI 10.1016/S0955-0674(98)80108-7; LIN HF, 1994, DEVELOPMENT, V120, P947; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; PEIFER M, 1993, DEVELOPMENT, V118, P1191; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; SONG X, UNPUB; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Tepass U, 1996, GENE DEV, V10, P672, DOI 10.1101/gad.10.6.672; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Xie T, 2000, SCIENCE, V290, P328, DOI 10.1126/science.290.5490.328; Xie T, 1998, CELL, V94, P251, DOI 10.1016/S0092-8674(00)81424-5; Xie T, 2001, COLD SPRING HARBOR M, P129; XU T, 1993, DEVELOPMENT, V117, P1223	26	366	379	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	2002	296	5574					1855	1857		10.1126/science.1069871	http://dx.doi.org/10.1126/science.1069871			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052957				2022-12-28	WOS:000176054300045
J	Camfield, CS; Camfield, PR; Veugelers, PJ				Camfield, CS; Camfield, PR; Veugelers, PJ			Death in children with epilepsy: a population-based study	LANCET			English	Article							LONG-TERM PROGNOSIS; SUDDEN UNEXPECTED DEATH; CHILDHOOD EPILEPSY; NOVA-SCOTIA; MORTALITY; SURVIVAL	Background Families of children with newly diagnosed epilepsy worry about death during a seizure. We aimed to assess the frequency and causes of death of children with epilepsy. Method We did a population-based cohort study. The Nova Scotia epilepsy cohort includes all children who developed epilepsy during 1977-85. In 1999, we matched names and birth dates with provincial health-care, death, and marriage registries. We examined death certificates, necropsy reports, and physician records of children who had died and contacted families if sudden unexpected death in epilepsy could have occurred. We measured the effect of sex, age, epilepsy type, and disorder sufficient to cause functional neurological deficit on death rate. We compared cohort mortality with rates in a reference population matched for age and sex. Findings 26 (3.8%) of 692 children with epilepsy died. Frequency of death was 5.3 times higher (95% Cl 2.29-8-32) than in the reference population in the 1980s and 8.8 times higher (4.16-13.43) in the 1990s. Kaplan-Meier curves showed 6.1% mortality 20 years after onset compared with 0.88% in the reference population, Deaths occurred in one (1%) of 97 children with absence epilepsy, 12 (2%) of 510 with partial and primary generalised epilepsy, and 13 (15%) of 85 with secondary generalised epilepsy. 22 deaths were caused by disorders sufficient to cause functional neurological deficit, one by probable sudden unexpected death in epilepsy, two by suicide, and one by homicide. Functional neurological deficit was the only independent determinant of mortality. Interpretation Death from epilepsy is uncommon in children without a severe neurological disorder sufficient to cause functional neurological deficit and sudden unexpected death in epilepsy is rare.	Dalhousie Univ, Dept Pediat, Halifax, NS, Canada; Dalhousie Univ, Dept Community Hlth & Epidemiol, Halifax, NS, Canada	Dalhousie University; Dalhousie University	Camfield, CS (corresponding author), IWK Hlth Ctr, Div Child Neurol, Halifax, NS B3J 3G9, Canada.	Camfield@is.dal.ca		Veugelers, Paul/0000-0001-8996-0822				[Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; BAUMER JH, 1981, DEV MED CHILD NEUROL, V23, P462; BRORSON LO, 1987, EPILEPSIA, V28, P324, DOI 10.1111/j.1528-1157.1987.tb03651.x; CAMFIELD C, 1993, J PEDIATR-US, V122, P861, DOI 10.1016/S0022-3476(09)90008-7; Camfield CS, 1996, EPILEPSIA, V37, P19, DOI 10.1111/j.1528-1157.1996.tb00506.x; Camfield PR, 1996, EPILEPSIA, V37, pS60, DOI 10.1111/j.1528-1157.1996.tb06023.x; COCKERELL OC, 1994, LANCET, V344, P918, DOI 10.1016/S0140-6736(94)92270-5; HARVEY AS, 1993, EPILEPSIA, V34, P597, DOI 10.1111/j.1528-1157.1993.tb00434.x; HAUSER WA, 1980, EPILEPSIA, V21, P399, DOI 10.1111/j.1528-1157.1980.tb04088.x; Hauser WA, 1997, EPILEPSIA, V38, pS26, DOI 10.1111/j.1528-1157.1997.tb06120.x; HAUSER WA, 1990, EPILEPSY FREQUENCY C, P297; Kurtz Z, 1998, BMJ-BRIT MED J, V316, P339, DOI 10.1136/bmj.316.7128.339; Nilsson L, 1999, LANCET, V353, P888, DOI 10.1016/S0140-6736(98)05114-9; Sillanpaa M, 1998, NEW ENGL J MED, V338, P1715, DOI 10.1056/NEJM199806113382402; SILLANPAA M, 1995, ARCH NEUROL-CHICAGO, V52, P589, DOI 10.1001/archneur.1995.00540300063014; Strauss D, 1997, J PEDIATR-US, V131, P712, DOI 10.1016/S0022-3476(97)70098-2; Wirrell EC, 1996, NEUROLOGY, V47, P912, DOI 10.1212/WNL.47.4.912	17	138	141	2	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 1	2002	359	9321					1891	1895		10.1016/S0140-6736(02)08779-2	http://dx.doi.org/10.1016/S0140-6736(02)08779-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PL	12057550				2022-12-28	WOS:000175975700007
J	Horton, R				Horton, R			Nurse-prescribing in the UK: right but also wrong	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Horton, R (corresponding author), The Lancet, London NW1 7BY, England.							Buchan J, 2002, BMJ-BRIT MED J, V324, P751, DOI 10.1136/bmj.324.7340.751; Dean B, 2002, LANCET, V359, P1373, DOI 10.1016/S0140-6736(02)08350-2; Jones AC, 2002, RHEUMATOLOGY, V41, P14, DOI 10.1093/rheumatology/41.1.14; Leathard HL, 2001, NURS EDUC TODAY, V21, P266, DOI 10.1054/nedt.2001.0553; McCann T V, 2002, J Psychiatr Ment Health Nurs, V9, P175, DOI 10.1046/j.1365-2850.2002.00454.x; Moher M, 2001, BMJ-BRIT MED J, V322, P1338, DOI 10.1136/bmj.322.7298.1338; Nolan P, 2001, J ADV NURS, V36, P527, DOI 10.1046/j.1365-2648.2001.02005.x; Shell R C, 2001, Nurse Pract, V26, P42; 2002, NURSE PRESCRIBING RO; 2002, BMA NEWS        0309, P3	10	27	27	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 1	2002	359	9321					1875	1876		10.1016/S0140-6736(02)08786-X	http://dx.doi.org/10.1016/S0140-6736(02)08786-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PL	12057548				2022-12-28	WOS:000175975700005
J	Ahmad, SM; Baker, BS				Ahmad, SM; Baker, BS			Sex-specific deployment of FGF signaling in Drosophila recruits mesodermal cells into the male genital imaginal disc	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; DOUBLESEX PROTEINS; COMPARTMENTAL ORGANIZATION; RECEPTOR HOMOLOG; GENE-EXPRESSION; GLIAL-CELLS; MELANOGASTER; MIGRATION; WINGLESS; TRACHEAL	A central issue in developmental biology is how the deployment of generic signaling proteins produces diverse specific outcomes, We show that Drosophila FGF is used, only in males, to recruit mesodermal cells expressing its receptor to become part of the genital imaginal disc. Male-specific deployment of FGF signaling is controlled by the sex determination regulatory gene doublesex. The recruited mesodermal cells become epithelial and differentiate into parts of the internal genitalia. Our results provide exceptions to two basic tenets of imaginal disc biology-that imaginal disc cells are derived from the embryonic ectoderm and belong to either an anterior or posterior compartment. The recruited mesodermal cells migrate into the disc late in development and are neither anterior nor posterior.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA	Stanford University; Stanford University	Baker, BS (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.			Ahmad, Shaad/0000-0001-5373-1710				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baker BS, 2001, CELL, V105, P13, DOI 10.1016/S0092-8674(01)00293-8; Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X; Bate Michael, 1993, P1013; Beiman M, 1996, GENE DEV, V10, P2993, DOI 10.1101/gad.10.23.2993; BELOTE JM, 1985, CELL, V40, P339, DOI 10.1016/0092-8674(85)90148-5; Bryant PJ, 1997, DEV GENET, V20, P75, DOI 10.1002/(SICI)1520-6408(1997)20:2<75::AID-DVG1>3.3.CO;2-G; Burtis K.C., 1992, SEMIN DEV BIOL, V3, P331; BURTIS KC, 1991, EMBO J, V10, P2577, DOI 10.1002/j.1460-2075.1991.tb07798.x; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Casares F, 1997, DEV GENES EVOL, V207, P216, DOI 10.1007/s004270050110; CHAPMAN KB, 1988, DEV BIOL, V126, P195, DOI 10.1016/0012-1606(88)90253-9; Chen EH, 1997, DEVELOPMENT, V124, P205; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; Cohen Stephen M., 1993, P747; Colvin JS, 2001, CELL, V104, P875, DOI 10.1016/S0092-8674(01)00284-7; COSCHIGANO KT, 1993, GENE DEV, V7, P42, DOI 10.1101/gad.7.1.42; DIBENEDETTO AJ, 1987, DEV BIOL, V119, P242, DOI 10.1016/0012-1606(87)90225-9; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; Emerald BS, 1998, DEV GENES EVOL, V208, P504, DOI 10.1007/s004270050209; EPPER F, 1981, DEV BIOL, V88, P104, DOI 10.1016/0012-1606(81)90222-0; EPPER F, 1980, THESIS U ZURICH SWIT; Erdman SE, 1996, GENETICS, V144, P1639; FEHON RG, 1994, DEVELOPMENT, V120, P545; FERVEUR JF, 1995, SCIENCE, V267, P902, DOI 10.1126/science.7846534; Freeland DE, 1996, MECH DEVELOP, V56, P61, DOI 10.1016/0925-4773(96)00511-4; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; Gisselbrecht S, 1996, GENE DEV, V10, P3003, DOI 10.1101/gad.10.23.3003; GLAZER L, 1991, GENE DEV, V5, P697, DOI 10.1101/gad.5.4.697; HAYASHI S, 1993, DEVELOPMENT, V118, P105; HILDRETH PE, 1965, GENETICS, V51, P659; Ito K, 1997, DEVELOPMENT, V124, P761; Keisman EL, 2001, DEVELOPMENT, V128, P1643; Keisman EL, 2001, DEV CELL, V1, P215, DOI 10.1016/S1534-5807(01)00027-2; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; Kopp A, 2000, NATURE, V408, P553, DOI 10.1038/35046017; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; Kozopas KM, 1998, GENE DEV, V12, P1155, DOI 10.1101/gad.12.8.1155; Marin I, 1998, SCIENCE, V281, P1990, DOI 10.1126/science.281.5385.1990; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Michelson AM, 1998, DEVELOPMENT, V125, P4379; NOTHIGER R, 1977, ROUX ARCH DEV BIOL, V181, P367, DOI 10.1007/BF00848062; PERANTONI AO, 1995, P NATL ACAD SCI USA, V92, P4696, DOI 10.1073/pnas.92.10.4696; Pignoni F, 1997, DEVELOPMENT, V124, P271; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Sanchez L, 1997, DEV GENES EVOL, V207, P229, DOI 10.1007/s004270050111; Sanchez L, 2001, BIOESSAYS, V23, P698, DOI 10.1002/bies.1099; SCHWARTZ C, 1995, DEVELOPMENT, V121, P1621; Shiga Y, 1996, DEV GROWTH DIFFER, V38, P99; Spradling AC, 1999, GENETICS, V153, P135; Sullivan W., 2000, DROSOPHILA PROTOCOLS; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Tan PBO, 1999, TRENDS GENET, V15, P145, DOI 10.1016/S0168-9525(99)01694-7; Weatherbee SD, 1998, GENE DEV, V12, P1474, DOI 10.1101/gad.12.10.1474; WHITELEY M, 1992, MECH DEVELOP, V36, P117, DOI 10.1016/0925-4773(92)90063-P; XU T, 1993, DEVELOPMENT, V117, P1223	58	76	77	0	7	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 31	2002	109	5					651	661		10.1016/S0092-8674(02)00744-4	http://dx.doi.org/10.1016/S0092-8674(02)00744-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	558GL	12062107	Bronze			2022-12-28	WOS:000175957900013
J	Gorry, PR; Zhang, CS; Wu, S; Kunstman, K; Trachtenberg, E; Phair, J; Wolinsky, S; Gabuzda, D				Gorry, PR; Zhang, CS; Wu, S; Kunstman, K; Trachtenberg, E; Phair, J; Wolinsky, S; Gabuzda, D			Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele	LANCET			English	Article							INFECTION	Entry of HIV-1 into a cell happens only after viral envelope glycoproteins have bound to CD4 and a chemokine receptor. Generally, macrophage-tropic strains use CCR5, and T cell-line-tropic strains use CXCR4 as coreceptors for virus entry. Dual-tropic viruses can use both CCR5 and CXCR4. About 1% of white people are homozygous for a non-functional CCR5 allele, containing a 32 base pair deletion (CCR5Delta32). We studied the persistence of dual-tropic HIV-1. In an individual homozygous for this deletion. Our results suggest that structural features of the HIV-1 envelope linked to CCR5 tropism could confer a selective advantage in vivo.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Northwestern University; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Gabuzda, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.		Wolinsky, Steven/B-2893-2012	Wolinsky, Steven/0000-0002-9625-6697	NCI NIH HHS [CA79458] Funding Source: Medline; NIAID NIH HHS [UO1 AI35039, P30 AI28691] Funding Source: Medline; NINDS NIH HHS [R01 NS37277] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA079458] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028691, U01AI035039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037277] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; Michael NL, 1998, J VIROL, V72, P6040, DOI 10.1128/JVI.72.7.6040-6047.1998; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; Theodorou I, 1997, LANCET, V349, P1219	5	54	55	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 25	2002	359	9320					1832	1834		10.1016/S0140-6736(02)08681-6	http://dx.doi.org/10.1016/S0140-6736(02)08681-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044382				2022-12-28	WOS:000175775500015
J	Zindrou, D; Taylor, KM; Bagger, JP				Zindrou, D; Taylor, KM; Bagger, JP			Preoperative haemoglobin concentration and mortality rate after coronary artery bypass surgery	LANCET			English	Article								We did an observational study in 2059 patients undergoing coronary artery bypass surgery to assess the effect of haemoglobin concentration on in-hospital mortality. We noted that Individuals with a preoperative haemoglobin concentration of 100 g/L or less had a five-fold higher In-hospital mortality rate after surgery than those with a higher haemoglobin concentration, despite having had blood transfusions or the pump primed with blood preoperatively as a routine precaution. Our findings suggest that a low haemoglobin concentration Is a marker of disease severity or comorbidity that has a major effect on survival rate.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Cardiothorac Directorate, London W12 0NN, England	Imperial College London	Zindrou, D (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Cardiothorac Directorate, London W12 0NN, England.							BEUTLER E, 1995, WILLIAMS HEMATOLOGY, P1622; Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9; Carson JL, 1998, JAMA-J AM MED ASSOC, V279, P199, DOI 10.1001/jama.279.3.199; HAGL S, 1977, BASIC RES CARDIOL, V72, P344, DOI 10.1007/BF02023594; MEHTA AB, 1999, POSTGRADUATE HAEMATO, P675	5	114	120	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 18	2002	359	9319					1747	1748		10.1016/S0140-6736(02)08614-2	http://dx.doi.org/10.1016/S0140-6736(02)08614-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049866				2022-12-28	WOS:000175740500014
J	Graveley, BR				Graveley, BR			Sex, AGility, and the regulation of alternative splicing	CELL			English	Review							PRE-MESSENGER-RNA; SITE AG; SPLICEOSOME; RECOGNITION; MECHANISMS; U2AF(35)	Alternative splicing is an important means of regulating the expression of eukaryotic genes and enhancing protein diversity. A detailed examination of the Drosophila Sex-lethal gene has led to two significant discoveries-the role of the splicing factor SPF45 in defining the site of exon ligation, and that alternative splicing can be regulated at the second step.	Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA	University of Connecticut	Graveley, BR (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, 263 Farmington Ave, Farmington, CT 06030 USA.		Graveley, Brenton R/C-3108-2013	Graveley, Brenton/0000-0001-5777-5892	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062516] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM062516-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson K, 1997, SCIENCE, V276, P1712, DOI 10.1126/science.276.5319.1712; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Burge CB, 1999, RNA WORLD, P525; Chua K, 1999, NATURE, V402, P207, DOI 10.1038/46086; KRAINER AR, 1985, RA WELCH FDN C CHEM, P353; Lallena MJ, 2002, CELL, V109, P285, DOI 10.1016/S0092-8674(02)00730-4; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; Moore MJ, 2000, NAT STRUCT BIOL, V7, P14, DOI 10.1038/71207; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; Penalva LOF, 2001, MOL CELL BIOL, V21, P1986, DOI 10.1128/MCB.21.6.1986-1996.2001; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Villa T, 2002, CELL, V109, P149, DOI 10.1016/S0092-8674(02)00726-2; WANG J, 2002, GENE DEV, V8, P2072; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHUANG Y, 1990, GENE, V90, P263, DOI 10.1016/0378-1119(90)90189-X; Zorio DAR, 1999, NATURE, V402, P835, DOI 10.1038/45597	20	27	27	1	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 17	2002	109	4					409	412		10.1016/S0092-8674(02)00750-X	http://dx.doi.org/10.1016/S0092-8674(02)00750-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	553VM	12086596	Bronze			2022-12-28	WOS:000175696800001
J	Kirchhausen, T				Kirchhausen, T			Clathrin adaptors really adapt	CELL			English	Review							SORTING SIGNALS; COATED VESICLES; RECOGNITION; MEMBRANE; PROTEINS	The clathrin pathway is the principal route for receptor-mediated endocytosis and growth factor downregulation. Heterotetrameric clathrin adaptors directly link the clathrin coat with cargo transmembrane proteins that are sorted into coated pits and vesicles. A paper in this issue of Call (Collins et al., 2002) describes the atomic structure of the adaptor-protein 2 (AP-2) core, the portion that makes contacts with the membrane and cytosolic tails of cargo proteins.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)	Kirchhausen, T (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.							Boehm M, 2001, EMBO J, V20, P6265, DOI 10.1093/emboj/20.22.6265; Boehm M, 2001, MOL BIOL CELL, V12, P2907, DOI 10.1091/mbc.12.10.2907; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Conner SD, 2002, J CELL BIOL, V156, P921, DOI 10.1083/jcb.200108123; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; Musacchio A, 1999, MOL CELL, V3, P761, DOI 10.1016/S1097-2765(01)80008-3; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; PEARSE BMF, 1976, P NATL ACAD SCI USA, V73, P1255, DOI 10.1073/pnas.73.4.1255; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Ricotta D, 2002, J CELL BIOL, V156, P791, DOI 10.1083/jcb.200111068; Shiba T, 2002, NATURE, V415, P937, DOI 10.1038/415937a; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635	20	80	82	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 17	2002	109	4					413	416		10.1016/S0092-8674(02)00751-1	http://dx.doi.org/10.1016/S0092-8674(02)00751-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	553VM	12086597	Bronze			2022-12-28	WOS:000175696800002
J	Rascol, O; Goetz, C; Koller, W; Poewe, W; Sampaio, C				Rascol, O; Goetz, C; Koller, W; Poewe, W; Sampaio, C			Treatment interventions for Parkinson's disease: an evidence based assessment	LANCET			English	Review							PLACEBO-CONTROLLED TRIAL; LONG-TERM TREATMENT; CONTROLLED-RELEASE CARBIDOPA/LEVODOPA; NEUROGENIC ORTHOSTATIC HYPOTENSION; DEEP-BRAIN-STIMULATION; 6-MONTH INTERIM-REPORT; DRUG-INDUCED PSYCHOSIS; LOW-DOSE BROMOCRIPTINE; 5-YEAR FOLLOW-UP; DOUBLE-BLIND	We did a systematic review, with a uniform method of assessment of efficacy and safety, to assess the different interventions available for the management of Parkinson's disease (drugs, surgical interventions, and physical treatments) with respect to the following Indications: prevention of disease progression, symptomatic treatment of motor features (parkinsonism), symptomatic control of motor complications, prevention of motor complications, and symptomatic treatment of non-motor features. Our aim was not to define practice guidelines, but rather to improve clinicians' knowledge of the presently available published clinical evidence, based mainly on randomised controlled trials. We hope that our review will help doctors to incorporate this background into their own decision-making strategy to make appropriate choices with respect to the treatment of individual patients with Parkinson's disease.	Toulouse Univ Hosp, Clin Invest Ctr, F-31073 Toulouse, France; Toulouse Univ Hosp, Dept Clin Pharmacol, INSERM, U455, F-31073 Toulouse, France; Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA; Univ Miami, Dept Neurol, Miami, FL 33152 USA; Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria; Fac Med Lisbon, Inst Pharmacol & Therapeut, Lisbon, Portugal	CHU de Toulouse; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Rush University; University of Miami; University of Innsbruck; Universidade de Lisboa	Rascol, O (corresponding author), Toulouse Univ Hosp, Clin Invest Ctr, F-31073 Toulouse, France.	rascol@cict.fr						Adler CH, 1997, NEUROLOGY, V49, P393, DOI 10.1212/WNL.49.2.393; Adler CH, 1998, ARCH NEUROL-CHICAGO, V55, P1089, DOI 10.1001/archneur.55.8.1089; Agid Y, 1999, MOVEMENT DISORD, V14, P38; Allain H, 2000, EUR NEUROL, V44, P22, DOI 10.1159/000008188; ANDERSEN J, 1980, ACTA NEUROL SCAND, V62, P210; [Anonymous], 1996, Ann Neurol, V39, P29; Barone P, 1999, NEUROLOGY, V53, P573, DOI 10.1212/WNL.53.3.573; Bergamasco B, 2000, ACTA NEUROL SCAND, V101, P372, DOI 10.1034/j.1600-0404.2000.90295a.x; Bjorklund A, 2000, NOVART FDN SYMP, V231, P7; Block G, 1997, EUR NEUROL, V37, P23, DOI 10.1159/000117399; Burchiel KJ, 1999, NEUROSURGERY, V45, P1375, DOI 10.1097/00006123-199912000-00024; BUTZER JF, 1975, NEUROLOGY, V25, P603; Chan PLS, 2001, ANNU REV PHARMACOL, V41, P625, DOI 10.1146/annurev.pharmtox.41.1.625; Colzi A, 1998, J NEUROL NEUROSUR PS, V64, P573, DOI 10.1136/jnnp.64.5.573; COOPER JA, 1992, BRAIN, V115, P1701, DOI 10.1093/brain/115.6.1701; COTZIAS GC, 1969, NEW ENGL J MED, V280, P337, DOI 10.1056/NEJM196902132800701; de Bie RMA, 1999, LANCET, V354, P1665, DOI 10.1016/S0140-6736(99)03556-4; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; Dewey RB, 2001, ARCH NEUROL-CHICAGO, V58, P1385, DOI 10.1001/archneur.58.9.1385; DIXON RA, 1997, CHECKLISTS CRITICAL; Dupont E, 1996, ACTA NEUROL SCAND, V93, P14; Factor S A, 1995, Adv Neurol, V65, P115; Fahn S., 1987, RECENT DEV PARKINSON, P153; FELDMAN RG, 1989, NEUROLOGY, V39, P96; Ferreira JJ, 2001, J NEUROL, V248, P426, DOI 10.1007/s004150170188; Ferreira JJ, 2000, LANCET, V355, P1333, DOI 10.1016/S0140-6736(00)02119-X; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Friedman J, 1999, NEW ENGL J MED, V340, P757; Frucht S, 1999, NEUROLOGY, V52, P1908, DOI 10.1212/WNL.52.9.1908; GimenezRoldan S, 1997, CLIN NEUROPHARMACOL, V20, P67, DOI 10.1097/00002826-199702000-00008; GOETZ CG, 1988, NEUROLOGY, V38, P1143, DOI 10.1212/WNL.38.7.1143; Goetz CG, 1999, MOVEMENT DISORD, V14, P48; Goetz CG, 2000, NEUROLOGY, V55, P789, DOI 10.1212/WNL.55.6.789; GOETZ CG, IN PRESS MOV DISORDE; GREENAMYRE JT, 1991, ARCH NEUROL-CHICAGO, V48, P977, DOI 10.1001/archneur.1991.00530210109030; Guttman M, 1997, NEUROLOGY, V49, P1060, DOI 10.1212/WNL.49.4.1060; Hauser RA, 2000, CLIN NEUROPHARMACOL, V23, P75, DOI 10.1097/00002826-200003000-00003; HELY MA, 1994, J NEUROL NEUROSUR PS, V57, P903, DOI 10.1136/jnnp.57.8.903; Honigfeld G, 1998, J CLIN PSYCHIAT, V59, P3; Hutton JT, 1996, NEUROLOGY, V46, P1062, DOI 10.1212/WNL.46.4.1062; JANKOVIC J, 1993, AM J MED, V95, P38, DOI 10.1016/0002-9343(93)90230-M; JANKOVIC J, 1995, NEUROSURGERY, V37, P680, DOI 10.1227/00006123-199510000-00011; Jankovic J., 1998, PARKINSONS DIS MOVEM; JOHNSON S, 1992, REV CONTEMP PHARMACO, V9, P51; Kaakkola S, 2000, DRUGS, V59, P1233, DOI 10.2165/00003495-200059060-00004; Koller WC, 1999, NEUROLOGY, V53, P1012, DOI 10.1212/WNL.53.5.1012; Kopyov OV, 1997, EXP NEUROL, V146, P536, DOI 10.1006/exnr.1997.6577; Korczyn AD, 1998, MOVEMENT DISORD, V13, P46, DOI 10.1002/mds.870130112; Korczyn AD, 1999, NEUROLOGY, V53, P364, DOI 10.1212/WNL.53.2.364; Kurth MC, 1997, NEUROLOGY, V48, P81, DOI 10.1212/WNL.48.1.81; Lang AE, 2000, ARCH NEUROL-CHICAGO, V57, P1118, DOI 10.1001/archneur.57.8.1118; LANG AE, 1989, HDB EXPT PHARM, V88; LEES AJ, 1993, BRIT MED J, V307, P469; Lieberman A, 1998, NEUROLOGY, V51, P1057, DOI 10.1212/WNL.51.4.1057; Limousin P, 1999, J NEUROL NEUROSUR PS, V66, P289, DOI 10.1136/jnnp.66.3.289; LINDVALL O, 1992, ANN NEUROL, V31, P155, DOI 10.1002/ana.410310206; Low PA, 1997, JAMA-J AM MED ASSOC, V277, P1046, DOI 10.1001/jama.277.13.1046; LUBKE KO, 1976, CARDIOLOGY, V61, P333, DOI 10.1159/000169827; Luginger E, 2000, MOVEMENT DISORD, V15, P873, DOI 10.1002/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I; Matheson AJ, 2000, CNS DRUGS, V14, P157, DOI 10.2165/00023210-200014020-00006; MAYEUX R, 1992, ARCH NEUROL-CHICAGO, V49, P492, DOI 10.1001/archneur.1992.00530290076015; McKeith I, 2000, LANCET, V356, P2031, DOI 10.1016/S0140-6736(00)03399-7; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; Metman LV, 1998, NEUROLOGY, V50, P1323, DOI 10.1212/WNL.50.5.1323; MIZUNO Y, 1994, CNS DRUGS, V1, P45, DOI 10.2165/00023210-199401010-00005; Mondal BK, 2000, INT J CLIN PRACT, V54, P403; MONTASTRUC JL, 1994, J NEUROL NEUROSUR PS, V57, P1034, DOI 10.1136/jnnp.57.9.1034; Morrish PK, 1998, J NEUROL NEUROSUR PS, V64, P314, DOI 10.1136/jnnp.64.3.314; Murer MG, 1999, DRUG SAFETY, V21, P339, DOI 10.2165/00002018-199921050-00001; Obeso JA, 2001, NEW ENGL J MED, V345, P956, DOI 10.1056/nejmoa000827; Oertel WH, 2001, ADV NEUROL, V86, P373; Olanow CW, 2000, TRENDS NEUROSCI, V23, pS117, DOI 10.1016/S1471-1931(00)00030-6; OLANOW CW, 1994, MOVEMENT DISORD, V9, P40, DOI 10.1002/mds.870090107; OLANOW CW, 1995, ANN NEUROL, V38, P771, DOI 10.1002/ana.410380512; OSTERGAARD L, 1995, J NEUROL NEUROSUR PS, V58, P681, DOI 10.1136/jnnp.58.6.681; Parkinson Study Group, 2000, JAMA, V284, P1931; Pinter MM, 1999, J NEUROL NEUROSUR PS, V66, P436, DOI 10.1136/jnnp.66.4.436; Poewe WH, 1998, MOVEMENT DISORD, V13, P39, DOI 10.1002/mds.870130111; Pollak P, 1999, LANCET, V353, P2041; Przuntek H, 1996, J NEURAL TRANSM, V103, P699, DOI 10.1007/BF01271230; Rascol O, 2001, ADV NEUROL, V86, P301; Rascol O, 2000, NEW ENGL J MED, V342, P1484, DOI 10.1056/NEJM200005183422004; Rascol O, 1996, CLIN NEUROPHARMACOL, V19, P234, DOI 10.1097/00002826-199619030-00005; Rinne UK, 1998, DRUGS, V55, P23, DOI 10.2165/00003495-199855001-00004; RINNE UK, 1989, NEUROLOGY, V39, P336, DOI 10.1212/WNL.39.3.336; Rinne UK, 1998, NEUROLOGY, V51, P1309, DOI 10.1212/WNL.51.5.1309; Ruottinen HM, 1996, J NEUROL NEUROSUR PS, V60, P36, DOI 10.1136/jnnp.60.1.36; SAVERY F, 1977, DIS NERV SYST, V38, P605; Schuurman PR, 2000, NEW ENGL J MED, V342, P461, DOI 10.1056/NEJM200002173420703; Senard JM, 1997, J NEUROL NEUROSUR PS, V63, P584, DOI 10.1136/jnnp.63.5.584; Shannon KM, 1997, NEUROLOGY, V49, P724, DOI 10.1212/WNL.49.3.724; Shannon KM, 1998, NEUROLOGY, V50, P434, DOI 10.1212/WNL.50.2.434; SHOULSON I, 1989, NEW ENGL J MED, V321, P1364; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; Snow BJ, 2000, CLIN NEUROPHARMACOL, V23, P82, DOI 10.1097/00002826-200003000-00004; SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201; STAALSCHREINEMACHERS AL, 1986, NEUROLOGY, V36, P291, DOI 10.1212/WNL.36.2.291; Steur ENHJ, 1997, J NEUROL NEUROSUR PS, V63, P547, DOI 10.1136/jnnp.63.4.547; Todman D H, 1990, Clin Exp Neurol, V27, P79; Tracik F, 2001, MOVEMENT DISORD, V16, P500, DOI 10.1002/mds.1083; VERHAGENMETMAN L, 1999, ARCH NEUROL-CHICAGO, V56, P1383; WALLACE W, 1982, PROG NEURO-PSYCHOPH, V6, P51; Waters CH, 1997, NEUROLOGY, V49, P665, DOI 10.1212/WNL.49.3.665	103	188	194	0	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 4	2002	359	9317					1589	1598		10.1016/S0140-6736(02)08520-3	http://dx.doi.org/10.1016/S0140-6736(02)08520-3			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047983				2022-12-28	WOS:000175460700027
J	Witt, E; Ashworth, A				Witt, E; Ashworth, A			Biomedicine - D-Day for BRCA2	SCIENCE			English	Editorial Material							FANCONI-ANEMIA		Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Witt, E (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England.							Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; SWIFT M, 1980, J NATL CANCER I, V65, P863; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Yu VPCC, 2000, GENE DEV, V14, P1400	10	11	13	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 26	2002	297	5581					534	534		10.1126/science.1074482	http://dx.doi.org/10.1126/science.1074482			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	577GY	12065747				2022-12-28	WOS:000177054200032
J	Hon, WC; Wilson, MI; Harlos, K; Claridge, TDW; Schofield, CJ; Pugh, CW; Maxwell, PH; Ratcliffe, PJ; Stuart, DI; Jones, EY				Hon, WC; Wilson, MI; Harlos, K; Claridge, TDW; Schofield, CJ; Pugh, CW; Maxwell, PH; Ratcliffe, PJ; Stuart, DI; Jones, EY			Structural basis for the recognition of hydroxyproline in alpha IF-1 alpha by pVHL	NATURE			English	Article							INDUCIBLE FACTOR-I; HIF-ALPHA; VHL; COMPLEX; DESTRUCTION; SOFTWARE; DOMAINS; BINDING; FAMILY	Hypoxia-inducible factor-1 (HIF-1) is a transcriptional complex that controls cellular and systemic homeostatic responses to oxygen availability(1). HIF-1alpha is the oxygen-regulated subunit of HIF-1, an alphabeta heterodimeric complex(1). HIF-1alpha is stable in hypoxia, but in the presence of oxygen it is targeted for proteasomal degradation by the ubiquitination complex pVHL, the protein of the von Hippel-Lindau (VHL) tumour suppressor gene and a component of an E3 ubiquitin ligase complex(2,3). Capture of HIF-1alpha by pVHL is regulated by hydroxylation of specific prolyl residues in two functionally independent regions of HIF-1alpha(4-7). The crystal structure of a hydroxylated HIF-1alpha peptide bound to VCB (pVHL, elongins C and B) and solution binding assays reveal a single, conserved hydroxyproline-binding pocket in pVHL. Optimized hydrogen bonding to the buried hydroxyprolyl group confers precise discrimination between hydroxylated and unmodified prolyl residues. This mechanism provides a new focus for development of therapeutic agents to modulate cellular responses to hypoxia.	Div Struct Biol, Oxford OX3 7BN, England; Cellular Physiol Grp, Oxford OX3 7BN, England; Oxford Ctr Mol Sci, Oxford OX1 3QY, England; Dyson Perrins Lab, Oxford OX1 3QY, England	University of Oxford; University of Oxford; University of Oxford; University of Oxford	Jones, EY (corresponding author), Div Struct Biol, Henry Wellcome Bldg Genom Med,Roosevelt Dr, Oxford OX3 7BN, England.	peter.ratcliffe@ndm.ox.ac.uk; yvonne@strubi.ox.ac.uk	Jones, Yvonne/J-2293-2016; Jones, Yvonne/N-8111-2019; Claridge, Tim/A-8324-2018; Maxwell, Patrick H/C-5557-2008	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Claridge, Tim/0000-0001-5583-6460; Maxwell, Patrick H/0000-0002-0338-2679; Ratcliffe, Peter/0000-0002-2853-806X; Stuart, David/0000-0002-3426-4210; Pugh, Chris/0000-0002-5170-1662; Schofield, Christopher/0000-0002-0290-6565				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P256, DOI 10.1093/nar/26.1.256; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hubbard S., 1996, NACCESS COMPUTER PRO; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	29	525	563	6	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 27	2002	417	6892					975	978		10.1038/nature00767	http://dx.doi.org/10.1038/nature00767			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	566RC	12050673				2022-12-28	WOS:000176441200045
J	Engelhart, MJ; Geerlings, MI; Ruitenberg, A; van Swieten, JC; Holman, A; Witteman, JCM; Breteler, MMB				Engelhart, MJ; Geerlings, MI; Ruitenberg, A; van Swieten, JC; Holman, A; Witteman, JCM; Breteler, MMB			Dietary intake of antioxidants and risk of Alzheimer disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							C SUPPLEMENT USE; VITAMIN-E; APOLIPOPROTEIN-E; OXIDATIVE STRESS; MENTAL STATE; ROTTERDAM; DEMENTIA; DIAGNOSIS; ATHEROSCLEROSIS; QUESTIONNAIRE	Context Laboratory findings have suggested that oxidative stress may contribute to the pathogenesis of Alzheimer disease. Therefore, the risk of Alzheimer disease might be reduced by intake of antioxidants that counteract the detrimental effects of oxidative stress. Objective To determine whether dietary intake of antioxidants is related to risk of Alzheimer disease. Design and Setting The Rotterdam Study, a population-based, prospective cohort study conducted in the Netherlands. Participants A total of 5395 participants who, at baseline (1990-1993), were aged at least 55 years, free of dementia, and noninstitutionalized and had reliable dietary assessment. Participants were reexamined in 1993-1994 and 1997-1999 and were continuously monitored for incident dementia. Main Outcome Measures Incidence of Alzheimer disease, based on Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition (DSM-III-R) criteria and National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer Disease and Related Disorders Association (NINCDS-ADRDA) criteria, associated with dietary intake of beta carotene, flavonoids, vitamin C, and vitamin E. Results After a mean follow-up of 6 years, 197 participants developed dementia, of whom 146 had Alzheimer disease. When adjustments were made for age, sex, baseline Mini-Mental State Examination score, alcohol intake, education, smoking habits, pack-years of smoking, body mass index, total energy intake, presence of carotid plaques, and use of antioxidative supplements, high intake of vitamin C and vitamin E was associated with lower risk of Alzheimer disease (rate ratios [RRs] per 1-SD increase in intake were 0.82 [95% confidence interval {CI}, 0.68-0.99] and 0.82 [95% CI, 0.66-1.00], respectively). Among current smokers, this relationship was most pronounced (RRs, 0.65 [95% CI, 0.37-1.14] and 0.58 [95% CI, 0.30-1.12], respectively) and also was present for intake of beta carotene (RR, 0.49 [95% CI, 0.27-0.92]) and flavonoids (RR, 0.54 [95% CI, 0.31-0.96]). The associations did not vary by education or apolipoprotein E genotype. Conclusion High dietary intake of vitamin C and vitamin E may lower the risk of Alzheimer disease.	Erasmus MC, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Erasmus MC, Dept Neurol, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Breteler, MMB (corresponding author), Erasmus MC, Dept Epidemiol & Biostat, POB 1738, NL-3000 DR Rotterdam, Netherlands.	breteler@epib.fgg.eur.nl	Zito, Giancarlo/F-9008-2010; Geerlings, Mirjam I/F-4087-2015; Breteler, Monique M.B./J-5058-2014	Geerlings, Mirjam I/0000-0002-4037-036X; Breteler, Monique M.B./0000-0002-0626-9305; van Swieten, John/0000-0001-6278-6844				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; Behl C, 1997, CELL TISSUE RES, V290, P471, DOI 10.1007/s004410050955; BENDER MM, 1992, J AM DIET ASSOC, V92, P1096; BOTS ML, 1993, LANCET, V341, P1232, DOI 10.1016/0140-6736(93)91144-B; Breteler MMB, 2000, NEUROBIOL AGING, V21, P153, DOI 10.1016/S0197-4580(99)00110-4; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; BRONNER F, 1993, J NUTR, V123, P797, DOI 10.1093/jn/123.5.797; Christen Y, 2000, AM J CLIN NUTR, V71, p621S, DOI 10.1093/ajcn/71.2.621s; Commenges D, 2000, EUR J EPIDEMIOL, V16, P357, DOI 10.1023/A:1007614613771; COPELAND JRM, 1976, PSYCHOL MED, V6, P439, DOI 10.1017/S0033291700015889; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DUTHIE GG, 1993, ANN NY ACAD SCI, V686, P120, DOI 10.1111/j.1749-6632.1993.tb39165.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Food and Nutrition Council, 1993, DUTCH FOOD COMP TABL; GOLDBOHM RA, 1994, EUR J CLIN NUTR, V48, P253; Grundman M, 2000, AM J CLIN NUTR, V71, p630S; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; Kalmijn S, 1997, ANN NEUROL, V42, P776, DOI 10.1002/ana.410420514; Kirk SFL, 1999, PUBLIC HEALTH NUTR, V2, P69, DOI 10.1017/S1368980099000099; Klipstein-Grobusch K, 1999, AM J CLIN NUTR, V69, P261; Klipstein-Grobusch K, 1998, EUR J CLIN NUTR, V52, P588, DOI 10.1038/sj.ejcn.1600611; Launer L J, 2000, J Nutr Health Aging, V4, P197; Masaki KH, 2000, NEUROLOGY, V54, P1265, DOI 10.1212/WNL.54.6.1265; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MEYDANI M, 1995, LANCET, V345, P170, DOI 10.1016/S0140-6736(95)90172-8; Morris MC, 1998, ALZ DIS ASSOC DIS, V12, P121, DOI 10.1097/00002093-199809000-00001; Ness AR, 1997, INT J EPIDEMIOL, V26, P1, DOI 10.1093/ije/26.1.1; Ott A, 1998, LANCET, V351, P1840, DOI 10.1016/S0140-6736(97)07541-7; Ott A, 1998, AM J EPIDEMIOL, V147, P574; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Slooter AJC, 1998, ARCH NEUROL-CHICAGO, V55, P964, DOI 10.1001/archneur.55.7.964; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	34	733	772	2	78	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	2002	287	24					3223	3229		10.1001/jama.287.24.3223	http://dx.doi.org/10.1001/jama.287.24.3223			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566FF	12076218	Green Published			2022-12-28	WOS:000176415800026
J	Osofsky, HJ				Osofsky, HJ			Dead man talking	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		*AM MED ASS COUNC, 1995, PHYS PART CAP PUN EV	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	2002	287	24					3181	3182		10.1001/jama.287.24.3181	http://dx.doi.org/10.1001/jama.287.24.3181			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566FF	12076197				2022-12-28	WOS:000176415800001
J	Wheatley, K; Stowe, RL; Clarke, CE; Hills, RK; Williams, AC; Gray, R				Wheatley, K; Stowe, RL; Clarke, CE; Hills, RK; Williams, AC; Gray, R			Evaluating drug treatments for Parkinson's disease: how good are the trials?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PUBLICATION; LEVODOPA		Univ Birmingham, Birmingham Clin Trials Unit, Birmingham B15 2RR, W Midlands, England; City Hosp, Birmingham B18 7QH, W Midlands, England; Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham	Wheatley, K (corresponding author), Univ Birmingham, Birmingham Clin Trials Unit, Birmingham B15 2RR, W Midlands, England.	k.wheatley@bham.ac.uk		STOWE, REBECCA/0000-0003-4007-6723; Clarke, Carl/0000-0003-2478-3436; Hills, Robert/0000-0003-0166-0062; Gray, Richard/0000-0003-4440-574X				Aarsland D, 1996, ARCH NEUROL-CHICAGO, V53, P538, DOI 10.1001/archneur.1996.00550060082020; Clarke CE, 2002, J NEUROL NEUROSUR PS, V72, pI22, DOI 10.1136/jnnp.72.suppl_1.i22; CLARKE CE, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002261; CLARKE CE, 2001, PARKINSONISM RELAT D, V7, pS53; COLLINS R, 1995, LANCET, V345, P669; Collins R, 1996, OXFORD TXB MED, V1, P21; Counsell C, 1998, BRIT MED J, V317, P1586, DOI 10.1136/bmj.317.7172.1586; CUMMINGS JL, 1992, AM J PSYCHIAT, V149, P443; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; Dickersin K, 1997, AIDS EDUC PREV, V9, P15; Gray RG, 2000, LANCET, V355, P1588; Jenkinson C, 1998, PARKINSONS DIS QUEST; LEES AJ, 1988, CLIN NEUROPHARMACOL, V11, P512, DOI 10.1097/00002826-198812000-00004; Lees AJ, 1995, BRIT MED J, V311, P1602, DOI 10.1136/bmj.311.7020.1602; Lees AJ, 2001, NEUROLOGY, V57, P1687, DOI 10.1212/WNL.57.9.1687; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Oertel WH, 1997, BAILLIERE CLIN NEUR, V6, P89; Quinn NP, 1997, BAILLIERE CLIN NEUR, V6, P1; Rascol O, 2002, LANCET, V359, P1589, DOI 10.1016/S0140-6736(02)08520-3; Rascol O, 2000, NEW ENGL J MED, V342, P1484, DOI 10.1056/NEJM200005183422004; Sandercock P, 1997, LANCET, V349, P1569; Shoulson I, 1998, ANN NEUROL, V43, P318	22	28	29	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 22	2002	324	7352					1508	1511		10.1136/bmj.324.7352.1508	http://dx.doi.org/10.1136/bmj.324.7352.1508			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567ZL	12077043	Green Published, Green Accepted			2022-12-28	WOS:000176517900028
J	Smith, AH; Lopipero, PA; Bates, MN; Steinmaus, CM				Smith, AH; Lopipero, PA; Bates, MN; Steinmaus, CM			Public health - Arsenic epidemiology and drinking water standards	SCIENCE			English	Editorial Material							CANCER RISK ASSESSMENT; DISEASE ENDEMIC AREA; MALIGNANT NEOPLASMS; INTERNAL CANCERS; BLADDER-CANCER; LUNG-CANCER; WELL WATER; MORTALITY; TAIWAN; METHYLATION		Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Smith, AH (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.		Smith, Allan H/F-9249-2011; Bates, Michael/ABC-2050-2021		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004705, P30ES001896] Funding Source: NIH RePORTER; NIEHS NIH HHS [P42ES04705, P30ES01896] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abernathy CO, 1999, ENVIRON HEALTH PERSP, V107, P593, DOI 10.2307/3434403; Abernathy CO, 1996, FUND APPL TOXICOL, V29, P168, DOI 10.1006/faat.1996.0018; AXELSON O, 1978, BRIT J IND MED, V35, P8; BATES MN, 1992, AM J EPIDEMIOL, V135, P462, DOI 10.1093/oxfordjournals.aje.a116313; BERGOGLIO R M, 1964, Prensa Med Argent, V51, P994; Biagini R E, 1966, Arch Argent Dermatol, V16, P172; CARLSONLYNCH H, 1994, ENVIRON HEALTH PERSP, V102, P354, DOI 10.2307/3431620; CHEN CJ, 1985, CANCER RES, V45, P5895; CHEN CJ, 1990, CANCER RES, V50, P5470; CHEN CJ, 1988, LANCET, V1, P414; CHIOU HY, 1995, CANCER RES, V55, P1296; Chiou HY, 2001, AM J EPIDEMIOL, V153, P411, DOI 10.1093/aje/153.5.411; Concha G, 1998, ENVIRON HEALTH PERSP, V106, P355, DOI 10.2307/3434042; *EPA, 1988, SPEC REP ING IN ARS; Ferreccio C, 2000, EPIDEMIOLOGY, V11, P673, DOI 10.1097/00001648-200011000-00010; Hopenhayn-Rich C, 1998, INT J EPIDEMIOL, V27, P561, DOI 10.1093/ije/27.4.561; HopenhaynRich C, 1996, ENVIRON HEALTH PERSP, V104, P1200, DOI 10.2307/3432913; HOPENHAYNRICH C, 1993, ENVIRON RES, V60, P161, DOI 10.1006/enrs.1993.1024; HopenhaynRich C, 1996, EPIDEMIOLOGY, V7, P117, DOI 10.1097/00001648-199603000-00003; HopenhaynRich C, 1996, ENVIRON HEALTH PERSP, V104, P620, DOI 10.2307/3433091; Hsueh YM, 1998, J TOXICOL ENV HEAL A, V54, P431, DOI 10.1080/009841098158728; Hutchinson J., 1887, BRIT MED J, V2, P1280; Hutchinson J, 1888, T PATH SOC LONDON, V39, P352; *INT AG RES CANC, 1980, EV CARC RISK CHEM MA; Kurttio P, 1998, ARCH ENVIRON CON TOX, V34, P297, DOI 10.1007/s002449900321; Mass MJ, 2001, CHEM RES TOXICOL, V14, P355, DOI 10.1021/tx000251l; Morales KH, 2000, ENVIRON HEALTH PERSP, V108, P655, DOI 10.2307/3434887; MUSHAK P, 1995, ENVIRON HEALTH PERSP, V103, P684, DOI 10.2307/3432859; Nakadaira H, 2002, J OCCUP ENVIRON MED, V44, P291, DOI 10.1097/00043764-200203000-00017; National Research Council (NRC), 2001, ARS DRINK WAT 2001 U; NEUBAUER O, 1947, BRIT J CANCER, V1, P192, DOI 10.1038/bjc.1947.22; NRC, 1999, ARS DRINK WAT; NRC (National Research Council), 1986, ENV TOB SMOK MEAS EX; Slayton TM, 1996, ENVIRON HEALTH PERSP, V104, P1012, DOI 10.2307/3433100; Smith AH, 1998, AM J EPIDEMIOL, V147, P660, DOI 10.1093/oxfordjournals.aje.a009507; SMITH AH, 1992, ENVIRON HEALTH PERSP, V97, P259, DOI 10.2307/3431362; Smith AH, 1999, ARSENIC EXPOSURE AND HEALTH EFFECTS, P191, DOI 10.1016/B978-008043648-7/50022-4; SMITH AH, 1988, ARCH ENVIRON HEALTH, V43, P124, DOI 10.1080/00039896.1988.9935838; Steinmaus CM, 2000, AM J EPIDEMIOL, V151, P693, DOI 10.1093/oxfordjournals.aje.a010264; STOHRER G, 1995, REGUL TOXICOL PHARM, V22, P118, DOI 10.1006/rtph.1995.1077; Thomas DJ, 2001, TOXICOL APPL PHARM, V176, P127, DOI 10.1006/taap.2001.9258; Tsai SM, 1999, ARCH ENVIRON HEALTH, V54, P186, DOI 10.1080/00039899909602258; TSENG WP, 1968, J NATL CANCER I, V40, P453; TSUDA T, 1995, AM J EPIDEMIOL, V141, P198, DOI 10.1093/oxfordjournals.aje.a117421; US Environmental Protection Agency (EPA), 2001, FED REGISTER, V66, P6976; *USPHS, 1962, FED REGISTER, V42, P2152; WARNER ML, 1994, CANCER EPIDEM BIOMAR, V3, P583; *WHO, 1993, GUID DRINK WAT QUAL, V1; [No title captured]	50	444	468	6	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 21	2002	296	5576					2145	2146		10.1126/science.1072896	http://dx.doi.org/10.1126/science.1072896			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077388				2022-12-28	WOS:000176379000027
J	McGill, TJI; Wu, C; Symons, SP; Cunningham, MJ				McGill, TJI; Wu, C; Symons, SP; Cunningham, MJ			A 13-year-old girl with a mass in the left parotid gland and regional lymph nodes - Castleman's disease, hyaline vascular type.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CAT-SCRATCH DISEASE; ALVEOLAR RHABDOMYOSARCOMA; CHILDREN; LYMPHADENITIS; INTERLEUKIN-6; TRANSLOCATION; HYPERPLASIA; MEDIASTINUM; EXPRESSION; FEATURES		Harvard Univ, Sch Med, Boston, MA USA; Childrens Hosp, Dept Otolaryngol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	McGill, TJI (corresponding author), Childrens Hosp, Dept Otolaryngol, 300 Longwood Ave, Boston, MA 02115 USA.							BALLOW M, 1974, J PEDIATR-US, V84, P418, DOI 10.1016/S0022-3476(74)80731-6; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BENJAMIN DR, 1987, ARCH PATHOL LAB MED, V111, P750; Carbone A, 1996, ANN OTO RHINOL LARYN, V105, P751, DOI 10.1177/000348949610500915; CASTLEMAN B, 1956, CANCER, V9, P822, DOI 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4; CHAN JKC, 1989, CANCER, V63, P1856; DAVIS RJ, 1994, CANCER RES, V54, P2869; DODD S, 1989, J PATHOL, V158, P13, DOI 10.1002/path.1711580105; FOSTER SV, 1993, SOUTHERN MED J, V86, P1147, DOI 10.1097/00007611-199310000-00013; FRIZZERA G, 1985, J CLIN ONCOL, V3, P1202, DOI 10.1200/JCO.1985.3.9.1202; FRIZZERA G, 1988, SEMIN DIAGN PATHOL, V5, P346; HALLETT M, 1984, NEW ENGL J MED, V311, P388; HSU SM, 1993, HUM PATHOL, V24, P833, DOI 10.1016/0046-8177(93)90132-Z; HYJEK E, 1988, HUM PATHOL, V19, P766, DOI 10.1016/S0046-8177(88)80259-4; JACKSON LA, 1993, AM J PUBLIC HEALTH, V83, P1707, DOI 10.2105/AJPH.83.12.1707; KELLER AR, 1972, CANCER-AM CANCER SOC, V29, P670, DOI 10.1002/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO;2-#; KINNEY MC, 1994, J CLIN IMMUNOL, V14, P382, DOI 10.1007/BF01546323; LEGERRAVET MB, 1991, BLOOD, V78, P2923; LUNA MA, 1991, ANN OTO RHINOL LARYN, V100, P869, DOI 10.1177/000348949110001016; MULLIKEN JB, 1982, PLAST RECONSTR SURG, V69, P412, DOI 10.1097/00006534-198203000-00002; Phillips D E, 1994, J R Coll Surg Edinb, V39, P100; PHILLIPS PP, 1995, ANN OTO RHINOL LARYN, V104, P100, DOI 10.1177/000348949510400203; SCHMIDT D, 1991, CANCER, V67, P1667, DOI 10.1002/1097-0142(19910315)67:6<1667::AID-CNCR2820670631>3.0.CO;2-U; SHIKHANI AH, 1988, HEAD NECK-J SCI SPEC, V10, P257, DOI 10.1002/j.1930-2398.1988.tb00009.x; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; VASEF M, 1992, AM J CLIN PATHOL, V98, P633, DOI 10.1093/ajcp/98.6.633; WOLINSKY E, 1995, CLIN INFECT DIS, V20, P954, DOI 10.1093/clinids/20.4.954; Wright D, 1997, J CLIN PATHOL, V50, P128, DOI 10.1136/jcp.50.2.128; Young AE, 1988, VASCULAR BIRTHMARKS, P24; ZANGWILL KM, 1993, NEW ENGL J MED, V329, P8, DOI 10.1056/NEJM199307013290102	30	5	6	1	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	2002	346	25					1989	1996		10.1056/NEJMcpc010155	http://dx.doi.org/10.1056/NEJMcpc010155			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563QC	12075061				2022-12-28	WOS:000176266200009
J	Urano, T; Saito, T; Tsukui, T; Fujita, M; Hosoi, T; Muramatsu, M; Ouchi, Y; Inoue, S				Urano, T; Saito, T; Tsukui, T; Fujita, M; Hosoi, T; Muramatsu, M; Ouchi, Y; Inoue, S			Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth	NATURE			English	Article							UBIQUITIN-PROTEIN LIGASE; ESTROGEN-RESPONSIVE GENE; FINGER PROTEIN; DNA-DAMAGE; CELL-CYCLE; RING; P53; PROTEASOME; INHIBITOR; CLONING	Oestrogen exerts its influence on target organs through activating oestrogen receptors (ERs) and regulating downstream genes by means of their oestrogen-responsive elements. Efp, a target gene product of ERalpha(1-3), is a member of the RING-finger B-box coiled-coil (RBCC) motif family(4). Efp is predominantly expressed in various female organs 2 as well as in breast cancers 5, and is thought to be essential for oestrogen-dependent cell proliferation and organ development-Efp-disrupted mice display underdeveloped uteri and reduced oestrogen responsiveness(6). Here we show that Efp is a RING-finger-dependent ubiquitin ligase (E3) that targets proteolysis of 14-3-3sigma, a negative cell cycle regulator that causes G2 arrest(7). We demonstrate that tumour growth of breast cancer MCF7 cells implanted in female athymic mice is reduced by treatment with antisense Efp oligonucleotide. Efp-overexpressing MCF7 cells in ovariectomized athymic mice generate tumours in the absence of oestrogen. Loss of Efp function in mouse embryonic fibroblasts results in an accumulation of 14-3-3sigma, which is responsible for reduced cell growth. These data provide an insight into the cell-cycle machinery and tumorigenesis of breast cancer by identifying 14-3-3sigma as a target for proteolysis by Efp, leading to cell proliferation.	Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Bunkyo Ku, Tokyo 1138655, Japan; Saitama Med Sch, Res Ctr Genom Med, Hidaka, Saitama 3501241, Japan; Saitama Med Sch, Dept Mol Biol, Hidaka, Saitama 3501241, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; Saitama Medical University; Saitama Medical University; Japan Science & Technology Agency (JST)	Inoue, S (corresponding author), Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Urano, Tomohiko/AFS-9574-2022					Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Ikeda K, 2000, FEBS LETT, V472, P9, DOI 10.1016/S0014-5793(00)01421-6; INOUE S, 1993, P NATL ACAD SCI USA, V90, P11117, DOI 10.1073/pnas.90.23.11117; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Muramatsu M, 2000, BIOCHEM BIOPH RES CO, V270, P1, DOI 10.1006/bbrc.2000.2214; ORIMO A, 1995, J BIOL CHEM, V270, P24406, DOI 10.1074/jbc.270.41.24406; Orimo A, 1999, P NATL ACAD SCI USA, V96, P12027, DOI 10.1073/pnas.96.21.12027; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Trockenbacher A, 2001, NAT GENET, V29, P287, DOI 10.1038/ng762; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Urano T, 1999, J BIOL CHEM, V274, P12197, DOI 10.1074/jbc.274.18.12197	30	286	307	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 20	2002	417	6891					871	875		10.1038/nature00826	http://dx.doi.org/10.1038/nature00826			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075357				2022-12-28	WOS:000176285600052
J	Fairfield, KM; Fletcher, RH				Fairfield, KM; Fletcher, RH			Vitamins for chronic disease prevention in adults - Scientific review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY-HEART-DISEASE; BREAST-CANCER RISK; BETA-CAROTENE SUPPLEMENTATION; BONE-MINERAL DENSITY; NEURAL-TUBE DEFECTS; DIETARY ANTIOXIDANT VITAMINS; FOLIC-ACID SUPPLEMENTATION; BASE-LINE CHARACTERISTICS; PLASMA ASCORBIC-ACID; ALPHA-TOCOPHEROL	Context Although vitamin deficiency is encountered infrequently in developed countries, inadequate intake of several vitamins is associated with chronic disease. Objective To review the clinically important vitamins with regard to their biological effects, food sources, deficiency syndromes, potential for toxicity, and relationship to chronic disease, Data Sources and Study Selection We searched MEDLINE for English-language articles about vitamins in relation to chronic diseases and their references published from 1966 through January 11, 2002. Data Extraction We reviewed articles jointly for the most clinically important information, emphasizing randomized trials where available. Data Synthesis Our review of 9 vitamins showed that elderly people, vegans, alcohol-dependent individuals, and patients with malabsorption are at higher risk of inadequate intake or absorption of several vitamins. Excessive doses of vitamin A during early pregnancy and fat-soluble vitamins taken anytime may result in adverse outcomes. Inadequate folate status is associated with neural tube defect and some cancers. Folate and vitamins B-6 and B-12 are required for homocysteine metabolism and are associated with coronary heart disease risk. Vitamin E and lycopene may decrease the risk of prostate cancer. Vitamin D is associated with decreased occurrence of fractures when taken with calcium. Conclusions Some groups of patients are at higher risk for vitamin deficiency and suboptimal vitamin status, Many physicians may be unaware of common food sources of vitamins or unsure which vitamins they should recommend for their patients. Vitamin excess is possible with supplementation, particularly for fat-soluble vitamins. Inadequate intake of several vitamins has been linked to chronic diseases, including coronary heart disease, cancer, and osteoporosis.	Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA; Harvard Univ, Med Sch Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health	Fairfield, KM (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Libby 330,330 Londwood Ave, Boston, MA 02215 USA.	kfairfie@caregroup.harvard.edu						Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560; Albanes D, 1997, AM J CLIN NUTR, V66, P366, DOI 10.1093/ajcn/66.2.366; ALPERIN JB, 1987, JAMA-J AM MED ASSOC, V258, P1916, DOI 10.1001/jama.258.14.1916; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; [Anonymous], 1991, Lancet, V338, P131, DOI 10.1016/0140-6736(91)90133-A; ANSELL JE, 1977, JAMA-J AM MED ASSOC, V238, P40, DOI 10.1001/jama.238.1.40; Balluz LS, 2000, ARCH FAM MED, V9, P258, DOI 10.1001/archfami.9.3.258; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; Boaz M, 2000, LANCET, V356, P1213, DOI 10.1016/S0140-6736(00)02783-5; Booth SL, 1999, NUTR REV, V57, P288; Booth SL, 2000, AM J CLIN NUTR, V71, P1201; Booth SL, 1997, NUTR REV, V55, P282, DOI 10.1111/j.1753-4887.1997.tb01619.x; BOSCOBOINIK D, 1991, J BIOL CHEM, V266, P6188; Bostom AG, 2000, LANCET, V355, P511, DOI 10.1016/S0140-6736(99)00437-7; BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894; BYERS T, 1995, AM J CLIN NUTR, V62, P1385, DOI 10.1093/ajcn/62.6.1385S; CERHAN J, 1998, CANCER EPIDEM BIOMAR, V7, P175; Chan JM, 1999, CANCER EPIDEM BIOMAR, V8, P893; Chen J, 1996, CANCER RES, V56, P4862; Christen WG, 2000, ANN EPIDEMIOL, V10, P125, DOI 10.1016/S1047-2797(99)00042-3; ClavelChapelon F, 1997, CANCER DETECT PREV, V21, P426; COMSTOCK GW, 1991, AM J CLIN NUTR, V53, pS260, DOI 10.1093/ajcn/53.1.260S; Cook NR, 1999, CANCER, V86, P1783, DOI 10.1002/(SICI)1097-0142(19991101)86:9&lt;1783::AID-CNCR21&gt;3.0.CO;2-N; Cook NR, 2000, CANCER CAUSE CONTROL, V11, P617, DOI 10.1023/A:1008995430664; Crowther MA, 2000, LANCET, V356, P1551, DOI 10.1016/S0140-6736(00)03125-1; Curhan GC, 1996, J UROLOGY, V155, P1847, DOI 10.1016/S0022-5347(01)66027-0; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; Davey PJ, 1998, AM J CARDIOL, V82, P414, DOI 10.1016/S0002-9149(98)00354-3; Dawson-Hughes B, 2000, AM J CLIN NUTR, V72, P745; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; DONG MH, 1980, J AM DIET ASSOC, V76, P156; Dorgan JF, 1998, CANCER CAUSE CONTROL, V9, P89, DOI 10.1023/A:1008857521992; Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; Evans RW, 1998, AM J EPIDEMIOL, V147, P180; FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898; Feskanich D, 1998, EPIDEMIOLOGY, V9, P535, DOI 10.1097/00001648-199809000-00011; Feskanich D, 2002, JAMA-J AM MED ASSOC, V287, P47, DOI 10.1001/jama.287.1.47; Feskanich D, 1999, AM J CLIN NUTR, V69, P74; Freudenheim JL, 1996, JNCI-J NATL CANCER I, V88, P340, DOI 10.1093/jnci/88.6.340; Fukao A, 1996, INT J EPIDEMIOL, V25, P300, DOI 10.1093/ije/25.2.300; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; Gandini S, 2000, EUR J CANCER, V36, P636, DOI 10.1016/S0959-8049(00)00022-8; Gann PH, 1999, CANCER RES, V59, P1225; GIOVANNUCCI E, 1995, JNCI-J NATL CANCER I, V87, P265, DOI 10.1093/jnci/87.4.265; Giovannucci E, 1998, ANN INTERN MED, V129, P517, DOI 10.7326/0003-4819-129-7-199810010-00002; Giovannucci E, 1999, JNCI-J NATL CANCER I, V91, P317, DOI 10.1093/jnci/91.4.317; GIOVANNUCCI E, 1995, J NATL CANCER I, V87, P1767, DOI 10.1093/jnci/87.23.1767; Giovannucci E, 2000, JNCI-J NATL CANCER I, V92, P1966, DOI 10.1093/jnci/92.24.1966; Glynn SA, 1996, CANCER CAUSE CONTROL, V7, P214, DOI 10.1007/BF00051297; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; GREEN R, 1995, NEUROLOGY, V45, P1435, DOI 10.1212/WNL.45.8.1435; Greenberg ER, 1996, JAMA-J AM MED ASSOC, V275, P699, DOI 10.1001/jama.275.9.699; HART JP, 1985, J CLIN ENDOCR METAB, V60, P1268, DOI 10.1210/jcem-60-6-1268; HEIKINHEIMO RJ, 1992, CALCIFIED TISSUE INT, V51, P105, DOI 10.1007/BF00298497; Helzlsouer KJ, 2000, J NATL CANCER I, V92, P2018, DOI 10.1093/jnci/92.24.2018; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HODGES SJ, 1993, J BONE MINER RES, V8, P1241; HODIS HN, 1995, JAMA-J AM MED ASSOC, V273, P1849, DOI 10.1001/jama.273.23.1849; HSING AW, 1990, J NATL CANCER I, V82, P941, DOI 10.1093/jnci/82.11.941; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; Jarvinen R, 1997, CANCER LETT, V114, P251, DOI 10.1016/S0304-3835(97)04675-2; Joshipura KJ, 2001, ANN INTERN MED, V134, P1106, DOI 10.7326/0003-4819-134-12-200106190-00010; Kanai T, 1997, INT J GYNECOL OBSTET, V56, P25, DOI 10.1016/S0020-7292(96)02790-7; Khaw KT, 2001, LANCET, V357, P657, DOI 10.1016/S0140-6736(00)04128-3; Kim Y, 1999, NUTR REV, V57, P314; Kitamura Y, 1997, INT J EPIDEMIOL, V26, P307, DOI 10.1093/ije/26.2.307; KNEKT P, 1990, AM J EPIDEMIOL, V132, P857, DOI 10.1093/oxfordjournals.aje.a115728; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; Knekt P, 1999, J NATL CANCER I, V91, P182, DOI 10.1093/jnci/91.2.182; KRITCHEVSKY SB, 1995, CIRCULATION, V92, P2142, DOI 10.1161/01.CIR.92.8.2142; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; Kushi LH, 1996, AM J EPIDEMIOL, V144, P165, DOI 10.1093/oxfordjournals.aje.a008904; LaVecchia C, 1996, CANCER CAUSE CONTROL, V7, P95, DOI 10.1007/BF00115641; LeBoff MS, 1999, JAMA-J AM MED ASSOC, V281, P1505, DOI 10.1001/jama.281.16.1505; Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102; Lips P, 2001, J CLIN ENDOCR METAB, V86, P1212, DOI 10.1210/jc.86.3.1212; Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477; Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003-4819-124-4-199602150-00003; Loria CM, 2000, AM J CLIN NUTR, V72, P139; Losonczy KG, 1996, AM J CLIN NUTR, V64, P190, DOI 10.1093/ajcn/64.2.190; Manson Joann E., 1995, Annals of Epidemiology, V5, P261, DOI 10.1016/1047-2797(94)00091-7; MCLARTY JW, 1995, AM J CLIN NUTR, V62, P1431; MCLAUGHLIN PJ, 1979, J AM DIET ASSOC, V75, P647; Melhus H, 1998, ANN INTERN MED, V129, P770, DOI 10.7326/0003-4819-129-10-199811150-00003; Meydani SN, 1997, JAMA-J AM MED ASSOC, V277, P1380, DOI 10.1001/jama.277.17.1380; Michaud DS, 2000, AM J CLIN NUTR, V72, P990; Michels KB, 2001, INT J CANCER, V91, P563, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1079&gt;3.0.CO;2-9; MILLS PK, 1989, CANCER, V64, P598, DOI 10.1002/1097-0142(19890801)64:3&lt;598::AID-CNCR2820640306&gt;3.0.CO;2-6; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; Morrison HI, 1996, JAMA-J AM MED ASSOC, V275, P1893, DOI 10.1001/jama.275.24.1893; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; Negri E, 2000, INT J CANCER, V86, P122, DOI 10.1002/(SICI)1097-0215(20000401)86:1&lt;122::AID-IJC19&gt;3.0.CO;2-2; Nelson DA, 2000, ANN RHEUM DIS, V59, P626, DOI 10.1136/ard.59.8.626; *NIH, 2002, FACTS DIET SUPPL; Nomura AMY, 1997, CANCER EPIDEM BIOMAR, V6, P487; Nygard O, 1998, AM J CLIN NUTR, V67, P263, DOI 10.1093/ajcn/67.2.263; Nyyssonen K, 1997, BRIT MED J, V314, P634, DOI 10.1136/bmj.314.7081.634; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Outila TA, 2001, AM J CLIN NUTR, V74, P206; RAMIREZ J, 1980, AM J CLIN NUTR, V33, P2079, DOI 10.1093/ajcn/33.10.2079; Rapola JM, 1997, LANCET, V349, P1715, DOI 10.1016/S0140-6736(97)01234-8; Rapola JM, 1996, JAMA-J AM MED ASSOC, V275, P693, DOI 10.1001/jama.275.9.693; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Robinson K, 1998, CIRCULATION, V97, P437; Rohan TE, 2000, J NATL CANCER I, V92, P266, DOI 10.1093/jnci/92.3.266; ROTHMAN KJ, 1995, NEW ENGL J MED, V333, P1369, DOI 10.1056/NEJM199511233332101; Sahyoun NR, 1996, AM J EPIDEMIOL, V144, P501, DOI 10.1093/oxfordjournals.aje.a008957; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; Selhub J, 1999, ANN INTERN MED, V131, P331, DOI 10.7326/0003-4819-131-5-199909070-00003; Sellers TA, 2001, EPIDEMIOLOGY, V12, P420, DOI 10.1097/00001648-200107000-00012; SHAW GM, 1995, EPIDEMIOLOGY, V6, P219, DOI 10.1097/00001648-199505000-00005; Slattery ML, 1999, CANCER EPIDEM BIOMAR, V8, P513; SMITHELLS RW, 1976, ARCH DIS CHILD, V51, P944, DOI 10.1136/adc.51.12.944; SMITHELLS RW, 1981, ARCH DIS CHILD, V56, P911, DOI 10.1136/adc.56.12.911; Speizer FE, 1999, CANCER CAUSE CONTROL, V10, P475, DOI 10.1023/A:1008931526525; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINER M, 1993, CLIN CARDIOL, V16, P16, DOI 10.1002/clc.4960161306; Steinmaus CM, 2000, AM J EPIDEMIOL, V151, P693, DOI 10.1093/oxfordjournals.aje.a010264; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Su LJ, 2001, ANN EPIDEMIOL, V11, P65, DOI 10.1016/S1047-2797(00)00188-5; Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; Toniolo P, 2001, AM J EPIDEMIOL, V153, P1142, DOI 10.1093/aje/153.12.1142; UBBINK JB, 1993, AM J CLIN NUTR, V57, P47, DOI 10.1093/ajcn/57.1.47; URIVETZKY M, 1992, J UROLOGY, V147, P1215, DOI 10.1016/S0022-5347(17)37521-3; VANDERSLICE JT, 1991, AM J CLIN NUTR, V54, pS1323, DOI 10.1093/ajcn/54.6.1323s; VANPOPPEL G, 1995, AM J CLIN NUTR, V62, P1393, DOI 10.1093/ajcn/62.6.1393S; VEMEER C, 1995, J NUTR, V125, P1812; Verhoeven DTH, 1997, BRIT J CANCER, V75, P149, DOI 10.1038/bjc.1997.25; Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847; Wald DS, 2001, ARCH INTERN MED, V161, P695, DOI 10.1001/archinte.161.5.695; WALD NJ, 1984, BRIT J CANCER, V49, P321, DOI 10.1038/bjc.1984.50; Wald NJ, 2001, LANCET, V358, P2069, DOI 10.1016/S0140-6736(01)07104-5; Weibert RT, 1997, ANN INTERN MED, V126, P959, DOI 10.7326/0003-4819-126-12-199706150-00005; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; WILLETT WC, 1984, NEW ENGL J MED, V310, P430, DOI 10.1056/NEJM198402163100705; WILLETT WC, 1994, NUTR REV, V52, P53; Wu K, 2000, CANCER CAUSE CONTROL, V11, P279, DOI 10.1023/A:1008983718924; You WC, 2000, J NATL CANCER I, V92, P1607, DOI 10.1093/jnci/92.19.1607; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; Zhang SM, 1999, JNCI-J NATL CANCER I, V91, P547, DOI 10.1093/jnci/91.6.547; Zhang SM, 1999, JAMA-J AM MED ASSOC, V281, P1632, DOI 10.1001/jama.281.17.1632; Ziegler E.E., 1996, PRESENT KNOWLEDGE NU	150	334	354	1	72	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	2002	287	23					3116	3126		10.1001/jama.287.23.3116	http://dx.doi.org/10.1001/jama.287.23.3116			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563NK	12069675	Bronze			2022-12-28	WOS:000176262300027
J	Souza, DCS; Pralong, V; Jacobson, AJ; Nazar, LF				Souza, DCS; Pralong, V; Jacobson, AJ; Nazar, LF			A reversible solid-state crystalline transformation in a metal phosphide induced by redox chemistry	SCIENCE			English	Article							INSERTION ELECTRODE; LITHIUM; LI2.6CO0.4N; NITRIDE	We demonstrate low-potential intercalation of lithium in a solid-state metal phosphide. A topotactic first-order transition between different but related crystal structures at room temperature takes place by an electrochemical redox process: MnP4 <----> Li7MnP4. The P-P bonds in the MnP4 structure are cleaved at the time of Li insertion (reduction) to produce crystalline Li7MnP4 and are reformed after reoxidation to MnP4, thereby acting as an electron storage reservoir. This is an unusual example of facile covalent bond breaking within the crystalline solid state that can be reversed by the input of electrochemical energy.	Univ Waterloo, Dept Chem, Waterloo, ON N2L 3G1, Canada; Univ Waterloo, Waterloo Ctr Mat Res, Waterloo, ON N2L 3G1, Canada; Univ Houston, Dept Chem, Houston, TX 77204 USA	University of Waterloo; University of Waterloo; University of Houston System; University of Houston	Nazar, LF (corresponding author), Univ Waterloo, Dept Chem, Waterloo, ON N2L 3G1, Canada.	lfnazar@uwaterloo.ca	Nazar, Linda F/H-2736-2014	Nazar, Linda F/0000-0002-3314-8197				BOUKAMP BA, 1981, J ELECTROCHEM SOC, V128, P725, DOI 10.1149/1.2127495; Courtney IA, 1997, J ELECTROCHEM SOC, V144, P2045, DOI 10.1149/1.1837740; JEITSCHKO W, 1975, ACTA CRYSTALLOGR B, V31, P574, DOI 10.1107/S0567740875003251; Kepler KD, 1999, ELECTROCHEM SOLID ST, V2, P307, DOI 10.1149/1.1390819; Kerr TA, 2000, ELECTROCHEM SOLID ST, V3, P460; MURPHY DW, 1976, J ELECTROCHEM SOC, V123, P960, DOI 10.1149/1.2133012; Obrovac MN, 2001, J ELECTROCHEM SOC, V148, pA576, DOI 10.1149/1.1370962; OHZUKU T, 1995, J ELECTROCHEM SOC, V142, P1431, DOI 10.1149/1.2048592; Poizot P, 2000, NATURE, V407, P496, DOI 10.1038/35035045; Pralong V, 2002, ELECTROCHEM COMMUN, V4, P516, DOI 10.1016/S1388-2481(02)00363-6; Rowsell JLC, 2001, J AM CHEM SOC, V123, P8598, DOI 10.1021/ja0112745; Shodai T, 1999, SOLID STATE IONICS, V122, P85, DOI 10.1016/S0167-2738(99)00038-7; Suzuki S, 1999, SOLID STATE IONICS, V116, P1, DOI 10.1016/S0167-2738(98)00337-3; Takeda Y, 2000, SOLID STATE IONICS, V130, P61, DOI 10.1016/S0167-2738(99)00293-3; Wang GX, 2000, J ALLOY COMPD, V299, pL12, DOI 10.1016/S0925-8388(99)00804-X; WEPPNER W, 1977, J ELECTROCHEM SOC, V124, P1569, DOI 10.1149/1.2133112; Whittingham MS, 1982, INTERCALATION CHEM; Winter M, 1998, ADV MATER, V10, P725, DOI 10.1002/(SICI)1521-4095(199807)10:10<725::AID-ADMA725>3.0.CO;2-Z	18	269	282	11	225	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	2002	296	5575					2012	2015		10.1126/science.1071079	http://dx.doi.org/10.1126/science.1071079			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065832				2022-12-28	WOS:000176273300048
J	A'Court, C				A'Court, C			10-minute consultation - Newly diagnosed hypertension	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Oxfordshire Miultidisciplinary Clin Audit Advisor, Oxford OX3 7LG, England		A'Court, C (corresponding author), Oxfordshire Miultidisciplinary Clin Audit Advisor, Badenoch Bldg, Oxford OX3 7LG, England.	christine.acourt@btinternet.com		A'Court, Christine/0000-0003-1829-3860				Muir J, 1999, BRIT J GEN PRACT, V49, P217; Ramsay LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/sj.jhh.1000917; Wood D, 1998, HEART, V80, pS1	3	4	4	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 8	2002	324	7350					1375	1375		10.1136/bmj.324.7350.1375	http://dx.doi.org/10.1136/bmj.324.7350.1375			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BQ	12052809	Green Published, Bronze			2022-12-28	WOS:000176234100024
J	Tomita, H; Yamada, K; Ghadami, M; Ogura, T; Yanai, Y; Nakatomi, K; Sadamatsu, M; Masui, A; Kato, N; Niikawa, N				Tomita, H; Yamada, K; Ghadami, M; Ogura, T; Yanai, Y; Nakatomi, K; Sadamatsu, M; Masui, A; Kato, N; Niikawa, N			Mapping of the wet/dry earwax locus to the pericentromeric region of chromosome 16	LANCET			English	Article							PAROXYSMAL KINESIGENIC CHOREOATHETOSIS	Human earwax Is a one-gene trait comprising two phenotypically distinct forms-wet and dry. This trait Is attributed to secretory products of the ceruminous apocrine glands, and frequencies of phenotypes vary between ethnic groups. We did linkage analysis of eight Japanese families segregating earwax dimorphism. We assigned the earwax locus within a similar to7.42-cM region between the loci D16S3093 and D16S3080 on chromosome 16p11.2-16q12.1, with a maximum two-point LOD score of 11.15 (theta=0.00) at the locus D16S3044. Identification of the earwax locus could contribute to further anthropogenetic studies and physiological and pathological understanding of the apocrine-gland development.	Nagasaki Univ, Sch Med, Dept Human Genet, Nagasaki 852, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi, Japan; Nagasaki Univ, Sch Med, Dept Internal Med 2, Nagasaki 852, Japan; Univ Tokyo, Hlth Serv Ctr, Tokyo, Japan; Shiga Univ Med Sci, Dept Psychiat, Otsu, Shiga 52021, Japan; Univ Tokyo, Fac Med, Dept Neuropsychiat, Tokyo 113, Japan	Nagasaki University; Japan Science & Technology Agency (JST); Nagasaki University; University of Tokyo; Shiga University of Medical Science; University of Tokyo	Tomita, H (corresponding author), Univ Calif Irvine, Dept Psychiat & Human Behav, D346 MED SCI I, Irvine, CA 92697 USA.			Tomita, Hiroaki/0000-0003-2628-880X				IBRAIMOV AI, 1991, AM J PHYS ANTHROPOL, V84, P209, DOI 10.1002/ajpa.1330840210; MATSUNAGA E, 1962, ANN HUM GENET, V25, P273, DOI 10.1111/j.1469-1809.1962.tb01766.x; PETRAKIS NL, 1986, BREAST CANCER RES TR, V8, P7, DOI 10.1007/BF01805919; Sadamatsu M, 1999, EPILEPSIA, V40, P942, DOI 10.1111/j.1528-1157.1999.tb00801.x; Tomita H, 1999, AM J HUM GENET, V65, P1688, DOI 10.1086/302682	5	13	13	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 8	2002	359	9322					2000	2002		10.1016/S0140-6736(02)08835-9	http://dx.doi.org/10.1016/S0140-6736(02)08835-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	563BA	12076558				2022-12-28	WOS:000176232500015
J	Bharathan, G; Goliber, TE; Moore, C; Kessler, S; Pham, T; Sinha, NR				Bharathan, G; Goliber, TE; Moore, C; Kessler, S; Pham, T; Sinha, NR			Homologies in leaf form inferred from KNOXI gene expression during development	SCIENCE			English	Article							HOMEOBOX GENE; COMPOUND LEAF; MORPHOGENESIS; ANGIOSPERMS; EVOLUTION; PHYLOGENY; DIFFERENTIATION; OVEREXPRESSION; EMBRYOGENESIS; BRASSICACEAE	KNOTTEDI-like homeobox (KNOXI) genes regulate development of the leaf from the shoot apical meristem (SAM) and may regulate leaf form. We examined KNOXI expression in SAMs of various vascular plants and found that KNOXI expression correlated with complex leaf primordia. However, complex primordia may mature into simple leaves. Therefore, not all simple leaves develop similarly, and final leaf morphology may not be an adequate predictor of homology.	Univ Calif Davis, Plant Biol Sect, Davis, CA 95616 USA; SUNY Stony Brook, Dept Ecol & Evolut, Stony Brook, NY 11794 USA	University of California System; University of California Davis; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Sinha, NR (corresponding author), Univ Calif Davis, Plant Biol Sect, Davis, CA 95616 USA.		R, Geeta/AAI-3545-2020; Kessler, Sharon A/T-4784-2017	R, Geeta/0000-0002-8498-470X; Kessler, Sharon A/0000-0002-7964-0451; Sinha, Neelima/0000-0002-1494-7065				Abouheif E, 1997, TRENDS GENET, V13, P432, DOI 10.1016/S0168-9525(97)01271-7; Averof M, 1997, NATURE, V388, P682, DOI 10.1038/41786; Banks Joseph, COMMUNICATION; Bowman JL, 1999, INT J PLANT SCI, V160, P917, DOI 10.1086/314194; Chen JJ, 1997, PLANT CELL, V9, P1289, DOI 10.1105/tpc.9.8.1289; Chory J, 1997, PLANT CELL ENVIRON, V20, P801, DOI 10.1046/j.1365-3040.1997.d01-99.x; Chuck G, 1996, PLANT CELL, V8, P1277, DOI 10.1105/tpc.8.8.1277; Dengler NG, 2001, INT J PLANT SCI, V162, P459, DOI 10.1086/320145; Doyle JA, 2000, INT J PLANT SCI, V161, pS121, DOI 10.1086/317578; Gleissberg S, 1999, INT J PLANT SCI, V160, P787, DOI 10.1086/314165; Gourlay CW, 2000, PLANT CELL, V12, P1279, DOI 10.1105/tpc.12.8.1279; Hagemann W, 1996, PLANT SYST EVOL, V199, P121, DOI 10.1007/BF00984901; Hareven D, 1996, CELL, V84, P735, DOI 10.1016/S0092-8674(00)81051-X; Hofer J, 1997, CURR BIOL, V7, P581, DOI 10.1016/S0960-9822(06)00257-0; Janssen BJ, 1998, PLANT PHYSIOL, V117, P771, DOI 10.1104/pp.117.3.771; Kenrick P., 1997, ORIGIN EARLY DIVERSI, P441, DOI DOI 10.1038/37918; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; MA YL, 1992, ANN BOT-LONDON, V70, P277, DOI 10.1093/oxfordjournals.aob.a088470; MADDISON WP, 1992, INTERACTIVE ANAL PHY; Mathews S, 1999, SCIENCE, V286, P947, DOI 10.1126/science.286.5441.947; Mummenhoff K, 2001, AM J BOT, V88, P2051, DOI 10.2307/3558431; MUMMENHOFF K, COMMUNICATION; Nishimura A, 1999, PLANT J, V18, P337, DOI 10.1046/j.1365-313X.1999.00457.x; Nishimura Asuka, 1998, Plant and Cell Physiology, V39, pS60; Qiu YL, 1999, NATURE, V402, P404, DOI 10.1038/46536; Sato Y, 1996, P NATL ACAD SCI USA, V93, P8117, DOI 10.1073/pnas.93.15.8117; Schneeberger R, 1998, DEVELOPMENT, V125, P2857; Sinha N. K., UNPUB; SINHA NR, 1993, GENE DEV, V7, P787, DOI 10.1101/gad.7.5.787; SMITH LG, 1995, DEV GENET, V16, P344, DOI 10.1002/dvg.1020160407; Soltis DE, 2000, BOT J LINN SOC, V133, P381, DOI [10.1111/j.1095-8339.2000.tb01588.x, 10.1006/bojl.2000.0380]; Taylor D.W., 1996, FLOWERING PLANT ORIG; Troll W., 1939, VERGLEICHENDE MORPHO, V1; VOLLBRECHT E, 1991, NATURE, V350, P241, DOI 10.1038/350241a0; Waites R, 1998, CELL, V93, P779, DOI 10.1016/S0092-8674(00)81439-7	35	329	352	5	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 7	2002	296	5574					1858	1860		10.1126/science.1070343	http://dx.doi.org/10.1126/science.1070343			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052958				2022-12-28	WOS:000176054300046
J	Humphreys, L; Sridhar, M				Humphreys, L; Sridhar, M			Clinical picture - Patellar metastasis	LANCET			English	Editorial Material									Staffordshire Gen Hosp, Thorac Dept, Stafford ST16 35A, England		Humphreys, L (corresponding author), Staffordshire Gen Hosp, Thorac Dept, Stafford ST16 35A, England.								0	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 18	2002	359	9319					1739	1739		10.1016/S0140-6736(02)08650-6	http://dx.doi.org/10.1016/S0140-6736(02)08650-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049863				2022-12-28	WOS:000175740500011
J	Troger, U; Stotzel, B; Martens-Lobenhoffer, J; Gollnick, H; Meyer, FP				Troger, U; Stotzel, B; Martens-Lobenhoffer, J; Gollnick, H; Meyer, FP			Severe myalgia from an interaction between treatments with pantoprazole and methotrexate	BRITISH MEDICAL JOURNAL			English	Letter							RHEUMATOID-ARTHRITIS											BECK O, 1991, THER DRUG MONIT, V13, P528, DOI 10.1097/00007691-199111000-00011; HALLA JT, 1994, J RHEUMATOL, V21, P1224; McKendry RJR, 1997, RHEUM DIS CLIN N AM, V23, P939, DOI 10.1016/S0889-857X(05)70367-7; van Ede AE, 1998, SEMIN ARTHRITIS RHEU, V27, P277, DOI 10.1016/S0049-0172(98)80049-8; VANDOORENGREEBE RJ, 1995, ACTA DERM-VENEREOL, V75, P393	5	34	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 22	2002	324	7352					1497	1497		10.1136/bmj.324.7352.1497	http://dx.doi.org/10.1136/bmj.324.7352.1497			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567ZL	12077038	Green Published, Bronze			2022-12-28	WOS:000176517900023
J	Brinster, RL				Brinster, RL			Germline stem cell transplantation and transgenesis	SCIENCE			English	Review							MOUSE TESTIS; SPERMATOGONIAL TRANSPLANTATION; SPERMATOGENESIS; RAT; FERTILITY; NICHE; MICE	The recently developed testis cell transplantation method provides a powerful approach to studying the biology of the male germline stem cell and its microenvironment, the stem cell niche. The technique also is being used to examine spermatogenic defects, correct male infertility, and generate transgenic animals.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Brinster, RL (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3850 Baltimore Ave, Philadelphia, PA 19104 USA.			Brinster, Ralph/0000-0003-1408-7656	NICHD NIH HHS [R01 HD036504] Funding Source: Medline; PHS HHS [36504] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036504] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Avarbock MR, 1996, NAT MED, V2, P693, DOI 10.1038/nm0696-693; Boettger-Tong HL, 2000, BIOL REPROD, V63, P1185, DOI 10.1095/biolreprod63.4.1185; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11303, DOI 10.1073/pnas.91.24.11303; Chiarini-Garcia H, 2001, BIOL REPROD, V65, P1179, DOI 10.1095/biolreprod65.4.1179; Clouthier DE, 1996, NATURE, V381, P418, DOI 10.1038/381418a0; De Rooij DG, 1998, INT J EXP PATHOL, V79, P67, DOI 10.1046/j.1365-2613.1998.00057.x; Dobrinski I, 2000, MOL REPROD DEV, V57, P270, DOI 10.1002/1098-2795(200011)57:3&lt;270::AID-MRD9&gt;3.0.CO;2-Z; Franca LR, 1998, BIOL REPROD, V59, P1371, DOI 10.1095/biolreprod59.6.1371; Honaramooz A, 2002, BIOL REPROD, V66, P21, DOI 10.1095/biolreprod66.1.21; Jiang FX, 1995, INT J ANDROL, V18, P326, DOI 10.1111/j.1365-2605.1995.tb00570.x; Johnston DS, 2001, ENDOCRINOLOGY, V142, P2405, DOI 10.1210/en.142.6.2405; Kanatsu-Shinohara M, 2002, P NATL ACAD SCI USA, V99, P1383, DOI 10.1073/pnas.022646399; Mahato D, 2000, ENDOCRINOLOGY, V141, P1273, DOI 10.1210/en.141.3.1273; Nagano M, 1998, TISSUE CELL, V30, P389, DOI 10.1016/S0040-8166(98)80053-0; Nagano M, 2001, P NATL ACAD SCI USA, V98, P13090, DOI 10.1073/pnas.231473498; Nagano M, 2001, BIOL REPROD, V64, P1409, DOI 10.1095/biolreprod64.5.1409; Ogawa T, 1999, TISSUE CELL, V31, P461, DOI 10.1054/tice.1999.0060; Ogawa T, 2000, NAT MED, V6, P29, DOI 10.1038/71496; Ohta H, 2000, DEVELOPMENT, V127, P2125; Radford JA, 1999, BRIT MED J, V319, P935, DOI 10.1136/bmj.319.7215.935; Russell L. D., 1983, REPRODUCTIVE DEV TOX, P227; Russell LD, 1990, HISTOLOGICAL HISTOPA, P1; Schlatt S, 1999, HUM REPROD, V14, P144, DOI 10.1093/humrep/14.1.144; Shinohara T, 2001, P NATL ACAD SCI USA, V98, P6186, DOI 10.1073/pnas.111158198; Shinohara T, 2000, P NATL ACAD SCI USA, V97, P8346, DOI 10.1073/pnas.97.15.8346; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; van der Kooy D, 2000, SCIENCE, V287, P1439, DOI 10.1126/science.287.5457.1439	28	316	372	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 21	2002	296	5576					2174	2176		10.1126/science.1071607	http://dx.doi.org/10.1126/science.1071607			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077400	Green Accepted			2022-12-28	WOS:000176379000041
J	Fong, YY; Bender, L; Wang, WC; Strome, S				Fong, YY; Bender, L; Wang, WC; Strome, S			Regulation of the different chromatin states of autosomes and X chromosomes in the germ line of C-elegans	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; POLYCOMB GROUP; GENE; MES-3; PROTEIN; PROLIFERATION; MAINTENANCE; EXPRESSION; ANTIBODIES; VIABILITY	The Maternal-Effect Sterile (MES) proteins are essential for germline viability in Caenorhabditis elegans. Here, we report that MES-4, a SET-domain protein, binds to the autosomes but not to the X chromosomes. MES-2, MES-3, and MES-6 are required to exclude MES-4 and markers of active chromatin from the X chromosomes. These findings strengthen the emerging view that in the C. elegans germ line, the X chromosomes differ in chromatin state from the autosomes and are generally silenced. We propose that all four MES proteins participate in X-chromosome silencing, and that the role of MES-4 is to exclude repressors from the autosomes, thus enabling efficient repression of the Xs.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Strome, S (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034059] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM034059, R01 GM034059-16, GM34059] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEANAN MJ, 1992, DEVELOPMENT, V116, P755; CAPOWSKI EE, 1991, GENETICS, V129, P1061; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Davies AG, 1999, GENETICS, V153, P117; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FONG Y, UNPUB; Garvin C, 1998, GENETICS, V148, P167; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; HERMAN RK, 1979, GENETICS, V92, P419; Holdeman R, 1998, DEVELOPMENT, V125, P2457; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kelly WG, 1998, DEVELOPMENT, V125, P2451; Kelly WG, 1997, GENETICS, V146, P227; Kelly WG, 2002, DEVELOPMENT, V129, P479; Korf I, 1998, DEVELOPMENT, V125, P2469; Marin I, 2000, BIOESSAYS, V22, P1106, DOI 10.1002/1521-1878(200012)22:12&lt;1106::AID-BIES8&gt;3.0.CO;2-W; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MONESTIER M, 1994, EUR J IMMUNOL, V24, P723, DOI 10.1002/eji.1830240335; O'Connell S, 2001, J BIOL CHEM, V276, P43065, DOI 10.1074/jbc.M104294200; PAULSEN JE, 1995, GENETICS, V141, P1383; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Reinke V, 2000, MOL CELL, V6, P605, DOI 10.1016/S1097-2765(00)00059-9; Rozovskaia T, 1999, MOL CELL BIOL, V19, P6441; SIMON J, COMMUNICATION; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Wang JB, 2001, NAT GENET, V28, P371, DOI 10.1038/ng574; Xu L, 2001, GENETICS, V159, P1007; Xu L, 2001, P NATL ACAD SCI USA, V98, P5061, DOI 10.1073/pnas.081016198	30	95	106	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 21	2002	296	5576					2235	2238		10.1126/science.1070790	http://dx.doi.org/10.1126/science.1070790			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077420	Green Accepted			2022-12-28	WOS:000176379000063
J	McTigue, KM; Garrett, JM; Popkin, BM				McTigue, KM; Garrett, JM; Popkin, BM			The natural history of the development of obesity in a cohort of young US adults between 1981 and 1998	ANNALS OF INTERNAL MEDICINE			English	Article							SELF-REPORTED WEIGHT; BODY-MASS INDEX; OVERWEIGHT; HEALTH; HEIGHT; VALIDITY; GAIN	Background: understanding the natural history of obesity in a population may be a critical step toward developing effective interventions. Objective: To assess the development of body mass and examine the role of race or ethnicity, sex, and birth year in obesity onset in young U.S. adults. Design: Prospective cohort study. Setting: The National Longitudinal Survey of Youth 1979, a national sample with oversampling of minority ethnic groups. Participants: 9179 persons. Measurements: Body mass index (BMI) calculated from 12 self-reported height and weight samples recorded between 1981 and 1998. Logistic regression identified predictors of obesity at age 35 to 37 years. Cox proportional hazards models compared the incidence of obesity by ethnicity and birth year. Results: Overall, 26% of men and 28% of women were obese (BMI greater than or equal to 30 kg/m(2)) by age 35 to 37 years. Race or ethnicity and baseline BMI were significant predictors of obesity. Obesity onset was 2.1 (95% Cl, 1.6 to 2.7) times faster for black women and 1.5 (Cl, 1.1 to 2.0) times faster for Hispanic women than for white women. The pattern for men differed: Overall, obesity developed most rapidly in Hispanic men, but relative rates of obesity onset for white men compared with black men varied according to age. The rate of obesity onset increased 26% to 28% over an 8-year span in birth year. Conclusions: Marked ethnic-based differences were found in rates of weight accumulation in young U.S. adults, with later birth cohorts experiencing earlier onset of obesity. To alter the course of obesity in the United States, interventions should target young adults, especially those of minority ethnic groups.	Univ N Carolina, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	McTigue, KM (corresponding author), Univ N Carolina, 5034 Old Clin Bldg,CB 7105, Chapel Hill, NC 27599 USA.	kathleen_mctigue@unc.edu	Popkin, Barry/T-6633-2019		NICHD NIH HHS [R01-HD39183] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039183] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Allison DB, 2000, MED CLIN N AM, V84, P305, DOI 10.1016/S0025-7125(05)70223-6; Cawley J, 2000, HEALTH SERV RES, V35, P1159; Galuska DA, 1999, JAMA-J AM MED ASSOC, V282, P1576, DOI 10.1001/jama.282.16.1576; Guo G, 2000, DEMOGRAPHY, V37, P431, DOI 10.2307/2648070; Johnson TP, 2001, ADDICTION, V96, P1187, DOI 10.1046/j.1360-0443.2001.968118711.x; Kuczmarski MF, 2001, J AM DIET ASSOC, V101, P28, DOI 10.1016/S0002-8223(01)00008-6; KUSKOWSKAWOLK A, 1989, INT J OBESITY, V13, P441; Lewis CE, 2000, AM J EPIDEMIOL, V151, P1172, DOI 10.1093/oxfordjournals.aje.a010167; Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523; NAJJAR MF, 1989, DHHS PUBLICATION PHS; *NAT CTR HLTH STAT, 2001, NAT VIT STAT REP, V49; *NAT I DIAB DIG KI, 1998, NIH PUBL; Nieto-Garcia F J, 1990, Epidemiology, V1, P146, DOI 10.1097/00001648-199003000-00011; *OH STAT U, 1999, US GUID GUID 1979 19; PISUNYER FX, 1991, AM J CLIN NUTR, V53, pS1595; PRSONS TJ, 1999, INT J OBES RELAT S8, V23, pS1; RISSANEN A, 1988, INT J OBESITY, V12, P391; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; SERDULA MK, 1993, PREV MED, V22, P167, DOI 10.1006/pmed.1993.1014; Thompson D, 1999, ARCH INTERN MED, V159, P2177, DOI 10.1001/archinte.159.18.2177; *US DEP HHS, 2000, DHHS PUBL PHS; *US DEP HHS, 2000, PREV OV OB AD US 199; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665	23	195	199	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 18	2002	136	12					857	864		10.7326/0003-4819-136-12-200206180-00006	http://dx.doi.org/10.7326/0003-4819-136-12-200206180-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563JL	12069559				2022-12-28	WOS:000176252500001
J	Garratt, AN; Schmidt, L; Mackintosh, A; Fitzpatrick, R				Garratt, AN; Schmidt, L; Mackintosh, A; Fitzpatrick, R			Quality of life measurement: bibliographic study of patient assessed health outcome measures	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIALS; PAIN	Objectives To assess the growth of quality of life measures and to examine the availability of measures across specialties. Design Systematic searches of electronic databases to identify developmental and evaluative work relating to health outcome measures assessed by patients. Main outcome measures Types of measures: disease or population specific, dimension specific, generic, individualised, and utility. Specialties in which measures have been developed and evaluated. Results 3921 reports that described the development and evaluation of patient assessed measures met the inclusion criteria. Of those that were classifiable, 1819 (46%) were disease or population specific, 865 (22%) were generic, 690 (18%) were dimension specific, 409 (10%) were utility, and 62 (1%) were individualised measures. During 1990-9 the number of new reports of development and evaluation rose from 144 to 650 per year. Reports of disease specific measures rose exponentially. Over 30% of evaluations were in cancer, rheumatology and musculoskeletal disorders, and older people's health. The generic measures-SF-36, sickness impact profile, and Nottingham health profile-accounted for 612 (16%) reports. Conclusions In some specialties there are numerous measures of quality of life and little standardisation. Primary research through the concurrent evaluation of measures and secondary research through structured reviews of measures are prerequisites for standardisation. Recommendations for the selection of patient assessed measures of health outcome are needed.	Univ Oxford, Inst Hlth Sci, Natl Ctr Hlth Outcomes Dev, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England; Univ Oxford, Inst Hlth Sci, Dept Publ Hlth, Oxford OX3 7LF, England	University of Oxford; University of Oxford	Garratt, AN (corresponding author), Univ Oxford, Inst Hlth Sci, Natl Ctr Hlth Outcomes Dev, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England.	andrew.garratt@uhce.ox.ac.uk						AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; [Anonymous], 1995, LANCET, V346, P1; Baker GA, 2000, EPILEPSIA, V41, P1357, DOI 10.1111/j.1528-1157.2000.tb00110.x; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bombardier C, 2000, SPINE, V25, P3097, DOI 10.1097/00007632-200012150-00002; BYRNE P, 1984, BRIT J PSYCHIAT, V144, P28, DOI 10.1192/bjp.144.1.28; Duncan PW, 2000, STROKE, V31, P1429, DOI 10.1161/01.STR.31.6.1429; FEENY D, 1995, PHARMACOECONOMICS, V7, P490, DOI 10.2165/00019053-199507060-00004; Fitzpatrick R, 1998, Health Technol Assess, V2, P1; FITZPATRICK R, 2001, ADV HDB METHODS EVID, P181; FITZPATRICK R, 2001, ADV HDB METHODS EVID, V181, P94; FRIED BJ, 1993, J RHEUMATOL, V20, P548; FRIES JF, 1982, J RHEUMATOL, V9, P789; Garratt AM, 2002, DIABETIC MED, V19, P1, DOI 10.1046/j.1464-5491.2002.00650.x; Garratt AM, 2000, RESP MED, V94, P597, DOI 10.1053/rmed.2000.0787; Hayes J A, 2000, Health Technol Assess, V4, P1; Higginson IJ, 2001, BRIT MED J, V322, P1297, DOI 10.1136/bmj.322.7297.1297; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; Kopec JA, 2000, SPINE, V25, P3110, DOI 10.1097/00007632-200012150-00005; Lacasse Y, 1997, CAN RESPIR J, V4, P152; MEENAN RF, 1992, ARTHRITIS RHEUM, V35, P1, DOI 10.1002/art.1780350102; Ruta DA, 1999, QUAL HEALTH CARE, V8, P22, DOI 10.1136/qshc.8.1.22; Sanders C, 1998, BRIT MED J, V317, P1191, DOI 10.1136/bmj.317.7167.1191; Stewart A, 2001, BRIT J OBSTET GYNAEC, V108, P74, DOI 10.1016/S0306-5456(00)00020-6; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	28	751	777	1	53	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 15	2002	324	7351					1417	1419		10.1136/bmj.324.7351.1417	http://dx.doi.org/10.1136/bmj.324.7351.1417			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	565CQ	12065262	Green Published, Bronze			2022-12-28	WOS:000176351400014
J	Lopert, R; Lang, DL; Hill, SR; Henry, DA				Lopert, R; Lang, DL; Hill, SR; Henry, DA			Differential pricing of drugs: a role for cost-effectiveness analysis?	LANCET			English	Article; Proceedings Paper	Workshop on Differential Pricing and Financing of Essential Drugs	APR 08-11, 2001	NORWEGIAN FOREIGN AFFAIRS MINIST, HOSBJOR, NORWAY	Global Hlth Council, WHO, World Trade Org Secretariats	NORWEGIAN FOREIGN AFFAIRS MINIST		ECONOMIC-EVALUATION GUIDELINES; SURVIVAL	Internationally, the high costs of pharmaceutical products limit access to treatment. The principle of differential pricing is that drug prices should vary according to some measure of affordability. How differential prices should be determined is, however, unclear. Here we describe a method whereby differential prices for essential drugs could be derived in countries of variable national wealth, and, using angiotensin-converting enzyme inhibitors provide an example of how the process might work. Indicative prices for drugs can be derived by cost-effectiveness analysis that incorporates a measure of national wealth, Such prices could be used internationally as a basis of differential price negotiations.	Univ Newcastle, Fac Hlth, Sch Med Practice & Populat Hlth, WHO Collaborating Ctr Training Pharmacol & Rat Dr, Newcastle, NSW 2308, Australia	University of Newcastle	Henry, DA (corresponding author), Newcastle Mater Hosp, Waratah, NSW 2298, Australia.	mddah@mail.newcastle.edu.au	Henry, David/AAU-4650-2020; Henry, David/AAJ-4332-2020	Henry, David/0000-0001-7169-7704; Henry, David/0000-0003-2934-2242; Lang, Danielle/0000-0002-3703-8112; Lopert, Ruth/0000-0002-0882-4288				Baladi JF, 1998, HEALTH ECON, V7, P221, DOI 10.1002/(SICI)1099-1050(199805)7:3<221::AID-HEC341>3.0.CO;2-N; Binswanger HP, 2001, SCIENCE, V292, P221, DOI 10.1126/science.1057504; DRUMMOND MF, 1992, HEALTH AFFAIR, V11, P191, DOI 10.1377/hlthaff.11.4.191; Gottlieb S, 2001, BRIT MED J, V322, P692; HENRY D, 1994, AUST PRESCRIBER S1, V17, P32; Kanavos P, 2000, INT J TECHNOL ASSESS, V16, P1179, DOI 10.1017/S0266462300103216; MCNEIL DG, 2001, NY TIMES        0207, P1; Neoptolemos JP, 2000, LANCET, V355, P1955, DOI 10.1016/S0140-6736(00)02327-8; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; VELASQUEZ G, 2001, WHODAP989; *WHO, 1999, WHO DRUG INFORMATION, V13, P249; WHO/ WTO [World Health Organization/ World Trade Organization Secretariats], 2001, WORKSH DIFF PRIC FIN; *WORLD TRAD ORG, 2001, DOH WTO MIN; WorldHealthOrganization, 2001, B WHO; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; 2001, WORLD BANK COUNTRY D; 2001, GLOBAL ALLIANCE VACC	18	22	22	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 15	2002	359	9323					2105	2107		10.1016/S0140-6736(02)08911-0	http://dx.doi.org/10.1016/S0140-6736(02)08911-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	562JX	12086780				2022-12-28	WOS:000176194600027
J	Wight, D; Raab, GM; Henderson, M; Abraham, C; Buston, K; Hart, G; Scott, S				Wight, D; Raab, GM; Henderson, M; Abraham, C; Buston, K; Hart, G; Scott, S			Limits of teacher delivered sex education: interim behavioural outcomes from randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADOLESCENT PREGNANCY PREVENTION; IMPACT EVALUATION; CLINICAL-TRIALS; YOUNG-PEOPLE; PROGRAM; CONTRACEPTIVES; INTERVENTIONS; CHILDBEARING; METAANALYSIS; INTERCOURSE	Objective To determine whether a theoretically based sex education programme for adolescents (SHARE) delivered by teachers reduced unsafe sexual intercourse compared with cur-rent practice. Design Cluster randomised trial with follow up two years after baseline (six months after intervention). A process evaluation investigated the delivery of sex education and broader features of each school. Setting Twenty five secondary schools in east Scotland. Participants 8430 pupils aged 13-15 years; 7616 completed the baseline questionnaire and 5854 completed the two year follow up questionnaire. Intervention SHARE programme (intervention group) versus existing sex education (control programme). Main outcome measures Self reported exposure to sexually transmitted disease, use of condoms and contraceptives at first and most recent sexual intercourse, and unwanted pregnancies. Results When the intervention group was compared with the conventional sex education group in an intention to treat analysis there were no differences in sexual activity or sexual risk taking by the age of 16 years. However, those in the intervention group reported less regret of first sexual intercourse with most recent partner (young men 9.9% difference, 95% confidence interval -18.7 to -1.0; young women 7.7% difference, -16.6 to 1.2). Pupils evaluated the intervention programme more positively, and their knowledge of sexual health improved. Lack of behavioural effect could not be linked to differential quality of delivery of intervention. Conclusions Compared with conventional sex education this specially designed intervention did not reduce sexual risk taking in adolescents.	MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland; Napier Univ, Sch Math & Stat, Appl Stat Grp, Edinburgh EH11 4BN, Midlothian, Scotland; Univ Sussex, Sch Social Sci, Brighton BN1 9SN, E Sussex, England; Univ Durham, Dept Sociol & Social Policy, Durham DH1 3JT, England	MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; Edinburgh Napier University; University of Sussex; Durham University	Wight, D (corresponding author), MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland.	danny@msoc.mrc.gla.ac.uk	Abraham, Charles/C-7130-2012; Henderson, Marion/G-3310-2019; Henderson, Marion/M-2136-2019; Henderson, Marion Mackay/AAS-2759-2021; Hart, Graham J/C-1591-2008	Henderson, Marion/0000-0001-7582-9516; Henderson, Marion/0000-0001-7582-9516; Hart, Graham/0000-0001-9676-6577; Abraham, Charles/0000-0002-0901-1975				*A GUTTM I, 2002, US PREGN RAT TEENS 1; Aarons SJ, 2000, J ADOLESCENT HEALTH, V27, P236, DOI 10.1016/S1054-139X(00)00102-6; Abraham C, 1996, INT J STD AIDS, V7, P39, DOI 10.1258/0956462961917762; AGGLETON PA, 1997, J ADOLESCENT RES, V12, P421; Allen JP, 1997, CHILD DEV, V68, P729, DOI 10.2307/1132122; Anderson N L, 1999, Sch Inq Nurs Pract, V13, P211; BAKER C, 1990, THESIS SETON HALL U; Barth, 1989, REDUCING RISK BUILDI; BONHAM GH, 1987, TROUBLE WAY OUT REPO; BOTVIN GJ, 1995, JAMA-J AM MED ASSOC, V273, P1106, DOI 10.1001/jama.273.14.1106; Brown S.S., 1995, BEST INTENTIONS UNIN; BURT MR, 1986, FAM PLANN PERSPECT, V18, P221, DOI 10.2307/2134980; Buston K, 2002, HEALTH EDUC RES, V17, P59, DOI 10.1093/her/17.1.59; Buston K, 2001, BRIT J SOCIOL EDUC, V22, P353, DOI 10.1080/01425690120067971; COHEN J, 1994, TAKING SEX SERIOUSLY; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; Coyle K, 2001, PUBLIC HEALTH REP, V116, P82, DOI 10.1093/phr/116.S1.82; DANIELSON R, 1990, FAM PLANN PERSPECT, V22, P115, DOI 10.2307/2135642; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DiCenso A, 2001, CAN J PUBLIC HEALTH, V92, P35, DOI 10.1007/BF03404840; DICENSO A, 1999, COMMUNITY NURSING PR; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; DIXON H, 1989, TAUGHT NOT CAUGHT ST; DIXON H, 1991, YES AIDS AGAIN HDB T; EISEN M, 1990, FAM PLANN PERSPECT, V22, P261, DOI 10.2307/2135683; Ferguson SL, 1998, J HEALTH CARE POOR U, V9, P322; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; Franklin C, 1997, J MARRIAGE FAM, V59, P551, DOI 10.2307/353945; GERONIMUS AT, 1992, Q J ECON, V107, P1187, DOI 10.2307/2118385; Grossman J. B., 1992, SUMMER TRAINING ED P; Guyatt GH, 2000, J CLIN EPIDEMIOL, V53, P167, DOI 10.1016/S0895-4356(99)00160-2; HAMBURG BA, 1991, B NEW YORK ACAD MED, V67, P606; HANDLER AS, THESIS U ILLINOIS CH; HANNA KM, 1990, THESIS U PITTSBURGH; HENDERSON M, IN PRESS J ADOLESCEN; HERCEGBARON R, 1986, FAM PLANN PERSPECT, V18, P61, DOI 10.2307/2135030; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JAY MS, 1984, PEDIATRICS, V73, P126; Johnson AM, 1994, SEXUAL ATTITUDES LIF; Kalichman SC, 1996, ANN BEHAV MED, V18, P6, DOI 10.1007/BF02903934; KETTING E, 1994, PATIENT EDUC COUNS, V23, P161, DOI 10.1016/0738-3991(94)90032-9; Kirby D, 1999, Adolesc Med, V10, P195; Kirby D, 1997, CHILD YOUTH SERV REV, V19, P415, DOI 10.1016/S0190-7409(97)00025-X; Kirby D, 1997, AIDS EDUC PREV, V9, P44; Kirby D, 1997, FAM PLANN PERSPECT, V29, P100, DOI 10.2307/2953331; KIRBY D, 1994, PUBLIC HEALTH REP, V109, P339; McBride D, 2000, FAM PLANN PERSPECT, V32, P227, DOI 10.2307/2648176; MELLANBY AR, 1995, BRIT MED J, V311, P414, DOI 10.1136/bmj.311.7002.414; MILLER BC, 1993, FAM RELAT, V42, P392, DOI 10.2307/585339; MitchellDiCenso A, 1997, HEALTH EDUC BEHAV, V24, P300, DOI 10.1177/109019819702400304; Moberg DP, 1998, AIDS EDUC PREV, V10, P128; Moore K A, 1993, J Res Adolesc, V3, P393, DOI 10.1207/s15327795jra0304_5; NHS Centre for Reviews and Dissemination University of York, 1997, EFFECTIVE HLTH CARE, V3, P1; *NHS CTR REV DISS, 1997, PREV RED ADV AFF UN; OAKLEY A, 1995, BRIT MED J, V310, P158, DOI 10.1136/bmj.310.6973.158; *OFF NAT STAT, 2000, POP TRENDS; Raab GM, 2001, STAT MED, V20, P351, DOI 10.1002/1097-0258(20010215)20:3<351::AID-SIM797>3.0.CO;2-C; Schinke S P, 1981, Soc Work Groups, V4, P121, DOI 10.1300/J009v04n01_12; SCHINKE SP, 1981, J COUNS PSYCHOL, V28, P451, DOI 10.1037/0022-0167.28.5.451; SLADE LN, 1989, THESIS EMORY U ATLAN; Smith M A, 1994, J Health Educ, V25, P24; *SOC EXCL UN, 1999, TEEN PREGN; Song EY, 2000, J SCHOOL HEALTH, V70, P413, DOI 10.1111/j.1746-1561.2000.tb07230.x; *STAT CAN, 1997, CAN PREGN RAT TEENS; STEVENSSIMON C, 1991, PEDIATR ANN, V20, P322, DOI 10.3928/0090-4481-19910601-09; Thomson R, 1998, MALE HEAD YOUNG PEOP; TUKEY JW, 1993, CONTROL CLIN TRIALS, V14, P266, DOI 10.1016/0197-2456(93)90225-3; VISSER AP, 1994, PATIENT EDUC COUNS, V23, P147, DOI 10.1016/0738-3991(94)90031-0; Wellings F, 2001, LANCET, V358, P1843, DOI 10.1016/S0140-6736(01)06885-4; WEST P, 1993, J ADOLESCENCE, V16, P367, DOI 10.1006/jado.1993.1031; Wight D, 1998, HEALTH EDUC RES, V13, P317, DOI 10.1093/her/13.3.317-a; Wight D, 2000, BRIT MED J, V320, P1243, DOI 10.1136/bmj.320.7244.1243; Wight D, 2000, HEALTH EDUC RES, V15, P25, DOI 10.1093/her/15.1.25; ZORITCH B, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000564	74	140	140	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 15	2002	324	7351					1430	1433		10.1136/bmj.324.7351.1430	http://dx.doi.org/10.1136/bmj.324.7351.1430			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	565CQ	12065268	Green Published, Green Accepted, Green Submitted, Bronze			2022-12-28	WOS:000176351400020
J	Allwood, DA; Xiong, G; Cooke, MD; Faulkner, CC; Atkinson, D; Vernier, N; Cowburn, RP				Allwood, DA; Xiong, G; Cooke, MD; Faulkner, CC; Atkinson, D; Vernier, N; Cowburn, RP			Submicrometer ferromagnetic NOT gate and shift register	SCIENCE			English	Article							ROOM-TEMPERATURE; GIANT-MAGNETORESISTANCE; MAGNETOELECTRONICS; INJECTION; DEVICES	An all-metallic submicrometer device is demonstrated experimentally at room temperature that performs logical NOT operations on magnetic logic signals. When this two-terminal ferromagnetic structure is incorporated into a magnetic feedback loop, the junction performs a frequency division operation on an applied oscillating magnetic field. Up to 11 of these junctions are then directly linked together to create a magnetic shift register.	Univ Durham, Dept Phys, Sci Labs, Durham DH1 3LE, England	Durham University	Cowburn, RP (corresponding author), Univ Durham, Dept Phys, Sci Labs, Rochester Bldg,South Rd, Durham DH1 3LE, England.	r.p.cowburn@durham.ac.uk	Cowburn, Russell/D-5820-2015; Cooke, Michael/J-6227-2012	Cowburn, Russell/0000-0003-0867-8900; Cooke, Michael/0000-0001-7558-6403; Atkinson, Del/0000-0002-9438-7407				BAIBICH MN, 1988, PHYS REV LETT, V61, P2472, DOI 10.1103/PhysRevLett.61.2472; Black WC, 2000, J APPL PHYS, V87, P6674, DOI 10.1063/1.372806; Cowburn RP, 1998, APPL PHYS LETT, V73, P3947, DOI 10.1063/1.122945; Cowburn RP, 2000, SCIENCE, V287, P1466, DOI 10.1126/science.287.5457.1466; Fiederling R, 1999, NATURE, V402, P787, DOI 10.1038/45502; Kawakami RK, 2001, SCIENCE, V294, P131, DOI 10.1126/science.1063186; Koshihara S, 1997, PHYS REV LETT, V78, P4617, DOI 10.1103/PhysRevLett.78.4617; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Monsma DJ, 1998, SCIENCE, V281, P407, DOI 10.1126/science.281.5375.407; MOODERA JS, 1995, PHYS REV LETT, V74, P3273, DOI 10.1103/PhysRevLett.74.3273; Ohno H, 2000, NATURE, V408, P944, DOI 10.1038/35050040; Ohno Y, 1999, NATURE, V402, P790, DOI 10.1038/45509; Ono T, 1999, SCIENCE, V284, P468, DOI 10.1126/science.284.5413.468; Prinz GA, 1998, SCIENCE, V282, P1660, DOI 10.1126/science.282.5394.1660; Redjdal M, 2002, J APPL PHYS, V91, P7547, DOI 10.1063/1.1456403; Smet JH, 2002, NATURE, V415, P281, DOI 10.1038/415281a; TRIEBEL WA, 1982, HDB SEMICONDUCTOR BU; Wolf SA, 2001, SCIENCE, V294, P1488, DOI 10.1126/science.1065389; Xiong G, 2001, APPL PHYS LETT, V79, P3461, DOI 10.1063/1.1419032; You CY, 2000, J APPL PHYS, V87, P5215, DOI 10.1063/1.373299	20	469	482	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 14	2002	296	5575					2003	2006		10.1126/science.1070595	http://dx.doi.org/10.1126/science.1070595			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065830				2022-12-28	WOS:000176273300045
J	Preusser, F; Radies, D; Matter, A				Preusser, F; Radies, D; Matter, A			A 160,000-year record of dune development and atmospheric circulation in southern Arabia	SCIENCE			English	Article							NORTHERN OMAN; INDIAN-OCEAN; MONSOON; CLIMATE; SEA; PALEOCLIMATE; GROUNDWATERS; HOLOCENE; EVENTS; LAKES	Aeolian deposits in the Wahiba Sands, Sultanate of Oman, reveal patterns of atmospheric circulation over the past 160,000 years. Luminescence dating indicates a correlation of dune activity with periods of tow global sea level and decreased monsoon intensity. Evidence from dune orientation and sedimentary structures shows exclusively northbound transport of sand during times of high-latitude glaciation. These results are in contrast to the current paleocirculation model that assumes an increase of northwesterly winds because of a southward shift of the Intertropical Convergence Zone. Our results indicate that the circulation pattern during glacial times was comparable to that of the present.	Univ Bern, Inst Geol, CH-3012 Bern, Switzerland	University of Bern	Preusser, F (corresponding author), Univ Bern, Inst Geol, Baltzerstr 1-3, CH-3012 Bern, Switzerland.							BASSINOT FC, 1994, EARTH PLANET SC LETT, V126, P91, DOI 10.1016/0012-821X(94)90244-5; BREED C, 1980, USGS PROF PAP, V1052, P305; Burns SJ, 2001, GEOLOGY, V29, P623, DOI 10.1130/0091-7613(2001)029<0623:SEFOFC>2.0.CO;2; Burns SJ, 1998, GEOLOGY, V26, P499, DOI 10.1130/0091-7613(1998)026<0499:SBPRFN>2.3.CO;2; CLARK ID, 1990, QUATERNARY RES, V33, P320, DOI 10.1016/0033-5894(90)90059-T; CLEMENS S, 1991, NATURE, V353, P720, DOI 10.1038/353720a0; Dutton, 1988, J OMAN STUDIES SPECI, V3, P95; Gardner R. A. M., 1988, J OMAN STUDIES SPECI, V3, P75; Glennie KW, 1998, QUATERNARY DESERTS AND CLIMATIC CHANGE, P279; Iyengar GR, 2001, CURR SCI INDIA, V80, P18; Jones J. R., 1988, Journal of Oman Studies, P61; Juyal N, 1998, QUATERNARY DESERTS AND CLIMATIC CHANGE, P315; Leuschner DC, 2000, QUATERNARY SCI REV, V19, P243, DOI 10.1016/S0277-3791(99)00064-5; Lezine AM, 1998, QUATERNARY RES, V50, P290, DOI 10.1006/qres.1998.1996; MCCLURE HA, 1976, NATURE, V263, P755, DOI 10.1038/263755a0; Naidu PD, 1996, PALEOCEANOGRAPHY, V11, P129, DOI 10.1029/95PA03198; NAIR RR, 1989, NATURE, V338, P749, DOI 10.1038/338749a0; Overpeck J, 1996, CLIM DYNAM, V12, P213, DOI 10.1007/BF00211619; PEDGLEY DE, 1970, METEOROL MAG, V99, P29; ROSSIGNOLSTRICK M, 1983, NATURE, V304, P46, DOI 10.1038/304046a0; SIROCKO F, 1991, QUATERNARY RES, V36, P72, DOI 10.1016/0033-5894(91)90018-Z; SIROCKO F, 1989, NATO ADV SCI I C-MAT, V282, P401; Stanger G., 1986, THESIS OPEN U MILTON; Stokes S, 1997, NATURE, V388, P154, DOI 10.1038/40596; Uchupi E, 1999, MAR GEOL, V160, P1, DOI 10.1016/S0025-3227(99)00011-0; VANCAMPO E, 1982, NATURE, V296, P56, DOI 10.1038/296056a0; Weyhenmeyer CE, 2000, SCIENCE, V287, P842, DOI 10.1126/science.287.5454.842	27	127	128	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 14	2002	296	5575					2018	2020		10.1126/science.1069875	http://dx.doi.org/10.1126/science.1069875			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065834				2022-12-28	WOS:000176273300050
J	HilleRisLambers, J; Clark, JS; Beckage, B				HilleRisLambers, J; Clark, JS; Beckage, B			Density-dependent mortality and the latitudinal gradient in species diversity	NATURE			English	Article							TROPICAL RAIN-FOREST; SEED PREDATION; TREE; COEXISTENCE; RECRUITMENT; REGENERATION; MAINTENANCE; HERBIVORES; DYNAMICS; DISTANCE	Ecologists have long postulated that density-dependent mortality maintains high tree diversity in the tropics(1-6). If species experience greater mortality when abundant, then more rare species can persist(1,2,7-9). Agents of density-dependent mortality (such as host-specific predators, and pathogens) may be more prevalent or have stronger effects in tropical forests, because they are not limited by climatic factors(1-5). If so, decreasing density-dependent mortality with increasing latitude could partially explain the observed latitudinal gradient in tree diversity(4-6). This hypothesis has never been tested with latitudinal data. Here we show that several temperate tree species experience density-dependent mortality between seed dispersal and seedling establishment. The proportion of species affected is equivalent to that in tropical forests(6,10-16), failing to support the hypothesis that this mechanism is more prevalent at tropical latitudes. We further show that density-dependent mortality is misinterpreted in previous studies. Our results and evidence from other studies suggest that density-dependent mortality is important in many forests. Thus, unless the strength of density-dependent mortality varies with latitude, this mechanism is not likely to explain the high diversity of tropical forests.	Duke Univ, Dept Biol, Durham, NC 27708 USA; Nicholas Sch Environm & Earth Sci, Durham, NC 27708 USA	Duke University	HilleRisLambers, J (corresponding author), Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA.	hille015@umn.edu						AUGSPURGER CK, 1984, ECOLOGY, V65, P1705, DOI 10.2307/1937766; BECKER P, 1985, OIKOS, V44, P382, DOI 10.2307/3565778; Carson WP, 2000, ECOL MONOGR, V70, P73, DOI 10.1890/0012-9615(2000)070[0073:HAPSCC]2.0.CO;2; CINTRA R, 1997, J TROP ECOL, V8, P529; CLARK DA, 1984, AM NAT, V124, P769, DOI 10.1086/284316; Clark JS, 1998, ECOL MONOGR, V68, P213, DOI 10.1890/0012-9615(1998)068[0213:SASSOR]2.0.CO;2; Coley PD, 1996, ANNU REV ECOL SYST, V27, P305, DOI 10.1146/annurev.ecolsys.27.1.305; CONDIT R, 1992, AM NAT, V140, P261, DOI 10.1086/285412; CONNELL J H, 1971, P298; CONNELL JH, 1984, ECOL MONOGR, V54, P141, DOI 10.2307/1942659; CONNELL JH, 1978, SCIENCE, V199, P1302, DOI 10.1126/science.199.4335.1302; GILBERT GS, 1994, OECOLOGIA, V98, P100, DOI 10.1007/BF00326095; Givnish TJ, 1999, J ECOL, V87, P193, DOI 10.1046/j.1365-2745.1999.00333.x; Harms KE, 2000, NATURE, V404, P493, DOI 10.1038/35006630; HOWE HF, 1982, ANNU REV ECOL SYST, V13, P201, DOI 10.1146/annurev.es.13.110182.001221; HUBBELL SP, 1990, PHILOS T R SOC B, V330, P269, DOI 10.1098/rstb.1990.0198; HUBBELL SP, 1980, OIKOS, V35, P214, DOI 10.2307/3544429; JANZEN DH, 1970, AM NAT, V104, P501, DOI 10.1086/282687; JONES RH, 1994, ECOL MONOGR, V64, P345, DOI 10.2307/2937166; LEIGH EG, 1999, TROPICAL FOREST ECOL, P190; MCCANNY SJ, 1985, OIKOS, V45, P148, DOI 10.2307/3565232; Okuda T, 1997, PLANT ECOL, V131, P155, DOI 10.1023/A:1009727109920; PACALA SW, 1992, AM NAT, V140, P243, DOI 10.1086/285411; Packer A, 2000, NATURE, V404, P278, DOI 10.1038/35005072; Penfold GC, 1999, J ECOL, V87, P316, DOI 10.1046/j.1365-2745.1999.00360.x; SCHUPP EW, 1992, AM NAT, V140, P526, DOI 10.1086/285426; STRENG DR, 1989, ECOL MONOGR, V59, P177, DOI 10.2307/2937285; Webb CO, 1999, ECOLOGY, V80, P2006, DOI 10.1890/0012-9658(1999)080[2006:SDDPCO]2.0.CO;2; Wills C, 1997, P NATL ACAD SCI USA, V94, P1252, DOI 10.1073/pnas.94.4.1252; Wills C, 1999, P ROY SOC B-BIOL SCI, V266, P1445, DOI 10.1098/rspb.1999.0799	30	252	273	7	155	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 13	2002	417	6890					732	735		10.1038/nature00809	http://dx.doi.org/10.1038/nature00809			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	561QY	12066182				2022-12-28	WOS:000176154700042
J	Hickson, GB; Federspiel, CF; Pichert, JW; Miller, CS; Gauld-Jaeger, J; Bost, P				Hickson, GB; Federspiel, CF; Pichert, JW; Miller, CS; Gauld-Jaeger, J; Bost, P			Patient complaints and malpractice risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY-CARE PHYSICIANS; CLAIMS HISTORY; EXPERIENCE; COMMUNICATION; SATISFACTION; RELATIVES; DOCTORS	Context A small number of physicians experience a disproportionate share of malpractice claims and expenses. if malpractice risk is related in large measure to factors such as patient dissatisfaction with interpersonal behaviors, care and treatment, and access, it might be possible to monitor physicians' risk of being sued. Objective To examine the association between physicians' patient complaint records and their risk management experiences. Design, Setting, and Participants Retrospective longitudinal cohort study of 645 general and specialist physicians in a large US medical group between January 1992 and March 1998, accounting for 2546 physician-years of care. Main Outcome Measures Computerized records of all unsolicited patient complaints were recorded by the medical center's patient affairs office, coded to characterize the nature of the problem and alleged offender, and compared with each physician's risk management records for the same period. Results Both patient complaints and risk management events were higher for surgeons than nonsurgeons. Specifically, 137 (32%) of the 426 nonsurgeons had at least 1 risk management file compared with nearly two thirds (137 [63%] of 219) of all surgeons (chi(1)(2), =54.7, P<.001). Both complaint and risk management data were positively correlated with physicians' volume of clinical activity. Logistic regression revealed that risk management file openings, file openings with expenditures, and lawsuits were significantly related to total numbers of patient complaints, even when data were adjusted for clinical activity. Predictive concordance of specialty group, complaint count, clinical activity, and sex for risk management file openings was 84%; file openings with expenditures, 83 %; lawsuits, 81 %; and multiple lawsuits, 87 %. Conclusions Unsolicited patient complaints captured and recorded by a medical group are positively associated with physicians' risk management experiences.	Vanderbilt Univ, Sch Med, Dept Pediat, Div Gen Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Social Work, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Off Patient Affairs, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Hickson, GB (corresponding author), Vanderbilt Univ, Sch Med, Dept Pediat, Div Gen Pediat, 221 Kirkland Hall, Nashville, TN 37232 USA.							AVIS M, 1995, J ADV NURS, V22, P316, DOI 10.1046/j.1365-2648.1995.22020316.x; BALDWIN LM, 1991, OBSTET GYNECOL, V78, P1050; BOVBJERG RR, 1994, JAMA-J AM MED ASSOC, V272, P1421, DOI 10.1001/jama.272.18.1421; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Brennan TA, 2000, NEW ENGL J MED, V342, P1123, DOI 10.1056/NEJM200004133421510; Brennan TA, 1999, JAMA-J AM MED ASSOC, V282, P381, DOI 10.1001/jama.282.4.381; *CAL MED ASS CAL H, 1977, REP MED INS FEAS STU; Clayton E., 1993, SUING MED MALPRACTIC SUING MED MALPRACTIC, P72; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; ENTMAN SS, 1994, JAMA-J AM MED ASSOC, V272, P1588, DOI 10.1001/jama.272.20.1588; Fitzpatrick R, 1983, Sociol Health Illn, V5, P297, DOI 10.1111/1467-9566.ep10491836; HICKSON G, 1997, LAW CONTEMP PROBL, V27, P8; HICKSON G, 1993, SUING MED MALPRACTIC, P92; HICKSON GB, 1994, JAMA-J AM MED ASSOC, V272, P1583, DOI 10.1001/jama.272.20.1583; Hinton J, 1996, SOC SCI MED, V43, P1229, DOI 10.1016/0277-9536(95)00437-8; LEVINSON W, 1993, J GEN INTERN MED, V8, P318, DOI 10.1007/BF02600146; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; MAY ML, 1990, LAW SOC REV, V24, P105, DOI 10.2307/3053788; *MED PROGR, 1992, FED REGISTER, V56, P59511; PICHERT J, 1999, JOINT COMM J QUAL IM, V6, P288; RAY WA, 1985, JAMA-J AM MED ASSOC, V253, P1774, DOI 10.1001/jama.253.12.1774; ROLPH JE, 1991, LAW CONTEMP PROBL, V54, P65; Sloan F., 1993, SUING MED MALPRACTIC, P1; SLOAN FA, 1989, JAMA-J AM MED ASSOC, V262, P3291, DOI 10.1001/jama.262.23.3291; SLORA EJ, 1991, SOCIOECONOMIC CHARAC, P15; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; Technical Assistance Research Program, 1986, CONS COMPL HANDL AM; VINCENT C, 1994, LANCET, V343, P1609, DOI 10.1016/S0140-6736(94)93062-7; Williams B, 1998, SOC SCI MED, V47, P1351, DOI 10.1016/S0277-9536(98)00213-5	29	359	359	3	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	2002	287	22					2951	2957		10.1001/jama.287.22.2951	http://dx.doi.org/10.1001/jama.287.22.2951			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	561EY	12052124	Bronze			2022-12-28	WOS:000176128300024
J	Roy, S; Hill, AVS; Knox, K; Griffiths, D; Crook, D				Roy, S; Hill, AVS; Knox, K; Griffiths, D; Crook, D			Association of common genetic variant with susceptibility to invasive pneumococcal disease	BRITISH MEDICAL JOURNAL			English	Article							C-REACTIVE PROTEIN; POLYSACCHARIDE		Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; John Radcliffe Hosp, Dept Microbiol, Oxford OX3 9DU, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	Hill, AVS (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.		HILL, Adrian V>S>/C-1306-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		HOROWITZ J, 1987, J IMMUNOL, V138, P2598; KAPLAN MH, 1974, J IMMUNOL, V112, P2135; VOLANAKI.JE, 1971, P SOC EXP BIOL MED, V136, P612	3	30	33	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 8	2002	324	7350					1369	1369		10.1136/bmj.324.7350.1369	http://dx.doi.org/10.1136/bmj.324.7350.1369			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BQ	12052806	Green Published, Bronze			2022-12-28	WOS:000176234100021
J	Lachmann, HJ; Booth, DR; Booth, SE; Bybee, A; Gilbertson, JA; Gillmore, JD; Pepys, MB; Hawkins, PN				Lachmann, HJ; Booth, DR; Booth, SE; Bybee, A; Gilbertson, JA; Gillmore, JD; Pepys, MB; Hawkins, PN			Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMARY SYSTEMIC AMYLOIDOSIS; FIBRINOGEN ALPHA-CHAIN; RENAL AMYLOIDOSIS; TRANSTHYRETIN AMYLOIDOSIS; CARDIAC AMYLOIDOSIS; APOLIPOPROTEIN AL; ENGLISH FAMILY; P COMPONENT; CONGO RED; VARIANT	Background: Hereditary, autosomal dominant amyloidosis, caused by mutations in the genes encoding transthyretin, fibrinogen A alpha-chain, lysozyme, or apolipoprotein A-I, is thought to be extremely rare and is not routinely included in the differential diagnosis of systemic amyloidosis unless there is a family history. Methods: We studied 350 patients with systemic amyloidosis, in whom a diagnosis of the light-chain (AL) type of the disorder had been suggested by clinical and laboratory findings and by the absence of a family history, to assess whether they had amyloidogenic mutations. Results: Amyloidogenic mutations were present in 34 of the 350 patients (9.7 percent), most often in the genes encoding fibrinogen A alpha-chain (18 patients) and transthyretin (13 patients). In all 34 of these patients, the diagnosis of hereditary amyloidosis was confirmed by additional investigations. A low-grade monoclonal gammopathy was detected in 8 of the 34 patients (24 percent). Conclusions: A genetic cause should be sought in all patients with amyloidosis that is not the reactive systemic amyloid A type and in whom confirmation of the AL type cannot be obtained.	UCL Royal Free & Univ Coll Med Sch, Dept Med, Natl Amyloidosis Ctr, London NW3 2PF, England; UCL Royal Free & Univ Coll Med Sch, Dept Med, Ctr Amyloidosis & Acute Phase Prot, London NW3 2PF, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School	Hawkins, PN (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Med, Natl Amyloidosis Ctr, Royal Free Campus,Rowland Hill St, London NW3 2PF, England.	p.n.hawkins@rfc.ucl.ac.uk	Hawkins, Philip N/C-5573-2008	Lachmann, Helen/0000-0001-8378-2498				Asl LH, 1999, AM J PATHOL, V154, P221, DOI 10.1016/S0002-9440(10)65268-6; BENSON MD, 1993, NAT GENET, V3, P252, DOI 10.1038/ng0393-252; Benson MD, 1996, AMYLOID, V3, P44, DOI 10.3109/13506129609014354; Benson MD, 2001, GENOMICS, V72, P272, DOI 10.1006/geno.2000.6499; BOOTH DR, 1995, CIRCULATION, V91, P962, DOI 10.1161/01.CIR.91.4.962; Connors LH, 2000, AMYLOID, V7, P54, DOI 10.3109/13506120009146826; Davison A M, 1985, Contrib Nephrol, V48, P24; de Sousa MM, 2000, AM J PATHOL, V156, P1911, DOI 10.1016/S0002-9440(10)65064-X; Gertz MA, 2000, BONE MARROW TRANSPL, V25, P465, DOI 10.1038/sj.bmt.1702178; Gillmore JD, 1999, NEPHROL DIAL TRANSPL, V14, P2639, DOI 10.1093/ndt/14.11.2639; Gillmore JD, 1998, BRIT J HAEMATOL, V100, P226, DOI 10.1046/j.1365-2141.1998.00527.x; Gillmore JD, 2000, QJM-INT J MED, V93, P269, DOI 10.1093/qjmed/93.5.269; HAWKINS PN, 1994, CLIN SCI, V87, P289, DOI 10.1042/cs0870289; HAWKINS PN, 1990, NEW ENGL J MED, V323, P508, DOI 10.1056/NEJM199008233230803; HOLMGREN G, 1993, LANCET, V341, P1113, DOI 10.1016/0140-6736(93)93127-M; HOLMGREN G, 1994, J MED GENET, V31, P351, DOI 10.1136/jmg.31.5.351; Jacobson DR, 1997, NEW ENGL J MED, V336, P466, DOI 10.1056/NEJM199702133360703; Kyle RA, 1997, NEW ENGL J MED, V336, P1202, DOI 10.1056/NEJM199704243361702; KYLE RA, 1995, SEMIN HEMATOL, V32, P45; Kyle RA, 2002, NEW ENGL J MED, V346, P564, DOI 10.1056/NEJMoa01133202; LINKE RP, 1995, J HISTOCHEM CYTOCHEM, V43, P863, DOI 10.1177/43.9.7642960; NICHOLS WC, 1988, BIOCHEM BIOPH RES CO, V156, P762, DOI 10.1016/S0006-291X(88)80909-4; PEPYS MB, 1993, NATURE, V362, P553, DOI 10.1038/362553a0; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; SOUTAR AK, 1992, P NATL ACAD SCI USA, V89, P7389, DOI 10.1073/pnas.89.16.7389; TAN SY, 1994, HISTOPATHOLOGY, V25, P403, DOI 10.1111/j.1365-2559.1994.tb00001.x; Tennent GA, 1999, METHOD ENZYMOL, V309, P26; UEMICHI T, 1994, J CLIN INVEST, V93, P731, DOI 10.1172/JCI117027; Uemichi T, 1996, QJM-MON J ASSOC PHYS, V89, P745, DOI 10.1093/qjmed/89.10.745; VIGUSHIN DM, 1994, Q J MED, V87, P149; Wardley AM, 1998, BRIT J CANCER, V78, P774, DOI 10.1038/bjc.1998.577	31	440	468	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	2002	346	23					1786	1791		10.1056/NEJMoa013354	http://dx.doi.org/10.1056/NEJMoa013354			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	559EK	12050338	Green Published			2022-12-28	WOS:000176012500004
J	Valla, T; Johnson, PD; Yusof, Z; Wells, B; Li, Q; Loureiro, SM; Cava, RJ; Mikami, M; Mori, Y; Yoshimura, M; Sasaki, T				Valla, T; Johnson, PD; Yusof, Z; Wells, B; Li, Q; Loureiro, SM; Cava, RJ; Mikami, M; Mori, Y; Yoshimura, M; Sasaki, T			Coherence-incoherence and dimensional crossover in layered strongly correlated metals	NATURE			English	Article							NORMAL-STATE; TRANSPORT; ANISOTROPY	The properties of an interacting electron system depend on the electron correlations and the effective dimensionality. For example, Coulomb repulsion between electrons may inhibit, or completely block, conduction by intersite electron hopping, thereby determining whether a material is a metal or an insulator(1). Furthermore, correlation effects increase as the number of effective dimensions decreases; in three-dimensional systems, the low-energy electronic states behave as quasiparticles, whereas in one-dimensional systems, even weak interactions break the quasiparticles into collective excitations(2). Dimensionality is particularly important for exotic low-dimensional materials where one- or two-dimensional building blocks are loosely connected into a three-dimensional whole. Here we examine two such layered metallic systems with angle-resolved photoemission spectroscopy and electronic transport measurements, and we find a crossover in the number of effective dimensions-from two to three-with decreasing temperature. This is apparent from the observation that, in the direction perpendicular to the layers, the materials have an insulating character at high temperatures but become metal-like at low temperatures, whereas transport within the layers remains metallic over the whole temperature range. We propose that this change in effective dimensionality correlates with the presence of coherent quasiparticles within the layers.	Brookhaven Natl Lab, Dept Phys, Upton, NY 11973 USA; Brookhaven Natl Lab, Dept Mat Sci, Upton, NY 11973 USA; Univ Connecticut, Dept Phys, Storrs, CT 06269 USA; Princeton Univ, Dept Chem, Princeton, NJ 08540 USA; Princeton Univ, Princeton Mat Inst, Princeton, NJ 08540 USA; Osaka Univ, Dept Elect Engn, Suita, Osaka 5650871, Japan	United States Department of Energy (DOE); Brookhaven National Laboratory; United States Department of Energy (DOE); Brookhaven National Laboratory; University of Connecticut; Princeton University; Princeton University; Osaka University	Valla, T (corresponding author), Brookhaven Natl Lab, Dept Phys, Upton, NY 11973 USA.	valla@bnl.gov	Valla, Tonica/ABD-7811-2021; Mori, Yusuke/C-3302-2014; Mikami, Masashi/L-8651-2016; Yoshimura, Masashi/N-7222-2013	Valla, Tonica/0000-0002-3237-9102; Mikami, Masashi/0000-0002-1866-824X; 				Anderson P. W., 1997, THEORY SUPERCONDUCTI; BIERMANN S, 2001, CONDMAT0107633; Carlson EW, 2000, PHYS REV B, V62, P3422, DOI 10.1103/PhysRevB.62.3422; Ding H, 1996, NATURE, V382, P51, DOI 10.1038/382051a0; FISK Z, 1988, SCIENCE, V239, P33, DOI 10.1126/science.239.4835.33; Georges A, 1996, REV MOD PHYS, V68, P13, DOI 10.1103/RevModPhys.68.13; Ioffe A. F., 1960, PROG SEMICOND, V4, P237; Ioffe LB, 1998, PHYS REV B, V58, P11631, DOI 10.1103/PhysRevB.58.11631; JAEROME D, 1987, LOW DIMENSIONAL COND; Lavrov AN, 1998, PHYS REV LETT, V81, P5636, DOI 10.1103/PhysRevLett.81.5636; Loureiro SM, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.094109; MAENO Y, 1994, NATURE, V372, P532, DOI 10.1038/372532a0; Merino J, 2000, PHYS REV B, V61, P7996, DOI 10.1103/PhysRevB.61.7996; Mihaly G, 2000, PHYS REV LETT, V84, P2670, DOI 10.1103/PhysRevLett.84.2670; Mott N.F., 1990, METAL INSULATOR TRAN; PRUSCHKE T, 1993, PHYS REV B, V47, P3553, DOI 10.1103/PhysRevB.47.3553; Reinert F, 2001, PHYS REV LETT, V87, part. no., DOI 10.1103/PhysRevLett.87.106401; TSUKADA I, 2000, CONDMAT0012395; Valla T, 2000, PHYS REV LETT, V85, P828, DOI 10.1103/PhysRevLett.85.828; Valla T, 1999, SCIENCE, V285, P2110, DOI 10.1126/science.285.5436.2110; VOIT J, 1995, REP PROG PHYS, V58, P977, DOI 10.1088/0034-4885/58/9/002; Watanabe T, 2000, PHYS REV LETT, V84, P5848, DOI 10.1103/PhysRevLett.84.5848; YUSOF Z, 2001, CONDMAT0104367	24	164	170	2	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 6	2002	417	6889					627	630		10.1038/nature00774	http://dx.doi.org/10.1038/nature00774			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050659	Green Submitted			2022-12-28	WOS:000176001200041
J	Megahed, M; Schon, M; Selimovic, D; Schon, MP				Megahed, M; Schon, M; Selimovic, D; Schon, MP			Reliability of diagnosis of melanoma in situ	LANCET			English	Article								Early and correct diagnosis of malignant melanoma Is of utmost Importance to ensure adequate treatment and the best outcome. Prompted by the death of a patient with an apparent metastasising melanoma In situ, we reassessed 104 people with this malignant disorder, whose diagnosis had been histopathologically verified. We did Immunohistochemical analysis of cells with the melanocytic marker melan-A/MART-1, and results of this analysis showed that 30 (29%) of 104 patients had invasive melanomas. One patient died of distant metastases, and the tumour recurred In another. Our finding could be relevant for diagnosis and treatment of melanoma In situ.	Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany; Otto Von Guericke Univ, Dept Dermatol, Magdeburg, Germany	Heinrich Heine University Dusseldorf; Otto von Guericke University	Megahed, M (corresponding author), Univ Dusseldorf, Dept Dermatol, Moorenstr 5, D-40225 Dusseldorf, Germany.	megahed@uni-duesseldorf.de		Schon, Michael/0000-0002-0698-4130				ACKERMAN AB, 1984, AM J DERMATOPATH, V6, P103; ARMSTRONG BK, 1994, CANCER SURV, V20, P219; Busam KJ, 1998, AM J SURG PATHOL, V22, P57, DOI 10.1097/00000478-199801000-00007; Busam KJ, 1998, AM J SURG PATHOL, V22, P976, DOI 10.1097/00000478-199808000-00007; GARBE C, 1995, CANCER-AM CANCER SOC, V75, P2492, DOI 10.1002/1097-0142(19950515)75:10<2492::AID-CNCR2820751015>3.0.CO;2-W	5	66	66	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 1	2002	359	9321					1921	1922		10.1016/S0140-6736(02)08741-X	http://dx.doi.org/10.1016/S0140-6736(02)08741-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PL	12057558				2022-12-28	WOS:000175975700015
J	Horrobin, DF				Horrobin, DF			Effective clinical innovation: an ethical imperative	LANCET			English	Article									Laxdale, Stirling FK7 9QL, Scotland		Horrobin, DF (corresponding author), Laxdale, Pk House,Laurelhill Business Pk,Polmaise Rd, Stirling FK7 9QL, Scotland.								0	26	26	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 25	2002	359	9320					1857	1858		10.1016/S0140-6736(02)08707-X	http://dx.doi.org/10.1016/S0140-6736(02)08707-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044395				2022-12-28	WOS:000175775500028
J	Maughan, TS; James, RD; Kerr, DJ; Ledermann, JA; McArdle, C; Seymour, MT; Cohen, D; Hopwood, P; Johnston, C; Stephens, RJ				Maughan, TS; James, RD; Kerr, DJ; Ledermann, JA; McArdle, C; Seymour, MT; Cohen, D; Hopwood, P; Johnston, C; Stephens, RJ		British MRC Colorectal Canc Work	Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial	LANCET			English	Article							HIGH-DOSE LEUCOVORIN; CONTINUOUS-INFUSION; CLINICAL-TRIALS; FLUOROURACIL; BOLUS; ONCOLOGY	Background This randomised trial compared three chemotherapy regimens in the first-line treatment of advanced colorectal cancer, in terms of their effect on overall and progression-free survival; other endpoints included toxicity, symptom palliation, and quality of life. Methods 905 patients were randomly assigned the de Gramont regimen (n=303; folinic acid 200 mg/m(2), fluorouracil bolus 400 mg/m(2), and infusion 600 mg/m(2) on days I and 2, repeated every 14 days), the Lokich regimen (n=301; protracted venous infusion of fluorouracil 300 mg/m(2) daily), or raltitrexed (n=301; 3 mg/m(2) intravenously every 21 days). Analyses were by intention to treat. Findings Median follow-up of survivors was 67 weeks. For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days. The hazard ratios for overall survival were 0.88 (95% Cl 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed. An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lolkich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity. Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning. Interpretation The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates. The Lokich regimen was associated with more central line complications and hand-foot syndrome. Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer, but resulted in greater toxicity and inferior quality of life.	MRC, Clin Trials Unit, Canc Div, London NW1 2DA, England; Velindre Hosp, Dept Oncol, Cardiff, S Glam, Wales; Maidstone Hlth Author, Kent Canc Ctr, Maidstone, Kent, England; Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England; UCL Hosp, Dept Oncol, London, England; Univ Glasgow, Royal Infirm, Dept Surg, Glasgow G31 2ER, Lanark, Scotland; Cookridge Hosp, Imperial Canc Res Fund, Ctr Clin, Leeds LS16 6QB, W Yorkshire, England; Univ Glamorgan, Sch Business, Pontypridd CF37 1DL, M Glam, Wales; Christie Hosp, Manchester, Lancs, England	Medical Research Council Clinical Trials Unit; Velindre Hospital; Radcliffe Infirmary; University College London Hospitals NHS Foundation Trust; University of London; University College London; Royal Infirmary of Edinburgh; University of Glasgow; Cookridge Hospital; University of South Wales; Christie NHS Foundation Trust; Christie Hospital	Stephens, RJ (corresponding author), MRC, Clin Trials Unit, Canc Div, London NW1 2DA, England.		Maughan, Timothy/D-5032-2011	Seymour, Matthew/0000-0002-2441-9629				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; *CANC RES CAMP, 1993, CANC LARG BOW UK; CLARKE SJ, 1994, ANN ONCOL, V5, P240; Cocconi G, 1998, J CLIN ONCOL, V16, P2943, DOI 10.1200/JCO.1998.16.9.2943; Cunningham D, 1996, ANN ONCOL, V7, P961, DOI 10.1093/oxfordjournals.annonc.a010800; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; DEGRAMONT A, 1988, EUR J CANCER CLIN ON, V24, P1499, DOI 10.1016/0277-5379(88)90341-0; deGramont A, 1997, EUR J CANCER, V33, P214, DOI 10.1016/S0959-8049(96)00370-X; deGramont A, 1997, J CLIN ONCOL, V15, P808, DOI 10.1200/JCO.1997.15.2.808; Farrugia DC, 2000, CLIN CANCER RES, V6, P3646; FAYERS P, 1995, EORTCQLQC30 SCORING; FLEMING TR, 1990, J ACQ IMMUN DEF SYND, V3, pS82; HEIDELBERGER C, 1957, NATURE, V179, P663, DOI 10.1038/179663a0; HOPWOOD P, 1994, QUAL LIFE RES, V3, P339, DOI 10.1007/BF00451726; JACKMAN AL, 1991, CANCER RES, V51, P5579; Judson I, 1998, BRIT J CANCER, V78, P1188, DOI 10.1038/bjc.1998.652; KELLER OR, 2001, P AN M AM SOC CLIN, V20, P141; Levy E, 1998, J CLIN ONCOL, V16, P3537, DOI 10.1200/JCO.1998.16.11.3537; LOKICH JJ, 1989, J CLIN ONCOL, V7, P425, DOI 10.1200/JCO.1989.7.4.425; *NHS EX, 1997, IMPR OUTC COL CANC R, P98; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Pazdur R, 1997, P AN M AM SOC CLIN, V16, P801; PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896; POON MA, 1991, J CLIN ONCOL, V9, P1967, DOI 10.1200/JCO.1991.9.11.1967; Seymour MT, 1998, ANN ONCOL, V9, P47; Seymour MT, 1996, J CLIN ONCOL, V14, P2280, DOI 10.1200/JCO.1996.14.8.2280; Simmonds P C, 2000, BMJ, V321, P531; SOBRERO A, 1999, P AM SOC CLIN ONCOL, V18, P915; SORENSEN JM, 1994, ANN ONCOL, V5, P132; Stephens RJ, 1997, QUAL LIFE RES, V6, P225; Stephens RJ, 1999, BRIT J CANCER, V79, P538, DOI 10.1038/sj.bjc.6690085; THIRION P, 1999, P AM SOC CLIN ONCOL, V18, P912; VINCENT M, 1999, P AM SOC CLIN ONCOL, V18, P930; WHO, 1979, WHO HDB REP RES CANC; Wolmark N, 1998, J CLIN ONCOL, V16, P301; Zalcberg J, 1997, ANTI-CANCER DRUG, V8, pS17, DOI 10.1097/00001813-199708002-00004; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	37	122	128	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 4	2002	359	9317					1555	1563		10.1016/S0140-6736(02)08514-8	http://dx.doi.org/10.1016/S0140-6736(02)08514-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047964				2022-12-28	WOS:000175460700008
J	Garrett, M; McElroy, AM; Staines, A				Garrett, M; McElroy, AM; Staines, A			Locomotor milestones and babywalkers: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									Univ Coll Dublin, Sch Physiotherapy, Mater Hosp, Dublin 7, Ireland; Univ Coll Dublin, Sch Med, Dept Publ Hlth Med & Epidemiol, Dublin 2, Ireland	Mater Misericordiae University Hospital; University College Dublin; University College Dublin	Garrett, M (corresponding author), Univ Coll Dublin, Sch Physiotherapy, Mater Hosp, Dublin 7, Ireland.		Staines, Anthony/AFQ-7565-2022	Staines, Anthony/0000-0001-9161-1357				CROUCHMAN M, 1986, DEV MED CHILD NEUROL, V28, P757; Kauffman I, 1987, PERCEPT MOTOR SKILL, V45, P1323; Siegel AC, 1999, J DEV BEHAV PEDIATR, V20, P355, DOI 10.1097/00004703-199910000-00010; Thein M M, 1997, Inj Prev, V3, P63, DOI 10.1136/ip.3.1.63; WELCH S, PUBLIC INTEREST CHIL	5	34	40	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 22	2002	324	7352					1494	1494		10.1136/bmj.324.7352.1494	http://dx.doi.org/10.1136/bmj.324.7352.1494			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567ZL	12077035	Green Published, Bronze			2022-12-28	WOS:000176517900020
J	Chandra, P; Coleman, P; Mydosh, JA; Tripathi, V				Chandra, P; Coleman, P; Mydosh, JA; Tripathi, V			Hidden orbital order in the heavy fermion metal URu2Si2	NATURE			English	Article							EXCITATIONS; PRESSURE; FIELD	When matter is cooled from high temperatures, collective instabilities develop among its constituent particles that lead to new kinds of order(1). An anomaly in the specific heat is a classic signature of this phenomenon. Usually the associated order is easily identified, but sometimes its nature remains elusive. The heavy fermion metal URu2Si2 is one such example, where the order responsible for the sharp specific heat anomaly at T-0 = 17 K has remained unidentified despite more than seventeen years of effort(2). In URu2Si2, the coexistence of large electron-electron repulsion and antiferromagnetic fluctuations leads to an almost incompressible heavy electron fluid, where anisotropically paired quasiparticle states are energetically favoured(3). Here we develop a proposal for the nature of the hidden order in URu2Si2. We show that incommensurate orbital antiferromagnetism, associated with circulating currents between the uranium ions, can account for the local fields and entropy loss observed at the 17 K transition. We make detailed predictions for the outcome of neutron scattering measurements based on this proposal, so that it can be tested experimentally.	Rutgers State Univ, Dept Phys & Astron, Ctr Mat Theory, Piscataway, NJ 08855 USA; NEC Corp Ltd, Princeton, NJ 08540 USA; Leiden Univ, Kamerlingh Onnes Lab, NL-2300 RA Leiden, Netherlands	Rutgers State University New Brunswick; NEC Corporation; Leiden University; Leiden University - Excl LUMC	Coleman, P (corresponding author), Rutgers State Univ, Dept Phys & Astron, Ctr Mat Theory, POB 849, Piscataway, NJ 08855 USA.	coleman@physics.rutgers.edu						Amitsuka H, 1999, PHYS REV LETT, V83, P5114, DOI 10.1103/PhysRevLett.83.5114; BERNAL OO, 2001, PHYS REV LETT, V87, P153; BROHOLM C, 1991, PHYS REV B, V43, P12809, DOI 10.1103/PhysRevB.43.12809; Buyers WJL, 1996, PHYSICA B, V223-24, P9, DOI 10.1016/0921-4526(96)00027-0; Chakravarty S, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.094503; CHANDRA P, 2001, CONDMAT0110048; DEVISSER A, 1986, PHYS REV B, V34, P8168, DOI 10.1103/PhysRevB.34.8168; FISHER RA, 1990, PHYSICA B, V163, P419, DOI 10.1016/0921-4526(90)90229-N; Goodstein D.L., 1985, STATES OF MATTER; HALPERIN BI, 1968, SOLID STATE PHYS, V21, P116; HSU TC, 1991, PHYS REV B, V43, P2866, DOI 10.1103/PhysRevB.43.2866; KEE HY, 2001, CONDMAT0111461; KOTLIAR G, 1988, PHYS REV B, V37, P3664, DOI 10.1103/PhysRevB.37.3664; LEE PA, 2002, CONDMAT0201052; LUKE GM, 1994, HYPERFINE INTERACT, V85, P397, DOI 10.1007/BF02069451; MASON TE, 1991, PHYS REV B, V43, P11471, DOI 10.1103/PhysRevB.43.11471; MASON TE, 1995, J PHYS-CONDENS MAT, V7, P5089, DOI 10.1088/0953-8984/7/26/014; Matsunami H., 1987, OPTOELECTRON DEVICES, V2, P29; Mentink SAM, 1996, PHYS REV B, V53, pR6014, DOI 10.1103/PhysRevB.53.R6014; MIYAKE K, 1986, PHYS REV B, V34, P6554, DOI 10.1103/PhysRevB.34.6554; MIYAKO Y, 1991, J APPL PHYS, V70, P5791, DOI 10.1063/1.350162; NERSESYAN AA, 1989, J LOW TEMP PHYS, V77, P293, DOI 10.1007/BF00681537; PALSTRA TTM, 1986, PHYS REV B, V33, P6527, DOI 10.1103/PhysRevB.33.6527; PALSTRA TTM, 1985, PHYS REV LETT, V55, P2727, DOI 10.1103/PhysRevLett.55.2727; RAMIREZ AP, 1992, PHYS REV LETT, V68, P2680, DOI 10.1103/PhysRevLett.68.2680; SCHULZ HJ, 1989, PHYS REV B, V39, P2940, DOI 10.1103/PhysRevB.39.2940; Shah N, 2000, PHYS REV B, V61, P564, DOI 10.1103/PhysRevB.61.564; vanDijk NH, 1997, PHYS REV B, V56, P14493, DOI 10.1103/PhysRevB.56.14493; [No title captured]	30	199	201	1	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 20	2002	417	6891					831	834		10.1038/nature00795	http://dx.doi.org/10.1038/nature00795			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075346	Green Submitted			2022-12-28	WOS:000176285600041
J	Cox, B; Sneyd, MJ; Paul, C; Delahunt, B; Skegg, DCG				Cox, B; Sneyd, MJ; Paul, C; Delahunt, B; Skegg, DCG			Vasectomy and risk of prostate cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES MEN; RETROSPECTIVE COHORT; SERUM; ASSOCIATION; ANDROGENS; CANADA	Context Vasectomy is a common method of contraception, but concern exists about a reported association with risk of prostate cancer. Objective To examine whether vasectomy increases risk of prostate cancer. Design, Setting, and Participants National population-based case-control study of 923 new cases of prostate cancer among men aged 40 to 74 years from the New Zealand Cancer Registry who were on the general electoral roll. Controls (n = 1224) were randomly selected from the general electoral roll, with frequency matching to cases in 5-year age groups. Cases (3-15 months after diagnosis) and controls were interviewed by telephone between January 1997 and November 1999. Main Outcome Measures Relative risk (RR) of prostate cancer for men who had had a vasectomy vs those who had not. Results There was no association between prostate cancer and vasectomy (RR, 0.92; 95% confidence interval [CI], 0,75-1.14) nor with time since vasectomy (RR, 0.92; 95% CI, 0.68-1.23 for greater than or equal to25 years since vasectomy). Adjustment for social class, geographic region, religious affiliation, and a family history of prostate cancer did not affect these RRs. Conclusions Vasectomy does not increase the risk of prostate cancer, even after 25 years or more.	Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand; Univ Otago, Wellington Sch Med, Dept Pathol, Dunedin, New Zealand	University of Otago; University of Otago	Cox, B (corresponding author), Univ Otago, Sch Med, Dept Prevent & Social Med, Hugh Adam Canc Epidemiol Unit, POB 913, Dunedin, New Zealand.	brian.cox@stonebow.otago.ac.nz	Cox, Brian/I-4510-2015; Delahunt, Brett/AAG-2382-2019		NICHD NIH HHS [Y1-HD-7053] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bernal-Delgado E, 1998, FERTIL STERIL, V70, P191, DOI 10.1016/S0015-0282(98)00142-3; Breslow RA, 1998, NUTR CANCER, V30, P1, DOI 10.1080/01635589809514633; Dillner J, 1998, INT J CANCER, V75, P564, DOI 10.1002/(SICI)1097-0215(19980209)75:4<564::AID-IJC12>3.0.CO;2-9; Dorgan JP, 1998, CANCER EPIDEM BIOMAR, V7, P1069; ELLEY WB, 1985, NEW ZEAL J EDUC STUD, V20, P115; Ghadirian P, 1996, CANCER CAUSE CONTROL, V7, P428, DOI 10.1007/BF00052669; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P873, DOI 10.1001/jama.269.7.873; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P878, DOI 10.1001/jama.269.7.878; Guess HA, 1997, CANCER EPIDEM BIOMAR, V6, P21; GUESS HA, 1990, AM J EPIDEMIOL, V132, P1062, DOI 10.1093/oxfordjournals.aje.a115748; HAYES RB, 1993, AM J EPIDEMIOL, V137, P263, DOI 10.1093/oxfordjournals.aje.a116673; HOWARDS SS, 1993, EUR J CANCER, V29A, P1060, DOI 10.1016/S0959-8049(05)80224-2; HSING AW, 1994, CANCER EPIDEM BIOMAR, V3, P285; JOHN EM, 1995, J NATL CANCER I, V87, P662, DOI 10.1093/jnci/87.9.662; Lesko SM, 1999, J UROLOGY, V161, P1848, DOI 10.1016/S0022-5347(05)68824-6; METTLIN C, 1990, AM J EPIDEMIOL, V132, P1056, DOI 10.1093/oxfordjournals.aje.a115747; MOLLER H, 1994, BRIT MED J, V309, P295, DOI 10.1136/bmj.309.6950.295; NEWELL GR, 1989, AM J EPIDEMIOL, V130, P395, DOI 10.1093/oxfordjournals.aje.a115346; NIENHUIS H, 1992, BRIT MED J, V304, P743, DOI 10.1136/bmj.304.6829.743; Nomura AMY, 1997, CANCER EPIDEM BIOMAR, V6, P487; Norrish AE, 2000, AM J EPIDEMIOL, V151, P119, DOI 10.1093/oxfordjournals.aje.a010176; PERLMAN JA, 1991, AM J EPIDEMIOL, V134, P107, DOI 10.1093/oxfordjournals.aje.a115985; Platz EA, 1997, INT J EPIDEMIOL, V26, P933, DOI 10.1093/ije/26.5.933; *POP INF PROGR, 1992, VAS NEW OPP, P17; Rohan TE, 1997, EUR J CANCER PREV, V6, P382, DOI 10.1097/00008469-199708000-00011; ROSENBERG L, 1990, AM J EPIDEMIOL, V132, P1051, DOI 10.1093/oxfordjournals.aje.a115746; ROSENBERG L, 1994, AM J EPIDEMIOL, V140, P431, DOI 10.1093/oxfordjournals.aje.a117265; Sandlow JI, 1996, FERTIL STERIL, V66, P281, DOI 10.1016/S0015-0282(16)58454-4; SCHRODER FH, 1992, PROSTATE, P129; Schwingl PJ, 2000, FERTIL STERIL, V73, P923, DOI 10.1016/S0015-0282(00)00482-9; SIDNEY S, 1991, CANCER CAUSE CONTROL, V2, P113, DOI 10.1007/BF00053130; SKEGG DCG, 1993, EUR J CANCER, V29A, P935, DOI 10.1016/S0959-8049(05)80196-0; Sneyd MJ, 2001, CONTRACEPTION, V64, P155, DOI 10.1016/S0010-7824(01)00242-6; Stanford JL, 1999, CANCER EPIDEM BIOMAR, V8, P881; Vatten LJ, 1997, CANCER EPIDEM BIOMAR, V6, P967; Willett WC, 1997, AM J CLIN NUTR, V66, P1557; World Health Organization, 1977, INT CLASS DIS MAN IN; Yoshizawa K, 1998, JNCI-J NATL CANCER I, V90, P1219, DOI 10.1093/jnci/90.16.1219; Zhu KM, 1996, AM J EPIDEMIOL, V144, P717, DOI 10.1093/oxfordjournals.aje.a008994	39	48	50	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	2002	287	23					3110	3115		10.1001/jama.287.23.3110	http://dx.doi.org/10.1001/jama.287.23.3110			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563NK	12069674	Bronze			2022-12-28	WOS:000176262300026
J	Perz, JF; Craig, AS; Coffey, CS; Jorgensen, DM; Mitchel, E; Hall, S; Schaffner, W; Griffin, MR				Perz, JF; Craig, AS; Coffey, CS; Jorgensen, DM; Mitchel, E; Hall, S; Schaffner, W; Griffin, MR			Changes in antibiotic prescribing for children after a community-wide campaign	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT STREPTOCOCCUS-PNEUMONIAE; RESPIRATORY-TRACT INFECTIONS; ANTIMICROBIAL RESISTANCE; JUDICIOUS USE; INTERVENTION; PHYSICIANS; IMPACT; SURVEILLANCE; PRINCIPLES; STRATEGIES	Context Overuse of antibiotics has contributed to microbial resistance, compromising the treatment of bacterial infections. Very high levels (>50%) of antibiotic resistance among invasive Streptococcus pneumoniae have been documented in Knox County, Tennessee. Objective To determine the effectiveness of a community-wide intervention aimed at reducing inappropriate antibiotic use among children. Design, Setting, and Participants The Knox County Health Department led a multifaceted year-long campaign (May 1997 through April 1998) aimed at decreasing unnecessary antibiotic use among children, Tennessee's 3 other major urban counties (Shelby, Hamilton, and Davidson) did not conduct similar campaigns and served as controls. Evaluation included white and black children (aged <15 years) enrolled in Tennessee's Medicaid Managed Care Program in the 4 study counties, representing 36% of the study counties' children (464200 person-years observed). Intervention Educational efforts were directed toward health care practitioners (primarily via peer leader presentations) and to the parents of young children and the public (primarily via printed materials). Main Outcome Measure The intervention-attributable effect on antibiotic use, defined as the excess percentage change in oral antibiotic prescription rates in Knox County between the 12-month preintervention and postintervention periods, relative to that of control counties. Results Antibiotic prescription rates declined 19% and 8% among Knox County and control county children, respectively, yielding an 11% intervention-attributable decline (95% confidence interval, 8%-14%; P < .001). The intervention-attributable decrease in prescription rates was greatest among children aged 1 to less than 5 years (among white children, 8% [P < .001]; among black children, 18% [P < .001]). Conclusions A community-wide educational intervention reduced antibiotic prescription levels among children in Knox County.	Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA USA; Tennessee Dept hlth, Communicable & Environm Dis Serv, Nashville, TN USA; Knox Cty Hlth Dept, Knoxville, TN USA	Vanderbilt University; Centers for Disease Control & Prevention - USA; Tennessee Department Health	Griffin, MR (corresponding author), Vanderbilt Univ, Sch Med, Dept Prevent Med, A-1124,Med Ctr N, Nashville, TN 37232 USA.	Marie.Griffin@vanderbilt.edu			ODCDC CDC HHS [U50/CCU416123, UR6 CCU417579] Funding Source: Medline	ODCDC CDC HHS		Arnold SR, 1999, CLIN INFECT DIS, V29, P312, DOI 10.1086/520207; Austin DJ, 1999, P NATL ACAD SCI USA, V96, P1152, DOI 10.1073/pnas.96.3.1152; Barden LS, 1998, CLIN PEDIATR, V37, P665, DOI 10.1177/000992289803701104; Bauchner H, 1998, PEDIATRICS, V102, P142, DOI 10.1542/peds.102.1.142; Bauchner H, 1999, PEDIATRICS, V103, P395, DOI 10.1542/peds.103.2.395; Bell DM, 2001, CLIN INFECT DIS, V33, pS245, DOI 10.1086/321857; Belongia EA, 1998, BRIT MED J, V317, P668, DOI 10.1136/bmj.317.7159.668; Belongia EA, 2001, PEDIATRICS, V108, P575, DOI 10.1542/peds.108.3.575; Bondy J, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.6.e72; Cameron AC., 2013, REGRESSION ANAL COUN, V2nd ed, DOI 10.1017/CBO9781139013567; *CDCP, 2001, PUBL HLTH ACT PLAN C; Craig AS, 1999, CLIN INFECT DIS, V29, P1257, DOI 10.1086/313451; Dowell SF, 1998, PEDIATRICS, V101, P163; EMIGH RC, 1999, NOVARTIS PHARM BENEF; Emmer CL, 2002, INFECT MED, V19, P160; Finkelstein JA, 2001, PEDIATRICS, V108, pU113; Freid V M, 1998, Vital Health Stat 13, P1; Gonzales R, 2001, ANN INTERN MED, V134, P479, DOI 10.7326/0003-4819-134-6-200103200-00013; Gonzales R, 1999, JAMA-J AM MED ASSOC, V281, P1512, DOI 10.1001/jama.281.16.1512; Jernigan DB, 1996, JAMA-J AM MED ASSOC, V275, P206, DOI 10.1001/jama.275.3.206; Levy SB, 1997, CIBA F SYMP, V207, P1; Mainous AG, 2000, FAM MED, V32, P22; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MCCAIG LF, 2000, 38 ANN M INF DIS SOC; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1235, DOI 10.1001/jama.274.15.1235; Nyquist AC, 1998, JAMA-J AM MED ASSOC, V279, P875, DOI 10.1001/jama.279.11.875; Pappas DE, 2000, SOUTHERN MED J, V93, P575; Perz JF, 2001, AM J EPIDEMIOL, V154, P1000, DOI 10.1093/aje/154.11.1000; PETERSEN KL, 1999, 37 ANN M INF DIS SOC; Schrag SJ, 2000, CLIN MICROBIOL REV, V13, P588, DOI 10.1128/CMR.13.4.588-601.2000; Schuchat A, 2001, EMERG INFECT DIS, V7, P92, DOI 10.3201/eid0701.010114; Schwartz B, 1999, CLIN INFECT DIS, V28, P211, DOI 10.1086/515115; Schwartz B, 1997, JAMA-J AM MED ASSOC, V278, P944, DOI 10.1001/jama.278.11.944; Skull SA, 2000, ARCH PEDIAT ADOL MED, V154, P180, DOI 10.1001/archpedi.154.2.180; *US BUR CENS, 2000, CO999; Watson RL, 1999, PEDIATRICS, V104, P1251, DOI 10.1542/peds.104.6.1251; Wenzel RP, 2000, NEW ENGL J MED, V343, P1961, DOI 10.1056/NEJM200012283432610; Whitney CG, 2000, NEW ENGL J MED, V343, P1917, DOI 10.1056/NEJM200012283432603; World Health Organization, 1977, INT CLASS DIS	39	136	140	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	2002	287	23					3103	3109		10.1001/jama.287.23.3103	http://dx.doi.org/10.1001/jama.287.23.3103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563NK	12069673				2022-12-28	WOS:000176262300025
J	Roubik, DW				Roubik, DW			Tropical agriculture - The value of bees to the coffee harvest	NATURE			English	Article									Smithsonian Trop Res Inst, Unit 0948, APO, AA 34002 USA	Smithsonian Institution; Smithsonian Tropical Research Institute	Roubik, DW (corresponding author), Smithsonian Trop Res Inst, Unit 0948, APO, AA 34002 USA.	roubikd@tivoli.si.edu						FREE J. B., 1955, INSECTES SOCIAUX, V2, P195, DOI 10.1007/BF02224381; Lyngbaek AE, 2001, AGROFOREST SYST, V53, P205, DOI 10.1023/A:1013332722014; MUNSCHLER RG, 2001, AGROFOREST SYST, V51, P131; ROUBIK DW, 1978, SCIENCE, V201, P1030, DOI 10.1126/science.201.4360.1030; ROUBIK DW, IN PRESS INT WORKSH	5	120	125	2	62	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 13	2002	417	6890					708	708		10.1038/417708a	http://dx.doi.org/10.1038/417708a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	561QY	12066176				2022-12-28	WOS:000176154700035
J	Berger, A				Berger, A			Science commentary: Probiotics	BRITISH MEDICAL JOURNAL			English	Editorial Material							ANTIBIOTIC-ASSOCIATED DIARRHEA; PLACEBO-CONTROLLED TRIAL; CLOSTRIDIUM-DIFFICILE COLITIS; CASEI STRAIN SHIROTA; SACCHAROMYCES-BOULARDII; LACTOBACILLUS GG; DOUBLE-BLIND; BIFIDOBACTERIUM-LONGUM; BIOTHERAPEUTIC AGENTS; TRAVELERS DIARRHEA											Adam J, 1977, GAZ MED FR, V84, P2072; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BELLOMO G, 1980, CURR THER RES CLIN E, V28, P927; Benno Y., 1996, NUTR TODAY, V31, p12S, DOI [10.1097/00017285-199611001-00004, DOI 10.1097/00017285-199611001-00004]; Berg RD, 1998, TRENDS MICROBIOL, V6, P89, DOI 10.1016/S0966-842X(98)01224-4; BILLER JA, 1995, J PEDIATR GASTR NUTR, V21, P224, DOI 10.1097/00005176-199508000-00016; Black FT, 1989, TRAVEL MED, V7, P333, DOI DOI 10.1007/978-3-642-73772-5_70; BLEHAUT H, 1989, BIOPHARM DRUG DISPOS, V10, P353, DOI 10.1002/bdd.2510100403; Bleichner G, 1997, INTENS CARE MED, V23, P517, DOI 10.1007/s001340050367; BORGIA M, 1983, CURR THER RES CLIN E, V33, P214; BUTS JP, 1993, J PEDIATR GASTR NUTR, V16, P419, DOI 10.1097/00005176-199305000-00013; Castagliuolo I, 1999, INFECT IMMUN, V67, P302, DOI 10.1128/IAI.67.1.302-307.1999; CHAPOY P, 1985, ANN PEDIATR-PARIS, V32, P561; CHICOINE L, 1973, UNION MED CAN, V102, P1114; CLEMENTS ML, 1981, ANTIMICROB AGENTS CH, V20, P104, DOI 10.1128/AAC.20.1.104; COLOMBEL JF, 1987, LANCET, V2, P43; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Elmer GW, 1996, JAMA-J AM MED ASSOC, V275, P870, DOI 10.1001/jama.275.11.870; FULLER R, 1991, GUT, V32, P439, DOI 10.1136/gut.32.4.439; GORBACH SL, 1987, LANCET, V2, P1519; Gorbach SL, 1996, NUTR TODAY, V31, P25, DOI DOI 10.1097/00017285-199611001-00002; GOTZ V, 1979, AM J HOSP PHARM, V36, P754, DOI 10.1093/ajhp/36.6.754; Guandalini S, 2000, J PEDIATR GASTR NUTR, V30, P54, DOI 10.1097/00005176-200001000-00018; HARTY DWS, 1994, INT J FOOD MICROBIOL, V24, P179, DOI 10.1016/0168-1605(94)90117-1; ISOLAURI E, 1994, DIGEST DIS SCI, V39, P2595, DOI 10.1007/BF02087695; ISOLAURI E, 1991, PEDIATRICS, V88, P90; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; KATELARIS PH, 1995, NEW ENGL J MED, V333, P1360, DOI 10.1056/NEJM199511163332016; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; Kollaritsch H, 1993, FORTSCHR MED, V11, P153; LEVY J, 1997, GASTROENTEROLOGY, V112, pA397; Lewis SJ, 1998, J INFECTION, V36, P171, DOI 10.1016/S0163-4453(98)80008-X; McCullough MJ, 1998, J CLIN MICROBIOL, V36, P2613, DOI 10.1128/JCM.36.9.2613-2617.1998; MCFARLAND LV, 1995, AM J GASTROENTEROL, V90, P439; McFarland LV, 1996, CLIN INFECT DIS, V22, P200, DOI 10.1093/clinids/22.1.200; MCFARLAND LV, 1994, JAMA-J AM MED ASSOC, V271, P1913, DOI 10.1001/jama.271.24.1913; McFarland LV, 1995, MICROECOL T, V23, P46; MITRA AK, 1990, GASTROENTEROLOGY, V99, P1149, DOI 10.1016/0016-5085(90)90638-H; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Murch SH, 2001, LANCET, V357, P1057, DOI 10.1016/S0140-6736(00)04305-1; Niault M, 1999, CLIN INFECT DIS, V28, P930, DOI 10.1086/517255; Oberhelman RA, 1999, J PEDIATR-US, V134, P15, DOI 10.1016/S0022-3476(99)70366-5; OKSANEN PJ, 1990, ANN MED, V22, P53, DOI 10.3109/07853899009147242; ORRHAGE K, 1994, MICROB ECOL HEALTH D, V7, P17, DOI 10.3109/08910609409141570; PEARCE JL, 1974, J PEDIATR-US, V84, P261, DOI 10.1016/S0022-3476(74)80618-9; POZOOLANO JDD, 1978, GASTROENTEROLOGY, V74, P829; REID G, 1992, CLIN THER, V14, P11; SAAVEDRA JM, 1994, LANCET, V344, P1046, DOI 10.1016/S0140-6736(94)91708-6; SAINTMARC T, 1991, ANN MED INTERNE, V142, P64; SCHELLENBERG D, 1994, LANCET, V343, P171, DOI 10.1016/S0140-6736(94)90960-1; Schlegel L, 1998, EUR J CLIN MICROBIOL, V17, P887, DOI 10.1007/s100960050216; SIITONEN S, 1990, ANN MED, V22, P57, DOI 10.3109/07853899009147243; Spanhaak S, 1998, EUR J CLIN NUTR, V52, P899, DOI 10.1038/sj.ejcn.1600663; SURAWICZ CM, 1989, GASTROENTEROLOGY, V96, P981, DOI 10.1016/0016-5085(89)91613-2; Szajewska H, 2001, J PEDIATR GASTR NUTR, V33, pS17, DOI 10.1097/00005176-200110002-00004; TANKANOW RM, 1990, DICP ANN PHARMAC, V24, P382, DOI 10.1177/106002809002400408; TOJO M, 1987, Acta Paediatrica Japonica, V29, P160; Vanderhoof JA, 1999, J PEDIATR-US, V135, P564, DOI 10.1016/S0022-3476(99)70053-3; WALTERS BAJ, 1983, GUT, V24, P206, DOI 10.1136/gut.24.3.206; WUNDERLICH PF, 1989, J INT MED RES, V17, P333, DOI 10.1177/030006058901700405; Yuki N, 1999, INT J FOOD MICROBIOL, V48, P51, DOI 10.1016/S0168-1605(99)00029-X	61	2	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 8	2002	324	7350					1364	1364B		10.1136/bmj.324.7350.1364	http://dx.doi.org/10.1136/bmj.324.7350.1364			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BQ	12052802	Green Published, Bronze			2022-12-28	WOS:000176234100017
J	McKerracher, L; Ellezam, B				McKerracher, L; Ellezam, B			Development: Putting the brakes on regeneration	SCIENCE			English	Editorial Material							GANGLION-CELL AXONS; RAT OPTIC-NERVE; POLARITY; NEURONS; INJURY; FIBERS; CNS		Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ H3T 1J4, Canada	Universite de Montreal	McKerracher, L (corresponding author), Univ Montreal, Dept Pathol & Biol Cellulaire, 2900 Edouard Montpetit, Montreal, PQ H3T 1J4, Canada.							Bartsch U, 1995, NEURON, V15, P1375, DOI 10.1016/0896-6273(95)90015-2; Berry M, 1996, J NEUROCYTOL, V25, P147, DOI 10.1007/BF02284793; CHO EYP, 1989, EXP BRAIN RES, V78, P567; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; DERGHAM P, IN PRESS J NEUROSCI; Goldberg JL, 2002, SCIENCE, V296, P1860, DOI 10.1126/science.1068428; GOSLIN K, 1989, J CELL BIOL, V108, P1507, DOI 10.1083/jcb.108.4.1507; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Leon S, 2000, J NEUROSCI, V20, P4615, DOI 10.1523/JNEUROSCI.20-12-04615.2000; MCKERRACHER L, 1990, J NEUROSCI, V10, P641; MCQUARRIE IG, 1984, AXONAL TRANSPORT NEU, P185; Neumann S, 1999, NEURON, V23, P83, DOI 10.1016/S0896-6273(00)80755-2; VIDALSANZ M, 1987, J NEUROSCI, V7, P2894; WEIBEL D, 1994, BRAIN RES, V642, P259, DOI 10.1016/0006-8993(94)90930-X	14	1	1	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 7	2002	296	5574					1819	1820		10.1126/science.1073590	http://dx.doi.org/10.1126/science.1073590			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052945				2022-12-28	WOS:000176054300033
J	Morice, M; Serruys, PW; Sousa, JE; Fajadet, J; Hayashi, EB; Perin, M; Colombo, A; Schuler, G; Barragan, P; Guagliumi, G; Molnar, F; Falotico, R				Morice, M; Serruys, PW; Sousa, JE; Fajadet, J; Hayashi, EB; Perin, M; Colombo, A; Schuler, G; Barragan, P; Guagliumi, G; Molnar, F; Falotico, R		RAVEL Study Grp	A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BALLOON ANGIOPLASTY; ARTERY DISEASE; INTRAVASCULAR ULTRASOUND; NEOINTIMAL FORMATION; COATED STENTS; RESTENOSIS; IMPLANTATION; ATHERECTOMY; RAPAMYCIN; MECHANISMS	Background: The need for repeated treatment of restenosis of a treated vessel remains the main limitation of percutaneous coronary revascularization. Because sirolimus (rapamycin) inhibits the proliferation of lymphocytes and smooth-muscle cells, we compared a sirolimus-eluting stent with a standard uncoated stent in patients with angina pectoris. Methods: We performed a randomized, double-blind trial to compare the two types of stents for revascularization of single, primary lesions in native coronary arteries. The trial included 238 patients at 19 medical centers. The primary end point was in-stent late luminal loss (the difference between the minimal luminal diameter immediately after the procedure and the diameter at six months). Secondary end points included the percentage of in-stent stenosis of the luminal diameter and the rate of restenosis (luminal narrowing of 50 percent or more). We also analyzed a composite clinical end point consisting of death, myocardial infarction, and percutaneous or surgical revascularization at 1, 6, and 12 months. Results: At six months, the degree of neointimal proliferation, manifested as the mean (+/-SD) late luminal loss, was significantly lower in the sirolimus-stent group (-0.01+/-0.33 mm) than in the standard-stent group (0.80+/-0.53 mm, P<0.001). None of the patients in the sirolimus-stent group, as compared with 26.6 percent of those in the standard-stent group, had restenosis of 50 percent or more of the luminal diameter (P<0.001). There were no episodes of stent thrombosis. During a follow-up period of up to one year, the overall rate of major cardiac events was 5.8 percent in the sirolimus-stent group and 28.8 percent in the standard-stent group (P<0.001). The difference was due entirely to a higher rate of revascularization of the target vessel in the standard-stent group. Conclusions: As compared with a standard coronary stent, a sirolimus-eluting stent shows considerable promise for the prevention of neointimal proliferation, restenosis, and associated clinical events.	Inst Cardiovasc Paris Sud, Massy, France; Erasmus Univ, Thoraxctr, NL-3000 DR Rotterdam, Netherlands; Inst Dante Pazzanese Cardiol, Sao Paulo, Brazil; Clin Pasteur, Toulouse, France; Inst Nacl Cardiol Ignacio Chavez, Mexico City, DF, Mexico; Univ Sao Paulo, Inst Heart, Sao Paulo, Brazil; Ctr Cuore Columbus, Milan, Italy; Herzzentrum, Leipzig, Germany; Ctr Hosp Prive Beauregard, Marseille, France; Osped Riuniti Bergamo, Azienda Osped, I-24100 Bergamo, Italy; Semmelweis Univ, Egeszegtudomanyi Kar, Budapest, Hungary; Johnson & Johnson, Cordis, Warren, NJ USA	UDICE-French Research Universities; Universite Paris Saclay; Erasmus University Rotterdam; Erasmus MC; Instituto Dante Pazzanese de Cardiologia; National Institute of Cardiology - Mexico; Universidade de Sao Paulo; Heart Center Leipzig GMBH; Ospedali Riuniti di Bergamo; Semmelweis University; Johnson & Johnson; Johnson & Johnson USA	Morice, M (corresponding author), Inst Hosp Jacques Cartier, Ave Noyer Lambert, F-91300 Massy, France.		Guagliumi, Giulio/K-8006-2016; Perin, Marco A/O-2309-2014					Baim DS, 1998, CIRCULATION, V97, P322; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; Burke SE, 1999, J CARDIOVASC PHARM, V33, P829, DOI 10.1097/00005344-199906000-00001; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; de Feyter PJ, 2000, Curr Interv Cardiol Rep, V2, P326; DUSSAILLANT GR, 1995, J AM COLL CARDIOL, V26, P720, DOI 10.1016/0735-1097(95)00249-4; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Gallo R, 1999, CIRCULATION, V99, P2164, DOI 10.1161/01.CIR.99.16.2164; Hoffmann R, 1996, CIRCULATION, V94, P1247, DOI 10.1161/01.CIR.94.6.1247; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; Kastrati A, 2000, CIRCULATION, V101, P2478, DOI 10.1161/01.CIR.101.21.2478; KUNTZ RE, 1992, J AM COLL CARDIOL, V19, P1493, DOI 10.1016/0735-1097(92)90609-Q; Marx SO, 2001, CIRCULATION, V104, P852, DOI 10.1161/01.CIR.104.8.852; Mehran R, 2000, CIRCULATION, V101, P2484, DOI 10.1161/01.CIR.101.21.2484; Mudra H, 2001, CIRCULATION, V104, P1343, DOI 10.1161/hc3701.096064; ROUBIN GS, 1992, CIRCULATION, V85, P916, DOI 10.1161/01.CIR.85.3.916; Saunders RN, 2001, KIDNEY INT, V59, P3, DOI 10.1046/j.1523-1755.2001.00460.x; Serruys P, 1998, LANCET, V352, P1478; Serruys PW, 2001, NEW ENGL J MED, V344, P1117, DOI 10.1056/NEJM200104123441502; Serruys PW, 2000, CIRCULATION, V102, P2930; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; Sousa JE, 2001, CIRCULATION, V103, P192; Suzuki T, 2001, CIRCULATION, V104, P1188, DOI 10.1161/hc3601.093987; Teirstein PS, 1997, NEW ENGL J MED, V336, P1697, DOI 10.1056/NEJM199706123362402; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; Versaci F, 1997, NEW ENGL J MED, V336, P817, DOI 10.1056/NEJM199703203361201	27	3091	3431	2	186	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 6	2002	346	23					1773	1780		10.1056/NEJMoa012843	http://dx.doi.org/10.1056/NEJMoa012843			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	559EK	12050336	Green Published			2022-12-28	WOS:000176012500002
J	Spyridonidis, A; Otto, F; Kraft, A; von Kalle, C				Spyridonidis, A; Otto, F; Kraft, A; von Kalle, C			Antibiotics for weight loss, osteolysis, hepatic and adrenal tumours	LANCET			English	Editorial Material							SYPHILIS		Univ Freiburg, Div Hematol & Oncol, D-79106 Freiburg, Germany	University of Freiburg	Spyridonidis, A (corresponding author), Univ Freiburg, Div Hematol & Oncol, Hugstetter Str 55, D-79106 Freiburg, Germany.							CLARK EG, 1964, MED CLIN N AM, V48, P613; Gerbase AC, 1998, LANCET, V351, P2, DOI 10.1016/S0140-6736(98)90001-0; Hook EW, 1998, LANCET, V351, P19; HOOK EW, 1992, NEW ENGL J MED, V326, P1060, DOI 10.1056/NEJM199204163261606; OSLER W, 1950, OSLER APHORISMS, P134	5	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 25	2002	359	9320					1828	1828		10.1016/S0140-6736(02)08714-7	http://dx.doi.org/10.1016/S0140-6736(02)08714-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044379				2022-12-28	WOS:000175775500012
J	Bottomley, A				Bottomley, A			Metastatic colorectal cancer: treatment challenges and quality of life	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED TRIALS; OF-LIFE		European Org Res Treatment Canc, EORTC Data Ctr, Qual Life Unit, B-1200 Brussels, Belgium	European Organisation for Research & Treatment of Cancer	Bottomley, A (corresponding author), European Org Res Treatment Canc, EORTC Data Ctr, Qual Life Unit, B-1200 Brussels, Belgium.	abo@eortc.be						Bottomley A, 2002, LANCET ONCOL, V3, P145, DOI 10.1016/S1470-2045(02)00677-0; Colorectal Canc Collaborative Grp, 2000, BMJ-BRIT MED J, V321, P531; Fayers P., 2007, QUALITY LIFE ASSESSM; FLECHTNER H, 2002, EXPERT REV PHARM OUT, V2, P89; Kong SX, 1997, ANN PHARMACOTHER, V31, P830, DOI 10.1177/106002809703100703; Kramer JA, 2000, EUR J CANCER, V36, P1488, DOI 10.1016/S0959-8049(00)00134-9; Marshall M, 2000, BRIT J PSYCHIAT, V176, P249, DOI 10.1192/bjp.176.3.249; Sanders C, 1998, BRIT MED J, V317, P1191, DOI 10.1136/bmj.317.7167.1191	8	3	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 4	2002	359	9317					1537	1538		10.1016/S0140-6736(02)08526-4	http://dx.doi.org/10.1016/S0140-6736(02)08526-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047959				2022-12-28	WOS:000175460700003
J	Terlau, H; Shon, KJ; Grilley, M; Stocker, M; Stuhmer, W; Olivera, BM				Terlau, H; Shon, KJ; Grilley, M; Stocker, M; Stuhmer, W; Olivera, BM			Strategy for rapid immobilization of prey by a fish-hunting marine snail	NATURE			English	Article							AMINO-ACID-SEQUENCE; POTASSIUM CHANNEL; DROSOPHILA; DIVERSITY; SHAKER; GENE; PATCHES; TOXIN; BRAIN	SOME venomous animals capture prey with remarkable efficiency and speed. The purple cone, Conus purpurascens, uses two parallel physiological mechanisms requiring multiple neurotoxins to immobilize fish rapidly: neuromuscular block(1), and excitotoxic shock, The latter requires the newly characterized peptide kappa-conotoxin PVIIA, which inhibits the Shaker potassium channel(2-4), and delta-conotoxin PVIA(5), which delays sodium-channel inactivation, Despite the extreme biochemical diversity in venoms, the number of effective strategic alternatives for prey capture are limited. How securely prey is initially tethered may strongly influence the venom strategy evolved by a predator.	MAX PLANCK INST EXPTL MED, MOL BIOL NEURONALER SIGNALE, D-37075 GOTTINGEN, GERMANY; UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA	Max Planck Society; Utah System of Higher Education; University of Utah			Stocker, Martin/C-1844-2008; Stuehmer, Walter/A-2176-2009	Stuehmer, Walter/0000-0002-0642-7764				ANEIROS A, 1993, BIOCHIM BIOPHYS ACTA, V1157, P86, DOI 10.1016/0304-4165(93)90082-J; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BERESS L, 1977, H-S Z PHYSIOL CHEM, V358, P985, DOI 10.1515/bchm2.1977.358.2.985; CASTANEDA O, 1995, TOXICON, V33, P603, DOI 10.1016/0041-0101(95)00013-C; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOPKINS C, 1995, J BIOL CHEM, V270, P22361, DOI 10.1074/jbc.270.38.22361; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KARLSSON E, 1991, TOXICON, V29, P521, DOI 10.1016/0041-0101(91)90027-O; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAZDUNSKI M, 1986, ANN NY ACAD SCI, V479, P204, DOI 10.1111/j.1749-6632.1986.tb15571.x; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; Rathmayer W, 1979, Adv Cytopharmacol, V3, P335; SATHER W, 1992, J PHYSIOL-LONDON, V450, P643, DOI 10.1113/jphysiol.1992.sp019148; SCHWEITZ H, 1995, J BIOL CHEM, V270, P25121, DOI 10.1074/jbc.270.42.25121; SEIFERT W, 1983, NEUROBIOLOGY HIPPOCA, P109; SHON KJ, 1995, BIOCHEMISTRY-US, V34, P4913, DOI 10.1021/bi00015a002; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; STUHMER W, 1992, METHOD ENZYMOL, V207, P319	24	241	255	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	1996	381	6578					148	151		10.1038/381148a0	http://dx.doi.org/10.1038/381148a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	12074021				2022-12-28	WOS:A1996UK13900047
J	Zwally, HJ; Abdalati, W; Herring, T; Larson, K; Saba, J; Steffen, K				Zwally, HJ; Abdalati, W; Herring, T; Larson, K; Saba, J; Steffen, K			Surface melt-induced acceleration of Greenland ice-sheet flow	SCIENCE			English	Article							VELOCITY; SURGE	Ice flow at a location in the equilibrium zone of the west-central Greenland Ice Sheet accelerates above the midwinter average rate during periods of summer melting. The near coincidence of the ice acceleration with the duration of surface melting, followed by deceleration after the melting ceases, indicates that glacial sliding is enhanced by rapid migration of surface meltwater to the ice-bedrock interface. Interannual variations in the ice acceleration are correlated with variations in the intensity of the surface melting, with larger increases accompanying higher amounts of summer melting. The indicated coupling between surface melting and ice-sheet flow provides a mechanism for rapid, large-scale, dynamic responses of ice sheets to climate warming.	NASA, Oceans & Ice Branch, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; NASA Headquarters, Washington, DC 20546 USA; MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; Univ Colorado, Dept Aerosp Engn Sci, Boulder, CO 80309 USA; NASA, Raytheon Inc, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Univ Colorado, CIRES, Boulder, CO 80309 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; National Aeronautics & Space Administration (NASA); Massachusetts Institute of Technology (MIT); University of Colorado System; University of Colorado Boulder; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of Colorado System; University of Colorado Boulder	Zwally, HJ (corresponding author), NASA, Oceans & Ice Branch, Goddard Space Flight Ctr, Code 971, Greenbelt, MD 20771 USA.	jay.zwally@gsfc.nasa.gov	Steffen, Konrad/C-6027-2013; Larson, Kristine M/J-7623-2018	Steffen, Konrad/0000-0001-8658-1026; Larson, Kristine M/0000-0003-4666-8885; Herring, Thomas/0000-0002-6030-0545				Abdalati W, 2001, J GEOPHYS RES-ATMOS, V106, P33983, DOI 10.1029/2001JD900181; ALLEY RB, 1984, J GEOPHYS RES-OCEANS, V89, P6487, DOI 10.1029/JC089iC04p06487; Bindschadler R., 1977, J GLACIOL, V18, P181, DOI [10.1017/S0022143000021298, DOI 10.1017/S0022143000021298]; BRAITHWAITE RJ, 1989, GLAC QUAT G, V6, P219; Braithwaite RJ., 1990, ANN GLACIOL, V14, P20; Clark PU, 1999, SCIENCE, V286, P1104, DOI 10.1126/science.286.5442.1104; ECHELMEYER K, 1990, J GLACIOL, V36, P82, DOI 10.3189/S0022143000005591; GUNDMUNDSSON GH, 2000, ANN GLACIOL, V31, P63; HERRING TA, 2001, DOCUMENTATION GLOBK; Houghton J. T., 2001, CLIMATE CHANGE 2001; Huybrechts P, 1999, J CLIMATE, V12, P2169, DOI 10.1175/1520-0442(1999)012<2169:TDROTG>2.0.CO;2; IKEN A, 1983, J GLACIOL, V29, P28, DOI 10.3189/S0022143000005128; Iken A, 1978, Z GLETSCHERKUNDE GLA, V13, P23; Joughin I, 1996, SCIENCE, V274, P228, DOI 10.1126/science.274.5285.228; King RW, 2001, DOCUMENTATION GAMIT; KOERNER RM, 1989, SCIENCE, V244, P964, DOI 10.1126/science.244.4907.964; LARSON K, 2002, POLAR GEOGR, V25, P22; LUTHI M, IN PRESS J GLACIOL; Mohr JJ, 1998, NATURE, V391, P273, DOI 10.1038/34635; OHMURA A, 1991, 1 ETH DEP GEOGR; RAYMOND CF, 1987, J GEOPHYS RES-SOLID, V92, P9121, DOI 10.1029/JB092iB09p09121; REEH N, 1985, NATURE, V317, P797, DOI 10.1038/317797a0; REEH N, 1986, ANN GLACIOL, V8, P146; Rignot E, 2001, J GEOPHYS RES-ATMOS, V106, P34007, DOI 10.1029/2001JD900071; Ritz C, 1996, CLIM DYNAM, V13, P11, DOI 10.1007/s003820050149; Robin G. Q., 1974, J GLACIOL, V13, P543, DOI 10.3189/S0022143000023285; Scambos TA, 2000, J GLACIOL, V46, P516, DOI 10.3189/172756500781833043; Steffen K, 2001, J GEOPHYS RES-ATMOS, V106, P33951, DOI 10.1029/2001JD900161; THOMSEN HH, 1998, 138 GRONL GEOL UND; WANG WL, IN PRESS ANN GLACIOL; Zwally HJ, 2001, J GEOPHYS RES-ATMOS, V106, P33717, DOI 10.1029/2001JD900120	31	755	770	4	187	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	2002	297	5579					218	222		10.1126/science.1072708	http://dx.doi.org/10.1126/science.1072708			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12052902				2022-12-28	WOS:000176738100032
J	Audet, AMJ; Hartman, EE				Audet, AMJ; Hartman, EE			A 40-year-old woman who noticed a medication error, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Bates DW, 2001, JAMA-J AM MED ASSOC, V285, P3134, DOI 10.1001/jama.285.24.3134	1	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	2002	287	24					3258	3258		10.1001/jama.287.24.3258	http://dx.doi.org/10.1001/jama.287.24.3258			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566FF	12076223				2022-12-28	WOS:000176415800031
J	Edwards, SGM; Playford, ED; Hobart, JC; Thompson, AJ				Edwards, SGM; Playford, ED; Hobart, JC; Thompson, AJ			Comparison of physician outcome measures and patients' perception of benefits of inpatient neurorehabilitation	BRITISH MEDICAL JOURNAL			English	Article							REHABILITATION; UNIT		UCL Natl Hosp Neurol & Neurosurg, Inst Neurol, London WC1N 3BG, England; UCL Natl Hosp Neurol & Neurosurg, Neurorehabil Unit, London WC1N 3BG, England; Derriford Hosp, Plymouth PL6 8DH, Devon, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Derriford Hospital	Thompson, AJ (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Inst Neurol, Queen Sq, London WC1N 3BG, England.	A.Thompson@ion.ucl.ac.uk	Playford, Diane/F-1467-2010; Thompson, Alan J/C-2654-2008	Thompson, Alan J/0000-0002-4333-8496; Playford, E Diane/0000-0001-7314-787X	Multiple Sclerosis Society [491] Funding Source: Medline	Multiple Sclerosis Society(National Multiple Sclerosis Society)		Freeman JA, 1996, J ROY COLL PHYS LOND, V30, P21; Hobart JC, 1996, CURR OPIN NEUROL, V9, P441, DOI 10.1097/00019052-199612000-00008; Indredavik B, 1998, STROKE, V29, P895, DOI 10.1161/01.STR.29.5.895; Wade DT, 2000, BMJ-BRIT MED J, V320, P1385, DOI 10.1136/bmj.320.7246.1385; Wade DT., 1992, MEASUREMENT NEUROLOG	5	20	20	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 22	2002	324	7352					1493	1493		10.1136/bmj.324.7352.1493	http://dx.doi.org/10.1136/bmj.324.7352.1493			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567ZL	12077034	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000176517900019
J	Primakoff, P; Myles, DG				Primakoff, P; Myles, DG			Penetration, adhesion, and fusion in mammalian sperm-egg interaction	SCIENCE			English	Review							SEQUENCE-SPECIFIC INTERACTION; SITE-DIRECTED MUTAGENESIS; ZONA-PELLUCIDA; MOUSE SPERM; PLASMA-MEMBRANE; FERTILIN-BETA; DISINTEGRIN DOMAIN; INTEGRIN ALPHA-6-BETA-1; CD9-DEFICIENT MICE; ACROSOME REACTION	Fertilization is the sum of the cellular mechanisms that pass the genome from one generation to the next and initiate development of a new organism. A typical, ovulated mammalian egg is enclosed by two layers: an outer layer of similar to5000 cumulus cells and an inner, thick extracellular matrix, the zona pellucida. To reach the egg plasma membrane, sperm must penetrate both layers in steps requiring sperm motility, sperm surface enzymes, and probably sperm-secreted enzymes. Sperm also bind transiently to the egg zona pellucida and the egg plasma membrane and then fuse. Signaling in the sperm is induced by sperm adhesion to the zona pellucida, and signaling in the egg by gamete fusion. The gamete molecules and molecular interactions with essential roles in these events are gradually being discovered.	Univ Calif Davis, Sch Med, Dept Cell Biol, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cell Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Primakoff, P (corresponding author), Univ Calif Davis, Sch Med, Dept Cell Biol, Davis, CA 95616 USA.	pdprimakoff@ucdavis.edu; dgmyles@ucdavis.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016580, R01HD016580, U54HD029125] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-16580, U54 HD-29125] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Bigler D, 2000, J BIOL CHEM, V275, P11576, DOI 10.1074/jbc.275.16.11576; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Chen H, 1999, CHEM BIOL, V6, P1, DOI 10.1016/S1074-5521(99)80015-5; Chen J, 1998, P NATL ACAD SCI USA, V95, P6193, DOI 10.1073/pnas.95.11.6193; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; Coonrod SA, 1999, DEV BIOL, V207, P334, DOI 10.1006/dbio.1998.9161; Easton RL, 2000, J BIOL CHEM, V275, P7731, DOI 10.1074/jbc.275.11.7731; Ensslin M, 1998, BIOL REPROD, V58, P1057, DOI 10.1095/biolreprod58.4.1057; Evans JD, 2001, BIOESSAYS, V23, P62, DOI 10.1002/1521-1878(200101)23:1&lt;62::AID-BIES1008&gt;3.0.CO;2-7; Foster JA, 1997, J BIOL CHEM, V272, P12714, DOI 10.1074/jbc.272.19.12714; Hagaman JR, 1998, P NATL ACAD SCI USA, V95, P2552, DOI 10.1073/pnas.95.5.2552; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Hickox JR, 2001, J BIOL CHEM, V276, P41502, DOI 10.1074/jbc.M106795200; Ikawa M, 2001, DEV BIOL, V240, P254, DOI 10.1006/dbio.2001.0462; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Kaji K, 2000, NAT GENET, V24, P279, DOI 10.1038/73502; KINLOCH RA, 1995, P NATL ACAD SCI USA, V92, P263, DOI 10.1073/pnas.92.1.263; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; LIN Y, 1994, J CELL BIOL, V125, P1157, DOI 10.1083/jcb.125.5.1157; Liu CY, 1996, P NATL ACAD SCI USA, V93, P5431, DOI 10.1073/pnas.93.11.5431; Lu QX, 1997, DEVELOPMENT, V124, P4121; Miller BJ, 2000, J CELL BIOL, V149, P1289, DOI 10.1083/jcb.149.6.1289; MILLER DJ, 1993, DEVELOPMENT, V118, P1279; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; Nishimura H, 2001, DEV BIOL, V233, P204, DOI 10.1006/dbio.2001.0166; O'Toole CMB, 2000, MOL BIOL CELL, V11, P1571, DOI 10.1091/mbc.11.5.1571; Ohmura K, 1999, J BIOL CHEM, V274, P29426, DOI 10.1074/jbc.274.41.29426; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Quill TA, 2001, P NATL ACAD SCI USA, V98, P12527, DOI 10.1073/pnas.221454998; Rankin T, 1996, DEVELOPMENT, V122, P2903; Rankin T, 1999, DEVELOPMENT, V126, P3847; Rankin TL, 2001, DEVELOPMENT, V128, P1119; Rankin TL, 1998, DEVELOPMENT, V125, P2415; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Runft LL, 2002, DEV BIOL, V245, P237, DOI 10.1006/dbio.2002.0600; Shamsadin R, 1999, BIOL REPROD, V61, P1445, DOI 10.1095/biolreprod61.6.1445; Takahashi Y, 2001, MOL BIOL CELL, V12, P809, DOI 10.1091/mbc.12.4.809; Wassarman PM, 1999, CELL, V96, P175, DOI 10.1016/S0092-8674(00)80558-9; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; YANAGIMACHI R, 1994, PHYSL REPROD, P152; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105; Zhu GZ, 2002, DEVELOPMENT, V129, P1995; Zhu GZ, 2001, J CELL SCI, V114, P1787	46	245	271	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	2002	296	5576					2183	2185		10.1126/science.1072029	http://dx.doi.org/10.1126/science.1072029			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077404				2022-12-28	WOS:000176379000045
J	Schwartz, LM; Woloshin, S				Schwartz, LM; Woloshin, S			News media coverage of screening mammography for women in their 40s and tamoxifen for primary prevention of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARCINOMA IN-SITU; DEBATE; TRIAL	Context In the late 1990s, 3 events pertaining to breast cancer prevention received considerable attention in the US news media: a National Institutes of Health (NIH) consensus panel recommended against routine screening mammography for women in their 40s (January 1997), the National Cancer Institute (NCI) subsequently reversed the recommendation (March 1997), and an NCI-sponsored study demonstrated the efficacy of tamoxifen in the primary prevention of breast cancer (April 1998). Objective To examine how the major US news media covered the potential benefits and harms of 2 breast cancer preventive strategies. Design and Setting Content analysis of US news stories reporting on the breast cancer prevention events. We used Lexis-Nexis to search for print news stories in the 10 highest-circulation US newspapers and requested transcripts from 3 major television networks to obtain all relevant news coverage in the 2 weeks following each event. Main Outcome Measures Attitude toward preventive strategy (encourage, neutral, discourage); level of uncertainty about benefit and how benefits and harms were presented. Results Twenty-seven stories about the NIH consensus panel, 24 about the NCI reversal, and 34 about tamoxifen appeared in high-profile news media within 2 weeks of each event. Sixty-seven percent of NIH consensus panel stories left the impression that there was a lot of uncertainty about whether women aged 40 to 49 years should undergo screening, but 59% suggested that women should probably or definitely be screened. Only 4 stories suggested that women faced a genuine decision about what to do. The level of uncertainty reported was substantially lower following the NCI reversal (21% suggested a lot of uncertainty), and most stories (96%) suggested that women should be screened. In contrast, tamoxifen stories highlighted uncertainty about what women at high risk should do (62% suggested there was a lot of uncertainty), and none left the impression that women should definitely take the drug (24% suggested they probably should). Sixty-five percent of these stories suggested that women faced a genuine choice and would have to weigh the risks and benefits themselves. Conclusions Most news stories favored routine use of screening mammography and urged caution about using tamoxifen. Almost all noted the potential harms of each preventive strategy; however, the negative aspects of tamoxifen received greater emphasis. Whereas taking tamoxifen was presented as a difficult decision, having a mammogram was presented as something women ought to do.	Dept Vet Affairs Med Ctr, VA Outcome Grp 111B, White River Jct, VT 05009 USA; Dartmouth Coll Sch Med, Ctr Evaluat Clin Sci, Hanover, NH USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Woloshin, S (corresponding author), Dept Vet Affairs Med Ctr, VA Outcome Grp 111B, White River Jct, VT 05009 USA.				NCI NIH HHS [R18 CA91052-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R18CA091052] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baxter N, 2001, CAN MED ASSOC J, V164, P1837; Centers for Disease Control and Prevention, 2002, BEH RISK FACT SURV S; Ernster V L, 1997, J Natl Cancer Inst Monogr, P151; Ernster VL, 1996, JAMA-J AM MED ASSOC, V275, P913, DOI 10.1001/jama.275.12.913; FISHER B, 1992, NAT SURG ADJ BREAST; Fletcher SW, 1997, NEW ENGL J MED, V336, P1180, DOI 10.1056/NEJM199704173361612; FORROW L, 1992, AM J MED, V92, P121, DOI 10.1016/0002-9343(92)90100-P; Gotzsche PC, 2000, LANCET, V355, P129, DOI 10.1016/S0140-6736(99)06065-1; MALENKA DJ, 1993, J GEN INTERN MED, V8, P543, DOI 10.1007/BF02599636; *MED RES INC, 1998, MED RES MAG TOT AUD; Miller AB, 2000, JNCI-J NATL CANCER I, V92, P1490, DOI 10.1093/jnci/92.18.1490; Moynihan R, 2000, NEW ENGL J MED, V342, P1645, DOI 10.1056/NEJM200006013422206; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; O'Malley M S, 1987, JAMA, V257, P2196, DOI 10.1001/jama.257.16.2196; Olsen O, 2001, LANCET, V358, P1340, DOI 10.1016/S0140-6736(01)06449-2; PAGE DL, 1995, CANCER, V76, P1197, DOI 10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0; Ransohoff DF, 1997, ANN INTERN MED, V127, P1029, DOI 10.7326/0003-4819-127-11-199712010-00016; Schwartz LM, 2000, BMJ-BRIT MED J, V320, P1635, DOI 10.1136/bmj.320.7250.1635; *US DEP HHS, 1997, BREAST CANC SCREEN W; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Welch HG, 1997, ANN INTERN MED, V127, P1023, DOI 10.7326/0003-4819-127-11-199712010-00014; Woloshin S, 2000, ARCH INTERN MED, V160, P1434, DOI 10.1001/archinte.160.10.1434	22	63	63	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	2002	287	23					3136	3142		10.1001/jama.287.23.3136	http://dx.doi.org/10.1001/jama.287.23.3136			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563NK	12069679	Bronze			2022-12-28	WOS:000176262300031
J	Lee, HN; Hesse, D; Zakharov, N; Gosele, U				Lee, HN; Hesse, D; Zakharov, N; Gosele, U			Ferroelectric Bi3.25La0.75Ti3O12 films of uniform a-axis orientation on silicon substrates	SCIENCE			English	Article							SRBI2TA2O9 THIN-FILMS; CHEMICAL-VAPOR-DEPOSITION; EPITAXIAL-GROWTH; BISMUTH TITANATE; LASER ABLATION; CAPACITORS; BI4TI3O12; SI(100); OXYGEN	The use of bismuth-layered perovskite films for planar-type nonvolatile ferroelectric random-access memories requires films with spontaneous polarization normal to the plane of growth. Epitaxially twinned a axis-oriented La-substituted Bi4Ti3O12 (BLT) thin films whose spontaneous polarization is entirely along the film normal were grown by pulsed laser deposition on yttria-stabilized zirconia-buffered Si(100) substrates using SrRuO3 as bottom electrodes. Even though the (118) orientation competes with the (100) orientation, epitaxial films with almost pure (100) orientation were grown using very thin, strained SrRuO3 electrode layers and kinetic growth conditions, including high growth rates and high oxygen background pressures to facilitate oxygen incorporation into the growing film. Films with the a-axis orientation and having their polarization entirely along the direction normal to the film plane can achieve a remanent polarization of 32 microcoulombs per square centimeter.	Max Planck Inst Mikrostrukturphys, D-06120 Halle Saale, Germany	Max Planck Society	Lee, HN (corresponding author), Max Planck Inst Mikrostrukturphys, Weinberg 2, D-06120 Halle Saale, Germany.		Lee, Ho Nyung/K-2820-2012	Lee, Ho Nyung/0000-0002-2180-3975				CUMMINS SE, 1968, J APPL PHYS, V39, P2268, DOI 10.1063/1.1656542; DEARAUJO CAP, 1995, NATURE, V374, P627, DOI 10.1038/374627a0; EOM CB, 1990, SCIENCE, V249, P1549, DOI 10.1126/science.249.4976.1549; FUJITA J, 1988, J APPL PHYS, V64, P1292, DOI 10.1063/1.341848; GEOHEGAN DB, 1992, APPL PHYS LETT, V60, P2732, DOI 10.1063/1.106859; GIRAULT C, 1989, APPL PHYS LETT, V55, P182, DOI 10.1063/1.102400; Gruverman A, 1999, APPL PHYS LETT, V75, P1452, DOI 10.1063/1.124722; HOU SY, 1995, APPL PHYS LETT, V67, P1387, DOI 10.1063/1.115542; Ishikawa K, 1999, APPL PHYS LETT, V75, P1970, DOI 10.1063/1.124888; KANAI M, 1990, APPL PHYS LETT, V57, P2716, DOI 10.1063/1.104194; KANEHORI K, 1989, J ELECTROCHEM SOC, V136, P1265, DOI 10.1149/1.2096903; KOREN G, 1989, APPL PHYS LETT, V54, P1920, DOI 10.1063/1.101496; Lee HN, 2000, J APPL PHYS, V88, P6658, DOI 10.1063/1.1321776; Lee HN, 2000, APPL PHYS LETT, V77, P3260, DOI 10.1063/1.1324982; Lee HN, 2000, APPL PHYS A-MATER, V71, P101; Lee HN, 2002, APPL PHYS LETT, V80, P1040, DOI 10.1063/1.1447321; Lee HN, 2001, APPL PHYS LETT, V79, P2961, DOI 10.1063/1.1415376; LEE HN, 2002, MAT RES S P, V688; Lettieri J, 2000, APPL PHYS LETT, V76, P2937, DOI 10.1063/1.126522; Moon SE, 1999, APPL PHYS LETT, V75, P2827, DOI 10.1063/1.125163; RAE AD, 1990, ACTA CRYSTALLOGR B, V46, P474, DOI 10.1107/S0108768190003251; RAMESH R, 1991, SCIENCE, V252, P944, DOI 10.1126/science.252.5008.944; Shimakawa Y, 2001, APPL PHYS LETT, V79, P2791, DOI 10.1063/1.1410877; Theis CD, 1998, APPL PHYS LETT, V72, P2817, DOI 10.1063/1.121468; WU SY, 1972, FERROELECTRICS, V3, P217, DOI 10.1080/00150197208235311; ZHONG Q, 1995, PHYSICA C, V246, P288, DOI 10.1016/0921-4534(95)00025-9	27	541	566	7	239	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 14	2002	296	5575					2006	2009		10.1126/science.1069958	http://dx.doi.org/10.1126/science.1069958			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065831				2022-12-28	WOS:000176273300046
J	Maiden, MCJ; Stuart, JM				Maiden, MCJ; Stuart, JM		UK Meningococcal Carriage Grp	Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination	LANCET			English	Article							VACCINES	The UK was the first place to introduce meningococcal serogroup C conjugate (MCC) vaccines. From November, 1999, all people younger than 18 years, about 14 million individuals, were offered MCC immunisation. The uptake rate was more than 70% by November, 2000. We compared the carriage of meningococci in isolates we obtained from 14 064 students aged 15-17 years during vaccination in 1999, with those from 16 583 students of the same age surveyed 1 year later. Carriage of serogroup C meningococci was reduced by 66% (p=0.004). Our results show that MCC vaccines protect against carriage of meningococci that express serogroup C polysaccharide capsules.	Univ Oxford, Dept Zool, Oxford OX1 3SY, England; Gloucester Royal Hosp, Publ Hlth Lab, Communicable Dis Surveillance Ctr SW, Gloucester, England	University of Oxford	Maiden, MCJ (corresponding author), Univ Oxford, Dept Zool, Peter Medawar Bldg Pathogen Res,S Parks Rd, Oxford OX1 3SY, England.		Maiden, Martin/N-6805-2019; Maiden, Martin C J/C-5055-2014; Evans, Meirion/C-2990-2008	Maiden, Martin/0000-0001-6321-5138; Maiden, Martin C J/0000-0001-6321-5138; Evans, Meirion/0000-0003-3578-1866	Wellcome Trust [062057] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		COLLETT D, 1991, MODELLING BINARY DAT, P199; Maiden MCJ, 1999, LANCET, V354, P615, DOI 10.1016/S0140-6736(99)00252-4; Miller E, 2001, VACCINE, V20, pS58, DOI 10.1016/S0264-410X(01)00299-7; Pollard AJ, 2000, PEDIATR INFECT DIS J, V19, P333, DOI 10.1097/00006454-200004000-00015; Ramsay ME, 2001, LANCET, V357, P195, DOI 10.1016/S0140-6736(00)03594-7	5	319	330	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 25	2002	359	9320					1829	1830		10.1016/S0140-6736(02)08679-8	http://dx.doi.org/10.1016/S0140-6736(02)08679-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044380				2022-12-28	WOS:000175775500013
J	Seeman, E				Seeman, E			Pathogenesis of bone fragility in women and men	LANCET			English	Article							RECEPTOR GENE POLYMORPHISMS; MINERAL DENSITY; VITAMIN-D; FEMORAL-NECK; OSTEOCLAST DIFFERENTIATION; VOLUMETRIC DENSITY; OSTEOPOROTIC FRACTURES; VERTEBRAL FRACTURES; GENDER-DIFFERENCES; II OSTEOPOROSIS	There is no one cause of bone fragility; genetic and environmental factors play a part in development of smaller bones, fewer or thinner trabeculae, and thin cortices, all of which result in low peak bone density. Material and structural strength is maintained In early adulthood by remodelling; the focal replacement of old with new bone. However, as age advances less new bone is formed than resorbed in each site remodelled, producing bone loss and structural damage. In women, menopause-related oestrogen deficiency increases remodelling, and at each remodelled site more bone is resorbed and less is formed, accelerating bone loss and causing trabecular thinning and disconnection, cortical thinning and porosity. There is no equivalent midlife event in men, though reduced bone formation and subsequent trabecular and cortical thinning do result in bone loss. Hypogonadism contributes to bone loss in 20-30% of elderly men, and in both sexes hyperparathyroidism secondary to calcium malabsorption increases remodelling, worsening the cortical thinning and porosity and predisposing to hip fractures. Concurrent bone formation on the outer (periosteal) cortical bone surface during ageing partly compensates for bone loss and is greater in men than in women, so internal bone loss is better offset in men. More women than men sustain fractures because their smaller skeleton incurs greater architectural damage and adapts less effectively by periosteal bone formation. The structural basis of bone fragility is determined before birth, takes root during growth, and gains full expression during ageing in both sexes.	Austin & Repatriat Med Ctr, Dept Endocrinol, Heidelberg, Vic 3084, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health	Seeman, E (corresponding author), Austin & Repatriat Med Ctr, Dept Endocrinol, Heidelberg, Vic 3084, Australia.	egos@unimelb.edu.au	Seeman, Ego/AAC-3656-2019	Seeman, Ego/0000-0002-9692-048X				AARON JE, 1987, CLIN ORTHOP RELAT R, P260; Bass S, 1999, J CLIN INVEST, V104, P795, DOI 10.1172/JCI7060; BECK TJ, 1992, CALCIFIED TISSUE INT, V50, P24, DOI 10.1007/BF00297293; Beck TJ, 2001, J BONE MINER RES, V16, P1108, DOI 10.1359/jbmr.2001.16.6.1108; Bertelloni S, 1998, J CLIN ENDOCR METAB, V83, P4280, DOI 10.1210/jc.83.12.4280; Bilezikian JP, 1998, NEW ENGL J MED, V339, P599, DOI 10.1056/NEJM199808273390905; BOONEN S, 1995, J BONE MINER RES, V10, P1908; Bousson V, 2001, J BONE MINER RES, V16, P1308, DOI 10.1359/jbmr.2001.16.7.1308; Bradney M, 2000, J BONE MINER RES, V15, P1871, DOI 10.1359/jbmr.2000.15.10.1871; BROWN JP, 1984, LANCET, V1, P1091; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296; Carani C, 1997, NEW ENGL J MED, V337, P91, DOI 10.1056/NEJM199707103370204; Cheng XG, 1997, BONE, V20, P213, DOI 10.1016/S8756-3282(96)00383-3; Chung UI, 2001, J CLIN INVEST, V107, P295, DOI 10.1172/JCI11706; Cohen-Solal ME, 1998, J BONE MINER RES, V13, P1909, DOI 10.1359/jbmr.1998.13.12.1909; CURREY JD, 1969, J BIOMECH, V2, P1, DOI 10.1016/0021-9290(69)90036-0; Duan YB, 2001, J BONE MINER RES, V16, P2267, DOI 10.1359/jbmr.2001.16.12.2267; Duan YB, 1999, J BONE MINER RES, V14, P1796, DOI 10.1359/jbmr.1999.14.10.1796; DUVALBEAUPERE G, 1971, ARCH FR PEDIATR, V28, P1057; EASTELL R, 1988, J CLIN ENDOCR METAB, V67, P741, DOI 10.1210/jcem-67-4-741; EASTELL R, 1989, J CLIN INVEST, V83, P168, DOI 10.1172/JCI113854; ERIKSEN EF, 1990, J BONE MINER RES, V5, P311, DOI 10.1002/jbmr.5650050402; Falahati-Nini A, 2000, J CLIN INVEST, V106, P1553, DOI 10.1172/JCI10942; Finkelstein JS, 1996, J CLIN ENDOCR METAB, V81, P1152, DOI 10.1210/jc.81.3.1152; FINKELSTEIN JS, 1992, NEW ENGL J MED, V326, P600, DOI 10.1056/NEJM199202273260904; FOLDES J, 1991, J BONE MINER RES, V6, P759; Garn S, 1970, EARLIER GAIN LATER L, P3; GARNERO P, 1995, J BONE MINER RES, V10, P1283; Giguere Y, 2000, J BONE MINER RES, V15, P1076, DOI 10.1359/jbmr.2000.15.6.1076; GILSANZ V, 1995, J CLIN INVEST, V95, P2332, DOI 10.1172/JCI117925; GILSANZ V, 1988, CALCIFIED TISSUE INT, V43, P260, DOI 10.1007/BF02555144; GILSANZ V, 1991, NEW ENGL J MED, V325, P1597, DOI 10.1056/NEJM199112053252302; Gilsanz V, 1998, J CLIN ENDOCR METAB, V83, P1420, DOI 10.1210/jc.83.5.1420; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654; Graafmans WC, 1997, J BONE MINER RES, V12, P1241, DOI 10.1359/jbmr.1997.12.8.1241; HEANEY RP, 1994, J BONE MINER RES, V9, P1515; Heegaard AM, 2000, CALCIFIED TISSUE INT, V66, P409, DOI 10.1007/s002230010083; Hordon LD, 2000, BONE, V27, P271, DOI 10.1016/S8756-3282(00)00329-X; Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096-1132; Jordan GR, 2000, BONE, V26, P305, DOI 10.1016/S8756-3282(99)00272-0; KALENDER WA, 1989, EUR J RADIOL, V9, P75; Karlsson KM, 1996, BONE, V18, P327, DOI 10.1016/8756-3282(96)00004-X; Khosla S, 2001, J CLIN ENDOCR METAB, V86, P3555, DOI 10.1210/jc.86.8.3555; KIMMEL DB, 1990, BONE MINER, V11, P217, DOI 10.1016/0169-6009(90)90061-J; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Langdahl BL, 2000, J BONE MINER RES, V15, P2222, DOI 10.1359/jbmr.2000.15.11.2222; Legrand E, 2000, J BONE MINER RES, V15, P13, DOI 10.1359/jbmr.2000.15.1.13; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; LIPS P, 1978, CALC TISS RES, V26, P13, DOI 10.1007/BF02013227; Loro ML, 2000, J CLIN ENDOCR METAB, V85, P3908; Lu PW, 1996, J CLIN ENDOCR METAB, V81, P1586, DOI 10.1210/jc.81.4.1586; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Marc J, 1999, OSTEOPOROSIS INT, V10, P303, DOI 10.1007/s001980050231; MARTIN TJ, 1994, J CELL BIOCHEM, V56, P357, DOI 10.1002/jcb.240560312; Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613; MATKOVIC V, 1994, J CLIN INVEST, V93, P799, DOI 10.1172/JCI117034; MEUNIER PJ, 1990, OSTEOPOROSIS RECENT, P293; Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641; Moore B., 1997, Hormone Research (Basel), V48, P91; MOSEKILDE L, 1990, BONE MINER, V10, P13, DOI 10.1016/0169-6009(90)90046-I; Nguyen TV, 2000, J BONE MINER RES, V15, P1253, DOI 10.1359/jbmr.2000.15.7.1253; Oleksik A, 2000, J BONE MINER RES, V15, P1368, DOI 10.1359/jbmr.2000.15.7.1368; Parfitt A.M., 2001, OSTEOPOROSIS, P433; Parfitt AM, 2000, BONE, V27, P487, DOI 10.1016/S8756-3282(00)00353-7; PARFITT AM, 1980, MINER ELECTROL METAB, V4, P273; Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763; RIGGS BL, 1981, J CLIN INVEST, V67, P328, DOI 10.1172/JCI110039; RIGGS BL, 1986, J CLIN INVEST, V77, P1487, DOI 10.1172/JCI112462; RIGGS BL, 1983, AM J MED, V75, P899, DOI 10.1016/0002-9343(83)90860-4; Sainz J, 1997, NEW ENGL J MED, V337, P77, DOI 10.1056/NEJM199707103370202; Schoenau E, 2000, J CLIN ENDOCR METAB, V85, P1095, DOI 10.1210/jc.85.3.1095; Seeman E, 2000, J BONE MINER RES, V15, P2259, DOI 10.1359/jbmr.2000.15.11.2259; Seeman E, 1996, AM J PHYSIOL-ENDOC M, V270, pE320, DOI 10.1152/ajpendo.1996.270.2.E320; Seeman E, 1998, J CLIN ENDOCR METAB, V83, P1414, DOI 10.1210/jc.83.5.1414; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; Seeman E, 2001, J BONE MINER RES, V16, P120, DOI 10.1359/jbmr.2001.16.1.120; SEEMAN E, 1997, J BONE MINER RES, V12, P1; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Sims NA, 2000, J CLIN INVEST, V106, P1095, DOI 10.1172/JCI10753; SMITH DM, 1973, J CLIN INVEST, V52, P2800, DOI 10.1172/JCI107476; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; SONE T, 1995, BONE, V17, P335, DOI 10.1016/S8756-3282(95)00243-X; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; SUDA T, 1995, ENDOCRINE REV MONOGR, V4, P266; Szulc P, 2001, J CLIN ENDOCR METAB, V86, P192, DOI 10.1210/jc.86.1.192; Tabensky A, 2001, J BONE MINER RES, V16, P1101, DOI 10.1359/jbmr.2001.16.6.1101; Tajima O, 2000, J APPL PHYSIOL, V88, P1271, DOI 10.1152/jappl.2000.88.4.1271; TUPMAN GS, 1962, J BONE JOINT SURG BR, V44, P42, DOI 10.1302/0301-620X.44B1.42; Turner CH, 2000, J BONE MINER RES, V15, P1126, DOI 10.1359/jbmr.2000.15.6.1126; Uitterlinden AG, 1998, NEW ENGL J MED, V338, P1016, DOI 10.1056/NEJM199804093381502; Vega E, 1998, CALCIFIED TISSUE INT, V62, P465, DOI 10.1007/s002239900462; Yamada Y, 2000, AM J MED, V109, P244, DOI 10.1016/S0002-9343(00)00468-X; Yamada Y, 2000, J BONE MINER RES, V15, P415, DOI 10.1359/jbmr.2000.15.3.415; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zamberlan N, 1996, EUR J PEDIATR, V155, P377, DOI 10.1007/s004310050421; Zhang XZ, 1999, J BONE MINER RES, V14, P802, DOI 10.1359/jbmr.1999.14.5.802	99	588	617	4	52	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 25	2002	359	9320					1841	1850		10.1016/S0140-6736(02)08706-8	http://dx.doi.org/10.1016/S0140-6736(02)08706-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044392				2022-12-28	WOS:000175775500025
J	Sandhu, MS; Heald, AH; Gibson, JM; Cruickshank, JK; Dunger, DB; Wareham, NJ				Sandhu, MS; Heald, AH; Gibson, JM; Cruickshank, JK; Dunger, DB; Wareham, NJ			Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study	LANCET			English	Article							FACTOR BINDING PROTEIN-1; IMPROVES GLYCEMIC CONTROL; IGF-I; SENSITIVITY; RISK; PROINSULIN; ADULTS; ASSAYS; GENE	Background Results of experimental and clinical studies suggest that insulin-like growth factor-I (IGF-I) and IGF binding protein-1 (IGFBP-1) could be important determinants of glucose homoeostasis. However, experimental models might also reflect compensatory and adaptive metabolic processes, We therefore prospectively examined the associations between circulating concentrations of IGF-I and IGFBP-1 and development of glucose tolerance. Methods Participants in this cohort study were a random sample of 615 normoglycaemic men and women aged 45-65 years. Participants underwent oral glucose tolerance testing based on WHO definitions and criteria in 1990-92 and 1994-96. At the baseline visit, we measured serum concentrations of IGF-I and IGFBP-1, and assessed the relation between these peptides and subsequent glucose intolerance. Findings At 4.5 years of follow-up, 51 (8%) of 615 participants developed impaired glucose tolerance or type-2 diabetes. After adjustment for correlates of IGF-I and risk factors for glucose intolerance, the odds ratio for risk of impaired glucose tolerance or type-2 diabetes for participants with IGF-I concentrations above the median ( greater than or equal to152 mug/L) compared with those with concentrations below the median (<152 mu g/L) was 0.50 (0.26-0.95). Consistent with this finding. IGF-I also showed a significant inverse association with subsequent 2-h glucose concentrations, which was independent of correlates of IGF-I and risk factors for glucose tolerance (p for linear trend=0.026). We also found that this inverse association was independently modified by IGFBP-1 (p for interaction=0.011). Interpretation These data show that circulating IGF-I and its interaction with IGFBP-1 could be important determinants of glucose homoeostasis and provide further evidence for the possible protective role of IGF-I against development of glucose intolerance.	Univ Cambridge, Inst Publ Hlth, Dept Hlth & Primary Care, Cambridge CB2 2SR, England; Univ Manchester, Dept Med, Endocrine Sci Res Grp, Manchester M13 9PL, Lancs, England; Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2QQ, England	University of Cambridge; University of Manchester; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Wareham, NJ (corresponding author), Univ Cambridge, Inst Publ Hlth, Dept Hlth & Primary Care, Univ Forvie Site, Cambridge CB2 2SR, England.	njw1004@medschl.cam.ac.uk		gibson, martin/0000-0002-1331-1524; Dunger, Professor David/0000-0002-2566-9304				Acerini CL, 1998, METABOLISM, V47, P1481, DOI 10.1016/S0026-0495(98)90074-9; Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; ALPHA B, 1992, EUR J CLIN CHEM CLIN, V30, P27; Bavenholm PN, 2001, DIABETES, V50, P1449, DOI 10.2337/diabetes.50.6.1449; Carroll PV, 2000, DIABETES, V49, P789, DOI 10.2337/diabetes.49.5.789; Clauson PG, 1998, SCAND J CLIN LAB INV, V58, P353, DOI 10.1080/00365519850186544; Crossey PA, 2000, DIABETES, V49, P457, DOI 10.2337/diabetes.49.3.457; Crowne EC, 2001, J CLIN ENDOCR METAB, V86, P3686, DOI 10.1210/jc.86.8.3686; Cruickshank JK, 2001, AM J EPIDEMIOL, V154, P504, DOI 10.1093/aje/154.6.504; Dunger DB, 1997, DIABETIC MED, V14, P723, DOI 10.1002/(SICI)1096-9136(199709)14:9<723::AID-DIA480>3.0.CO;2-S; Ferry RJ, 1999, HORM RES, V51, P53; Frystyk J, 1999, DIABETES-METAB RES, V15, P314, DOI 10.1002/(SICI)1520-7560(199909/10)15:5<314::AID-DMRR56>3.0.CO;2-E; Heald AH, 2001, DIABETOLOGIA, V44, P333, DOI 10.1007/s001250051623; HUSSAIN MA, 1993, LANCET, V341, P1536, DOI 10.1016/0140-6736(93)90674-6; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kaaks R, 2000, JNCI-J NATL CANCER I, V92, P1592, DOI 10.1093/jnci/92.19.1592; Kunst A., 1984, METHOD ENZYMAT AN, VVI, P163; Lee PDK, 1997, P SOC EXP BIOL MED, V216, P319; MORROW LA, 1994, J CLIN ENDOCR METAB, V79, P205, DOI 10.1210/jc.79.1.205; Mortensen DL, 1997, ENDOCRINOLOGY, V138, P2073, DOI 10.1210/en.138.5.2073; Moses AC, 1996, DIABETES, V45, P91, DOI 10.2337/diabetes.45.1.91; Nam SY, 1997, INT J OBESITY, V21, P355, DOI 10.1038/sj.ijo.0800412; Pratley RE, 2001, DIABETOLOGIA, V44, P929, DOI 10.1007/s001250100580; Quattrin T, 1997, DIABETES CARE, V20, P374, DOI 10.2337/diacare.20.3.374; *RH IGF I NIDDM ST, 1996, DIABETES S2, V45, pA27; Sjogren K, 2001, DIABETES, V50, P1539, DOI 10.2337/diabetes.50.7.1539; SOBEY WJ, 1989, BIOCHEM J, V260, P535, DOI 10.1042/bj2600535; THISSEN JP, 1994, ENDOCR REV, V15, P80, DOI 10.1210/er.15.1.80; Thrailkill K M, 2000, Diabetes Technol Ther, V2, P69, DOI 10.1089/152091599316775; Vaessen N, 2001, DIABETES, V50, P637, DOI 10.2337/diabetes.50.3.637; VAESSEN N, 2001, THESIS ROTTERDAM NET; Wareham NJ, 1999, DIABETES CARE, V22, P262, DOI 10.2337/diacare.22.2.262; *WHO STUD GROUP, 1985, DIAB MELL; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Yakar S, 2001, DIABETES, V50, P1110, DOI 10.2337/diabetes.50.5.1110	35	379	391	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 18	2002	359	9319					1740	1745		10.1016/S0140-6736(02)08655-5	http://dx.doi.org/10.1016/S0140-6736(02)08655-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049864				2022-12-28	WOS:000175740500012
J	Taniguchi, T; Garcia-Higuera, I; Xu, B; Andreassen, PR; Gregory, RC; Kim, ST; Lane, WS; Kastan, MB; D'Andrea, AD				Taniguchi, T; Garcia-Higuera, I; Xu, B; Andreassen, PR; Gregory, RC; Kim, ST; Lane, WS; Kastan, MB; D'Andrea, AD			Convergence of the Fanconi anemia and ataxia telangiectasia signaling pathways	CELL			English	Article							NIJMEGEN-BREAKAGE-SYNDROME; DNA-DAMAGE RESPONSE; ATM-DEPENDENT PHOSPHORYLATION; TARGETED DISRUPTION; CHECKPOINT PATHWAY; IONIZING-RADIATION; X-IRRADIATION; NUCLEAR-COMPLEX; MAMMALIAN-CELLS; S-PHASE	Fanconi anemia (FA) and ataxia telangiectasia (AT) are clinically distinct autosomal recessive disorders characterized by spontaneous chromosome breakage and hematological cancers. FA cells are hypersensitive to mitomycin C (MMC), while AT cells are hypersensitive to ionizing radiation (IR). Here, we identify the Fanconi anemia protein, FANCD2, as a link between the FA and ATM damage response pathways. ATM phosphorylates FANCD2 on serine 222 in vitro. This site is also phosphorylated in vivo in an ATM-dependent manner following IR. Phosphorylation of FANCD2 is required for activation of an S phase checkpoint. The ATM-dependent phosphorylation of FANCD2 on S222 and the FA pathway-dependent monoubiquitination of FANCD2 on K561 are independent posttranslational modifications regulating discrete cellular signaling pathways. Biallelic disruption of FANCD2 results in both MMC and IR hypersensitivity.	Harvard Univ, Childrens Hosp, Sch Med, Dana Farber Canc Inst,Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat, Boston, MA 02115 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Harvard Univ, Harvard Microchem & Proteom Anal Facil, Cambridge, MA 02138 USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; St Jude Children's Research Hospital; Harvard University	D'Andrea, AD (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dana Farber Canc Inst,Dept Pediat Oncol, Boston, MA 02115 USA.	alan_dandrea@dfci.harvard.edu	Kim, Seong-Tae/A-9917-2013; Taniguchi, Toshiyasu/ADD-8489-2022; Garcia-Higuera, Irene/L-5004-2014	Garcia-Higuera, Irene/0000-0001-6331-075X; Taniguchi, Toshiyasu/0000-0002-7746-3658	NCI NIH HHS [CA21765, CA71387] Funding Source: Medline; NHLBI NIH HHS [R01HL52725, P01HL54785] Funding Source: Medline; NIDDK NIH HHS [R01DK43889] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071387, P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052725, P50HL054785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043889] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn JY, 2000, CANCER RES, V60, P5934; Alter BP, 1996, AM J HEMATOL, V53, P99, DOI 10.1002/(SICI)1096-8652(199610)53:2<99::AID-AJH7>3.3.CO;2-M; Andreassen PR, 2001, CANCER RES, V61, P7660; ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; BIGELOW SB, 1979, MUTAT RES, V63, P189, DOI 10.1016/0027-5107(79)90115-5; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Carreau M, 1999, MUTAT RES-DNA REPAIR, V435, P103, DOI 10.1016/S0921-8777(99)00041-5; Chen M, 1996, NAT GENET, V12, P448, DOI 10.1038/ng0496-448; Cheng NC, 2000, HUM MOL GENET, V9, P1805, DOI 10.1093/hmg/9.12.1805; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; Djuzenova CS, 2001, LAB INVEST, V81, P185, DOI 10.1038/labinvest.3780226; DUCKWORTHRYSIECKI G, 1985, CANCER RES, V45, P416; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Girard PM, 2000, CANCER RES, V60, P4881; GLUCKMAN E, 1983, BRIT J HAEMATOL, V54, P431, DOI 10.1111/j.1365-2141.1983.tb02117.x; Grompe M, 2001, HUM MOL GENET, V10, P2253, DOI 10.1093/hmg/10.20.2253; HOUGHTALING S, 2001, AM SOC HUM GEN 51 AN; Jakobs PM, 1996, SOMAT CELL MOLEC GEN, V22, P151, DOI 10.1007/BF02369905; Joenje H, 1997, AM J HUM GENET, V61, P940, DOI 10.1086/514881; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA K, 1999, DNA DAMAGE REPAIR; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; KNOX SJ, 1981, BLOOD, V57, P1043; Kupfer GM, 1997, BLOOD, V90, P1047, DOI 10.1182/blood.V90.3.1047.1047_1047_1054; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Marcou Y, 2001, RADIOTHER ONCOL, V60, P75, DOI 10.1016/S0167-8140(01)00370-X; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Naf D, 1998, MOL CELL BIOL, V18, P5952; Nakanishi K, 2001, EXP HEMATOL, V29, P842, DOI 10.1016/S0301-472X(01)00663-4; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PARSHAD R, 1983, P NATL ACAD SCI-BIOL, V80, P5612, DOI 10.1073/pnas.80.18.5612; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Whitney MA, 1996, BLOOD, V88, P49; Wu X, 2000, Science, V289, P11; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yang Y, 2001, BLOOD, V98, P3435, DOI 10.1182/blood.V98.12.3435; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	62	350	358	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	2002	109	4					459	472		10.1016/S0092-8674(02)00747-X	http://dx.doi.org/10.1016/S0092-8674(02)00747-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	553VM	12086603	Bronze			2022-12-28	WOS:000175696800008
J	Ellsberg, M; Heise, L				Ellsberg, M; Heise, L			Bearing witness: ethics in domestic violence research	LANCET			English	Article							ISSUES; AFRICA; WOMEN	Epidemiological research involving people has inherent risks. The Council for International Organization of Medical Sciences provides guidance on the ethical principles of epidemiological research, including respect for people, non-maleficence, beneficience, and justice. In this article we discuss the challenges of applying each principle to population research on domestic violence, an Issue In which poorly designed research could put women In violent relationships at substantial risk. Main concerns include ensuring safety of respondents in a context In which many live with their abuser, protecting confidentiality when breaches could provoke an attack, and ensuring the Interview process Is affirming and does not cause distress. The inherent risks entailed in research can only be justified if the Interview Is used to provide Information on available services and Is a source of immediate referral when necessary, if high-quality data are obtained, and If findings are used to raise awareness of, and Improve services for, women who experience domestic violence.	Program Appropriate Technol Hlth, Washington, DC USA		Ellsberg, M (corresponding author), Program Appropriate Technol Hlth, 1800 K St NW,Suite 800, Washington, DC USA.		Heise, LORI/AAI-6251-2020					Brush LD, 1990, GENDER SOC, V4, P56, DOI 10.1177/089124390004001005; Council for International Organizations of Medical Sciences, 1991, INT GUID ETH REV EP; Ellsberg M, 2000, SOC SCI MED, V51, P1595, DOI 10.1016/S0277-9536(00)00056-3; Ellsberg M, 2001, STUD FAMILY PLANN, V32, P1, DOI 10.1111/j.1728-4465.2001.00001.x; Ellsberg M., 1997, REPRODUCTIVE HLTH MA, V5, P82, DOI [DOI 10.1016/S0968-8080(97)90088-4, https://doi.org/10.1016/S0968-8080(97)90088-4]; ELLSBERG M, IN PRESS RES VIOLENC; Finkelhor D., 1988, STOPPING FAMILY VIOL; Fontes LA, 1998, FAM RELAT, V47, P53, DOI 10.2307/584851; HAKIMI M, 2002, SILENCE SAKE HARMONY; Herman J., 1992, TRAUMA RECOVERY; *HLTH DEV POL PROJ, 1995, MEAS VIOL WOM CROSS; JACKSON LA, 1997, DIRECTLY QUESTIONING, P24; Jewkes R, 2000, REPROD HEALTH MATTER, V8, P93, DOI 10.1016/S0968-8080(00)90010-7; JOHNSON H, 1996, DANGEROUS DOMAINS VI; KOSS MP, 1993, J INTERPERS VIOLENCE, V8, P198, DOI 10.1177/088626093008002004; LACHMAN P, 1997, 4 INT C FAM VIOL, P19; LISS M, 1996, ETHICAL CONSIDERATIO, P31; Newman E, 1999, GEN HOSP PSYCHIAT, V21, P187, DOI 10.1016/S0163-8343(99)00011-0; PARKER B, 1990, NURS RES, V39, P248; SMITH MD, 1994, GENDER SOC, V8, P109, DOI 10.1177/089124394008001007; Usdin S, 2000, REPROD HEALTH MATTER, V8, P55, DOI 10.1016/S0968-8080(00)90187-3; Watts C, 1997, SAfAIDS News, V5, P2; *WHO, 1997, PROT WHO MULT STUD W; *WHO, 1999, PUTT WOM SAF 1 ETH S, P13; ZIMMERMAN K, 1995, PLATES BASKET RATTLE	25	135	137	2	17	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 4	2002	359	9317					1599	1604		10.1016/S0140-6736(02)08521-5	http://dx.doi.org/10.1016/S0140-6736(02)08521-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	549RN	12047984				2022-12-28	WOS:000175460700028
J	Horton, R				Horton, R			WHO: the casualties and compromises of renewal	LANCET			English	Article							HEALTH; ORGANIZATION	The World Health Organization is the leading International agency in health. WHO's reputation reached a peak In the 1970s with the then director-general Halfdan Mahler's advocacy of Health for All by the Year 2000 and the successful worldwide eradication of smallpox. The 1980s and 1990s saw WHO lose much of its authority. Too easily, the blame was put on one man-Mahler's successor, Hiroshi Nakajima. In 1998, Gro Harlem Brundtland, a former Prime Minister of Norway, took office and WHO began a period of major strategic and structural reform. Almost 4 years Into her first term as director-general, I visited WHO's headquarters In Geneva to learn about Dr Brundtland's successes and failures. The ground rules of my visit were that I could talk with anybody and attend almost any meeting (budget discussions were excluded). I interviewed Dr Brundtland, executive directors, members of the staff association, and directors and project managers of programmes such as StopTB, Roll Back Malaria, HIV-AIDS, violence prevention, polio eradication, essential drugs and medicines, and sustainable development. At senior levels, WHO is confident and clear about its purpose-in a way that matches Mahler's vision and goes beyond it in results. Brundtland told me that her most Important achievements were to have "strengthened the credibility of WHO" and to have "raised the awareness of health on to the political and global development agendas". But there is a troubling schism between the aspirations of Its leadership and the realities faced by the organisation on the ground. Rapid change during the past 4 years has reinvigorated WHO's mandate, but poor management has created new tensions that the organisation's leadership seems unwilling to address.	Lancet, London NW1 7BY, England		Horton, R (corresponding author), Lancet, 32 Jamestown Rd, London NW1 7BY, England.	richard.horton@lancet.com						AlMazrou Y, 1997, LANCET, V350, P750; [Anonymous], 2001, MACR HLTH INV HLTH E; BOSELEY S, 2002, GUARDIAN        0206, P18; Brugha R, 2002, LANCET, V359, P435, DOI 10.1016/S0140-6736(02)07607-9; CLINTON B, 2002, GUARDIAN SATURD 0126, P1; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Frenk J, 2002, B WORLD HEALTH ORGAN, V80, P88; GODLEE F, 1994, BRIT MED J, V309, P1424, DOI 10.1136/bmj.309.6966.1424; Harries AD, 2001, LANCET, V358, P410, DOI 10.1016/S0140-6736(01)05551-9; Horton R, 2001, LANCET, V358, P2141, DOI 10.1016/S0140-6736(01)07221-X; Kapp C, 2002, LANCET, V359, P329, DOI 10.1016/S0140-6736(02)07562-1; Lucas A, 1998, LANCET, V351, P743, DOI 10.1016/S0140-6736(97)12451-5; Pollock AM, 2000, LANCET, V356, P1995, DOI 10.1016/S0140-6736(00)03317-1; QUICK J, 2001, B WORLD HEALTH ORGAN, V790, P1093; Quick JD, 2001, B WORLD HEALTH ORGAN, V79, P776; Siddiqi Javed, 1995, WORLD HLTH WORLD POL; WALT G, 1993, HEALTH POLICY, V24, P125, DOI 10.1016/0168-8510(93)90030-S; World Health Organization, 2000, WORLD HLTH REP 2000	18	33	35	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 4	2002	359	9317					1605	1611		10.1016/S0140-6736(02)08523-9	http://dx.doi.org/10.1016/S0140-6736(02)08523-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047986				2022-12-28	WOS:000175460700030
J	Wang, KC; Koprivica, V; Kim, JA; Sivasankaran, R; Guo, Y; Neve, RL; He, ZG				Wang, KC; Koprivica, V; Kim, JA; Sivasankaran, R; Guo, Y; Neve, RL; He, ZG			Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; AXONAL REGENERATION; SPINAL-CORD; IN-VIVO; IDENTIFICATION; GROWTH; PROTEINS; BRAIN; NEUROBIOLOGY; CONTAINS	The inhibitory activity associated with myelin is a major obstacle for successful axon regeneration in the adult mammalian central nervous system (CNS)(1,2). In addition to myelin-associated glycoprotein (MAG)(3,4) and Nogo-A(5-7), available evidence suggests the existence of additional inhibitors in CNS myelin(8). We show here that a glycosylphosphatidylinositol (GPI)-anchored CNS myelin protein, oligodendrocyte-myelin glycoprotein (OMgp), is a potent inhibitor of neurite outgrowth in cultured neurons. Like Nogo-A, OMgp contributes significantly to the inhibitory activity associated with CNS myelin. To further elucidate the mechanisms that mediate this inhibitory activity of OMgp, we screened an expression library and identified the Nogo receptor (NgR)(9) as a high-affinity OMgp-binding protein. Cleavage of NgR and other GPI-linked proteins from the cell surface renders axons of dorsal root ganglia insensitive to OMgp. Introduction of exogenous NgR confers OMgp responsiveness to otherwise insensitive neurons. Thus, OMgp is an important inhibitor of neurite outgrowth that acts through NgR and its associated receptor complex. Interfering with the OMgp/NgR pathway may allow lesioned axons to regenerate after injury in vivo.	Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02115 USA; Aventis Pharmaceut, Bridgewater, NJ 08807 USA; McLean Hosp, Belmont, MA 02478 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Sanofi-Aventis; Harvard University; McLean Hospital	He, ZG (corresponding author), Childrens Hosp, Div Neurosci, 320 Longwood Ave, Boston, MA 02115 USA.			Wang, Kevin/0000-0002-5305-6791				Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; Flanagan JG, 2000, METHOD ENZYMOL, V327, P198, DOI 10.1016/S0076-6879(00)27277-7; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Habib AA, 1998, J NEUROCHEM, V70, P1704; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; Liu BP, 2001, CURR OPIN CELL BIOL, V13, P619, DOI 10.1016/S0955-0674(00)00260-X; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MIKOL DD, 1988, J CELL BIOL, V106, P1273, DOI 10.1083/jcb.106.4.1273; MIKOL DD, 1990, J CELL BIOL, V110, P471, DOI 10.1083/jcb.110.2.471; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Neve RL, 1997, NEUROSCIENCE, V79, P435, DOI 10.1016/S0306-4522(96)00645-8; Niederost BP, 1999, J NEUROSCI, V19, P8979, DOI 10.1523/JNEUROSCI.19-20-08979.1999; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Spillmann AA, 1998, J BIOL CHEM, V273, P19283, DOI 10.1074/jbc.273.30.19283; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; Tessier-Lavigne M, 2000, SCIENCE, V287, P813, DOI 10.1126/science.287.5454.813	23	736	838	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 27	2002	417	6892					941	944		10.1038/nature00867	http://dx.doi.org/10.1038/nature00867			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	566RC	12068310				2022-12-28	WOS:000176441200037
J	Baldini, JUL; McDermott, F; Fairchild, IJ				Baldini, JUL; McDermott, F; Fairchild, IJ			Structure of the 8200-year cold event revealed by a speleothem trace element record	SCIENCE			English	Article							OXYGEN-ISOTOPE RECORDS; CLIMATE RECORD; HOLOCENE; GREENLAND; OCEAN; BP; INSTABILITY; PRECIPITATION; STALAGMITES; RESOLUTION	Abrupt first-order shifts in strontium and phosphorus concentrations in stalagmite calcite deposited in western Ireland during the 8200-year event (the major cooling episode 8200 years before the present) are interpreted as responses to a drier climate lasting about 37 years. Both shifts are centered on 8330 +/- 80 years before the present, coinciding with a large oxygen isotope anomaly and a change in the calcite petrography. In this very high resolution (monthly) record, antipathetic second-order oscillations in phosphorus and strontium reveal decreased growth rates and increased rainfall seasonality. Growth rate variations within the event reveal a two-pronged structure consistent with recent model simulations.	Univ Coll Dublin, Dept Geol, Dublin 4, Ireland; Keele Univ, Sch Earth Sci & Geog, Keele ST5 5BG, Staffs, England	University College Dublin; Keele University	Baldini, JUL (corresponding author), Univ Coll Dublin, Dept Geol, Dublin 4, Ireland.	james.baldini@ucd.ie	Fairchild, Ian/A-6200-2013; Facility, Edinburgh Ion Microprobe/AAD-8512-2020; McDermott, Frank/F-3096-2010	Fairchild, Ian/0000-0003-4822-2895; Facility, Edinburgh Ion Microprobe/0000-0001-6248-6657; McDermott, Frank/0000-0001-7037-7936				Alley RB, 1997, GEOLOGY, V25, P483, DOI 10.1130/0091-7613(1997)025<0483:HCIAPW>2.3.CO;2; ALLEY RB, 1993, NATURE, V362, P527, DOI 10.1038/362527a0; Ayalon A, 1999, HOLOCENE, V9, P715, DOI 10.1191/095968399673664163; BAKER A, 1993, PALAEOGEOGR PALAEOCL, V100, P291, DOI 10.1016/0031-0182(93)90059-R; Barber DC, 1999, NATURE, V400, P344, DOI 10.1038/22504; BLUNIER T, 1995, NATURE, V374, P46, DOI 10.1038/374046a0; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; Campbell ID, 1998, GEOLOGY, V26, P471, DOI 10.1130/0091-7613(1998)026<0471:LHYCPA>2.3.CO;2; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Dean, 1993, GEOLOGICAL SOC AM SP, P135; Fairchild IJ, 2001, J GEOL SOC LONDON, V158, P831, DOI 10.1144/jgs.158.5.831; Fairchild IJ, 2000, CHEM GEOL, V166, P255, DOI 10.1016/S0009-2541(99)00216-8; Finch AA, 2001, EARTH PLANET SC LETT, V186, P255, DOI 10.1016/S0012-821X(01)00253-9; Genty D, 1996, J SEDIMENT RES, V66, P275; Genty D, 2001, CHEM GEOL, V176, P191, DOI 10.1016/S0009-2541(00)00399-5; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; Hinton R.W., 1995, MICROPROBE TECHNIQUE, P235, DOI DOI 10.1007/978-1-4615-2053-5_6; Hu FS, 1999, NATURE, V400, P437, DOI 10.1038/22728; Huang HM, 2001, CHEM GEOL, V175, P429; Huang YM, 2001, GEOCHIM COSMOCHIM AC, V65, P47, DOI 10.1016/S0016-7037(00)00513-5; Hughen KA, 1996, NATURE, V380, P51, DOI 10.1038/380051a0; Klitgaard-Kristensen D, 1998, J QUATERNARY SCI, V13, P165, DOI 10.1002/(SICI)1099-1417(199803/04)13:2<165::AID-JQS365>3.0.CO;2-#; Korhola A, 2000, QUATERNARY RES, V54, P284, DOI 10.1006/qres.2000.2153; LORENS RB, 1981, GEOCHIM COSMOCHIM AC, V45, P553, DOI 10.1016/0016-7037(81)90188-5; Mayer J, 1999, J CAVE KARST STUD, V61, P131; McDermott F, 2001, SCIENCE, V294, P1328, DOI 10.1126/science.1063678; Nesje A, 2001, J QUATERNARY SCI, V16, P155, DOI 10.1002/jqs.567; Renssen H, 2001, GEOPHYS RES LETT, V28, P1567, DOI 10.1029/2000GL012602; Roberts MS, 1998, EARTH PLANET SC LETT, V154, P237, DOI 10.1016/S0012-821X(97)00116-7; Rousseau DD, 1998, GEOLOGY, V26, P651, DOI 10.1130/0091-7613(1998)026<0651:BLGAHC>2.3.CO;2; Schmittner A, 2002, SCIENCE, V295, P1489, DOI 10.1126/science.1066174; STREETPERROTT FA, 1990, NATURE, V343, P607, DOI 10.1038/343607a0; Stuiver M, 1995, QUATERNARY RES, V44, P341, DOI 10.1006/qres.1995.1079; von Grafenstein U, 1999, SCIENCE, V284, P1654, DOI 10.1126/science.284.5420.1654; von Grafenstein U, 1998, CLIM DYNAM, V14, P73, DOI 10.1007/s003820050210	35	131	145	2	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	2002	296	5576					2203	+		10.1126/science.1071776	http://dx.doi.org/10.1126/science.1071776			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077412				2022-12-28	WOS:000176379000053
J	Molina, JM; Tourneur, M; Sarfati, C; Chevret, S; de Gouvello, A; Gobert, JG; Balkan, S; Derouin, F				Molina, JM; Tourneur, M; Sarfati, C; Chevret, S; de Gouvello, A; Gobert, JG; Balkan, S; Derouin, F		Agence Natl Recherches SIDA 090 St	Fumagillin treatment of intestinal microsporidiosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE-CHAIN-REACTION; VIRUS-INFECTED PATIENTS; ENTEROCYTOZOON-BIENEUSI; ENCEPHALITOZOON-CUNICULI; METHIONINE AMINOPEPTIDASE-2; ANTIRETROVIRAL THERAPY; HIV-INFECTION; IN-VITRO; AIDS; DIARRHEA	Background: Intestinal microsporidiosis due to Enterocytozoon bieneusi is a cause of chronic diarrhea, malabsorption, and wasting in immunocompromised patients. Currently, there is no effective treatment. Methods: We conducted a randomized, double-blind, placebo-controlled trial of fumagillin (60 mg per day orally for two weeks) in patients with chronic E. bieneusi infection. Efficacy was assessed primarily by the clearance of microsporidia, as evidenced by analysis of stool specimens. Patients in whom microsporidia were not cleared received treatment for two weeks with open-label fumagillin. After clearance of the parasite, follow-up stool examinations were performed monthly to detect relapses. Results: Twelve patients were enrolled in this study, 10 with the acquired immunodeficiency syndrome and 2 who had received organ transplants. Clearance of microsporidia occurred in all six of the patients in the fumagillin group, as compared with none of the six in the placebo group (P=0.002). Treatment with fumagillin was also associated with increases in absorption of d-xylose (P=0.003) and in Karnofsky performance scores (P<0.001) and with decreases in loperamide use (P=0.01) and total stool weight (P=0.04). There were serious adverse events (neutropenia and thrombocytopenia) in three patients in the fumagillin group; one patient in the placebo group had severe diarrhea. All six controls subsequently had clearance of microsporidia after open-label treatment with fumagillin. Relapses of the infection were identified in two patients during follow-up (median follow-up, 10 months). Conclusions: Fumagillin is an effective treatment for chronic E. bieneusi infection in immunocompromised patients.	Hop St Louis, Dept Infect Dis, F-75475 Paris 10, France; Hop St Louis, Parasitol Lab, F-75475 Paris 10, France; Hop St Louis, Dept Biostat, F-75475 Paris 10, France; Univ Paris 07, Paris, France; Grp Hosp Pitie Salpetriere, Assistance Publ Hop Paris, Parasitol Lab, F-75634 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite	Molina, JM (corresponding author), Hop St Louis, Dept Infect Dis, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.	jean-michel.molina@sls.ap-hop-paris.fr		chevret, sylvie/0000-0001-6449-4730				AnwarBruni DM, 1996, AIDS, V10, P619, DOI 10.1097/00002030-199606000-00007; BEAUVAIS B, 1994, ANTIMICROB AGENTS CH, V38, P2440, DOI 10.1128/AAC.38.10.2440; Carr A, 1998, LANCET, V351, P256, DOI 10.1016/S0140-6736(97)07529-6; Coyle C, 1998, J INFECT DIS, V177, P515, DOI 10.1086/517390; DESPORTES I, 1985, J PROTOZOOL, V32, P250; Dezube BJ, 1998, J CLIN ONCOL, V16, P1444, DOI 10.1200/JCO.1998.16.4.1444; Didier ES, 1997, ANTIMICROB AGENTS CH, V41, P1541, DOI 10.1128/AAC.41.7.1541; DIESENHOUSE MC, 1993, AM J OPHTHALMOL, V115, P293, DOI 10.1016/S0002-9394(14)73578-0; DIETERICH DT, 1994, J INFECT DIS, V169, P178, DOI 10.1093/infdis/169.1.178; DIPAOLO JA, 1958, ANTIBIOT ANNU, P541; Gainzarain JC, 1998, CLIN INFECT DIS, V27, P394, DOI 10.1086/514660; Goguel J, 1997, AIDS, V11, P1658; Griffith EC, 1998, P NATL ACAD SCI USA, V95, P15183, DOI 10.1073/pnas.95.26.15183; Guerard A, 1999, TRANSPLANTATION, V68, P699, DOI 10.1097/00007890-199909150-00017; Katinka MD, 2001, NATURE, V414, P450, DOI 10.1038/35106579; KATZNELSON H, 1952, SCIENCE, V115, P70, DOI 10.1126/science.115.2977.70; KILLOUGH JH, 1952, SCIENCE, V115, P71, DOI 10.1126/science.115.2977.71; KOTLER DP, 1999, MICROSPORIDIA MICROS, V258, P92; Liguory O, 1997, AIDS, V11, P723, DOI 10.1097/00002030-199706000-00004; Liu SP, 1998, SCIENCE, V282, P1324, DOI 10.1126/science.282.5392.1324; MCCOWEN MC, 1951, SCIENCE, V113, P202, DOI 10.1126/science.113.2930.202; MOLINA JM, 1993, J INFECT DIS, V167, P217, DOI 10.1093/infdis/167.1.217; Molina JM, 2000, AIDS, V14, P1341, DOI 10.1097/00002030-200007070-00006; Molina JM, 1997, AIDS, V11, P1603, DOI 10.1097/00002030-199713000-00009; ORENSTEIN JM, 1990, HUM PATHOL, V21, P475; SAX PE, 1995, TRANSPLANTATION, V60, P617, DOI 10.1097/00007890-199509270-00018; SCHATTENKERK JKME, 1991, LANCET, V337, P895, DOI 10.1016/0140-6736(91)90215-B; SHADDUCK JA, 1980, J PROTOZOOL, V27, P202, DOI 10.1111/j.1550-7408.1980.tb04681.x; VANGOOL T, 1993, J CLIN PATHOL, V46, P694, DOI 10.1136/jcp.46.8.694; WEBER R, 1992, NEW ENGL J MED, V326, P161, DOI 10.1056/NEJM199201163260304; WILKINS JH, 1994, EYE, V8, P703, DOI 10.1038/eye.1994.177; YEE RW, 1991, OPHTHALMOLOGY, V98, P196, DOI 10.1016/S0161-6420(91)32331-5	32	156	194	1	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 20	2002	346	25					1963	1969		10.1056/NEJMoa012924	http://dx.doi.org/10.1056/NEJMoa012924			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563QC	12075057				2022-12-28	WOS:000176266200005
J	Vollmer, SV; Palumbi, SR				Vollmer, SV; Palumbi, SR			Hybridization and the evolution of reef coral diversity	SCIENCE			English	Article							GENUS ACROPORA; SCLERACTINIA; CNIDARIA; MITOCHONDRIAL; POPULATIONS; PATTERNS; HISTORY	Hundreds of coral species coexist sympatrically on reefs, reproducing in mass-spawning events where hybridization appears common. In the Caribbean, DNA sequence data from all three sympatric Acropora corals show that mass spawning does not erode species barriers. Species A. cervicornis and A. palmata are distinct at two nuclear loci or share ancestral alleles. Morphotypes historically given the name Acropora prolifera are entirety F-1 hybrids of these two species, showing morphologies that depend on which species provides the egg for hybridization. Although selection limits the evolutionary potential of hybrids, F-1 individuals can reproduce asexually and form long-lived, potentially immortal hybrids with unique morphologies.	Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA	Harvard University	Vollmer, SV (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, 16 Divin Ave, Cambridge, MA 02138 USA.	svollmer@oeb.harvard.edu						Arnold M. L., 1997, NATURAL HYBRIDIZATIO; Avise John C., 1994, pi; BOWDENKERBY A, 1997, P 8 INT COR REEF S, V2, P2063; Budd A.F., 1997, P423; BUDD AF, 1994, J PALEONTOL, V68, P951, DOI 10.1017/S0022336000026585; BURTON RS, 1990, EVOLUTION, V44, P1814, DOI 10.1111/j.1558-5646.1990.tb05252.x; Cairns SD, 1982, STONY CORALS CNIDARI; de Graaf M, 1999, B MAR SCI, V64, P189; GOLDMAN N, 1993, J MOL EVOL, V36; GOREAU TF, 1959, ECOLOGY, V40, P67, DOI 10.2307/1929924; HARRISON PL, 1984, SCIENCE, V223, P1186, DOI 10.1126/science.223.4641.1186; Hatta M, 1999, MOL BIOL EVOL, V16, P1607, DOI 10.1093/oxfordjournals.molbev.a026073; HIGHSMITH RC, 1982, MAR ECOL PROG SER, V7, P207, DOI 10.3354/meps007207; NASON JD, 1992, AM J BOT, V79, P101, DOI 10.2307/2445203; Nielsen R, 2001, GENETICS, V158, P885; Odorico DM, 1997, MOL BIOL EVOL, V14, P465, DOI 10.1093/oxfordjournals.molbev.a025783; Palumbi SR, 2001, EVOLUTION, V55, P859, DOI 10.1554/0014-3820(2001)055[0859:PNGCFM]2.0.CO;2; PAMILO P, 1988, MOL BIOL EVOL, V5, P568; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; SWOFFORD DL, 1996, PAUP STAR PHYLOGENET; TAKAHATA N, 1990, THEOR POPUL BIOL, V38, P331, DOI 10.1016/0040-5809(90)90018-Q; Van Oppen MJH, 2000, MOL ECOL, V9, P1363, DOI 10.1046/j.1365-294x.2000.01010.x; van Oppen MJH, 2001, MOL BIOL EVOL, V18, P1315, DOI 10.1093/oxfordjournals.molbev.a003916; Veron J.E.N., 2000, CORALS WORLD, V1-3; VERON JEN, 1995, CORALS SPACE TIME BI; VERON JEN, 1988, ASS AUST PALAEONTOL, V6, P1; VRIJENHOEK RC, 1984, POPULATION BIOL EVOL, P175; WALLACE CC, 1994, ANNU REV ECOL SYST, V25, P237, DOI 10.1146/annurev.es.25.110194.001321; WALLACE CC, 2000, STAGHORN CORALS WORL; Willis BL, 1997, CORAL REEFS, V16, pS53, DOI 10.1007/s003380050242	30	206	215	2	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 14	2002	296	5575					2023	2025		10.1126/science.1069524	http://dx.doi.org/10.1126/science.1069524			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065836				2022-12-28	WOS:000176273300052
J	Buve, A; Bishikwabo-Nsarhaza, K; Mutangadura, G				Buve, A; Bishikwabo-Nsarhaza, K; Mutangadura, G			The spread and effect of HIV-1 infection in sub-Saharan Africa	LANCET			English	Article							SEXUAL-BEHAVIOR; PREVALENCE; AIDS; RISK; IMMUNODEFICIENCY; WOMEN; ZAIRE; POPULATION; PATTERNS; ZAMBIA	Africa is the continent most severely affected by the global HIV-1 epidemic, with east and southern Africa in general more severely affected than west and central Africa. Differences in the spread of the epidemic can be accounted for by a complex interplay of sexual behaviour and biological factors that affect the probability of HIV-1 transmission per sex act. Sexual behaviour patterns are determined by cultural and socioeconomic contexts. In sub-Saharan Africa, some traditions and socioeconomic developments have contributed to the extensive spread of HIV-1 infection, including the subordinate position of women, impoverishment and decline of social services, rapid urbanisation and modernisation, and wars and conflicts. Populations in many parts of Africa are becoming trapped in a vicious circle as the HIV-1 epidemic leads to high mortality rates in young and economically productive age groups, and thus leads to further impoverishment. Interventions to control HIV-1 should not only target individuals, but also aim to change those aspects of cultural and socioeconomic context that increase the vulnerability to HIV-1 of people and communities.	Inst Trop Med, Dept Microbiol, STD HIV Res & Intervent Unit, B-2000 Antwerp, Belgium; UNAIDS, Country & Reg Support Dept, Geneva, Switzerland	Institute of Tropical Medicine (ITM); UNAIDS	Buve, A (corresponding author), Inst Trop Med, Dept Microbiol, STD HIV Res & Intervent Unit, B-2000 Antwerp, Belgium.							Amowitz LL, 2002, JAMA-J AM MED ASSOC, V287, P513, DOI 10.1001/jama.287.4.513; [Anonymous], 1981, MORBIDITY MORTALITY, V30, P250; ASIIMWEOKIROR G, 1997, AIDS, V11, P1157; Auvert B, 2001, AIDS, V15, pS31, DOI 10.1097/00002030-200108004-00004; Auvert B, 2001, AIDS, V15, P885, DOI 10.1097/00002030-200105040-00009; BERKLEY S, 1991, AIDS, V5, pS87; BOERMA TJ, 1998, AIDS S1, V12, pS3; BONNEL R, 2000, INT AIDS EC NETW S D; BONNEL R, 2000, EC ANAL HIV AIDS; BROCKERHOFF M, 1998, 111 POP COUNC; Buve A, 2001, TROP MED INT HEALTH, V6, P971, DOI 10.1046/j.1365-3156.2001.00809.x; Buve A, 2001, AIDS, V15, pS127, DOI 10.1097/00002030-200108004-00014; Buve A, 2001, AIDS, V15, pS5, DOI 10.1097/00002030-200108004-00002; CALDWELL JC, 1989, POPUL DEV REV, V15, P185, DOI 10.2307/1973703; CARAEL M, 1995, SOC AS AIDS, P75; CLUMECK N, 1983, LANCET, V1, P642; DORRINGTON R, 2002, IMPACT HIV AIDS ADUL; Ferry B, 2001, AIDS, V15, pS41, DOI 10.1097/00002030-200108004-00005; FETTERS T, 1998, YOUTH TALK SEXUALITY; Fylkesnes K, 1997, AIDS, V11, P339, DOI 10.1097/00002030-199703110-00012; Fylkesnes K, 2001, AIDS, V15, P907, DOI 10.1097/00002030-200105040-00011; Glynn JR, 2001, AIDS, V15, pS51, DOI 10.1097/00002030-200108004-00006; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; GREGSON S, 2000, IUSSP C SEX NETW SPR; Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607; HOOPER E, 1949, RIVER, P31; Janssens W, 1997, AIDS, V11, P705, DOI 10.1097/00002030-199706000-00002; Kilian AHD, 1999, AIDS, V13, P391, DOI 10.1097/00002030-199902250-00012; Kirunga C T, 1997, Health Transit Rev, V7 Suppl, P175; Laga M, 2001, AIDS, V15, P931, DOI 10.1097/00002030-200105040-00014; Lagarde E, 2001, AIDS, V15, P1399, DOI 10.1097/00002030-200107270-00009; LEROY V, 1995, LANCET, V346, P1488, DOI 10.1016/S0140-6736(95)92504-X; LOEWENSON R, 1997, SAFAIDS 1997, V2; MACAULEY I, 2001, 12 INT C AIDS STDS A; Mills S, 1997, AIDS, V11, pS43; Morison L, 2001, AIDS, V15, pS109, DOI 10.1097/00002030-200108004-00012; Morison L, 2001, AIDS, V15, pS61, DOI 10.1097/00002030-200108004-00007; NAHMIAS AJ, 1986, LANCET, V1, P1279; *NAT CTR HIV AIDS, 2002, BEH SURV SURV CAMB 1; NZILAMBI N, 1988, NEW ENGL J MED, V318, P276, DOI 10.1056/NEJM198802043180503; PIOT P, 1984, LANCET, V2, P65; Quigley M, 1997, AIDS, V11, P237, DOI 10.1097/00002030-199702000-00015; QUINN TC, 1986, SCIENCE, V234, P955, DOI 10.1126/science.3022379; Ryan CA, 1998, LANCET, V351, P1175, DOI 10.1016/S0140-6736(98)24016-5; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SHAH A, 2002, CONFLICTS AFRICA; SITTITRAI W, 1994, INT J STD AIDS, V5, P377, DOI 10.1177/095646249400500523; SMITH S, 2000, DEV HIV EPIDEMIC; SONNET J, 1987, SCAND J INFECT DIS, V19, P511, DOI 10.3109/00365548709032415; Tarantola D, 1997, AIDS, V11 Suppl B, pS5; Todaro M. P., 1997, POLICY RES DIVISION; UNAIDS, 2001, POP MOB AIDS TECHN U; UNDP, 1999, HUM DEV REP 1999; *UNPFA, 1999, STAT WORLD POP 1999; Weiss HA, 2001, AIDS, V15, pS97, DOI 10.1097/00002030-200108004-00011; *WORLD BANK, 1993, WORLD DEV REP, P238; *WORLD BANK, 1997, CONFR AIDS PUBL PRIO, P27; World Bank, 2001, WORLD DEV IND; ZULU EM, 2000, 17 AFR POP HLTH RES	59	171	178	0	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 8	2002	359	9322					2011	2017		10.1016/S0140-6736(02)08823-2	http://dx.doi.org/10.1016/S0140-6736(02)08823-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076570				2022-12-28	WOS:000176232500027
J	van Hinsbergh, VWM				van Hinsbergh, VWM			Coagulation signals for intact blood vessels	LANCET			English	Editorial Material							ENDOTHELIAL-CELLS; THROMBIN RECEPTOR; MICE		TNO Prevent & Hlth, Gaubius Lab, NL-2301 CE Leiden, Netherlands; Vrije Univ Amsterdam, Inst Cardiovasc Res, Amsterdam, Netherlands	Netherlands Organization Applied Science Research; Vrije Universiteit Amsterdam	van Hinsbergh, VWM (corresponding author), TNO Prevent & Hlth, Gaubius Lab, NL-2301 CE Leiden, Netherlands.							Balconi G, 2000, ARTERIOSCL THROM VAS, V20, P1443, DOI 10.1161/01.ATV.20.6.1443; Carmeliet P, 1998, THROMB RES, V91, P255, DOI 10.1016/S0049-3848(98)00122-4; Cines DB, 1998, BLOOD, V91, P3527; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Cui JS, 1996, NATURE, V384, P66, DOI 10.1038/384066a0; Darrow AL, 1996, THROMB HAEMOSTASIS, V76, P860; Griffin CT, 2001, SCIENCE, V293, P1666, DOI 10.1126/science.1061259; Hatzopoulos AK, 1998, DEVELOPMENT, V125, P1457	9	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 8	2002	359	9322					1958	1960		10.1016/S0140-6736(02)08846-3	http://dx.doi.org/10.1016/S0140-6736(02)08846-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076547				2022-12-28	WOS:000176232500004
J	Ni, SD; Tan, E; Gurnis, M; Helmberger, D				Ni, SD; Tan, E; Gurnis, M; Helmberger, D			Sharp sides to the African superplume	SCIENCE			English	Article							DYNAMIC TOPOGRAPHY; MANTLE; HETEROGENEITY; HOTSPOTS; VELOCITY; DENSITY	Beneath southern Africa is a large structure about 1200 kilometers across and extending obliquely 1500 kilometers upward from the core-mantle boundary with a shear velocity reduction of about 3%. Using a fortuitous set of SKS phases that travel along its eastern side, we show that the boundary of the anomaly appears to be sharp, with a width less than 50 kilometers, and is tilted outward from its center. Dynamic models that fit the seismic constraints have a dense chemical layer within an upwardly flowing thermal structure. The tilt suggests that the layer is dynamically unstable on geological time scales.	CALTECH, Seismol Lab, Pasadena, CA 91125 USA	California Institute of Technology	Ni, SD (corresponding author), CALTECH, Seismol Lab, Pasadena, CA 91125 USA.	stone@gps.caltech.edu	Tan, Eh/N-8320-2013	Tan, Eh/0000-0002-1815-9613; Ni, Sidao/0000-0003-2988-4850				CONRAD CP, UNPUB GEOCHEM GEOPHY; DAVIES GF, 1986, GEOPHYS RES LETT, V13, P1517, DOI 10.1029/GL013i013p01517; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; GURNIS M, 1986, J GEOPHYS RES-SOLID, V91, P1407, DOI 10.1029/JB091iB11p11407; Gurnis M., 2000, GEOCHEM GEOPHY GEOSY, V1, DOI DOI 10.1029/1999GC000035; HAGER BH, 1985, NATURE, V313, P541, DOI 10.1038/313541a0; HANSEN U, 1988, NATURE, V334, P237, DOI 10.1038/334237a0; Ishii M, 1999, SCIENCE, V285, P1231, DOI 10.1126/science.285.5431.1231; Lithgow-Bertelloni C, 1998, NATURE, V395, P269, DOI 10.1038/26212; Masters G., 2000, EARTHS DEEP INTERIOR, V117, P63, DOI DOI 10.1029/GM117P0063; MULLER RD, 1993, GEOLOGY, V21, P275, DOI 10.1130/0091-7613(1993)021<0275:RPMRTT>2.3.CO;2; NI S, IN PRESS J GEOPHYS R; Ni SD, 2001, EARTH PLANET SC LETT, V187, P301, DOI 10.1016/S0012-821X(01)00273-4; RICHARDS MA, 1988, J GEOPHYS RES-SOLID, V93, P7690, DOI 10.1029/JB093iB07p07690; Ritsema J, 1999, SCIENCE, V286, P1925, DOI 10.1126/science.286.5446.1925; Sidorin I, 1998, GEODYNAMICS, V28, P209; Tackley PJ, 1998, GEODYNAMICS, V28, P231	17	317	323	2	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	2002	296	5574					1850	1852		10.1126/science.1070698	http://dx.doi.org/10.1126/science.1070698			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052955				2022-12-28	WOS:000176054300043
J	Huber, KE; Waldor, MK				Huber, KE; Waldor, MK			Filamentous phage integration requires the host recombinases XerC and XerD	NATURE			English	Article							SITE-SPECIFIC RECOMBINATION; VIBRIO-CHOLERAE; ESCHERICHIA-COLI; CTX-PHI; GENOME SEQUENCE; CHROMOSOME; DNA; PLASMIDS; DIF; INSERTION	Many bacteriophages and animal viruses integrate their genomes into the chromosomal DNA of their hosts as a method of promoting vertical transmission. Phages that integrate in a site-specific fashion encode an integrase enzyme that catalyses recombination between the phage and host genomes(1,2). CTXphi is a filamentous bacteriophage that contains the genes encoding cholera toxin, the principal virulence factor of the diarrhoea-causing Gram-negative bacterium Vibrio cholerae(3). CTXphi integrates into the V. cholerae genome in a site-specific manner(4,5); however, the similar to6.9-kilobase (kb) CTXphi genome does not encode any protein with significant homology to known recombinases. Here we report that XerC and XerD, two chromosome-encoded recombinases that ordinarily function to resolve chromosome dimers at the dif recombination site(6), are essential for CTXphi integration into the V. cholerae genome. The CTXphi integration site was found to overlap with the dif site of the larger of the two V. cholerae chromosomes. Examination of sequences of the integration sites of other filamentous phages indicates that the XerCD recombinases also mediate the integration of these phage genomes at dif-like sites in various bacterial species.	Tufts Univ New England Med Ctr, Div Geog Med Infect Dis, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Microbiol, Boston, MA 02111 USA; Howard Hughes Med Inst, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Howard Hughes Medical Institute	Waldor, MK (corresponding author), Tufts Univ New England Med Ctr, Div Geog Med Infect Dis, 750 Washington St, Boston, MA 02111 USA.			Waldor, Matthew/0000-0003-1843-7000; Huber, Kathryn/0000-0001-8194-5871				BLAKELY G, 1993, CELL, V75, P351, DOI 10.1016/0092-8674(93)80076-Q; BUTTERTON JR, 1995, INFECT IMMUN, V63, P2689, DOI 10.1128/IAI.63.7.2689-2696.1995; CAMPBELL AM, 1992, J BACTERIOL, V174, P7495, DOI 10.1128/JB.174.23.7495-7499.1992; DAI H, 1988, VIROLOGY, V167, P613, DOI 10.1016/0042-6822(88)90124-9; Davis BM, 1999, J BACTERIOL, V181, P6779, DOI 10.1128/JB.181.21.6779-6787.1999; Davis BM, 2000, P NATL ACAD SCI USA, V97, P8572, DOI 10.1073/pnas.140109997; Davis BM, 2000, J BACTERIOL, V182, P6992, DOI 10.1128/JB.182.24.6992-6998.2000; Dillard JP, 2001, MOL MICROBIOL, V41, P263, DOI 10.1046/j.1365-2958.2001.02520.x; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KUEMPEL PL, 1991, NEW BIOL, V3, P799; LESSL M, 1992, J BACTERIOL, V174, P2493, DOI 10.1128/jb.174.8.2493-2500.1992; Lin NT, 2001, MOL GENET GENOMICS, V266, P425, DOI 10.1007/s004380100532; Metcalf WW, 1996, PLASMID, V35, P1, DOI 10.1006/plas.1996.0001; Moyer KE, 2001, MOL MICROBIOL, V41, P311, DOI 10.1046/j.1365-2958.2001.02517.x; Nash H, 1996, ESCHERICHIA COLI SAL, P2363; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; PEARSON GDN, 1993, P NATL ACAD SCI USA, V90, P3750, DOI 10.1073/pnas.90.8.3750; Simpson AJG, 2000, NATURE, V406, P151, DOI 10.1038/35018003; Steiner W, 1999, MOL MICROBIOL, V31, P579, DOI 10.1046/j.1365-2958.1999.01198.x; TECKLENBURG M, 1995, P NATL ACAD SCI USA, V92, P1352, DOI 10.1073/pnas.92.5.1352; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910	22	138	153	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	2002	417	6889					656	659		10.1038/nature00782	http://dx.doi.org/10.1038/nature00782			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050668				2022-12-28	WOS:000176001200050
J	Nowak, MA; Komarova, NL; Niyogi, P				Nowak, MA; Komarova, NL; Niyogi, P			Computational and evolutionary aspects of language	NATURE			English	Review							UNIVERSAL GRAMMAR; NATURAL-LANGUAGE; NEURAL NETWORKS; DISORDER; QUERIES; SPEECH; COMMUNICATION; EMERGENCE	Language is our legacy. It is the main evolutionary contribution of humans, and perhaps the most interesting trait that has emerged in the past 500 million years. Understanding how darwinian evolution gives rise to human language requires the integration of formal language theory, learning theory and evolutionary dynamics. Formal language theory provides a mathematical description of language and grammar. Learning theory formalizes the task of language acquisition-it can be shown that no procedure can learn an unrestricted set of languages. Universal grammar specifies the restricted set of languages learnable by the human brain. Evolutionary dynamics can be formulated to describe the cultural evolution of language and the biological evolution of universal grammar.	Inst Adv Study, Princeton, NJ 08540 USA; Univ Leeds, Dept Math, Leeds LS2 9JT, W Yorkshire, England; Univ Chicago, Dept Comp Sci, Chicago, IL 60637 USA	Institute for Advanced Study - USA; University of Leeds; University of Chicago	Nowak, MA (corresponding author), Inst Adv Study, Einstein Dr, Princeton, NJ 08540 USA.		Nowak, Martin A/A-6977-2008; Galantucci, Bruno/E-5770-2010					AITCHINSON J, 1996, SEEDS SPEECH; ANGLUIN D, 1995, J COMPUT SYST SCI, V50, P336, DOI 10.1006/jcss.1995.1026; ANGLUIN D, 1987, INFORM COMPUT, V75, P87, DOI 10.1016/0890-5401(87)90052-6; [Anonymous], 1991, SET PARAMETERS ARGUM; AOKI K, 1987, P NATL ACAD SCI USA, V84, P7164, DOI 10.1073/pnas.84.20.7164; Baker M., 2001, ATOMS LANGUAGE; Batali J., 1998, APPROACHES EVOLUTION; Bates E., 1982, LANG ACQUIS, P174; Bickerton Derek, 1990, LANGUAGE SPECIES; BRANDON R, 1986, PHIL BIOL, V1, P169; Bresnan Joan, 2001, LEXICAL FUNCTIONAL S; Cangelosi A, 2002, SIMULATING EVOLUTION; CavalliSforza LL, 1997, P NATL ACAD SCI USA, V94, P7719, DOI 10.1073/pnas.94.15.7719; Chomsky N., 1981, EXPLANATION LINGUIST, P123; Chomsky N., 1984, LECT GOVT BINDING PI, V3; Chomsky N., 2002, JANUA LINGUARUM; CHOMSKY N., 1972, LANGUAGE MIND; Christiansen MH, 2002, SIMULATING THE EVOLUTION OF LANGUAGE, P165; Comrie, 1989, LANGUAGE UNIVERSALS; Deacon T., 1997, SYMBOLIC SPECIES; DEGRAFF M, 1999, LANGUAGE CREATION; DUNBAR R, 1996, GROOMING GOSSOP EVOL; Elman JL, 1996, RETHINKING INNATENES; Emberts Zachary, 2020, EVOLUTION, V74, P897, DOI [10.1111/evo.13948, DOI 10.1111/EVO.13580]; Fitch WT, 2000, TRENDS COGN SCI, V4, P258, DOI 10.1016/S1364-6613(00)01494-7; GASARCH WI, 1992, J ACM, V39, P649, DOI 10.1145/146637.146670; GEMAN S, 1992, NEURAL COMPUT, V4, P1, DOI 10.1162/neco.1992.4.1.1; GOLD EM, 1967, INFORM CONTROL, V10, P447, DOI 10.1016/S0019-9958(67)91165-5; GOPNIK M, 1991, COGNITION, V39, P1, DOI 10.1016/0010-0277(91)90058-C; Greenberg Joseph., 1978, UNIVERSALS HUMAN LAN; Harrison M., 1978, INTRO FORMAL LANGUAG; Hashimoto T, 1996, BIOSYSTEMS, V38, P1, DOI 10.1016/0303-2647(95)01563-9; Hauser, 1996, EVOL COMMUN; Hawkins J. A., 1992, EVOLUTION HUMAN LANG, VXI; Hazlehurst B, 1998, LANG COGNITIVE PROC, V13, P373, DOI 10.1080/016909698386564; Hopper P.J., 1993, GRAMMATICALIZATION; HURFORD JR, 1989, LINGUA, V77, P187, DOI 10.1016/0024-3841(89)90015-6; Jackendoff R, 1999, TRENDS COGN SCI, V3, P272, DOI 10.1016/S1364-6613(99)01333-9; Jackendoff R., 2001, FDN LANGUAGE; KIRBY S, 1997, P 4 EUR C ART LIF, P493; Komarova NL, 2001, B MATH BIOL, V63, P451, DOI 10.1006/bulm.2000.0222; KOMAROVA NL, 2001, MATHPR0105235; Kroch A., 1989, J LANGUAGE VARIATION, V1, P199, DOI [DOI 10.1017/S0954394500000168, 10.1017/S0954394500000168]; Lai CSL, 2001, NATURE, V413, P519, DOI 10.1038/35097076; Lakoff George, 1987, WOMEN FIRE, DOI DOI 10.7208/CHICAGO/9780226471013.001.0001; Langacker Ronald Wayne, 1987, FDN COGNITIVE LINGUI, V1; Lieberman P., 1984, BIOL EVOLUTION LANGU; Lightfoot D, 1999, DEV LANGUAGE ACQUISI; NEWMEYER FJ, 1991, LANG COMMUN, V11, P97, DOI 10.1016/0271-5309(91)90028-T; NEWMEYER FJ, 1991, LANG COMMUN, V11, P3, DOI 10.1016/0271-5309(91)90011-J; Niyogi P, 1997, LINGUIST PHILOS, V20, P697, DOI 10.1023/A:1005319718167; Nowak MA, 2000, NATURE, V404, P495, DOI 10.1038/35006635; Nowak MA, 1999, P NATL ACAD SCI USA, V96, P8028, DOI 10.1073/pnas.96.14.8028; Nowak MA, 2001, SCIENCE, V291, P114, DOI 10.1126/science.291.5501.114; OSHERSON DN, 1986, SYSTEMS LEARN; PINKER S, 1990, BEHAV BRAIN SCI, V13, P707, DOI 10.1017/S0140525X00081061; PINKER S, 1979, COGNITION, V7, P217, DOI 10.1016/0010-0277(79)90001-5; Pinker Steven, 1994, LANGUAGE INSTINCT; Pollard Carl, 1994, HEAD DRIVEN PHRASE S; Prince A, 1997, SCIENCE, V275, P1604, DOI 10.1126/science.275.5306.1604; PULLUM GK, 1982, LINGUIST PHILOS, V4, P471, DOI 10.1007/BF00360802; RIVIN I, 2001, CSLG0107033; Sadock J., 1991, AUTOLEXICAL SYNTAX T; Sampson G., 1999, ED EVE LANGUAGE INST; SHIEBER SM, 1985, LINGUIST PHILOS, V8, P333, DOI 10.1007/BF00630917; Smith W.J., 1977, BEHAV COMMUNICATING; STEELS L, 1996, P 5 ART LIF C, P113; Szathmary E, 1995, MAJOR TRANSITIONS EV; Tomasello Michael, 1999, CULTURAL ORIGINS HUM; VALIANT LG, 1984, COMMUN ACM, V27, P436; Vapnik V., 1998, STAT LEARNING THEORY; VAPNIK VN, 1971, THEOR PROBAB APPL+, V16, P264, DOI 10.1137/1116025; Vargha-Khadem F, 1998, P NATL ACAD SCI USA, V95, P12695, DOI 10.1073/pnas.95.21.12695; Wang W. S.-Y., 1998, ORIGINS MODERN HUMAN, P247; WEXLER K, 1980, FORMAL PRINCIPLES LA	75	234	239	4	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	2002	417	6889					611	617		10.1038/nature00771	http://dx.doi.org/10.1038/nature00771			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	559AE	12050656				2022-12-28	WOS:000176001200038
J	Pui, CH; Gaynon, PS; Boyett, JM; Chessells, JM; Baruchel, A; Kamps, W; Silverman, LB; Biondi, A; Harms, DO; Vilmer, E; Schrappe, M; Camitta, B				Pui, CH; Gaynon, PS; Boyett, JM; Chessells, JM; Baruchel, A; Kamps, W; Silverman, LB; Biondi, A; Harms, DO; Vilmer, E; Schrappe, M; Camitta, B			Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region	LANCET			English	Article							ACUTE MYELOID-LEUKEMIA; MLL-GENE REARRANGEMENTS; CHILDRENS CANCER GROUP; INFANT ACUTE-LEUKEMIA; POOR-PROGNOSIS; CLINICAL CHARACTERISTICS; TRANSPLANTATION; CHEMOTHERAPY; FEATURES; AGE	Background The prognosis and optimum treatment of childhood acute lymphoblastic leukaemia (ALL) with abnormalities of chromosomal band 11q23 are controversial. We aimed to identify prognostic factors that might help in planning future therapy, and to assess the effectiveness of haemopoietic stem-cell transplantation in patients with the t(4;11) translocation, which is associated with a particularly poor outcome. Methods We reviewed data on 497 children and young adults who had ALL with various 11q23 abnormalities, including the translocations t(4;11), t(9;11), and t(11;19). All patients were treated with intensive chemotherapy, with or without haemopoietic stem-cell transplantation in first complete remission, by 11 study groups and single institutions from 1983 to 1995. Findings Age was the most important prognostic factor. In a Cox's proportional-hazard model stratified by 11q23 abnormalities, infants younger than 1 year fared significantly worse than patients 1 year of age or older (hazard ratio for event-free survival 1.84 [95% CI 1.38-2.47], p=0.0001). Among infants, any category of 11q23 abnormality conferred a dismal outcome, whereas in older patients, t(4;11) and t(9;11) were associated with a worse outcome than were other 11q23 changes. In the largest subgroup-256 patients with t(4;11)-any type of transplantation was associated with significantly worse disease-free survival (1.61 [1.10-2.35], p=0.014) and overall survival (1.76 [1.08-2.45], p=0.004) compared with chemotherapy only. Even transplantation with stem cells from HLA-matched related or HLA-matched unrelated donors tended to be associated with a worse outcome than chemotherapy alone. Interpretation The prognosis of acute lymphoblastic leukaemia with an 11q23 abnormality is particularly dismal in infants. Allogeneic transplantation with haemopoietic stem cells from an HLA-matched related donor does not seem to improve the clinical outcome in patients with t(4:11)-positive leukaemia.	St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Univ Tennessee, Coll Med, Memphis, TN 38163 USA; Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA; Univ So Calif, Los Angeles, CA USA; Inst Child Hlth, Mol Haematol Unit, London, England; Hop St Louis, Serv Pediat Hematol, Paris, France; Dutch Childhood Leukemia Study Grp, The Hague, Netherlands; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA USA; Univ Milano Bicocca, Dept Pediat, Monza, Italy; Osped San Gerardo, Monza, Italy; Univ Hamburg, Dept Pediat Hematol & Oncol, Hamburg, Germany; Hop Robert Debre, Serv Hematoimmunol, F-75019 Paris, France; Hannover Med Sch, Dept Pediat Hematol Oncol, Childrens Univ Hosp, Hannover, Germany; Med Coll Wisconsin, Dept Pediat, Midwest Childrens Canc Ctr, Milwaukee, WI 53226 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Children's Hospital Los Angeles; University of Southern California; University of London; University College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of Milano-Bicocca; San Gerardo Hospital; University of Hamburg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf; Medical College of Wisconsin	Pui, CH (corresponding author), St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.	ching-hon.pui@stjude.org	Raimondi, Susana C/N-8166-2018; Schrappe, Martin/ABA-6144-2020; Schrappe, Martin/A-8109-2010; Pui, Ching-Hon/N-8076-2018; Biondi, Andrea/AAX-1865-2020; Biondi, Andrea/K-9997-2016	Pui, Ching-Hon/0000-0003-0303-5658; Biondi, Andrea/0000-0002-6757-6173; 	NCI NIH HHS [CA37379, CA29139, CA51001, CA 31566, CA21765, CA78224] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051001, R01CA078224, U10CA031566, U10CA029139, P30CA021765, R29CA051001, U10CA037379] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arico M, 2000, NEW ENGL J MED, V342, P998, DOI 10.1056/NEJM200004063421402; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Behm FG, 1996, BLOOD, V87, P2870, DOI 10.1182/blood.V87.7.2870.bloodjournal8772870; Biondi A, 2000, BLOOD, V96, P24, DOI 10.1182/blood.V96.1.24; BORDIGONI P, 1989, BRIT J HAEMATOL, V72, P293, DOI 10.1111/j.1365-2141.1989.tb07702.x; CHEN CS, 1993, BLOOD, V81, P2386; Dordelmann M, 1999, BLOOD, V94, P1209, DOI 10.1182/blood.V94.4.1209.416k05_1209_1217; Dreyer Z. E., 1998, P AN M AM SOC CLIN, V17, p529a; Forestier E, 2000, BRIT J HAEMATOL, V110, P147, DOI 10.1046/j.1365-2141.2000.02153.x; HEEREMA NA, 1994, BLOOD, V83, P2274, DOI 10.1182/blood.V83.8.2274.bloodjournal8382274; Heerema NA, 1999, LEUKEMIA, V13, P679, DOI 10.1038/sj.leu.2401413; Johansson B, 1998, LEUKEMIA, V12, P779, DOI 10.1038/sj.leu.2401012; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Kumagai MA, 1996, J CLIN INVEST, V97, P755, DOI 10.1172/JCI118474; LEWIS M, IN PRESS BLOOD; Ludwig WD, 1998, BLOOD, V92, P1898; Marco F, 2000, J CLIN ONCOL, V18, P3256, DOI 10.1200/JCO.2000.18.18.3256; MOOREMAN AV, 1988, LEUKEMIA, V12, P805; Nakano Y, 1999, BRIT J HAEMATOL, V104, P659, DOI 10.1046/j.1365-2141.1999.01256.x; Pieters R, 1998, LEUKEMIA, V12, P1344, DOI 10.1038/sj.leu.2401129; Pirich L, 1999, MED PEDIATR ONCOL, V32, P1, DOI 10.1002/(SICI)1096-911X(199901)32:1<1::AID-MPO2>3.0.CO;2-J; PUI CH, 1994, J CLIN ONCOL, V12, P909, DOI 10.1200/JCO.1994.12.5.909; Pui CH, 2000, LEUKEMIA, V14, P684, DOI 10.1038/sj.leu.2401725; PUI CH, 1991, BLOOD, V77, P440; RAIMONDI SC, 1995, BLOOD, V86, P1881, DOI 10.1182/blood.V86.5.1881.bloodjournal8651881; REITER A, 1994, BLOOD, V84, P3122, DOI 10.1182/blood.V84.9.3122.3122; RUBNITZ JE, 1994, BLOOD, V84, P570; Rubnitz JE, 1999, J CLIN ONCOL, V17, P191, DOI 10.1200/JCO.1999.17.1.191; Silverman LB, 1997, CANCER-AM CANCER SOC, V80, P2285; SIMON R, 1984, STAT MED, V3, P35, DOI 10.1002/sim.4780030106; Smith M, 1996, J CLIN ONCOL, V14, P680, DOI 10.1200/JCO.1996.14.2.680; Stram DO, 1996, BIOMETRICS, V52, P1079, DOI 10.2307/2533069; Taki T, 1996, LEUKEMIA, V10, P1303; UCKUN FM, 1995, BLOOD, V85, P873, DOI 10.1182/blood.V85.4.873.bloodjournal854873; VONBUELTZINGSLOEWEN A, 1995, BONE MARROW TRANSPL, V16, P521	35	272	293	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 1	2002	359	9321					1909	1915		10.1016/S0140-6736(02)08782-2	http://dx.doi.org/10.1016/S0140-6736(02)08782-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PL	12057554				2022-12-28	WOS:000175975700011
J	Sheth, SS; Chalmers, I				Sheth, SS; Chalmers, I			Magnesium for preventing and treating eclampsia: time for international action	LANCET			English	Editorial Material									2 2 Navjivan Soc, Mumbai 400008, India; UK Cochrane Ctr, Oxford, England	Cochrane Centre	Sheth, SS (corresponding author), 2 2 Navjivan Soc, Lamington Rd, Mumbai 400008, India.	silsai@bom2.vsnl.net.in						CHALMERS I, 1996, EVIDENCE BASED MED, V1, P39; DULEY L, 1995, LANCET, V345, P1455; DULEY L, 2002, COCHRANE LIB; Horton R, 2002, LANCET, V359, P1605, DOI 10.1016/S0140-6736(02)08523-9; Jones P, 1998, LANCET, V352, P1988, DOI 10.1016/S0140-6736(05)61334-7; Mahomed K, 1998, LANCET, V351, P293, DOI 10.1016/S0140-6736(05)78237-4; NEILSON JP, 1995, BRIT MED J, V311, P701; Rubin PC, 1998, LANCET, V352, P1861, DOI 10.1016/S0140-6736(05)79932-3; *WHO UNFPA UNICEF, 2000, WHORHR007 UNFPA UNIC; WHO/UNICEF, 1996, WHOFRHMSM9611 UNICEF	10	35	35	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 1	2002	359	9321					1872	1873		10.1016/S0140-6736(02)08783-4	http://dx.doi.org/10.1016/S0140-6736(02)08783-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PL	12057545				2022-12-28	WOS:000175975700002
J	Ishihara, T; Iino, Y; Mohri, A; Mori, I; Gengyo-Ando, K; Mitani, S; Katsura, I				Ishihara, T; Iino, Y; Mohri, A; Mori, I; Gengyo-Ando, K; Mitani, S; Katsura, I			HEN-1, a secretory protein with an LDL receptor motif, regulates sensory integration and learning in Caenorhabditis elegans	CELL			English	Article							C-ELEGANS; LIPOPROTEIN RECEPTORS; SYNAPTIC PLASTICITY; NERVOUS-SYSTEM; HEAVY-CHAIN; DROSOPHILA; GENE; MEMORY; NEURONS; THERMOTAXIS	Animals sense many environmental stimuli simultaneously and integrate various sensory signals within the nervous system both to generate proper behavioral responses and also to form relevant memories. HEN-1, a secretory protein with an LDL receptor motif, regulates such processes in Caenorhabditis elegans. The hen-1 mutants show defects in the integration of two sensory signals and in behavioral plasticity by paired stimuli, although their sensation capability seems to be identical to that of the wild-type. The HEN-1 protein is expressed in two pairs of neurons, but expression in other neurons is sufficient for wild-type behavior. In addition, expression of HEN-1 at the adult stage is sufficient. Thus, HEN-1 regulates sensory processing non-cell-autonomously in the mature neuronal circuit.	Natl Inst Genet, Struct Biol Ctr, Mishima, Shizuoka 4118540, Japan; Grad Univ Adv Studies, Dept Genet, Mishima, Shizuoka 4118540, Japan; Univ Tokyo, Mol Genet Res Lab, Tokyo 1130033, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4648602, Japan; Tokyo Womens Med Univ, Sch Med, Japan Sci & Technol Corp, PRESTO, Tokyo 1628666, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan; University of Tokyo; Nagoya University; Japan Science & Technology Agency (JST); Tokyo Women's Medical University	Ishihara, T (corresponding author), Natl Inst Genet, Struct Biol Ctr, Mishima, Shizuoka 4118540, Japan.	tishihar@lab.nig.ac.jp	Gengyo-Ando, Keiko/B-2753-2012; Gengyo-Ando, Keiko/AAC-4504-2019; IINO, YUICHI/G-4962-2014					Altun-Gultekin Z, 2001, DEVELOPMENT, V128, P1951; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; BARGMANN CI, 1993, ANNU REV NEUROSCI, V16, P47, DOI 10.1146/annurev.ne.16.030193.000403; Bargmann CI, 1998, ANNU REV NEUROSCI, V21, P279, DOI 10.1146/annurev.neuro.21.1.279; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; BRENNER S, 1974, GENETICS, V77, P71; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHALFIE M, 1985, J NEUROSCI, V5, P956; Cheng YZ, 2001, CELL, V105, P757, DOI 10.1016/S0092-8674(01)00386-5; Colbert HA, 1997, LEARN MEMORY, V4, P179, DOI 10.1101/lm.4.2.179; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; Dubnau J, 1998, ANNU REV NEUROSCI, V21, P407, DOI 10.1146/annurev.neuro.21.1.407; Gengyo-Ando K, 2000, BIOCHEM BIOPH RES CO, V269, P64, DOI 10.1006/bbrc.2000.2260; Grotewiel MS, 1998, NATURE, V391, P455, DOI 10.1038/35079; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HEDGECOCK EM, 1975, P NATL ACAD SCI USA, V72, P4061, DOI 10.1073/pnas.72.10.4061; Hobert O, 1997, NEURON, V19, P345, DOI 10.1016/S0896-6273(00)80944-7; Joiner MA, 2000, LEARN MEMORY, V7, P32, DOI 10.1101/lm.7.1.32; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LASITER PS, 1982, J COMP PHYSIOL PSYCH, V96, P376, DOI 10.1037/h0077894; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Milner B, 1998, NEURON, V20, P445, DOI 10.1016/S0896-6273(00)80987-3; MORI I, 1995, NATURE, V376, P344, DOI 10.1038/376344a0; Mori I, 1999, ANNU REV GENET, V33, P399, DOI 10.1146/annurev.genet.33.1.399; Morrison GE, 1999, BEHAV NEUROSCI, V113, P358, DOI 10.1037/0735-7044.113.2.358; Nelson LS, 1998, SCIENCE, V281, P1686, DOI 10.1126/science.281.5383.1686; Nonet ML, 1997, J NEUROSCI, V17, P8061; Nonet ML, 1998, J NEUROSCI, V18, P70; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; Rankin CH, 2000, BEHAV NEUROSCI, V114, P496, DOI 10.1037/0735-7044.114.3.496; Rosay P, 2001, NEURON, V30, P759, DOI 10.1016/S0896-6273(01)00323-3; Saeki S, 2001, J EXP BIOL, V204, P1757; Sambongi Y, 2000, NEUROREPORT, V11, P2229, DOI 10.1097/00001756-200007140-00033; Sawin ER, 2000, NEURON, V26, P619, DOI 10.1016/S0896-6273(00)81199-X; Shioi G, 2001, GENETICS, V157, P1611; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Waddell S, 2000, CELL, V103, P805, DOI 10.1016/S0092-8674(00)00183-5; Weiss JB, 2001, CELL, V107, P387, DOI 10.1016/S0092-8674(01)00540-2; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wicks SR, 2000, DEV BIOL, V221, P295, DOI 10.1006/dbio.2000.9686; WILLIAMS BD, 1992, GENETICS, V131, P609; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	49	111	116	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 31	2002	109	5					639	649		10.1016/S0092-8674(02)00748-1	http://dx.doi.org/10.1016/S0092-8674(02)00748-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	558GL	12062106	Bronze			2022-12-28	WOS:000175957900012
J	de Jong, JTVM; Komproe, IH				de Jong, JTVM; Komproe, IH			Closing the gap between psychiatric epidemiology and mental health in post-conflict situations	LANCET			English	Editorial Material							REFUGEES		Vrije Univ Amsterdam, WHO, Collaborating Ctr Ethn Minor & Refugees, Trancultural Psychosocial Org, NL-1016 EE Amsterdam, Netherlands	Vrije Universiteit Amsterdam; World Health Organization	de Jong, JTVM (corresponding author), Vrije Univ Amsterdam, WHO, Collaborating Ctr Ethn Minor & Refugees, Trancultural Psychosocial Org, NL-1016 EE Amsterdam, Netherlands.		Komproe, Ivan/AAJ-8699-2021					Ager A., 1993, MENTAL HLTH REFUGEE; de Jong J., 2002, TRAUMA WAR VIOLENCE; de Jong JTVM, 2001, JAMA-J AM MED ASSOC, V286, P555, DOI 10.1001/jama.286.5.555; Fukuyama Francis, 1999, GREAT DISRUPTION HUM; Mollica RF, 1999, JAMA-J AM MED ASSOC, V282, P433, DOI 10.1001/jama.282.5.433; Narrow WE, 2002, ARCH GEN PSYCHIAT, V59, P115, DOI 10.1001/archpsyc.59.2.115; Orley J., 1994, AMIDST PERIL PAIN ME, P193; Van Ommeren M, 2001, ARCH GEN PSYCHIAT, V58, P475, DOI 10.1001/archpsyc.58.5.475; WHO, 2001, ATL MENT HLTH RES WO	9	20	20	1	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 25	2002	359	9320					1793	1794		10.1016/S0140-6736(02)08729-9	http://dx.doi.org/10.1016/S0140-6736(02)08729-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044372				2022-12-28	WOS:000175775500005
J	Llovet, JM; Real, MI; Montana, X; Planas, R; Coll, S; Aponte, J; Ayuso, C; Sala, M; Muchart, J; Sola, R; Rodes, J; Bruix, J				Llovet, JM; Real, MI; Montana, X; Planas, R; Coll, S; Aponte, J; Ayuso, C; Sala, M; Muchart, J; Sola, R; Rodes, J; Bruix, J		Barcelona Clin Liver Canc Grp	Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial	LANCET			English	Article							OILY CHEMOEMBOLIZATION; NATURAL-HISTORY; CANCER; EMBOLIZATION; MANAGEMENT; PROGNOSIS; CIRRHOSIS; LIPIODOL	Background There is no standard treatment for unresectable hepatocellular carcinoma. Arterial embolisation is widely used. but evidence of survival benefits is lacking. Methods We did a randomised controlled trial in patients with unresectable hepatocellular carcinoma not suitable for curative treatment, of Child-Pugh class A or B and Okuda stage I or II, to assess the survival benefits of regularly repeated arterial embolisation (gelatin sponge) or chemoembolisation (gelatin sponge plus doxorubicin) compared with conservative treatment. 903 patients were assessed. and 112 (12%) patients were finally included in the study. The primary endpoint was survival, Analyses were by intention to treat. Findings The trial was stopped when the ninth sequential inspection showed that chemoembolisation had survival benefits compared with conservative treatment (hazard ratio of death 0.47 [95% CI 0.25-0.91], p=0.025). 25 of 37 patients assigned embolisation, 21 of 40 assigned chemoembolisation, and 25 of 35 assigned conservative treatment died. Survival probabilities at 1 year and 2 years were 75% and 50% for embolisation: 82% and 63% for chemoembolisation, and 63% and 27% for control (chemoembolisation vs control p=0.009). Chemoembolisation induced objective responses sustained for at least 6 months in 35% (14) of cases, and was associated with a significantly lower rate of portal-vein invasion than conservative treatment. Treatment allocation was the only variable independently related to survival (odds ratio 0.45 [95% CI 0.25-0.81], P=0.02). Interpretation Chemoembolisation improved survival of stringently selected patients with unresectable hepatocellular carcinoma.	Univ Barcelona, Hosp Clin, Inst Digest Dis, Liver Unit, Barcelona, Spain; Univ Barcelona, Hosp Clin, Dept Radiol, Imaging Diagnost Ctr, Barcelona, Spain; Univ Barcelona, Hosp Clin, Dept Stat, Barcelona, Spain; Hosp Germans Trias & Pujol, Dept Gastroenterol, Badalona, Spain; Hosp Germans Trias & Pujol, Dept Radiol, Badalona, Spain; Hosp Mar, Liver Sect, Barcelona, Catalonia, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; Hospital Germans Trias i Pujol; Hospital Germans Trias i Pujol; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Bruix, J (corresponding author), Hosp Clin Barcelona, Liver Unit, BCLC Grp, Villarroel 170, Barcelona 08036, Catalonia, Spain.		Sala, Margarita/AAP-6515-2020; Llovet, Josep M/ABB-6264-2021; Llovet, Josep M/D-4340-2014	Llovet, Josep M/0000-0003-0547-2667; Llovet, Josep M/0000-0003-0547-2667; Ayuso, Carmen/0000-0002-9606-6957; Coll, Susanna/0000-0002-0395-9685; Bruix, Jordi/0000-0002-9826-0753				[Anonymous], 1992, DESIGN ANAL SEQUENTI; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Bruix J, 1998, HEPATOLOGY, V27, P1578, DOI 10.1002/hep.510270617; Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1; Bruix J, 2002, HEPATOLOGY, V35, P519, DOI 10.1053/jhep.2002.32089; LIN DY, 1988, GASTROENTEROLOGY, V94, P453, DOI 10.1016/0016-5085(88)90436-2; Llovet JM, 1999, HEPATOLOGY, V29, P62, DOI 10.1002/hep.510290145; Llovet JM, 1999, SEMIN LIVER DIS, V19, P329, DOI 10.1055/s-2007-1007122; MADDEN MV, 1993, GUT, V34, P1598, DOI 10.1136/gut.34.11.1598; Mathurin P, 1998, ALIMENT PHARM THERAP, V12, P111; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MONDAZZI L, 1994, HEPATOLOGY, V19, P1115, DOI 10.1002/hep.1840190508; OBERTI F, 1995, NEW ENGL J MED, V332, P1256; OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E; PELLETIER G, 1990, J HEPATOL, V11, P181, DOI 10.1016/0168-8278(90)90110-D; Pelletier G, 1998, J HEPATOL, V29, P129, DOI 10.1016/S0168-8278(98)80187-6; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; Simonetti RG, 1997, ANN ONCOL, V8, P117, DOI 10.1023/A:1008285123736; SORENSEN JB, 1993, BRIT J CANCER, V67, P773, DOI 10.1038/bjc.1993.140; Trinchet JC, 1997, J HEPATOL, V27, P756, DOI 10.1016/S0168-8278(97)80095-5; VENOOK AP, 1990, J CLIN ONCOL, V8, P1108, DOI 10.1200/JCO.1990.8.6.1108; VETTER D, 1991, HEPATOLOGY, V13, P427, DOI 10.1002/hep.1840130308	22	2607	2733	5	132	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 18	2002	359	9319					1734	1739		10.1016/S0140-6736(02)08649-X	http://dx.doi.org/10.1016/S0140-6736(02)08649-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049862				2022-12-28	WOS:000175740500010
J	Pathania, S; Jayaram, M; Harshey, RM				Pathania, S; Jayaram, M; Harshey, RM			Path of DNA within the Mu transpososome: Transposase interactions bridging two Mu ends and the enhancer trap five DNA supercoils	CELL			English	Article							PHAGE-MU; TOPOLOGICAL SELECTIVITY; STRAND EXCHANGE; SITE ALIGNMENT; RECOMBINATION; COMPLEX; SYNAPSIS; CONDENSATION; MECHANISM; BINDING	The phage Mu transpososome is assembled by interactions of transposase subunits with the left (L) and right (R) ends of Mu and an enhancer (E) located in between. A metastable three-site complex LER progresses into a more stable type 0 complex in which a tetrameric transposase is poised for DNA cleavage. "Difference topology" has revealed five trapped negative supercoils within type 0, three contributed by crossings of E with L and R, and two by crossings of L with R. This is the most complex DNA arrangement seen to date within a recombination synapse. Contrary to the prevailing notion, the enhancer appears not to be released immediately following type 0 assembly. Difference topology provides a simple method for determining the ordered sequestration of DNA segments within nucleoprotein assemblies.	Univ Texas, Sch Mol Genet & Microbiol, Austin, TX 78712 USA; Univ Texas, Inst Cellular Biol & Pathol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Harshey, RM (corresponding author), Univ Texas, Sch Mol Genet & Microbiol, Austin, TX 78712 USA.	rasika@uts.cc.utexas.edu			NIGMS NIH HHS [GM35654, GM33247] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035654, R01GM033247] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON RG, 1992, J BIOL CHEM, V267, P19963; Chaconas George, 2002, P384; Chalmers R, 1998, CELL, V93, P897, DOI 10.1016/S0092-8674(00)81449-X; Colloms SD, 1997, CELL, V88, P855, DOI 10.1016/S0092-8674(00)81931-5; Grainge I, 2000, J MOL BIOL, V298, P749, DOI 10.1006/jmbi.2000.3679; GRINDLEY NDF, 1994, NUCLEIC ACIDS MOL BI, V8, P236; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Halford SE, 2001, BIOCHEM SOC T, V29, P363, DOI 10.1042/BST0290363; HEICHMAN KA, 1991, GENE DEV, V5, P1622, DOI 10.1101/gad.5.9.1622; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; Holmes VF, 2000, P NATL ACAD SCI USA, V97, P1322, DOI 10.1073/pnas.040576797; Jiang H, 2001, J BIOL CHEM, V276, P4373, DOI 10.1074/jbc.M008523200; Jiang H, 1999, EMBO J, V18, P3845, DOI 10.1093/emboj/18.13.3845; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; Kilbride E, 1999, J MOL BIOL, V289, P1219, DOI 10.1006/jmbi.1999.2864; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; KLIPPEL A, 1993, EMBO J, V12, P1047, DOI 10.1002/j.1460-2075.1993.tb05746.x; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Wang ZG, 1996, J BIOL CHEM, V271, P9619, DOI 10.1074/jbc.271.16.9619; WASSERMAN SA, 1985, P NATL ACAD SCI USA, V82, P1079, DOI 10.1073/pnas.82.4.1079; Watson MA, 1996, CELL, V85, P435, DOI 10.1016/S0092-8674(00)81121-6; WHITE JH, 1984, P NATL ACAD SCI-BIOL, V81, P3322, DOI 10.1073/pnas.81.11.3322; YANG JY, 1995, GENE DEV, V9, P2545, DOI 10.1101/gad.9.20.2545; Zechiedrich EL, 1999, METH MOL B, V94, P99	33	53	55	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	2002	109	4					425	436		10.1016/S0092-8674(02)00728-6	http://dx.doi.org/10.1016/S0092-8674(02)00728-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	553VM	12086600	Bronze			2022-12-28	WOS:000175696800005
J	Kim, JH; Auerbach, JM; Rodriguez-Gomez, JA; Velasco, I; Gavin, D; Lumelsky, N; Lee, SH; Nguyen, J; Sanchez-Pernaute, R; Bankiewicz, K; McKay, R				Kim, JH; Auerbach, JM; Rodriguez-Gomez, JA; Velasco, I; Gavin, D; Lumelsky, N; Lee, SH; Nguyen, J; Sanchez-Pernaute, R; Bankiewicz, K; McKay, R			Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; NURR1-DEFICIENT MICE; ISTHMIC ORGANIZER; NEURAL PLATE; SPINAL-CORD; MUTANT MICE; IN-VITRO; DIFFERENTIATION; TRANSPLANTATION; EXPRESSION	Parkinson's disease is a widespread condition caused by the loss of midbrain neurons that synthesize the neurotransmitter dopamine. Cells derived from the fetal midbrain can modify the course of the disease, but they are an inadequate source of dopamine-synthesizing neurons because their ability to generate these neurons is unstable. In contrast, embryonic stem (ES) cells proliferate extensively and can generate dopamine neurons. If ES cells are to become the basis for cell therapies, we must develop methods of enriching for the cell of interest and demonstrate that these cells show functions that will assist in treating the disease. Here we show that a highly enriched population of midbrain neural stem cells can be derived from mouse ES cells. The dopamine neurons generated by these stem cells show electrophysiological and behavioural properties expected of neurons from the midbrain. Our results encourage the use of ES cells in cell-replacement therapy for Parkinson's disease.	NINCDS, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	McKay, R (corresponding author), NINCDS, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.		Kim, Jong-Hoon/H-1476-2015; Sanchez-Pernaute, Rosario/ABD-8661-2021; Velasco, Ivan/AAE-4249-2019; Sanchez-Pernaute, Rosario/AAZ-9566-2021; Velasco, Iván/D-3593-2014; Rodríguez-Gómez, José A./C-8313-2015; Kim, Jong-Hoon/F-2504-2013	Velasco, Ivan/0000-0002-8953-6578; Sanchez-Pernaute, Rosario/0000-0003-1144-9025; Velasco, Iván/0000-0002-8953-6578; Rodríguez-Gómez, José A./0000-0002-4107-7229; Kim, Jong-Hoon/0000-0003-3419-0538	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002981, ZIANS002981, Z01NS002881, ZIANS002881] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABROUS DN, 1993, NEUROSCIENCE, V53, P187, DOI 10.1016/0306-4522(93)90297-S; Auerbach JM, 2000, EUR J NEUROSCI, V12, P1696, DOI 10.1046/j.1460-9568.2000.00067.x; Bader A, 2000, CIRC RES, V86, P787, DOI 10.1161/01.RES.86.7.787; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Broccoli V, 1999, NATURE, V401, P164, DOI 10.1038/43670; Fiorillo CD, 1998, NATURE, V394, P78, DOI 10.1038/27919; GERFEN CR, 1987, J NEUROSCI, V7, P3935; Gross C, 2002, NATURE, V416, P396, DOI 10.1038/416396a; HUDSON JL, 1994, J NEUROSCI, V14, P283; Hynes M, 1999, CURR OPIN NEUROBIOL, V9, P26, DOI 10.1016/S0959-4388(99)80004-X; Joyner AL, 2000, CURR OPIN CELL BIOL, V12, P736, DOI 10.1016/S0955-0674(00)00161-7; Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3; Le W, 1999, J NEUROCHEM, V73, P2218; Le WD, 1999, EXP NEUROL, V159, P451, DOI 10.1006/exnr.1999.7191; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Lumelsky N, 2001, SCIENCE, V292, P1389, DOI 10.1126/science.1058866; Mallamaci A, 1996, MECH DEVELOP, V58, P165, DOI 10.1016/S0925-4773(96)00571-0; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Molne M, 2000, J NEUROSCI RES, V59, P301, DOI 10.1002/(SICI)1097-4547(20000201)59:3<301::AID-JNR3>3.0.CO;2-H; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; NIKKHAH G, 1993, NEUROSCIENCE, V56, P33, DOI 10.1016/0306-4522(93)90559-X; Offield MF, 1996, DEVELOPMENT, V122, P983; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; OLSSON M, 1995, J NEUROSCI, V15, P3863; REYPORT S, 1992, J NEUROSCI, V12, P4264; Rideout WM, 2002, CELL, V109, P17, DOI 10.1016/S0092-8674(02)00681-5; Rohrbacher J, 2000, NEUROSCIENCE, V97, P703, DOI 10.1016/S0306-4522(00)00046-4; Sanchez-Pernaute R, 2001, J NEUROSCI RES, V65, P284, DOI 10.1002/jnr.1152; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Sawa A, 2002, SCIENCE, V296, P692, DOI 10.1126/science.1070532; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; Smidt MP, 2000, NAT NEUROSCI, V3, P337, DOI 10.1038/73902; Studer L, 1998, NAT NEUROSCI, V1, P290, DOI 10.1038/1105; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wallen A, 1999, EXP CELL RES, V253, P737, DOI 10.1006/excr.1999.4691; WURST W, 1994, DEVELOPMENT, V120, P2065; Wurst W, 2001, NAT REV NEUROSCI, V2, P99, DOI 10.1038/35053516; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; ZUDDAS A, 1991, EUR J NEUROSCI, V3, P77	43	1235	1398	2	244	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 4	2002	418	6893					50	56		10.1038/nature00900	http://dx.doi.org/10.1038/nature00900			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12077607				2022-12-28	WOS:000176599200034
J	Sassone-Corsi, P				Sassone-Corsi, P			Unique chromatin remodeling and transcriptional regulation in spermatogenesis	SCIENCE			English	Review							POLYMERASE-II TRANSCRIPTION; TBP-LIKE FACTOR; MICE LACKING; RNA; SPERMIOGENESIS; PHOSPHORYLATION; DIFFERENTIATION; INACTIVATION; FERTILITY; TLF/TRF2	Most of our knowledge of transcriptional regulation comes from studies in somatic cells. However, increasing evidence reveals that gene regulation mechanisms are different in haploid germ cells. A number of highly specialized strategies operate during spermatogenesis. These include a unique chromatin reorganization program and the use of distinct promoter elements and specific transcription factors. Deciphering the rules governing transcriptional control during spermatogenesis will provide valuable insights of biomedical importance.	Inst Genet & Biol Mol & Cellulaire, F-67404 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Sassone-Corsi, P (corresponding author), Inst Genet & Biol Mol & Cellulaire, BP 10142, F-67404 Strasbourg, France.	paolosc@igbmc.u-strasbg.fr	Sassone-Corsi, Paolo/H-6182-2011					Ayoub N, 1997, CHROMOSOMA, V106, P1, DOI 10.1007/s004120050218; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; CROWLEY WF, 1991, RECENT PROG HORM RES, V47, P27; Dantonel JC, 2000, MOL CELL, V6, P715, DOI 10.1016/S1097-2765(00)00069-1; Eddy EM, 1998, CURR TOP DEV BIOL, V37, P141; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; HANDEL MA, 1994, CYTOGENET CELL GENET, V66, P83, DOI 10.1159/000133672; Hecht NB, 1998, BIOESSAYS, V20, P555, DOI 10.1002/(SICI)1521-1878(199807)20:7<555::AID-BIES6>3.3.CO;2-J; Hiller MA, 2001, GENE DEV, V15, P1021, DOI 10.1101/gad.869101; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kleene KC, 2001, MECH DEVELOP, V106, P3, DOI 10.1016/S0925-4773(01)00413-0; Lee K, 1995, P NATL ACAD SCI USA, V92, P12451, DOI 10.1073/pnas.92.26.12451; Martianov I, 2001, MOL CELL, V7, P509, DOI 10.1016/S1097-2765(01)00198-8; Martianov I, 2002, DEVELOPMENT, V129, P945; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Meetei AR, 2002, BIOCHEMISTRY-US, V41, P185, DOI 10.1021/bi0117652; MEISTRICH ML, HISTONES OTHER BASIC, P165; MILLS NC, 1977, BIOL REPROD, V17, P760, DOI 10.1095/biolreprod17.5.760; Muller F, 2001, CURR BIOL, V11, P282, DOI 10.1016/S0960-9822(01)00076-8; Ozer J, 2000, J BIOL CHEM, V275, P122, DOI 10.1074/jbc.275.1.122; PALMER DK, 1991, P NATL ACAD SCI USA, V88, P3734, DOI 10.1073/pnas.88.9.3734; Roest HP, 1996, CELL, V86, P799, DOI 10.1016/S0092-8674(00)80154-3; Sassone-Corsi P, 1998, SEMIN CELL DEV BIOL, V9, P475, DOI 10.1006/scdb.1998.0200; SassoneCorsi P, 1997, CELL, V88, P163, DOI 10.1016/S0092-8674(00)81834-6; SCHMIDT EE, 1995, DEVELOPMENT, V121, P2373; SOLARI AJ, 1974, INT REV CYTOL, V38, P273, DOI 10.1016/S0074-7696(08)60928-6; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Upadhyaya AB, 1999, J BIOL CHEM, V274, P18040, DOI 10.1074/jbc.274.25.18040; Veenstra GJC, 2000, SCIENCE, V290, P2312, DOI 10.1126/science.290.5500.2312; Wang PJ, 2001, NAT GENET, V27, P422, DOI 10.1038/86927; Wu JY, 2000, NAT GENET, V25, P448, DOI 10.1038/78153; Yu YE, 2000, P NATL ACAD SCI USA, V97, P4683, DOI 10.1073/pnas.97.9.4683; Zhang D, 2001, SCIENCE, V292, P1153, DOI 10.1126/science.1059188; Zhao M, 2001, MOL CELL BIOL, V21, P7243, DOI 10.1128/MCB.21.21.7243-7255.2001	34	339	354	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	2002	296	5576					2176	2178		10.1126/science.1070963	http://dx.doi.org/10.1126/science.1070963			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077401				2022-12-28	WOS:000176379000042
J	Wentworth, P				Wentworth, P			Antibody design by man and nature	SCIENCE			English	Editorial Material							CATALYTIC ANTIBODIES; REACTIVE IMMUNIZATION; STRATEGY; HYDROLYSIS; BAIT		Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Wentworth, P (corresponding author), Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.							ARLAUD GJ, 1987, IMMUNOL TODAY, V8, P1076; Blackburn GM, 1998, ADV PHYS ORG CHEM, V31, P249; Gao CS, 1998, J AM CHEM SOC, V120, P2211, DOI 10.1021/ja9720220; HEIN MB, 1991, BIOTECHNOL PROGR, V7, P455, DOI 10.1021/bp00011a011; JANDA KD, 1990, J AM CHEM SOC, V112, P1274, DOI 10.1021/ja00159a074; JANDA KD, 1993, SCIENCE, V259, P490, DOI 10.1126/science.8424171; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P3; JONES LH, 2001, J AM CHEM SOC, V123; KLEBANOFF S, 1998, ENCY IMMUNOL, V3, P1713; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LI TY, 1994, SCIENCE, V264, P1289, DOI 10.1126/science.8191282; Lo CHL, 1997, J AM CHEM SOC, V119, P10251, DOI 10.1021/ja971442m; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; SIM RB, 1991, IMMUNOL TODAY, V12, P307, DOI 10.1016/0167-5699(91)90004-D; Toker JD, 2000, J AM CHEM SOC, V122, P3244, DOI 10.1021/ja994423g; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; WAGNER J, 1995, SCIENCE, V270, P1797, DOI 10.1126/science.270.5243.1797; WENTOWRTH P, 1999, COMPREHENSIVE ASYMME, V1, P1403; Wentworth AD, 2000, P NATL ACAD SCI USA, V97, P10930, DOI 10.1073/pnas.97.20.10930; Wentworth P, 2001, SCIENCE, V293, P1806, DOI 10.1126/science.1062722; Wentworth P, 1998, P NATL ACAD SCI USA, V95, P5971, DOI 10.1073/pnas.95.11.5971; Wentworth P, 1998, CURR OPIN CHEM BIOL, V2, P138, DOI 10.1016/S1367-5931(98)80046-X; Wentworth P, 1997, J AM CHEM SOC, V119, P2315, DOI 10.1021/ja961625t; Wentworth P, 1996, P NATL ACAD SCI USA, V93, P799, DOI 10.1073/pnas.93.2.799; WIRSCHING P, 1995, SCIENCE, V270, P1775, DOI 10.1126/science.270.5243.1775	25	10	15	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 21	2002	296	5576					2247	2249		10.1126/science.296.5576.2247	http://dx.doi.org/10.1126/science.296.5576.2247			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077422				2022-12-28	WOS:000176379000066
J	Seidler, RD; Purushotham, A; Kim, SG; Ugurbil, K; Willingham, D; Ashe, J				Seidler, RD; Purushotham, A; Kim, SG; Ugurbil, K; Willingham, D; Ashe, J			Cerebellum activation associated with performance change but not motor learning	SCIENCE			English	Article							ARM MOVEMENTS; BRAIN; LESIONS; MEMORY; REFLEX; TIME; HAND	The issue of whether the cerebellum contributes to motor skill learning is controversial, principally because of the difficulty of separating the effects of motor learning from changes in performance. We performed a functional magnetic resonance imaging investigation during an implicit, motor sequence-learning task that was designed to separate these two processes. During the sequence-encoding phase, human participants performed a concurrent distractor task that served to suppress the performance changes associated with learning. Upon removal of the distractor, participants showed evidence of having learned. No cerebellar activation was associated with the learning phase, despite extensive involvement of other cortical and subcortical regions. There was, however, significant cerebellar activation during the expression of learning; thus, the cerebellum does not contribute to learning of the motor skill itself but is engaged primarily in the modification of performance.	Vet Affairs Med Ctr, Brain Sci Ctr 11B, Minneapolis, MN 55417 USA; Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Magnet Resonance Res, Minneapolis, MN 55455 USA; Univ Virginia, Dept Psychol, Charlottesville, VA 22904 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Virginia	Ashe, J (corresponding author), Vet Affairs Med Ctr, Brain Sci Ctr 11B, Minneapolis, MN 55417 USA.	ashe@umn.edu	Ugurbil, Kamil/AAD-6058-2022; Kim, Seong-Gi/A-2691-2008	Seidler, Rachael/0000-0003-2452-9024	NCRR NIH HHS [RR08079] Funding Source: Medline; NINDS NIH HHS [NS40106] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040106] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; BLOEDEL JR, 1995, BEHAV BRAIN RES, V68, P1, DOI 10.1016/0166-4328(94)00171-B; EVANS AC, 1994, NATO ADV SCI INST A, V264, P263; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; FRISTON KJ, 1992, P ROY SOC B-BIOL SCI, V248, P223, DOI 10.1098/rspb.1992.0065; GILBERT PFC, 1977, BRAIN RES, V128, P309, DOI 10.1016/0006-8993(77)90997-0; Grill SE, 1997, EXP BRAIN RES, V113, P33; HOLMES G, 1939, BRAIN, V63, P1; Horwitz B, 2000, NEUROIMAGE, V12, P434, DOI 10.1006/nimg.2000.0632; Imamizu H, 2000, NATURE, V403, P192, DOI 10.1038/35003194; ITO M, 1982, ANNU REV NEUROSCI, V5, P275, DOI 10.1146/annurev.ne.05.030182.001423; IVRY RB, 1989, J COGNITIVE NEUROSCI, V1, P134; Kitazawa S, 1998, NATURE, V392, P494, DOI 10.1038/33141; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MEYERLOHMANN J, 1977, J NEUROPHYSIOL, V40, P1038, DOI 10.1152/jn.1977.40.5.1038; NISSEN MJ, 1987, COGNITIVE PSYCHOL, V19, P1, DOI 10.1016/0010-0285(87)90002-8; Sakai K, 1998, J NEUROSCI, V18, P1827; Schmahmann J.D., 2000, MRI ATLAS HUMAN CERE; Seitz R J, 1990, Neuroreport, V1, P57, DOI 10.1097/00001756-199009000-00016; STEINMETZ JE, 1992, J NEUROSCI, V12, P4403; Talairach J., 1988, COPLANAR STEREOTAXIC; THOMPSON RF, 1994, ANNU REV NEUROSCI, V17, P519, DOI 10.1146/annurev.neuro.17.1.519; Toni I, 1998, NEUROIMAGE, V8, P50, DOI 10.1006/nimg.1998.0349; TSUJIMOTO T, 1993, BRAIN RES, V629, P1, DOI 10.1016/0006-8993(93)90473-Z; van Mier H, 1998, J NEUROPHYSIOL, V80, P2177, DOI 10.1152/jn.1998.80.4.2177; Vaughan T., 2001, IEEE Antennas and Propagation Society International Symposium. 2001 Digest. Held in conjunction with: USNC/URSI National Radio Science Meeting (Cat. No.01CH37229), P378, DOI 10.1109/APS.2001.958871; WELSH JP, 1989, J NEUROSCI, V9, P299; Willingham DB, 2000, MEM COGNITION, V28, P366, DOI 10.3758/BF03198552; YEO CH, 1984, BEHAV BRAIN RES, V13, P261, DOI 10.1016/0166-4328(84)90168-2	29	161	162	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 14	2002	296	5575					2043	2046		10.1126/science.1068524	http://dx.doi.org/10.1126/science.1068524			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	563UD	12065841				2022-12-28	WOS:000176273300058
J	van Leeuwen, F; Gafken, PR; Gottschling, DE				van Leeuwen, F; Gafken, PR; Gottschling, DE			Dot1p modulates silencing in yeast by methylation of the nucleosome core	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; HISTONE H3; CHROMATIN; PROTEIN; BINDING; METHYLTRANSFERASE; IDENTIFICATION; PROMOTER; HETEROCHROMATIN; PARTICLE	DOT1 was originally identified as a gene affecting telomeric silencing in S. cerevisiae. We now find that Dot1p methylates histone H3 on lysine 79, which maps to the top and bottom of the nucleosome core. Methylation occurs only when histone H3 is assembled in chromatin. In vivo, Dot1p is solely responsible for this methylation and methylates similar to90% of histone H3. In dot1Delta cells, silencing is compromised and silencing proteins become redistributed at the expense of normally silenced loci. We suggest that methylation of histone H3 lysine 79 limits silencing to discrete loci by preventing the binding of Sir proteins elsewhere along the genome. Because Dot1p and histone H3 are conserved, similar mechanisms are likely at work in other eukaryotes.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Proteom Facil, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Gottschling, DE (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.	dgottsch@fhcrc.org	van Leeuwen, Fred/A-7698-2010	van Leeuwen, Fred/0000-0002-7267-7251	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043893] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43893] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brachmann CB, 1998, YEAST, V14, P115; Brehm A, 2000, EMBO J, V19, P4332, DOI 10.1093/emboj/19.16.4332; Carmen AA, 2002, J BIOL CHEM, V277, P4778, DOI 10.1074/jbc.M110532200; Dlakic M, 2001, TRENDS BIOCHEM SCI, V26, P405, DOI 10.1016/S0968-0004(01)01856-4; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Fajkus J, 2001, BIOCHEM BIOPH RES CO, V280, P961, DOI 10.1006/bbrc.2000.4208; Fan JY, 2002, NAT STRUCT BIOL, V9, P172, DOI 10.1038/nsb767; Fourel G, 1999, EMBO J, V18, P2522, DOI 10.1093/emboj/18.9.2522; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; Georgel PT, 2001, P NATL ACAD SCI USA, V98, P8584, DOI 10.1073/pnas.151258798; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; Gottschling DE, 2000, CURR BIOL, V10, pR708, DOI 10.1016/S0960-9822(00)00714-4; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Guyon JR, 1999, MOL CELL BIOL, V19, P2088; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Horn PJ, 2002, NAT STRUCT BIOL, V9, P167, DOI 10.1038/nsb762; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; Kelly TJ, 2000, MOL CELL BIOL, V20, P7051, DOI 10.1128/MCB.20.19.7051-7058.2000; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Lebrun E, 2001, GENETICS, V158, P167; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MANN RK, 1992, EMBO J, V11, P3297, DOI 10.1002/j.1460-2075.1992.tb05408.x; McBride AE, 2000, J BIOL CHEM, V275, P3128, DOI 10.1074/jbc.275.5.3128; Mizzen CA, 1999, METHOD ENZYMOL, V304, P675; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; Peterson SE, 2001, NAT GENET, V27, P64, DOI 10.1038/83778; Pryde FE, 1999, EMBO J, V18, P2538, DOI 10.1093/emboj/18.9.2538; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; San-Segundo PA, 2000, MOL BIOL CELL, V11, P3601, DOI 10.1091/mbc.11.10.3601; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Singer MS, 1998, GENETICS, V150, P613; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; VANLEEUWEN F, 2002, IN PRESS METHODS ENZ, V350; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207; Woodcock CL, 2001, CURR OPIN GENET DEV, V11, P130, DOI 10.1016/S0959-437X(00)00169-6; Wyrick JJ, 2001, SCIENCE, V294, P2357, DOI 10.1126/science.1066101; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	45	639	657	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	2002	109	6					745	756		10.1016/S0092-8674(02)00759-6	http://dx.doi.org/10.1016/S0092-8674(02)00759-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	563PW	12086673	Bronze			2022-12-28	WOS:000176265600005
J	Barnetson, RS; Rogers, M				Barnetson, RS; Rogers, M			Childhood atopic eczema	BRITISH MEDICAL JOURNAL			English	Review							CONTROLLED TRIAL; DERMATITIS; CHILDREN; CYCLOSPORINE; ADULTS		Royal Prince Alfred Hosp, Dept Dermatol, Camperdown, NSW 2050, Australia; New Childrens Hosp, Dept Dermatol, Sydney, NSW, Australia	University of Sydney; University of Sydney	Barnetson, RS (corresponding author), Royal Prince Alfred Hosp, Dept Dermatol, Camperdown, NSW 2050, Australia.							BARNETSON RS, 1989, CLIN EXP ALLERGY, V19, P321, DOI 10.1111/j.1365-2222.1989.tb02390.x; BerthJones J, 1996, J AM ACAD DERMATOL, V34, P1016, DOI 10.1016/S0190-9622(96)90281-9; Boguniewicz M, 1998, J ALLERGY CLIN IMMUN, V102, P637, DOI 10.1016/S0091-6749(98)70281-7; Carucci JA, 1998, ARCH DERMATOL, V134, P785, DOI 10.1001/archderm.134.7.785; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; GOODYEAR HM, 1991, BRIT J DERMATOL, V125, P604, DOI 10.1111/j.1365-2133.1991.tb14807.x; GRAHAMBROWN R, 1992, LANCET, V340, P673, DOI 10.1016/0140-6736(92)92208-W; HANNUKSELA M, 1993, ANN ALLERGY, V70, P127; Harper J, 2001, BRIT J DERMATOL, V144, P781, DOI 10.1046/j.1365-2133.2001.04133.x; Harper JI, 2001, DERMATOLOGY, V203, P3, DOI 10.1159/000051694; HOLGATE ST, 1993, ALLERGY; Howlett S, 1999, BRIT J DERMATOL, V140, P381; Kang S, 2001, J AM ACAD DERMATOL, V44, pS58, DOI 10.1067/mjd.2001.109812; MITCHELL EB, 1982, LANCET, V1, P127; Murphy L, 2001, BRIT J DERMATOL, V144, P927; Pei AYS, 2001, PEDIAT ALLERG IMM-UK, V12, P154, DOI 10.1034/j.1399-3038.2001.012003154.x; Roehr CC, 2001, J ALLERGY CLIN IMMUN, V107, P548, DOI 10.1067/mai.2001.112849; Sporik R, 1997, J ALLERGY CLIN IMMUN, V99, P861, DOI 10.1016/S0091-6749(97)80029-2; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1	19	92	96	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 8	2002	324	7350					1376	1379		10.1136/bmj.324.7350.1376	http://dx.doi.org/10.1136/bmj.324.7350.1376			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BQ	12052810	Green Published			2022-12-28	WOS:000176234100025
J	Borgdorff, AJ; Choquet, D				Borgdorff, AJ; Choquet, D			Regulation of AMPA receptor lateral movements	NATURE			English	Article							LONG-TERM DEPRESSION; SYNAPTIC TRANSMISSION; HIPPOCAMPAL CULTURES; MOLECULAR MECHANISMS; NEURONS; ENDOCYTOSIS; PLASTICITY; EXPRESSION; SYNAPSES; LTD	An essential feature in the modulation of the efficacy of synaptic transmission is rapid changes in the number of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors at post-synaptic sites on neurons(1-4). Regulation of receptor endo- and exocytosis has been shown to be involved in this process(5-14). Whether regulated lateral diffusion of receptors in the plasma membrane also participates in receptor exchange to and from post-synaptic sites remains unknown. We analysed the lateral mobility of native AMPA receptors containing the glutamate receptor subunit GluR2 in rat cultured hippocampal neurons, using single-particle tracking and video microscopy. Here we show that AMPA receptors alternate within seconds between rapid diffusive and stationary behaviour. During maturation of neurons, stationary periods increase in frequency and length, often in spatial correlation with synaptic sites. Raising intracellular calcium, a central element in synaptic plasticity, triggers rapid receptor immobilization and local accumulation on the neuronal surface. We suggest that calcium influx prevents AMPA receptors from diffusing, and that lateral receptor diffusion to and from synaptic sites acts in the rapid and controlled regulation of receptor numbers at synapses.	Univ Bordeaux 2, CNRS, UMR 5091, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Choquet, D (corresponding author), Univ Bordeaux 2, CNRS, UMR 5091, F-33077 Bordeaux, France.		Choquet, Daniel/E-4203-2013; Choquet, Daniel/K-7893-2018; Choquet, Daniel/GOJ-8825-2022	Choquet, Daniel/0000-0003-4726-9763; Choquet, Daniel/0000-0003-4726-9763				Beattie EC, 2000, NAT NEUROSCI, V3, P1291, DOI 10.1038/81823; Benmerah A, 2000, J BIOL CHEM, V275, P3288, DOI 10.1074/jbc.275.5.3288; Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; FLETCHER TL, 1994, J NEUROSCI, V14, P6695; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Hemar A, 1997, J NEUROSCI, V17, P9026; Kiss JZ, 2001, REV NEUROSCIENCE, V12, P297; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Lin JW, 2000, NAT NEUROSCI, V3, P1282, DOI 10.1038/81814; Liu SQJ, 2000, NATURE, V405, P454, DOI 10.1038/35013064; Lu WY, 2001, NEURON, V29, P243, DOI 10.1016/S0896-6273(01)00194-5; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Luthi A, 1999, NEURON, V24, P389, DOI 10.1016/S0896-6273(00)80852-1; Malinow R, 2000, CURR OPIN NEUROBIOL, V10, P352, DOI 10.1016/S0959-4388(00)00099-4; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Meier J, 2001, NAT NEUROSCI, V4, P253, DOI 10.1038/85099; Noel J, 1999, NEURON, V23, P365, DOI 10.1016/S0896-6273(00)80786-2; Nusser Z, 2000, CURR OPIN NEUROBIOL, V10, P337, DOI 10.1016/S0959-4388(00)00086-6; Pickard L, 2000, J NEUROSCI, V20, P7922; SERGE A, IN PRESS J NEUROSCI; Sheng M, 2001, CELL, V105, P825, DOI 10.1016/S0092-8674(01)00406-8; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; SIMSON R, 1995, BIOPHYS J, V69, P989, DOI 10.1016/S0006-3495(95)79972-6; Simson R, 1998, BIOPHYS J, V74, P297, DOI 10.1016/S0006-3495(98)77787-2; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; Yang SN, 1999, J NEUROPHYSIOL, V81, P781, DOI 10.1152/jn.1999.81.2.781	29	389	400	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	2002	417	6889					649	653		10.1038/nature00780	http://dx.doi.org/10.1038/nature00780			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050666				2022-12-28	WOS:000176001200048
J	Pedley, TA; Hauser, WA				Pedley, TA; Hauser, WA			Sudden death in epilepsy: a wake-up call for management	LANCET			English	Editorial Material							UNEXPECTED DEATH; RISK-FACTORS; UNEXPLAINED DEATH; SUDEP; SEIZURES		Neurol Inst, New York, NY 10032 USA		Pedley, TA (corresponding author), Neurol Inst, 710 W 168th St, New York, NY 10032 USA.		Hauser, W Allen/AAB-5277-2020					Annegers JF, 1999, SEIZURE-EUR J EPILEP, V8, P347, DOI 10.1053/seiz.1999.0306; Donner EJ, 2001, NEUROLOGY, V57, P430, DOI 10.1212/WNL.57.3.430; EARNEST MP, 1992, EPILEPSIA, V33, P310, DOI 10.1111/j.1528-1157.1992.tb02321.x; Ficker DM, 2000, EPILEPSIA, V41, pS7, DOI 10.1111/j.1528-1157.2000.tb01519.x; Kloster R, 1999, J NEUROL NEUROSUR PS, V67, P439, DOI 10.1136/jnnp.67.4.439; Langan Y, 2000, SEIZURE-EUR J EPILEP, V9, P179, DOI 10.1053/seiz.2000.0388; Langan Y, 2000, J NEUROL NEUROSUR PS, V68, P211, DOI 10.1136/jnnp.68.2.211; LEESTMA JE, 1984, EPILEPSIA, V25, P84, DOI 10.1111/j.1528-1157.1984.tb04159.x; Nashef L, 1998, J NEUROL NEUROSUR PS, V64, P349, DOI 10.1136/jnnp.64.3.349; Nei M, 2000, EPILEPSIA, V41, P542, DOI 10.1111/j.1528-1157.2000.tb00207.x; Nilsson L, 1999, LANCET, V353, P888, DOI 10.1016/S0140-6736(98)05114-9; Opeskin K, 2000, J CLIN NEUROSCI, V7, P34, DOI 10.1054/jocn.1999.0137; Simon RP, 1997, EPILEPSIA, V38, pS35, DOI 10.1111/j.1528-1157.1997.tb06124.x; So EL, 2000, EPILEPSIA, V41, P1494, DOI 10.1111/j.1528-1157.2000.tb00128.x; TERRENCE CF, 1975, NEUROLOGY, V25, P594, DOI 10.1212/WNL.25.6.594; Timmings PL, 1998, SEIZURE-EUR J EPILEP, V7, P289, DOI 10.1016/S1059-1311(98)80020-4; Walczak TS, 2001, NEUROLOGY, V56, P519, DOI 10.1212/WNL.56.4.519	17	55	56	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 25	2002	359	9320					1790	1791		10.1016/S0140-6736(02)08726-3	http://dx.doi.org/10.1016/S0140-6736(02)08726-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044369				2022-12-28	WOS:000175775500002
J	Lassen, MR; Bauer, KA; Eriksson, BI; Turpie, AGG				Lassen, MR; Bauer, KA; Eriksson, BI; Turpie, AGG		European Pentasaccharide Hip Elec	Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison	LANCET			English	Article							DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; SYNTHETIC PENTASACCHARIDE; RECOMBINANT HIRUDIN; PULMONARY-EMBOLISM; FACTOR XA; INHIBITION; GENERATION; TRIALS; RISK	Background Despite use of thromboprophylaxis, elective hip-replacement surgery carries a high risk of venous thromboembolic complications. We aimed to assess the ability of the pentasaccharide fondaparinux, the first of a new class of synthetic antithrombotic agents, to further reduce this risk. Methods In a double-blind study, we randomly assigned 2309 consecutive patients aged 18 years or older who were undergoing elective hip-replacement surgery to once daily, subcutaneous injections of either 2.5 mg fondaparinux, starting postoperatively, or 40 mg enoxaparin, starting preoperatively. The primary efficacy outcome was venous thromboembolism up to day 11, defined as deep-vein thrombosis detected by mandatory bilateral venography, documented symptomatic deep-vein thrombosis, or documented symptomatic pulmonary embolism. The main safety outcomes were bleeding and death. The duration of follow-up was 6 weeks. Analysis was per protocol. Findings We assessed the primary efficacy outcome in 1827 (79%) of 2309 patients. By day 11, venous thromboembolisms were recorded in 37 (4%) of 908 patients assigned to fondaparinux and in 85 (9%) of 919 assigned to enoxaparin (difference -5.2% [95% Cl -8.1 to -2.7], p<0.0001). The relative reduction in risk was 55.9% (95% CI 33.1-72.8). The two groups did not differ in frequency of death or clinically relevant bleeding. Interpretation Drugs that act through specific inhibition of factor Xa, such as fondaparinux, could be more effective than low molecular weight heparins in prevention of venous thromboembolism in patients undergoing hip-replacement surgery.	Copenhagen Univ Hosp, Dept Orthopaed, DK-3400 Hillerod, Denmark; VA Boston Healthcare Syst, Dept Med, Boston, MA USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Sahlgrenska Univ Hosp Ostra, Dept Orthopaed, Gothenburg, Sweden; Hamilton Hlth Sci Corp, Dept Med, Gen Div, Hamilton, ON, Canada	University of Copenhagen; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Beth Israel Deaconess Medical Center; Sahlgrenska University Hospital; McMaster University	Lassen, MR (corresponding author), Copenhagen Univ Hosp, Dept Orthopaed, DK-3400 Hillerod, Denmark.			Eriksson, Bengt/0000-0001-6894-7434				Bauer KA, 2001, NEW ENGL J MED, V345, P1305, DOI 10.1056/NEJMoa011099; BORRIS LC, 1991, ARCH INTERN MED, V151, P1621; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; Davidson BL, 1998, HAEMOSTASIS, V28, P113; ERIKSSON BI, 1991, J BONE JOINT SURG AM, V73A, P484, DOI 10.2106/00004623-199173040-00002; Eriksson BI, 1997, NEW ENGL J MED, V337, P1329, DOI 10.1056/NEJM199711063371901; Eriksson BI, 1996, LANCET, V347, P635, DOI 10.1016/S0140-6736(96)91200-3; Eriksson BI, 2001, NEW ENGL J MED, V345, P1298, DOI 10.1056/NEJMoa011100; Geerts WH, 2001, CHEST, V119, p132S, DOI 10.1378/chest.119.1_suppl.132S; Havig O, 1977, Acta Chir Scand Suppl, V478, P1; Hull RD, 2000, ARCH INTERN MED, V160, P2199, DOI 10.1001/archinte.160.14.2199; Lie SA, 2000, ACTA ORTHOP SCAND, V71, P19, DOI 10.1080/00016470052943838; Lormeau JC, 1995, THROMB HAEMOSTASIS, V74, P1474; MOSER KM, 1981, ANN INTERN MED, V94, P439, DOI 10.7326/0003-4819-94-4-439; MURRAY DW, 1995, J BONE JOINT SURG BR, V77B, P3, DOI 10.1302/0301-620X.77B1.7822392; Nicolaides AN, 2001, INT ANGIOL, V20, P1; PETITOU M, 1991, NATURE, V350, P30; PLANES A, 1988, THROMB HAEMOSTASIS, V60, P407; Planes A, 1998, BLOOD COAGUL FIBRIN, V9, P499, DOI 10.1097/00001721-199809000-00007; Planes A, 1999, THROMB HAEMOSTASIS, V81, P22; Planes A, 1996, LANCET, V348, P224, DOI 10.1016/S0140-6736(96)01453-5; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; Turpie AGG, 2002, LANCET, V359, P1721, DOI 10.1016/S0140-6736(02)08648-8; Turpie AGG, 2001, NEW ENGL J MED, V344, P619, DOI 10.1056/NEJM200103013440901; VANBOECKEL CAA, 1993, ANGEW CHEM INT EDIT, V32, P1671, DOI 10.1002/anie.199316713; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WALENGA JM, 1988, THROMB RES, V51, P23, DOI 10.1016/0049-3848(88)90279-4	27	381	394	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 18	2002	359	9319					1715	1720		10.1016/S0140-6736(02)08652-X	http://dx.doi.org/10.1016/S0140-6736(02)08652-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049858				2022-12-28	WOS:000175740500006
J	Odze, R				Odze, R			Cytokeratin 7/20 immunostaining: Barrett's oesophagus or gastric intestinal metaplasia?	LANCET			English	Editorial Material							GASTROESOPHAGEAL REFLUX DISEASE; ESOPHAGOGASTRIC JUNCTION; HELICOBACTER-PYLORI; ESOPHAGUS; INFLAMMATION; CARDIA; IMMUNOREACTIVITY; EXPRESSION; PATTERNS; SUBSETS		Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Odze, R (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.	rodze@partners.org						Chandrasoma PT, 2000, AM J SURG PATHOL, V24, P344, DOI 10.1097/00000478-200003000-00002; Couvelard A, 2001, GUT, V49, P761, DOI 10.1136/gut.49.6.761; El-Zimaity HMT, 2001, AM J GASTROENTEROL, V96, P1378; Glickman JN, 2001, AM J SURG PATHOL, V25, P87, DOI 10.1097/00000478-200101000-00010; Glickman JN, 2001, AM J SURG PATHOL, V25, P569, DOI 10.1097/00000478-200105000-00002; Goldblum JR, 2000, DIGEST DIS, V18, P14, DOI 10.1159/000016929; Goldblum JR, 1998, GASTROENTEROLOGY, V114, P633, DOI 10.1016/S0016-5085(98)70576-1; Kirchner T, 2001, VIRCHOWS ARCH, V439, P512, DOI 10.1007/s004280100477; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Nandurkar S, 1997, GUT, V40, P710, DOI 10.1136/gut.40.6.710; Oberg S, 1997, ANN SURG, V226, P522, DOI 10.1097/00000658-199710000-00013; Ormsby AH, 1999, HUM PATHOL, V30, P288, DOI 10.1016/S0046-8177(99)90007-2; Ormsby AH, 2000, GASTROENTEROLOGY, V119, P683, DOI 10.1053/gast.2000.16482; ORMSBY AH, 2000, MODERN PATHOL, V31, pA86; SARBIA M, 1993, PATHOL RES PRACT, V189, P530, DOI 10.1016/S0344-0338(11)80361-4; Shields HM, 2001, AM J GASTROENTEROL, V96, P3268; Trudgill NJ, 1997, GUT, V41, P585, DOI 10.1136/gut.41.5.585; Wallner B, 2001, SCAND J GASTROENTERO, V36, P910, DOI 10.1080/003655201750305404	18	15	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 18	2002	359	9319					1711	1713		10.1016/S0140-6736(02)08661-0	http://dx.doi.org/10.1016/S0140-6736(02)08661-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049855				2022-12-28	WOS:000175740500003
J	Bassler, BL				Bassler, BL			Small talk: Cell-to-cell communication in bacteria	CELL			English	Review							QUORUM-SENSING SIGNAL; STAPHYLOCOCCUS-AUREUS; VIRULENCE; BIOSYNTHESIS	In a process called quorum sensing, groups of bacteria communicate with one another to coordinate their behavior and function like a multicellular organism. A diverse array of secreted chemical signal molecules and signal detection apparatuses facilitate highly productive intra- and interspecies relationships.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Bassler, BL (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.			Bassler, Bonnie/0000-0002-0043-746X				Chen X, 2002, NATURE, V415, P545, DOI 10.1038/415545a; Dong YH, 2000, P NATL ACAD SCI USA, V97, P3526, DOI 10.1073/pnas.060023897; Dong YH, 2001, NATURE, V411, P813, DOI 10.1038/35081101; Lyon GJ, 2000, P NATL ACAD SCI USA, V97, P13330, DOI 10.1073/pnas.97.24.13330; Mayville P, 1999, P NATL ACAD SCI USA, V96, P1218, DOI 10.1073/pnas.96.4.1218; Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165; PIERSON LS, 1994, J BACTERIOL, V176, P3966, DOI 10.1128/JB.176.13.3966-3974.1994; Schauder S, 2001, MOL MICROBIOL, V41, P463, DOI 10.1046/j.1365-2958.2001.02532.x; Watson WT, 2002, MOL CELL, V9, P685, DOI 10.1016/S1097-2765(02)00480-X; ZHANG P, 2002, IN PRESS NATURE; Zhu J, 2001, P NATL ACAD SCI USA, V98, P1507, DOI 10.1073/pnas.98.4.1507	11	521	562	13	168	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 17	2002	109	4					421	424		10.1016/S0092-8674(02)00749-3	http://dx.doi.org/10.1016/S0092-8674(02)00749-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	553VM	12086599	Bronze			2022-12-28	WOS:000175696800004
J	Dabis, F; Orne-Gliemann, J; Perez, F; Leroy, V; Newell, ML; Coutsoudis, A; Coovadia, H				Dabis, F; Orne-Gliemann, J; Perez, F; Leroy, V; Newell, ML; Coutsoudis, A; Coovadia, H		Working Grp Women Child Hlth	Improving child health: the role of research	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VITAMIN-A SUPPLEMENTATION; INSECTICIDE-TREATED NETS; VERTICAL TRANSMISSION; COTE-DIVOIRE; DOUBLE-BLIND; MORTALITY; MALARIA; ZIDOVUDINE; MORBIDITY		Univ Bordeaux 2, Inst Sante Publ Epidemiol & Dev, Working Grp, F-33076 Bordeaux, France; Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 3JH, England; Univ KwaZulu Natal, Dept Paediat & Child Hlth, ZA-4001 Durban, South Africa	UDICE-French Research Universities; Universite de Bordeaux; University of London; University College London; University of Kwazulu Natal	Dabis, F (corresponding author), Univ Bordeaux 2, Inst Sante Publ Epidemiol & Dev, Working Grp, Case 11, F-33076 Bordeaux, France.	francois.dabis@isped.u-bordeaux2.fr	Leroy, Valeriane/GQB-1102-2022; Leroy, Valeriane/AAO-5175-2020; Leroy, Valeriane/F-8129-2013; Orne-Gliemann, Joanna/T-2787-2019; DABIS, FRANCOIS/S-9298-2019; Newell, Marie-Louise/AAE-8222-2019; Perez, Freddy/AAN-3893-2020	Leroy, Valeriane/0000-0003-3542-8616; Leroy, Valeriane/0000-0003-3542-8616; Leroy, Valeriane/0000-0003-3542-8616; DABIS, FRANCOIS/0000-0002-1614-8857; Newell, Marie-Louise/0000-0002-1074-7699; Perez, Freddy/0000-0003-2001-0057				Abdulla S, 2001, BMJ-BRIT MED J, V322, P270, DOI 10.1136/bmj.322.7281.270; ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; [Anonymous], 1998, B WORLD HEALTH ORGAN, V76, P101; [Anonymous], INV HLTH RES DEV; [Anonymous], 1999, WORLD HLTH REPORT 19; Baggaley R, 2000, B WORLD HEALTH ORGAN, V78, P1036; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *COUNC HLTH RES DE, 2000, ENHR HDB GUID ESS NA; *COUNC HLTH RES DE, 2000, HLTH POLICY PLAN, V15, P130; *COUNC HLTH RES DE, 2000, LESS RES ACT CAS STU; COUTSOUDIS A, 1995, AM J PUBLIC HEALTH, V85, P1076, DOI 10.2105/AJPH.85.8_Pt_1.1076; Cutts FT, 1999, VACCINE, V17, pS47, DOI 10.1016/S0264-410X(99)00309-6; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0; Deen JL, 1999, B WORLD HEALTH ORGAN, V77, P518; FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898; Global Forum for Health Research, 2000, 10 90 REP HLTH RES; Goodman CA, 1999, HEALTH POLICY PLANN, V14, P301, DOI 10.1093/heapol/14.4.301; GREENBERG AE, 1998, PEDIAT AIDS CHALLENG; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; Kidane G, 2000, LANCET, V356, P550, DOI 10.1016/S0140-6736(00)02580-0; Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435; MAGESA SM, 1991, ACTA TROP, V49, P97, DOI 10.1016/0001-706X(91)90057-Q; Martines J, 1998, LANCET, V352, P1257, DOI 10.1016/S0140-6736(98)02487-8; Msellati P, 2001, B WORLD HEALTH ORGAN, V79, P641; Mulholland K, 1999, PEDIATR INFECT DIS J, V18, pS17; MURRAY CJL, 1996, GLOBAL BURDEN DIS ME; Nacul LC, 1997, BMJ-BRIT MED J, V315, P505, DOI 10.1136/bmj.315.7107.505; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; Nevill CG, 1996, TROP MED INT HEALTH, V1, P139; Nolan T, 2001, LANCET, V357, P106, DOI 10.1016/S0140-6736(00)03542-X; PELLETIER DL, 1995, B WORLD HEALTH ORGAN, V73, P443; ROSS DA, 1993, LANCET, V342, P7, DOI 10.1016/0140-6736(93)91879-Q; Rutstein SO, 2000, B WORLD HEALTH ORGAN, V78, P1256; Schellenberg JRMA, 2001, LANCET, V357, P1241, DOI 10.1016/S0140-6736(00)04404-4; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Sommer A, 1995, B WORLD HEALTH ORGAN, V73, P609; Thisyakorn U, 2000, AIDS, V14, P2921, DOI 10.1097/00002030-200012220-00014; World Health Organization, 2001, NEW DAT PREV MOTH TO	40	6	7	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 15	2002	324	7351					1444	1447						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	565CQ	12065272				2022-12-28	WOS:000176351400024
J	Steinhart, M; Wendorff, JH; Greiner, A; Wehrspohn, RB; Nielsch, K; Schilling, J; Choi, J; Gosele, U				Steinhart, M; Wendorff, JH; Greiner, A; Wehrspohn, RB; Nielsch, K; Schilling, J; Choi, J; Gosele, U			Polymer nanotubes by wetting of ordered porous templates	SCIENCE			English	Article									Max Planck Inst Microstruct Phys, D-06120 Halle An Der Saale, Germany; Univ Marburg, Inst Phys Chem, D-35032 Marburg, Germany; Univ Marburg, Ctr Mat Sci, D-35032 Marburg, Germany	Max Planck Society; Philipps University Marburg; Philipps University Marburg	Wehrspohn, RB (corresponding author), Max Planck Inst Microstruct Phys, Weinberg 2, D-06120 Halle An Der Saale, Germany.	wehrspoh@mpi-halle.de	Steinhart, Martin/B-7811-2011; Choi, Jinsub/D-7131-2012; Wehrspohn, Ralf/B-9197-2011; Greiner, Andreas/AAQ-9488-2020; Nielsch, Kornelius/S-3196-2016	Steinhart, Martin/0000-0002-5241-8498; Wehrspohn, Ralf/0000-0002-6588-8544; Greiner, Andreas/0000-0002-5310-3850; Nielsch, Kornelius/0000-0003-2271-7726				Bognitzki M, 2000, ADV MATER, V12, P637, DOI 10.1002/(SICI)1521-4095(200005)12:9<637::AID-ADMA637>3.0.CO;2-W; DEGENNES PG, 1985, REV MOD PHYS, V57, P827, DOI 10.1103/RevModPhys.57.827; KISTLER SF, 1993, SURFACTANT SCI SERIE, V49, pCH6; Wehrspohn RB, 2001, MRS BULL, V26, P623, DOI 10.1557/mrs2001.156	4	797	836	8	262	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	2002	296	5575					1997	1997		10.1126/science.1071210	http://dx.doi.org/10.1126/science.1071210			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065828	Green Submitted			2022-12-28	WOS:000176273300043
J	Jesson, LK; Barrett, SCH				Jesson, LK; Barrett, SCH			Enantiostyly: Solving the puzzle of mirror-image flowers	NATURE			English	Article							EVOLUTION		Univ Toronto, Dept Bot, Toronto, ON M5S 3B2, Canada	University of Toronto	Jesson, LK (corresponding author), Univ Toronto, Dept Bot, 25 Willcocks St, Toronto, ON M5S 3B2, Canada.	barrett@botany.utoronto.ca	Barrett, Spencer C.H./S-5782-2019; Jesson, Linley/G-3285-2018; Barrett, Spencer CH/M-3751-2013	Barrett, Spencer C.H./0000-0002-7762-3455; Jesson, Linley/0000-0003-4969-160X; 				Barrett SCH, 2002, NAT REV GENET, V3, P274, DOI 10.1038/nrg776; Barrett SCH, 2000, ANN BOT-LONDON, V85, P253, DOI 10.1006/anbo.1999.1067; BOWERS KAW, 1975, AM J BOT, V62, P633, DOI 10.2307/2441943; HARDER LD, 1995, NATURE, V373, P512, DOI 10.1038/373512a0; Jesson LK, 2002, AM J BOT, V89, P253, DOI 10.3732/ajb.89.2.253; Todd J.E., 1882, AM NAT, V16, P281, DOI DOI 10.1086/273056	6	86	102	3	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	2002	417	6890					707	707		10.1038/417707a	http://dx.doi.org/10.1038/417707a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	561QY	12066175	Bronze			2022-12-28	WOS:000176154700034
J	Basnyat, B				Basnyat, B			A developing country perspective	LANCET			English	Editorial Material									Tribhuvan Univ, Inst Med, Kathmandu, Nepal	Tribhuvan University; Institute of Medicine (IoM) - Nepal	Basnyat, B (corresponding author), Tribhuvan Univ, Inst Med, Lal Durbar,GPO Box 3596, Kathmandu, Nepal.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 8	2002	359	9322					2026	2026		10.1016/S0140-6736(02)08824-4	http://dx.doi.org/10.1016/S0140-6736(02)08824-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076572				2022-12-28	WOS:000176232500029
J	Conte, MH; Weber, JC				Conte, MH; Weber, JC			Plant biomarkers in aerosols record isotopic discrimination of terrestrial photosynthesis	NATURE			English	Article							ATMOSPHERIC CO2; CARBON-DIOXIDE; ORGANIC-MATTER; LIPIDS; DELTA-C-13; BIOSPHERE; TRENDS; CYCLE	Carbon uptake by the oceans and by the terrestrial biosphere can be partitioned using changes in the C-12/C-13 isotopic ratio (delta(13)C) of atmospheric carbon dioxide(1-4), because terrestrial photosynthesis strongly discriminates against (CO2)-C-13,whereas ocean uptake does not. This approach depends on accurate estimates of the carbon isotopic discrimination of terrestrial photosynthesis (Delta; ref. 5) at large regional scales(6), yet terrestrial ecosystem heterogeneity(7) makes such estimates problematic. Here we show that ablated plant wax compounds in continental air masses can be used to estimate Delta over large spatial scales and at less than monthly temporal resolution. We measured plant waxes in continental air masses advected to Bermuda, which are mainly of North American origin, and used the wax isotopic composition to estimate Delta simply. Our estimates indicate a large (5-6parts per thousand) seasonal variation in Delta of the temperate North American biosphere, with maximum discrimination occurring in late spring, coincident with the onset of production. We suggest that the observed seasonality arises from several factors, including seasonal shifts in the proportions of production by C-3 and C-4 plants, and environmentally controlled adjustments in the photosynthetic discrimination of C-3-plant-dominated ecosystems.	Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA	Woods Hole Oceanographic Institution	Conte, MH (corresponding author), Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA.							Bakwin PS, 1998, GLOBAL BIOGEOCHEM CY, V12, P555, DOI 10.1029/98GB02265; Ballentine DC, 1996, ORG GEOCHEM, V25, P97, DOI 10.1016/S0146-6380(96)00110-6; CIAIS P, 1995, J GEOPHYS RES-ATMOS, V100, P5051, DOI 10.1029/94JD02847; COLLISTER JW, 1994, ORG GEOCHEM, V21, P619, DOI 10.1016/0146-6380(94)90008-6; CONTE MH, 2001, EOS T AGU, V82, pS77; CONTE MH, 2001, IN PRESS ORG GEOCHEM; EHLERINGER JR, 1993, OECOLOGIA, V95, P340, DOI 10.1007/BF00320986; Ehleringer JR, 1997, OECOLOGIA, V112, P285, DOI 10.1007/s004420050311; Farquhar G. D., 1993, Stable isotopes and plant carbon-water relations., P47; Flanagan LB, 1998, TRENDS ECOL EVOL, V13, P10, DOI 10.1016/S0169-5347(97)01275-5; FRANCEY RJ, 1995, NATURE, V373, P326, DOI 10.1038/373326a0; Fung I, 1997, GLOBAL BIOGEOCHEM CY, V11, P507, DOI 10.1029/97GB01751; GULZ PG, 1994, J PLANT PHYSIOL, V143, P453, DOI 10.1016/S0176-1617(11)81807-9; HADLEY JL, 1989, ARCTIC ALPINE RES, V21, P392, DOI 10.2307/1551648; Kawamura, 1995, BIOGEOCHEMICAL PROCE, P31; KORNER C, 1991, OECOLOGIA, V88, P30, DOI 10.1007/BF00328400; LLOYD J, 1994, OECOLOGIA, V99, P201, DOI 10.1007/BF00627732; Lockheart MJ, 1997, ORG GEOCHEM, V26, P137, DOI 10.1016/S0146-6380(96)00135-0; MARSHALL JD, 1994, ECOLOGY, V75, P1887, DOI 10.2307/1941593; MOODY JL, 1995, J GEOPHYS RES-ATMOS, V100, P7179, DOI 10.1029/94JD02830; Peltzer E.T., 1989, CHEM OCEANOGR, V10, P282; Randerson JT, 1997, GLOBAL BIOGEOCHEM CY, V11, P535, DOI 10.1029/97GB02268; Rayner PJ, 1999, TELLUS B, V51, P213, DOI 10.1034/j.1600-0889.1999.t01-1-00008.x; ROGGE WF, 1994, ENVIRON SCI TECHNOL, V28, P1375, DOI 10.1021/es00056a030; SIMONEIT BRT, 1989, J ATMOS CHEM, V8, P251, DOI 10.1007/BF00051497; SMEDLEY MP, 1991, OECOLOGIA, V85, P314, DOI 10.1007/BF00320605; STILL CJ, 1999, EOS T AGU, V80, pF93; TANS PP, 1993, GLOBAL BIOGEOCHEM CY, V7, P353, DOI 10.1029/93GB00053; Vogel J., 1993, STABLE ISOTOPES PLAN, P26; ZAFIRIOU OC, 1985, J GEOPHYS RES-ATMOS, V90, P2409, DOI 10.1029/JD090iD01p02409	30	86	91	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	2002	417	6889					639	641		10.1038/nature00777	http://dx.doi.org/10.1038/nature00777			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050663				2022-12-28	WOS:000176001200045
J	Duncan, RP; Williams, PA				Duncan, RP; Williams, PA			Ecology - Darwin's naturalization hypothesis challenged	NATURE			English	Article									Lincoln Univ, Soil Plant & Ecol Sci Div, Ecol & Entomol Grp, Canterbury, New Zealand; Landcare Res, Nelson, New Zealand	Lincoln University - New Zealand; Landcare Research - New Zealand	Duncan, RP (corresponding author), Lincoln Univ, Soil Plant & Ecol Sci Div, Ecol & Entomol Grp, POB 84, Canterbury, New Zealand.		Duncan, Richard P/E-7899-2013; Duncan, Richard/ABD-4099-2020	Duncan, Richard P/0000-0003-2295-449X; Duncan, Richard/0000-0003-2295-449X				Daehler CC, 2001, AM NAT, V158, P324, DOI 10.1086/321316; Darwin C., 1877, ORIGIN SPECIES; Heenan PB, 1998, NEW ZEAL J BOT, V36, P155, DOI 10.1080/0028825X.1998.9512556; Jackson B. D., 1895, INDEX KEWENSIS PLANT; Mabberley DJ, 1987, PLANT BOOK PORTABLE; MACK RN, 1995, BRIT CROP PROTECTION, V64, P65; Rejmanek M., 1999, Invasive species and biodiversity management. Based on papers presented at the Norway/United Nations (UN) Conference on Alien Species, 2nd Trondheim Conference on Biodiversity, Trondheim, Norway, 1-5 July 1996., P79; SAS Institute, 1999, SAS STAT VERS 8; Vitousek PM, 1997, NEW ZEAL J ECOL, V21, P1; Webb CO, 2000, AM NAT, V156, P145, DOI 10.1086/303378; Williams C. B., 1947, JOUR ANIMAL ECOL, V16, P11, DOI 10.2307/1502; Williamson M., 1996, BIOL INVASIONS	12	187	192	2	88	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	2002	417	6889					608	609		10.1038/417608a	http://dx.doi.org/10.1038/417608a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050652				2022-12-28	WOS:000176001200034
J	Mahajna, A; Aboud, N; Harbaji, I; Agbaria, A; Lankovsky, Z; Michaelson, M; Fisher, D; Krausz, MM				Mahajna, A; Aboud, N; Harbaji, I; Agbaria, A; Lankovsky, Z; Michaelson, M; Fisher, D; Krausz, MM			Blunt and penetrating injuries caused by rubber bullets during the Israeli-Arab conflict in October, 2000: a retrospective study	LANCET			English	Article							PLASTIC BULLETS; BALLISTICS; MECHANISMS; INTIFADA; CHILDREN; WOUNDS	Background Low-velocity rubber bullets were used by Israeli police to control riots by Israeli-Arabs in early October, 2000. We aimed to establish the factors that contribute to severity of blunt and penetrating injuries caused by these missiles. Methods We analysed medical records of 595 casualties admitted. We assessed relation of severity of injury to type of bullet, anatomical region of injury, and final outcome. Severity of injury was established by the abbreviated injury scale, and we calculated injury severity score. Findings 151 males and one female (age range 11-59 years) were included in the study, in whom 201 proven injuries by rubber bullets were detected. Injuries were distributed randomly over the body surface and were mostly located in the limbs (n=73), but those to the head, neck, and face (61), chest (39), back (16), and abdomen (12) were also frequently noted. 93 (61%) patients had blunt injuries and 59 (39%) penetrating ones. Severity of injury was dependent on ballistic features of the bullet, firing range, and anatomic site of impact. Two casualties died after a penetrating ocular injury into the brain and one died as a result of postoperative aspiration after a knee injury. Interpretation Resistance of the body surface at the site of impact (elastic limit) is the important factor that ascertains whether a blunt or penetrating injury is inflicted and its severity. Inaccuracy of rubber bullets and improper aiming and range of use resulted in severe injury and death in a substantial number of people. This ammunition should therefore not be considered a safe method of crowd control.	Technion Israel Inst Technol, Rambam Med Ctr, Dept Gen Surg, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel; Nazareth Hosp, Edembre Missionary Med Soc, Nazareth, Israel; Holy Family Hosp, Nazareth, Israel; El Haiat Clin, Umm El Faham, Israel; Israeli Police Force Headquarters, Jerusalem, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Krausz, MM (corresponding author), Technion Israel Inst Technol, Rambam Med Ctr, Dept Gen Surg, POB 9602, IL-31096 Haifa, Israel.							BALOURIS CA, 1990, LANCET, V335, P415, DOI 10.1016/0140-6736(90)90252-Z; BARACH E, 1986, J TRAUMA, V26, P225, DOI 10.1097/00005373-198603000-00003; BELLAMY RF, 1990, CONVENTIONAL WARFARE, P107; COHEN MA, 1985, S AFR MED J, V68, P849; Feliciano DV, 1996, TRAUMA, P85; GUO W, 1993, INT J ARTIF ORGANS, V16, P276, DOI 10.1177/039139889301600508; HISS J, 1994, J FORENSIC SCI SOC, V34, P225, DOI 10.1016/S0015-7368(94)72924-8; Hiss J, 1997, MED SCI LAW, V37, P139, DOI 10.1177/002580249703700209; Jaouni ZM, 1997, EYE, V11, P392, DOI 10.1038/eye.1997.83; MENDELSON JA, 1991, J TRAUMA, V31, P1181, DOI 10.1097/00005373-199109000-00001; MILLAR R, 1975, BRIT J SURG, V62, P480, DOI 10.1002/bjs.1800620613; National Research Council Committee on Trauma Research, 1985, INJ AM CONT PUBL HLT, P48; ORDOG GJ, 1984, ANN EMERG MED, V13, P1113, DOI 10.1016/S0196-0644(84)80336-4; RITCHIE AJ, 1990, BRIT MED J, V301, P1332, DOI 10.1136/bmj.301.6764.1332; ROCKE L, 1983, LANCET, V1, P919; SCHNITZER JJ, 1993, SURG GYNECOL OBSTET, V176, P172; SHAW J, 1972, BRIT MED J, V4, P764, DOI 10.1136/bmj.4.5843.764; WHITLOCK RIH, 1978, INT J ORAL MAXILLOF, V7, P240, DOI 10.1016/S0300-9785(78)80087-8; YELLIN A, 1992, J THORAC CARDIOV SUR, V103, P381	19	48	52	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 25	2002	359	9320					1795	1800		10.1016/S0140-6736(02)08708-1	http://dx.doi.org/10.1016/S0140-6736(02)08708-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044373				2022-12-28	WOS:000175775500006
J	Jull, A; Waters, J; Arroll, B				Jull, A; Waters, J; Arroll, B			Pentoxifylline for treatment of venous leg ulcers: a systematic review	LANCET			English	Review							EXPRESSION; MANAGEMENT; ICAM-1	Introduction Venous ulcers are usually treated with compression therapy, but, because this treatment may not be effective for some people, adjuvant therapy could be beneficial. We did a systematic review of randomised controlled trials that compared pentoxifylline (with and without compression treatment) with placebo, or other treatments, in patients with venous leg ulcers. Methods We identified eight trials (547 adults), five of which compared pentoxifylline and compression with placebo and compression (n=445), and three of which compared pentoxifylline alone with placebo (102). Our main aim was to determine whether pentoxifylline, with or without compression, was effective in treatment of venous leg ulcers. Analysis was by intention to treat. Findings Pentoxifylline was more effective than placebo in complete healing or substantial improvement of venous leg ulcers (relative risk 1.49, 95% Cl 1.11-2.01). Pentoxifylline with compression was also more effective than placebo and compression in complete healing (1.30, 1.10-1.54). Patients taking pentoxifylline had no more adverse events than those on placebo (1.25, 0.87-1.80). The most frequent adverse event was mild gastrointestinal disturbance (43%). Interpretation Our results suggest that pentoxifylline gives additional benefit to compression for venous leg ulcers, and is possibly effective for patients not receiving compression.	Auckland Hosp, Ctr Evidence Based Nursing Aotearoa, Auckland, New Zealand; Univ Auckland, Dept Gen Practice, Auckland 1, New Zealand	Auckland City Hospital; University of Auckland	Jull, A (corresponding author), Auckland Hosp, Ctr Evidence Based Nursing Aotearoa, Private Bag 92024, Auckland, New Zealand.	a.jull@auckland.ac.nz	Jull, Andrew/I-1737-2013	Jull, Andrew/0000-0002-8484-3771				Angle N, 1997, BRIT MED J, V314, P1019, DOI 10.1136/bmj.314.7086.1019; [Anonymous], 1997, ARQ BRAS MED; [Anonymous], 1988, DERMATOL REV MEX SEG; BARBARINO C, 1992, CURR MED RES OPIN, V12, P547, DOI 10.1185/03007999209111520; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; Bosanquet N, 1995, PHLEBOLOGY S, P36; CALLAM MJ, 1987, BRIT MED J, V295, P1382, DOI 10.1136/bmj.295.6610.1382; COLGAN MP, 1990, BRIT MED J, V300, P972, DOI 10.1136/bmj.300.6730.972; CROUCH SPM, 1992, INFECT IMMUN, V60, P4504, DOI 10.1128/IAI.60.11.4504-4509.1992; CULLUM N, 2000, COCHRANE LIB; Dale JJ, 1999, BRIT MED J, V319, P875, DOI 10.1136/bmj.319.7214.875; Falanga V, 1999, WOUND REPAIR REGEN, V7, P208, DOI 10.1046/j.1524-475X.1999.00208.x; Franzini E, 1996, FREE RADICAL BIO MED, V21, P15, DOI 10.1016/0891-5849(95)02209-0; Hood SC, 1996, CAN MED ASSOC J, V155, P1053; Krakauer T, 2000, IMMUNOPHARMACOLOGY, V46, P253, DOI 10.1016/S0162-3109(99)00186-1; Margolis DJ, 2000, AM J MED, V109, P15, DOI 10.1016/S0002-9343(00)00379-X; NELZEN O, 1994, BRIT J SURG, V81, P182, DOI 10.1002/bjs.1800810206; Neuner P, 1997, IMMUNOLOGY, V90, P435, DOI 10.1111/j.1365-2567.1997.00435.x; Peschen M, 1999, ACTA DERM-VENEREOL, V79, P27; SALIM AS, 1991, WORLD J SURG, V15, P264, DOI 10.1007/BF01659062; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schurmann W, 1986, THERAPIEWOCHE, V36, P2343; SMITH PDC, 1993, YALE J BIOL MED, V66, P47; Song, 2000, HEALTH TECHNOL ASSES, V4, P1, DOI DOI 10.3310/HTA4100; WARD A, 1987, DRUGS, V34, P50, DOI 10.2165/00003495-198734010-00003; Weitgasser H., 1983, PHARMATHERAPEUTICA, V3, P143	26	59	63	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 4	2002	359	9317					1550	1554		10.1016/S0140-6736(02)08513-6	http://dx.doi.org/10.1016/S0140-6736(02)08513-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047963				2022-12-28	WOS:000175460700007
J	Brun, VH; Otnaess, MK; Molden, S; Steffenach, HA; Witter, MP; Moser, MB; Moser, EI				Brun, VH; Otnaess, MK; Molden, S; Steffenach, HA; Witter, MP; Moser, MB; Moser, EI			Place cells and place recognition maintained by direct entorhinal-hippocampal circuitry	SCIENCE			English	Article							PYRAMIDAL CELLS; SPATIAL MEMORY; GOAL LOCATION; UNIT-ACTIVITY; RATS; CORTEX; FIELDS; MODEL; ACID; CA3	Place cells in hippocampal area CA1 may receive positional information from the intrahippocampal associative network in area CA3 or directly from the entorhinal cortex. To determine whether direct entorhinal connections support spatial ring and spatial memory, we removed all input from areas CA3 to CA1, thus isolating the CA1 area. Pyramidal cells in the isolated CA1 area developed sharp and stable place fields. Rats with an isolated CA1 area showed normal acquisition of an associative hippocampal-dependent spatial recognition task. Spatial recall was impaired. These results suggest that the hippocampus contains two functionally separable memory circuits: The direct entorhinal-CA1 system is sufficient for recollection-based recognition memory, but recall depends on intact CA3-CA1 connectivity.	Norwegian Univ Sci & Technol, Med Tech Res Ctr, Neurosci Unit, N-7489 Trondheim, Norway; Vrije Univ Amsterdam, Med Ctr, Dept Anat, Neurosci Res Inst, Amsterdam, Netherlands	Norwegian University of Science & Technology (NTNU); Vrije Universiteit Amsterdam	Moser, EI (corresponding author), Norwegian Univ Sci & Technol, Med Tech Res Ctr, Neurosci Unit, N-7489 Trondheim, Norway.		Brun, Vegard Heimly/ADZ-5405-2022	Brun, Vegard Heimly/0000-0002-4136-3073				AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; [Anonymous], 1998, NEURAL NETWORKS BRAI; Brown MW, 2001, NAT REV NEUROSCI, V2, P51, DOI 10.1038/35049064; Eichenbaum H, 2000, NAT REV NEUROSCI, V1, P41, DOI 10.1038/35036213; Fortin NJ, 2002, NAT NEUROSCI, V5, P458, DOI 10.1038/nn834; HANDELMANN GE, 1981, BRAIN RES, V217, P41, DOI 10.1016/0006-8993(81)90183-9; Hollup SA, 2001, J NEUROSCI, V21, P4505, DOI 10.1523/JNEUROSCI.21-12-04505.2001; Hollup SA, 2001, J NEUROSCI, V21, P1635, DOI 10.1523/JNEUROSCI.21-05-01635.2001; Iijima T, 1996, SCIENCE, V272, P1176, DOI 10.1126/science.272.5265.1176; JARRARD LE, 1989, J NEUROSCI METH, V29, P251, DOI 10.1016/0165-0270(89)90149-0; Kali S, 2000, J NEUROSCI, V20, P7463; Kocsis B, 1999, J NEUROSCI, V19, P6200, DOI 10.1523/JNEUROSCI.19-14-06200.1999; MCNAUGHTON BL, 1989, EXP BRAIN RES, V76, P485, DOI 10.1007/BF00248904; MCNAUGHTON BL, 1983, EXP BRAIN RES, V52, P41; MIZUMORI SJY, 1989, J NEUROSCI, V9, P3915; Moser EI, 2001, CURR OPIN NEUROBIOL, V11, P745, DOI 10.1016/S0959-4388(01)00279-3; Moser MB, 1998, J NEUROSCI, V18, P7535; MOSER MB, 1995, P NATL ACAD SCI USA, V92, P9697, DOI 10.1073/pnas.92.21.9697; MULLER RU, 1987, J NEUROSCI, V7, P1935; NAKAZAWA K, IN PRESS SCIENCE; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; QUIRK GJ, 1992, J NEUROSCI, V12, P1945; Samsonovich A, 1997, J NEUROSCI, V17, P5900; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Steffenach HA, 2002, P NATL ACAD SCI USA, V99, P3194, DOI 10.1073/pnas.042700999; TREVES A, 1991, NETWORK-COMP NEURAL, V2, P371, DOI 10.1088/0954-898X/2/4/004; Witter MP, 2000, HIPPOCAMPUS, V10, P398; YECKEL MF, 1990, P NATL ACAD SCI USA, V87, P5832, DOI 10.1073/pnas.87.15.5832	29	446	453	2	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 21	2002	296	5576					2243	2246		10.1126/science.1071089	http://dx.doi.org/10.1126/science.1071089			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077421				2022-12-28	WOS:000176379000065
J	Chikkatur, AP; Shin, Y; Leanhardt, AE; Kielpinski, D; Tsikata, E; Gustavson, TL; Pritchard, DE; Ketterle, W				Chikkatur, AP; Shin, Y; Leanhardt, AE; Kielpinski, D; Tsikata, E; Gustavson, TL; Pritchard, DE; Ketterle, W			A continuous source of Bose-Einstein condensed atoms	SCIENCE			English	Article							PHASE-COHERENT AMPLIFICATION; LASER	A continuous source of Bose-Einstein condensed sodium atoms was created by periodically replenishing a condensate held in an optical dipole trap with new condensates delivered using optical tweezers. The source contained more than 1 x 10(6) atoms at all times, raising the possibility of realizing a continuous atom laser.	MIT, MIT Harvard Ctr Ultracold Atoms, Dept Phys, Cambridge, MA 02139 USA; MIT, Elect Res Lab, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Chikkatur, AP (corresponding author), MIT, MIT Harvard Ctr Ultracold Atoms, Dept Phys, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	ananth@mit.edu	Shin, Yong-il/B-1955-2008	Shin, Yong-il/0000-0003-0481-9841; Kielpinski, David/0000-0002-2816-6892				Anderson BP, 1998, SCIENCE, V282, P1686, DOI 10.1126/science.282.5394.1686; Bloch I, 1999, PHYS REV LETT, V82, P3008, DOI 10.1103/PhysRevLett.82.3008; CREN P, 2002, PREPRINT; Dalfovo F, 1999, REV MOD PHYS, V71, P463, DOI 10.1103/RevModPhys.71.463; Gorlitz A, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.130402; GORLITZ A, UNPUB; Gustavson TL, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.020401; Hagley EW, 1999, SCIENCE, V283, P1706, DOI 10.1126/science.283.5408.1706; Hall DS, 1998, PHYS REV LETT, V81, P1543, DOI 10.1103/PhysRevLett.81.1543; Inouye S, 1999, NATURE, V402, P641, DOI 10.1038/45194; JAVAN A, 1961, PHYS REV LETT, V6, P106, DOI 10.1103/PhysRevLett.6.106; Ketterle W, 1999, P INT SCH PHYS, V140, P67; Kozuma M, 1999, SCIENCE, V286, P2309, DOI 10.1126/science.286.5448.2309; LEANHARDT AE, 2002, PREPRINT; MAIMAN TH, 1960, NATURE, V187, P493, DOI 10.1038/187493a0; Mandonnet E, 2000, EUR PHYS J D, V10, P9, DOI 10.1007/s100530050521; Mewes MO, 1997, PHYS REV LETT, V78, P582, DOI 10.1103/PhysRevLett.78.582; Olskanii R., 1996, Laser Spectroscopy. 12th International Conference, P7; ROOIJAKKERS W, COMMUNICATION; SPREEUW RJC, 1995, EUROPHYS LETT, V32, P469, DOI 10.1209/0295-5075/32/6/002; Stamper-Kurn DM, 1998, PHYS REV LETT, V80, P2027, DOI 10.1103/PhysRevLett.80.2027; TEO BK, 2001, PHYS REV A, V63, P1492	22	96	99	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	2002	296	5576					2193	2195		10.1126/science.296.5576.2193	http://dx.doi.org/10.1126/science.296.5576.2193			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077408				2022-12-28	WOS:000176379000049
J	Bouchama, A; Knochel, JP				Bouchama, A; Knochel, JP			Medical progress - Heat stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TUMOR-NECROSIS-FACTOR; HUMAN SKELETAL-MUSCLE; NF-KAPPA-B; COMPARATIVE EFFICACY; INDUCED HYPERTHERMIA; STRENUOUS EXERCISE; LAVAGE TREATMENT; GENE-EXPRESSION; STRESS-PROTEINS; SHOCK PROTEINS		Presbyterian Med Ctr, Dept Internal Med, Dallas, TX 75231 USA; King Faisal Specialist Hosp & Res Ctr, Med & Surg Intens Care Unit, Riyadh 11211, Saudi Arabia; King Faisal Specialist Hosp & Res Ctr, Dept Comparat Med, Riyadh 11211, Saudi Arabia	King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center	Knochel, JP (corresponding author), Presbyterian Med Ctr, Dept Internal Med, 8198 Walnut Hill Ln, Dallas, TX 75231 USA.	jamesknochel@texashealth.org	Winwood, Peter/A-6363-2008	BOUCHAMA, abderrezak/0000-0003-3089-5936				ADAMS WC, 1975, J APPL PHYSIOL, V38, P1030, DOI 10.1152/jappl.1975.38.6.1030; Akimoto T, 2000, EUR J APPL PHYSIOL, V81, P510, DOI 10.1007/s004210050076; ALASKA AK, 1987, LANCET, V1, P381; ALMASHHADANI SA, 1994, BLOOD COAGUL FIBRIN, V5, P731, DOI 10.1097/00001721-199410000-00009; Alzeer AH, 1999, INTENS CARE MED, V25, P58; ANG C, 1994, BLOOD COAGUL FIBRIN, V5, P193, DOI 10.1097/00001721-199404000-00006; BEAL AL, 1994, JAMA-J AM MED ASSOC, V271, P226, DOI 10.1001/jama.271.3.226; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; BOSENBERG AT, 1988, J APPL PHYSIOL, V65, P106, DOI 10.1152/jappl.1988.65.1.106; BOUCHAMA A, 1993, CHEST, V104, P1498, DOI 10.1378/chest.104.5.1498; BOUCHAMA A, 1991, J APPL PHYSIOL, V70, P2640, DOI 10.1152/jappl.1991.70.6.2640; BOUCHAMA A, 1991, CRIT CARE MED, V19, P176, DOI 10.1097/00003246-199102000-00011; Bouchama A, 1996, CRIT CARE MED, V24, P1173, DOI 10.1097/00003246-199607000-00018; BOUCHAMA A, 1995, J APPL PHYSIOL, V79, P1391, DOI 10.1152/jappl.1995.79.4.1391; Bouchama A, 1996, THROMB HAEMOSTASIS, V76, P909; Bouchama A, 2000, INTENS CARE MED, V26, P1646, DOI 10.1007/s001340000665; BUCKLEY IK, 1972, LAB INVEST, V26, P201; BUONO MJ, 1988, J APPL PHYSIOL, V65, P811, DOI 10.1152/jappl.1988.65.2.811; BYNUM GD, 1978, AM J PHYSIOL, V235, pR228, DOI 10.1152/ajpregu.1978.235.5.R228; Camus G, 1998, EUR J APPL PHYSIOL O, V79, P62, DOI 10.1007/s004210050474; CANNON JG, 1983, SCIENCE, V220, P617, DOI 10.1126/science.6836306; Cannon JG, 2000, NEWS PHYSIOL SCI, V15, P298, DOI 10.1152/physiologyonline.2000.15.6.298; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P470; CHANG DM, 1993, IMMUNOL INVEST, V22, P553, DOI 10.3109/08820139309084183; Changnon SA, 2000, SCIENCE, V289, P2053, DOI 10.1126/science.289.5487.2053; CHAO TC, 1981, PATHOLOGY, V13, P145, DOI 10.3109/00313028109086837; Dematte JE, 1998, ANN INTERN MED, V129, P173, DOI 10.7326/0003-4819-129-3-199808010-00001; DESCHAMPS A, 1989, J APPL PHYSIOL, V66, P2799, DOI 10.1152/jappl.1989.66.6.2799; Easterling DR, 2000, SCIENCE, V289, P2068, DOI 10.1126/science.289.5487.2068; ELKASSIMI FA, 1986, CHEST, V90, P571, DOI 10.1378/chest.90.4.571; ESPERSEN GT, 1990, APMIS, V98, P395, DOI 10.1111/j.1699-0463.1990.tb01049.x; Febbraio MA, 2000, J APPL PHYSIOL, V89, P1055, DOI 10.1152/jappl.2000.89.3.1055; Fehrenbach E, 2000, J APPL PHYSIOL, V89, P704, DOI 10.1152/jappl.2000.89.2.704; Gabay C, 1999, NEW ENGL J MED, V340, P1376; GATHIRAM P, 1988, CIRC SHOCK, V25, P223; GATHIRAM P, 1987, CIRC SHOCK, V23, P157; GHAZNAWI HI, 1987, ANN SAUDI MED, V7, P323, DOI 10.5144/0256-4947.1987.323; GRAHAM BS, 1986, ARCH INTERN MED, V146, P87, DOI 10.1001/archinte.146.1.87; Hall DM, 1999, AM J PHYSIOL-GASTR L, V276, pG1195, DOI 10.1152/ajpgi.1999.276.5.G1195; Hall DM, 2001, AM J PHYSIOL-HEART C, V280, pH509, DOI 10.1152/ajpheart.2001.280.2.H509; Hammami MM, 1998, INTENS CARE MED, V24, P988, DOI 10.1007/PL00012687; Hammami MM, 1997, CRIT CARE MED, V25, P1314, DOI 10.1097/00003246-199708000-00017; Hammani MM, 1998, J APPL PHYSIOL, V84, P1615, DOI 10.1152/jappl.1998.84.5.1615; HIETALA J, 1982, EUR J APPL PHYSIOL O, V49, P271, DOI 10.1007/BF02334075; JONES TS, 2002, JAMA-J AM MED ASSOC, V247, P3327; Kalkstein LS, 2000, BRIT MED J, V321, P650, DOI 10.1136/bmj.321.7262.650; KATSOUYANNI K, 1988, LANCET, V2, P573; Kellermann AL, 1996, NEW ENGL J MED, V335, P126, DOI 10.1056/NEJM199607113350210; KILBOURNE EM, 1982, JAMA-J AM MED ASSOC, V247, P3332, DOI 10.1001/jama.247.24.3332; KNOCHEL JP, 1990, KIDNEY INT, V38, P709, DOI 10.1038/ki.1990.263; KNOCHEL JP, 1975, JAMA-J AM MED ASSOC, V233, P513, DOI 10.1001/jama.233.6.513; Knochel JP, 1994, MAXWELL KLEEMANS CLI, P1549; KNOCHEL JP, 1998, PRIMER KIDNEY DIS, P273; Kurahashi K, 1999, J CLIN INVEST, V104, P743, DOI 10.1172/JCI7124; LEFOR AT, 1994, SURGERY, V116, P214; Li PL, 2001, CIRCULATION, V103, P2114; Lin MT, 1997, AM J PHYSIOL-HEART C, V273, pH2072, DOI 10.1152/ajpheart.1997.273.4.H2072; LIN MT, 1994, NEUROSCI LETT, V174, P17, DOI 10.1016/0304-3940(94)90108-2; Liu CC, 2000, J PHYSIOL-LONDON, V527, P333, DOI 10.1111/j.1469-7793.2000.t01-1-00333.x; Mackowiak PA, 1997, FEVER BASIC MECH MAN, P35; MALAMUD N, 1946, Mil Surg, V99, P397; MILNER CM, 1992, IMMUNOGENETICS, V36, P357; Moldoveanu AI, 2000, J APPL PHYSIOL, V89, P1499, DOI 10.1152/jappl.2000.89.4.1499; Moseley PL, 1997, J APPL PHYSIOL, V83, P1413, DOI 10.1152/jappl.1997.83.5.1413; Nakai S, 1999, INT J BIOMETEOROL, V43, P124, DOI 10.1007/s004840050127; NELSON N, 1947, AM J PHYSIOL, V151, P626, DOI 10.1152/ajplegacy.1947.151.2.626; Ostrowski K, 1998, J PHYSIOL-LONDON, V508, P949, DOI 10.1111/j.1469-7793.1998.949bp.x; Pals KL, 1997, J APPL PHYSIOL, V82, P571, DOI 10.1152/jappl.1997.82.2.571; Pedersen BK, 2000, PHYSIOL REV, V80, P1055, DOI 10.1152/physrev.2000.80.3.1055; Polla BS, 1998, ANN NY ACAD SCI, V851, P75, DOI 10.1111/j.1749-6632.1998.tb08979.x; RIABOWOL KT, 1988, SCIENCE, V242, P433, DOI 10.1126/science.3175665; ROBINS HI, 1995, CANCER LETT, V97, P195, DOI 10.1016/0304-3835(95)03976-4; Rooney C, 1998, J EPIDEMIOL COMMUN H, V52, P482, DOI 10.1136/jech.52.8.482; ROWELL LB, 1983, CIRC RES, V52, P367, DOI 10.1161/01.RES.52.4.367; RYAN AJ, 1991, J APPL PHYSIOL, V70, P466, DOI 10.1152/jappl.1991.70.1.466; SAKAGUCHI Y, 1995, CANCER RES, V55, P5459; Sakurada S, 1998, J APPL PHYSIOL, V84, P207, DOI 10.1152/jappl.1998.84.1.207; Sartor F, 1995, ENVIRON RES, V70, P105, DOI 10.1006/enrs.1995.1054; Semenza JC, 1996, NEW ENGL J MED, V335, P84, DOI 10.1056/NEJM199607113350203; SHAPIRO Y, 1986, EUR J APPL PHYSIOL O, V55, P410, DOI 10.1007/BF00422742; SHIEH SD, 1995, CLIN SCI, V89, P261, DOI 10.1042/cs0890261; SOHAL RS, 1968, ARCH INTERN MED, V122, P43, DOI 10.1001/archinte.122.1.43; Suzuki K, 2000, EUR J APPL PHYSIOL, V81, P281, DOI 10.1007/s004210050044; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; VITI A, 1985, J APPL PHYSIOL, V59, P426, DOI 10.1152/jappl.1985.59.2.426; Wang ZZ, 2001, AM J MED, V111, P654, DOI 10.1016/S0002-9343(01)00974-3; WEINER JS, 1980, LANCET, V1, P507; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WHITE JD, 1987, CRIT CARE MED, V15, P748, DOI 10.1097/00003246-198708000-00007; WHITE JD, 1993, AM J EMERG MED, V11, P1, DOI 10.1016/0735-6757(93)90047-F; WYNDHAM CH, 1959, J APPL PHYSIOL, V14, P771, DOI 10.1152/jappl.1959.14.5.771; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Yang YL, 1999, AM J PHYSIOL-HEART C, V276, pH1961, DOI 10.1152/ajpheart.1999.276.6.H1961	94	1263	1397	7	111	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 20	2002	346	25					1978	1988		10.1056/NEJMra011089	http://dx.doi.org/10.1056/NEJMra011089			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563QC	12075060				2022-12-28	WOS:000176266200008
J	Foley, S; Tiepolo, M; Vannucci, R				Foley, S; Tiepolo, M; Vannucci, R			Growth of early continental crust controlled by melting of amphibolite in subduction zones	NATURE			English	Article							PARTITION-COEFFICIENTS; TRACE-ELEMENTS; TITANIAN PARGASITE; ORTHO-PYROXENE; HIGH-PRESSURE; ICP-MS; MANTLE; PLAGIOCLASE; NB; TA	It is thought that the first continental crust formed by melting of either eclogite or amphibolite, either at subduction zones 1 or on the underside of thick oceanic crust(2). However, the observed compositions of early crustal rocks and experimental studies have been unable to distinguish between these possibilities(3-5). Here we show a clear contrast in trace-element ratios of melts derived from amphibolites and those from eclogites. Partial melting of low-magnesium amphibolite can explain the low niobium/tantalum and high zirconium/samarium ratios in melts, as required for the early continental crust, whereas the melting of eclogite cannot. This indicates that the earliest continental crust formed by melting of amphibolites in subductionzone environments and not by the melting of eclogite or magnesium-rich amphibolites in the lower part of thick oceanic crust. Moreover, the low niobium/tantalum ratio seen in subductionzone igneous rocks of all ages is evidence that the melting of rutile-eclogite has never been a volumetrically important process.	Univ Greifswald, Inst Geol Wissensch, D-17487 Greifswald, Germany; Univ Pavia, Dipartimento Sci Terra, I-27100 Pavia, Italy; CNR, Ist Geosci & Georisorse, Sez Pavia, I-27100 Pavia, Italy	Ernst Moritz Arndt Universitat Greifswald; University of Pavia; Consiglio Nazionale delle Ricerche (CNR); Istituto di Geoscienze e Georisorse (IGG-CNR)	Foley, S (corresponding author), Univ Greifswald, Inst Geol Wissensch, FL Jahnstr 17A, D-17487 Greifswald, Germany.		Foley, Stephen/C-1923-2009; Foley, Stephen/I-1759-2013; Tiepolo, Massimo/I-5825-2017	Tiepolo, Massimo/0000-0001-7575-8105; Foley, Stephen/0000-0001-7510-0223				Arndt N, 1998, GEOLOGY, V26, P739, DOI 10.1130/0091-7613(1998)026<0739:WKW>2.3.CO;2; Barth MG, 2002, PRECAMBRIAN RES, V113, P323, DOI 10.1016/S0301-9268(01)00216-9; BICKLE MJ, 1994, J GEOL, V102, P121, DOI 10.1086/629658; Bindeman IN, 1998, GEOCHIM COSMOCHIM AC, V62, P1175, DOI 10.1016/S0016-7037(98)00047-7; BLUNDY JD, 1991, GEOCHIM COSMOCHIM AC, V55, P193, DOI 10.1016/0016-7037(91)90411-W; Bottazzi P, 1999, CONTRIB MINERAL PETR, V137, P36, DOI 10.1007/s004100050580; DRUMMOND MS, 1990, J GEOPHYS RES-SOLID, V95, P21503, DOI 10.1029/JB095iB13p21503; DUNN T, 1994, GEOCHIM COSMOCHIM AC, V58, P717, DOI 10.1016/0016-7037(94)90501-0; Eggins SM, 1998, EARTH PLANET SC LETT, V154, P53, DOI 10.1016/S0012-821X(97)00195-7; Foley SF, 2000, GEOCHIM COSMOCHIM AC, V64, P933, DOI 10.1016/S0016-7037(99)00355-5; GREEN TH, 1987, GEOCHIM COSMOCHIM AC, V51, P55, DOI 10.1016/0016-7037(87)90006-8; IONOV DA, 1995, EARTH PLANET SC LETT, V131, P341, DOI 10.1016/0012-821X(95)00037-D; Jacob DE, 1999, LITHOS, V48, P317, DOI 10.1016/S0024-4937(99)00034-1; JENNER GA, 1993, GEOCHIM COSMOCHIM AC, V57, P5099, DOI 10.1016/0016-7037(93)90611-Y; Karsten JL, 1996, LITHOS, V37, P143, DOI 10.1016/0024-4937(95)00034-8; KENNEDY AK, 1993, EARTH PLANET SC LETT, V115, P177, DOI 10.1016/0012-821X(93)90221-T; KLEMME S, IN PRESS GEOCHIM COS; KRONER A, 1985, ANNU REV EARTH PL SC, V13, P49, DOI 10.1146/annurev.ea.13.050185.000405; Martin H, 1999, LITHOS, V46, P411, DOI 10.1016/S0024-4937(98)00076-0; Martin H., 1994, ARCHEAN CRUSTAL EVOL, V11, P205, DOI DOI 10.1016/S0166-2635(08)70224-X; PANJASAWATWONG Y, 1995, CONTRIB MINERAL PETR, V118, P420, DOI 10.1007/s004100050024; RAPP RP, 1991, PRECAMBRIAN RES, V51, P1, DOI 10.1016/0301-9268(91)90092-O; Rollinson H, 1999, CONTRIB MINERAL PETR, V134, P86, DOI 10.1007/s004100050470; Rudnick RL, 2000, SCIENCE, V287, P278, DOI 10.1126/science.287.5451.278; Saunders AD, 1996, LITHOS, V37, P81, DOI 10.1016/0024-4937(95)00030-5; Scambelluri M, 2001, EARTH PLANET SC LETT, V192, P457, DOI 10.1016/S0012-821X(01)00457-5; Stolz AJ, 1996, GEOLOGY, V24, P587, DOI 10.1130/0091-7613(1996)024<0587:FAMREI>2.3.CO;2; Tiepolo M, 2000, EARTH PLANET SC LETT, V176, P185, DOI 10.1016/S0012-821X(00)00004-2; Tiepolo M, 2001, J PETROL, V42, P221, DOI 10.1093/petrology/42.1.221; WOLF MB, 1994, CONTRIB MINERAL PETR, V115, P369, DOI 10.1007/BF00320972	30	781	877	4	152	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 20	2002	417	6891					837	840		10.1038/nature00799	http://dx.doi.org/10.1038/nature00799			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075348				2022-12-28	WOS:000176285600043
J	Harnden, A; Alves, B; Sheikh, A				Harnden, A; Alves, B; Sheikh, A			Rising incidence of Kawasaki disease in England: analysis of hospital admission data	BRITISH MEDICAL JOURNAL			English	Article									Univ Oxford, Inst Hlth Sci, Dept Primary Hlth Care, Oxford OX3 7LF, England; Univ London Imperial Coll Sci Technol & Med, Dept Primary Hlth Care, London W2 1PG, England	University of Oxford; Imperial College London	Harnden, A (corresponding author), Univ Oxford, Inst Hlth Sci, Dept Primary Hlth Care, Oxford OX3 7LF, England.		Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056				Curtis N, 1997, BRIT MED J, V315, P322; DHILLON R, 1993, ARCH DIS CHILD, V69, P631, DOI 10.1136/adc.69.6.631; Dixon J, 1998, J PUBLIC HEALTH MED, V20, P63, DOI 10.1093/oxfordjournals.pubmed.a024721; Royle JA, 1998, ARCH DIS CHILD, V78, P33, DOI 10.1136/adc.78.1.33; Yanagawa H, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e33	5	81	85	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 15	2002	324	7351					1424	1425		10.1136/bmj.324.7351.1424	http://dx.doi.org/10.1136/bmj.324.7351.1424			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	565CQ	12065266	Green Published, Bronze			2022-12-28	WOS:000176351400018
J	Mohr, S; Stryker, JM; Lambowitz, AM				Mohr, S; Stryker, JM; Lambowitz, AM			A DEAD-box protein functions as an ATP-dependent RNA chaperone in group I intron splicing	CELL			English	Article							LARGE RIBOSOMAL-RNA; NEUROSPORA MITOCHONDRIA; CATALYTIC CORE; TETRAHYMENA RIBOZYME; NUCLEAR MUTANTS; SYNTHETASE; VITRO; HELICASE	The Neurospora crassa CYT-18 protein, the mitochondrial tyrosyl-tRNA synthetase, functions in splicing group I introns by inducing formation of the catalytically active RNA structure. Here, we identified a DEAD-box protein (CYT-19) that functions in concert with CYT-18 to promote group I intron splicing in vivo and vitro. CYT-19 does not bind specifically to group I intron RNAs and instead functions as an ATP-dependent RNA chaperone to destabilize nonnative RNA structures that constitute kinetic traps in the CYT-18-assisted RNA-folding pathway. Our results demonstrate that a DExH/ D-box protein has a specific, physiologically relevant chaperone function in the folding of a natural RNA substrate.	Univ Texas, Inst Mol & Cellular Biol, Dept Chem & Biochem, Sect Mol Genet & Microbiol,Sch Biol Sci, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Lambowitz, AM (corresponding author), Univ Texas, Inst Mol & Cellular Biol, Dept Chem & Biochem, Sect Mol Genet & Microbiol,Sch Biol Sci, Austin, TX 78712 USA.				NIGMS NIH HHS [GM37951] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037951, R01GM037951] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; AKINS RA, 1985, MOL CELL BIOL, V5, P2272, DOI 10.1128/MCB.5.9.2272; BERTRAND H, 1982, CELL, V29, P517, DOI 10.1016/0092-8674(82)90168-4; Caprara MG, 1996, J MOL BIOL, V257, P512, DOI 10.1006/jmbi.1996.0182; Caprara MG, 1996, CELL, V87, P1135, DOI 10.1016/S0092-8674(00)81807-3; Clodi E, 1999, EMBO J, V18, P3776, DOI 10.1093/emboj/18.13.3776; COETZEE T, 1994, GENE DEV, V8, P1575, DOI 10.1101/gad.8.13.1575; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; Golden BL, 1998, SCIENCE, V282, P259, DOI 10.1126/science.282.5387.259; GUO QB, 1991, J BIOL CHEM, V266, P1809; HENDERSON MF, 1981, THESIS ST LOUIS U ST; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Jankowsky E, 2000, NATURE, V403, P447, DOI 10.1038/35000239; Jankowsky E, 2001, SCIENCE, V291, P121, DOI 10.1126/science.291.5501.121; KARPEL RL, 1982, BIOCHEMISTRY-US, V21, P2102, DOI 10.1021/bi00538a019; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; Lambowitz AM., 1999, GROUP GROUP 2 RIBOZY, P451; MANNELLA CA, 1979, P NATL ACAD SCI USA, V76, P2635, DOI 10.1073/pnas.76.6.2635; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOHR G, 1994, NATURE, V370, P147, DOI 10.1038/370147a0; Myers CA, 2002, P NATL ACAD SCI USA, V99, P2630, DOI 10.1073/pnas.052596299; NIEMER I, 1995, NUCLEIC ACIDS RES, V23, P2966, DOI 10.1093/nar/23.15.2966; Pan J, 1998, J MOL BIOL, V280, P597, DOI 10.1006/jmbi.1998.1901; Saldanha R, 1999, BIOCHEMISTRY-US, V38, P9069, DOI 10.1021/bi982799l; SALDANHA RJ, 1995, BIOCHEMISTRY-US, V34, P1275, DOI 10.1021/bi00004a022; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; TURCQ B, 1992, P NATL ACAD SCI USA, V89, P1676, DOI 10.1073/pnas.89.5.1676; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; Wallweber GJ, 1997, RNA, V3, P114; Webb AE, 2001, J MOL BIOL, V309, P1087, DOI 10.1006/jmbi.2001.4714; WOLLENZIEN PL, 1983, CELL, V32, P397, DOI 10.1016/0092-8674(83)90459-2; Woodson SA, 2000, CELL MOL LIFE SCI, V57, P796, DOI 10.1007/s000180050042; ZHANG A, 1995, RNA, V1, P783	34	152	157	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 14	2002	109	6					769	779		10.1016/S0092-8674(02)00771-7	http://dx.doi.org/10.1016/S0092-8674(02)00771-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	563PW	12086675	Bronze			2022-12-28	WOS:000176265600007
J	Park, J; Pasupathy, AN; Goldsmith, JI; Chang, C; Yaish, Y; Petta, JR; Rinkoski, M; Sethna, JP; Abruna, HD; McEuen, PL; Ralph, DC				Park, J; Pasupathy, AN; Goldsmith, JI; Chang, C; Yaish, Y; Petta, JR; Rinkoski, M; Sethna, JP; Abruna, HD; McEuen, PL; Ralph, DC			Coulomb blockade and the Kondo effect in single-atom transistors	NATURE			English	Article							CARBON NANOTUBES; CONDUCTANCE; ELECTRODES; JUNCTION; WIRES; SPIN	Using molecules as electronic components is a powerful new direction in the science and technology of nanometre-scale systems(1). Experiments to date have examined a multitude of molecules conducting in parallel(2,3), or, in some cases, transport through single molecules. The latter includes molecules probed in a two-terminal geometry using mechanically controlled break junctions(4,5) or scanning probes(6,7) as well as three-terminal single-molecule transistors made from carbon nanotubes(8), C-60 molecules (9), and conjugated molecules diluted in a less-conducting molecular layer(10). The ultimate limit would be a device where electrons hop on to, and off from, a single atom between two contacts. Here we describe transistors incorporating a transitionmetal complex designed so that electron transport occurs through well-defined charge states of a single atom. We examine two related molecules containing a Co ion bonded to polypyridyl ligands, attached to insulating tethers of different lengths. Changing the length of the insulating tether alters the coupling of the ion to the electrodes, enabling the fabrication of devices that exhibit either single-electron phenomena, such as Coulomb blockade, or the Kondo effect.	Cornell Univ, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA; Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA	Cornell University; Cornell University; University of California System; University of California Berkeley	McEuen, PL (corresponding author), Cornell Univ, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA.		Park, Jiwoong/C-2327-2013; Petta, Jason R/J-6663-2013; Ralph, Daniel C/G-3251-2010	Petta, Jason R/0000-0002-6416-0789; 				Akera H, 1999, PHYS REV B, V60, P10683, DOI 10.1103/PhysRevB.60.10683; AVIRAM A, 1974, CHEM PHYS LETT, V29, P277, DOI 10.1016/0009-2614(74)85031-1; Bard A. J., 2001, ELECTROCHEMICAL METH; Bezryadin A, 1997, APPL PHYS LETT, V71, P1273, DOI 10.1063/1.119871; Bonet E, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.045317; Bumm LA, 1996, SCIENCE, V271, P1705, DOI 10.1126/science.271.5256.1705; Chen J, 1999, SCIENCE, V286, P1550, DOI 10.1126/science.286.5444.1550; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; Cui XD, 2001, SCIENCE, V294, P571, DOI 10.1126/science.1064354; Dekker C, 1999, PHYS TODAY, V52, P22, DOI 10.1063/1.882658; Deshmukh MM, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.073301; Goldhaber-Gordon D, 1998, NATURE, V391, P156, DOI 10.1038/34373; GRABERT H, 1992, SINGLE CHARGE TUNNEL; Kergueris C, 1999, PHYS REV B, V59, P12505, DOI 10.1103/PhysRevB.59.12505; Maskus M, 1996, LANGMUIR, V12, P4455, DOI 10.1021/la960308x; Mathis JM, 1997, SYNTHETIC COMMUN, V27, P2943, DOI 10.1080/00397919708005000; Nygard J, 2000, NATURE, V408, P342, DOI 10.1038/35042545; Oshio H, 2001, INORG CHEM, V40, P1143, DOI 10.1021/ic000714a; Park H, 1999, APPL PHYS LETT, V75, P301, DOI 10.1063/1.124354; Park H, 2000, NATURE, V407, P57, DOI 10.1038/35024031; Ralph DC, 1997, PHYS REV LETT, V78, P4087, DOI 10.1103/PhysRevLett.78.4087; Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252; Schon JH, 2001, SCIENCE, V294, P2138, DOI 10.1126/science.1066171; TESTAFERRI L, 1983, SYNTHESIS-STUTTGART, P751; van der Wiel WG, 2000, SCIENCE, V289, P2105, DOI 10.1126/science.289.5487.2105; WOLF EL, 1989, PRINCIPLES ELECT TUN, pCH8	26	1386	1412	21	594	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 13	2002	417	6890					722	725		10.1038/nature00791	http://dx.doi.org/10.1038/nature00791			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	561QY	12066179				2022-12-28	WOS:000176154700039
J	Lederle, FA; Johnson, GR; Wilson, SE; Ballard, DJ; Jordan, WD; Blebea, J; Littooy, FN; Freischlag, JA; Bandyk, D; Rapp, JH; Salam, AA				Lederle, FA; Johnson, GR; Wilson, SE; Ballard, DJ; Jordan, WD; Blebea, J; Littooy, FN; Freischlag, JA; Bandyk, D; Rapp, JH; Salam, AA		Vet Affairs Cooperat Study 417 Invest	Rupture rate of large abdominal aortic aneurysms in patients refusing or unfit for elective repair	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	87th Annual Clinical Congress of the American-College-of-Surgeons	OCT 07-12, 2001	NEW ORLEANS, LA	Amer Coll Surg			AUTOPSY; RISK	Context Among patients with abdominal aortic aneurysm (AAA) who have high operative risk, repair is usually deferred until the AAA reaches a diameter at which rupture risk is thought to outweigh operative risk, but few data exist on rupture risk of large AAA. Objective To determine the incidence of rupture in patients with large AAA. Design and Setting Prospective cohort study in 47 Veterans Affairs medical centers. Patients Veterans (n= 198) with AAA of at least 5.5 cm for whom elective AAA repair was not planned because of medical contraindication or patient refusal. Patients were enrolled between April 1995 and April 2000 and followed up through July 2000 (mean, 1.52 years). Main Outcome Measure Incidence of AAA rupture by strata of initial and attained diameter. Results Outcome ascertainment was complete for all patients. There were 112 deaths (57%) and the autopsy rate was 46%. Forty-five patients had probable AAA rupture. The 1-year incidence of probable rupture by initial AAA diameter was 9.4% for AAA of 5.5 to 5.9 cm, 10.2% for AAA of 6.0 to 6.9 cm (19.1 % for the subgroup of 6.5-6.9 cm), and 32.5% for AAA of 7.0 cm or more. Much of the increased risk of rupture associated with initial AAA diameters of 6.5-7.9 cm was related to the likelihood that the AAA diameter would reach 8.0 cm during follow-up, after which 25.7% ruptured within 6 months. Conclusion The rupture rate is substantial in high-operative-risk patients with AAA of at least 5.5 cm in diameter and increases with larger diameter.	Vet Affairs Med Ctr, Dept Med, Minneapolis, MN 55417 USA; Vet Affairs Med Ctr, Cooperat Studies Program Coordinating Ctr, West Haven, CT USA; Univ Calif Irvine, Dept Surg, Orange, CA 92668 USA; Baylor Hlth Care Syst, Dallas, TX USA; Vet Affairs Med Ctr, Dept Surg, Birmingham, AL USA; Penn State Univ, Dept Surg, Hershey, PA USA; Vet Affairs Med Ctr, Dept Surg, Hines, IL USA; Vet Affairs Med Ctr, Dept Surg, Los Angeles, CA USA; Vet Affairs Med Ctr, Dept Surg, Tampa, FL USA; Vet Affairs Med Ctr, Dept Surg, San Francisco, CA 94121 USA; Dept Surg, Atlanta, GA 30033 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; University of California System; University of California Irvine; Baylor Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)	Lederle, FA (corresponding author), Vet Affairs Med Ctr, Dept Med 3 0, Minneapolis, MN 55417 USA.	frank.lederle@med.va.gov	Ballard, David J/H-1062-2018					Conway KP, 2001, J VASC SURG, V33, P752, DOI 10.1067/mva.2001.112800; DARLING RC, 1977, CIRCULATION, V56, P161; Jones A, 1998, BRIT J SURG, V85, P1382; LEDERLE FA, 1994, AM J MED, V96, P163, DOI 10.1016/0002-9343(94)90137-6; Lederle FA, 1996, ARCH INTERN MED, V156, P1007, DOI 10.1001/archinte.156.9.1007; Lederle FA, 2002, NEW ENGL J MED, V346, P1437, DOI 10.1056/NEJMoa012573; Lederle FA, 1997, ANN INTERN MED, V126, P441, DOI 10.7326/0003-4819-126-6-199703150-00004; McPhee SJ, 1996, MEDICINE, V75, P41, DOI 10.1097/00005792-199601000-00005; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Powell JT, 2001, ACTA CHIR BELG, V101, P11; Powell JT, 1998, LANCET, V352, P1649; Reed WW, 1997, ARCH INTERN MED, V157, P2064, DOI 10.1001/archinte.157.18.2064; SCOTT RAP, 1995, BRIT J SURG, V82, P1066, DOI 10.1002/bjs.1800820821; SULLIVAN CA, 1990, J VASC SURG, V11, P799, DOI 10.1067/mva.1990.19420; SZILAGYI DE, 1966, ANN SURG, V164, P678, DOI 10.1097/00000658-196610000-00014; THOMAS AC, 1988, BRIT MED J, V297, P1453, DOI 10.1136/bmj.297.6661.1453	16	385	398	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	2002	287	22					2968	2972		10.1001/jama.287.22.2968	http://dx.doi.org/10.1001/jama.287.22.2968			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	561EY	12052126	Bronze			2022-12-28	WOS:000176128300026
J	Kroll, L; Rothwell, J; Bradley, D; Shah, P; Bailey, S; Harrington, RC				Kroll, L; Rothwell, J; Bradley, D; Shah, P; Bailey, S; Harrington, RC			Mental health needs of boys in secure care for serious or persistent offending: a prospective, longitudinal study	LANCET			English	Article							JUVENILE-OFFENDERS; ADOLESCENTS	Background The mental health needs of children and adolescents in secure care are a matter of concern, but little systematic research has been done. Our aim was to assess the mental health, social, and educational needs of these young people in a prospective, longitudinal study. Methods We enrolled 97 boys aged 12-17 years who had been admitted to secure care. We assessed their needs (n=97) at the time of admission and 3 months later (n=90) with standardised interviews and psychometric tests. Results 26 (27%) boys had an intelligence quotient (IQ) of less than 70. The need for psychiatric help was high on admission to a secure unit, with the most frequent disorders being depression and anxiety. There were high rates of aggression, substance misuse, self harm, and social, family, and educational problems, and associated needs. The mean number of needs was 8.5 (SD 2.9) on admission and 2.9 (SD 2.4) after 3 months (mean difference 5.6, 95% CI 5.0-6.3). Areas in which needs were mostly met included education, substance misuse, self care, and diet. Areas where the frequency of need fell substantially, but remained high, were social and family problems, and aggressive behaviours. Psychological needs persisted, with new onsets of depression, anxiety problems, and post-traumatic-stress symptoms shortly after admission. The most frequently required interventions were psychological assessment and cognitive behavioural work. Interpretation Boys in secure care have many needs and a high rate of psychiatric morbidity. During the admission period, secure care units address some domains of need, but others remain unchanged or get worse. Psychological and psychiatric provision in secure units need to be improved.	Univ Manchester, Royal Manchester Childrens Hosp, Dept Child Psychiat, Manchester M27 4HA, Lancs, England; Manchester Childrens Trust, Manchester, Lancs, England; Salford Mental Hlth Trust, Manchester, Lancs, England	Royal Manchester Children's Hospital; University of Manchester	Harrington, RC (corresponding author), Univ Manchester, Royal Manchester Childrens Hosp, Dept Child Psychiat, Manchester M27 4HA, Lancs, England.		Lorente, Rosa/AAL-5850-2021					Bailey S, 1996, J ADOLESCENCE, V19, P19, DOI 10.1006/jado.1996.0003; Bailey S., 2000, YOUNG PEOPLE MENTAL, P91; BAILEY SM, 1994, J ADOLESCENCE, V17, P207, DOI 10.1006/jado.1994.1021; Boswell G., 2000, VIOLENT CHILDREN ADO; Bullock R, 1998, SECURE TREATMENT OUT; DITCHFILD J, 1992, JUVENILES SENTENCED; Goldstein, 1987, AGGRESSION REPLACEME; Goldstein A.P., 1994, PROSOCIAL GANG IMPLE; Harrington RC, 1999, EUR CHILD ADOLES PSY, V8, P1; Henggeler SW, 1996, J ADOLESCENCE, V19, P47, DOI 10.1006/jado.1996.0005; JAMESON EJ, 1989, J ADOLESCENT HEALTH, V10, P490, DOI 10.1016/0197-0070(89)90011-9; Kaufman J, 1996, SCHEDULE AFFECTIVE D; Kazdin AE, 1997, J CHILD PSYCHOL PSYC, V38, P161, DOI 10.1111/j.1469-7610.1997.tb01851.x; Kroll L, 1999, PSYCHOL MED, V29, P891, DOI 10.1017/S0033291799008752; KURTZ Z, 1997, STUDY DEMAND NEEDS F; LADER D, 2000, PSYCHIAT MORBIDITY Y; MILIN R, 1991, J AM ACAD CHILD PSY, V30, P569, DOI 10.1097/00004583-199107000-00007; *PSYCH CORP, 1992, WESCHL INT SCAL CHIL; TimmonsMitchell J, 1997, BEHAV SCI LAW, V15, P195, DOI 10.1002/(SICI)1099-0798(199721)15:2<195::AID-BSL269>3.0.CO;2-8	19	101	101	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 8	2002	359	9322					1975	1979		10.1016/S0140-6736(02)08829-3	http://dx.doi.org/10.1016/S0140-6736(02)08829-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	563BA	12076552				2022-12-28	WOS:000176232500009
J	Mao, BY; Wu, W; Davidson, G; Marhold, J; Li, MF; Mechler, BM; Delius, H; Hoppe, D; Stannek, P; Walter, C; Glinka, A; Niehrs, C				Mao, BY; Wu, W; Davidson, G; Marhold, J; Li, MF; Mechler, BM; Delius, H; Hoppe, D; Stannek, P; Walter, C; Glinka, A; Niehrs, C			Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling	NATURE			English	Article							ENERGY-TRANSFER BRET; WNT; TRANSDUCTION; DROSOPHILA; MECHANISM; MEMBER; FAMILY	The Wnt family of secreted glycoproteins mediate cell-cell interactions during cell growth and differentiation in both embryos and adults(1,2). Canonical Wnt signalling by way of the beta-catenin pathway is transduced by two receptor families. Frizzled proteins and lipoprotein-receptor-related proteins 5 and 6 (LRP5/6) bind Wnts and transmit their signal by stabilizing intracellular beta-catenin(3-6). Wnt/beta-catenin signalling is inhibited by the secreted protein Dickkopf1 (Dkk1), a member of a multigene family, which induces head formation in amphibian embryos(7). Dkk1 has been shown to inhibit Wnt signalling by binding to and antagonizing LRP5/6(8-10). Here we show that the transmembrane proteins Kremen1 and Kremen2 are high-affinity Dkk1 receptors that functionally cooperate with Dkk1 to block Wnt/beta-catenin signalling. Kremen2 forms a ternary complex with Dkk1 and LRP6, and induces rapid endocytosis and removal of the Wnt receptor LRP6 from the plasma membrane. The results indicate that Kremen1 and Kremen2 are components of a membrane complex modulating canonical Wnt signalling through LRP6 in vertebrates.	Deutsch Krebsforschungszentrum, Mol Embryol Div, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Dev Genet Div, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Appl Tumor Virol Div, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Niehrs, C (corresponding author), Deutsch Krebsforschungszentrum, Mol Embryol Div, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Mao, Bingyu/L-9955-2014; Davidson, Gary/AAA-7321-2021; Davidson, Gary/J-6059-2013	Davidson, Gary/0000-0002-2264-5518; Mao, Bingyu/0000-0002-7993-3158				Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; COUSO JP, 1994, DEVELOPMENT, V120, P621; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Nakamura T, 2001, BBA-GENE STRUCT EXPR, V1518, P63, DOI 10.1016/S0167-4781(01)00168-3; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wu W, 2000, CURR BIOL, V10, P1611, DOI 10.1016/S0960-9822(00)00868-X; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151	19	815	879	1	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	2002	417	6889					664	667		10.1038/nature756	http://dx.doi.org/10.1038/nature756			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050670				2022-12-28	WOS:000176001200052
J	Rauch, H; Lemmel, H; Baron, M; Loidl, R				Rauch, H; Lemmel, H; Baron, M; Loidl, R			Measurement of a confinement induced neutron phase	NATURE			English	Article							STANDING-WAVE; DIFFRACTION; SHIFT; ATOMS	Particle physicists see neutrons as tiny massive particles with a confinement radius of about 0.7 fm and a distinct internal quark-gluon structure. In quantum mechanics, neutrons are described by wave packets whose spatial extent may become ten orders of magnitude larger than the confinement radius, and can even reach macroscopic dimensions, depending on the degree of monochromaticity. For neutrons passing through narrow slits, it has been predicted(1,2) that quantization of the transverse momentum component changes the longitudinal momentum component, resulting in a phase shift that should be measurable using interferometric methods(3). Here we use neutron interferometry to measure the phase shift arising from lateral confinement of a neutron beam passing through a narrow slit system. The phase shift arises mainly from neutrons whose classical trajectories do not touch the walls of the slits. In this respect, the non-locality of quantum physics is apparent.	Univ Vienna, Atominst, A-1020 Vienna, Austria; Inst Max Von Laue Paul Langevin, F-38042 Grenoble, France	University of Vienna; Institut Laue-Langevin (ILL)	Rauch, H (corresponding author), Univ Vienna, Atominst, A-1020 Vienna, Austria.	rauch@ati.ac.at		Lemmel, Hartmut/0000-0002-4348-5891				Allman BE, 1999, FOUND PHYS, V29, P325, DOI 10.1023/A:1018858630047; CASIMIR HBG, 1948, PHYS REV, V73, P360, DOI 10.1103/PhysRev.73.360; FERRY DK, 1995, QUANTUM TRANSPORT UL; Flugge S., 1971, PRACTICAL QUANTUM ME, VVolume 2; FONDA L, 1973, NUOVO CIMENTO A, VA 15, P689, DOI 10.1007/BF02748082; GREENBERGER DM, 1988, PHYSICA B & C, V151, P374, DOI 10.1016/0378-4363(88)90198-2; Grisenti RE, 1999, PHYS REV LETT, V83, P1755, DOI 10.1103/PhysRevLett.83.1755; HAROCHE S, 1993, SCI AM, V268, P54, DOI 10.1038/scientificamerican0493-54; Hegerfeldt GC, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.023606; Keller C, 1999, APPL PHYS B-LASERS O, V69, P303, DOI 10.1007/s003400050810; LEVYLEBLOND JM, 1987, PHYS LETT A, V125, P441, DOI 10.1016/0375-9601(87)90180-0; MISRA B, 1977, J MATH PHYS, V18, P756, DOI 10.1063/1.523304; Nesvizhevsky VV, 2002, NATURE, V415, P297, DOI 10.1038/415297a; Pokotilovski YN, 1998, PHYS LETT A, V248, P114, DOI 10.1016/S0375-9601(98)00638-0; RAUCH H, 1992, PHYS REV A, V46, P7284, DOI 10.1103/PhysRevA.46.7284; Rauch H, 1996, PHYS REV A, V53, P902, DOI 10.1103/PhysRevA.53.902; Rauch H., 2000, NEUTRON INTERFEROMET; SALOMON C, 1987, PHYS REV LETT, V59, P1659, DOI 10.1103/PhysRevLett.59.1659	18	30	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 6	2002	417	6889					630	632		10.1038/nature00773	http://dx.doi.org/10.1038/nature00773			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050660				2022-12-28	WOS:000176001200042
J	Jansen, LA; Sulmasy, DP				Jansen, LA; Sulmasy, DP			Sedation, alimentation, hydration, and equivocation: Careful conversation about care at the end of life	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PHYSICIAN-ASSISTED SUICIDE; VOLUNTARY ACTIVE EUTHANASIA; TERMINAL SEDATION; LAST RESORT; REFUSAL; PATIENT	In the recent medical ethics literature, several authors have recommended terminal sedation and refusal of hydration and nutrition as important, morally acceptable, and relatively uncontroversial treatment options for end-of-life suffering. However, not all authors use these terms to refer to the same practices. This paper examines the various ways that the terms terminal sedation and refusal of hydration and nutrition have been used in the medical literature. Although some of these practices are ethically appropriate responses to end-of-life suffering, others (at least as they are currently described in the medical ethics literature) are not. This paper identifies and discusses the principles that morally distinguish these practices from one another and specifically describes different features of medical practices and moral principles that affect the moral acceptability of various medical treatments. These distinctions reveal the complexity of the issues surrounding terminal sedation and refusal of hydration and nutrition, a complexity that has not been adequately addressed in recent discussions.	St Vincents Hosp & Med Ctr, John J Conley Dept Eth, New York, NY 10011 USA; New York Med Coll, Bioeth Inst, Valhalla, NY USA	Saint Vincents Hospital Manhattan; New York Medical College	Jansen, LA (corresponding author), St Vincents Hosp & Med Ctr, John J Conley Dept Eth, 153 West 11th St NR815, New York, NY 10011 USA.	ljansen@saintvincentsnyc.org						Beauchamp Tom, 1993, MATTERS LIFE DEATH N, P69; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; Cherny N I, 1994, J Palliat Care, V10, P31; JACOBSEN PB, 2000, CANC CARE J, V3, P1; Kamm FM, 1999, PHILOS PUBLIC AFF, V28, P169, DOI 10.1111/j.1088-4963.1999.00169.x; Keenan J F, 1995, Health Prog, V76, P23; Krakauer E L, 2000, Oncologist, V5, P53, DOI 10.1634/theoncologist.5-1-53; Miller FG, 1998, ANN INTERN MED, V128, P559, DOI 10.7326/0003-4819-128-7-199804010-00007; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; Quill TE, 2000, ANN INTERN MED, V132, P488, DOI 10.7326/0003-4819-132-6-200003210-00011; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; QUINN WS, 1989, PHILOS PUBLIC AFF, V18, P334; Rousseau P, 1996, ARCH INTERN MED, V156, P1785, DOI 10.1001/archinte.156.16.1785; Sulmasy DP, 2000, ANN INTERN MED, V133, P560, DOI 10.7326/0003-4819-133-7-200010030-00021; Sulmasy DP, 1996, CLIN PULM MED, V3, P86; Wein S, 2000, ONCOLOGY-NY, V14, P585	17	89	90	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 4	2002	136	11					845	849		10.7326/0003-4819-136-11-200206040-00014	http://dx.doi.org/10.7326/0003-4819-136-11-200206040-00014			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	558KG	12044133				2022-12-28	WOS:000175964500008
J	Iijima, M; Devreotes, P				Iijima, M; Devreotes, P			Tumor suppressor PTEN mediates sensing of chemoattractant gradients	CELL			English	Article							DICTYOSTELIUM-DISCOIDEUM; SIGNAL-TRANSDUCTION; LIVING CELLS; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; NEUTROPHIL MIGRATION; PHOSPHATASE-ACTIVITY; ADENYLYL-CYCLASE; CHEMOTAXIS; PROTEIN; ACTIVATION	Shallow gradients of chemoattractants, sensed by G protein-linked signaling pathways, elicit localized binding of PH domains specific for PI(3,4,5)P-3 at sites on the membrane where rearrangements of the cytoskeleton and pseudopod extension occur. Disruption of the PI 3-phosphatase, PTEN, in Dictyostelium discoideum dramatically prolonged and broadened the PH domain relocation and actin polymerization responses, causing the cells lacking PTEN to follow a circuitous route toward the attractant. Exogenously expressed PTEN-GFP localized to the surface membrane at the rear of the cell. Membrane localization required a putative PI(4,5)P-2 binding motif and was required for chemotaxis. These results suggest that specific phosphoinositides direct actin polymerization to the cell's leading edge and regulation of PTEN through a feedback loop plays a critical role in gradient sensing and directional migration.	Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Devreotes, P (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA.				NIGMS NIH HHS [GM57874, GM34933] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034933, R01GM057874] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1808, DOI 10.1006/bbrc.1994.2880; Baggiolini M, 2001, J INTERN MED, V250, P91, DOI 10.1046/j.1365-2796.2001.00867.x; Buczynski G, 1997, J CELL BIOL, V136, P1271, DOI 10.1083/jcb.136.6.1271; COCUCCI SM, 1970, J CELL BIOL, V45, P399, DOI 10.1083/jcb.45.2.399; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; DEVREOTES PN, 1983, DEV BIOL, V96, P405, DOI 10.1016/0012-1606(83)90178-1; Funamoto S, 2001, J CELL BIOL, V153, P795, DOI 10.1083/jcb.153.4.795; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Kim CH, 1999, J CLIN INVEST, V104, P1751, DOI 10.1172/JCI7310; Kim JY, 1997, J BIOL CHEM, V272, P27313, DOI 10.1074/jbc.272.43.27313; KONIJN TM, 1970, EXPERIENTIA, V26, P367, DOI 10.1007/BF01896891; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Levchenko A, 2002, BIOPHYS J, V82, P50, DOI 10.1016/S0006-3495(02)75373-3; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; LILLY PJ, 1995, J CELL BIOL, V129, P1659, DOI 10.1083/jcb.129.6.1659; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Niggli V, 2000, FEBS LETT, V473, P217, DOI 10.1016/S0014-5793(00)01534-9; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Parent CA, 1996, ANNU REV BIOCHEM, V65, P411; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; Ueda M, 2001, SCIENCE, V294, P864, DOI 10.1126/science.1063951; van Es S, 1999, CELL MOL LIFE SCI, V55, P1341, DOI 10.1007/s000180050374; VANHAASTERT PJM, 1982, MOL CELL ENDOCRINOL, V26, P1, DOI 10.1016/0303-7207(82)90002-8; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Wardlaw AJ, 2000, BRIT MED BULL, V56, P985, DOI 10.1258/0007142001903490; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu DQ, 2000, J CELL SCI, V113, P2935; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wymann MP, 2000, IMMUNOL TODAY, V21, P260, DOI 10.1016/S0167-5699(00)01649-2; Xiao Z, 1997, J CELL BIOL, V139, P365, DOI 10.1083/jcb.139.2.365; Zhou KM, 1998, J CELL SCI, V111, P283	49	530	538	0	18	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 31	2002	109	5					599	610		10.1016/S0092-8674(02)00745-6	http://dx.doi.org/10.1016/S0092-8674(02)00745-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	558GL	12062103	Bronze			2022-12-28	WOS:000175957900009
J	Bancewicz, J; Clark, PI; Smith, DB; Donnelly, RJ; Fayers, PM; Weeden, S; Girling, DJ; Hutchinson, T; Harvey, A; Lyddiard, J; Al-Jilaihawi, AN; Bown, SG; Cottier, B; Jeyasingham, K; Lea, RE; Matthews, HR; Moghissi, K; Morritt, GN; Myskow, MW; Pagliero, KM; Rowland, CR; Yosef, HMA				Bancewicz, J; Clark, PI; Smith, DB; Donnelly, RJ; Fayers, PM; Weeden, S; Girling, DJ; Hutchinson, T; Harvey, A; Lyddiard, J; Al-Jilaihawi, AN; Bown, SG; Cottier, B; Jeyasingham, K; Lea, RE; Matthews, HR; Moghissi, K; Morritt, GN; Myskow, MW; Pagliero, KM; Rowland, CR; Yosef, HMA		Med Res Council Oesophageal Canc	Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial	LANCET			English	Article							SQUAMOUS-CELL CARCINOMA; ESOPHAGEAL CANCER; ADENOCARCINOMA; RADIOTHERAPY; SURVIVAL; SURGERY; THERAPY	Background The outlook for patients with oesophageal cancer undergoing surgical resection with curative intent is poor. We aimed to assess the effects of preoperative chemotherapy on survival, dysphagia. and performance status in this group of patients. Methods 802 previously untreated patients with resectable oesophageal cancer of any cell type were randomly allocated either two 4-day cycles, 3 weeks apart, of cisplatin 80 mg/m(2) by infusion over 4 h plus fluorouracil 1000 mg/m(2) daily by continuous infusion for 4 days followed by surgical resection (CS group, n=400), or resection alone (S group, 402). Clinicians could choose to give preoperative radiotherapy to all their patients irrespective of randomisation. Primary outcome measure was survival time, Analysis was by intention to treat, Findings No patients dropped out of the study. Resection was microscopically complete in 233 (60%) of 390 assessable CS patients and 215 (54%) of 397 S patients (p<0.0001). Postoperative complications were reported in 146 (41%) CS and 161 (42%) S patients. Overall survival was better in the CS group (hazard ratio 0.79; 95% Cl 0.67-0.93: p=0.004). Median survival was 512 days (16.8 months) in the CS group compared with 405 days (13.3 months) in the S group (difference 107 days; 95% Cl 30-196), and 2-year survival rates were 43% and 34% (difference 9%: 3-14). Interpretation Two cycles of preoperative cisplatin and fluorouracil improve survival without additional serious adverse events in the treatment of patients with resectable oesophageal cancer.	MRC, Clin Trials Unit, Canc Div, London NW1 2DA, England; Hope Hosp, Salford M6 8HD, Lancs, England; Ctr Cardiothorac, Liverpool, Merseyside, England; Clatterbridge Ctr Oncol, Liverpool, Merseyside, England	Medical Research Council Clinical Trials Unit; Clatterbridge Cancer Centre	Girling, DJ (corresponding author), MRC, Clin Trials Unit, Canc Div, 222 Euston Rd, London NW1 2DA, England.		Bown, Stephen/AAX-6573-2020	Fayers, Peter/0000-0003-4778-1513				AJANI JA, 1990, J CLIN ONCOL, V8, P1231, DOI 10.1200/JCO.1990.8.7.1231; ANCONA E, 1998, CAN J GASTROENTER SB, V12; CAREY RW, 1986, J CLIN ONCOL, V4, P697, DOI 10.1200/JCO.1986.4.5.697; CAREY RW, 1990, P AN M AM SOC CLIN, V9, P105; Fayers PM, 1997, STAT MED, V16, P1413, DOI 10.1002/(SICI)1097-0258(19970630)16:12<1413::AID-SIM578>3.0.CO;2-U; FORASTIERE AA, 1987, J CLIN ONCOL, V5, P1143, DOI 10.1200/JCO.1987.5.8.1143; HILGENBERG AD, 1988, ANN THORAC SURG, V45, P357, DOI 10.1016/S0003-4975(98)90004-2; KELSEN D P, 1986, Seminars in Surgical Oncology, V2, P170, DOI 10.1002/ssu.2980020310; KELSEN DP, 1990, J CLIN ONCOL, V8, P1352, DOI 10.1200/JCO.1990.8.8.1352; Kelsen DP, 1998, NEW ENGL J MED, V339, P1979, DOI 10.1056/NEJM199812313392704; KOK TC, 1997, P AN M AM SOC CLIN, V16, pA277; Law S, 1997, J THORAC CARDIOV SUR, V114, P210, DOI 10.1016/S0022-5223(97)70147-8; MAIPANG T, 1994, J SURG ONCOL, V56, P191, DOI 10.1002/jso.2930560314; NEUHAUS P, 1992, ARCH SURG-CHICAGO, V127, P1446; NYGAARD K, 1992, WORLD J SURG, V16, P1104, DOI 10.1007/BF02067069; Organization W.H, 1979, WHO HDB REP RES CANC; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; ROTH JA, 1988, J THORAC CARDIOV SUR, V96, P242; SHIELDS TW, 1984, ARCH SURG-CHICAGO, V119, P558; Sutton P, 2000, GI CANCER, V3, P231	20	1115	1134	2	33	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 18	2002	359	9319					1727	1733						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049861				2022-12-28	WOS:000175740500009
J	Gleich, GJ; Leiferman, KM; Pardanani, A; Tefferi, A; Butterfield, JH				Gleich, GJ; Leiferman, KM; Pardanani, A; Tefferi, A; Butterfield, JH			Treatment of hypereosinophilic syndrome with imatinib mesilate	LANCET			English	Article								Patients with hypereosinophilic syndrome show persistent eosinophilia without recognised cause. We treated five such patients with 100 mg imatinib mesilate (formerly STI-571) daily; four male patients with normal serum interleukin 5 showed complete haematological responses; a female patient who did not respond had raised serum interleukin-5 concentrations. One patient developed leucopenia after 4 days of treatment; counts returned to normal when treatment was stopped. After I month, eosinophilia recurred; with further treatment for 2 days, eosinophil counts again became normal. All patients who responded stopped other treatments and reduced imatinib mesilate to 200 mg per week. This drug effectively controls eosinophilia In patients with hypereosinophilic syndrome and normal Interleukin-5 concentrations.	4B454 Sch Med, Dept Dermatol, Salt Lake City, UT 84132 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Dermatol, Allerg Dis Res Lab, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Gleich, GJ (corresponding author), 4B454 Sch Med, Dept Dermatol, 30 North 1900 East, Salt Lake City, UT 84132 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI009728, R01AI009728, U19AI034577, U01AI034577] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 09728, AI 34577] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUTTERFIELD JH, 1994, ANN INTERN MED, V121, P648, DOI 10.7326/0003-4819-121-9-199411010-00003; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; HARDY WR, 1968, ANN INTERN MED, V68, P1220, DOI 10.7326/0003-4819-68-6-1220; LEIFERMAN KM, 1982, JAMA-J AM MED ASSOC, V247, P1018, DOI 10.1001/jama.247.7.1018; WELLER PF, 1994, BLOOD, V83, P2759, DOI 10.1182/blood.V83.10.2759.2759	5	265	274	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 4	2002	359	9317					1577	1578		10.1016/S0140-6736(02)08505-7	http://dx.doi.org/10.1016/S0140-6736(02)08505-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047970				2022-12-28	WOS:000175460700014
J	Wilkins, MR; Aldashev, A; Morrell, NW				Wilkins, MR; Aldashev, A; Morrell, NW			Nitric oxide, phosphodiesterase inhibition, and adaption to hypoxic conditions	LANCET			English	Editorial Material							PULMONARY-HYPERTENSION; HIGH-ALTITUDE; CIRCULATION; ADAPTATION; SILDENAFIL; SYNTHASE; CATTLE; RATS; YAK		Hammersmith Hosp, Imperial Coll Sch Med, Clin Pharmacol Sect, London W12 0NN, England	Imperial College London	Wilkins, MR (corresponding author), Hammersmith Hosp, Imperial Coll Sch Med, Clin Pharmacol Sect, London W12 0NN, England.	m.wilkins@ic.ac.uk		ALDASHEV, Almaz/0000-0002-4793-2206; Morrell, Nicholas/0000-0001-5700-9792				ANAND IS, 1986, THORAX, V41, P696, DOI 10.1136/thx.41.9.696; Beall CM, 2001, NATURE, V414, P411, DOI 10.1038/35106641; Budts W, 2000, CIRCULATION, V102, P2880; DURMOWICZ AG, 1993, J APPL PHYSIOL, V74, P2276, DOI 10.1152/jappl.1993.74.5.2276; Fagan KA, 2000, PHYSIOL RES, V49, P539; Hackett PH, 2001, NEW ENGL J MED, V345, P107, DOI 10.1056/NEJM200107123450206; Hanasato N, 1999, AM J PHYSIOL-LUNG C, V277, pL225, DOI 10.1152/ajplung.1999.277.2.L225; HEATH D, 1989, THORAX, V44, P981, DOI 10.1136/thx.44.12.981; MacLean MR, 1997, J PHARMACOL EXP THER, V283, P619; Moore LG, 1998, YEARB PHYS ANTHROPOL, V41, P25; Moore LG, 2001, HIGH ALT MED BIOL, V2, P257, DOI 10.1089/152702901750265341; STAMLER JS, 1994, CIRCULATION, V89, P2035, DOI 10.1161/01.CIR.89.5.2035; Steudel W, 1999, ANESTHESIOLOGY, V91, P1090, DOI 10.1097/00000542-199910000-00030; WEIR EK, 1974, CARDIOVASC RES, V8, P745, DOI 10.1093/cvr/8.6.745; WEST JB, 1995, EUR RESPIR J, V8, P523; Wilkens H, 2001, CIRCULATION, V104, P1218, DOI 10.1161/hc3601.096826; YUAN XJ, 1990, AM J PHYSIOL, V259, pH281, DOI 10.1152/ajpheart.1990.259.2.H281; Zhao L, 2001, CIRCULATION, V103, P442; Zhao L, 2001, CIRCULATION, V104, P424, DOI 10.1161/hc2901.093117	19	20	20	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 4	2002	359	9317					1539	1540		10.1016/S0140-6736(02)08528-8	http://dx.doi.org/10.1016/S0140-6736(02)08528-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047961				2022-12-28	WOS:000175460700005
J	Feng, LX; Chen, YL; Dettin, L; Pera, RAR; Herr, JC; Goldberg, E; Dym, M				Feng, LX; Chen, YL; Dettin, L; Pera, RAR; Herr, JC; Goldberg, E; Dym, M			Generation and in vitro differentiation of a spermatogonial cell line	SCIENCE			English	Article							PRIMORDIAL GERM-CELLS; KIT RECEPTOR; STEM-CELLS; C-KIT; MOUSE; PROLIFERATION; TELOMERASE; EXPRESSION; GENE; RAT	Spermatogenesis is the process by which spermatogonial stem cells divide and differentiate to produce sperm. In vitro sperm production has been difficult to achieve because of the lack of culture system to maintain viable spermatogonia for long periods of time. Here we report the in vitro generation of spermatocytes and spermatids from telomerase-immortalized mouse type A spermatogonial cells in the presence of stem cell factor. This differentiation can occur in the absence of supportive cells. The immortalized spermatogonial cell line may serve as powerful tool in elucidating the molecular mechanisms of spermatogenesis. Furthermore, through genomic modi cation and transplantation techniques, this male germ cell line may be used to generate transgenic mice and to develop germ cell gene therapy.	Georgetown Univ, Med Ctr, Dept Cell Biol, Washington, DC 20007 USA; Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; Univ Virginia, Sch Med, Dept Cell Biol, Charlottesville, VA 22908 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Georgetown University; University of California System; University of California San Francisco; University of Virginia; Northwestern University	Feng, LX (corresponding author), Georgetown Univ, Med Ctr, Dept Cell Biol, Washington, DC 20007 USA.			Reijo Pera, Renee/0000-0002-6487-1329	NICHD NIH HHS [HD-36483] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036483] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Blume-Jensen P, 2000, NAT GENET, V24, P157, DOI 10.1038/72814; de Rooij DG, 1998, CURR OPIN CELL BIOL, V10, P694, DOI 10.1016/S0955-0674(98)80109-9; DONOVAN PJ, 1986, CELL, V44, P831, DOI 10.1016/0092-8674(86)90005-X; DYM M, 1995, BIOL REPROD, V52, P8, DOI 10.1095/biolreprod52.1.8; DYM M, 1994, P NATL ACAD SCI USA, V91, P11287, DOI 10.1073/pnas.91.24.11287; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HOFMANN MC, 1994, P NATL ACAD SCI USA, V91, P5533, DOI 10.1073/pnas.91.12.5533; KASHIWABARA S, 1990, BIOCHEM BIOPH RES CO, V173, P240, DOI 10.1016/S0006-291X(05)81047-2; Kissel H, 2000, EMBO J, V19, P1312, DOI 10.1093/emboj/19.6.1312; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LIANG ZG, 1986, J EXP ZOOL, V240, P377, DOI 10.1002/jez.1402400312; MALI P, 1989, REPROD FERT DEVELOP, V1, P369, DOI 10.1071/RD9890369; McLaren A, 2000, MOL CELL ENDOCRINOL, V163, P3, DOI 10.1016/S0303-7207(99)00234-8; Meng XJ, 2001, CANCER RES, V61, P3267; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nagano M, 2001, P NATL ACAD SCI USA, V98, P13090, DOI 10.1073/pnas.231473498; Nakanishi T, 1999, FEBS LETT, V449, P277, DOI 10.1016/S0014-5793(99)00433-0; Ohta H, 2000, DEVELOPMENT, V127, P2125; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pesce M, 1998, BIOESSAYS, V20, P722, DOI 10.1002/(SICI)1521-1878(199809)20:9&lt;722::AID-BIES5&gt;3.0.CO;2-I; Ravindranath N, 1997, ENDOCRINOLOGY, V138, P4026, DOI 10.1210/en.138.9.4026; Reddi PP, 1999, BIOL REPROD, V61, P1256, DOI 10.1095/biolreprod61.5.1256; Ruggiu M, 1997, NATURE, V389, P73, DOI 10.1038/37987; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; Starz-Gaiano M, 2001, MECH DEVELOP, V105, P5, DOI 10.1016/S0925-4773(01)00392-6; TAM PPL, 1981, J EMBRYOL EXP MORPH, V64, P133; Wolkowicz MJ, 1996, BIOL REPROD, V55, P923, DOI 10.1095/biolreprod55.4.923; Yeager TR, 1999, CURR OPIN BIOTECH, V10, P465, DOI 10.1016/S0958-1669(99)00011-7	28	186	227	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 19	2002	297	5580					392	395		10.1126/science.1073162	http://dx.doi.org/10.1126/science.1073162			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12077424				2022-12-28	WOS:000176892600049
J	Sun, ZW; Allis, CD				Sun, ZW; Allis, CD			Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast	NATURE			English	Article							N-END RULE; SACCHAROMYCES-CEREVISIAE; CONJUGATING ENZYME; RAD6 PROTEIN; ACETYLATION; NUCLEOSOME; PARTICLE; DOMAINS; CODE	In eukaryotes, the DNA of the genome is packaged with histone proteins to form nucleosomal filaments, which are, in turn, folded into a series of less well understood chromatin structures(1). Post-translational modifications of histone tail domains modulate chromatin structure and gene expression(2-4). Of these, histone ubiquitination is poorly understood. Here we show that the ubiquitin-conjugating enzyme Rad6 (Ubc2) mediates methylation of histone H3 at lysine 4 (Lys 4) through ubiquitination of H2B at Lys 123 in yeast (Saccharomyces cerevisiae). Moreover, H3 (Lys 4) methylation is abolished in the H2B-K123R mutant, whereas H3-K4R retains H2B (Lys 123) ubiquitination. These data indicate a unidirectional regulatory pathway in which ubiquitination of H2B (Lys 123) is a prerequisite for H3 (Lys 4) methylation. We also show that an H2B-K123R mutation perturbs silencing at the telomere, providing functional links between Rad6-mediated H2B (Lys 123) ubiquitination, Set1-mediated H3 (Lys 4) methylation, and transcriptional silencing. Thus, these data reveal a pathway leading to gene regulation through concerted histone modifications on distinct histone tails. We refer to this as 'trans-tail' regulation of histone modification, a stated prediction of the histone code hypothesis(5,6)	Univ Virginia Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Allis, CD (corresponding author), Univ Virginia Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.							Bailly V, 1997, MOL CELL BIOL, V17, P4536, DOI 10.1128/MCB.17.8.4536; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; MADURA K, 1993, J BIOL CHEM, V268, P12046; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Smith JS, 1999, MOL CELL BIOL, V19, P3184; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Sun ZW, 1999, GENETICS, V152, P921; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Turner SD, 2002, MOL CELL BIOL, V22, P4011, DOI 10.1128/MCB.22.12.4011-4019.2002; Urnov FD, 2001, J MAMMARY GLAND BIOL, V6, P153, DOI 10.1023/A:1011304606604; VANHOLDE KE, 1989, CHROMATIN, P111; Varshavsky A, 1995, COLD SPRING HARB SYM, V60, P461, DOI 10.1101/SQB.1995.060.01.051; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; WATKINS JF, 1993, GENE DEV, V7, P250, DOI 10.1101/gad.7.2.250; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	30	804	828	0	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 4	2002	418	6893					104	108		10.1038/nature00883	http://dx.doi.org/10.1038/nature00883			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12077605				2022-12-28	WOS:000176599200048
J	Fazel, S; Vassos, E; Danesh, V				Fazel, S; Vassos, E; Danesh, V			Prevalence of epilepsy in prisoners: systematic review	BRITISH MEDICAL JOURNAL			English	Article							PSYCHIATRIC-DISORDER		Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; Univ Cambridge, Inst Hlth Sci, Dept Publ Hlth & Primary Care, Cambridge, England	University of Oxford; University of Cambridge	Fazel, S (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.		Vassos, Evangelos/F-9825-2013; Fazel, Seena/B-5307-2008	Vassos, Evangelos/0000-0001-6363-0438; Fazel, Seena/0000-0002-5383-5365	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Agbahowe SA, 1998, E AFR MED J, V75, P19; BLUGRASS R, 1966, THESIS U ST ANDREWS; DERRO RA, 1978, MINN MED, V61, P333; Fazel S, 2002, LANCET, V359, P545, DOI 10.1016/S0140-6736(02)07740-1; GUNN J, 1991, BRIT MED J, V303, P338, DOI 10.1136/bmj.303.6798.338; MADEN T, 1994, BRIT J PSYCHIAT, V164, P44, DOI 10.1192/bjp.164.1.44; ROBERTSON RG, 1987, CAN J PSYCHIAT, V32, P749, DOI 10.1177/070674378703200902; Rowan A J, 1976, Trans Am Neurol Assoc, V101, P281; Sander JWAS, 1996, J NEUROL NEUROSUR PS, V61, P433, DOI 10.1136/jnnp.61.5.433; SWANK GE, 1976, AM J PSYCHIAT, V133, P1331; TOONE B, 2000, NEW OXFORD TXB PSYCH, P1153; [No title captured]	12	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 22	2002	324	7352					1495	+		10.1136/bmj.324.7352.1495	http://dx.doi.org/10.1136/bmj.324.7352.1495			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567ZL	12077036	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000176517900021
J	Goodman, R; Ford, T; Meltzer, H				Goodman, R; Ford, T; Meltzer, H			Mental health problems of children in the community: 18 month follow up	BRITISH MEDICAL JOURNAL			English	Article							DIFFICULTIES QUESTIONNAIRE; STRENGTHS		Kings Coll London, Inst Psychiat, Dept Child & Adolescent Psychiat, London SE5 8AF, England; Off Natl Stat, London SW1V 2QQ, England	University of London; King's College London	Goodman, R (corresponding author), Kings Coll London, Inst Psychiat, Dept Child & Adolescent Psychiat, London SE5 8AF, England.	r.goodman@iop.kcl.ac.uk	Ford, Tamsin/V-5908-2019	Ford, Tamsin/0000-0001-5295-4904; Goodman, Robert/0000-0001-5596-1667	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Goodman R, 1999, J CHILD PSYCHOL PSYC, V40, P791, DOI 10.1017/S0021963099004096; Goodman R, 2001, J AM ACAD CHILD PSY, V40, P1337, DOI 10.1097/00004583-200111000-00015; Graham P, 2000, BRIT J PSYCHIAT, V176, P414, DOI 10.1192/bjp.176.5.414; Harrington R, 2001, BRIT J PSYCHIAT, V179, P189, DOI 10.1192/bjp.179.3.189; Meltzer H., 2000, MENTAL HLTH CHILDREN	5	50	52	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 22	2002	324	7352					1496	1497		10.1136/bmj.324.7352.1496	http://dx.doi.org/10.1136/bmj.324.7352.1496			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567ZL	12077037	Bronze, Green Published			2022-12-28	WOS:000176517900022
J	Levison, HF; Morbidelli, A; Dones, L; Jedicke, R; Wiegert, PA; Bottke, WF				Levison, HF; Morbidelli, A; Dones, L; Jedicke, R; Wiegert, PA; Bottke, WF			The mass disruption of Oort cloud comets	SCIENCE			English	Article							LONG-PERIOD COMETS; JUPITER-FAMILY COMETS; MAGNITUDE DISTRIBUTION; SOLAR-SYSTEM; KUIPER BELT; OBJECTS; CAMERA; ORIGIN; MANTLE	We have calculated the number of dormant, nearly isotropic Oort cloud comets in the solar system by (i) combining orbital distribution models with statistical models of dormant comet discoveries by well-defined surveys and (ii) comparing the model results to observations of a population of dormant comets. Dynamical models that assume that comets are not destroyed predict that we should have discovered similar to100 times more dormant nearly isotropic comets than are actually seen. Thus, as comets evolve inward from the Oort cloud, the majority of them must physically disrupt.	SW Res Inst, Boulder, CO 80302 USA; Observ Cote Azur, F-06034 Nice 4, France; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Queens Univ, Dept Phys, Kingston, ON K7L 3N6, Canada	UDICE-French Research Universities; Universite Cote d'Azur; Observatoire de la Cote d'Azur; University of Arizona; Queens University - Canada	Levison, HF (corresponding author), SW Res Inst, 1050 Walnut St,Suite 426, Boulder, CO 80302 USA.	hal@gort.boulder.swri.edu	Levison, Harold F/C-6061-2013	Levison, Harold F/0000-0001-5847-8099; Jedicke, Robert/0000-0001-7830-028X				BAILEY M, 1984, MON NOT R ASTRON SOC, V221, P247; BAILEY ME, 1988, MON NOT R ASTRON SOC, V235, P1; Boehnhardt H, 2001, SCIENCE, V292, P1307, DOI 10.1126/science.1061654; Bottke WF, 2002, ICARUS, V156, P399, DOI 10.1006/icar.2001.6788; BRIN GD, 1979, ASTROPHYS J, V229, P402, DOI 10.1086/156966; Chambers JE, 1997, ICARUS, V125, P32, DOI 10.1006/icar.1996.5567; DONES L, 2001, AM ASTRON SOC DIV AS, V32, P1103; DUNCAN M, 1987, ASTRON J, V94, P1330, DOI 10.1086/114571; DUNCAN M, 1988, ASTROPHYS J, V328, P69; Duncan MJ, 1997, SCIENCE, V276, P1670, DOI 10.1126/science.276.5319.1670; EVERHART E, 1967, ASTRON J, V72, P1002, DOI 10.1086/110376; Fernandez JA, 1999, ASTRON ASTROPHYS, V352, P327; Fernandez YR, 2001, ASTROPHYS J, V553, pL197, DOI 10.1086/320689; Hughes DW, 2001, MON NOT R ASTRON SOC, V326, P515, DOI 10.1046/j.1365-8711.2001.04544.x; JEDICKE R, IN PRESS ASTEROIDS, V3; JEDICKE R, 2002, IN PRESS ICARUS; KELLER HU, 1986, NATURE, V321, P320, DOI 10.1038/321320a0; Levison HF, 2001, ASTRON J, V121, P2253, DOI 10.1086/319943; Levison HF, 1997, ICARUS, V127, P13, DOI 10.1006/icar.1996.5637; Levison HF, 1996, ASTR SOC P, V107, P173; LOWRY SC, 2001, THESIS QUEENS U BELF; Oort J. H., 1950, B ASTRON I NETH, V11, P91; Press W. H., 1992, NUMERICAL RECIPES FO, P640; PRIALNIK D, 1988, ICARUS, V74, P272, DOI 10.1016/0019-1035(88)90042-5; Shoemaker E. M, 1982, SATELLITES JUPITER, P277; Soderblom LA, 2002, SCIENCE, V296, P1087, DOI 10.1126/science.1069527; Stern SA, 1997, ASTROPHYS J, V490, P879, DOI 10.1086/304912; Stokes GH, 2000, ICARUS, V148, P21, DOI 10.1006/icar.2000.6493; WEISSMAN PR, 1980, ASTRON ASTROPHYS, V85, P191; WEISSMAN PR, 1990, GEOL SOC AM SPEC PAP, V247, P171; WEISSMAN PR, 1979, IAU S, V81, P277; WEISSMAN PR, 2001, B AM ASTRON SOC, V33, P1094; WHIPPLE FL, 1962, ASTRON J, V67, P1, DOI 10.1086/108596; Wiegert P, 1999, ICARUS, V137, P84, DOI 10.1006/icar.1998.6040	35	71	72	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	2002	296	5576					2212	2215		10.1126/science.1070226	http://dx.doi.org/10.1126/science.1070226			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077415				2022-12-28	WOS:000176379000056
J	Dominguez, P; Jacobson, AG; Jefferies, RPS				Dominguez, P; Jacobson, AG; Jefferies, RPS			Paired gill slits in a fossil with a calcite skeleton	NATURE			English	Article							ICHNOLOGICAL EVIDENCE; BEHAVIOR; ECHINODERMS; MITRATE	The chordates, hemichordates (such as acorn worms) and echinoderms (such as starfish) comprise the group Deuterostomia, well established as monophyletic(1,2). Among extant deuterostomes, a skeleton in which each plate has the crystallographic structure of a single crystal of calcite is characteristic of echinoderms and is always associated with radial symmetry and never with gill slits. Among fossils, however, such a skeleton sometimes occurs without radial symmetry. This is true of Jaekelocarpus oklahomensis, from the Upper Carboniferous of Oklahoma, USA, which, being externally almost bilaterally symmetrical, is traditionally placed in the group Mitrata (Ordovician to Carboniferous periods, 530-280 million years ago), by contrast with the bizarrely asymmetrical Cornuta (Cambrian to Ordovician periods, 540 to 440 million years ago). Using computer X-ray microtomography, we describe the anatomy of Jaekelocarpus in greater detail than formerly possible, reveal evidence of paired gill slits internally and interpret its functional anatomy. On this basis we suggest its phylogenetic position within the deuterostomes.	Nat Hist Museum, Dept Palaeontol, London SW7 5BD, England; Univ Texas, MCDB, Patterson Labs, Austin, TX 78712 USA; Univ Complutense Madrid, Dept Palaeontol, E-28040 Madrid, Spain	Natural History Museum London; University of Texas System; University of Texas Austin; Complutense University of Madrid	Jefferies, RPS (corresponding author), Nat Hist Museum, Dept Palaeontol, Cromwell Rd, London SW7 5BD, England.		Domínguez Alonso, Patricio/C-2679-2013					Cameron CB, 2000, P NATL ACAD SCI USA, V97, P4469, DOI 10.1073/pnas.97.9.4469; CRIPPS AP, 1989, ZOOL J LINN SOC-LOND, V96, P49, DOI 10.1111/j.1096-3642.1989.tb01821.x; David B, 2000, PALEOBIOLOGY, V26, P529, DOI 10.1666/0094-8373(2000)026<0529:AHEAAF>2.0.CO;2; Jefferies R.P.S., 1998, Integrative Biology, V1, P115, DOI 10.1002/(SICI)1520-6602(1998)1:4<115::AID-INBI2>3.0.CO;2-0; JEFFERIES R. P. S., 1967, SYMP ZOOL SOC LONDON, V20, P163; Jefferies RPS, 1997, LETHAIA, V30, P1; Jefferies RPS, 2001, LETHAIA, V34, P262, DOI 10.1080/002411601753292999; JEFFERIES RPS, 1986, ZOOL J LINN SOC; JEFFERIES RPS, 2000, MAJOR EVENTS VERTEBR, P20; JORGENSEN CB, 1989, COMP BIOCHEM PHYS A, V94, P383, DOI 10.1016/0300-9629(89)90562-8; Ketcham RA, 2001, COMPUT GEOSCI-UK, V27, P381, DOI 10.1016/S0098-3004(00)00116-3; KOLATA DR, 1991, J PALEONTOL, V65, P844, DOI 10.1017/S0022336000037811; KOTT P, 1990, Memoirs of the Queensland Museum, V29, P1; KOTT P, 1985, MEMOIRS QUEENSLAND M, V20, P1; Kott Patricia, 1992, Memoirs of the Queensland Museum, V32, P375; Lefebvre B, 2001, LETHAIA, V34, P260; MARTINUCCI GB, 1991, SELECTED S MONOGRAPH, P123; PARSLEY RL, 1988, ECHINODERM PHYLOGENY, P347; Peterson KJ, 2001, EVOL DEV, V3, P170, DOI 10.1046/j.1525-142x.2001.003003170.x; PHILIP GM, 1979, BIOL REV, V54, P439, DOI 10.1111/j.1469-185X.1979.tb00845.x; Ruta M, 1999, EVOL DEV, V1, P123, DOI 10.1046/j.1525-142x.1999.99008.x; Sutcliffe OE, 2000, LETHAIA, V33, P1; UBAGHS G, 1968, TREATISE INVERTEBR S, pS297; VANGEET, 2000, SEDIM GEOL, V132, P1	24	67	69	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 20	2002	417	6891					841	U6		10.1038/nature00805	http://dx.doi.org/10.1038/nature00805			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075349				2022-12-28	WOS:000176285600044
J	Light, RW				Light, RW			Pleural effusion	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIAGNOSTIC-SIGNIFICANCE; CHEST ROENTGENOGRAPHY; ADENOSINE-DEAMINASE; FLUID; PNEUMOTHORAX; SEPARATION; GLUCOSE; AMYLASE		St Thomas Hosp, Pulm Dis Program, Nashville, TN 37205 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA	Saint Thomas Hospital; Vanderbilt University	Light, RW (corresponding author), St Thomas Hosp, Pulm Dis Program, 4220 Harding Rd, Nashville, TN 37205 USA.	rlight98@yahoo.com						ADELMAN M, 1984, AM J MED, V77, P915, DOI 10.1016/0002-9343(84)90542-4; Ahearn GS, 2000, SEMIN RESP CRIT CARE, V21, P521; Aleman C, 1999, AM J MED, V107, P340, DOI 10.1016/S0002-9343(99)00238-7; Branca P, 2001, ARCH INTERN MED, V161, P228, DOI 10.1001/archinte.161.2.228; BROADDUS VC, 1992, CHEST, V102, P658, DOI 10.1378/chest.102.3.658; BURGESS LJ, 1995, CHEST, V107, P1604, DOI 10.1378/chest.107.6.1604; Colicc GL, 2000, CHEST, V118, P1158, DOI 10.1378/chest.118.4.1158; Colice, 2001, CHEST, V119, P319; Doyle JJ, 1996, ANN INTERN MED, V124, P816, DOI 10.7326/0003-4819-124-9-199605010-00005; Ferrer JS, 1996, CHEST, V109, P1508, DOI 10.1378/chest.109.6.1508; HEFFNER JE, 1995, AM J RESP CRIT CARE, V152, P823; Heyderman RS, 1998, TROP MED INT HEALTH, V3, P14, DOI 10.1046/j.1365-3156.1998.00167.x; KOHAN JM, 1986, AM REV RESPIR DIS, V133, P1124; Lee YC, 1999, AUST NZ J MED, V29, P765, DOI 10.1111/j.1445-5994.1999.tb00777.x; Lee YCG, 2001, CHEST, V120, P356, DOI 10.1378/chest.120.2.356; LIGHT RW, 1973, JAMA-J AM MED ASSOC, V225, P257; LIGHT RW, 1973, ARCH INTERN MED, V132, P854, DOI 10.1001/archinte.132.6.854; LIGHT RW, 1972, ANN INTERN MED, V77, P507, DOI 10.7326/0003-4819-77-4-507; Light RW, 2001, PLEURAL DIS; MORIARTY AT, 1993, DIAGN CYTOPATHOL, V9, P252, DOI 10.1002/dc.2840090303; OCANA I, 1983, CHEST, V84, P51, DOI 10.1378/chest.84.1.51; PETERMAN TA, 1984, JAMA-J AM MED ASSOC, V252, P1051, DOI 10.1001/jama.252.8.1051; PRAKASH UBS, 1985, MAYO CLIN PROC, V60, P158, DOI 10.1016/S0025-6196(12)60212-2; RAPTOPOULOS V, 1991, AM J ROENTGENOL, V156, P917, DOI 10.2214/ajr.156.5.2017951; RODRIGUEZPANADERO F, 1989, AM REV RESPIR DIS, V139, P663, DOI 10.1164/ajrccm/139.3.663; ROMERO S, 1993, CHEST, V104, P399, DOI 10.1378/chest.104.2.399; ROPER WH, 1955, AM REV TUBERC PULM, V71, P616; Sadikot RT, 2000, ARCH INTERN MED, V160, P2665, DOI 10.1001/archinte.160.17.2665; SHINTO RA, 1990, AM J MED, V88, P230, DOI 10.1016/0002-9343(90)90147-6; SPRIGGS AI, 1968, CYTOLOGY EFFUSIONS P; Valdes L, 1998, ARCH INTERN MED, V158, P2017, DOI 10.1001/archinte.158.18.2017; Villena V, 1996, EUR RESPIR J, V9, P2635, DOI 10.1183/09031936.96.09122635; Wang DY, 2000, EUR RESPIR J, V15, P1106, DOI 10.1034/j.1399-3003.2000.01520.x; Xiol X, 1996, HEPATOLOGY, V23, P719, DOI 10.1053/jhep.1996.v23.pm0008666323; YAM LT, 1967, ANN INTERN MED, V66, P972, DOI 10.7326/0003-4819-66-5-972	35	411	441	1	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 20	2002	346	25					1971	1977		10.1056/NEJMcp010731	http://dx.doi.org/10.1056/NEJMcp010731			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563QC	12075059				2022-12-28	WOS:000176266200007
J	Panza, JA				Panza, JA			Perspective - Myocardial ischemia and the pains of the heart	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Washington Hosp Ctr, Washington, DC 20010 USA	MedStar Washington Hospital Center	Panza, JA (corresponding author), Washington Hosp Ctr, Washington, DC 20010 USA.								0	38	42	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	2002	346	25					1934	1935		10.1056/NEJMp020047	http://dx.doi.org/10.1056/NEJMp020047			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563QC	12075053				2022-12-28	WOS:000176266200001
J	McManus, IC; Winder, BC; Gordon, D				McManus, IC; Winder, BC; Gordon, D			The causal links between stress and burnout in a longitudinal study of UK doctors	LANCET			English	Article								Burnout and stress are common, linked problems in health-care workers. We aimed to clarify their causal associations. We assessed stress and the three components of burnout (emotional exhaustion, depersonalisation, and low personal accomplishment) using structural equation modelling in a 3-year longitudinal study of a representative sample of 331 UK doctors. Emotional exhaustion and stress showed reciprocal causation: high levels of emotional exhaustion caused stress (beta=0.189), and high levels of stress caused emotional exhaustion (beta=0.175). High levels of personal accomplishment increased stress levels (beta=0.080), whereas depersonalisation lowered stress levels (beta=-0.105).	UCL, Dept Psychol, London WC1E 6BT, England; Royal Free & Univ Coll Med Sch, CHIME, London, England	University of London; University College London; University of London; University College London	McManus, IC (corresponding author), UCL, Dept Psychol, Gower St, London WC1E 6BT, England.	i.mcmanus@ucl.ac.uk		Winder, Belinda/0000-0002-9118-679X; McManus, Ian/0000-0003-3510-4814				Goldberg DP, 1997, PSYCHOL MED, V27, P191, DOI 10.1017/S0033291796004242; Maslach C, 2001, ANNU REV PSYCHOL, V52, P397, DOI 10.1146/annurev.psych.52.1.397; McManus C, 2001, MED EDUC, V35, P60; McManus IC, 1999, LANCET, V354, P1358, DOI 10.1016/S0140-6736(99)02112-1; McManus IC, 2000, QUAL HEALTH CARE, V9, P14, DOI 10.1136/qhc.9.1.14	5	235	238	1	32	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 15	2002	359	9323					2089	2090		10.1016/S0140-6736(02)08915-8	http://dx.doi.org/10.1016/S0140-6736(02)08915-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	562JX	12086767				2022-12-28	WOS:000176194600015
J	Senior, K				Senior, K			Collated evidence confirms the value of atrial fibrillation prevention	LANCET			English	Article																			0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 15	2002	359	9323					2093	2093		10.1016/S0140-6736(02)08960-2	http://dx.doi.org/10.1016/S0140-6736(02)08960-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086771				2022-12-28	WOS:000176194600019
J	Yao, LN; Arolfo, MP; Dohrman, DP; Jiang, Z; Fan, PD; Fuchs, S; Janak, PH; Gordon, AS; Diamond, I				Yao, LN; Arolfo, MP; Dohrman, DP; Jiang, Z; Fan, PD; Fuchs, S; Janak, PH; Gordon, AS; Diamond, I			beta gamma dimers mediate synergy of dopamine D2 and adenosine A2 receptor-stimulated PKA signaling and regulate ethanol consumption	CELL			English	Article							DEPENDENT PROTEIN-KINASE; ADENYLYL-CYCLASE; NUCLEUS-ACCUMBENS; CAMP LEVELS; ACTIVATION; EXPRESSION; RAT; HIPPOCAMPUS; RELEASE; CELLS	Dopamine release is activated by ethanol and addicting drugs, but molecular mechanisms linking dopaminergic signaling to neuronal responses and drinking behavior are poorly understood. We report that dopamine-D2 receptors induce PKA Calpha translocation and increase CRE-regulated gene expression. Ethanol also activates PKA signaling. Subthreshold concentrations of the D2 agonist NPA and ethanol, without effect alone, together cause synergistic PKA translocation and CRE-mediated gene transcription. D2 or adenosine A2 receptor blockade, pertussis toxin, Rp-cAMPS, or overexpression of dominant-negative peptides that sequester betagamma dimers; prevent synergy. Importantly, overexpression of a betagamma inhibitor peptide in the nucleus accumbens strikingly reduces sustained alcohol consumption. We propose that synergy of D2 and A2 confers ethanol hypersensitivity and that betagamma dimers are required for voluntary drinking.	Univ Calif San Francisco, Ernest Gallo Clin, San Francisco, CA 94110 USA; Univ Calif San Francisco, Res Ctr, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Grad Program Neurosci, San Francisco, CA 94110 USA; Univ Calif San Francisco, Wheeler Ctr Neurobiol Addict, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94110 USA; Weizmann Inst Sci, Dept Immunol, Rehovot, Israel	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Weizmann Institute of Science	Diamond, I (corresponding author), Univ Calif San Francisco, Ernest Gallo Clin, San Francisco, CA 94110 USA.	diamond@itsa.ucsf.edu		Janak, Patricia/0000-0002-3333-9049	NIAAA NIH HHS [AA10039, AA10030] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010030, R01AA010039, R37AA010030] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Asai K, 1998, ALCOHOL CLIN EXP RES, V22, P163, DOI 10.1111/j.1530-0277.1998.tb03633.x; Asher O, 2002, J PHARMACOL EXP THER, V301, P66, DOI 10.1124/jpet.301.1.66; Baker LP, 1999, J NEUROSCI, V19, P180, DOI 10.1523/JNEUROSCI.19-01-00180.1999; Boyadjieva N, 1999, BRAIN RES, V824, P112, DOI 10.1016/S0006-8993(99)01170-1; Chakrabarti S, 1998, MOL PHARMACOL, V54, P655; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Constantinescu A, 1999, J BIOL CHEM, V274, P26985, DOI 10.1074/jbc.274.38.26985; Cunningham CL, 2000, PHARMACOL BIOCHEM BE, V67, P693, DOI 10.1016/S0091-3057(00)00414-7; Dar MS, 2001, BRAIN RES BULL, V55, P513, DOI 10.1016/S0361-9230(01)00552-4; Dohrman DP, 2002, ALCOHOL CLIN EXP RES, V26, P407, DOI 10.1111/j.1530-0277.2002.tb02553.x; Dohrman DP, 1996, P NATL ACAD SCI USA, V93, P10217, DOI 10.1073/pnas.93.19.10217; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FINK JS, 1992, MOL BRAIN RES, V14, P186, DOI 10.1016/0169-328X(92)90173-9; GOLDSMITH SK, 1994, HIPPOCAMPUS, V4, P354, DOI 10.1002/hipo.450040318; GORDON AS, 1986, P NATL ACAD SCI USA, V83, P2105, DOI 10.1073/pnas.83.7.2105; Gordon AS, 2001, MOL PHARMACOL, V59, P153, DOI 10.1124/mol.59.1.153; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hodge CW, 1997, ALCOHOL CLIN EXP RES, V21, P1083, DOI 10.1111/j.1530-0277.1997.tb04257.x; Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560; IMPERATO A, 1986, J PHARMACOL EXP THER, V239, P219; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; Klinker JF, 1996, NEUROSCI LETT, V213, P25, DOI 10.1016/0304-3940(96)12816-0; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LEVEY AI, 1993, P NATL ACAD SCI USA, V90, P8861, DOI 10.1073/pnas.90.19.8861; Lissin DV, 1999, J NEUROSCI, V19, P1263; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; Moore MS, 1998, CELL, V93, P997, DOI 10.1016/S0092-8674(00)81205-2; NAGY LE, 1989, MOL PHARMACOL, V36, P744; NAGY LE, 1990, J BIOL CHEM, V265, P1946; O'Kane EM, 1998, EUR J PHARMACOL, V362, P17, DOI 10.1016/S0014-2999(98)00730-4; Obadiah J, 1999, CELL MOL NEUROBIOL, V19, P653, DOI 10.1023/A:1006988603199; Pandey SC, 2001, J PHARMACOL EXP THER, V296, P857; Park SK, 2000, J BIOL CHEM, V275, P20588, DOI 10.1074/jbc.M002460200; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Phillips TJ, 1998, NAT NEUROSCI, V1, P610, DOI 10.1038/2843; PIOMELLI D, 1991, NATURE, V353, P164, DOI 10.1038/353164a0; Risinger FO, 2000, PSYCHOPHARMACOLOGY, V152, P343, DOI 10.1007/s002130000548; Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208; RuizGomez A, 1997, J BIOL CHEM, V272, P9601; SAPRU MK, 1994, J PHARMACOL EXP THER, V271, P542; Svenningsson P, 1999, PROG NEUROBIOL, V59, P355, DOI 10.1016/S0301-0082(99)00011-8; Swanson TH, 1995, J COMP NEUROL, V363, P517, DOI 10.1002/cne.903630402; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; Thanos PK, 2001, J NEUROCHEM, V78, P1094, DOI 10.1046/j.1471-4159.2001.00492.x; Thibault C, 2000, MOL PHARMACOL, V58, P1593, DOI 10.1124/mol.58.6.1593; Thiele TE, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-10-j0003.2000; VALLAR L, 1989, TRENDS PHARMACOL SCI, V10, P74, DOI 10.1016/0165-6147(89)90082-5; Wand G, 2001, J NEUROSCI, V21, P5297, DOI 10.1523/JNEUROSCI.21-14-05297.2001; Waszczak BL, 1998, P NATL ACAD SCI USA, V95, P11440, DOI 10.1073/pnas.95.19.11440; Watts VJ, 1996, MOL PHARMACOL, V50, P966; Watts VJ, 1997, MOL PHARMACOL, V52, P181, DOI 10.1124/mol.52.2.181; WEISS F, 1993, J PHARMACOL EXP THER, V267, P250; Weng GZ, 1996, J BIOL CHEM, V271, P26445, DOI 10.1074/jbc.271.43.26445; Wise A, 1999, BIOCHEMISTRY-US, V38, P2272, DOI 10.1021/bi982054f; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; Yan SZ, 1998, MOL PHARMACOL, V53, P182, DOI 10.1124/mol.53.2.182; Yoshimura M, 1999, ALCOHOL CLIN EXP RES, V23, P1457, DOI 10.1097/00000374-199909000-00006	58	107	110	1	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	2002	109	6					733	743		10.1016/S0092-8674(02)00763-8	http://dx.doi.org/10.1016/S0092-8674(02)00763-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	563PW	12086672	Bronze			2022-12-28	WOS:000176265600004
J	Diaz-Arrastia, R; Agostini, MA; Van Ness, PC				Diaz-Arrastia, R; Agostini, MA; Van Ness, PC			Evolving treatment strategies for epilepsy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TEMPORAL LOBECTOMY; CARBAMAZEPINE; LAMOTRIGINE; STIMULATION; SURGERY		Univ Texas, SW Med Ctr, Parkland Mem Hosp, Dept Neurol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Parkland Mem Hosp, Comprehens Epilepsy Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Diaz-Arrastia, R (corresponding author), Univ Texas, SW Med Ctr, Dept Neurol, 5323 Harry Hines Blvd,Room F2-302, Dallas, TX 75390 USA.	Ramon.Diaz-Arrastia@UTSouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	NATIONAL INSTITUTE OF MENTAL HEALTH [R24MH059656, R03MH064889] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG012300, R01AG017861] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG17861, P30 AG12300] Funding Source: Medline; NIMH NIH HHS [R03 MH 64889, R24 MH59656] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Annegers J.F., 1996, TREATMENT EPILEPSY P, P165; Bazil CW, 1998, ANNU REV MED, V49, P135; Blum DE, 1996, NEUROLOGY, V47, P260, DOI 10.1212/WNL.47.1.260; BRODIE MJ, 1995, LANCET, V345, P476, DOI 10.1016/S0140-6736(95)90581-2; Chadwick D, 2001, LANCET, V357, P1726, DOI 10.1016/S0140-6736(00)04933-3; DODRILL CB, 1997, SEIZURES EPILEPSY EL, P179; Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008; Engel J, 2001, NEW ENGL J MED, V345, P365, DOI 10.1056/NEJM200108023450510; Gillham R, 2000, SEIZURE-EUR J EPILEP, V9, P375, DOI 10.1053/seiz.2000.0428; Gilliam F, 1999, NEUROLOGY, V53, P687, DOI 10.1212/WNL.53.4.687; Holmes LB, 2001, NEW ENGL J MED, V344, P1132, DOI 10.1056/NEJM200104123441504; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Leppik IE, 2001, EPILEPSIA, V42, P1; Litt B, 2001, EPILEPSY BEHAV, V2, pS61, DOI 10.1006/ebeh.2001.0208; Luders H, 2001, ATLAS EPILEPTIC SEIZ; Marson AG, 1996, BMJ-BRIT MED J, V313, P1169, DOI 10.1136/bmj.313.7066.1169; Martinerie J, 1998, NAT MED, V4, P1173, DOI 10.1038/2667; Meador KJ, 2001, EPILEPSY BEHAV, V2, pSS1, DOI 10.1006/ebeh.2001.0235; Meador KJ, 2001, NEUROLOGY, V56, P1177, DOI 10.1212/WNL.56.9.1177; Meador KJ, 1999, EPILEPSIA, V40, P1279, DOI 10.1111/j.1528-1157.1999.tb00858.x; Regis J, 2000, J NEUROSURG, V93, P141, DOI 10.3171/jns.2000.93.supplement_3.0141; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; Sillanpaa M, 1990, Acta Paediatr Scand Suppl, V368, P1; Sperling MR, 1996, JAMA-J AM MED ASSOC, V276, P470, DOI 10.1001/jama.276.6.470; Steiner TJ, 1999, EPILEPSIA, V40, P601, DOI 10.1111/j.1528-1157.1999.tb05562.x; Willmore LJ, 2001, PEDIATRIC EPILEPSY: DIAGNOSIS AND THERAPY, SECOND EDITION, P343	26	11	13	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	2002	287	22					2917	2920		10.1001/jama.287.22.2917	http://dx.doi.org/10.1001/jama.287.22.2917			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	561EY	12052105				2022-12-28	WOS:000176128300002
J	Gershenwald, JE; Fidler, IJ				Gershenwald, JE; Fidler, IJ			Cancer: Targeting lymphatic metastasis	SCIENCE			English	Editorial Material							LYMPHANGIOGENESIS; LYMPHEDEMA; MELANOMA; THERAPY		Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Gershenwald, JE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Gershenwald, Jeff/AAX-4367-2020	Gershenwald, Jeff/0000-0003-4519-5369				Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; CARR I, 1983, CANCER METAST REV, V2, P307, DOI 10.1007/BF00048483; deWaal RMW, 1997, AM J PATHOL, V150, P1951; FIDLER J, 2000, CLIN ONCOLOGY, P29; Foster R S Jr, 1996, Surg Oncol Clin N Am, V5, P1; Gershenwald JE, 1999, J CLIN ONCOL, V17, P976, DOI 10.1200/JCO.1999.17.3.976; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karpanen T, 2001, J EXP MED, V194, pF37, DOI 10.1084/jem.194.6.F37; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Padera TP, 2002, SCIENCE, V296, P1883, DOI 10.1126/science.1071420; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Van Trappen PO, 2002, LANCET ONCOL, V3, P44, DOI 10.1016/S1470-2045(01)00621-0	12	42	50	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 7	2002	296	5574					1811	1812		10.1126/science.10731318	http://dx.doi.org/10.1126/science.10731318			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052939				2022-12-28	WOS:000176054300027
J	Crittenden, SL; Bernstein, DS; Bachorik, JL; Thompson, BE; Gallegos, M; Petcherski, AG; Moulder, G; Barstead, R; Wickens, M; Kimble, J				Crittenden, SL; Bernstein, DS; Bachorik, JL; Thompson, BE; Gallegos, M; Petcherski, AG; Moulder, G; Barstead, R; Wickens, M; Kimble, J			A conserved RNA-binding protein controls germline stem cells in Caenorhabditis elegans	NATURE			English	Article							TUMOR-SUPPRESSOR GENE; IN-VIVO; GLD-1; PUMILIO; PATHWAY; GLP-1; NANOS; ROLES; LINE; FBF	Germline stem cells are defined by their unique ability to generate more of themselves as well as differentiated gametes(1). The molecular mechanisms controlling the decision between self-renewal and differentiation are central unsolved problems in developmental biology with potentially broad medical implications. In Caenorhabditis elegans, germline stem cells are controlled by the somatic distal tip cell(2,3). FBF-1 and FBF-2, two nearly identical proteins, which together are called FBF ('fem-3 mRNA binding factor'), were originally discovered as regulators of germline sex determination(4). Here we report that FBF also controls germline stem cells: in an fbf-1 fbf-2 double mutant, germline proliferation is initially normal, but stem cells are not maintained. We suggest that FBF controls germline stem cells, at least in part, by repressing gld-1, which itself promotes commitment to the meiotic cell cycle(5,6). FBF belongs to the PUF family ('Pumilio and FBF') of RNA-binding proteins(7). Pumilio controls germline stem cells in Drosophila females(8,9),and, in lower eukaryotes, PUF proteins promote continued mitoses(10,11). We suggest that regulation by PUF proteins may be an ancient and widespread mechanism for control of stem cells.	Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Program Mol & Cellular Biol, Madison, WI 53706 USA; Oklahoma Med Res Fdn, Program Mol Biol, Oklahoma City, OK 73104 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Oklahoma Medical Research Foundation	Kimble, J (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA.			Thompson, Beth/0000-0002-5358-0796; Bernstein, David/0000-0002-4564-8578				Bernstein DS, 2002, METHODS, V26, P123, DOI 10.1016/S1046-2023(02)00015-4; CRITTENDEN SL, 1994, DEVELOPMENT, V120, P2901; Dernburg AF, 1998, CELL, V94, P387, DOI 10.1016/S0092-8674(00)81481-6; Forbes A, 1998, DEVELOPMENT, V125, P679; FRANCIS R, 1995, GENETICS, V139, P579; FRANCIS R, 1995, GENETICS, V139, P607; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Jan E, 1999, EMBO J, V18, P258, DOI 10.1093/emboj/18.1.258; Jones AR, 1996, DEV BIOL, V180, P165, DOI 10.1006/dbio.1996.0293; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Kadyk LC, 1998, DEVELOPMENT, V125, P1803; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KIMBLE JE, 1981, DEV BIOL, V81, P208, DOI 10.1016/0012-1606(81)90284-0; Kraemer B, 1999, CURR BIOL, V9, P1009, DOI 10.1016/S0960-9822(99)80449-7; Lee MH, 2001, GENE DEV, V15, P2408, DOI 10.1101/gad.915901; Lin HF, 1997, DEVELOPMENT, V124, P2463; SCHEDL T, 1997, C ELEGANS, V2, P241; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Souza GM, 1999, DEVELOPMENT, V126, P3263; Tadauchi T, 2001, EMBO J, V20, P552, DOI 10.1093/emboj/20.3.552; WARD S, 1986, J CELL BIOL, V102, P1778, DOI 10.1083/jcb.102.5.1778; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; Wickens M, 2002, TRENDS GENET, V18, P150, DOI 10.1016/S0168-9525(01)02616-6; Xu L, 2001, GENETICS, V159, P1007; Zhang BL, 1997, NATURE, V390, P477, DOI 10.1038/37297	26	322	334	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	2002	417	6889					660	663		10.1038/nature754	http://dx.doi.org/10.1038/nature754			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050669				2022-12-28	WOS:000176001200051
J	Michelow, IC; Wendel, GD; Norgard, MV; Zeray, F; Leos, NK; Alsaadi, R; Sanchez, PJ				Michelow, IC; Wendel, GD; Norgard, MV; Zeray, F; Leos, NK; Alsaadi, R; Sanchez, PJ			Central nervous system infection in congenital syphilis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Joint Meeting of the Pediatric-Academic-Societies/American-Academy-of-Pediatrics	MAY 12-16, 2000	BOSTON, MA	Pediat Acad Soc, Amer Acad Pediat			BENZATHINE PENICILLIN-G; TREPONEMA-PALLIDUM ANTIGENS; POLYMERASE-CHAIN-REACTION; CEREBROSPINAL-FLUID; AMNIOTIC-FLUID; DIAGNOSIS; IGM; ANTIBODIES; FETAL; DNA	Background: Identification of infants with Treponema pallidum infection of the central nervous system remains challenging. Methods: We used rabbit-infectivity testing of the cerebrospinal fluid to detect T. pallidum infection of the central nervous system in infants born to mothers with syphilis. The results were compared with those of clinical, radiographic, and conventional laboratory evaluations; IgM immunoblotting of serum and cerebrospinal fluid; polymerase-chain-reaction (PCR) assay testing of serum or blood and cerebrospinal fluid; and rabbit-infectivity testing of serum or blood. Results: Spirochetes were detected in the cerebrospinal fluid of 19 of 148 infants by rabbit-infectivity testing. Exposure of the infant to antibiotics before cerebrospinal fluid was obtained for rabbit-infectivity testing was associated with a negative test result (P=0.001). Spirochetes were detected in the cerebrospinal fluid in 17 of 76 infants (22 percent) who had no prior antibiotic exposure. These 17 infants included 41 percent (16 of 39) of those with some abnormality on clinical, laboratory, or radiographic evaluation; 60 percent (15 of 25) of those with abnormal findings on physical examination that were consistent with congenital syphilis; and 41 percent (17 of 41) of those with a positive result on IgM immunoblotting or PCR testing of serum, blood, or cerebrospinal fluid, or a positive result on rabbit-infectivity testing of serum or blood. Only one infant who had normal findings on clinical evaluation had a positive cerebrospinal fluid rabbit-infectivity test. Overall, central nervous system infection was best predicted by IgM immunoblotting of serum or PCR assay of serum or blood. Conclusions: Most infants with T. pallidum infection of the central nervous system can be identified by physical examination, conventional laboratory tests, and radiographic studies. However, the identification of all such infants requires the use of additional tests, including IgM immunoblotting and PCR assay.	Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Obstet & Gynecol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sanchez, PJ (corresponding author), Univ Texas, SW Med Ctr, Dept Pediat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	pablo.sanchez@utsouthwestern.edu	Michelow, Ian C./AAH-2373-2020	Michelow, Ian C./0000-0002-8399-480X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034932] Funding Source: NIH RePORTER; NIAID NIH HHS [1R29 AI 34932-01] Funding Source: Medline; PHS HHS [C1000 689] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ahmed A, 1996, PEDIATR INFECT DIS J, V15, P298, DOI 10.1097/00006454-199604000-00004; BECKSAGUE C, 1987, PEDIATR INFECT DIS J, V6, P1061, DOI 10.1097/00006454-198706110-00014; Beeram MR, 1996, J PEDIATR-US, V128, P125, DOI 10.1016/S0022-3476(96)70441-9; Benzick AE, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.1.e4; BROMBERG K, 1993, J INFECT DIS, V168, P238, DOI 10.1093/infdis/168.1.238; BURSTAIN JM, 1991, J CLIN MICROBIOL, V29, P62, DOI 10.1128/JCM.29.1.62-69.1991; DOBSON SRM, 1988, J INFECT DIS, V157, P903, DOI 10.1093/infdis/157.5.903; Gomez E, 1998, PEDIATR INFECT DIS J, V17, P782, DOI 10.1097/00006454-199809000-00006; GRIMPREL E, 1991, J CLIN MICROBIOL, V29, P1711, DOI 10.1128/JCM.29.8.1711-1718.1991; Hall C, 1991, PRACTICAL STAT MED R, P404; HAY PE, 1990, GENITOURIN MED, V66, P428; HAY PE, 1990, FEMS MICROBIOL LETT, V68, P233, DOI 10.1111/j.1574-6968.1990.tb13943.x; INGALL D, 2000, INFECT DIS FETUS NEW, P643; KAPLAN JM, 1973, J PEDIATR-US, V82, P1069, DOI 10.1016/S0022-3476(73)80450-0; LEWIS LL, 1992, INFECT DIS CLIN N AM, V6, P31; LEWIS LL, 1990, J CLIN MICROBIOL, V28, P296, DOI 10.1128/JCM.28.2.296-302.1990; LUKEHART SA, 1988, ANN INTERN MED, V109, P855, DOI 10.7326/0003-4819-109-11-855; Magnuson Harold J., 1948, AMER JOUR SYPHILIS GONORRHEA AND VENEREAL DIS, V32, P1; MEYER MP, 1994, J CLIN MICROBIOL, V32, P629, DOI 10.1128/JCM.32.3.629-633.1994; MULLER F, 1984, J NEUROIMMUNOL, V7, P43, DOI 10.1016/S0165-5728(84)80005-3; NOORDHOEK GT, 1991, J CLIN MICROBIOL, V29, P1976, DOI 10.1128/JCM.29.9.1976-1984.1991; PARYANI SG, 1994, J PEDIATR-US, V125, P471, DOI 10.1016/S0022-3476(05)83300-1; PICKERING LK, 2000, 2000 RED BOOK REPORT, P547; PLATOU RV, 1949, ADV PEDIATR, V4, P39; Radcliffe M, 1997, S AFR MED J, V87, P62; SANCHEZ PJ, 1993, J INFECT DIS, V167, P148, DOI 10.1093/infdis/167.1.148; SANCHEZ PJ, 1992, AM J DIS CHILD, V146, P1171, DOI 10.1001/archpedi.1992.02160220057022; SANCHEZ PJ, 1989, J INFECT DIS, V159, P508, DOI 10.1093/infdis/159.3.508; SCHMITZ JL, 1994, CLIN DIAGN LAB IMMUN, V1, P32, DOI 10.1128/CDLI.1.1.32-37.1994; SPEER ME, 1977, J PEDIATR-US, V91, P996, DOI 10.1016/S0022-3476(77)80914-1; STOLL BJ, 1993, J INFECT DIS, V167, P1093, DOI 10.1093/infdis/167.5.1093; THORLEY JD, 1975, LANCET, V1, P651; TURNER TB, 1969, BRIT J VENER DIS, V45, P183; WENDEL GD, 1991, OBSTET GYNECOL, V78, P890; WICHER K, 1992, J CLIN MICROBIOL, V30, P497, DOI 10.1128/JCM.30.2.497-500.1992; WOOLF A, 1980, N C MED J, V41, P443; 1998, MMWR MORB MORTAL WKL, V47, P41	37	49	66	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 6	2002	346	23					1792	1798		10.1056/NEJMoa012684	http://dx.doi.org/10.1056/NEJMoa012684			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	559EK	12050339				2022-12-28	WOS:000176012500005
J	Gregson, S; Nyamukapa, CA; Garnett, GP; Mason, PR; Zhuwau, T; Carael, M; Chandiwana, SK; Anderson, RM				Gregson, S; Nyamukapa, CA; Garnett, GP; Mason, PR; Zhuwau, T; Carael, M; Chandiwana, SK; Anderson, RM			Sexual mixing patterns and sex-differentials in teenage exposure to HIV infection in rural Zimbabwe	LANCET			English	Article							CONCURRENT PARTNERSHIPS; DEMOGRAPHIC-IMPACT; CONTACT PATTERNS; SPREAD; DYNAMICS; TRANSMISSION; POPULATION; EPIDEMIC; BEHAVIOR; HIV/AIDS	Background HIV-1 prevalence typically rises more rapidly at young ages in women than in men in sub-Saharan Africa. Greater susceptibility to infection on exposure in women is believed to be a contributory factor as is greater exposure to previously infected sexual partners of the opposite sex. We investigated the latter hypothesis using data from a field study in rural Manicaland, Zimbabwe. Methods Quantitative data on onset and degree of sexual activity, numbers of partners, concurrent partnerships, condom use, and partner characteristics were used in conjunction with epidemiological data on age and sex specific prevalence of HIV infection to do statistical analyses of association between key variables. Mathematical models and qualitative data were used to aid analysis and interpretation. Findings Older age of sexual partner was associated with increased risk of HIV-1 infection in men (odds ratio 1.13 [95% CI 1.02-1.25]) and women (1.04 [1.01-1.07]). Young women form partnerships with men 5-10 years older than themselves, whereas young men have relationships with women of a similar age or slightly younger. Greater number of lifetime partners is also associated with increased risk of HIV (1.03 [1.00-1.05]). Young men report more partners than do women but infrequent coital acts and greater use of condoms. These behaviour patterns are underpinned by cultural factors including the expectation that women should marry earlier than men. A strong gender effect remains after factors that affect exposure to infected partners are controlled for (6.04 [1.49-24.47]). Interpretation The substantial age difference between female and male sexual partners in Manicaland is the major behavioural determinant of the more rapid rise in HIV prevalence in young women than in men. Theoretical studies have suggested that this difference is an important determinant of observed epidemiological patterns but the study reported in this paper provides clear empirical evidence of association.	Univ London, Imperial Coll Fac Med, Dept Infect Dis Epidemiol, London W2 1PG, England; Biomed Res & Training Inst, Harare, Zimbabwe; UNAIDS, Geneva, Switzerland	Imperial College London; University of London; Biomedical Research Training Institute; UNAIDS	Gregson, S (corresponding author), Univ London, Imperial Coll Fac Med, Dept Infect Dis Epidemiol, Norfolk Pl, London W2 1PG, England.		Garnett, Geoffrey P/A-9312-2008	Gregson, Simon/0000-0003-2707-0714; Anderson, Roy/0000-0002-9528-3175; Nyamukapa, Constance/0000-0001-6779-4069				ANDERSON RM, 1991, NATURE, V352, P581, DOI 10.1038/352581a0; Aral SO, 1996, INT J STD AIDS, V7, P30, DOI 10.1258/0956462961917753; Bourdillon M.F.C., 1993, ARE ANCESTORS CHANGI; Fylkesnes K, 1998, AIDS, V12, P1227, DOI 10.1097/00002030-199810000-00015; Garnett G, 2000, MATH POPUL STUD, V8, P251, DOI DOI 10.1080/08898480009525485; GARNETT GP, 1993, PHILOS T R SOC B, V342, P137, DOI 10.1098/rstb.1993.0143; Garnett GP, 1999, PHILOS T R SOC B, V354, P787, DOI 10.1098/rstb.1999.0431; Ghani AC, 2000, SEX TRANSM DIS, V27, P579, DOI 10.1097/00007435-200011000-00006; Glynn JR, 2001, AIDS, V15, pS51, DOI 10.1097/00002030-200108004-00006; Gregson S, 1997, AIDS, V11, P1269, DOI 10.1097/00002030-199710000-00011; Gregson S, 1998, SOC SCI MED, V46, P321, DOI 10.1016/S0277-9536(97)00165-2; Gregson S, 2001, INT J STD AIDS, V12, P189, DOI 10.1258/0956462011917009; Gregson S, 2000, AIDS, V14, pS85; GREGSON S, IN PRESS SEX TRANSM; JACQUEZ JA, 1988, MATH BIOSCI, V92, P119, DOI 10.1016/0025-5564(88)90031-4; Mbizvo M. T., 1994, Central African Journal of Medicine, V40, P294; MORGAN DL, 1988, FOCUS GROUPS QUANTIT; Morris M, 1997, AIDS, V11, P641, DOI 10.1097/00002030-199705000-00012; Morris M, 1996, AIDS, V10, P1265, DOI 10.1097/00002030-199609000-00013; NUNN AJ, 1994, AIDS, V8, P81, DOI 10.1097/00002030-199401000-00012; *PANOS I, 1989, WORLD AIDS, V6, P10; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; Ray CS, 1997, TROP MED INT HEALTH, V2, P83, DOI 10.1046/j.1365-3156.1997.d01-125.x; Ray S., 1996, REPROD HEALTH MATTER, V4, P34, DOI [10.1016/S0968-8080(96)90004-X, DOI 10.1016/S0968-8080(96)90004-X]; RUNGANGA A, 1992, SOC SCI MED, V35, P1037, DOI 10.1016/0277-9536(92)90243-J; *US BUR CENS, 1993, CENS POP; WATTS CH, 1992, MATH BIOSCI, V108, P89, DOI 10.1016/0025-5564(92)90006-I; WAWER MJ, 1991, BRIT MED J, V303, P1303, DOI 10.1136/bmj.303.6813.1303	28	398	404	1	23	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 1	2002	359	9321					1896	1903		10.1016/S0140-6736(02)08780-9	http://dx.doi.org/10.1016/S0140-6736(02)08780-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PL	12057552				2022-12-28	WOS:000175975700009
J	Williams, AN; Birmingham, L				Williams, AN; Birmingham, L			The art of making ineffective treatments effective	LANCET			English	Review									N Warwickshire PCT, St Nicolas Pk Clin, Nuneaton CV11 6HH, Warwick, England; Ravenswood House, Medium Secure Unit, Fareham, Hants, England		Williams, AN (corresponding author), N Warwickshire PCT, St Nicolas Pk Clin, Windermere Ave, Nuneaton CV11 6HH, Warwick, England.							BLUEGLASS R, 1990, PRINCIPLES PRACTICE, P523; DEWHURST K, 1980, WILLISS OXFORD LECT, P86; DEWHURST K, 1980, WILLISS OXFORD LECT, P9; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Gagnier, 2000, CHILD ABUSE REV, V9, P19, DOI [10.1002/(SICI)1099-0852(200001/02)9:13.0.CO;2-4, DOI 10.1002/CAR.584]; HOBBS CJ, 1991, CURRENT PAEDIAT, V1, P116; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; Levitt CJ, 1994, CHILD ABUSE MED DIAG, P1; LOCKE J, BODLEIAN LIB, P48; PORTER R, 1997, GREATEST BENEFIT MAN, P136; SMITH WL, 1997, BATTERED CHILD, P235; Williams AN, 2001, SEIZURE-EUR J EPILEP, V10, P471, DOI 10.1053/seiz.2001.0534; WILLIS T, 1667, PATHOLOGIAE CEREBRI, P49; Willis Thomas, 1681, ESSAY PATHOLOGY BRAI	14	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 1	2002	359	9321					1937	1939		10.1016/S0140-6736(02)08762-7	http://dx.doi.org/10.1016/S0140-6736(02)08762-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PL	12057570				2022-12-28	WOS:000175975700027
J	Rosenberg, MI; Parkhurst, SM				Rosenberg, MI; Parkhurst, SM			Drosophila Sir2 is required for heterochromatic silencing and by euchromatic Hairy/E(Spl) bHLH repressors in segmentation and sex determination	CELL			English	Article							PAN-NEURAL GENE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; DNA-BINDING; CHROMATIN STRUCTURE; PROTEIN SIR2; HAIRY; DOMAIN; YEAST	Yeast SIR2 is a NAD(+)-dependent histone deacetylase required for heterochromatic silencing at telomeres, rDNA, and mating-type loci. We find that the Drosophila homolog of Sir2 (dSir2) also encodes deacetylase activity and is required for heterochromatic silencing, but unlike ySir2, is not required for silencing at telomeres. We show that dSir2 interacts genetically and physically with members of the Hairy/Deadpan/E(Spl) family of bHLH euchromatic repressors, key regulators of Drosophila development. dSir2 is an essential gene whose loss of function results in both segmentation defects and skewed sex ratios, associated with reduced activities of the Hairy and Deadpan bHLH repressors. These results indicate that Sir2 in higher organisms plays an essential role in both euchromatic repression and heterochromatic silencing.	Univ Washington, Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98195 USA; Univ Washington, Fred Hutchinson Canc Res Ctr, Program Dev Biol, Seattle, WA 98195 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Parkhurst, SM (corresponding author), Univ Washington, Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98195 USA.			Rosenberg, Miriam/0000-0001-5348-8247; Parkhurst, Susan/0000-0001-5806-9930	NIGMS NIH HHS [GM 47852, T32 GM07270] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM047852, T32GM007270, R01GM047852] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Bedalov A, 2001, P NATL ACAD SCI USA, V98, P15113, DOI 10.1073/pnas.261574398; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; BIER E, 1992, GENE DEV, V6, P2137, DOI 10.1101/gad.6.11.2137; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Cockell MM, 2000, GENETICS, V154, P1069; Cryderman DE, 1999, EMBO J, V18, P3724, DOI 10.1093/emboj/18.13.3724; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DAWSON SR, 1995, MOL CELL BIOL, V15, P6923; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; Gottschling DE, 2000, CURR BIOL, V10, pR708, DOI 10.1016/S0960-9822(00)00714-4; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guarente L, 2000, GENE DEV, V14, P1021; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; ISHHOROWICZ D, 1985, COLD SPRING HARB SYM, V50, P135, DOI 10.1101/SQB.1985.050.01.019; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Magie CR, 1999, DEVELOPMENT, V126, P5353; Mannervik M, 1999, P NATL ACAD SCI USA, V96, P6797, DOI 10.1073/pnas.96.12.6797; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; MOZER B, 1985, MOL CELL BIOL, V5, P885, DOI 10.1128/MCB.5.4.885; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PARKHURST SM, 1991, GENE DEV, V5, P341, DOI 10.1101/gad.5.3.341; PARKHURST SM, 1993, DEVELOPMENT, V117, P737; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Poux S, 2001, GENE DEV, V15, P2509, DOI 10.1101/gad.208901; RINE J, 1987, GENETICS, V116, P9; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Smith RL, 2000, TRENDS BIOCHEM SCI, V25, P325, DOI 10.1016/S0968-0004(00)01592-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; TOROK T, 1993, GENETICS, V135, P71; van Steensel B, 2000, NAT BIOTECHNOL, V18, P424, DOI 10.1038/74487; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; Wieschaus E., 1986, P199; YOUNGERSHEPHERD S, 1992, CELL, V70, P911, DOI 10.1016/0092-8674(92)90242-5	53	103	106	1	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 17	2002	109	4					447	458		10.1016/S0092-8674(02)00732-8	http://dx.doi.org/10.1016/S0092-8674(02)00732-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	553VM	12086602	Bronze			2022-12-28	WOS:000175696800007
J	Davies, H; Bignell, GR; Cox, C; Stephens, P; Edkins, S; Clegg, S; Teague, J; Woffendin, H; Garnett, MJ; Bottomley, W; Davis, N; Dicks, N; Ewing, R; Floyd, Y; Gray, K; Hall, S; Hawes, R; Hughes, J; Kosmidou, V; Menzies, A; Mould, C; Parker, A; Stevens, C; Watt, S; Hooper, S; Wilson, R; Jayatilake, H; Gusterson, BA; Cooper, C; Shipley, J; Hargrave, D; Pritchard-Jones, K; Maitland, N; Chenevix-Trench, G; Riggins, GJ; Bigner, DD; Palmieri, G; Cossu, A; Flanagan, A; Nicholson, A; Ho, JWC; Leung, SY; Yuen, ST; Weber, BL; Siegler, HF; Darrow, TL; Paterson, H; Marais, R; Marshall, CJ; Wooster, R; Stratton, MR; Futreal, PA				Davies, H; Bignell, GR; Cox, C; Stephens, P; Edkins, S; Clegg, S; Teague, J; Woffendin, H; Garnett, MJ; Bottomley, W; Davis, N; Dicks, N; Ewing, R; Floyd, Y; Gray, K; Hall, S; Hawes, R; Hughes, J; Kosmidou, V; Menzies, A; Mould, C; Parker, A; Stevens, C; Watt, S; Hooper, S; Wilson, R; Jayatilake, H; Gusterson, BA; Cooper, C; Shipley, J; Hargrave, D; Pritchard-Jones, K; Maitland, N; Chenevix-Trench, G; Riggins, GJ; Bigner, DD; Palmieri, G; Cossu, A; Flanagan, A; Nicholson, A; Ho, JWC; Leung, SY; Yuen, ST; Weber, BL; Siegler, HF; Darrow, TL; Paterson, H; Marais, R; Marshall, CJ; Wooster, R; Stratton, MR; Futreal, PA			Mutations of the BRAF gene in human cancer	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; TYROSINE KINASE; B-RAF; ACTIVATION; PATHWAY; PROLIFERATION; INHIBITOR	Cancers arise owing to the accumulation of mutations in critical genes that alter normal programmes of cell proliferation, differentiation and death. As the first stage of a systematic genome-wide screen for these genes, we have prioritized for analysis signalling pathways in which at least one gene is mutated in human cancer. The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals(1). RAS is mutated to an oncogenic formin about 15% of human cancer. The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS(1-3). Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers. All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%. Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells. Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation. As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.	Wellcome Trust Sanger Inst, Canc Genome Project, Hinxton CB10 1SA, England; Inst Canc Res, Chester Beatty Labs, Canc Res UK Ctr Cell & Mol Biol, London SW3 6JB, England; Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; Inst Canc Res, Sect Mol Carcinogenesis, Sutton SM2 5NG, Surrey, England; Inst Canc Res, Paediat Sect, Sutton SM2 5NG, Surrey, England; Univ Glasgow, Western Infirm, Dept Pathol, Glasgow S11 6NT, Lanark, Scotland; Univ York, Dept Biol, YCR Canc Res Unit, York YO10 5YW, N Yorkshire, England; Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; CNR, Inst Mol Genet, I-07040 Alghero, Italy; Univ Sassari, Dept Pathol, I-07100 Sassari, Italy; UCL Royal Free & Univ Coll Med Sch, London WC1E 6JJ, England; Royal Brompton Hosp, London SW3 6NP, England; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Penn, Ctr Canc, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	Wellcome Trust Sanger Institute; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; University of Glasgow; University of York - UK; QIMR Berghofer Medical Research Institute; Duke University; Duke University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Sassari; University of London; University College London; UCL Medical School; Royal Brompton Hospital; University of Hong Kong; University of Hong Kong; University of Pennsylvania; Pennsylvania Medicine	Wooster, R (corresponding author), Wellcome Trust Sanger Inst, Canc Genome Project, Wellcome Trust Genome Campus, Hinxton CB10 1SA, England.	rw1@sanger.ac.uk	Leung, Suet Yi/C-4340-2009; Chenevix-Trench, Georgia/AAV-2014-2020; Hargrave, Darren R/H-1066-2014; Toon, Christopher W/G-3610-2012; Pritchard-Jones, Kathy/F-4286-2014; Cossu, Antonio/I-8836-2018; Palmieri, G/K-6095-2016; Yuen, Siu/K-6311-2014; Palmieri, Giuseppe/AAX-2627-2021; Leung, Suet Yi/T-9620-2019	Chenevix-Trench, Georgia/0000-0002-1878-2587; Hargrave, Darren R/0000-0001-8219-9807; Pritchard-Jones, Kathy/0000-0002-2384-9475; Cossu, Antonio/0000-0002-2390-2205; Palmieri, G/0000-0002-4350-2276; Leung, Suet Yi/0000-0001-8614-4619; Maitland, Norman/0000-0003-1607-9035; Marais, Richard/0000-0001-7484-4183; Shipley, Janet/0000-0001-6748-8678; Hughes, Jaime/0000-0001-6045-4053; Edkins, Sarah/0000-0003-0717-1972; Gray, Kristian/0000-0002-7035-7107				Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Caduff RF, 1999, AM J SURG PATHOL, V23, P323, DOI 10.1097/00000478-199903000-00012; COOKE M P, 1989, New Biologist, V1, P66; DAYAGROSJEAN L, 1995, J PHOTOCH PHOTOBIO B, V28, P115, DOI 10.1016/1011-1344(95)07130-T; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Grant BD, 1998, BIOCHEMISTRY-US, V37, P7708, DOI 10.1021/bi972987w; Halaban R, 2000, PIGM CELL RES, V13, P4, DOI 10.1034/j.1600-0749.2000.130103.x; Hemmer W, 1997, J BIOL CHEM, V272, P16946, DOI 10.1074/jbc.272.27.16946; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Rozycka M, 2000, GENOMICS, V70, P34, DOI 10.1006/geno.2000.6354; STACEY DW, 1987, EXP CELL RES, V171, P232, DOI 10.1016/0014-4827(87)90266-7; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114, DOI 10.1128/MCB.9.7.3114; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429	24	7665	8013	23	805	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 27	2002	417	6892					949	954		10.1038/nature00766	http://dx.doi.org/10.1038/nature00766			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	566RC	12068308	Green Accepted			2022-12-28	WOS:000176441200039
J	Hobbs, FDR; Davis, RC; Roalfe, AK; Hare, R; Davies, MK; Kenkre, JE				Hobbs, FDR; Davis, RC; Roalfe, AK; Hare, R; Davies, MK; Kenkre, JE			Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VENTRICULAR SYSTOLIC DYSFUNCTION; MORBIDITY; MORTALITY; ELECTROCARDIOGRAM; SURVIVAL; ACCURACY; CARE	Objective To investigate die performance of a novel assay for N-terminal pro-brain natriuretic peptide (NT-proBNP) in diagnosing heart failure in various randomly selected general and high risk community populations. Design Community cohort study (substudy of the echocardiographic heart of England screening study). Setting Four randomly selected general practices in the West Midlands of England. Participants 591 randomly sampled patients over the age of 45, stratified for age and socioeconomic status and falling into four cohorts (general population patients with an existing clinical label of heart failure, patients prescribed diuretics, and patients deemed at high risk of heart failure). Main outcome measure Sensitivity, specificity, positive and negative predictive values, likelihood ratios, and area under receiver operating characteristic curve for NT-proBNP assay in the diagnosis of heart failure. Results For NT-proBNP in the diagnosis of heart failure in the general population (population screen), a level of > 3 6 pmol/l had a sensitivity of 100%, a specificity of 70%, a positive predictive value of 7%, a negative predictive value of 100%, and an area under the receiver operating characteristic curve of 0.92 (95% confidence interval 0.82 to 1.0). Similar negative predictive values were found for patients from the three other populations screened. Conclusions This NT-proBNP assay seems to have value in the diagnosis of heart failure in the community. High negative predictive values indicate that the assay's chief use would be to rule out heart failure in patients with suspected heart failure with normal concentrations of NT-proBNP. Positive results may identify patients who need cardiac imaging.	Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England; Selly Oak Hosp, Dept Cardiol, Birmingham B29 2PE, W Midlands, England	University of Birmingham	Hobbs, FDR (corresponding author), Univ Birmingham, Dept Primary Care & Gen Practice, Primary Care Clin Sci Bldg, Birmingham B15 2TT, W Midlands, England.	f.d.r.hobbs@bham.ac.uk		hobbs, richard/0000-0001-7976-7172				*AG HLTH CAR POL, 1994, HEART FAIL EV CAR PA; *AG HLTH CAR POL R, 1994, HEART FAIL EV CAR PA; BONNEUX L, 1994, AM J PUBLIC HEALTH, V84, P20, DOI 10.2105/AJPH.84.1.20; CLELAND JG, 1995, EUR HEART J, V16, P741; Davie AP, 1996, BRIT MED J, V312, P222; Davies MK, 2001, LANCET, V358, P439, DOI 10.1016/S0140-6736(01)05620-3; DAVIS R, 1998, EUR HEART J, V19, pS639; Davis RC, 1998, J AM COLL CARDIOL, V31, p303A, DOI 10.1016/S0735-1097(97)85025-5; FAHEY MT, 1995, AM J EPIDEMIOL, V141, P680, DOI 10.1093/oxfordjournals.aje.a117485; Fruhwald FM, 1999, EUR HEART J, V20, P1415, DOI 10.1053/euhj.1999.1633; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GILLUM RF, 1993, AM HEART J, V126, P1042, DOI 10.1016/0002-8703(93)90738-U; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; Hobbs FDR, 2000, EUR HEART J, V21, P1877, DOI 10.1053/euhj.2000.2170; Hobbs FDR, 1999, EUR J HEART FAIL, V1, P11, DOI 10.1016/S1388-9842(98)00006-3; HOBBS FDR, 1968, J AM COLL CARDIOL, V31, pC85; Hobbs R, 2000, BMJ-BRIT MED J, V321, P188, DOI 10.1136/bmj.321.7255.188; Hunt PJ, 1997, CLIN ENDOCRINOL, V47, P287, DOI 10.1046/j.1365-2265.1997.2361058.x; Landray MJ, 2000, BRIT MED J, V320, P985, DOI 10.1136/bmj.320.7240.985; Lechat P, 1999, LANCET, V353, P9; McClure SJ, 1998, BRIT MED J, V317, P516; Mitchell MF, 1998, OBSTET GYNECOL, V91, P626, DOI 10.1016/S0029-7844(98)00006-4; Nagaya N, 1998, J AM COLL CARDIOL, V31, P202, DOI 10.1016/S0735-1097(97)00452-X; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Sur DKC, 2000, FAM MED, V32, P315; SWETS JA, 1991, MED DECIS MAKING, V11, P9, DOI 10.1177/0272989X9101100102; WESTON MJ, 1976, AUST NZ J MED, V6, P429, DOI 10.1111/j.1445-5994.1976.tb03029.x; WILLIAMS JF, 1995, CIRCULATION, V92, P2764	29	166	181	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 22	2002	324	7352					1498	1500A		10.1136/bmj.324.7352.1498	http://dx.doi.org/10.1136/bmj.324.7352.1498			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567ZL	12077039	Green Published, Bronze			2022-12-28	WOS:000176517900024
J	Freeman, BC; Yamamoto, KR				Freeman, BC; Yamamoto, KR			Disassembly of transcriptional regulatory complexes by molecular chaperones	SCIENCE			English	Article							GLUCOCORTICOID RECEPTOR; ORDERED RECRUITMENT; PROMOTER; CELLS; GENE; EXPRESSION; ACTIVATION; ENHANCER; BINDING; SITES	Many biological processes are initiated by cooperative assembly of large multicomponent complexes; however, mechanisms for modulating or terminating the actions of these complexes are not well understood. For example, hormone-bound intracellular receptors (IRs) nucleate formation of transcriptional regulatory complexes whose actions cease promptly upon hormone withdrawal. Here, we show that the p23 molecular chaperone localizes in vivo to genomic response elements in a hormone-dependent manner, disrupting receptor-mediated transcriptional activation in vivo and in vitro; Hsp90 weakly displayed similar activities. Indeed, p23 and Hsp90 also disrupted the activities of some non IR-containing transcriptional regulatory complexes. We suggest that molecular chaperones promote disassembly of transcriptional regulatory complexes, thus enabling regulatory machineries to detect and respond to signaling changes.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA	University of California System; University of California San Francisco; University of Illinois System; University of Illinois Urbana-Champaign	Yamamoto, KR (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, 513 Parnassus, San Francisco, CA 94143 USA.							Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Chi Y, 2001, GENE DEV, V15, P1078, DOI 10.1101/gad.867501; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; DANESCH U, 1987, EMBO J, V6, P625, DOI 10.1002/j.1460-2075.1987.tb04800.x; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; DONG Y, 1988, MOL ENDOCRINOL, V2, P1256, DOI 10.1210/mend-2-12-1256; Freeman BC, 2000, GENE DEV, V14, P422; Freeman BC, 2001, TRENDS BIOCHEM SCI, V26, P285, DOI 10.1016/S0968-0004(01)01834-5; FREEMAN BC, UNPUB; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Munshi N, 1999, COLD SPRING HARB SYM, V64, P149, DOI 10.1101/sqb.1999.64.149; NARDULLI AM, 1986, ENDOCRINOLOGY, V119, P2038, DOI 10.1210/endo-119-5-2038; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; ODDOS J, 1989, NUCLEIC ACIDS RES, V17, P8877, DOI 10.1093/nar/17.21.8877; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; RINGOLD GM, 1977, P NATL ACAD SCI USA, V74, P2879, DOI 10.1073/pnas.74.7.2879; ROUSSEAU GG, 1973, J MOL BIOL, V79, P539, DOI 10.1016/0022-2836(73)90405-1; UCKER DS, 1984, J BIOL CHEM, V259, P7416; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	23	337	351	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 21	2002	296	5576					2232	2235		10.1126/science.1073051	http://dx.doi.org/10.1126/science.1073051			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077419				2022-12-28	WOS:000176379000062
J	Hughes, AL				Hughes, AL			Genetic markers: Strength in numbers	NATURE			English	Article									Univ S Carolina, Inst Biotechnol, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Hughes, AL (corresponding author), Univ S Carolina, Inst Biotechnol, Columbia, SC 29208 USA.								0	3	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 20	2002	417	6891					795	795		10.1038/417795a	http://dx.doi.org/10.1038/417795a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075328	Bronze			2022-12-28	WOS:000176285600025
J	Pasparakis, M; Courtois, G; Hafner, M; Schmidt-Supprian, M; Nenci, A; Toksoy, A; Krampert, M; Goebeler, M; Gillitzer, R; Israel, A; Krieg, T; Rajewsky, K; Haase, I				Pasparakis, M; Courtois, G; Hafner, M; Schmidt-Supprian, M; Nenci, A; Toksoy, A; Krampert, M; Goebeler, M; Gillitzer, R; Israel, A; Krieg, T; Rajewsky, K; Haase, I			TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2	NATURE			English	Article							NF-KAPPA-B; SEVERE LIVER DEGENERATION; GAMMA-DEFICIENT MICE; INCONTINENTIA PIGMENTI; ACTIVATION; ALPHA; LACKING; KINASE; EXPRESSION; RECEPTOR	The IkappaB kinase (IKK), consisting of the IKK1 and IKK2 catalytic subunits and the NEMO (also known as IKKgamma) regulatory subunit, phosphorylates IkappaB proteins, targeting them for degradation and thus inducing activation of NF-kappaB (reviewed in refs 1, 2). IKK2 and NEMO are necessary for NF-kappaB activation through pro-inflammatory signals(3-8). IKK1 seems to be dispensable for this function but controls epidermal differentiation independently of NF-kappaB(9-12). Previous studies suggested that NF-kappaB has a function in the growth regulation of epidermal keratinocytes(12-14). Mice lacking RelB or IkappaBalpha, as well as both mice and humans with heterozygous NEMO mutations, develop skin lesions(7,8,15-18). However, the function of NF-kappaB in the epidermis remains unclear(19). Here we used Cre/loxP-mediated gene targeting to investigate the function of IKK2 specifically in epidermal keratinocytes. IKK2 deficiency inhibits NF-kappaB activation, but does not lead to cell-autonomous hyperproliferation or impaired differentiation of keratinocytes. Mice with epidermis-specific deletion of IKK2 develop a severe inflammatory skin disease, which is caused by a tumour necrosis factor-mediated, alphabeta T-cell-independent inflammatory response that develops in the skin shortly after birth. Our results suggest that the critical function of IKK2-mediated NF-kappaB activity in epidermal keratinocytes is to regulate mechanisms that maintain the immune homeostasis of the skin.	Univ Cologne, Inst Genet, D-50931 Cologne, Germany; EMBL Mouse Biol Programme, I-00016 Monterotondo, Italy; Inst Pasteur, CNRS, URA 1773, Unite Biol Mol Express Gen, F-75724 Paris 15, France; Univ Cologne, Dept Dermatol, D-50924 Cologne, Germany; Univ Cologne, Ctr Mol Med, D-50924 Cologne, Germany; Univ Wurzburg, Dept Dermatol, D-97080 Wurzburg, Germany; ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland	University of Cologne; European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Cologne; University of Cologne; University of Wurzburg; Swiss Federal Institutes of Technology Domain; ETH Zurich	Pasparakis, M (corresponding author), Univ Cologne, Inst Genet, Weyertal 121, D-50931 Cologne, Germany.	pasparakis@embl-monterotondo.it	Hafner, Martin/B-9040-2008; Goebeler, Matthias/P-3612-2019; Pasparakis, Manolis/N-4350-2019; Pasparakis, Manolis/H-9292-2017; Schmidt-Supprian, Marc/F-5893-2011; Goebeler, Matthias/F-7118-2013	Hafner, Martin/0000-0003-0769-1812; Pasparakis, Manolis/0000-0002-9870-0966; Pasparakis, Manolis/0000-0002-9870-0966; Schmidt-Supprian, Marc/0000-0002-8543-6166; Rajewsky, Klaus/0000-0002-6633-6370; COURTOIS, Gilles/0000-0003-3117-9595				Barton D, 2000, EUR J IMMUNOL, V30, P2323, DOI 10.1002/1521-4141(2000)30:8<2323::AID-IMMU2323>3.0.CO;2-H; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Goebeler M, 2001, AM J PATHOL, V158, P431, DOI 10.1016/S0002-9440(10)63986-7; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KONTGEN F, 1993, INT IMMUNOL, V5, P957, DOI 10.1093/intimm/5.8.957; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Romero MR, 1999, EXP DERMATOL, V8, P53, DOI 10.1111/j.1600-0625.1999.tb00348.x; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; Rudolph D, 2000, GENE DEV, V14, P854; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Seitz CS, 2000, CANCER RES, V60, P4085; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Smahi A, 2000, NATURE, V405, P466; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X	30	381	393	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 20	2002	417	6891					861	866		10.1038/nature00820	http://dx.doi.org/10.1038/nature00820			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075355	Bronze			2022-12-28	WOS:000176285600050
J	Rosenwald, A; Wright, G; Chan, WC; Connors, JM; Campo, E; Fisher, RI; Gascoyne, RD; Muller-Hermelink, HK; Smeland, EB; Staudt, LM				Rosenwald, A; Wright, G; Chan, WC; Connors, JM; Campo, E; Fisher, RI; Gascoyne, RD; Muller-Hermelink, HK; Smeland, EB; Staudt, LM		Lymphoma Leukemia Mol Profiling Pr	The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENE-EXPRESSION; PROLIFERATION; THERAPY	Background: The survival of patients with diffuse large-B-cell lymphoma after chemotherapy is influenced by molecular features of the tumors. We used the gene-expression profiles of these lymphomas to develop a molecular predictor of survival. Methods: Biopsy samples of diffuse large-B-cell lymphoma from 240 patients were examined for gene expression with the use of DNA microarrays and analyzed for genomic abnormalities. Subgroups with distinctive gene-expression profiles were defined on the basis of hierarchical clustering. A molecular predictor of risk was constructed with the use of genes with expression patterns that were associated with survival in a preliminary group of 160 patients and was then tested in a validation group of 80 patients. The accuracy of this predictor was compared with that of the international prognostic index. Results: Three gene-expression subgroups -- germinal-center B-cell-like, activated B-cell-like, and type 3 diffuse large-B-cell lymphoma -- were identified. Two common oncogenic events in diffuse large-B-cell lymphoma, bcl-2 translocation and c-rel amplification, were detected only in the germinal-center B-cell-like subgroup. Patients in this subgroup had the highest five-year survival rate. To identify other molecular determinants of outcome, we searched for individual genes with expression patterns that correlated with survival in the preliminary group of patients. Most of these genes fell within four gene-expression signatures characteristic of germinal-center B cells, proliferating cells, reactive stromal and immune cells in the lymph node, or major-histocompatibility-complex class II complex. We used 17 genes to construct a predictor of overall survival after chemotherapy. This gene-based predictor and the international prognostic index were independent prognostic indicators. Conclusions: DNA microarrays can be used to formulate a molecular predictor of survival after chemotherapy for diffuse large-B-cell lymphoma.	NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Biometr Res Branch, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; British Columbia Canc Ctr, Vancouver, BC, Canada; Univ Barcelona, Hosp Clin, Barcelona, Spain; Univ Rochester, Sch Med, James P Wilmot Canc Ctr, Rochester, NY USA; Univ Rochester, Sch Med, SW Oncol Grp, Rochester, NY USA; Univ Wurzburg, Dept Pathol, D-8700 Wurzburg, Germany; Norwegian Radium Hosp, Dept Immunol, Oslo, Norway; NIH, Ctr Informat Technol, Bethesda, MD 20892 USA; NIA, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA; Univ Arizona, Ctr Canc, Tucson, AZ USA; SW Oncol Grp, Tucson, AZ USA; SW Oncol Grp, Seattle, WA USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Nebraska System; University of Nebraska Medical Center; British Columbia Cancer Agency; University of Barcelona; Hospital Clinic de Barcelona; University of Rochester; Southwest Oncology Group; University of Rochester; University of Wurzburg; University of Oslo; National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Arizona; Southwest Oncology Group; Southwest Oncology Group; Fred Hutchinson Cancer Center	Staudt, LM (corresponding author), NCI, Metab Branch, Ctr Canc Res, NIH, Bldg 10,Rm 4N114, Bethesda, MD 20892 USA.		Jaffe, Elaine S/G-8984-2014; Campo, Elias/AAC-5593-2019; Smeland, Erlend/AAO-3214-2020; Connors, Joseph/AAF-5284-2019; Wright, George W/M-1660-2017; Staudt, Louis/AAC-5324-2019	Jaffe, Elaine S/0000-0003-4632-0301; Campo, Elias/0000-0001-9850-9793; Connors, Joseph/0000-0002-1361-7531; Delabie, Jan/0000-0001-5023-0689	NCI NIH HHS [UO1-CA84967] Funding Source: Medline; CENTER FOR INFORMATION TECHNOLOGY [Z01CT000260, ZIACT000260] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [U01CA084967] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh A, 1999, COLD SPRING HARB SYM, V64, P71, DOI 10.1101/sqb.1999.64.71; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Coiffier B, 2001, CURR OPIN ONCOL, V13, P325, DOI 10.1097/00001622-200109000-00003; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; Goff LK, 2000, BRIT J HAEMATOL, V111, P618, DOI 10.1046/j.1365-2141.2000.02352.x; GROGAN TM, 1988, BLOOD, V71, P1157; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Huang JZ, 2002, BLOOD, V99, P2285, DOI 10.1182/blood.V99.7.2285; MILLER TP, 1988, J CLIN INVEST, V82, P370, DOI 10.1172/JCI113598; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Shipp MA, 1999, J CLIN ONCOL, V17, P423, DOI 10.1200/JCO.1999.17.1.423; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; SILVESTRINI R, 1993, INT J CANCER, V54, P231, DOI 10.1002/ijc.2910540212; STETLERSTEVENSON M, 1988, BLOOD, V72, P1822	17	2806	2959	2	91	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	2002	346	25					1937	1947		10.1056/NEJMoa012914	http://dx.doi.org/10.1056/NEJMoa012914			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563QC	12075054				2022-12-28	WOS:000176266200002
J	Yoshikawa, K; Okazaki, IM; Eto, T; Kinoshita, K; Muramatsu, M; Nagaoka, H; Honjo, T				Yoshikawa, K; Okazaki, IM; Eto, T; Kinoshita, K; Muramatsu, M; Nagaoka, H; Honjo, T			AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts	SCIENCE			English	Article							CLASS-SWITCH RECOMBINATION; CYTIDINE DEAMINASE AID; SOMATIC HYPERMUTATION; SEQUENCES; MUTATION; MECHANISM; TARGETS	Activation-induced cytidine deaminase (AID), a putative RNA-editing enzyme, is indispensable for somatic hypermutation (SHM), class switch recombination, and gene conversion of immunoglobulin genes, which indicates a common molecular mechanism for these phenomena. Here we show that ectopic expression of AID alone can induce hypermutation in an artificial GFP substrate in NIH 3T3 murine fibroblast cells. The frequency of mutations was closely correlated with the level of transcription of the target gene, and the distribution of mutations in NIH 3T3 cells was similar to those of SHM in B lymphocytes. These results indicate that AID is sufficient for the generation of SHIM in an actively transcribed gene in fibroblasts, as well as B cells, and that any of the required cofactors must be present in these fibroblasts.	Kyoto Univ, Grad Sch Med, Dept Med Chem & Mol Biol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Radioisotope Res Ctr, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Honjo, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med Chem & Mol Biol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	honjo@mfour.med.kyoto-u.ac.jp	Muramatsu, Masamichi/C-4339-2015; Honjo, Tasuku/N-4470-2016	Muramatsu, Masamichi/0000-0002-0153-3533; Okazaki, Il-mi/0000-0001-8644-0100				Arakawa H, 2002, SCIENCE, V295, P1301, DOI 10.1126/science.1067308; Bachl J, 1996, P NATL ACAD SCI USA, V93, P851, DOI 10.1073/pnas.93.2.851; Bachl J, 2001, J IMMUNOL, V166, P5051, DOI 10.4049/jimmunol.166.8.5051; Chen XC, 2001, P NATL ACAD SCI USA, V98, P13860, DOI 10.1073/pnas.241524898; Denepoux S, 1997, IMMUNITY, V6, P35, DOI 10.1016/S1074-7613(00)80240-X; Fugmann SD, 2002, SCIENCE, V295, P1244, DOI 10.1126/science.1070023; Gearhart PJ, 2001, NAT REV IMMUNOL, V1, P187, DOI 10.1038/35105009; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Kinoshita K, 2001, NAT REV MOL CELL BIO, V2, P493, DOI 10.1038/35080033; KOLCHANOV NA, 1987, FEBS LETT, V214, P87, DOI 10.1016/0014-5793(87)80018-2; Martin A, 2002, NATURE, V415, P802, DOI 10.1038/nature714; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nagaoka H, 2002, J EXP MED, V195, P529, DOI 10.1084/jem.20012144; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; Okazaki IM, 2002, NATURE, V416, P340, DOI 10.1038/nature727; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L; Sale JE, 1998, IMMUNITY, V9, P859, DOI 10.1016/S1074-7613(00)80651-2; Sale JE, 2001, NATURE, V412, P921, DOI 10.1038/35091100; Smith DS, 1996, J IMMUNOL, V156, P2642; Spencer J, 1999, J IMMUNOL, V162, P6596; Tashiro J, 2001, INT IMMUNOL, V13, P495, DOI 10.1093/intimm/13.4.495; Wiesendanger M, 2000, J EXP MED, V191, P579, DOI 10.1084/jem.191.3.579; YOSHIKAWA K, UNPUB	28	303	322	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	2002	296	5575					2033	2036		10.1126/science.1071556	http://dx.doi.org/10.1126/science.1071556			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065838				2022-12-28	WOS:000176273300055
J	Morrison, AB				Morrison, AB			Counteracting cigarette advertising	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Stanford Sch Law, Stanford, CA 94305 USA	Stanford University	Morrison, AB (corresponding author), Stanford Sch Law, 559 Nathan Way,Room 215, Stanford, CA 94305 USA.							Bayer R, 2002, JAMA-J AM MED ASSOC, V287, P2990, DOI 10.1001/jama.287.22.2990; *CDCP, 2002, MMWR-MORBID MORTAL W, V51, P300; Ling PM, 2002, JAMA-J AM MED ASSOC, V287, P2983, DOI 10.1001/jama.287.22.2983; Rabin Robert L., 2001, DEPAUL L REV, V51, P331	4	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	2002	287	22					3001	3003		10.1001/jama.287.22.3001	http://dx.doi.org/10.1001/jama.287.22.3001			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	561EY	12052131				2022-12-28	WOS:000176128300031
J	Armstrong, J; Reilly, JJ				Armstrong, J; Reilly, JJ		Child Hlth Information Team	Breastfeeding and lowering the risk of childhood obesity	LANCET			English	Article								Breastfeeding might confer protection against obesity later in life, but the evidence is inconclusive. We tested the hypothesis that breastfeeding is associated with a reduced risk of obesity in a population-based sample of 32 200 Scottish children studied at age 39-42 months in 1998 and 1999. Obesity was defined as body-mass index (BMI) at the 95th and 98th percentiles or higher. The prevalence of obesity was significantly lower in breastfed children, and the association persisted after adjustment for socioeconomic status, birthweight, and sex. The adjusted odds ratio for obesity (BMI greater than or equal to98th percentile) was 0.70 (95% CI 0.61-0.80). Our results suggest that breastfeeding Is associated with a reduction in childhood obesity risk.	Univ Glasgow, Royal Hosp Sick Children, Dept Human Nutr, Glasgow G3 8SJ, Lanark, Scotland; Glasgow Caledonian Univ, Glasgow G4 0BA, Lanark, Scotland; Child Hlth Informat Team, Hosp & Community Informat Unit, Informat & Stat Div, Edinburgh, Midlothian, Scotland	University of Glasgow; Glasgow Caledonian University	Reilly, JJ (corresponding author), Univ Glasgow, Royal Hosp Sick Children, Dept Human Nutr, Glasgow G3 8SJ, Lanark, Scotland.							CARSTAIRS V, 1991, DEPRIVATION HLTH SCO, P18; Dietz WH, 2001, JAMA-J AM MED ASSOC, V285, P2506, DOI 10.1001/jama.285.19.2506; Parsons TJ, 1999, INT J OBESITY, V23, pS1; Reilly JJ, 1999, LANCET, V354, P1874, DOI 10.1016/S0140-6736(99)04555-9; von Kries R, 1999, BRIT MED J, V319, P147, DOI 10.1136/bmj.319.7203.147	5	273	282	0	38	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 8	2002	359	9322					2003	2004		10.1016/S0140-6736(02)08837-2	http://dx.doi.org/10.1016/S0140-6736(02)08837-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076560				2022-12-28	WOS:000176232500017
J	Ferguson, LP; Beattie, TF				Ferguson, LP; Beattie, TF			Lesson of the week - Osteomyelitis in the well looking afebrile child	BRITISH MEDICAL JOURNAL			English	Review							ACUTE HEMATOGENOUS OSTEOMYELITIS; ERYTHROCYTE SEDIMENTATION-RATE; C-REACTIVE PROTEIN; BONE		Royal Hosp Sick Children, Dept Accid & Emergency Med, Edinburgh EH9 1LF, Midlothian, Scotland		Beattie, TF (corresponding author), Royal Hosp Sick Children, Dept Accid & Emergency Med, Edinburgh EH9 1LF, Midlothian, Scotland.							APLEY AG, 1993, APLEYS SYSTEM ORTHOP, P31; DICH VQ, 1975, AM J DIS CHILD, V129, P1273, DOI 10.1001/archpedi.1975.02120480007004; Fischer SU, 1999, J BONE JOINT SURG BR, V81B, P1029, DOI 10.1302/0301-620X.81B6.9607; Hall J E, 1966, Appl Ther, V8, P331; Kabak S, 1999, Eur J Emerg Med, V6, P219; MORREY BF, 1975, ORTHOP CLIN N AM, V6, P935; MORRISSY RT, 1989, J PEDIATR ORTHOPED, V9, P447; MORRISSY RT, 1986, PEDIATR CLIN N AM, V33, P1551; Perry M, 1996, J ROY COLL SURG EDIN, V41, P116; Sonnen GM, 1996, PEDIATR CLIN N AM, V43, P933, DOI 10.1016/S0031-3955(05)70443-0; UNKILAKALLIO L, 1994, PEDIATRICS, V93, P59; WARNER WC, 1998, CAMPBELLS OPERATIVE, P578	12	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 8	2002	324	7350					1380	1381		10.1136/bmj.324.7350.1380	http://dx.doi.org/10.1136/bmj.324.7350.1380			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BQ	12052811	Green Published			2022-12-28	WOS:000176234100026
J	Goodacre, S; McLeod, K				Goodacre, S; McLeod, K			ABC of clinical electrocardiography - Paediatric electrocardiography	BRITISH MEDICAL JOURNAL			English	Article									No Gen Hosp, Dept Accid & Emergency, Sheffield S5 7AU, S Yorkshire, England; Royal Hosp Sick Children, Glasgow G3 8SJ, Lanark, Scotland	Northern General Hospital; University of Glasgow	Goodacre, S (corresponding author), No Gen Hosp, Dept Accid & Emergency, Sheffield S5 7AU, S Yorkshire, England.			Goodacre, Steve/0000-0003-0803-8444					0	18	18	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 8	2002	324	7350					1382	1385		10.1136/bmj.324.7350.1382	http://dx.doi.org/10.1136/bmj.324.7350.1382			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BQ	12052812	Green Published			2022-12-28	WOS:000176234100027
J	Marscher, AP; Jorstad, SG; Gomez, JL; Aller, MF; Terasranta, H; Lister, ML; Stirling, AM				Marscher, AP; Jorstad, SG; Gomez, JL; Aller, MF; Terasranta, H; Lister, ML; Stirling, AM			Observational evidence for the accretion-disk origin for a radio jet in an active galaxy	NATURE			English	Article							RELATIVISTIC JETS; BLACK-HOLE; 3C-120	Accretion of gas onto black holes is thought to power the relativistic jets of material ejected from active galactic nuclei (AGN) and the 'microquasars' located in our Galaxy(1-3). In microquasars, superluminal radio-emitting features appear and propagate along the jet shortly after sudden decreases in the Xray fluxes(1). This establishes a direct observational link between the black hole and the jet: the X-ray dip is probably caused by the disappearance of a section of the inner accretion disk(4) as it falls past the event horizon, while the remainder of the disk section is ejected into the jet, creating the appearance of a superluminal bright spot(5). No such connection has hitherto been established for AGN, because of insufficient multi-frequency data. Here we report the results of three years of monitoring the X-ray and radio emission of the galaxy 3C120. As has been observed for microquasars, we find that dips in the X-ray emission are followed by ejections of bright superluminal knots in the radio jet. The mean time between X-ray dips appears to scale roughly with the mass of the black hole, although there are at present only a few data points.	Boston Univ, Inst Astrophys Res, Boston, MA 02215 USA; St Petersburg State Univ, Sobolev Astron Inst, St Petersburg 198504, Russia; CSIC, Inst Astrofis Andalucia, E-18080 Granada, Spain; Univ Michigan, Dept Astron, Ann Arbor, MI 48109 USA; Helsinki Univ Technol, Metsahovi Radio Observ, Kylmala 02540, Finland; Natl Radio Astron Observ, Charlottesville, VA 22903 USA; Univ Cent Lancashire, Ctr Astrophys, Preston PR1 2HE, Lancs, England	Boston University; Saint Petersburg State University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Astrofisica de Andalucia (IAA); University of Michigan System; University of Michigan; Aalto University; National Radio Astronomy Observatory (NRAO); University of Central Lancashire	Marscher, AP (corresponding author), Boston Univ, Inst Astrophys Res, 725 Commonwealth Ave, Boston, MA 02215 USA.		Jorstad, Svetlana G/H-6913-2013; Jorstad, Svetlana/AAM-3279-2021; Gómez, José L/C-4195-2008	Jorstad, Svetlana G/0000-0001-9522-5453; Jorstad, Svetlana/0000-0001-6158-1708; Gómez, José L/0000-0003-4190-7613; Lister, Matthew/0000-0003-1315-3412				Belloni T, 2001, ASTROPHYS SPACE SCI, V276, P145, DOI 10.1023/A:1011622708440; DALY RA, 1988, ASTROPHYS J, V334, P539, DOI 10.1086/166858; FELLER W, 1971, INTRO PROBABILITY TH, V1; Fender RP, 1999, MON NOT R ASTRON SOC, V304, P865, DOI 10.1046/j.1365-8711.1999.02364.x; Gomez JL, 2000, SCIENCE, V289, P2317, DOI 10.1126/science.289.5488.2317; Gomez JL, 1997, ASTROPHYS J, V482, pL33, DOI 10.1086/310671; Gomez JL, 2001, ASTROPHYS J, V561, pL161, DOI 10.1086/324759; Grandi P, 1997, ASTROPHYS J, V487, P636, DOI 10.1086/304630; Greiner J, 2001, NATURE, V414, P522, DOI 10.1038/35107019; HALPERN JP, 1985, ASTROPHYS J, V290, P130, DOI 10.1086/162967; Junor W, 1999, NATURE, V401, P891, DOI 10.1038/44780; Klein-Wolt M, 2002, MON NOT R ASTRON SOC, V331, P745, DOI 10.1046/j.1365-8711.2002.05223.x; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; MARASCHI L, 1991, ASTROPHYS J, V368, P138, DOI 10.1086/169676; MARSCHER AP, 1980, ASTROPHYS J, V235, P386, DOI 10.1086/157642; Meier DL, 2001, SCIENCE, V291, P84, DOI 10.1126/science.291.5501.84; Mirabel IF, 1998, NATURE, V392, P673, DOI 10.1038/33603; REYNOLDS SP, 1982, ASTROPHYS J, V256, P13, DOI 10.1086/159881; SHAPIRO SI, 1983, BLACK HOLES WHITE DW, P362; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591; Wandel A, 1999, ASTROPHYS J, V526, P579, DOI 10.1086/308017; Zdziarski AA, 2001, ASTROPHYS J, V551, P186, DOI 10.1086/320064	22	234	235	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	2002	417	6889					625	627		10.1038/nature00772	http://dx.doi.org/10.1038/nature00772			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050658	Green Published			2022-12-28	WOS:000176001200040
J	Wikelski, M; Wong, V; Chevalier, B; Rattenborg, N; Snell, HL				Wikelski, M; Wong, V; Chevalier, B; Rattenborg, N; Snell, HL			Marine iguanas die from trace oil pollution	NATURE			English	Article							GALAPAGOS; SPILL		Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Univ Wisconsin, Sch Med, Dept Psychiat, Madison, WI 53719 USA; Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA; Charles Darwin Res Stn, Galapagos, Ecuador	Princeton University; University of Wisconsin System; University of Wisconsin Madison; University of New Mexico	Wikelski, M (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.		Snell, Howard/N-2455-2015; /ABD-1334-2021	Snell, Howard/0000-0001-8770-7540; 				Fowler GS, 1995, AUK, V112, P382, DOI 10.2307/4088725; MACKIE RI, UNPUB PHYS BIOCH ZOO; Ormseth OA, 2000, J COMP PHYSIOL B, V170, P419, DOI 10.1007/s003600000119; Paine RT, 1996, ANNU REV ECOL SYST, V27, P197, DOI 10.1146/annurev.ecolsys.27.1.197; Prichard AK, 1997, CHEMOSPHERE, V35, P1531, DOI 10.1016/S0045-6535(97)00223-3; Romero LM, 2001, P NATL ACAD SCI USA, V98, P7366, DOI 10.1073/pnas.131091498; van Tamelen PG, 1997, MAR ECOL PROG SER, V160, P265, DOI 10.3354/meps160265; WIKELSKI M, 1993, OECOLOGIA, V94, P373, DOI 10.1007/BF00317112; Wikelski M, 2001, SCIENCE, V292, P437; Wikelski M, 1997, EVOLUTION, V51, P922, DOI 10.1111/j.1558-5646.1997.tb03673.x; 2001, SEA TECHNOL, V42, P74	11	69	71	3	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	2002	417	6889					607	608		10.1038/417607a	http://dx.doi.org/10.1038/417607a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050651				2022-12-28	WOS:000176001200033
J	Kanis, JA				Kanis, JA			Diagnosis of osteoporosis and assessment of fracture risk	LANCET			English	Article							PREDICT HIP FRACTURE; BONE-DENSITY; ELDERLY-WOMEN; POSTMENOPAUSAL OSTEOPOROSIS; QUANTITATIVE ULTRASOUND; VERTEBRAL DEFORMITY; SKELETAL SITES; MASS; MEN; GUIDELINES	The diagnosis of osteoporosis centres on the assessment of bone mineral density (BMD). Osteoporosis Is defined as a BMD 2.5 SD or more below the average value for premenopausal women (T score <-2.5 SD). Severe osteoporosis denotes osteoporosis in the presence of one or more fragility fractures. The same absolute value for BMD used in women can be used in men. The recommended site for diagnosis Is the proximal femur with dual energy X-ray absorptiometry (DXA). Other sites and validated techniques, however, can be used for fracture prediction. Although hip fracture prediction with BMD alone is at least as good as blood pressure readings to predict stroke, the predictive value of BMD can be enhanced by use of other factors, such as biochemical indices of bone resorption and clinical risk factors. Clinical risk factors that contribute to fracture risk independently of BMD include age, previous fragility fracture, premature menopause, a family history of hip fracture, and the use of oral corticosteroids. In the absence of validated population screening strategies, a case finding strategy is recommended based on the finding of risk factors. Treatment should be considered In individuals subsequently shown to have a high fracture risk. Because of the many techniques available for fracture risk assessment, the 10-year probability of fracture Is the desirable measurement to determine Intervention thresholds. Many treatments can be provided cost-effectively to men and women if hip fracture probability over 10 years ranges from 2% to 10% dependent on age.	Univ Sheffield, Sch Med, WHO, Collaborating Ctr Metab Bone Dis, Sheffield S10 2RX, S Yorkshire, England	University of Sheffield; World Health Organization	Kanis, JA (corresponding author), Univ Sheffield, Sch Med, WHO, Collaborating Ctr Metab Bone Dis, Sheffield S10 2RX, S Yorkshire, England.	w.j.pontefract@sheffield.ac.uk						Arlot ME, 1997, J BONE MINER RES, V12, P683, DOI 10.1359/jbmr.1997.12.4.683; Bonjour Jean-Philippe, 1996, P465; Committee for 2011 Guidelines for Prevention and Treatment of Osteoporosis (Director Orimo H), 2011, GUIDELINES PREVENTIO; COMPSTON JE, 1992, CLIN ENDOCRINOL, V36, P223, DOI 10.1111/j.1365-2265.1992.tb01435.x; COOPER C, 1994, Q J MED, V87, P203; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; De Laet CED, 2001, J BONE MINER RES, V16, pS456; De Laet CEDH, 1998, J BONE MINER RES, V13, P1587, DOI 10.1359/jbmr.1998.13.10.1587; DELMAS PD, 2000, OSTEOPOROSIS INT S6, V11, pS1; Faulkner KG, 1999, J CLIN DENSITOM, V2, P343, DOI 10.1385/JCD:2:3:343; Formica CA, 1998, OSTEOPOROSIS INT, V8, P1, DOI 10.1007/s001980050040; Garnero P, 1998, OSTEOPOROSIS INT, V8, P563, DOI 10.1007/s001980050100; Garnero P, 2000, J BONE MINER RES, V15, P1526, DOI 10.1359/jbmr.2000.15.8.1526; Garnero P, 1996, J BONE MINER RES, V11, P1531; GENANT HK, 1982, ANN INTERN MED, V97, P699, DOI 10.7326/0003-4819-97-5-699; Genant HK, 1996, J BONE MINER RES, V11, P707; Gluer CC, 1997, J BONE MINER RES, V12, P1280, DOI 10.1359/jbmr.1997.12.8.1280; Grampp S, 1997, J BONE MINER RES, V12, P697, DOI 10.1359/jbmr.1997.12.5.697; Gregg EW, 1997, OSTEOPOROSIS INT, V7, P89, DOI 10.1007/BF01623682; Hans D, 1996, LANCET, V348, P511, DOI 10.1016/S0140-6736(95)11456-4; HANSEN MA, 1991, BMJ-BRIT MED J, V303, P961, DOI 10.1136/bmj.303.6808.961; Heaney RP, 1996, BONE, V18, P491, DOI 10.1016/8756-3282(96)00089-0; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; JOHNELL O, 1995, J BONE MINER RES, V10, P1802, DOI 10.1002/jbmr.5650101125; JOHNELL O, IN PRESS OSTEOPOROS; Jonsson B, 1999, OSTEOPOROSIS INT, V10, P193, DOI 10.1007/s001980050215; Kanis J, 1999, OSTEOPOROSIS INT, V9, P45, DOI 10.1007/s001980050115; Kanis JA, 1997, OSTEOPOROSIS INT, V7, P390, DOI 10.1007/BF01623782; Kanis JA, 2000, BONE, V26, P387, DOI 10.1016/S8756-3282(00)00238-6; Kanis JA, 2002, BONE, V30, P251, DOI 10.1016/S8756-3282(01)00653-6; Kanis JA, 1996, BONE, V18, pS127, DOI 10.1016/8756-3282(95)00493-9; Kanis JA, 2000, OSTEOPOROSIS INT, V11, P192, DOI 10.1007/s001980050281; Kanis JA, 2001, OSTEOPOROSIS INT, V12, P989, DOI 10.1007/s001980170006; Kanis JA, 2000, TRENDS ENDOCRIN MET, V11, P28, DOI 10.1016/S1043-2760(99)00214-3; Kanis JA, 1999, OSTEOPOROSIS INT, V9, P24, DOI 10.1007/PL00004157; Kanis JA, 2001, CALCIFIED TISSUE INT, V69, P218, DOI 10.1007/s00223-001-1046-6; Kanis JA, 2001, OSTEOPOROSIS INT, V12, P356, DOI 10.1007/s001980170102; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; Kanis JA, 2000, OSTEOPOROSIS INT, V11, P120, DOI 10.1007/PL00004173; Kanis JA, 2000, OSTEOPOROSIS INT, V11, P669, DOI 10.1007/s001980070064; Kanis JA, 2001, OSTEOPOROSIS INT, V12, P417, DOI 10.1007/s001980170112; KANIS JA, IN PRESS BONE; Klotzbuecher CM, 2000, J BONE MINER RES, V15, P721, DOI 10.1359/jbmr.2000.15.4.721; Lang T, 1998, BONE, V22, p149S, DOI 10.1016/S8756-3282(98)00005-2; Lunt M, 1997, J BONE MINER RES, V12, P1883, DOI 10.1359/jbmr.1997.12.11.1883; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; Melton LJ, 1998, J BONE MINER RES, V13, P1915, DOI 10.1359/jbmr.1998.13.12.1915; NGUYEN T, 1993, BRIT MED J, V307, P1111, DOI 10.1136/bmj.307.6912.1111; Oden A, 1998, OSTEOPOROSIS INT, V8, P599, DOI 10.1007/s001980050105; Orwoll E, 2000, J BONE MINER RES, V15, P1867, DOI 10.1359/jbmr.2000.15.10.1867; PECK WA, 1993, AM J MED, V94, P646; POOR G, 1995, J BONE MINER RES, V10, P1900; PORTER RW, 1990, BMJ-BRIT MED J, V301, P638, DOI 10.1136/bmj.301.6753.638; RIBOT C, 1992, CLIN ENDOCRINOL, V36, P225, DOI 10.1111/j.1365-2265.1992.tb01436.x; ROSS P, 1995, BONE, V16, P325, DOI 10.1016/8756-3282(94)00045-X; ROSS PD, 1993, OSTEOPOROSIS INT, V3, P120, DOI 10.1007/BF01623272; RUEGSEGGER P, 1976, RADIOLOGY, V121, P93; Selby PL, 2000, OSTEOPOROSIS INT, V11, P153, DOI 10.1007/PL00004177; STANLEY HL, 1991, J AM GERIATR SOC, V39, P766, DOI 10.1111/j.1532-5415.1991.tb02698.x; van Staa TP, 2001, J BONE MINER RES, V16, P581, DOI 10.1359/jbmr.2001.16.3.581; Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993; *WHO, 1994, TECH REP SER WHO, V843	62	1418	1482	3	139	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 1	2002	359	9321					1929	1936		10.1016/S0140-6736(02)08761-5	http://dx.doi.org/10.1016/S0140-6736(02)08761-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PL	12057569				2022-12-28	WOS:000175975700025
J	Parent, CA				Parent, CA			PI 3-kinases and PTEN: How opposites chemoattract	CELL			English	Review							TUMOR-SUPPRESSOR PTEN; NEUTROPHIL CHEMOTAXIS; CELLS; LOCALIZATION; ACTIVATION; MIGRATION	Phosphatidylinositol lipids, such as PI(4,5)P-2 and PI(3,4,5)P-3, are key mediators in diverse intracellular signaling pathways. Two recent reports examine how the metabolism of these lipids by phosphatidylinositol 3-kinases and the PTEN 3-phosphoinositide phosphatase may coordinate G protein coupled signaling pathways during eukaryotic chemotaxis.	NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Natl Inst Gen Med Sci, PRAT Res Fellowship Program, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of General Medical Sciences (NIGMS)	Parent, CA (corresponding author), NCI, Cellular & Mol Biol Lab, NIH, 37 Convent Dr,MSC 4255,Bldg 37,Room 1E24, Bethesda, MD 20892 USA.							Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Field SJ, 2002, DEV CELL, V2, P407, DOI 10.1016/S1534-5807(02)00150-8; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Katanaev VL, 2001, BIOCHEMISTRY-MOSCOW+, V66, P351, DOI 10.1023/A:1010293809553; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; Seminario MC, 2002, SEMIN IMMUNOL, V14, P27, DOI 10.1006/smim.2001.0339; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Stephens L, 2002, CURR OPIN CELL BIOL, V14, P203, DOI 10.1016/S0955-0674(02)00311-3; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Yamada KM, 2001, J CELL SCI, V114, P2375	20	107	118	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 31	2002	109	5					541	544		10.1016/S0092-8674(02)00765-1	http://dx.doi.org/10.1016/S0092-8674(02)00765-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	558GL	12062096	Bronze			2022-12-28	WOS:000175957900002
J	Pal, B				Pal, B			10-minute consultation - Paraesthesia	BRITISH MEDICAL JOURNAL			English	Article									Withington Hosp, Manchester M20 2LR, Lancs, England		Pal, B (corresponding author), Withington Hosp, Room 10,Home 4, Manchester M20 2LR, Lancs, England.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 22	2002	324	7352					1501	1501		10.1136/bmj.324.7352.1501	http://dx.doi.org/10.1136/bmj.324.7352.1501			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567ZL	12077040	Green Published, Bronze			2022-12-28	WOS:000176517900025
J	Schumacher, HR; Boice, JA; Daikh, DI; Mukhopadhyay, S; Malmstrom, K; Ng, J; Tate, GA; Molina, J				Schumacher, HR; Boice, JA; Daikh, DI; Mukhopadhyay, S; Malmstrom, K; Ng, J; Tate, GA; Molina, J			Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ORAL INDOMETHACIN; CLINICAL-TRIAL; CYCLOOXYGENASE-2; CELECOXIB; OSTEOARTHRITIS; DICLOFENAC; MANAGEMENT; EFFICACY; INHIBITOR; ROFECOXIB	Objective To assess the safety and efficacy of etoricoxib, a selective cyclo-oxygenase-2 inhibitor, in comparison with indometacin in the treatment of acute gouty arthritis. Design Randomised, double blind, active comparator controlled trial. Setting 43 outpatient study centres in 11 countries. Participants 142 men and eight women (75 patients per treatment group) aged 18 years or over presenting with clinically diagnosed acute gout within 48 hours of onset. Interventions Etoricoxib 120 mg administered orally once daily versus indometacin 50 mg administered orally three times daily, both for 8 days Main outcome measures Patients' assessment of pain in the study joint over days 2 to 5 (primary end point); investigators' and patients' global assessments of response to treatment and tenderness of the study joint (key secondary end points). Results Etoricoxib showed efficacy comparable to indometacin. Patients' assessment of pain in the study joint (0-4 point Likert scale, "no pain" to "extreme pain") over days 2 to 5 showed a least squares mean change from baseline of - 1.72 (95% confidence interval - 1.90 to - 1.55) for etoricoxib and - 1.83 (- 2.01 to - 1.65) for indometacin. The difference between treatment groups met prespecified comparability criteria. All other efficacy end points, including those reflecting reduction in inflammation and analgesia, provided corroborative evidence of comparable efficacy. Significant pain relief was evident at the first measurement, 4 hours after the first dose of treatment. Prespecified safety analyses revealed that drug related adverse experiences occurred significantly less frequently with etoricoxib (22.7%) than with indometacin (46.7%) (P=.003), although overall adverse experience rates were similar between the two treatment groups. Conclusion Etoricoxib 120 mg once daily provides rapid and effective treatment for acute gouty arthritis comparable to indometacin 50 mg three times daily. Etoricoxib was generally safe and well tolerated in this study.	Merck Res Labs, Dept Clin Immunol & Analgesia, Rahway, NJ 07065 USA; Univ Penn, Sch Med, Div Rheumatol, Philadelphia, PA 19104 USA; Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA; Merck Res Labs, Dept Clin Biostat & Res Data Syst, Rahway, NJ USA; Univ Calif San Francisco, Div Rheumatol, San Francisco, CA 94121 USA; Dept Vet Affairs Med Ctr, San Francisco, CA 94121 USA; Ctr Ospeopatias Reumatol & Invest Clin, RA-1012 Buenos Aires, DF, Argentina; Antioquia Univ, Dept Internal Med, Medellin 1226, Colombia	Merck & Company; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Merck & Company; University of California System; University of California San Francisco; Universidad de Antioquia	Boice, JA (corresponding author), Merck Res Labs, Dept Clin Immunol & Analgesia, Rahway, NJ 07065 USA.	judith_boice@merck.com						Agrawal NGB, 2001, J CLIN PHARMACOL, V41, P1106, DOI 10.1177/00912700122012715; ALTMAN RD, 1988, J RHEUMATOL, V15, P1422; AXELROD D, 1988, ARTHRITIS RHEUM-US, V31, P803, DOI 10.1002/art.1780310618; BELLAMY N, 1992, J RHEUMATOL, V19, P451; BELLAMY N, 1987, BRIT J CLIN PHARMACO, V24, P33, DOI 10.1111/j.1365-2125.1987.tb03132.x; Cannon GW, 2000, ARTHRITIS RHEUM-US, V43, P978, DOI 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0; Emery P, 1999, LANCET, V354, P2106, DOI 10.1016/S0140-6736(99)02332-6; Gimbel JS, 2001, CLIN THER, V23, P228, DOI 10.1016/S0149-2918(01)80005-9; Iniguez MA, 1998, BRIT J RHEUMATOL, V37, P773; KLIPPEL JH, 1997, PRIMER RHEUMATIC DIS, P457; LOMEN PL, 1986, AM J MED, V80, P134, DOI 10.1016/0002-9343(86)90131-2; Malmstrom K, 1999, CLIN THER, V21, P1653, DOI 10.1016/S0149-2918(99)80045-9; McKenna F, 2001, SCAND J RHEUMATOL, V30, P11; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Pittman JR, 1999, AM FAM PHYSICIAN, V59, P1799; Pouliot M, 1998, BLOOD, V91, P1769, DOI 10.1182/blood.V91.5.1769.1769_1769_1776; Reicin A, 2001, Am J Orthop (Belle Mead NJ), V30, P40; ROUBENOFF R, 1990, RHEUM DIS CLIN N AM, V16, P539; RUOTSI A, 1978, SCAND J RHEUMATOL, P15; Schlesinger N, 1999, Curr Opin Rheumatol, V11, P441, DOI 10.1097/00002281-199909000-00020; SHRESTHA M, 1995, ANN EMERG MED, V26, P682, DOI 10.1016/S0196-0644(95)70037-4; Singh G, 1998, J RHEUMATOL, V25, P8; THOMPSON M, 1966, BMJ-BRIT MED J, V1, P80, DOI 10.1136/bmj.1.5479.80; WALLACE SL, 1977, ARTHRITIS RHEUM, V20, P895, DOI 10.1002/art.1780200320	24	158	175	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 22	2002	324	7352					1488	1492		10.1136/bmj.324.7352.1488	http://dx.doi.org/10.1136/bmj.324.7352.1488			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567ZL	12077033	Bronze, Green Published			2022-12-28	WOS:000176517900018
J	Lee, SB; Mitchell, DT; Trofin, L; Nevanen, TK; Soderlund, H; Martin, CR				Lee, SB; Mitchell, DT; Trofin, L; Nevanen, TK; Soderlund, H; Martin, CR			Antibody-based bio-nanotube membranes for enantiomeric drug separations	SCIENCE			English	Article							IMMUNOAFFINITY CHROMATOGRAPHY; FACILITATED TRANSPORT; OPTICAL RESOLUTION; AMINO-ACIDS; POLYMERIC MEMBRANES; SERUM-ALBUMIN; AFFINITY; MUTAGENESIS; SELECTIVITY; SITE	Synthetic bio-nanotube membranes were developed and used to separate two enantiomers of a chiral drug. These membranes are based on alumina films that have cylindrical pores with monodisperse nanoscopic diameters (for example, 20 nanometers). Silica nanotubes were chemically synthesized within the pores of these films, and an antibody that selectively binds one of the enantiomers of the drug was attached to the inner walls of the silica nanotubes. These membranes selectively transport the enantiomer that specifically binds to the antibody, relative to the enantiomer that has lower affinity for the antibody. The solvent dimethyl sulfoxide was used to tune the antibody binding affinity. The enantiomeric selectivity coefficient increases as the inside diameter of the silica nanotubes decreases.	Univ Florida, Dept Chem, Gainesville, FL 32611 USA; Univ Florida, Ctr Res BioNano Interface, Gainesville, FL 32611 USA; VTT Biotechnol, FIN-02044 Espoo, Finland	State University System of Florida; University of Florida; State University System of Florida; University of Florida; VTT Technical Research Center Finland	Martin, CR (corresponding author), Univ Florida, Dept Chem, Gainesville, FL 32611 USA.		Lee, Sang Bok/B-4421-2009; Martin, Charles/AAA-1040-2019	Lee, Sang Bok/0000-0003-1375-7099; Nevanen, Tarja/0000-0001-8964-1012				Aoki T, 1997, POLYMER, V38, P235, DOI 10.1016/S0032-3861(96)00630-1; Bayley H, 2000, CHEM REV, V100, P2575, DOI 10.1021/cr980099g; Brinker C.J., 1990, SOL GEL SCI, DOI [10.1016/B978-0-08-057103-4.50013-1, DOI 10.1016/C2009-0-22386-5]; BRUNING C, 1995, CHEM COMMUN, P2323; CHASE HA, 1984, CHEM ENG SCI, V39, P1099; Chowdhury PS, 1999, NAT BIOTECHNOL, V17, P568, DOI 10.1038/9872; CROSBY J, 1991, TETRAHEDRON, V47, P4789, DOI 10.1016/S0040-4020(01)80950-9; FOSS CA, 1994, J PHYS CHEM-US, V98, P2963, DOI 10.1021/j100062a037; HARLOW E, 1988, ANTIBODIES, P8; Hemminki A, 1998, IMMUNOTECHNOLOGY, V4, P59, DOI 10.1016/S1380-2933(98)00002-5; Hemminki A, 1998, PROTEIN ENG, V11, P311, DOI 10.1093/protein/11.4.311; HIGUCHI A, 1994, J MEMBRANE SCI, V93, P157, DOI 10.1016/0376-7388(94)80004-9; Hulteen JC, 1998, J AM CHEM SOC, V120, P6603, DOI 10.1021/ja980045o; Javaid A, 2001, J MEMBRANE SCI, V187, P141, DOI 10.1016/S0376-7388(01)00341-6; Jirage KB, 1997, SCIENCE, V278, P655, DOI 10.1126/science.278.5338.655; Kim CK, 2001, J PHYS CHEM A, V105, P9024, DOI 10.1021/jp011338y; Kojima K, 2001, J BIOCHEM BIOPH METH, V49, P241, DOI 10.1016/S0165-022X(01)00201-9; Lakshmi BB, 1997, CHEM MATER, V9, P2544, DOI 10.1021/cm970268y; Lakshmi BB, 1997, NATURE, V388, P758, DOI 10.1038/41978; Lee SB, 2001, ANAL CHEM, V73, P768, DOI 10.1021/ac0008901; Lee SB, 2001, CHEM MATER, V13, P3236, DOI 10.1021/cm0101071; LIU C, 1991, NATURE, V352, P50, DOI 10.1038/352050a0; Masuda H, 1996, JPN J APPL PHYS 2, V35, pL126, DOI 10.1143/JJAP.35.L126; MATHEWS CK, 1996, BIOCHEMISTRY-US, P247; Miller SA, 2001, J AM CHEM SOC, V123, P12335, DOI 10.1021/ja011926p; NACHMAN M, 1992, J CHROMATOGR, V597, P167, DOI 10.1016/0021-9673(92)80106-5; Nakamura M, 1998, J CHROMATOGR A, V822, P53, DOI 10.1016/S0021-9673(98)00501-9; Nevanen TK, 2001, J CHROMATOGR A, V925, P89, DOI 10.1016/S0021-9673(01)01021-4; NISHIZAWA M, 1995, SCIENCE, V268, P700, DOI 10.1126/science.268.5211.700; NOBLE RD, 1992, J MEMBRANE SCI, V75, P121, DOI 10.1016/0376-7388(92)80011-8; OVERDEVEST PEM, 1999, SURFACTANT BASED SEP, pCH9; Park YS, 2000, LANGMUIR, V16, P9662, DOI 10.1021/la000466v; Paugam MF, 1996, J AM CHEM SOC, V118, P9820, DOI 10.1021/ja9615076; STUBBINGS D, 1993, ANAL BIOCHEM, V210, P159, DOI 10.1006/abio.1993.1167; Tone S, 1996, J MEMBRANE SCI, V118, P31, DOI 10.1016/0376-7388(96)00071-3; Ward TJ, 2000, ANAL CHEM, V72, P4521, DOI 10.1021/ac000841o; Westmark PR, 1996, J AM CHEM SOC, V118, P11093, DOI 10.1021/ja961264h; Wolpert S, 1997, J MEMBRANE SCI, V132, P23, DOI 10.1016/S0376-7388(97)00011-2; Yang JP, 2000, CHEM MATER, V12, P2693, DOI 10.1021/cm0010506; YELTON DE, 1995, J IMMUNOL, V155, P1994; Yoshikawa M, 1996, MACROMOLECULES, V29, P8197, DOI 10.1021/ma951716v; Yu SF, 2001, NANO LETT, V1, P495, DOI 10.1021/nl010044l	42	592	620	6	208	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 21	2002	296	5576					2198	2200		10.1126/science.1071396	http://dx.doi.org/10.1126/science.1071396			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077410				2022-12-28	WOS:000176379000051
J	Wolfe, MS; Selkoe, DJ				Wolfe, MS; Selkoe, DJ			Perspectives: Biochemistry - Intramembrane proteases - Mixing oil and water	SCIENCE			English	Editorial Material							GAMMA-SECRETASE; PRESENILIN; INHIBITORS; CLEAVAGE; FAMILY; NOTCH; IDENTIFICATION; PROTEOLYSIS; RELEASE; BETA		Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Wolfe, MS (corresponding author), Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA.	mwolfe@rics.bwh.harvard.edu; dselkoe@rics.bwh.harvard.edu						Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Esler WP, 2002, NAT CELL BIOL, V4, pE110, DOI 10.1038/ncb0502-e110b; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; LaPointe CF, 2000, J BIOL CHEM, V275, P1502, DOI 10.1074/jbc.275.2.1502; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Sisodia SS, 2001, TRENDS NEUROSCI, V24, pS2, DOI 10.1016/S0166-2236(00)01987-1; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Tam A, 2001, J BIOL CHEM, V276, P46798, DOI 10.1074/jbc.M106150200; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Urban S, 2001, CELL, V107, P173, DOI 10.1016/S0092-8674(01)00525-6; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	24	53	54	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	2002	296	5576					2156	2157		10.1126/science.1073844	http://dx.doi.org/10.1126/science.1073844			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077393				2022-12-28	WOS:000176379000034
J	Le Masson, G; Renaud-Le Masson, S; Debay, D; Bal, T				Le Masson, G; Renaud-Le Masson, S; Debay, D; Bal, T			Feedback inhibition controls spike transfer in hybrid thalamic circuits	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; THALAMOCORTICAL OSCILLATIONS; NEURONS; CAT; MECHANISMS; CONDUCTANCES; DYNAMICS; AROUSAL; CELLS; MODEL	Sensory information reaches the cerebral cortex through the thalamus, which differentially relays this input depending on the state of arousal(1-5). Such 'gating' involves inhibition of the thalamocortical relay neurons by the reticular nucleus of the thalamus(6-8), but the underlying mechanisms are poorly understood. We reconstructed the thalamocortical circuit as an artificial and biological hybrid network in vitro. With visual input simulated as retinal cell activity, we show here that when the gain in the thalamic inhibitory feedback loop is greater than a critical value, the circuit tends towards oscillations-and thus imposes a temporal decorrelation of retinal cell input and thalamic relay output. This results in the functional disconnection of the cortex from the sensory drive, a feature typical of sleep states. Conversely, low gain in the feedback inhibition and the action of noradrenaline, a known modulator of arousal(4,9,10), converge to increase input-output correlation in relay neurons. Combining gain control of feedback inhibition and modulation of membrane excitability thus enables thalamic circuits to finely tune the gating of spike transmission from sensory organs to the cortex.	Inst Neurobiol Alfred Fessard, CNRS, UPR 2191, Unite Neurosci Integrat & Computat, F-91198 Gif Sur Yvette, France; Univ Bordeaux 2, Inst Francois Magendie, Lab Physiopathol Reseaux Neuronaux Medullaires, INSERM,EPI 9914, F-33077 Bordeaux, France; Univ Bordeaux 1, ENSEIRB, CNRS, UMR 5818,Lab IXL, F-33405 Talence, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Bal, T (corresponding author), Inst Neurobiol Alfred Fessard, CNRS, UPR 2191, Unite Neurosci Integrat & Computat, F-91198 Gif Sur Yvette, France.	thierry.bal@iaf.cnrs-gif.fr		Renaud, Sylvie/0000-0001-5632-7991				AHLSEN G, 1985, EXP BRAIN RES, V58, P134; ASTONJONES G, 1991, PROG BRAIN RES, V88, P501; Bal T, 1996, NEURON, V17, P297, DOI 10.1016/S0896-6273(00)80161-0; Bal T, 2000, J NEUROSCI, V20, P7478; COENEN AML, 1972, EXP BRAIN RES, V14, P227, DOI 10.1007/BF00816160; Contreras D, 1996, SCIENCE, V274, P771, DOI 10.1126/science.274.5288.771; Destexhe A, 1994, J Comput Neurosci, V1, P195, DOI 10.1007/BF00961734; Destexhe A, 1996, J NEUROPHYSIOL, V76, P2049, DOI 10.1152/jn.1996.76.3.2049; FUNKE K, 1993, J PHYSIOL-LONDON, V463, P169, DOI 10.1113/jphysiol.1993.sp019590; Kim U, 1998, J NEUROSCI, V18, P9500; Kim U, 1997, SCIENCE, V278, P130, DOI 10.1126/science.278.5335.130; Le Masson S, 1999, IEEE T BIO-MED ENG, V46, P638, DOI 10.1109/10.764940; Lee CC, 1996, AM J NEURORADIOL, V17, P321; LeMasson G, 1995, PROG BIOPHYS MOL BIO, V64, P201, DOI 10.1016/S0079-6107(96)00004-1; LIVINGSTONE MS, 1981, NATURE, V291, P554, DOI 10.1038/291554a0; McCormick DA, 1997, ANNU REV NEUROSCI, V20, P185, DOI 10.1146/annurev.neuro.20.1.185; MCCORMICK DA, 1992, PROG NEUROBIOL, V39, P337, DOI 10.1016/0301-0082(92)90012-4; MCCORMICK DA, 1992, J NEUROPHYSIOL, V68, P1384, DOI 10.1152/jn.1992.68.4.1384; Montero VM, 1999, NEUROSCIENCE, V91, P805, DOI 10.1016/S0306-4522(98)00632-0; MUKHERJEE P, 1995, J NEUROPHYSIOL, V74, P1222, DOI 10.1152/jn.1995.74.3.1222; SHARP AA, 1993, J NEUROPHYSIOL, V69, P992, DOI 10.1152/jn.1993.69.3.992; Sherman SM, 1996, J NEUROPHYSIOL, V76, P1367, DOI 10.1152/jn.1996.76.3.1367; SNEAD OC, 1995, ANN NEUROL, V37, P146, DOI 10.1002/ana.410370204; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; STERIADE M, 1997, THALAMUS ORG FUNCTIO, P533; TROY JB, 1992, VISUAL NEUROSCI, V9, P535, DOI 10.1017/S0952523800001784; Usrey WM, 1999, ANNU REV PHYSIOL, V61, P435, DOI 10.1146/annurev.physiol.61.1.435; VONKROSIGK M, 1993, SCIENCE, V261, P361, DOI 10.1126/science.8392750; Williams SR, 2000, J NEUROSCI, V20, P1307; Yingling C.D., 1977, PROG CLIN NEUROPHYS, V1, P70	30	153	155	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 20	2002	417	6891					854	858		10.1038/nature00825	http://dx.doi.org/10.1038/nature00825			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075353				2022-12-28	WOS:000176285600048
J	Panting, JR; Gatehouse, PD; Yang, GZ; Grothues, F; Firmin, DN; Collins, P; Pennell, DJ				Panting, JR; Gatehouse, PD; Yang, GZ; Grothues, F; Firmin, DN; Collins, P; Pennell, DJ			Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NORMAL CORONARY ARTERIOGRAMS; LEFT-VENTRICULAR FUNCTION; MYOCARDIAL BLOOD-FLOW; ANGINA-PECTORIS; CHEST-PAIN; ARTERY-DISEASE; VASODILATOR RESERVE; LACTATE PRODUCTION; ISCHEMIA; DYSFUNCTION	Background: In cardiac syndrome X (a syndrome characterized by typical angina, abnormal exercise-test results, and normal coronary arteries), conventional investigations have not found that chest pain is due to myocardial ischemia. Magnetic resonance techniques have higher resolution and therefore may be more sensitive. Methods: We performed myocardial-perfusion cardiovascular magnetic resonance imaging in 20 patients with syndrome X and 10 matched controls, both at rest and during an infusion of adenosine. Quantitative perfusion analysis was performed by using the normalized upslope of myocardial signal enhancement to derive the myocardial perfusion index and the myocardial-perfusion reserve index (defined as the ratio of the myocardial perfusion index during stress to the index at rest). Results: In the controls, the myocardial perfusion index increased in both myocardial layers with adenosine (in the subendocardium, from a mean [+/-SD] of 0.12+/-0.03 to 0.16+/-0.03 [P=0.02]; in the subepicardium, from 0.11+/-0.02 to 0.17+/-0.05 [P=0.002]); in patients with syndrome X, the myocardial perfusion index did not change significantly in the subendocardium (0.13+/-0.02 vs. 0.14+/-0.03, P=0.11; P=0.09 as compared with controls) but increased in the subepicardium (from 0.11+/-0.02 to 0.20+/-0.04, P<0.001; P=0.11 for the comparison with controls). Adenosine provoked chest pain in 95 percent of patients with syndrome X and 40 percent of controls (P<0.001). Conclusions: In patients with syndrome X, cardiovascular magnetic resonance imaging demonstrates subendocardial hypoperfusion during the intravenous administration of adenosine, which is associated with intense chest pain. These data support the notion that the chest pain may have an ischemic cause.	Royal Brompton Hosp, Cardiovasc Magnet Resonance Unit, London SW3 6NP, England; Royal Brompton Hosp, Dept Cardiovasc Med, London SW3 6NP, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; Univ London Imperial Coll Sci Technol & Med, Dept Comp, London, England	Royal Brompton Hospital; Royal Brompton Hospital; Imperial College London; Imperial College London	Pennell, DJ (corresponding author), Royal Brompton Hosp, Cardiovasc Magnet Resonance Unit, Sydney St, London SW3 6NP, England.			Pennell, Dudley/0000-0001-5523-1314; Firmin, David/0000-0003-3894-7489; Gatehouse, Peter/0000-0002-0260-4719				Al-Saadi N, 2000, CIRCULATION, V101, P1379, DOI 10.1161/01.CIR.101.12.1379; ARBOGAST R, 1973, AM J CARDIOL, V32, P257, DOI 10.1016/S0002-9149(73)80130-4; Bellamy MF, 1998, CARDIOVASC RES, V40, P410, DOI 10.1016/S0008-6363(98)00184-9; BOUDOULAS H, 1974, AM J CARDIOL, V34, P501, DOI 10.1016/0002-9149(74)90118-0; Buchthal SD, 2000, NEW ENGL J MED, V342, P829, DOI 10.1056/NEJM200003233421201; Buffon A, 2000, AM J PHYSIOL-HEART C, V279, pH2627, DOI 10.1152/ajpheart.2000.279.6.H2627; CAMICI PG, 1992, CIRCULATION, V86, P179, DOI 10.1161/01.CIR.86.1.179; CAMICI PG, 1991, J AM COLL CARDIOL, V17, P1461, DOI 10.1016/0735-1097(91)90632-J; CANNON RO, 1985, CIRCULATION, V71, P218, DOI 10.1161/01.CIR.71.2.218; CANNON RO, 1983, J AM COLL CARDIOL, V1, P1359, DOI 10.1016/S0735-1097(83)80037-0; CANNON RO, 1988, AM J CARDIOL, V61, P1338, DOI 10.1016/0002-9149(88)91180-0; CANTY JM, 1985, CIRCULATION, V71, P370, DOI 10.1161/01.CIR.71.2.370; Cullen JHS, 1999, J AM COLL CARDIOL, V33, P1386, DOI 10.1016/S0735-1097(99)00004-2; EMDIN M, 1989, J AM COLL CARDIOL, V14, P1450, DOI 10.1016/0735-1097(89)90380-X; GALASSI AR, 1993, AM J CARDIOL, V72, P134, DOI 10.1016/0002-9149(93)90148-6; GREENBERG MA, 1987, J AM COLL CARDIOL, V9, P743, DOI 10.1016/S0735-1097(87)80227-9; KASKI JC, 1995, J AM COLL CARDIOL, V25, P807, DOI 10.1016/0735-1097(94)00507-M; KASKI JC, 1991, J AM COLL CARDIOL, V18, P50, DOI 10.1016/S0735-1097(10)80216-5; Keijer JT, 2000, J CARDIOV MAGN RESON, V2, P189, DOI 10.3109/10976640009146567; KEMP HG, 1986, J AM COLL CARDIOL, V7, P479, DOI 10.1016/S0735-1097(86)80456-9; KEMP HG, 1973, AM J CARDIOL, V32, P375, DOI 10.1016/S0002-9149(73)80150-X; Lanza GA, 1997, CIRCULATION, V96, P821; Lauerma K, 1997, CIRCULATION, V96, P2859, DOI 10.1161/01.CIR.96.9.2859; LEGRAND V, 1985, J AM COLL CARDIOL, V6, P1245, DOI 10.1016/S0735-1097(85)80209-6; MASERI A, 1991, J AM COLL CARDIOL, V17, P499, DOI 10.1016/S0735-1097(10)80122-6; Meeder JG, 1995, EUR HEART J, V16, P1571, DOI 10.1093/oxfordjournals.eurheartj.a060780; NIHOYANNOPOULOS P, 1991, J AM COLL CARDIOL, V18, P1463, DOI 10.1016/0735-1097(91)90676-Z; OPHERK D, 1981, CIRCULATION, V63, P817, DOI 10.1161/01.CIR.63.4.817; OPHERK D, 1989, CIRCULATION, V80, P1610, DOI 10.1161/01.CIR.80.6.1610; ROSEN SD, 1994, CIRCULATION, V90, P50, DOI 10.1161/01.CIR.90.1.50; Schwitter J, 2001, CIRCULATION, V103, P2230; TWEDDEL AC, 1992, BRIT HEART J, V68, P48; WILKE N, 1993, MAGNET RESON MED, V29, P485, DOI 10.1002/mrm.1910290410; Wood D, 1998, HEART, V80, pS1	34	543	567	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 20	2002	346	25					1948	1953		10.1056/NEJMoa012369	http://dx.doi.org/10.1056/NEJMoa012369			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563QC	12075055				2022-12-28	WOS:000176266200003
J	Poynard, T; Munteanu, M; Ratzlu, V; Benhamou, Y; Di Martino, V; Taieb, J; Opolon, P				Poynard, T; Munteanu, M; Ratzlu, V; Benhamou, Y; Di Martino, V; Taieb, J; Opolon, P			Truth survival in clinical research: An evidence-based requiem?	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC HEPATITIS-B; RANDOMIZED CONTROLLED-TRIALS; PRIMARY BILIARY-CIRRHOSIS; EVIDENCE-BASED MEDICINE; ALPHA-INTERFERON; LEUKOCYTE INTERFERON; URSODEOXYCHOLIC-ACID; ALCOHOLIC HEPATITIS; VIRUS-INFECTION; HALF-LIFE	Purpose: Factors associated with the survival of truth of clinical conclusions in the medical literature are unknown. The authors hypothesized that conclusions derived from studies using better methodology should have a longer half-life. Data Sources: MEDLINE and hand searches of journals with studies on cirrhosis and hepatitis. Study Selection: Original articles and meta-analyses published from 1945 to 1999 about cirrhosis or hepatitis In adults. Data Synthesis: In 2000, 285 of 474 conclusions (60%) were still considered to be true, 91 (19%) were considered to be obsolete, and 98 (21%) were considered to be false. The half-life of truth was 45 years. The 20-year survival of conclusions derived from meta-analysis was lower (57% +/- 10%) than that from non-randomized studies (87% +/- 2%) (P < 0.001) or randomized trials (85% +/- 3%) (P < 0.001). The survival of conclusions was not different when studies of high methodologic quality were compared with those of low quality. In randomized trials, the 50-year survival rate was higher for 52 negative conclusions (68% +/- 13%) than for 118 positive conclusions (14% +/- 4%) (P < 0.001). Conclusions: contrary to the authors' hypothesis, conclusions based on recognized, good methodology had no clear survival advantage. To better convince clinicians of the long-term utility of evidence-based medicine, better prognostic factors should be developed.	Grp Hosp Pitie Salpetriere, Serv Hepatogastroenterol, F-75651 Paris 13, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Poynard, T (corresponding author), Grp Hosp Pitie Salpetriere, Serv Hepatogastroenterol, 47-83 Blvd Hop, F-75651 Paris 13, France.	tpoynard@teaser.fr	Poynard, Thierry/C-1355-2010	Poynard, Thierry/0000-0002-3726-7230; Di Martino, Vincent/0000-0002-2022-690X; Poynard, Thierry/0000-0002-2050-640X; Munteanu, Mona/0000-0003-4517-2757				ALEXANDER GJM, 1987, LANCET, V2, P66; Auperin A, 1997, ALIMENT PHARM THER, V11, P215, DOI 10.1046/j.1365-2036.1997.131302000.x; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Bernard B, 1997, HEPATOLOGY, V25, P63, DOI 10.1053/jhep.1997.v25.pm0008985266; Blau JN, 1998, LANCET, V351, P376, DOI 10.1016/S0140-6736(05)78289-1; BRACHOTT D, 1972, TRANSFUSION, V12, P389; BURKE CA, 1986, J HEPATOL, V3, pS261, DOI 10.1016/S0168-8278(86)80130-1; CHRISTENSEN E, 1995, GUT, V37, P113, DOI 10.1136/gut.37.1.113; DESMYTER J, 1976, LANCET, V2, P645; Goulis J, 1999, LANCET, V354, P1053, DOI 10.1016/S0140-6736(98)11293-X; GREENBERG HB, 1976, NEW ENGL J MED, V295, P517, DOI 10.1056/NEJM197609022951001; Hall JC, 1997, LANCET, V350, P1752, DOI 10.1016/S0140-6736(05)63577-5; HOOFNAGLE JH, 1988, GASTROENTEROLOGY, V95, P1318, DOI 10.1016/0016-5085(88)90367-8; Jadad AR, 1998, JAMA-J AM MED ASSOC, V280, P278, DOI 10.1001/jama.280.3.278; Kernick DP, 1998, LANCET, V351, P1824, DOI 10.1016/S0140-6736(05)78797-3; KROGSGAARD K, 1994, J HEPATOL, V21, P646, DOI 10.1016/S0168-8278(94)80114-2; KROHN K, 1970, LANCET, V2, P379; Mathurin P, 2002, J HEPATOL, V36, P480, DOI 10.1016/S0168-8278(01)00289-6; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; Polanyi M., 1964, SCI FAITH SOC; Poupon RE, 1997, GASTROENTEROLOGY, V113, P884, DOI 10.1016/S0016-5085(97)70183-5; POYNARD T, 1985, CONTROL CLIN TRIALS, V6, P271, DOI 10.1016/0197-2456(85)90103-5; POYNARD T, 1988, PRESSE MED, V17, P315; RYFF JC, 1993, J HEPATOL, V17, pS42, DOI 10.1016/S0168-8278(05)80422-2; Sackett DL, 1995, J ROY SOC MED, V88, P620; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; Sacks HS, 1996, MT SINAI J MED, V63, P216; SAMA S, 1973, LANCET, V1, P14; SERRA MA, 1991, MED CLIN-BARCELONA, V97, P681; TINE F, 1993, J HEPATOL, V18, P154, DOI 10.1016/S0168-8278(05)80241-7; WEIMAR W, 1980, LANCET, V1, P336; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011	33	81	83	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 18	2002	136	12					888	895		10.7326/0003-4819-136-12-200206180-00010	http://dx.doi.org/10.7326/0003-4819-136-12-200206180-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563JL	12069563				2022-12-28	WOS:000176252500006
J	DiCenso, A; Guyatt, G; Willan, A; Griffith, L				DiCenso, A; Guyatt, G; Willan, A; Griffith, L			Interventions to reduce unintended pregnancies among adolescents: systematic review of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREVENTION; CHILDBEARING; PROJECT	Objective To review the effectiveness of primary prevention strategies aimed at delaying sexual intercourse, improving use of birth control, and reducing incidence of unintended pregnancy in adolescents. Data sources 12 electronic bibliographic databases, 10 key journals, citations of relevant articles, and contact with authors. Study selection 26 trials described in 22 published and unpublished reports that randomised adolescents to an intervention or a control group (alternate intervention or nothing). Data extraction Two independent reviewers assessed methodological quality and abstracted data. Data synthesis The interventions did not delay initiation of sexual intercourse in young women (pooled odds ratio 1.12; 95% confidence interval 0.96 to 1.30) or young men (0.99; 0.84 to 1.16); did not improve use of birth control by young women at every intercourse (0.95; 0.69 to 1.30) or at last intercourse (1.05; 0.50 to 2.19) or by young men at every intercourse (0.90; 0.70 to 1.16) or at last intercourse (1.25; 0.99 to 1.59); and did not reduce pregnancy rates in young women (1.04; 0.78 to 1.40). Four abstinence programmes and one school based sex education programme were associated with an increase in number of pregnancies among partners of young male participants (1.54; 1.03 to 2.29). There were significantly fewer pregnancies in young women who received a multifaceted programme (0.41, 0.20 to 0.83), though baseline differences in this study favoured the intervention. Conclusions Primary prevention strategies evaluated to date do not delay the initiation of sexual intercourse, improve use of birth control an-long young men and women, or reduce the number of pregnancies in young women.	McMaster Univ, Sch Nursing, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Clin Epidemiol, Hamilton, ON L8N 1G6, Canada; McMaster Univ, Dept Biostat, Hamilton, ON L8N 1G6, Canada	McMaster University; McMaster University; McMaster University	DiCenso, A (corresponding author), McMaster Univ, Sch Nursing, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	dicensoa@mcmaster.ca						*A GUTTM I, 2002, US PREGN RAT TEENS 1; Aarons SJ, 2000, J ADOLESCENT HEALTH, V27, P236, DOI 10.1016/S1054-139X(00)00102-6; Allen JP, 1997, CHILD DEV, V68, P729, DOI 10.2307/1132122; BONHAM GH, 1987, TROUBLE WAY OUT REPO; BOTVIN GJ, 1995, JAMA-J AM MED ASSOC, V273, P1106, DOI 10.1001/jama.273.14.1106; Brown S.S., 1995, BEST INTENTIONS UNIN; BURT MR, 1986, FAM PLANN PERSPECT, V18, P221, DOI 10.2307/2134980; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; DiCenso A, 2001, CAN J PUBLIC HEALTH, V92, P35, DOI 10.1007/BF03404840; DICENSO A, 1999, COMMUNITY NURSING PR; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; GERONIMUS AT, 1992, Q J ECON, V107, P1187, DOI 10.2307/2118385; Guyatt GH, 2000, J CLIN EPIDEMIOL, V53, P167, DOI 10.1016/S0895-4356(99)00160-2; HANDLER AS, 1987, THESIS U ILLINOIS CH; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; KETTING E, 1994, PATIENT EDUC COUNS, V23, P161, DOI 10.1016/0738-3991(94)90032-9; Kirby D, 1997, AIDS EDUC PREV, V9, P44; Moberg DP, 1998, AIDS EDUC PREV, V10, P128; Moore K A, 1993, J Res Adolesc, V3, P393, DOI 10.1207/s15327795jra0304_5; *OFF NAT STAT, 2000, POP TRENDS; *STAT CAN, 1997, CAN PREGN RAT TEENS; STEVENSSIMON C, 1991, PEDIATR ANN, V20, P322, DOI 10.3928/0090-4481-19910601-09; ZORITCH B, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000564	23	251	258	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 15	2002	324	7351					1426	1430		10.1136/bmj.324.7351.1426	http://dx.doi.org/10.1136/bmj.324.7351.1426			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	565CQ	12065267	Green Published, Bronze			2022-12-28	WOS:000176351400019
J	Macian, F; Garcia-Cozar, F; Im, SH; Horton, HF; Byrne, MC; Rao, A				Macian, F; Garcia-Cozar, F; Im, SH; Horton, HF; Byrne, MC; Rao, A			Transcriptional mechanisms underlying lymphocyte tolerance	CELL			English	Article							T-CELL ANERGY; NEGATIVE REGULATION; GENE-EXPRESSION; SELF-TOLERANCE; ACTIVATION; RECEPTOR; PROTEIN; NFAT; CLEAVAGE; IL-2	In lymphocytes, integration of Call and other signaling pathways results in productive activation, while unopposed Call signaling leads to tolerance or anergy. We show that the Ca2+-regulated transcription factor NFAT has an integral role in both aspects of lymphocyte function. Ca2+/calcineurin signaling induces a limited set of anergy-associated genes, distinct from genes induced in the productive immune response; these genes are upregulated in vivo in tolerant T cells and are largely NFAT dependent. T cells lacking NFAT1 are resistant to anergy induction; conversely, NFAT1 induces T cell anergy if prevented from interacting with its transcriptional partner AP-1 (Fos/Jun). Thus, in the absence of AP-1, NFAT imposes a genetic program of lymphocyte anergy that counters the program of productive activation mediated by the cooperative NFAT:AP-1 complex.	Harvard Univ, Sch Med, Ctr Blood Res, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Rao, A (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.	arao@cbr.med.harvard.edu	Garcia-Cozar, Francisco/A-6212-2013; Im, Sin-Hyeog/E-6811-2013; Im, Sin-Hyeog/AAM-9586-2021	Garcia-Cozar, Francisco/0000-0003-3720-259X; Im, Sin-Hyeog/0000-0002-3173-1856; Im, Sin-Hyeog/0000-0002-3173-1856; Macian, Fernando/0000-0003-2666-035X	NCI NIH HHS [CA42471] Funding Source: Medline; NIAID NIH HHS [AI48213] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042471, R37CA042471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048213] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Buer J, 1998, J EXP MED, V187, P177, DOI 10.1084/jem.187.2.177; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; Garside P, 2001, SEMIN IMMUNOL, V13, P177, DOI 10.1006/smim.2001.0310; Gastman BR, 1999, CANCER RES, V59, P1422; Glynne R, 2000, NATURE, V403, P672, DOI 10.1038/35001102; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Harhaj EW, 1998, J BIOL CHEM, V273, P25185, DOI 10.1074/jbc.273.39.25185; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; Hofmann TG, 2000, ONCOGENE, V19, P1153, DOI 10.1038/sj.onc.1203406; JAIN JN, 1993, J IMMUNOL, V151, P837; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamradt T, 2001, NEW ENGL J MED, V344, P655, DOI 10.1056/NEJM200103013440907; Kane LP, 2001, NAT IMMUNOL, V2, P37, DOI 10.1038/83144; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; Lanoue A, 1997, J EXP MED, V185, P405, DOI 10.1084/jem.185.3.405; Lechner O, 2001, CURR BIOL, V11, P587, DOI 10.1016/S0960-9822(01)00160-9; Li LW, 2000, SEMIN IMMUNOL, V12, P75, DOI 10.1006/smim.2000.0209; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; Li XC, 2000, CURR OPIN IMMUNOL, V12, P522, DOI 10.1016/S0952-7915(00)00133-3; Li YS, 1998, TRANSPLANTATION, V66, P1387, DOI 10.1097/00007890-199811270-00021; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Rabinowitz JD, 1996, IMMUNITY, V5, P125, DOI 10.1016/S1074-7613(00)80489-6; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Sabbattini P, 2001, EMBO J, V20, P2812, DOI 10.1093/emboj/20.11.2812; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SloanLancaster J, 1996, J EXP MED, V184, P1525, DOI 10.1084/jem.184.4.1525; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Suga K, 2001, FEBS LETT, V489, P249, DOI 10.1016/S0014-5793(00)02222-5; Teague TK, 1999, P NATL ACAD SCI USA, V96, P12691, DOI 10.1073/pnas.96.22.12691; Telander DG, 1999, J IMMUNOL, V162, P1460; Toyoda M, 2000, BIOCHEM BIOPH RES CO, V274, P332, DOI 10.1006/bbrc.2000.3138; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; Yankee TM, 2001, P NATL ACAD SCI USA, V98, P6789, DOI 10.1073/pnas.111158598	61	528	561	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	2002	109	6					719	731		10.1016/S0092-8674(02)00767-5	http://dx.doi.org/10.1016/S0092-8674(02)00767-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	563PW	12086671	Bronze			2022-12-28	WOS:000176265600003
J	Aluwihare, A; Cohen-Tannoudji, C; Erzan, A; Jacob, F; Polanyi, J; van Dijk, P; Vesentini, E; Wiesel, T				Aluwihare, A; Cohen-Tannoudji, C; Erzan, A; Jacob, F; Polanyi, J; van Dijk, P; Vesentini, E; Wiesel, T			In support of scientific exchange	NATURE			English	Letter									Acad & Scholarly Soc, Int Human Rights Network, Washington, DC 20001 USA		Aluwihare, A (corresponding author), Acad & Scholarly Soc, Int Human Rights Network, 500 5th St NW,Suite 5-530, Washington, DC 20001 USA.							2002, NATURE, V417, P221	1	0	0	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 13	2002	417	6890					690	690		10.1038/417690c	http://dx.doi.org/10.1038/417690c			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	561QY	12066157	Bronze			2022-12-28	WOS:000176154700019
J	Steinbrook, R				Steinbrook, R			Perspective - Preventing HIV infection in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	8	8	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	2002	346	24					1842	1843		10.1056/NEJMp020046	http://dx.doi.org/10.1056/NEJMp020046			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	561NA	12063367				2022-12-28	WOS:000176146100001
J	Merrell, DS; Butler, SM; Qadri, F; Dolganov, NA; Alam, A; Cohen, MB; Calderwood, SB; Schoolnik, GK; Camilli, A				Merrell, DS; Butler, SM; Qadri, F; Dolganov, NA; Alam, A; Cohen, MB; Calderwood, SB; Schoolnik, GK; Camilli, A			Host-induced epidemic spread of the cholera bacterium	NATURE			English	Article							VIBRIO-CHOLERAE; GENE-EXPRESSION; DNA MICROARRAY; TOXR REGULON; VIRULENCE; INFECTION; MOTILITY	The factors that enhance the transmission of pathogens during epidemic spread are ill defined. Water-borne spread of the diarrhoeal disease cholera occurs rapidly in nature, whereas infection of human volunteers with bacteria grown in vitro is difficult in the absence of stomach acid buffering(1). It is unclear, however, whether stomach acidity is a principal factor contributing to epidemic spread(2). Here we report that characterization of Vibrio cholerae from human stools supports a model whereby human colonization creates a hyperinfectious bacterial state that is maintained after dissemination and that may contribute to epidemic spread of cholera. Transcriptional profiling of V. cholerae from stool samples revealed a unique physiological and behavioural state characterized by high expression levels of genes required for nutrient acquisition and motility, and low expression levels of genes required for bacterial chemotaxis.	Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Int Ctr Diarrhoeal Dis Res, Dhaka 1212, Bangladesh; Stanford Univ, Sch Med, Beckman Ctr, Stanford, CA 94305 USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Tufts University; International Centre for Diarrhoeal Disease Research (ICDDR); Stanford University; Cincinnati Children's Hospital Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Camilli, A (corresponding author), Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA.	Andrew.Camilli@Tufts.edu	Al, Mamun M./AAF-5850-2019; Qadri, Firdausi/AAF-4583-2019	Cohen, Mitchell/0000-0002-4412-350X	Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R01 AI045746-02, R01 AI045746] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045746] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Camilli A, 1995, MOL MICROBIOL, V18, P671, DOI 10.1111/j.1365-2958.1995.mmi_18040671.x; Carroll PA, 1997, MOL MICROBIOL, V25, P1099, DOI 10.1046/j.1365-2958.1997.5371901.x; CASH RA, 1974, J INFECT DIS, V129, P45, DOI 10.1093/infdis/129.1.45; DIRITA VJ, 1991, P NATL ACAD SCI USA, V88, P5403, DOI 10.1073/pnas.88.12.5403; FRETER R, 1961, J INFECT DIS, V109, P35, DOI 10.1093/infdis/109.1.35; Gardel CL, 1996, INFECT IMMUN, V64, P2246, DOI 10.1128/IAI.64.6.2246-2255.1996; GITELSON S, 1971, ISRAEL J MED SCI, V7, P663; Hase CC, 1998, P NATL ACAD SCI USA, V95, P730, DOI 10.1073/pnas.95.2.730; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; HERRINGTON DA, 1988, J EXP MED, V168, P1487, DOI 10.1084/jem.168.4.1487; Lee SH, 2001, P NATL ACAD SCI USA, V98, P6889, DOI 10.1073/pnas.111581598; Merrell DS, 1999, MOL MICROBIOL, V34, P836, DOI 10.1046/j.1365-2958.1999.01650.x; Merrell DS, 2002, MOL MICROBIOL, V43, P1471, DOI 10.1046/j.1365-2958.2002.02857.x; MILLER VL, 1984, P NATL ACAD SCI-BIOL, V81, P3471, DOI 10.1073/pnas.81.11.3471; RICHARDSON K, 1991, INFECT IMMUN, V59, P2727, DOI 10.1128/IAI.59.8.2727-2736.1991; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schoolnik GK, 2001, METHOD ENZYMOL, V336, P3, DOI 10.1016/S0076-6879(01)36573-4; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498	18	368	397	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 6	2002	417	6889					642	645		10.1038/nature00778	http://dx.doi.org/10.1038/nature00778			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050664	Green Accepted, Bronze			2022-12-28	WOS:000176001200046
J	Patrinos, A; Drell, D				Patrinos, A; Drell, D			The times they are a-changin'	NATURE			English	Editorial Material							DRAFT SEQUENCE		US DOE, Off Biol & Environm Res, Off Sci, Germantown, MD 20874 USA	United States Department of Energy (DOE)	Patrinos, A (corresponding author), US DOE, Off Biol & Environm Res, Off Sci, 19901 Germantown Rd, Germantown, MD 20874 USA.			Drell, Daniel/0000-0001-8756-5837				Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Marshall E, 2002, SCIENCE, V295, P1625, DOI 10.1126/science.295.5560.1625; Petsko GA, 2002, GENOME BIOL, V3; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037	6	8	8	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 6	2002	417	6889					589	590		10.1038/417589a	http://dx.doi.org/10.1038/417589a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050635				2022-12-28	WOS:000176001200021
J	Morris, MC; Evans, DA; Bienias, JL; Tangney, CC; Bennett, DA; Aggarwal, N; Wilson, RS; Scherr, PA				Morris, MC; Evans, DA; Bienias, JL; Tangney, CC; Bennett, DA; Aggarwal, N; Wilson, RS; Scherr, PA			Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease on a biracial community study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUCED OXIDATIVE STRESS; E PREVENTS APOPTOSIS; C SUPPLEMENT USE; VITAMIN-E; LIPID-PEROXIDATION; ALPHA-TOCOPHEROL; RAT-BRAIN; COGNITIVE FUNCTION; CORTICAL-NEURONS; APOLIPOPROTEIN-E	Context Oxidative processes have been suggested as elements in the development of Alzheimer disease (AD), but whether dietary intake of vitamin E and other antioxidant nutrients prevents its development is unknown. Objective To examine whether intake of antioxidant nutrients, vitamin E, vitamin C, and beta carotene is associated with incident AD. Design, Setting, and Participants Prospective study, conducted from 1993 to 2000, of individuals selected in a stratified random sample of community-dwelling residents. The 815 residents 65 years and older were free of AD at baseline and were followed up for a mean of 3.9 years. They completed food frequency questionnaires an average of 1.7 years after baseline. Main Outcome Measure Incident AD diagnosed in clinical evaluations with standardized criteria. Results Increasing vitamin E intake from foods was associated with decreased risk of developing AD after adjustment for age, education, sex, race, APOE epsilon4, and length of follow-up. Relative risks (95% confidence intervals [CIs]) from lowest to highest quintiles of intake were 1.00, 0.71 (0.24-2.07), 0.62 (0.26-1.45), 0.71 (0.27-1.88), and 0.30 (0.10-0.92) (P for trend =.05). The protective association of vitamin E was observed only among persons who were APOE epsilon4 negative, Adjustment for other dietary factors reduced the protective association. After adjustment for baseline memory score, the risk was 0.36 (95% CI, 0.11-1.17). Intake of vitamin C, beta carotene, and vitamin E from supplements was not significantly associated with risk of AD. Conclusion This study suggests that vitamin E from food, but not other antioxidants, may be associated with a reduced risk of AD. Unexpectedly, this association was observed only among individuals without the APOE epsilon4 allele.	Rush Presbyterian St Lukes Med Ctr, Rush Inst Hlth Aging, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Internal Med, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Prevent Med, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Clin Nutr, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Psychol, Chicago, IL 60612 USA	Rush University; Rush University; Rush University; Rush University; Rush University; Rush University; Rush University	Morris, MC (corresponding author), Rush Presbyterian St Lukes Med Ctr, Rush Inst Hlth Aging, 1645 W Jackson,Suite 675, Chicago, IL 60612 USA.	mmorris@rush.edu			NIA NIH HHS [AG13170, AG11101] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011101, R01AG013170] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahlemeyer B, 2000, NEUROCHEM INT, V36, P1, DOI 10.1016/S0197-0186(99)00101-1; ALBERT M, 1991, INT J NEUROSCI, V57, P167, DOI 10.3109/00207459109150691; Bagchi D, 1998, GEN PHARMACOL, V30, P771, DOI 10.1016/S0306-3623(97)00332-7; BERTONIFREDDARI C, 1995, SCANNING MICROSCOPY, V9, P289; BIENIAS JL, 2001, P 14 ANN M NE SAS US; Cardoso SM, 1998, BIOCHEM BIOPH RES CO, V246, P703, DOI 10.1006/bbrc.1998.8563; Christen Y, 2000, AM J CLIN NUTR, V71, p621S, DOI 10.1093/ajcn/71.2.621s; El-Fattah AAA, 1998, BIOCHEM MOL BIOL INT, V46, P1175; Escames G, 1997, NEUROSCI LETT, V230, P147, DOI 10.1016/S0304-3940(97)00498-9; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Giray B, 2001, TOXICOL LETT, V118, P139, DOI 10.1016/S0378-4274(00)00277-0; Guerrero AL, 1999, NEUROREPORT, V10, P1689, DOI 10.1097/00001756-199906030-00012; HIXSON JE, 1990, J LIPID RES, V31, P545; Huang HM, 2000, LIFE SCI, V66, P1879, DOI 10.1016/S0024-3205(00)00511-7; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; LEE ES, 1989, ANAL COMPLEX SURVEY; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Masaki KH, 2000, NEUROLOGY, V54, P1265, DOI 10.1212/WNL.54.6.1265; Mason RP, 1999, J NEUROCHEM, V72, P1448, DOI 10.1046/j.1471-4159.1999.721448.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; Morris MC, 1998, ANN EPIDEMIOL, V8, P342, DOI 10.1016/S1047-2797(97)00236-6; Morris MC, 1998, ALZ DIS ASSOC DIS, V12, P121, DOI 10.1097/00002093-199809000-00001; Morris MC, 2000, J GERONTOL A-BIOL, V55, pM130, DOI 10.1093/gerona/55.3.M130; MORRIS MC, IN PRESS ARCH NEUROL; O'Donnell E, 1998, NEUROBIOL AGING, V19, P461, DOI 10.1016/S0197-4580(98)00082-7; Post A, 1998, J NEUROSCI, V18, P8236; Rockett HRH, 1997, PREV MED, V26, P808, DOI 10.1006/pmed.1997.0200; Rose G, 1982, CARDIOVASCULAR SURVE; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; SCHERR PA, 1988, AM J EPIDEMIOL, V128, P1084; Sen CK, 2000, J BIOL CHEM, V275, P13049, DOI 10.1074/jbc.275.17.13049; Smith A., 1984, SYMBOL DIGIT MODALIT; Sopher BL, 1996, MOL CHEM NEUROPATHOL, V29, P153, DOI 10.1007/BF02814999; Subramaniam R, 1998, NEUROCHEM RES, V23, P1403, DOI 10.1023/A:1020754807671; Tagami M, 1998, LAB INVEST, V78, P1415; Tagami M, 1999, LAB INVEST, V79, P609; Urano S, 1997, EUR J BIOCHEM, V245, P64, DOI 10.1111/j.1432-1033.1997.00064.x; Willett W.C., 1998, SAUPTIKAPARVAN MAHAB, DOI [10.1093/acprof:oso/9780195122978.001.0001, DOI 10.1093/ACPROF:OSO/9780195122978.001.0001, DOI 10.1093/ACPROF:OSO/9780195122978.003.11]; Wilson RS, 1999, J GERONTOL B-PSYCHOL, V54, pP155, DOI 10.1093/geronb/54B.3.P155; Yallampalli S, 1998, NEUROSCI LETT, V251, P105, DOI 10.1016/S0304-3940(98)00515-1; Zhang P, 2000, TOXICOLOGY, V146, P37, DOI 10.1016/S0300-483X(00)00160-8	42	498	529	1	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	2002	287	24					3230	3237		10.1001/jama.287.24.3230	http://dx.doi.org/10.1001/jama.287.24.3230			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566FF	12076219				2022-12-28	WOS:000176415800027
J	Wolfe, RM; Sharp, LK; Lipsky, MS				Wolfe, RM; Sharp, LK; Lipsky, MS			Content and design attributes of antivaccination Web sites	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERTUSSIS VACCINATION; RUBELLA VACCINE; MEASLES; IMMUNIZATION; CHILDREN; AUTISM; ASTHMA; ASSOCIATION; EXEMPTIONS; CHILDHOOD	Context Individuals searching the Internet for vaccine information may find anti-vaccination Web sites. Few published studies have systematically evaluated these sites. Objectives To examine antivaccination Web site attributes and to delineate the specific claims and concerns expressed by antivaccination groups. Design and Setting In late 2000, using a metasearch program that incorporates 10 other search engines, we reviewed and analyzed 772 links to find 12 Web sites that promulgated antivaccination information. Analyzing links from these 12 sites yielded another 10 sites, producing a total of 22 sites for study. Using a standardized form, 2 authors (R.M.W., L.K.S.) systematically evaluated these sites based on specific content and design attributes. Main Outcome Measures Presence or absence of 11 Web site content attributes (antivaccination claims) and 10 Web site design attributes. Results The most commonly found content claims were that vaccines cause idiopathic illness (100% of sites), vaccines erode immunity (95%), adverse vaccine reactions are underreported (95%), and vaccination policy is motivated by profit (91%). The most common design attributes were the presence of links to other antivaccination sites (100% of sites), information for legally avoiding immunizations (64%), and the use of emotionally charged stories of children who had allegedly been killed or harmed by vaccines (55%). Conclusion Antivaccination Web sites express a range of concerns related to vaccine safety and varying levels of distrust in medicine. The sites rely heavily on emotional appeal to convey their message.	Northwestern Univ, Feinberg Sch Med, Dept Family Med, Chicago, IL 60611 USA; Evanston NW Healthcare, Evanston, IL USA	Northwestern University; Feinberg School of Medicine; NorthShore University Health System	Wolfe, RM (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Family Med, 710 N Lake Shore Dr,Room 1417, Chicago, IL 60611 USA.	r-wolfe@northwestern.edu	Lipsky, Martin/L-6382-2019	Wolfe, Robert/0000-0003-1005-7660; Sharp, Lisa/0000-0002-7809-9042				Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; *AM MED ASS, RES INF DIS AUG 3 19; CDC (U.S. Centers for Disease Control and Prevention), 1999, MMWR-MORBID MORTAL W, V48, P243; Feikin DR, 2000, JAMA-J AM MED ASSOC, V284, P3145, DOI 10.1001/jama.284.24.3145; Friedlander ER, 2001, SCI REV ALT MED, V5, P18; Gellin BG, 2000, PEDIATRICS, V106, P1097, DOI 10.1542/peds.106.5.1097; Gerber MA, 2001, PEDIATRICS, V107, P612, DOI 10.1542/peds.107.5.e84; GOLDING J, 1986, BIRTH 5 STUDY HLTH B, P295; Greenberg SB, 2000, SOUTHERN MED J, V93, P763; Henderson J, 1999, BRIT MED J, V318, P1173, DOI 10.1136/bmj.318.7192.1173; *I MED IMM SAF REV, 2001, MEASL MUMPS RUB VACC; Kaye JA, 2001, BRIT MED J, V322, P460, DOI 10.1136/bmj.322.7284.460; Kemp T, 1997, EPIDEMIOLOGY, V8, P678, DOI 10.1097/00001648-199710000-00011; Kim P, 1999, BMJ-BRIT MED J, V318, P647, DOI 10.1136/bmj.318.7184.647; Leask JA, 1998, AUST NZ J PUBL HEAL, V22, P17, DOI 10.1111/j.1467-842X.1998.tb01140.x; *MED EC, 2002, PHYS DESK REF; Montgomery SM, 1999, GASTROENTEROLOGY, V116, P796, DOI 10.1016/S0016-5085(99)70062-4; *NAT VACC INF CTR, 2000, PAR RES CALL ACT END; Nilsson L, 1996, JAMA-J AM MED ASSOC, V275, P760, DOI 10.1001/jama.275.10.760; ODENT MR, 1994, JAMA-J AM MED ASSOC, V272, P592, DOI 10.1001/jama.1994.03520080034035; Pew Internet & American Life Project, 2000, ONL HLTH CAR REV WEB; Poland GA, 2000, MAYO CLIN PROC, V75, P135; Salmon DA, 1999, JAMA-J AM MED ASSOC, V282, P47, DOI 10.1001/jama.282.1.47; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Taylor B, 1999, LANCET, V353, P2026, DOI 10.1016/S0140-6736(99)01239-8; TAYLOR H, 2002, HARRIS POLL, V18; TAYLOR H, 2002, HARRIS POLL, V21; *US CDCP, 6 COMM MISC VACC RES; Vastag B, 2001, JAMA-J AM MED ASSOC, V285, P2567, DOI 10.1001/jama.285.20.2567; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; WOLFE RM, IN PRESS BMJ	31	196	200	0	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	2002	287	24					3245	3248		10.1001/jama.287.24.3245	http://dx.doi.org/10.1001/jama.287.24.3245			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566FF	12076221	Bronze			2022-12-28	WOS:000176415800029
J	Lockwood, DNJ				Lockwood, DNJ			Leprosy elimination - a virtual phenomenon or a reality?	BRITISH MEDICAL JOURNAL			English	Article									Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Lockwood, DNJ (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.							Croft RP, 2000, LEPROSY REV, V71, P154; Fine PEM, 1997, LEPROSY REV, V68, P201; Girdhar BK, 2000, LEPROSY REV, V71, P144; KLATSER PR, 1993, J CLIN MICROBIOL, V31, P2947, DOI 10.1128/JCM.31.11.2947-2951.1993; Lockwood DNJ, 2000, LEPROSY REV, V71, pS111; Noordeen S, 1994, LEPROSY, P68; Saunderson P, 2000, LEPROSY REV, V71, P285; *WHO, 2002, REP 3 M WHO TECHN AD; *WHO, 2002, FIN PUSH STRAT EL LE; WHO Expert Committee on Leprosy, 1998, WHO TECH REP SER, V874, P20; *WORLD HLTH ASS, 1991, FLUM LEPR RES 44TH W; 2000, WKLY EPIDEMIOL REC, V75, P225; 1998, WKLY EPIDEMIOL REC, V73, P40; 2002, IN PRESS LEP REV; 2002, WKLY EPIDEMIOL REC, V77, P1	15	70	77	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 22	2002	324	7352					1516	1518		10.1136/bmj.324.7352.1516	http://dx.doi.org/10.1136/bmj.324.7352.1516			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567ZL	12077045	Green Accepted, Green Published			2022-12-28	WOS:000176517900030
J	Croll, DA; Clark, CW; Acevedo, A; Tershy, B; Flores, S; Gedamke, J; Urban, J				Croll, DA; Clark, CW; Acevedo, A; Tershy, B; Flores, S; Gedamke, J; Urban, J			Bioacoustics: Only male fin whales sing loud songs - These mammals need to call long-distance when it comes to attracting females.	NATURE			English	Editorial Material							BLUE		Univ Calif Santa Cruz, Ctr Ocean Hlth, Dept Ecol & Evolutionary Biol, Santa Cruz, CA 95060 USA; Cornell Lab Ornithol, Bioacoust Res Program, Ithaca, NY 14850 USA; Calif Acad Sci, San Francisco, CA 94118 USA; Univ Autonoma Baja Calif Sur, La Paz, BCS, Mexico	University of California System; University of California Santa Cruz; Cornell University; California Academy of Sciences; Universidad Autonoma de Baja California	Croll, DA (corresponding author), Univ Calif Santa Cruz, Ctr Ocean Hlth, Dept Ecol & Evolutionary Biol, Santa Cruz, CA 95060 USA.	croll@biology.ucsc.edu	R., Jorge Urbán/J-8126-2019	R., Jorge Urbán/0000-0003-1423-8573; Acevedo-Gutierrez, Alejandro/0000-0002-9128-826X				Andrew R. K., 2002, Acoustics Research Letters Online, V3, P65, DOI 10.1121/1.1461915; Aroyan JL, 2000, SPR HDB AUD, V12, P409; Berube M, 1996, MOL ECOL, V5, P283; Charif RA, 2002, MAR MAMMAL SCI, V18, P81, DOI 10.1111/j.1748-7692.2002.tb01020.x; Clapham PJ, 1996, MAMMAL REV, V26, P27, DOI 10.1111/j.1365-2907.1996.tb00145.x; CLARK CW, IN PRESS ECHOLOCATIO; Croll DA, 2001, COMP BIOCHEM PHYS A, V129, P797, DOI 10.1016/S1095-6433(01)00348-8; PAYNE R, 1971, ANN NY ACAD SCI, V188, P110, DOI 10.1111/j.1749-6632.1971.tb13093.x; Popper Arthur N., 1997, Bioacoustics, V8, P163; Richardson WJ, 1995, MARINE MAMMALS NOISE, V1st; SCHEVILL WE, 1964, MARINE BIOACOUSTICS, P147; Thode AM, 2000, J ACOUST SOC AM, V107, P1286, DOI 10.1121/1.428417; WATKINS WA, 1987, J ACOUST SOC AM, V82, P1901, DOI 10.1121/1.395685	13	161	171	1	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 20	2002	417	6891					809	809		10.1038/417809a	http://dx.doi.org/10.1038/417809a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075339				2022-12-28	WOS:000176285600034
J	Davis, ME				Davis, ME			Ordered porous materials for emerging applications	NATURE			English	Review							MOLECULAR-SIEVE CRYSTALS; ZEOLITE COMPOSITE MEMBRANES; MESOPOROUS SILICA FILMS; MFI MEMBRANES; THIN-FILMS; ELECTRON-MICROSCOPY; METAL-COMPLEXES; PORE STRUCTURES; CARBON; FRAMEWORK	"Space-the final frontier." This preamble to a well-known television series captures the challenge encountered not only in space travel adventures, but also in the field of porous materials, which aims to control the size, shape and uniformity of the porous space and the atoms and molecules that define it. The past decade has seen significant advances in the ability to fabricate new porous solids with ordered structures from a wide range of different materials. This has resulted in materials with unusual properties and broadened their application range beyond the traditional use as catalysts and adsorbents. In fact, porous materials now seem set to contribute to developments in areas ranging from microelectronics to medical diagnosis.	CALTECH, Pasadena, CA 91125 USA	California Institute of Technology	Davis, ME (corresponding author), CALTECH, Pasadena, CA 91125 USA.	mdavis@cheme.caltech.edu						Anderson MW, 2000, ANGEW CHEM INT EDIT, V39, P2707, DOI 10.1002/1521-3773(20000804)39:15<2707::AID-ANIE2707>3.0.CO;2-M; ANNEN MJ, 1991, MATER RES SOC SYMP P, V233, P245, DOI 10.1557/PROC-233-245; ANNEN MJ, 1993, MICROPOROUS MATER, V1, P57, DOI 10.1016/0927-6513(93)80008-I; Attard GS, 2001, CHEM MATER, V13, P1444, DOI 10.1021/cm000850d; Balkus Jr K. J., 1991, MAT RES SOC S SER P, V223, P225; Balkus K.J., 1992, U.S.Patent, V5, P122, Patent No. 5122363; Balkus KJ, 1996, LANGMUIR, V12, P6277, DOI 10.1021/la9605100; Balkus KJ, 1996, J PHYS CHEM-US, V100, P16429, DOI 10.1021/jp961478l; Balkus KJ, 1998, CHEM MATER, V10, P464, DOI 10.1021/cm970684i; Baskaran S, 2000, ADV MATER, V12, P291, DOI 10.1002/(SICI)1521-4095(200002)12:4<291::AID-ADMA291>3.0.CO;2-P; Bein T, 1996, CHEM MATER, V8, P1636, DOI 10.1021/cm960148a; Boudreau LC, 1997, CHEM MATER, V9, P1705, DOI 10.1021/cm970151+; Bruinsma PJ, 1997, CHEM MATER, V9, P2507, DOI 10.1021/cm970282a; BRUNNER GO, 1989, NATURE, V337, P146, DOI 10.1038/337146a0; Bull I, 2000, J AM CHEM SOC, V122, P7128, DOI 10.1021/ja000885e; CACHERIS WP, 1990, MAGN RESON IMAGING, V8, P467, DOI 10.1016/0730-725X(90)90055-7; CARO J, 1992, ADV MATER, V4, P273, DOI 10.1002/adma.19920040405; Cheetham AK, 2001, STUD SURF SCI CATAL, V135; Chen BL, 2001, SCIENCE, V291, P1021, DOI 10.1126/science.1056598; CHEN CY, 1993, MICROPOROUS MATER, V2, P17, DOI 10.1016/0927-6513(93)80058-3; CHEN CY, 1995, MICROPOROUS MATER, V4, P1, DOI 10.1016/0927-6513(94)00077-9; Chiola V., 1971, US Pat., Patent No. 3556725; Corma A, 2001, NATURE, V412, P423, DOI 10.1038/35086546; Corma A, 1997, CHEM REV, V97, P2373, DOI 10.1021/cr960406n; Dagani R, 2000, CHEM ENG NEWS, V78, P9; DAVIS ME, 1992, CHEM MATER, V4, P756, DOI 10.1021/cm00022a005; DAVIS ME, 1988, NATURE, V331, P698, DOI 10.1038/331698a0; DAVIS ME, 1989, J AM CHEM SOC, V111, P3919, DOI 10.1021/ja00193a024; DAVIS ME, 1994, MATER RES SOC SYMP P, V346, P831, DOI 10.1557/PROC-346-831; DAVIS ME, 1989, NATURE, V337, P117, DOI 10.1038/337117a0; DAVIS ME, 2001, STUD SURF SCI CATAL, V135, P29; DEMAN AJM, 1992, ZEOLITES, V12, P789, DOI 10.1016/0144-2449(92)90051-P; DESSAU RM, 1990, ZEOLITES, V10, P522, DOI 10.1016/S0144-2449(05)80306-9; DiRenzo F, 1997, MICROPOROUS MATER, V10, P283, DOI 10.1016/S0927-6513(97)00028-X; Doshi DA, 2000, SCIENCE, V290, P107, DOI 10.1126/science.290.5489.107; Eddaoudi M, 2002, SCIENCE, V295, P469, DOI 10.1126/science.1067208; ENZEL P, 1992, CHEM MATER, V4, P819, DOI 10.1021/cm00022a014; ESTERMANN M, 1991, NATURE, V352, P320, DOI 10.1038/352320a0; Fan HY, 2000, NATURE, V405, P56, DOI 10.1038/35011026; FENG S, 1994, SCIENCE, V265, P1839, DOI 10.1126/science.265.5180.1839; FENG S, 1994, NATURE, V368, P834, DOI 10.1038/368834a0; GEUS ER, 1993, MICROPOROUS MATER, V1, P131, DOI 10.1016/0927-6513(93)80019-Q; Grun M, 1996, J CHROMATOGR A, V740, P1, DOI 10.1016/0021-9673(96)00205-1; HAAG WO, 1991, Patent No. 5019263; Hillhouse HW, 1997, CHEM MATER, V9, P1505, DOI 10.1021/cm970140g; HOSKINS BF, 1990, J AM CHEM SOC, V112, P1546, DOI 10.1021/ja00160a038; Huang LM, 2000, J AM CHEM SOC, V122, P3530, DOI 10.1021/ja994240u; HUO QH, 1992, J CHEM SOC CHEM COMM, P875, DOI 10.1039/c39920000875; HUO QS, 1994, NATURE, V368, P317, DOI 10.1038/368317a0; Ihlein G, 1998, ADV MATER, V10, P1117, DOI 10.1002/(SICI)1521-4095(199810)10:14<1117::AID-ADMA1117>3.0.CO;2-W; Inagaki S, 2002, NATURE, V416, P304, DOI 10.1038/416304a; INAGAKI S, 1993, J CHEM SOC CHEM COMM, P680, DOI 10.1039/c39930000680; Inagaki S, 1999, J AM CHEM SOC, V121, P9611, DOI 10.1021/ja9916658; JIA MD, 1993, J MEMBRANE SCI, V82, P15, DOI 10.1016/0376-7388(93)85089-F; JIA MD, 1994, J MEMBRANE SCI, V90, P1, DOI 10.1016/0376-7388(94)80029-4; Johnson SA, 1997, CHEM MATER, V9, P2448, DOI 10.1021/cm9703278; Jones CW, 1998, NATURE, V393, P52, DOI 10.1038/29959; Joo SH, 2001, NATURE, V412, P169, DOI 10.1038/35084046; Katovic A, 2001, MICROPOR MESOPOR MAT, V44, P275, DOI 10.1016/S1387-1811(01)00193-7; Kepert CJ, 2000, J AM CHEM SOC, V122, P5158, DOI 10.1021/ja993814s; Kimura T, 2000, ANGEW CHEM INT EDIT, V39, P3855, DOI 10.1002/1521-3773(20001103)39:21<3855::AID-ANIE3855>3.0.CO;2-M; KINOSHITA Y, 1959, B CHEM SOC JPN, V32, P1221, DOI 10.1246/bcsj.32.1221; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Kruk M, 2000, J PHYS CHEM B, V104, P7960, DOI 10.1021/jp000861u; Kuznicki SM, 2001, NATURE, V412, P720, DOI 10.1038/35089052; Kyotani T, 1997, CHEM MATER, V9, P609, DOI 10.1021/cm960430h; Landry CC, 2001, CHEM MATER, V13, P1600, DOI 10.1021/cm000373z; LAUFFER RB, 1987, CHEM REV, V87, P901, DOI 10.1021/cr00081a003; Lee J, 1999, CHEM COMMUN, P2177, DOI 10.1039/a906872d; LEONOWICZ ME, 1994, SCIENCE, V264, P1910, DOI 10.1126/science.264.5167.1910; Li H, 1999, NATURE, V402, P276, DOI 10.1038/46248; LI HX, 1994, CATAL TODAY, V19, P61, DOI 10.1016/0920-5861(94)85004-6; LIU J, 2001, Patent No. 6329017; Lobo RF, 1997, J AM CHEM SOC, V119, P8474, DOI 10.1021/ja9708528; LOISEAU T, 1994, J SOLID STATE CHEM, V111, P403, DOI 10.1006/jssc.1994.1246; Loiseau T, 1996, MAT RES S C, V431, P27, DOI 10.1557/PROC-431-27; Lovallo MC, 1996, AICHE J, V42, P3020, DOI 10.1002/aic.690421104; Lu YF, 2000, J AM CHEM SOC, V122, P5258, DOI 10.1021/ja9935862; Ma ZX, 2001, CHEM MATER, V13, P4413, DOI 10.1021/crm0107301; MANTON MRS, 1979, J CATAL, V60, P156, DOI 10.1016/0021-9517(79)90078-2; MATSUKATA M, 1994, J CHEM SOC CHEM COMM, P339, DOI 10.1039/c39940000339; McCoy M, 2000, CHEM ENG NEWS, V78, P13, DOI 10.1021/cen-v078n042.p013; McCusker LB, 1996, MICROPOROUS MATER, V6, P295, DOI 10.1016/0927-6513(96)00015-6; Meier W.M., 1986, STUDIES SURFACE SCI, P13; Miller RD, 1999, SCIENCE, V286, P421, DOI 10.1126/science.286.5439.421; Mintova S, 2001, CHEM MATER, V13, P901, DOI 10.1021/cm000671w; NAVROTSKY A, 1995, MICROPOROUS MATER, V4, P95, DOI 10.1016/0927-6513(94)00082-7; Okubo T, 2001, ANGEW CHEM INT EDIT, V40, P1069, DOI 10.1002/1521-3773(20010316)40:6<1069::AID-ANIE10690>3.0.CO;2-W; Rhodes KH, 2000, CHEM MATER, V12, P2832, DOI 10.1021/cm000438y; ROHRIG C, 1995, ANGEW CHEM INT EDIT, V34, P63, DOI 10.1002/anie.199500631; Ryoo R, 1999, J PHYS CHEM B, V103, P7743, DOI 10.1021/jp991673a; Sakamoto Y, 1998, MICROPOR MESOPOR MAT, V21, P589, DOI 10.1016/S1387-1811(98)00053-5; Scandella L, 1996, ADV MATER, V8, P137, DOI 10.1002/adma.19960080206; Schacht S, 1996, SCIENCE, V273, P768, DOI 10.1126/science.273.5276.768; SCHREYECK L, 1995, J CHEM SOC CHEM COMM, P2187, DOI 10.1039/c39950002187; Seki K, 2001, CHEM COMMUN, P1496, DOI 10.1039/b104204c; Seo JS, 2000, NATURE, V404, P982, DOI 10.1038/35010088; Shimizu S, 2000, ADV MATER, V12, P1332, DOI 10.1002/1521-4095(200009)12:18<1332::AID-ADMA1332>3.0.CO;2-Y; SIERRA L, 2001, STUD SURF SCI CATAL, V135; Stein A, 2001, MICROPOR MESOPOR MAT, V44, P227, DOI 10.1016/S1387-1811(01)00189-5; STUCKY GD, 1990, SCIENCE, V247, P669, DOI 10.1126/science.247.4943.669; SUN JT, 1995, MATER RES SOC SYMP P, V360, P359; SUZUKI H, 1987, Patent No. 4699892; Tang ZK, 2001, SCIENCE, V292, P2462, DOI 10.1126/science.1060470; Thoelen C, 1999, CHEM COMMUN, P1841, DOI 10.1039/a904487f; Tolbert SH, 1997, SCIENCE, V278, P264, DOI 10.1126/science.278.5336.264; TSAPATSIS M, 1995, MATER RES SOC SYMP P, V371, P21; UEDA S, 1986, 7 INT ZEOL C TOK; Velev OD, 1997, NATURE, V389, P447, DOI 10.1038/38921; Vietze U, 1998, PHYS REV LETT, V81, P4628, DOI 10.1103/PhysRevLett.81.4628; VOGT ETC, 1990, J SOLID STATE CHEM, V87, P469, DOI 10.1016/0022-4596(90)90052-Y; Vroon ZAEP, 1996, J MEMBRANE SCI, V113, P293, DOI 10.1016/0376-7388(95)00128-X; Wada Y, 2000, J AM CHEM SOC, V122, P8583, DOI 10.1021/ja0020557; WAKIHARA T, 2001, STUD SURF SCI CATAL, V135; Wang HT, 2001, CHEM COMMUN, P1364, DOI 10.1039/b104275k; Wang N, 2000, NATURE, V408, P50, DOI 10.1038/35040702; Wang XD, 2000, CHEM COMMUN, P2161, DOI 10.1039/b006539k; WANG Z, 2001, STUD SURF SCI CATAL, V135; Wang ZB, 2001, CHEM MATER, V13, P1101, DOI 10.1021/cm000849e; Wang ZB, 2001, ADV MATER, V13, P746, DOI 10.1002/1521-4095(200105)13:10<746::AID-ADMA746>3.0.CO;2-J; WEISS O, 2001, STUD SURF SCI CATAL, V135; Wilson E, 2001, CHEM ENG NEWS, V79, P8, DOI 10.1021/cen-v079n006.p008a; Wirnsberger G, 2000, CHEM MATER, V12, P2525, DOI 10.1021/cm001078h; Wirnsberger G, 2001, CHEM COMMUN, P119, DOI 10.1039/b003995k; Wu CN, 1996, ADV MATER, V8, P1008, DOI 10.1002/adma.19960081215; Xomeritakis G, 2001, IND ENG CHEM RES, V40, P544, DOI 10.1021/ie000613k; YAN YG, 1992, CHEM MATER, V4, P975, DOI 10.1021/cm00023a007; YAN YS, 1995, J CHEM SOC CHEM COMM, P227, DOI 10.1039/c39950000227; YANAGISAWA T, 1990, B CHEM SOC JPN, V63, P988, DOI 10.1246/bcsj.63.988; Yang CM, 2001, ADV MATER, V13, P1099, DOI 10.1002/1521-4095(200107)13:14<1099::AID-ADMA1099>3.0.CO;2-0; Yang GY, 1999, J AM CHEM SOC, V121, P8389, DOI 10.1021/ja991985r; Yang PD, 2000, SCIENCE, V287, P465, DOI 10.1126/science.287.5452.465; Yoon SB, 2001, CHEM COMMUN, P559, DOI 10.1039/b009691l; Yoshikawa M, 1998, J PHYS CHEM B, V102, P7139, DOI 10.1021/jp982169t; Zhao D, 1998, ADV MATER, V10, P1380, DOI 10.1002/(SICI)1521-4095(199811)10:16<1380::AID-ADMA1380>3.0.CO;2-8	135	4445	4601	100	3949	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 20	2002	417	6891					813	821		10.1038/nature00785	http://dx.doi.org/10.1038/nature00785			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075343				2022-12-28	WOS:000176285600038
J	Baarslag, HJ; van Beek, EJR; Koopman, MMW; Reekers, JA				Baarslag, HJ; van Beek, EJR; Koopman, MMW; Reekers, JA			Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities	ANNALS OF INTERNAL MEDICINE			English	Article							SUBCLAVIAN VEIN-THROMBOSIS; DOPPLER ULTRASOUND; DIAGNOSIS; CANCER; THROMBOEMBOLISM; SONOGRAPHY; MALIGNANCY; CATHETERS; AXILLARY; LEG	Background: The optimal strategy for diagnosis of deep venous thrombosis (DVT) is less well established for the upper extremities than for the lower extremities. Duplex color ultrasonography can be difficult to perform in the upper extremities because of their anatomy, and contrast venography is often indicated. Moreover, limited data exist on the use of duplex color ultrasonography in this setting. Objective: To determine the accuracy of duplex ultrasonography for diagnosis of DVT of the upper extremities. Design: Prospective study of duplex ultrasonography compared with venography. Setting: A teaching hospital in Amsterdam, the Netherlands. Patients: 126 consecutive inpatients and outpatients with suspected DVT of the upper extremities. Measurements: Contrast venography was obtained after duplex ultrasonography and was judged independently. A three-step protocol, involving compression ultmonography, color ultrasonography, and color Doppler ultrasonography, was used. Sensitivity, specificity, and likelihood ratios for ultrasonography as a whole were calculated. The independent value of each step was assessed. Results: Venography and ultrasonography were not feasible in 23 of 126 patients (18%) and 1 of 126 patients (0.8%), respectively. Results of ultrasonography were inconclusive in 3 patients. Venography demonstrated thrombosis in 44 of 99 patients (44%); in 36 patients (36%), thrombosis was related to intravenous catheters or malignant disease, Sensitivity and specificity of duplex ultrasonography were 82% (95% Cl, 70% to 93%) and 82% (Cl, 72% to 92%), respectively. Venous incompressibility correlated well with thrombosis, whereas only 50% of isolated flow abnormalities proved to be thrombosis-related. Conclusions: Duplex ultrasonography may be the method of choice for initial diagnosis of patients with suspected thrombosis of the upper extremities. However, in patients with isolated flow abnormalities, contrast venography should be performed.	Acad Med Ctr, Dept Radiol, NL-1105 AZ Amsterdam, Netherlands; Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England	University of Amsterdam; Academic Medical Center Amsterdam; University of Sheffield	Baarslag, HJ (corresponding author), Acad Med Ctr, Dept Radiol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	H.J.Baarslag@AMC.UvA.nl	Reekers, Jim/ABF-7580-2021					Allen AW, 2000, J VASC INTERV RADIOL, V11, P1309, DOI 10.1016/S1051-0443(07)61307-4; APPELMAN PT, 1987, RADIOLOGY, V163, P743, DOI 10.1148/radiology.163.3.3554343; Baron JA, 1998, LANCET, V351, P1077, DOI 10.1016/S0140-6736(97)10018-6; BAXTER GM, 1990, CLIN RADIOL, V42, P32, DOI 10.1016/S0009-9260(05)81618-6; BAXTER GM, 1991, BRIT J RADIOL, V64, P777, DOI 10.1259/0007-1285-64-765-777; BERN MM, 1990, ANN INTERN MED, V112, P423, DOI 10.7326/0003-4819-76-3-112-6-423; Buller H, 1998, NEW ENGL J MED, V338, P1221, DOI 10.1056/NEJM199804233381709; CRONAN JJ, 1987, RADIOLOGY, V162, P191, DOI 10.1148/radiology.162.1.3538148; FALK RL, 1987, AM J ROENTGENOL, V149, P677, DOI 10.2214/ajr.149.4.677; GAITINI D, 1988, J ULTRAS MED, V7, P621; Girolami A, 1999, BLOOD COAGUL FIBRIN, V10, P455, DOI 10.1097/00001721-199912000-00001; HAIRE WD, 1991, J ULTRAS MED, V10, P493, DOI 10.7863/jum.1991.10.9.493; HUNG SSJ, 1989, CANCER, V64, P531, DOI 10.1002/1097-0142(19890715)64:2<531::AID-CNCR2820640229>3.0.CO;2-M; KNUDSON GJ, 1990, AM J ROENTGENOL, V154, P399, DOI 10.2214/ajr.154.2.2136963; KOKSOY C, 1995, CLIN RADIOL, V50, P687, DOI 10.1016/S0009-9260(05)83313-6; Kroger K, 1998, CLIN SCI, V94, P657; LENSING AWA, 1992, THROMB HAEMOSTASIS, V67, P8; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LENSING AWA, 2001, HEMOSTASIS THROMBOSI, P1277; LOKICH JJ, 1983, CANCER, V52, P1586, DOI 10.1002/1097-0142(19831101)52:9<1586::AID-CNCR2820520908>3.0.CO;2-4; Martin C, 1999, CRIT CARE MED, V27, P2626, DOI 10.1097/00003246-199912000-00004; MATTOS MA, 1992, J VASC SURG, V15, P366, DOI 10.1016/0741-5214(92)90258-A; MCLACHLAN MSF, 1979, AM J ROENTGENOL, V132, P227, DOI 10.2214/ajr.132.2.227; Monreal M, 1996, THROMB HAEMOSTASIS, V75, P251; MONREAL M, 1999, PULMONARY EMBOLISM, P71; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; Prandoni P, 1997, ARCH INTERN MED, V157, P57, DOI 10.1001/archinte.157.1.57; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; ROSE SC, 1990, RADIOLOGY, V175, P639, DOI 10.1148/radiology.175.3.2188293; Ruehm SG, 2001, EUR RADIOL, V11, P102, DOI 10.1007/s003300000586; SCHINDLER JM, 1990, BRIT MED J, V301, P1369, DOI 10.1136/bmj.301.6765.1369; Shinde TS, 1999, RADIOLOGY, V213, P555, DOI 10.1148/radiology.213.2.r99nv27555; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; VALENSTEIN PN, 1990, AM J CLIN PATHOL, V93, P252, DOI 10.1093/ajcp/93.2.252	34	108	118	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 18	2002	136	12					865	872		10.7326/0003-4819-136-12-200206180-00007	http://dx.doi.org/10.7326/0003-4819-136-12-200206180-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563JL	12069560				2022-12-28	WOS:000176252500002
J	Donnelly, R; Yeung, JMC				Donnelly, R; Yeung, JMC			Therapeutic angiogenesis: a step forward in intermittent claudication	LANCET			English	Editorial Material							FIBROBLAST-GROWTH-FACTOR; PERFUSION; ISCHEMIA; TRIAL		So Derbyshire Acute Hosp NHS Trust, Derby DE1 2QY, England; Univ Nottingham, Sch Med & Surg Sci, Nottingham NG7 2RD, England	University of Nottingham	Donnelly, R (corresponding author), So Derbyshire Acute Hosp NHS Trust, Derby DE1 2QY, England.							Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; Beebe HG, 1999, ARCH INTERN MED, V159, P2041, DOI 10.1001/archinte.159.17.2041; Hendel RC, 2000, CIRCULATION, V101, P118, DOI 10.1161/01.CIR.101.2.118; Laham RJ, 2000, J AM COLL CARDIOL, V36, P2132, DOI 10.1016/S0735-1097(00)00988-8; Lazarous DF, 2000, J AM COLL CARDIOL, V36, P1239, DOI 10.1016/S0735-1097(00)00882-2; Lazarous DF, 1997, CARDIOVASC RES, V36, P78, DOI 10.1016/S0008-6363(97)00142-9; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; PADUA RR, 1995, MOL CELL BIOCHEM, V143, P129, DOI 10.1007/BF01816946; Rajanayagam MAS, 2000, J AM COLL CARDIOL, V35, P519, DOI 10.1016/S0735-1097(99)00550-1; Shintani S, 2001, CIRCULATION, V103, P897, DOI 10.1161/01.CIR.103.6.897; Yang HT, 1996, CIRC RES, V79, P62, DOI 10.1161/01.RES.79.1.62	11	15	18	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 15	2002	359	9323					2048	2050		10.1016/S0140-6736(02)08946-8	http://dx.doi.org/10.1016/S0140-6736(02)08946-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086754				2022-12-28	WOS:000176194600002
J	Reeve, AE; Becroft, DMO; Morison, IM; Fukuzawa, R				Reeve, AE; Becroft, DMO; Morison, IM; Fukuzawa, R			Insulin-like growth factor-II imprinting in cancer	LANCET			English	Editorial Material							WILMS-TUMOR; GENE; RELAXATION; EXPRESSION; DISOMY		Univ Otago, Dept Biochem, Canc Genet Lab, Dunedin, New Zealand; Univ Auckland, Dept Obstet & Gynaecol, Auckland 1, New Zealand	University of Otago; University of Auckland	Reeve, AE (corresponding author), Univ Otago, Dept Biochem, Canc Genet Lab, Dunedin, New Zealand.	a.reeve@otago.ac.nz	Morison, Ian M/A-1236-2008	Morison, Ian M/0000-0003-3616-0025				BECKWITH J B, 1990, Pediatric Pathology, V10, P1; Becroft DMO, 1998, PEDIATR DEVEL PATHOL, V1, P200, DOI 10.1007/s100249900027; BRESLOW N, 1993, MED PEDIATR ONCOL, V21, P172, DOI 10.1002/mpo.2950210305; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; Grundy P, 1996, MED PEDIATR ONCOL, V27, P429, DOI 10.1002/(SICI)1096-911X(199611)27:5<429::AID-MPO7>3.0.CO;2-O; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; LITTLE M, 1991, NATURE, V351, P609, DOI 10.1038/351609a0; Miyagawa K, 1998, NAT GENET, V18, P15, DOI 10.1038/ng0198-15; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Ravenel JD, 2001, JNCI-J NATL CANCER I, V93, P1698, DOI 10.1093/jnci/93.22.1698; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; Schumacher V, 1997, P NATL ACAD SCI USA, V94, P3972, DOI 10.1073/pnas.94.8.3972; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; Wang WH, 1996, J BIOL CHEM, V271, P27863, DOI 10.1074/jbc.271.44.27863; WILKINS RJ, 1988, LANCET, V1, P329	18	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 15	2002	359	9323					2050	2051		10.1016/S0140-6736(02)08947-X	http://dx.doi.org/10.1016/S0140-6736(02)08947-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086755				2022-12-28	WOS:000176194600003
J	Terray, A; Oakey, J; Marr, DWM				Terray, A; Oakey, J; Marr, DWM			Microfluidic control using colloidal devices	SCIENCE			English	Article							LIQUID FLOW; SYSTEMS; MANIPULATION; POLY(DIMETHYLSILOXANE); MICROMACHINES; SEPARATIONS; DRIVEN; LIGHT; PUMPS	By manipulating colloidal microspheres within customized channels, we have created micrometer-scale fluid pumps and particulate valves. We describe two positive-displacement designs, a gear and a peristaltic pump, both of which are about the size of a human red blood cell. Two colloidal valve designs,are also demonstrated, one actuated and one passive, for the direction of cells or small particles. The use of colloids as both valves and pumps wit[ allow device integration at a density far beyond what is currently achievable by other approaches and may provide a link between fluid manipulation at the macro- and nanoscale.	Colorado Sch Mines, Dept Chem Engn, Golden, CO 80401 USA	Colorado School of Mines	Oakey, J (corresponding author), Colorado Sch Mines, Dept Chem Engn, Golden, CO 80401 USA.	joakey@mines.edu; dmarr@mines.edu						BART SF, 1990, SENSOR ACTUAT A-PHYS, V21, P193, DOI 10.1016/0924-4247(90)85037-5; Beebe DJ, 2000, NATURE, V404, P588, DOI 10.1038/35007047; Duffy DC, 1999, J MICROMECH MICROENG, V9, P211, DOI 10.1088/0960-1317/9/3/301; Duffy DC, 1998, ANAL CHEM, V70, P4974, DOI 10.1021/ac980656z; EFFENHAUSER CS, 1993, ANAL CHEM, V65, P2637, DOI 10.1021/ac00067a015; Galajda P, 2001, APPL PHYS LETT, V78, P249, DOI 10.1063/1.1339258; Gauthier RC, 2001, APPL OPTICS, V40, P930, DOI 10.1364/AO.40.000930; Hatch A, 2001, J MICROELECTROMECH S, V10, P215, DOI 10.1109/84.925748; Hertzberg RP, 2000, CURR OPIN CHEM BIOL, V4, P445, DOI 10.1016/S1367-5931(00)00110-1; Jager EWH, 2000, SCIENCE, V288, P2335, DOI 10.1126/science.288.5475.2335; Kamholz AE, 1999, ANAL CHEM, V71, P5340, DOI 10.1021/ac990504j; Kataoka DE, 1999, NATURE, V402, P794, DOI 10.1038/45521; Kawata S, 2001, NATURE, V412, P697, DOI 10.1038/35089130; Kenis PJA, 1999, SCIENCE, V285, P83, DOI 10.1126/science.285.5424.83; Kuebler SM, 2000, PROC SPIE, V3937, P97, DOI 10.1117/12.382799; MANZ A, 1994, J MICROMECH MICROENG, V4, P257, DOI 10.1088/0960-1317/4/4/010; Maruo S, 2001, PROC IEEE MICR ELECT, P594, DOI 10.1109/MEMSYS.2001.906611; McDonald JC, 2000, ELECTROPHORESIS, V21, P27, DOI 10.1002/(SICI)1522-2683(20000101)21:1<27::AID-ELPS27>3.0.CO;2-C; Mio C, 2000, ADV MATER, V12, P917, DOI 10.1002/1521-4095(200006)12:12<917::AID-ADMA917>3.0.CO;2-K; Mio C, 2000, REV SCI INSTRUM, V71, P2196, DOI 10.1063/1.1150605; Service RF, 1998, SCIENCE, V282, P400, DOI 10.1126/science.282.5388.400; SHOJI S, 1994, J MICROMECH MICROENG, V4, P157, DOI 10.1088/0960-1317/4/4/001; Unger MA, 2000, SCIENCE, V288, P113, DOI 10.1126/science.288.5463.113; VANDENBERG A, 2000, MICRO TOTAL ANAL SYS; Whitesides GM, 2001, PHYS TODAY, V54, P42, DOI 10.1063/1.1387591; WILDING P, 1994, CLIN CHEM, V40, P1815; Yu Q, 2001, APPL PHYS LETT, V78, P2589, DOI 10.1063/1.1367010; Zhao B, 2001, SCIENCE, V291, P1023, DOI 10.1126/science.291.5506.1023	28	331	379	0	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 7	2002	296	5574					1841	1844		10.1126/science.1072133	http://dx.doi.org/10.1126/science.1072133			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052952				2022-12-28	WOS:000176054300040
J	Swales, J				Swales, J			The dangers of conformity	LANCET			English	Editorial Material									Univ Leicester, Fac Med, Leicester LE2 7LX, Leics, England	University of Leicester	Swales, J (corresponding author), Univ Leicester, Fac Med, Leicester LE2 7LX, Leics, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 1	2002	359	9321					1936	1936		10.1016/S0140-6736(05)71111-9	http://dx.doi.org/10.1016/S0140-6736(05)71111-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PL	12057559				2022-12-28	WOS:000175975700026
J	Ishii, K; Arib, G; Lin, C; Van Houwe, G; Laemmli, UK				Ishii, K; Arib, G; Lin, C; Van Houwe, G; Laemmli, UK			Chromatin boundaries in budding yeast: The nuclear pore connection	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMOSOMAL DOMAINS; BINDING-PROTEINS; GENE-EXPRESSION; LIVING CELLS; TRANSFER-RNA; COMPLEX; EXPORT; DNA; HETEROCHROMATIN	Chromatin boundary activities (BAs) were identified in Saccharomyces cerevisiae by genetic screening. Such BAs bound to sites flanking a reporter gene establish a nonsilenced domain within the silent mating-type locus HML. Interestingly, various proteins involved in nuclear-cytoplasmic traffic, such as exportins Cse1p, Mex67p, and Los1p, exhibit a robust BA. Genetic studies, immunolocalization, live imaging, and chromatin immunoprecipitation experiments show that these transport proteins block spreading of heterochromatin by physical tethering of the HML locus to the Nup2p receptor of the nuclear pore complex. Genetic deletion of NUP2 abolishes the BA of all transport proteins, while direct targeting of Nup2p to the bracketing DNA elements restores activity. The data demonstrate that physical tethering of genomic loci to the NPC can dramatically alter their epigenetic activity.	Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland; Univ Geneva, Dept Mol Biol, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Laemmli, UK (corresponding author), Univ Geneva, Dept Biochem, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.		Ishii, Kojiro/L-5102-2017	Galora De Mora, Raul Pavlov/0000-0001-8342-9782				Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Belmont AS, 2001, TRENDS CELL BIOL, V11, P250, DOI 10.1016/S0962-8924(01)02000-1; Bi X, 1997, MOL CELL BIOL, V17, P7077, DOI 10.1128/MCB.17.12.7077; Bi X, 1999, GENE DEV, V13, P1089, DOI 10.1101/gad.13.9.1089; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Booth JW, 1999, J BIOL CHEM, V274, P32360, DOI 10.1074/jbc.274.45.32360; Cheng TH, 2000, GENE DEV, V14, P452; Cheng TH, 1998, P NATL ACAD SCI USA, V95, P5521, DOI 10.1073/pnas.95.10.5521; Cockell M, 1999, CURR OPIN GENET DEV, V9, P199, DOI 10.1016/S0959-437X(99)80030-6; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Damelin M, 2000, MOL CELL, V5, P133, DOI 10.1016/S1097-2765(00)80409-8; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; Donze D, 2001, EMBO J, V20, P520, DOI 10.1093/emboj/20.3.520; Galy V, 2000, NATURE, V403, P108, DOI 10.1038/47528; Gaszner M, 1999, GENE DEV, V13, P2098, DOI 10.1101/gad.13.16.2098; Gerasimova TI, 2000, MOL CELL, V6, P1025, DOI 10.1016/S1097-2765(00)00101-5; Gerasimova TI, 2001, ANNU REV GENET, V35, P193, DOI 10.1146/annurev.genet.35.102401.090349; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Hart CM, 1997, MOL CELL BIOL, V17, P999, DOI 10.1128/MCB.17.2.999; Hart CM, 1998, CURR OPIN GENET DEV, V8, P519, DOI 10.1016/S0959-437X(98)80005-1; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Heun P, 2001, J CELL BIOL, V152, P385, DOI 10.1083/jcb.152.2.385; HOLDRIDGE C, 1991, MOL CELL BIOL, V11, P1894, DOI 10.1128/MCB.11.4.1894; Hood JK, 1998, J BIOL CHEM, V273, P35142, DOI 10.1074/jbc.273.52.35142; Hood JK, 2000, J CELL SCI, V113, P1471; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; Marshall WF, 1997, CURR BIOL, V7, P930, DOI 10.1016/S0960-9822(06)00412-X; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Rosenblum JS, 1997, J CELL BIOL, V139, P1655, DOI 10.1083/jcb.139.7.1655; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Sekinger EA, 2001, CELL, V105, P403, DOI 10.1016/S0092-8674(01)00329-4; Strambio-de-Castillia C, 1999, J CELL BIOL, V144, P839, DOI 10.1083/jcb.144.5.839; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; ZHAO K, 1995, CELL, V81, P879, DOI 10.1016/0092-8674(95)90008-X	48	286	291	1	9	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 31	2002	109	5					551	562		10.1016/S0092-8674(02)00756-0	http://dx.doi.org/10.1016/S0092-8674(02)00756-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	558GL	12062099	Bronze			2022-12-28	WOS:000175957900005
J	Saitoh, S; Chabes, A; McDonald, WH; Thelander, L; Yates, JR; Russell, P				Saitoh, S; Chabes, A; McDonald, WH; Thelander, L; Yates, JR; Russell, P			Cid13 is a cytoplasmic poly(A) polymerase that regulates ribonucleotide reductase mRNA	CELL			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; PROTEIN IDENTIFICATION TECHNOLOGY; S-M CHECKPOINT; FISSION YEAST; DNA-REPLICATION; MESSENGER-RNA; CELL-CYCLE; POLY(A)-BINDING PROTEIN; SPISULA OOCYTES; POLYADENYLATION	Fission yeast Cid13 and budding yeast Trf4/5 are members of a newly identified nucleotidyltransferase family conserved from yeast to man. Trf4/5 are thought to be essential DNA polymerases. We report that Cid13 is a poly(A) polymerase. Unlike conventional poly(A) polymerases, which act in the nucleus and indiscriminately polyadenylate, all mRNA, Cid13 is a cytoplasmic enzyme that specifically targets suc22 mRNA that encodes a subunit of ribonucleotide reductase (RNR). cid13 mutants have reduced dNTP pools and are sensitive to hydroxyurea, an RNR inhibitor. We propose that Cid13 defines a cytoplasmic form of poly(A) polymerase important for DNA replication and genome maintenance.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	Scripps Research Institute; Scripps Research Institute; Umea University	Russell, P (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	prussell@scripps.edu	McDonald, W. Hayes/B-4109-2016	McDonald, W. Hayes/0000-0002-3510-426X; Chabes, Andrei/0000-0003-1708-8259; Saitoh, Shigeaki/0000-0001-5408-296X	NCI NIH HHS [CA81665] Funding Source: Medline; NCRR NIH HHS [RR11823] Funding Source: Medline; NEI NIH HHS [R01 EY1328801] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA081665] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1609, DOI 10.1093/nar/27.7.1609; BALLANTYNE S, 1995, RNA, V1, P64; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; Carson DR, 2001, P NATL ACAD SCI USA, V98, P8270, DOI 10.1073/pnas.131022798; Castano IB, 1996, NUCLEIC ACIDS RES, V24, P2404, DOI 10.1093/nar/24.12.2404; Chapon C, 1997, RNA, V3, P1337; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; GEBAUER F, 1995, MOL CELL BIOL, V15, P1422; HAGAN IM, 1988, J CELL SCI, V89, P343; Harris P, 1996, MOL GEN GENET, V252, P284; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hofer A, 1998, J BIOL CHEM, V273, P34098, DOI 10.1074/jbc.273.51.34098; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Lubkowitz MA, 1998, MOL MICROBIOL, V28, P729, DOI 10.1046/j.1365-2958.1998.00827.x; Mangus DA, 1998, MOL CELL BIOL, V18, P7383, DOI 10.1128/MCB.18.12.7383; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MCDONALD WH, 2002, IN PRESS INT J MASS; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Moser BA, 2000, MOL CELL BIOL, V20, P4288, DOI 10.1128/MCB.20.12.4288-4294.2000; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; REYMOND A, 1992, MOL GEN GENET, V234, P449, DOI 10.1007/BF00538705; Richter JD, 1999, MICROBIOL MOL BIOL R, V63, P446, DOI 10.1128/MMBR.63.2.446-456.1999; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; ROSENTHAL ET, 1983, J MOL BIOL, V166, P309, DOI 10.1016/S0022-2836(83)80087-4; ROSENTHAL ET, 1987, DEV BIOL, V121, P237, DOI 10.1016/0012-1606(87)90155-2; Sambrook J., 2001, MOL CLONING; SARABIA MJF, 1993, MOL GEN GENET, V238, P241, DOI 10.1007/BF00279553; STANDART NM, 1985, J CELL BIOL, V100, P1968, DOI 10.1083/jcb.100.6.1968; SWENSON KI, 1987, DEV BIOL, V123, P10, DOI 10.1016/0012-1606(87)90421-0; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uhlmann F, 2000, CURR BIOL, V10, pR698, DOI 10.1016/S0960-9822(00)00709-0; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Wang SW, 1999, J CELL SCI, V112, P927; Wang SW, 2000, MOL CELL BIOL, V20, P3234, DOI 10.1128/MCB.20.9.3234-3244.2000; Wang ZH, 2000, SCIENCE, V289, P774, DOI 10.1126/science.289.5480.774; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544	57	113	120	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 31	2002	109	5					563	573		10.1016/S0092-8674(02)00753-5	http://dx.doi.org/10.1016/S0092-8674(02)00753-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	558GL	12062100	Bronze			2022-12-28	WOS:000175957900006
J	Pruyne, D; Evangelista, M; Yang, CS; Bi, EF; Zigmond, S; Bretscher, A; Boone, C				Pruyne, D; Evangelista, M; Yang, CS; Bi, EF; Zigmond, S; Bretscher, A; Boone, C			Role of formins in actin assembly: Nucleation and barbed-end association	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; ARP2/3 COMPLEX; BUDDING YEAST; CELL-CYCLE; PROTEINS; BNI1P; CYTOSKELETON; CYTOKINESIS; INHERITANCE; DROSOPHILA	Nucleation of branched actin laments by the Arp2/3 complex is a conserved process in eukaryotic cells, yet the source of unbranched actin laments has remained obscure. In yeast, formins stimulate assembly of actin cables independently of Arp2/3. Here, the conserved core of formin homology domains 1 and 2 of Bni1p (Bni1pFH1FH2) was found to nucleate unbranched actin laments in vitro. Bni1pFH2 provided the minimal region sufficient for nucleation. Unique among actin nucleators, Bni1pFH1FH2 remained associated with the growing barbed ends of laments. This combination of properties suggests a direct role for formins in regulating nucleation and polarization of unbranched filamentous actin structures.	Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA; Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada	Queens University - Canada; Cornell University; University of Pennsylvania; University of Pennsylvania; University of Toronto; University of Toronto	Bretscher, A (corresponding author), Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019883, R37AI019883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059216] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19883] Funding Source: Medline; NIGMS NIH HHS [GM59216] Funding Source: Medline; CGH CDC HHS [GH39066] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); CGH CDC HHS		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; Amberg DC, 1998, MOL BIOL CELL, V9, P3259, DOI 10.1091/mbc.9.12.3259; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; CALDWELL JE, 1989, BIOCHEMISTRY-US, V28, P8506, DOI 10.1021/bi00447a036; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; COOPER JA, 1987, J CELL BIOL, V104, P491, DOI 10.1083/jcb.104.3.491; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; Evangelista M, 2002, NAT CELL BIOL, V4, P32, DOI 10.1038/ncb718; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; GLENNEY JR, 1981, CELL, V24, P471, DOI 10.1016/0092-8674(81)90338-X; Hill KL, 1996, J CELL BIOL, V135, P1535, DOI 10.1083/jcb.135.6.1535; Hoepfner D, 2001, J CELL BIOL, V155, P979, DOI 10.1083/jcb.200107028; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; Kamei T, 1998, J BIOL CHEM, V273, P28341, DOI 10.1074/jbc.273.43.28341; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; LIN DC, 1980, ANAL BIOCHEM, V103, P316; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; Ozaki-Kuroda K, 2001, MOL CELL BIOL, V21, P827, DOI 10.1128/MCB.21.3.827-839.2001; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Pruyne DW, 1998, J CELL BIOL, V143, P1931, DOI 10.1083/jcb.143.7.1931; Ridley AJ, 1999, NAT CELL BIOL, V1, pE64, DOI 10.1038/11034; Rossanese OW, 2001, J CELL BIOL, V153, P47, DOI 10.1083/jcb.153.1.47; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; Schott DH, 2002, J CELL BIOL, V156, P35, DOI 10.1083/jcb.200110086; TELLAM R, 1982, BIOCHEMISTRY-US, V21, P3207, DOI 10.1021/bi00256a027; Theesfeld CL, 1999, J CELL BIOL, V146, P1019, DOI 10.1083/jcb.146.5.1019; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Winter DC, 1999, P NATL ACAD SCI USA, V96, P7288, DOI 10.1073/pnas.96.13.7288; Yang HC, 2002, P NATL ACAD SCI USA, V99, P751, DOI 10.1073/pnas.022462899; Zeller R, 1999, CELL TISSUE RES, V296, P85, DOI 10.1007/s004410051269	32	548	560	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 26	2002	297	5581					612	615		10.1126/science.1072309	http://dx.doi.org/10.1126/science.1072309			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	577GY	12052901				2022-12-28	WOS:000177054200054
J	Canli, T; Sivers, H; Whitfield, SL; Gotlib, IH; Gabrieli, JDE				Canli, T; Sivers, H; Whitfield, SL; Gotlib, IH; Gabrieli, JDE			Amygdala response to happy faces as a function of extraversion	SCIENCE			English	Article							FACIAL EXPRESSIONS		Stanford Univ, Dept Psychol, Stanford, CA 94305 USA	Stanford University	Canli, T (corresponding author), SUNY Stony Brook, Dept Psychol, Stony Brook, NY 11794 USA.		Canli, Turhan/F-9274-2019; Gabrieli, John/AAJ-2869-2020	Canli, Turhan/0000-0003-3646-239X; 	NIMH NIH HHS [MH59259] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059259] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Breiter HC, 1996, NEURON, V17, P875, DOI 10.1016/S0896-6273(00)80219-6; Canli T, 2001, BEHAV NEUROSCI, V115, P33, DOI 10.1037//0735-7044.115.1.33; COSTA PT, 1991, NEO 5 FACTOR INVENTO; DAVIDSON RJ, 1990, J PERS SOC PSYCHOL, V58, P330, DOI 10.1037/0022-3514.58.2.330; Davis M, 2001, MOL PSYCHIATR, V6, P13, DOI 10.1038/sj.mp.4000812; Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0; Pervin L., 1999, HDB PERSONALITY THEO, V2nd; Whalen PJ, 1998, J NEUROSCI, V18, P411	8	372	382	1	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 21	2002	296	5576					2191	2191		10.1126/science.1068749	http://dx.doi.org/10.1126/science.1068749			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077407				2022-12-28	WOS:000176379000048
J	Pfau, T				Pfau, T			Perspectives: Atom optics - Continuous progress on atom lasers	SCIENCE			English	Editorial Material							PHASE-COHERENT AMPLIFICATION; MATTER WAVES; OUTPUT COUPLER; INTERFERENCE		Univ Stuttgart, Inst Phys, D-70550 Stuttgart, Germany	University of Stuttgart	Pfau, T (corresponding author), Univ Stuttgart, Inst Phys, D-70550 Stuttgart, Germany.		Pfau, Tilman/G-1774-2011	Pfau, Tilman/0000-0003-3272-3468				Anderson BP, 1998, SCIENCE, V282, P1686, DOI 10.1126/science.282.5394.1686; ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/science.269.5221.198; Andrews MR, 1997, SCIENCE, V275, P637, DOI 10.1126/science.275.5300.637; Bloch I, 1999, PHYS REV LETT, V82, P3008, DOI 10.1103/PhysRevLett.82.3008; Chikkatur AP, 2002, SCIENCE, V296, P2193, DOI 10.1126/science.296.5576.2193; Holland M, 1996, PHYS REV A, V54, pR1757, DOI 10.1103/PhysRevA.54.R1757; Inouye S, 1999, NATURE, V402, P641, DOI 10.1038/45194; Kozuma M, 1999, SCIENCE, V286, P2309, DOI 10.1126/science.286.5448.2309; Mandonnet E, 2000, EUR PHYS J D, V10, P9, DOI 10.1007/s100530050521; Mewes MO, 1997, PHYS REV LETT, V78, P582, DOI 10.1103/PhysRevLett.78.582; Santos L, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.063408; SPREEUW RJC, 1995, EUROPHYS LETT, V32, P469, DOI 10.1209/0295-5075/32/6/002	12	3	3	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 21	2002	296	5576					2155	2156		10.1126/science.1073984	http://dx.doi.org/10.1126/science.1073984			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077392				2022-12-28	WOS:000176379000033
J	McCullough, PC; McCullough, AE				McCullough, PC; McCullough, AE			Nodular sarcoidosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Mayo Clin Scottsdale, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix									0	7	8	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	2002	346	25					1970	1970		10.1056/NEJMicm990757	http://dx.doi.org/10.1056/NEJMicm990757			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563QC	12075058				2022-12-28	WOS:000176266200006
J	Hoitsma, E; Marziniak, M; Faber, CG; Reulen, JPH; Sommer, C; De Baets, M; Drent, M				Hoitsma, E; Marziniak, M; Faber, CG; Reulen, JPH; Sommer, C; De Baets, M; Drent, M			Small fibre neuropathy in sarcoidosis	LANCET			English	Article								Some patients with sarcoidosis have unexplained pain and dysaesthesia. We did quantitative sensory testing in 31 sarcoidosis patients with pain or autonomic dysfunction. 25 patients had reduced warmth sensitivity, cold sensitivity, or both. Intraepidermal nerve fibre density (IENFD) was measured in punch biopsy skin samples in seven consecutive patients. All seven patients had reduced IENFD compared with controls, which confirmed the presence of small fibre neuropathy in these patients. Some patients with sarcoidosis may have small fibre neuropathy with autonomic involvement.	Univ Hosp, Dept Neurol, Maastricht, Netherlands; Univ Hosp, Dept Clin Neurophysiol, Maastricht, Netherlands; Univ Hosp, Dept Pulmonol, Maastricht, Netherlands; Sarcoidosis Management Ctr, Maastricht, Netherlands; Univ Hosp Wuerzburg, Dept Neurol, Wurzburg, Germany	Maastricht University; Maastricht University; Maastricht University; University of Wurzburg	Hoitsma, E (corresponding author), POB 5800, NL-6202 AZ Maastricht, Netherlands.		Sommer, Claudia/A-9820-2010; Drent, Marjolein/ABA-9526-2020	Sommer, Claudia/0000-0002-7064-5002; Drent, Marjolein/0000-0003-1586-0110; Faber, Catharina G./0000-0002-2467-067X				Hunninghake GW, 1999, SARCOIDOSIS VASC DIF, V16, P149; Kennedy WR, 1999, NEUROLOGY, V53, P1614, DOI 10.1212/WNL.53.8.1614; Newman LS, 1997, NEW ENGL J MED, V336, P1224, DOI 10.1056/NEJM199704243361706; Sharma OP, 1999, EUR RESPIR J, V13, P713, DOI 10.1034/j.1399-3003.1999.13d01.x; YARNITSKY D, 1994, J NEUROL SCI, V125, P39, DOI 10.1016/0022-510X(94)90239-9	5	136	140	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 15	2002	359	9323					2085	2086		10.1016/S0140-6736(02)08912-2	http://dx.doi.org/10.1016/S0140-6736(02)08912-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086764				2022-12-28	WOS:000176194600012
J	Schmitz, N; Pfistner, B; Sextro, M; Sieber, M; Carella, AM; Haenel, M; Boissevain, F; Zschaber, R; Muller, P; Kirchner, H; Lohri, A; Decker, S; Koch, B; Hasenclever, D; Goldstone, AH; Diehl, V				Schmitz, N; Pfistner, B; Sextro, M; Sieber, M; Carella, AM; Haenel, M; Boissevain, F; Zschaber, R; Muller, P; Kirchner, H; Lohri, A; Decker, S; Koch, B; Hasenclever, D; Goldstone, AH; Diehl, V		GHSG; EBMT	Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial	LANCET			English	Article							BONE-MARROW-TRANSPLANTATION; COMBINATION CHEMOTHERAPY; SALVAGE CHEMOTHERAPY; ADULT PATIENTS; 1ST RELAPSE; THERAPY; REGIMEN; LYMPHOMA; BLOOD; CYTOREDUCTION	Background High-dose chemotherapy followed by transplantation of autologous haemopoietic stem cells (BEAM-HSCT) is frequently used to treat patients with relapsed Hodgkin's disease. We aimed to compare this treatment with conventional aggressive chemotherapy without stem-cell transplantation (Dexa-BEAM), Methods 161 patients between 16 and 60 years of age with relapsed Hodgkin's disease were randomly assigned two cycles of Dexa-BEAM (dexamethasone and carmustine, etoposide, cytarabine, and melphalan) and either two further courses of Dexa-BEAM or high-dose BEAM and transplantation of haemopoietic stem cells. Only patients with chemosensitive disease (complete or partial remission after two courses of Dexa-BEAM) proceeded to further treatment. The primary endpoint was freedom from treatment failure for patients with chemosensitive disease. Analysis was per protocol. Findings 17 patients were excluded from the study after randomisation (ten given Dexa-BEAM and seven given BEAM-HSCT). Median follow-up was 39 months (lQR 3-78). Freedom from treatment failure at 3 years was significantly better for patients given BEAM-HSCT (55%) than for those on Dexa-BEAM (34%; difference -21%, 95% CI -39.87 to -2.13; p=0.019). Overall survival of patients given either treatment did not differ significantly. Interpretation High-dose BEAM and transplantation of haemopoietic stem cells improves freedom from treatment failure in patients with chemosensitive first relapse of Hodgkin's disease irrespective of length of initial remission.	Univ Kiel, Dept Internal Med 2, D-2300 Kiel, Germany; Univ Cologne, Med Klin 1, D-5000 Cologne, Germany; Osped San Martino Genova, Genoa, Italy; Klinikum Chemnitz, Chemnitz, Germany; Klinikum Nurnberg, Nurnberg, Germany; Dept Haematol & Oncol, Hamburg, Germany; Zent Klinikum, Augsburg, Germany; Krankenhaus Siloah, Hannover, Germany; SAKK Bern, Bern, Switzerland; Univ Rostock, Dept Haematol & Oncol, Rostock, Germany; Univ Leipzig, Inst Med Informat Stat & Epidemiol, Leipzig, Germany; UCL Hosp, Dept Haematol, London, England	University of Kiel; University of Cologne; University of Genoa; IRCCS AOU San Martino IST; Chemnitz Clinic; Klinikum Nurnberg Nord; University of Rostock; Leipzig University; University College London Hospitals NHS Foundation Trust; University of London; University College London	Schmitz, N (corresponding author), Allgemein Krankenhaus St Georg, Dept Haematol, Lohmuhlenstr 5, D-20099 Hamburg, Germany.	Norbert.Schmitz@ak-stgeorg.lbk-hh.de						Andre M, 1999, J CLIN ONCOL, V17, P222, DOI 10.1200/JCO.1999.17.1.222; Bonfante V, 1997, J CLIN ONCOL, V15, P528, DOI 10.1200/JCO.1997.15.2.528; Brice P, 1997, BONE MARROW TRANSPL, V20, P21, DOI 10.1038/sj.bmt.1700838; CANELLOS GP, 1992, NEW ENGL J MED, V327, P1478, DOI 10.1056/NEJM199211193272102; Carella AM, 2000, J CLIN ONCOL, V18, P3918, DOI 10.1200/JCO.2000.18.23.3918; CHOPRA R, 1993, BLOOD, V81, P1137; CRUMP M, 1993, J CLIN ONCOL, V11, P704, DOI 10.1200/JCO.1993.11.4.704; Diehl V, 1998, J CLIN ONCOL, V16, P3810, DOI 10.1200/JCO.1998.16.12.3810; DREGER P, 1995, BLOOD, V86, P3970, DOI 10.1182/blood.V86.10.3970.bloodjournal86103970; Engert A, 1997, BLOOD, V89, P403, DOI 10.1182/blood.V89.2.403; FERME C, 1995, ANN ONCOL, V6, P543, DOI 10.1093/oxfordjournals.annonc.a059242; Gajewski JL, 1996, J CLIN ONCOL, V14, P572, DOI 10.1200/JCO.1996.14.2.572; Hartmann F, 1997, BLOOD, V89, P2042, DOI 10.1182/blood.V89.6.2042; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; Horning SJ, 2000, J CLIN ONCOL, V18, P972, DOI 10.1200/JCO.2000.18.5.972; LINCH DC, 1993, LANCET, V341, P1051, DOI 10.1016/0140-6736(93)92411-L; LOHRI A, 1991, BLOOD, V77, P2292; LONGO DL, 1992, J CLIN ONCOL, V10, P210, DOI 10.1200/JCO.1992.10.2.210; Milpied N, 1996, J CLIN ONCOL, V14, P1291, DOI 10.1200/JCO.1996.14.4.1291; Pfreundschuh M, 2001, ANN ONCOL, V12, P471, DOI 10.1023/A:1011108722666; PFREUNDSCHUH MG, 1994, J CLIN ONCOL, V12, P580, DOI 10.1200/JCO.1994.12.3.580; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P84; REECE DE, 1994, BLOOD, V83, P1193; Rodriguez J, 1999, BLOOD, V93, P3632, DOI 10.1182/blood.V93.11.3632.411k13_3632_3636; Slavin S, 1998, BLOOD, V91, P756, DOI 10.1182/blood.V91.3.756.756_756_763; Sweetenham JW, 1999, J CLIN ONCOL, V17, P3101, DOI 10.1200/JCO.1999.17.10.3101; Sweetenham JW, 1997, BONE MARROW TRANSPL, V20, P745, DOI 10.1038/sj.bmt.1700963; TOURANI JM, 1992, J CLIN ONCOL, V10, P1086, DOI 10.1200/JCO.1992.10.7.1086; van Leeuwen FE, 1999, HODGKIN'S DISEASE, P607; Yuen AR, 1997, BLOOD, V89, P814, DOI 10.1182/blood.V89.3.814	30	778	815	1	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 15	2002	359	9323					2065	2071		10.1016/S0140-6736(02)08938-9	http://dx.doi.org/10.1016/S0140-6736(02)08938-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086759				2022-12-28	WOS:000176194600007
J	Baxter-Burrell, A; Yang, ZB; Springer, PS; Bailey-Serres, J				Baxter-Burrell, A; Yang, ZB; Springer, PS; Bailey-Serres, J			RopGAP4-dependent Rop GTPase rheostat control of Arabidopsis oxygen deprivation tolerance	SCIENCE			English	Article							GENE-EXPRESSION; BINDING PROTEIN; TIP GROWTH; CALCIUM; POLLEN; SWITCH; RAC; INVOLVEMENT; METABOLISM; MOTIF	Transient soil flooding limits cellular oxygen to roots and reduces crop yield. Plant response to oxygen deprivation involves increased expression of the alcohol dehydrogenase gene (ADH) and ethanolic fermentation. Disruption of the Arabidopsis gene that encodes Rop (RHO-like small G protein of plants) guanosine triphosphatase (GTPase) activating protein 4 (ROPGAP4), a Rop deactivator, elevates ADH expression in response to oxygen deprivation but decreases tolerance to stress. Rop-dependent production of hydrogen peroxide via a diphenylene iodonium chloride-sensitive calcium-dependent reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is necessary for induction of both ADH and RopGAP4 expression. Tolerance to oxygen deprivation requires Rop activation and RopGAP4-dependent negative feedback regulation. This Rop signal transduction rheostat balances the ability to increase ethanolic fermentation with survival.	Univ Calif Riverside, Ctr Plant Cell Biol, Dept Bot & Plant Sci, Riverside, CA 92521 USA	University of California System; University of California Riverside	Bailey-Serres, J (corresponding author), Univ Calif Riverside, Ctr Plant Cell Biol, Dept Bot & Plant Sci, Riverside, CA 92521 USA.	serres@mail.ucr.edu	Bailey-Serres, Julia/A-2470-2010	Bailey-Serres, Julia/0000-0002-8568-7125				BAXTERBURRELL A, IN PRESS ANN BOT, V90; Chung HJ, 1999, PLANT PHYSIOL, V121, P429, DOI 10.1104/pp.121.2.429; Dennis ES, 2000, J EXP BOT, V51, P89, DOI 10.1093/jexbot/51.342.89; Drew MC, 1997, ANNU REV PLANT PHYS, V48, P223, DOI 10.1146/annurev.arplant.48.1.223; Fu Y, 2001, J CELL BIOL, V152, P1019, DOI 10.1083/jcb.152.5.1019; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; JACOBS M, 1988, BIOCHEM GENET, V26, P105, DOI 10.1007/BF00555492; Kawasaki T, 1999, P NATL ACAD SCI USA, V96, P10922, DOI 10.1073/pnas.96.19.10922; Kost B, 1999, CURR OPIN PLANT BIOL, V2, P462, DOI 10.1016/S1369-5266(99)00024-2; Lemichez E, 2001, GENE DEV, V15, P1808, DOI 10.1101/gad.900401; Li H, 2001, PLANT PHYSIOL, V126, P670, DOI 10.1104/pp.126.2.670; Li H, 1999, PLANT CELL, V11, P1731, DOI 10.1105/tpc.11.9.1731; Li H, 1998, PLANT PHYSIOL, V118, P407, DOI 10.1104/pp.118.2.407; Lin YK, 1997, PLANT CELL, V9, P1647, DOI 10.1105/tpc.9.9.1647; Molendijk AJ, 2001, EMBO J, V20, P2779, DOI 10.1093/emboj/20.11.2779; Moller IM, 2001, ANNU REV PLANT PHYS, V52, P561, DOI 10.1146/annurev.arplant.52.1.561; Park J, 2000, PLANT PHYSIOL, V124, P725, DOI 10.1104/pp.124.2.725; Potikha TS, 1999, PLANT PHYSIOL, V119, P849, DOI 10.1104/pp.119.3.849; Sagi M, 2001, PLANT PHYSIOL, V126, P1281, DOI 10.1104/pp.126.3.1281; Sedbrook JC, 1996, PLANT PHYSIOL, V111, P243, DOI 10.1104/pp.111.1.243; SUBBAIAH CC, 1994, PLANT PHYSIOL, V105, P369, DOI 10.1104/pp.105.1.369; SUBBAIAH CC, 1994, PLANT CELL, V6, P1747, DOI 10.1105/tpc.6.12.1747; SUNDARESAN V, 1995, GENE DEV, V9, P1797, DOI 10.1101/gad.9.14.1797; Wu G, 2001, PLANT CELL, V13, P2841, DOI 10.1105/tpc.13.12.2841; Wu G, 2000, PLANT PHYSIOL, V124, P1625, DOI 10.1104/pp.124.4.1625; Zheng ZL, 2000, TRENDS PLANT SCI, V5, P298, DOI 10.1016/S1360-1385(00)01654-X; Zheng ZL, 2000, PLANT MOL BIOL, V44, P1, DOI 10.1023/A:1006402628948	27	266	299	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	2002	296	5575					2026	2028		10.1126/science.1071505	http://dx.doi.org/10.1126/science.1071505			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065837				2022-12-28	WOS:000176273300053
J	McGill, GG; Horstmann, M; Widlund, HR; Du, JY; Motyckova, G; Nishimura, EK; Lin, YL; Ramaswamy, S; Avery, W; Ding, HF; Jordan, SA; Jackson, IJ; Korsmeyer, SJ; Golub, TR; Fisher, DE				McGill, GG; Horstmann, M; Widlund, HR; Du, JY; Motyckova, G; Nishimura, EK; Lin, YL; Ramaswamy, S; Avery, W; Ding, HF; Jordan, SA; Jackson, IJ; Korsmeyer, SJ; Golub, TR; Fisher, DE			Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability	CELL			English	Article							MICROPHTHALMIA TRANSCRIPTION FACTOR; ELEMENT-BINDING PROTEIN; MALIGNANT-MELANOMA; GROWTH-FACTOR; BCL-2-DEFICIENT MICE; POLYCYSTIC KIDNEY; FAMILY MEMBERS; NEURAL CREST; EXPRESSION; GENE	Kit/SCF signaling and Mitf-dependent transcription are both essential for melanocyte development and pigmentation. To identify Mitf-dependent Kit transcriptional targets in primary melanocytes, microarray studies were undertaken. Among identified targets was BCL2, whose germline deletion produces melanocyte loss and which exhibited phenotypic synergy with Mitf in mice. BCL2's regulation by Mitf was verified in melanocytes and melanoma cells and by chromatin immunoprecipitation of the BCL2 promoter. Mitf also regulates BCL2 in osteoclasts, and both Mitf(mi/mi) and Bcl2(-/-) mice exhibit severe osteopetrosis. Disruption of Mitf in melanocytes or melanoma triggered profound apoptosis susceptible to rescue by BCL2 overexpression. Clinically, primary human melanoma expression microarrays revealed tight nearest neighbor linkage for MITF and BCL2. This linkage helps explain the vital roles of both Mitf and Bcl2 in the melanocyte lineage and the well-known treatment resistance of melanoma.	Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Whitehead MIT Ctr Genome Res, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02115 USA; Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; University of Edinburgh	Fisher, DE (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.			Widlund, Hans/0000-0002-7506-2447; Jackson, Ian/0000-0001-6526-0688; Ding, Han-Fei/0000-0001-5702-3439	NCI NIH HHS [CA50239] Funding Source: Medline; NIAMS NIH HHS [AR45662, AR43369] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA050239, R01CA050239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045662, R01AR043369] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Banerjee D, 2001, Curr Opin Investig Drugs, V2, P574; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Blume-Jensen P, 2000, NAT GENET, V24, P157, DOI 10.1038/72814; Bullock ED, 1996, J BIOL CHEM, V271, P27500, DOI 10.1074/jbc.271.44.27500; Carreira S, 2000, J BIOL CHEM, V275, P21920, DOI 10.1074/jbc.M000035200; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; CERRONI L, 1995, AM J DERMATOPATH, V17, P7, DOI 10.1097/00000372-199502000-00002; Chang KL, 2001, ADV ANAT PATHOL, V8, P273, DOI 10.1097/00125480-200109000-00004; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Costa JJ, 1996, J EXP MED, V183, P2681, DOI 10.1084/jem.183.6.2681; Dorvault CC, 2001, CANCER CYTOPATHOL, V93, P337, DOI 10.1002/cncr.9049; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; Goding CR, 2000, GENE DEV, V14, P1712; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Grover R, 1996, EUR J SURG ONCOL, V22, P347, DOI 10.1016/S0748-7983(96)90176-6; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; HUGHES AE, 1994, NAT GENET, V7, P509, DOI 10.1038/ng0894-509; Ito A, 2001, BLOOD, V97, P2075, DOI 10.1182/blood.V97.7.2075; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; KAMADA S, 1995, CANCER RES, V55, P354; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; King R, 2001, AM J SURG PATHOL, V25, P51, DOI 10.1097/00000478-200101000-00005; Koch MB, 2001, AM J SURG PATHOL, V25, P58, DOI 10.1097/00000478-200101000-00006; Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092-8674(00)80290-1; LERNER AB, 1986, J INVEST DERMATOL, V87, P299, DOI 10.1111/1523-1747.ep12524353; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MacKenzie MAF, 1997, DEV BIOL, V192, P99, DOI 10.1006/dbio.1997.8738; Mekori YA, 2001, J CLIN IMMUNOL, V21, P171, DOI 10.1023/A:1011083031272; Miettinen M, 2001, AM J SURG PATHOL, V25, P205, DOI 10.1097/00000478-200102000-00008; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; Nakayama A, 1998, MECH DEVELOP, V70, P155, DOI 10.1016/S0925-4773(97)00188-3; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Nishimura EK, 2002, NATURE, V416, P854, DOI 10.1038/416854a; Price ER, 2001, NEURON, V30, P15, DOI 10.1016/S0896-6273(01)00259-8; Price ER, 1998, J BIOL CHEM, V273, P17983, DOI 10.1074/jbc.273.29.17983; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; RAMSAY JA, 1995, MODERN PATHOL, V8, P150; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Selzer E, 1998, MELANOMA RES, V8, P197, DOI 10.1097/00008390-199806000-00001; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097-2765(01)00360-4; Weilbaecher KN, 1998, J EXP MED, V187, P775, DOI 10.1084/jem.187.5.775; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; Wu M, 2000, GENE DEV, V14, P301; Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803; Yamamura K, 1996, CANCER RES, V56, P3546	57	558	580	1	34	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 14	2002	109	6					707	718		10.1016/S0092-8674(02)00762-6	http://dx.doi.org/10.1016/S0092-8674(02)00762-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	563PW	12086670	Bronze			2022-12-28	WOS:000176265600002
J	Rignot, E; Jacobs, SS				Rignot, E; Jacobs, SS			Rapid bottom melting widespread near Antarctic ice sheet grounding lines	SCIENCE			English	Article							RADAR INTERFEROMETRY; SHELF; GLACIER; CIRCULATION; DISCHARGE; GREENLAND; BENEATH; ISLAND; OCEAN	As continental ice from Antarctica reaches the grounding tine and begins to float, its underside melts into the ocean. Results obtained with satellite radar interferometry reveal that bottom melt rates experienced by large outlet glaciers near their grounding lines are far higher than generally assumed. The melting rate is positively correlated with thermal forcing, increasing by 1 meter per year for each 0.1degreesC rise in ocean temperature. Where deep water has direct access to grounding lines, glaciers and ice shelves are vulnerable to ongoing increases in ocean temperature.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Columbia University	Rignot, E (corresponding author), CALTECH, Jet Prop Lab, MAil Stop 300-235, Pasadena, CA 91109 USA.	eric@adelie.jpl.nasa.gov; sjacobs@ldeo.columbia.edu	Rignot, Eric/A-4560-2014	Rignot, Eric/0000-0002-3366-0481				BUDD WF, 1987, DYNAMICS W ANTARCTIC, P322; Doake C, 1976, POLAR REC, V18, P37, DOI [10.1017/S0032247400028692, DOI 10.1017/S0032247400028692]; Frezzotti M, 2000, J GLACIOL, V46, P253, DOI 10.3189/172756500781832855; GORDON A, 1983, P CO2 RES C SCI CONS; Grosfeld K., 1998, ANTARCT RES SER, V75, P83; Hellmer HH, 1998, ANTARCT RES SER, V75, P83; Huybrechts P, 1999, J CLIMATE, V12, P2169, DOI 10.1175/1520-0442(1999)012<2169:TDROTG>2.0.CO;2; Jacobs SS, 1996, GEOPHYS RES LETT, V23, P957, DOI 10.1029/96GL00723; JACOBS SS, IN PRESS SCIENCE; JENKINS A, 1993, ICE CLIMATE SYSTEM, P217; Lambrecht A, 1999, ANN GLACIOL-SER, V29, P250, DOI 10.3189/172756499781820996; Lefevre F, 2000, GEOPHYS RES LETT, V27, P2717, DOI 10.1029/1999GL011315; Lythe MB, 2001, J GEOPHYS RES-SOL EA, V106, P11335, DOI 10.1029/2000JB900449; MACAYEAL DR, 1984, J GEOPHYS RES-OCEANS, V89, P597, DOI 10.1029/JC089iC01p00597; Makinson K, 2002, J PHYS OCEANOGR, V32, P202, DOI 10.1175/1520-0485(2002)032<0202:MTCPAV>2.0.CO;2; Michel R, 1999, J GLACIOL, V45, P93, DOI 10.3189/S0022143000003075; Nicholls KW, 2001, J GEOPHYS RES-OCEANS, V106, P11481, DOI 10.1029/2000JC000350; Nicholls KW, 1998, ANTARCT RES SER, V75, P301; Nicholls KW, 1997, NATURE, V388, P460, DOI 10.1038/41302; Nost OA, 1998, ANTARCT RES SER, V75, P267; OERTER H, 1992, NATURE, V358, P399, DOI 10.1038/358399a0; Orsi AH, 2001, GEOPHYS RES LETT, V28, P2923, DOI 10.1029/2001GL012830; Potter J. R., 1985, ANTARCT RES SER, V43, P35, DOI DOI 10.1029/AR043P0035; Rignot E, 2002, ANN GLACIOL, V34, P189, DOI 10.3189/172756402781817950; Rignot E, 2001, J GLACIOL, V47, P213, DOI 10.3189/172756501781832340; Rignot EJ, 1998, SCIENCE, V281, P549, DOI 10.1126/science.281.5376.549; Rignot EJ, 1997, SCIENCE, V276, P934, DOI 10.1126/science.276.5314.934; ROBERTSON R, IN PRESS DEEP SEA RE; ROBIN GD, 1979, J GLACIOL, V24, P259; Russell-Head D., 1980, ANN GLACIOL, V1, P119, DOI [10.3189/S0260305500017092, DOI 10.3189/S0260305500017092]; Shepherd A, 2001, SCIENCE, V291, P862, DOI 10.1126/science.291.5505.862; Smith AM, 1996, J GEOPHYS RES-OCEANS, V101, P22749, DOI 10.1029/96JC02173; Thomas R., 1979, J GLACIOL, V24, P167, DOI DOI 10.3189/S0022143000014726; *UNESCO, 1978, 28 UNESCO, P29; USHIO S, 1993, JAPANESE ANTARCTIC R, V184; VANDERVEEN CJ, 1986, ANN GEOPHYS B-TERR P, V4, P45; Warner RC, 1998, ANN GLACIOL, V27, P161; Weertman J., 1974, J GLACIOL, V13, P3, DOI [DOI 10.3189/S0022143000023327, 10.3189/S0022143000023327]; Wendler G, 1996, J GLACIOL, V42, P447, DOI 10.3189/S0022143000003439; ZWALLY J, COMMUNICATION	40	383	394	2	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	2002	296	5575					2020	2023		10.1126/science.1070942	http://dx.doi.org/10.1126/science.1070942			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065835	Green Submitted			2022-12-28	WOS:000176273300051
J	Foster, G				Foster, G			Supporting community efforts to assist orphans in Africa	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CHILDREN; FAMILY; AIDS; CARE		Mutare Prov Hosp, Mutare, Zimbabwe		Foster, G (corresponding author), Mutare Prov Hosp, Mutare, Zimbabwe.							*AG INT DEV, 2001, PRINC GUID PROGR ORP; ANKRAH EM, 1993, AIDS CARE, V5, P5, DOI 10.1080/09540129308258580; Caldwell J. C., 1997, HLTH T REV S2, V7, P169; Drew RS, 1998, AIDS CARE, V10, pS9, DOI 10.1080/09540129850124325; Foster C, 2000, AIDS, V14, pS275; Foster G, 1996, AIDS CARE, V8, P389, DOI 10.1080/09540129650125597; Foster G, 1998, AIDS CARE, V10, pS17, DOI 10.1080/09540129850124334; FOSTER G, 1995, AIDS CARE, V7, P3, DOI 10.1080/09540129550126911; Foster G., 1997, HLTH T REV S2, V7, P155; FOSTER G, 2002, 14 INT C AIDS BARC S; FOSTER G, IN PRESS HIV DEV; Foster G., 2000, PSYCHOL HEALTH MED, V5, P55, DOI DOI 10.1080/135485000106007; FOSTER G, IN PRESS AIDS AFRICA; Hunter S, 2000, CHILDREN BRINK EXECU; HUNTER S, 1998, CHIDLREN BRINK STRAT; LEE T, 1999, FOCUS EVALUATION REP; LEVINE C, 1994, ORPHANS HIV EPIDEMIC; Makame V, 2002, ACTA PAEDIATR, V91, P459, DOI 10.1080/080352502317371724; Ntozi J P, 1997, Health Transit Rev, V7 Suppl, P1; PHIRI SN, 2001, EXPANDING STRENGTHEN; *SYN PROJ, 2001, USAID PROJ PROF CHIL; *UNAIDS, 1999, REV HOUS COMM RESP H; *UNAIDS, 2001, CAR OUR CHILDR PROM; *UNICEF, 2001, SIT AN ORPH CHILDR N; VERHOEF HS, 2002, PROMOTING POSITIVE C, V3; WOODS E, 2002, REALITY US RHETORIC	26	51	52	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 13	2002	346	24					1907	1910		10.1056/NEJMsb020718	http://dx.doi.org/10.1056/NEJMsb020718			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	561NA	12063378				2022-12-28	WOS:000176146100012
J	Thompson, JN; Cunningham, BM				Thompson, JN; Cunningham, BM			Geographic structure and dynamics of coevolutionary selection	NATURE			English	Article							YUCCA MOTH LINEAGE; LODGEPOLE PINE; GENE FLOW; MUTUALISM; PLANT; CROSSBILLS; GRADIENTS; EVOLUTION; VIRULENCE; PARASITES	Coevolution of species is one of the major processes organizing the Earth's biodiversity. Recent coevolutionary theory has indicated that the geographic structure of species has the potential to impose powerful and continuing effects on coevolutionary dynamics, if that structure creates selection mosaics and coevolutionary hotspots across landscapes(1-7). Here we confirm that current coevolutionary selection in interspecific interactions can be highly divergent across both narrow and broad geographic scales, thereby fuelling continuing coevolution of taxa. Study of a widespread plant-insect interaction across a broad range of habitats for several years showed that an insect functioning both as a pollinator and a floral parasite can be strongly mutualistic in some habitats but commensal or antagonistic in neighbouring habitats. The results for one of the habitats span seven years, demonstrating that the local structure of coevolutionary selection can remain stable across multiple generations. Conservation of the evolutionary processes maintaining long-term biological diversity may require preservation of the conditions that allow a long-term shifting geographic mosaic of coevolutionary hotspots and coldspots.	Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Santa Cruz, CA 95064 USA; Washington State Univ, Sch Life Sci, Pullman, WA 99164 USA	University of California System; University of California Santa Cruz; Washington State University	Thompson, JN (corresponding author), Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Earth & Marine Sci Bldg, Santa Cruz, CA 95064 USA.		Thompson, Jessica/GXW-0323-2022					Benkman CW, 1999, AM NAT, V153, pS75, DOI 10.1086/303213; Benkman CW, 2001, EVOLUTION, V55, P282, DOI 10.1111/j.0014-3820.2001.tb01293.x; Berenbaum MR, 1998, P NATL ACAD SCI USA, V95, P13743, DOI 10.1073/pnas.95.23.13743; Brodie ED, 1999, EVOLUTION, V53, P626, DOI 10.1111/j.1558-5646.1999.tb03798.x; Burdon JJ, 1999, AM NAT, V153, pS15, DOI 10.1086/303209; CAICCO SL, 1995, CONSERV BIOL, V9, P498, DOI 10.1046/j.1523-1739.1995.09030498.x; Case TJ, 2000, AM NAT, V155, P583, DOI 10.1086/303351; de Jong PW, 2001, MOL ECOL, V10, P1323, DOI 10.1046/j.1365-294X.2001.01268.x; Gomulkiewicz R, 2000, AM NAT, V156, P156, DOI 10.1086/303382; Hochberg ME, 1998, AM NAT, V152, P620, DOI 10.1086/286194; Hochberg ME, 2000, J EVOLUTION BIOL, V13, P213, DOI 10.1046/j.1420-9101.2000.00157.x; Holland JN, 1999, OECOLOGIA, V121, P405, DOI 10.1007/s004420050945; Kraaijeveld AR, 1999, AM NAT, V153, pS61, DOI 10.1086/303212; Lively CM, 1999, AM NAT, V153, pS34, DOI 10.1086/303210; Nuismer SL, 1999, P ROY SOC B-BIOL SCI, V266, P605, DOI 10.1098/rspb.1999.0679; Nuismer SL, 2000, EVOLUTION, V54, P1102; Parker MA, 1999, AM NAT, V153, pS48, DOI 10.1086/303211; PELLMYR O, 1992, P NATL ACAD SCI USA, V89, P2927, DOI 10.1073/pnas.89.7.2927; Pellmyr O, 1996, AM NAT, V148, P827, DOI 10.1086/285958; Pellmyr O, 1996, OECOLOGIA, V107, P595, DOI 10.1007/BF00333953; Radtkey RR, 1997, P NATL ACAD SCI USA, V94, P9740, DOI 10.1073/pnas.94.18.9740; Ricketts T. H., 1999, TERRESTRIAL ECOREGIO; Thompson JD., 1994, COEVOLUTIONARY PROCE; THOMPSON JN, 1992, ECOLOGY, V73, P1780, DOI 10.2307/1940029	24	346	355	6	250	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 13	2002	417	6890					735	738		10.1038/nature00810	http://dx.doi.org/10.1038/nature00810			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	561QY	12066183				2022-12-28	WOS:000176154700043
J	Douglas, SA; Tayara, L; Ohlstein, EH; Halawa, N; Giaid, A				Douglas, SA; Tayara, L; Ohlstein, EH; Halawa, N; Giaid, A			Congestive heart failure and expression of myocardial urotensin II	LANCET			English	Article							CARDIOVASCULAR ACTIONS; CONFOCAL MICROSCOPY; ENDOTHELIUM; ARTERIES	Background Human urotensin II has several cardiovascular actions, including potent vasoactive, and cardiac inotropic and hypertropic properties. Our aim was to ascertain degree of expression of urotensin II and its receptor GPR14 (now known as UT receptor) in the myocardium of patients with congestive heart failure (CHF). Methods We obtained specimens of myocardium from the hearts of 19 patients with end-stage CHF (12 ischaemic heart disease, seven dilated cardiomyopathy), five patients with early-stage CHF, and eight healthy controls. We used immunohistochemistry, in-situ hybridisation, reverse transcriptase-PCR (RT-PCR), and fluorescein isothiocyanate (FITC)-conjugated urotensin II to ascertain degree of myocardial expression of urotensin II and binding urotensin receptor. Findings Our results showed strong expression of urotensin II in the cardiomyocytes, and to a lesser extent in the vascular smooth muscle cells, endothelial cells, and inflammatory cells of patients with end-stage CHF. There was significantly less urotensin II expression in the myocardium of patients with early-stage CHF (p<0.0001). Also, there was little to no urotensin II expression in the myocardium of healthy controls. Myocardial expression of urotensin II correlated significantly with left ventricular end-diastolic dimension (p=0.0092), and inversely with election fraction (p=0.0002). RT-PCR showed increased concentrations of urotensin II and presence of urotensin receptor mRNA in the myocardium of patients with CHF. The confocal microscopy results showed a significant increase in the binding sites for urotensin in the myocardium of patients with end-stage CHF (P<0.0001). Interpretation Our findings suggest a possible role for urotensin II in the cardiac dysfunction and remodelling characteristic of CHF.	McGill Univ, Ctr Hlth, Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada; GlaxoSmithKline, Cardiovasc & Urogenital Ctr Excellence Drug Disco, King Of Prussia, PA USA	McGill University; GlaxoSmithKline	Giaid, A (corresponding author), McGill Univ, Ctr Hlth, Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada.	adel.giaid@mcgill.ca						Ames RS, 1999, NATURE, V401, P282, DOI 10.1038/45809; AMES RS, 1998, P NATL ACAD SCI USA, V22, P5803; Beaudet A, 1998, BRAZ J MED BIOL RES, V31, P1479, DOI 10.1590/S0100-879X1998001100017; BELL JR, 1974, AM J MED SCI, V268, P2, DOI 10.1097/00000441-197407000-00001; Bern H.A., 1985, Recent Progress in Hormone Research, V41, P533; Bkaily G, 1997, MOL CELL BIOCHEM, V172, P171, DOI 10.1023/A:1006840228104; Bottrill FE, 2000, BRIT J PHARMACOL, V130, P1865, DOI 10.1038/sj.bjp.0703513; Camarda V, 2002, N-S ARCH PHARMACOL, V365, P141, DOI 10.1007/s00210-001-0503-0; Douglas SA, 2000, CIRCULATION, V102, P113; Douglas SA, 2000, J CARDIOVASC PHARM, V36, pS163, DOI 10.1097/00005344-200036051-00051; DOUGLAS SA, 2000, IUPHAR COMPENDIUM RE, P365; Fukuchi M, 1998, CIRCULATION, V98, P132, DOI 10.1161/01.CIR.98.2.132; GONZALEZ GC, 1992, PEPTIDES, V13, P695, DOI 10.1016/0196-9781(92)90175-3; HAZON N, 1993, AM J PHYSIOL, V265, pR573, DOI 10.1152/ajpregu.1993.265.3.R573; Hillier C, 2001, CIRCULATION, V103, P1378, DOI 10.1161/01.CIR.103.10.1378; LeMevel JC, 1996, AM J PHYSIOL-REG I, V271, pR1335, DOI 10.1152/ajpregu.1996.271.5.R1335; Leslie SJ, 2000, CIRCULATION, V102, P113; LIMA JAC, 1993, J AM COLL CARDIOL, V21, P1741, DOI 10.1016/0735-1097(93)90397-J; Maguire JJ, 2000, BRIT J PHARMACOL, V131, P441, DOI 10.1038/sj.bjp.0703601; Opgaard OS, 2000, EUR J PHARMACOL, V406, P265, DOI 10.1016/S0014-2999(00)00672-5; PERKINS TDJ, 1990, BIOCHEM SOC T, V18, P918, DOI 10.1042/bst0180918; Russell FD, 2001, BRIT J PHARMACOL, V132, P5, DOI 10.1038/sj.bjp.0703811; SABBAH HN, 1981, AM J PHYSIOL, V240, pH920, DOI 10.1152/ajpheart.1981.240.6.H920; Tzanidis A, 2000, EUR HEART J, V21, P72; Wilkinson IB, 2002, CARDIOVASC RES, V53, P341, DOI 10.1016/S0008-6363(01)00485-0; YANO K, 1995, GEN COMP ENDOCR, V97, P103, DOI 10.1006/gcen.1995.1010	26	225	256	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 8	2002	359	9322					1990	1997		10.1016/S0140-6736(02)08831-1	http://dx.doi.org/10.1016/S0140-6736(02)08831-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076554				2022-12-28	WOS:000176232500011
J	Kessler, C				Kessler, C			Need for attention to mental health of young offenders	LANCET			English	Editorial Material									Albert Einstein Coll Med, Bronx Lebanon Clin & Adolescent Psychiat Inst, Bronx, NY 10457 USA	Yeshiva University; Albert Einstein College of Medicine	Kessler, C (corresponding author), Albert Einstein Coll Med, Bronx Lebanon Clin & Adolescent Psychiat Inst, Bronx, NY 10457 USA.							ARROYO W, 2001, AACAP TASK FORC JUV; BORDUIN CM, 1990, INT J OFFENDER THER, V34, P105, DOI 10.1177/0306624X9003400204; *COAL JUV JUST, 1999, AINTS PLAC ANYB WOUL; COOPER CS, 2002, JUVENILE FAMILY DRUG; HANSEN G, 2001, AACAP TASK FORC JUV; KAMRAOTT B, 2000, JUVENILLE JUNCTICE J, V7, P1; KESSLER C, 2000, YOUNG FORCE S BRONX; LEONE P, 1907, CHILDRENS LEGAL RIGH, V8, P1	8	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 8	2002	359	9322					1956	1957		10.1016/S0140-6736(02)08843-8	http://dx.doi.org/10.1016/S0140-6736(02)08843-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	563BA	12076545				2022-12-28	WOS:000176232500002
J	Paxinos, EE; James, HF; Olson, SL; Ballou, JD; Leonard, JA; Fleischer, RC				Paxinos, EE; James, HF; Olson, SL; Ballou, JD; Leonard, JA; Fleischer, RC			Prehistoric decline of genetic diversity in the nene	SCIENCE			English	Article							POPULATIONS		Smithsonian Inst, Conservat & Res Ctr, Washington, DC 20008 USA; Smithsonian Inst, Natl Museum Nat Hist, Dept Systemat Biol, Washington, DC 20560 USA; Univ Calif Los Angeles, Dept Ecol Evolut & Organismal Biol, Los Angeles, CA 90095 USA	Smithsonian Institution; Smithsonian Institution; Smithsonian National Museum of Natural History; University of California System; University of California Los Angeles	Fleischer, RC (corresponding author), Smithsonian Inst, Conservat & Res Ctr, 3001 Connecticut Ave NW, Washington, DC 20008 USA.		Paxinos, Ellen/AAG-2907-2019; Leonard, Jennifer/A-7894-2010	Paxinos, Ellen/0000-0002-1710-8064; James, Helen/0000-0002-2495-6133; Leonard, Jennifer/0000-0003-0291-7819				Frankham R, 1997, HEREDITY, V78, P311, DOI 10.1038/hdy.1997.46; JAMES HF, UNPUB; Kirch P.V., 1985, FEATHERED GODS FISHH; Olson SL, 1991, ORNITHOL MONOGR, V45, P1, DOI DOI 10.2307/40166794; Paxinos EE, 2002, P NATL ACAD SCI USA, V99, P1399, DOI 10.1073/pnas.032166399; RAVE EH, 1994, CONSERV BIOL, V8, P744, DOI 10.1046/j.1523-1739.1994.08030744.x; [No title captured]	7	50	51	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 7	2002	296	5574					1827	1827		10.1126/science.296.5574.1827	http://dx.doi.org/10.1126/science.296.5574.1827			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052947	Green Submitted			2022-12-28	WOS:000176054300035
J	Schneider, DS				Schneider, DS			Plant immunity and film noir: What gumshoe detectives can teach us about plant-pathogen interactions	CELL			English	Review							COMMON	Plant cells practice constant vigilance using resistance (R) proteins to monitor pathogenic processes. Three papers published recently in Cell and one in Science provide support for a model in which plant cells set up surveillance of signal transduction pathways, preparing to destroy the cell if any untoward fiddling with cellular physiology is detected. The demonstration of three separate examples of such a system suggests that it is broadly used and should provoke a reexamination of microbial pathogenesis in animal cells to look for similar mechanisms.	Stanford Med Sch, Dept Microbiol & Immunol, Palo Alto, CA 94303 USA	Stanford University	Schneider, DS (corresponding author), Stanford Med Sch, Dept Microbiol & Immunol, Palo Alto, CA 94303 USA.							Austin MJ, 2002, SCIENCE, V295, P2077, DOI 10.1126/science.1067747; Azevedo C, 2002, SCIENCE, V295, P2073, DOI 10.1126/science.1067554; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; INITIATIVE TAG, 2000, NATURE, V408, P796, DOI DOI 10.1038/35048692; Kim YJ, 2002, CELL, V109, P589, DOI 10.1016/S0092-8674(02)00743-2; Kruger J, 2002, SCIENCE, V296, P744, DOI 10.1126/science.1069288; Mackey D, 2002, CELL, V108, P743, DOI 10.1016/S0092-8674(02)00661-X; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Monack D, 2000, INT J MED MICROBIOL, V290, P7; Reyburn HT, 1997, NATURE, V386, P514, DOI 10.1038/386514a0; Shao F, 2002, CELL, V109, P575, DOI 10.1016/S0092-8674(02)00766-3; Staskawicz BJ, 2001, SCIENCE, V292, P2285, DOI 10.1126/science.1062013; van der Biezen EA, 1998, TRENDS BIOCHEM SCI, V23, P454, DOI 10.1016/S0968-0004(98)01311-5	15	48	51	0	11	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 31	2002	109	5					537	540		10.1016/S0092-8674(02)00764-X	http://dx.doi.org/10.1016/S0092-8674(02)00764-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	558GL	12062095	Bronze			2022-12-28	WOS:000175957900001
J	Ebnoether, M; Stentoft, J; Ford, J; Buhl, L; Gratwohl, A				Ebnoether, M; Stentoft, J; Ford, J; Buhl, L; Gratwohl, A			Cerebral oedema as a possible complication of treatment with imatinib	LANCET			English	Article							CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; INHIBITOR	Imatinib Is a potent drug used In treatment of chronic myeloid leukaemia (CML). It acts by Inhibition of the CML-specific p210 BCR-ABL tyrosine kinase, but also blocks other pathways such as platelet-derived growth factor (PDGF) and c-kit receptor signalling. Clinical trials have confirmed the efficacy of imatinib, which has toxic effects In cells that express BCR-ABL. Side-effects, although frequent, are generally mild and Include superficial oedema and fluid retention. Here, we describe two patients with cerebral oedema, which In one patient was fatal. The pathophysiological mechanisms remain unknown, although the drug could act through Inhibition of the PDGF receptor.	Univ Basel Hosp, Dept Internal Med, Div Haematol, CH-4031 Basel, Switzerland; Novartis Pharma Schweiz AG, Basel, Switzerland; Aarhus Univ Hosp, Dept Haematol, Aarhus, Denmark; Aarhus Univ Hosp, Dept Pathol, Aarhus, Denmark	University of Basel; Novartis; Aarhus University; Aarhus University	Gratwohl, A (corresponding author), Univ Basel Hosp, Dept Internal Med, Div Haematol, CH-4031 Basel, Switzerland.							Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Heuchel R, 1999, P NATL ACAD SCI USA, V96, P11410, DOI 10.1073/pnas.96.20.11410; Pietras K, 2001, CANCER RES, V61, P2929	5	43	46	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 18	2002	359	9319					1751	1752		10.1016/S0140-6736(02)08616-6	http://dx.doi.org/10.1016/S0140-6736(02)08616-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049868				2022-12-28	WOS:000175740500016
J	Biellik, R; Madema, S; Taole, A; Kutsulukuta, A; Allies, E; Eggers, R; Ngcobo, N; Nxumalo, M; Shearley, A; Mabuzane, E; Kufa, E; Okwo-Bele, JM				Biellik, R; Madema, S; Taole, A; Kutsulukuta, A; Allies, E; Eggers, R; Ngcobo, N; Nxumalo, M; Shearley, A; Mabuzane, E; Kufa, E; Okwo-Bele, JM			First 5 years of measles elimination in southern Africa: 1996-2000	LANCET			English	Article							AMERICA	Background Measles is the leading cause of vaccine-preventable death in Africa. Regional measles elimination is considered feasible using current vaccines and a series of WHO-recommended strategies. We aimed to interrupt transmission of measles, and to use case-based surveillance to show the effect of such interruption. Methods In southern Africa from 1996, seven countries with a total population of approximately 70 million and with relatively high routine vaccination coverage implemented measles elimination strategies. In addition to routine measles immunisation at 9 months of age, these included nationwide catch-up campaigns among children aged 9 months to 14 years, then follow-up campaigns every 3-4 years among children aged 9-59 months, and the establishment of case-based measles surveillance with serological diagnostic confirmation. Results Nearly 24 million children aged 9 months to 14 years were vaccinated, with overall vaccination coverage of 91%. Reported clinical measles cases declined from 60 000 in 1996 to 117 laboratory-confirmed measles cases in 2000. Reported measles deaths declined from 166 in 1996 to zero in 2000. No increase in adverse events was noted after the measles vaccination campaign. Conclusion A reduction in measles mortality and morbidity can be achieved in very low-income countries, in countries that split their vaccination campaigns by geographical area or by age-group of the target population, and where initial routine measles vaccination coverage among infants was <90%, even when prevalance of HIV/AIDS was extremely high. Continued high-level national commitment will be crucial to implementation and maintenance of proven strategies in southern Africa.	WHO, Harare, Zimbabwe; Minist Hlth, Gaborone, Botswana; Minist Hlth & Social Serv, Maseru, Lesotho; Minist Hlth & Populat, Lilongwe, Malawi; Minist Hlth, Windhoek, Namibia; Dept Hlth, Pretoria, South Africa; Minist Hlth, Mbabane, Eswatini; Minist Hlth & Child Welf, Harare, Zimbabwe	World Health Organization	Biellik, R (corresponding author), WHO, POB 5160, Harare, Zimbabwe.	biellikr@who.co.zw						[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; [Anonymous], 1999, Wkly Epidemiol Rec, V74, P429; BABAD HR, 1995, EPIDEMIOL INFECT, V114, P319, DOI 10.1017/S0950268800057976; BIELLIK RJ, 1995, INT VIR C JOH JUL 14; Cai ZJ, 1999, WHO TECH REP SER, V887, P1; CHRISTOPHER JL, 1996, GLOBAL BURDEN DIS CO, P17; CUTTS FT, 1995, BIOLOGICALS, V23, P95; De Serres G, 2000, AM J EPIDEMIOL, V151, P1039, DOI 10.1093/oxfordjournals.aje.a010145; deQuadros CA, 1996, JAMA-J AM MED ASSOC, V275, P224, DOI 10.1001/jama.275.3.224; Helfand RF, 1997, J INFECT DIS, V175, P195, DOI 10.1093/infdis/175.1.195; Hersh BS, 2000, LANCET, V355, P1943, DOI 10.1016/S0140-6736(00)02325-4; MARSHALL T, IN PRESS NOSOCOMIAL; *UNICEF, 1990, PLAN ACT IMPL WORLD; UZICANIN A, IN PRESS IMPACT 1996; VANDENHEEVER J, 1999, SO AFR MEASL EL M HA; *WHO, 2001, WHOVB0113; *WORLD HLTH ASS, 1989, WHA4232	18	98	102	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 4	2002	359	9317					1564	1568		10.1016/S0140-6736(02)08517-3	http://dx.doi.org/10.1016/S0140-6736(02)08517-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047966				2022-12-28	WOS:000175460700010
J	Springer, J				Springer, J			A slice of bread	LANCET			English	Editorial Material									Amer Acad Clin Endocrinologists, Overland Pk, KS 66210 USA		Springer, J (corresponding author), Amer Acad Clin Endocrinologists, Overland Pk, KS 66210 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 4	2002	359	9317					1604	1604		10.1016/S0140-6736(02)08519-7	http://dx.doi.org/10.1016/S0140-6736(02)08519-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047985				2022-12-28	WOS:000175460700029
J	Akagi, H; Kumar, TM				Akagi, H; Kumar, TM			Lesson of the week - Akathisia: overlooked at a cost	BRITISH MEDICAL JOURNAL			English	Review							INDUCED MOVEMENT-DISORDERS; METOCLOPRAMIDE		St Jamess Univ Hosp, Dept Liaison Psychiat, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Akagi, H (corresponding author), St Jamess Univ Hosp, Dept Liaison Psychiat, Leeds LS9 7TF, W Yorkshire, England.							Chow LY, 1997, INT J CLIN PRACT, V51, P330; Eberstein S, 1996, BIOL PSYCHIAT, V40, P798, DOI 10.1016/0006-3223(96)00268-5; Eichhammer P, 2000, AM J MED GENET, V96, P187, DOI 10.1002/(SICI)1096-8628(20000403)96:2<187::AID-AJMG13>3.0.CO;2-8; FLEISHMAN SB, 1994, AM J PSYCHIAT, V151, P763; Horikawa N, 1999, GEN HOSP PSYCHIAT, V21, P134; Hung Y C, 1999, Acta Anaesthesiol Sin, V37, P151; JimenezJimenez FJ, 1997, DRUG SAFETY, V16, P180, DOI 10.2165/00002018-199716030-00004; LaGorio J, 1998, ANESTH ANALG, V87, P224, DOI 10.1097/00000539-199807000-00045; LopezAlemany M, 1997, J NEUROL, V244, P131, DOI 10.1007/s004150050062; POWER AC, 1992, BRIT J PSYCHIAT, V161, P735, DOI 10.1192/bjp.161.6.735; SACHDEV P, 1991, J NERV MENT DIS, V179, P381, DOI 10.1097/00005053-199107000-00001; WEIDEN PJ, 1987, AM J PSYCHIAT, V144, P1148	12	22	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 22	2002	324	7352					1506	1507		10.1136/bmj.324.7352.1506	http://dx.doi.org/10.1136/bmj.324.7352.1506			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567ZL	12077042	Green Published			2022-12-28	WOS:000176517900027
J	Cassell, OCS				Cassell, OCS			Lesson of the week - Death from tetanus after a pretibial laceration	BRITISH MEDICAL JOURNAL			English	Review									Radcliffe Infirm, Dept Plast & Reconstruct Surg, Oxford OX2 6HE, England	Radcliffe Infirmary	Cassell, OCS (corresponding author), Radcliffe Infirm, Dept Plast & Reconstruct Surg, Oxford OX2 6HE, England.							AMY BW, 1985, J TRAUMA, V25, P654, DOI 10.1097/00005373-198507000-00014; BRAND DA, 1983, NEW ENGL J MED, V309, P636, DOI 10.1056/NEJM198309153091104; Cassell OCS, 2002, BRIT J PLAST SURG, V55, P215, DOI 10.1054/bjps.2001.3742; DIXON AM, 1988, BMJ-BRIT MED J, V297, P598, DOI 10.1136/bmj.297.6648.598; LUISTO M, 1993, ANN CHIR GYNAECOL FE, V82, P25; MONTAGUE A, 1990, ARCH EMERG MED, V7, P163; Richardson James P., 1993, Journal of Emergency Medicine, V11, P737, DOI 10.1016/0736-4679(93)90634-J; SALISBURY RM, 1996, IMMUNISATION INFECT; WHITE WG, 1980, LANCET, V8158, P42	9	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 15	2002	324	7351					1442	1443		10.1136/bmj.324.7351.1442	http://dx.doi.org/10.1136/bmj.324.7351.1442			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	565CQ	12065271	Green Published			2022-12-28	WOS:000176351400023
J	Perl, TM; Cullen, JJ; Wenzel, RP; Zimmerman, MB; Pfaller, MA; Sheppard, D; Twombley, J; French, PP; Herwaldt, LA				Perl, TM; Cullen, JJ; Wenzel, RP; Zimmerman, MB; Pfaller, MA; Sheppard, D; Twombley, J; French, PP; Herwaldt, LA		Mupirocin Risk Staphyloccocus Aure	Intranasal mupirocin to prevent postoperative staphylococcus aureus infections	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURGICAL-SITE INFECTIONS; NASAL CARRIAGE; NOSOCOMIAL INFECTIONS; METHICILLIN-RESISTANT; HEMODIALYSIS-PATIENTS; WOUND INFECTIONS; ELIMINATION; OINTMENT; CALCIUM; COST	Background: Patients with nasal carriage of Staphylococcus aureus have an increased risk of surgical-site infections caused by that organism. Treatment with mupirocin ointment can reduce the rate of nasal carriage and may prevent postoperative S. aureus infections. Methods: We conducted a randomized, double-blind, placebo-controlled trial to determine whether intranasal treatment with mupirocin reduces the rate of S. aureus infections at surgical sites and prevents other nosocomial infections. Results: Of 4030 enrolled patients who underwent general, gynecologic, neurologic, or cardiothoracic surgery, 3864 were included in the intention-to-treat analysis. Overall, 2.3 percent of mupirocin recipients and 2.4 percent of placebo recipients had S. aureus infections at surgical sites. Of the 891 patients (23.1 percent of the 3864 who completed the study) who had S. aureus in their anterior nares, 444 received mupirocin and 447 received placebo. Among the patients with nasal carriage of S. aureus, 4.0 percent of those who received mupirocin had nosocomial S. aureus infections, as compared with 7.7 percent of those who received placebo (odds ratio for infection, 0.49; 95 percent confidence interval, 0.25 to 0.92; P=0.02). Conclusions: Prophylactic intranasal application of mupirocin did not significantly reduce the rate of S. aureus surgical-site infections overall, but it did significantly decrease the rate of all nosocomial S. aureus infections among the patients who were S. aureus carriers.	Johns Hopkins Univ Hosp, Johns Hopkins Med Inst, Div Infect Dis, Baltimore, MD 21287 USA; Johns Hopkins Univ Hosp, Dept Hosp Epidemiol & Infect Control, Baltimore, MD 21287 USA; Univ Iowa, Coll Med, Iowa City, IA USA; Univ Iowa, Coll Publ Hlth, Iowa City, IA USA; Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA; GlaxoSmithKline, Collegeville, PA USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Iowa; University of Iowa; University of Iowa; GlaxoSmithKline	Perl, TM (corresponding author), Johns Hopkins Univ Hosp, Johns Hopkins Med Inst, Div Infect Dis, 425 Osler,600 N Wolfe St, Baltimore, MD 21287 USA.			Cullen, Joseph/0000-0002-2222-1328; Herwaldt, Loreen/0000-0002-9530-6859				Baron E.J., 1999, MANUAL CLIN MICROBIO, V7th; Bloom BS, 1996, AM J KIDNEY DIS, V27, P687, DOI 10.1016/S0272-6386(96)90104-3; BOELAERT JR, 1991, J HOSP INFECT, V19, P41, DOI 10.1016/0195-6701(91)90202-J; BOELAERT JR, 1993, NEPHROL DIAL TRANSPL, V8, P235; BOYCE JM, 1990, INFECT CONT HOSP EP, V11, P89; BRODERICK A, 1990, AM J EPIDEMIOL, V131, P734, DOI 10.1093/oxfordjournals.aje.a115558; Campbell W, 1999, CRIT CARE MED, V27, P798, DOI 10.1097/00003246-199904000-00039; Cimochowski GE, 2001, ANN THORAC SURG, V71, P1572, DOI 10.1016/S0003-4975(01)02519-X; CULVER DH, 1991, AM J MED, V91, pS152, DOI 10.1016/0002-9343(91)90361-Z; DOEBBELING BN, 1993, CLIN INFECT DIS, V17, P466, DOI 10.1093/clinids/17.3.466; EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428, DOI 10.1128/CMR.6.4.428-442.1993; Finlay JE, 1997, ANTIMICROB AGENTS CH, V41, P1137, DOI 10.1128/AAC.41.5.1137; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Gernaat-van der Sluis AJ, 1998, ACTA ORTHOP SCAND, V69, P412; GREEN JW, 1977, ANN SURG, V185, P264, DOI 10.1097/00000658-197703000-00002; HALL M, 1998, DHHS PHS PUBL, P98; HORAN TC, 1993, INFECT CONT HOSP EP, V14, P73, DOI 10.2307/30147164; Kirkland KB, 1999, INFECT CONT HOSP EP, V20, P725, DOI 10.1086/501572; Kluytmans J, 1997, CLIN MICROBIOL REV, V10, P505, DOI 10.1128/CMR.10.3.505; Kluytmans JAJW, 1996, INFECT CONT HOSP EP, V17, P793; Kluytmans JAJW, 1996, INFECT CONT HOSP EP, V17, P780; MCCABE WR, 1962, ARCH INTERN MED, V110, P856, DOI 10.1001/archinte.1962.03620240038007; MEST DR, 1994, ANESTH ANALG, V78, P644; MOR V, 1984, CANCER-AM CANCER SOC, V53, P2002, DOI 10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W; MORALES E, 1993, 33 INT C ANT AG CHEM; *NAT COMM CLIN LAB, 1999, M100S9 NCCLS, V19; NELSON RM, 1986, ANN THORAC SURG, V42, P240, DOI 10.1016/S0003-4975(10)62726-9; Perl TM, 1998, ANN PHARMACOTHER, V32, pS7, DOI 10.1177/106002809803200104; Pujol M, 1996, AM J MED, V100, P509, DOI 10.1016/S0002-9343(96)00014-9; REAGAN DR, 1991, ANN INTERN MED, V114, P101, DOI 10.7326/0003-4819-114-2-101; Tenover FC, 1997, INFECT CONT HOSP EP, V18, P426; TRILLA A, 1993, INFECT CONT HOSP EP, V14, P29; VandenBergh MFQ, 1996, INFECT CONT HOSP EP, V17, P786; von Eiff C, 2001, NEW ENGL J MED, V344, P11, DOI 10.1056/NEJM200101043440102; WENZEL RP, 1995, J HOSP INFECT, V31, P13, DOI 10.1016/0195-6701(95)90079-9	35	521	532	1	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 13	2002	346	24					1871	1877		10.1056/NEJMoa003069	http://dx.doi.org/10.1056/NEJMoa003069			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	561NA	12063371				2022-12-28	WOS:000176146100005
J	Balk, EM; Bonis, PAL; Moskowitz, H; Schmid, CH; Ioannidis, JPA; Wang, CC; Lau, J				Balk, EM; Bonis, PAL; Moskowitz, H; Schmid, CH; Ioannidis, JPA; Wang, CC; Lau, J			Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CLINICAL-TRIALS; SYSTEMATIC REVIEWS; METHODOLOGICAL QUALITY; OTITIS-MEDIA; HEALTH-CARE; EFFICACY; THERAPY; MORTALITY; BIAS	Context Specific features of trial quality maybe associated with exaggeration or shrinking of the observed treatment effect in randomized studies. Therefore, assessment of trial quality is often used in meta-analysis. However, the degree to which specific quality measures are associated with treatment effects has not been well established across a broad range of clinical areas. Objective To determine if quality measures are associated with treatment effect size in randomized controlled trials (RCTs). Design Quality measures from published quality assessment scales were evaluated in RCTs included in meta-analyses from 4 medical areas (cardiovascular disease, infectious disease, pediatrics, and surgery). Included meta-analyses incorporated at least 6 RCTs, examined dichotomous outcomes, and demonstrated significant between-study heterogeneity in the odds ratio (OR) scale. Main Outcome Measures Relative ORs comparing overall treatment effect (summary OR) of high- vs low-quality studies, as determined by each quality measure, with relative ORs less than 1 indicating larger treatment effect in low-quality studies. Results Twenty-four quality measures were analyzed for 276 RCTs from 26 meta-analyses. Relative ORs of high- vs low-quality studies for these quality measures ranged from 0.83 to 1.26; none was statistically significantly associated with treatment effect. The proportion of studies fulfilling specific quality measures varied widely in the 4 medical areas. In analyses limited to specific medical areas, placebo control, multicenter studies, study country, caregiver blinding, and statistical methods were significantly associated with treatment effect on 7 occasions. These relative ORs ranged from 0.40 to 1.74. However, the directions of these associations were not consistent. Conclusions Individual quality measures are not reliably associated with the strength of treatment effect across studies and medical areas. Although use of specific quality measures may be appropriate in specific well-defined areas in which there is pertinent evidence, findings of associations with treatment effect cannot be generalized to all clinical areas or meta-analyses.	Tufts Univ, New England Med Ctr, Sch Med, Div Clin Care Res,Evidence Based Practice Ctr, Boston, MA 02111 USA; Univ Ioannina, Sch Med,Fdn Res & Technol Hellas, Dept Hyg & Epidemiol,Biomed Res Inst, Clin Trials & Evidence Based Med Unit, GR-45110 Ioannina, Greece	Tufts Medical Center; Tufts University; Foundation for Research & Technology - Hellas (FORTH); University of Ioannina	Lau, J (corresponding author), Tufts Univ, New England Med Ctr, Sch Med, Div Clin Care Res,Evidence Based Practice Ctr, 750 Washington St,63, Boston, MA 02111 USA.	JLau1@lifespan.org	Schmid, Christopher H./J-2398-2014; Ioannidis, John P. A./G-9836-2011; Balk, Ethan/AAJ-2547-2020	Schmid, Christopher H./0000-0002-0855-5313; 	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000060] Funding Source: NIH RePORTER; AHRQ HHS [T32 HS00060] Funding Source: Medline; PHS HHS [290-97-0019] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1988, BRIT MED J, V296, P320; ASSENDELFT WJJ, 1995, JAMA-J AM MED ASSOC, V274, P1942, DOI 10.1001/jama.274.24.1942; Ausejo M, 1999, BRIT MED J, V319, P595, DOI 10.1136/bmj.319.7210.595; BECKERMAN H, 1992, PHYS THER, V72, P483, DOI 10.1093/ptj/72.7.483; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Berlin JA, 1999, JAMA-J AM MED ASSOC, V282, P1083, DOI 10.1001/jama.282.11.1083; Bhuta T, 1998, ARCH DIS CHILD-FETAL, V79, pF26, DOI 10.1136/fn.79.1.F26; BROWN SA, 1991, NURS RES, V40, P352; Cates C, 2000, LANCET, V355, P750, DOI 10.1016/S0140-6736(05)72157-7; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CHAN VMY, 1994, CAN J SURG, V37, P457; CHO MK, 1994, JAMA-J AM MED ASSOC, V272, P101, DOI 10.1001/jama.272.2.101; Chung RS, 1999, SURG ENDOSC-ULTRAS, V13, P689, DOI 10.1007/s004649901074; Clark HD, 1999, CONTROL CLIN TRIALS, V20, P448, DOI 10.1016/S0197-2456(99)00026-4; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; de Koning HJ, 2000, LANCET, V355, P80, DOI 10.1016/S0140-6736(99)00419-5; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; EVANS M, 1985, BRIT J SURG, V72, P256, DOI 10.1002/bjs.1800720403; Gelman Andrew, 1995, BAYESIAN DATA ANAL; GOODMAN SN, 1994, ANN INTERN MED, V121, P11, DOI 10.7326/0003-4819-121-1-199407010-00003; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; Gotzsche PC, 2000, LANCET, V355, P129, DOI 10.1016/S0140-6736(99)06065-1; HINE LK, 1989, JAMA-J AM MED ASSOC, V262, P3037, DOI 10.1001/jama.262.21.3037; Ioannidis JPA, 1998, LANCET, V352, P590, DOI 10.1016/S0140-6736(98)22034-4; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P281, DOI 10.1001/jama.279.4.281; Ioannidis JPA, 2001, P NATL ACAD SCI USA, V98, P831, DOI 10.1073/pnas.021529998; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JEFFERSON TO, 2000, COCHRANE DATABASE SY, V2; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; Kellner JD, 1996, ARCH PEDIAT ADOL MED, V150, P1166, DOI 10.1001/archpedi.1996.02170360056009; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; Kozyrskyj AL, 1998, JAMA-J AM MED ASSOC, V279, P1736, DOI 10.1001/jama.279.21.1736; Lachin JM, 2000, CONTROL CLIN TRIALS, V21, P167, DOI 10.1016/S0197-2456(00)00046-5; LANGLEY JM, 1993, CLIN INFECT DIS, V17, P98, DOI 10.1093/clinids/17.1.98; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LEIZOROVICZ A, 1983, EUR J CLIN PHARMACOL, V24, P333, DOI 10.1007/BF00610050; Linde K, 1999, J CLIN EPIDEMIOL, V52, P631, DOI 10.1016/S0895-4356(99)00048-7; MacRae HM, 1998, DIS COLON RECTUM, V41, P180, DOI 10.1007/BF02238246; MARTINHIRSCH PL, 2000, COCHRANE DATABASE SY, V2; MCINTOSH HM, 2000, COCHRANE DATABASE SY, V2; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Moher D, 1999, Health Technol Assess, V3, pi; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; Moher D, 2000, BRIT J SURG, V87, P1448, DOI 10.1046/j.1365-2168.2000.01610.x; MULROW CD, 1998, COCHRANE COLLABORATI, V4; Nelson RL, 1999, DIS COLON RECTUM, V42, P1424, DOI 10.1007/BF02235041; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; ROSENFELD RM, 1992, OTOLARYNG HEAD NECK, V106, P378, DOI 10.1177/019459989210600411; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; Sauerland S, 1998, LANGENBECK ARCH SURG, V383, P289, DOI 10.1007/s004230050135; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schulz KF, 1996, BRIT MED J, V312, P742; SMAILL F, 2000, COCHRANE DATABASE SY, V2; Smieja MJ, 2000, COCHRANE DATABASE SY, V2, DOI 10.1002/14651858.CD001363; TEO KK, 1993, DRUGS, V46, P347, DOI 10.2165/00003495-199346030-00002; Verhagen AP, 2001, J CLIN EPIDEMIOL, V54, P651, DOI 10.1016/S0895-4356(00)00360-7; Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1988, LANCET, V1, P1088	69	335	337	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	2002	287	22					2973	2982		10.1001/jama.287.22.2973	http://dx.doi.org/10.1001/jama.287.22.2973			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	561EY	12052127	Bronze			2022-12-28	WOS:000176128300027
J	Demers, LM; Ginger, DS; Park, SJ; Li, Z; Chung, SW; Mirkin, CA				Demers, LM; Ginger, DS; Park, SJ; Li, Z; Chung, SW; Mirkin, CA			Direct patterning of modified oligonucleotides on metals and insulators by dip-pen nanolithography	SCIENCE			English	Article							DNA; INK; GOLD	The use of direct-write dip-pen nanolithography (DPN) to generate covalently anchored, nanoscale patterns of oligonucleotides on both metallic and insulating substrates is described. Modification of DNA with hexanethiol groups allowed patterning on gold, and oligonucleotides bearing 5'-terminal acrylamide groups could be patterned on derivatized silica. Feature sizes ranging from many micrometers to less than 100 nanometers were achieved, and the resulting patterns exhibited the sequence-specific binding properties of the DNA from which they were composed. The patterns can be used to direct the assembly of individual oligonucleotide-modified particles on a surface, and the deposition of multiple DNA sequences in a single array is demonstrated.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Ctr Nanofabricat & Mol Self Assembly, Evanston, IL 60208 USA	Northwestern University; Northwestern University	Mirkin, CA (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	camirkin@chem.nwu.edu	Chung, Sungwook/ABH-7052-2020; Chung, Sungwook/H-6248-2012; Park, So-Jung/F-9471-2017; Ginger, David S/C-4866-2011; Mirkin, Chad A/E-3911-2010	Chung, Sungwook/0000-0001-7479-8025; Ginger, David S/0000-0002-9759-5447; Mirkin, Chad/0000-0002-6634-7627	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [F32HG002463] Funding Source: NIH RePORTER; NHGRI NIH HHS [1 F32 HG02463] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; Cui Y, 2001, SCIENCE, V293, P1289, DOI 10.1126/science.1062711; Demers LM, 2001, ANGEW CHEM INT EDIT, V40, P3071, DOI 10.1002/1521-3773(20010817)40:16<3071::AID-ANIE3071>3.0.CO;2-S; Herne TM, 1997, J AM CHEM SOC, V119, P8916, DOI 10.1021/ja9719586; Hong SH, 2000, SCIENCE, V288, P1808, DOI 10.1126/science.288.5472.1808; Hong SH, 1999, SCIENCE, V286, P523, DOI 10.1126/science.286.5439.523; Ivanisevic A, 2001, J AM CHEM SOC, V123, P7887, DOI 10.1021/ja010671c; Jang JY, 2001, J CHEM PHYS, V115, P2721, DOI 10.1063/1.1384550; Kenney M, 1998, BIOTECHNIQUES, V25, P516, DOI 10.2144/98253pf01; KURTH DG, 1993, LANGMUIR, V9, P2965, DOI 10.1021/la00035a039; Lee KB, 2002, SCIENCE, V295, P1702, DOI 10.1126/science.1067172; Levicky R, 1998, J AM CHEM SOC, V120, P9787, DOI 10.1021/ja981897r; Maynor BW, 2001, LANGMUIR, V17, P2575, DOI 10.1021/la001755m; Mirkin CA, 2000, INORG CHEM, V39, P2258, DOI 10.1021/ic991123r; Mirkin CA, 2000, MRS BULL, V25, P43, DOI 10.1557/S0883769400065015; Nicewarner-Pena SR, 2001, SCIENCE, V294, P137, DOI 10.1126/science.294.5540.137; Niemeyer CM, 2001, ANGEW CHEM INT EDIT, V40, P4128, DOI 10.1002/1521-3773(20011119)40:22<4128::AID-ANIE4128>3.0.CO;2-S; Noy A, 2002, NANO LETT, V2, P109, DOI 10.1021/nl010081c; Piner RD, 1999, SCIENCE, V283, P661, DOI 10.1126/science.283.5402.661; Piner RD, 1999, LANGMUIR, V15, P5457, DOI 10.1021/la990408d; Schwartz PV, 2001, LANGMUIR, V17, P5971, DOI 10.1021/la001625d; Storhoff JJ, 1999, CHEM REV, V99, P1849, DOI 10.1021/cr970071p; Weinberger DA, 2000, ADV MATER, V12, P1600, DOI 10.1002/1521-4095(200011)12:21<1600::AID-ADMA1600>3.0.CO;2-6; Wilson DL, 2001, P NATL ACAD SCI USA, V98, P13660, DOI 10.1073/pnas.241323198	24	610	643	2	178	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	2002	296	5574					1836	1838		10.1126/science.1071480	http://dx.doi.org/10.1126/science.1071480			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052950				2022-12-28	WOS:000176054300038
J	von Andrian, UH				von Andrian, UH			Immunology: T cell-activation in six dimensions	SCIENCE			English	Editorial Material							HIGH ENDOTHELIAL VENULES; LYMPH-NODES; FLUORESCENCE MICROSCOPY; DENDRITIC CELLS; CHEMOKINES		Harvard Univ, Sch Med, Dept Pathol, Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	von Andrian, UH (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Ctr Blood Res, Boston, MA 02115 USA.	uva@cbr.med.harvard.edu	von Andrian, Ulrich H/A-5775-2008					Bousso P, 2002, SCIENCE, V296, P1876, DOI 10.1126/science.1070945; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Gretz JE, 2000, J EXP MED, V192, P1425, DOI 10.1084/jem.192.10.1425; Gunzer M, 2000, IMMUNITY, V13, P323, DOI 10.1016/S1074-7613(00)00032-7; Helmchen F, 2001, NEURON, V31, P903, DOI 10.1016/S0896-6273(01)00421-4; HENDRIKS HR, 1987, EUR J IMMUNOL, V17, P1691, DOI 10.1002/eji.1830171203; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; MANJUNATH N, 1995, NATURE, V377, P535, DOI 10.1038/377535a0; MEBIUS RE, 1991, J CELL BIOL, V115, P85, DOI 10.1083/jcb.115.1.85; Miller MJ, 2002, SCIENCE, V296, P1869, DOI 10.1126/science.1070051; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Norbury CC, 2002, NAT IMMUNOL, V3, P265, DOI 10.1038/ni762; Palframan RT, 2001, J EXP MED, V194, P1361, DOI 10.1084/jem.194.9.1361; So PTC, 2000, ANNU REV BIOMED ENG, V2, P399, DOI 10.1146/annurev.bioeng.2.1.399; Stein JV, 2000, J EXP MED, V191, P61, DOI 10.1084/jem.191.1.61; Stoll S, 2002, SCIENCE, V296, P1873, DOI 10.1126/science.1071065; TORRES IP, 1994, P NATL ACAD SCI USA, V91, P2081, DOI 10.1073/pnas.91.6.2081; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407	20	30	33	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	2002	296	5574					1815	1817		10.1126/science.296.5574.1815	http://dx.doi.org/10.1126/science.296.5574.1815			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052942				2022-12-28	WOS:000176054300030
J	Denker, JA; Zuckerman, DM; Maroney, PA; Nilsen, TW				Denker, JA; Zuckerman, DM; Maroney, PA; Nilsen, TW			New components of the spliced leader RNP required for nematode trans-splicing	NATURE			English	Article							FACTOR SF1; TRI-SNRNP; SM	Pre-messenger-RNA maturation in nematodes and in several other lower eukaryotic phyla involves spliced leader (SL) addition trans-splicing(1,2). In this unusual RNA processing reaction, a short common 5' exon, the SL, is affixed to the 5'-most exon of multiple pre-mRNAs. The nematode SL is derived from a trans-splicing-specific similar to100-nucleotide RNA (SL RNA) that bears striking similarities to the cis-spliceosomal U small nuclear RNAs U1, U2, U4 and U5 (refs 3, 4); for example, the SL RNA functions only if it is assembled into an Sm small nuclear ribonucleoprotein (snRNP)(5). Here we have purified and characterized the SL RNP and show that it contains two proteins (relative molecular masses 175,000 and 30,000 (M-r 175K and 30K)) in addition to core Sm proteins. Immunodepletion and reconstitution with recombinant proteins demonstrates that both proteins are essential for SL trans-splicing; however, neither protein is required either for conventional cis-splicing or for bimolecular (trans-) splicing of fragmented cis constructs. The M-r 175K and 30K SL RNP proteins are the first factors identified that are involved uniquely in SL trans- splicing. Several lines of evidence indicate that the SL RNP proteins function by participating in a trans- splicing specific network of protein-protein interactions analogous to the U1 snRNP-SF1/BBP-U2AF complex that comprises the cross-intron bridge in cis-splicing.	Case Western Reserve Univ, Sch Med, Ctr RNA Mol Biol, Cleveland, OH 44106 USA	Case Western Reserve University	Nilsen, TW (corresponding author), Case Western Reserve Univ, Sch Med, Ctr RNA Mol Biol, 10900 Euclid Ave, Cleveland, OH 44106 USA.							Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; BLUMENTHAL T, 1997, C ELEGANS, V2, P117; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; BRUZIK JP, 1995, P NATL ACAD SCI USA, V92, P7056, DOI 10.1073/pnas.92.15.7056; CHIARA MD, 1995, NATURE, V375, P510, DOI 10.1038/375510a0; Davis RE, 1996, PARASITOL TODAY, V12, P33, DOI 10.1016/0169-4758(96)80643-0; Denker JA, 1996, RNA, V2, P746; HANNON GJ, 1991, J BIOL CHEM, V266, P22792; Makarova OV, 2001, EMBO J, V20, P2553, DOI 10.1093/emboj/20.10.2553; MARONEY PA, 1990, EMBO J, V9, P3667, DOI 10.1002/j.1460-2075.1990.tb07578.x; Maroney PA, 2000, MOL CELL, V6, P317, DOI 10.1016/S1097-2765(00)00032-0; Mazroui R, 1999, RNA, V5, P1615, DOI 10.1017/S1355838299991872; Nilsen TW, 2001, TRENDS GENET, V17, P678, DOI 10.1016/S0168-9525(01)02499-4; NILSEN TW, 1997, FRONTIERS MOL BIOL E, P310; Rain JC, 1998, RNA, V4, P551, DOI 10.1017/S1355838298980335; Stover NA, 2001, P NATL ACAD SCI USA, V98, P5693, DOI 10.1073/pnas.101049998; THOMAS JD, 1988, CELL, V54, P533, DOI 10.1016/0092-8674(88)90075-X	17	41	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	2002	417	6889					667	670		10.1038/nature00783	http://dx.doi.org/10.1038/nature00783			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050671				2022-12-28	WOS:000176001200053
J	Imperiale, TF; Wagner, DR; Lin, CY; Larkin, GN; Rogge, JD; Ransohoff, DF				Imperiale, TF; Wagner, DR; Lin, CY; Larkin, GN; Rogge, JD; Ransohoff, DF			Results of screening colonoscopy among persons 40 to 49 years of age.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COST-EFFECTIVENESS; COLORECTAL-CANCER; ASYMPTOMATIC ADULTS; COLONIC NEOPLASIA; LARGE-BOWEL; POLYPS; ADENOMAS; SIZE; RISK	Background: The prevalence of colorectal lesions in persons 40 to 49 years of age, as identified on colonoscopy, has not been determined. Methods: We reviewed the procedure and pathology reports for 906 consecutive persons 40 to 49 years of age who voluntarily participated in an employer-based screening-colonoscopy program. The histologic features of lesions that were identified and removed on endoscopy were categorized according to those of the most advanced lesion removed proximally (up to the junction of the splenic flexure and the descending colon) and the most advanced lesion removed distally. An advanced lesion was defined as an adenoma at least 1 cm in diameter, a polyp with villous histologic features or severe dysplasia, or a cancer. Results: Among those who underwent colonoscopic screening, 78.9 percent had no detected lesions, 10.0 percent had hyperplastic polyps, 8.7 percent had tubular adenomas, and 3.5 percent had advanced neoplasms, none of which were cancerous (95 percent confidence interval for cancer, 0 to 0.4 percent). Eighteen of 33 advanced neoplasms (55 percent) were located distally and were potentially within reach of a sigmoidoscope. If these results are applicable to the general population, at least 250 persons, and perhaps 1000 or more, would need to be screened to detect one cancer in this age group. Conclusions: Colonoscopic detection of colorectal cancer is uncommon in asymptomatic persons 40 to 49 years of age. The noncancerous lesions are equally distributed proximally and distally. The low yield of screening colonoscopy in this age group is consistent with current recommendations about the age at which to begin screening in persons at average risk.	Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Div Gastroenterol & Hepatol, Indianapolis, IN USA; Indiana Univ, Sch Med, Div Gen Internal Med, Indianapolis, IN USA; Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA; Indianapolis Gastroenterol Res Fdn, Indianapolis, IN USA; Eli Lilly & Co, Indianapolis, IN 46285 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Eli Lilly	Imperiale, TF (corresponding author), Regenstrief Inst Hlth Care, 1050 Wishard Blvd, Indianapolis, IN 46202 USA.			Imperiale, Thomas/0000-0001-7586-1073	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK002756] Funding Source: NIH RePORTER; NIDDK NIH HHS [1 K24 DK 02756] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Frazier AL, 2000, JAMA-J AM MED ASSOC, V284, P1954, DOI 10.1001/jama.284.15.1954; Gopalswamy N, 1997, GASTROINTEST ENDOSC, V46, P497, DOI 10.1016/S0016-5107(97)70003-8; Imperiale TF, 2000, NEW ENGL J MED, V343, P169, DOI 10.1056/NEJM200007203430302; KONISHI F, 1982, J CLIN PATHOL, V35, P830, DOI 10.1136/jcp.35.8.830; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; Levin TR, 1999, JAMA-J AM MED ASSOC, V281, P1611, DOI 10.1001/jama.281.17.1611; Lieberman DA, 2000, NEW ENGL J MED, V343, P162, DOI 10.1056/NEJM200007203430301; LIEBERMAN DA, 1995, GASTROENTEROLOGY, V109, P1781, DOI 10.1016/0016-5085(95)90744-0; MARBLE K, 1992, J SURG ONCOL, V51, P179, DOI 10.1002/jso.2930510311; MILLER BA, 1993, NIH PUBLICATION; Ness RM, 2000, AM J GASTROENTEROL, V95, P1800; Read TE, 1997, NEW ENGL J MED, V336, P8, DOI 10.1056/NEJM199701023360102; Rex DK, 2000, AM J GASTROENTEROL, V95, P868, DOI 10.1111/j.1572-0241.2000.02059.x; REX DK, 1993, AM J GASTROENTEROL, V88, P825; Rex DK, 2000, GASTROINTEST ENDOSC, V51, P524, DOI 10.1016/S0016-5107(00)70283-5; RICKERT RR, 1979, CANCER-AM CANCER SOC, V43, P1847, DOI 10.1002/1097-0142(197905)43:5<1847::AID-CNCR2820430538>3.0.CO;2-L; RIES LAG, 1997, NIH PUBLICATION; Schoen RE, 1997, GASTROINTEST ENDOSC, V46, P492, DOI 10.1016/S0016-5107(97)70002-6; Sonnenberg A, 2000, ANN INTERN MED, V133, P573, DOI 10.7326/0003-4819-133-8-200010170-00007; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; VATN MH, 1982, CANCER, V49, P819, DOI 10.1002/1097-0142(19820215)49:4<819::AID-CNCR2820490435>3.0.CO;2-D; WILLIAMS AR, 1982, GUT, V23, P835, DOI 10.1136/gut.23.10.835; Winawer SJ, 1998, GASTROENTEROLOGY, V114, P625	23	271	283	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 6	2002	346	23					1781	1785		10.1056/NEJM200206063462304	http://dx.doi.org/10.1056/NEJM200206063462304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	559EK	12050337				2022-12-28	WOS:000176012500003
J	Nitabach, MN; Blau, J; Holmes, TC				Nitabach, MN; Blau, J; Holmes, TC			Electrical silencing of Drosophila pacemaker neurons stops the free-running circadian clock	CELL			English	Article							AMYOTROPHIC LATERAL SCLEROSIS; GENE-EXPRESSION; SUPRACHIASMATIC NUCLEUS; NERVOUS-SYSTEM; SYNAPTIC TRANSMISSION; BEHAVIORAL RHYTHMS; CALCIUM REGULATION; AXONAL SWELLINGS; K+ CHANNEL; PERIOD	Electrical silencing of Drosophila circadian pacemaker neurons through targeted expression of K+ channels causes severe deficits in free-running circadian locomotor rhythmicity in complete darkness. Pacemaker electrical silencing also stops the free-running oscillation of PERIOD (PER) and TIMELESS (TIM) proteins that constitutes the core of the cell-autonomous molecular clock. In contrast, electrical silencing fails to abolish PER and TIM oscillation in light-dark cycles, although it does impair rhythmic behavior. On the basis of these findings, we propose that electrical activity is an essential element of the free-running molecular clock of pacemaker neurons along with the transcription factors and regulatory enzymes that have been previously identified as required for clock function.	NYU, Dept Biol, New York, NY 10003 USA	New York University	Holmes, TC (corresponding author), NYU, Dept Biol, New York, NY 10003 USA.			Holmes, Todd/0000-0001-8152-8832	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063911] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baines RA, 2001, J NEUROSCI, V21, P1523, DOI 10.1523/JNEUROSCI.21-05-01523.2001; Barish ME, 1998, J NEUROBIOL, V37, P146, DOI 10.1002/(SICI)1097-4695(199810)37:1<146::AID-NEU11>3.3.CO;2-K; Belvin MP, 1999, NEURON, V22, P777, DOI 10.1016/S0896-6273(00)80736-9; Blanchardon E, 2001, EUR J NEUROSCI, V13, P871, DOI 10.1046/j.0953-816x.2000.01450.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cajal S., 1928, DEGENERATION REGENER; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Claridge-Chang A, 2001, NEURON, V32, P657, DOI 10.1016/S0896-6273(01)00515-3; Colwell CS, 2001, EUR J NEUROSCI, V13, P1420, DOI 10.1046/j.0953-816x.2001.01517.x; Colwell CS, 2000, EUR J NEUROSCI, V12, P571, DOI 10.1046/j.1460-9568.2000.00939.x; DELISLE MB, 1984, J NEUROL SCI, V63, P241, DOI 10.1016/0022-510X(84)90199-0; Emery P, 2000, NEURON, V26, P493, DOI 10.1016/S0896-6273(00)81181-2; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; GOLD BG, 1987, TOXICOLOGY, V46, P125, DOI 10.1016/0300-483X(87)90123-5; Goldstein SAN, 1996, P NATL ACAD SCI USA, V93, P13256, DOI 10.1073/pnas.93.23.13256; HAMBLENCOYLE MJ, 1992, J INSECT BEHAV, V5, P417, DOI 10.1007/BF01058189; Helfrich-Forster C, 2001, NEURON, V30, P249, DOI 10.1016/S0896-6273(01)00277-X; HELFRICHFORSTER C, 1995, P NATL ACAD SCI USA, V92, P612, DOI 10.1073/pnas.92.2.612; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; Johns DC, 1999, J NEUROSCI, V19, P1691; Kaneko M, 1997, J NEUROSCI, V17, P6745; Kaneko M, 2000, J BIOL RHYTHM, V15, P13, DOI 10.1177/074873040001500103; Kaneko M, 2000, J NEUROBIOL, V43, P207, DOI 10.1002/(SICI)1097-4695(20000605)43:3<207::AID-NEU1>3.0.CO;2-0; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; McDonald MJ, 2001, CELL, V107, P567, DOI 10.1016/S0092-8674(01)00545-1; Michel S, 1999, J BIOL RHYTHM, V14, P141, DOI 10.1177/074873099129000533; MICHEL S, 1993, SCIENCE, V259, P239, DOI 10.1126/science.8421785; Millar JA, 2000, P NATL ACAD SCI USA, V97, P3614, DOI 10.1073/pnas.050012597; Nadeau H, 2000, J NEUROPHYSIOL, V84, P1062, DOI 10.1152/jn.2000.84.2.1062; Nitabach MN, 2001, P NATL ACAD SCI USA, V98, P705, DOI 10.1073/pnas.031446198; Paradis S, 2001, NEURON, V30, P737, DOI 10.1016/S0896-6273(01)00326-9; Park JH, 2000, P NATL ACAD SCI USA, V97, P3608, DOI 10.1073/pnas.070036197; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; Reppert SM, 2000, J BIOL RHYTHM, V15, P357, DOI 10.1177/074873000129001459; Ruppersberg JP, 2000, PFLUG ARCH EUR J PHY, V441, P1, DOI 10.1007/s004240000380; SOKALOVE G, 1978, J THEOR BIOL, V72, P131; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Svoboda KR, 2001, DEVELOPMENT, V128, P3511; Talley EM, 2000, NEURON, V25, P399, DOI 10.1016/S0896-6273(00)80903-4; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; White BH, 2001, NEURON, V31, P699, DOI 10.1016/S0896-6273(01)00415-9; Williams JA, 2001, ANNU REV PHYSIOL, V63, P729, DOI 10.1146/annurev.physiol.63.1.729; YAO KM, 1994, J NEUROCHEM, V63, P41; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135; Zilberberg N, 2000, J GEN PHYSIOL, V116, P721, DOI 10.1085/jgp.116.5.721	49	341	345	0	20	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 17	2002	109	4					485	495		10.1016/S0092-8674(02)00737-7	http://dx.doi.org/10.1016/S0092-8674(02)00737-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	553VM	12086605	Bronze			2022-12-28	WOS:000175696800010
J	Wong, PWY; Yeo, AHJ; Deol, HK; Saunders, SMF; Ham, RJ				Wong, PWY; Yeo, AHJ; Deol, HK; Saunders, SMF; Ham, RJ			Ischaemic ulcer from a chemical burn	LANCET			English	Editorial Material									Barts & London NHS Trust, Royal London Hosp, Dept Vasc Surg, London, England	Barts Health NHS Trust; Royal London Hospital	Wong, PWY (corresponding author), Barts & London NHS Trust, Royal London Hosp, Dept Vasc Surg, London, England.								0	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 4	2002	359	9317					1563	1563		10.1016/S0140-6736(02)08515-X	http://dx.doi.org/10.1016/S0140-6736(02)08515-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047965				2022-12-28	WOS:000175460700009
J	Keenan, SP; Powers, C; McCormack, DG; Block, G				Keenan, SP; Powers, C; McCormack, DG; Block, G			Noninvasive positive-pressure ventilation for postextubation respiratory distress - A Randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; NASAL MASK VENTILATION; MECHANICAL VENTILATION; SUPPORT VENTILATION; FACE MASK; ACUTE EXACERBATIONS; FAILURE	Context Noninvasive positive-pressure ventilation (NPPV) has been demonstrated to be effective in preventing the need for endotracheal intubation in some patients who present with acute respiratory failure. It is also used for patients who develop acute respiratory distress after extubation, but there are no randomized controlled trials that address its effectiveness in this population. Objective To determine the effectiveness of NPPV compared with standard medical therapy in preventing the need for endotracheal reintubation in high-risk patients who develop respiratory distress during the first 48 hours after extubation. Design Randomized, controlled, unblinded study with concealed allocation conducted between August 1, 1996 and October 31, 1999. Setting An intensive care unit (ICU) in an academic, tertiary care hospital in Ontario. Patients Eighty-one patients with a history of cardiac or respiratory disease or who initially required ventilatory support for more than 2 days and who developed respiratory distress within 48 hours of extubation. Interventions Patients were randomly assigned to receive standard medical therapy alone (supplemental oxygen to maintain oxygen saturation by pulse oximetry greater than or equal to95%; n=42) or NPPV by face mask plus standard medical therapy (n=39). Main Outcome Measures Rates of reintubation, duration of mechanical ventilation, lengths of ICU and hospital stay, and hospital mortality. Results Comparing the NPPV group with the standard-therapy group, there was no difference in the rate of reintubation (72% vs 69%; relative risk, 1.04; 95% confidence interval, 0.78-1.38) or hospital mortality (31% for both groups; relative risk, 0.99; 95% confidence interval, 0.52-1.91). Similarly, no difference was found in duration of mechanical ventilation or length of ICU or hospital stay. Conclusions The addition of NPPV to standard medical therapy does not improve outcome in heterogeneous groups of patients who develop respiratory distress during the first 48 hours after extubation.	Royal Columbian Hosp, Dept Med, New Westminster, BC, Canada; St Pauls Hosp, Ctr Hth Evaluat & Outcome Sci, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Univ Western Ontario, Dept Med, Div Crit Care, London Hlth Sci Ctr, London, ON, Canada; Univ Western Ontario, Dept Med, Div Resp Med, London Hlth Sci Ctr, London, ON, Canada; Univ Western Ontario, Dept Anaesthesia, London Hlth Sci Ctr, London, ON, Canada	St. Paul's Hospital; University of Saskatchewan; University of British Columbia; London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario)	Keenan, SP (corresponding author), Suite 103,250 Keary St, New Westminster, BC V3L 5E7, Canada.	Sean_Keenan@telus.net	Block, Geoffrey/AAV-8070-2021; Mccormack, David/G-3331-2011	Block, Geoffrey/0000-0002-4646-7074; 				Andeev S, 1998, J ANESTIZIOL REA MAY, V3, P45; Angus RM, 1996, THORAX, V51, P1048, DOI 10.1136/thx.51.10.1048; Antonelli M, 1998, NEW ENGL J MED, V339, P429, DOI 10.1056/NEJM199808133390703; Antonelli M, 2000, JAMA-J AM MED ASSOC, V283, P235, DOI 10.1001/jama.283.2.235; Barbe F, 1996, EUR RESPIR J, V9, P1240, DOI 10.1183/09031936.96.09061240; BENHAMOU D, 1992, CHEST, V102, P912, DOI 10.1378/chest.102.3.912; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; Celikel T, 1998, CHEST, V114, P1636, DOI 10.1378/chest.114.6.1636; Confalonieri M, 1999, AM J RESP CRIT CARE, V160, P1585, DOI 10.1164/ajrccm.160.5.9903015; FOGLIO C, 1992, CHEST, V101, P1533, DOI 10.1378/chest.101.6.1533; Girault C, 1999, AM J RESP CRIT CARE, V160, P86, DOI 10.1164/ajrccm.160.1.9802120; Hilbert G, 1998, EUR RESPIR J, V11, P1349, DOI 10.1183/09031936.98.11061349; Hilbert G, 2001, NEW ENGL J MED, V344, P481, DOI 10.1056/NEJM200102153440703; Jiang J S, 1999, Respirology, V4, P161, DOI 10.1046/j.1440-1843.1999.00168.x; Keenan SP, 2000, JAMA-J AM MED ASSOC, V284, P2376, DOI 10.1001/jama.284.18.2376; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; MARION W, 1994, CRIT CARE MED, V99, P681; Martin TJ, 2000, AM J RESP CRIT CARE, V161, P807, DOI 10.1164/ajrccm.161.3.9808143; Masip J, 2000, LANCET, V356, P2126, DOI 10.1016/S0140-6736(00)03492-9; Meduri GU, 1996, CHEST, V109, P179, DOI 10.1378/chest.109.1.179; MEDURI GU, 1994, CRIT CARE MED, V22, P1584; MEDURI GU, 1989, CHEST, V95, P865, DOI 10.1378/chest.95.4.865; MEDURI GU, 1991, CHEST, V100, P445, DOI 10.1378/chest.100.2.445; Nava S, 1998, ANN INTERN MED, V128, P721, DOI 10.7326/0003-4819-128-9-199805010-00004; PENNOCK BE, 1994, CHEST, V105, P441, DOI 10.1378/chest.105.2.441; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0; ROSINHA SRP, 2000, AM J RESP CRIT CARE, V161, pA262; Wood KA, 1998, CHEST, V113, P1339, DOI 10.1378/chest.113.5.1339; WYSOCKI M, 1995, CHEST, V107, P761, DOI 10.1378/chest.107.3.761; WYSOCKI M, 1993, CHEST, V103, P907, DOI 10.1378/chest.103.3.907	31	246	267	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	2002	287	24					3238	3244		10.1001/jama.287.24.3238	http://dx.doi.org/10.1001/jama.287.24.3238			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566FF	12076220	Bronze			2022-12-28	WOS:000176415800028
J	Alencar, AM; Arold, SP; Buldyrev, SV; Majumdar, A; Stamenovic, D; Stanley, HE; Suki, B				Alencar, AM; Arold, SP; Buldyrev, SV; Majumdar, A; Stamenovic, D; Stanley, HE; Suki, B			Physiology - Dynamic instabilities in the inflating lung	NATURE			English	Editorial Material							AIRWAY		Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA; Boston Univ, Ctr Polymer Studies, Boston, MA 02215 USA; Boston Univ, Dept Phys, Boston, MA 02215 USA	Boston University; Boston University; Boston University	Alencar, AM (corresponding author), Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.		Majumdar, Arnab/A-8096-2008; Alencar, Adriano M/L-5071-2013; Buldyrev, Sergey V/I-3933-2015	Alencar, Adriano M/0000-0001-9324-2698; Stanley, H./0000-0003-2800-4495; Buldyrev, Sergey/0000-0002-3008-1070				CLEMENTS JA, 1961, J APPL PHYSIOL, V16, P444, DOI 10.1152/jappl.1961.16.3.444; FUKAYA H, 1968, J APPL PHYSIOL, V25, P689, DOI 10.1152/jappl.1968.25.6.689; GAVER DP, 1990, J APPL PHYSIOL, V69, P74, DOI 10.1152/jappl.1990.69.1.74; Lutchen KR, 2001, AM J RESP CRIT CARE, V164, P207, DOI 10.1164/ajrccm.164.2.2008119; MEAD J, 1967, J APPL PHYSIOL, V22, P95, DOI 10.1152/jappl.1967.22.1.95; MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774; PATTLE RE, 1962, LANCET, V2, P469; PEDLEY TJ, 1970, RESP PHYSIOL, V9, P387, DOI 10.1016/0034-5687(70)90094-0; SHLESINGER MF, 1991, PHYS REV LETT, V67, P2106, DOI 10.1103/PhysRevLett.67.2106; STAMENOVIC D, 1992, J APPL PHYSIOL, V73, P596, DOI 10.1152/jappl.1992.73.2.596; SUKI B, 1994, NATURE, V368, P615, DOI 10.1038/368615a0; Tobin MJ, 2002, AM J RESP CRIT CARE, V165, P598, DOI 10.1164/ajrccm.165.5.2201062	12	44	47	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 20	2002	417	6891					809	811		10.1038/417809b	http://dx.doi.org/10.1038/417809b			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075340				2022-12-28	WOS:000176285600035
J	Crackower, MA; Sarao, R; Oudit, GY; Yagil, C; Kozieradzki, I; Scanga, SE; Oliveira-dos-Santos, AJ; da Costa, J; Zhang, LY; Pei, Y; Scholey, J; Ferrario, CM; Manoukian, AS; Chappell, MC; Backx, PH; Yagil, Y; Penninger, JM				Crackower, MA; Sarao, R; Oudit, GY; Yagil, C; Kozieradzki, I; Scanga, SE; Oliveira-dos-Santos, AJ; da Costa, J; Zhang, LY; Pei, Y; Scholey, J; Ferrario, CM; Manoukian, AS; Chappell, MC; Backx, PH; Yagil, Y; Penninger, JM			Angiotensin-converting enzyme 2 is an essential regulator of heart function	NATURE			English	Article							BLOOD-PRESSURE; CARDIOVASCULAR-DISEASES; DEFICIENT MICE; RISK-FACTORS; MOUSE HEART; PART I; DROSOPHILA; EXPRESSION; RAT; HYPERTENSION	Cardiovascular diseases are predicted to be the most common cause of death worldwide by 2020. Here we show that angiotensin-converting enzyme 2 (ace2) maps to a defined quantitative trait locus (QTL) on the X chromosome in three different rat models of hypertension. In all hypertensive rat strains, ACE2 messenger RNA and protein expression were markedly reduced, suggesting that ace2 is a candidate gene for this QTL. Targeted disruption of ACE2 in mice results in a severe cardiac contractility defect, increased angiotensin II levels, and upregulation of hypoxia-induced genes in the heart. Genetic ablation of ACE on an ACE2 mutant background completely rescues the cardiac phenotype. But disruption of ACER, a Drosophila ACE2 homologue, results in a severe defect of heart morphogenesis. These genetic data for ACE2 show that it is an essential regulator of heart function in vivo.	Univ Toronto, Ontario Canc Inst, Amgen Res Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Heart & Stroke Richard Lewar Ctr Excellence Cardi, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 2M9, Canada; Univ Toronto, Univ Hlth Network, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ontario Canc Inst, Univ Hlth Network, Div Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada; Austrian Acad Sci, Inst Mol Biotechnol, IMBA, A-1030 Vienna, Austria; Ben Gurion Univ Negev, Barzilai Med Ctr, Fac Hlth Sci, Dept Nephrol & Hypertens,Lab Mol Med, IL-78306 Ashqelon, Israel; Wake Forest Univ, Bowman Gray Sch Med, Hypertens & Vasc Dis Ctr, Winston Salem, NC 27157 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Ben Gurion University; Barzilai Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Penninger, JM (corresponding author), Univ Toronto, Ontario Canc Inst, Amgen Res Inst, Univ Ave, Toronto, ON M5G 2M9, Canada.		Ferrario, Carlos/ABD-2791-2020; Penninger, Josef M/I-6860-2013; Ferrario, Carlos/ABB-4165-2021	Ferrario, Carlos/0000-0003-0792-6239; Penninger, Josef M/0000-0002-8194-3777; 				Allred AJ, 2000, AM J PHYSIOL-RENAL, V279, pF636, DOI 10.1152/ajprenal.2000.279.4.F636; Azpiazu N, 1996, GENE DEV, V10, P3183, DOI 10.1101/gad.10.24.3183; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Carretero OA, 2000, CIRCULATION, V101, P329, DOI 10.1161/01.CIR.101.3.329; CHAPPELL MC, 1991, J HYPERTENS, V9, P751, DOI 10.1097/00004872-199108000-00008; CORNEL MJ, 1995, J BIOL CHEM, V270, P13613, DOI 10.1074/jbc.270.23.13613; CORVOL P, 1998, HDB PROTEOLYTIC ENZY, P1066; Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1; Elkind MS, 1998, SEMIN NEUROL, V18, P429, DOI 10.1055/s-2008-1040896; Enseleit F, 2001, J CARDIOVASC PHARM, V37, pS21, DOI 10.1097/00005344-200109011-00004; Esther CR, 1996, LAB INVEST, V74, P953; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Giordano FJ, 2001, P NATL ACAD SCI USA, V98, P5780, DOI 10.1073/pnas.091415198; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Heusch G, 1998, PHYSIOL REV, V78, P1055, DOI 10.1152/physrev.1998.78.4.1055; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; Hollenberg N K, 1988, Curr Opin Cardiol, V3, pS19, DOI 10.1097/00001573-198801001-00003; Jacob HJ, 1999, CLIN EXP PHARMACOL P, V26, P530, DOI 10.1046/j.1440-1681.1999.03078.x; Kietzmann T, 1999, BLOOD, V94, P4177, DOI 10.1182/blood.V94.12.4177.424k14_4177_4185; Kloner RA, 1998, CIRCULATION, V97, P1848, DOI 10.1161/01.CIR.97.18.1848; Kloting I, 1998, LIFE SCI, V62, P973, DOI 10.1016/S0024-3205(98)00017-4; KOIKE G, 1995, HYPERTENSION, V26, P998, DOI 10.1161/01.HYP.26.6.998; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; LARAGH JH, 1986, J HYPERTENS, V4, pS79; Murphy AM, 2000, SCIENCE, V287, P488, DOI 10.1126/science.287.5452.488; Rapp JP, 2000, PHYSIOL REV, V80, P135, DOI 10.1152/physrev.2000.80.1.135; Skeggs L T, 1980, Adv Exp Med Biol, V130, P1; Sowter HM, 2001, CANCER RES, V61, P6669; Spradling AC, 1999, GENETICS, V153, P135; Stoll M, 2001, SCIENCE, V294, P1723, DOI 10.1126/science.1062117; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; Taylor CAM, 1996, GENE, V181, P191, DOI 10.1016/S0378-1119(96)00503-3; Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200; Wickenden AD, 1999, CIRC RES, V85, P1067; Wuyts B, 1997, ACTA CLIN BELG, V52, P338, DOI 10.1080/17843286.1997.11718599; Yagil C, 1999, HYPERTENSION, V33, P261, DOI 10.1161/01.HYP.33.1.261; YAGIL C, 1996, J HYPERTENS, V14, P175; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487; ZHIZHANG Y, 1998, DEV GENET, V22, P187; Zvaritch E, 2000, J BIOL CHEM, V275, P14985, DOI 10.1074/jbc.275.20.14985	42	1419	1580	8	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 20	2002	417	6891					822	828		10.1038/nature00786	http://dx.doi.org/10.1038/nature00786			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075344				2022-12-28	WOS:000176285600039
J	McCaig, LF; Besser, RE; Hughes, JM				McCaig, LF; Besser, RE; Hughes, JM			Trends in antimicrobial prescribing rates for children and adolescents	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT STREPTOCOCCUS-PNEUMONIAE; RESPIRATORY-TRACT INFECTIONS; ANTIBIOTIC USE; OTITIS-MEDIA; RISK-FACTORS; PHYSICIANS; AGENTS; ADULTS; INTERVENTION; PRINCIPLES	Context Annual rates of antimicrobial prescribing for children by office-based physicians increased from 1980 through 1992. The development of antimicrobial resistance, which increased for many organisms during the 1990s, is associated with antimicrobial use. To combat development of antimicrobial resistance, professional and public health organizations undertook efforts to promote appropriate antimicrobial prescribing. Objective To assess changes in antimicrobial prescribing rates overall and for respiratory tract infections for children and adolescents younger than 15 years. Design, Setting, and Participants National Ambulatory Medical Care Survey data provided by 2500 to 3500 office-based physicians for 6500 to 13 600 pediatric visits during 2-year periods from 1989-1990 through 1999-2000. Main Outcome Measures Population- and visit-based antimicrobial prescribing rates overall and for respiratory tract infections (otitis media, pharyngitis, bronchitis, sinusitis, and upper respiratory tract infection) among children and adolescents younger than 15 years. Results The average population-based annual rate of overall antimicrobial prescriptions per 1000 children and adolescents younger than 15 years decreased from 838 (95% confidence interval [CI], 711-966) in 1989-1990 to 503 (95% CI, 419-588) in 1999-2000 (P for slope <.001). The visit-based rate decreased from 330 antimicrobial prescriptions per 1000 off ice visits (95% CI, 305-355) to 234 (95% CI, 210-257; P for slope <.001). For the 5 respiratory tract infections, the population-based prescribing rate decreased from 674 (95% CI, 568-781) to 379 (95% CI, 311-447; P for slope <.001) and the visit-based prescribing rate decreased from 715 (95% CI, 682748) to 613 (95% CI, 570-657; P for slope <.001). Both population- and visit-based prescribing rates decreased for pharyngitis and upper respiratory tract infection; however, for otitis media and bronchitis, declines were only observed in the population-based rate. Prescribing rates for sinusitis remained stable. Conclusion The rate of antimicrobial prescribing overall and for respiratory tract infections by office-based physicians for children and adolescents younger than 15 years decreased significantly between 1989-1990 and 1999-2000.	Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Off Director, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Ambulatory Care Stat Branch, Div Hlth Care Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	McCaig, LF (corresponding author), Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, 1600 Clifton Rd NE,MS C23, Atlanta, GA 30333 USA.	lfm1@cdc.gov; rbesser@cdc.gov						Barden LS, 1998, CLIN PEDIATR, V37, P665, DOI 10.1177/000992289803701104; Bauchner H, 1999, PEDIATRICS, V103, P395, DOI 10.1542/peds.103.2.395; Belongia EA, 2001, PEDIATRICS, V108, P575, DOI 10.1542/peds.108.3.575; Bergman DA, 1999, PEDIATRICS, V103, P843; Besser RE, 2001, ROY SOC MED INT CONG, V247, P151; BILLUPS NF, 1989, AM DRUG IND; BLOCK SL, 1995, PEDIATR INFECT DIS J, V14, P751, DOI 10.1097/00006454-199509000-00005; BRYANT E, 1988, VITAL HLTH STAT 2, V108, P1; Burke JP, 1998, JAMA-J AM MED ASSOC, V280, P1270, DOI 10.1001/jama.280.14.1270; *CDCP, 2002, PREV EM INF DIS ADDR; Dowell SF, 1998, PEDIATRICS, V101, P163; DUCHIN JS, 1995, PEDIATR INFECT DIS J, V14, P745, DOI 10.1097/00006454-199509000-00004; Finkelstein JA, 2001, PEDIATRICS, V108, pU113; Forum on Emerging Infections Institute of Medicine, 1998, ANT RES ISS OPT; Gonzales R, 2001, ANN INTERN MED, V134, P479, DOI 10.7326/0003-4819-134-6-200103200-00013; Gonzales R, 1998, J GEN INTERN MED, V13, P541, DOI 10.1046/j.1525-1497.1998.00165.x; Gonzales R, 1999, JAMA-J AM MED ASSOC, V281, P1512, DOI 10.1001/jama.281.16.1512; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; Institute of Medicine, 1992, EM INF MICR THREATS; Jernigan DB, 1996, JAMA-J AM MED ASSOC, V275, P206, DOI 10.1001/jama.275.3.206; KOCH H, 1982, VITAL HLTH STAT 2, V90, P1; Levy SB, 1998, NEW ENGL J MED, V338, P1376, DOI 10.1056/NEJM199805073381909; Low DE, 1998, JAMA-J AM MED ASSOC, V279, P394, DOI 10.1001/jama.279.5.394; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MCCAIG LF, 2001, ADV DATA VITAL HLTH, V320; MCEVOY CK, 1996, AM HOSP FORMULARY SE; MCGOWAN JE, 1983, REV INFECT DIS, V5, P1033; *MED EC CO INC, 1989, PHYS DESK REF; *MED EC CO INC, 1996, PHYS DESK REF; Metlay JP, 1998, ARCH INTERN MED, V158, P1813, DOI 10.1001/archinte.158.16.1813; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Nyquist AC, 1998, JAMA-J AM MED ASSOC, V279, P875, DOI 10.1001/jama.279.11.875; PALLARES R, 1987, NEW ENGL J MED, V317, P18, DOI 10.1056/NEJM198707023170104; PARADISE JL, 1995, PEDIATRICS, V96, P712; *PHS US DEP HLTH H, 1988, INT CLASS DIS 9 REV; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; SAAH AJ, 1980, JAMA-J AM MED ASSOC, V243, P1824, DOI 10.1001/jama.1980.03300440026020; Schwartz B, 1997, JAMA-J AM MED ASSOC, V278, P944, DOI 10.1001/jama.278.11.944; SHAH BV, 1991, SUDAAN USERS MANUAL; SIRKEN MG, 1990, MANUAL STANDARDS PRO; Swartz MN, 1997, NEW ENGL J MED, V337, P491, DOI 10.1056/NEJM199708143370709; *US BUR CENS, 2002, POP CENS; Whitney CG, 2000, NEW ENGL J MED, V343, P1917, DOI 10.1056/NEJM200012283432603; *WOLT KLUW CO, 1999, DRUG FACTS COMP	45	368	383	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	2002	287	23					3096	3102		10.1001/jama.287.23.3096	http://dx.doi.org/10.1001/jama.287.23.3096			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563NK	12069672	Bronze			2022-12-28	WOS:000176262300024
J	Ramesh, R; Schlom, DG				Ramesh, R; Schlom, DG			Materials science - Orienting ferroelectric films	SCIENCE			English	Editorial Material							EPITAXIAL-GROWTH; HETEROSTRUCTURES		Univ Maryland, Dept Mat & Nucl Engn, College Pk, MD 20742 USA; Univ Maryland, Ctr Supercond Res, College Pk, MD 20742 USA; Penn State Univ, Dept Mat Sci & Engn, University Pk, PA 16802 USA	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ramesh, R (corresponding author), Univ Maryland, Dept Mat & Nucl Engn, College Pk, MD 20742 USA.		Schlom, Darrell G/J-2412-2013	Schlom, Darrell G/0000-0003-2493-6113				Asayama G, 2002, APPL PHYS LETT, V80, P2371, DOI 10.1063/1.1463697; Auciello O, 1998, PHYS TODAY, V51, P22, DOI 10.1063/1.882324; EOM CB, 1990, SCIENCE, V249, P1549, DOI 10.1126/science.249.4976.1549; FUJITA J, 1988, J APPL PHYS, V64, P1292, DOI 10.1063/1.341848; Lee HN, 2002, SCIENCE, V296, P2006, DOI 10.1126/science.1069958; Lettieri J, 2000, APPL PHYS LETT, V76, P2937, DOI 10.1063/1.126522; Lin A, 2001, APPL PHYS LETT, V78, P2034, DOI 10.1063/1.1358848; MATSUBARA S, 1985, JPN J APPL PHYS 1, V24, P10, DOI 10.7567/JJAPS.24S3.10; RAMESH R, 1991, APPL PHYS LETT, V59, P1782, DOI 10.1063/1.106199; RAMESH R, 1991, SCIENCE, V252, P944, DOI 10.1126/science.252.5008.944; TAKEI WJ, 1975, J CRYST GROWTH, V28, P188, DOI 10.1016/0022-0248(75)90234-1; Wang Y, 2002, APPL PHYS LETT, V80, P97, DOI 10.1063/1.1428413; WU SY, 1972, FERROELECTRICS, V3, P217, DOI 10.1080/00150197208235311	13	125	135	3	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 14	2002	296	5575					1975	1976		10.1126/science.1072855	http://dx.doi.org/10.1126/science.1072855			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065821				2022-12-28	WOS:000176273300035
J	Dissmann, W; de Ridder, M				Dissmann, W; de Ridder, M			The soft science of German cardiology	LANCET			English	Editorial Material							ASSOCIATION TASK-FORCE; PRACTICE GUIDELINES COMMITTEE; ACUTE MYOCARDIAL-INFARCTION; AMERICAN-COLLEGE; CORONARY ANGIOGRAPHY; MANAGEMENT; EVENT		Klinikum Urban, Emergency Dept, D-10967 Berlin, Germany; Klinikum Urban, Dept Cardiol, D-10967 Berlin, Germany		de Ridder, M (corresponding author), Klinikum Urban, Emergency Dept, Dieffenbachstr 1, D-10967 Berlin, Germany.							*AM HEART ASS, 2001, 2001 HEART STROK STA; ARNTZ HR, 2001, CARDIO NEWS, V7, P7; Becker RC, 2001, ARCH INTERN MED, V161, P601, DOI 10.1001/archinte.161.4.601; Beecham L, 2000, BRIT MED J, V320, P1293, DOI 10.1136/bmj.320.7245.1293; Brignole M, 2001, EUR HEART J, V22, P1256, DOI 10.1053/euhj.2001.2739; *BRIT CARD INT SOC, 2001, BCIS AUD RET INT PRO; BRUCKENBERGER E, 2000, HERZBERICHT 1999 TRA; Fischer M, 2001, Z KARDIOL, V90, P104, DOI 10.1007/s003920170196; Fuster V, 2001, J AM COLL CARDIOL, V38, P1231, DOI 10.1016/S0735-1097(01)01587-X; *GERM CARD SOC, 2001, STELL KONZ AKT GES U; Gibbons RJ, 1999, CIRCULATION, V99, P2829, DOI 10.1161/01.CIR.99.21.2829; GOSH P, 2000, COR EUROPAEUM, V8, P128; Graboys TB, 1999, JAMA-J AM MED ASSOC, V282, P184, DOI 10.1001/jama.282.2.184; Holmes DR, 1997, LANCET, V349, P75, DOI 10.1016/S0140-6736(96)03031-0; Kotseva K, 2001, LANCET, V357, P995, DOI 10.1016/S0140-6736(00)04235-5; Kuulasmaa K, 2000, LANCET, V355, P675, DOI 10.1016/S0140-6736(99)11180-2; Montaye M, 2000, EUR HEART J, V21, P808, DOI 10.1053/euhj.1999.1854; Orth-Gomer K, 2001, EUR HEART J, V22, P276, DOI 10.1053/euhj.2000.2437; Peterson ED, 1997, ANN INTERN MED, V126, P561, DOI 10.7326/0003-4819-126-7-199704010-00012; PRAETORIUS F, 1999, ETHIK MED, V11, P89; Scanlon PJ, 1999, J AM COLL CARDIOL, V33, P1756, DOI 10.1016/S0735-1097(99)00126-6; SCHUFFEL W, 2000, DTSCH ARZTEBL, V43, P2410; The world health report, 2000, HLTH SYST IMPR PERF; VIRCHOW R, 1849, EINHEITSBESTREBUNGEN, P48; Wagner S, 1999, Z KARDIOL, V88, P857, DOI 10.1007/s003920050362; WILLICH SN, 2001, EUR HEART J, V22, P707; 2001, FRANKFURTER ALL 0425, pN3	27	36	36	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 8	2002	359	9322					2027	2029		10.1016/S0140-6736(02)08825-6	http://dx.doi.org/10.1016/S0140-6736(02)08825-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076573				2022-12-28	WOS:000176232500030
J	Bousso, P; Bhakta, NR; Lewis, RS; Robey, E				Bousso, P; Bhakta, NR; Lewis, RS; Robey, E			Dynamics of thymocyte-stromal cell interactions visualized by two-photon microscopy	SCIENCE			English	Article							T-CELLS; ANTIGEN PRESENTATION; POSITIVE SELECTION; ACTIVATION	Thymocytes are selected to mature according to their ability to interact with self major histocompatibility complex (MHC)-peptide complexes displayed on the thymic stroma. Using two-photon microscopy, we performed real-time analysis of the cellular contacts made by developing thymocytes undergoing positive selection in a three-dimensional thymic organ culture. A large fraction of thymocytes within these cultures were highly motile. MHC recognition was found to increase the duration of thymocyte-stromal cell interactions and occurred as both long-lived cellular associations displaying stable cell-cell contacts and as shorter, highly dynamic contacts. Our results identify the diversity and dynamics of thymocyte interactions during positive selection.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	University of California System; University of California Berkeley; Stanford University	Robey, E (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.		BOUSSO, Philippe/M-6547-2014	BOUSSO, Philippe/0000-0002-6362-561X; Lewis, Richard/0000-0002-6010-7403	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042033, R01AI032985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045374, R37GM045374] Funding Source: NIH RePORTER; NIAID NIH HHS [AI42033, AI32985] Funding Source: Medline; NIGMS NIH HHS [R01 GM045374, GM45374] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON G, 1994, J IMMUNOL, V153, P1915; Berg LJ, 2001, CURR OPIN IMMUNOL, V13, P232, DOI 10.1016/S0952-7915(00)00209-0; BOUSSO P, UNPUB; Brelinska R, 1997, MICROSC RES TECHNIQ, V38, P250; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Gunzer M, 2000, IMMUNITY, V13, P323, DOI 10.1016/S1074-7613(00)00032-7; Hogquist KA, 2001, CURR OPIN IMMUNOL, V13, P225, DOI 10.1016/S0952-7915(00)00208-9; Ingulli E, 1997, J EXP MED, V185, P2133, DOI 10.1084/jem.185.12.2133; JENKINSON EJ, 1992, J EXP MED, V176, P845, DOI 10.1084/jem.176.3.845; MAMALAKI C, 1993, DEV IMMUNOL, V3, P159, DOI 10.1155/1993/98015; Marrack P, 1997, CURR OPIN IMMUNOL, V9, P250, DOI 10.1016/S0952-7915(97)80144-6; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Pezzano M, 2001, MICROBIOL MOL BIOL R, V65, P390, DOI 10.1128/MMBR.65.3.390-403.2001; Tanaka Y, 1997, INT IMMUNOL, V9, P381, DOI 10.1093/intimm/9.3.381; Underhill DM, 1999, J EXP MED, V190, P1909, DOI 10.1084/jem.190.12.1909	16	222	231	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 7	2002	296	5574					1876	1880		10.1126/science.1070945	http://dx.doi.org/10.1126/science.1070945			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052962				2022-12-28	WOS:000176054300051
J	Durr, M; Biedermann, A; Hu, Z; Hofer, U; Heinz, TF				Durr, M; Biedermann, A; Hu, Z; Hofer, U; Heinz, TF			Probing high-barrier pathways of surface reactions by scanning tunneling microscopy	SCIENCE			English	Article							INDUCED THERMAL-DESORPTION; DISSOCIATIVE ADSORPTION; SILICON SURFACES; HYDROGEN ADSORPTION; H-2; DIFFUSION; DYNAMICS; KINETICS; SI(001); SI(100)	The ability of scanning tunneling microscopy to probe the pathways of thermally activated high-barrier surface processes is frequently limited by competing low-barrier processes that can confuse measurement of the true initial and final configuration. We introduce an approach to circumvent this difficulty by driving the surface process with nanosecond laser heating. The method is applied to determine the pathway of recombinative desorption in the H/Si(001) system. The observed configuration of dangling bonds after laser heating reveals that the desorbed hydrogen molecules are not formed on single dimers, but rather from neighboring silicon dimers via an interdimer reaction pathway.	Columbia Univ, Dept Phys, New York, NY 10027 USA; Columbia Univ, Dept Elect Engn, New York, NY 10027 USA; Univ Marburg, Fachbereich Phys, D-35032 Marburg, Germany; Univ Marburg, Zentrum Mat Wissensch, D-35032 Marburg, Germany; Vienna Univ Technol, Inst Allgemeine Phys, A-1040 Vienna, Austria	Columbia University; Columbia University; Philipps University Marburg; Philipps University Marburg; Technische Universitat Wien	Durr, M (corresponding author), Columbia Univ, Dept Phys, 538 W 120th St, New York, NY 10027 USA.		Hofer, Ulrich/A-1310-2009; Heinz, Tony/K-7797-2015	Hofer, Ulrich/0000-0002-5706-1205; Heinz, Tony/0000-0003-1365-9464				Biedermann A, 1999, PHYS REV LETT, V83, P1810, DOI 10.1103/PhysRevLett.83.1810; BOLAND JJ, 1991, PHYS REV LETT, V67, P1539, DOI 10.1103/PhysRevLett.67.1539; Bonn M, 1999, SCIENCE, V285, P1042, DOI 10.1126/science.285.5430.1042; Brenig W, 2001, J PHYS-CONDENS MAT, V13, pR61, DOI 10.1088/0953-8984/13/9/201; COWIN JP, 1978, SURF SCI, V78, P545, DOI 10.1016/0039-6028(78)90232-7; Doren DJ, 1996, ADV CHEM PHYS, V95, P1, DOI 10.1002/9780470141540.ch1; Durr M, 1999, J CHEM PHYS, V111, P10411, DOI 10.1063/1.480395; Durr M, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.076107; Durr M, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.046104; Durr M, 2001, PHYS REV LETT, V86, P123, DOI 10.1103/PhysRevLett.86.123; ERTL G, 1972, Z NATURFORSCH A, VA 27, P1607, DOI 10.1515/zna-1972-1112; GEORGE SM, 1985, SURF SCI, V159, pL425, DOI 10.1016/0039-6028(85)90097-4; HALL RB, 1984, SURF SCI, V137, P421, DOI 10.1016/0039-6028(84)90521-1; Hofer U, 1996, APPL PHYS A-MATER, V63, P533, DOI 10.1007/BF01567209; HOFER U, 1992, PHYS REV B, V45, P9485, DOI 10.1103/PhysRevB.45.9485; Horch S, 1999, NATURE, V398, P134, DOI 10.1038/18185; JOHNSON NM, 1991, PHYSICA B, V170, P3, DOI 10.1016/0921-4526(91)90104-M; KOLASINSKI KW, 1994, PHYS REV LETT, V72, P1356, DOI 10.1103/PhysRevLett.72.1356; KOLASINSKI KW, 1995, INT J MOD PHYS B, V9, P2753, DOI 10.1142/S0217979295001038; Kratzer P, 1998, PHYS REV LETT, V81, P5596, DOI 10.1103/PhysRevLett.81.5596; McEllistrem M, 1998, SCIENCE, V279, P545, DOI 10.1126/science.279.5350.545; Owen JHG, 1996, PHYS REV B, V54, P14153, DOI 10.1103/PhysRevB.54.14153; Pehlke E, 2000, PHYS REV B, V62, P12932, DOI 10.1103/PhysRevB.62.12932; Sachs C, 2001, SCIENCE, V293, P1635, DOI 10.1126/science.1062883; van Santen RA, 1995, CHEM KINETICS CATALY; Wintterlin J, 1997, SCIENCE, V278, P1931, DOI 10.1126/science.278.5345.1931; Zimmermann FM, 2000, PHYS REV LETT, V85, P618, DOI 10.1103/PhysRevLett.85.618	27	66	66	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 7	2002	296	5574					1838	1841		10.1126/science.1070859	http://dx.doi.org/10.1126/science.1070859			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052951				2022-12-28	WOS:000176054300039
J	Renne, PR				Renne, PR			Geology: Flood basalts - Bigger and badder	SCIENCE			English	Editorial Material							TRIASSIC BOUNDARY		Berkeley Geochronol Ctr, Berkeley, CA 94709 USA; Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA	Berkeley Geochronolgy Center; University of California System; University of California Berkeley	Renne, PR (corresponding author), Berkeley Geochronol Ctr, Berkeley, CA 94709 USA.			Renne, Paul/0000-0003-1769-5235				Courtillot Vincent, 1994, Israel Journal of Earth Sciences, V43, P255; King SD, 1998, EARTH PLANET SC LETT, V160, P289, DOI 10.1016/S0012-821X(98)00089-2; LYONS JO, IN PRESS J GEOPHYS R; Marzoli A, 1999, SCIENCE, V284, P616, DOI 10.1126/science.284.5414.616; Morgan W.J., 1981, SEA VOLUME 7 OCEANIC, V7, P443; Olsen PE, 2002, SCIENCE, V296, P1305, DOI 10.1126/science.1065522; Reichow MK, 2002, SCIENCE, V296, P1846, DOI 10.1126/science.1071671; RENNE PR, 1991, SCIENCE, V253, P176, DOI 10.1126/science.253.5016.176; RENNE PR, 1995, SCIENCE, V269, P1413, DOI 10.1126/science.269.5229.1413; RICHARDS MA, 1989, SCIENCE, V246, P103, DOI 10.1126/science.246.4926.103	10	4	6	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 7	2002	296	5574					1812	1813		10.1126/science.1073209	http://dx.doi.org/10.1126/science.1073209			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052940				2022-12-28	WOS:000176054300028
J	Riewald, M; Petrovan, RJ; Donner, A; Mueller, BM; Ruf, W				Riewald, M; Petrovan, RJ; Donner, A; Mueller, BM; Ruf, W			Activation of endothelial cell protease activated receptor 1 by the protein C pathway	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; COLI SEPTIC SHOCK; ESCHERICHIA-COLI; TISSUE FACTOR; FACTOR VIIA; RESPONSES; SEPSIS; COAGULATION; MECHANISMS; EXPRESSION	The coagulant and inflammatory exacerbation in sepsis is counterbalanced by the protective protein C (PC) pathway. Activated PC (APC) was shown to use the endothelial cell PC receptor (EPCR) as a coreceptor for cleavage of protease activated receptor 1 (PAR1) on endothelial cells. Gene profiling demonstrated that PAR1 signaling could account for all APC-induced protective genes, including the immunomodulatory monocyte chemoattractant protein-1 (MCP-1), which was selectively induced by activation of PAR1, but not PAR2. Thus, the prototypical thrombin receptor is the target for EPCR-dependent APC signaling, suggesting a role for this receptor cascade in protection from sepsis.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; La Jolla Inst Mol Med, Div Canc Biol, San Diego, CA 92121 USA	Scripps Research Institute	Ruf, W (corresponding author), Scripps Res Inst, Dept Immunol, C204,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ruf@scripps.edu			NHLBI NIH HHS [P01-HL16411] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Bone-Larson CL, 2000, AM J PATHOL, V157, P1177, DOI 10.1016/S0002-9440(10)64633-0; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Compton SJ, 2001, BRIT J PHARMACOL, V134, P705, DOI 10.1038/sj.bjp.0704303; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; Esmon CT, 1999, THROMB HAEMOSTASIS, V82, P251; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Faust SN, 2001, NEW ENGL J MED, V345, P408, DOI 10.1056/NEJM200108093450603; GREY ST, 1994, J IMMUNOL, V153, P3664; Grinnell BW, 1996, AM J PHYSIOL-HEART C, V270, pH603, DOI 10.1152/ajpheart.1996.270.2.H603; HANSON SR, 1993, J CLIN INVEST, V92, P2003, DOI 10.1172/JCI116795; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Liaw PCY, 2001, J BIOL CHEM, V276, P8364, DOI 10.1074/jbc.M010572200; O'Brien PJ, 2001, ONCOGENE, V20, P1570, DOI 10.1038/sj.onc.1204194; Riewald M, 2001, P NATL ACAD SCI USA, V98, P7742, DOI 10.1073/pnas.141126698; Riewald M, 2001, BLOOD, V97, P3109, DOI 10.1182/blood.V97.10.3109; Shu F, 2000, FEBS LETT, V477, P208, DOI 10.1016/S0014-5793(00)01740-3; Taylor FB, 2000, BLOOD, V95, P1680, DOI 10.1182/blood.V95.5.1680.005k33_1680_1686; Taylor FB, 1998, BLOOD, V91, P1609, DOI 10.1182/blood.V91.5.1609.1609_1609_1615; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; TAYLOR FB, 1994, BACTERIAL ENDOTOXINS; Zisman DA, 1997, J CLIN INVEST, V99, P2832, DOI 10.1172/JCI119475	26	698	737	3	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 7	2002	296	5574					1880	1882		10.1126/science.1071699	http://dx.doi.org/10.1126/science.1071699			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052963				2022-12-28	WOS:000176054300052
J	Chassin, MR; Becher, EC				Chassin, MR; Becher, EC			The wrong patient	ANNALS OF INTERNAL MEDICINE			English	Article							INFORMED-CONSENT; INTENSIVE-CARE; ADVERSE EVENTS; HUMAN ERROR; COMMUNICATION; PHYSICIANS; MANAGEMENT; PERFORMANCE; PATTERNS; QUALITY	Among all types of medical errors, cases in which the wrong patient undergoes an invasive procedure are sufficiently distressing to warrant special attention. Nevertheless, institutions under-report such procedures, and the medical literature contains no discussions about them. This article examines the case of a patient who was mistakenly taken for another patient's invasive electrophysiology procedure. After reviewing the case and the results of the institution's "root-cause analysis," the discussants discovered at least 17 distinct errors, no single one of which could have caused this adverse event by itself. The discussants illustrate how these specific "active" errors interacted with a few underlying "latent conditions" (system weaknesses) to cause harm. The most remediable of these were absent or misused protocols for patient identification and informed consent, systematically faulty exchange of information among caregivers, and poorly functioning teams.	CUNY Mt Sinai Sch Med, Dept Hlth Policy, New York, NY 10029 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of California System; University of California San Francisco	Chassin, MR (corresponding author), CUNY Mt Sinai Sch Med, Dept Hlth Policy, Box 1077,1 Gustave L Levy Pl, New York, NY 10029 USA.	mark.chassin@mssm.edu						ALLEN ML, 1980, HEART LUNG, V9, P836; Anderson FD, 1996, MIL MED, V161, P411, DOI 10.1093/milmed/161.7.411; CASSILETH BR, 1980, NEW ENGL J MED, V302, P896, DOI 10.1056/NEJM198004173021605; Chassin MR, 1998, MILBANK Q, V76, P565, DOI 10.1111/1468-0009.00106; CULLEN DJ, 1995, JOINT COMM J QUAL IM, V21, P541, DOI 10.1016/S1070-3241(16)30180-8; *DEP PUBL JOINT CO, 2000, WHAT EV HOSP SHOULD; Duldt B W, 1981, Nurs Outlook, V29, P640; Epstein R M, 1995, Arch Fam Med, V4, P403, DOI 10.1001/archfami.4.5.403; FRIEDMAN FC, 1973, J MED EDUC, V48, P436; FRIEDMAN RC, 1971, NEW ENGL J MED, V285, P201, DOI 10.1056/NEJM197107222850405; HELMREICH RL, 1990, AVIAT SPACE ENVIR MD, V61, P576; Helmreich RL, 2000, BRIT MED J, V320, P781, DOI 10.1136/bmj.320.7237.781; Helmreich RL, 1997, SCI AM, V276, P62, DOI 10.1038/scientificamerican0597-62; HELMREICH RL, 1994, HUMAN ERROR MED, P179; HERZ DA, 1992, NEUROSURGERY, V30, P453, DOI 10.1227/00006123-199203000-00028; James BC, 1997, MED J AUSTRALIA, V166, P484, DOI 10.5694/j.1326-5377.1997.tb123221.x; *JOINT COMM ACCR H, 2001, SENT EV AL FOLL UP R; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; Kohn KT, 2000, ERR IS HUMAN BUILDIN; LAVELLEJONES C, 1993, BRIT MED J, V306, P885, DOI 10.1136/bmj.306.6882.885; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LINDEN JV, 1992, TRANSFUSION, V32, P601, DOI 10.1046/j.1537-2995.1992.32792391030.x; MacKay R C, 1991, Qual Assur Health Care, V3, P11; MARK JS, 1990, ARCH INTERN MED, V150, P777, DOI 10.1001/archinte.150.4.777; MCCUE JD, 1994, J GEN INTERN MED, V9, P158, DOI 10.1007/BF02600033; MCPHEE SJ, 1984, ARCH INTERN MED, V144, P1265, DOI 10.1001/archinte.144.6.1265; MISHRA R, 2000, BOSTON GLOBE    1223, pB1; MULHERN RK, 1981, J PEDIATR-US, V99, P480, DOI 10.1016/S0022-3476(81)80355-1; *NY STAT DEP HLTH, 2001, NEW YORK PAT OCC TRA; PRILUCK IA, 1979, AM J OPHTHALMOL, V87, P620, DOI 10.1016/0002-9394(79)90292-7; Reason J, 2000, BMJ-BRIT MED J, V320, P768, DOI 10.1136/bmj.320.7237.768; Reason J., 1997, MANAGING RISK ORG AC; ROSEN M, 1998, ST PETERSBURG T 0711, pA1; SAMKOFF JS, 1991, ACAD MED, V66, P687, DOI 10.1097/00001888-199111000-00013; SAW KC, 1994, J ROY SOC MED, V87, P143; Schulmeister L, 1999, Oncol Nurs Forum, V26, P1033; SERIG DI, 1994, HUMAN ERROR MED, P179; Sexton JB, 2000, BMJ-BRIT MED J, V320, P745, DOI 10.1136/bmj.320.7237.745; SHORTELL SM, 1994, MED CARE, V32, P508, DOI 10.1097/00005650-199405000-00009; SNYDER J, 1998, ARIZONA REPUBLI 0826, pB1; STEINHAUER J, 2001, NY TIMES        0213, P7; STEINHAUER J, 2001, NY TIMES        0213, pB1; Weingart SN, 2000, J GEN INTERN MED, V15, P470, DOI 10.1046/j.1525-1497.2000.06269.x; Young GJ, 1998, HEALTH SERV RES, V33, P1211	44	158	158	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 4	2002	136	11					826	833		10.7326/0003-4819-136-11-200206040-00012	http://dx.doi.org/10.7326/0003-4819-136-11-200206040-00012			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	558KG	12044131				2022-12-28	WOS:000175964500006
J	Owens, PL; Bradley, EH; Horwitz, SM; Viscoll, CM; Kernan, WN; Brass, LM; Sarrel, PM; Horwitz, RI				Owens, PL; Bradley, EH; Horwitz, SM; Viscoll, CM; Kernan, WN; Brass, LM; Sarrel, PM; Horwitz, RI			Clinical assessment of function among women with a recent cerebrovascular event: A self-reported versus performance-based measure	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICAL PERFORMANCE; DISABILITY; STROKE; CAPACITY; ABILITY; SCALES	Background: Self-reported functional status is a commonly used health measure in clinical settings, yet the optimal approach for assessing function is often debated. Objective: To examine the agreement between a self-reported and a performance-based measure of function and the relative ability of each measure to predict long-term health outcomes. Design: Prospective cohort study. Setting: 20 hospitals in Connecticut and Massachusetts. Participants: 620 postmenopausal women (46 to 91 years of age) who had experienced a stroke or transient ischemic attack. Measurements: A self-reported and a performance-based measure of function were assessed at baseline (before intervention) by using the Barthel index and the Physical Performance Test. Results: Disagreement between the self-reported and performance-based measure of function was common (slight disagreement, 55.0%; substantial disagreement, 19.3%). Most women (95.4%) overreported their level of function. Women who were more clinically impaired (risk ratio [RR] for more comorbid conditions, 1.52 [95% CI, 1.17 to 1.97]; RR for recent stroke, 2.33 [CI, 1.45 to 3.73]; and RR for cognitive Impairment, 1.76 [CI, 1.34 to 2.32]); who were less educated (RR = 1.30 [CI, 1.02 to 1.67]); and who were of nonwhite ethnicity (RR 1.43 [CI, 1.07 to 1.91]) were more likely to overreport their level of function. An impaired performance-based measure of function predicted subsequent stroke or death (hazard ratio, 1.50, [CI, 1.06 to 2.11]); however, an impaired self-reported measure of function was not likely to predict these outcomes. Conclusions: Clinicians should be aware that results of self-reported and performance-based measures of function can differ In women who have experienced a recent cerebrovascular event Although more difficult to collect, results of a performance-based measure may provide information about long-term health outcomes that is not available from a self-reported measure.	Agcy Healthcare Res & Qual, Rockville, MD 20852 USA	Agency for Healthcare Research & Quality	Owens, PL (corresponding author), Agcy Healthcare Res & Qual, 2101 E Jefferson,Suite 605, Rockville, MD 20852 USA.	POwens@ahrq.gov		Horwitz, Sarah/0000-0002-5262-1170	NIMH NIH HHS [5T32-MH19545, 5T32-MH15783] Funding Source: Medline; PHS HHS [R01-N531251] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH015783, T32MH019545] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Brown M, 2000, J GERONTOL A-BIOL, V55, pM350, DOI 10.1093/gerona/55.6.M350; CRESS ME, 1995, J AM GERIATR SOC, V43, P93, DOI 10.1111/j.1532-5415.1995.tb06372.x; DOMBOVY ML, 1986, STROKE, V17, P363, DOI 10.1161/01.STR.17.3.363; ELAM JT, 1991, AM J PUBLIC HEALTH, V81, P1127, DOI 10.2105/AJPH.81.9.1127; Ferrer M, 1999, AM J EPIDEMIOL, V149, P228; FLANDERS WD, 1987, J CHRON DIS, V40, P697, DOI 10.1016/0021-9681(87)90106-8; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; FLEISS JL, 1973, EDUC PSYCHOL MEAS, V33, P613, DOI 10.1177/001316447303300309; FOLSTEIN M, 1985, J AM GERIATR SOC, V33, P228, DOI 10.1111/j.1532-5415.1985.tb07109.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gill TM, 1998, ANN INTERN MED, V128, P96, DOI 10.7326/0003-4819-128-2-199801150-00004; GURALNIK JM, 1989, J GERONTOL, V44, pM141, DOI 10.1093/geronj/44.5.M141; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; GURALNIK JM, 1995, GERIATRIC ASSESSMENT, P59; Hoeymans N, 1996, J CLIN EPIDEMIOL, V49, P1103, DOI 10.1016/0895-4356(96)00210-7; Hosmer DW, 1999, WILEY PS TX; HUBER MR, 1994, FAULKNER GRAYS MED O, V2, P9; KEITH RA, 1994, ARCH PHYS MED REHAB, V75, P478, DOI 10.1016/0003-9993(94)90175-9; KELLYHAYES M, 1992, AM J PUBLIC HEALTH, V82, P841, DOI 10.2105/AJPH.82.6.841; Kempen GIJM, 1996, J GERONTOL B-PSYCHOL, V51, pP254, DOI 10.1093/geronb/51B.5.P254; Kempen GIJM, 1996, AGE AGEING, V25, P458, DOI 10.1093/ageing/25.6.458; Kernan W N, 1998, J Stroke Cerebrovasc Dis, V7, P85, DOI 10.1016/S1052-3057(98)80026-8; KERNAN WN, 1991, ANN INTERN MED, V114, P552, DOI 10.7326/0003-4819-114-7-552; Kivinen P, 1998, J CLIN EPIDEMIOL, V51, P1243, DOI 10.1016/S0895-4356(98)00115-2; KURIANSKY JB, 1976, J CLIN PSYCHOL, V32, P95, DOI 10.1002/1097-4679(197601)32:1<95::AID-JCLP2270320129>3.0.CO;2-J; LAPLANTE M, 1996, DISABILITY US PREVAL; LITTLE AG, 1986, BRIT J CLIN PSYCHOL, V25, P51, DOI 10.1111/j.2044-8260.1986.tb00670.x; MAHONEY F I, 1965, Md State Med J, V14, P61; MCDOWELL I, 1996, MEASURING HLTH GUIDE, P47; Merrill SS, 1997, J GERONTOL A-BIOL, V52, pM19, DOI 10.1093/gerona/52A.1.M19; MYERS AM, 1993, J GERONTOL, V48, pM196, DOI 10.1093/geronj/48.5.M196; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; REUBEN DB, 1992, J GERONTOL, V47, pM106, DOI 10.1093/geronj/47.4.M106; REUBEN DB, 1990, J AM GERIATR SOC, V38, P1105, DOI 10.1111/j.1532-5415.1990.tb01373.x; REUBEN DB, 1995, J AM GERIATR SOC, V43, P17, DOI 10.1111/j.1532-5415.1995.tb06236.x; RODGERS H, 1993, AGE AGEING, V22, P161, DOI 10.1093/ageing/22.3.161; ROZZINI R, 1993, J AM GERIATR SOC, V41, P1109, DOI 10.1111/j.1532-5415.1993.tb06460.x; SAGER MA, 1992, J AM GERIATR SOC, V40, P457, DOI 10.1111/j.1532-5415.1992.tb02011.x; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; Sherman SE, 1998, J GEN INTERN MED, V13, P817, DOI 10.1046/j.1525-1497.1998.00245.x; WADE DT, 1987, J NEUROL NEUROSUR PS, V50, P177, DOI 10.1136/jnnp.50.2.177	42	13	14	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 4	2002	136	11					802	811		10.7326/0003-4819-136-11-200206040-00008	http://dx.doi.org/10.7326/0003-4819-136-11-200206040-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	558KG	12044128				2022-12-28	WOS:000175964500003
J	Lowe, L; Murray, CS; Custovic, A; Simpson, BM; Kissen, PM; Woodcock, A				Lowe, L; Murray, CS; Custovic, A; Simpson, BM; Kissen, PM; Woodcock, A		NAC Manchester Asthma Allergy Stud	Specific airway resistance in 3-year-old children: a prospective cohort study	LANCET			English	Article							PASSIVE RESPIRATORY MECHANICS; LUNG-FUNCTION; EARLY-LIFE; BRONCHIAL RESPONSIVENESS; PULMONARY-FUNCTION; MANCHESTER ASTHMA; YOUNG-CHILDREN; FAMILY HISTORY; INFANTS; PREGNANCY	Background The development of a method to assess lung function in young children may provide new insight into asthma development. Plethysmographic measurement of specific airway resistance (sR(aw)) is feasible in this age group. We aimed to identify risk factors associated with low lung function in early childhood in a prospective birth cohort. Methods Children were prenatally assigned to risk group according to parental atopic status (high risk, both parents atopic; medium risk, one parent atopic; low risk, neither parent atopic) and followed prospectively until age 3 years. We measured sR(aw) in 503 symptom-free children using whole-body plethysmography during tidal breathing. Findings 803 of 868 children attended the clinic, of whom 503 obtained satisfactory sR(aw) readings, 200 who wheezed at least once during first 3 years of life had significantly higher sR(aw) than the 303 who had never wheezed (mean difference 5.8%, 95% CI 2.2-9.3, p=0.002). For children who had never wheezed there were significant differences in sR(aw) between risk groups (p<0.001). Children at high risk (n=87) had a higher sR(aw) (geometric mean 1.17 kPa/s, 1.12-1.22) than children at medium risk (n=162; 1.02 kPa/s, 1.00-1.05) and at low risk (54; 1.04 kPa/s, 0.99-1.11). Atopic children (n=62) had significantly higher sR(aw) (1.15 kPa/s, 1.09-1.21) than those who were not atopic (232; 1.05 kPa/s, 1.02-1.07, p=0.002). For non-atopic children, those at high risk (58) had higher sR(aw) (1.13 kPa/s, 1.07-1.18) than those at medium risk (125, 1.01 kPa/s, 0.98-1.05) or at low risk (49, 1.04 kPa/s, 0.97-1.10, p=0.003). We showed a significant interaction between history of maternal asthma and child's atopic status (p=0.006). Interpretation Even in the absence of respiratory symptoms, children of atopic parents and those with personal atopy have impaired lung function in early life.	Wythenshawe Hosp, N W Lung Ctr, Manchester M23 9LT, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Woodcock, A (corresponding author), Wythenshawe Hosp, N W Lung Ctr, Southmoor Rd, Manchester M23 9LT, Lancs, England.	awoodcock@fs1.with.man.ac.uk	Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Murray, Clare/0000-0002-8961-8055; Woodcock, Ashley/0000-0002-5428-8578				Bates JHT, 2000, EUR RESPIR J, V16, P1180, DOI 10.1034/j.1399-3003.2000.16f26.x; Bisgaard H, 1995, EUR RESPIR J, V8, P2067, DOI 10.1183/09031936.95.08122067; CLARKE JR, 1995, AM J RESP CRIT CARE, V151, P1434, DOI 10.1164/ajrccm.151.5.7735597; *COMM PROF STAND C, 1995, AM J RESP CRIT CARE, V152, P1107, DOI DOI 10.1164/AJRCCM; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; DAB I, 1978, PEDIATR RES, V12, P878, DOI 10.1203/00006450-197808000-00016; DAB I, 1976, PEDIATR RES, V10, P996, DOI 10.1203/00006450-197612000-00009; Dezateux C, 1997, BRIT MED BULL, V53, P40; Gappa M, 2001, EUR RESPIR J, V17, P141, DOI 10.1183/09031936.01.17101410; Goetz I, 2001, EUR RESPIR J, V17, P449, DOI 10.1183/09031936.01.17304490; Holgate ST, 2000, AM J RESP CRIT CARE, V162, pS113, DOI 10.1164/ajrccm.162.supplement_2.ras-12; Klug B, 1998, PEDIATR PULM, V25, P322, DOI 10.1002/(SICI)1099-0496(199805)25:5<322::AID-PPUL6>3.0.CO;2-K; Klug B, 1997, EUR RESPIR J, V10, P1599, DOI 10.1183/09031936.97.10071599; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; Morris MG, 2001, EUR RESPIR J, V17, P529, DOI 10.1183/09031936.01.17305290; Nielsen KG, 2001, AM J RESP CRIT CARE, V164, P554, DOI 10.1164/ajrccm.164.4.2006119; Phagoo SB, 1996, EUR RESPIR J, V9, P1374, DOI 10.1183/09031936.96.09071374; POHUNEK P, 1997, EUR RESP J S25, V12, pS160; REID L, 1977, PEDIATR RES, V11, P210; SILVERMAN M, 1998, LUNG FUNCTION TESTS, P170; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; Sly PD, 2000, EUR RESPIR J, V16, P741, DOI 10.1034/j.1399-3003.2000.16d29.x; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; Stocks J, 2001, EUR RESPIR J, V17, P302, DOI 10.1183/09031936.01.17203020; Stocks J, 1996, INFANT RESP FUNCTION; Ulrik CS, 1999, AM J RESP CRIT CARE, V160, P40, DOI 10.1164/ajrccm.160.1.9806059; Young S, 2000, EUR RESPIR J, V15, P151, DOI 10.1034/j.1399-3003.2000.15a28.x; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704	29	110	114	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 1	2002	359	9321					1904	1908		10.1016/S0140-6736(02)08781-0	http://dx.doi.org/10.1016/S0140-6736(02)08781-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PL	12057553				2022-12-28	WOS:000175975700010
J	Meller, S; Treleaven, J				Meller, S; Treleaven, J			Translocations at 11q23 in childhood ALL: age under 1 and poor prognosis	LANCET			English	Editorial Material							ACUTE LYMPHOBLASTIC-LEUKEMIA; REARRANGEMENTS; INFANTS		Royal Marsden Hosp, Haematooncol Univ, Sutton SM2 5PT, Surrey, England; Royal Marsden Hosp, Chidrens Dept, Sutton SM2 5PT, Surrey, England	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust	Treleaven, J (corresponding author), Royal Marsden Hosp, Haematooncol Univ, Downs Rd, Sutton SM2 5PT, Surrey, England.							Andersson A, 2001, LEUKEMIA, V15, P1293, DOI 10.1038/sj.leu.2402189; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Levis M, 2002, BLOOD, V99, P3885, DOI 10.1182/blood.V99.11.3885; Ludwig WD, 1998, BLOOD, V92, P1898; PUI CH, 1994, J CLIN ONCOL, V12, P909, DOI 10.1200/JCO.1994.12.5.909; Rini BI, 2002, J IMMUNOTHER, V25, P269, DOI 10.1097/00002371-200205000-00010; RUBNITZ JE, 1994, BLOOD, V84, P570; Rubnitz JE, 1996, LEUKEMIA, V10, P74; Rubnitz JE, 1999, CHILDHOOD LEUKEMIAS, P197; Silverman LB, 1997, CANCER-AM CANCER SOC, V80, P2285	11	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 1	2002	359	9321					1873	1874		10.1016/S0140-6736(02)08784-6	http://dx.doi.org/10.1016/S0140-6736(02)08784-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PL	12057546				2022-12-28	WOS:000175975700003
J	Heyland, DK; Paterson, WG				Heyland, DK; Paterson, WG			Fluid restriction for postoperative patients?	LANCET			English	Editorial Material							CRITICALLY ILL PATIENTS; ILEUS; INHIBITION; SURGERY; ALBUMIN		Queens Univ, Dept Med, Div Gastroenterol, Kingston, ON K7L 5G2, Canada	Queens University - Canada	Heyland, DK (corresponding author), Queens Univ, Dept Med, Div Gastroenterol, Kingston, ON K7L 5G2, Canada.	dkh2@post.queensu.ca						Basse L, 2001, Ugeskr Laeger, V163, P913; BOOTH CM, IN PRESS CRIT CARE M; Bungard TJ, 1999, PHARMACOTHERAPY, V19, P416, DOI 10.1592/phco.19.6.416.31040; DEVILLOTA ED, 1980, INTENS CARE MED, V7, P19, DOI 10.1007/BF01692917; DUBOIS A, 1973, ANN SURG, V178, P781, DOI 10.1097/00000658-197312000-00017; Heyland DK, 1996, INTENS CARE MED, V22, P1339, DOI 10.1007/BF01709548; HOLZER P, 1992, NEUROSCIENCE, V48, P715, DOI 10.1016/0306-4522(92)90414-W; Mentec H, 2001, CRIT CARE MED, V29, P1955, DOI 10.1097/00003246-200110000-00018; MITCHELL JP, 1992, AM REV RESPIR DIS, V145, P990, DOI 10.1164/ajrccm/145.5.990; MOBARHAN S, 1988, J AM COLL NUTR, V7, P445; OGILVY AJ, 1995, EUR J ANAESTH, V12, P35; Prasad M, 1999, GASTROENTEROLOGY, V117, P489, DOI 10.1053/gast.1999.0029900489; REISSMAN P, 1995, ANN SURG, V222, P73, DOI 10.1097/00000658-199507000-00012; Schwarz NT, 2002, ANN SURG, V235, P31, DOI 10.1097/00000658-200201000-00005; Schwenk W, 1998, LANGENBECK ARCH SURG, V383, P49, DOI 10.1007/s004230050091; Tack J, 2001, GUT, V49, P317; Taguchi A, 2001, NEW ENGL J MED, V345, P935, DOI 10.1056/NEJMoa010564	17	6	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 25	2002	359	9320					1792	1793		10.1016/S0140-6736(02)08728-7	http://dx.doi.org/10.1016/S0140-6736(02)08728-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044371				2022-12-28	WOS:000175775500004
J	Cummings, SR; Melton, LJ				Cummings, SR; Melton, LJ			Epidemiology and outcomes of osteoporotic fractures	LANCET			English	Article							DISTAL FOREARM FRACTURES; BONE-MINERAL DENSITY; HIP FRACTURE; VERTEBRAL FRACTURE; RISK-FACTORS; OLDER WOMEN; UNITED-STATES; WHITE WOMEN; ELDERLY MEN; PREVALENCE	Bone mass declines and the risk of fractures Increases as people age, especially as women pass through the menopause. Hip fractures, the most serious outcome of osteoporosis, are becoming more frequent than before because the world's population is ageing and because the frequency of hip fractures is increasing by:1-3% per year in most areas of the world. Rates of hip fracture vary more widely from region to region than does the prevalance of vertebral fractures. Low bone density and previous fractures are risk factors for almost all types of fracture, but each type of fracture also has its own unique risk factors. Prevention of fractures with drugs could potentially be as expensive as medical treatment of fractures. Therefore, epidemiological research should be done and used to identify individuals at high-risk of disabling fractures, thereby allowing careful allocation of expensive treatments to individuals most in need.	Univ Calif San Francisco, Dept Med, Coordinating Ctr, San Francisco, CA 94105 USA; Univ Calif San Francisco, Dept Epidemiol, Coordinating Ctr, San Francisco, CA 94105 USA; Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Rochester, MN 55905 USA	California Pacific Medical Center; California Pacific Medical Center Research Institute; University of California System; University of California San Francisco; California Pacific Medical Center; California Pacific Medical Center Research Institute; University of California System; University of California San Francisco; Mayo Clinic	Cummings, SR (corresponding author), Univ Calif San Francisco, Dept Med, Coordinating Ctr, San Francisco, CA 94105 USA.	SCummings@psg.ucsf.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035583, R01AR035582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004875] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM 35584] Funding Source: Medline; NIAMS NIH HHS [AR 35583, AR 35582] Funding Source: Medline; NIA NIH HHS [AG 05394, AG 05407, AG 04875] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLACK DM, 1995, J BONE MINER RES, V10, P890; BONAR SK, 1990, J AM GERIATR SOC, V38, P1139, DOI 10.1111/j.1532-5415.1990.tb01378.x; Browner WS, 1996, ARCH INTERN MED, V156, P1521, DOI 10.1001/archinte.156.14.1521; Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140-6736(98)09075-8; CHRISCHILLES EA, 1991, ARCH INTERN MED, V151, P2026, DOI 10.1001/archinte.151.10.2026; COOPER C, 1993, AM J EPIDEMIOL, V137, P1001, DOI 10.1093/oxfordjournals.aje.a116756; COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214; COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184; Cooper C, 2001, OSTEOPOROSIS INT, V12, P623, DOI 10.1007/s001980170061; Cummings SR, 1998, OSTEOPOROSIS INT, V8, pS8; CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; Davies KM, 1996, OSTEOPOROSIS INT, V6, P160, DOI 10.1007/BF01623941; Diaz MN, 1997, OSTEOPOROSIS INT, V7, P65, DOI 10.1007/BF01623463; DONALDSON LJ, 1990, J EPIDEMIOL COMMUN H, V44, P241, DOI 10.1136/jech.44.3.241; EASTELL R, 1991, J BONE MINER RES, V6, P207; Eddy DM, 1998, OSTEOPOROSIS INT S4, V8, P1; EINHORN TA, 1992, CALCIFIED TISSUE INT, V51, P333, DOI 10.1007/BF00316875; ELFFORS I, 1994, OSTEOPOROSIS INT, V4, P253, DOI 10.1007/BF01623349; Ensrud KE, 1997, ARCH INTERN MED, V157, P857, DOI 10.1001/archinte.157.8.857; ETTINGER B, 1992, J BONE MINER RES, V7, P449; Evans JG, 1997, J EPIDEMIOL COMMUN H, V51, P424, DOI 10.1136/jech.51.4.424; Felsenberg D, 2002, J BONE MINER RES, V17, P716; GARDSELL P, 1991, J BONE MINER RES, V6, P67; Gehlbach SH, 2000, OSTEOPOROSIS INT, V11, P577, DOI 10.1007/s001980070078; GILLESPIE LD, 2000, COCHRANE LIB; Gold DT, 2001, OSTEOPOROSIS, P479; Graafmans WC, 1996, OSTEOPOROSIS INT, V6, P427, DOI 10.1007/BF01629573; GREENDALE GA, 2001, OSTEOPOROSIS, P819; GREENSPAN SL, 1994, JAMA-J AM MED ASSOC, V271, P128, DOI 10.1001/jama.271.2.128; Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148; Hoerger TJ, 1999, J WOMEN HEALTH GEN-B, V8, P1077, DOI 10.1089/jwh.1.1999.8.1077; Huusko TM, 1999, BONE, V24, P257, DOI 10.1016/S8756-3282(98)00182-3; Jacobsen SJ, 1999, OSTEOPOROSIS INT, V9, P254, DOI 10.1007/s001980050145; JACOBSEN SJ, 1990, JAMA-J AM MED ASSOC, V264, P500, DOI 10.1001/jama.264.4.500; Janott J, 1996, SCAND J RHEUMATOL, P123; JENSEN JS, 1982, ACTA ORTHOP SCAND, V53, P97, DOI 10.3109/17453678208992185; JOHNELL O, 1992, OSTEOPOROSIS INT, V2, P298, DOI 10.1007/BF01623186; Jonsson B, 1999, OSTEOPOROSIS INT, V10, P193, DOI 10.1007/s001980050215; Kado DM, 1999, ARCH INTERN MED, V159, P1215, DOI 10.1001/archinte.159.11.1215; Kanis JA, 2000, BONE, V27, P585, DOI 10.1016/S8756-3282(00)00381-1; Kannus P, 2000, NEW ENGL J MED, V343, P1506, DOI 10.1056/NEJM200011233432101; KAUKONEN JP, 1988, ANN CHIR GYNAECOL FE, V77, P27; KELSEY JL, 1992, AM J EPIDEMIOL, V135, P477, DOI 10.1093/oxfordjournals.aje.a116314; Klotzbuecher CM, 2000, J BONE MINER RES, V15, P721, DOI 10.1359/jbmr.2000.15.4.721; Koh LKH, 2001, OSTEOPOROSIS INT, V12, P311, DOI 10.1007/s001980170121; KRISTIANSEN B, 1987, ACTA ORTHOP SCAND, V58, P75, DOI 10.3109/17453678709146347; Lau EMC, 2001, OSTEOPOROSIS INT, V12, P239, DOI 10.1007/s001980170135; Lau EMC, 1996, CLIN ORTHOP RELAT R, P65; Lau EMC, 1996, J BONE MINER RES, V11, P1364; Lauderdale DS, 1997, AM J EPIDEMIOL, V146, P502; LEIDIG G, 1990, BONE MINER, V8, P217, DOI 10.1016/0169-6009(90)90107-Q; Ling X, 1996, AM J EPIDEMIOL, V144, P901; Lippuner K, 1997, OSTEOPOROSIS INT, V7, P414, DOI 10.1007/PL00004149; Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761; Marquez MA, 2001, OSTEOPOROSIS INT, V12, P595, DOI 10.1007/s001980170083; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; McColl A, 1998, J PUBLIC HEALTH MED, V20, P196, DOI 10.1093/oxfordjournals.pubmed.a024743; Melton L III, 1995, OSTEOPOROSIS ETIOLOG, P225; Melton LJ, 1998, OSTEOPOROSIS INT, V8, P68; Melton LJ, 1996, BONE, V18, pS121, DOI 10.1016/8756-3282(95)00492-0; Melton LJ, 1999, BONE, V24, P49, DOI 10.1016/S8756-3282(98)00150-1; Melton LJ, 2000, J AM GERIATR SOC, V48, P338, DOI 10.1111/j.1532-5415.2000.tb02658.x; Melton LJ, 1997, SPINE, V22, p2S, DOI 10.1097/00007632-199712151-00002; Melton LJ, 2000, J BONE MINER RES, V15, P2309, DOI 10.1359/jbmr.2000.15.12.2309; MELTON LJ, IN PRESS BONE; MELTON LJ, 1981, CLIN ORTHOP RELAT R, V155, P43; MELTON LJ, 1991, NEW DIMENSIONS OSTEO, V125, P13; MELTON LJ, IN PRESS OSTEOPOROSI; Melton LJ, 2001, OSTEOPOROSIS, P557, DOI [10.1016/B978-012470862-4/50022-2, DOI 10.1016/B978-012470862-4/50022-2]; MILLER CW, 1978, J BONE JOINT SURG AM, V60, P930, DOI 10.2106/00004623-197860070-00010; Myers ER, 1997, SPINE, V22, p25S, DOI 10.1097/00007632-199712151-00005; NEVITT MC, 1993, J AM GERIATR SOC, V41, P1226, DOI 10.1111/j.1532-5415.1993.tb07307.x; Nguyen TV, 1996, AM J EPIDEMIOL, V144, P255, DOI 10.1093/oxfordjournals.aje.a008920; ONeill TW, 1996, J EPIDEMIOL COMMUN H, V50, P288, DOI 10.1136/jech.50.3.288; ONeill TW, 1997, OSTEOPOROSIS INT, V7, P72, DOI 10.1007/BF01623464; ONeill TW, 1996, J BONE MINER RES, V11, P1010; POOR G, 1995, J BONE MINER RES, V10, P1900; POOR G, 1995, CLIN ORTHOP RELAT R, P260; Praemer A, 1992, MUSCULOSKELETAL COND; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; Rogmark C, 1999, ACTA ORTHOP SCAND, V70, P19, DOI 10.3109/17453679909000950; ROSS PD, 1994, J CLIN EPIDEMIOL, V47, P231, DOI 10.1016/0895-4356(94)90004-3; Ross PD, 1995, INT J EPIDEMIOL, V24, P1171, DOI 10.1093/ije/24.6.1171; *ROYAL COLL PHYS U, 1999, GUID PREV TREATM OST; Sanders KM, 1998, J BONE MINER RES, V13, P1337, DOI 10.1359/jbmr.1998.13.8.1337; SANTAVIRTA S, 1992, ACTA ORTHOP SCAND, V63, P198, DOI 10.3109/17453679209154823; Schwartz A. V., 2001, OSTEOPOROSIS, V1, P795; Schwartz AV, 2001, J CLIN ENDOCR METAB, V86, P32, DOI 10.1210/jc.86.1.32; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; Seeley DG, 1996, J BONE MINER RES, V11, P1347; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; Tsai KS, 1996, CALCIFIED TISSUE INT, V59, P249, DOI 10.1007/s002239900118; Villa ML, 2001, OSTEOPOROSIS, P569; WASNICH RD, 1987, OSTEOPOROSIS 1987, V1, P394; WINNER SJ, 1989, BRIT MED J, V298, P1486, DOI 10.1136/bmj.298.6686.1486; Wu F, 2002, ARCH INTERN MED, V162, P33, DOI 10.1001/archinte.162.1.33; Xu L, 2000, J BONE MINER RES, V15, P2019, DOI 10.1359/jbmr.2000.15.10.2019; Youm T, 1999, Am J Orthop (Belle Mead NJ), V28, P190	100	2507	2674	7	225	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 18	2002	359	9319					1761	1767		10.1016/S0140-6736(02)08657-9	http://dx.doi.org/10.1016/S0140-6736(02)08657-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049882				2022-12-28	WOS:000175740500030
J	Lindholm, LH				Lindholm, LH			Uses of error - A goose named Lindholm	LANCET			English	Editorial Material									Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden	Umea University	Lindholm, LH (corresponding author), Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 18	2002	359	9319					1720	1720		10.1016/S0140-6736(02)98678-2	http://dx.doi.org/10.1016/S0140-6736(02)98678-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049859				2022-12-28	WOS:000175740500007
J	Bear, JE; Svitkina, TM; Krause, M; Schafer, DA; Loureiro, JJ; Strasser, GA; Maly, IV; Chaga, OY; Cooper, JA; Borisy, GG; Gertler, FB				Bear, JE; Svitkina, TM; Krause, M; Schafer, DA; Loureiro, JJ; Strasser, GA; Maly, IV; Chaga, OY; Cooper, JA; Borisy, GG; Gertler, FB			Antagonism between Ena/VASP proteins and actin filament capping regulates fibroblast motility	CELL			English	Article							LISTERIA-MONOCYTOGENES; CULTURED-CELLS; PHOSPHOPROTEIN VASP; ARP2/3 COMPLEX; EVH1 DOMAIN; DYNAMICS; CYTOSKELETON; POLYMERIZATION; ORGANIZATION; LAMELLIPODIA	Cell motility requires lamellipodial protrusion, a process driven by actin polymerization. Ena/VASP proteins accumulate in protruding lamellipodia and promote the rapid actin-driven motility of the pathogen Listeria. In contrast, Ena/VASP negatively regulate cell translocation. To resolve this paradox, we analyzed the function of Ena/VASP during lamellipodial protrusion. Ena/VASP-deficient lamellipodia protruded slower but more persistently, consistent with their increased cell translocation rates. Actin networks in Ena/VASP-deficient lamellipodia contained shorter, more highly branched filaments compared to controls. Lamellipodia with excess Ena/VASP contained longer, less branched filaments. In vitro, Ena/VASP promoted actin filament elongation by interacting with barbed ends, shielding them from capping protein. We conclude that Ena/VASP regulates cell motility by controlling the geometry of actin filament networks within lamellipodia.	MIT, Dept Biol, Cambridge, MA 02139 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Massachusetts Institute of Technology (MIT); Northwestern University; Washington University (WUSTL)	Gertler, FB (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Krause, Matthias/D-9814-2013; Cooper, John/E-9389-2012; Cooper, John/D-4448-2014	Krause, Matthias/0000-0002-3200-3199; Borisy, Gary/0000-0002-0266-8018; Cooper, John/0000-0002-0933-4571	NIGMS NIH HHS [R01 GM038542, GM38542, GM62431, GM58801, R01 GM038542-13, IU54 GM63126] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062431, R01GM038542, R01GM058801] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Bailly M, 1998, EXP CELL RES, V241, P285, DOI 10.1006/excr.1998.4031; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Bear JE, 2001, CURR OPIN CELL BIOL, V13, P158, DOI 10.1016/S0955-0674(00)00193-9; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; Boujemaa-Paterski R, 2001, BIOCHEMISTRY-US, V40, P11390, DOI 10.1021/bi010486b; BROWN SS, 1979, J CELL BIOL, V80, P499, DOI 10.1083/jcb.80.2.499; Cameron LA, 2000, NAT REV MOL CELL BIO, V1, P110, DOI 10.1038/35040061; Carl UD, 1999, CURR BIOL, V9, P715, DOI 10.1016/S0960-9822(99)80315-7; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; DINUBILE MJ, 1995, MOL BIOL CELL, V6, P1659, DOI 10.1091/mbc.6.12.1659; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Hinz B, 1999, EXP CELL RES, V251, P234, DOI 10.1006/excr.1999.4541; Huttelmaier S, 1999, FEBS LETT, V451, P68, DOI 10.1016/S0014-5793(99)00546-3; Lambrechts A, 2000, J BIOL CHEM, V275, P36143, DOI 10.1074/jbc.M006274200; Lasa I, 1997, EMBO J, V16, P1531, DOI 10.1093/emboj/16.7.1531; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Maly IV, 2001, P NATL ACAD SCI USA, V98, P11324, DOI 10.1073/pnas.181338798; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; Nakagawa H, 2001, J CELL SCI, V114, P1555; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Palmgren S, 2001, J CELL BIOL, V155, P251, DOI 10.1083/jcb.200106157; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; PISTOR S, 1994, EMBO J, V13, P758, DOI 10.1002/j.1460-2075.1994.tb06318.x; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Raucher D, 2000, J CELL BIOL, V148, P127, DOI 10.1083/jcb.148.1.127; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; Rottner K, 1999, NAT CELL BIOL, V1, P321, DOI 10.1038/13040; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; Skoble J, 2001, J CELL BIOL, V155, P89, DOI 10.1083/jcb.200106061; SMALHEISER NR, 1991, DEV BRAIN RES, V62, P81, DOI 10.1016/0165-3806(91)90192-L; SMALL JV, 1978, NATURE, V272, P638, DOI 10.1038/272638a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Svitkina TM, 1998, METHOD ENZYMOL, V298, P570, DOI 10.1016/S0076-6879(98)98045-4; SVITKINA TM, 1986, J CELL SCI, V82, P235	37	642	659	0	41	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 17	2002	109	4					509	521		10.1016/S0092-8674(02)00731-6	http://dx.doi.org/10.1016/S0092-8674(02)00731-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	553VM	12086607	Green Published, Bronze			2022-12-28	WOS:000175696800012
J	Harmar, AJ; Marston, HM; Shen, SB; Spratt, C; West, KM; Sheward, WJ; Morrison, CF; Dorin, JR; Piggins, HD; Reubi, JC; Kelly, JS; Maywood, ES; Hastings, MH				Harmar, AJ; Marston, HM; Shen, SB; Spratt, C; West, KM; Sheward, WJ; Morrison, CF; Dorin, JR; Piggins, HD; Reubi, JC; Kelly, JS; Maywood, ES; Hastings, MH			The VPAC(2) receptor is essential for circadian function in the mouse suprachiasmatic nuclei	CELL			English	Article							CYCLASE-ACTIVATING POLYPEPTIDE; PHOTIC INDUCTION; GENE-EXPRESSION; PHASE-SHIFTS; MICE LACKING; PERIOD GENE; CLOCK GENE; PEPTIDE; MPER1; LIGHT	The neuropeptides pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) are implicated in the photic entrainment of circadian rhythms in the suprachiasmatic nuclei (SON). We now report that mice carrying a null mutation of the VPAC(2) receptor for VIP and PACAP(Vipr2(-/-)) are incapable of sustaining normal circadian rhythms of rest/activity behavior. These mice also fail to exhibit circadian expression of the core clock genes mPer1, mPer2, and mCry1 and the clock-controlled gene arginine vasopressin (AVP) in the SON. Moreover, the mutants fail to show acute induction of mPer1 and mPer2 by nocturnal illumination. This study highlights the role of intercellular neuropeptidergic signaling in maintenance of circadian function within the SCN.	Univ Edinburgh, Dept Neurosci, Edinburgh EH8 9JZ, Midlothian, Scotland; Univ Edinburgh, Fujisawa Inst Neurosci, Edinburgh EH8 9JZ, Midlothian, Scotland; Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Bern, Inst Pathol, CH-3010 Bern, Switzerland; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Manchester; University of Bern; MRC Laboratory Molecular Biology	Harmar, AJ (corresponding author), Univ Edinburgh, Dept Neurosci, 1 George Sq, Edinburgh EH8 9JZ, Midlothian, Scotland.	tony.harmar@ed.ac.uk	Shen, Sanbing/E-3750-2015; Marston, Hugh M/G-8555-2011	Marston, Hugh M/0000-0002-7460-0581; Hastings, Michael Harvey/0000-0001-8576-6651; Harmar, Anthony/0000-0002-3838-9264; Shen, Sanbing/0000-0002-8217-9811; Piggins, Hugh/0000-0003-2555-9858				Abe M, 2002, J NEUROSCI, V22, P350, DOI 10.1523/JNEUROSCI.22-01-00350.2002; Aida R, 2002, MOL PHARMACOL, V61, P26, DOI 10.1124/mol.61.1.26; Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; ASCHOFF J, 1960, COLD SPRING HARB SYM, V25, P11, DOI 10.1101/SQB.1960.025.01.004; Bae K, 2001, NEURON, V30, P525, DOI 10.1016/S0896-6273(01)00302-6; Buijs RM, 2001, NAT REV NEUROSCI, V2, P521, DOI 10.1038/35081582; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Chen D, 1999, P NATL ACAD SCI USA, V96, P13468, DOI 10.1073/pnas.96.23.13468; Clark AJ, 1997, NUCLEIC ACIDS RES, V25, P1009, DOI 10.1093/nar/25.5.1009; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Field MD, 2000, NEURON, V25, P437, DOI 10.1016/S0896-6273(00)80906-X; Fukuhara C, 1997, NEUROSCI LETT, V229, P49, DOI 10.1016/S0304-3940(97)00415-1; Gourlet P, 1997, PEPTIDES, V18, P403, DOI 10.1016/S0196-9781(96)00322-1; Hannibal J, 2000, J COMP NEUROL, V418, P147; Hannibal J, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-01-j0002.2002; Hannibal J, 1997, J NEUROSCI, V17, P2637, DOI 10.1523/jneurosci.17-07-02637.1997; Hannibal J, 2001, J NEUROSCI, V21, P4883, DOI 10.1523/JNEUROSCI.21-13-04883.2001; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Harrington ME, 1999, J NEUROSCI, V19, P6637; Hastings M H, 1999, J Neurosci, V19, pRC11; Hastings MH, 2000, NAT REV NEUROSCI, V1, P143, DOI 10.1038/35039080; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; JOHNSON RF, 1988, BRAIN RES, V462, P301, DOI 10.1016/0006-8993(88)90558-6; Laemle LK, 1999, PHYSIOL BEHAV, V66, P461, DOI 10.1016/S0031-9384(98)00318-7; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Mackay M, 1996, GENOMICS, V37, P345, DOI 10.1006/geno.1996.0569; Masubuchi S, 2001, EUR J NEUROSCI, V14, P1177, DOI 10.1046/j.0953-816x.2001.01749.x; Okamura H, 1999, SCIENCE, V286, P2531, DOI 10.1126/science.286.5449.2531; PIGGINS HD, 1995, J NEUROSCI, V15, P5612; Piggins HD, 2001, NEUROSCI LETT, V305, P25, DOI 10.1016/S0304-3940(01)01796-7; Pinnock SB, 2001, EUR J NEUROSCI, V13, P576, DOI 10.1046/j.0953-816x.2000.01406.x; Redlin U, 1999, J COMP PHYSIOL A, V184, P439, DOI 10.1007/s003590050343; Reed HE, 2001, EUR J NEUROSCI, V13, P839, DOI 10.1046/j.0953-816x.2000.01437.x; REPPERT SM, 1989, RES PERINATAL MED, V9, P25; Reubi JC, 2000, CANCER RES, V60, P3105; Romijn HJ, 1996, J COMP NEUROL, V372, P1; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Shearman LP, 1999, NEUROREPORT, V10, P613, DOI 10.1097/00001756-199902250-00031; Shen SB, 2000, P NATL ACAD SCI USA, V97, P11575, DOI 10.1073/pnas.97.21.11575; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Shimomura K, 2001, GENOME RES, V11, P959, DOI 10.1101/gr.171601; Silva AJ, 1997, NEURON, V19, P755, DOI 10.1016/S0896-6273(00)80958-7; Ueyama T, 1999, NAT NEUROSCI, V2, P1051, DOI 10.1038/15973; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Watanabe K, 2000, BRAIN RES, V877, P361, DOI 10.1016/S0006-8993(00)02724-4; Weaver DR, 1998, J BIOL RHYTHM, V13, P100, DOI 10.1177/074873098128999952; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4	50	408	418	1	42	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	2002	109	4					497	508		10.1016/S0092-8674(02)00736-5	http://dx.doi.org/10.1016/S0092-8674(02)00736-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	553VM	12086606	Bronze			2022-12-28	WOS:000175696800011
J	Goff, DC				Goff, DC			A 23-year-old man with schizophrenia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ATYPICAL ANTIPSYCHOTIC-DRUGS; DOUBLE-BLIND; CIGARETTE-SMOKING; NEGATIVE SYMPTOMS; BIPOLAR DISORDER; OLDER PATIENTS; WEIGHT-GAIN; COCAINE USE; CLOZAPINE; HALOPERIDOL		Freedom Trail Clin, Boston, MA 02114 USA; Harvard Med Sch, Boston, MA USA; Massachusetts Gen Hosp, Schizophrenia Program, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Goff, DC (corresponding author), Freedom Trail Clin, 25 Staniford St, Boston, MA 02114 USA.	goff@psych.mgh.harvard.edu						ADLER LE, 1993, AM J PSYCHIAT, V150, P1856; AKBARIAN S, 1993, ARCH GEN PSYCHIAT, V50, P178; AKBARIAN S, 1993, ARCH GEN PSYCHIAT, V50, P169; Allison DB, 1999, AM J PSYCHIAT, V156, P1686; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Andreasen NC, 1999, BIOL PSYCHIAT, V46, P908, DOI 10.1016/S0006-3223(99)00152-3; Andreasen NC, 1997, LANCET, V349, P1730, DOI 10.1016/S0140-6736(96)08258-X; ARNDT S, 1995, ARCH GEN PSYCHIAT, V52, P352; BALDESSARINI RJ, 1988, ARCH GEN PSYCHIAT, V45, P79; BALDESSARINI RJ, 1991, NEW ENGL J MED, V324, P746; BARTELS SJ, 1993, J NERV MENT DIS, V181, P227, DOI 10.1097/00005053-199304000-00003; BELL DS, 1973, ARCH GEN PSYCHIAT, V29, P35; Benes FM, 1998, BIOL PSYCHIAT, V44, P88, DOI 10.1016/S0006-3223(98)00138-3; Berrettini WH, 2000, BIOL PSYCHIAT, V47, P245, DOI 10.1016/S0006-3223(99)00226-7; BREIER A, 1991, ARCH GEN PSYCHIAT, V48, P239; BREIER A, 1984, AM J PSYCHIAT, V141, P206; Brown AS, 2001, BIOL PSYCHIAT, V49, P473, DOI 10.1016/S0006-3223(01)01068-X; Cannon M, 2002, ARCH GEN PSYCHIAT, V59, P449, DOI 10.1001/archpsyc.59.5.449; Cannon M, 1996, J NEUROL NEUROSUR PS, V60, P604, DOI 10.1136/jnnp.60.6.604; Chakos M, 2001, AM J PSYCHIAT, V158, P518, DOI 10.1176/appi.ajp.158.4.518; CLEGHORN JM, 1989, PSYCHIAT RES, V28, P119, DOI 10.1016/0165-1781(89)90040-1; Csernansky JG, 2002, NEW ENGL J MED, V346, P16, DOI 10.1056/NEJMoa002028; Davidson M, 1999, AM J PSYCHIAT, V156, P1328; DAVIS KL, 1991, AM J PSYCHIAT, V148, P1474; DeLisi LE, 1997, SCHIZOPHR RES, V23, P119, DOI 10.1016/S0920-9964(96)00079-5; Dolder CR, 2002, AM J PSYCHIAT, V159, P103, DOI 10.1176/appi.ajp.159.1.103; Druss BG, 2001, ARCH GEN PSYCHIAT, V58, P565, DOI 10.1001/archpsyc.58.6.565; Egan MF, 2001, BIOL PSYCHIAT, V50, P98, DOI 10.1016/S0006-3223(01)01133-7; Frankle WG, 2001, AM J PSYCHIAT, V158, P270, DOI 10.1176/appi.ajp.158.2.270; Gitlin M, 2001, AM J PSYCHIAT, V158, P1835, DOI 10.1176/appi.ajp.158.11.1835; Goff DC, 2001, AM J PSYCHIAT, V158, P1367, DOI 10.1176/appi.ajp.158.9.1367; GOFF DC, 1992, AM J PSYCHIAT, V149, P1189; Goff DC, 1998, HARVARD REV PSYCHIAT, V6, P59, DOI 10.3109/10673229809000313; Goff DC, 2001, MED CLIN N AM, V85, P663, DOI 10.1016/S0025-7125(05)70335-7; GOTTESMAN II, 1989, ARCH GEN PSYCHIAT, V46, P867; Green MF, 1998, SCHIZOPHRENIA NEUROC; Hakak Y, 2001, P NATL ACAD SCI USA, V98, P4746, DOI 10.1073/pnas.081071198; Heaton RK, 2001, ARCH GEN PSYCHIAT, V58, P24, DOI 10.1001/archpsyc.58.1.24; Heckers S, 1999, ARCH GEN PSYCHIAT, V56, P1117, DOI 10.1001/archpsyc.56.12.1117; Henderson DC, 2000, AM J PSYCHIAT, V157, P975, DOI 10.1176/appi.ajp.157.6.975; Herz MI, 2000, ARCH GEN PSYCHIAT, V57, P277, DOI 10.1001/archpsyc.57.3.277; Honigfeld G, 1998, J CLIN PSYCHIAT, V59, P3; INGVAR DH, 1974, LANCET, V2, P1484, DOI 10.1016/S0140-6736(74)90221-9; Jablensky A, 1992, Psychol Med Monogr Suppl, V20, P1; JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301; JESTE DV, 1995, ARCH GEN PSYCHIAT, V52, P756; JESTE DV, 1993, SCHIZOPHRENIA BULL, V19, P303, DOI 10.1093/schbul/19.2.303; Jones PB, 1998, AM J PSYCHIAT, V155, P355, DOI 10.1176/ajp.155.3.355; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; Kane JM, 1996, NEW ENGL J MED, V334, P34, DOI 10.1056/NEJM199601043340109; Kapur S, 2001, AM J PSYCHIAT, V158, P360, DOI 10.1176/appi.ajp.158.3.360; Kapur S, 2001, ANNU REV MED, V52, P503, DOI 10.1146/annurev.med.52.1.503; Keefe RSE, 1999, SCHIZOPHRENIA BULL, V25, P201, DOI 10.1093/oxfordjournals.schbul.a033374; Keith S. J., 1991, PSYCHIAT DISORDERS A, P33; Kendell RE, 1996, BRIT J PSYCHIAT, V168, P556, DOI 10.1192/bjp.168.5.556; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kirkpatrick B, 2001, ARCH GEN PSYCHIAT, V58, P165, DOI 10.1001/archpsyc.58.2.165; Laruelle M, 1996, P NATL ACAD SCI USA, V93, P9235, DOI 10.1073/pnas.93.17.9235; LIEBERMAN J, 1993, ARCH GEN PSYCHIAT, V50, P369; Lieberman J, 2001, BIOL PSYCHIAT, V49, P487, DOI 10.1016/S0006-3223(01)01067-8; LIEBERMAN JA, 1993, BRIT J PSYCHIAT, V163, P7, DOI 10.1192/S0007125000292544; Lieberman JA, 2001, BIOL PSYCHIAT, V50, P884, DOI 10.1016/S0006-3223(01)01303-8; Malaspina D, 2001, ARCH GEN PSYCHIAT, V58, P361, DOI 10.1001/archpsyc.58.4.361; Marder SR, 1997, J CLIN PSYCHIAT, V58, P538, DOI 10.4088/JCP.v58n1205; MCFARLANE WR, 1995, ARCH GEN PSYCHIAT, V52, P679; Moller P, 2000, SCHIZOPHRENIA BULL, V26, P217, DOI 10.1093/oxfordjournals.schbul.a033442; Mortensen PB, 1999, NEW ENGL J MED, V340, P603, DOI 10.1056/NEJM199902253400803; Mueser KT, 1998, SCHIZOPHRENIA BULL, V24, P37, DOI 10.1093/oxfordjournals.schbul.a033314; Okubo Y, 1997, NATURE, V385, P634, DOI 10.1038/385634a0; Pierri JN, 1999, AM J PSYCHIAT, V156, P1709; Poulton R, 2000, ARCH GEN PSYCHIAT, V57, P1053, DOI 10.1001/archpsyc.57.11.1053; Pulver AE, 2000, BIOL PSYCHIAT, V47, P221; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; Rosenheck R, 1997, NEW ENGL J MED, V337, P809, DOI 10.1056/NEJM199709183371202; Schneider K., 1959, CLIN PSYCHOPATHOLOGY; SEEMAN P, 1976, NATURE, V261, P717, DOI 10.1038/261717a0; SERPER MR, 1995, AM J PSYCHIAT, V152, P1464; SHANER A, 1995, NEW ENGL J MED, V333, P777, DOI 10.1056/NEJM199509213331207; Shiloh R, 1997, BRIT J PSYCHIAT, V171, P569, DOI 10.1192/bjp.171.6.569; Susser E, 1996, ARCH GEN PSYCHIAT, V53, P25; TARDIFF K, 1992, ARCH GEN PSYCHIAT, V49, P493; Tollefson GD, 1997, AM J PSYCHIAT, V154, P466; Tollefson GD, 1999, BIOL PSYCHIAT, V46, P365, DOI 10.1016/S0006-3223(99)00049-9; TORREY EF, 1990, SCHIZOPHRENIA BULL, V16, P591, DOI 10.1093/schbul/16.4.591; Torrey EF, 1997, SCHIZOPHR RES, V28, P1, DOI 10.1016/S0920-9964(97)00092-3; Tran PV, 1998, BRIT J PSYCHIAT, V172, P499, DOI 10.1192/bjp.172.6.499; WILKINS JN, 1991, PSYCHOPHARMACOL BULL, V27, P149; WILSON WH, 1993, BIOL PSYCHIAT, V33, P806, DOI 10.1016/0006-3223(93)90022-6; Wright IC, 2000, AM J PSYCHIAT, V157, P16, DOI 10.1176/ajp.157.1.16	89	0	0	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	2002	287	24					3249	3257		10.1001/jama.287.24.3249	http://dx.doi.org/10.1001/jama.287.24.3249			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566FF	12076222				2022-12-28	WOS:000176415800030
J	Nordstrom, DK				Nordstrom, DK			Public health - Worldwide occurrences of arsenic in ground water	SCIENCE			English	Editorial Material									US Geol Survey, Div Water Resources, Boulder, CO 80303 USA	United States Department of the Interior; United States Geological Survey	Nordstrom, DK (corresponding author), US Geol Survey, Div Water Resources, Boulder, CO 80303 USA.	dkn@usgs.gov	张, 楠/B-1010-2010					ALAERTS K, UNPUB; Bagla P, 1996, SCIENCE, V274, P174, DOI 10.1126/science.274.5285.174; Farago M., 1997, ARSENIC EXPOSURE HLT, P210; Gleick Peter H., 1998, WORLDS WATER 1998 19; Gooch F.A., 1888, US GEOL SURVEY B, V47; HERNANDEZ M, THESIS COMPLUTENSE U; Hsu KH., 1997, ARSENIC EXPOSURE HLT, P190, DOI DOI 10.1007/978-94-011-5864-0_16; KOLKER A, US GEOL SURV WORKSH; Kumar S, 1997, LANCET, V349, P1378, DOI 10.1016/S0140-6736(05)63226-6; Matschullat J, 2000, APPL GEOCHEM, V15, P181, DOI 10.1016/S0883-2927(99)00039-6; MUELLER S, 2001, FS11101 USGS; Nickson R, 1998, NATURE, V395, P338, DOI 10.1038/26387; Schreiber ME, 2000, HYDROGEOL J, V8, P161; Smedley PL, 2002, APPL GEOCHEM, V17, P517, DOI 10.1016/S0883-2927(02)00018-5; WEBSTER J, IN PRESS ARSENIC GRO; WEDEPOHL KH, 1995, GEOCHIM COSMOCHIM AC, V59, P1217, DOI 10.1016/0016-7037(95)00038-2; Welch AH, 2000, GROUND WATER, V38, P589, DOI 10.1111/j.1745-6584.2000.tb00251.x	17	1171	1262	12	378	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	2002	296	5576					2143	2145		10.1126/science.1072375	http://dx.doi.org/10.1126/science.1072375			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077387				2022-12-28	WOS:000176379000026
J	Schultz, RM; Williams, CJ				Schultz, RM; Williams, CJ			The science of ART	SCIENCE			English	Review							INTRACYTOPLASMIC SPERM INJECTION; PREIMPLANTATION EMBRYO DEVELOPMENT; LOW-BIRTH-WEIGHT; IN-VITRO; CELL-CYCLE; FERTILIZATION; CULTURE; CHILDREN; BORN; ICSI	The methods of gamete manipulation used in assisted reproductive technology (ART) are rapidly proliferating and in some instances outpacing the underlying science. In this review, we discuss two major advances in the ART laboratory intracytoplasmic sperm injection and extended embryo culture before embryo transfer. We outline the rationale for these approaches, discuss results of experiments obtained from animal model systems and human preimplantation embryos that provide the scientific basis for these procedures, and point out potential concerns that have arisen from these studies.	Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Obstet & Gynecol, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Schultz, RM (corresponding author), Univ Penn, Dept Biol, Philadelphia, PA 19104 USA.	rschultz@mail.sas.upenn.edu	Williams, Carmen J/E-2170-2013	Williams, Carmen J/0000-0001-6440-7086	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD022681] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD022681] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 22681, HD 22732] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Barritt JA, 2001, HUM REPROD, V16, P513, DOI 10.1093/humrep/16.3.513; BEHBOODI E, 1995, THERIOGENOLOGY, V44, P227, DOI 10.1016/0093-691X(95)00172-5; Bonduelle M, 2002, HUM REPROD, V17, P671, DOI 10.1093/humrep/17.3.671; Doherty AS, 2000, BIOL REPROD, V62, P1526, DOI 10.1095/biolreprod62.6.1526; Gardner DK, 1998, THERIOGENOLOGY, V49, P83, DOI 10.1016/S0093-691X(97)00404-4; Gerris J, 2000, HUM REPROD, V15, P1884, DOI 10.1093/humrep/15.9.1884; Hack M, 1999, EARLY HUM DEV, V53, P193, DOI 10.1016/S0378-3782(98)00052-8; Hansen M, 2002, NEW ENGL J MED, V346, P725, DOI 10.1056/NEJMoa010035; Hewitson L, 1999, NAT MED, V5, P431, DOI 10.1038/7430; HO YG, 1994, MOL REPROD DEV, V38, P131, DOI 10.1002/mrd.1080380203; Houghton FD, 2002, HUM REPROD, V17, P999, DOI 10.1093/humrep/17.4.999; HUDSN H, 2002, NATURE, V416, P539; Khosla S, 2001, BIOL REPROD, V64, P918, DOI 10.1095/biolreprod64.3.918; Lane M, 1998, HUM REPROD, V13, P991, DOI 10.1093/humrep/13.4.991; Liu L, 2000, BIOL REPROD, V62, P1828, DOI 10.1095/biolreprod62.6.1828; Luetjens CM, 1999, LANCET, V353, P1240, DOI 10.1016/S0140-6736(99)80059-2; Menezo YJR, 2002, HUM REPROD, V17, P247, DOI 10.1093/humrep/17.1.247; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; Ramalho-Santos J, 2000, HUM REPROD, V15, P2610, DOI 10.1093/humrep/15.12.2610; Schieve LA, 2002, NEW ENGL J MED, V346, P731, DOI 10.1056/NEJMoa010806; Stromberg B, 2002, LANCET, V359, P461, DOI 10.1016/S0140-6736(02)07674-2; Sutovsky P, 1997, DEV BIOL, V188, P75, DOI 10.1006/dbio.1997.8618; Wang WH, 2001, FERTIL STERIL, V75, P348, DOI 10.1016/S0015-0282(00)01692-7; Young LE, 2001, NAT GENET, V27, P153, DOI 10.1038/84769	24	102	106	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	2002	296	5576					2188	2190		10.1126/science.1071741	http://dx.doi.org/10.1126/science.1071741			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077406				2022-12-28	WOS:000176379000047
J	Wang, ZH; Pakoulev, A; Dlott, DD				Wang, ZH; Pakoulev, A; Dlott, DD			Watching vibrational energy transfer in liquids with atomic spatial resolution	SCIENCE			English	Article							POLYATOMIC LIQUIDS; RAMAN-SPECTROSCOPY; INFRARED-RAMAN; RELAXATION; REDISTRIBUTION; ETHANOL; REORIENTATION; MOLECULES; METHANOL; DYNAMICS	Ultrafast spectroscopy was used to study vibrational energy transfer between vibrational reporter groups on different parts of a molecule in a liquid. When OH stretching vibrations of different alcohols were excited by mid-infrared laser pulses, vibrational energy was observed to move through intervening CH2 or CH groups, taking steps up and down in energy, ending up at terminal CH3 groups. For each additional CH2 group in the path between OH and CH3, the time for vibrational energy transfer increased by about 0.4 picosecond.	Univ Illinois, Sch Chem Sci, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Dlott, DD (corresponding author), Univ Illinois, Sch Chem Sci, Box 01-6 CLSL,600 S Mathews Ave, Urbana, IL 61801 USA.			Dlott, Dana/0000-0001-8719-7093				Deak JC, 2000, J RAMAN SPECTROSC, V31, P263, DOI 10.1002/(SICI)1097-4555(200004)31:4<263::AID-JRS538>3.0.CO;2-Q; Deak JC, 1997, OPT LETT, V22, P1796, DOI 10.1364/OL.22.001796; Deak JC, 1998, J PHYS CHEM A, V102, P8193, DOI 10.1021/jp9822743; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; HEILWEIL EJ, 1986, J CHEM PHYS, V85, P5004, DOI 10.1063/1.451690; HONG XY, 1995, J PHYS CHEM-US, V99, P9102, DOI 10.1021/j100022a023; HUTCHINSON JS, 1983, J CHEM PHYS, V79, P4247, DOI 10.1063/1.446351; Iwaki LK, 2000, J PHYS CHEM A, V104, P9101, DOI 10.1021/jp002246w; Iwaki LK, 1999, CHEM PHYS LETT, V303, P176, DOI 10.1016/S0009-2614(99)00169-4; Iwaki LK, 2000, CHEM PHYS LETT, V321, P419, DOI 10.1016/S0009-2614(00)00356-0; IWAKI LK, 2000, ULTRAFAST INFRARED R; KENKRE VM, 1994, J CHEM PHYS, V101, P10618, DOI 10.1063/1.467876; Laenen R, 1997, J PHYS CHEM A, V101, P3201, DOI 10.1021/jp961718x; Laenen R, 1997, CHEM PHYS LETT, V274, P63, DOI 10.1016/S0009-2614(97)00644-1; Laenen R, 1999, CHEM PHYS LETT, V299, P589, DOI 10.1016/S0009-2614(98)01303-7; LAUBEREAU A, 1978, REV MOD PHYS, V50, P607, DOI 10.1103/RevModPhys.50.607; LIDE DR, 1996, HDB CHEM PHYSICS; NITZAN A, 1975, J CHEM PHYS, V63, P200, DOI 10.1063/1.431045; PERCHARD JP, 1968, J CHIM PHYS PCB, V65, P1834, DOI 10.1051/jcp/1968651834; Schrader B., 1989, RAMAN INFRARED ATLAS, pA7; Voth GA, 1996, J PHYS CHEM-US, V100, P13034, DOI 10.1021/jp960317e; Woutersen S, 1999, NATURE, V402, P507, DOI 10.1038/990058; Woutersen S, 1997, J CHEM PHYS, V107, P1483, DOI 10.1063/1.474501	23	125	125	0	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 21	2002	296	5576					2201	2203		10.1126/science.1071293	http://dx.doi.org/10.1126/science.1071293			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077411				2022-12-28	WOS:000176379000052
J	Worm, B; Lotze, HK; Hillebrand, H; Sommer, U				Worm, B; Lotze, HK; Hillebrand, H; Sommer, U			Consumer versus resource control of species diversity and ecosystem functioning	NATURE			English	Article							BOTTOM-UP; PRODUCTIVITY; DISTURBANCE; COMPETITION; CONSEQUENCES; PREDATION; RICHNESS	A key question in ecology is which factors control species diversity in a community(1-3). Two largely separate groups of ecologists have emphasized the importance of productivity or resource supply, and consumers or physical disturbance, respectively. These variables show unimodal relationships with diversity when manipulated in isolation(4-8). Recent multivariate models(9-10), however, predict that these factors interact, such that the disturbance-diversity relationship depends on productivity, and vice versa. We tested these models in marine food webs, using field manipulations of nutrient resources and consumer pressure on rocky shores of contrasting productivity. Here we show that the effects of consumers and nutrients on diversity consistently depend on each other, and that the direction of their effects and peak diversity shift between sites of low and high productivity. Factorial meta-analysis of published experiments confirms these results across widely varying aquatic communities. Furthermore, our experiments demonstrate that these patterns extend to important ecosystem functions such as carbon storage and nitrogen retention. This suggests that human impacts on nutrient supply(11) and food-web structure(12,13) have strong and interdependent effects on species diversity and ecosystem functioning, and must therefore be managed together.	Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada; Univ Kiel, Inst Marine Sci, Sect Marine Ecol, D-24105 Kiel, Germany; Uppsala Univ, Dept Limnol, Erken Lab, S-76173 Norrtalje, Sweden	Dalhousie University; University of Kiel; Uppsala University	Worm, B (corresponding author), Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada.	bworm@is.dal.ca	Hillebrand, Helmut/I-1717-2014	Hillebrand, Helmut/0000-0001-7449-1613; Lotze, Heike/0000-0001-6258-1304; Worm, Boris/0000-0002-5742-8716				Buckling A, 2000, NATURE, V408, P961, DOI 10.1038/35050080; Chapin FS, 2000, NATURE, V405, P234, DOI 10.1038/35012241; CONNELL JH, 1978, SCIENCE, V199, P1302, DOI 10.1126/science.199.4335.1302; Floder S, 1999, LIMNOL OCEANOGR, V44, P1114; Gough L, 1998, ECOLOGY, V79, P1586, DOI 10.1890/0012-9658(1998)079[1586:HEOPSD]2.0.CO;2; Gurevitch J, 2000, AM NAT, V155, P435, DOI 10.1086/303337; Hillebrand H, 2000, MAR ECOL PROG SER, V204, P27, DOI 10.3354/meps204027; Hillebrand H, 2001, LIMNOL OCEANOGR, V46, P1881, DOI 10.4319/lo.2001.46.8.1881; Huston M.A., 1994, BIOL DIVERSITY; HUTCHINSON GE, 1959, AM NAT, V93, P145, DOI 10.1086/282070; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; Kassen R, 2000, NATURE, V406, P508, DOI 10.1038/35020060; Kondoh M, 2001, P ROY SOC B-BIOL SCI, V268, P269, DOI 10.1098/rspb.2000.1384; Lotze HK, 2001, LIMNOL OCEANOGR, V46, P749, DOI 10.4319/lo.2001.46.4.0749; MANN KH, 1973, SCIENCE, V182, P975, DOI 10.1126/science.182.4116.975; MENGE BA, 1987, AM NAT, V130, P730, DOI 10.1086/284741; Nielsen KJ, 2001, ECOL MONOGR, V71, P187, DOI 10.1890/0012-9615(2001)071[0187:BUATDF]2.0.CO;2; Pauly D, 1998, SCIENCE, V279, P860, DOI 10.1126/science.279.5352.860; Proulx M, 1996, OIKOS, V76, P191, DOI 10.2307/3545761; SOMMER U, 2002, CONNETITION COEXISTE; Sorokin Y. I., 1995, CORAL REEF ECOLOGY; Stirling G, 2001, AM NAT, V158, P286, DOI 10.1086/321317; Terborgh J, 2001, SCIENCE, V294, P1923, DOI 10.1126/science.1064397; TILMAN D, 1994, ECOLOGY, V75, P2, DOI 10.2307/1939377; Tilman D, 2000, NATURE, V405, P208, DOI 10.1038/35012217; Tilman D., 1982, Monographs in Population Biology, pi; Vitousek PM, 1997, ECOL APPL, V7, P737, DOI 10.2307/2269431; Watling L, 1998, CONSERV BIOL, V12, P1180, DOI 10.1046/j.1523-1739.1998.0120061180.x; Worm B, 2000, INT REV HYDROBIOL, V85, P359; Worm B, 2000, LIMNOL OCEANOGR, V45, P339, DOI 10.4319/lo.2000.45.2.0339	30	363	371	5	262	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 20	2002	417	6891					848	851		10.1038/nature00830	http://dx.doi.org/10.1038/nature00830			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075351				2022-12-28	WOS:000176285600046
J	Bellini, LM; Baime, M; Shea, JA				Bellini, LM; Baime, M; Shea, JA			Variation of mood and empathy during internship	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPRESSIVE SYMPTOMS; MEDICAL-STUDENTS; HOUSE OFFICERS; STRESS; RESIDENTS	Context Internship is a time of great transition, during which mood disturbances are common. However, variations in mood and empathy levels throughout the internship year have not been investigated. Objective To examine mood patterns and changes in empathy among internal medicine residents over the course of the internship year. Design Cohort study of interns involving completion of survey instruments at 4 points: time I (June 2000; Profile of Mood States [POMS] and Interpersonal Reactivity Index [IRI]), times 2 and 3 (November 2000 and February 2001; POMS), and time 4 (June 2001; POMS and IRI). Setting Internal medicine residency program at a University-based medical center. Participants Sixty-one interns. Main Outcome Measures Baseline scores of mood states and empathy; trends in mood states and empathy over the internship year. Results Response rates for time 1 were 98%; for time 2, 72%; for time 3, 79%; and for time 4, 79%. Results of the POMS revealed that physicians starting their internship exhibit less tension, depression, anger, fatigue, and confusion and have more vigor than general adult and college student populations (P < .001 for all). Results of the IRI showed better baseline scores for perspective taking (P < .001) and empathic concern (P = .007) and lower scores for personal distress (P < .001) among interns compared with norms. Five months into internship, however, POMS scores revealed significant increases in the depression-dejection (P < .001), anger-hostility (P < .001), and fatigue-inertia (P < .001) scales, as well as an increase in IRI personal distress level (P < .001). These increases corresponded with decreases in the POMS vigor-activity scores (P < .001) and I RI empathic concern measures (P = .005). Changes persisted throughout the internship period. Conclusions We found that, in this sample, enthusiasm at the beginning of internship soon gave way to depression, anger, and fatigue. Future research should be aimed at determining whether these changes persist beyond internship.	Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Bellini, LM (corresponding author), 100 Centrex,3400 Spruce St, Philadelphia, PA 19104 USA.	Bellini@mail.med.upenn.edu	Winwood, Peter/A-6363-2008					*AM BOARD INT MED, 1999, PROJ PROF; ASKEN MJ, 1983, J MED EDUC, V58, P382; Becker H, 1988, J Nurs Educ, V27, P198; BOYLE BP, 1971, J MED EDUC, V46, P882; CLARK DC, 1984, AM J PSYCHIAT, V141, P1095; COLFORD JM, 1989, JAMA-J AM MED ASSOC, V261, P889, DOI 10.1001/jama.261.6.889; *COMM INT RES, 2001, PET REQ LIM MED RES; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; Elliot D L, 1986, J Am Med Womens Assoc (1972), V41, P54; FRIEDMAN FC, 1973, J MED EDUC, V48, P436; Godenick M T, 1995, Fam Med, V27, P646; Hainer BL, 1998, ACAD MED, V73, P1305, DOI 10.1097/00001888-199812000-00023; HENDRIE HC, 1990, J NERV MENT DIS, V178, P204, DOI 10.1097/00005053-199003000-00009; HUS K, 1997, AM J PSYCHIAT, V144, P1561; KIRSLING RA, 1989, PSYCHOL REP, V65, P355, DOI 10.2466/pr0.1989.65.2.355; MADDUX JF, 1986, AM J PSYCHIAT, V143, P187; McNair D. M, 1992, PROFILE MOOD STATES; REUBEN DB, 1985, ARCH INTERN MED, V145, P286, DOI 10.1001/archinte.145.2.286; Shapiro SL, 2000, ACAD MED, V75, P748, DOI 10.1097/00001888-200007000-00023; Tyssen R, 2000, MED EDUC, V34, P374, DOI 10.1046/j.1365-2923.2000.00540.x; WELNER A, 1979, ARCH GEN PSYCHIAT, V36, P169	21	243	249	0	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	2002	287	23					3143	3146		10.1001/jama.287.23.3143	http://dx.doi.org/10.1001/jama.287.23.3143			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563NK	12069680				2022-12-28	WOS:000176262300032
J	Harris, KD; Henze, DA; Hirase, H; Leinekugel, X; Dragoi, G; Czurko, A; Buzsaki, G				Harris, KD; Henze, DA; Hirase, H; Leinekugel, X; Dragoi, G; Czurko, A; Buzsaki, G			Spike train dynamics predicts theta-related phase precession in hippocampal pyramidal cells	NATURE			English	Article							BEHAVING RAT; IN-VIVO; NEURONS; SYNCHRONIZATION; EVENTS; CORTEX	According to the temporal coding hypothesis(1), neurons encode information by the exact timing of spikes. An example of temporal coding is the hippocampal phase precession phenomenon, in which the timing of pyramidal cell spikes relative to the theta rhythm shows a unidirectional forward precession during spatial behaviour(2,3). Here we show that phase precession occurs in both spatial and non-spatial behaviours. We found that spike phase correlated with instantaneous discharge rate, and precessed unidirectionally at high rates, regardless of behaviour. The spatial phase precession phenomenon is therefore a manifestation of a more fundamental principle governing the timing of pyramidal cell discharge. We suggest that intrinsic properties of pyramidal cells have a key role in determining spike times, and that the interplay between the magnitude of dendritic excitation and rhythmic inhibition of the somatic region is responsible for the phase assignment of spikes(4,5)	Rutgers State Univ, Ctr Mol & Behav Neurosci, Newark, NJ 07102 USA	Rutgers State University Newark; Rutgers State University New Brunswick	Buzsaki, G (corresponding author), Rutgers State Univ, Ctr Mol & Behav Neurosci, 197 Univ Ave, Newark, NJ 07102 USA.		Leinekugel, Xavier/F-4034-2014; Harris, Kenneth/B-3469-2009; Hirase, Hajime/A-3709-2012; Leinekugel, Xavier/ABD-8347-2021; Czurkó, András/H-5500-2019	Leinekugel, Xavier/0000-0003-2878-3791; Hirase, Hajime/0000-0003-3806-6905; Czurko, Andras/0000-0002-1985-7296; Harris, Kenneth/0000-0002-5930-6456; Buzsaki, Gyorgy/0000-0002-3100-4800				Adrian ED, 1926, J PHYSIOL-LONDON, V61, P151, DOI 10.1113/jphysiol.1926.sp002281; BURGESS N, 1994, NEURAL NETWORKS, V7, P1065, DOI 10.1016/S0893-6080(05)80159-5; BUZSAKI G, 1995, CURR OPIN NEUROBIOL, V5, P504, DOI 10.1016/0959-4388(95)80012-3; Csicsvari J, 2000, NEURON, V28, P585, DOI 10.1016/S0896-6273(00)00135-5; Csicsvari J, 1999, J NEUROSCI, V19, P274, DOI 10.1523/JNEUROSCI.19-01-00274.1999; Csicsvari J, 1998, NEURON, V21, P179, DOI 10.1016/S0896-6273(00)80525-5; Fisher NI, 1995, STAT ANAL CIRCULAR D; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; Harris KD, 2000, J NEUROPHYSIOL, V84, P401, DOI 10.1152/jn.2000.84.1.401; Harris KD, 2001, NEURON, V32, P141, DOI 10.1016/S0896-6273(01)00447-0; Henze DA, 2001, NEUROSCIENCE, V105, P121, DOI 10.1016/S0306-4522(01)00167-1; Hirase H, 1999, EUR J NEUROSCI, V11, P4373, DOI 10.1046/j.1460-9568.1999.00853.x; HOPFIELD JJ, 1995, NATURE, V376, P33, DOI 10.1038/376033a0; Kamondi A, 1998, HIPPOCAMPUS, V8, P244, DOI 10.1002/(SICI)1098-1063(1998)8:3<244::AID-HIPO7>3.0.CO;2-J; Magee JC, 2001, J NEUROPHYSIOL, V86, P528, DOI 10.1152/jn.2001.86.1.528; MIGLIORE M, 1995, J NEUROPHYSIOL, V73, P1157, DOI 10.1152/jn.1995.73.3.1157; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; Quirk MC, 2001, J NEUROSCI, V21, P240, DOI 10.1523/JNEUROSCI.21-01-00240.2001; Riehle A, 1997, SCIENCE, V278, P1950, DOI 10.1126/science.278.5345.1950; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; Skaggs WE, 1996, HIPPOCAMPUS, V6, P149, DOI 10.1002/(SICI)1098-1063(1996)6:2<149::AID-HIPO6>3.0.CO;2-K; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0	23	272	278	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 13	2002	417	6890					738	741		10.1038/nature00808	http://dx.doi.org/10.1038/nature00808			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	561QY	12066184				2022-12-28	WOS:000176154700044
J	Kradin, RL; Mark, EJ; Belley, G; Norris, PJ; Ton, F				Kradin, RL; Mark, EJ; Belley, G; Norris, PJ; Ton, F			A 48-year-old man with a cough and bloody sputum - Wegener's granulomatosis, with microabscesses, capillaritis, granulomatous vasculitis, diffuse granulomatous tissue, and palisading granuloma.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; OPEN LUNG BIOPSIES; PULMONARY HEMORRHAGE; LYMPHOMATOID GRANULOMATOSIS; PATHERGIC GRANULOMATOSIS; NATURAL-HISTORY; DISEASE; ANGIITIS		Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University	Kradin, RL (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.							BEER DJ, 1992, AM REV RESPIR DIS, V146, P1128; CHUMBLEY LC, 1977, MAYO CLIN PROC, V52, P477; COLBY TV, 1993, LUNG CURRENT CONCEPT, P195; Davies SF, 1996, CLIN CHEST MED, V17, P725, DOI 10.1016/S0272-5231(05)70342-7; DELBUONO EA, 1991, HUM PATHOL, V22, P107, DOI 10.1016/0046-8177(91)90030-S; FAUCI AS, 1982, NEW ENGL J MED, V306, P68, DOI 10.1056/NEJM198201143060203; FIENBERG R, 1981, HUM PATHOL, V12, P458, DOI 10.1016/S0046-8177(81)80027-5; FIENBERG R, 1993, HUM PATHOL, V24, P160, DOI 10.1016/0046-8177(93)90295-R; FIENBERG R, 1953, AM J PATHOL, V29, P913; FIENBERG R, 1989, SEMIN RESPIR MED, V10, P126, DOI 10.1055/s-2007-1006159; Hoffman GS, 1998, ARTHRITIS RHEUM, V41, P2257, DOI 10.1002/1529-0131(199812)41:12<2257::AID-ART22>3.0.CO;2-K; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; JENNETTE JC, 1991, INT REV EXP PATHOL, V32, P193; LIEBOW AA, 1973, AM REV RESPIR DIS, V108, P1; LIEBOW AA, 1972, HUM PATHOL, V3, P457, DOI 10.1016/S0046-8177(72)80005-4; MARK EJ, 1988, HUM PATHOL, V19, P1065, DOI 10.1016/S0046-8177(88)80088-1; MARK EJ, 1985, ARCH PATHOL LAB MED, V109, P413; Mark EJ, 1997, HUM PATHOL, V28, P450, DOI 10.1016/S0046-8177(97)90034-4; MYERS JL, 1987, AM J SURG PATHOL, V11, P895, DOI 10.1097/00000478-198711000-00008; Niles J L, 1993, Curr Opin Rheumatol, V5, P18; PATTERSON R, 1986, ARCH INTERN MED, V146, P916, DOI 10.1001/archinte.146.5.916; Potter MB, 1999, CHEST, V116, P1480, DOI 10.1378/chest.116.5.1480; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P315, DOI 10.1097/00000478-199104000-00001; TRAVIS WD, 1990, AM J SURG PATHOL, V14, P1112, DOI 10.1097/00000478-199012000-00003; WIIK A, 1993, CLIN EXP RHEUMATOL, V11, P191; YOSHIKAWA Y, 1986, HUM PATHOL, V17, P401, DOI 10.1016/S0046-8177(86)80465-8; YOSHIMURA N, 1992, ACTA PATHOL JAPON, V42, P657	27	8	8	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 13	2002	346	24					1892	1899		10.1056/NEJMcpc020103	http://dx.doi.org/10.1056/NEJMcpc020103			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	561NA	12063374				2022-12-28	WOS:000176146100008
J	Waern, M; Rubenowitz, E; Runeson, B; Skoog, I; Wilhelmson, K; Allebeck, P				Waern, M; Rubenowitz, E; Runeson, B; Skoog, I; Wilhelmson, K; Allebeck, P			Burden of illness and suicide in elderly people: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LAST YEAR; POPULATION; LIFE	Objectives To study the association between physical illness and suicide in elderly people. Design Case-control with illness determined from interviews with relatives of people who committed suicide and with control participants and from medical records. Setting Gothenburg and two surrounding counties (210 703 people aged 65 years and over). Participants Consecutive records of people who had committed suicide and had undergone forensic examination (46 men, 39 women) and living control participants from the tax register (84 men, 69 women). Main outcome measures Physical illness rated in 13 organ systems according to the cumulative illness rating scale-geriatrics; serious physical illness (organ category score 3 or 4); overall score for burden of physical illness. Results Visual impairment (odds ratio 7.0, 95% confidence interval 2.3 to 21.4), neurological disorders (3.8, 1.5 to 9.4), and malignant disease (3.4, 1.2 to 9.8) were associated with increased risk for suicide. Serious physical illness in any organ category was an independent risk factor for suicide in the multivariate regression model (6.4,2.0 to 20.0). When the sexes were analysed separately, serious physical illness was associated with suicide in men (4.2,; 1.8 to 9.5) as was high burden of physical illness (2.8,; 1.2 to 6.5). Such associations were not seen in women, possibly because of the small sample size. Conclusions Visual impairment, neurological disorders, and malignant disease were independently associated with increased risk of suicide in elderly people. Serious physical illness may be a stronger risk factor for suicide in men than in women.	Univ Gothenburg, Sahlgrens Univ Hosp, Inst Clin Neurosci, Sect Psychiat, S-41345 Gothenburg, Sweden; Univ Gothenburg, Dept Social Med, S-41345 Gothenburg, Sweden; Karolinska Inst, St Gorans Hosp, Dept Psychiat, Stockholm, Sweden	Sahlgrenska University Hospital; University of Gothenburg; University of Gothenburg; Karolinska Institutet; Saint Goran's Hospital	Waern, M (corresponding author), Univ Gothenburg, Sahlgrens Univ Hosp, Inst Clin Neurosci, Sect Psychiat, S-41345 Gothenburg, Sweden.	margda.waern@neuro.gu.se		Runeson, Bo/0000-0003-4122-4636				ALLEBECK P, 1991, PSYCHOL MED, V21, P979, DOI 10.1017/S0033291700029962; ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; BARRACLOUGH BM, 1971, RECENT DEV PSYCHOGER, P87; CARNEY SS, 1994, J AM GERIATR SOC, V42, P174, DOI 10.1111/j.1532-5415.1994.tb04948.x; CLARK DC, 1993, SUICIDAL BEHAV STATE, P161; Conwell Y, 2000, J AM GERIATR SOC, V48, P23, DOI 10.1111/j.1532-5415.2000.tb03024.x; Forsell Y, 1997, ACTA PSYCHIAT SCAND, V95, P108, DOI 10.1111/j.1600-0447.1997.tb00382.x; Grabbe L, 1997, AM J PUBLIC HEALTH, V87, P434, DOI 10.2105/AJPH.87.3.434; HARRIS EC, 1994, MEDICINE, V73, P281, DOI 10.1097/00005792-199411000-00001; Harwood DMJ, 2000, INT J GERIATR PSYCH, V15, P736, DOI 10.1002/1099-1166(200008)15:8<736::AID-GPS214>3.0.CO;2-K; Heikkinen M E, 1995, Int Psychogeriatr, V7, P287, DOI 10.1017/S1041610295002043; Henriksson M M, 1995, Int Psychogeriatr, V7, P275, DOI 10.1017/S1041610295002031; Hepple J, 1997, BRIT J PSYCHIAT, V171, P42, DOI 10.1192/bjp.171.1.42; KENNEDY GJ, 1989, AM J PSYCHIAT, V146, P220; LYNESS JM, 1992, J AM GERIATR SOC, V40, P320, DOI 10.1111/j.1532-5415.1992.tb02129.x; MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N; Sainsbury P., 1955, MAUDSLEY MONOGRAPHS, V1; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; STENAGER E, 1998, DIS PAIN SUICIDAL BE, P31; Stenager EN, 1998, BRIT MED J, V316, P1206, DOI 10.1136/bmj.316.7139.1206; STENSMAN R, 1988, SCAND J SOC MED, V16, P149, DOI 10.1177/140349488801600305; Waern M, 1999, LANCET, V354, P917, DOI 10.1016/S0140-6736(99)93099-4	22	229	234	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 8	2002	324	7350					1355	1357		10.1136/bmj.324.7350.1355	http://dx.doi.org/10.1136/bmj.324.7350.1355			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	563BQ	12052799	Green Published, Bronze			2022-12-28	WOS:000176234100014
J	Watson, AR				Watson, AR			Rejection, recurrence, or non-adherence?	LANCET			English	Editorial Material									City Hosp Nottingham, Nottingham NG5 1PB, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital	Watson, AR (corresponding author), City Hosp Nottingham, Hucknall Rd, Nottingham NG5 1PB, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 8	2002	359	9322					1997	1997		10.1016/S0140-6736(02)08832-3	http://dx.doi.org/10.1016/S0140-6736(02)08832-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076555				2022-12-28	WOS:000176232500012
J	Kennedy, TA; Naeem, S; Howe, KM; Knops, JMH; Tilman, D; Reich, P				Kennedy, TA; Naeem, S; Howe, KM; Knops, JMH; Tilman, D; Reich, P			Biodiversity as a barrier to ecological invasion	NATURE			English	Article							PLANT DIVERSITY; BIOLOGICAL INVASIONS; SPECIES-DIVERSITY; INVASIBILITY; RESISTANCE; INTERFERENCE; COMMUNITIES; ECOSYSTEM; RICHNESS; PATTERN	Biological invasions are a pervasive and costly environmental problem(1,2) that has been the focus of intense management and research activities over the past half century. Yet accurate predictions of community susceptibility to invasion remain elusive. The diversity resistance hypothesis, which argues that diverse communities are highly competitive and readily resist invasion(3-5), is supported by both theory(6) and experimental studies(7-14) conducted at small spatial scales. However, there is also convincing evidence that the relationship between the diversity of native and invading species is positive when measured at regional scales(3,11,15,16). Although this latter relationship may arise from extrinsic factors, such as resource heterogeneity, that covary with diversity of native and invading species at large scales, the mechanisms conferring greater invasion resistance to diverse communities at local scales remain unknown. Using neighbourhood analyses, a technique from plant competition studies(17-19), we show here that species diversity in small experimental grassland plots enhances invasion resistance by increasing crowding and species richness in localized plant neighbourhoods. Both the establishment (number of invaders) and success (proportion of invaders that are large) of invading plants are reduced. These results suggest that local biodiversity represents an important line of defence against the spread of invaders.	Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA; Univ Washington, Dept Zool, Seattle, WA 98195 USA; Univ Nebraska, Sch Biol Sci, Lincoln, NE 68588 USA; Univ Minnesota, Dept Forest Resources, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle; University of Nebraska System; University of Nebraska Lincoln; University of Minnesota System; University of Minnesota Twin Cities	Kennedy, TA (corresponding author), Univ Minnesota, Dept Ecol Evolut & Behav, 1987 Upper Buford Circle, St Paul, MN 55108 USA.		Knops, Johannes/AAA-8546-2020; Tilman, David/ABD-5309-2021	Kennedy, Theodore/0000-0003-3477-3629; Reich, Peter/0000-0003-4424-662X				CASE TJ, 1990, P NATL ACAD SCI USA, V87, P9610, DOI 10.1073/pnas.87.24.9610; Crawley M. J., 1987, COLONIZATION SUCCESS, V26, P429; Drake, 1986, ECOLOGY BIOL INVASIO; Dukes JS, 2001, OECOLOGIA, V126, P563, DOI 10.1007/s004420000549; Elton C. S., 1958, ECOLOGY INVASIONS; Knops JMH, 1999, ECOL LETT, V2, P286, DOI 10.1046/j.1461-0248.1999.00083.x; Levine JM, 1999, OIKOS, V87, P15, DOI 10.2307/3546992; Levine JM, 2000, SCIENCE, V288, P852, DOI 10.1126/science.288.5467.852; MACK RN, 1977, J ECOL, V65, P345, DOI 10.2307/2259487; McGradySteed J, 1997, NATURE, V390, P162, DOI 10.1038/36561; Naeem S, 2000, OIKOS, V91, P97, DOI 10.1034/j.1600-0706.2000.910108.x; PACALA SW, 1987, OIKOS, V48, P217, DOI 10.2307/3565858; PlantyTabacchi AM, 1996, CONSERV BIOL, V10, P598, DOI 10.1046/j.1523-1739.1996.10020598.x; REJMANEK M, 1989, RM185 USDA, P97; Stachowicz JJ, 1999, SCIENCE, V286, P1577, DOI 10.1126/science.286.5444.1577; Stohlgren TJ, 1999, ECOL MONOGR, V69, P25, DOI 10.1890/0012-9615(1999)069[0025:EPSIHS]2.0.CO;2; Symstad AJ, 2000, ECOLOGY, V81, P99, DOI 10.1890/0012-9658(2000)081[0099:ATOTEO]2.0.CO;2; Tilman D, 1997, ECOLOGY, V78, P81, DOI 10.1890/0012-9658(1997)078[0081:CIRLAG]2.0.CO;2; Tilman D, 1999, ECOLOGY, V80, P1455, DOI 10.1890/0012-9658(1999)080[1455:TECOCI]2.0.CO;2; Tilman D, 1996, NATURE, V379, P718, DOI 10.1038/379718a0; Vitousek PM, 1996, AM SCI, V84, P468; Wardle DA, 2001, OIKOS, V95, P161, DOI 10.1034/j.1600-0706.2001.950119.x	22	790	878	10	528	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	2002	417	6889					636	638		10.1038/nature00776	http://dx.doi.org/10.1038/nature00776			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050662	Green Published			2022-12-28	WOS:000176001200044
J	Letinic, K; Zoncu, R; Rakic, P				Letinic, K; Zoncu, R; Rakic, P			Origin of GABAergic neurons in the human neocortex	NATURE			English	Article							LOCAL CIRCUIT NEURONS; CELL-MIGRATION; GANGLIONIC EMINENCE; CEREBRAL-CORTEX; FOREBRAIN; INTERNEURONS; PROGENITORS; DIVERSITY; DYNAMICS; MONKEY	The mammalian neocortex contains two major classes of neurons, projection and local circuit neurons(1-4). Projection neurons contain the excitatory neurotransmitter glutamate, while local circuit neurons are inhibitory, containing GABA(2,4). The complex function of neocortical circuitry depends on the number and diversity of GABAergic (gamma-aminobutyric-acid-releasing) local circuit neurons(1-3). Using retroviral labelling in organotypic slice cultures of the embryonic human forebrain, we demonstrate the existence of two distinct lineages of neocortical GABAergic neurons. One lineage expresses Dlx1/2 and Mash1 transcription factors, represents 65% of neocortical GABAergic neurons in humans, and originates from Mash1-expressing progenitors of the neocortical ventricular and subventricular zone of the dorsal forebrain. The second lineage, characterized by the expression of Dlx1/2 but not Mash1, forms around 35% of the GABAergic neurons and originates from the ganglionic eminence of the ventral forebrain. We suggest that modifications in the expression pattern of transcription factors in the forebrain may underlie species-specific programmes for the generation of neocortical local circuit neurons(5-11) and that distinct lineages of cortical interneurons may be differentially affected in genetic and acquired diseases of the human brain.	Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA	Yale University	Rakic, P (corresponding author), Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA.	pasko.rakic@yale.edu						Anderson S, 1999, CEREB CORTEX, V9, P646, DOI 10.1093/cercor/9.6.646; CAJAL SRY, 1911, HIST SYSTEME NERVEUX; Casarosa S, 1999, DEVELOPMENT, V126, P525; DeCarlos JA, 1996, J NEUROSCI, V16, P6146; Fairen A., 1984, CEREB CORTEX, V1, P201; Fode C, 2000, GENE DEV, V14, P67; Gleeson JG, 2000, TRENDS NEUROSCI, V23, P352, DOI 10.1016/S0166-2236(00)01607-6; Gupta A, 2000, SCIENCE, V287, P273, DOI 10.1126/science.287.5451.273; Haydar TF, 1999, BRAIN RES PROTOC, V4, P425, DOI 10.1016/S1385-299X(99)00033-1; He WL, 2001, J NEUROSCI, V21, P8854, DOI 10.1523/JNEUROSCI.21-22-08854.2001; HENDRY SHC, 1993, VISUAL NEUROSCI, V10, P1109, DOI 10.1017/S095252380001021X; Horton S, 1999, MOL CELL NEUROSCI, V14, P355, DOI 10.1006/mcne.1999.0791; JONES EG, 1993, CEREB CORTEX, V3, P361, DOI 10.1093/cercor/3.5.361-a; Jones EG, 1997, SCHIZOPHRENIA BULL, V23, P483, DOI 10.1093/schbul/23.3.483; Kakita A, 1999, NEURON, V23, P461, DOI 10.1016/S0896-6273(00)80800-4; KORNACK DR, 1995, NEURON, V15, P311, DOI 10.1016/0896-6273(95)90036-5; Lavdas AA, 1999, J NEUROSCI, V19, P7881; Letinic K, 2001, NAT NEUROSCI, V4, P931, DOI 10.1038/nn0901-931; Lewis DA, 2000, BRAIN RES REV, V31, P270, DOI 10.1016/S0165-0173(99)00042-9; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; Marin O, 2001, SCIENCE, V293, P872, DOI 10.1126/science.1061891; Neyt C, 1997, J NEUROSCI, V17, P9194; ORourke NA, 1997, DEVELOPMENT, V124, P997; Powell EM, 2001, NEURON, V30, P79, DOI 10.1016/S0896-6273(01)00264-1; Preuss TM, 2000, BRAIN BEHAV EVOLUT, V55, P287, DOI 10.1159/000006664; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1975, NEUROSCI RES PROGR B, V13, P1; SIDMAN RL, 1973, BRAIN RES, V62, P1, DOI 10.1016/0006-8993(73)90617-3; Tan SS, 1998, NEURON, V21, P295, DOI 10.1016/S0896-6273(00)80539-5; Tarabykin V, 2001, DEVELOPMENT, V128, P1983; Ware ML, 1999, CEREB CORTEX, V9, P636, DOI 10.1093/cercor/9.6.636	32	509	522	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 6	2002	417	6889					645	649		10.1038/nature00779	http://dx.doi.org/10.1038/nature00779			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050665				2022-12-28	WOS:000176001200047
J	Clark, P; Twaddle, S; Walker, ID; Scott, L; Greer, IA				Clark, P; Twaddle, S; Walker, ID; Scott, L; Greer, IA			Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women	LANCET			English	Article								The factor V Leiden (FVL) mutation Is associated with vascular complications In pregnancy, and routine screening of all pregnant women has been suggested. We did a prospective, unselected study In 967 pregnant women to evaluate the cost-effectiveness of screening all women, or only those with a personal or family history of venous thrombosis (n=113). When anticoagulant prophylaxis was assumed to effect a 50% reduction In vascular complications, we recorded an additional management cost of UKpound3768 with selective screening and pound39 841 with universal screening. This additional cost would result In prevention of less than one and three vascular events, respectively. Our findings, therefore, suggest that screening of pregnant women for the FVL mutation Is not cost-effective.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Transfus Med, Dundee DD1 9SY, Scotland; Royal Infirm, Dept Haematol, Glasgow G31 2ER, Lanark, Scotland; Univ Glasgow, Royal Infirm, Dept Obstet & Gynaecol, Glasgow, Lanark, Scotland; Stobhill Gen Hosp, Dept Res & Dev, Glasgow G21 3UW, Lanark, Scotland	University of Dundee; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; University of Glasgow	Clark, P (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Transfus Med, Dundee DD1 9SY, Scotland.							Clark P, 1999, BLOOD REV, V13, P127, DOI 10.1054/blre.1999.0114; Clark P, 2001, THROMB HAEMOSTASIS, V85, P30; Greer IA, 1999, LANCET, V353, P1258, DOI 10.1016/S0140-6736(98)10265-9; Rai R, 1997, BRIT MED J, V314, P253, DOI 10.1136/bmj.314.7076.253	4	54	54	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 1	2002	359	9321					1919	1920		10.1016/S0140-6736(02)08740-8	http://dx.doi.org/10.1016/S0140-6736(02)08740-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PL	12057557				2022-12-28	WOS:000175975700014
J	Vaideanu, D; Fraser, K; Deady, JP				Vaideanu, D; Fraser, K; Deady, JP			Just another corneal abrasion?	LANCET			English	Editorial Material							CAVERNOUS SINUS; MENINGIOMAS		Sunderland Eye Infirm, Dept Ophthalmol, Sunderland SR2 9HP, England		Vaideanu, D (corresponding author), Sunderland Eye Infirm, Dept Ophthalmol, Sunderland SR2 9HP, England.							ANDERSON D, 1981, CAN J OPHTHALMOL, V16, P10; LARSON JJ, 1995, J NEUROSURG, V83, P596, DOI 10.3171/jns.1995.83.4.0596; MILLER NR, 1988, WALSH HOYTS CLIN NEU, P1332; Sen C, 1997, J NEUROSURG, V87, P535, DOI 10.3171/jns.1997.87.4.0535	4	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 1	2002	359	9321					1916	1916		10.1016/S0140-6736(02)08744-5	http://dx.doi.org/10.1016/S0140-6736(02)08744-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PL	12057555				2022-12-28	WOS:000175975700012
J	Young, BA; Gruber, TM; Gross, CA				Young, BA; Gruber, TM; Gross, CA			Views of transcription initiation	CELL			English	Review							COLI RNA-POLYMERASE; SIGMA(70) SUBUNIT; ELONGATION; COMPLEX	Initiation of transcription is the first step in gene expression and a major point of regulation. Recent structural studies reveal the nature of the initiating complex and suggest new ways of accomplishing the processes required for initiation.	Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gross, CA (corresponding author), Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA.							Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; Darst SA, 2002, P NATL ACAD SCI USA, V99, P4296, DOI 10.1073/pnas.052054099; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; Mekler V, 2002, CELL, V108, P599, DOI 10.1016/S0092-8674(02)00667-0; MURAKAMI KS, 2002, IN PRESS SCIENCE; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; Naryshkina T, 2001, J BIOL CHEM, V276, P13308, DOI 10.1074/jbc.M011041200; Vuthoori S, 2001, J MOL BIOL, V309, P561, DOI 10.1006/jmbi.2001.4690; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	12	82	88	0	9	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 17	2002	109	4					417	420		10.1016/S0092-8674(02)00752-3	http://dx.doi.org/10.1016/S0092-8674(02)00752-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	553VM	12086598	Bronze			2022-12-28	WOS:000175696800003
J	Howlett, NG; Taniguchi, T; Olson, S; Cox, B; Waisfisz, Q; de Die-Smulders, C; Persky, N; Grompe, M; Joenje, H; Pals, G; Ikeda, H; Fox, EA; D'Andrea, AD				Howlett, NG; Taniguchi, T; Olson, S; Cox, B; Waisfisz, Q; de Die-Smulders, C; Persky, N; Grompe, M; Joenje, H; Pals, G; Ikeda, H; Fox, EA; D'Andrea, AD			Biallelic inactivation of BRCA2 in Fanconi anemia	SCIENCE			English	Article							MITOMYCIN-C RESISTANCE; DNA-REPAIR; CANCER SUSCEPTIBILITY; GENE; MICE; MUTATIONS; RECOMBINATION; DEFICIENCY; FREQUENCY; PROTEINS	Fanconi anemia ( FA) is a rare autosomal recessive cancer susceptibility disorder characterized by cellular hypersensitivity to mitomycin C (MMC). Six FA genes have been cloned, but the gene or genes corresponding to FA subtypes B and D1 remain unidentified. Here we show that cell lines derived from FA-B and FA-D1 patients have biallelic mutations in BRCA2 and express truncated BRCA2 proteins. Functional complementation of FA-D1 fibroblasts with wild-type BRCA2 complementary DNA restores MMC resistance. Our results link the six cloned FA genes with BRCA1 and BRCA2 in a common pathway. Germ-line mutation of genes in this pathway may result in cancer risks similar to those observed in families with BRCA1 or BRCA2 mutations.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat, Boston, MA 02115 USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA; Free Univ Amsterdam, Med Ctr, Dept Clin Genet & Human Genet, NL-1081 BT Amsterdam, Netherlands; Univ Limburg, Acad Hosp Maastricht, Dept Clin Genet, Maastricht, Netherlands; Sapporo Med Univ, Sch Med, Dept Pathol, Chuo Ku, Sapporo, Hokkaido 0608557, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Oregon Health & Science University; Oregon Health & Science University; Vrije Universiteit Amsterdam; Hasselt University; Maastricht University; Maastricht University Medical Centre (MUMC); Sapporo Medical University	D'Andrea, AD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.	alan_dandrea@dfci.harvard.edu	Pals, Gerard/A-5198-2011; Taniguchi, Toshiyasu/ADD-8489-2022	Waisfisz, Quinten/0000-0002-7384-9182; Grompe, Markus/0000-0002-6616-4345; Pals, Gerard/0000-0003-4091-7115	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054785, R01HL052725] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043889] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL52725, P01HL54785] Funding Source: Medline; NIDDK NIH HHS [R01DK43889] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alter BP, 1996, AM J HEMATOL, V53, P99, DOI 10.1002/(SICI)1096-8652(199610)53:2<99::AID-AJH7>3.3.CO;2-M; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; BUCHWALD M, 1987, MUTAT RES, V184, P153, DOI 10.1016/0167-8817(87)90072-1; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; CUTHBERT AP, 1995, CYTOGENET CELL GENET, V71, P68, DOI 10.1159/000134066; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Goggins M, 1996, CANCER RES, V56, P5360; Grompe M, 2001, HUM MOL GENET, V10, P2253, DOI 10.1093/hmg/10.20.2253; Hakansson S, 1997, AM J HUM GENET, V60, P1068; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joenje H, 1997, AM J HUM GENET, V61, P940, DOI 10.1086/514881; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Mazoyer S, 1996, NAT GENET, V14, P253, DOI 10.1038/ng1196-253; McAllister KA, 2002, CANCER RES, V62, P990; Moynahan ME, 2001, CANCER RES, V61, P4842; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; STRATHDEE CA, 1992, NAT GENET, V1, P196, DOI 10.1038/ng0692-196; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; SWIFT M, 1980, J NATL CANCER I, V65, P863; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; TANIGUCHI T, 2002, BLOOD; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; WHITNEY M, 1995, NAT GENET, V11, P341, DOI 10.1038/ng1195-341; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498	31	884	909	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 26	2002	297	5581					606	609		10.1126/science.1073834	http://dx.doi.org/10.1126/science.1073834			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	577GY	12065746				2022-12-28	WOS:000177054200052
J	Dragon, F; Gallagher, JEG; Compagnone-Post, PA; Mitchell, BM; Porwancher, KA; Wehner, KA; Wormsley, S; Settlage, RE; Shabanowitz, J; Osheim, Y; Beyer, AL; Hunt, DF; Baserga, SJ				Dragon, F; Gallagher, JEG; Compagnone-Post, PA; Mitchell, BM; Porwancher, KA; Wehner, KA; Wormsley, S; Settlage, RE; Shabanowitz, J; Osheim, Y; Beyer, AL; Hunt, DF; Baserga, SJ			A large nucleolar U3 ribonucleoprotein required for 18S ribosomal RNA biogenesis	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN; YEAST; DISRUPTION; COMPONENT; COMPLEXES; SNORNP; RCL1P; SNRNP	Although the U3 small nucleolar RNA (snoRNA), a member of the box C/D class of snoRNAs, was identified with the spliceosomal small nuclear RNAs (snRNAs) over 30 years ago(1,2), its function and its associated protein components have remained more elusive. The U3 snoRNA is ubiquitous in eukaryotes and is required for nucleolar processing of pre-18S ribosomal RNA in all organisms where it has been tested(3,4). Biochemical and genetic analyses suggest that U3-pre-rRNAbase-pairing interactions mediate endonucleolytic pre-rRNA cleavages(3). Here we have purified a large ribonucleoprotein (RNP) complex from Saccharomyces cerevisiae that contains the U3 snoRNA and 28 proteins. Seventeen new proteins (Utp1-17) and Rrp5 were present, as were ten known components. The Utp proteins are nucleolar and specifically associated with the U3 snoRNA. Depletion of the Utp proteins impedes production of the 18S rRNA, indicating that they are part of the active pre-rRNA processing complex. On the basis of its large size (80S; calculated relative molecular mass of at least 2,200,000) and function, this complex may correspond to the terminal knobs present at the 5' ends of nascent pre-rRNAs. We have termed this large RNP the small subunit (SSU) processome.	Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; ProteoMS LLC, Charlottesville, VA 22903 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22904 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22904 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22904 USA	Yale University; Yale University; Yale University; University of Virginia; University of Virginia; University of Virginia	Baserga, SJ (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, 333 Cedar St, New Haven, CT 06520 USA.	susan.baserga@yale.edu	Bernstein, Kara Anne/S-4943-2016; Hunt, Donald F/I-6936-2012; Dragon, François/K-7094-2019	Bernstein, Kara Anne/0000-0003-2247-6459; Hunt, Donald F/0000-0003-2815-6368; Gallagher, Jennifer/0000-0002-6163-3181	NIGMS NIH HHS [F31 GM020905] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM020905] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Billy E, 2000, EMBO J, V19, P2115, DOI 10.1093/emboj/19.9.2115; Chung SY, 1999, RNA, V5, P1042, DOI 10.1017/S1355838299990635; Dunbar DA, 2000, P NATL ACAD SCI USA, V97, P13027, DOI 10.1073/pnas.97.24.13027; Dunbar DA, 1997, MOL CELL BIOL, V17, P5803, DOI 10.1128/MCB.17.10.5803; FOURNIER MJ, 1993, TRENDS BIOCHEM SCI, V18, P131, DOI 10.1016/0968-0004(93)90020-N; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; Kamakaka RT, 1998, GENETICS, V149, P903; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Lee SJ, 1997, P NATL ACAD SCI USA, V94, P13536, DOI 10.1073/pnas.94.25.13536; Lee SJ, 1999, MOL CELL BIOL, V19, P5441; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LUBBEN B, 1993, NUCLEIC ACIDS RES, V21, P5377, DOI 10.1093/nar/21.23.5377; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; MILLER OL, 1969, SCIENCE, V164, P955, DOI 10.1126/science.164.3882.955; MOUGEY EB, 1993, GENE DEV, V7, P1609, DOI 10.1101/gad.7.8.1609; NAKAMURA T, 1968, J BIOL CHEM, V243, P1368; OSHEIM YN, 1989, METHOD ENZYMOL, V180, P481; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Ross-Macdonald P, 1999, NATURE, V402, P413, DOI 10.1038/46558; Samarsky DA, 1998, MOL CELL BIOL, V18, P3431, DOI 10.1128/MCB.18.6.3431; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; Warner JR, 2001, CELL, V107, P133, DOI 10.1016/S0092-8674(01)00531-1; Watkins NJ, 2000, CELL, V103, P457, DOI 10.1016/S0092-8674(00)00137-9; Wegierski T, 2001, RNA, V7, P1254, DOI 10.1017/S1355838201012079; Wehner KA, 2002, MOL CELL, V9, P329, DOI 10.1016/S1097-2765(02)00438-0; WEINBERG RA, 1968, J MOL BIOL, V38, P289, DOI 10.1016/0022-2836(68)90387-2; Wiederkehr T, 1998, RNA, V4, P1357, DOI 10.1017/S1355838298980955	30	541	585	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 27	2002	417	6892					967	970		10.1038/nature00769	http://dx.doi.org/10.1038/nature00769			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	566RC	12068309				2022-12-28	WOS:000176441200043
J	Serruys, PWJC; de Feyter, P; Macaya, C; Kokott, N; Puel, J; Vrolix, M; Branzi, A; Bertolami, MC; Jackson, G; Strauss, B; Meier, B				Serruys, PWJC; de Feyter, P; Macaya, C; Kokott, N; Puel, J; Vrolix, M; Branzi, A; Bertolami, MC; Jackson, G; Strauss, B; Meier, B		Lescol Intervention Prevention St	Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYOCARDIAL-INFARCTION; ANGIOGRAPHIC RESTENOSIS; CONSERVATIVE STRATEGIES; ANGIOPLASTY; PRAVASTATIN; CHOLESTEROL; PLACEBO	Context Percutaneous coronary intervention (PCI) is associated with excellent short-term improvements in ischemic symptoms, yet only three fifths of PCI patients at 5 years and one third of patients at 10 years remain free of major adverse cardiac events (MACE). Objective To determine whether treatment with fluvastatin reduces MACE in patients who have undergone PCI. Design and Setting Randomized, double-blind, placebo-controlled trial conducted at 77 referral centers in Europe, Canada, and Brazil. Patients A total of 1677 patients (aged 18-80 years) recruited between April 1996 and October 1998 with stable or unstable angina or silent ischemia following successful completion of their first PCI who had baseline total cholesterol levels between 135 and 270 mg/dL (3.5-7.0 mmol/L), with fasting triglyceride levels of less than 400 mg/dL (4.5 mmol/L). Interventions Patients were randomly assigned to receive treatment with fluvastatin, 80 mg/d (n = 844), or matching placebo (n = 833) at hospital discharge for 3 to 4 years. Main Outcome Measure Survival time free of MACE, defined as cardiac death, nonfatal myocardial infarction, or reintervention procedure, compared between the treatment and placebo groups. Results Median time between PCI and first dose of study medication was 2.0 days, and median follow-up was 3.9 years. MACE-free survival time was significantly longer in the fluvastatin group (P=.01). One hundred eighty-one (21.4%) of 844 patients in the fluvastatin group and 222 (26.7%) of 833 patients in the placebo group had at least 1 MACE (relative risk [RR], 0.78; 95% confidence interval [CI], 0.64-0.95; P=.01). This result was independent of baseline total cholesterol levels (above [RR, 0.76; 95% CI, 0.56-1.041 vs below [RR, 0.77; 95% CI, 0.57-1.02] the median). In subgroup analysis, the risk of MACE was reduced in patients with diabetes (n=202; RR, 0.53; 95% CI, 0,29-0.97; P=.04) and in those with multivessel disease (n = 614; RR, 0.66; 95% CI, 0.48-0.91; P=.01) who received fluvastatin compared with those who received placebo. There were no instances of creatine phosphokinase elevations 10 or more times the upper limit of normal or rhabdomyolysis in the fluvastatin group. Conclusion Fluvastatin treatment in patients with average cholesterol levels undergoing their first successful PCI significantly reduces the risk of major adverse cardiac events.	Acad Hosp, Thoraxctr, NL-3015 GD Rotterdam, Netherlands; Hosp San Carlos, Dept Cardiol, Madrid, Spain; Hop Purpan, Dept Cardiol, Toulouse, France; St Jan Hosp, Dept Cardiol, Genk, Belgium; Osped Santa Orsola, Dept Cardiol, Bologna, Italy; Inst Dante Pazzanese Cardiol, Sao Paulo, Brazil; Guys Hosp, Dept Cardiol, London SE1 9RT, England; St Michaels Hosp, Div Cardiol, Toronto, ON M5B 1W8, Canada; Univ Hosp Insel, Dept Med, Bern, Switzerland; Koepenick Hosp, Berlin, Germany	Hospital Clinico San Carlos; CHU de Toulouse; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Instituto Dante Pazzanese de Cardiologia; Guy's & St Thomas' NHS Foundation Trust; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Bern; University Hospital of Bern	Serruys, PWJC (corresponding author), Acad Hosp, Thoraxctr, Bd 418,Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands.	serruys@card.azr.nl	Bertolami, Marcelo/B-9806-2012					*AM HEART ASS, 2002, 2002 HEART STROK STA; ANDERSON HV, 1995, J AM COLL CARDIOL, V26, P1643, DOI 10.1016/0735-1097(95)00404-1; Bertrand ME, 1997, J AM COLL CARDIOL, V30, P863, DOI 10.1016/S0735-1097(97)00259-3; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; Boden WE, 1998, NEW ENGL J MED, V339, P1397; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; Chan AW, 2002, CIRCULATION, V105, P691, DOI 10.1161/hc0602.103586; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2002, INT J CLIN PRACT, V56, P53; Flaker GC, 1999, J AM COLL CARDIOL, V34, P106, DOI 10.1016/S0735-1097(99)00145-X; Kannel W B, 1979, Diabetes Care, V2, P120, DOI 10.2337/diacare.2.2.120; PEDERSEN TR, 1994, LANCET, V344, P1383; Pfeffer MA, 1999, J AM COLL CARDIOL, V33, P125, DOI 10.1016/S0735-1097(98)00522-1; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; Rensing BJ, 2001, EUR HEART J, V22, P2125, DOI 10.1053/euhj.2001.2892; Ruygrok PN, 1996, J AM COLL CARDIOL, V27, P1669, DOI 10.1016/0735-1097(96)00046-0; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Serruys Patrick WJC, 2001, Int J Cardiovasc Intervent, V4, P165; Serruys PW, 2001, NEW ENGL J MED, V344, P1117, DOI 10.1056/NEJM200104123441502; Serruys PW, 1999, EUR HEART J, V20, P58, DOI 10.1053/euhj.1998.1150; Sousa JE, 2001, CIRCULATION, V104, P2007, DOI 10.1161/hc4201.098056; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; VIOLARIS AG, 1994, CIRCULATION, V90, P2267, DOI 10.1161/01.CIR.90.5.2267; Wallentin L, 1999, LANCET, V354, P708; WEINTRAUB WS, 1994, NEW ENGL J MED, V331, P1331, DOI 10.1056/NEJM199411173312002	26	542	590	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	2002	287	24					3215	3222		10.1001/jama.287.24.3215	http://dx.doi.org/10.1001/jama.287.24.3215			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566FF	12076217	Bronze			2022-12-28	WOS:000176415800025
J	Davies, SJC; Cooke, LB; Moore, AG; Potokar, J				Davies, SJC; Cooke, LB; Moore, AG; Potokar, J			Discontinuation of thioridazine in patients with learning disabilities: balancing cardiovascular toxicity with adverse consequences of changing drugs	BRITISH MEDICAL JOURNAL			English	Article									Univ Bristol, Sch Med Sci, Psychopharmacol Unit, Bristol BS8 1TD, Avon, England; Bristol Cent Community Learning Disabil Team, Bristol BS16 1EQ, Avon, England; Blackberry Hill Hosp, Bristol BS16 2EW, Avon, England; Bristol Royal Infirm & Gen Hosp, Liaison Psychiat, Bristol BS2 8HW, Avon, England	University of Bristol; Bristol Royal Infirmary	Davies, SJC (corresponding author), Univ Bristol, Sch Med Sci, Psychopharmacol Unit, Bristol BS8 1TD, Avon, England.			Davies, Simon/0000-0003-0095-5993				[Anonymous], [No title captured]; HartiganGo K, 1996, CLIN PHARMACOL THER, V60, P543, DOI 10.1016/S0009-9236(96)90150-2; Medicines Control Agency, 2001, CURRENT PROBLEMS PHA, V27, P4; MEHTONEN OP, 1991, ACTA PSYCHIAT SCAND, V84, P58, DOI 10.1111/j.1600-0447.1991.tb01421.x; Reilly JG, 2000, LANCET, V355, P1048, DOI 10.1016/S0140-6736(00)02035-3; SHAPIRO AK, 1984, J AM ACAD CHILD PSY, V23, P161, DOI 10.1097/00004583-198403000-00007; SHAVLEV A, 1989, J CLIN PSYCHIAT, V50, P18	7	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 22	2002	324	7352					1519	1521		10.1136/bmj.324.7352.1519	http://dx.doi.org/10.1136/bmj.324.7352.1519			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	567ZL	12077046	Green Published			2022-12-28	WOS:000176517900031
J	Lynn, A; Koehler, KE; Judis, L; Chan, ER; Cherry, JP; Schwartz, S; Seftel, A; Hunt, PA; Hassold, TJ				Lynn, A; Koehler, KE; Judis, L; Chan, ER; Cherry, JP; Schwartz, S; Seftel, A; Hunt, PA; Hassold, TJ			Covariation of synaptonemal complex length and mammalian meiotic exchange rates	SCIENCE			English	Article							CROSSING-OVER; CROSSOVER INTERFERENCE; DNA-SEQUENCE; HUMAN MALES; RECOMBINATION; PROTEIN; MLH1; MICE	Analysis of recombination between loci (linkage analysis) has been a cornerstone of human genetic research, enabling investigators to localize and, ultimately, identify genetic loci. However, despite these efforts little is known about patterns of meiotic exchange in human germ cells or the mechanisms that control these patterns. Using recently developed immuno fluorescence methodology to examine exchanges in human spermatocytes, we have identified remarkable variation in the rate of recombination within and among individuals. Subsequent analyses indicate that, in humans and mice, this variation is linked to differences in the length of the synaptonemal complex. Thus, at least in mammals, a physical structure, the synaptonemal complex, reflects genetic rather than physical distance.	Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Ctr Human Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Urol, Cleveland, OH 44106 USA; Cleveland VA Med Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Hassold, TJ (corresponding author), Case Western Reserve Univ, Dept Genet, 10900 Euclid Ave, Cleveland, OH 44106 USA.			Chan, Ernest/0000-0001-9277-5329	NICHD NIH HHS [HD21341, HD07518, HD37502] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD021341] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037502, R01HD021341] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Agarwal S, 2000, CELL, V102, P245, DOI 10.1016/S0092-8674(00)00029-5; Anderson LK, 1999, GENETICS, V151, P1569; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; Barlow AL, 1998, EUR J HUM GENET, V6, P350, DOI 10.1038/sj.ejhg.5200200; Broman KW, 2000, AM J HUM GENET, V66, P1911, DOI 10.1086/302923; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; Carpenter ATC, 1988, GENETIC RECOMBINATIO, P529, DOI [10.1038/ng1287, DOI 10.1038/NG1287]; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; HALDANE J. B. S., 1931, CYTOLOGIA, V3, P54; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; HAWLEY RS, 1993, TRENDS GENET, V9, P310; KOEHLER KM, UNPUB; LAURIE DA, 1985, ANN HUM GENET, V49, P189, DOI 10.1111/j.1469-1809.1985.tb01693.x; LYNN A, UNPUB; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; MANLY BFJ, 1997, RADNOMIZATION BOOTST; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; Page SL, 2001, GENE DEV, V15, P3130, DOI 10.1101/gad.935001; Reeves A., 2000, MICROMEASURE WINDOWS; SOLARI AJ, 1980, CHROMOSOMA, V81, P315, DOI 10.1007/BF00368145; STACK SM, 1984, J CELL SCI, V71, P159; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; TEASE C, IN PRESS AM J HUM GE; Woods LM, 1999, J CELL BIOL, V145, P1395, DOI 10.1083/jcb.145.7.1395; Yu J, 1996, AM J HUM GENET, V59, P1186	25	208	229	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 21	2002	296	5576					2222	2225		10.1126/science.1071220	http://dx.doi.org/10.1126/science.1071220			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12052900				2022-12-28	WOS:000176379000059
J	Nederbragt, AJ; van Loon, AE; Dictus, JAG				Nederbragt, AJ; van Loon, AE; Dictus, JAG			Evolutionary biology - Hedgehog crosses the snail's midline	NATURE			English	Editorial Material							DROSOPHILA		Univ Utrecht, Dept Dev Biol, NL-3584 CH Utrecht, Netherlands	Utrecht University	Nederbragt, AJ (corresponding author), Univ Utrecht, Dept Dev Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.			Nederbragt, Lex/0000-0001-5539-0999				Arendt D, 1997, MECH DEVELOP, V61, P7, DOI 10.1016/S0925-4773(96)00620-X; ARENDT D, 1994, NATURE, V371, P26, DOI 10.1038/371026a0; Arendt D, 1999, DEVELOPMENT, V126, P2309; CROWTHER RJ, 1992, J NEUROBIOL, V23, P280, DOI 10.1002/neu.480230307; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; Geoffroy St-Hilaire E., 1822, M M MUS HIST NAT, V9, P89; KENNEDY JJ, 1992, J MAR BIOL ASSOC UK, V72, P783, DOI 10.1017/S0025315400060045; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Menne TV, 1997, DEVELOPMENT, V124, P4949; Morrill J.B., 1982, P399; Nielsen C, 2001, ANIMAL EVOLUTION, VSecond; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; VONWERNER B, 1955, HELGOL WISS MEERESUN, V5, P169	13	24	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 20	2002	417	6891					811	812		10.1038/417811b	http://dx.doi.org/10.1038/417811b			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075342				2022-12-28	WOS:000176285600037
J	Khan, MA				Khan, MA			Update on spondyloarthropathies	ANNALS OF INTERNAL MEDICINE			English	Review							INFLAMMATORY-BOWEL-DISEASE; NECROSIS-FACTOR-ALPHA; COMPLICATING ANKYLOSING-SPONDYLITIS; RANDOMIZED CONTROLLED-TRIAL; SPINAL-CORD-INJURY; REACTIVE ARTHRITIS; PSORIATIC-ARTHRITIS; DOUBLE-BLIND; REITERS-SYNDROME; RHEUMATOID-ARTHRITIS	Spondyloarthropathies are a cluster of Interrelated and overlapping chronic Inflammatory rheumatic diseases that primarily include ankylosing spondylitis, reactive arthritis, and the arthritis associated with psoriasis and inflammatory bowel diseases. The primary pathologic sites are the entheses (the sites of bony insertion of ligaments and tendons); the axial skeleton, including the sacroiliac joints; the limb joints; and some nonarticular structures, such as the gut skin, eye, and aortic valve. Although spondyloarthropathles are not associated with rheumatoid factor, they show a strong association with HLA-1327; however, this association varies markedly among various spondyloarthropathles and among ethnic groups. The most widely used classification criterion, from the European Spondyloarthropathy Study Group, encompasses the currently recognized wider disease spectrum, with a sensitivity and specificity that generally exceed 85%. Spondyloarthropathies occur in genetically predisposed persons and are triggered by environmental factors, but the cellular and molecular mechanisms of Inflammation are not yet fully understood. Chlamyclial and many enterobacterial infections can trigger reactive arthritis, but an infectious trigger for ankylosing spondylitis has not yet been established. HLA-1327 Itself is involved In enhancing genetic susceptibility, but the underlying molecular basis Is still unknown; additional genes include the putative susceptibility genes for Crohn disease, ulcerative colitis, and psoriasis. A specific susceptibility gene for Crohn disease, NOD2, Is located on chromosome 16q12, and one of the candidate genes for psoriasis, PSORS1, has been mapped to a 60-kb fragment on chromosome 6p, which Is telomeric to the HLA-C locus. This paper reviews the efficacy of anti-tumor necrosis factor-a therapy and other therapeutic advances.	Case Western Reserve Univ, Metrohlth Med Ctr, Div Rheumatol, Cleveland, OH 44109 USA	Case Western Reserve University; MetroHealth System	Khan, MA (corresponding author), Case Western Reserve Univ, Metrohlth Med Ctr, Div Rheumatol, 2500 Metrohlth Dr, Cleveland, OH 44109 USA.		Khan, Muhammad/AAJ-8391-2021		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046208] Funding Source: NIH RePORTER; NIAMS NIH HHS [1R01 AR46208-01] Funding Source: Medline; PHS HHS [UT 201.2.5101] Funding Source: Medline; FDA HHS [CFDA 93.846] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); FDA HHS		AHLSTROM H, 1990, ARTHRITIS RHEUM, V33, P1763, DOI 10.1002/art.1780331202; Al-Arfaj A, 2001, CLIN EXP RHEUMATOL, V19, P184; Alaranta H, 2002, CLIN EXP RHEUMATOL, V20, P66; Alharbi SA, 1996, EUR J IMMUNOGENET, V23, P67, DOI 10.1111/j.1744-313X.1996.tb00265.x; Alvarez I, 2000, CURR OPIN RHEUMATOL, V12, P248, DOI 10.1097/00002281-200007000-00003; Amor B, 1998, RHEUM DIS CLIN N AM, V24, P677, DOI 10.1016/S0889-857X(05)70037-5; BAFIARES A, 1998, RHEUM DIS CLIN N AM, V24, P771; BAKKER C, 1994, J RHEUMATOL, V21, P264; Ball EJ, 2001, JOINT BONE SPINE, V68, P378, DOI 10.1016/S1297-319X(01)00294-9; BARDIN T, 1992, ARTHRITIS RHEUM, V35, P190, DOI 10.1002/art.1780350210; Barton AC, 2001, J RHEUMATOL, V28, P3; Bellow M, 2000, ANN RHEUM DIS, V59, P135, DOI 10.1136/ard.59.2.135; Benjamin M, 2001, J ANAT, V199, P503, DOI 10.1046/j.1469-7580.2001.19950503.x; Bergfeldt L, 1997, ANN INTERN MED, V127, P621, DOI 10.7326/0003-4819-127-8_Part_1-199710150-00007; Bhalerao J, 1998, HUM MOL GENET, V7, P1537, DOI 10.1093/hmg/7.10.1537; BLACKBURN WD, 1988, AM J MED, V85, P766; Bollow M, 1998, J RHEUMATOL, V25, P556; Boyer GS, 1997, ARCH INTERN MED, V157, P2111, DOI 10.1001/archinte.157.18.2111; Boyer GS, 1999, J RHEUMATOL, V26, P1537; Brandt J, 2000, ARTHRITIS RHEUM-US, V43, P1346, DOI 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E; Braun J, 2002, LANCET, V359, P1187, DOI 10.1016/S0140-6736(02)08215-6; Braun J, 1998, RHEUM DIS CLIN N AM, V24, P697, DOI 10.1016/S0889-857X(05)70038-7; Braun J, 1998, ARTHRITIS RHEUM-US, V41, P58, DOI 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G; Braun J, 2001, CURR OPIN RHEUMATOL, V13, P245, DOI 10.1097/00002281-200107000-00001; Braun J, 2000, ANN RHEUM DIS, V59, P85, DOI 10.1136/ard.59.12.985; Breban M, 1999, ARTHRITIS RHEUM, V42, P580, DOI 10.1002/1529-0131(199904)42:3<580::AID-ANR27>3.0.CO;2-D; BREWERTON DA, 1973, LANCET, V1, P904; Brown MA, 1996, ANN RHEUM DIS, V55, P268, DOI 10.1136/ard.55.4.268; Brown MA, 1997, ARTHRITIS RHEUM, V40, P1823, DOI 10.1002/art.1780401015; Bruce IN, 2001, RHEUMATOLOGY, V40, P363, DOI 10.1093/rheumatology/40.4.363; BULSTRODE SJ, 1987, BRIT J RHEUMATOL, V26, P40; Calabrese L, 2000, AM J MED, V108, P487, DOI 10.1016/S0002-9343(99)00408-8; Calin A, 1998, SPONDYLARTHRITIDES, P1; CASSIDY JT, 2001, TXB PEDIAT RHEUMATOL; Colbert RA, 2000, J RHEUMATOL, V27, P1107; Collantes E, 2000, JOINT BONE SPINE, V67, P516, DOI 10.1016/S1297-319X(00)00201-3; DAWES PT, 1988, POSTGRAD MED J, V64, P27, DOI 10.1136/pgmj.64.747.27; de Vlam K, 2000, J RHEUMATOL, V27, P2860; DOUGADOS M, 2002, IN PRESS ANN RHEUM D; DOUGADOS M, 1998, THERAPY SYSTEMIC RHE, P375; Duchmann R, 2001, CLIN EXP IMMUNOL, V123, P315, DOI 10.1046/j.1365-2249.2001.01440.x; Ebringer A, 2000, J MED MICROBIOL, V49, P305, DOI 10.1099/0022-1317-49-4-305; Edwards JCW, 2000, IMMUNOL TODAY, V21, P256, DOI 10.1016/S0167-5699(00)01625-X; Erturk M, 1997, REV RHUM, V64, P293; Feldtkeller E, 2000, CURR OPIN RHEUMATOL, V12, P239, DOI 10.1097/00002281-200007000-00002; Finkelstein JA, 1999, SPINAL CORD, V37, P444, DOI 10.1038/sj.sc.3100837; Fiorillo MT, 2000, J CLIN INVEST, V106, P47, DOI 10.1172/JCI9295; Francois RJ, 2000, ARTHRITIS RHEUM-US, V43, P2011, DOI 10.1002/1529-0131(200009)43:9<2011::AID-ANR12>3.0.CO;2-Y; Francois RJ, 2001, CURR OPIN RHEUMATOL, V13, P255, DOI 10.1097/00002281-200107000-00003; FRYDEN A, 1990, BRIT MED J, V301, P1299, DOI 10.1136/bmj.301.6764.1299; Garcia F, 1997, TISSUE ANTIGENS, V49, P23, DOI 10.1111/j.1399-0039.1997.tb02705.x; Gorman JD, 2002, NEW ENGL J MED, V346, P1349, DOI 10.1056/NEJMoa012664; GRAN JT, 1985, ANN RHEUM DIS, V44, P359, DOI 10.1136/ard.44.6.359; Granfors Kaisa, 2002, Arthritis Rheum, V46, P606, DOI 10.1002/art.10041; Gratacos J, 1999, ARTHRITIS RHEUM, V42, P2319, DOI 10.1002/1529-0131(199911)42:11<2319::AID-ANR9>3.0.CO;2-G; Hampe J, 2001, LANCET, V357, P1925, DOI 10.1016/S0140-6736(00)05063-7; Hannu T, 1999, RHEUMATOLOGY, V38, P411, DOI 10.1093/rheumatology/38.5.411; Hidding A, 1994, Arthritis Care Res, V7, P90, DOI 10.1002/art.1790070208; Hohler T, 2001, CURR OPIN RHEUMATOL, V13, P273, DOI 10.1097/00002281-200107000-00005; HUGHES RA, 1994, SEMIN ARTHRITIS RHEU, V24, P190, DOI 10.1016/0049-0172(94)90075-2; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Hukuda S, 2001, J RHEUMATOL, V28, P554; Huppertz HI, 2000, PEDIATR CARDIOL, V21, P141, DOI 10.1007/s002469910023; Inman RD, 2000, CURR OPIN RHEUMATOL, V12, P254, DOI 10.1097/00002281-200007000-00004; Kanakoudi-Tsakalidou F, 1998, SCAND J RHEUMATOL, V27, P431; Keat A, 1999, ADV EXP MED BIOL, V455, P201; KHAN MA, 1977, ARTHRITIS RHEUM, V20, P909, DOI 10.1002/art.1780200401; Khan MA, 2000, J RHEUMATOL, V27, P1110; KHAN MA, 1990, SEMIN ARTHRITIS RHEU, V20, P107, DOI 10.1016/0049-0172(90)90023-9; KHAN MA, 1982, ANN INTERN MED, V96, P70, DOI 10.7326/0003-4819-96-1-70; KHAN MA, 1985, ARTHRITIS RHEUM, V28, P40, DOI 10.1002/art.1780280107; KHAN MA, 1999, CONNS CURRENT THERAP, P944; KHAN MA, 1992, SPONDYLOARTROPATHIES; KHAN MA, 1984, PROGR CLIN RHEUMATOL, V1, P145; Khan MA, 1998, RHEUMATOLOGY; KHAN MA, 1998, ATLAS RHEUMATOLOGY; Khan Muhammad Asim, 1995, Current Opinion in Rheumatology, V7, P263, DOI 10.1097/00002281-199507000-00001; Khare Sanjay D., 1998, Current Opinion in Rheumatology, V10, P282, DOI 10.1097/00002281-199807000-00002; KIDD BL, 1988, BRIT J RHEUMATOL, V27, P230; Kim TH, 1997, SCAND J RHEUMATOL, V26, P218, DOI 10.3109/03009749709065685; Koh WH, 1997, J RHEUMATOL, V24, P2158; KRAAG G, 1990, J RHEUMATOL, V17, P228; Laloux L, 2001, ANN RHEUM DIS, V60, P316, DOI 10.1136/ard.60.4.316; Lange U, 2001, OSTEOPOROSIS INT, V12, P1031, DOI 10.1007/s001980170013; LAUHIO A, 1991, ARTHRITIS RHEUM-US, V34, P6, DOI 10.1002/art.1780340103; Laval SH, 2001, AM J HUM GENET, V68, P918, DOI 10.1086/319509; LORIG KR, 1993, ARTHRITIS RHEUM, V36, P439, DOI 10.1002/art.1780360403; Lovell DJ, 2000, NEW ENGL J MED, V342, P763, DOI 10.1056/NEJM200003163421103; Mader R, 1999, SEMIN ARTHRITIS RHEU, V29, P191, DOI 10.1016/S0049-0172(99)80030-4; Maksymowych WP, 2002, ARTHRITIS RHEUM, V46, P766, DOI 10.1002/art.10139; Maksymowych WP, 2001, J RHEUMATOL, V28, P144; Maksymowych WP, 2000, J RHEUMATOL, V27, P2295; Martinez-Borra J, 2000, HUM IMMUNOL, V61, P131, DOI 10.1016/S0198-8859(99)00145-7; McGonagle D, 1998, LANCET, V352, P1137, DOI 10.1016/S0140-6736(97)12004-9; McGonagle Dennis, 1999, Current Opinion in Rheumatology, V11, P244, DOI 10.1097/00002281-199907000-00004; Mease PJ, 2000, LANCET, V356, P385, DOI 10.1016/S0140-6736(00)02530-7; Mijiyawa M, 2000, CURR OPIN RHEUMATOL, V12, P281, DOI 10.1097/00002281-200007000-00008; Mitra D, 2000, RHEUMATOLOGY, V39, P85, DOI 10.1093/rheumatology/39.1.85; MOLL J M H, 1973, Seminars in Arthritis and Rheumatism, V3, P55, DOI 10.1016/0049-0172(73)90035-8; MOLL JMH, 1974, MEDICINE, V53, P343, DOI 10.1097/00005792-197409000-00002; Nair RP, 2000, AM J HUM GENET, V66, P1833, DOI 10.1086/302932; Nasution AR, 1997, J RHEUMATOL, V24, P1111; Nesher G, 1999, J RHEUMATOL, V26, P1638; Njobvu P, 2000, J RHEUMATOL, V27, P1699; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Olivieri I, 2002, ARTHRITIS RHEUM-US, V46, P553, DOI 10.1002/art.10127; Olivieri I, 2001, CURR OPIN RHEUMATOL, V13, P280, DOI 10.1097/00002281-200107000-00006; Pal B, 1998, CLIN RHEUMATOL, V17, P306, DOI 10.1007/BF01451010; Pato E, 2000, J RHEUMATOL, V27, P2198; Poole AR, 1998, AM J MED SCI, V316, P228, DOI 10.1097/00000441-199810000-00002; Queiro R, 2000, CLIN RHEUMATOL, V19, P445, DOI 10.1007/s100670070003; RESNICK D, 1981, Clinical Nuclear Medicine, V6, P213, DOI 10.1097/00003072-198105000-00007; Reveille JD, 2001, CURR OPIN RHEUMATOL, V13, P265, DOI 10.1097/00002281-200107000-00004; Roldan CA, 1998, J AM COLL CARDIOL, V32, P1397, DOI 10.1016/S0735-1097(98)00393-3; Roychowdhury B, 2001, RHEUMATOLOGY, V40, P43; Said-Nahal R, 2000, ARTHRITIS RHEUM-US, V43, P1356, DOI 10.1002/1529-0131(200006)43:6<1356::AID-ANR20>3.0.CO;2-Y; Said-Nahal R, 2002, ANN RHEUM DIS, V61, P201, DOI 10.1136/ard.61.3.201; Salmi M, 2001, J IMMUNOL, V166, P4650, DOI 10.4049/jimmunol.166.7.4650; Saraux A, 1999, J RHEUMATOL, V26, P2622; Schwartzenberg JM, 1999, J RHEUMATOL, V26, P933; SCOFIELD RH, 1993, P NATL ACAD SCI USA, V90, P9330, DOI 10.1073/pnas.90.20.9330; Shih TTF, 2001, J COMPUT ASSIST TOMO, V25, P164, DOI 10.1097/00004728-200103000-00002; Sieper J, 1999, ARTHRITIS RHEUM-US, V42, P1386, DOI 10.1002/1529-0131(199907)42:7<1386::AID-ANR12>3.0.CO;2-E; Sieper J, 2002, ARTHRITIS RHEUM-US, V46, P319, DOI 10.1002/art.504; Smale S, 2001, ARTHRITIS RHEUM-US, V44, P2728, DOI 10.1002/1529-0131(200112)44:12<2728::AID-ART459>3.0.CO;2-8; Spoorenberg A, 1999, J RHEUMATOL, V26, P980; Taurog JD, 1999, IMMUNOL REV, V169, P209; Tico N, 1998, SPINAL CORD, V36, P349, DOI 10.1038/sj.sc.3100619; TOIVANEN A, 1993, CLIN EXP RHEUMATOL, V11, P301; Van den Bosch F, 2002, ARTHRITIS RHEUM, V46, P755, DOI 10.1002/art.511; van der Heijde D, 1999, J RHEUMATOL, V26, P951; van der Heijde D, 1999, J RHEUMATOL, V26, P945; van der Linden S, 1998, RHEUM DIS CLIN N AM, V24, P663, DOI 10.1016/S0889-857X(05)70036-3; VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361; VANDERLINDEN SM, 1988, J RHEUMATOL, V15, P836; Wakefield D, 1999, ARTHRITIS RHEUM, V42, P1894, DOI 10.1002/1529-0131(199909)42:9<1894::AID-ANR14>3.0.CO;2-V; Wendling D, 2000, JOINT BONE SPINE, V67, P259; WINCHESTER R, 1987, ANN INTERN MED, V106, P19, DOI 10.7326/0003-4819-106-1-19; Winchester Robert, 1999, Current Opinion in Rheumatology, V11, P251, DOI 10.1097/00002281-199907000-00005; YU D, 2000, KELLEYS TXB RHEUMATO, P1039; Zabraniecki L, 2001, JOINT BONE SPINE, V68, P106, DOI 10.1016/S1297-319X(01)00257-3; ZEIDLER H, 1992, RHEUM DIS CLIN N AM, V18, P187	142	340	367	0	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 18	2002	136	12					896	907		10.7326/0003-4819-136-12-200206180-00011	http://dx.doi.org/10.7326/0003-4819-136-12-200206180-00011			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563JL	12069564				2022-12-28	WOS:000176252500007
J	Woloshin, S; Schwartz, LM; Welch, HG				Woloshin, S; Schwartz, LM; Welch, HG			Tobacco money: up in smoke?	LANCET			English	Editorial Material							COMPUTED-TOMOGRAPHY SCANNER; MAYO LUNG PROJECT; CANCER; RATES; CARCINOMA; SURVIVAL; NECROPSY; CT		Vet Affairs Med Ctr, Vet Affairs Outcomes Grp, White River Jct, VT 05009 USA; Dartmouth Coll Sch Med, Ctr Evaluat Clin Sci, Hanover, NH USA; Dartmouth Coll Sch Med, Dept Med, Hanover, NH USA; Dartmouth Coll Sch Med, Dept Community & Family Med, Hanover, NH USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Dartmouth College; Dartmouth College; Dartmouth College	Woloshin, S (corresponding author), Vet Affairs Med Ctr, Vet Affairs Outcomes Grp, 111B 215 N Main St, White River Jct, VT 05009 USA.				NATIONAL CANCER INSTITUTE [R18CA091052] Funding Source: NIH RePORTER; NCI NIH HHS [R18 CA91052-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoki T, 2000, AM J ROENTGENOL, V174, P763, DOI 10.2214/ajr.174.3.1740763; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; CHAN CK, 1989, CHEST, V96, P291, DOI 10.1378/chest.96.2.291; Devita V., 1989, CANC PRINCIPLES PRAC, V3rd; DOLL R, 1956, BRIT MED J, V2, P1071, DOI 10.1136/bmj.2.5001.1071; FONTANA RS, 1991, CANCER-AM CANCER SOC, V67, P1155, DOI 10.1002/1097-0142(19910215)67:4+<1155::AID-CNCR2820671509>3.0.CO;2-0; GRADY D, 1999, NY TIMES        0925, pA8; GRADY D, 1999, NY TIMES        0709, pA1; Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6; Kramer BS, 2000, HEMATOL ONCOL CLIN N, V14, P831, DOI 10.1016/S0889-8588(05)70314-2; KUBIK A, 1986, CANCER-AM CANCER SOC, V57, P2427, DOI 10.1002/1097-0142(19860615)57:12<2427::AID-CNCR2820571230>3.0.CO;2-M; Marcus PM, 2000, J NATL CANCER I, V92, P1308, DOI 10.1093/jnci/92.16.1308; MCFARLANE MJ, 1987, JAMA-J AM MED ASSOC, V258, P331, DOI 10.1001/jama.258.3.331; Merrill RM, 1999, CHEST, V116, P697, DOI 10.1378/chest.116.3.697; *OFF MAYOR, 2001, NEW YORK CIT COMM BI; Pigula FA, 1996, ANN THORAC SURG, V61, P174, DOI 10.1016/0003-4975(95)00828-4; Sone S, 2001, BRIT J CANCER, V84, P25, DOI 10.1054/bjoc.2000.1531; Sone S, 2000, BRIT J RADIOL, V73, P137, DOI 10.1259/bjr.73.866.10884725; Sone S, 1998, LANCET, V351, P1242, DOI 10.1016/S0140-6736(97)08229-9; Spratt JS, 1996, J SURG ONCOL, V61, P68, DOI 10.1002/1096-9098(199601)61:1<68::AID-JSO2930610102>3.0.CO;2-E; Welch HG, 1997, ANN INTERN MED, V127, P1023, DOI 10.7326/0003-4819-127-11-199712010-00014	21	13	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 15	2002	359	9323					2108	2111		10.1016/S0140-6736(02)08939-0	http://dx.doi.org/10.1016/S0140-6736(02)08939-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086781				2022-12-28	WOS:000176194600028
J	Alley, WM; Healy, RW; LaBaugh, JW; Reilly, TE				Alley, WM; Healy, RW; LaBaugh, JW; Reilly, TE			Hydrology - Flow and storage in groundwater systems	SCIENCE			English	Review							SYNTHETIC-APERTURE RADAR; ENVIRONMENTAL TRACERS; LAND SUBSIDENCE; LAS-VEGAS; WATER; RECHARGE; AQUIFER; MODELS; BASIN; SCALE	The dynamic nature of groundwater is not readily apparent, except where discharge is focused at springs or where recharge enters sinkholes. Yet groundwater flow and storage are continually changing in response to human and climatic stresses. Wise development of groundwater resources requires a more complete understanding of these changes in flow and storage and of their effects on the terrestrial environment and on numerous surface-water features and their biota.	US Geol Survey, Natl Ctr 411, Reston, VA 20192 USA; US Geol Survey, Denver Fed Ctr, Lakewood, CO 80225 USA	United States Department of the Interior; United States Geological Survey; United States Department of the Interior; United States Geological Survey	Alley, WM (corresponding author), US Geol Survey, Natl Ctr 411, Reston, VA 20192 USA.	walley@usgs.gov		Reilly, Thomas/0000-0002-2988-9881				ALLEY WM, 1999, US GEOL SURV CIRC, V1186; Amelung F, 1999, GEOLOGY, V27, P483, DOI 10.1130/0091-7613(1999)027<0483:STUADO>2.3.CO;2; Basu AR, 2001, SCIENCE, V293, P1470, DOI 10.1126/science.1060524; Bawden GW, 2001, NATURE, V412, P812, DOI 10.1038/35090558; BEAR J, 1999, METHODS PRACTICES; BENTLEY HW, 1986, WATER RESOUR RES, V22, P1991, DOI 10.1029/WR022i013p01991; Beyerle U, 1998, SCIENCE, V282, P731, DOI 10.1126/science.282.5389.731; Boulton AJ, 2000, ECOSYST HEALTH, V6, P108, DOI 10.1046/j.1526-0992.2000.00011.x; BOYD RA, 2001, 004274 US GEOL SURV; Bruce BW, 2001, J AM WATER RESOUR AS, V37, P1389, DOI 10.1111/j.1752-1688.2001.tb03647.x; CLARKE R, 1996, UN ENV PROGR LIBR, V15; Constantz J, 1998, WATER RESOUR RES, V34, P1609, DOI 10.1029/98WR00998; Cook P.G., 1999, ENV TRACERS SUBSURFA, P1; Cook PG, 1997, J HYDROL, V191, P245, DOI 10.1016/S0022-1694(96)03051-X; Cooper HiltonH., 1982, SCI BASIS WATER RESO, V51, P57; Council N.R. Studies D.E.L. Commission on Geosciences E.R. Flow C.F.C.F., 1996, ROCK FRACTURES FLUID; DOMENICO P, 1998, PHYSICAL CHEM HYDROG; Edmunds WM, 2002, HYDROGEOL J, V10, P216, DOI 10.1007/s10040-001-0180-6; Favreau G, 2002, GROUND WATER, V40, P144, DOI 10.1111/j.1745-6584.2002.tb02499.x; Flint AL, 2001, REV GEOPHYS, V39, P447, DOI 10.1029/1999RG000075; Fraser CJD, 2001, J HYDROL, V246, P142, DOI 10.1016/S0022-1694(01)00362-6; GALLOWAY D, 1999, US GEOL SURV CIRC, V1182; Galloway DL, 1998, WATER RESOUR RES, V34, P2573, DOI 10.1029/98WR01285; GARVEN G, 1995, ANNU REV EARTH PL SC, V23, P89, DOI 10.1146/annurev.earth.23.1.89; HOFFMAN J, 2001, EOS, V82; Hoffmann J, 2001, WATER RESOUR RES, V37, P1551, DOI 10.1029/2000WR900404; Huisman JA, 2001, J HYDROL, V245, P48, DOI 10.1016/S0022-1694(01)00336-5; JOHNSTON RH, 1997, 1425 US GEOL SURV PR; JONES JA, 2000, STREAMS GROUNDWATER; Kooi H, 2001, J HYDROL, V246, P19, DOI 10.1016/S0022-1694(01)00354-7; Kotb THS, 2000, AGR WATER MANAGE, V43, P239, DOI 10.1016/S0378-3774(99)00052-9; Lahm TD, 2000, WATER RESOUR RES, V36, P3167, DOI 10.1029/2000WR900140; Laroche J, 1997, GLOB CHANGE BIOL, V3, P397, DOI 10.1046/j.1365-2486.1997.00117.x; Lerner DN, 2002, HYDROGEOL J, V10, P143, DOI 10.1007/s10040-001-0177-1; LERNER DN, 1990, INT ASS HYDROGEOLOGI, V8; LICHTNER P, 1996, MEDIA REV MINERAL, V34; LOOSLI HH, 1998, EOS, V79, P576; Malard F, 2001, CAN J FISH AQUAT SCI, V58, P1319, DOI 10.1139/cjfas-58-7-1319; Manga M, 2001, ANNU REV EARTH PL SC, V29, P201, DOI 10.1146/annurev.earth.29.1.201; Mantua NJ, 1997, B AM METEOROL SOC, V78, P1069, DOI 10.1175/1520-0477(1997)078<1069:APICOW>2.0.CO;2; Marmonier P, 2000, ECOSY WORLD, V30, P513; McPherson BJOL, 2001, WATER RESOUR RES, V37, P857, DOI 10.1029/2000WR900260; Moore WS, 1999, MAR CHEM, V65, P111, DOI 10.1016/S0304-4203(99)00014-6; Mortimer RJG, 1999, LIMNOL OCEANOGR, V44, P1802, DOI 10.4319/lo.1999.44.7.1802; NEUZIL CE, 1993, WATER RESOUR RES, V29, P2007, DOI 10.1029/93WR00406; Norin M, 1999, INT ASSOC HYDROGEOL, V21, P209; PHILLIPS FM, 1994, SOIL SCI SOC AM J, V58, P15, DOI 10.2136/sssaj1994.03615995005800010003x; Plummer LN, 1998, APPL GEOCHEM, V13, P995, DOI 10.1016/S0883-2927(98)00031-6; Poeter EP, 1997, GROUND WATER, V35, P250, DOI 10.1111/j.1745-6584.1997.tb00082.x; POOL DR, 1995, GROUND WATER, V33, P425, DOI 10.1111/j.1745-6584.1995.tb00299.x; POSTEL S, 1999, PILLAR SAND IRRIGATI; Power G, 1999, HYDROL PROCESS, V13, P401, DOI 10.1002/(SICI)1099-1085(19990228)13:3<401::AID-HYP746>3.3.CO;2-1; Rayne TW, 2001, HYDROGEOL J, V9, P432, DOI 10.1007/s100400100154; REILLY TE, 1994, WATER RESOUR RES, V30, P421, DOI 10.1029/93WR02655; Rosenberry DO, 2000, GROUND WATER, V38, P296, DOI 10.1111/j.1745-6584.2000.tb00340.x; SAHAGIAN DL, 1994, NATURE, V367, P54, DOI 10.1038/367054a0; Sanford W. E., 1996, HYDROGEOL J, V4, P26, DOI DOI 10.1007/S100400050083; Scanlon BR, 2002, HYDROGEOL J, V10, P18, DOI 10.1007/s10040-001-0176-2; SCHLESINGER WH, 1997, BIOGEOCHEM ANAL GLOB, pCH10; Schneiderman J, 2000, EARTH AROUND US MAIN, P154; Schwartz FW, 2001, GROUND WATER, V39, P492, DOI 10.1111/j.1745-6584.2001.tb02337.x; Shapiro AM, 2001, WATER RESOUR RES, V37, P507, DOI 10.1029/2000WR900301; Shelton J. L., 2001, 014188 US GEOL SURV; Sneed M., 2000, 004015 US GEOL SURV; SOLLEY WB, 1998, US GEOL SURV CIRC, V1200; SOPHOCLEOUS M, 1992, J HYDROL, V137, P113, DOI 10.1016/0022-1694(92)90051-V; Sophocleous M, 2000, J HYDROL, V236, P185, DOI 10.1016/S0022-1694(00)00293-6; SVERJENSKY DA, 1992, NATURE, V356, P481, DOI 10.1038/356481a0; TAYLOR CJ, 2001, US GEOL SURV CIRC, V1217; Top Z, 2001, J COASTAL RES, V17, P859; vanderKamp G, 1997, GEOPHYS RES LETT, V24, P719, DOI 10.1029/97GL00521; Vorosmarty C., 2001, EOS T AM GEOPHYS UN, V82, P54, DOI [DOI 10.1029/01EO00031, 10.1029/01EO00031, 10.1029/01-o00031]; Wahr J, 1998, J GEOPHYS RES-SOL EA, V103, P30205, DOI 10.1029/98JB02844; Winter T.C., 1998, US GEOL SURV CIRC; Woessner WW, 2000, GROUND WATER, V38, P423, DOI 10.1111/j.1745-6584.2000.tb00228.x; Yang CH, 1999, GEOPHYSICS, V64, P417, DOI 10.1190/1.1444546; York JP, 2002, ADV WATER RESOUR, V25, P221, DOI 10.1016/S0309-1708(01)00021-5; 2001, AQUIFER STORGE RECOV	78	428	447	13	334	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	2002	296	5575					1985	1990		10.1126/science.1067123	http://dx.doi.org/10.1126/science.1067123			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065826	Green Submitted			2022-12-28	WOS:000176273300041
J	Mukouyama, Y; Shin, D; Britsch, S; Taniguchi, M; Anderson, DJ				Mukouyama, Y; Shin, D; Britsch, S; Taniguchi, M; Anderson, DJ			Sensory nerves determine the pattern of arterial differentiation and blood vessel branching in the skin	CELL			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR SMOOTH-MUSCLE; GLIAL-CELL DEVELOPMENT; CARDIOVASCULAR DEVELOPMENT; VENOUS DIFFERENTIATION; PERIPHERAL-NERVE; RECEPTOR; GENE; MICE; EXPRESSION	Nerves and blood vessels are branched structures, but whether their branching patterns are established independently or coordinately is not clear. Here we show that arteries, but not veins, are specifically aligned with peripheral nerves in embryonic mouse limb skin. Mutations that eliminate peripheral sensory nerves or Schwann cells prevent proper arteriogenesis, while those that disorganize the nerves maintain the alignment of arteries with misrouted axons. In vitro, sensory neurons or Schwann cells can induce arterial marker expression in isolated embryonic endothelial cells, and VEGF(164/120) is necessary and sufficient to mediate this induction. These data suggest that peripheral nerves provide a template that determines the organotypic pattern of blood vessel branching and arterial differentiation in the skin, via local secretion of VEGF.	CALTECH, Div Biol 216 76, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Tokyo 1130033, Japan	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Tokyo	Mukouyama, Y (corresponding author), CALTECH, Div Biol 216 76, 1201 E Calif Blvd, Pasadena, CA 91125 USA.		Shin, Donghun/A-2092-2012	Mukouyama, Yoh-suke/0000-0002-9084-4922; Shin, Donghun/0000-0002-7975-9014	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066221] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66221] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; BALUK P, 1997, J INVEST DERMATOL S, V2, P76; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; BURNSTOCK G, 1994, BRIT J PLAST SURG, V47, P527, DOI 10.1016/0007-1226(94)90136-8; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Donovan MJ, 2000, DEVELOPMENT, V127, P4531; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 2000, RECENT PROG HORM RES, V55, P15; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Francis N, 1999, DEV BIOL, V210, P411, DOI 10.1006/dbio.1999.9269; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Garratt AN, 2000, BIOESSAYS, V22, P987, DOI 10.1002/1521-1878(200011)22:11<987::AID-BIES5>3.0.CO;2-5; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kolodkin AL, 1998, PROG BRAIN RES, V117, P115; KURTZ A, 1994, DEVELOPMENT, V120, P2637; Lawson ND, 2001, DEVELOPMENT, V128, P3675; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Ma QF, 1999, GENE DEV, V13, P1717, DOI 10.1101/gad.13.13.1717; MARTIN P, 1989, International Journal of Developmental Biology, V33, P379; Morris JK, 1999, NEURON, V23, P273, DOI 10.1016/S0896-6273(00)80779-5; Moyon D, 2001, DEVELOPMENT, V128, P3359; Murphy P, 1996, DEVELOPMENT, V122, P2847; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; SCARISBRICK IA, 1993, J NEUROSCI, V13, P875; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shima DT, 2000, CURR OPIN GENET DEV, V10, P536, DOI 10.1016/S0959-437X(00)00124-6; Shin D, 2001, DEV BIOL, V230, P139, DOI 10.1006/dbio.2000.9957; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; Studer L, 2000, J NEUROSCI, V20, P7377; Taniguchi M, 1997, NEURON, V19, P519, DOI 10.1016/S0896-6273(00)80368-2; Thurston G, 2001, NATURE, V414, P163, DOI 10.1038/35102664; Urness LD, 2000, NAT GENET, V26, P328, DOI 10.1038/81634; van Kempen MJA, 1999, HISTOCHEM CELL BIOL, V112, P479, DOI 10.1007/s004180050432; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zhong TP, 2001, NATURE, V414, P216, DOI 10.1038/35102599; ZUKOWSKAGROJEC Z, 1993, PEPTIDES, V14, P263, DOI 10.1016/0196-9781(93)90040-N	44	491	511	1	22	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 14	2002	109	6					693	705		10.1016/S0092-8674(02)00757-2	http://dx.doi.org/10.1016/S0092-8674(02)00757-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	563PW	12086669	Bronze			2022-12-28	WOS:000176265600001
J	Taylor, JP; Hardy, J; Fischbeck, KH				Taylor, JP; Hardy, J; Fischbeck, KH			Biomedicine - Toxic proteins in neurodegenerative disease	SCIENCE			English	Review							PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; EXPANDED POLYGLUTAMINE; MOUSE MODEL; SUSCEPTIBILITY LOCUS; NUCLEAR-LOCALIZATION; GLUTAMINE REPEATS; APOLIPOPROTEIN-E; TRANSGENIC MICE	A broad range of neurodegenerative disorders is characterized by neuronal damage that may be caused by toxic, aggregation-prone proteins. As genes are identified for these disorders and cell culture and animal models are developed, it has become clear that a major effect of mutations in these genes is the abnormal processing and accumulation of misfolded protein in neuronal inclusions and plaques. Increased understanding of the cellular mechanisms for disposal of abnormal proteins and of the effects of toxic protein accumulation on neuronal survival may allow the development of rational, effective treatment for these disorders.	NINCDS, Neurogenet Branch, NIH, Bethesda, MD 20892 USA; NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Taylor, JP (corresponding author), NINCDS, Neurogenet Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.	taylorjp@ninds.nih.gov	Hardy, John/C-2451-2009; Taylor, J. Paul/N-2482-2018	Hardy, John/0000-0002-3122-0423; Taylor, J. Paul/0000-0002-5794-0349	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002974, ZIANS002974] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguzzi A, 1998, BRAIN PATHOL, V8, P695, DOI 10.1111/j.1750-3639.1998.tb00195.x; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Cleveland DW, 2000, NAT MED, V6, P1320, DOI 10.1038/82122; Cleveland DW, 1999, NEURON, V24, P515, DOI 10.1016/S0896-6273(00)81108-3; Cole N, 1999, SEMIN NEUROL, V19, P407, DOI 10.1055/s-2008-1040855; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Diamond MI, 2000, P NATL ACAD SCI USA, V97, P657, DOI 10.1073/pnas.97.2.657; Dragatsis I, 2000, NAT GENET, V26, P300, DOI 10.1038/81593; Ertekin-Taner N, 2000, SCIENCE, V290, P2303, DOI 10.1126/science.290.5500.2303; Farrer M, 1999, HUM MOL GENET, V8, P81, DOI 10.1093/hmg/8.1.81; Farrer M, 2001, ANN NEUROL, V50, P293, DOI 10.1002/ana.1132; Funayama M, 2002, ANN NEUROL, V51, P296, DOI 10.1002/ana.10113; Gasser T, 1998, NAT GENET, V18, P262, DOI 10.1038/ng0398-262; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; HERSHKO A, 1997, CELL, V79, P13; Hicks A, 2001, AM J HUM GENET, V69, P200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Maraganore DM, 1999, NEUROLOGY, V53, P1858, DOI 10.1212/WNL.53.8.1858; Martin ER, 2001, JAMA-J AM MED ASSOC, V286, P2245, DOI 10.1001/jama.286.18.2245; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; McCampbell A, 2001, P NATL ACAD SCI USA, V98, P15179, DOI 10.1073/pnas.261400698; McCampbell A, 2001, NAT MED, V7, P528, DOI 10.1038/87842; Meriin AB, 2001, J CELL BIOL, V153, P851, DOI 10.1083/jcb.153.4.851; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Muchowski PJ, 2002, P NATL ACAD SCI USA, V99, P727, DOI 10.1073/pnas.022628699; Myers A, 2000, SCIENCE, V290, P2304, DOI 10.1126/science.290.5500.2304; Nakamura K, 2001, HUM MOL GENET, V10, P1441, DOI 10.1093/hmg/10.14.1441; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; Reed LA, 2001, NEUROBIOL AGING, V22, P89, DOI 10.1016/S0197-4580(00)00202-5; Refolo LM, 1999, J NEUROCHEM, V73, P2383, DOI 10.1046/j.1471-4159.1999.0732383.x; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Subramaniam JR, 2002, NAT NEUROSCI, V5, P301, DOI 10.1038/nn823; Valente EM, 2001, AM J HUM GENET, V68, P895, DOI 10.1086/319522; Van Duijn CM, 2001, AM J HUM GENET, V69, P505; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581	74	913	974	1	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	2002	296	5575					1991	1995		10.1126/science.1067122	http://dx.doi.org/10.1126/science.1067122			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065827				2022-12-28	WOS:000176273300042
J	Iglehart, JK				Iglehart, JK			Medicare's declining payments to physicians	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RELATIVE-VALUE SCALE											ASTON G, 2001, AM MED NEWS, V44, P7; Centers for Medicare & Medicaid Services (CMS) HHS, 2001, Fed Regist, V66, P55245; CRIPPEN DL, 2002, MIDCARES PAYMENT PHY; HAYMAN H, 2001, AM MED NEWS, V44, P25; HSIAO WC, 1988, NEW ENGL J MED, V319, P881, DOI 10.1056/NEJM198809293191330; HSIAO WC, 1988, NEW ENGL J MED, V319, P835, DOI 10.1056/NEJM198809293191305; Iglehart JK, 2001, NEW ENGL J MED, V345, P1920, DOI 10.1056/NEJM200112273452617; KENT C, 2002, PHYSICIANS WKLY, V19, P1; Levit K, 2002, HEALTH AFFAIR, V21, P172, DOI 10.1377/hlthaff.21.1.172; MCCALL NT, 2002, VALIDATION PHYSICIAN; *MED PAYM ADV COMM, 2002, REP C MED PAYM POL; Pear Robert, 2002, NY TIMES        0517, pA1; ROPER WL, 1988, NEW ENGL J MED, V319, P865, DOI 10.1056/NEJM198809293191311; SCANLON WJ, 2002, MEDICARE PHYSICIAN P; SCULLY TA, 2002, MEDICARE PAYMENT PHY; SERAFINI MW, 2002, NATL J WASH, V34, P28; Textron Inc. Barbara Martinez, 2002, WALL STREET J; ZELLER S, 2002, NATL J WASH, V34, P1218	18	31	31	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	2002	346	24					1924	1930		10.1056/NEJMhpr020324	http://dx.doi.org/10.1056/NEJMhpr020324			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	561NA	12063387				2022-12-28	WOS:000176146100037
J	Brattebo, G; Hofoss, D; Flaatten, H; Muri, AK; Gjerde, S; Plsek, PE				Brattebo, G; Hofoss, D; Flaatten, H; Muri, AK; Gjerde, S; Plsek, PE			Quality improvement report - Effect of a scoring system and protocol for sedation on duration of patients' need for ventilator support in a surgical intensive care unit	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Problem Need for improved sedation strategy for adults receiving ventilator support. Design Observational study of effect of introduction of guidelines to improve the doctors' and nurses' Performance. The project was a prospective improvement and was part of a national quality improvement collaborative. Background and setting A general mixed surgical. intensive care unit in a university hospital; all doctors and nurses in the unit; all adult patients (> 18 years) treated by intermittent positive pressure ventilation for more than 24 hours. Key measures for improvement Reduction in patients' mean time on a ventilator and length of stay in intensive care over a period of 11 months; anonymous reporting of critical incidents; staff perceptions of ease and of consequences of changes. Strategies for change Multiple measures (protocol development, educational presentations, written guidelines, posters, flyers, emails, personal discussions, and continuous feedback) were tested, rapidly assessed, and adopted if beneficial. Effects of change Mean ventilator time decreased by 9.1 days (95% confidence interval 0.7 to 3.6 days) from 7.4 days before intervention to 5.3 days after. Mean stay decreased by 1.0 day (-0.9 to 2.9 days) from 9.3 days to 8.3 days. No accidental extubations or other incidents were identified. Lessons learnt Relatively simple changes in sedation practice had significant effects on length of ventilator support. The change process was well received by e staff and increased their interest in identifying other areas for improvement,	Haukeland Hosp, Dept Anaesthesia & Intens Care, N-5021 Bergen, Norway; HELTEF, Fdn Hlth Serv Res, N-1474 Nordbyhagen, Norway; Paul E Plsek & Associates, Roswell, GA 30075 USA	University of Bergen; Haukeland University Hospital	Brattebo, G (corresponding author), Haukeland Hosp, Dept Anaesthesia & Intens Care, N-5021 Bergen, Norway.	gbra@haukeland.no	Flaatten, Hans/AAG-7030-2020	Flaatten, Hans/0000-0001-9186-3482; Brattebo, Guttorm/0000-0002-7124-5641				BARR J, 1995, CRIT CARE CLIN, V11, P827, DOI 10.1016/S0749-0704(18)30041-1; Brock WA, 1998, NEW HORIZ-SCI PRACT, V6, P61; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Carey RG, 1995, MEASURING QUALITY IM; Clemmer TP, 1999, CRIT CARE MED, V27, P1768, DOI 10.1097/00003246-199909000-00011; Devlin JW, 1999, CRIT CARE MED, V27, P1271, DOI 10.1097/00003246-199907000-00008; Flaatten Hans, 1997, Acta Anaesthesiologica Scandinavica, V41, P193; Flaatten Hans, 1997, Acta Anaesthesiologica Scandinavica, V41, P175; Kollef MH, 1998, NEW HORIZ-SCI PRACT, V6, P52; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Marx WH, 1999, J TRAUMA, V46, P625, DOI 10.1097/00005373-199904000-00011; Plsek P E, 1999, Pediatrics, V103, P203; RAINEY TG, 1998, BREAKTHROUGH SERIES	15	144	152	1	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 8	2002	324	7350					1386	1389		10.1136/bmj.324.7350.1386	http://dx.doi.org/10.1136/bmj.324.7350.1386			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BQ	12052813	Green Published			2022-12-28	WOS:000176234100028
J	LiPuma, JJ; Spilker, T; Coenye, T; Gonzalez, CF				LiPuma, JJ; Spilker, T; Coenye, T; Gonzalez, CF			An epidemic Burkholderia cepacia complex strain identified in soil	LANCET			English	Article							ENDEMICITY	Life threatening infection with species of the Burkholderia cepacia complex frequently occurs as a result of cross Infection among Individuals with cystic fibrosis. Stringent infection control measures have decreased but not eliminated such infection in this vulnerable population, implying that non-patient reservoirs contribute to ongoing acquisition. However, strains common to both the natural environment and patients with cystic fibrosis have not yet been described. By use of various genotyping methods, we have identified from agricultural soil the B cepacia genomovar III strain that is most frequently recovered from cystic fibrosis patients in the mid-Atlantic region of the USA. This finding indicates that human pathogenic strains are not necessarily distinct from environmental strains, and might help explain ongoing human acquisition despite strict infection control measures.	Univ Michigan, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; Texas A&M Univ, Dept Plant Pathol & Microbiol, College Stn, TX 77843 USA	University of Michigan System; University of Michigan; Texas A&M University System; Texas A&M University College Station	LiPuma, JJ (corresponding author), Univ Michigan, Dept Pediat & Communicable Dis, 8323 MSRB III,Box 0646, Ann Arbor, MI 48109 USA.	jlipuma@umich.edu	Coenye, Tom/Z-1928-2019; Meis, Jacques F/A-9241-2010; Coenye, Tom/A-6291-2014	Coenye, Tom/0000-0002-6407-0601; Meis, Jacques F/0000-0003-3253-6080; Coenye, Tom/0000-0002-6407-0601				Chen JS, 2001, J PEDIATR-US, V139, P643, DOI 10.1067/mpd.2001.118430; Cho JC, 2000, APPL ENVIRON MICROB, V66, P5448, DOI 10.1128/AEM.66.12.5448-5456.2000; Holmes A, 1999, J INFECT DIS, V179, P1197, DOI 10.1086/314699; LiPuma JJ, 2001, AM J RESP CRIT CARE, V164, P92, DOI 10.1164/ajrccm.164.1.2011153; Parke JL, 2001, ANNU REV PHYTOPATHOL, V39, P225, DOI 10.1146/annurev.phyto.39.1.225	5	133	134	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 8	2002	359	9322					2002	2003		10.1016/S0140-6736(02)08836-0	http://dx.doi.org/10.1016/S0140-6736(02)08836-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076559				2022-12-28	WOS:000176232500016
J	Taylor, DM; Tillery, SIH; Schwartz, AB				Taylor, DM; Tillery, SIH; Schwartz, AB			Direct cortical control of 3D neuroprosthetic devices	SCIENCE			English	Article							COMPUTER; NEURONS	Three-dimensional (3D) movement of neuroprosthetic devices can be controlled by the activity of cortical neurons when appropriate algorithms are used to decode intended movement in real time. Previous studies assumed that neurons maintain fixed tuning properties, and the studies used subjects who were unaware of the movements predicted by their recorded units. In this study, subjects had real-time visual feedback of their brain-controlled trajectories. Cell tuning properties changed when used for brain-controlled movements. By using control algorithms that track these changes, subjects made long sequences of 3D movements using far fewer cortical units than expected. Daily practice improved movement accuracy and the directional tuning of these units.	Arizona State Univ, Dept Bioengn, Tempe, AZ 85287 USA; Inst Neurosci, San Diego, CA 92121 USA	Arizona State University; Arizona State University-Tempe	Schwartz, AB (corresponding author), Arizona State Univ, Dept Bioengn, Tempe, AZ 85287 USA.		Taylor, Dawn/J-2447-2015	Taylor, Dawn/0000-0002-9878-0054	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [N01NS062347, N01NS092321] Funding Source: NIH RePORTER; NINDS NIH HHS [N01-NS-6-2347, N01-NS-9-2321] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chapin JK, 1999, NAT NEUROSCI, V2, P664, DOI 10.1038/10223; Craggs M D, 1975, Adv Neurol, V10, P91; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2931; Kennedy PR, 2000, IEEE T REHABIL ENG, V8, P198, DOI 10.1109/86.847815; Shoham S, 2001, NATURE, V413, P793, DOI 10.1038/35101651; Wessberg J, 2000, NATURE, V408, P361, DOI 10.1038/35042582; Williams JC, 1999, NEUROCOMPUTING, V26-7, P1069, DOI 10.1016/S0925-2312(99)00106-X; Wolpaw JR, 2000, IEEE T REHABIL ENG, V8, P164, DOI 10.1109/TRE.2000.847807	8	1232	1296	7	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 7	2002	296	5574					1829	1832		10.1126/science.1070291	http://dx.doi.org/10.1126/science.1070291			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052948				2022-12-28	WOS:000176054300036
J	Katz, JN; Simmons, BP				Katz, JN; Simmons, BP			Carpal tunnel syndrome.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOCAL STEROID INJECTION; RISK-FACTORS; RELEASE; TRIAL; TERM; EFFICACY; SYMPTOMS; HISTORY	A 64-year-old, right-handed, retired woman presents with intermittent numbness, tingling, and burning pain in the three radial digits of both hands. She has had these symptoms for three months, and they awaken her several times each night. She has no atrophy of the thenar muscles. Sensation to light touch is intact. How should she be evaluated and treated?	Harvard Univ, Sch Med,Brigham & Womens Hosp, Robert B Brigham Arthrit Res Ctr, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Katz, JN (corresponding author), Harvard Univ, Sch Med,Brigham & Womens Hosp, Robert B Brigham Arthrit Res Ctr, Div Rheumatol Allergy & Immunol, 75 Francis St, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K24AR002123, P60AR047782] Funding Source: NIH RePORTER; NIAMS NIH HHS [P60 AR 47782, K24 AR 02123] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGEE JM, 1992, J HAND SURG-AM, V17A, P987, DOI 10.1016/S0363-5023(09)91044-9; *AM AC ORTH SURG, 1996, CLIN GUID WRIST PAIN, V10, P2002; Atcheson SG, 1998, ARCH INTERN MED, V158, P1506, DOI 10.1001/archinte.158.14.1506; Atroshi I, 1999, JAMA-J AM MED ASSOC, V282, P153, DOI 10.1001/jama.282.2.153; Ayhan-Ardic FF, 2000, FUNCT NEUROL, V15, P157; BANTA CA, 1994, J OCCUP ENVIRON MED, V36, P166, DOI 10.1097/00043764-199402000-00012; Bernard B. P., 1997, DHHS NIOSH PUBLICATI; BROWN RA, 1993, J BONE JOINT SURG AM, V75A, P1265, DOI 10.2106/00004623-199309000-00002; BUCHJAEGER N, 1994, J HAND SURG-BRIT EUR, V19B, P720, DOI 10.1016/0266-7681(94)90244-5; BURKE DT, 1994, ARCH PHYS MED REHAB, V75, P1241, DOI 10.1016/0003-9993(94)90012-4; Chang MH, 1998, NEUROLOGY, V51, P390, DOI 10.1212/WNL.51.2.390; Chow JCY, 1999, ARTHROSCOPY, V15, P417, DOI 10.1016/S0749-8063(99)70060-5; D'Arcy CA, 2000, JAMA-J AM MED ASSOC, V283, P3110, DOI 10.1001/jama.283.23.3110; Dammers JWHH, 1999, BRIT MED J, V319, P884, DOI 10.1136/bmj.319.7214.884; DArcy CA, 2000, JAMA-J AM MED ASSOC, V284, P1384; Davis PT, 1998, J MANIP PHYSIOL THER, V21, P317; Dennerlein JT, 2002, J OCCUP ENVIRON MED, V44, P176, DOI 10.1097/00043764-200202000-00013; DURKAN JA, 1991, J BONE JOINT SURG AM, V73A, P535, DOI 10.2106/00004623-199173040-00009; DURKAN JA, 1992, J BONE JOINT SURG AM, V74, P311; Ferry S, 1998, ARTHRITIS RHEUM, V41, P720, DOI 10.1002/1529-0131(199804)41:4<720::AID-ART20>3.0.CO;2-6; FRANZBLAU A, 1994, J OCCUP REHABIL, V4, P185, DOI 10.1007/BF02331615; Garfinkel MS, 1998, JAMA-J AM MED ASSOC, V280, P1601, DOI 10.1001/jama.280.18.1601; GELBERMAN RH, 1980, J BONE JOINT SURG AM, V62, P1181, DOI 10.2106/00004623-198062070-00020; GELBERMAN RH, 1988, ORTHOP CLIN N AM, V19, P115; GERR F, 1995, J OCCUP ENVIRON MED, V37, P1108, DOI 10.1097/00043764-199509000-00012; GIANNINI F, 1991, ARCH PHYS MED REHAB, V72, P738; GIRLANDA P, 1993, J NEUROL, V240, P187, DOI 10.1007/BF00857526; GOLDING DN, 1986, BRIT J RHEUMATOL, V25, P388; HALLOCK GG, 1995, PLAST RECONSTR SURG, V96, P941, DOI 10.1097/00006534-199509001-00027; HAMANAKA I, 1995, J HAND SURG-AM, V20A, P848, DOI 10.1016/S0363-5023(05)80442-3; HARRIS JS, 1998, OCCUPATIONAL MED PRA; Homan MM, 1999, SCAND J WORK ENV HEA, V25, P115, DOI 10.5271/sjweh.413; Institute of Medicine and National Research Council, 2001, MUSC DIS WORKPL LOW; KATZ JN, 1995, J HAND SURG-AM, V20A, P549, DOI 10.1016/S0363-5023(05)80265-5; KATZ JN, 1990, ANN INTERN MED, V112, P321, DOI 10.7326/0003-4819-112-5-321; Katz JN, 1998, J HAND SURG-AM, V23A, P697, DOI 10.1016/S0363-5023(98)80058-0; Katz JN, 1999, J HAND SURG-AM, V24A, P201; Katz JN, 2001, ARTHRITIS RHEUM-US, V44, P1184, DOI 10.1002/1529-0131(200105)44:5<1184::AID-ANR202>3.3.CO;2-1; Nathan PA, 1998, MUSCLE NERVE, V21, P711, DOI 10.1002/(SICI)1097-4598(199806)21:6<711::AID-MUS2>3.3.CO;2-D; PHALEN GS, 1966, J BONE JOINT SURG AM, VA 48, P211, DOI 10.2106/00004623-196648020-00001; Praemer A., 1992, MUSCULOSKELETAL COND, P143; PRYSEPHILLIPS WEM, 1984, J NEUROL NEUROSUR PS, V47, P870, DOI 10.1136/jnnp.47.8.870; Rempel D, 1999, J BONE JOINT SURG AM, V81A, P1600, DOI 10.2106/00004623-199911000-00013; Rempel D, 1998, AM J PUBLIC HEALTH, V88, P1447, DOI 10.2105/AJPH.88.10.1447; Roquelaure Y, 1997, SCAND J WORK ENV HEA, V23, P364, DOI 10.5271/sjweh.233; SERADGE H, 1995, J HAND SURG-AM, V20A, P855, DOI 10.1016/S0363-5023(05)80443-5; SILVERSTEIN B, 1999, 4021999 SHARP PROGR; Solomon DH, 1999, J GEN INTERN MED, V14, P310, DOI 10.1046/j.1525-1497.1999.00340.x; STEVENS JC, 1992, MAYO CLIN PROC, V67, P541, DOI 10.1016/S0025-6196(12)60461-3; Vasen AP, 1999, J HAND SURG-AM, V24A, P1109; Walker WC, 2000, ARCH PHYS MED REHAB, V81, P424, DOI 10.1053/mr.2000.3856	51	172	176	1	17	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	2002	346	23					1807	1812		10.1056/NEJMcp013018	http://dx.doi.org/10.1056/NEJMcp013018			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	559EK	12050342				2022-12-28	WOS:000176012500009
J	Funamoto, S; Meili, R; Lee, S; Parry, L; Firtel, RA				Funamoto, S; Meili, R; Lee, S; Parry, L; Firtel, RA			Spatial and temporal regulation of 3-phosphoinositides by PI 3-kinase and PTEN mediates chemotaxis	CELL			English	Article							PLECKSTRIN-HOMOLOGY-DOMAIN; DICTYOSTELIUM-DISCOIDEUM; CHEMOATTRACTANT RECEPTOR; MEMBRANE LOCALIZATION; GENE-EXPRESSION; CELL-MIGRATION; LIVING CELLS; PROTEIN; KINASE; PI3K-GAMMA	We have investigated the mechanisms of leading edge formation in chemotaxing Dictyostelium cells. We demonstrate that while phosphatidylinositol 3-kinase (PI3K) transiently translocates to the plasma membrane in response to chemoattractant stimulation and to the leading edge in chemotaxing cells, PTEN, a negative regulator of PI3K pathways, exhibits a reciprocal pattern of localization. By uniformly localizing PI3K along the plasma membrane, we show that chemotaxis pathways are activated along the lateral sides of cells and PI3K can initiate pseudopod formation, providing evidence for a direct instructional role of PI3K in leading edge formation. These findings provide evidence that differential subcellular localization and activation of PI3K and PTEN is required for proper chemotaxis.	Univ Calif San Diego, Ctr Mol Genet, Div Biol, Sect Cell & Dev Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Firtel, RA (corresponding author), Univ Calif San Diego, Ctr Mol Genet, Div Biol, Sect Cell & Dev Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	rafirtel@ucsd.edu						Blaauw M, 2000, GENE, V252, P71, DOI 10.1016/S0378-1119(00)00227-4; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Chung CY, 1999, J CELL BIOL, V147, P559, DOI 10.1083/jcb.147.3.559; Chung CY, 2001, MOL CELL, V7, P937, DOI 10.1016/S1097-2765(01)00247-7; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Firtel RA, 2000, BIOESSAYS, V22, P603, DOI 10.1002/1521-1878(200007)22:7<603::AID-BIES3>3.0.CO;2-#; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Fukui Y, 2001, NATURE, V412, P826, DOI 10.1038/35090591; Funamoto S, 2001, J CELL BIOL, V153, P795, DOI 10.1083/jcb.153.4.795; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Katanaev VL, 2001, BIOCHEMISTRY-MOSCOW+, V66, P351, DOI 10.1023/A:1010293809553; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Lee S, 1999, MOL BIOL CELL, V10, P2829, DOI 10.1091/mbc.10.9.2829; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Lim CJ, 2001, EMBO J, V20, P4490, DOI 10.1093/emboj/20.16.4490; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Meili R, 2000, CURR BIOL, V10, P708, DOI 10.1016/S0960-9822(00)00536-4; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Tuxworth RI, 1997, J CELL BIOL, V138, P605, DOI 10.1083/jcb.138.3.605; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Wessels D, 1998, TECH MOD B, P101; Xiao Z, 1997, J CELL BIOL, V139, P365, DOI 10.1083/jcb.139.2.365; ZHOU KM, 1995, MOL CELL BIOL, V15, P5645	36	598	604	0	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 31	2002	109	5					611	623		10.1016/S0092-8674(02)00755-9	http://dx.doi.org/10.1016/S0092-8674(02)00755-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	558GL	12062104	Bronze			2022-12-28	WOS:000175957900010
J	Heissig, B; Hattori, K; Dias, S; Friedrich, M; Ferris, B; Hackett, NR; Crystal, RG; Besmer, P; Lyden, D; Moore, MAS; Werb, Z; Rafii, S				Heissig, B; Hattori, K; Dias, S; Friedrich, M; Ferris, B; Hackett, NR; Crystal, RG; Besmer, P; Lyden, D; Moore, MAS; Werb, Z; Rafii, S			Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of Kit-ligand	CELL			English	Article							ENDOTHELIAL GROWTH-FACTOR; COLONY-STIMULATING FACTOR; HEMATOPOIETIC PROGENITOR; FACTOR-I; MATRIX METALLOPROTEINASES; GELATINASE-B; MOBILIZATION; MATRIX-METALLOPROTEINASE-9; EXPRESSION; VIVO	Stem cells within the bone marrow (BM) exist in a quiescent state or are instructed to differentiate and mobilize to circulation following specific signals. Matrix metalloproteinase-9 (MMP-9), induced in BM cells, releases soluble Kit-ligand (sKitL), permitting the transfer of endothelial and hematopoietic stem cells (HSCs) from the quiescent to proliferative niche. BM ablation induces SDF-1, which upregulates MMP-9 expression, and causes shedding of sKitL and recruitment of c-Kit(+) stem/progenitors. In MMP-9(-/-) mice, release of sKitL and HSC motility are impaired, resulting in failure of hematopoietic recovery and increased mortality, while exogenous sKitL restores hematopoiesis and survival after BM ablation. Release of sKitL by MMP-9 enables BM repopulating cells to translocate to a permissive vascular niche favoring differentiation and reconstitution of the stem/progenitor cell pool.	Cornell Univ, Coll Med, Dept Hematol Oncol, New York, NY 10021 USA; Sloan Kettering Inst Canc Res, New York, NY 10021 USA; Cornell Univ, Coll Med, Div Med Genet, New York, NY 10021 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; University of California System; University of California San Francisco	Rafii, S (corresponding author), Cornell Univ, Coll Med, Dept Hematol Oncol, 1300 York Ave,Room D601, New York, NY 10021 USA.		Heissig, Beate/AAF-6771-2021; Dias, Sergio/L-1250-2014	Heissig, Beate/0000-0002-0348-5934; Dias, Sergio/0000-0002-7603-4616	NCI NIH HHS [P01 CA072006-07, CA 75072, R01 CA075072-03, P01 CA072006, CA 72006] Funding Source: Medline; NHLBI NIH HHS [R01 HL061849, HL-58707, HL-66592, HL-67839, HL-61849, P01 HL067839] Funding Source: Medline; NIAMS NIH HHS [R01 AR046238-06A2, R01 AR046238, AR 46238] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072006, R01CA075072] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067839, R01HL061849, R01HL058707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046238] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879; Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; HEINRICH MC, 1993, BLOOD, V82, P771, DOI 10.1182/blood.V82.3.771.bloodjournal823771; HUANG CY, 1992, NAT PROD LETT, V1, P3; Jo DY, 2000, J CLIN INVEST, V105, P101, DOI 10.1172/JCI7954; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kridel SJ, 2001, J BIOL CHEM, V276, P20572, DOI 10.1074/jbc.M100900200; Lane WJ, 2000, BLOOD, V96, P4152; Levesque JP, 2001, BLOOD, V98, P1289, DOI 10.1182/blood.V98.5.1289; LONG MW, 1992, J CLIN INVEST, V90, P251, DOI 10.1172/JCI115844; Longley BJ, 1997, P NATL ACAD SCI USA, V94, P9017, DOI 10.1073/pnas.94.17.9017; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Marquez-Curtis LA, 2001, BRIT J HAEMATOL, V115, P595, DOI 10.1046/j.1365-2141.2001.03160.x; Masure S, 1997, EUR J BIOCHEM, V244, P21, DOI 10.1111/j.1432-1033.1997.00021.x; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Morrison SJ, 1997, P NATL ACAD SCI USA, V94, P1908, DOI 10.1073/pnas.94.5.1908; MURPHY G, 1982, BIOCHEM J, V203, P209, DOI 10.1042/bj2030209; Ohta H, 2000, DEVELOPMENT, V127, P2125; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Papayannopoulou T, 1998, BLOOD, V91, P2231, DOI 10.1182/blood.V91.7.2231.2231_2231_2239; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Ponomaryov T, 2000, J CLIN INVEST, V106, P1331, DOI 10.1172/JCI10329; Pruijt JFM, 1999, P NATL ACAD SCI USA, V96, P10863, DOI 10.1073/pnas.96.19.10863; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Tajima Y, 1998, P NATL ACAD SCI USA, V95, P11903, DOI 10.1073/pnas.95.20.11903; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Xie T, 2000, SCIENCE, V290, P328, DOI 10.1126/science.290.5490.328	35	1378	1507	1	98	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 31	2002	109	5					625	637		10.1016/S0092-8674(02)00754-7	http://dx.doi.org/10.1016/S0092-8674(02)00754-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	558GL	12062105	Bronze, Green Accepted			2022-12-28	WOS:000175957900011
J	Callaway, RM; Brooker, RW; Choler, P; Kikvidze, Z; Lortie, CJ; Michalet, R; Paolini, L; Pugnaire, FI; Newingham, B; Aschehoug, ET; Armas, C; Kikodze, D; Cook, BJ				Callaway, RM; Brooker, RW; Choler, P; Kikvidze, Z; Lortie, CJ; Michalet, R; Paolini, L; Pugnaire, FI; Newingham, B; Aschehoug, ET; Armas, C; Kikodze, D; Cook, BJ			Positive interactions among alpine plants increase with stress	NATURE			English	Article							COMPETITION; GRADIENTS; BALANCE; MODEL	Plants can have positive effects on each other(1). For example, the accumulation of nutrients, provision of shade, amelioration of disturbance, or protection from herbivores by some species can enhance the performance of neighbouring species. Thus the notion that the distributions and abundances of plant species are independent of other species may be inadequate as a theoretical underpinning for understanding species coexistence and diversity(2). But there have been no large-scale experiments designed to examine the generality of positive interactions in plant communities and their importance relative to competition. Here we show that the biomass, growth and reproduction of alpine plant species are higher when other plants are nearby. In an experiment conducted in subalpine and alpine plant communities with 115 species in 11 different mountain ranges, we find that competition generally, but not exclusively, dominates interactions at lower elevations where conditions are less physically stressful. In contrast, at high elevations where abiotic stress is high the interactions among plants are predominantly positive. Furthermore, across all high and low sites positive interactions are more important at sites with low temperatures in the early summer, but competition prevails at warmer sites.	Univ Montana, Div Biol Sci, Missoula, MT 59812 USA; CEH Banchory Res Stn, Ctr Ecol & Hydrol, Banchory AB31 4BY, Kincardine, Scotland; Univ Grenoble 1, CNRS, UMR 5553, Stn Alpine Lautaret, F-38041 Grenoble, France; Univ Grenoble 1, CNRS, UMR 5553, Lab Biol Populat Altitude, F-38041 Grenoble, France; Georgian Acad Sci, Inst Bot, GE-380007 Tbilisi, Georgia; Univ British Columbia, Dept Bot, Vancouver, BC V6T 1Z4, Canada; UNT, Lab Invest Ecol Yungas, Yerba Buena, Tucuman, Argentina; CSIC, Estac Expt Zonas Aridas, Almeria 04001, Spain	University of Montana System; University of Montana; UK Centre for Ecology & Hydrology (UKCEH); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite de Savoie; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite de Savoie; National Academy of Sciences of Georgia; University of British Columbia; Universidad Nacional de Tucuman; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental de Zonas Aridas (EEZA)	Callaway, RM (corresponding author), Univ Montana, Div Biol Sci, Missoula, MT 59812 USA.	callaway@selway.umt.edu	Brooker, Rob W/F-9569-2012; Choler, Philippe/A-7270-2008; lortie, christopher j/F-6241-2014; Kikvidze, Zaal/ABC-7252-2021; Armas, Cristina/A-1128-2012; Pugnaire, Francisco I./A-7150-2008	Brooker, Rob W/0000-0002-7014-0071; Choler, Philippe/0000-0002-9062-2721; lortie, christopher j/0000-0002-4291-7023; Kikvidze, Zaal/0000-0002-5007-4484; Armas, Cristina/0000-0003-0356-8075; Pugnaire, Francisco I./0000-0002-1227-6827; Newingham, Beth A./0000-0002-3324-500X; Paolini, Leonardo/0000-0001-8556-2712				[Anonymous], 2001, PLANT STRATEGIES VEG; [Anonymous], 1975, COMMUNITIES ECOSYSTE; Archibold O. W, 1995, ECOLOGY WORLD VEGETA, P280; AUSTIN MP, 1985, ANNU REV ECOL SYST, V16, P39, DOI 10.1146/annurev.es.16.110185.000351; BEGON M, 1990, ECOLOGY, P626; Berlow EL, 1999, NATURE, V398, P330, DOI 10.1038/18672; BERTNESS MD, 1994, TRENDS ECOL EVOL, V9, P191, DOI 10.1016/0169-5347(94)90088-4; Brooker RW, 1998, OIKOS, V81, P196, DOI 10.2307/3546481; Callaway RM, 1998, OIKOS, V82, P202, DOI 10.2307/3546931; Callaway RM, 1997, OECOLOGIA, V112, P143, DOI 10.1007/s004420050293; Choler P, 2001, ECOLOGY, V82, P3295, DOI 10.1890/0012-9658(2001)082[3295:FACOGI]2.0.CO;2; CONNELL JH, 1983, AM NAT, V122, P661, DOI 10.1086/284165; Curtis JT, 1959, VEGETATION WISCONSIN; Dodds WK, 1997, OIKOS, V78, P377, DOI 10.2307/3546305; Gleason H.A., 1926, B TORREY BOT CLUB, V53, P7, DOI DOI 10.2307/2479933; GRIME JP, 1977, AM NAT, V111, P1169, DOI 10.1086/283244; JOHNSON HB, 1992, J RANGE MANAGE, V45, P322, DOI 10.2307/4003077; Markham JH, 1996, FUNCT ECOL, V10, P548; MILLER TE, 1994, AM NAT, V143, P1007, DOI 10.1086/285646; PRENTICE IC, 1992, J BIOGEOGR, V19, P117, DOI 10.2307/2845499; Pugnaire FI, 2001, OIKOS, V93, P42, DOI 10.1034/j.1600-0706.2001.930104.x; *SAS I INC, 2000, JIMPIN 4 0 2; Shaver GR, 1999, POLAR RES, V18, P245, DOI 10.1111/j.1751-8369.1999.tb00300.x; WHITTAKER RH, 1953, ECOL MONOGR, V23, P41, DOI 10.2307/1943519; WOODWARD FI, 1995, GLOBAL BIOGEOCHEM CY, V9, P471, DOI 10.1029/95GB02432	25	1392	1506	24	727	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 20	2002	417	6891					844	848		10.1038/nature00812	http://dx.doi.org/10.1038/nature00812			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075350				2022-12-28	WOS:000176285600045
J	Adachi, JA; Mathewson, JJ; Jiang, ZD; Ericsson, CD; DuPont, HL				Adachi, JA; Mathewson, JJ; Jiang, ZD; Ericsson, CD; DuPont, HL			Enteric pathogens in Mexican sauces of popular restaurants in Guadalajara, Mexico, and Houston, Texas	ANNALS OF INTERNAL MEDICINE			English	Article							ENTEROAGGREGATIVE ESCHERICHIA-COLI; TRAVELERS DIARRHEA; FOOD-CONSUMPTION; LOCATION	Background: The transmission of traveler's diarrhea is primarily foodborne. Objective: To examine the level of microbial contamination of tabletop sauces found in Mexican-style restaurants. Design: Cross-sectional study of Mexican sauces. Setting: Mexican restaurants in Guadalajara, Mexico, and Houston, Texas, during the summer of 1998. Measurements: 71 sauces from Guadalajara and 25 sauces from Houston were examined. The number of sauces contaminated with Escherichia coli, the median number of E. coli colonies per gram of sauce, and enteropathogens were identified. Results: 47 of 71 sauces from Guadalajara were contaminated with E. coli versus 10 of 25 sauces from Houston (P = 0.03); the median number of E. coli colonies per gram of sauce was 1000 In the Guadalajara sauces versus 0.0 in the Houston sauces (P = 0.007). Among sauces from Guadalajara tested for diarrheogenic E. coli, 4 of 43 sauces contained enterotoxigenic E. coli and 14 of 32 contained enteroaggregative E. coli. Conclusions: contamination with E. coli was common In samples of Mexican tabletop sauces from Guadalajara restaurants. These sauces commonly contained enteric pathogens.	Univ Texas, St Lukes Episcopal Hosp, Internal Med Serv, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA	Saint Lukes Episcopal Hospital; University of Texas System; Baylor College of Medicine	DuPont, HL (corresponding author), Univ Texas, St Lukes Episcopal Hosp, Internal Med Serv, 6720 Bertner Ave,MC 1-164, Houston, TX 77030 USA.	hdupont@sleh.com	DuPont, Herbert/AAH-6776-2021					Adachi JA, 2001, CLIN INFECT DIS, V32, P1706, DOI 10.1086/320756; ADACHI JA, 2002, IN PRESS J INFECT DI; Bower CK, 1999, INT J FOOD MICROBIOL, V50, P33, DOI 10.1016/S0168-1605(99)00075-6; Brudzinski L, 1998, J FOOD PROTECT, V61, P542, DOI 10.4315/0362-028X-61.5.542; DUPONT HL, 1992, JAMA-J AM MED ASSOC, V267, P1932, DOI 10.1001/jama.267.14.1932; ERICSSON CD, 1980, GASTROENTEROLOGY, V79, P812; FENG PCS, 1982, APPL ENVIRON MICROB, V43, P1320, DOI 10.1128/AEM.43.6.1320-1329.1982; FRAMPTON EW, 1993, J APPL BACTERIOL, V74, P223, DOI 10.1111/j.1365-2672.1993.tb03019.x; Jiang ZD, 2002, J INFECT DIS, V185, P497, DOI 10.1086/338834; Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403; NATARO JP, 1995, J INFECT DIS, V171, P465, DOI 10.1093/infdis/171.2.465; TJOA WS, 1977, AM J EPIDEMIOL, V106, P61, DOI 10.1093/oxfordjournals.aje.a112433; von Sonnenburg F, 2000, LANCET, V356, P133, DOI 10.1016/S0140-6736(00)02451-X; WOOD LV, 1983, APPL ENVIRON MICROB, V46, P328, DOI 10.1128/AEM.46.2.328-332.1983	14	55	56	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 18	2002	136	12					884	887		10.7326/0003-4819-136-12-200206180-00009	http://dx.doi.org/10.7326/0003-4819-136-12-200206180-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563JL	12069562				2022-12-28	WOS:000176252500005
J	Hendrickson, BA; Turner, JR				Hendrickson, BA; Turner, JR			MMR vaccination, ileal lymphoid nodular hyperplasia, and pervasive developmental disorder	LANCET			English	Editorial Material							INFLAMMATORY-BOWEL-DISEASE; POLYMERASE CHAIN-REACTION; MEASLES-VIRUS; CHILDREN; INTESTINE; COLITIS; DNA		Univ Chicago, Sect Pediat Infect Dis, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Hendrickson, BA (corresponding author), Univ Chicago, Sect Pediat Infect Dis, Chicago, IL 60637 USA.	bhendric@peds.bsd.uchicago.edu	Turner, Jerrold/H-1502-2019; Turner, Jerrold R/A-6895-2009	Turner, Jerrold R/0000-0003-0627-9455				Afzal MA, 2000, B WORLD HEALTH ORGAN, V78, P199; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P65; Fombonne E, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e58; Gerber MA, 2001, PEDIATRICS, V107, P612, DOI 10.1542/peds.107.5.e84; Horvath K, 1999, J PEDIATR-US, V135, P559, DOI 10.1016/S0022-3476(99)70052-1; Iizuka M, 2000, GUT, V46, P163, DOI 10.1136/gut.46.2.163; Kawashima H, 2000, DIGEST DIS SCI, V45, P723, DOI 10.1023/A:1005443726670; LEWIN J, 1995, GUT, V36, P564, DOI 10.1136/gut.36.4.564; Torrente F, 2002, MOL PSYCHIATR, V7, P375, DOI 10.1038/sj/mp/4001077; Uhlmann V, 2002, J CLIN PATHOL-MOL PA, V55, P84, DOI 10.1136/mp.55.2.84; VERNON SD, 1993, 12 INT PAP C; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; WAKEFIELD AJ, 1992, J MED VIROL, V38, P183, DOI 10.1002/jmv.1890380306; Wakefield AJ, 2000, AM J GASTROENTEROL, V95, P2285; *WHO, 2001, ADV EV FOLL MEASL MU; ZITZ JC, 1994, MODERN PATHOL, V7, P407; 1998, COMMUN DIS REP CDR W, V8, P113	17	4	4	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 15	2002	359	9323					2051	2052		10.1016/S0140-6736(02)08948-1	http://dx.doi.org/10.1016/S0140-6736(02)08948-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086756				2022-12-28	WOS:000176194600004
J	Feachem, RGA; Medlin, CA				Feachem, RGA; Medlin, CA			Global public goods: Health is wealth	NATURE			English	Editorial Material									Univ Calif San Francisco, Inst Global Hlth, San Francisco, CA 94105 USA; Univ Calif Berkeley, Inst Global Hlth, San Francisco, CA 94105 USA	University of California System; University of California San Francisco; University of California System; University of California Berkeley	Feachem, RGA (corresponding author), Univ Calif San Francisco, Inst Global Hlth, 74 New Montgomery St, San Francisco, CA 94105 USA.							*WHO, 2001, REP COMM MACR HLTH	1	9	9	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 13	2002	417	6890					695	695		10.1038/417695a	http://dx.doi.org/10.1038/417695a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	561QY	12066165	Bronze			2022-12-28	WOS:000176154700026
J	Hainzl, T; Huang, SH; Sauer-Eriksson, AE				Hainzl, T; Huang, SH; Sauer-Eriksson, AE			Structure of the SRP19-RNA complex and implications for signal recognition particle assembly	NATURE			English	Article							CRYSTAL-STRUCTURE; RNA; DOMAIN	The signal recognition particle (SRP) is a phylogenetically conserved ribonucleoprotein. It associates with ribosomes to mediate co-translational targeting of membrane and secretory proteins to biological membranes. In mammalian cells, the SRP consists of a 7S RNA and six protein components. The S domain of SRP comprises the 7S. S part of RNA bound to SRP19, SRP54 and the SRP68/72 heterodimer; SRP54 has the main role in recognizing signal sequences of nascent polypeptide chains and docking SRP to its receptor(1-3). During assembly of the SRP, binding of SRP19 precedes and promotes the association of SRP54 (refs 4, 5). Here we report the crystal structure at 2.3 Angstrom resolution of the complex formed between 7S. S RNA and SRP19 in the archaeon Methanococcus jannaschii. SRP19 bridges the tips of helices 6 and 8 of 7S. S RNA by forming an extensive network of direct protein-RNA interactions. Helices 6 and 8 pack side by side; tertiary RNA interactions, which also involve the strictly conserved tetraloop bases, stabilize helix 8 in a conformation competent for SRP54 binding. The structure explains the role of SRP19 and provides a molecular framework for SRP54 binding and SRP assembly in Eukarya and Archaea.	Umea Univ, Umea Ctr Mol Pathogenesis, SE-90187 Umea, Sweden	Umea University	Hainzl, T (corresponding author), Umea Univ, Umea Ctr Mol Pathogenesis, SE-90187 Umea, Sweden.	tobias.hainzl@ucmp.umu.se		Sauer-Eriksson, Elisabeth/0000-0003-0124-0199				ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; Agalarov SC, 2000, SCIENCE, V288, P107, DOI 10.1126/science.288.5463.107; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Batey RT, 2000, SCIENCE, V287, P1232, DOI 10.1126/science.287.5456.1232; Bhuiyan SH, 2000, NUCLEIC ACIDS RES, V28, P1365, DOI 10.1093/nar/28.6.1365; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clemons WM, 1999, J MOL BIOL, V292, P697, DOI 10.1006/jmbi.1999.3090; Correll CC, 1997, CELL, V91, P705, DOI 10.1016/S0092-8674(00)80457-2; Diener JL, 2000, BIOCHEMISTRY-US, V39, P12862, DOI 10.1021/bi001180s; Gorodkin J, 2001, NUCLEIC ACIDS RES, V29, P169, DOI 10.1093/nar/29.1.169; Harris M, 2001, ACTA CRYSTALLOGR D, V57, P1201, DOI 10.1107/S0907444901007697; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jovine L, 2000, STRUCTURE, V8, P527, DOI 10.1016/S0969-2126(00)00137-4; Jucker FM, 1996, J MOL BIOL, V264, P968, DOI 10.1006/jmbi.1996.0690; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Politz JC, 2000, P NATL ACAD SCI USA, V97, P55, DOI 10.1073/pnas.97.1.55; PRICE SR, 1995, J MOL BIOL, V249, P398, DOI 10.1006/jmbi.1995.0305; Rose MA, 2001, NAT STRUCT BIOL, V8, P515, DOI 10.1038/88577; UHLENBECK OC, 1990, NATURE, V346, P613, DOI 10.1038/346613a0; WALTER P, 1983, CELL, V34, P525, DOI 10.1016/0092-8674(83)90385-9; Weichenrieder O, 2000, NATURE, V408, P167, DOI 10.1038/35041507; Wild K, 1999, STRUCTURE, V7, P1345, DOI 10.1016/S0969-2126(00)80024-6; Wild K, 2002, CURR OPIN STRUC BIOL, V12, P72, DOI 10.1016/S0959-440X(02)00292-0; Wild K, 2001, SCIENCE, V294, P598, DOI 10.1126/science.1063839; ZWIEB C, 1994, EUR J BIOCHEM, V222, P885, DOI 10.1111/j.1432-1033.1994.tb18936.x; ZWIEB C, 1992, J BIOL CHEM, V267, P15650	29	86	89	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	2002	417	6890					767	771		10.1038/nature00768	http://dx.doi.org/10.1038/nature00768			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	561QY	12050674				2022-12-28	WOS:000176154700051
J	Shankar, N; Baghdayan, AS; Gilmore, MS				Shankar, N; Baghdayan, AS; Gilmore, MS			Modulation of virulence within a pathogenicity island in vancomycin-resistant Enterococcus faecalis	NATURE			English	Article							VARIANT ESP GENE; AGGREGATION SUBSTANCE; SURFACE PROTEIN; NUCLEOTIDE-SEQUENCE; INFECTION; IDENTIFICATION; EXPRESSION; GENTAMICIN; FAECIUM	Enterococci are members of the healthy human intestinal flora, but are also leading causes of highly antibiotic-resistant, hospital-acquired infection(1). We examined the genomes of a strain of Enterococcus faecalis that caused an infectious outbreak in a hospital ward in the mid-1980s (ref. 2), and a strain that was identified as the first vancomycin-resistant isolate in the United States(3), and found that virulence determinants were clustered on a large pathogenicity island, a genetic element previously unknown in this genus. The pathogenicity island, which varies only subtly between strains, is approximately 150 kilobases in size, has a lower G + C content than the rest of the genome, and is flanked by terminal repeats. Here we show that subtle variations within the structure of the pathogenicity island enable strains harbouring the element to modulate virulence, and that these variations occur at high frequency. Moreover, the enterococcal pathogenicity island, in addition to coding for most known auxiliary traits that enhance virulence of the organism, includes a number of additional, previously unstudied genes that are rare in non-infection-derived isolates, identifying a class of new targets associated with disease which are not essential for the commensal behaviour of the organism.	Univ Oklahoma, Hlth Sci Ctr, Dept Pharmaceut Sci, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Shankar, N (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Pharmaceut Sci, POB 26901, Oklahoma City, OK 73190 USA.	nathan-shankar@ouhsc.edu						ARTHUR M, 1993, ANTIMICROB AGENTS CH, V37, P1563, DOI 10.1128/AAC.37.8.1563; Baldassarri L, 2001, LANCET, V357, P1802, DOI 10.1016/S0140-6736(00)04919-9; Brown JS, 2001, MOL MICROBIOL, V40, P572, DOI 10.1046/j.1365-2958.2001.02414.x; DODD HM, 1994, J BACTERIOL, V176, P3393, DOI 10.1128/jb.176.11.3393-3396.1994; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; Fierer J, 2001, J CLIN INVEST, V107, P775, DOI 10.1172/JCI12561; Francia MV, 2001, PLASMID, V46, P117, DOI 10.1006/plas.2001.1533; GALLI D, 1991, J BACTERIOL, V173, P3029, DOI 10.1128/JB.173.9.3029-3033.1991; Giard JC, 2000, J BACTERIOL, V182, P4512, DOI 10.1128/JB.182.16.4512-4520.2000; GOLD OG, 1975, ARCH ORAL BIOL, V20, P473, DOI 10.1016/0003-9969(75)90236-8; Haas W, 2002, NATURE, V415, P84, DOI 10.1038/415084a; Hacker J, 2000, ANNU REV MICROBIOL, V54, P641, DOI 10.1146/annurev.micro.54.1.641; Huang CC, 1999, GENE, V239, P361, DOI 10.1016/S0378-1119(99)00388-1; HUYCKE MM, 1991, ANTIMICROB AGENTS CH, V35, P1626, DOI 10.1128/AAC.35.8.1626; IKE Y, 1984, INFECT IMMUN, V45, P528, DOI 10.1128/IAI.45.2.528-530.1984; JETT BD, 1994, CLIN MICROBIOL REV, V7, P462, DOI 10.1128/CMR.7.4.462-478.1994; Novick RP, 2001, MICROBES INFECT, V3, P585, DOI 10.1016/S1286-4579(01)01414-9; Rakita RM, 1999, INFECT IMMUN, V67, P6067, DOI 10.1128/IAI.67.11.6067-6075.1999; Richards MJ, 2000, INFECT CONT HOSP EP, V21, P510, DOI 10.1086/501795; ROUCH DA, 1987, J GEN MICROBIOL, V133, P3039; Rozdzinski E, 2001, MICROB PATHOGENESIS, V30, P211, DOI 10.1006/mpat.2000.0429; Rutherford K, 2000, BIOINFORMATICS, V16, P944, DOI 10.1093/bioinformatics/16.10.944; SAHM DF, 1989, ANTIMICROB AGENTS CH, V33, P1588, DOI 10.1128/AAC.33.9.1588; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; Shankar N, 2001, INFECT IMMUN, V69, P4366, DOI 10.1128/IAI.69.7.4366-4372.2001; Shankar V, 1999, INFECT IMMUN, V67, P193, DOI 10.1128/IAI.67.1.193-200.1999; Toledo-Arana A, 2001, APPL ENVIRON MICROB, V67, P4538, DOI 10.1128/AEM.67.10.4538-4545.2001; Willems RJL, 2001, LANCET, V357, P853, DOI 10.1016/S0140-6736(00)04205-7; Woodford N, 2001, LANCET, V358, P584, DOI 10.1016/S0140-6736(01)05726-9	29	274	302	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	2002	417	6890					746	750		10.1038/nature00802	http://dx.doi.org/10.1038/nature00802			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	561QY	12066186				2022-12-28	WOS:000176154700046
J	Contractor, A; Rogers, C; Maron, C; Henkemeyer, M; Swanson, GT; Heinemann, SF				Contractor, A; Rogers, C; Maron, C; Henkemeyer, M; Swanson, GT; Heinemann, SF			Trans-synaptic Eph receptor-ephrin signaling in hippocampal mossy fiber LTP	SCIENCE			English	Article							LONG-TERM POTENTIATION; TRANSMEMBRANE LIGANDS; KAINATE RECEPTORS; AMPA RECEPTORS; SYNAPSES; PROTEIN; PHOSPHORYLATION; NEURONS; PLASTICITY; RESPONSES	The site of induction of long-term potentiation (LTP) at mossy fiber-CA3 synapses in the hippocampus is unresolved, with data supporting both pre- and postsynaptic mechanisms. Here we report that mossy fiber LTP was reduced by perfusion of postsynaptic neurons with peptides and antibodies that interfere with binding of EphB receptor tyrosine kinases (EphRs) to the PDZ protein GRIP. Mossy fiber LTP was also reduced by extracellular application of soluble forms of B-ephrins, which are normally membrane-anchored presynaptic ligands for the EphB receptors. The application of soluble ligands for presynaptic ephrins increased basal excitatory transmission and occluded both tetanus and forskolin-induced synaptic potentiation. These findings suggest that PDZ interactions in the postsynaptic neuron and trans-synaptic interactions between postsynaptic EphB receptors and presynaptic B-ephrins are necessary for the induction of mossy fiber LTP.	Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA; Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Kent Waldrep Fdn Ctr Basic Neurosci Res Nerve Gro, Dallas, TX 75235 USA; Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA	Salk Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Medical Branch Galveston	Contractor, A (corresponding author), Salk Inst Biol Studies, Mol Neurobiol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Contractor, Anis/0000-0002-5131-2536; Henkemeyer, Mark/0000-0002-7525-1061	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH066332] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH066332] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bortolotto ZA, 1999, NATURE, V402, P297, DOI 10.1038/46290; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Chung HJ, 2000, J NEUROSCI, V20, P7258; Contractor A, 2001, NEURON, V29, P209, DOI 10.1016/S0896-6273(01)00191-X; Cowan CA, 2001, NATURE, V413, P174, DOI 10.1038/35093123; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Daw MI, 2000, NEURON, V28, P873, DOI 10.1016/S0896-6273(00)00160-4; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Grunwald IC, 2001, NEURON, V32, P1027, DOI 10.1016/S0896-6273(01)00550-5; Henderson JT, 2001, NEURON, V32, P1041, DOI 10.1016/S0896-6273(01)00553-0; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; Kamiya H, 1996, J PHYSIOL-LONDON, V493, P447, DOI 10.1113/jphysiol.1996.sp021395; KATSUKI H, 1991, NEUROSCI RES, V12, P393, DOI 10.1016/0168-0102(91)90070-F; Kim CH, 2001, P NATL ACAD SCI USA, V98, P11725, DOI 10.1073/pnas.211132798; Klein R, 2001, CURR OPIN CELL BIOL, V13, P196, DOI 10.1016/S0955-0674(00)00197-6; Lu Q, 2001, CELL, V105, P69, DOI 10.1016/S0092-8674(01)00297-5; Matsuda S, 1999, J NEUROCHEM, V73, P1765, DOI 10.1046/j.1471-4159.1999.731765.x; Mellor J, 2001, NAT NEUROSCI, V4, P125, DOI 10.1038/83941; Moreno-Flores MT, 1999, NEUROSCIENCE, V91, P193, DOI 10.1016/S0306-4522(98)00568-5; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WEISSKOPF MG, 1995, NATURE, V376, P256, DOI 10.1038/376256a0; WILLIAMS S, 1989, NEURON, V3, P583, DOI 10.1016/0896-6273(89)90268-7; XIANG ZX, 1994, J NEUROPHYSIOL, V71, P2552, DOI 10.1152/jn.1994.71.6.2552; Yeckel MF, 1999, NAT NEUROSCI, V2, P625, DOI 10.1038/10180; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	32	199	212	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 7	2002	296	5574					1864	1869		10.1126/science.1069081	http://dx.doi.org/10.1126/science.1069081			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052960				2022-12-28	WOS:000176054300048
J	Daulton, TL; Bernatowicz, TJ; Lewis, RS; Messenger, S; Stadermann, FJ; Amari, S				Daulton, TL; Bernatowicz, TJ; Lewis, RS; Messenger, S; Stadermann, FJ; Amari, S			Polytype distribution in circumsteller silicon carbide	SCIENCE			English	Article							ISOTOPIC COMPOSITIONS; CARBON; GROWTH; GRAINS; ENVELOPES; METEORITE; NITROGEN; ORIGIN	The inferred crystallographic class of circumstellar silicon carbide based on astronomical infrared spectra is controversial. We have directly determined the polytype distribution of circumstellar SiC from transmission electron microscopy of presolar silicon carbide from the Murchison carbonaceous meteorite. Only two polytypes (of a possible several hundred) were observed: cubic 3C and hexagonal 2H silicon carbide and their intergrowths. We conclude that this structural simplicity is a direct consequence of the low pressures in circumstellar outflows and the corresponding low silicon carbide condensation temperatures.	USN, Marine Geosci Div, Res Lab, Stennis Space Ctr, MS 39529 USA; Argonne Natl Lab, Div Mat Sci, Argonne, IL 60439 USA; Washington Univ, Space Sci Lab, St Louis, MO 63130 USA; Univ Chicago, Enrico Fermi Inst, Chicago, IL 60637 USA	United States Department of Defense; United States Navy; Naval Research Laboratory; United States Department of Energy (DOE); Argonne National Laboratory; Washington University (WUSTL); University of Chicago	Daulton, TL (corresponding author), USN, Marine Geosci Div, Res Lab, Stennis Space Ctr, MS 39529 USA.	tdaulton@nrlssc.navy.mil						AMARI S, 1994, GEOCHIM COSMOCHIM AC, V58, P459, DOI 10.1016/0016-7037(94)90477-4; Andersen AC, 1999, ASTRON ASTROPHYS, V343, P933; BERNATOWICZ T, 1987, NATURE, V330, P728, DOI 10.1038/330728a0; Bernatowicz TJ, 1997, PHYS TODAY, V50, P26, DOI 10.1063/1.882049; BLANCO A, 1994, ASTRON ASTROPHYS, V283, P561; Blanco A, 1998, ASTRON ASTROPHYS, V330, P505; BOOTSMA GA, 1971, J CRYST GROWTH, V8, P341, DOI 10.1016/0022-0248(71)90263-6; GROENEWEGEN MAT, 1995, ASTRON ASTROPHYS, V293, P463; Henning T, 2001, SPECTROCHIM ACTA A, V57, P815, DOI 10.1016/S1386-1425(00)00446-7; HOPPE P, 1994, ASTROPHYS J, V430, P870, DOI 10.1086/174458; Hoppe P, 1998, METEORIT PLANET SCI, V33, pA71; Hoppe P, 1997, AIP CONF PROC, P27, DOI 10.1063/1.53314; Hoppe P, 1996, GEOCHIM COSMOCHIM AC, V60, P883, DOI 10.1016/0016-7037(95)00435-1; HUSS GR, 1995, GEOCHIM COSMOCHIM AC, V59, P115, DOI 10.1016/0016-7037(94)00376-W; Huss GR, 1997, AIP CONF PROC, P721, DOI 10.1063/1.53338; KRISHNA P, 1971, J CRYST GROWTH, V9, P319, DOI 10.1016/0022-0248(71)90249-1; KRISHNA P, 1971, J CRYST GROWTH, V8, P129, DOI 10.1016/0022-0248(71)90033-9; LEWIS RS, 1987, NATURE, V326, P160, DOI 10.1038/326160a0; LODDERS K, 1995, METEORITICS, V30, P661, DOI 10.1111/j.1945-5100.1995.tb01164.x; MATSUNAMI H, 1993, PHYSICA B, V185, P65, DOI 10.1016/0921-4526(93)90215-R; Mendybaev RA, 2002, GEOCHIM COSMOCHIM AC, V66, P661, DOI 10.1016/S0016-7037(01)00802-X; Mutschke H, 1999, ASTRON ASTROPHYS, V345, P187; Papoular R, 1998, ASTRON ASTROPHYS, V329, P1035; PATRICK L, 1966, PHYS REV, V143, P526, DOI 10.1103/PhysRev.143.526; RAMSDELL LS, 1947, AM MINERAL, V32, P64; SHARP CM, 1995, GEOCHIM COSMOCHIM AC, V59, P1633, DOI 10.1016/0016-7037(95)00069-C; Speck AK, 1999, ASTROPHYS J, V513, pL87, DOI 10.1086/311891; Speck AK, 1997, MON NOT R ASTRON SOC, V288, P431, DOI 10.1093/mnras/288.2.431; STAN MA, 1994, APPL PHYS LETT, V64, P2667, DOI 10.1063/1.111486; Treffers R., 1974, Astrophysical Journal, V188, P545, DOI 10.1086/152746; Zinner E, 2001, METEORIT PLANET SCI, V36, pA8, DOI 10.1111/j.1945-5100.2001.tb01533.x	31	59	61	5	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	2002	296	5574					1852	1855		10.1126/science.1071136	http://dx.doi.org/10.1126/science.1071136			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052956				2022-12-28	WOS:000176054300044
J	Patrakka, J; Martin, P; Salonen, R; Kestila, M; Ruotsalainen, V; Mannikko, M; Ryynanen, M; Rapola, J; Holmberg, C; Tryggvason, K; Jalanko, H				Patrakka, J; Martin, P; Salonen, R; Kestila, M; Ruotsalainen, V; Mannikko, M; Ryynanen, M; Rapola, J; Holmberg, C; Tryggvason, K; Jalanko, H			Proteinuria and prenatal diagnosis of congenital nephrosis in fetal carriers of nephrin gene mutations	LANCET			English	Article							NPHS1	High concentrations of alpha-fetoprotein (AFP) are used for prenatal diagnosis of the Finnish type of congenital nephrotic syndrome (NPHS1). We investigated the validity of this test. We retrospectively established fetal NPHS1 genotype and assessed renal pathology in 21 pregnancies that had been terminated because of raised concentrations of AFP in amniotic fluid. 12 fetuses were homozygous and nine were heterozygous (carriers) for NPHS1 mutations. Raised concentrations of AFP and similar proteinuric features in fetal kidneys were seen in both groups, Indicating that these signs are unreliable for prenatal diagnosis of congenital nephrosis. We strongly recommend the use of mutation analysis of the NPHS1 gene to confirm the AFP results In prenatal diagnosis of NPHS1.	Univ Helsinki, Hosp Children & Adolescents, FIN-00290 Helsinki, Finland; Univ Helsinki, Biomedicum Helsinki, FIN-00290 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, Electron Microscopy Unit, FIN-00290 Helsinki, Finland; Univ Helsinki, Dept Med Genet, FIN-00290 Helsinki, Finland; Univ Helsinki, Dept Obstet & Gynecol, FIN-00290 Helsinki, Finland; Univ Oulu, Bioctr, Oulu, Finland; Univ Oulu, Dept Biochem, Oulu, Finland; Univ Oulu, Dept Obstet & Gynecol, SF-90220 Oulu, Finland; Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, Stockholm, Sweden	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; Karolinska Institutet	Patrakka, J (corresponding author), Univ Helsinki, Hosp Children & Adolescents, FIN-00290 Helsinki, Finland.		Patrakka, Jaakko/AAG-8796-2019; Mannikko, Minna/C-5877-2008	Mannikko, Minna/0000-0002-6857-6423	NIDDK NIH HHS [DK 54724] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054724] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beltcheva O, 2001, HUM MUTAT, V17, P368, DOI 10.1002/humu.1111; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; LIU L, HUMAN MOL GENET, V10, P2637; Mannikko M, 1997, KIDNEY INT, V51, P868, DOI 10.1038/ki.1997.122; Patrakka J, 2000, KIDNEY INT, V58, P972, DOI 10.1046/j.1523-1755.2000.00254.x	5	42	48	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 4	2002	359	9317					1575	1577		10.1016/S0140-6736(02)08504-5	http://dx.doi.org/10.1016/S0140-6736(02)08504-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047969				2022-12-28	WOS:000175460700013
J	Fee, MS; Shraiman, B; Pesaran, B; Mitra, PP				Fee, MS; Shraiman, B; Pesaran, B; Mitra, PP			The role of nonlinear dynamics of the syrinx in the vocalizations of a songbird	NATURE			English	Article							ZEBRA FINCH SONG; BIRD SONG; MODEL; CANARY	Birdsong is characterized by the modulation of sound properties over a wide range of timescales'. Understanding the mechanisms by which the brain organizes this complex temporal behaviour is a central motivation in the study of the song control and learning system(2-8). Here we present evidence that, in addition to central neural control, a further level of temporal organization is provided by nonlinear oscillatory dynamics that are intrinsic to the avian vocal organ. A detailed temporal and spectral examination of song of the zebra finch (Taeniopygia guttata) reveals a class of rapid song modulations that are consistent with transitions in the dynamical state of the syrinx. Furthermore, in vitro experiments show that the syrinx can produce a sequence of oscillatory states that are both spectrally and temporally complex in response to the slow variation of respiratory or syringeal parameters. As a consequence, simple variations in a small number of neural signals can result in a complex acoustic sequence.	Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA; CALTECH, Dept Phys, Pasadena, CA 91125 USA	Alcatel-Lucent; Lucent Technologies; AT&T; California Institute of Technology	Fee, MS (corresponding author), Lucent Technol, Bell Labs, 600 Mt Ave, Murray Hill, NJ 07974 USA.			Mitra, Partha/0000-0001-8818-6804; Fee, Michale/0000-0001-7539-1745				BERRY DA, 1994, J ACOUST SOC AM, V95, P3595, DOI 10.1121/1.409875; BERTRAM CD, 1982, J BIOMECH, V15, P39, DOI 10.1016/0021-9290(82)90033-1; FLETCHER NH, 1978, J ACOUST SOC AM, V64, P1566, DOI 10.1121/1.382139; FLETCHER NH, 1988, J THEOR BIOL, V135, P455, DOI 10.1016/S0022-5193(88)80270-4; Goller F, 1997, P NATL ACAD SCI USA, V94, P14787, DOI 10.1073/pnas.94.26.14787; GOLLER F, 1995, NATURE, V373, P63, DOI 10.1038/373063a0; GREENEWALT CH, 1968, BRID SONG ACOUSTICS; HARTLEY RS, 1989, J COMP PHYSIOL A, V165, P15, DOI 10.1007/BF00613795; HERZEL H, 1994, J SPEECH HEAR RES, V37, P1008, DOI 10.1044/jshr.3705.1008; Immelmann K., 1969, P61; ISHIZAKA K, 1972, AT&T TECH J, V51, P1233, DOI 10.1002/j.1538-7305.1972.tb02651.x; Jackson E., 1992, PERSPECTIVES NONLINE; Konishi Masakazu, 1994, Current Opinion in Neurobiology, V4, P827, DOI 10.1016/0959-4388(94)90130-9; MCCASLAND JS, 1987, J NEUROSCI, V7, P23; NOTTEBOHM F, 1976, J COMP NEUROL, V165, P457, DOI 10.1002/cne.901650405; NOTTEBOHM F, 1982, J COMP NEUROL, P207; PRICE PH, 1979, J COMP PHYSIOL PSYCH, V93, P260, DOI 10.1037/h0077553; SCHARFF C, 1991, J NEUROSCI, V11, P2896; THOMSON DJ, 1982, P IEEE, V70, P1055, DOI 10.1109/PROC.1982.12433; VU ET, 1994, J NEUROSCI, V14, P6924; Yu AC, 1996, SCIENCE, V273, P1871, DOI 10.1126/science.273.5283.1871	21	190	194	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1998	395	6697					67	71		10.1038/25725	http://dx.doi.org/10.1038/25725			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116JY	12071206				2022-12-28	WOS:000075722200047
J	Scott, BA; Avidan, MS; Crowder, CM				Scott, BA; Avidan, MS; Crowder, CM			Regulation of hypoxic death in C-elegans by the insulin/IGF receptor homolog DAF-2	SCIENCE			English	Article							AGE-1 PI3 KINASE; CAENORHABDITIS-ELEGANS; LIFE-SPAN; TRANSCRIPTION FACTOR; SIGNALING PATHWAY; CELL-DEATH; LONGEVITY; DIAPAUSE; GENE; FAMILY	To identify genetic determinants of hypoxic cell death, we screened for hypoxia-resistant (Hyp) mutants in Caenorhabditis elegans and found that specific reduction-of-function (rf) mutants of daf-2, an insulin/insulinlike growth factor (IGF) receptor (INR) homolog gene, were profoundly Hyp. The hypoxia resistance was acutely inducible just before hypoxic exposure and was mediated through an AKT-1/PDK-1/forkhead transcription factor pathway overlapping with but distinct from signaling pathways regulating life-span and stress resistance. Selective neuronal and muscle expression of daf-2(+) restored hypoxic death, and daf-2(rf) prevented hypoxia-induced muscle and neuronal cell death, which demonstrates a potential for INR modulation in prophylaxis against hypoxic injury of neurons and myocytes.	Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Crowder, CM (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA.			Avidan, Michael/0000-0001-6248-044X	NINDS NIH HHS [R01 NS045905] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045905] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Apfeld J, 1998, CELL, V95, P199, DOI 10.1016/S0092-8674(00)81751-1; Braeckman BP, 2002, MECH AGEING DEV, V123, P105, DOI 10.1016/S0047-6374(01)00331-1; Crowder CM, 1996, ANESTHESIOLOGY, V85, P901, DOI 10.1097/00000542-199610000-00027; Crowder CM, 2001, J BIOL CHEM, V276, P44369, DOI 10.1074/jbc.C100535200; DORMAN JB, 1995, GENETICS, V141, P1399; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gems D, 1998, GENETICS, V150, P129; Gil EB, 1999, P NATL ACAD SCI USA, V96, P2925, DOI 10.1073/pnas.96.6.2925; Hobert O, 1998, J NEUROSCI, V18, P2084; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; LARSEN PL, 1995, GENETICS, V139, P1567; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Mihaylova VT, 1999, P NATL ACAD SCI USA, V96, P7427, DOI 10.1073/pnas.96.13.7427; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Murakami S, 2001, CURR BIOL, V11, P1517, DOI 10.1016/S0960-9822(01)00453-5; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; O'Connor R, 2000, BIOCHEM SOC T, V28, P47, DOI 10.1042/bst0280047; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; SCOTT B, UNPUB; Van Voorhies WA, 1999, P NATL ACAD SCI USA, V96, P11399, DOI 10.1073/pnas.96.20.11399; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8; Wolkow Catherine A., 2000, Science (Washington D C), V290, P147, DOI 10.1126/science.290.5489.147	27	195	213	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 28	2002	296	5577					2388	2391		10.1126/science.1072302	http://dx.doi.org/10.1126/science.1072302			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12065745				2022-12-28	WOS:000176467200040
J	Reid, IN				Reid, IN			Perspectives: Brown dwarfs - Failed stars or overachieving planets?	SCIENCE			English	Editorial Material									Space Telescope Sci Inst, Baltimore, MD 21218 USA	Space Telescope Science Institute	Reid, IN (corresponding author), Space Telescope Sci Inst, 3700 San Martin Dr, Baltimore, MD 21218 USA.							ALLEN PR, IN PRESS IAU S, V211; Bate MR, 2002, MON NOT R ASTRON SOC, V332, pL65, DOI 10.1046/j.1365-8711.2002.05539.x; Close LM, 2002, ASTROPHYS J, V567, pL53, DOI 10.1086/339795; Gizis JE, 2001, ASTROPHYS J, V551, pL163, DOI 10.1086/320017; Koerner DW, 1999, ASTROPHYS J, V526, pL25, DOI 10.1086/312367; PEDANT EL, 1999, SCIENCE, V283, P1718; Reid IN, 1999, ASTROPHYS J, V521, P613, DOI 10.1086/307589; Reid IN, 2001, ASTRON J, V121, P489, DOI 10.1086/318023; Reipurth B, 2001, ASTRON J, V122, P432, DOI 10.1086/321121; Shelley Percy Bysshe, 1991, POSTHUMOUS POEMS	10	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 21	2002	296	5576					2154	2155		10.1126/science.1074261	http://dx.doi.org/10.1126/science.1074261			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077391				2022-12-28	WOS:000176379000032
J	Park, JS; Marr, MT; Roberts, JW				Park, JS; Marr, MT; Roberts, JW			E-coli transcription repair coupling factor (Mfd protein) rescues arrested complexes by promoting forward translocation	CELL			English	Article							RNA-POLYMERASE-II; MUTATION FREQUENCY DECLINE; CLEAVAGE FACTORS GREA; ESCHERICHIA-COLI; ELONGATION COMPLEX; COCKAYNE-SYNDROME; SIGMA-70 SUBUNIT; STRUCTURAL BASIS; DNA; GENE	Transcription and DNA repair are coupled in E. coli by the Mfd protein, which dissociates transcription elongation complexes blocked at nonpairing lesions and mediates recruitment of DNA repair proteins. We show that Mfd influences the elongation state of RNA polymerase (RNAP); transcription complexes that have reverse translocated into the backtracked position, a potentially important intermediate in RNA proofreading and repair, are restored to the forward position by the activity of Mfd, and arrested complexes are rescued into productive elongation. Mfd may act through a translocase activity that rewinds upstream DNA, leading either to translocation or to release of RNA polymerase when the enzyme active site cannot continue elongation.	Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University	Roberts, JW (corresponding author), Cornell Univ, Dept Mol Biol & Genet, Biotechnol Bldg, Ithaca, NY 14853 USA.				NIGMS NIH HHS [GM 21941] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021941, R01GM021941] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Borukhov S, 1996, METHOD ENZYMOL, V274, P315; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; Bown JA, 1999, J BIOL CHEM, V274, P2263, DOI 10.1074/jbc.274.4.2263; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Komissarova N, 1998, P NATL ACAD SCI USA, V95, P14699, DOI 10.1073/pnas.95.25.14699; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Lee SK, 2001, MOL CELL BIOL, V21, P8651, DOI 10.1128/MCB.21.24.8651-8656.2001; Marr MT, 2001, P NATL ACAD SCI USA, V98, P8972, DOI 10.1073/pnas.161253298; Marr MT, 2000, MOL CELL, V6, P1275, DOI 10.1016/S1097-2765(00)00126-X; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; RAINJC, 2001, NATURE, V409, P211; REINES D, 1989, J BIOL CHEM, V264, P10799; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; Ring BZ, 1996, CELL, V86, P485, DOI 10.1016/S0092-8674(00)80121-X; RYDER AM, 2002, THESIS CORNELL U ITH; Schneider S, 1996, BIOTECHNIQUES, V20, P960; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; SELBY CP, 1994, MICROBIOL REV, V58, P317, DOI 10.1128/MMBR.58.3.317-329.1994; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1995, J BIOL CHEM, V270, P4890, DOI 10.1074/jbc.270.9.4890; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; Singleton MR, 2001, CELL, V107, P79, DOI 10.1016/S0092-8674(01)00501-3; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; WHITBY MC, 1994, EMBO J, V13, P5220, DOI 10.1002/j.1460-2075.1994.tb06853.x; WITKIN EM, 1994, BIOESSAYS, V16, P437, DOI 10.1002/bies.950160613; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816; Xie Z, 1997, J BIOL CHEM, V272, P31902, DOI 10.1074/jbc.272.50.31902; YARNELL WS, 1992, CELL, V69, P1181, DOI 10.1016/0092-8674(92)90639-T; Yarnell WS, 1999, SCIENCE, V284, P611, DOI 10.1126/science.284.5414.611; Zakharova N, 1998, J BIOL CHEM, V273, P19371, DOI 10.1074/jbc.273.31.19371; Zalieckas JM, 1998, MOL MICROBIOL, V27, P1031, DOI 10.1046/j.1365-2958.1998.00751.x; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	42	221	226	1	14	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 14	2002	109	6					757	767		10.1016/S0092-8674(02)00769-9	http://dx.doi.org/10.1016/S0092-8674(02)00769-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	563PW	12086674	Bronze			2022-12-28	WOS:000176265600006
J	Roosild, TP; Miller, S; Booth, IR; Choe, S				Roosild, TP; Miller, S; Booth, IR; Choe, S			A mechanism of regulating transmembrane potassium flux through a ligand-mediated conformational switch	CELL			English	Article							ESCHERICHIA-COLI; K+-CHANNEL; EFFLUX SYSTEM; PROTEIN TRKA; TRANSPORT; GLUTATHIONE; ACTIVATION; DOMAIN; REPLACEMENT; COMPLEX	The regulation of cation content is critical for cell growth. However, the molecular mechanisms that gate the systems that control K+ movements remain unclear. KTN is a highly conserved cytoplasmic domain present ubiquitously in a variety of prokaryotic and eukaryotic K+ channels and transporters. Here we report crystal structures for two representative KTN domains that reveal a dimeric hinged assembly. Alternative ligands NAD(+) and NADH block or vacate, respectively, the hinge region affecting the dimer's conformational flexibility. Conserved, surface-exposed hydrophobic patches that become coplanar upon hinge closure provide an assembly interface for KTN tetramerization. Mutational analysis using the KefC system demonstrates that this domain directly interacts with its respective transmembrane constituent, coupling ligand-mediated KTN conformational changes to the permease's activity.	Univ Calif San Diego, Salk Inst, Struct Biol Lab, San Diego, CA 92037 USA; Univ Calif San Diego, Div Biol, San Diego, CA 92037 USA; Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland	Salk Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Aberdeen	Choe, S (corresponding author), Univ Calif San Diego, Salk Inst, Struct Biol Lab, San Diego, CA 92037 USA.	choe@salk.edu	Miller, Samantha/A-4799-2010	Miller, Samantha/0000-0002-8223-9693	NCI NIH HHS [CA64041] Funding Source: Medline; NIGMS NIH HHS [GM6241, GM56653] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA064041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056653] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMUNDSEN S, 1997, POVRAY PERSISTENCE V; ANDERSEN KB, 1977, J BIOL CHEM, V252, P4151; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Booth I. R., 1996, HDB BIOL PHYS, V2, P693; BOSSEMEYER D, 1989, J BIOL CHEM, V264, P16403; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dauter Z, 2001, ACTA CRYSTALLOGR D, V57, P239, DOI 10.1107/S0907444900015249; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Derst C, 1998, J EXP BIOL, V201, P2791; Durell SR, 1999, BIOPHYS J, V77, P789, DOI 10.1016/S0006-3495(99)76932-8; ELMORE MJ, 1990, MOL MICROBIOL, V4, P405, DOI 10.1111/j.1365-2958.1990.tb00607.x; EPSTEIN W, 1986, FEMS MICROBIOL LETT, V39, P73; FERGUSON GP, 1993, MOL MICROBIOL, V9, P1297, DOI 10.1111/j.1365-2958.1993.tb01259.x; Flynn GE, 2001, NAT REV NEUROSCI, V2, P643, DOI 10.1038/35090015; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Jez JM, 2000, BIOCHEMISTRY-US, V39, P890, DOI 10.1021/bi991489f; Jiang YX, 2001, NEURON, V29, P593, DOI 10.1016/S0896-6273(01)00236-7; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MEURY J, 1982, EMBO J, V1, P339, DOI 10.1002/j.1460-2075.1982.tb01171.x; MILKMAN R, 1994, P NATL ACAD SCI USA, V91, P3510, DOI 10.1073/pnas.91.9.3510; Miller S, 1997, J BIOL CHEM, V272, P24942, DOI 10.1074/jbc.272.40.24942; Miller S, 2000, J BACTERIOL, V182, P6536, DOI 10.1128/JB.182.22.6536-6540.2000; Nakamura T, 1998, J BACTERIOL, V180, P3491, DOI 10.1128/JB.180.13.3491-3494.1998; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARRALOPEZ C, 1994, EMBO J, V13, P3964, DOI 10.1002/j.1460-2075.1994.tb06712.x; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; RHOADS DB, 1977, J BIOL CHEM, V252, P1394; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHLOSSER A, 1993, MOL MICROBIOL, V9, P533, DOI 10.1111/j.1365-2958.1993.tb01714.x; Schreiber M, 1997, BIOPHYS J, V73, P1355, DOI 10.1016/S0006-3495(97)78168-2; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; STEWART LMD, 1985, J GEN MICROBIOL, V131, P77; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	41	104	111	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	2002	109	6					781	791		10.1016/S0092-8674(02)00768-7	http://dx.doi.org/10.1016/S0092-8674(02)00768-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	563PW	12086676	Bronze			2022-12-28	WOS:000176265600008
J	Hargreaves, S				Hargreaves, S			Time to right the wrongs: improving basic health care in Nigeria	LANCET			English	Article							EPIDEMIC	Nigeria, once heralded as the beacon of Africa, has fallen somewhat short of this potential, Years of kleptocratic repressive dictators and military rule, coupled with widespread corruption, have resulted In large-scale neglect and deterioration of public services. Nowhere is this more apparent than within the health sector. Government-run health-care services barely function: half the population are unvaccinated for routine diseases, and a burgeoning epidemic of HIV/AIDS, only now being adequately addressed, leaves 3.5 million already infected and without access to the most basic of care. A poorly structured health service that relies on vertical programmes for HIV, tuberculosis, and malaria, means that coordination is chaotic, and already scant resources fail to reach the lower levels In which they are needed most. I visited Nigeria in October, 2001, with Medecins Sans Frontieres, a humanitarian aid organisation that has been working in Nigeria since 1996. I witnessed the poor level of health care In Nigeria for myself-a country that is more than capable of providing effective services-and concluded that, even now, political priorities are being put ahead of the population's basic needs. The challenges to the new civilian government are monumental, and it Is yet to show any solid commitment to improving the health of Africa's biggest nation.	Lancet, London NW1 7BY, England		Hargreaves, S (corresponding author), Lancet, 32 Jamestown Rd, London NW1 7BY, England.	salhargreaves@hotmail.com		Hargreaves, Sally/0000-0003-2974-4348				Adu FD, 1997, J INFECTION, V35, P241, DOI 10.1016/S0163-4453(97)92890-5; *CHIN ACH, 1983, TROUBL NIG; Das P, 2001, LANCET, P7; EGUNJOBI L, 1993, SOC SCI MED, V36, P1267, DOI 10.1016/0277-9536(93)90216-Q; Etchegorry MG, 2001, LANCET, V357, P1046, DOI 10.1016/S0140-6736(05)71623-8; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; *FED MIN HLTH, 2001, 2001 HIV AIDS SENT S; Hargreaves S, 2001, LANCET, V358, P1900, DOI 10.1016/S0140-6736(01)06895-7; HARGREAVES S, 2002, LANCET, V359, P364; *HUM RIGHTS WATCH, 1995, OG CRIS CAS STUD MIL; *HUM RIGHTS WATCH, 2001, JOS CIT TORN APART; MAIER K, 2000, THIS HOUSE HAS FALLE, P289; MILLER M, 1999, INT J INFECT DIS, V4, P14; *NAT ACT COMM HIV, 2001, HIV AIDS EM ACT PLAN; Odusanya OO, 2001, MED EDUC, V35, P482, DOI 10.1046/j.1365-2923.2001.00896.x; OTUFODUNRIN L, 2001, ANGLICAN CHURCH POLI; PALLISTER D, 2001, GUARDIAN        1004; Taylor RB, 2001, LANCET, V357, P1933, DOI 10.1016/S0140-6736(00)05065-0; *TRANSP INT, 2001, GLOB CORR REP 2001; Uplekar M, 2001, LANCET, V358, P912, DOI 10.1016/S0140-6736(01)06076-7; Veeken H, 1998, B WORLD HEALTH ORGAN, V76, P135; 2001, EC INTELLIGENCE UNIT, P20; 2001, HUMAN DEV REPORT 200; 2001, MMWR MORB MORTAL WKL, V50, P826; 2002, EC SURVEYS	25	29	29	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 8	2002	359	9322					2030	2035		10.1016/S0140-6736(02)08826-8	http://dx.doi.org/10.1016/S0140-6736(02)08826-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076574				2022-12-28	WOS:000176232500031
J	John, JH; Ziebland, S; Yudkin, P; Roe, LS; Neil, HAW				John, JH; Ziebland, S; Yudkin, P; Roe, LS; Neil, HAW		Oxford Fruit Vegetable Study Grp	Effects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure: a randomised controlled trial	LANCET			English	Article							CARDIOVASCULAR-DISEASE; ASCORBIC-ACID; BETA-CAROTENE; DIETARY; INTERVENTION; LIPIDS; CANCER	Background High dietary intakes of fruit and vegetables are associated with reduced risks of cancer and cardiovascular disease. Short-term intensive dietary interventions in selected populations increase fruit and vegetable intake, raise plasma antioxidant concentrations, and lower blood pressure, but long-term effects of interventions in the general population are not certain. We assessed the effect of an intervention to increase fruit and vegetable consumption on plasma concentrations of antioxidant vitamins, daily fruit and vegetable intake, and blood pressure. Methods We undertook a 6-month, randomised, controlled trial of a brief negotiation method to encourage an increase in consumption of fruit and vegetables to at least five daily portions. We included 690 healthy participants aged 25-64 years recruited from a primary-care health centre. Findings Plasma concentrations of a-carotene, beta-carotene, lutein, beta-cryptoxanthin, and ascorbic acid increased by more in the intervention group than in controls (significance of between-group differences ranged from p=0.032 to 0.0002). Groups did not differ for changes in lycopene, retinol, alpha-tocopherol, gamma-tocopherol, or total cholesterol concentrations. Self-reported fruit and vegetable intake increased by a mean 1.4 (SD 1.7) portions in the intervention group and by 0.1 (1.3) portion in the control group (between-group difference=1.4, 95% CI 1.2-1.6; p<0.0001). Systolic blood pressure fell more in the intervention group than in controls (difference=4.0 mm Hg, 2.0-6.0; p<0.0001), as did diastolic blood pressure (1.5 mm Hg, 0.2-2.7; p=0.02). Interpretation The effects of the intervention on fruit and vegetable consumption, plasma antioxidants, and blood pressure would be expected to reduce cardiovascular disease in the general population.	Univ Oxford, Inst Hlth Sci, Div Publ Hlth & Primary Hlth Care, Oxford OX3 7LF, England; Univ Oxford, Dept Primary Hlth Care, Gen Practice Res Grp, Imperial Canc Res Fund, Oxford OX3 7LF, England	University of Oxford; University of Oxford	Neil, HAW (corresponding author), Univ Oxford, Inst Hlth Sci, Div Publ Hlth & Primary Hlth Care, Oxford OX3 7LF, England.			Ziebland, Sue/0000-0002-6496-4859				Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Block G, 2001, HYPERTENSION, V37, P261, DOI 10.1161/01.HYP.37.2.261; *CARD REV GROUP CO, 1994, NUTR ASP CARD DIS 46; COOK NR, 1995, ARCH INTERN MED, V155, P701, DOI 10.1001/archinte.155.7.701; Cox DN, 1998, BRIT J NUTR, V80, P123, DOI 10.1017/S0007114598001020; Dwyer JH, 2001, CIRCULATION, V103, P2922, DOI 10.1161/01.CIR.103.24.2922; Employment Department Group Office of Population Censuses and Surveys, 1990, STAND OCC CLASS, V2; Gaziano J. Michael, 1995, Annals of Epidemiology, V5, P255, DOI 10.1016/1047-2797(94)00090-G; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Hunt CJ, 2000, EUR J PUBLIC HEALTH, V10, P178, DOI 10.1093/eurpub/10.3.178; MARGOLIS SA, 1988, CLIN CHEM, V34, P2217; MORRIS R, 1991, J PUBLIC HEALTH MED, V13, P318; NEIL HAW, 1995, BMJ-BRIT MED J, V310, P569, DOI 10.1136/bmj.310.6979.569; Ness AR, 1997, INT J EPIDEMIOL, V26, P1, DOI 10.1093/ije/26.1.1; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037/0022-006X.51.3.390; ROE L, 1994, FAM PRACT, V11, P375, DOI 10.1093/fampra/11.4.375; ROLLNICK S, 1993, BRIT MED J, V307, P188, DOI 10.1136/bmj.307.6897.188; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; Whelton PK, 1997, JAMA-J AM MED ASSOC, V277, P1624, DOI 10.1001/jama.277.20.1624; WILLIAMS C, 1997, LEAST 5 DAY STRATEGI; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; Zino S, 1997, BMJ-BRIT MED J, V314, P1787, DOI 10.1136/bmj.314.7097.1787	26	337	349	1	35	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 8	2002	359	9322					1969	1974		10.1016/S0140-6736(02)98858-6	http://dx.doi.org/10.1016/S0140-6736(02)98858-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076551				2022-12-28	WOS:000176232500008
J	Scoular, A; Norrie, J; Gillespie, G; Mir, N; Carman, WF				Scoular, A; Norrie, J; Gillespie, G; Mir, N; Carman, WF			Longitudinal stud of genital infection by herpes simplex virus type 1 in western Scotland over 15 years	BRITISH MEDICAL JOURNAL			English	Article									Sandyford Initiat, Dept Genitourinary Med, Glasgow G3 7NB, Lanark, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland; Gartnavel Royal Hosp, W Scotland Specialist Virol Ctr, Glasgow G12 0XN, Lanark, Scotland; Russell Inst, Dept Genitourinary Med, Paisley PA1 1UR, Renfrew, Scotland	University of Glasgow; Gartnavel Royal Hospital	Scoular, A (corresponding author), Sandyford Initiat, Dept Genitourinary Med, Glasgow G3 7NB, Lanark, Scotland.							Johnson AM, 1994, SEXUAL ATTITUDES LIF; LAFFERTY WE, 1987, NEW ENGL J MED, V316, P1444, DOI 10.1056/NEJM198706043162304; LAMEY PJ, 1999, HERPES, V6, P20; Scoular A, 2002, SEX TRANSM INFECT, V78, P21, DOI 10.1136/sti.78.1.21; Vyse AJ, 2000, SEX TRANSM INFECT, V76, P183, DOI 10.1136/sti.76.3.183	5	53	55	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 8	2002	324	7350					1366	1367		10.1136/bmj.324.7350.1366	http://dx.doi.org/10.1136/bmj.324.7350.1366			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BQ	12052804	Bronze, Green Published			2022-12-28	WOS:000176234100019
J	Wallace, P; Haines, A; Harrison, R; Barber, J; Thompson, S; Jacklin, P; Roberts, J; Lewis, L; Wainwright, P				Wallace, P; Haines, A; Harrison, R; Barber, J; Thompson, S; Jacklin, P; Roberts, J; Lewis, L; Wainwright, P		Virtual Outreach Project Grp	Joint teleconsultations (virtual outreach) versus standard outpatient appointments for patients referred by their general practitioner for a specialist opinion: a randomised trial	LANCET			English	Article							FOLLOW-UP; TELEMEDICINE; CLINICS; SATISFACTION; CARE; CONSULTATIONS	Background The current model of general practitioner referral of patients to hospital specialists in the UK is sometimes associated with unnecessary duplication of investigations and treatments. We aimed to compare joint teleconsultations between general practitioners, specialists, and patients (virtual outreach) with standard outpatient referral. Methods Virtual outreach services were established in London and Shrewsbury. The general practitioners referred 3170 patients, of whom 2094 consented to participate in the study and were eligible for inclusion. 1051 patients were randomly assigned virtual outreach, and 1043 standard outpatient appointments, We followed up the patients for 6 months after their index consultation. The primary outcome measure was the offer of a follow-up outpatient appointment. Analysis was by intention to treat. Findings More patients in the virtual outreach group than the standard group were offered a follow-up appointment (502 [52%] vs 400 [41%], odds ratio 1.52 [95% CI 1.27-1.82], p<0.0001). Significant differences in effects were observed between the two sites (p=0.009) and across different specialties (p<0.0001). Virtual outreach increased the offers of follow-up appointments more in Shrewsbury than in London, and more in ear, nose, and throat surgery and orthopaedics than in the other specialties, Fewer tests and investigations were ordered in the virtual outreach group by an average of 0.79 per patient (0.37-1.21, p=0.0002). Patients' satisfaction (analysed per protocol) was greater after a virtual outreach consultation than after a standard outpatient consultation (mean difference 0.33 scale points [95% CI 0.23-0.43], p<0.0001), with no heterogeneity between specialties or sites. Interpretation The trial showed that allocation of patients to virtual outreach consultations is variably associated with increased offers of follow-up appointments according to site and specialty, but leads to significant increases in patients' satisfaction and substantial reductions in tests and investigations. Efficient operation of such services will require appropriate selection of patients, significant service reorganisation, and provision of logistical support.	Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England; London Sch Hyg & Trop Med, London WC1, England; UCL Hosp, Res & Dev Directorate, London, England; MRC, Biostat Unit, Cambridge CB2 2BW, England; Univ Coll Swansea, Sch Hlth Sci, Swansea, W Glam, Wales	University of London; University College London; University of London; London School of Hygiene & Tropical Medicine; University College London Hospitals NHS Foundation Trust; University of London; University College London; MRC Biostatistics Unit; Swansea University	Wallace, P (corresponding author), Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, Rowland Hill St, London NW3 2PF, England.	p.wallace@pcps.ucl.ac.uk		Barber, Julie/0000-0001-5762-762X; Haines, Andy/0000-0002-8053-4605				BAILEY JJ, 1994, BRIT MED J, V308, P1083, DOI 10.1136/bmj.308.6936.1083; Barber JA, 1998, BRIT MED J, V317, P1195, DOI 10.1136/bmj.317.7167.1195; Black M, 1997, BRIT J GEN PRACT, V47, P558; Bowling A, 2001, BRIT J GEN PRACT, V51, P264; Burns T, 1999, LANCET, V353, P2185, DOI 10.1016/S0140-6736(98)12191-8; Deeks JJ, 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15; Elford D R, 1997, J Telemed Telecare, V3, P1, DOI 10.1258/1357633971930139; FISHER LD, 1993, BIOSTATISTICS; Freeman GK, 2002, BRIT MED J, V324, P880, DOI 10.1136/bmj.324.7342.880; GRACE JF, 1986, FAM PRACT, V3, P143, DOI 10.1093/fampra/3.3.143; GROL R, 1990, BRIT J GEN PRACT, V40, P134; Harrison R, 1999, J TELEMED TELECARE, V5, P126, DOI 10.1258/1357633991933440; Harrison R, 1996, BRIT MED J, V313, P1377, DOI 10.1136/bmj.313.7069.1377; Howie JGR, 1998, FAM PRACT, V15, P165, DOI 10.1093/fampra/15.2.165; Jenkinson C, 1997, J PUBLIC HEALTH MED, V19, P179, DOI 10.1093/oxfordjournals.pubmed.a024606; LANDGRAF ML, 1996, CHILD HLTH QUESTIONN; Mair F, 2000, BMJ-BRIT MED J, V320, P1517, DOI 10.1136/bmj.320.7248.1517; MARSH GN, 1982, BRIT MED J, V284, P1176, DOI 10.1136/bmj.284.6323.1176; Marshall MN, 1998, BRIT J GEN PRACT, V48, P1379; MERCER S.W, 2001, ENABLEMENT THERAPEUT; Parkerson GR, 1996, FAM PRACT, V13, P303, DOI 10.1093/fampra/13.3.303; Reeve H, 1997, FAM PRACT, V14, P24, DOI 10.1093/fampra/14.1.24; ROLAND M, 1992, HOSP REFERRALS, P62; Snowden S, 2001, J TELEMED TELECARE, V7, P32, DOI 10.1258/1357633011936110; Taylor P, 1998, J TELEMED TELECARE, V4, P63, DOI 10.1258/1357633981931948; VIERHOUT WPM, 1995, LANCET, V346, P990, DOI 10.1016/S0140-6736(95)91686-5; WALLACE P, 1992, GEN PRACTITIONERS HO; Wallace Paul, 2002, BMC Fam Pract, V3, P1, DOI 10.1186/1471-2296-3-1; Ware J E Jr, 1983, Eval Program Plann, V6, P247, DOI 10.1016/0149-7189(83)90005-8; Williams TL, 2001, TELEMED J E-HEALTH, V7, P293, DOI 10.1089/15305620152814700; Winkens R, 2002, BRIT MED J, V324, P783, DOI 10.1136/bmj.324.7340.783; Wootton R., 1999, Journal of Telemedicine and Telecare, V5, P27, DOI 10.1258/1357633991933495; 1992, 56 ROYAL COLL GEN PR	33	107	109	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 8	2002	359	9322					1961	1968		10.1016/S0140-6736(02)08828-1	http://dx.doi.org/10.1016/S0140-6736(02)08828-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076550				2022-12-28	WOS:000176232500007
J	Kim, YJ; Lin, NC; Martin, GB				Kim, YJ; Lin, NC; Martin, GB			Two distinct pseudomonas effector proteins 589 interact with the Pto kinase and activate plant immunity	CELL			English	Article							SYRINGAE PV. TOMATO; DISEASE RESISTANCE GENES; AVIRULENCE GENE; RECOGNITION SPECIFICITY; AVRPTO; HRP; IDENTIFICATION; SECRETION; HOST; VIRULENCE	The Pto serine/threonine kinase of tomato confers resistance to speck disease by recognizing strains of Pseudomonas syringae that express the protein AvrPto. Pto and AvrPto physically interact, and this interaction is required for activation of host resistaince. We identified a second Pseudomonas protein, AvrPtoB, that interacts specifically with Pto and is widely distributed among plant pathogens. AvrPtoB is delivered into the plant cell by the bacterial type III secretion system, and it elicits Pto-specific defenses. AvrPtoB has little overall sequence similarity with AvrPto. However, AvrPto amino acids, which are required for interaction with Pto, are present in AvrPtoB and required for its interaction with Pto. Thus, two distinct bacterial effectors activate plant immunity by interacting with the same host protein kinase through a similar structural mechanism.	Cornell Univ, Boyce Thompson Inst Plant Res, Ithaca, NY 14853 USA; Cornell Univ, Dept Plant Pathol, Ithaca, NY 14853 USA	Cornell University; Boyce Thompson Institute for Plant Research; Cornell University	Martin, GB (corresponding author), Cornell Univ, Boyce Thompson Inst Plant Res, Tower Rd, Ithaca, NY 14853 USA.	gbm7@cornell.edu	Martin, Gregory B/F-6262-2011	Martin, Gregory B/0000-0003-0044-6830; LIN, NAI-CHUN/0000-0002-6485-9776				Bogdanove AJ, 2000, P NATL ACAD SCI USA, V97, P8836, DOI 10.1073/pnas.97.16.8836; Chang JH, 2000, MOL PLANT MICROBE IN, V13, P568, DOI 10.1094/MPMI.2000.13.5.568; Chang JH, 2001, MOL PLANT MICROBE IN, V14, P451, DOI 10.1094/MPMI.2001.14.4.451; Cohn J, 2001, CURR OPIN IMMUNOL, V13, P55, DOI 10.1016/S0952-7915(00)00182-5; Collmer A, 2000, P NATL ACAD SCI USA, V97, P8770, DOI 10.1073/pnas.97.16.8770; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Fouts DE, 2002, P NATL ACAD SCI USA, V99, P2275, DOI 10.1073/pnas.032514099; Frederick RD, 1998, MOL CELL, V2, P241, DOI 10.1016/S1097-2765(00)80134-3; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Hammond-Kosack K., 2000, BIOCH MOL BIOL PLANT, P1102; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; INNES RW, 1993, J BACTERIOL, V175, P4859, DOI 10.1128/JB.175.15.4859-4869.1993; Jackson RW, 1999, P NATL ACAD SCI USA, V96, P10875, DOI 10.1073/pnas.96.19.10875; Jia Y, 2000, EMBO J, V19, P4004, DOI 10.1093/emboj/19.15.4004; Jia YL, 1997, PLANT CELL, V9, P61, DOI 10.1105/tpc.9.1.61; Jin QL, 2001, SCIENCE, V294, P2556, DOI 10.1126/science.1066397; Kjemtrup S, 2000, CURR OPIN MICROBIOL, V3, P73, DOI 10.1016/S1369-5274(99)00054-5; Lindgren PB, 1997, ANNU REV PHYTOPATHOL, V35, P129, DOI 10.1146/annurev.phyto.35.1.129; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MARTIN GB, 1994, PLANT CELL, V6, P1543, DOI 10.1105/tpc.6.11.1543; Martin GB, 1999, CURR OPIN PLANT BIOL, V2, P273, DOI 10.1016/S1369-5266(99)80049-1; Michelmore RW, 1998, GENOME RES, V8, P1113, DOI 10.1101/gr.8.11.1113; Mudgett MB, 1999, MOL MICROBIOL, V32, P927, DOI 10.1046/j.1365-2958.1999.01403.x; Nimchuk Z, 2000, CELL, V101, P353, DOI 10.1016/S0092-8674(00)80846-6; Nimchuk Z, 2001, CURR OPIN PLANT BIOL, V4, P288, DOI 10.1016/S1369-5266(00)00175-8; Preston GM, 2000, MOL PLANT PATHOL, V1, P263, DOI 10.1046/j.1364-3703.2000.00036.x; Riely BK, 2001, P NATL ACAD SCI USA, V98, P2059, DOI 10.1073/pnas.98.4.2059; RONALD PC, 1992, J BACTERIOL, V174, P1604, DOI 10.1128/jb.174.5.1604-1611.1992; SALMERON JM, 1993, MOL GEN GENET, V239, P6, DOI 10.1007/BF00281595; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; Scofield SR, 1996, SCIENCE, V274, P2063, DOI 10.1126/science.274.5295.2063; Sessa G, 2000, EMBO J, V19, P2257, DOI 10.1093/emboj/19.10.2257; Shan LB, 2000, MOL PLANT MICROBE IN, V13, P592, DOI 10.1094/MPMI.2000.13.6.592; Shan LB, 2000, PLANT CELL, V12, P2323, DOI 10.1105/tpc.12.12.2323; Staskawicz BJ, 2001, SCIENCE, V292, P2285, DOI 10.1126/science.1062013; Tang XY, 1996, SCIENCE, V274, P2060, DOI 10.1126/science.274.5295.2060; VandenAckerveken G, 1996, CELL, V87, P1307, DOI 10.1016/S0092-8674(00)81825-5; White FF, 2000, CURR OPIN PLANT BIOL, V3, P291, DOI 10.1016/S1369-5266(00)00082-0; XIAO YX, 1994, J BACTERIOL, V176, P1025, DOI 10.1128/JB.176.4.1025-1036.1994; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2; Zhu SP, 1999, COMPUTAT ENGN, V1, P1	41	213	225	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 31	2002	109	5					589	598		10.1016/S0092-8674(02)00743-2	http://dx.doi.org/10.1016/S0092-8674(02)00743-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	558GL	12062102	Green Published, Bronze			2022-12-28	WOS:000175957900008
J	Lobo, DN; Bostock, KA; Neal, KR; Perkins, AC; Rowlands, BJ; Allison, SP				Lobo, DN; Bostock, KA; Neal, KR; Perkins, AC; Rowlands, BJ; Allison, SP			Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomised controlled trial	LANCET			English	Article							FLUID BALANCE; ALBUMIN	Background Low concentrations of albumin in serum and long gastric emptying times have been returned to normal in dogs by salt and water restriction, or a high protein intake. We aimed to determine the effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection in human beings. Methods We randomly allocated ten patients to receive postoperative intravenous fluids in accordance present hospital practice (greater than or equal to3 L water and 154 mmol sodium per day) and ten to receive a restricted intake (less than or equal to2 L water and 77 mmol sodium per day). All patients had no disease other than colonic cancer. The primary endpoint was solid and liquid-phase gastric emptying time, measured by dual isotope radionuclide scintigraphy on the fourth postoperative day. Secondary endpoints included time to first bowel movement and length of postoperative hospital stay. Analysis was by intention to treat. Findings Median solid and liquid phase gastric emptying times (T-50) on the fourth postoperative day were significantly longer in the standard group than in the restricted group (175 vs 72.5 min, difference 56 [95% CI 12-132], p=0.028; and 110 vs 73.5 min, 52 [9-95], p=0.017, respectively). Median passage of flatus was 1 day later (4 vs 3 days, 2 [1-2], p=0.001); median passage of stool 2.5 days later (6.5 vs 4 days, 3 [2-4], p=0.001); and median postoperative hospital stay 3 days longer (9 vs 6 days, 3 [1-8], p=0.001) in the standard group than in the restricted group. One patient in the restricted group developed hypokalaemia, whereas seven patients in the standard group had side-effects or complications (p=0.01). Interpretation Positive salt and water balance sufficient to cause a 3 kg weight gain after surgery delays return of gastrointestinal function and prolongs hospital stay in patients undergoing elective colonic resection.	Univ Nottingham Hosp, Queens Med Ctr, Sect Surg, Nottingham NG7 2UH, England; Univ Nottingham Hosp, Queens Med Ctr, Dept Epidemiol & Publ Hlth Med, Nottingham NG7 2UH, England; Univ Nottingham Hosp, Queens Med Ctr, Dept Med Phys, Nottingham NG7 2UH, England; Univ Nottingham Hosp, Queens Med Ctr, Clin Nutr Unit, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham; University of Nottingham; University of Nottingham	Lobo, DN (corresponding author), Univ Nottingham Hosp, Queens Med Ctr, Sect Surg, E Floor,W Block, Nottingham NG7 2UH, England.	dileep.lobo@nottingham.ac.uk	Lobo, Dileep/AAC-6207-2020	Lobo, Dileep/0000-0003-1187-5796; Perkins, Alan/0000-0002-1054-8200				Alsous F, 2000, CHEST, V117, P1749, DOI 10.1378/chest.117.6.1749; [Anonymous], RADIOIMMUNOASSAY BAS; Arieff AI, 1999, CHEST, V115, P1371, DOI 10.1378/chest.115.5.1371; BARDEN R. P., 1938, Surgery, Gynecology and Obstetrics, V66, P819; Callum K., 1999, EXTREMES AGE 1999 RE; Coller FA, 1944, ANN SURG, V119, P533, DOI 10.1097/00000658-194404000-00007; DURR ED, 1986, GASTROENTEROLOGY, V90, P1401; Frost A., 2001, Proceedings of the Nutrition Society, V60, p113A; Gil MJ, 1997, NUTRITION, V13, P26, DOI 10.1016/S0899-9007(97)90875-3; Heyland DK, 1996, INTENS CARE MED, V22, P1339, DOI 10.1007/BF01709548; Keys A, 1950, BIOL HUMAN STARVATIO; Lobo DN, 1999, CLIN NUTR, V18, P197, DOI 10.1016/S0261-5614(99)80070-3; Lobo DN, 2002, NUCL MED COMMUN, V23, P97, DOI 10.1097/00006231-200201000-00015; Lobo DN, 2001, CLIN SCI, V101, P173, DOI 10.1042/CS20000316; Lobo DN, 2001, CLIN NUTR, V20, P125, DOI 10.1054/clnu.2000.0154; MACKIE C, 1986, ANN SURG, V204, P537, DOI 10.1097/00000658-198611000-00005; MeCray PM, 1937, SURGERY, V1, P53; MOORE FD, 1967, ANN SURG, V166, P300; MOORE FD, 1959, METABOLIC CARE SURG; *PEN LAB INC, 2000, GEN PROT RAD KIT; STARKER PM, 1983, ANN SURG, V198, P720, DOI 10.1097/00000658-198312000-00010; STIGESSERRA A, 1998, CURR OPIN CLIN NUTR, V1, P9; Stoneham MD, 1997, BRIT J CLIN PRACT, V51, P82; WILKINSON AW, 1949, LANCET, V256, P640; WOODS MS, 1993, AM SURGEON, V59, P758	25	675	738	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 25	2002	359	9320					1812	1818		10.1016/S0140-6736(02)08711-1	http://dx.doi.org/10.1016/S0140-6736(02)08711-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044376				2022-12-28	WOS:000175775500009
J	Clark, S				Clark, S			Osteoporosis-the disease of the 21st century?	LANCET			English	Editorial Material									Lancet, London NW1 7BY, England		Clark, S (corresponding author), Lancet, London NW1 7BY, England.								0	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 18	2002	359	9319					1714	1714		10.1016/S0140-6736(02)08662-2	http://dx.doi.org/10.1016/S0140-6736(02)08662-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049857				2022-12-28	WOS:000175740500005
J	Collins, BM; McCoy, AJ; Kent, HM; Evans, PR; Owen, DJ				Collins, BM; McCoy, AJ; Kent, HM; Evans, PR; Owen, DJ			Molecular architecture and functional model of the endocytic AP2 complex	CELL			English	Article							CLATHRIN-COATED VESICLES; SORTING SIGNALS; CRYSTAL-STRUCTURE; ASSEMBLY POLYPEPTIDES; ADAPTER COMPLEXES; APPENDAGE DOMAIN; AP-2 COMPLEXES; PROTEIN AP-2; MU-2 SUBUNIT; IN-VITRO	AP2 is the best-characterized member of the family of heterotetrameric clathrin adaptor complexes that play pivotal roles in many vesicle trafficking pathways within the cell. AP2 functions in clathrin-mediated endocytosis, the process whereby cargo enters the endosomal system from the plasma membrane. We describe the structure of the 200 kDa AP2 "core" (alpha trunk, beta2 trunk, mu2, and sigma2) complexed with the polyphosphatidylinositol headgroup mimic inositolhexakisphosphate at 2.6 Angstrom resolution. Two potential polyphosphatidylinositide binding sites are observed, one on alpha and one on mu2. The binding site for Yxxphi endocytic motifs is buried, indicating that a conformational change, probably triggered by phosphorylation in the disordered mu2 linker, is necessary to allow Yxxphi motif binding. A model for AP2 recruitment and activation is proposed.	Univ Cambridge, Wellcome Med Res Inst, Dept Clin Biochem, Cambridge CB2 2XY, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Cambridge; MRC Laboratory Molecular Biology	Owen, DJ (corresponding author), Univ Cambridge, Wellcome Med Res Inst, Dept Clin Biochem, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.		Collins, Brett/J-1563-2014	Collins, Brett/0000-0002-6070-3774				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BECK KA, 1991, J BIOL CHEM, V266, P4442; Boehm M, 2001, MOL BIOL CELL, V12, P2907, DOI 10.1091/mbc.12.10.2907; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; CADENA DL, 1994, J BIOL CHEM, V269, P260; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; Conner SD, 2002, J CELL BIOL, V156, P921, DOI 10.1083/jcb.200108123; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Engqvist-Goldstein AEY, 2001, J CELL BIOL, V154, P1209, DOI 10.1083/jcb.200106089; Fingerhut A, 2001, J BIOL CHEM, V276, P5476, DOI 10.1074/jbc.M009516200; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Gonzalez LC, 2001, J BIOL CHEM, V276, P24203, DOI 10.1074/jbc.M101584200; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Haffner C, 2000, CURR BIOL, V10, P471, DOI 10.1016/S0960-9822(00)00446-2; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; Johnson LN, 2001, CHEM REV, V101, P2209, DOI 10.1021/cr000225s; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Levine TP, 1998, CURR BIOL, V8, P729, DOI 10.1016/S0960-9822(98)70296-9; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; Meyer C, 2000, EMBO J, V19, P2193, DOI 10.1093/emboj/19.10.2193; Morgan JR, 2001, NEURON, V32, P289, DOI 10.1016/S0896-6273(01)00467-6; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Olusanya O, 2001, CURR BIOL, V11, P896, DOI 10.1016/S0960-9822(01)00240-8; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Owen DJ, 2001, TRAFFIC, V2, P105, DOI 10.1034/j.1600-0854.2001.020205.x; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; PAULOIN A, 1993, BIOCHEM J, V296, P409, DOI 10.1042/bj2960409; PEARSE BMF, 1975, J MOL BIOL, V97, P93, DOI 10.1016/S0022-2836(75)80024-6; Peden AA, 2002, J CELL BIOL, V156, P327, DOI 10.1083/jcb.200107140; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Ricotta D, 2002, J CELL BIOL, V156, P791, DOI 10.1083/jcb.200111068; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; Tochio H, 2001, SCIENCE, V293, P698, DOI 10.1126/science.1062950; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Traub LM, 1997, TRENDS CELL BIOL, V7, P43, DOI 10.1016/S0962-8924(96)20042-X; Umeda A, 2000, EUR J CELL BIOL, V79, P336, DOI 10.1078/S0171-9335(04)70037-0; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; ZAREMBA S, 1985, J CELL BIOCHEM, V28, P47, DOI 10.1002/jcb.240280108	60	423	436	0	42	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 17	2002	109	4					523	535		10.1016/S0092-8674(02)00735-3	http://dx.doi.org/10.1016/S0092-8674(02)00735-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	553VM	12086608	Bronze			2022-12-28	WOS:000175696800013
J	Robyr, D; Suka, Y; Xenarios, I; Kurdistani, SK; Wang, A; Suka, N; Grunstein, M				Robyr, D; Suka, Y; Xenarios, I; Kurdistani, SK; Wang, A; Suka, N; Grunstein, M			Microarray deacetylation maps determine genome-wide functions for yeast histone deacetylases	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; RPD3; REPLICATION; HETEROCHROMATIN; ACETYLATION; EXPRESSION; REPRESSION; COMPLEX; SIR2; SITE	Yeast contains a family of five related histone deacetylases (HDACs) whose functions are known at few genes. Therefore, we used chromatin immunoprecipitation and intergenic microarrays to generate genome-wide HDAC enzyme activity maps. Rpd3 and Hda1 deacetylate mainly distinct promoters and gene classes where they are recruited largely by novel mechanisms. Hda1 also deacetylates subtelomeric domains containing normally repressed genes that are used instead for gluconeogenesis, growth on carbon sources other than glucose, and adverse growth conditions. These domains have certain features of heterochromatin but are distinct from subtelomeric heterochromatin repressed by the deacetylase Sir2. Finally, Hos1/Hos3 and Hos2 preferentially affect ribosomal DNA and ribosomal protein genes, respectively. Thus, acetylation microarrays uncover the "division of labor" for yeast histone deacetylases.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, US DOE, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; United States Department of Energy (DOE); University of California System; University of California Los Angeles	Grunstein, M (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Boyer Hall, Los Angeles, CA 90095 USA.		Xenarios, Ioannis/ABD-5045-2021	Xenarios, Ioannis/0000-0002-3413-6841; Kurdistani, Siavash/0000-0003-3295-3511	NIGMS NIH HHS [GM23674, GM42421] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042421, R01GM023674, R37GM023674] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; Carmen AA, 2002, J BIOL CHEM, V277, P4778, DOI 10.1074/jbc.M110532200; CLARK T, 1983, J COMPUT CHEM, V4, P294, DOI 10.1002/jcc.540040303; Davie JK, 2002, MOL CELL BIOL, V22, P693, DOI 10.1128/MCB.22.3.693-703.2002; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DeRubertis F, 1996, NATURE, V384, P589; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KURDISTANI SK, 2002, IN PRESS NAT GENET, V31; LAMAN H, 1995, MOL CELL BIOL, V15, P3608; LUCCHINI R, 1994, MOL CELL BIOL, V14, P318, DOI 10.1128/MCB.14.1.318; Moazed D, 2001, CURR OPIN CELL BIOL, V13, P232, DOI 10.1016/S0955-0674(00)00202-7; Raghuraman MK, 2001, SCIENCE, V294, P115, DOI 10.1126/science.294.5540.115; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Van Helden J, 2000, YEAST, V16, P177, DOI 10.1002/(SICI)1097-0061(20000130)16:2<177::AID-YEA516>3.0.CO;2-9; Vannier D, 1996, GENETICS, V144, P1343; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Watson AD, 2000, GENE DEV, V14, P2737, DOI 10.1101/gad.829100; White DA, 1999, METHODS, V19, P417, DOI 10.1006/meth.1999.0878; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5; Yamashita M, 1997, GENES CELLS, V2, P655, DOI 10.1046/j.1365-2443.1997.1530351.x	36	363	371	0	27	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 17	2002	109	4					437	446		10.1016/S0092-8674(02)00746-8	http://dx.doi.org/10.1016/S0092-8674(02)00746-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	553VM	12086601	Bronze			2022-12-28	WOS:000175696800006
J	Popp, W; Mentfewitz, J; Gotz, R; Voshaar, T				Popp, W; Mentfewitz, J; Gotz, R; Voshaar, T			Phosphine poisoning in a German office	LANCET			English	Article									Univ Med Ctr, D-45122 Essen, Germany; N Rhine Westphalia State Environm Agcy, Essen, Germany; Bethanien Hosp, Div Gastroenterol Hepatol & Metab Dis, D-47441 Moers, Germany; Bethanien Hosp, Med Clin 3, D-47441 Moers, Germany	University of Duisburg Essen	Popp, W (corresponding author), Univ Med Ctr, Hufelandstr 55, D-45122 Essen, Germany.							American Conference of Governmental Industrial Hygienists (ACGIH), 2000, TLVS BEIS; *DFG, 2001, LIST MAK BAT VAL 200; MISRA UK, 1988, TOXICOL LETT, V42, P257, DOI 10.1016/0378-4274(88)90110-5; Stokinger H.E., 1981, PATTYS IND HYGIENE T, V2A, P1807; WILSON R, 1980, JAMA-J AM MED ASSOC, V244, P148, DOI 10.1001/jama.244.2.148	5	17	18	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 4	2002	359	9317					1574	1574		10.1016/S0140-6736(02)08518-5	http://dx.doi.org/10.1016/S0140-6736(02)08518-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047968				2022-12-28	WOS:000175460700012
J	Roy, S; Knox, K; Segal, S; Griffiths, D; Moore, CE; Welsh, KI; Smarason, A; Day, NP; McPheat, WL; Crook, DW; Hill, AVS				Roy, S; Knox, K; Segal, S; Griffiths, D; Moore, CE; Welsh, KI; Smarason, A; Day, NP; McPheat, WL; Crook, DW; Hill, AVS		Oxford Pneumococcal Surveillance	MBL genotype and risk of invasive pneumococcal disease: a case-control study	LANCET			English	Article							MANNOSE-BINDING-PROTEIN; LECTIN MBL; GENE; INFECTION; ASSOCIATION; SUSCEPTIBILITY; MUTATIONS; VARIANTS; ALLELES; PATHOGENS	Background Streptococcus pneumoniae is a major cause of morbidity and mortality in developed and developing countries. No common genetic determinants of susceptibility have been defined. Mannose-binding lectin (MBL) is a key mediator of innate host immunity that activates the complement pathway and directly opsonises some infectious pathogens. Mutations in three codons in the MBL gene have been identified, and individuals homozygous for a mutant genotype have very little or no serum MBL. We did a case-control study in the UK to assess whether these mutant genotypes were associated with invasive pneumococcal disease. Methods The frequencies of genotypes defined by the three mutations in codons 52, 54, and 57, and a functional promoter polymorphism at -221, were compared in a two-stage study of 337 patients with invasive pneumococcal disease and 1032 controls. All individuals were recruited from an ethnically homogeneous white population in Oxfordshire, UK. Patients had S pneumoniae isolated from a normally sterile site. Findings In our initial set of participants, 28 (12%) of 229 patients and 18 (5%) of 353 controls were homozygotes for MBL codon variants (odds ratio 2.59 [95% CI 1.39-4.83], p=0.002). Neither heterozygosity for these codon variants nor the promoter polymorphism was associated with susceptibility. In a confirmatory study, 11 (10%) of 108 patients were MBL homozygotes compared with 36 (5%) of 679 controls (p=0.046). Interpretation Homozygotes for MBL codon variants, who represent about 5% of north Europeans and north Americans and larger proportions of populations in many developing countries, could be at substantially increased risk of invasive pneumococcal disease.	John Radcliffe Hosp, Dept Microbiol, Oxford OX3 9DU, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; John Radcliffe Hosp, Dept Paediat, Oxford Vaccine Grp, Oxford OX3 9DU, England; John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England; Churchill Hosp, Dept Surg, Oxford OX3 7LJ, England; AstraZeneca, Macclesfield, Cheshire, England	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Oxford; University of Oxford; AstraZeneca	Hill, AVS (corresponding author), John Radcliffe Hosp, Dept Microbiol, Room 7501, Oxford OX3 9DU, England.	adrian.hill@well.ox.ac.uk	Moore, Catrin/K-1980-2017; HILL, Adrian V>S>/C-1306-2008	Moore, Catrin/0000-0002-8639-9846; 				Bellamy R, 1998, QJM-INT J MED, V91, P13, DOI 10.1093/qjmed/91.1.13; Colman G, 1998, J MED MICROBIOL, V47, P17, DOI 10.1099/00222615-47-1-17; Davies J, 2000, LANCET, V355, P1885, DOI 10.1016/S0140-6736(00)02297-2; EZEKOWITZ RAB, 1989, J EXP MED, V169, P185, DOI 10.1084/jem.169.1.185; FINLAND M, 1982, BACTERIAL INFECT HUM; GABOLDE M, 1999, ASS VARIANT ALLELES, P1166; Garred P, 1997, LANCET, V349, P236, DOI 10.1016/S0140-6736(96)08440-1; Garred P, 1999, ARTHRITIS RHEUM, V42, P2145, DOI 10.1002/1529-0131(199910)42:10<2145::AID-ANR15>3.0.CO;2-#; Garred P, 1999, J CLIN INVEST, V104, P431, DOI 10.1172/JCI6861; GARRED P, 1994, EUR J IMMUNOGENET, V21, P125, DOI 10.1111/j.1744-313X.1994.tb00183.x; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; GARRED P, 1993, SCAND J IMMUNOL, V37, P468, DOI 10.1111/j.1365-3083.1993.tb03320.x; Hibberd ML, 1999, LANCET, V353, P1049, DOI 10.1016/S0140-6736(98)08350-0; Hill AVS, 2001, ANNU REV GENOM HUM G, V2, P373, DOI 10.1146/annurev.genom.2.1.373; Hoal-van Helden EG, 1999, PEDIATR RES, V45, P459, DOI 10.1203/00006450-199904010-00002; Homoe P, 1999, SCAND J INFECT DIS, V31, P363, DOI 10.1080/00365549950163798; Koch A, 2001, JAMA-J AM MED ASSOC, V285, P1316, DOI 10.1001/jama.285.10.1316; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LINDBERG B, 1977, CARBOHYD RES, V58, P177, DOI 10.1016/S0008-6215(00)83413-8; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; MADSEN HO, 1995, J IMMUNOL, V155, P3013; Matsushita M, 1998, IMMUNOBIOLOGY, V199, P340, DOI 10.1016/S0171-2985(98)80038-7; Mead R, 1997, LANCET, V349, P1669, DOI 10.1016/S0140-6736(05)62635-9; Nepomuceno RR, 1997, IMMUNITY, V6, P119, DOI 10.1016/S1074-7613(00)80419-7; Neth O, 2000, INFECT IMMUN, V68, P688, DOI 10.1128/IAI.68.2.688-693.2000; SASTRY K, 1989, J EXP MED, V170, P1175, DOI 10.1084/jem.170.4.1175; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; Sumiya M, 1996, QJM-MON J ASSOC PHYS, V89, P723, DOI 10.1093/qjmed/89.10.723; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; Summerfield JA, 1997, BRIT MED J, V314, P1229, DOI 10.1136/bmj.314.7089.1229; Tang C, 1999, LANCET, V354, P336, DOI 10.1016/S0140-6736(05)75240-5; Turner MW, 1998, IMMUNOBIOLOGY, V199, P327, DOI 10.1016/S0171-2985(98)80037-5; Valdimarsson H, 1998, SCAND J IMMUNOL, V48, P116; VANEMMERIK LC, 1994, CLIN EXP IMMUNOL, V97, P411; *WHO, 1998, WHO VACC RES DEV STE	35	237	250	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 4	2002	359	9317					1569	1573		10.1016/S0140-6736(02)08516-1	http://dx.doi.org/10.1016/S0140-6736(02)08516-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047967				2022-12-28	WOS:000175460700011
J	Irwin, RP; Maxwell, TA; Howard, AD; Craddock, RA; Leverington, DW				Irwin, RP; Maxwell, TA; Howard, AD; Craddock, RA; Leverington, DW			A large paleolake basin at the head of Ma'adim Vallis, Mars	SCIENCE			English	Article							MARGARITIFER SINUS; CRATER; EVOLUTION; DRAINAGE; MODELS	At 8 to 15 kilometers wide, Ma'adim Vallis is one of the largest valleys in the martian highlands. Although a groundwater source was previously suggested, the channel originates at a spillway in the divide of a similar to3,000,000-square-kilometer closed drainage basin. The interior morphology of this source basin, including likely shoreline features following topographic contours, suggests that Ma'adim Vallis was created through catastrophic overflow of a similar to1,100,000-square-kilometer highland lake. The size, constant levels, and interior morphology of three regional paleolake basins require a warmer paleoclimate and a long-term, recharged, stable highland water table more than similar to3.5 billion years ago.	Smithsonian Inst, Natl Air & Space Museum, Ctr Earth & Planetary Studies, Washington, DC 20560 USA; Univ Virginia, Dept Environm Sci, Charlottesville, VA 22904 USA	Smithsonian Institution; University of Virginia	Irwin, RP (corresponding author), Smithsonian Inst, Natl Air & Space Museum, Ctr Earth & Planetary Studies, Washington, DC 20560 USA.		Craddock, Robert/B-3884-2013	Howard, Alan/0000-0002-5423-1600				[Anonymous], 1993, 274 GEOL SOC AM; Cabrol NA, 1999, ICARUS, V142, P160, DOI 10.1006/icar.1999.6191; Cabrol NA, 1997, ICARUS, V125, P455, DOI 10.1006/icar.1996.5625; Cabrol NA, 1996, ICARUS, V123, P269, DOI 10.1006/icar.1996.0157; Cabrol NA, 1998, ICARUS, V132, P362, DOI 10.1006/icar.1998.5903; Cabrol NA, 1998, ICARUS, V133, P98, DOI 10.1006/icar.1998.5914; Carr M.H, 1996, WATER MARS; CARR MH, 1979, J GEOPHYS RES, V84, P2995, DOI 10.1029/JB084iB06p02995; CARTER BL, 2001, LUNAR LANET SCI C, V32, P2042; Craddock RA, 1997, J GEOPHYS RES-PLANET, V102, P13321, DOI 10.1029/97JE01084; Forsythe RD, 1998, J GEOPHYS RES-PLANET, V103, P31421, DOI 10.1029/98JE01966; FREY HV, 2001, 2001 GSA ANN M BOST; Grant JA, 2000, GEOLOGY, V28, P223, DOI 10.1130/0091-7613(2000)028<0223:VFIMSM>2.3.CO;2; Hartmann WK, 2001, SPACE SCI REV, V96, P165, DOI 10.1023/A:1011945222010; Head JW, 1999, SCIENCE, V286, P2134, DOI 10.1126/science.286.5447.2134; HOWARD AD, 2000, EOS S, V81; IRWIN RP, IN PRESS J GEOPHYS R; KOMAR PD, 1980, ICARUS, V42, P317, DOI 10.1016/0019-1035(80)90097-4; Malin MC, 2000, SCIENCE, V288, P2330, DOI 10.1126/science.288.5475.2330; MANENT LS, 1986, EARTH MOON PLANETS, V34, P149, DOI 10.1007/BF00055132; PARKER TJ, 1989, ICARUS, V82, P111, DOI 10.1016/0019-1035(89)90027-4; PARKER TJ, 2000, LUNAR PLANET SCI, V31, P2033; SHARP RP, 1975, GEOL SOC AM BULL, V86, P593, DOI 10.1130/0016-7606(1975)86<593:COM>2.0.CO;2; Smith DE, 2001, J GEOPHYS RES-PLANET, V106, P23689, DOI 10.1029/2000JE001364; TANAKA KL, 1986, J GEOPHYS RES-SOLID, V91, pE139, DOI 10.1029/JB091iB13p0E139; THORNHILL GD, 1993, J GEOPHYS RES-PLANET, V98, P23581, DOI 10.1029/93JE03153; [No title captured]	27	115	115	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 21	2002	296	5576					2209	2212		10.1126/science.1071143	http://dx.doi.org/10.1126/science.1071143			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077414				2022-12-28	WOS:000176379000055
J	Chou, SY; Keimel, C; Gu, J				Chou, SY; Keimel, C; Gu, J			Ultrafast and direct imprint of nanostructures in silicon	NATURE			English	Article							LASER; LITHOGRAPHY	The fabrication of micrometre- and nanometre-scale devices in silicon typically involves lithography and etching. These processes are costly and tend to be either limited in their resolution or slow in their throughput(1). Recent work has demonstrated the possibility of patterning substrates on the nanometre scale by `imprinting('2,3) or directed self-assembly(4), although an etching step is still required to generate the final structures. We have devised and here demonstrate a rapid technique for patterning nanostructures in silicon that does not require etching. In our technique-which we call 'laser-assisted direct imprint' (LADI)a single excimer laser pulse melts a thin surface layer of silicon, and a mould is embossed into the resulting liquid layer. A variety of structures with resolution better than 10 nm have been imprinted into silicon using LADI, and the embossing time is less than 250 ns. The high resolution and speed of LADI, which we attribute to molten silicon's low viscosity (one-third that of water), could open up a variety of applications and be extended to other materials and processing techniques.	Princeton Univ, Dept Elect Engn, NanoStruct Lab, Princeton, NJ 08544 USA	Princeton University	Chou, SY (corresponding author), Princeton Univ, Dept Elect Engn, NanoStruct Lab, Princeton, NJ 08544 USA.							CAREY PG, 1989, APPL SURF SCI, V43, P325, DOI 10.1016/0169-4332(89)90234-1; Chou SY, 1999, J VAC SCI TECHNOL B, V17, P3197, DOI 10.1116/1.590979; Chou SY, 1996, SCIENCE, V272, P85, DOI 10.1126/science.272.5258.85; Glazov V. M., 1969, LIQUID SEMICONDUCTOR; Ito T, 2000, NATURE, V406, P1027, DOI 10.1038/35023233; Ivlev GD, 2000, SEMICONDUCTORS+, V34, P759, DOI 10.1134/1.1188068; Langen M, 1998, J CRYST GROWTH, V186, P550, DOI 10.1016/S0022-0248(97)00619-2; POUTE JM, 1982, LASER ANNEALING SEMI; ROGERS JA, 2001, MAT RES B, V26; Silvestrelli PL, 1996, PHYS REV LETT, V77, P3149, DOI 10.1103/PhysRevLett.77.3149; WEINER KH, 1989, IEEE ELECTR DEVICE L, V10, P260, DOI 10.1109/55.31740	11	385	476	6	159	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 20	2002	417	6891					835	837		10.1038/nature00792	http://dx.doi.org/10.1038/nature00792			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075347				2022-12-28	WOS:000176285600042
J	Higashi, Y; Sasaki, S; Nakagawa, K; Matsuura, H; Oshima, T; Chayama, K				Higashi, Y; Sasaki, S; Nakagawa, K; Matsuura, H; Oshima, T; Chayama, K			Endothelial function and oxidative stress in renovascular hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEPENDENT VASCULAR RELAXATION; LOW-DENSITY-LIPOPROTEIN; NITRIC-OXIDE; REACTIVE HYPEREMIA; ANGIOTENSIN-II; RELAXING FACTOR; IN-VIVO; DYSFUNCTION; VASODILATION; ACTIVATION	Background: It has been reported that renovascular hypertension activates the renin-angiotensin system, leading to an increase in oxidative stress. We sought to determine whether renal-artery angioplasty improves endothelial dysfunction in patients with renovascular hypertension through a reduction in oxidative stress. Methods: We evaluated the response of forearm blood flow to acetylcholine, an endothelium-dependent vasodilator, and isosorbide dinitrate, an endothelium-independent vasodilator, before and after renal-artery angioplasty in 15 subjects with renovascular hypertension and 15 controls without hypertension who were matched for age and sex. Forearm blood flow was measured with the use of a mercury-filled Silastic strain-gauge plethysmograph. Results: The forearm blood flow in response to acetylcholine was less in subjects with renovascular hypertension than in controls, although the forearm blood flow in response to isosorbide dinitrate was similar in the two groups. Angioplasty decreased systolic and diastolic blood pressures, forearm vascular resistance, and urinary excretion of 8-hydroxy-2'-deoxyguanosine and serum malondialdehyde-modified low-density lipoprotein (LDL), indexes of oxidative stress. After angioplasty, the mean (+/-SD) forearm blood flow in response to acetylcholine was increased in the patients with renovascular hypertension (19.3+/-6.8 vs. 29.6+/-7.1 ml per minute per 100 ml, P=0.002). The increase in the maximal forearm blood flow in response to acetylcholine correlated significantly with the decrease in urinary excretion of 8-hydroxy-2'-deoxyguanosine (r=-0.51, P=0.004) and serum malondialdehyde-modified LDL (r=-0.39, P=0.02). Coinfusion of ascorbic acid (vitamin C) augmented the response of forearm blood flow to acetylcholine before angioplasty (P<0.001) but not after angioplasty. Conclusions: These findings suggest that excessive oxidative stress is involved, at least in part, in impaired endothelium-dependent vasodilatation in patients with renovascular hypertension.	Hiroshima Univ, Fac Med, Dept Internal Med 1, Div Hypertens & Cardiol,Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Fac Med, Dept Clin Lab Med, Hiroshima 7348551, Japan	Hiroshima University; Hiroshima University	Higashi, Y (corresponding author), Hiroshima Univ, Fac Med, Dept Internal Med 1, Div Hypertens & Cardiol,Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	yhigashi@hiroshima-u.ac.jp	Chayama, Kazuaki/B-2493-2016; Higashi, Yukihito/G-5343-2019	Chayama, Kazuaki/0000-0002-5530-5341				Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; CREAGER MA, 1994, HYPERTENSION, V24, P499, DOI 10.1161/01.HYP.24.4.499; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; Dijkhorst-Oei LT, 1999, J CARDIOVASC PHARM, V33, P420, DOI 10.1097/00005344-199903000-00012; DOHI Y, 1990, HYPERTENSION, V16, P170, DOI 10.1161/01.HYP.16.2.170; Drexler H, 1999, J MOL CELL CARDIOL, V31, P51, DOI 10.1006/jmcc.1998.0843; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; GREENBERG SS, 1990, AM J HYPERTENS, V3, P211, DOI 10.1093/ajh/3.3.211; Hegde LG, 1998, CLIN EXP HYPERTENS, V20, P885, DOI 10.3109/10641969809053253; Higashi Y, 1999, CIRCULATION, V100, P1194, DOI 10.1161/01.CIR.100.11.1194; Higashi Y, 2000, J AM COLL CARDIOL, V35, P284, DOI 10.1016/S0735-1097(99)00561-6; Higashi Y, 2001, J AM COLL CARDIOL, V37, P863, DOI 10.1016/S0735-1097(00)01177-3; Iwatsubo H, 1997, HYPERTENSION, V29, P286, DOI 10.1161/01.HYP.29.1.286; Leinonen J, 1997, FEBS LETT, V417, P150, DOI 10.1016/S0014-5793(97)01273-8; Lerman LO, 2001, HYPERTENSION, V37, P541, DOI 10.1161/01.HYP.37.2.541; MAGGI E, 1995, J HYPERTENS, V13, P129; Nakae D, 1997, CANCER RES, V57, P1281; OHYANAGI M, 1992, CIRC RES, V71, P188, DOI 10.1161/01.RES.71.1.188; PALINSKI W, 1995, P NATL ACAD SCI USA, V92, P821, DOI 10.1073/pnas.92.3.821; PANZA JA, 1993, CIRCULATION, V87, P1468, DOI 10.1161/01.CIR.87.5.1468; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Rizzoni D, 1998, HYPERTENSION, V31, P335, DOI 10.1161/01.HYP.31.1.335; Romero JC, 1999, HYPERTENSION, V34, P943, DOI 10.1161/01.HYP.34.4.943; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SCHIFFRIN EL, 1995, HYPERTENSION, V25, P699, DOI 10.1161/01.HYP.25.4.699; Taddei S, 1998, CIRCULATION, V97, P2222, DOI 10.1161/01.CIR.97.22.2222; TADDEI S, 1993, HYPERTENSION, V21, P929, DOI 10.1161/01.HYP.21.6.929	28	396	413	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 20	2002	346	25					1954	1962		10.1056/NEJMoa013591	http://dx.doi.org/10.1056/NEJMoa013591			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563QC	12075056				2022-12-28	WOS:000176266200004
J	Badri, M; Wilson, D; Wood, R				Badri, M; Wilson, D; Wood, R			Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study	LANCET			English	Article							SUB-SAHARAN AFRICA; HIV-INFECTION; PULMONARY TUBERCULOSIS; MORTALITY; ADULTS; IMMUNODEFICIENCY; PREVALENCE; PREVENTION; ILLNESSES; IMPACT	Background Studies of the effect of highly active antiretroviral therapy (HAART) on the risk of HIV-1-associated tuberculosis have had variable results, We set out to determine the effect of HAART on the risk of tuberculosis in South Africa. Methods We compared the risk of tuberculosis in 264 patients who received HAART in phase III clinical trials and a prospective cohort of 770 non-HAART patients who were attending Somerset Hospital adult HIV clinic, University of Cape Town, between 1992 and 2001. Poisson regression models were fitted to determine risk of tuberculosis; patients were stratified by CD4 count, WHO clinical stage, and socioeconomic status. Findings HAART was associated with a lower incidence of tuberculosis (2.4 vs 9.7 cases per 100 patient-years, adjusted rate ratio 0.19 [95% Cl 0.09-0.38]; p<0.0001). This finding was apparent across all strata of socioeconomic status, baseline WHO stage, and CD4 count, except in patients with CD4 counts of more than 350 cells/&mu;L. The number of tuberculosis cases averted by HAART was greatest in patients with WHO stage 3 or 4 (18.8 averted cases per 100 patient-years, adjusted rate ratio 0.22 [0.09-0.41]; p=0.03) and in those with CD4 counts of less than 200 cells/&mu;L (14.2 averted cases per 100 patient-years, adjusted rate ratio 0.18 [0.07-0.47]; P<0.0001). Interpretation HAART reduced the incidence of HIV-1-associated tuberculosis by more than 80% (95% Cl 62-91) in an area endemic with tuberculosis and HIV-1. The protective effect of HAART was greatest in symptomatic patients and those with advanced immune suppression.	Univ Cape Town, Somerset Hosp, HIV Clin Res Unit, ZA-8005 Cape Town, South Africa	University of Cape Town	Wood, R (corresponding author), Univ Cape Town, Somerset Hosp, HIV Clin Res Unit, ZA-8005 Cape Town, South Africa.		Wood, Robin/G-8509-2011; Badri, Motasim/E-1141-2013	Badri, Motasim/0000-0002-5268-6492				ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7; Badri M, 2002, INT J TUBERC LUNG D, V6, P231; Badri M, 2001, INT J TUBERC LUNG D, V5, P225; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; *CAP METR COUNC, 1997, LEV LIV CAP METR AR; De Cock KM, 1999, INT J TUBERC LUNG D, V3, P457; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Girardi E, 2000, AIDS, V14, P1985, DOI 10.1097/00002030-200009080-00015; Halsey NA, 1998, LANCET, V351, P786, DOI 10.1016/S0140-6736(97)06532-X; Harries AD, 2001, LANCET, V357, P1519, DOI 10.1016/S0140-6736(00)04639-0; Jones JL, 2000, INT J TUBERC LUNG D, V4, P1026; LANGE JMA, 1993, AIDS, V7, P1675, DOI 10.1097/00002030-199312000-00021; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; LEROY V, 1997, AM J EPIDEMIOL, V145, P295; MUKADI Y, 1993, LANCET, V342, P143, DOI 10.1016/0140-6736(93)91346-N; NAIDO P, 2001, 11 JOINT C STD ID SO; Santoro-Lopes G, 2002, CLIN INFECT DIS, V34, P543, DOI 10.1086/338641; UNAIDS, 2000, AIDS EP UPD DEC 2000; WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542; Whalen CC, 2000, AIDS, V14, P1219, DOI 10.1097/00002030-200006160-00020; *WHO, 2000, 1 M GLOB WORK GROUP; *WHO, 1990, WKLY EPIDEMIOL REC, V65, P221; Wilkinson D, 1998, BRIT MED J, V317, P625, DOI 10.1136/bmj.317.7159.625; Wood R, 2000, J ACQ IMMUN DEF SYND, V23, P75; World Health Organization, 2002, SCAL ANT THER RES LT	26	430	433	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 15	2002	359	9323					2059	2064		10.1016/S0140-6736(02)08904-3	http://dx.doi.org/10.1016/S0140-6736(02)08904-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086758				2022-12-28	WOS:000176194600006
J	Shiraki, K; Kamo, M; Sai, T; Kamo, R				Shiraki, K; Kamo, M; Sai, T; Kamo, R			Rare site for an intramuscular lipoma	LANCET			English	Editorial Material									Osaka City Kita Municipal Hosp, Dept Ophthalmol, Abeno Ku, Osaka 5458585, Japan; Osaka City Univ, Grad Sch Med, Dept Ophthalmol, Abeno Ku, Osaka 5458585, Japan; Osaka City Univ, Grad Sch Med, Dept Dermatol, Abeno Ku, Osaka 5458585, Japan	Osaka Metropolitan University; Osaka Metropolitan University	Shiraki, K (corresponding author), Osaka City Kita Municipal Hosp, Dept Ophthalmol, Abeno Ku, Osaka 5458585, Japan.								0	7	7	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 15	2002	359	9323					2077	2077		10.1016/S0140-6736(02)08906-7	http://dx.doi.org/10.1016/S0140-6736(02)08906-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086761				2022-12-28	WOS:000176194600009
J	Leinekugel, X; Khazipov, R; Cannon, R; Hirase, H; Ben-Ari, Y; Buzsaki, G				Leinekugel, X; Khazipov, R; Cannon, R; Hirase, H; Ben-Ari, Y; Buzsaki, G			Correlated bursts of activity in the neonatal hippocampus in vivo	SCIENCE			English	Article							LONG-TERM POTENTIATION; VISUAL-CORTEX; NETWORK; RAT; NEURONS; GABA(A); NMDA; OSCILLATIONS; MECHANISMS; PLASTICITY	The behavior of immature cortical networks in vivo remains largely unknown. Using multisite extracellular and patch-clamp recordings, we observed recurrent bursts of synchronized neuronal activity lasting 0.5 to 3 seconds that occurred spontaneously in the hippocampus of freely moving and anesthetized rat pups. The influence of slow rhythms (0.33 and 0.1 hertz) and the contribution of both gamma-aminobutyric acid A-mediated and glutamate receptor-mediated synaptic signals in the generation of hippocampal bursts was reminiscent of giant depolarizing potentials observed in vitro. This earliest pattern, which diversifies during the second postnatal week, could provide correlated activity for immature neurons and may underlie activity-dependent maturation of the hippocampal network.	INSERM, U29, INMED, F-13273 Marseille 09, France; Rutgers State Univ, Ctr Mol & Behav Neurosci, Newark, NJ 07102 USA; Univ Paris 06, Fac Med Pitie Salpetriere, INSERM, EMI 0224, F-75013 Paris, France; Harvard Univ, Childrens Hosp, Sch Med, Boston, MA 02115 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Rutgers State University Newark; Rutgers State University New Brunswick; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Harvard University; Boston Children's Hospital; Harvard Medical School	Leinekugel, X (corresponding author), INSERM, U29, INMED, Ave Luminy,Boite Postale 13, F-13273 Marseille 09, France.	xlkg@noos.fr	Hirase, Hajime/A-3709-2012; Leinekugel, Xavier/F-4034-2014; Leinekugel, Xavier/ABD-8347-2021; Khazipov, Roustem/M-1834-2016	Hirase, Hajime/0000-0003-3806-6905; Leinekugel, Xavier/0000-0003-2878-3791; Khazipov, Roustem/0000-0002-6763-2841; Buzsaki, Gyorgy/0000-0002-3100-4800; Ben-Ari, Yehezkel/0000-0001-6208-8480	FIC NIH HHS [FO6 TW02290] Funding Source: Medline; NCRR NIH HHS [RR09754] Funding Source: Medline; NINDS NIH HHS [NS 34994, NS 43157] Funding Source: Medline; PHS HHS [N0T 43994] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F06TW002290] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR009754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043157, R01NS034994] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGMON A, 1992, J NEUROPHYSIOL, V68, P345, DOI 10.1152/jn.1992.68.1.345; Aguilo A, 1999, J NEUROSCI, V19, P10856, DOI 10.1523/JNEUROSCI.19-24-10856.1999; Ben-Ari Y, 2001, TRENDS NEUROSCI, V24, P353, DOI 10.1016/S0166-2236(00)01813-0; BenAri Y, 1997, TRENDS NEUROSCI, V20, P523, DOI 10.1016/S0166-2236(97)01147-8; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; BUZSAKI G, 1995, CURR OPIN NEUROBIOL, V5, P504, DOI 10.1016/0959-4388(95)80012-3; BUZSAKI G, 1989, EXP NEUROL, V105, P10, DOI 10.1016/0014-4886(89)90167-2; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; Csicsvari J, 2000, NEURON, V28, P585, DOI 10.1016/S0896-6273(00)00135-5; de la Prida LM, 1998, EUR J NEUROSCI, V10, P899, DOI 10.1046/j.1460-9568.1998.00097.x; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; Garaschuk O, 1998, J PHYSIOL-LONDON, V507, P219, DOI 10.1111/j.1469-7793.1998.219bu.x; Garaschuk O, 2000, NAT NEUROSCI, V3, P452, DOI 10.1038/74823; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; Isaac JTR, 1997, NEURON, V18, P269, DOI 10.1016/S0896-6273(00)80267-6; Kandler Karl, 1995, Current Opinion in Neurobiology, V5, P98, DOI 10.1016/0959-4388(95)80093-X; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Khazipov R, 1997, J PHYSIOL-LONDON, V498, P763, DOI 10.1113/jphysiol.1997.sp021900; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; LEBLANC MO, 1979, EXP NEUROL, V66, P220, DOI 10.1016/0014-4886(79)90076-1; LEINEKUGEL X, 1995, J PHYSIOL-LONDON, V487, P319, DOI 10.1113/jphysiol.1995.sp020882; Leinekugel X, 1997, NEURON, V18, P243, DOI 10.1016/S0896-6273(00)80265-2; Mooney R, 1996, NEURON, V17, P863, DOI 10.1016/S0896-6273(00)80218-4; REITER HO, 1986, EXP BRAIN RES, V65, P182; Schwartz TH, 1998, NEURON, V20, P541, DOI 10.1016/S0896-6273(00)80993-9; Weliky M, 1999, SCIENCE, V285, P599, DOI 10.1126/science.285.5427.599; YLINEN A, 1995, J NEUROSCI, V15, P30; YUSTE R, 1992, SCIENCE, V257, P666, DOI 10.1126/science.1496379; YUSTE R, 1991, NEURON, V6, P333, DOI 10.1016/0896-6273(91)90243-S	30	242	246	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	2002	296	5575					2049	2052		10.1126/science.1071111	http://dx.doi.org/10.1126/science.1071111			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065842				2022-12-28	WOS:000176273300060
J	Abraham, WT; Fisher, WG; Smith, AL; Delurgio, DB; Leon, AR; Loh, E; Kocovic, DZ; Packer, M; Clavell, AL; Hayes, DL; Ellestad, M; Messenger, J; Trupp, RJ; Underwood, J; Pickering, F; Truex, C; McAtee, P				Abraham, WT; Fisher, WG; Smith, AL; Delurgio, DB; Leon, AR; Loh, E; Kocovic, DZ; Packer, M; Clavell, AL; Hayes, DL; Ellestad, M; Messenger, J; Trupp, RJ; Underwood, J; Pickering, F; Truex, C; McAtee, P		MIRACLE Study Grp	Cardiac resynchronization in chronic heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVENTRICULAR-CONDUCTION DELAY; LEFT-VENTRICULAR FUNCTION; DILATED CARDIOMYOPATHY; EXERCISE CAPACITY; RANDOMIZED TRIAL; MORTALITY; VESNARINONE; EXPERIENCE; RATIONALE; PROGNOSIS	Background: Previous studies have suggested that cardiac resynchronization achieved through atrial-synchronized biventricular pacing produces clinical benefits in patients with heart failure who have an intraventricular conduction delay. We conducted a double-blind trial to evaluate this therapeutic approach. Methods: Four hundred fifty-three patients with moderate-to-severe symptoms of heart failure associated with an ejection fraction of 35 percent or less and a QRS interval of 130 msec or more were randomly assigned to a cardiac-resynchronization group (228 patients) or to a control group (225 patients) for six months, while conventional therapy for heart failure was maintained. The primary end points were the New York Heart Association functional class, quality of life, and the distance walked in six minutes. Results: As compared with the control group, patients assigned to cardiac resynchronization experienced an improvement in the distance walked in six minutes (+39 vs. +10 m, P=0.005), functional class (P<0.001), quality of life (-18.0 vs. -9.0 points, P=0.001), time on the treadmill during exercise testing (+81 vs. +19 sec, P=0.001), and ejection fraction (+4.6 percent vs. -0.2 percent, P<0.001). In addition, fewer patients in the group assigned to cardiac resynchronization than control patients required hospitalization (8 percent vs. 15 percent) or intravenous medications (7 percent vs. 15 percent) for the treatment of heart failure (P<0.05 for both comparisons). Implantation of the device was unsuccessful in 8 percent of patients and was complicated by refractory hypotension, bradycardia, or asystole in four patients (two of whom died) and by perforation of the coronary sinus requiring pericardiocentesis in two others. Conclusions: Cardiac resynchronization results in significant clinical improvement in patients who have moderate-to-severe heart failure and an intraventricular conduction delay.	Univ Kentucky, Coll Med, Div Cardiovasc Med, Kentucky Clin, Lexington, KY 40536 USA; Emory Univ, Atlanta, GA 30322 USA; Crawford W Long Mem Hosp, Atlanta, GA USA; Univ Penn, Philadelphia, PA 19104 USA; Columbia Univ, Coll Phys & Surg, New York, NY USA; Mayo Med Ctr, Rochester, MN USA; Long Beach Mem Med Ctr, Long Beach, CA USA; Long Beach Mem Hosp Med Ctr, Long Beach, CA USA	University of Kentucky; Emory University; University of Pennsylvania; Columbia University; Mayo Clinic	Abraham, WT (corresponding author), Univ Kentucky, Coll Med, Div Cardiovasc Med, Kentucky Clin, Rm L-543,740 Limestone St, Lexington, KY 40536 USA.		Tang, Anthony S/E-6203-2014					Aaronson KD, 1997, CIRCULATION, V95, P2660, DOI 10.1161/01.CIR.95.12.2660; Abraham WT, 2000, J CARD FAIL, V6, P369, DOI 10.1054/jcaf.2000.20841; Auricchio A, 1999, CIRCULATION, V99, P2993, DOI 10.1161/01.CIR.99.23.2993; Braunschweig F, 2000, EUR J HEART FAIL, V2, P399, DOI 10.1016/S1388-9842(00)00113-6; Bristow MR, 2000, J CARD FAIL, V6, P276, DOI 10.1054/jcaf.2000.9501; BROPHY JM, 1994, CAN J CARDIOL, V10, P543; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; Cleland JGF, 2001, EUR J HEART FAIL, V3, P481, DOI 10.1016/S1388-9842(01)00176-3; Cohn JN, 1998, NEW ENGL J MED, V339, P1810, DOI 10.1056/NEJM199812173392503; COX DR, 1972, J R STAT SOC B, V34, P187; Daubert JC, 1998, PACE, V21, P239, DOI 10.1111/j.1540-8159.1998.tb01096.x; Etienne Y, 2001, EUR J HEART FAIL, V3, P441, DOI 10.1016/S1388-9842(01)00145-3; Farwell D, 2000, EUR HEART J, V21, P1246, DOI 10.1053/euhj.1999.1985; FELDMAN AM, 1993, NEW ENGL J MED, V329, P149, DOI 10.1056/NEJM199307153290301; GOLDSTEIN S, 1988, JAMA-J AM MED ASSOC, V259, P539; Gras D, 1998, PACE, V21, P2249, DOI 10.1111/j.1540-8159.1998.tb01162.x; GUNDERSEN T, 1994, EUR HEART J, V15, P1659; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kass DA, 1999, CIRCULATION, V99, P1567, DOI 10.1161/01.CIR.99.12.1567; Kerwin WF, 2000, J AM COLL CARDIOL, V35, P1221, DOI 10.1016/S0735-1097(00)00555-6; Lau CP, 2000, PACE, V23, P1722; Leclercq C, 2000, AM HEART J, V140, P862, DOI 10.1067/mhj.2000.110570; Leclercq C, 1998, J AM COLL CARDIOL, V32, P1825, DOI 10.1016/S0735-1097(98)00492-6; Littmann L, 2000, J ELECTROCARDIOL, V33, P115, DOI 10.1054/jelc.2000.20330; Naughton JHR, 1973, EXERCISE TESTING EXE, P79; Packer M, 1996, CIRCULATION, V94, P2793, DOI 10.1161/01.CIR.94.11.2793; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; Packer M, 2001, J CARD FAIL, V7, P176, DOI 10.1054/jcaf.2001.25652; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; Rector TS, 1987, HEART FAIL, V3, P198; SAVAGE IR, 1956, ANN MATH STAT, V27, P590, DOI 10.1214/aoms/1177728170; Saxon LA, 1998, J CARDIOVASC ELECTR, V9, P13, DOI 10.1111/j.1540-8167.1998.tb00862.x; Shamim W, 1999, INT J CARDIOL, V70, P171, DOI 10.1016/S0167-5273(99)00077-7; The Criteria Committee of the New York Heart Association, 1994, NOM CRIT DIAGN DIS H; UNVERFERTH DV, 1984, AM J CARDIOL, V54, P147, DOI 10.1016/0002-9149(84)90320-5; Valls-Bertault V, 2001, EUROPACE, V3, P60, DOI 10.1053/eupc.2000.0138; Xiao HB, 1996, INT J CARDIOL, V53, P163, DOI 10.1016/0167-5273(95)02502-2; XIAO HB, 1992, BRIT HEART J, V68, P403	40	3456	3665	1	91	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	2002	346	24					1845	1853		10.1056/NEJMoa013168	http://dx.doi.org/10.1056/NEJMoa013168			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	561NA	12063368				2022-12-28	WOS:000176146100002
J	Kielpinski, D; Monroe, C; Wineland, DJ				Kielpinski, D; Monroe, C; Wineland, DJ			Architecture for a large-scale ion-trap quantum computer	NATURE			English	Article							THERMAL MOTION; GROUND-STATE; DECOHERENCE; COMPUTATION; MANIPULATION; ENTANGLEMENT; INFORMATION; PARTICLES; MEMORY; LOGIC	Among the numerous types of architecture being explored for quantum computers are systems utilizing ion traps, in which quantum bits (qubits) are formed from the electronic states of trapped ions and coupled through the Coulomb interaction. Although the elementary requirements for quantum computation have been demonstrated in this system, there exist theoretical and technical obstacles to scaling up the approach to large numbers of qubits. Therefore, recent efforts have been concentrated on using quantum communication to link a number of small ion-trap quantum systems. Developing the array-based approach, we show how to achieve massively parallel gate operation in a large-scale quantum computer, based on techniques already demonstrated for manipulating small quantum registers. The use of decoherence-free subspaces significantly reduces decoherence during ion transport, and removes the requirement of clock synchronization between the interaction regions.	MIT, Elect Res Lab, Cambridge, MA 02139 USA; MIT, Ctr Ultracold Atoms, Cambridge, MA 02139 USA; Univ Michigan, FOCUS Ctr, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Phys, Ann Arbor, MI 48109 USA; Natl Inst Stand & Technol, Div Time & Frequency, Boulder, CO 80305 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Institute of Standards & Technology (NIST) - USA	Kielpinski, D (corresponding author), MIT, Elect Res Lab, Cambridge, MA 02139 USA.		Monroe, Christopher R/G-8105-2011	Kielpinski, David/0000-0002-2816-6892				Blatt R., 1988, European Journal of Physics, V9, P250, DOI 10.1088/0143-0807/9/4/002; BLINOV BB, 2001, QUANTPH0112084; CIRAC JI, 1995, PHYS REV LETT, V74, P4091, DOI 10.1103/PhysRevLett.74.4091; Cirac JI, 2000, NATURE, V404, P579, DOI 10.1038/35007021; DeVoe RG, 1998, PHYS REV A, V58, P910, DOI 10.1103/PhysRevA.58.910; DIVINCENZO DP, 2001, SCALABLE QUANTUM COM, P1; ENZER DG, 2001, EXPT IMPLEMENTATION; Grover LK, 1997, PHYS REV LETT, V79, P325, DOI 10.1103/PhysRevLett.79.325; Guthohrlein GR, 2001, NATURE, V414, P49, DOI 10.1038/35102129; Hughes RJ, 1996, PHYS REV LETT, V77, P3240, DOI 10.1103/PhysRevLett.77.3240; Kielpinski D, 2001, SCIENCE, V291, P1013, DOI 10.1126/science.1057357; Kielpinski D, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.032310; KIELPINSKI D, 2001, ENTANGLEMENT DECOHER; King BE, 1998, PHYS REV LETT, V81, P1525, DOI 10.1103/PhysRevLett.81.1525; LARSON DJ, 1986, PHYS REV LETT, V57, P70, DOI 10.1103/PhysRevLett.57.70; Lidar DA, 1998, PHYS REV LETT, V81, P2594, DOI 10.1103/PhysRevLett.81.2594; MONROE C, 1995, PHYS REV LETT, V75, P4011, DOI 10.1103/PhysRevLett.75.4011; Morigi G, 2001, EUR PHYS J D, V13, P261, DOI 10.1007/s100530170275; Nagerl HC, 1999, PHYS REV A, V60, P145, DOI 10.1103/PhysRevA.60.145; Nielsen M.A., 2000, QUANTUM COMPUTATION, P425; PAUL W, 1990, REV MOD PHYS, V62, P531, DOI 10.1103/RevModPhys.62.531; PELLIZZARI T, 1995, PHYS REV LETT, V75, P3788, DOI 10.1103/PhysRevLett.75.3788; Rohde H, 2001, J OPT B-QUANTUM S O, V3, pS34, DOI 10.1088/1464-4266/3/1/357; Roos C, 1999, PHYS REV LETT, V83, P4713, DOI 10.1103/PhysRevLett.83.4713; Rowe MA, 2001, NATURE, V409, P791, DOI 10.1038/35057215; ROWE MA, 2002, QUANTPH0205094; Sackett CA, 2000, NATURE, V404, P256, DOI 10.1038/35005011; Shor P. W., 1994, Proceedings. 35th Annual Symposium on Foundations of Computer Science (Cat. No.94CH35717), P124, DOI 10.1109/SFCS.1994.365700; Steane A, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.042305; Steane A, 1997, APPL PHYS B-LASERS O, V64, P623, DOI 10.1007/s003400050225; Steane AM, 2000, FORTSCHR PHYS, V48, P839, DOI 10.1002/1521-3978(200009)48:9/11<839::AID-PROP839>3.0.CO;2-V; Turchette QA, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.063418; Van Enk SJ, 2001, J MOD OPTIC, V48, P2049, DOI 10.1080/09500340110065763; Young BC, 1999, PHYS REV LETT, V82, P3799, DOI 10.1103/PhysRevLett.82.3799	39	983	1002	5	140	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 13	2002	417	6890					709	711		10.1038/nature00784	http://dx.doi.org/10.1038/nature00784			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	561QY	12066177	Green Published			2022-12-28	WOS:000176154700036
J	Hellmann, DB				Hellmann, DB			Temporal arteritis - A cough, toothache, and tongue infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GIANT-CELL ARTERITIS; ERYTHROCYTE SEDIMENTATION-RATE; PLACEBO-CONTROLLED TRIAL; POLYMYALGIA-RHEUMATICA; DOUBLE-BLIND; DIAGNOSIS; DISEASE; BIOPSY; ULTRASONOGRAPHY; CLASSIFICATION	Temporal arteritis, the most common form of systemic vasculitis in adults, is a panarteritis that chiefly involves the extracranial branches of the carotid artery. The condition is illustrated in this article by the case of a 79-year-old woman with a dry cough, toothache, tongue infarction, and vision loss. The mean age of onset is 72 years and the disease rarely occurs in persons younger than 50 years. The most common presenting manifestations are headache, jaw claudication, polymyalgia rheumatica, and visual symptoms. Eighty-nine percent of patients have an erythrocyte sedimentation rate greater than 50 mm/h. However, about 40% of patients present with atypical manifestations, including fever of unknown origin, respiratory tract symptoms (especially dry cough), and large artery involvement. Familiarity with such unusual manifestations of temporal arteritis facilitates early diagnosis and treatment, thereby reducing the risk of vision loss.	Johns Hopkins Univ, Sch Med, Dept Med, Johns Hopkins Bayview Med Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Hellmann, DB (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Johns Hopkins Bayview Med Ctr, 4940 Eastern Ave, Baltimore, MD 21224 USA.							ACHKAR AA, 1994, ANN INTERN MED, V120, P987, DOI 10.7326/0003-4819-120-12-199406150-00003; Blockmans D, 2000, AM J MED, V108, P246, DOI 10.1016/S0002-9343(99)00424-6; Boyev LR, 1999, AM J OPHTHALMOL, V128, P211, DOI 10.1016/S0002-9394(99)00101-4; Brack A, 1999, ARTHRITIS RHEUM, V42, P311, DOI 10.1002/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F; CALAMIA KT, 1981, ARTHRITIS RHEUM, V24, P1414, DOI 10.1002/art.1780241113; Cantini F, 2001, ARTHRITIS RHEUM, V44, P1155, DOI 10.1002/1529-0131(200105)44:5<1155::AID-ANR198>3.0.CO;2-N; CASELLI RJ, 1988, NEUROLOGY, V38, P352, DOI 10.1212/WNL.38.3.352; CASELLI RJ, 1994, SEMIN NEUROL, V14, P349, DOI 10.1055/s-2008-1041094; Danesh-Meyer HV, 2000, J NEURO-OPHTHALMOL, V20, P213, DOI 10.1097/00041327-200020030-00011; EVANS JM, 1995, ANN INTERN MED, V122, P502, DOI 10.7326/0003-4819-122-7-199504010-00004; Gabriel SE, 1997, ARTHRITIS RHEUM, V40, P1873, DOI 10.1002/art.1780401022; Gonzalez-Gay MA, 2001, ANN RHEUM DIS, V60, P367, DOI 10.1136/ard.60.4.367; GOODMAN BW, 1979, AM J MED, V67, P839, DOI 10.1016/0002-9343(79)90744-7; HEALEY LA, 1980, ARTHRITIS RHEUM, V23, P641, DOI 10.1002/art.1780230605; Hellmann DB, 1989, MED ROUNDS, V2, P296; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; Hunder GG, 1997, MED CLIN N AM, V81, P195, DOI 10.1016/S0025-7125(05)70511-3; HUSTON KA, 1980, AM HEART J, V100, P99, DOI 10.1016/0002-8703(80)90285-9; HUSTON KA, 1978, ANN INTERN MED, V88, P162, DOI 10.7326/0003-4819-88-2-162; IRWIN RS, 1977, ARCH INTERN MED, V137, P1186, DOI 10.1001/archinte.137.9.1186; Jover JA, 2001, ANN INTERN MED, V134, P106, DOI 10.7326/0003-4819-134-2-200101160-00010; Kariv R, 2000, MEDICINE, V79, P349, DOI 10.1097/00005792-200011000-00001; KLEIN RG, 1975, ANN INTERN MED, V83, P806, DOI 10.7326/0003-4819-83-6-806; LARSON TS, 1984, ANN INTERN MED, V101, P594, DOI 10.7326/0003-4819-101-5-594; Le Hello C, 2001, J RHEUMATOL, V28, P1407; Levine SM, 2002, CURR OPIN RHEUMATOL, V14, P3, DOI 10.1097/00002281-200201000-00002; MACHADO EBV, 1988, ARTHRITIS RHEUM, V31, P745, DOI 10.1002/art.1780310607; MILLER NR, IN PRESS RHEUMATIC D; NAVAEZ J, 2001, ANN RHEUM DIS, V60, P1060; Pless M, 2000, J NEURO-OPHTHALMOL, V20, P216, DOI 10.1097/00041327-200020030-00012; Rao JK, 1998, ANN INTERN MED, V129, P345, DOI 10.7326/0003-4819-129-5-199809010-00001; Salvarani C, 2001, ARTHRIT RHEUM-ARTHR, V45, P140, DOI 10.1002/1529-0131(200104)45:2<140::AID-ANR166>3.0.CO;2-2; Schmidt WA, 1997, NEW ENGL J MED, V337, P1336, DOI 10.1056/NEJM199711063371902; Schmidt WA, 2000, CLIN EXP RHEUMATOL, V18, pS40; Smetana GW, 2002, JAMA-J AM MED ASSOC, V287, P92, DOI 10.1001/jama.287.1.92; SONNENBLICK M, 1989, SEMIN ARTHRITIS RHEU, V19, P183, DOI 10.1016/0049-0172(89)90031-0; Spiera RF, 2001, CLIN EXP RHEUMATOL, V19, P495; Walsh SJ, 2001, RHEUMATOLOGY, V40, P714, DOI 10.1093/rheumatology/40.6.714; Weyand CM, 1997, ARTHRITIS RHEUM, V40, P19, DOI 10.1002/art.1780400105; WEYAND CM, 1992, J CLIN INVEST, V90, P2355, DOI 10.1172/JCI116125; Weyand CM, 1999, ARTHRITIS RHEUM-US, V42, P844, DOI 10.1002/1529-0131(199905)42:5<844::AID-ANR2>3.0.CO;2-M; WONG RL, 1986, AM J MED, V80, P959, DOI 10.1016/0002-9343(86)90645-5	42	61	62	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	2002	287	22					2996	3000		10.1001/jama.287.22.2996	http://dx.doi.org/10.1001/jama.287.22.2996			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	561EY	12052130				2022-12-28	WOS:000176128300030
J	Delmas, PD				Delmas, PD			Treatment of postmenopausal osteoporosis	LANCET			English	Review							BONE-MINERAL DENSITY; HORMONE REPLACEMENT THERAPY; VERTEBRAL FRACTURE RISK; VITAMIN-D SUPPLEMENTATION; BREAST-CANCER; RANDOMIZED-TRIAL; HIP FRACTURE; BIOCHEMICAL MARKERS; DOUBLE-BLIND; ESTABLISHED OSTEOPOROSIS	The aim of treatment of postmenopausal osteoporosis Is to reduce the frequency of vertebral and non-vertebral fractures (especially at the hip), which are responsible for morbidity associated with the disease. Results of large placebo controlled trials have shown that alendronate, raloxifene, risedronate, the 1-34 fragment of parathyroid hormone, and nasal calcitonin, greatly reduce the risk of vertebral fractures. Furthermore, a large reduction of non-vertebral fractures has been shown for alendronate, risedronate, and the 1-34 fragment of parathyroid hormone. Calcium and vitamin D supplementation is not sufficient to treat individuals with osteoporosis but Is useful, especially In elderly women in care homes. Hormone replacement therapy remains a valuable option for the prevention of osteoporosis in early postmenopausal women. Choice of treatment depends on age, the presence or absence of prevalent fractures, especially at the spine, and the degree of bone mineral density measured at the spine and hip. Non-pharmacological interventions include adequate calcium Intake and diet, selected exercise programmes, reduction of other risk factors for osteoporotic fractures, and reduction of the risk of falls in elderly individuals.	Univ Lyon 1, F-69365 Lyon, France; INSERM Res, U403, F-69008 Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm)	Delmas, PD (corresponding author), Hop Edouard Herriot, Pavillon F, F-69437 Lyon 03, France.	delmas@lyon151.inserm.fr						Alexandersen P, 2001, JAMA-J AM MED ASSOC, V285, P1482, DOI 10.1001/jama.285.11.1482; [Anonymous], 1994, JAMA, V272, P1942; Barrett-Connor E, 2002, JAMA-J AM MED ASSOC, V287, P847, DOI 10.1001/jama.287.7.847; Beresford SAA, 1997, LANCET, V349, P458, DOI 10.1016/S0140-6736(96)07365-5; Bergkvist L, 1996, DRUG SAFETY, V15, P360, DOI 10.2165/00002018-199615050-00006; Berning B, 1996, BONE, V19, P395, DOI 10.1016/S8756-3282(96)00219-0; Bjarnason NH, 1996, J CLIN ENDOCR METAB, V81, P2419, DOI 10.1210/jc.81.7.2419; Bjarnason NH, 2001, OSTEOPOROSIS INT, V12, P922, DOI 10.1007/s001980170020; Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Boivin GY, 2000, BONE, V27, P687, DOI 10.1016/S8756-3282(00)00376-8; Bone HG, 2000, J CLIN ENDOCR METAB, V85, P720, DOI 10.1210/jc.85.2.720; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; Cauley JA, 2001, BREAST CANCER RES TR, V65, P125, DOI 10.1023/A:1006478317173; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHAPUY MC, 1994, BRIT MED J, V308, P1081, DOI 10.1136/bmj.308.6936.1081; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; Chesnut CH, 2000, AM J MED, V109, P267, DOI 10.1016/S0002-9343(00)00490-3; CHRISTIANSEN C, 1981, LANCET, V1, P459; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Cranney A, 2001, OSTEOPOROSIS INT, V12, P140, DOI 10.1007/s001980170147; Cummings SR, 2000, JAMA-J AM MED ASSOC, V283, P1318, DOI 10.1001/jama.283.10.1318; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403; Delmas P D, 1997, Osteoporos Int, V7 Suppl 1, pS3; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Delmas PD, 1997, J CLIN ONCOL, V15, P955, DOI 10.1200/JCO.1997.15.3.955; Delmas PD, 2000, OSTEOPOROSIS INT, V11, pS2, DOI 10.1007/s001980070002; Delmas PD, 2000, BONE, V26, P553, DOI 10.1016/S8756-3282(00)00271-4; Delmas PD, 2000, BONE, V27, P1, DOI 10.1016/S8756-3282(00)00301-X; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; Feskanich D, 1999, AM J CLIN NUTR, V69, P74; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; Fleisch H., 2000, BISPHOSPHONATES BONE; GALLAGHER JC, 1990, ANN INTERN MED, V113, P649, DOI 10.7326/0003-4819-113-9-649; GALLAGHER JC, 1989, P SOC EXP BIOL MED, V191, P287; GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P1693, DOI 10.1210/jc.79.6.1693; GREY AB, 1995, AM J MED, V99, P636, DOI 10.1016/S0002-9343(99)80251-4; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; HARRIS ST, 1993, AM J MED, V95, P557, DOI 10.1016/0002-9343(93)90350-X; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; Harris ST, 2001, J CLIN ENDOCR METAB, V86, P1890, DOI 10.1210/jc.86.5.1890; HEIKINHEIMO RJ, 1992, CALCIFIED TISSUE INT, V51, P105, DOI 10.1007/BF00298497; Hosking D, 1998, NEW ENGL J MED, V338, P485, DOI 10.1056/NEJM199802193380801; Jiang G, 2000, J BONE MINER RES, V15, pS169; JOHANNES EJ, 1997, GYNECOL ENDOCRINOL, V11, P25; Johnell O, 2002, J CLIN ENDOCR METAB, V87, P985, DOI 10.1210/jc.87.3.985; Kannus P, 2000, NEW ENGL J MED, V343, P1506, DOI 10.1056/NEJM200011233432101; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; Klibanski A, 2001, JAMA-J AM MED ASSOC, V285, P785; Lane JM, 2000, OSTEOPOROSIS INT, V11, pS206; LAURITZEN JB, 1993, LANCET, V341, P11, DOI 10.1016/0140-6736(93)92480-H; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; LINDSAY R, 1980, LANCET, V2, P1151; Lindsay R, 2001, JAMA-J AM MED ASSOC, V285, P320, DOI 10.1001/jama.285.3.320; Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8; LINDSAY R, 1981, LANCET, V1, P729; Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003-4819-124-4-199602150-00003; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LUFKIN EG, 1994, OSTEOPOROSIS INT, V4, P320, DOI 10.1007/BF01622190; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MAMELLE N, 1988, LANCET, V2, P361, DOI 10.1016/S0140-6736(88)92834-6; Marcus R., 1996, PRINCIPLES BONE BIOL, P1435; MARIE PJ, 1993, J BONE MINER RES, V8, P607; MAXIM P, 1995, OSTEOPOROSIS INT, V5, P23, DOI 10.1007/BF01623654; McCloskey E, 2001, BONE, V28, P310, DOI 10.1016/S8756-3282(00)00437-3; McClung M, 1998, ANN INTERN MED, V128, P253, DOI 10.7326/0003-4819-128-4-199802150-00001; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; Meunier PJ, 2002, J CLIN ENDOCR METAB, V87, P2060, DOI 10.1210/jc.87.5.2060; Meunier PJ, 1998, OSTEOPOROSIS INT, V8, P4, DOI 10.1007/s001980050041; Mortensen L, 1998, J CLIN ENDOCR METAB, V83, P396, DOI 10.1210/jc.83.2.396; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; NIELSEN SP, 1994, BRIT J OBSTET GYNAEC, V101, P319, DOI 10.1111/j.1471-0528.1994.tb13618.x; Nieves JW, 1998, AM J CLIN NUTR, V67, P18, DOI 10.1093/ajcn/67.1.18; ORIMO H, 1994, CALCIFIED TISSUE INT, V54, P370, DOI 10.1007/BF00305521; ORIMO H, 1987, BONE MINER, V3, P47; ORIMO H, 1993, 4TH P INT S OST, P148; OVERGAARD K, 1989, BRIT MED J, V299, P477, DOI 10.1136/bmj.299.6697.477; OVERGAARD K, 1992, BRIT MED J, V305, P556, DOI 10.1136/bmj.305.6853.556; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; Pols HAP, 1999, OSTEOPOROSIS INT, V9, P461, DOI 10.1007/PL00004171; Ravn P, 1998, BONE, V22, P559, DOI 10.1016/S8756-3282(98)00044-1; Recker RR, 1996, J BONE MINER RES, V11, P1961; Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010; REGINSTER JY, 1995, AM J MED, V98, P452, DOI 10.1016/S0002-9343(99)80344-1; REID IR, 1995, AM J MED, V98, P331, DOI 10.1016/S0002-9343(99)80310-6; REID IR, 1994, J CLIN ENDOCR METAB, V79, P1595, DOI 10.1210/jc.79.6.1595; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; Riggs BL, 1996, BONE, V18, pS197, DOI 10.1016/8756-3282(95)00502-1; Schnitzer T, 2000, AGING CLIN EXP RES, V12, P1; Seeman E, 2001, TRENDS ENDOCRIN MET, V12, P281, DOI 10.1016/S1043-2760(01)00460-X; Shiraki M, 2000, J BONE MINER RES, V15, P515, DOI 10.1359/jbmr.2000.15.3.515; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; SZULC P, 1993, J CLIN INVEST, V91, P1769, DOI 10.1172/JCI116387; Taaffe DR, 1999, J AM GERIATR SOC, V47, P1208, DOI 10.1111/j.1532-5415.1999.tb05201.x; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Tonino RP, 2000, J CLIN ENDOCR METAB, V85, P3109, DOI 10.1210/jc.85.9.3109; Torgerson D J, 2001, BMC Musculoskelet Disord, V2, P7, DOI 10.1186/1471-2474-2-7; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; Walsh BW, 1998, JAMA-J AM MED ASSOC, V279, P1445, DOI 10.1001/jama.279.18.1445; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; Yaffe K, 2001, NEW ENGL J MED, V344, P1207, DOI 10.1056/NEJM200104193441604	111	458	486	0	54	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 8	2002	359	9322					2018	2026		10.1016/S0140-6736(02)08827-X	http://dx.doi.org/10.1016/S0140-6736(02)08827-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076571				2022-12-28	WOS:000176232500028
J	Quaden, C; Ghaye, B; Dondelinger, RF; Belaiche, J; Bartsch, P; Cataldo, DD				Quaden, C; Ghaye, B; Dondelinger, RF; Belaiche, J; Bartsch, P; Cataldo, DD			Multiple pulmonary arteriovenous malformations	LANCET			English	Editorial Material									Univ Liege, CHU Sart Tilman, Dept Internal Med, B-4000 Liege, Belgium; Univ Liege, CHU Sart Tilman, Dept Radiol, B-4000 Liege, Belgium	University of Liege; University of Liege	Cataldo, DD (corresponding author), Univ Liege, CHU Sart Tilman, Dept Internal Med, B-4000 Liege, Belgium.		Barbuhatti, K.O./L-6028-2018; Cataldo, Didier/GPG-3453-2022	Cataldo, Didier/0000-0002-3079-7941				Blanco P, 1998, REV MED INTERNE, V19, P938, DOI 10.1016/S0248-8663(99)80070-8; BURKE CM, 1986, AM REV RESPIR DIS, V134, P334; Desproges-Gotteron R, 1973, Vie Med Can Fr, V2, P223; EDIGO R, 1991, ACTA UROL ESP, V15, P580; Gossage JR, 1998, AM J RESP CRIT CARE, V158, P643, DOI 10.1164/ajrccm.158.2.9711041	5	3	4	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 8	2002	359	9322					1998	1998		10.1016/S0140-6736(02)08833-5	http://dx.doi.org/10.1016/S0140-6736(02)08833-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076556				2022-12-28	WOS:000176232500013
J	Halter, WE; Pettke, T; Heinrich, CA				Halter, WE; Pettke, T; Heinrich, CA			The origin of Cu/Au ratios in porphyry-type ore deposits	SCIENCE			English	Article							COPPER; GOLD; ELEMENTS; SYSTEM; MAGMAS; PHASE; MELT	Microanalysis of major and trace elements in sulfide and silicate melt inclusions by laser-ablation inductively coupled plasma mass spectrometry indicates a direct link between a magmatic sulfide liquid and the composition of porphyry-type ore deposits. Copper (Cu), gold (Au), and iron (Fe) are first concentrated in a sulfide melt during magmatic evolution and then released to an ore-forming hydrothermal fluid exsolved late in the history of a magma chamber. The composition of sulfide liquids depends on the initial composition and source of the magma, but it also changes during the evolution of the magma in the crust. Magmatic sulfide melts may exert the dominant direct control on the economic metal ratios of porphyry-type ore deposits.	ETH Zentrum NO, Dept Earth Sci, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Halter, WE (corresponding author), ETH Zentrum NO, Dept Earth Sci, CH-8092 Zurich, Switzerland.		Pettke, Thomas/M-5834-2018; Heinrich, Christoph A/D-3921-2014	Pettke, Thomas/0000-0002-5784-0639; Heinrich, Christoph A/0000-0001-5838-4607				Ballhaus C, 2001, J PETROL, V42, P1911, DOI 10.1093/petrology/42.10.1911; CAELLES JC, 1971, ECON GEOL, V66, P961, DOI 10.2113/gsecongeo.66.6.961; CANDELA PA, 1986, ECON GEOL, V81, P1, DOI 10.2113/gsecongeo.81.1.1; Gaetani GA, 1997, GEOCHIM COSMOCHIM AC, V61, P1829, DOI 10.1016/S0016-7037(97)00033-1; Gill J., 1981, OROGENIC ANDESITES P; Gunther D, 1998, J ANAL ATOM SPECTROM, V13, P263, DOI 10.1039/a707372k; Halter WE, 2002, CHEM GEOL, V183, P63, DOI 10.1016/S0009-2541(01)00372-2; HALTER WE, UNPUB; Hattori KH, 2001, MINER DEPOSITA, V36, P799, DOI 10.1007/s001260100209; HEDENQUIST JW, 1994, NATURE, V370, P519, DOI 10.1038/370519a0; JAUPART C, 1995, J GEOPHYS RES-SOL EA, V100, P17615, DOI 10.1029/95JB01239; Jugo PJ, 1999, LITHOS, V46, P573, DOI 10.1016/S0024-4937(98)00083-8; KEITH JD, 1997, J PETROL, V38, P16790; Koepke J, 2001, GEOCHIM COSMOCHIM AC, V65, P1481, DOI 10.1016/S0016-7037(01)00550-6; Larocque ACL, 2000, CAN MINERAL, V38, P1233, DOI 10.2113/gscanmin.38.5.1233; LLAMBIAS EJ, 1972, REV ASOC GEOL ARGENT, V27, P161; Longerich HP, 1996, J ANAL ATOM SPECTROM, V11, P899, DOI 10.1039/ja9961100899; LOWENSTERN JB, 1991, SCIENCE, V252, P1405, DOI 10.1126/science.252.5011.1405; SASSO AM, 1998, SOC EC GEOLOGISTS NE, V34, P8; Sillitoe RH, 1997, AUST J EARTH SCI, V44, P373, DOI 10.1080/08120099708728318; Ulrich T, 1999, NATURE, V399, P676, DOI 10.1038/21406; Ulrich T, 2001, ECON GEOL BULL SOC, V96, P1743; VAUGHAN DJ, 1997, GEOCHEMISTRY HYDROTH, P367	23	145	168	0	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 7	2002	296	5574					1844	1846		10.1126/science.1070139	http://dx.doi.org/10.1126/science.1070139			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052953				2022-12-28	WOS:000176054300041
J	Fuchs, VR				Fuchs, VR			What's ahead for health insurance in the United States?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Stanford Univ, Stanford, CA 94305 USA	Stanford University	Fuchs, VR (corresponding author), Stanford Univ, Stanford, CA 94305 USA.							Aaron HJ, 1996, NBER CONF R, P107; FREUDENHEIM M, 2001, NY TIMES        0313, pA1; SIU AL, 1986, NEW ENGL J MED, V315, P1259, DOI 10.1056/NEJM198611133152005	3	16	16	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	2002	346	23					1822	1824		10.1056/NEJM200206063462314	http://dx.doi.org/10.1056/NEJM200206063462314			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	559EK	12050346				2022-12-28	WOS:000176012500013
J	Janvier, P; Arsenault, M				Janvier, P; Arsenault, M			Palaeobiology - Calcification of early vertebrate cartilage	NATURE			English	Article							PETROMYZON-MARINUS; LAMPREY		Museum Natl Hist Nat, CNRS, UMR 8569, F-75231 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN)	Janvier, P (corresponding author), Museum Natl Hist Nat, CNRS, UMR 8569, F-75231 Paris 05, France.							Donoghue PCJ, 2000, BIOL REV, V75, P191, DOI 10.1017/S0006323199005472; Janvier P, 1996, PALAEONTOLOGY, V39, P259; Janvier P., 1996, EARLY VERTEBRATES; LANGILLE RM, 1993, ACTA ZOOL-STOCKHOLM, V74, P31, DOI 10.1111/j.1463-6395.1993.tb01218.x; Robson P, 1997, COMP BIOCHEM PHYS B, V118, P71, DOI 10.1016/S0305-0491(97)00026-6	5	31	32	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	2002	417	6889					609	609		10.1038/417609a	http://dx.doi.org/10.1038/417609a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050653	Bronze			2022-12-28	WOS:000176001200035
J	Klar, AJS				Klar, AJS			Fibonacci's flowers	NATURE			English	Editorial Material							INHERITANCE; PATTERN		NCI, Ctr Canc Res, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Klar, AJS (corresponding author), NCI, Ctr Canc Res, NIH, Frederick, MD 21702 USA.							GREEN PB, 1987, AM ZOOL, V27, P657; KLAR AJS, 1990, EMBO J, V9, P1407, DOI 10.1002/j.1460-2075.1990.tb08256.x; SUSSEX IM, 1989, CELL, V56, P225, DOI 10.1016/0092-8674(89)90895-7; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012	4	21	21	5	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	2002	417	6889					595	595		10.1038/417595a	http://dx.doi.org/10.1038/417595a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050641	Bronze			2022-12-28	WOS:000176001200025
J	Harvell, CD; Mitchell, CE; Ward, JR; Altizer, S; Dobson, AP; Ostfeld, RS; Samuel, MD				Harvell, CD; Mitchell, CE; Ward, JR; Altizer, S; Dobson, AP; Ostfeld, RS; Samuel, MD			Ecology - Climate warming and disease risks for terrestrial and marine biota	SCIENCE			English	Review							EMERGING INFECTIOUS-DISEASES; MASS-MORTALITY; PERKINSUS-MARINUS; PHYTOPHTHORA-CINNAMOMI; CULEX-QUINQUEFASCIATUS; POPULATION BIOLOGY; GLOBAL CLIMATE; UNITED-STATES; CORAL DISEASE; TEMPERATURE	Infectious diseases can cause rapid population declines or species extinctions. Many pathogens of terrestrial and marine taxa are sensitive to temperature, rainfall, and humidity, creating synergisms that could affect biodiversity. Climate warming can increase pathogen development and survival rates, disease transmission, and host susceptibility. Although most host-parasite systems are predicted to experience more frequent or severe disease impacts with warming, a subset of pathogens might decline with warming, releasing hosts from disease. Recently, changes in El Nino Southern Oscillation events have had a detectable influence on marine and terrestrial pathogens, including coral diseases, oyster pathogens, crop pathogens, Rift Valley fever, and human cholera. To improve our ability to predict epidemics in wild populations, it will be necessary to separate the independent and interactive effects of multiple climate drivers on disease impact.	Cornell Univ, Dept Ecol & Evolutionary Biol, Ithaca, NY 14853 USA; Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA; Emory Univ, Dept Environm Studies, Atlanta, GA 30322 USA; Cornell Lab Ornithol, Ithaca, NY 14850 USA; Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Inst Ecosyst Studies, Millbrook, NY 12545 USA; US Geol Survey, Natl Wildlife Res Ctr, Madison, WI 53711 USA	Cornell University; University of Minnesota System; University of Minnesota Twin Cities; Emory University; Cornell University; Princeton University; Cary Institute of Ecosystem Studies; United States Department of the Interior; United States Geological Survey	Harvell, CD (corresponding author), Cornell Univ, Dept Ecol & Evolutionary Biol, Ithaca, NY 14853 USA.	cdh5@cornell.edu	Mitchell, Charles E/I-3709-2014	Mitchell, Charles E/0000-0002-1633-1993; Ostfeld, Richard/0000-0002-3707-9301				Alker AP, 2001, HYDROBIOLOGIA, V460, P105, DOI 10.1023/A:1013145524136; Altizer SM, 2000, ECOL ENTOMOL, V25, P125, DOI 10.1046/j.1365-2311.2000.00246.x; Altstatt JM, 1996, MAR ECOL PROG SER, V142, P185, DOI 10.3354/meps142185; ANAGNOSTAKIS SL, 1987, MYCOLOGIA, V79, P23, DOI 10.2307/3807741; Anyamba A, 2001, Cad Saude Publica, V17 Suppl, P133, DOI 10.1590/S0102-311X2001000700022; Atkinson CT, 2000, J WILDLIFE DIS, V36, P197, DOI 10.7589/0090-3558-36.2.197; Banin F, 2000, WATER AIR SOIL POLL, V123, P337, DOI 10.1023/A:1005274331988; Brasier CM, 1996, ANN SCI FOREST, V53, P347, DOI 10.1051/forest:19960217; BURDON JJ, 1982, ANNU REV PHYTOPATHOL, V20, P143, DOI 10.1146/annurev.py.20.090182.001043; Burdon JJ, 1996, PLANT PATHOL, V45, P933, DOI 10.1111/j.1365-3059.1996.tb02904.x; CAMP JW, 1982, J PARASITOL, V68, P709, DOI 10.2307/3280932; Carefoot G. L., 1967, FAMINE WIND MANS BAT; Carey C, 1999, DEV COMP IMMUNOL, V23, P459, DOI 10.1016/S0145-305X(99)00028-2; Cerrano C, 2000, ECOL LETT, V3, P284, DOI 10.1046/j.1461-0248.2000.00152.x; Coakley SM, 1999, ANNU REV PHYTOPATHOL, V37, P399, DOI 10.1146/annurev.phyto.37.1.399; COLES SL, 1976, PAC SCI, V30, P159; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; Cook T, 1998, ESTUAR COAST SHELF S, V46, P587, DOI 10.1006/ecss.1997.0283; Cunningham AA, 1998, CONSERV BIOL, V12, P1139, DOI 10.1046/j.1523-1739.1998.97485.x; DAILY GC, 1993, P NATL ACAD SCI USA, V90, P592, DOI 10.1073/pnas.90.2.592; Daszak P, 1999, EMERG INFECT DIS, V5, P735, DOI 10.3201/eid0506.990601; Daszak P, 2000, SCIENCE, V287, P443, DOI 10.1126/science.287.5452.443; Daszak P, 1999, TRENDS ECOL EVOL, V14, P279, DOI 10.1016/S0169-5347(99)01665-1; Davis MB, 2001, SCIENCE, V292, P673, DOI 10.1126/science.292.5517.673; DOBSON A, 1993, LANCET, V342, P1096, DOI 10.1016/0140-6736(93)92069-6; Dobson A., 1992, Global warming and biological diversity., P201; DUNGAN ML, 1982, SCIENCE, V216, P989, DOI 10.1126/science.216.4549.989; DWYER G, 1993, J ANIM ECOL, V62, P1, DOI 10.2307/5477; DYE C, 1992, ANNU REV ENTOMOL, V37, P1, DOI 10.1146/annurev.en.37.010192.000245; Enfield DB, 1988, OCEANOGRAPHY, V1, P23; Etterson JR, 2001, SCIENCE, V294, P151, DOI 10.1126/science.1063656; EVANS NA, 1985, PARASITOLOGY, V90, P269, DOI 10.1017/S0031182000050976; FEINGOLD JS, 1988, 6TH P INT COR REEF S, V3, P157; FORD SE, 1982, J INVERTEBR PATHOL, V40, P118, DOI 10.1016/0022-2011(82)90043-X; Ford SE, 1996, J SHELLFISH RES, V15, P45; FRIEND M, 1991, ACT 20 C INT ORN, V4, P2331; Gijzen M, 1996, PHYSIOL MOL PLANT P, V48, P209, DOI 10.1006/pmpp.1996.0018; Gilles T, 2000, PLANT PATHOL, V49, P498, DOI 10.1046/j.1365-3059.2000.00474.x; Glass GE, 2000, EMERG INFECT DIS, V6, P238, DOI 10.3201/eid0603.000303; GORDON R. M., 1934, ANN TROP MED AND PARASITOL, V28, P323; Gratz NG, 1999, ANNU REV ENTOMOL, V44, P51, DOI 10.1146/annurev.ento.44.1.51; Green EP, 2000, BIOL CONSERV, V96, P347, DOI 10.1016/S0006-3207(00)00073-2; Gulland FMD, 1996, J WILDLIFE DIS, V32, P572, DOI 10.7589/0090-3558-32.4.572; Hajek Ann E., 1995, American Entomologist, V41, P31; Harrington R., 1995, P125; Harvell D, 2001, HYDROBIOLOGIA, V460, P97, DOI 10.1023/A:1013169331913; Hay SI, 2002, NATURE, V415, P905, DOI 10.1038/415905a; Hay SI, 2000, P NATL ACAD SCI USA, V97, P9335, DOI 10.1073/pnas.97.16.9335; Hayes ML, 2001, HYDROBIOLOGIA, V460, P213, DOI 10.1023/A:1013121503937; HEIDEJORGENSEN MP, 1992, DIS AQUAT ORGAN, V13, P37, DOI 10.3354/dao013037; Hoegh-Guldberg O, 1999, MAR FRESHWATER RES, V50, P839, DOI 10.1071/MF99078; Hoerling MP, 2001, SCIENCE, V292, P90, DOI 10.1126/science.1058582; Hofmann E, 2001, HYDROBIOLOGIA, V460, P195, DOI 10.1023/A:1013159329598; Holmes F.W., 1980, P133; HOLMQUIST GU, 1983, J FOOD SCI, V48, P778, DOI 10.1111/j.1365-2621.1983.tb14897.x; Holt R. A., 1989, Journal of Aquatic Animal Health, V1, P94, DOI 10.1577/1548-8667(1989)001&lt;0094:ROWTTB&gt;2.3.CO;2; Hooper PT, 1999, AUST VET J, V77, P529, DOI 10.1111/j.1751-0813.1999.tb12127.x; Houghton JT, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P1; HOUSTON DR, 1988, CAN J FOREST RES, V18, P38, DOI 10.1139/x88-007; HSU CK, 1977, AM J VET RES, V38, P1115; Hudson PJ, 1997, WILDLIFE BIOL, V3, P79, DOI 10.2981/wlb.1997.010; Ishiguro K., 1991, Rice blast modeling and forecasting. Selected papers from the International Rice Research Conference, 27-31 August 1990, Seoul, Korea Republic., P39; Israely T, 2001, AQUAT MICROB ECOL, V24, P1, DOI 10.3354/ame024001; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; Johnson DA, 1996, PHYTOPATHOLOGY, V86, P480, DOI 10.1094/Phyto-86-480; Kiesecker JM, 2001, NATURE, V410, P681, DOI 10.1038/35070552; KITTHAWEE S, 1990, AM J TROP MED HYG, V43, P328, DOI 10.4269/ajtmh.1990.43.328; Kovats RS, 2001, PHILOS T R SOC B, V356, P1057, DOI 10.1098/rstb.2001.0894; Kushmaro A, 1998, MAR ECOL PROG SER, V171, P131, DOI 10.3354/meps171131; Kuta KG, 1996, CORAL REEFS, V15, P219, DOI 10.1007/BF01787455; LAFFERTY KD, 1993, MAR ECOL PROG SER, V96, P239, DOI 10.3354/meps096239; Lindgren E, 2000, ENVIRON HEALTH PERSP, V108, P119, DOI 10.2307/3454509; Linthicum KJ, 1999, SCIENCE, V285, P397, DOI 10.1126/science.285.5426.397; Lobitz B, 2000, P NATL ACAD SCI USA, V97, P1438, DOI 10.1073/pnas.97.4.1438; Marcais B, 1996, ANN SCI FOREST, V53, P369, DOI 10.1051/forest:19960219; Marcogliese DJ, 2001, CAN J ZOOL, V79, P1331, DOI 10.1139/cjz-79-8-1331; MARTENS JW, 1967, CAN J BOTANY, V45, P451, DOI 10.1139/b67-046; MARTENS WJM, 1995, GLOBAL ENVIRON CHANG, V5, P195, DOI 10.1016/0959-3780(95)00051-O; Massad E, 1998, ECOSYST HEALTH, V4, P119, DOI 10.1046/j.1526-0992.1998.00079.x; Mattson D. J., 2001, WHITEBARK PINE COMMU, P121; MCCARTNEY HA, 1997, ENV SAFE APPROACHES, P3; Mellor PS, 2000, ANNU REV ENTOMOL, V45, P307, DOI 10.1146/annurev.ento.45.1.307; MOLYNEUX A S, 1985, Revue de Nematologie, V8, P165; Oda T, 1999, J AM MOSQUITO CONTR, V15, P153; OPLER PA, 1979, AM CHESTN S, P83; Packer C, 1999, J ANIM ECOL, V68, P1161, DOI 10.1046/j.1365-2656.1999.00360.x; Palumbi SR, 2001, SCIENCE, V293, P1786, DOI 10.1126/science.293.5536.1786; Pascual M, 2000, SCIENCE, V289, P1766, DOI 10.1126/science.289.5485.1766; Patz JA, 1998, TROP MED INT HEALTH, V3, P818, DOI 10.1046/j.1365-3156.1998.00309.x; Porter JW, 2001, HYDROBIOLOGIA, V460, P1, DOI 10.1023/A:1013177617800; Powell EN, 1996, J SHELLFISH RES, V15, P141; RASMUSSEN E, 1977, SEAGRASS ECOSYSTEMS, P00001; REEVES WC, 1994, J MED ENTOMOL, V31, P323, DOI 10.1093/jmedent/31.3.323; RIND D, 1993, GLOBAL CHANGES PERSP, P36; Rodbell DT, 1999, SCIENCE, V283, P516, DOI 10.1126/science.283.5401.516; ROGERS D, 1979, J ANIM ECOL, V48, P825, DOI 10.2307/4197; Rogers DJ, 2000, SCIENCE, V289, P1763, DOI 10.1126/science.289.5485.1763; RUEDA LM, 1990, J MED ENTOMOL, V27, P892, DOI 10.1093/jmedent/27.5.892; SCHEIBLING RE, 1984, MAR BIOL, V78, P153, DOI 10.1007/BF00394695; SCHERM H, 1995, PHYTOPATHOLOGY, V85, P970, DOI 10.1094/Phyto-85-970; SCHERM H, 1994, PHYTOPATHOLOGY, V84, P1380; Schmidt KA, 2001, ECOLOGY, V82, P609, DOI 10.1890/0012-9658(2001)082[0609:BATDEI]2.0.CO;2; SHIAH FK, 1994, MAR ECOL PROG SER, V103, P297; Shinn EA, 2000, GEOPHYS RES LETT, V27, P3029, DOI 10.1029/2000GL011599; Short FT, 1999, AQUAT BOT, V63, P169, DOI 10.1016/S0304-3770(98)00117-X; SMITH G, 1990, PARASITOLOGY, V101, P309, DOI 10.1017/S003118200006337X; Strong A.E., 1998, REEF ENCOUNTERS, V24, P20; SUBBARAO KV, 1993, PHYTOPATHOLOGY, V83, P1454, DOI 10.1094/Phyto-83-1454; Sutherland ML, 1997, PHYTOPATHOLOGY, V87, P576, DOI 10.1094/PHYTO.1997.87.6.576; Tang YQ, 1999, ENVIRON ENTOMOL, V28, P895, DOI 10.1093/ee/28.5.895; VALENT B, 1990, PHYTOPATHOLOGY, V80, P33, DOI 10.1094/Phyto-80-33; Valkonen JPT, 1997, ANN APPL BIOL, V130, P91, DOI 10.1111/j.1744-7348.1997.tb05785.x; VANRIPER C, 1986, ECOL MONOGR, V56, P327, DOI 10.2307/1942550; WADIA KDR, 1994, PLANT PATHOL, V43, P121, DOI 10.1111/j.1365-3059.1994.tb00561.x; Walther GR, 2002, NATURE, V416, P389, DOI 10.1038/416389a; WATSON DW, 1993, J INVERTEBR PATHOL, V61, P10, DOI 10.1006/jipa.1993.1003; WATSON DW, 1993, BIOL CONTROL, V3, P182, DOI 10.1006/bcon.1993.1026; WESTE G, 1987, ANNU REV PHYTOPATHOL, V25, P207, DOI 10.1146/annurev.py.25.090187.001231; Wilkinson C, 1999, AMBIO, V28, P188; Wilson WH, 2001, AQUAT MICROB ECOL, V25, P99, DOI 10.3354/ame025099; WINDINGSTAD RM, 1998, P INT CANADA GOOSE S, P283; Woodroffe R, 1999, ANIM CONSERV, V2, P185, DOI 10.1111/j.1469-1795.1999.tb00064.x	122	1752	1816	31	1320	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	2002	296	5576					2158	2162		10.1126/science.1063699	http://dx.doi.org/10.1126/science.1063699			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077394	Green Submitted			2022-12-28	WOS:000176379000035
J	Hunt, PA; Hassold, TJ				Hunt, PA; Hassold, TJ			Sex matters in meiosis	SCIENCE			English	Review							DNA MISMATCH REPAIR; CHROMOSOME SYNAPSIS; MOUSE; MICE; GENE; HOMOLOG; ANEUPLOIDY; CHECKPOINT; DEFICIENT; DEFECTS	In mammals, fertilization typically involves the ovulation of one or a few eggs at one end of the female reproductive tract and the entry of millions of sperm at the other. Given this disparity in numbers, it might be expected that the more precious commodity-eggs-would be subject to more stringent quality-control mechanisms. However, information from engineered mutations of meiotic genes suggests just the opposite. Specifically, the available mutants demonstrate striking sexual dimorphism in response to meiotic disruption; for example, faced with adversity, male meiosis grinds to a halt, whereas female meiosis soldiers on. This female "robustness" comes with a cost, however, because aneuploidy appears to be increased in the resultant oocytes.	Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA	Case Western Reserve University	Hunt, PA (corresponding author), Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.		Holt, Janet E/B-2415-2013		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD021341] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037502, R01HD021341, R01HD031866] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21341, HD31866, HD37502] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baudat F, 2000, MOL CELL, V6, P989, DOI 10.1016/S1097-2765(00)00098-8; BETTS DE, UNPUB; Burke DJ, 2000, CURR OPIN GENET DEV, V10, P26, DOI 10.1016/S0959-437X(99)00040-4; CHANDLEY AC, 1976, ANN HUM GENET, V40, P165, DOI 10.1111/j.1469-1809.1976.tb00176.x; de Vries SS, 1999, GENE DEV, V13, P523, DOI 10.1101/gad.13.5.523; Edelmann W, 1999, NAT GENET, V21, P123, DOI 10.1038/5075; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; Hodges CA, 2002, HUM REPROD, V17, P1171, DOI 10.1093/humrep/17.5.1171; Kneitz B, 2000, GENE DEV, V14, P1085; Libby BJ, 2002, DEV BIOL, V242, P174, DOI 10.1006/dbio.2001.0535; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; MARTIN RH, 1991, AM J MED GENET, V39, P321, DOI 10.1002/ajmg.1320390315; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Roeder GS, 2000, TRENDS GENET, V16, P395, DOI 10.1016/S0168-9525(00)02080-1; Romanienko PJ, 2000, MOL CELL, V6, P975, DOI 10.1016/S1097-2765(00)00097-6; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Tanaka SS, 2000, GENE DEV, V14, P841; Tay J, 2001, DEV CELL, V1, P201, DOI 10.1016/S1534-5807(01)00025-9; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yin H, 1998, CHROMOSOMA, V107, P514, DOI 10.1007/s004120050337; Yoshida K, 1998, MOL CELL, V1, P707, DOI 10.1016/S1097-2765(00)80070-2; Yuan L, 2002, SCIENCE, V296, P1115, DOI 10.1126/science.1070594; Yuan L, 2000, MOL CELL, V5, P73, DOI 10.1016/S1097-2765(00)80404-9	27	301	312	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 21	2002	296	5576					2181	2183		10.1126/science.1071907	http://dx.doi.org/10.1126/science.1071907			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077403				2022-12-28	WOS:000176379000044
J	Blumenthal, T; Evans, D; Link, CD; Guffanti, A; Lawson, D; Thierry-Mieg, J; Thierry-Mieg, D; Chiu, WL; Duke, K; Kiraly, M; Kim, SK				Blumenthal, T; Evans, D; Link, CD; Guffanti, A; Lawson, D; Thierry-Mieg, J; Thierry-Mieg, D; Chiu, WL; Duke, K; Kiraly, M; Kim, SK			A global analysis of Caenorhabditis elegans operons	NATURE			English	Article							C-ELEGANS; GENE-EXPRESSION; LIN-15; GENOME; SL2	The nematode worm Caenorhabditis elegans and its relatives are unique among animals in having operons(1). Operons are regulated multigene transcription units, in which polycistronic premessenger RNA (pre-mRNA coding for multiple peptides) is processed to monocistronic mRNAs. This occurs by 3' end formation and trans-splicing using the specialized SL2 small nuclear ribonucleoprotein particle(2) for downstream mRNAs(1). Previously, the correlation between downstream location in an operon and SL2 trans-splicing has been strong, but anecdotal(3). Although only 28 operons have been reported, the complete sequence of the C. elegans genome reveals numerous gene clusters(4). To determine how many of these clusters represent operons, we probed full-genome microarrays for SL2-containing mRNAs. We found significant enrichment for about 1,200 genes, including most of a group of several hundred genes represented by complementary DNAs that contain SL2 sequence. Analysis of their genomic arrangements indicates that >90% are downstream genes, falling in 790 distinct operons. Our evidence indicates that the genome contains at least 1,000 operons, 2-8 genes long, that contain about 15% of all C. elegans genes. Numerous examples of co-transcription of genes encoding functionally related proteins are evident. Inspection of the operon list should reveal previously unknown functional relationships.	Univ Colorado, Sch Med, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA; Sanger Ctr, Cambridge CB10 1SA, England; Natl Inst Genet, Gene Network Lab, Mishima, Shizuoka 411, Japan; Natl Ctr Biotechnol Informat, Bethesda, MD USA; Pfizer Global Res & Dev, Dept Mol Sci & Technol, Ann Arbor, MI 48105 USA; Stanford Univ, Med Ctr, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Dept Dev Biol, Stanford, CA 94305 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Boulder; Wellcome Trust Sanger Institute; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Pfizer; Stanford University; Stanford University	Blumenthal, T (corresponding author), Univ Colorado, Sch Med, Dept Biochem & Mol Genet, Box B121,4200 E 9th Ave, Denver, CO 80262 USA.		THIERRY-MIEG, Jean/F-1975-2017	THIERRY-MIEG, Jean/0000-0002-0396-6789; Lawson, Daniel/0000-0001-7765-983X; Thierry-Mieg, Danielle/0000-0001-9568-4211				BLUMENTHAL T, 1997, C ELEGANS, V2, P117; CLARK SG, 1994, GENETICS, V137, P987; Culetto E, 2000, HUM MOL GENET, V9, P869, DOI 10.1093/hmg/9.6.869; Evans D, 1997, P NATL ACAD SCI USA, V94, P9751, DOI 10.1073/pnas.94.18.9751; Furst J, 2002, J BIOL CHEM, V277, P4435, DOI 10.1074/jbc.M107372200; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; Huynen MA, 2001, TRENDS GENET, V17, P304, DOI 10.1016/S0168-9525(01)02302-2; Jiang M, 2001, P NATL ACAD SCI USA, V98, P218, DOI 10.1073/pnas.011520898; Kent WJ, 2000, NUCLEIC ACIDS RES, V28, P91, DOI 10.1093/nar/28.1.91; Mazroui R, 1999, RNA, V5, P1615, DOI 10.1017/S1355838299991872; Page AP, 1997, DNA CELL BIOL, V16, P1335, DOI 10.1089/dna.1997.16.1335; RABOUL J, 2000, NAT GENET, V27, P332; Reinke V, 2000, MOL CELL, V6, P605, DOI 10.1016/S1097-2765(00)00059-9; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; Stein L, 2001, NUCLEIC ACIDS RES, V29, P82, DOI 10.1093/nar/29.1.82; Treinin M, 1998, P NATL ACAD SCI USA, V95, P15492, DOI 10.1073/pnas.95.26.15492; Williams C, 1999, MOL CELL BIOL, V19, P376; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0	19	269	273	6	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 20	2002	417	6891					851	854		10.1038/nature00831	http://dx.doi.org/10.1038/nature00831			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075352				2022-12-28	WOS:000176285600047
J	Delmonico, FL; Arnold, R; Scheper-Hughes, N; Siminoff, LA; Kahn, J; Youngner, SJ				Delmonico, FL; Arnold, R; Scheper-Hughes, N; Siminoff, LA; Kahn, J; Youngner, SJ			Sounding board - Ethical incentives - Not payment - For organ donation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PRESUMED CONSENT; KIDNEY		Massachusetts Gen Hosp, Boston, MA 02114 USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA; Univ Calif Berkeley, Berkeley, CA 94720 USA; Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA; Univ Minnesota, Minneapolis, MN 55455 USA	Harvard University; Massachusetts General Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California Berkeley; Case Western Reserve University; University of Minnesota System; University of Minnesota Twin Cities	Delmonico, FL (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.		Siminoff, Laura A/H-6277-2012	Kahn, Jeffrey/0000-0003-2493-2016				Abecassis M, 2000, JAMA-J AM MED ASSOC, V284, P2919; Adams AF, 1999, CONTEMP ECON POLICY, V17, P147; Arnold R, 2002, TRANSPLANTATION, V73, P1361, DOI 10.1097/00007890-200204270-00034; BAARD E, 2001, VILLAGE VOICE   0508; COHEN C, 1992, TRANSPLANT P, V24, P2168; Cohen L, 1999, DAEDALUS, V128, P135; COHEN L, 1998, GRAFT, V1, P122; ELLISON MD, 2002, AM J TRANSPLANT S3, V2, P226; Friedlaender MM, 2002, LANCET, V359, P971, DOI 10.1016/S0140-6736(02)08030-3; GLASSON J, 1994, JAMA-J AM MED ASSOC, V272, P809, DOI 10.1001/jama.1994.03520100071036; LAND W, 1992, TRANSPLANT P, V24, P2165; Levine DZ, 2000, AM J KIDNEY DIS, V35, P1002, DOI 10.1016/S0272-6386(00)70280-0; Mahoney JD, 2000, VA LAW REV, V86, P163, DOI 10.2307/1073915; MATAS A, 2002, AM J TRANSPLANT S3, V2, P138; *OFF ASS SECR PLAN, 2000, FED REGISTER, V65, P82803; *OFF ASS SECR PLAN, 2000, FED REGISTER, V65, P82475; *OFF ASS SECR PLAN, 2000, FED REGISTER, V65, P82812; *OFF ASS SECR PLAN, 2000, FED REGISTER, V65, P82810; PROTTAS JM, 1992, TRANSPLANTATION, V53, P1371, DOI 10.1097/00007890-199206000-00040; Radcliffe-Richards J, 1998, LANCET, V351, P1950, DOI 10.1016/S0140-6736(97)08211-1; ROELS L, 1991, TRANSPLANT P, V23, P903; Ross LF, 1997, NEW ENGL J MED, V336, P1752, DOI 10.1056/NEJM199706123362412; Scheper-Hughes N, 2000, CURR ANTHROPOL, V41, P191, DOI 10.1086/300123; *SE ORG PROC FDN, 2001, LIV ORG DON NETW; Siminoff L A, 1999, J Transpl Coord, V9, P250; Siminoff LA, 1999, HASTINGS CENT REP, V29, P34, DOI 10.2307/3527870; SMITH C, 2001, SEATTLE POST IN 1122; SMITH C, 2001, NY TIMES        1108; Smith CraigS, 2001, NY TIMES        1101, p1A; STARZL TE, 1992, PUZZLE PEOPLE MEMOIR, P147; SWARTZ TR, 2001, TAKING SIDES CLASHIN, P114; TERASAKI P, 2001, CLIN TRANSPLANTS 200; *TX DEP PUBL SAF, 1994, STAT AUST; *UN NETW ORG SHAR, ALL POL 3 5 11; *UN NETW ORG SHAR, 2002, 2001 ANN REP, V1, P32; Watt SM, 1991, PEOPLE FEEL ORGAN DO	36	163	165	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 20	2002	346	25					2002	2005		10.1056/NEJMsb013216	http://dx.doi.org/10.1056/NEJMsb013216			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	563QC	12075064				2022-12-28	WOS:000176266200012
J	Newby, LK; Kristinsson, A; Bhapkar, MV; Aylward, PE; Dimas, AP; Klein, WW; McGuire, DK; Moliterno, DJ; Verheugt, FWA; Weaver, WD; Califf, RM				Newby, LK; Kristinsson, A; Bhapkar, MV; Aylward, PE; Dimas, AP; Klein, WW; McGuire, DK; Moliterno, DJ; Verheugt, FWA; Weaver, WD; Califf, RM		SYMPHONY Investigators; 2nd SYMPHONY Investigators	Early statin initiation and outcomes in patients with acute coronary syndromes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							C-REACTIVE PROTEIN; IMPROVES ENDOTHELIAL FUNCTION; ACUTE MYOCARDIAL-INFARCTION; LIPID-LOWERING THERAPY; A REDUCTASE INHIBITOR; ACC/AHA GUIDELINES; COLLAGEN CONTENT; ARTERY DISEASE; HEART-DISEASE; PRAVASTATIN	Context The secondary prevention benefit of therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) has been clearly demonstrated; however, the role of early initiation of statins after acute coronary syndromes (ACSs) is unknown. Objective To evaluate the association of early statin initiation (less than or equal to7 days) after ACS with 90-day and 1-year outcomes. Design Observational cohort from databases of 2 randomized clinical trials, SYMPHONY and 2nd SYMPHONY. Setting Nine hundred thirty-one clinical centers in 37 countries. Patients A total of 12365 ACS patients randomized from August 1997 to August 1999 who were not taking statins prior to the index ACS and who either started statin therapy early (median, 2.0 [interquartile range, 1.0-3.1] days after ACS; n = 3952) or survived more than 5 days after ACS and never received statin therapy (n = 8413). Main Outcome Measures Ninety-day incidence of death; death or myocardial infarction (MI); and death, MI, or severe recurrent ischemia; as well as 1-year incidence of death. Results Ninety-day and 1-year unadjusted mortality comparison suggested early statin benefit (1.2% for early statins vs 2.1% for no statins; hazard ratio [HR], 0.58; 95% confidence interval [CI], 0.42-0.81 for 90-day comparisons and 2.3% for early statins vs 4.4% for no statins; HR, 0.52; 95% CI, 0.40-0.68 for 1-year comparison). However, no benefit was evident for 90-day death or MI (6.5% vs 6.9%; HR, 0.95; 95% CI, 0.82-1.11) or death, MI, or severe recurrent ischemia (9.2% vs 8.9%; HR, 1.04; 95% CI, 0.92-1.18). After propensity and covariate adjustment, there were no 90-day or 1-year differences between the early-statin group and the no-statin group. The 90-day adjusted HR for death was 1.08 (95% CI, 0.75-1.56); for death or MI, 1.08 (95% CI, 0.91-1.29); and for death, MI, or severe recurrent ischemia, 1.15 (95% CI, 0.99-1.34). One-year mortality-adjusted HR was 0.99 (95% CI, 0.73-1.33). Among 2711 patients with core laboratory lipid analysis, early statin was associated with higher adjusted risk for death or death or MI at cholesterol levels below treatment guidelines but was more favorable at higher levels. Conclusions In this study, there was no relationship between early initiation of statin therapy and improved outcomes although our subset analysis suggests that outcomes after early statin initiation may vary with cholesterol levels. Confirmation of early treatment effects of statins on outcomes awaits the results of adequately powered randomized clinical trials.	Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27715 USA; Landspitalinn Univ Hosp, Dept Cardiol, Reykjavik, Iceland; Flinders Med Ctr, Dept Cardiovasc Med, Bedford Pk, SA, Australia; Hygela Hosp, Dept Cardiol, Athens, Greece; Graz Univ, Med Klin, Kardiol Abt, A-8036 Graz, Austria; Univ Texas, SW Med Ctr, Dept Cardiol, Dallas, TX USA; Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA; Acad Ziekenhuis Nijmegen, Nijmegen, Netherlands; Henry ford Med Ctr, Div Cardiol, Detroit, MI USA	Duke University; Landspitali National University Hospital; Flinders Medical Centre; Hygeia Hospital; University of Graz; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cleveland Clinic Foundation; Radboud University Nijmegen; Henry Ford Health System	Newby, LK (corresponding author), Duke Univ, Med Ctr, Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA.	newby001@mc.duke.edu	Verheugt, F.W.A./H-8105-2014	Aylward, Philip/0000-0002-5358-8552				Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64; Arntz HR, 2000, AM J CARDIOL, V86, P1293, DOI 10.1016/S0002-9149(00)01230-3; Aronow HD, 2001, LANCET, V357, P1063, DOI 10.1016/S0140-6736(00)04257-4; Braunwald E, 2000, J AM COLL CARDIOL, V36, P970, DOI 10.1016/S0735-1097(00)00889-5; Buemi M, 1999, EUR J PHARMACOL, V370, P201, DOI 10.1016/S0014-2999(99)00122-3; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Corsini A, 1998, J CARDIOVASC PHARM, V31, P773, DOI 10.1097/00005344-199805000-00017; Crisby M, 2001, CIRCULATION, V103, P926, DOI 10.1161/01.cir.103.7.926; Dupuis J, 1999, CIRCULATION, V99, P3227, DOI 10.1161/01.CIR.99.25.3227; Fonarow GC, 2001, CIRCULATION, V103, P2768; Fonarow GC, 2001, AM J CARDIOL, V87, P819, DOI 10.1016/S0002-9149(00)01519-8; Fukumoto Y, 2001, CIRCULATION, V103, P993; Huggins GS, 1998, CIRCULATION, V98, P1291, DOI 10.1161/01.CIR.98.13.1291; Jialal I, 2001, CIRCULATION, V103, P1933; LACOSTE L, 1995, CIRCULATION, V92, P3172, DOI 10.1161/01.CIR.92.11.3172; LIEM A, 2000, CIRCULATION, V102, pD2672; MASANORI A, 2001, CIRCULATION, V103, P276; Muhlestein JB, 2001, AM J CARDIOL, V87, P257, DOI 10.1016/S0002-9149(00)01354-0; Newby K, 2001, CIRCULATION, V103, P1727; Newby LK, 1999, AM HEART J, V138, P210, DOI 10.1016/S0002-8703(99)70104-3; NOTARBARTOLO A, 1995, ARTERIOSCL THROM VAS, V15, P247, DOI 10.1161/01.ATV.15.2.247; ODriscoll G, 1997, CIRCULATION, V95, P1126, DOI 10.1161/01.cir.95.5.1126; PEDERSEN TR, 1994, LANCET, V344, P1383; Ridker PM, 2001, CIRCULATION, V103, P1191; Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230; Rosenson RS, 1999, LANCET, V353, P983, DOI 10.1016/S0140-6736(98)05917-0; Ryan TJ, 1999, J AM COLL CARDIOL, V34, P890, DOI 10.1016/S0735-1097(99)00351-4; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Stenestrand U, 2001, JAMA-J AM MED ASSOC, V285, P430, DOI 10.1001/jama.285.4.430; STROES ESG, 1995, LANCET, V346, P467, DOI 10.1016/S0140-6736(95)91322-X; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Topol CE, 2000, LANCET, V355, P337; Undas A, 2001, CIRCULATION, V103, P2248; Vaughan CJ, 2000, J AM COLL CARDIOL, V35, P1, DOI 10.1016/S0735-1097(99)00525-2; Weber C, 1997, J AM COLL CARDIOL, V30, P1212, DOI 10.1016/S0735-1097(97)00324-0	36	115	122	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	2002	287	23					3087	3095		10.1001/jama.287.23.3087	http://dx.doi.org/10.1001/jama.287.23.3087			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563NK	12069671	Bronze			2022-12-28	WOS:000176262300023
J	Chiasson, JL; Josse, RG; Gomis, R; Hanefeld, M; Karasik, A; Laakso, M				Chiasson, JL; Josse, RG; Gomis, R; Hanefeld, M; Karasik, A; Laakso, M		STOP-NIDDM Trial Res Grp	Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial	LANCET			English	Article							IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; INSULIN; NIDDM; PREVALENCE; EFFICACY	Background The worldwide increase in type 2 diabetes mellitus is becoming a major health concern. We aimed to assess the effect of acarbose in preventing or delaying conversion of impaired glucose tolerance to type 2 diabetes. Methods In a multicentre, placebo-controlled randomised trial, we randomly allocated patients with impaired glucose tolerance to 100 mg acarbose or placebo three times daily. The primary endpoint was development of diabetes on the basis of a yearly oral glucose tolerance test (OGTT). Analyses were by intention to treat. Findings We randomly allocated 714 patients with impaired glucose tolerance to acarbose and 715 to placebo. We excluded 61 (4%) patients because they did not have impaired glucose tolerance or had no postrandomisation data. 211 (31%) of 682 patients in the acarbose group and 130 (19%) of 686 on placebo discontinued treatment early. 221 (32%) patients randomised to acarbose and 285 (42%) randomised to placebo developed diabetes (relative hazard 0.75 [95% Cl 0.63-0.90]; p=0.0015). Furthermore, acarbose significantly increased reversion of impaired glucose tolerance to normal glucose tolerance (p<0.0001). At the end of the study, treatment with placebo for 3 months was associated with an increase in conversion of impaired glucose tolerance to diabetes. The most frequent side-effects to acarbose treatment were flatulence and diarrhoea. Interpretation Acarbose could be used, either as an alternative or in addition to changes in lifestyle, to delay development of type 2 diabetes in patients with impaired glucose tolerance.	Univ Montreal, Ctr Hosp, Hotel Dieu, Res Ctr,Dept Med, Montreal, PQ H2W 1T7, Canada; Univ Toronto, St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada; Univ Barcelona, Hosp Clin, Diabet Unit, Barcelona, Spain; Tech Univ Dresden, Ctr Clin Studies GWT, Dresden, Germany; Chaim Sheba Med Ctr, Inst Endocrinol, IL-52621 Tel Hashomer, Israel; Univ Kuopio, FIN-70211 Kuopio, Finland	Laval University; Universite de Montreal; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Barcelona; Hospital Clinic de Barcelona; Technische Universitat Dresden; Chaim Sheba Medical Center; University of Eastern Finland	Chiasson, JL (corresponding author), Univ Montreal, Ctr Hosp, Hotel Dieu, Res Ctr,Dept Med, 3850 St Urbain St,Room 8-202, Montreal, PQ H2W 1T7, Canada.	jean.louis.chiasson@umontreal.ca	קרסיק, אברהם/AAV-1374-2021					BAILEY CJ, 2001, BR J DIABETES VASC D, V1, P62; BECKNIELSEN H, 1994, J CLIN INVEST, V94, P1714, DOI 10.1172/JCI117518; Chen HD, 1997, DIABETES RES CLIN PR, V38, P199, DOI 10.1016/S0168-8227(97)00104-6; Chiasson JL, 1998, DIABETES CARE, V21, P1720, DOI 10.2337/diacare.21.10.1720; CHIASSON JL, 1994, ANN INTERN MED, V121, P928, DOI 10.7326/0003-4819-121-12-199412150-00004; Chiasson JL, 1996, DIABETES CARE, V19, P1190, DOI 10.2337/diacare.19.11.1190; COLE RA, 1978, METABOLISM, V27, P289, DOI 10.1016/0026-0495(78)90109-9; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; Dittler J, 1998, DIABETES, V47, P592, DOI 10.2337/diabetes.47.4.592; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gavin JR, 1997, DIABETES CARE, V20, P1183; Harris MI, 1998, DIABETES CARE, V21, pC11, DOI 10.2337/diacare.21.3.C11; Harris MI, 1996, DIABETIC MED, V13, pS9; Heine RJ, 1996, DIABETIC MED, V13, pS12; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; MYKKANEN L, 1993, DIABETOLOGIA, V36, P553, DOI 10.1007/BF02743273; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; SAAD MF, 1988, NEW ENGL J MED, V319, P1500, DOI 10.1056/NEJM198812083192302; SOBEY WJ, 1989, BIOCHEM J, V260, P535, DOI 10.1042/bj2600535; Tripathy D, 2000, DIABETES, V49, P975, DOI 10.2337/diabetes.49.6.975; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; WARNICK GR, 1982, CLIN CHEM, V28, P1379; World Health Organization, 1985, WHO TECH REP SER, V727, P7; Zimmet P, 1999, DIABETES CARE, V22, pB59	26	1732	1851	8	144	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 15	2002	359	9323					2072	2077		10.1016/S0140-6736(02)08905-5	http://dx.doi.org/10.1016/S0140-6736(02)08905-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086760				2022-12-28	WOS:000176194600008
J	Dabis, F; Ekpini, ER				Dabis, F; Ekpini, ER			HIV-1/AIDS and maternal and child health in Africa	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-INFECTED WOMEN; COTE-DIVOIRE; PERINATAL TRANSMISSION; VERTICAL TRANSMISSION; PROSPECTIVE COHORT; PREGNANT-WOMEN; RECEIVING NEVIRAPINE; HIV-1-INFECTED WOMEN; DEVELOPING-COUNTRIES	Every day, 1900 children acquire HIV-1 infection from their mother in Africa. The 25-45% risk of mother-to-child transmission can be reduced in several ways: prevention of sexual transmission for women of child-bearing age, access to HIV-1 testing, reduction of unwanted pregnancies by education of HIVA.-infected women, and antiretroviral-based prevention. All antiretroviral regimens of proven efficacy can be used in a minimum package of care for HIV-1-infected pregnant women. At present, programmes in 13 countries reach less than 3% of HIV-1-infected African women. 35-59% of African children infected with HIV-1. die by their second birthday. Infectious complications are preventable by primary prophylaxis with co-trimoxazole. A rapid scaling-up and comprehensive continuum of care is needed for all members of affected families, including access to antiretroviral treatment and community-based responses to the increasing number of orphans. Prevention of mother-to-child transmission should become a universal standard of care in Africa, and research should continue to reduce the transmission risk to well below 5%.	Univ Victor Segalen, ISPED, INSERM, U330, F-33076 Bordeaux, France; CHU Treichville, Projet RETRO CI, Abidjan, Cote Ivoire	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Dabis, F (corresponding author), Univ Victor Segalen, ISPED, INSERM, U330, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	francois.dabis@isped.u-bordeaux2.fr	DABIS, FRANCOIS/S-9298-2019	DABIS, FRANCOIS/0000-0002-1614-8857				Alioum A, 2001, STAT MED, V20, P3539, DOI 10.1002/sim.1076; [Anonymous], 2001, Wkly Epidemiol Rec, V76, P381; ANZALA OA, 1995, J INFECT DIS, V171, P686, DOI 10.1093/infdis/171.3.686; AsiimweOkiror G, 1997, AIDS, V11, P1757, DOI 10.1097/00002030-199714000-00013; Bassett MT, 2002, AM J PUBLIC HEALTH, V92, P347, DOI 10.2105/AJPH.92.3.347; Beckerman KP, 2002, LANCET, V359, P1168, DOI 10.1016/S0140-6736(02)08248-X; Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5; BRAHMBHATT H, 2001, 3 C GLOB STRATEGIES; Bulterys M, 2002, BMJ-BRIT MED J, V324, P222, DOI 10.1136/bmj.324.7331.222; Cartoux M, 1998, AIDS, V12, P2489, DOI 10.1097/00002030-199818000-00019; Coutsoudis A, 1999, LANCET, V354, P471, DOI 10.1016/S0140-6736(99)01101-0; Coutsoudis A, 1999, AIDS, V13, P1517, DOI 10.1097/00002030-199908200-00012; Coutsoudis A, 2001, AIDS, V15, P653, DOI 10.1097/00002030-200103300-00019; Coutsoudis A, 2001, AIDS, V15, P379, DOI 10.1097/00002030-200102160-00011; Dabis F, 2001, AIDS, V15, pS71, DOI 10.1097/00002030-200102001-00100; Dabis F, 2001, AIDS, V15, P771, DOI 10.1097/00002030-200104130-00013; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; Dabis F, 2000, AIDS, V14, P1017, DOI 10.1097/00002030-200005260-00014; Dabis F, 2000, HEALTH POLICY PLANN, V15, P34, DOI 10.1093/heapol/15.1.34; DABIS F, 2001, 13 INT C AIDS STDS A; DANEL C, 2002, 9 C RETR OPP INF FEB; De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175; Desgrees-du-Lou A, 2001, AIDS, V15, P2327, DOI 10.1097/00002030-200111230-00018; Dray-Spira R, 2000, AIDS, V14, P1091, DOI 10.1097/00002030-200006160-00005; du Lou AD, 1999, AIDS, V13, P517, DOI 10.1097/00002030-199903110-00011; Ekpini RA, 2002, AIDS, V16, P625, DOI 10.1097/00002030-200203080-00015; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; FAWZI WW, 1999, J ACQUI IMMUNE DEFIC, V13, P1517; FOSTER G, 1995, AIDS CARE, V7, P3, DOI 10.1080/09540129550126911; FOWLER MG, 2002, C RETROV OPP INF FEB; Gaillard P, 2001, AIDS, V15, P389, DOI 10.1097/00002030-200102160-00012; GAILLARD P, 2001, STAT MED, V15, P379; GLAZER E, 2002, PEDIATRIC AIDS F; Glynn JR, 2000, J ACQ IMMUN DEF SYND, V25, P345, DOI 10.1097/00126334-200012010-00008; Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157; Grant AD, 1997, AIDS, V11, P1357, DOI 10.1097/00002030-199711000-00010; Grassly NC, 2001, B WORLD HEALTH ORGAN, V79, P1121; Gray RH, 1998, LANCET, V351, P98, DOI 10.1016/S0140-6736(97)09381-1; Gray RH, 2001, AM J OBSTET GYNECOL, V185, P1209, DOI 10.1067/mob.2001.118158; GREENBERG AE, 1998, PEDIATRICS AIDS CHAL; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Hunter S, 2000, CHILDREN BRINK EXECU; Jackson JB, 2000, AIDS, V14, pF111, DOI 10.1097/00002030-200007280-00001; John GC, 2001, J INFECT DIS, V183, P206, DOI 10.1086/317918; KANSHANA, IN PRESS AIDS; KERLIKOWSKE KM, 1994, AIDS, V8, P963, DOI 10.1097/00002030-199407000-00014; Kiarie J, 2000, AIDS, V14, P1468, DOI 10.1097/00002030-200007070-00030; Kilewo C, 2001, J ACQ IMMUN DEF SYND, V28, P458, DOI 10.1097/00042560-200112150-00009; LAMPTEY PR, 1911, BRIT MED J, V324, P207; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; Leroy V, 2002, AIDS, V16, P631, DOI 10.1097/00002030-200203080-00016; Leroy V, 2001, AIDS, V15, P517, DOI 10.1097/00002030-200103090-00011; LEROY V, 1995, J ACQ IMMUN DEF SYND, V9, P415; Loening-Voysey H, 2001, APPROACHES CARING CH; *MAILM SCH PUBL HL, 2002, UNPR COLL PRIV FUNDA; MANIGART O, 2001, 13 I C AIDS STDS AFR; MARSEILLE E, 2001, 3 C GLOB STRAT PREV; MARSHALAGA NR, 2002, BRIT MED J, V324, P185; Mbori-Ngacha D, 2001, JAMA-J AM MED ASSOC, V286, P2413, DOI 10.1001/jama.286.19.2413; Miotti PG, 1999, JAMA-J AM MED ASSOC, V282, P744, DOI 10.1001/jama.282.8.744; Mofenson LM, 2000, LANCET, V355, P2237, DOI 10.1016/S0140-6736(00)02415-6; Mofenson LM, 1999, NEW ENGL J MED, V341, P385, DOI 10.1056/NEJM199908053410601; MOODLEY D, 2000, 13 INT AIDS C JUL 9; Morgan D, 2002, BRIT MED J, V324, P193, DOI 10.1136/bmj.324.7331.193; Morgan D, 1997, AIDS, V11, P633, DOI 10.1097/00002030-199705000-00011; Msellati P, 2001, B WORLD HEALTH ORGAN, V79, P641; MSELLATI P, 1995, J ACQ IMMUN DEF SYND, V8, P506; Muller O, 1999, AIDS, V13, P146; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; Nebie Y, 2001, J ACQ IMMUN DEF SYND, V28, P367, DOI 10.1097/00126334-200112010-00010; Newell ML, 2001, B WORLD HEALTH ORGAN, V79, P1138; Nicoll A, 2000, AIDS, V14, pS57; Nyambedha EO, 2001, HEALTH POLICY, V58, P83, DOI 10.1016/S0168-8510(01)00145-2; OWOR M, 2000, 13 INT AIDS C JUL 9; Saba J, 2002, LANCET, V359, P1178; Salamon R, 2002, J ACQ IMMUN DEF SYND, V29, P149, DOI 10.1097/00042560-200202010-00007; Semba RD, 1999, J INFECT DIS, V180, P93, DOI 10.1086/314854; Shaffer N, 1999, J INFECT DIS, V179, P590, DOI 10.1086/314641; SHERRY AK, 2001, 3 C GLOB STRAT PREV; Sinkala M, 2001, LANCET, V358, P1611, DOI 10.1016/S0140-6736(01)06662-4; Spira R, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e56; Taha TE, 1999, PEDIATR INFECT DIS J, V18, P689, DOI 10.1097/00006454-199908000-00007; *UN SECR GEN, 2001, CHILDR MEET PROM WOR; *UNAIDS REF GROUP, IN PRESS AIDS; *UNAIDS WHO, 2002, PROV WHO UNAIDS SECR; *UNAIDS WHO, 2002, UNAIDS0174EWHOCDSCSR; *UNFAP UNICEF WHO, 2001, WHORHR0128; *UNICEF, 2001, MOTH CHILD TRANSM HI; *UNICEF UNAIDS WHO, 1998, HIV INF FEED GUID HE; Van Rompay KKA, 2001, J INFECT DIS, V184, P429, DOI 10.1086/322781; *WHO, 2001, EFF BREASTF MORT HIV; *WHO, 2002, WHOFCHCAH023; *WHO, 2001, 20013 WHO HIV AIDS; *WHO, 2002, WHO UNAIDS CONT SUPP; *WHO, 2000, NEW DAT PREV MOTH CH; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; Willumsen JF, 2001, AIDS, V15, P1896, DOI 10.1097/00002030-200109280-00026	97	156	158	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 15	2002	359	9323					2097	2104		10.1016/S0140-6736(02)08909-2	http://dx.doi.org/10.1016/S0140-6736(02)08909-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086778				2022-12-28	WOS:000176194600025
J	Reynolds, GP; Zhang, ZJ; Zhang, XB				Reynolds, GP; Zhang, ZJ; Zhang, XB			Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism	LANCET			English	Article							OBESITY	A side-effect of treatment with antipsychotic drugs for schizophrenia is Increased body fat, which leads to further morbidity and poor adherence to treatment. The 5-hydroxytryptamine 2C receptor (5-HT2C) has been associated with this effect; we aimed to establish whether a genetic polymorphism of the promoter region of this receptor affects weight gain after drug treatment In first-episode patients with schizophrenia. We noted significantly less weight gain in patients with the -759T variant allele (p=0.0003) than In those without this allele, who were more likely to have substantial (>7%) weight gain (p=0.002). We have identified a genetic factor that Is associated with antipsychotic drug-induced weight gain.	Univ Sheffield, Dept Biomed Sci, Sheffield S10 2TN, S Yorkshire, England; Nanjing Brain Hosp, Dept Psychiat, Nanjing, Peoples R China; Nanjing Med Univ, Nanjing, Peoples R China	University of Sheffield; Nanjing Medical University	Reynolds, GP (corresponding author), Univ Sheffield, Dept Biomed Sci, Sheffield S10 2TN, S Yorkshire, England.		Reynolds, Gavin/AAM-9985-2020	Reynolds, Gavin/0000-0001-9026-7726				Allison DB, 1999, AM J PSYCHIAT, V156, P1686; Hong CJ, 2001, PHARMACOGENETICS, V11, P265, DOI 10.1097/00008571-200104000-00010; Lentes KU, 1997, LIFE SCI, V61, pPL9, DOI 10.1016/S0024-3205(97)00361-5; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; Yuan X, 2000, DIABETOLOGIA, V43, P373, DOI 10.1007/s001250050056	5	309	324	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 15	2002	359	9323					2086	2087		10.1016/S0140-6736(02)08913-4	http://dx.doi.org/10.1016/S0140-6736(02)08913-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086765				2022-12-28	WOS:000176194600013
J	Aguado, E; Richelme, S; Nunez-Cruz, S; Miazek, A; Mura, AM; Richelme, M; Guo, XJ; Sainty, D; He, HT; Malissen, B; Malissen, M				Aguado, E; Richelme, S; Nunez-Cruz, S; Miazek, A; Mura, AM; Richelme, M; Guo, XJ; Sainty, D; He, HT; Malissen, B; Malissen, M			Induction of T helper type 2 immunity by a point mutation in the LAT adaptor	SCIENCE			English	Article							CELL DEVELOPMENT; TYROSINE RESIDUES; ACTIVATION; MICE; LYMPHOCYTES; RECEPTOR; LINKER; HOMEOSTASIS; EXPRESSION; CD5	The transmembrane protein LAT (tinker for activation of T cells) couples the T cell receptor (TCR) to downstream signaling effectors. Mice homozygous for a mutation of a single LAT tyrosine residue showed impeded T cell development. However, later they accumulated polyclonal helper T (T-H) cells that chronically produced type 2 cytokines in large amounts. This exaggerated T(H)2 differentiation caused tissue eosinophilia and massive maturation of plasma cells secreting to immunoglobulins of the E and G1 isotypes. This paradoxical phenotype establishes an unanticipated inhibitory function for LAT that is critical for the differentiation and homeostasis of T-H cells.	Ctr Immunol Marseille Luminy, INSERM, F-13288 Marseille 9, France; Univ Mediterranee, CNRS, F-13288 Marseille 9, France; Inst J Paoli I Calmettes, Dept Biol, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC)	Malissen, B (corresponding author), Ctr Immunol Marseille Luminy, INSERM, Parc Sci Luminy, F-13288 Marseille 9, France.	bernardm@ciml.univ-mrs.fr	Guo, Xiao-Jun/M-9454-2016; Aguado, Enrique/L-4908-2014; HE, Hai-Tao/O-6551-2016; Malissen, Bernard/AAK-4659-2020	Aguado, Enrique/0000-0002-7232-2661; HE, Hai-Tao/0000-0002-6594-290X; Malissen, Bernard/0000-0003-1340-9342; Miazek, Arkadiusz/0000-0002-7210-2706; Malissen, Marie/0000-0003-2331-1445				Azzam HS, 1998, J EXP MED, V188, P2301, DOI 10.1084/jem.188.12.2301; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; Emson CL, 1998, J EXP MED, V188, P399, DOI 10.1084/jem.188.2.399; Erb KJ, 1997, J EXP MED, V185, P329, DOI 10.1084/jem.185.2.329; Foote LC, 1998, J EXP MED, V187, P847, DOI 10.1084/jem.187.6.847; Goldman M, 2001, TRENDS IMMUNOL, V22, P247, DOI 10.1016/S1471-4906(01)01893-2; Goldrath AW, 1999, NATURE, V402, P255, DOI 10.1038/35005508; Lin J, 2001, J BIOL CHEM, V276, P29588, DOI 10.1074/jbc.M102221200; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; MALISSEN M, UNPUB; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; Paz PE, 2001, BIOCHEM J, V356, P461, DOI 10.1042/0264-6021:3560461; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Smith K, 2001, J EXP MED, V194, P1253, DOI 10.1084/jem.194.9.1253; Sommers CL, 2001, J EXP MED, V194, P135, DOI 10.1084/jem.194.2.135; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; TARAKHOVSKY A, 1995, SCIENCE, V269, P535, DOI 10.1126/science.7542801; Van Parijs L, 1998, SCIENCE, V280, P243; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	21	216	225	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	2002	296	5575					2036	2040		10.1126/science.1069057	http://dx.doi.org/10.1126/science.1069057			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065839				2022-12-28	WOS:000176273300056
J	O'Neill, BC; Oppenheimer, M				O'Neill, BC; Oppenheimer, M			Climate change - Dangerous climate impacts and the Kyoto protocol	SCIENCE			English	Article							CO2; STABILITY		Brown Univ, Watson Inst Int Studies, Providence, RI 02912 USA; Brown Univ, Ctr Environm Studies, Providence, RI 02912 USA; Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA; Princeton Univ, Woodrow Wilson Sch Publ & Int Affairs, Princeton, NJ 08544 USA	Brown University; Brown University; Princeton University; Princeton University	O'Neill, BC (corresponding author), Brown Univ, Watson Inst Int Studies, Providence, RI 02912 USA.	bconeill@brown.edu; omichael@princeton.edu	O'Neill, Brian C./E-6531-2013	O'Neill, Brian C./0000-0001-7505-8897; Oppenheimer, Michael/0000-0002-9708-5914				Azar C, 1997, SCIENCE, V276, P1818, DOI 10.1126/science.276.5320.1818; Azar C, 1998, INT J ENVIRON POLLUT, V10, P508, DOI 10.1504/IJEP.1998.002246; Baker AC, 2001, NATURE, V411, P765, DOI 10.1038/35081151; Broecker WS, 1997, SCIENCE, V278, P1582, DOI 10.1126/science.278.5343.1582; Cubasch U, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P525; HaDuong M, 1997, NATURE, V390, P270, DOI 10.1038/36825; Hoegh-Guldberg O, 1999, MAR FRESHWATER RES, V50, P839, DOI 10.1071/MF99078; JAIN AK, 1995, GLOBAL BIOGEOCHEM CY, V9, P153, DOI 10.1029/94GB02394; Mastrandrea MD, 2001, CLIM POLICY, V1, P433, DOI 10.3763/cpol.2001.0146; Nakicenovic N., 2000, IPCC SPECIAL REPORT; NORDHAUS J, 2000, WARMING WORLD; Oppenheimer M, 1998, NATURE, V393, P325, DOI 10.1038/30661; Rijsberman FR, 1990, TARGETS INDICATORS C; SEAGER R, IN PRESS Q J R METEO; SMITH JB, 2001, CLIMATE CHANGE; Smith JB, 2001, CLIMATE CHANGE 2001: IMPACTS, ADAPTATION, AND VULNERABILITY, P913; Stocker TF, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P417; Stocker TF, 1997, NATURE, V388, P862, DOI 10.1038/42224; Watson RT, 2001, CLIMATE CHANGE 2001: IMPACTS, ADAPTATION, AND VULNERABILITY, pIX; Wigley TML, 1996, NATURE, V379, P240, DOI 10.1038/379240a0; Wigley TML, 1998, GEOPHYS RES LETT, V25, P2285, DOI 10.1029/98GL01855; WIGLEY TML, COMMUNICATION	22	205	212	2	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	2002	296	5575					1971	1972		10.1126/science.1071238	http://dx.doi.org/10.1126/science.1071238			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065820				2022-12-28	WOS:000176273300030
J	Egolf, DA				Egolf, DA			Statistical mechanics: Far from equilibrium	SCIENCE			English	Editorial Material							FREE-ENERGY DIFFERENCES; NONEQUILIBRIUM		Georgetown Univ, Dept Phys, Washington, DC 20057 USA; Wesleyan Univ, Dept Phys, Middletown, CT 06459 USA	Georgetown University; Wesleyan University	Egolf, DA (corresponding author), Georgetown Univ, Dept Phys, Washington, DC 20057 USA.							Frauenfelder H, 2002, P NATL ACAD SCI USA, V99, P2479, DOI 10.1073/pnas.012579999; Isralewitz B, 2001, CURR OPIN STRUC BIOL, V11, P224, DOI 10.1016/S0959-440X(00)00194-9; Jarzynski C, 1997, PHYS REV LETT, V78, P2690, DOI 10.1103/PhysRevLett.78.2690; Jarzynski C, 1997, PHYS REV E, V56, P5018, DOI 10.1103/PhysRevE.56.5018; LANDAU LD, 1980, STAT PHYSICS; Liphardt J, 2002, SCIENCE, V296, P1832, DOI 10.1126/science.1071152	6	10	10	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 7	2002	296	5574					1813	+		10.1126/science.1073595	http://dx.doi.org/10.1126/science.1073595			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	12052941				2022-12-28	WOS:000176054300029
J	Duley, L; Farrell, B; Spark, P; Roberts, B; Watkins, K; Bricker, L; Wang, L; Armstrong, N; Tivnin, M; Salih, N; Hurst, A; Smyth, R; Cooper, S; Wilson, A; Bowler, U; Notman, J				Duley, L; Farrell, B; Spark, P; Roberts, B; Watkins, K; Bricker, L; Wang, L; Armstrong, N; Tivnin, M; Salih, N; Hurst, A; Smyth, R; Cooper, S; Wilson, A; Bowler, U; Notman, J		Magpie Trial Collaborative Grp	Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial	LANCET			English	Article							PREGNANCY-INDUCED HYPERTENSION; UNITED-KINGDOM; SULFATE; PREECLAMPSIA; NIFEDIPINE; MORTALITY; BIRTH	Background Anticonvulsants are used for pre-eclampsia in the belief they prevent eclamptic convulsions, and so improve outcome. Evidence supported magnesium sulphate as the drug to evaluate. Methods Eligible women (n=10 141) had not given birth or were 24 h or less postpartum; blood pressure of 140/90 mm Hg or more, and proteinuria of 1+ (30 mg/dL) or more; and there was clinical uncertainty about magnesium sulphate. Women were randomised in 33 countries to either magnesium sulphate (n=5071) or placebo (n=5070). Primary outcomes were eclampsa and, for women randomised before delivery, death of the baby. Follow up was until discharge from hospital after delivery. Analyses were by intention to treat. Findings Follow-up data were available for 10 110 (99.7%) women, 9992 (99%) of whom received the allocated treatment. 1201 of 4999 (24%) women given magnesium sulphate reported side-effects versus 228 of 4993 (5%) given placebo. Women allocated magnesium sulphate had a 58% lower risk of eclampsia (95% CI40-71) than those allocated placebo (40, 0.8%, vs 96, 1.9%; 11 fewer women with eclampsia per 1000 women). Maternal mortality was also lower among women allocated magnesium sulphate (relative risk 0-55, 0.26-1.14) For women randomised before delivery, there was no clear difference in the risk of the baby dying (576, 12.7%, vs 558, 12.4%; relative risk 1.02, 99% CI 0.92-1.14). The only notable difference in maternal or neonatal morbidity was for placental abruption (relative risk 0.67, 99% CI 0.45-0.89). Interpretation Magnesium sulphate halves the risk of eclampsia, and probably reduces the risk of maternal death. There do not appear to be substantive harmful effects to mother or baby in the short term.	Inst Hlth Sci, Resource Ctr Randomised Trials, Oxford OX3 7LF, England	University of Oxford	Duley, L (corresponding author), Inst Hlth Sci, Resource Ctr Randomised Trials, Oxford OX3 7LF, England.		Dodd, Jodie/Y-6849-2019; Colditz, Paul B/F-6772-2010; ADEPONLE, ADESINA OLUBUKOLA/AAP-9289-2020; Pritchard, Margo A/G-5188-2010; Cuervo, Luis Gabriel/A-9464-2009; Duley, Lelia/E-8107-2015; Ardila-Montealegre, Javier/J-7814-2016	Dodd, Jodie/0000-0002-6363-4874; Colditz, Paul B/0000-0002-6408-8238; Pritchard, Margo A/0000-0002-1058-9117; Cuervo, Luis Gabriel/0000-0003-2732-5019; Duley, Lelia/0000-0001-6721-5178; Jamieson, Nina/0000-0002-8776-5000; Ardila-Montealegre, Javier/0000-0001-7208-2306; Tan, Kok Hian/0000-0003-1945-0266				BELFORT MA, 1992, AM J OBSTET GYNECOL, V167, P661, DOI 10.1016/S0002-9378(11)91567-1; BENAMI M, 1994, BRIT J OBSTET GYNAEC, V101, P262, DOI 10.1111/j.1471-0528.1994.tb13126.x; BERGSTROM S, 1992, J PERINAT MED, V20, P153; Coetzee EJ, 1998, BRIT J OBSTET GYNAEC, V105, P300, DOI 10.1111/j.1471-0528.1998.tb10090.x; CROWTHER CA, 1985, S AFR MED J, V68, P927; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; DULEY L, 1995, LANCET, V345, P1455; DULEY L, 1992, BRIT J OBSTET GYNAEC, V99, P547, DOI 10.1111/j.1471-0528.1992.tb13818.x; DULEY L, 2002, COCHRANE LIB; FOX R, 1995, BRIT MED J, V311, P1433, DOI 10.1136/bmj.311.7017.1433; GOLDMAN RS, 1988, NEW ENGL J MED, V319, P1224; Graham KM, 1998, LANCET, V351, P1061, DOI 10.1016/S0140-6736(05)79030-9; GUIDOTTI R, 1988, AM J OBSTET GYNECOL, V158, P80; Gulmezoglu AM, 1998, BRIT MED J, V316, P975, DOI 10.1136/bmj.316.7136.975; Hannah ME, 2000, LANCET, V356, P1375, DOI 10.1016/S0140-6736(00)02840-3; LUCAS MJ, 1995, NEW ENGL J MED, V333, P201, DOI 10.1056/NEJM199507273330401; Mahomed K, 1998, LANCET, V351, P293, DOI 10.1016/S0140-6736(05)78237-4; *NAT I CLIN EXC, 2001, WHY MOTH DIE 1997 19; Nelson KB, 1996, JAMA-J AM MED ASSOC, V276, P1843, DOI 10.1001/jama.276.22.1843; PRITCHARD JA, 1984, AM J OBSTET GYNECOL, V148, P951, DOI 10.1016/0002-9378(84)90538-6; ROBERTS JM, 1995, NEW ENGL J MED, V333, P250, DOI 10.1056/NEJM199507273330409; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; SADEH M, 1989, STROKE, V20, P1273, DOI 10.1161/01.STR.20.9.1273; Scudiero R, 2000, OBSTET GYNECOL, V96, P178, DOI 10.1016/S0029-7844(00)00893-0; WAISMAN GD, 1988, AM J OBSTET GYNECOL, V159, P308, DOI 10.1016/S0002-9378(88)80072-3; WHO/UNICEF, 1996, WHOFRHMSM9611 UNICEF; WIGGLESWORTH JS, 1980, LANCET, V2, P684; World Health Organization, 1996, WHOFRHMSM967; ZUSPAN FP, 1978, AM J OBSTET GYNECOL, V131, P591, DOI 10.1016/0002-9378(78)90816-5	29	830	882	1	25	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 1	2002	359	9321					1877	1890		10.1016/s0140-6736(02)08778-0	http://dx.doi.org/10.1016/s0140-6736(02)08778-0			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PL	12057549				2022-12-28	WOS:000175975700006
J	Ogunkolade, BW; Boucher, BJ; Fairclough, PD; Hitman, GA; Dorudi, S; Jenkins, PJ; Bustin, SA				Ogunkolade, BW; Boucher, BJ; Fairclough, PD; Hitman, GA; Dorudi, S; Jenkins, PJ; Bustin, SA			Expression of 25-hydroxyvitamin D-1-alpha-hydroxylase mRNA in individuals with colorectal cancer	LANCET			English	Article							VITAMIN-D; MUCOSA	Vitamin D prevents proliferation, promotes differentiation, and induces apoptosis of colon cells, and reduced intake or insufficiency of the vitamin in the body are associated with increased risk of colorectal cancer. Results of previous studies have suggested that mRNA that codes for 25-hydroxyvitamin D-1-alpha-hydroxylase (1alphaOHase), which converts 25-hydroxyvitamin D to its active metabolite, might be up regulated in human colon carcinomas. We used real-time reverse transcription PCR assays to measure absolute 1alphaOHase mRNA concentrations in the colonic mucosa of 44 individuals without cancer, and in paired healthy colon and cancerous colon samples taken from 27 individuals with the disease, to ascertain whether or not such up regulation takes place. Our results suggest that concentrations of 1alphaOHase mRNA in tumour samples and In healthy colon samples from individuals without cancer are similar, but that concentrations are significantly lower in the paired, phenotypically healthy mucosa of individuals with cancer.	Univ London, Queen Marys Sch Med & Dent, Barts & London, Acad Dept Surg, London E1 1BB, England; Univ London, Queen Marys Sch Med & Dent, Barts & London, Dept Diabet & Metab Med, London E1 1BB, England; Univ London, Queen Marys Sch Med & Dent, Barts & London, Dept Endocrinol, London E1 1BB, England; Univ London, Queen Marys Sch Med & Dent, Barts & London, Dept Gastroenterol, London E1 1BB, England	University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; Queen Mary University London	Bustin, SA (corresponding author), Univ London, Queen Marys Sch Med & Dent, Barts & London, Acad Dept Surg, London E1 1BB, England.		Bustin, Stephen/HHT-0617-2022; Bustin, Stephen/H-3086-2013	Bustin, Stephen/0000-0003-1870-6098; Bustin, Stephen/0000-0003-1870-6098; Boucher, Barbara J/0000-0003-1206-7555				Bareis P, 2001, BIOCHEM BIOPH RES CO, V285, P1012, DOI 10.1006/bbrc.2001.5289; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Cross HS, 2001, STEROIDS, V66, P287, DOI 10.1016/S0039-128X(00)00153-7; Tangpricha V, 2001, LANCET, V357, P1673, DOI 10.1016/S0140-6736(00)04831-5; THOMAS MG, 1992, GUT, V33, P1660, DOI 10.1136/gut.33.12.1660	5	42	46	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 25	2002	359	9320					1831	1832		10.1016/S0140-6736(02)08680-4	http://dx.doi.org/10.1016/S0140-6736(02)08680-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044381				2022-12-28	WOS:000175775500014
J	Arrieta, VA; de Tejerina, JMCF; Etxeberria, D; Garcia-Bragado, F				Arrieta, VA; de Tejerina, JMCF; Etxeberria, D; Garcia-Bragado, F			Fever and anasarca	LANCET			English	Editorial Material							INTRAVASCULAR LYMPHOMATOSIS; CELL LYMPHOMA		Virgen Camino Hosp, Dept Internal Med & Pathol, Pamplona 31004, Spain	Servicio Navarro de Salud - Osasunbidea	Arrieta, VA (corresponding author), Virgen Camino Hosp, Dept Internal Med & Pathol, Pamplona 31004, Spain.	jcortes@infomed.es	Casas, Juan Manuel/ABD-4528-2020; Messier, Claude/A-2322-2008	Casas, Juan Manuel/0000-0003-0449-9833; Messier, Claude/0000-0002-4791-1763				Estalilla OC, 1999, AM J CLIN PATHOL, V112, P248; GLASS J, 1993, CANCER-AM CANCER SOC, V71, P3156, DOI 10.1002/1097-0142(19930515)71:10<3156::AID-CNCR2820711043>3.0.CO;2-O; Jillella AP, 2000, LEUKEMIA LYMPHOMA, V38, P419, DOI 10.3109/10428190009087034; Nakahara T, 1999, J NEUROL NEUROSUR PS, V67, P403, DOI 10.1136/jnnp.67.3.403; Suzumiya J, 1998, LEUKEMIA LYMPHOMA, V32, P179, DOI 10.3109/10428199809059259	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 18	2002	359	9319					1746	1746		10.1016/S0140-6736(02)08656-7	http://dx.doi.org/10.1016/S0140-6736(02)08656-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049865				2022-12-28	WOS:000175740500013
J	Lawrence, D				Lawrence, D			Cancer incidence in the USA could double by 2050, report predicts	LANCET			English	News Item																		Edwards BK, 2002, CANCER-AM CANCER SOC, V94, P2766, DOI 10.1002/cncr.10593	1	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 18	2002	359	9319					1755	1755		10.1016/S0140-6736(02)08668-3	http://dx.doi.org/10.1016/S0140-6736(02)08668-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049905				2022-12-28	WOS:000175740500020
J	Turpie, AGG; Bauer, KA; Eriksson, BI; Lassen, MR				Turpie, AGG; Bauer, KA; Eriksson, BI; Lassen, MR		PENTATHLON 2000 Study Steering	Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial	LANCET			English	Article							MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; SYNTHETIC PENTASACCHARIDE; RECOMBINANT HIRUDIN; KNEE ARTHROPLASTY; FACTOR XA; PROPHYLAXIS; INHIBITION; GENERATION	Background Elective hip-replacement surgery carries significant risk of venous thromboembolism, despite use of thromboprophylaxis. We aimed to see whether the pentasaccharide fondaparinux, the first drug of a new class of synthetic antithrombotic agents, could reduce this risk to a greater extent than other available treatments. Methods In a double-blind study, we randomly assigned 2275 consecutive patients aged 18 years or older who were undergoing elective hip-replacement surgery to receive postoperative subcutaneous injections of either 2.5 mg fondaparinux once daily or 30 mg enoxaparin twice daily. The primary efficacy outcome was venous thromboembolism to day 11. The main safety outcomes were bleeding and death. Patients were followed up for 6 weeks. Findings We assessed venous thromboembolism to day 11 in 1584 (70%) of 2275 patients. By day 11, venous thromboembolisms were recorded in 48 (6%) of 787 patients on fondaparinux and in 66 (8%) of 797 patients on enoxaparin. The relative reduction in risk was 26.3% (95% Cl -10.8 to 52.8, p=0.099). The two groups did not differ in the number of patients who died or in the number who had clinically relevant bleeding. Interpretation In patients undergoing elective hip-replacement surgery, 2.5 mg fondaparinux once daily was not significantly more effective than 30 mg enoxaparin twice daily in reducing risk of venous thromboembolism. However, the lower risk recorded with fondaparinux than enoxaparin was clinically important, with no increase in clinically relevant bleeding.	Hamilton Hlth Sci Corp, Dept Med, Gen Div, Hamilton, ON, Canada; Vet Affairs, Dept Med, Boston, MA USA; Healthcare Syst & Boston Israel Deaconess Med Ctr, Boston, MA USA; Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden; Univ Hosp Copenhagen Hillerod, Dept Orthopaed, Hillerod, Denmark	McMaster University; Harvard University; Beth Israel Deaconess Medical Center; Sahlgrenska University Hospital; University of Copenhagen	Turpie, AGG (corresponding author), Gen Hosp, Hamilton Hlth Sci Gen, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.			Eriksson, Bengt/0000-0001-6894-7434				Bauer KA, 2001, NEW ENGL J MED, V345, P1305, DOI 10.1056/NEJMoa011099; COLWELL CW, 1994, J BONE JOINT SURG AM, V76A, P3, DOI 10.2106/00004623-199401000-00002; Eriksson BI, 1997, NEW ENGL J MED, V337, P1329, DOI 10.1056/NEJM199711063371901; Eriksson BI, 1996, LANCET, V347, P635, DOI 10.1016/S0140-6736(96)91200-3; Eriksson BI, 2001, NEW ENGL J MED, V345, P1298, DOI 10.1056/NEJMoa011100; Geerts WH, 2001, CHEST, V119, p132S, DOI 10.1378/chest.119.1_suppl.132S; Hull RD, 2000, ARCH INTERN MED, V160, P2199, DOI 10.1001/archinte.160.14.2199; Lassen MR, 2002, LANCET, V359, P1715, DOI 10.1016/S0140-6736(02)08652-X; Leclerc JR, 1998, ARCH INTERN MED, V158, P873, DOI 10.1001/archinte.158.8.873; Lieberman JR, 1997, J BONE JOINT SURG AM, V79A, P319, DOI 10.2106/00004623-199703000-00001; Lormeau JC, 1995, THROMB HAEMOSTASIS, V74, P1474; MOHR DN, 1992, MAYO CLIN PROC, V67, P861, DOI 10.1016/S0025-6196(12)60825-8; Nicolaides AN, 2001, INT ANGIOL, V20, P1; PETITOU M, 1991, NATURE, V350, P30; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; Robinson KS, 1997, ANN INTERN MED, V127, P439, DOI 10.7326/0003-4819-127-6-199709150-00004; SPIRO TE, 1994, ANN INTERN MED, V121, P81, DOI 10.7326/0003-4819-121-2-199407150-00001; TURPIE AG, 1980, NEW ENGL J MED, V315, P925; Turpie AGG, 2001, NEW ENGL J MED, V344, P619, DOI 10.1056/NEJM200103013440901; VANBOECKEL CAA, 1993, ANGEW CHEM INT EDIT, V32, P1671, DOI 10.1002/anie.199316713; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WALENGA JM, 1988, THROMB RES, V51, P23, DOI 10.1016/0049-3848(88)90279-4	22	382	397	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 18	2002	359	9319					1721	1726		10.1016/S0140-6736(02)08648-8	http://dx.doi.org/10.1016/S0140-6736(02)08648-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049860				2022-12-28	WOS:000175740500008
J	Groisman, I; Jung, MY; Sarkissian, M; Cao, QP; Richter, JD				Groisman, I; Jung, MY; Sarkissian, M; Cao, QP; Richter, JD			Translational control of the embryonic cell cycle	CELL			English	Article							XENOPUS OOCYTE MATURATION; CAP-DEPENDENT TRANSLATION; CYTOPLASMIC POLYADENYLATION; MESSENGER-RNA; C-MOS; POLY(A) POLYMERASE; SPECIFICITY FACTOR; PROTEIN-SYNTHESIS; FROG OOCYTES; CPEB	The synthesis and destruction of cyclin B drives mitosis in eukaryotic cells. Cell cycle progression is also regulated at the level of cyclin B translation. In cycling extracts from Xenopus embryos, progression into M phase requires the polyadenylation-induced translation of cyclin B1 mRNA. Polyadenylation is mediated by the phosphorylation of CPEB by Aurora, a kinase whose activity oscillates with the cell cycle. Exit from M phase seems to require deadenylation and subsequent translational silencing of cyclin B1 mRNA by Maskin, a CPEB and eIF4E binding factor, whose expression is cell cycle regulated. These observations suggest that regulated cyclin B1 mRNA translation is essential for the embryonic cell cycle. Mammalian cells also display a cell cycle-dependent cytoplasmic polyadenylation, suggesting that translational control by polyadenylation might be a general feature of mitosis in animal cells.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Richter, JD (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.	joel.richter@umassmed.edu		Groisman, Irina/0000-0001-8909-678X; Groisman, Sonia/0000-0003-1153-3841				Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; BALLANTYNE S, 1995, RNA, V1, P64; Colgan DF, 1996, NATURE, V384, P282, DOI 10.1038/384282a0; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; de Moor CH, 1999, EMBO J, V18, P2294, DOI 10.1093/emboj/18.8.2294; deMoor CH, 1997, MOL CELL BIOL, V17, P6419, DOI 10.1128/MCB.17.11.6419; Dickson KS, 1999, MOL CELL BIOL, V19, P5707; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; FOX CA, 1990, GENE DEV, V4, P2287, DOI 10.1101/gad.4.12b.2287; GEBAUER F, 1995, MOL CELL BIOL, V15, P3460; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; Hake LE, 1998, MOL CELL BIOL, V18, P685, DOI 10.1128/MCB.18.2.685; Hinchcliffe EH, 2001, METHOD CELL BIOL, V67, P269; Hodgman R, 2001, DEVELOPMENT, V128, P2815; HUANG YS, 2002, IN PRESS EMBO J; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Korner CG, 1997, J BIOL CHEM, V272, P10448; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; Mendez R, 2000, MOL CELL, V6, P1253, DOI 10.1016/S1097-2765(00)00121-0; Mendez R, 2002, EMBO J, V21, P1833, DOI 10.1093/emboj/21.7.1833; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Nebreda AR, 2000, CURR OPIN CELL BIOL, V12, P666, DOI 10.1016/S0955-0674(00)00150-2; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Richter JD, 2000, COLD SPRING HARBOR M, V39, P785; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; StebbinsBoaz B, 1996, EMBO J, V15, P2582, DOI 10.1002/j.1460-2075.1996.tb00616.x; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; Tay J, 2001, DEV CELL, V1, P201, DOI 10.1016/S1534-5807(01)00025-9; Topalian SL, 2001, MOL CELL BIOL, V21, P5614, DOI 10.1128/MCB.21.16.5614-5623.2001; VARNUM SM, 1990, GENE DEV, V4, P2278, DOI 10.1101/gad.4.12b.2278; Wakiyama M, 2000, CURR BIOL, V10, P1147, DOI 10.1016/S0960-9822(00)00701-6; Wickens M, 2000, COLD SPRING HARBOR M, V39, P295; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3; Zhao WQ, 1996, MOL CELL BIOL, V16, P2378	49	153	157	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	2002	109	4					473	483		10.1016/S0092-8674(02)00733-X	http://dx.doi.org/10.1016/S0092-8674(02)00733-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	553VM	12086604	Bronze			2022-12-28	WOS:000175696800009
J	Gibbons, RJ				Gibbons, RJ			Abnormal heart-rate recovery after exercise	LANCET			English	Editorial Material							ASSOCIATION TASK-FORCE; PRACTICE GUIDELINES; TREADMILL EXERCISE; MORTALITY; PREDICTORS		Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, Rochester, MN 55905 USA	Mayo Clinic	Gibbons, RJ (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, 200 1st St SW, Rochester, MN 55905 USA.							Cole CR, 2000, ANN INTERN MED, V132, P552, DOI 10.7326/0003-4819-132-7-200004040-00007; Cole CR, 1999, NEW ENGL J MED, V341, P1351, DOI 10.1056/NEJM199910283411804; Desai MY, 2001, AM J CARDIOL, V87, P1164, DOI 10.1016/S0002-9149(01)01487-4; Diaz LA, 2001, J AM COLL CARDIOL, V37, P1558, DOI 10.1016/S0735-1097(01)01205-0; Gibbons RJ, 1997, J AM COLL CARDIOL, V30, P260; Gibbons RJ, 1999, J AM COLL CARDIOL, V33, P2092, DOI 10.1016/S0735-1097(99)00150-3; Krone RJ, 2001, J AM COLL CARDIOL, V38, P136, DOI 10.1016/S0735-1097(01)01312-2; Lauer MS, 1999, J AM COLL CARDIOL, V34, P618, DOI 10.1016/S0735-1097(99)00250-8; Nishime EO, 2000, JAMA-J AM MED ASSOC, V284, P1392, DOI 10.1001/jama.284.11.1392; Watanabe J, 2001, CIRCULATION, V104, P1911, DOI 10.1161/circ.104.16.1911; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	11	47	51	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 4	2002	359	9317					1536	1537		10.1016/S0140-6736(02)08525-2	http://dx.doi.org/10.1016/S0140-6736(02)08525-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047958				2022-12-28	WOS:000175460700002
J	Smith, GD; Gunthorpe, J; Kelsell, RE; Hayes, PD; Reilly, P; Facer, P; Wright, JE; Jerman, JC; Walhin, JP; Ooi, L; Egerton, J; Charles, KJ; Smart, D; Randall, AD; Anand, P; Davis, JB				Smith, GD; Gunthorpe, J; Kelsell, RE; Hayes, PD; Reilly, P; Facer, P; Wright, JE; Jerman, JC; Walhin, JP; Ooi, L; Egerton, J; Charles, KJ; Smart, D; Randall, AD; Anand, P; Davis, JB			TRPV3 is a temperature-sensitive vanilloid receptor-like protein	NATURE			English	Article							CAPSAICIN-RECEPTOR; SENSORY NEURONS; NOXIOUS HEAT; CHANNELS; GENE; IDENTIFICATION; EXPRESSION; RESPONSES; SUBUNITS; AGONIST	Vanilloid receptor-1 (VR1, also known as TRPV1) is a thermosensitive, nonselective cation channel that is expressed by capsaicin-sensitive sensory afferents and is activated by noxious heat, acidic pH and the alkaloid irritant capsaicin(1). Although VR1 gene disruption results in a loss of capsaicin responses, it has minimal effects on thermal nociception(2,3). This and other experiments-such as those showing the existence of capsaicin-insensitive heat sensors in sensory neurons(4)-suggest the existence of thermosensitive receptors distinct from VR1. Here we identify a member of the vanilloid receptor/TRP gene family, vanilloid receptor-like protein 3 (VRL3, also known as TRPV3), which is heat-sensitive but capsaicin-insensitive. VRL3 is coded for by a 2,370-base-pair open reading frame, transcribed from a gene adjacent to VR1, and is structurally homologous to VR1. VRL3 responds to noxious heat with a threshold of about 39 degreesC and is co-expressed in dorsal root ganglion neurons with VR1. Furthermore, when heterologously expressed, VRL3 is able to associate with VR1 and may modulate its responses. Hence, not only is VRL3 a thermosensitive ion channel but it may represent an additional vanilloid receptor subunit involved in the formation of heteromeric vanilloid receptor channels.	GlaxoSmithKline, Neurol CEDD, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Genet Res, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Discovery Res, Harlow CM19 5AW, Essex, England; Hammersmith Hosp, Imperial Coll, Peripheral Neuropathy Unit, London W12 0NN, England	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Imperial College London	Davis, JB (corresponding author), GlaxoSmithKline, Neurol CEDD, 3rd ave, Harlow CM19 5AW, Essex, England.			Ooi, Lezanne/0000-0001-9241-8268; Randall, Andrew/0000-0001-8852-3671				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Babinski K, 2000, J BIOL CHEM, V275, P28519, DOI 10.1074/jbc.M004114200; Birney E, 2000, GENOME RES, V10, P547, DOI 10.1101/gr.10.4.547; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Coward K, 2000, PAIN, V85, P41, DOI 10.1016/S0304-3959(99)00251-1; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Delany NS, 2001, PHYSIOL GENOMICS, V4, P165, DOI 10.1152/physiolgenomics.2001.4.3.165; Dempster J., 1993, COMPUTER ANAL ELECTR; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Gunthorpe MJ, 2002, TRENDS PHARMACOL SCI, V23, P183, DOI 10.1016/S0165-6147(02)01999-5; Hayes P, 2000, PAIN, V88, P205, DOI 10.1016/S0304-3959(00)00353-5; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Liu M, 2001, J PHARMACOL EXP THER, V296, P1043; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Moore DJ, 2001, BBA-GENE STRUCT EXPR, V1521, P107, DOI 10.1016/S0167-4781(01)00291-3; Muller D, 2000, GENOMICS, V67, P48, DOI 10.1006/geno.2000.6203; Muller D, 2000, BIOCHEM BIOPH RES CO, V275, P47, DOI 10.1006/bbrc.2000.3227; Nagy I, 1999, J NEUROSCI, V19, P10647, DOI 10.1523/JNEUROSCI.19-24-10647.1999; Peng JB, 2000, BIOCHEM BIOPH RES CO, V278, P326, DOI 10.1006/bbrc.2000.3716; Peng JB, 2001, GENOMICS, V76, P99, DOI 10.1006/geno.2001.6606; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Touchman JW, 2000, GENOME RES, V10, P165, DOI 10.1101/gr.10.2.165; [No title captured]	28	589	639	2	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	2002	418	6894					186	190		10.1038/nature00894	http://dx.doi.org/10.1038/nature00894			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12077606				2022-12-28	WOS:000176710400041
J	Spencer, MD; Knight, RSG; Will, RG				Spencer, MD; Knight, RSG; Will, RG			First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric andneurological features	BRITISH MEDICAL JOURNAL			English	Article							UK	Objective To describe the early psychiatric and neurological features of variant Creutzfeldt-Jakob disease. Design Cohort study. Setting National surveillance system for Creutzfeldt-Jakob disease in the United Kingdom. Participants The first 100 cases of variant Creutzfeldt-jakob disease identified in the United Kingdom. Main outcome measures The timing and nature of early psychiatric and neurological symptoms in variant Creutzfeldt-Jakob disease. Results The early stages of variant Creutzfeldt Jakob disease are dominated by psychiatric symptoms, but neurological symptoms precede psychiatric symptoms in 15% of cases and are present in combination with psychiatric symptoms in 22% of cases from the onset of disease. Common early psychiatric features include dysphoria, withdrawal, anxiety, insomnia, and loss of interest. No common early neurological features exist, but a significant proportion of patients do exhibit neurological symptoms within 4 months of clinical onset, including poor memory, pain, sensory symptoms, unsteadiness of gait, and dysarthria. Conclusions Although the diagnosis of variant Creutzfeldt-jakob disease may be impossible in the early stages of the illness, particular combinations of psychiatric and neurological features may allow early diagnosis in an appreciable proportion. of patients.	Western Gen Hosp, Natl CJD Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Addenbrookes Hosp, Dept Psychiat, Cambridge CB2 2QQ, England	University of Edinburgh; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Will, RG (corresponding author), Western Gen Hosp, Natl CJD Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland.			Spencer, Michael/0000-0002-1646-5254				Allroggen H, 2000, J NEUROL NEUROSUR PS, V68, P375, DOI 10.1136/jnnp.68.3.375; Andrews NJ, 2000, LANCET, V356, P481, DOI 10.1016/S0140-6736(00)02559-9; Dervaux A, 2001, BRIT J PSYCHIAT, V178, P276, DOI 10.1192/bjp.178.3.276-a; MacLeod M. A., 2000, Journal of Neurology Neurosurgery and Psychiatry, V69, P413; Will RG, 2000, ANN NEUROL, V47, P575; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WILL RG, 1999, PSYCHIAT B, V23, P264; Zeidler M, 1997, LANCET, V350, P908, DOI 10.1016/S0140-6736(97)03148-6	8	97	103	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 22	2002	324	7352					1479	1482		10.1136/bmj.324.7352.1479	http://dx.doi.org/10.1136/bmj.324.7352.1479			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567ZL	12077031	Green Published, Bronze			2022-12-28	WOS:000176517900016
J	Grant, P				Grant, P			Is a bell tolling for Bell Labs?	NATURE			English	Editorial Material									Elect Power Res Inst, Palo Alto, CA 94303 USA	Electric Power Research Institute (EPRI)	Grant, P (corresponding author), Elect Power Res Inst, POB 10412,3412 Hillview Ave, Palo Alto, CA 94303 USA.							BEASLEY M, 2002, NATURE, V417, P367; BURROUGHES JH, 1988, NATURE, V335, P137, DOI 10.1038/335137a0; Schneider JM, 1999, APPL PHYS LETT, V74, P200, DOI 10.1063/1.123292	3	3	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 20	2002	417	6891					789	789		10.1038/417789a	http://dx.doi.org/10.1038/417789a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075321				2022-12-28	WOS:000176285600020
J	Malliri, A; van der Kammen, RA; Clark, K; van der Valk, M; Michiels, F; Collard, JG				Malliri, A; van der Kammen, RA; Clark, K; van der Valk, M; Michiels, F; Collard, JG			Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours	NATURE			English	Article							CELL-CELL ADHESION; RHO GTPASES; MOUSE SKIN; EPITHELIAL-CELLS; IN-VIVO; INVASION; CARCINOGENESIS; PROGRESSION; CARCINOMA; PROTEINS	Proteins of the Rho family control signalling pathways that regulate the actin cytoskeleton and gene transcription(1,2). In vitro studies have implicated Rho-like GTP-hydrolysing enzymes (GTPases) in cell migration(3-5), cell-cycle progression(6,7), and Ras-induced focus formation 8,9, suggesting a role for these GTPases in the formation and progression of tumours in vivo. To study this, we have generated mice lacking the Rac-specific activator Tiam1(10-12), a T-lymphoma invasion and metastasis inducing protein. Here we show that such Tiam1(-/-) mice are resistant to the development of Ras-induced skin tumours initiated with 7,12-dimethylbenzanthracene and promoted with 12-O-tetradecanoylphorbol-13-acetate. Moreover, the few tumours produced in Tiam1(-/-) mice grew much slower than did tumours in wild-type mice. Tiam1-deficient primary embryonic fibroblasts were also resistant to Ras(V12)-induced focus formation. Analysis of Tiam1 heterozygotes indicated that both tumour initiation and promotion were dependent on the Tiam1 gene dose. Tiam1 deficiency was associated with increased apoptosis during initiation, and with impeded proliferation during promotion. Although the number of tumours in Tiam1(-/-) mice was small, a greater proportion progressed to malignancy, suggesting that Tiam1 deficiency promotes malignant conversion. Our studies identify the Rac activator Tiam1 as a critical regulator of different aspects of Ras-induced tumour formation.	Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Collard, JG (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.collard@nki.nl		Malliri, Angeliki/0000-0001-6848-090X				Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BUCHMANN A, 1991, CANCER RES, V51, P4097; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Ehler E, 1997, MOL CELL NEUROSCI, V9, P1, DOI 10.1006/mcne.1997.0602; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732	29	285	307	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 20	2002	417	6891					867	871		10.1038/nature00848	http://dx.doi.org/10.1038/nature00848			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075356				2022-12-28	WOS:000176285600051
J	Parkinson, GN; Lee, MPH; Neidle, S				Parkinson, GN; Lee, MPH; Neidle, S			Crystal structure of parallel quadruplexes from human telomeric DNA	NATURE			English	Article							ANGSTROM RESOLUTION; G-QUARTETS; OLIGONUCLEOTIDES; DERIVATIVES; MECHANISMS; INHIBITION; TETRAPLEX; COMPLEX; TARGET; DESIGN	Telomeric ends of chromosomes, which comprise noncoding repeat sequences of guanine-rich DNA, are fundamental in protecting the cell from recombination and degradation(1). Disruption of telomere maintenance leads to eventual cell death, which can be exploited for therapeutic intervention in cancer. Telomeric DNA sequences can form four-stranded (quadruplex) structures(2-4), which may be involved in the structure of telomere ends(5). Here we describe the crystal structure of a quadruplex formed from four consecutive human telomeric DNA repeats and grown at a K+ concentration that approximates its intracellular concentration. K+ ions are observed in the structure. The folding and appearance of the DNA in this intramolecular quadruplex is fundamentally different from the published Na+-containing quadruplex structures(2,4,6). All four DNA strands are parallel, with the three linking trinucleotide loops positioned on the exterior of the quadruplex core, in a propeller-like arrangement. The adenine in each TTA linking trinucleotide loop is swung back so that it intercalates between the two thymines. This DNA structure suggests a straightforward path for telomere folding and unfolding, as well as ways in which it can recognize telomere-associated proteins.	Inst Canc Res, Chester Beatty Labs, Canc Res UK Biomol Struct Unit, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Neidle, S (corresponding author), Inst Canc Res, Chester Beatty Labs, Canc Res UK Biomol Struct Unit, 237 Fulham Rd, London SW3 6JB, England.							BALAGURUMOORTHY P, 1994, J BIOL CHEM, V269, P21858; Bearss DJ, 2000, ONCOGENE, V19, P6632, DOI 10.1038/sj.onc.1204092; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; Fedoroff OY, 1998, BIOCHEMISTRY-US, V37, P12367, DOI 10.1021/bi981330n; Gowan SM, 2002, MOL PHARMACOL, V61, P1154, DOI 10.1124/mol.61.5.1154; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; Han HY, 1999, BIOCHEMISTRY-US, V38, P6981, DOI 10.1021/bi9905922; Han HY, 2001, J AM CHEM SOC, V123, P8902, DOI 10.1021/ja002179j; Harrison RJ, 1999, BIOORG MED CHEM LETT, V9, P2463, DOI 10.1016/S0960-894X(99)00394-7; Horvath MP, 2001, J MOL BIOL, V310, P367, DOI 10.1006/jmbi.2001.4766; Koeppel F, 2001, NUCLEIC ACIDS RES, V29, P1087, DOI 10.1093/nar/29.5.1087; Li JL, 2001, BIOCHEMISTRY-US, V40, P15194, DOI 10.1021/bi011067h; Mergny JL, 1998, NAT MED, V4, P1366, DOI 10.1038/3949; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Phillips K, 1997, J MOL BIOL, V273, P171, DOI 10.1006/jmbi.1997.1292; Read M, 2001, P NATL ACAD SCI USA, V98, P4844, DOI 10.1073/pnas.081560598; Read MA, 1999, J MED CHEM, V42, P4538, DOI 10.1021/jm990287e; Read MA, 2000, BIOCHEMISTRY-US, V39, P13422, DOI 10.1021/bi001584k; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; Schaffitzel C, 2001, P NATL ACAD SCI USA, V98, P8572, DOI 10.1073/pnas.141229498; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Simonsson T, 2001, BIOL CHEM, V382, P621, DOI 10.1515/BC.2001.073; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; SMITH FW, 1995, STRUCTURE, V3, P997, DOI 10.1016/S0969-2126(01)00236-2; Sun H, 2001, P NATL ACAD SCI USA, V98, P12444, DOI 10.1073/pnas.231479198; WANG Y, 1992, BIOCHEMISTRY-US, V31, P8112, DOI 10.1021/bi00150a002; WANG Y, 1993, STRUCTURE, V1, P263, DOI 10.1016/0969-2126(93)90015-9; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801	29	1668	1694	7	356	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 20	2002	417	6891					876	880		10.1038/nature755	http://dx.doi.org/10.1038/nature755			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12050675				2022-12-28	WOS:000176285600053
J	Adam, A; Cugno, M; Molinaro, G; Perez, M; Lepage, Y; Agostoni, A				Adam, A; Cugno, M; Molinaro, G; Perez, M; Lepage, Y; Agostoni, A			Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors	LANCET			English	Article							CONVERTING ENZYME-INHIBITOR; BRADYKININ; PLASMA	Anglo-oedema Is a rare but potentially life threatening side-effect of angiotensin-converting-enzyme (ACE) inhibitor treatment. Identification of individuals at risk of this adverse effect is not possible. Anglo-oedema is associated with raised concentrations of bradykinin, which is mainly inactivated by ACE. We assessed the plasma activity of two other enzymes that catabolise bradykinin (aminopeptidase P and carboxypeptidase N) in 39 hypertensive patients with a history of angio-oedema during ACE inhibitor treatment and In 39 hypertensive patients who had never had ACE inhibitor associated side-effects. Patients with previous angio-oedema had a lower plasma activity of aminopeptidase P than did those who never presented with angio-oedema (p=0.003). Our data suggest that low plasma concentrations of aminopeptidase P could be a predisposing factor for development of angio-oedema in patients treated with ACE inhibitors.	Univ Montreal, Dept Math & Stat, Fac Pharm, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Math & Stat, Fac Arts & Sci, Montreal, PQ H3C 3J7, Canada; Univ Milan, Dept Internal Med, Milan, Italy	Universite de Montreal; Universite de Montreal; University of Milan	Adam, A (corresponding author), Univ Montreal, Dept Math & Stat, Fac Pharm, Montreal, PQ H3C 3J7, Canada.		Cugno, Massimo/K-8106-2016	Cugno, Massimo/0000-0002-9918-0763				Agostoni A, 2001, DRUG SAFETY, V24, P599, DOI 10.2165/00002018-200124080-00004; Cyr M, 2001, AM J PHYSIOL-HEART C, V281, pH275, DOI 10.1152/ajpheart.2001.281.1.H275; Kim KS, 2000, J PHARMACOL EXP THER, V292, P295; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Sigler C, 1997, ARCH DERMATOL, V133, P972, DOI 10.1001/archderm.133.8.972	5	138	142	1	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 15	2002	359	9323					2088	2089		10.1016/S0140-6736(02)08914-6	http://dx.doi.org/10.1016/S0140-6736(02)08914-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086766				2022-12-28	WOS:000176194600014
J	Fortey, RA				Fortey, RA			Retrospective - Evolution - Stephen Jay Gould (1941-2002)	SCIENCE			English	Biographical-Item									Inst Adv Studies, Bristol BS8 1UJ, Avon, England		Fortey, RA (corresponding author), Inst Adv Studies, Bristol BS8 1UJ, Avon, England.	r.fortey@bristol.ac.uk							0	1	1	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 14	2002	296	5575					1984	1984		10.1126/science.1074307	http://dx.doi.org/10.1126/science.1074307			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065825				2022-12-28	WOS:000176273300040
J	Blum, JD; Klaue, A; Nezat, CA; Driscoll, CT; Johnson, CE; Siccama, TG; Eagar, C; Fahey, TJ; Likens, GE				Blum, JD; Klaue, A; Nezat, CA; Driscoll, CT; Johnson, CE; Siccama, TG; Eagar, C; Fahey, TJ; Likens, GE			Mycorrhizal weathering of apatite as an important calcium source in base-poor forest ecosystems	NATURE			English	Article							UNITED-STATES; SR-87/SR-86 RATIOS; ACIDIC DEPOSITION; SUGAR MAPLE; STRONTIUM; DEPLETION; INPUTS; RATES	The depletion of calcium in forest ecosystems of the northeastern USA(1-3) is thought to be a consequence of acidic deposition and to be at present restricting the recovery of forest and aquatic systems(4-7) now that acidic deposition itself is declining. This depletion of calcium has been inferred from studies(1-3) showing that sources of calcium in forest ecosystems-namely, atmospheric deposition and mineral weathering of silicate rocks such as plagioclase, a calcium-sodium silicate-do not match calcium outputs observed in forest streams. It is therefore thought that calcium is being lost from exchangeable and organically bound calcium in forest soils. Here we investigate the sources of calcium in the Hubbard Brook experimental forest, through analysis of calcium and strontium abundances and strontium isotope ratios within various soil, vegetation and hydrological pools. We show that the dissolution of apatite (calcium phosphate) represents a source of calcium that is comparable in size to known inputs from atmospheric sources and silicate weathering. Moreover, apatite-derived calcium was utilized largely by ectomycorrhizal tree species, suggesting that mycorrhizae may weather apatite and absorb the released ions directly, without the ions entering the exchangeable soil pool. Therefore, it seems that apatite weathering can compensate for some of the calcium lost from base-poor ecosystems, and should be considered when estimating soil acidification impacts and calcium cycling.	Univ Michigan, Dept Geol Sci, Ann Arbor, MI 48109 USA; Syracuse Univ, Dept Civil & Environm Engn, Syracuse, NY 13244 USA; Yale Univ, Sch Forestry & Environm Studies, New Haven, CT 06511 USA; US Forest Serv, NE Res Stn, USDA, Durham, NH 03824 USA; Cornell Univ, Dept Nat Resources, Ithaca, NY 14853 USA; Inst Ecosyst Studies, Millbrook, NY 12545 USA	University of Michigan System; University of Michigan; Syracuse University; Yale University; United States Department of Agriculture (USDA); United States Forest Service; Cornell University; Cary Institute of Ecosystem Studies	Blum, JD (corresponding author), Univ Michigan, Dept Geol Sci, 425 E Univ Ave, Ann Arbor, MI 48109 USA.	jdblum@umich.edu	Driscoll, Charles/F-9832-2014; Johnson, Chris E/A-6979-2011	Driscoll, Charles/0000-0003-2692-2890; Johnson, Chris E/0000-0001-9079-813X; Nezat, Carmen/0000-0002-0432-4163				ABERG G, 1989, J HYDROL, V109, P65, DOI 10.1016/0022-1694(89)90007-3; Bailey SW, 1996, WATER RESOUR RES, V32, P707, DOI 10.1029/95WR03642; BAILEY SW, UNPUB ECOLOGY; BLUM AE, 1995, CHEM WEATHERING RATE, V31, P291; Blum JD, 2000, BIOGEOCHEMISTRY, V49, P87, DOI 10.1023/A:1006390707989; BRANTLEY SL, 1995, CHEM WEATHERING RATE, P119; Capo RC, 1998, GEODERMA, V82, P197, DOI 10.1016/S0016-7061(97)00102-X; CREASER RA, 1992, GEOCHIM COSMOCHIM AC, V56, P2789, DOI 10.1016/0016-7037(92)90359-Q; Driscoll CT, 2001, BIOSCIENCE, V51, P180, DOI 10.1641/0006-3568(2001)051[0180:ADITNU]2.0.CO;2; FEDERER CA, 1989, ENVIRON MANAGE, V13, P593, DOI 10.1007/BF01874965; Hogan JF, 2000, WATER RESOUR RES, V36, P3701, DOI 10.1029/2000WR900233; Huntington TG, 2000, GLOBAL BIOGEOCHEM CY, V14, P623, DOI 10.1029/1999GB001193; Johnson CE, 1998, SOIL SCI SOC AM J, V62, P782, DOI 10.2136/sssaj1998.03615995006200030035x; Johnson CE, 2000, ECOSYSTEMS, V3, P159, DOI 10.1007/s100210000017; Jones E. V., 1998, CHEM GEOL, V15, P215; KISTLER RW, 1986, CONTRIB MINERAL PETR, V94, P205, DOI 10.1007/BF00592937; Lawrence GB, 1999, ECOL APPL, V9, P1059, DOI 10.1890/1051-0761(1999)009[1059:SCSATR]2.0.CO;2; Likens G. E., 1995, BIOGEOCHEMISTRY FORE; Likens GE, 1998, BIOGEOCHEMISTRY, V41, P89, DOI 10.1023/A:1005984620681; Likens GE, 1996, SCIENCE, V272, P244, DOI 10.1126/science.272.5259.244; Long RP, 1997, CAN J FOREST RES, V27, P1560, DOI 10.1139/cjfr-27-10-1560; MILLER EK, 1993, NATURE, V362, P438, DOI 10.1038/362438a0; Poszwa A, 2000, PLANT SOIL, V225, P299, DOI 10.1023/A:1026570812307; RUNIA LT, 1987, J ARCHAEOL SCI, V14, P599, DOI 10.1016/0305-4403(87)90078-1; van Breemen N, 2000, BIOGEOCHEMISTRY, V49, P53, DOI 10.1023/A:1006256231670; Vitousek PM, 1999, OECOLOGIA, V121, P255, DOI 10.1007/s004420050927; Wallander H, 2000, PLANT SOIL, V218, P249, DOI 10.1023/A:1014936217105; WALLANDER H, 2002, FEMS MICROBIOL ECOL, V1320, P1; YANAI RD, 1992, BIOGEOCHEMISTRY, V17, P1, DOI 10.1007/BF00002757; YAWNEY WJ, 1990, NEW PHYTOL, V114, P47, DOI 10.1111/j.1469-8137.1990.tb00372.x	30	287	295	5	122	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	2002	417	6890					729	731		10.1038/nature00793	http://dx.doi.org/10.1038/nature00793			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	561QY	12066181	Green Published			2022-12-28	WOS:000176154700041
J	Lamas, GA; Lee, KL; Sweeney, MO; Silverman, R; Leon, A; Yee, R; Marinchak, RA; Flaker, G; Schron, E; Orav, EJ; Hellkamp, AS; Goldman, L; Greer, S; McAnulty, J; Ellenbogen, K; Ehlert, F; Freedman, RA; Estes, NAM; Greenspon, A				Lamas, GA; Lee, KL; Sweeney, MO; Silverman, R; Leon, A; Yee, R; Marinchak, RA; Flaker, G; Schron, E; Orav, EJ; Hellkamp, AS; Goldman, L; Greer, S; McAnulty, J; Ellenbogen, K; Ehlert, F; Freedman, RA; Estes, NAM; Greenspon, A		Mode Select Trial Sinus-Node Dysfunct	Ventricular pacing or dual-chamber pacing for sinus-node dysfunction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERM FOLLOW-UP; MYOCARDIAL-INFARCTION; PACEMAKER SYNDROME; RANDOMIZED TRIAL; CLINICAL-TRIALS; MODE SELECTION; ATRIAL; MORBIDITY; SURVIVAL; LIFE	Background: Dual-chamber (atrioventricular) and single-chamber (ventricular) pacing are alternative treatment approaches for sinus-node dysfunction that causes clinically significant bradycardia. However, it is unknown which type of pacing results in the better outcome. Methods: We randomly assigned a total of 2010 patients with sinus-node dysfunction to dual-chamber pacing (1014 patients) or ventricular pacing (996 patients) and followed them for a median of 33.1 months. The primary end point was death from any cause or nonfatal stroke. Secondary end points included the composite of death, stroke, or hospitalization for heart failure; atrial fibrillation; heart-failure score; the pacemaker syndrome; and the quality of life. Results: The incidence of the primary end point did not differ significantly between the dual-chamber group (21.5 percent) and the ventricular-paced group (23.0 percent, P=0.48). In patients assigned to dual-chamber pacing, the risk of atrial fibrillation was lower (hazard ratio, 0.79; 95 percent confidence interval, 0.66 to 0.94; P=0.008), and heart-failure scores were better (P<0.001). The differences in the rates of hospitalization for heart failure and of death, stroke, or hospitalization for heart failure were not significant in unadjusted analyses but became marginally significant in adjusted analyses. Dual-chamber pacing resulted in a small but measurable increase in the quality of life, as compared with ventricular pacing. Conclusions: In sinus-node dysfunction, dual-chamber pacing does not improve stroke-free survival, as compared with ventricular pacing. However, dual-chamber pacing reduces the risk of atrial fibrillation, reduces signs and symptoms of heart failure, and slightly improves the quality of life. Overall, dual-chamber pacing offers significant improvement as compared with ventricular pacing.	Univ Miami, Sch Med, Miami Beach, FL USA; Mt Sinai Med Ctr, Div Cardiol, Miami Beach, FL 33140 USA; Duke Univ, Sch Med, Durham, NC USA; Duke Clin Res Inst, Durham, NC USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Heart Care Ctr, Fayetteville, AR USA; Emory Univ, Atlanta, GA 30322 USA; Crawford W Long Mem Hosp, Atlanta, GA USA; Univ Hosp London, London, ON, Canada; Lankenau Hosp, Wynnewood, PA USA; Univ Missouri Hosp & Clin, Columbia, MO USA; NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Baptist Med Ctr, Little Rock, AR USA; Oregon Hlth Sci Univ, Portland, OR 97201 USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; St Lukes Roosevelt Hosp, New York, NY USA; Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA	University of Miami; Mount Sinai Medical Center; Duke University; Duke University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Emory University; Western University (University of Western Ontario); Lankenau Medical Center; University of Missouri System; University of Missouri Columbia; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of California System; University of California San Francisco; Oregon Health & Science University; Virginia Commonwealth University; Mount Sinai St. Luke's; Mount Sinai West; Utah System of Higher Education; University of Utah; Tufts Medical Center; Jefferson University	Lamas, GA (corresponding author), Cardiovasc Associates Miami, 4300 Alton Rd,Suite 207, Miami Beach, FL 33140 USA.		Ellenbogen, Kenneth/AAJ-3992-2021		NHLBI NIH HHS [U01 HL 55981, U01 HL 49804, U01 HL 53973] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL055981, U01HL053973, U01HL049804] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSEN HR, 1994, LANCET, V344, P1523, DOI 10.1016/S0140-6736(94)90347-6; Andersen HR, 1997, LANCET, V350, P1210, DOI 10.1016/S0140-6736(97)03425-9; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Connolly SJ, 1996, CIRCULATION, V94, P578, DOI 10.1161/01.CIR.94.3.578; Connolly SJ, 2000, NEW ENGL J MED, V342, P1385, DOI 10.1056/NEJM200005113421902; COX DR, 1972, J R STAT SOC B, V34, P187; Ellenbogen KA, 1997, AM J CARDIOL, V79, P1226, DOI 10.1016/S0002-9149(97)00085-4; Ellenbogen KA, 2000, AM J CARDIOL, V86, P59, DOI 10.1016/S0002-9149(00)00828-6; Elmqvist R, 1960, P 2 INT C MED EL, P253; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; Gregoratos G, 1998, J AM COLL CARDIOL, V31, P1175; HELDMAN D, 1990, PACE, V13, P1742, DOI 10.1111/j.1540-8159.1990.tb06883.x; HESSELSON AB, 1992, J AM COLL CARDIOL, V19, P1542, DOI 10.1016/0735-1097(92)90616-U; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN SH, 1987, J CHRON DIS, V40, pS27, DOI 10.1016/S0021-9681(87)80029-2; Lamas G A, 1989, J Card Surg, V4, P89, DOI 10.1111/j.1540-8191.1989.tb00261.x; Lamas GA, 1997, HEART, V78, P218, DOI 10.1136/hrt.78.3.218; Lamas GA, 2000, AM HEART J, V140, P541, DOI 10.1067/mhj.2000.109652; LAMAS GA, 1989, AM J CARDIOL, V63, P1167, DOI 10.1016/0002-9149(89)90173-2; LAMAS GA, 1995, CIRCULATION, V91, P1063, DOI 10.1161/01.CIR.91.4.1063; Lamas GA, 1998, NEW ENGL J MED, V338, P1097, DOI 10.1056/NEJM199804163381602; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Nielsen JC, 1998, CIRCULATION, V97, P987; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Ovsyshcher IE, 1998, CIRCULATION, V97, P2368, DOI 10.1161/01.CIR.97.23.2368; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; SAMET P, 1966, AM J CARDIOL, V18, P522, DOI 10.1016/0002-9149(66)90004-X; STEWART WJ, 1984, AM J CARDIOL, V54, P308, DOI 10.1016/0002-9149(84)90188-7; TSEVAT J, 1991, MED CARE, V29, P1153, DOI 10.1097/00005650-199111000-00007; Ware J.E, 1994, PHYS MENTAL HLTH SUM; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wharton JM, 1998, CIRCULATION, V98, P494	33	661	693	0	12	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	2002	346	24					1854	1862		10.1056/NEJMoa013040	http://dx.doi.org/10.1056/NEJMoa013040			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	561NA	12063369	Green Published			2022-12-28	WOS:000176146100003
J	Skalen, K; Gustafsson, M; Rydberg, EK; Hulten, LM; Wiklund, O; Innerarity, TL; Boren, J				Skalen, K; Gustafsson, M; Rydberg, EK; Hulten, LM; Wiklund, O; Innerarity, TL; Boren, J			Subendothelial retention of atherogenic lipoproteins in early atherosclerosis	NATURE			English	Article							LOW-DENSITY-LIPOPROTEIN; ARTERIAL PROTEOGLYCANS; RECEPTOR-BINDING; APOLIPOPROTEIN-B; CELL BIOLOGY; IDENTIFICATION; MACROPHAGES; MICE; OXIDATION; APO-B100	Complications of atherosclerosis are the most common cause of death in Western societies(1). Among the many risk factors identified by epidemiological studies, only elevated levels of lipoproteins containing apolipoprotein (apo) B can drive the development of atherosclerosis in humans and experimental animals even in the absence of other risk factors(2). However, the mechanisms that lead to atherosclerosis are still poorly understood. We tested the hypothesis that the subendothelial retention of atherogenic apoB-containing lipoproteins is the initiating event in atherogenesis(3). The extracellular matrix of the subendothelium, particularly proteoglycans, is thought to play a major role in the retention of atherogenic lipoproteins(4). The interaction between atherogenic lipoproteins and proteoglycans involves an ionic interaction between basic amino acids in apoB100 and negatively charged sulphate groups on the proteoglycans(5). Here we present direct experimental evidence that the atherogenicity of apoB-containing low-density lipoproteins (LDL) is linked to their affinity for artery wall proteoglycans. Mice expressing proteoglycan-binding-defective LDL developed significantly less atherosclerosis than mice expressing wild-type control LDL. We conclude that subendothelial retention of apoB100-containing lipoprotein is an early step in atherogenesis.	Gothenburg Univ, Wallenberg Lab Cardiovasc Res, S-41345 Gothenburg, Sweden; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA	University of Gothenburg; University of California System; University of California San Francisco; The J David Gladstone Institutes	Boren, J (corresponding author), Gothenburg Univ, Wallenberg Lab Cardiovasc Res, S-41345 Gothenburg, Sweden.							BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boren J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847; Boren J, 1998, J CLIN INVEST, V101, P2658, DOI 10.1172/JCI2265; BRISSETTE L, 1986, J BIOL CHEM, V261, P1631; CAMEJO G, 1988, ARTERIOSCLEROSIS, V8, P368, DOI 10.1161/01.ATV.8.4.368; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; GOLDMAN MH, 1998, ADV TISSUE BANKING, V2, P273; HIROSE N, 1987, BIOCHEMISTRY-US, V26, P5505, DOI 10.1021/bi00391a044; HURTCAMEJO E, 1992, ARTERIOSCLER THROMB, V12, P569, DOI 10.1161/01.ATV.12.5.569; Ji ZS, 1998, J BIOL CHEM, V273, P13452, DOI 10.1074/jbc.273.22.13452; MAHLEY RW, 1977, J BIOL CHEM, V252, P7279; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; Nicoletti A, 1998, J CLIN INVEST, V102, P910, DOI 10.1172/JCI119892; Ohlsson BG, 1996, J CLIN INVEST, V98, P78, DOI 10.1172/JCI118780; PUHL H, 1994, METHOD ENZYMOL, V233, P425; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; Randle DH, 2001, P NATL ACAD SCI USA, V98, P9654, DOI 10.1073/pnas.171217498; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Schwenke DC, 1997, ARTERIOSCL THROM VAS, V17, P2150, DOI 10.1161/01.ATV.17.10.2150; SIMIONESCU M, 1991, CELL BIOL REV, V25, P5; SRINIVASAN SR, 1986, ATHEROSCLEROSIS, V62, P201, DOI 10.1016/0021-9150(86)90094-8; STANLEY ER, 1985, METHOD ENZYMOL, V116, P564; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; YAGI K, 1976, BIOCHEM MED METAB B, V15, P212, DOI 10.1016/0006-2944(76)90049-1; YAO ZM, 1992, J BIOL CHEM, V267, P1175	28	649	698	3	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 13	2002	417	6890					750	754		10.1038/nature00804	http://dx.doi.org/10.1038/nature00804			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	561QY	12066187				2022-12-28	WOS:000176154700047
J	Watts, DH				Watts, DH			Drug therapy - Management of human immunodeficiency virus infection in pregnancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TO-CHILD TRANSMISSION; MATERNAL-INFANT TRANSMISSION; ACUTE FATTY LIVER; PERINATAL TRANSMISSION; VERTICAL TRANSMISSION; HIV TRANSMISSION; CESAREAN-SECTION; RISK-FACTORS; HIV-1-INFECTED WOMEN; ORAL ZIDOVUDINE		NICHHD, Pediat Adolescent & Maternal AIDS Branch, Ctr Res Mothers & Children, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Watts, DH (corresponding author), NICHHD, Pediat Adolescent & Maternal AIDS Branch, Ctr Res Mothers & Children, 6100 Execut Blvd,Rm 4B11, Bethesda, MD 20892 USA.	hw59i@nih.gov						Aebi C, 2000, AIDS, V14, P2913, DOI 10.1097/00002030-200012220-00013; *AM COLL OBST GYN, 2000, 234 AM COLL OBST GYN; *AM COLL OBST GYN, 2001, PRACT B AM COLL OBST, V27; Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; Andiman W, 2001, AIDS, V15, P357, DOI 10.1097/00002030-200102160-00009; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; *ANT PREGN REG, 2001, INT REP 1 1 89 1 31; Ayers KM, 1997, FUND APPL TOXICOL, V38, P195, DOI 10.1006/faat.1997.2342; BARDEGUEZ A, 1998, 12 WORLD AIDS C GEN, P58; Bersoff-Matcha SJ, 2001, CLIN INFECT DIS, V32, P124, DOI 10.1086/317536; Blanche S, 1999, LANCET, V354, P1084, DOI 10.1016/S0140-6736(99)07219-0; Brinkman K, 1998, AIDS, V12, P1735, DOI 10.1097/00002030-199814000-00004; Brocklehurst P, 1998, BRIT J OBSTET GYNAEC, V105, P836, DOI 10.1111/j.1471-0528.1998.tb10227.x; Bucceri A, 1997, EUR J OBSTET GYN R B, V72, P169, DOI 10.1016/S0301-2115(97)02699-7; Bulterys M, 2000, J ACQ IMMUN DEF SYND, V25, P261, DOI 10.1097/00126334-200011010-00009; Burns DN, 1998, AM J OBSTET GYNECOL, V178, P355, DOI 10.1016/S0002-9378(98)80025-2; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009; CUNNINGHAM CK, IN PRESS J INFECT DI; Dabis F, 2001, AIDS, V15, P771, DOI 10.1097/00002030-200104130-00013; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175; DESCHAMPS MM, 1993, J ACQ IMMUN DEF SYND, V6, P446; DITRAME ANRS 049 Study Grp, 1999, LANCET, V354, P2050, DOI 10.1016/S0140-6736(99)04388-3; DORENBAUM A, 2001, P 8 C RETR OPP INF C, P277; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; DUNN DT, 1994, J ACQ IMMUN DEF SYND, V7, P1064; Eastman PS, 1998, J INFECT DIS, V177, P557, DOI 10.1086/514228; EMBREE JE, 1989, PEDIATR INFECT DIS J, V8, P700, DOI 10.1097/00006454-198910000-00008; Fiscus SA, 1999, J INFECT DIS, V180, P99, DOI 10.1086/314840; FORTGANG IS, 1995, AM J GASTROENTEROL, V90, P1433; Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602; Gerard Y, 2000, AIDS, V14, P2723; GRIMBERT S, 1993, HEPATOLOGY, V17, P628, DOI 10.1002/hep.1840170417; GRIMBERT S, 1995, AM J PHYSIOL-GASTR L, V268, pG107, DOI 10.1152/ajpgi.1995.268.1.G107; Grubert TA, 1999, LANCET, V354, P1612, DOI 10.1016/S0140-6736(99)03141-4; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Hanson IC, 1999, J ACQ IMMUN DEF SYND, V20, P463, DOI 10.1097/00042560-199904150-00008; Hayashi S, 2000, AIDS, V14, P1061, DOI 10.1097/00002030-200005260-00020; Hirsch MS, 2000, JAMA-J AM MED ASSOC, V283, P2417, DOI 10.1001/jama.283.18.2417; Ibdah JA, 2000, MOL GENET METAB, V71, P182, DOI 10.1006/mgme.2000.3065; Ioannidis JPA, 2001, J INFECT DIS, V183, P539, DOI 10.1086/318530; Johnson VA, 2001, J INFECT DIS, V183, P1688, DOI 10.1086/320697; Kuhn L, 1996, J ACQ IMMUN DEF SYND, V11, P478, DOI 10.1097/00042560-199604150-00008; Kully C, 1999, J INFECT DIS, V179, P705, DOI 10.1086/314615; Kumar RM, 1997, J REPROD MED, V42, P429; Lallemant M, 2000, NEW ENGL J MED, V343, P982, DOI 10.1056/NEJM200010053431401; Lambert JS, 2000, AIDS, V14, P1389, DOI 10.1097/00002030-200007070-00012; Landesman SH, 1996, NEW ENGL J MED, V334, P1617, DOI 10.1056/NEJM199606203342501; LANGE J, 1999, 2 C GLOB STRAT PREV, P87; Leroy V, 1998, AIDS, V12, P643, DOI 10.1097/00002030-199806000-00014; Lorenzi P, 1998, AIDS, V12, pF241, DOI 10.1097/00002030-199818000-00002; Madar J, 1999, ACTA PAEDIATR, V88, P1244, DOI 10.1080/080352599750030365; Maguire A, 1997, AIDS, V11, P1851, DOI 10.1097/00002030-199715000-00010; Maiques-Montesinos V, 1999, ACTA OBSTET GYN SCAN, V78, P789, DOI 10.1034/j.1600-0412.1999.780909.x; Mandelbrot L, 1996, AM J OBSTET GYNECOL, V175, P661; MANDELBROT L, 2001, JAMA-J AM MED ASSOC, V285, P2129; *MED EC, 2001, PHYS DESK REF; Miller V, 2001, AIDS, V15, P309, DOI 10.1097/00002030-200102160-00003; Minkoff H, 2001, AM J OBSTET GYNECOL, V184, P1221, DOI 10.1067/mob.2001.113871; Mirochnick M, 2001, PEDIATR INFECT DIS J, V20, P803, DOI 10.1097/00006454-200108000-00017; Mock PA, 1999, AIDS, V13, P407, DOI 10.1097/00002030-199902250-00014; MOFENSON L, 2000, 13 INT AIDS C DURB S, V1, P337; Mofenson LM, 1999, NEW ENGL J MED, V341, P385, DOI 10.1056/NEJM199908053410601; MOODLEY D, 2000, 13 INT AIDS C DURB S, P16; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; NIELSEN TF, 1983, AM J OBSTET GYNECOL, V146, P911, DOI 10.1016/0002-9378(83)90963-8; Olivero OA, 1997, J NATL CANCER I, V89, P1602, DOI 10.1093/jnci/89.21.1602; OWOR M, 2000, 13 INT AIDS C DURB S, P16; Palumbo P, 2001, J INFECT DIS, V184, P1120, DOI 10.1086/323804; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; *PHS TASK FORC, 1998, MMWR-MORBID MORTAL W, V47, P1; *PHS TASK FORC, 1998, MMWR-MORBID MORTAL W, V47, P287; Read JS, 2001, J ACQ IMMUN DEF SYND, V26, P236, DOI 10.1097/00126334-200103010-00005; Rodriguez EJ, 2001, AM J OBSTET GYNECOL, V184, P1108, DOI 10.1067/mob.2001.115179; Saada M, 2000, AIDS, V14, P2355, DOI 10.1097/00002030-200010200-00017; Saba J, 2002, LANCET, V359, P1178; SEMPRINI AE, 1995, AIDS, V9, P913, DOI 10.1097/00002030-199508000-00013; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Sinei SK, 1998, LANCET, V351, P1238, DOI 10.1016/S0140-6736(97)10319-1; Sitnitskaya Y, 2001, CLIN INFECT DIS, V33, pE3, DOI 10.1086/320877; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Stiehm ER, 1999, J INFECT DIS, V179, P567, DOI 10.1086/314637; Stratton P, 1999, J ACQ IMMUN DEF SYND, V20, P179, DOI 10.1097/00042560-199902010-00011; Tess BH, 1998, AIDS, V12, P513, DOI 10.1097/00002030-199805000-00013; Thorne C, 2001, AIDS, V15, P761, DOI 10.1097/00002030-200104130-00012; Tuomala RE, 1997, OBSTET GYNECOL, V89, P967, DOI 10.1016/S0029-7844(97)00129-4; *UNAIDS, 2002, UNAIDS WHO AIDS EP U; vanHam MAPC, 1997, EUR J OBSTET GYN R B, V74, P1, DOI 10.1016/S0301-2115(97)02725-5; Vimercati A, 2000, EUR J OBSTET GYN R B, V90, P73, DOI 10.1016/S0301-2115(99)00229-8; Wade NA, 1998, NEW ENGL J MED, V339, P1409, DOI 10.1056/NEJM199811123392001; WARA D, 1999, 2 C GLOB STRAT PREV, P191; Watts DH, 2000, AM J OBSTET GYNECOL, V183, P100, DOI 10.1067/mob.2000.105423; Weisser M, 1998, J ACQ IMMUN DEF SYND, V17, P404, DOI 10.1097/00042560-199804150-00004; Welles SL, 2000, AIDS, V14, P263, DOI 10.1097/00002030-200002180-00008; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; 1998, MMWR MORB MORTAL WKL, V47, P315	98	76	82	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 13	2002	346	24					1879	1891		10.1056/NEJMra013338	http://dx.doi.org/10.1056/NEJMra013338			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	561NA	12063373				2022-12-28	WOS:000176146100007
J	Spencer, S; Sharp, D				Spencer, S; Sharp, D			Bridges to Iran	LANCET			English	Editorial Material									Lancet, London NW1 7BY, England		Spencer, S (corresponding author), Lancet, London NW1 7BY, England.								0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 8	2002	359	9322					1960	1960		10.1016/S0140-6736(02)08847-5	http://dx.doi.org/10.1016/S0140-6736(02)08847-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076548				2022-12-28	WOS:000176232500005
J	O'Dowd, CD; Jimenez, JL; Bahreini, R; Flagan, RC; Seinfeld, JH; Hameri, K; Pirjola, L; Kulmala, M; Jennings, SG; Hoffmann, T				O'Dowd, CD; Jimenez, JL; Bahreini, R; Flagan, RC; Seinfeld, JH; Hameri, K; Pirjola, L; Kulmala, M; Jennings, SG; Hoffmann, T			Marine aerosol formation from biogenic iodine emissions	NATURE			English	Article							BOUNDARY-LAYER; ATMOSPHERIC PARTICLES; SIZE; MACROALGAE; NUCLEATION; CHEMISTRY; CLIMATE; RELEASE; BROMINE	The formation of marine aerosols and cloud condensation nuclei-from which marine clouds originate-depends ultimately on the availability of new, nanometre-scale particles in the marine boundary layer. Because marine aerosols and clouds scatter incoming radiation and contribute a cooling effect to the Earth's radiation budget(1), new particle production is important in climate regulation. It has been suggested that sulphuric acid-derived from the oxidation of dimethyl sulphide-is responsible for the production of marine aerosols and cloud condensation nuclei. It was accordingly proposed that algae producing dimethyl sulphide play a role in climate regulation 2, but this has been difficult to prove and, consequently, the processes controlling marine particle formation remains largely undetermined(3,4). Here, using smog chamber experiments under coastal atmospheric conditions, we demonstrate that new particles can form from condensable iodine-containing vapours, which are the photolysis products of biogenic iodocarbons emitted from marine algae. Moreover, we illustrate, using aerosol formation models, that concentrations of condensable iodine-containing vapours over the open ocean are sufficient to influence marine particle formation. We suggest therefore that marine iodocarbon emissions have a potentially significant effect on global radiative forcing.	Natl Univ Ireland Univ Coll Galway, Dept Phys, Galway, Ireland; Univ Helsinki, Dept Phys Sci, Div Atmospher Sci, FIN-00014 Helsinki, Finland; CALTECH, Dept Environm Sci & Engn, Pasadena, CA 91125 USA; CALTECH, Dept Chem Engn, Pasadena, CA 91125 USA; Finnish Inst Occupat Hlth, FIN-00250 Helsinki, Finland; Helsinki Polytech Technol, PL 4020, FIN-00099 Helsinki, Finland; Inst Spectrochem & Appl Spect, D-44139 Dortmund, Germany	Ollscoil na Gaillimhe-University of Galway; University of Helsinki; California Institute of Technology; California Institute of Technology; Finnish Institute of Occupational Health	O'Dowd, CD (corresponding author), Natl Univ Ireland Univ Coll Galway, Dept Phys, Galway, Ireland.	colin.odowd@cmas.demon.co.uk	O'Dowd, Colin D/K-8904-2012; Jimenez, Jose L/A-5294-2008; Kulmala, Markku T/I-7671-2016; Hoffmann, Thorsten/A-7490-2012	O'Dowd, Colin D/0000-0002-3068-2212; Jimenez, Jose L/0000-0001-6203-1847; Kulmala, Markku T/0000-0003-3464-7825; Hameri, Kaarle/0000-0003-2667-2174; Hoffmann, Thorsten/0000-0003-0939-271X				Allan BJ, 2001, GEOPHYS RES LETT, V28, P1945, DOI 10.1029/2000GL012468; ANACHE S, 2001, APPL ENVIRON MICROB, V67, P2718; Baker AR, 2000, ATMOS ENVIRON, V34, P4331, DOI 10.1016/S1352-2310(00)00208-9; BERRESHEIM H, IN PRESS J GEOPHYS R; Bloss WJ, 2001, J PHYS CHEM A, V105, P7840, DOI 10.1021/jp0044936; Capaldo KP, 1999, J GEOPHYS RES-ATMOS, V104, P3483, DOI 10.1029/1998JD100080; Carpenter LJ, 1999, J GEOPHYS RES-ATMOS, V104, P1679, DOI 10.1029/98JD02746; CHARLSON RJ, 1987, NATURE, V326, P655, DOI 10.1038/326655a0; Cocker DR, 2001, ENVIRON SCI TECHNOL, V35, P2594, DOI 10.1021/es0019169; DALMASO M, IN PRESS J GEOPHYS R; GABLER HE, 1993, INT J ENVIRON AN CH, V50, P129, DOI 10.1080/03067319308027591; Giese B, 1999, ENVIRON SCI TECHNOL, V33, P2432, DOI 10.1021/es980731n; Goodwin KD, 1997, LIMNOL OCEANOGR, V42, P1725, DOI 10.4319/lo.1997.42.8.1725; Houghton J. T., 2001, CLIMATE CHANGE 2001; Huang S, 2001, ATMOS ENVIRON, V35, P1421, DOI 10.1016/S1352-2310(00)00368-X; Jayne JT, 2000, AEROSOL SCI TECH, V33, P49, DOI 10.1080/027868200410840; Katoshevski D, 1999, J AEROSOL SCI, V30, P503, DOI 10.1016/S0021-8502(98)00740-X; Korhonen P, 1999, J GEOPHYS RES-ATMOS, V104, P26349, DOI 10.1029/1999JD900784; Kulmala M, 2000, NATURE, V404, P66, DOI 10.1038/35003550; Laturnus F, 2000, FRESEN J ANAL CHEM, V368, P297, DOI 10.1007/s002160000491; Leck C, 1999, GEOPHYS RES LETT, V26, P3577, DOI 10.1029/1999GL010807; Lushnikov AA, 1998, PHYS REV LETT, V81, P5165, DOI 10.1103/PhysRevLett.81.5165; MAKELA JM, IN PRESS J GEOPHYS R; McFiggans G, 2000, J GEOPHYS RES-ATMOS, V105, P14371, DOI 10.1029/1999JD901187; Murphy DM, 1997, GEOPHYS RES LETT, V24, P3197, DOI 10.1029/97GL03195; ODOWD CD, IN PRESS J GEOPHYS R; Pirjola L, 2000, J GEOPHYS RES-ATMOS, V105, P26531, DOI 10.1029/2000JD900310; SLINGO A, 1990, NATURE, V343, P49, DOI 10.1038/343049a0; VAKEVA M, IN PRESS J GEOPHYS R; WIMSCHNEIDER A, 1995, FRESEN J ANAL CHEM, V353, P191, DOI 10.1007/BF00322957	30	553	565	5	234	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	2002	417	6889					632	636		10.1038/nature00775	http://dx.doi.org/10.1038/nature00775			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050661				2022-12-28	WOS:000176001200043
J	Toft, A; Beckett, G				Toft, A; Beckett, G			Use of recombinant thyrotropin	LANCET			English	Editorial Material							THYROID-HORMONE WITHDRAWAL; CANCER; CARCINOMA		Royal Infirm, Endocrine Clin, Edinburgh EH3 9YW, Midlothian, Scotland; Univ Edinburgh, Royal Infirm, Dept Clin Biochem, Edinburgh EH3 9YW, Midlothian, Scotland	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Toft, A (corresponding author), Royal Infirm, Endocrine Clin, Edinburgh EH3 9YW, Midlothian, Scotland.							*BRIT THYR ASS, 2002, GUID MAN THYR CANC; Clark PM, 2002, ANN CLIN BIOCHEM, V39, P196, DOI 10.1258/0004563021902125; Dow KH, 1997, THYROID, V7, P613, DOI 10.1089/thy.1997.7.613; Haugen BR, 1999, J CLIN ENDOCR METAB, V84, P3877, DOI 10.1210/jc.84.11.3877; Hjiyiannakis P, 1999, CLIN ONCOL-UK, V11, P240, DOI 10.1053/clon.1999.9056; Huysmans DA, 2000, J CLIN ENDOCR METAB, V85, P3592, DOI 10.1210/jc.85.10.3592; Ladenson P W, 2001, Endocr Pract, V7, P195; Ladenson PW, 1997, NEW ENGL J MED, V337, P888, DOI 10.1056/NEJM199709253371304; Mazzaferri EL, 2002, J CLIN ENDOCR METAB, V87, P1490, DOI 10.1210/jc.87.4.1490; Robbins RJ, 2001, THYROID, V11, P865, DOI 10.1089/105072501316973127; Robbins RJ, 2001, J CLIN ENDOCR METAB, V86, P619, DOI 10.1210/jc.86.2.619; Wartofsky L, 2002, J CLIN ENDOCR METAB, V87, P1486, DOI 10.1210/jc.87.4.1486	12	7	7	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 1	2002	359	9321					1874	1875		10.1016/S0140-6736(02)08785-8	http://dx.doi.org/10.1016/S0140-6736(02)08785-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PL	12057547				2022-12-28	WOS:000175975700004
J	Thabet, AAM; Abed, Y; Vostanis, P				Thabet, AAM; Abed, Y; Vostanis, P			Emotional problems in Palestinian children living in a war zone: a cross-sectional study	LANCET			English	Article							POSTTRAUMATIC-STRESS; DISORDER; GAZA	Background Children living in war zones are at high risk of developing post-traumatic stress and other emotional disorders, but little is known about the effect of traumatic events during war. We aimed to assess the nature and severity of emotional problems in Palestinian children whose homes had been bombarded and demolished during the crisis in Palestine, compared with children living in other parts of the Gaza strip. Methods 91 children exposed to home bombardment and demolition during Al Aqsa Intifada and 89 controls who had been exposed to other types of traumatic events related to political violence completed self-report measures of post-traumatic stress, anxiety, and fears. Findings Significantly more children exposed to bombardment and home demolition reported symptoms of post-traumatic stress (p=0.0008) and fear (p=0.002) than controls. 54 (59%) of 91 exposed children and 22 (25%) of 89 controls reported post-traumatic stress reactions of clinical importance. Exposure to bombardment was the strongest socioeconomic predictor of post-traumatic stress reactions (odds ratio 0.25 [95% CI 0.12-0-53], p=0.0008). By contrast, children exposed to other events, mainly through the media and adults, reported more anticipatory anxiety and cognitive expressions of distress (p=0.001) than children who were directly exposed. Interpretation Children living in war zones can express acute distress from various traumatic events through emotional problems that are not usually recognised. Health professionals and other agencies coming in contact with children who have been affected by war and political violence need to be trained in detection and treatment of such presentations.	Univ Leicester, Greenwood Inst Child Hlth, Leicester LE3 0QU, Leics, England; Al Quds Univ, Sch Publ Hlth, Gaza, Israel	University of Leicester	Vostanis, P (corresponding author), Univ Leicester, Greenwood Inst Child Hlth, Westcotes House,Westcotes Dr, Leicester LE3 0QU, Leics, England.	pv11@ie.ac.uk		Abed, Yehia/0000-0002-8613-2973				Ahmad A, 2000, EUR CHILD ADOLES PSY, V9, P235, DOI 10.1007/s007870070026; Ajdukovic M, 1998, ADOLESCENCE, V33, P209; Allden K, 1996, AM J PUBLIC HEALTH, V86, P1561, DOI 10.2105/AJPH.86.11.1561; Almqvist K, 1997, CHILD ABUSE NEGLECT, V21, P351, DOI 10.1016/S0145-2134(96)00176-7; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BAKER AM, 1990, AM J ORTHOPSYCHIAT, V60, P496, DOI 10.1037/h0079207; ELTAIB MA, 1986, VALIDITY CHILDREN FE; Frederick C, 1985, PERSPECTIVES DISASTE, P110; GOENJIAN AK, 1995, J AM ACAD CHILD PSY, V34, P1174, DOI 10.1097/00004583-199509000-00015; KUTEROVAC G, 1994, BRIT J MED PSYCHOL, V67, P363, DOI 10.1111/j.2044-8341.1994.tb01804.x; Laor N, 1997, J AM ACAD CHILD PSY, V36, P349, DOI 10.1097/00004583-199703000-00013; *MENT HLTH FDN, 1999, BIG PICT PROM CHILDR; *MIN HLTH PAL NAT, 2001, EFF AL AQS INT PAL P; MONTGOMERY LE, 1974, J ABNORM CHILD PSYCH, V12, P293; NADER KO, 1993, BRIT J CLIN PSYCHOL, V32, P407, DOI 10.1111/j.2044-8260.1993.tb01075.x; *OFF NAT STAT, 2000, MENT HLTH CHILDR AD; PAARDEKOOPER B, 1999, J CHILD PSYCHO PSYCH, V40, P385; Papageorgiou V, 2000, EUR CHILD ADOLES PSY, V9, P84, DOI 10.1007/s007870050002; PYNOOS RS, 1987, ARCH GEN PSYCHIAT, V44, P1057; REYNOLDS CR, 1980, J CONSULT CLIN PSYCH, V48, P774, DOI 10.1037/0022-006X.48.6.774; Smith P, 2001, J CHILD PSYCHOL PSYC, V42, P395, DOI 10.1017/S0021963001007065; Thabet AAM, 1999, J CHILD PSYCHOL PSYC, V40, P385, DOI 10.1111/1469-7610.00456; Thabet AAM, 1998, ARCH DIS CHILD, V78, P439, DOI 10.1136/adc.78.5.439; Thabet AZ, 2000, CHILD ABUSE NEGLECT, V24, P291, DOI 10.1016/S0145-2134(99)00127-1	24	139	140	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 25	2002	359	9320					1801	1804		10.1016/S0140-6736(02)08709-3	http://dx.doi.org/10.1016/S0140-6736(02)08709-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	555CK	12044374				2022-12-28	WOS:000175775500007
J	Simmonds, P; Kurtz, J; Tedder, RS				Simmonds, P; Kurtz, J; Tedder, RS			The UK blood transfusion service: over a (patent) barrel?	LANCET			English	Editorial Material							TRANSMITTED VIRAL-INFECTIONS; COST-EFFECTIVENESS; HEPATITIS-C; INTERFERON-ALPHA-2B		Univ Edinburgh, Lab Clin & Mol Biol, Edinburgh EH9 1QH, Midlothian, Scotland; Windeyer Inst Med Sci, Dept Virol, London, England; Birmingham Ctr, Natl Blood Serv, Birmingham, W Midlands, England	University of Edinburgh; University of London; University College London	Simmonds, P (corresponding author), Univ Edinburgh, Lab Clin & Mol Biol, Edinburgh EH9 1QH, Midlothian, Scotland.			Simmonds, Peter/0000-0002-7964-4700				Briggs A, 2000, BRIT MED J, V320, P246, DOI 10.1136/bmj.320.7229.246; Courouce AM, 1996, NEW ENGL J MED, V335, P1609; Jaeckel E, 2001, NEW ENGL J MED, V345, P1452, DOI 10.1056/NEJMoa011232; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; *SER HAZ TRANSF ST, 2000, SER HAZ TRANSF ANN R; VAMVAKAS EC, 1994, TRANSFUSION, V34, P471, DOI 10.1046/j.1537-2995.1994.34694295060.x; Younossi ZM, 1999, HEPATOLOGY, V30, P1318, DOI 10.1002/hep.510300518	7	32	32	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 18	2002	359	9319					1713	1714		10.1016/S0140-6736(02)08663-4	http://dx.doi.org/10.1016/S0140-6736(02)08663-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049856				2022-12-28	WOS:000175740500004
J	Hanauer, SB; Feagan, BG; Lichtenstein, GR; Mayer, LF; Schreiber, S; Colombel, JF; Rachmilewitz, D; Wolf, DC; Olson, A; Bao, WH; Rutgeerts, P				Hanauer, SB; Feagan, BG; Lichtenstein, GR; Mayer, LF; Schreiber, S; Colombel, JF; Rachmilewitz, D; Wolf, DC; Olson, A; Bao, WH; Rutgeerts, P		ACCENT I Study Grp	Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; INFLAMMATORY-BOWEL-DISEASE; FACTOR-ALPHA; THERAPEUTIC-EFFICACY; SHORT-TERM; METHOTREXATE	Background We did a randomised controlled trial to assess the benefit of maintenance infliximab therapy in patients with active Crohn's disease who respond to a single infusion of infliximab. Methods 573 patients with a score of at least 220 on the Crohn's disease activity index (CDAI) received a 5 mg/kg intravenous infusion of infliximab at week 0. After assessment of response at week 2, patients were randomly assigned repeat infusions of placebo at weeks 2 and 6 and then every 8 weeks thereafter until week 46 (group 1), repeat infusions of 5 mg/kg infliximab at the same timepoints (group 11), or 5 mg/kg infliximab at weeks 2 and 6 followed by 10 mg/kg (group 111). The prespecified co-primary endpoints were the proportion of patients who responded at week 2 and were in remission (CDAI <150) at week 30 and the time to loss of response up to week 54 in patients who responded. Analyses of the co-primary endpoints were by intention to treat. Findings 335 (58%) patients responded to a single infusion of infliximab within 2 weeks. At week 30, 23 of 110 (21%) group I patients were in remission, compared with 44 of 113 (39%) group 11 (p=0.003) and 50 of 112 (45%) group III (p=0.0002) patients. Thus, patients in groups 11 and III combined were more likely to sustain clinical remission than patients in group I (odds ratio 2.7, 95% Cl 1.6-4-6). Throughout the 54-week trial, the median time to loss of response was 38 weeks (IQR 15 to >54) and more than 54 weeks (21 to >54) for groups 11 and 111, respectively, compared with 19 weeks (10-45) for group I (p=0.002 and p=0.0002, respectively). Infliximab safety was consistent with that seen in other trials of infliximab in Crohn's disease and rheumatoid arthritis. In particular, the incidence of serious infections was similar across treatment groups. Interpretation Patients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remission at weeks 30 and 54, to discontinue corticosteroids, and to maintain their response for a longer period of time, if infliximab treatment is maintained every 8 weeks.	Univ Chicago, Med Ctr, Dept Gastroenterol & Nutr, Chicago, IL 60637 USA; Univ Western Ontario, London Hlth Sci Ctr, London, ON, Canada; Hosp Univ Penn, Dept Gastroenterol, Philadelphia, PA 19104 USA; Mt Sinai Med Ctr, Dept Clin Immunol, New York, NY 10029 USA; Christian Albrechts Univ Kiel Klinikum, Kiel, Germany; CHU Lille, Hop Claude Huriez, F-59037 Lille, France; Tel Aviv Sourasky Med Ctr, Div Med, Tel Aviv, Israel; Atlanta Gastroenterol Associates, Atlanta, GA USA; Centocor Inc, Malvern, PA 19355 USA; Univ Ziekenhuis Gasthuisberg, Afdeling Gastroenterol, Louvain, Belgium	University of Chicago; University of Chicago Medical Center; London Health Sciences Centre; Western University (University of Western Ontario); University of Pennsylvania; Pennsylvania Medicine; Icahn School of Medicine at Mount Sinai; University of Kiel; Schleswig Holstein University Hospital; Universite de Lille - ISITE; CHU Lille; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; KU Leuven; University Hospital Leuven	Hanauer, SB (corresponding author), Univ Chicago, Med Ctr, Dept Gastroenterol & Nutr, 5758 S Maryland Ave,MC-9028, Chicago, IL 60637 USA.	shanauer@medicine.bsd.uchicago.edu	Feagan, Brian/G-3292-2011; Feagan, Brian G/M-4283-2015					Baker DG, 2001, ARTHRITIS RHEUM, V44, pS105; Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; BRAEGGER CP, 1992, LANCET, V339, P89, DOI 10.1016/0140-6736(92)90999-J; BREESE EJ, 1994, GASTROENTEROLOGY, V106, P1455, DOI 10.1016/0016-5085(94)90398-0; Cohen RD, 2000, AM J GASTROENTEROL, V95, P3469; EKBOM A, 1991, CANCER-AM CANCER SOC, V67, P2015, DOI 10.1002/1097-0142(19910401)67:7<2015::AID-CNCR2820670731>3.0.CO;2-R; Faubion WA, 2001, GASTROENTEROLOGY, V121, P255, DOI 10.1053/gast.2001.26279; FEAGAN BG, 1995, NEW ENGL J MED, V332, P292, DOI 10.1056/NEJM199502023320503; GREENSTEIN AJ, 1992, CANCER-AM CANCER SOC, V69, P1119; IRVINE EJ, 1994, GASTROENTEROLOGY, V106, P287, DOI 10.1016/0016-5085(94)90585-1; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; KNIGHT DM, 1993, MOL IMMUNOL, V30, P1443, DOI 10.1016/0161-5890(93)90106-L; MACDONALD TT, 1990, CLIN EXP IMMUNOL, V81, P301; Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W; MUNKHOLM P, 1994, GUT, V35, P360, DOI 10.1136/gut.35.3.360; Nikolaus S, 2000, LANCET, V356, P1475, DOI 10.1016/S0140-6736(00)02871-3; Ricart E, 2001, AM J GASTROENTEROL, V96, P722, DOI 10.1111/j.1572-0241.2001.03612.x; Rutgeerts P, 1999, GASTROENTEROLOGY, V117, P761, DOI 10.1016/S0016-5085(99)70332-X; Sachmechian A, 2001, GASTROENTEROLOGY, V120, pA619, DOI 10.1016/S0016-5085(01)83081-X; Sandborn W., 2000, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000545; Schaible T F, 2000, Can J Gastroenterol, V14 Suppl C, p29C; Schreiber S, 1999, LANCET, V353, P459, DOI 10.1016/S0140-6736(98)03339-X; Steinhart H, 2000, Can J Gastroenterol, V14 Suppl C, p23C; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Toy LS, 2000, GASTROENTEROLOGY, V118, pA569	27	3145	3299	2	153	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 4	2002	359	9317					1541	1549		10.1016/S0140-6736(02)08512-4	http://dx.doi.org/10.1016/S0140-6736(02)08512-4			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047962				2022-12-28	WOS:000175460700006
J	Le Couteur, DG; Fraser, R; Cogger, VC; McLean, AJ				Le Couteur, DG; Fraser, R; Cogger, VC; McLean, AJ			Hepatic pseudocapillarisation and atherosclerosis in ageing	LANCET			English	Article							LIPOPROTEIN CHANGES; LIVER SIEVE; RAT-LIVER; CLEARANCE; METABOLISM; SINUSOIDS	Cardiovascular disease secondary to atherosclerosis Is the main cause of death and disability In Industriallsed countries, and ageing Is the foremost risk factor for atherosclerosis. We present a hypothesis linking age-specific structural change In the liver with accepted pathogenic mechanisms leading to atherosclerosis. Ageing In the liver Is associated with pseudocapillarisation of the sinusoidal endothelium, which Is characterised by thickening of endothellum, basement membrane formation, and defenestration (loss of pores). Fenestrations (pores) normally form a liver sieve that allows passage of chylomicron remnants for subsequent uptake and metabolism by hepatocytes. Ageing Is associated with Impaired clearance of chylomicron remnants, postprandial hypertriglyceridaemia, and hence, atherosclerosis, which we propose Is linked directly to loss of permeability of the liver sieve because of defenestration associated with pseudocapillarisation. Development of methods to maintain fenestrations of sinusoidal endothellum or to facilitate refenestration might be a new therapeutic strategy for management of cardiovascular disease In old people.	Univ Sydney, Concord RG Hosp, Ctr Educ & Res Ageing, Sydney, NSW 2006, Australia; Univ Sydney, Concord RG Hosp, Anzac Res Inst, Sydney, NSW 2006, Australia; Univ Otago, Christchurch Sch Med & Hlth Sci, Dept Pathol, Christchurch, New Zealand	Concord Repatriation General Hospital; University of Sydney; Concord Repatriation General Hospital; University of Sydney; ANZAC Research Institute; University of Otago	Le Couteur, DG (corresponding author), Concord Hosp, Ctr Educ & Res Ageing, Sydney, NSW 2139, Australia.		Ekanayake, Kanchana/P-8817-2016; Research Institute, ANZAC/CAE-9030-2022	Le Couteur, David/0000-0002-4227-5817				Abbott RD, 1998, AM J CARDIOL, V82, P172, DOI 10.1016/S0002-9149(98)00310-5; Cassader M, 1996, AGING CLIN EXP RES, V8, P421, DOI 10.1007/BF03339605; CLARK SA, 1988, LANCET, V2, P1225; Cogger VC, 2001, PHARMACOL TOXICOL, V89, P306, DOI 10.1034/j.1600-0773.2001.d01-165.x; COGGER VC, 2001, 2 INT C HEP SPLANCHN; COHN JS, 1988, J LIPID RES, V29, P469; Field PA, 2000, METABOLISM, V49, P492, DOI 10.1016/S0026-0495(00)80014-1; FLOREN CH, 1984, SCAND J GASTROENTERO, V19, P473, DOI 10.1080/00365521.1984.12005755; FRASER R, 1995, HEPATOLOGY, V21, P863, DOI 10.1016/0270-9139(95)90542-1; FRASER R, 1974, ATHEROSCLEROSIS, V19, P327, DOI 10.1016/0021-9150(74)90067-7; FRASER R, 1978, ATHEROSCLEROSIS, V29, P113, DOI 10.1016/0021-9150(78)90001-1; Grundy SM, 1999, J AM COLL CARDIOL, V34, P1348, DOI 10.1016/S0735-1097(99)00387-3; Hazzard W R, 1992, Clin Geriatr Med, V8, P89; KRASINSKI SD, 1990, J CLIN INVEST, V85, P883, DOI 10.1172/JCI114515; LATRY P, 1987, HUM PATHOL, V18, P775, DOI 10.1016/S0046-8177(87)80050-3; Le Couteur DG, 1998, CLIN PHARMACOKINET, V34, P359, DOI 10.2165/00003088-199834050-00003; Le Couteur DG, 2001, HEPATOLOGY, V33, P537, DOI 10.1053/jhep.2001.22754; MORETON JR, 1947, SCIENCE, V106, P190, DOI 10.1126/science.106.2748.190; Phillips C, 2000, ATHEROSCLEROSIS, V148, P283, DOI 10.1016/S0021-9150(99)00275-0; RAPP JH, 1994, ARTERIOSCLER THROMB, V14, P1767, DOI 10.1161/01.ATV.14.11.1767; REDGRAVE T G, 1970, Journal of Clinical Investigation, V49, P465, DOI 10.1172/JCI106255; Watts GF, 2001, ATHEROSCLEROSIS, V157, P519, DOI 10.1016/S0021-9150(01)00534-2; Weintraub MS, 1996, BRIT MED J, V312, P935, DOI 10.1136/bmj.312.7036.935; WISSE E, 1970, J ULTRA MOL STRUCT R, V31, P125, DOI 10.1016/S0022-5320(70)90150-4; WISSE E, 1985, HEPATOLOGY, V5, P683, DOI 10.1002/hep.1840050427; Yu KC, 2001, FRONT BIOSCI, V6, P332; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	27	101	102	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 4	2002	359	9317					1612	1615		10.1016/S0140-6736(02)08524-0	http://dx.doi.org/10.1016/S0140-6736(02)08524-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047987				2022-12-28	WOS:000175460700031
J	Jiang, YH; Jahagirdar, BN; Reinhardt, RL; Schwartz, RE; Keene, CD; Ortiz-Gonzalez, XR; Reyes, M; Lenvik, T; Lund, T; Blackstad, M; Du, JB; Aldrich, S; Lisberg, A; Low, WC; Largaespada, DA; Verfaillie, CM				Jiang, YH; Jahagirdar, BN; Reinhardt, RL; Schwartz, RE; Keene, CD; Ortiz-Gonzalez, XR; Reyes, M; Lenvik, T; Lund, T; Blackstad, M; Du, JB; Aldrich, S; Lisberg, A; Low, WC; Largaespada, DA; Verfaillie, CM			Pluripotency of mesenchymal stem cells derived from adult marrow	NATURE			English	Article							BONE-MARROW; PROGENITOR CELLS; IN-VIVO; MOUSE; MICE; EXPRESSION; DIFFERENTIATE; MUSCLE; ENGRAFTMENT; HEPATOCYTES	We report here that cells co-purifying with mesenchymal stem cells-termed here multipotent adult progenitor cells or MAPCs-differentiate, at the single cell level, not only into mesenchymal cells, but also cells with visceral mesoderm, neuroectoderm and endoderm characteristics in vitro. When injected into an early blastocyst, single MAPCs contribute to most, if not all, somatic cell types. On transplantation into a non-irradiated host, MAPCs engraft and differentiate to the haematopoietic lineage, in addition to the epithelium of liver, lung and gut. Engraftment in the haematopoietic system as well as the gastrointestinal tract is increased when MAPCs are transplanted in a minimally irradiated host. As MAPCs proliferate extensively without obvious senescence or loss of differentiation potential, they may be an ideal cell source for therapy of inherited or degenerative diseases.	Univ Minnesota, Sch Med, Stem Cell Inst, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Ctr Immunol, Dept Microbiol, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Neurosurg, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Verfaillie, CM (corresponding author), Univ Minnesota, Sch Med, Stem Cell Inst, Minneapolis, MN 55455 USA.	verfa001@umn.edu	Schwartz, Robert/AAE-7153-2021; Keene, Christopher D/N-1806-2015; Largaespada, David/C-9832-2014; Ortiz-Gonzalez, Xilma/AAD-2211-2021; Mordwinkin, Nicholas M/A-4347-2010; Verfaillie, Catherine/H-5148-2013	Ortiz-Gonzalez, Xilma/0000-0002-1710-4696; Keene, Christopher/0000-0002-5291-1469; Verfaillie, Catherine/0000-0001-7564-4079				Alison M, 1998, J HEPATOL, V29, P676, DOI 10.1016/S0168-8278(98)80165-7; Anderson DJ, 2001, NAT MED, V7, P393, DOI 10.1038/86439; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; BJORNSON C, 1999, SCIENCE, V283, P354; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Frankel MS, 2000, SCIENCE, V287, P1397, DOI 10.1126/science.287.5457.1397; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; Kawada H, 2001, BLOOD, V98, P2008, DOI 10.1182/blood.V98.7.2008; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; LENVIK T, IN PRESS MOL THERAPY; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Morshead CM, 2002, NAT MED, V8, P268, DOI 10.1038/nm0302-268; Nolta JA, 1996, P NATL ACAD SCI USA, V93, P2414, DOI 10.1073/pnas.93.6.2414; Odorico JS, 2001, STEM CELLS, V19, P193, DOI 10.1634/stemcells.19-3-193; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Palmer TD, 1999, J NEUROSCI, V19, P8487; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Potten CS, 1998, PHILOS T R SOC B, V353, P821, DOI 10.1098/rstb.1998.0246; PROCHAZKA M, 1992, P NATL ACAD SCI USA, V89, P3290, DOI 10.1073/pnas.89.8.3290; Reinhardt RL, 2001, NATURE, V410, P101, DOI 10.1038/35065111; Reyes M, 2001, BLOOD, V98, P2615, DOI 10.1182/blood.V98.9.2615; Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327; Rideout WM, 2000, NAT GENET, V24, P109, DOI 10.1038/72753; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; Schwartz RE, 2002, J CLIN INVEST, V109, P1291, DOI 10.1172/JCI200215182; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; WATT F, 1997, PHIL T R SOC LOND B, V353, P831; WEISS MJ, 1995, EXP HEMATOL, V23, P99; Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789	49	4401	5286	11	704	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 4	2002	418	6893					41	49		10.1038/nature00870	http://dx.doi.org/10.1038/nature00870			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12077603				2022-12-28	WOS:000176599200033
J	Homann, CN; Wenzel, K; Suppan, K; Ivanic, G; Kriechbaum, N; Crevenna, R; Ott, E				Homann, CN; Wenzel, K; Suppan, K; Ivanic, G; Kriechbaum, N; Crevenna, R; Ott, E			Sleep attacks in patients taking dopamine agonists: review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MOTOR-VEHICLE MISHAPS; PARKINSONS-DISEASE; DAYTIME SLEEPINESS; FALLING ASLEEP; EPISODES; PRAMIPEXOLE; WHEEL	Objectives To assess the evidence for the existence and prevalence of sleep attacks in patients taking dopamine agonists for Parkinson's disease, the type of drugs implicated, and strategies for prevention and treatment. Design Review of publications between July 1999 and May 2001 in which sleep attacks or narcoleptic-like attacks were discussed in patients with Parkinson's disease. Results 124 patients with sleep events were found in 20 publications. Overall, 6.6% of patients taking dopamine agonists who attended movement disorder centres had sleep events. Men were over-represented. Sleep events occurred at both high and low doses of the drugs, with different durations of treatment (0-20 years), and with or without preceding signs of tiredness. Sleep attacks are a class effect, having been found in patients taking the following dopamine agonists: levodopa (monotherapy in 8 patients), ergot agonists (apomorphine in 2 patients, bromocriptine in 13, cabergoline in 1, lisuride or piribedil in 23, pergolide in 5,) and non-ergot agonists (pramipexole in 32, ropinirole in 38). Reports suggest two distinct types of events: those of sudden onset without warning and those of slow onset with prodrome drowsiness. Conclusion Insufficient data are available to provide effective guidelines for prevention and treatment of sleep events in patients taking dopamine agonists for Parkinson's disease. Prospective population based studies are needed to provide this information.	Karl Franzens Univ Hosp, Dept Neurol, A-8036 Graz, Austria; Karl Franzens Univ Hosp, Dept Psychiat, Graz, Austria		Homann, CN (corresponding author), Karl Franzens Univ Hosp, Dept Neurol, A-8036 Graz, Austria.	nik.homann@kfunigraz.ac.at						Arnold G, 2000, NEUROLOGY, V54, P275; Clarenbach P, 2000, J NEUROL, V247, P20; EBERSBACH G, 2000, MOVEMENT DISORD, V15, P187; Ferreira JJ, 2000, LANCET, V355, P1333, DOI 10.1016/S0140-6736(00)02119-X; Ferreira JJ, 2000, MOV DISORD S3, V15, P187; FERREIRA JJ, 2000, MOVEMENT DISORD, V15, P129; Frucht S, 2000, NEUROLOGY, V54, P276; Frucht S, 1999, NEUROLOGY, V52, P1908, DOI 10.1212/WNL.52.9.1908; Frucht SJ, 2000, MOVEMENT DISORD, V15, P601, DOI 10.1002/1531-8257(200007)15:4<601::AID-MDS1003>3.0.CO;2-Q; Gottwald MD, 1997, ANN PHARMACOTHER, V31, P1205, DOI 10.1177/106002809703101014; Hauser RA, 2000, MOVEMENT DISORD, V15, P658, DOI 10.1002/1531-8257(200007)15:4<658::AID-MDS1009>3.0.CO;2-N; Hobson DE, 2002, JAMA-J AM MED ASSOC, V287, P455, DOI 10.1001/jama.287.4.455; HOEGL B, 2000, MOVEMENT DISORD, V15, P227; Hoehn MM, 2000, NEUROLOGY, V54, P275; Hogl B, 2000, NEUROPSYCHIATRIE, V14, P191; Homann CN, 2002, WIEN KLIN WOCHENSCHR, V114, P430; HOMANN CN, 2001, MOVEMENT DISORD, V16, P44; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Lachenmayer L, 2000, J NEUROL, V247, P28; LANG AE, 2001, NEUROLOGY, V56; Lledo A, 2000, NEUROLOGY, V54, P275; Montastruc JL, 2000, MOVEMENT DISORD, V15, P361, DOI 10.1002/1531-8257(200003)15:2<361::AID-MDS1034>3.0.CO;2-J; Montastruc JL, 2001, CLIN NEUROPHARMACOL, V24, P181, DOI 10.1097/00002826-200105000-00013; Olanow CW, 2000, MOVEMENT DISORD, V15, P212, DOI 10.1002/1531-8257(200003)15:2<212::AID-MDS1002>3.0.CO;2-6; PAL S, 2000, MOVEMENT DISORD, V15, P110; PALADINI D, 2000, MOV DISORD S3, V15, P130; Parkinson Study Group, 2000, JAMA, V284, P1931; Pirker W, 2000, LANCET, V356, P597, DOI 10.1016/S0140-6736(05)73981-7; POEWE W, 1996, BEWEGUNGSSTORUNGEN N, P30; Rye DB, 2000, J SLEEP RES, V9, P63, DOI 10.1046/j.1365-2869.2000.00201.x; Rye DB, 2000, NEUROLOGY, V54, P276; SCHAFER D, 2000, SOMNOLOGIE, V4, P84; Schapira AHV, 2000, LANCET, V355, P1332, DOI 10.1016/S0140-6736(00)02118-8	33	94	97	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 22	2002	324	7352					1483	1487		10.1136/bmj.324.7352.1483	http://dx.doi.org/10.1136/bmj.324.7352.1483			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567ZL	12077032	Bronze, Green Published			2022-12-28	WOS:000176517900017
J	Small, GW				Small, GW			What we need to know about age related memory loss	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ALZHEIMERS-DISEASE; RISK; IMPAIRMENT; DEMENTIA; STRESS		Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles	Small, GW (corresponding author), Univ Calif Los Angeles, Inst Neuropsychiat, Suite 88-201,760 Westwood Plaza, Los Angeles, CA 90024 USA.	gsmall@mednet.ucla.edu						BRANDMILLER J, 1999, GLUCOSE REVOLUTION; Del Ser T, 1999, BRAIN, V122, P2309, DOI 10.1093/brain/122.12.2309; Eriksson J, 2001, BRIT MED BULL, V60, P183, DOI 10.1093/bmb/60.1.183; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Friedland RP, 2001, P NATL ACAD SCI USA, V98, P3440, DOI 10.1073/pnas.061002998; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Joseph J.A., 2002, COLOR CODE REVOLUTIO; KAHN RI, 1998, SUCCESSFUL AGING; Kramer AF, 2001, HUMAN FACTORS INTERVENTIONS FOR THE HEALTH CARE OF OLDER ADULTS, P91; Larrabee G J, 1994, Int Psychogeriatr, V6, P95, DOI 10.1017/S1041610294001663; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Mattson MP, 2000, ANN NY ACAD SCI, V924, P153; Mayeux R, 1998, Alzheimer Dis Assoc Disord, V12 Suppl 3, pS10; Merchant C, 1999, NEUROLOGY, V52, P1408, DOI 10.1212/WNL.52.7.1408; Morris MC, 1998, ALZ DIS ASSOC DIS, V12, P121, DOI 10.1097/00002093-199809000-00001; Newcomer JW, 1999, ARCH GEN PSYCHIAT, V56, P527, DOI 10.1001/archpsyc.56.6.527; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Relkin NR, 1996, LANCET, V347, P1091, DOI 10.1016/S0140-6736(96)90284-6; Ruitenberg A, 2002, LANCET, V359, P281, DOI 10.1016/S0140-6736(02)07493-7; Sapolsky RM, 1999, EXP GERONTOL, V34, P721, DOI 10.1016/S0531-5565(99)00047-9; Silverman DHS, 2001, JAMA-J AM MED ASSOC, V286, P2120, DOI 10.1001/jama.286.17.2120; SMALL G, 2002, MEMORY BIBLE INNOVAT; Small GW, 1997, JAMA-J AM MED ASSOC, V278, P1363, DOI 10.1001/jama.278.16.1363; Solfrizzi V, 1999, NEUROLOGY, V52, P1563, DOI 10.1212/WNL.52.8.1563; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558	25	62	67	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 22	2002	324	7352					1502	1505		10.1136/bmj.324.7352.1502	http://dx.doi.org/10.1136/bmj.324.7352.1502			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567ZL	12077041	Green Published			2022-12-28	WOS:000176517900026
J	Richard, D; Clanet, C; Quere, D				Richard, D; Clanet, C; Quere, D			Surface phenomena - Contact time of a bouncing drop	NATURE			English	Editorial Material							LIQUID		Coll France, Phys Mat Condensee Lab, CNRS, URA 792, F-75231 Paris 05, France; Inst Rech Phenomenes Hors Equilibre, CNRS, UMR 6594, F-13384 Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Richard, D (corresponding author), Coll France, Phys Mat Condensee Lab, CNRS, URA 792, F-75231 Paris 05, France.			clanet, christophe/0000-0003-2448-0443				Aussillous P, 2001, NATURE, V411, P924, DOI 10.1038/35082026; FROHN A, 2000, DYNAMICS DROPLETS; Hartley R., 1958, SURFACE PHENOMENA CH, P214; Hertz H., 1882, J ANGEW MATH, V92, P156, DOI [10.1515/9783112342404-004, DOI 10.1515/CRLL.1882.92.156, 10.1515/crll.1882.92.156]; Landau LD, 1986, THEORY ELASTICITY, DOI 10.1016/C2009-0-25521-8; Nakajima A, 2001, MONATSH CHEM, V132, P31, DOI 10.1007/s007060170142; Perez M, 1999, EUROPHYS LETT, V47, P189, DOI 10.1209/epl/i1999-00371-6; Rayleigh L., 1879, P R SOC LONDON, V29, P71; Richard D, 2000, EUROPHYS LETT, V50, P769, DOI 10.1209/epl/i2000-00547-6; WACHTERS LH, 1966, CHEM ENG SCI, V21, P1047, DOI 10.1016/0009-2509(66)85100-X	10	762	792	22	417	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 20	2002	417	6891					811	811		10.1038/417811a	http://dx.doi.org/10.1038/417811a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563YM	12075341				2022-12-28	WOS:000176285600036
J	Koide, T; Nakajima, T; Makifuchi, T; Fukuhara, N				Koide, T; Nakajima, T; Makifuchi, T; Fukuhara, N			Systemic mastocytosis and recurrent anaphylactic shock	LANCET			English	Article									Natl Saigata Hosp, Dept Neurol, Ogata, Niigata, Japan; Natl Saigata Hosp, Dept Neuropathol, Ogata, Niigata, Japan		Fukuhara, N (corresponding author), Natl Saigata Hosp, Dept Neurol, Ogata, Niigata, Japan.	fukuhara@saigata-nh.go.jp						Golkar L, 1997, LANCET, V349, P1379, DOI 10.1016/S0140-6736(96)07056-0; Hartmann K, 2001, BRIT J DERMATOL, V144, P682, DOI 10.1046/j.1365-2133.2001.04123.x; Karnam US, 1999, DIGEST DIS, V17, P299, DOI 10.1159/000016955; OLAFSSON JH, 1985, ACTA DERM-VENEREOL, P1; Roberts L J 2nd, 1982, Trans Assoc Am Physicians, V95, P36	5	20	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 15	2002	359	9323					2084	2084		10.1016/S0140-6736(02)08908-0	http://dx.doi.org/10.1016/S0140-6736(02)08908-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086763				2022-12-28	WOS:000176194600011
J	Bada, JL; Lazcano, A				Bada, JL; Lazcano, A			Origin of life - Some like it hot, but not the first biomolecules	SCIENCE			English	Editorial Material							ACID; RNA		Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Univ Nacl Autonoma Mexico, Fac Ciencias, Mexico City 04510, DF, Mexico	University of California System; University of California San Diego; Scripps Institution of Oceanography; Universidad Nacional Autonoma de Mexico	Bada, JL (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.	alar@hp.fciencias.unam.mx		Lazcano, Antonio/0000-0001-7365-8557				BADA JL, 1994, P NATL ACAD SCI USA, V91, P1248, DOI 10.1073/pnas.91.4.1248; Barnes I, 2002, SCIENCE, V295, P2267, DOI 10.1126/science.1067814; Brochier C, 2002, NATURE, V417, P244, DOI 10.1038/417244a; Cody GD, 2001, GEOCHIM COSMOCHIM AC, V65, P3557, DOI 10.1016/S0016-7037(01)00674-3; Ferris JP, 1996, NATURE, V381, P59, DOI 10.1038/381059a0; FLEGMANN AW, 1979, J MOL EVOL, V12, P349, DOI 10.1007/BF01732029; Kanavarioti A, 2001, ASTROBIOLOGY, V1, P271, DOI 10.1089/15311070152757465; Levy M, 1998, P NATL ACAD SCI USA, V95, P7933, DOI 10.1073/pnas.95.14.7933; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Morowitz HJ, 2000, P NATL ACAD SCI USA, V97, P7704, DOI 10.1073/pnas.110153997; Nelson KE, 2000, P NATL ACAD SCI USA, V97, P3868, DOI 10.1073/pnas.97.8.3868; NIELSEN PE, 1993, ORIGINS LIFE EVOL B, V23, P323, DOI 10.1007/BF01582083; Nisbet EG, 2001, NATURE, V409, P1083, DOI 10.1038/35059210; Orgel LE, 2000, P NATL ACAD SCI USA, V97, P12503, DOI 10.1073/pnas.220406697; Poinar HN, 1996, SCIENCE, V272, P864, DOI 10.1126/science.272.5263.864; Schoning KU, 2000, SCIENCE, V290, P1347, DOI 10.1126/science.290.5495.1347; SCHOPF JW, 1999, CRADLE LIFE DISCOVER, P336; Sowerby SJ, 2001, ASTROBIOLOGY, V1, P481, DOI 10.1089/153110701753593883; WACHTERSHAUSER G, 1994, P NATL ACAD SCI USA, V91, P4283, DOI 10.1073/pnas.91.10.4283; Wachtershauser G, 2000, SCIENCE, V289, P1307, DOI 10.1126/science.289.5483.1307; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X; Wills C., 2000, SPARK LIFE DARWIN PR; YCAS M, 1955, P NATL ACAD SCI USA, V41, P714, DOI 10.1073/pnas.41.10.714	23	166	172	2	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	2002	296	5575					1982	1983		10.1126/science.1069487	http://dx.doi.org/10.1126/science.1069487			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	12065824				2022-12-28	WOS:000176273300039
J	Shalitin, D; Yang, HY; Mockler, TC; Maymon, M; Guo, HW; Whitelam, GC; Lin, CT				Shalitin, D; Yang, HY; Mockler, TC; Maymon, M; Guo, HW; Whitelam, GC; Lin, CT			Regulation of Arabidopsis cryptochrome 2 by blue-light-dependent phosphorylation	NATURE			English	Article							FLOWERING TIME; RECEPTOR CRYPTOCHROME-2; PHYTOCHROME-B; PHOTORECEPTORS; PLANT; MUTANTS; GROWTH; CRY1; COP1	Cryptochromes are blue/ultraviolet-A light receptors that mediate various light responses in plants and animals(1,2). But the initial photochemical reaction of cryptochrome is still unclear. For example, although most photoreceptors are known to undergo light-dependent protein modification such as phosphorylation (3,4), no blue-light dependent phosphorylation has been reported for a cryptochrome. Arabidopsis cryptochrome 2 (cry2) mediates light regulation of seedling development and photoperiodic flowering(5,6). The physiological activity and cellular level of cry2 protein are light-dependent(5-8), and protein-protein interactions are important for cry2 function(9,10). Here we report that cry2 undergoes a blue-light-dependent phosphorylation, and that cry2 phosphorylation is associated with its function and regulation. Our results suggest that, in the absence of light, cry2 remains unphosphorylated, inactive and stable; absorption of blue light induces the phosphorylation of cry2, triggering photomorphogenic responses and eventually degradation of the photoreceptor.	Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Leicester, Dept Biol, Leicester LE1 7RH, Leics, England	University of California System; University of California Los Angeles; University of Leicester	Lin, CT (corresponding author), Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.	clin@mcdb.ucla.edu	Mockler, Todd C/L-2609-2013	Mockler, Todd C/0000-0002-0462-5775	NIGMS NIH HHS [R01 GM056265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056265] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1998, PLANT CELL, V10, P197, DOI 10.1105/tpc.10.2.197; Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; Buche C, 2000, PLANT CELL, V12, P547, DOI 10.1105/tpc.12.4.547; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; CHORY J, 1989, CELL, V58, P991, DOI 10.1016/0092-8674(89)90950-1; DENG XW, 1991, GENE DEV, V5, P1172, DOI 10.1101/gad.5.7.1172; Devlin PF, 1999, PLANT PHYSIOL, V119, P909, DOI 10.1104/pp.119.3.909; Devlin PF, 1998, PLANT CELL, V10, P1479, DOI 10.1105/tpc.10.9.1479; El-Assal SED, 2001, NAT GENET, V29, P435, DOI 10.1038/ng767; Fankhauser C, 1997, ANNU REV CELL DEV BI, V13, P203, DOI 10.1146/annurev.cellbio.13.1.203; Guo HW, 1999, PLANT J, V19, P279, DOI 10.1046/j.1365-313X.1999.00525.x; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; Guo HW, 2001, SCIENCE, V291, P487, DOI 10.1126/science.291.5503.487; HOLMES MG, 1991, PHOTORECEPTOR EVOLUT; Kwok SF, 1996, PLANT PHYSIOL, V110, P731, DOI 10.1104/pp.110.3.731; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; Lin CT, 1996, PLANT J, V10, P893, DOI 10.1046/j.1365-313X.1996.10050893.x; Mas P, 2000, NATURE, V408, P207, DOI 10.1038/35041583; MCNELLIS TW, 1994, PLANT CELL, V6, P487, DOI 10.1105/tpc.6.4.487; Mockler TC, 1999, DEVELOPMENT, V126, P2073; Osterlund MT, 2000, NATURE, V405, P462, DOI 10.1038/35013076; PARKS BM, 1991, PLANT CELL, V3, P1177, DOI 10.1105/tpc.3.11.1177; Sancar A, 2000, ANNU REV BIOCHEM, V69, P31, DOI 10.1146/annurev.biochem.69.1.31; Wang HY, 2001, SCIENCE, V294, P154, DOI 10.1126/science.1063630; Yang HQ, 2001, PLANT CELL, V13, P2573, DOI 10.1105/tpc.13.12.2573; Yang HQ, 2000, CELL, V103, P815, DOI 10.1016/S0092-8674(00)00184-7; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976	29	213	232	6	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	2002	417	6890					763	767		10.1038/nature00815	http://dx.doi.org/10.1038/nature00815			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	561QY	12066190				2022-12-28	WOS:000176154700050
J	Tuomala, RE; Shapiro, DE; Mofenson, LM; Bryson, Y; Culnane, M; Hughes, MD; O'Sullivan, MJ; Scott, G; Stek, AM; Wara, D; Bulterys, M				Tuomala, RE; Shapiro, DE; Mofenson, LM; Bryson, Y; Culnane, M; Hughes, MD; O'Sullivan, MJ; Scott, G; Stek, AM; Wara, D; Bulterys, M			Antiretroviral therapy during pregnancy and the risk of an adverse outcome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MATERNAL-INFANT TRANSMISSION; PERINATAL TRANSMISSION; WOMEN; PREVENTION; TRENDS; IMPACT	Background: Some studies suggest that combination antiretroviral therapy in pregnant women with human immunodeficiency virus type 1 (HIV-1) infection increases the risk of premature birth and other adverse outcomes of pregnancy. Methods: We studied pregnant women with HIV-1 infection who were enrolled in seven clinical studies and delivered their infants from 1990 through 1998. The cohort comprised 2123 women who received antiretroviral therapy during pregnancy (monotherapy in 1590, combination therapy without protease inhibitors in 396, and combination therapy with protease inhibitors in 137) and 1143 women who did not receive antiretroviral therapy. Results: After standardization for the CD4+ cell count and use or nonuse of tobacco, alcohol, and illicit drugs, the rate of premature delivery (<37 weeks of gestation) was similar among the women who received antiretroviral therapy and those who did not (16 percent and 17 percent, respectively); the rate of low birth weight (<2500 g) was 16 percent among the infants born to both groups; and the rate of very low birth weight (<1500 g) was 2 percent for the group that received antiretroviral therapy and 1 percent for the group that did not. The rates of low Apgar scores (<7) and stillbirth were also similar or the same in the two groups. After adjustment for multiple risk factors, combination antiretroviral therapy was not associated with an increased risk of premature delivery as compared with monotherapy (odds ratio, 1.08; 95 percent confidence interval, 0.71 to 1.62) or delivery of an infant with low birth weight (odds ratio, 1.03; 95 percent confidence interval, 0.64 to 1.63). Seven of the women who received combination therapy with protease inhibitors (5 percent) had infants with very low birth weight, as compared with nine women who received combination therapy without protease inhibitors (2 percent) (adjusted odds ratio, 3.56; 95 percent confidence interval, 1.04 to 12.19). Conclusions: As compared with no antiretroviral therapy or monotherapy, combination therapy for HIV-1 infection in pregnant women is not associated with increased rates of premature delivery or with low birth weight, low Apgar scores, or stillbirth in their infants. The association between combination therapy with protease inhibitors and an increased risk of very low birth weight requires confirmation.	Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Pediat AIDS Clin Trials Grp Study 076, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Stat & Data Management Ctr, Pediat AIDS Clin Trials Grp, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Women & Infants Transmiss Study, Boston, MA 02115 USA; NICHHD, Pediat Adolescent & Maternal AIDS Branch, Rockville, MD USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Pediat AIDS Clin Trials Grp Study 185, Los Angeles, CA USA; Univ Calif Los Angeles, Maternal Infant HIV Transmiss Study, Los Angeles, CA USA; NIAID, Pediat Med Branch, Div AIDS, Bethesda, MD 20892 USA; Univ Miami, Sch Med, Pediat AIDS Clin Trials Grp Study 076, Miami, FL USA; Univ Miami, Sch Med, Dept Obstet, Miami, FL USA; Univ Miami, Sch Med, Dept Pediat, Miami, FL USA; Univ Miami, Infants HIV Seropost Mothers Study 1, Miami, FL USA; Univ So Calif, Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA; Univ So Calif, Los Angeles Cty Perinatal Transmiss Study, Los Angeles, CA 90033 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Bay Area Pediat AIDS Consortium, Atlanta, GA USA; Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Miami; University of Miami; University of Miami; University of Miami; University of Southern California; University of Southern California; University of California System; University of California San Francisco; Centers for Disease Control & Prevention - USA	Tuomala, RE (corresponding author), Brigham & Womens Hosp, Dept Obstet & Gynecol, 75 Francis St, Boston, MA 02115 USA.	rtuomala@partners.org	Mofenson, Lynne/P-9631-2019	Mofenson, Lynne/0000-0002-2818-9808; Culnane, Mary/0000-0003-2070-4454	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD033162, N01HD082913, R01HD025714, U01HD036117, R01HD030629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027560, U01AI027541, U01AI027550, U01AI041110, U01AI034842, U01AI034840, U01AI034858, U01AI034841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [U01DA015054] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR-43] Funding Source: Medline; NIAID NIH HHS [AI-27541, AI-27560, AI-34840, AI-34841, AI-27550, AI-34842, AI-41110, AI-34858] Funding Source: Medline; NICHD NIH HHS [HD-36117, HD-82913, HD-33162, R01 HD 30629, HD-2-5714] Funding Source: Medline; NIDA NIH HHS [DA-15054] Funding Source: Medline; PHS HHS [M015501271, R01 A123524] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aebi C, 2000, AIDS, V14, P2913, DOI 10.1097/00002030-200012220-00013; Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Blattner W, 2000, 13 INT AIDS C DURB S; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 2000, J ACQ IMMUN DEF SYND, V24, P45; DORENBAUM A, 2001, 8 C RETR OPP INF CHI; Fiscus SA, 1999, J INFECT DIS, V180, P99, DOI 10.1086/314840; Goldenberg RL, 1998, NEW ENGL J MED, V339, P313, DOI 10.1056/NEJM199807303390506; HOSMER DW, 1989, APPL LOGISTIC REGRES, P135; KUMAR RM, 1995, INT J GYNECOL OBSTET, V49, P137, DOI 10.1016/0020-7292(95)02356-H; Lambert JS, 2000, AIDS, V14, P1389, DOI 10.1097/00002030-200007070-00012; Lorenzi P, 1998, AIDS, V12, pF241, DOI 10.1097/00002030-199818000-00002; Mandelbrot L, 2001, JAMA-J AM MED ASSOC, V285, P2083, DOI 10.1001/jama.285.16.2083; Minkoff H, 1997, AM J OBSTET GYNECOL, V176, P478, DOI 10.1016/S0002-9378(97)70519-2; Morris AB, 2000, J ACQ IMMUN DEF SYND, V25, P306, DOI 10.1097/00126334-200012010-00003; Newell ML, 1996, AIDS, V10, P1675; *NIH PAN DEF PRINC, 1998, MMWR-MORBID MORTAL W, V47, P43; *PHS TASK FORC, 1998, MMWR-MORBID MORTAL W, V47, P1; *PHS TASK FORC, 1998, MMWR-MORBID MORTAL W, V47, P287; Rothman K., 1998, MODERN EPIDEMIOLOGY; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SHEON AR, 1996, J WOMENS HEALTH, V5, P69, DOI DOI 10.1089/JWH.1996.5.69; Simonds RJ, 1998, AIDS, V12, P301, DOI 10.1097/00002030-199803000-00008; Stiehm ER, 1999, J INFECT DIS, V179, P567, DOI 10.1086/314637; Stratton P, 1999, J ACQ IMMUN DEF SYND, V20, P179, DOI 10.1097/00042560-199902010-00011; Thorne C, 2001, AIDS, V15, P761, DOI 10.1097/00002030-200104130-00012; Turner BJ, 1999, ANN INTERN MED, V130, P979, DOI 10.7326/0003-4819-130-12-199906150-00005; Wortley Pascale M., 2001, Morbidity and Mortality Weekly Report, V50, P17	28	271	279	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 13	2002	346	24					1863	1870		10.1056/NEJMoa991159	http://dx.doi.org/10.1056/NEJMoa991159			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	561NA	12063370				2022-12-28	WOS:000176146100004
J	Ling, PM; Glantz, SA				Ling, PM; Glantz, SA			Using tobacco-industry marketing research to design more effective tobacco-control campaigns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CALIFORNIA EXPERIENCE; DOCUMENTS; YOUTH; SMOKING; SMOKERS	To improve tobacco-control efforts by applying tobacco-industry marketing research and strategies to clinical and public health smoking interventions, we analyzed previously secret tobacco-industry marketing documents. In contrast to public health, the tobacco industry divides markets and defines targets according to consumer attitudes, aspirations, activities, and lifestyles. Tobacco marketing targets smokers of all ages; young adults are particularly important. During the 1980s, cost affected increasing numbers of young and older smokers. During the 1990s, eroding social acceptability of smoking emerged as a major threat, largely from increasing awareness of the dangers of secondhand smoke among nonsmokers and smokers. Physicians and public health professionals should use tobacco-industry psychographic approaches to design more relevant tobacco-control interventions. Efforts to counter tobacco marketing campaigns should include people of all ages, particularly young adults, rather than concentrating on teens and young children. Many young smokers are cost sensitive. Tobacco-control messages emphasizing the dangers of secondhand smoke to smokers and nonsmokers undermine the social acceptability of smoking.	Univ Calif San Francisco, Cardiovasc Res Inst, Inst Hlth Policy Studies, Ctr Tobacco Control Res & Educ, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Glantz, SA (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Inst Hlth Policy Studies, Ctr Tobacco Control Res & Educ, Box 0130, San Francisco, CA 94143 USA.			Ling, Pamela/0000-0001-6166-9347	NATIONAL CANCER INSTITUTE [R01CA087472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019105] Funding Source: NIH RePORTER; NCI NIH HHS [CA-87472] Funding Source: Medline; NIMH NIH HHS [T32 MH-19105] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ansberry C, 1992, TODAYS ADULT YOUNG M; *B ECKM INC, 1992, VIAB MARLB MAN 18 24; Balbach ED, 1998, TOB CONTROL, V7, P397, DOI 10.1136/tc.7.4.397; Bauer UE, 2000, JAMA-J AM MED ASSOC, V284, P723, DOI 10.1001/jama.284.6.723; BEANE T, 1983, MARKET SEGMENTATION; *BUS INF AN CORP, 1985, RJR YOUNG AD MOT RES; *CA DEP HLTH SERV, 1998, MOD CHANG; ELLIOTT S, 1999, NY TIMES C      1111, P12; *ENT MARK COMM INT, 2002, CAM MAK YOUR OWN MUS; Farkas AJ, 1999, TOB CONTROL, V8, P261, DOI 10.1136/tc.8.3.261; FIELDS TF, 1982, 1981 SEGMENTATION ST; FRIEDMAN L, 2002, MOTIVATIONAL CONFLIC; GENNARO MJ, 1994, MARLBORO COUNTRY NIG; Gilpin E A, 1999, Nicotine Tob Res, V1, P153, DOI 10.1080/14622299050011261; Glantz SA, 2000, PEDIATRICS, V106, part. no., DOI 10.1542/peds.106.6.e82; GLANTZ SA, 2000, TOBACCO WAR; Goldman LK, 1998, JAMA-J AM MED ASSOC, V279, P772, DOI 10.1001/jama.279.10.772; GUGLIOTTA G, 1999, WASHINGTON POST 1013, pA16; Hastings G, 2000, BRIT MED J, V321, P366, DOI 10.1136/bmj.321.7257.366; Healton C, 2001, AM J PUBLIC HEALTH, V91, P554, DOI 10.2105/AJPH.91.4.554; HOWE K, 1991, SPEC MARK 91 MARLB R; JOHNSTON M, 1983, MARKET SEGMENTATION; JOHNSTON ME, 2002, YOUNG SMOKERS PREVAL; *K BY ASS, 1994, TREND INFL MARK PROG; Kotler P, 1999, PRINCIPLES MARKETING; LAYNE S, 1989, DAYTONA PROMOTIONS; LING PM, IN PRESS AM J PUBLIC; *M NORM MARK, 1990, PROP NEW BRAND ID CO; *M NORM MARK, 1990, YOUNG AD SMOK OPP PR; Magzamen S, 2001, AM J PUBLIC HEALTH, V91, P245, DOI 10.2105/AJPH.91.2.245; Magzamen S, 2001, TOB CONTROL, V10, P154, DOI 10.1136/tc.10.2.154; Malone RE, 2000, TOB CONTROL, V9, P334, DOI 10.1136/tc.9.3.334; MANN J, 1999, KANSAS CITY STA 1217, pC1; *MARPL RES, 1968, PIL STUD CIG MARK SE; MCCANN R, 1982, MARKET OVERVIEW PROD; MENDELL S, 1983, MARKET SEGMENTATION; MOWERY P, 2000, 3 AM LEG FDN, P1; NASSAR SC, 1985, MARLBORO VULNERABILI; NORMILE M, 1986, MARKET RES SEMINAR 8, V4; Perry CL, 1999, ARCH PEDIAT ADOL MED, V153, P935, DOI 10.1001/archpedi.153.9.935; *PHIL MORR, 1994, US CIG MARK; *PHIL MORR, 2002, CIG MARK NAT TRACK S; *PHIL MORR TOB CO, 1989, NONSM VIEWS SMOK ISS; *PHIL MORR TOB CO, 1994, GMR MARK PARL PART Z; *PHIL MORR TOB CO, 1988, AN CAM THREAT PHIL M; *PHIL MORR TOB CO, 1993, MARLB RAC BAR NIGHTS; *PHIL MORR TOB CO, 1992, 910000 1991 STUD SMO; *PHIL MORR TOB CO, 1988, HOW TOD SMOK FEEL SM; *PHIL MORR TOB CO, 1994, PFO YOUNG AD MARLB 1; *PHIL MORR TOB CO, 1993, YAS SEGM STUD; *PHIL MORR TOB CO, 2002, CONJ SIM MOD; *PHIL MORR TOB CO, 1993, MILLW BROWN AW ADV I; *PHIL MORR TOB CO, 1994, SMOK NONSM SEGM STUD; *PHIL MORR TOB CO, 1993, YOUNG AD MAL SMOK YO; *PHIL MORR TOB CO, 2002, MENTH EV SPONS MARLB; *PHIL MORR TOB CO, 2002, MARLB COUNTR 1994 DA; *PHIL MORR TOB CO, 1990, CAM SMOK PROF DEM; Pierce JP, 1998, CANCER EPIDEM BIOMAR, V7, P459; Pierce JP., 1998, TOBACCO CONTROL CALI; Pollay RW, 2000, TOB CONTROL, V9, P136, DOI 10.1136/tc.9.2.136; *PROM MARK INC, 1989, CAM SPRING RES PROGR; *RJ REYN, 2002, 1985 SEGM DESCR STUD; *RJ REYN, 2002, QUEST AR YOUNG AD SM; *RJ REYN, 1995, PROJ SCUM; *RJ REYN, 1977, CIG MARK SEGM STUD L; *RJ REYN, 1982, STRAT RES REP 1981 B; *RJ REYN, 2002, SEGM FACT SHEETS; *RJ REYN, 1988, YOUNG AD SMOK OPP PU; *RJ REYN, 1976, CIG MARK SEGM STUD; *RJ REYN TOB CO, 1987, INP LONG TERM STRAT; *RJ REYN TOB CO, 1990, RJRTC 1991 1995 STRA; Sepe E, 2002, AM J PUBLIC HEALTH, V92, P414, DOI 10.2105/AJPH.92.3.414; Sepe E, 2002, AM J PUBLIC HEALTH, V92, P75, DOI 10.2105/AJPH.92.1.75; Teague CE, 1973, RES PLANNING MEMORAN; TINDALL J, 1992, CIGARETTE MARKET HIS; *U CAL, 2002, AN VIR SEGM; *U CAL, 1989, PROM MARK, V1; *U CAL, 2002, 837791 U CAL; *U CAL, 2002, STRAT PLAN 1990 1992; Urban GL, 1993, DESIGN MARKETING NEW; *YOUNG RUB, 1994, BRAND X QUAL EXPL YO	81	108	109	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	2002	287	22					2983	2989		10.1001/jama.287.22.2983	http://dx.doi.org/10.1001/jama.287.22.2983			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	561EY	12052128				2022-12-28	WOS:000176128300028
J	Davies, RJ; Freeman, A; Morris, LS; Bingham, S; Dilworth, S; Scott, I; Laskey, RA; Miller, R; Coleman, N				Davies, RJ; Freeman, A; Morris, LS; Bingham, S; Dilworth, S; Scott, I; Laskey, RA; Miller, R; Coleman, N			Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool	LANCET			English	Article							DNA	Colorectal cancer Is a common disease, and more reliable screening methods are needed for early detection. We aim to develop a non-Invasive, stool-based assay that can identify colorectal cancer by detection of minichromosome maintenance protein 2 (MCM2) expression in colonocytes retrieved from the faecal surface. We devised a cell line model to investigate methods and conditions for optimum colonocyte retrieval. In our clinical evaluation study, MCM2-positive cells were retrieved from 37 of 40 patients with symptomatic colorectal cancer, but from none of 25 healthy control Individuals. These results suggest that immunocytochemical analysis of retrieved colonocytes might enable accurate detection of colorectal cancer in stool.	MRC, Canc Cell Univ, Hutchison MRC Res Ctr, Cambridge CB2 2XZ, England; Addenbrookes NHS Trust, Dept Surg, Cambridge CB2 2QQ, England; MRC, Dunn Human Nutr Unit, Cambridge, England; Hammersmith Hosp, Imperial Coll Sch Med, Dept Metab Med, London, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; Imperial College London	Coleman, N (corresponding author), MRC, Canc Cell Univ, Hutchison MRC Res Ctr, Cambridge CB2 2XZ, England.							Freeman A, 1999, CLIN CANCER RES, V5, P2121; Loktionov A, 1998, CLIN CANCER RES, V4, P337; Mukherjee G, 2001, INT J GYNECOL CANCER, V11, P187, DOI 10.1046/j.1525-1438.2001.01014.x; Traverso G, 2002, NEW ENGL J MED, V346, P311, DOI 10.1056/NEJMoa012294; Williams GH, 1998, P NATL ACAD SCI USA, V95, P14932, DOI 10.1073/pnas.95.25.14932	5	120	129	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 1	2002	359	9321					1917	1919		10.1016/S0140-6736(02)08739-1	http://dx.doi.org/10.1016/S0140-6736(02)08739-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PL	12057556				2022-12-28	WOS:000175975700013
J	Corcoy, R				Corcoy, R			Uses of error - Iatrogenic adrenergic crisis	LANCET			English	Editorial Material									Hosp Sant Pau, Barcelona 08025, Spain	Hospital of Santa Creu i Sant Pau	Corcoy, R (corresponding author), Hosp Sant Pau, Barcelona 08025, Spain.		Corcoy, Rosa/A-2140-2009	Corcoy, Rosa/0000-0001-5055-6814					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 25	2002	359	9320					1850	1850		10.1016/S0140-6736(02)08704-4	http://dx.doi.org/10.1016/S0140-6736(02)08704-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044393				2022-12-28	WOS:000175775500026
J	Lezec, HJ; Degiron, A; Devaux, E; Linke, RA; Martin-Moreno, L; Garcia-Vidal, FJ; Ebbesen, TW				Lezec, HJ; Degiron, A; Devaux, E; Linke, RA; Martin-Moreno, L; Garcia-Vidal, FJ; Ebbesen, TW			Beaming light from a subwavelength aperture	SCIENCE			English	Article							EXTRAORDINARY OPTICAL-TRANSMISSION	Light usually diffracts in all directions when it emerges from a subwavelength aperture, which puts a lower limit on the size of features that can be used in photonics. This limitation can be overcome by creating a periodic texture on the exit side of a single aperture in a metal film. The transmitted light emerges from the aperture as a beam with a small angular divergence ( approximately +/-3degrees) whose directionality can be controlled. This finding is especially surprising, considering that the radiating region is mainly confined to an area with lateral dimensions comparable to the wavelength of the light. The device occupies no more than one cubic micrometer and, when combined with enhanced transmission, suggests that a wide range of photonic applications is possible.	Univ Strasbourg, ISIS, F-67000 Strasbourg, France; NEC Res Inst, Princeton, NJ 08540 USA; Univ Zaragoza, CSIC, ICMA, Dept Fis Mat Condensada, Zaragoza 50015, Spain; Univ Autonoma Madrid, Dept Fis Teor Mat Condensada, E-28049 Madrid, Spain	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; NEC Corporation; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Quimica y Materiales de Aragon (CEQMA); CSIC - Instituto de Ciencia de Materiales de Aragon (ICMA); University of Zaragoza; Autonomous University of Madrid	Ebbesen, TW (corresponding author), Univ Strasbourg, ISIS, 4 Rue Blaise Pascal, F-67000 Strasbourg, France.	ebbesen@isis-ulp.org	Garcia-Vidal, Francisco J./B-8280-2011; Martin-Moreno, Luis/O-4161-2014	Garcia-Vidal, Francisco J./0000-0003-4354-0982; Martin-Moreno, Luis/0000-0001-9273-8165				Barnes WL, 1999, J LIGHTWAVE TECHNOL, V17, P2170, DOI 10.1109/50.803008; Collin S, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.033107; Ebbesen TW, 1998, NATURE, V391, P667, DOI 10.1038/35570; ERDOGAN T, 1992, APPL PHYS LETT, V60, P1921, DOI 10.1063/1.107151; Ghaemi HF, 1998, PHYS REV B, V58, P6779, DOI 10.1103/PhysRevB.58.6779; Greffet JJ, 2002, NATURE, V416, P61, DOI 10.1038/416061a; Grupp DE, 1999, ADV MATER, V11, P860, DOI 10.1002/(SICI)1521-4095(199907)11:10<860::AID-ADMA860>3.3.CO;2-M; HECHT E, 1990, OPTICS; Hibbins AP, 2000, J APPL PHYS, V87, P2677, DOI 10.1063/1.372241; Kitson SC, 1996, PHYS REV LETT, V77, P2670, DOI 10.1103/PhysRevLett.77.2670; KOCK A, 1990, APPL PHYS LETT, V57, P2327, DOI 10.1063/1.103883; Krenn JR, 1999, PHYS REV LETT, V82, P2590, DOI 10.1103/PhysRevLett.82.2590; Krishnan A, 2001, OPT COMMUN, V200, P1, DOI 10.1016/S0030-4018(01)01558-9; Martin-Moreno L, 2001, PHYS REV LETT, V86, P1114, DOI 10.1103/PhysRevLett.86.1114; Pendry J, 1999, SCIENCE, V285, P1687, DOI 10.1126/science.285.5434.1687; Popov E, 2000, PHYS REV B, V62, P16100, DOI 10.1103/PhysRevB.62.16100; Porto JA, 1999, PHYS REV LETT, V83, P2845, DOI 10.1103/PhysRevLett.83.2845; Salomon L, 2001, PHYS REV LETT, V86, P1110, DOI 10.1103/PhysRevLett.86.1110; Shubin VA, 2000, PHYS REV B, V62, P11230, DOI 10.1103/PhysRevB.62.11230; Vigoureux JM, 2001, OPT COMMUN, V198, P257, DOI 10.1016/S0030-4018(01)01522-X; Worthing PT, 2001, APPL PHYS LETT, V79, P3035, DOI 10.1063/1.1414294	21	1553	1641	9	386	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 2	2002	297	5582					820	822		10.1126/science.1071895	http://dx.doi.org/10.1126/science.1071895			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	579RZ	12077423				2022-12-28	WOS:000177192800045
J	Paria, BC; Reese, J; Das, SK; Dey, SK				Paria, BC; Reese, J; Das, SK; Dey, SK			Deciphering the cross-talk of implantation: Advances and challenges	SCIENCE			English	Review							BLASTOCYST IMPLANTATION; EMBRYO IMPLANTATION; UTERINE RECEPTIVITY; MICE; EXPRESSION; ESTROGEN; FAILURE; MARKERS; DISEASE	Implantation involves a series of steps leading to an effective reciprocal signaling between the blastocyst and the uterus. Except for a restricted period when ovarian hormones induce a uterine receptive phase, the uterus is an unfavorable environment for blastocyst implantation. Because species-specific variations in implantation strategies exist, these differences preclude the formulation of a unifying theme for the molecular basis of this event. However, an increased understanding of mammalian implantation has been gained through the use of the mouse model. This review summarizes recognized signaling cascades and new research in mammalian implantation, based primarily on available genetic and molecular evidence from implantation studies in the mouse. Although the identification of new molecules associated with implantation in various species provides valuable insight, important questions remain regarding the common molecular mechanisms that govern this process. Understanding the mechanisms of implantation promises to help alleviate infertility, enhance fetal health, and improve contraceptive design.	Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Pediat, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Obstet & Gynecol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Dey, SK (corresponding author), Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	sk.dey@vanderbilt.edu		Reese, Jeff/0000-0001-8751-6146	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD012304, R01HD012304, U01HD029968, K08HD040221, R01HD037830, R01HD037394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA006668, R01DA006668] Funding Source: NIH RePORTER; NICHD NIH HHS [HD37394, HD12304, HD33994, HD29968, HD37830, HD40221] Funding Source: Medline; NIDA NIH HHS [DA06668] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Carson DD, 2000, DEV BIOL, V223, P217, DOI 10.1006/dbio.2000.9767; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Ernst M, 2001, J EXP MED, V194, P189, DOI 10.1084/jem.194.2.189; Giudice LC, 1999, HUM REPROD, V14, P3, DOI 10.1093/humrep/14.suppl_2.3; Kimber SJ, 2000, SEMIN CELL DEV BIOL, V11, P77, DOI 10.1006/scdb.2000.0154; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Lim HJ, 2002, VITAM HORM, V64, P43, DOI 10.1016/S0083-6729(02)64002-6; Ma L, 1998, DEV BIOL, V197, P141, DOI 10.1006/dbio.1998.8907; Ma W, 2001, MOL ENDOCRINOL, V15, P1983, DOI 10.1210/me.15.11.1983; Maccarrone M, 2002, MOL HUM REPROD, V8, P188, DOI 10.1093/molehr/8.2.188; Mechoulam R, 1998, EUR J PHARMACOL, V359, P1, DOI 10.1016/S0014-2999(98)00649-9; Mulac-Jericevic B, 2000, SCIENCE, V289, P1751, DOI 10.1126/science.289.5485.1751; Norwitz ER, 2001, NEW ENGL J MED, V345, P1400, DOI 10.1056/NEJMra000763; Paria BC, 2001, J BIOL CHEM, V276, P20523, DOI 10.1074/jbc.M100679200; Paria BC, 2001, P NATL ACAD SCI USA, V98, P1047, DOI 10.1073/pnas.98.3.1047; PARIA BC, 2001, J BIOL CHEM, V98, P1047; Psychoyos A, 1973, Vitam Horm, V31, P201; Reese J, 2001, J BIOL CHEM, V276, P44137, DOI 10.1074/jbc.M107563200; Renfree MB, 2000, ANNU REV PHYSIOL, V62, P353, DOI 10.1146/annurev.physiol.62.1.353; Salamonsen LA, 2000, SEMIN REPROD MED, V18, P299, DOI 10.1055/s-2000-12567; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wang WD, 1998, DEVELOPMENT, V125, P621; Wilcox AJ, 1999, NEW ENGL J MED, V340, P1796, DOI 10.1056/NEJM199906103402304	26	371	403	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	2002	296	5576					2185	2188		10.1126/science.1071601	http://dx.doi.org/10.1126/science.1071601			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	12077405				2022-12-28	WOS:000176379000046
J	Dickel, H; Kuss, O; Schmidt, A; Diepgen, TL				Dickel, H; Kuss, O; Schmidt, A; Diepgen, TL			Impact of preventive strategies on trend of occupational skin disease in hairdressers: population based register study	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; LIFE-EVENTS; SURVIVAL; PROGNOSIS; STRESS; RISK; RECURRENCE; WOMEN		Univ Heidelberg Hosp, Dept Clin Social Med, Ctr Occupat & Environm Dermatol, D-69115 Heidelberg, Germany; Bavarian Hlth & Safety Execut, Dept Occupat Med, D-90429 Nurnberg, Germany	Ruprecht Karls University Heidelberg	Diepgen, TL (corresponding author), Univ Heidelberg Hosp, Dept Clin Social Med, Ctr Occupat & Environm Dermatol, D-69115 Heidelberg, Germany.			Kuss, Oliver/0000-0003-3301-5869				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; BARRACLOUGH J, 1992, BRIT MED J, V304, P1078, DOI 10.1136/bmj.304.6834.1078; BARRACLOUGH J, 1993, BRIT MED J, V307, P25; Breslow NE, 1980, STAT METHODS CANC RE; Brown G., 1978, SOCIAL ORIGINS DEPRE; Brown GW, 1989, LIFE EVENTS ILLNESS; Dickel H, 2001, BRIT J DERMATOL, V145, P453, DOI 10.1046/j.1365-2133.2001.04377.x; Edelman S, 2000, J PSYCHOSOM RES, V49, P149, DOI 10.1016/S0022-3999(00)00153-7; FAWZY FI, 1993, ARCH GEN PSYCHIAT, V50, P681; FORSEN A, 1991, PSYCHOTHER PSYCHOSOM, V55, P176, DOI 10.1159/000288427; FUNCH DP, 1983, J PSYCHOSOM RES, V27, P77, DOI 10.1016/0022-3999(83)90112-5; Giraldi T, 1997, PSYCHOTHER PSYCHOSOM, V66, P229, DOI 10.1159/000289140; HAYWARD JL, 1978, SEMIN ONCOL, V5, P445; HOGAN DJ, 1994, OCCUP MED, V9, P53; Karasek R., 1990, HLTH WORK STRESS PRO; Kiecolt-Glaser JK, 1999, EUR J CANCER, V35, P1603, DOI 10.1016/S0959-8049(99)00197-5; Kvikstad A, 1996, INT J CANCER, V67, P165, DOI 10.1002/(SICI)1097-0215(19960717)67:2<165::AID-IJC2>3.3.CO;2-4; KVIKSTAD A, 1995, BRIT J CANCER, V71, P1343, DOI 10.1038/bjc.1995.261; MAUNSELL E, 1998, PSYCHOONCOLOGY S, V7, P281; PARMAR M, 1995, SURVIVAL ANAL PRACTI; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Petticrew M, 1999, BRIT J HEALTH PSYCH, V4, P1, DOI 10.1348/135910799168434; RAMIREZ AJ, 1989, BRIT MED J, V298, P291, DOI 10.1136/bmj.298.6669.291; SCHLESINGER T, 2001, DERMATOL BERUF UMWEL, V49, P185; SPIEGEL D, 1989, LANCET, V2, P888; Spitzer RL, 1990, STRUCTURED CLIN INTE; STRESEMANN E, 1998, DERMATOSEN, V46, P166	27	45	45	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 15	2002	324	7351					1422	1423		10.1136/bmj.324.7351.1422	http://dx.doi.org/10.1136/bmj.324.7351.1422			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	565CQ	12065264	Green Published, Bronze			2022-12-28	WOS:000176351400016
J	Hazeltine, E; Ivry, RB				Hazeltine, E; Ivry, RB			Neuroscience - Can we teach the cerebelum new tricks?	SCIENCE			English	Editorial Material									NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of California System; University of California Berkeley	Hazeltine, E (corresponding author), NASA, Ames Res Ctr, Moffett Field, CA 94035 USA.	ehazeltine@mail.arc.nasa.gov		Hazeltine, Richard/0000-0002-0893-5789				Gomez-Beldarrain M, 1998, EXP BRAIN RES, V120, P25, DOI 10.1007/s002210050374; GRAFTON ST, 1995, J COGNITIVE NEUROSCI, V7, P497, DOI 10.1162/jocn.1995.7.4.497; Hazeltine E, 1997, BRAIN, V120, P123, DOI 10.1093/brain/120.1.123; Imamizu H, 2000, NATURE, V403, P192, DOI 10.1038/35003194; Ivry R, 1997, INT REV NEUROBIOL, V41, P555; KEELE SW, 1995, J MOTOR BEHAV, V27, P17, DOI 10.1080/00222895.1995.9941696; LOGAN CG, 1995, P NATL ACAD SCI USA, V92, P7500, DOI 10.1073/pnas.92.16.7500; Miall RC, 2001, NAT NEUROSCI, V4, P638, DOI 10.1038/88465; Molinari M, 1997, BRAIN, V120, P1753, DOI 10.1093/brain/120.10.1753; PASCUALLEONE A, 1993, ANN NEUROL, V34, P594, DOI 10.1002/ana.410340414; Seidler RD, 2002, SCIENCE, V296, P2043, DOI 10.1126/science.1068524; Thach WT, 1996, BEHAV BRAIN SCI, V19, P501, DOI 10.1017/S0140525X00082017; THOMPSON RF, 1990, PHILOS T ROY SOC B, V329, P161, DOI 10.1098/rstb.1990.0161; Timmann D, 1999, J NEUROPHYSIOL, V82, P103, DOI 10.1152/jn.1999.82.1.103	14	10	11	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	2002	296	5575					1979	1980		10.1126/science.1073926	http://dx.doi.org/10.1126/science.1073926			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	563UD	12065822				2022-12-28	WOS:000176273300037
J	West, SEH; Zeng, L; Lee, BL; Kosorok, MR; Laxova, A; Rock, MJ; Splaingard, MJ; Farrell, PM				West, SEH; Zeng, L; Lee, BL; Kosorok, MR; Laxova, A; Rock, MJ; Splaingard, MJ; Farrell, PM			Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis - Early detection by serology and assessment of risk factors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EARLY DIAGNOSIS; YOUNG-CHILDREN; OROPHARYNGEAL CULTURES; CHANGING EPIDEMIOLOGY; PULMONARY-FUNCTION; SERUM ANTIBODIES; LUNG-DISEASE; COLONIZATION; ACQUISITION; MANAGEMENT	Context Patients with cystic fibrosis (CF) are susceptible to lower respiratory tract infections with Pseudomonas aeruginosa and typically acquire this organism in early childhood. Once P aeruginosa infection is established, eradication may be impossible, and progressive lung disease often aggravates morbidity and mortality risks. The ability to diagnose CF by genetic testing at birth makes it possible to determine the temporal sequence of events that result in P aeruginosa-associated pulmonary infections. Objective To evaluate the longitudinal relationship between the production of an antibody response against P aeruginosa and clinical factors associated with P aeruginosa pulmonary infections in patients with CF diagnosed in early life. Design, Setting, and Patients Serum samples and oropharyngeal cultures (protocol cultures) were obtained at 6-month intervals from April 15, 1985, to April 15, 2000 (or for up to 180 months depending on their enrollment date) from 68 patients at 2 centers in Madison and Milwaukee, Wis, diagnosed through the Wisconsin CF Neonatal Screening Project, a longitudinal cohort study. Additional cultures were obtained at examining physicians' discretion (all cultures). Main Outcome Measures Time to serum IgG, IgA, and IgM antibody titer of at least 1:256 against P aeruginosa, assessed by enzyme-linked immunosorbent assay using cell lysate, exotoxin A, and elastase as antigens; time to organism isolation from respiratory samples; time to Wisconsin Cystic Fibrosis Radiograph (WCXR) score of 5 or more. Results The median time to an antibody titer of at least 1:256 was 17.8, 24.2, and 70.9 months for cell lysate, exotoxin A, and elastase, respectively. The rise of anti-cell lysate and anti-exotoxin A titers to 1:256 or more occurred a mean of 11.9 (P<.001) and 5.6 (P=.04) months, respectively, before the isolation of Paeruginosa for all cultures and 18.2 (P<.001) and 11.9 (P=.006) months, respectively, before protocol cultures. There was no significant difference between the rise of anti-cell lysate and anti-exotoxin A titer and a WCXR score of 5 or more (P=.24 and.32, respectively). Treatment with long-term, non-Pseudomonas oral antibiotics and integration of CF infants with older, chronically infected patients were associated with a significantly increased risk of P aeruginosa pulmonary infection. Conclusions In CF patients diagnosed through neonatal screening, Paeruginosa pulmonary infections occurred 6 to 12 months before the organism was isolated from respiratory secretions. The longitudinal monitoring of P aeruginosa antibody titers, in concert with WCXR score, should facilitate diagnosis and treatment of P aeruginosa pulmonary infections in young children with CF.	Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Biostat & Med Informat, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Pathobiol Sci, Madison, WI 53706 USA; Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Medical College of Wisconsin	Farrell, PM (corresponding author), Univ Wisconsin, Sch Med, Dept Pediat, 1300 Univ Ave, Madison, WI 53706 USA.	pmfarrel@facstaff.wisc.edu	Splaingard, Mark/AAL-7356-2021; Kosorok, Michael/ABB-7427-2021; Splaingard, Mark/D-9206-2012	Splaingard, Mark/0000-0002-1361-4947	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034108] Funding Source: NIH RePORTER; NCRR NIH HHS [RR03186] Funding Source: Medline; NIDDK NIH HHS [R01 DK34108] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABMAN SH, 1991, J PEDIATR-US, V119, P211, DOI 10.1016/S0022-3476(05)80729-2; ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; ARMSTRONG DS, 1995, BRIT MED J, V310, P1571, DOI 10.1136/bmj.310.6994.1571; Armstrong DS, 1996, PEDIATR PULM, V21, P267, DOI 10.1002/(SICI)1099-0496(199605)21:5<267::AID-PPUL1>3.0.CO;2-K; BALOUGH K, 1995, PEDIATR PULM, V20, P63, DOI 10.1002/ppul.1950200203; Bartholomew D, 1983, ENCY STAT SCI, V4, P260; BRETT MM, 1992, ARCH DIS CHILD, V67, P1086, DOI 10.1136/adc.67.9.1086; BRETT MM, 1988, J CLIN MICROBIOL, V26, P1565, DOI 10.1128/JCM.26.8.1565-1570.1988; BRETT MM, 1986, ARCH DIS CHILD, V61, P1114, DOI 10.1136/adc.61.11.1114; BRETT MM, 1990, ARCH DIS CHILD, V65, P259, DOI 10.1136/adc.65.3.259; BRETT MM, 1987, ARCH DIS CHILD, V62, P357, DOI 10.1136/adc.62.4.357; Burns JL, 2001, J INFECT DIS, V183, P444, DOI 10.1086/318075; Burns JL, 1998, CLIN INFECT DIS, V27, P158, DOI 10.1086/514631; Ciske DJ, 2001, PEDIATRICS, V107, P699, DOI 10.1542/peds.107.4.699; CORDON SM, 1992, ARCH DIS CHILD, V67, P737, DOI 10.1136/adc.67.6.737; COTTLE RW, 1992, LINEAR COMPLEMENTARI, P265; *CYST FIBR FDN, 1999, PAT REG 1998 ANN DAT; *CYST FIBR FDN, 1994, CONSENSUS C CONCEPTS, V5, P5; DEMKO CA, 1995, J CLIN EPIDEMIOL, V48, P1041, DOI 10.1016/0895-4356(94)00230-N; Farrell P M, 2000, Adv Pediatr, V47, P79; Farrell PM, 1998, BRIT MED J, V317, P1017, DOI 10.1136/bmj.317.7164.1017; Farrell PM, 1997, NEW ENGL J MED, V337, P963, DOI 10.1056/NEJM199710023371403; Farrell PM, 1997, PEDIATRICS, V100, DOI 10.1542/peds.100.5.e2; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; FLEMING TR, 1991, COUNTING PROCESSES S, P163; FOST N, 1989, CLIN RES, V37, P495; Frederiksen B, 1999, PEDIATR PULM, V28, P159, DOI 10.1002/(SICI)1099-0496(199909)28:3<159::AID-PPUL1>3.0.CO;2-1; Frederiksen B, 1997, PEDIATR PULM, V23, P330, DOI 10.1002/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O; GRANSTROM M, 1984, ACTA PAEDIATR SCAND, V73, P772, DOI 10.1111/j.1651-2227.1984.tb17774.x; HANCOCK REW, 1983, INFECT IMMUN, V42, P170, DOI 10.1128/IAI.42.1.170-177.1983; HARLOW E, 1988, ANTIBODIES LAB MANUA, P563; HOIBY N, 1989, ACTA PAEDIATR SCAND, V78, P395, DOI 10.1111/j.1651-2227.1989.tb11099.x; HOLLOWAY BW, 1979, MICROBIOL REV, V43, P73, DOI 10.1128/MMBR.43.1.73-102.1979; HOLLSING AE, 1987, J CLIN MICROBIOL, V25, P1868, DOI 10.1128/JCM.25.10.1868-1874.1987; HOMMA JY, 1978, JPN J EXP MED, V48, P111; HUDSON VL, 1993, J PEDIATR-US, V122, P854, DOI 10.1016/S0022-3476(09)90007-5; KELLY HW, 1984, DRUG INTEL CLIN PHAR, V18, P772, DOI 10.1177/106002808401801001; KEREM E, 1990, PEDIATR INFECT DIS J, V9, P494, DOI 10.1097/00006454-199007000-00008; Klein JP., 2003, SURVIVAL ANAL TECHNI; Koscik RE, 2000, PEDIATR PULM, V29, P457, DOI 10.1002/(SICI)1099-0496(200006)29:6<457::AID-PPUL8>3.3.CO;2-0; Kosorok MR, 2001, PEDIATR PULM, V32, P277, DOI 10.1002/ppul.2009.abs; Kosorok MR, 1998, PEDIATR PULM, V26, P81, DOI 10.1002/(SICI)1099-0496(199808)26:2<81::AID-PPUL2>3.0.CO;2-K; LOENINGBAUCKE VA, 1979, J PEDIATR-US, V95, P630, DOI 10.1016/S0022-3476(79)80785-4; MAHENTHIRALINGAM E, 1994, INFECT IMMUN, V62, P596, DOI 10.1128/IAI.62.2.596-605.1994; Merelle ME, 2001, EUR RESPIR J, V18, P306, DOI 10.1183/09031936.01.00080101; MOHR CD, 1990, MOL MICROBIOL, V4, P2103, DOI 10.1111/j.1365-2958.1990.tb00571.x; Murray S, 2000, BIOMETRICS, V56, P984, DOI 10.1111/j.0006-341X.2000.0984.x; Nixon GM, 2001, J PEDIATR-US, V138, P699, DOI 10.1067/mpd.2001.112897; OHMAN DE, 1981, INFECT IMMUN, V33, P142, DOI 10.1128/IAI.33.1.142-148.1981; RAMSEY BW, 1991, AM REV RESPIR DIS, V144, P331, DOI 10.1164/ajrccm/144.2.331; Ramsey BW, 1996, NEW ENGL J MED, V335, P179, DOI 10.1056/NEJM199607183350307; Ramsey BW, 1996, PEDIATR PULM, V21, P265, DOI 10.1002/1099-0496(199605)21:5<265::AID-PPUL1950210502>3.0.CO;2-5; Rosenfeld M, 1999, PEDIATR PULM, V28, P321, DOI 10.1002/(SICI)1099-0496(199911)28:5<321::AID-PPUL3>3.0.CO;2-V; Stutman HR, 2002, J PEDIATR-US, V140, P299, DOI 10.1067/mpd.2002.121930; VALERIUS NH, 1991, LANCET, V338, P725, DOI 10.1016/0140-6736(91)91446-2; Wang SS, 2001, PEDIATRICS, V107, P274, DOI 10.1542/peds.107.2.274; WINNIE GB, 1991, PEDIATR PULM, V10, P92, DOI 10.1002/ppul.1950100210; WOOD RE, 1979, SOUTHERN MED J, V72, P189, DOI 10.1097/00007611-197902000-00019; WOODS DE, 1991, J INFECT DIS, V163, P143, DOI 10.1093/infdis/163.1.143	59	140	151	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	2002	287	22					2958	2967		10.1001/jama.287.22.2958	http://dx.doi.org/10.1001/jama.287.22.2958			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	561EY	12052125				2022-12-28	WOS:000176128300025
J	Bhandari, N; Bahl, R; Taneja, S; Strand, T; Molbak, K; Ulvik, RJ; Sommerfelt, H; Bhan, MK				Bhandari, N; Bahl, R; Taneja, S; Strand, T; Molbak, K; Ulvik, RJ; Sommerfelt, H; Bhan, MK			Effect of routine zinc supplementation on pneumonia in children aged 6 months to 3 years: randomised controlled trial in an urban slum	BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY-TRACT INFECTIONS; ACUTE DIARRHEA; DOUBLE-BLIND; BANGLADESHI CHILDREN; PERSISTENT DIARRHEA; CLINICAL PREDICTORS; DEFICIENCY; HYPOXEMIA; CRITERIA; IMMUNITY	Objectives To evaluate the effect of daily zinc supplementation in children on the incidence of acute lower respiratory tract infections and pneumonia. Design Double masked, randomised placebo controlled trial. Setting A slum community in New Delhi, India. Participants 2482 children aged 6 to 30 months. Interventions Daily elemental zinc, 10 mg to infants and 20 mg to older children or placebo for four months. Both groups received single massive dose of vitamin A (100 000 IU for infants and 200 000 IU for older children) at enrolment. Main outcome measures All households were visited weekly. Any children with cough and lower chest indrawing or respiratory rate 5 breaths per minute less than the World Health Organization criteria for fast breathing were brought to study physicians. Results At four months the mean plasma zinc concentration was higher in the zinc group (19.8 (SD 10.1) v 9.3 (2.1) mumol/l, P <0.001). The proportion of children who had acute lower respiratory, tract infection during follow up was no different in the two groups (absolute risk reduction - 0.2% 95% confidence interval - 3.9% to 3.6%). Zinc supplementation resulted in a lower incidence of pneumonia than placebo (absolute risk reduction 2.5%,, 95% confidence interval 0.4% to 4.6%). After correction for multiple episodes in the same child by generalised estimating equations analysis the odds ratio was 0.74, 95% confidence interval 0.56 to 0.99. Conclusions Zinc supplementation substantially reduced the incidence of pneumonia in children who had received vitamin A.	All India Inst Med Sci, Dept Paediat, New Delhi 110029, India; Univ Bergen, Ctr Int Hlth, N-5021 Bergen, Norway; Statens Serum Inst, DK-2300 Copenhagen, Denmark; Univ Bergen, Inst Clin Biochem, Bergen, Norway	All India Institute of Medical Sciences (AIIMS) New Delhi; University of Bergen; Statens Serum Institut; University of Bergen	Bhan, MK (corresponding author), All India Inst Med Sci, Dept Paediat, New Delhi 110029, India.		Trilok-Kumar, Geeta/AAF-5978-2021; Strand, Tor/D-9836-2016; Sommerfelt, Halvor/ABD-3552-2020	Trilok-Kumar, Geeta/0000-0001-8442-2881; Strand, Tor/0000-0002-4038-151X; Sommerfelt, Halvor/0000-0002-5670-9786; Molbak, Kare/0000-0002-3100-4990				Bhandari N, 1996, ACTA PAEDIATR, V85, P148, DOI 10.1111/j.1651-2227.1996.tb13981.x; Bhutta ZA, 1999, J PEDIATR-US, V135, P689, DOI 10.1016/S0022-3476(99)70086-7; Black RE, 1998, AM J CLIN NUTR, V68, p476S, DOI 10.1093/ajcn/68.2.476S; CAMPBELL H, 1989, LANCET, V1, P297, DOI 10.1016/S0140-6736(89)91308-1; CASTILLODURAN C, 1988, J PEDIATR-US, V113, P452, DOI 10.1016/S0022-3476(88)80627-9; CHVAPIL M, 1973, LIFE SCI, V13, P1041, DOI 10.1016/0024-3205(73)90372-X; FERNANDES G, 1979, P NATL ACAD SCI USA, V76, P457, DOI 10.1073/pnas.76.1.457; GARDNER MJ, 1989, STAT CONFIDENCE CONF; HAMBIDGE KM, 1990, J TRACE ELEM ELECT H, V4, P229; MELTON LA, 1990, CLIN CHEM, V36, P247; PRASAD AS, 1979, ANNU REV PHARMACOL, V19, P393, DOI 10.1146/annurev.pa.19.040179.002141; Rahman MM, 2001, BMJ-BRIT MED J, V323, P314, DOI 10.1136/bmj.323.7308.314; ROY SK, 1992, J PEDIATR GASTR NUTR, V15, P289, DOI 10.1097/00005176-199210000-00010; Roy SK, 1989, BANGLADESH J NUTR, V2, P1; RUZ M, 1995, J TRACE ELEM EXP MED, V7, P89; Sazawal S, 1996, J NUTR, V126, P443, DOI 10.1093/jn/126.2.443; Sazawal S, 1997, Indian Pediatr, V34, P589; Sazawal S, 1998, PEDIATRICS, V102, P1, DOI 10.1542/peds.102.1.1; Sazawal S, 1997, AM J CLIN NUTR, V66, P413, DOI 10.1093/ajcn/66.2.413; Sempertegui F, 1996, EUR J CLIN NUTR, V50, P42; Shankar AH, 1998, AM J CLIN NUTR, V68, p447S, DOI 10.1093/ajcn/68.2.447S; SHANN F, 1984, B WORLD HEALTH ORGAN, V62, P749; SMITH P, 1996, FIELD TRIALS HLTH IN; Smyth A, 1998, ANN TROP PAEDIATR, V18, P31, DOI 10.1080/02724936.1998.11747923; Usen S, 1999, BMJ-BRIT MED J, V318, P86, DOI 10.1136/bmj.318.7176.86; *WHO DIV CHILD HLT, 1997, INT MAN CHILDH ILLN; 1990, NUTR REV, V48, P19	27	106	109	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 8	2002	324	7350					1358	1361		10.1136/bmj.324.7350.1358	http://dx.doi.org/10.1136/bmj.324.7350.1358			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BQ	12052800	Green Published, Bronze			2022-12-28	WOS:000176234100015
J	Rinde, E; Balteskard, L				Rinde, E; Balteskard, L			Is there a future for telemedicine?	LANCET			English	Editorial Material									Telenor Res, N-9001 Tromso, Norway; Univ Hosp No Norway, Dept Oncol, Tromso, Norway	UiT The Arctic University of Tromso; University Hospital of North Norway	Rinde, E (corresponding author), Telenor Res, N-9001 Tromso, Norway.							BASHUR RL, 1977, AVIAT SPACE ENV MED, V177, P65; Einthoven W., 1906, NED TIJDSCHR GEENESK, V50, P1517; Ferris DG, 2002, OBSTET GYNECOL, V99, P248, DOI 10.1016/S0029-7844(01)01671-4; Hailey D, 2002, J TELEMED TELECARE, V8, P1; JOSENDAL O, 1991, Tidsskrift for den Norske Laegeforening, V111, P20; Moseng D, 2000, Tidsskr Nor Laegeforen, V120, P1893; Oakley A, 2001, J TELEMED TELECARE, V7, P59, DOI 10.1258/1357633011937155; Olsen DR, 2000, RADIOTHER ONCOL, V54, P255, DOI 10.1016/S0167-8140(99)00185-1; Sable CA, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.1.e3; Sund T, 1995, LANCET, V346, pS24, DOI 10.1016/0140-6736(95)90023-3; Williams TL, 2001, BRIT J DERMATOL, V145, P911, DOI 10.1046/j.1365-2133.2001.04472.x	11	15	15	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 8	2002	359	9322					1957	1958		10.1016/S0140-6736(02)08845-1	http://dx.doi.org/10.1016/S0140-6736(02)08845-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076546				2022-12-28	WOS:000176232500003
J	Jha, AK; Collard, HR; Tierney, LM				Jha, AK; Collard, HR; Tierney, LM			Diagnosis still in question.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNKNOWN ORIGIN; FOLLOW-UP; FEVER; DISEASE		Univ Calif San Francisco, Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Jha, AK (corresponding author), Vet Affairs Med Ctr, Gen Internal Med Sect 111, 4150 Clement St, San Francisco, CA 94121 USA.							Arnow PM, 1997, LANCET, V350, P575, DOI 10.1016/S0140-6736(97)07061-X; DEKLEIJN EMHA, 1995, NETH J MED, V47, P54, DOI 10.1016/0300-2977(95)00037-N; IIKUNI Y, 1994, INTERNAL MED, V33, P67, DOI 10.2169/internalmedicine.33.67; KAUR S, 1994, DERMATOLOGY, V188, P241, DOI 10.1159/000247150; KNOCKAERT DC, 1992, ARCH INTERN MED, V152, P51, DOI 10.1001/archinte.152.1.51; LARSON EB, 1984, MEDICINE, V63, P82, DOI 10.1097/00005792-198403000-00002; LARSON EB, 1982, MEDICINE, V61, P269, DOI 10.1097/00005792-198209000-00001; LEE MH, 1995, AM J MED, V98, P566, DOI 10.1016/S0002-9343(99)80015-1; OHTA A, 1987, J RHEUMATOL, V14, P1139; PETERSDORF R, 1961, MEDICINE, V40, P1, DOI 10.1097/00005792-196102000-00001; PETERSDORF RG, 1992, ARCH INTERN MED, V152, P21, DOI 10.1001/archinte.152.1.21; SAMPALIS JS, 1995, AM J MED, V98, P384, DOI 10.1016/S0002-9343(99)80318-0; YAMAGUCHI M, 1992, J RHEUMATOL, V19, P424	13	2	2	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	2002	346	23					1813	1816		10.1056/NEJMcps013038	http://dx.doi.org/10.1056/NEJMcps013038			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	559EK	12050343				2022-12-28	WOS:000176012500010
J	Kerzner, R; Barzilai, B; Satyanarayana, R				Kerzner, R; Barzilai, B; Satyanarayana, R			Constrictive pericarditis and hepatic encephalopathy	LANCET			English	Editorial Material									Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Kerzner, R (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.								0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 1	2002	359	9321					1895	1895		10.1016/S0140-6736(02)08742-1	http://dx.doi.org/10.1016/S0140-6736(02)08742-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PL	12057551				2022-12-28	WOS:000175975700008
J	Marseille, E; Hofmann, PB; Kahn, JG				Marseille, E; Hofmann, PB; Kahn, JG			HIV prevention before HAART in sub-Saharan Africa	LANCET			English	Article							COST-EFFECTIVENESS; SEXUAL TRANSMISSION; INFECTION; TANZANIA; HEALTH; AIDS	Data on the cost-effectiveness of HIV prevention in sub-Saharan Africa and on highly active antiretroviral therapy (HAART) indicate that prevention is at least 28 times more cost effective than HAART. We aim to show that funding HAART at the expense of prevention means greater loss of life. To maximise health benefits, the next major increments of HIV funding in sub-Saharan Africa should be devoted mainly to prevention and to some non-HAART treatment and care. Funds should be allocated to HAART primarily for demonstration projects that will help prepare for scaled-up HAART provision following broad population coverage by prevention programmes. UNAIDS and the London School of Hygiene and Tropical Medicine recently estimated that at least US$9.2 billion annually is required to mount an appropriate response to the HIV pandemic, including substantial funding for HAART. To date, US$1.96 billion has been committed to the newly-established UN Global Fund to Fight AIDS, Tuberculosis, and Malaria. It is a moral Imperative that expanded programmes to control HIV be implemented without delay, and that the goal of US$9.2 billion or more in annual spending be attained as rapidly as possible. The findings and recommendations of this analysis pertain to the phasing in of additional HIV-related activities during the current period of improved but inadequate funding.	Univ Calif San Francisco, Ctr AIDS Prevent Studies, Inst Hlth Policy Studies, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, AIDS Res Inst, San Francisco, CA 94143 USA; Provenance Hlth Partners, Moraga, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Marseille, E (corresponding author), Univ Calif San Francisco, Ctr AIDS Prevent Studies, Inst Hlth Policy Studies, Dept Epidemiol & Biostat, Box 0936, San Francisco, CA 94143 USA.				NIDA NIH HHS [DA09531] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009531] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		[Anonymous], 2000, WORLD HLTH REP; [Anonymous], 1997, CONFR AIDS PUBL PRIO; Attaran A, 2001, LANCET, V357, P57, DOI 10.1016/S0140-6736(00)03576-5; Blower SM, 2000, SCIENCE, V287, P650, DOI 10.1126/science.287.5453.650; CALLAHAN D, 1990, NEW ENGL J MED, V322, P1810, DOI 10.1056/NEJM199006213222511; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Jha P, 2001, SCIENCE, V292, P224, DOI 10.1126/science.1058187; Jonsen A R, 1986, Law Med Health Care, V14, P172; KIRK P, 2000, GUARDIAN        0331; KLURFELD J, 2001, NEWSDAY         0701; Lamptey P R, 1997, AIDS, V11 Suppl B, pS63; Law MG, 2001, AIDS, V15, P1287, DOI 10.1097/00002030-200107060-00011; Marseille E, 1999, LANCET, V354, P803, DOI 10.1016/S0140-6736(99)80009-9; Marseille E, 2001, SOC SCI MED, V52, P135, DOI 10.1016/S0277-9536(00)00282-3; MARSEILLE E, 2001, UN GEN ASS SPEC SESS; Merson MH, 2000, AIDS, V14, pS68; MOSES S, 1991, AIDS, V5, P407, DOI 10.1097/00002030-199104000-00008; PAGESHAFER KA, 1999, MMWR-MORBID MORTAL W, V48, P45; Parker RG, 2000, AIDS, V14, pS22, DOI 10.1097/00002030-200006001-00004; Pilcher CD, 2001, JAMA-J AM MED ASSOC, V286, P1713, DOI 10.1001/jama.286.14.1713; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Schwartlander B, 2001, SCIENCE, V292, P2434, DOI 10.1126/science.1062876; Sweat M, 2000, LANCET, V356, P113, DOI 10.1016/S0140-6736(00)02447-8; *UNAIDS, 2001, CALC COST EFF GLOB C; *UNAIDS WHO, 2000, AIDS EP UPD; 2001, WASHINGTON TIME 0802, pA15	28	153	154	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 25	2002	359	9320					1851	1856		10.1016/S0140-6736(02)08705-6	http://dx.doi.org/10.1016/S0140-6736(02)08705-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044394				2022-12-28	WOS:000175775500027
J	De Costa, C				De Costa, C			St Anthony's fire and living ligatures: a short history of ergometrine	LANCET			English	Review									Cairns Base Hosp, Dept Obstet & Gynaecol, Cairns, Qld 4870, Australia		De Costa, C (corresponding author), Cairns Base Hosp, Dept Obstet & Gynaecol, POB 902, Cairns, Qld 4870, Australia.	carolinedec@hotkey.net.au						BAR P, 1890, PRATIQUE ART ACCOUCH, P609; CLARK BJ, 1984, DISCOVERIES PHARM, P3; DAVIS DD, 1836, PRINCIPLES PRACTICE, P1064; DEYEBENES JG, 1991, ARCH NEUROBIOL, V54, P37; Donnay F, 2000, INT J GYNECOL OBSTET, V70, P89, DOI 10.1016/S0020-7292(00)00236-8; Dudley HW, 1935, BRIT MED J, V1935, P520, DOI 10.1136/bmj.1.3871.520; EDGAR JC, 1913, PRACTICE OBSTET, P475; FARRER D, 1978, OXFORD DICT SAINTS, P19; HARRISON J, 1938, SOC AGRIC BACT ABST, P12; KING B, 1979, LANCET, V1, P1411; Moir C, 1932, BRIT MED J, V1932, P1119, DOI 10.1136/bmj.1.3728.1119; MOIR JC, 1971, M KERRS OPERATIVE OB, P950; NORRIS RC, 1896, AM TXB OBSTET, P602; PARFITT K, 1999, MARTINDALE COMPLETE, P1575; PEROUTKA SJ, 1996, GOODMAN GILMANS PHAR; PRENDIVILLE W, 1988, BRIT J OBSTET GYNAEC, V95, P3, DOI 10.1111/j.1471-0528.1988.tb06475.x; RAMSBOTHAM F, 1877, OBSTET MED SURG, P321; RAMSBOTHAM F, 1841, PRINCIPLES PRACTICE, P702; THOMS HERBERT, 1931, AMER JOUR OBSTET & GYNECOL, V22, P418; VANDONGEN PWJ, 1995, EUR J OBSTET GYN R B, V60, P109, DOI 10.1016/0028-2243(95)02104-Z	20	55	58	1	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 18	2002	359	9319					1768	1770		10.1016/S0140-6736(02)08658-0	http://dx.doi.org/10.1016/S0140-6736(02)08658-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049883				2022-12-28	WOS:000175740500031
J	Skoog, I				Skoog, I			Magnetic-resonance imaging to assess Alzheimer's disease	LANCET			English	Editorial Material							FRONTOTEMPORAL DEMENTIA; ATROPHY; DIAGNOSIS; AD		Sahlgrenska Univ Hosp, Inst Clin Neurosci, Sect Psychiat, Neuropsychiat Epidemiol Unit, S-41345 Gothenburg, Sweden	Sahlgrenska University Hospital	Skoog, I (corresponding author), Sahlgrenska Univ Hosp, Inst Clin Neurosci, Sect Psychiat, Neuropsychiat Epidemiol Unit, S-41345 Gothenburg, Sweden.							Andreasen N, 2001, ARCH NEUROL-CHICAGO, V58, P373, DOI 10.1001/archneur.58.3.373; Chan D, 2001, NEUROLOGY, V57, P1756, DOI 10.1212/WNL.57.10.1756; Fox NC, 2001, LANCET, V358, P201, DOI 10.1016/S0140-6736(01)05408-3; Frisoni GB, 1999, NEUROLOGY, V52, P91, DOI 10.1212/WNL.52.1.91; Jack CR, 1998, NEUROLOGY, V51, P993, DOI 10.1212/WNL.51.4.993; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; Mayeux R, 1998, NEW ENGL J MED, V338, P506, DOI 10.1056/NEJM199802193380804; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; O'Brien JT, 2001, NEUROLOGY, V56, P1386, DOI 10.1212/WNL.56.10.1386	9	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 4	2002	359	9317					1538	1539		10.1016/S0140-6736(02)08527-6	http://dx.doi.org/10.1016/S0140-6736(02)08527-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047960				2022-12-28	WOS:000175460700004
